<SEC-DOCUMENT>0001396814-22-000021.txt : 20220228
<SEC-HEADER>0001396814-22-000021.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228162622
ACCESSION NUMBER:		0001396814-22-000021
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		139
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pacira BioSciences, Inc.
		CENTRAL INDEX KEY:			0001396814
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510619477
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35060
		FILM NUMBER:		22690090

	BUSINESS ADDRESS:	
		STREET 1:		5401 WEST KENNEDY BOULEVARD
		STREET 2:		SUITE 890
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33609
		BUSINESS PHONE:		813-553-6680

	MAIL ADDRESS:	
		STREET 1:		5 SYLVAN WAY
		STREET 2:		SUITE 300
		CITY:			PARSIPPANY
		STATE:			NJ
		ZIP:			07054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pacira Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20101029

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIRA INC
		DATE OF NAME CHANGE:	20080318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Acquisition Corp
		DATE OF NAME CHANGE:	20070418
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pcrx-20211231.htm
<DESCRIPTION>10-K - PCRX - 12.31.2021
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:66f2c054-d932-41b4-84f1-797b86c41d80,g:418797a4-960d-471e-b290-1e4b5463b147,d:284a0cec603b490382d0f8422359e7e8--><html xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:pcrx="http://www.pacira.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pcrx-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y18yLTEtMS0xLTA_64ad56aa-2c84-4def-831c-48ce0de9a553">0001396814</ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y18zLTEtMS0xLTA_f9b313b5-d90c-49d1-b03e-7a7ac3be1e5f">false</ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y180LTEtMS0xLTMwNTgx_52f1dfe0-6c00-45dc-9be4-bc03e36ff8a0">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y181LTEtMS0xLTA_4a6c95ce-eaa8-4c47-8b0b-04b1dab54417">2021</ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y182LTEtMS0xLTA_66f05894-a901-45be-af1a-c07a7bd73494">FY</ix:nonNumeric><ix:nonNumeric contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEyLTAtMS0xLTA_54d63146-003c-4c28-a1fa-c0f426679644">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonNumeric contextRef="i42a9830d9b244758b1ed6841c20a7f8a_D20210101-20211231" name="pcrx:AccountsReceivablePaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzI3NzA_1d583239-02d3-4c41-bc38-abbb200a0e6b">P0D</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-5" name="us-gaap:InterestCostsCapitalized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMTE4L2ZyYWc6ZWRiYzkzZDZhMDFiNGVhMjgxMTUyODMyNjliODFhZmIvdGV4dHJlZ2lvbjplZGJjOTNkNmEwMWI0ZWEyODExNTI4MzI2OWI4MWFmYl8zODQ4MjkwNjk3Mjcz_6e45b1c1-6579-4cf5-8878-1fb56d5b63a3">0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i65dfbd8ff8d7419f9e7bcef5200f53b6_I20211231" decimals="INF" name="pcrx:DebtInstrumentMarketPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzI4_fb2e2ff2-2f6b-488e-be15-f6cf7bb95fe4">1.144</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzcz_37e3d9d5-af23-4178-aef5-d28d2ffa1f78">0.0149</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i029b2fd1da9b426aa281eb6edf9c4164_I20211231" decimals="INF" name="pcrx:DebtInstrumentMarketPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzEwMw_bbee9464-7fdf-44df-ae86-657a0b25df5e">1.113</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1e7d5628512b4a3e8635bfd28f644363_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzE0Nw_e2d8af03-8e1b-4b8c-a62c-f0088df9f8fd">.0139324</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i292dc4ba96214be2a65fdd56033cc528_I20211206" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzM4NDgyOTA2OTc3MTU_109bd95c-ac0f-4aa1-bf22-3db3fc08027a">317.40</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i292dc4ba96214be2a65fdd56033cc528_I20211206" decimals="INF" name="pcrx:DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzM4NDgyOTA2OTc3MjQ_cbfd9eaf-bca8-493f-acc0-d676498d6165">37.3413</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie1a4dffa829749ac815dd4fff21096ef_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzM4NDgyOTA2OTc0OTM_0fe9dc10-5620-4491-ae84-2fc746db190b">0.0373413</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0b7a7512ce0f40b38a5bd571e54d9751_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMTExL2ZyYWc6NzQwN2ZhNGZhODhjNDFjZWJhNTY2NGZiYmUxNjYwNDMvdGV4dHJlZ2lvbjo3NDA3ZmE0ZmE4OGM0MWNlYmE1NjY0ZmJiZTE2NjA0M180Mzk4MDQ2NTExMTY1_daeeaf76-be2d-48ed-8d83-feb892ae7642">12.2</ix:nonFraction><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDU1L2ZyYWc6NTFjMWVlMGQ4Y2IwNDg5MjkyNWY4M2Y5NjM2N2U5NjYvdGV4dHJlZ2lvbjo1MWMxZWUwZDhjYjA0ODkyOTI1ZjgzZjk2MzY3ZTk2Nl8zODQ4MjkwNjk3NDA3_f57f52e2-2167-409b-b4fe-39de49a3048b" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 22&#8212;SUBSEQUENT EVENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Placeholder</span></div></ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pcrx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f5b792563940c3a6ac3952c900baba_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib74a5ff7f32a4742bb95a41a5c1e0be2_I20220227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7ad81457b8d40ec98c994382d3d81b3_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib97087953997481c9eb9531b2899f6a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia919a337f89e4501a657825c42e3742f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f0515519fd468ea2893c1d1449bb1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d43a54915fb471a881eb7c22d53ebb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if920c61660554030b10993e6540fa419_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2cf381db5a940f290c4b8ce845a8a32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c32d4b9517d48699bd04bc765bd4313_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34416a5edad84520b386d27a329de124_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b952c5725b44f818a3a4608b206c6b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87676acfa0004a61af3790653d502de3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d4add3e8085457381bf09ffb890926b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ddbaa9a26c6475c851117daf9454009_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6f38afdcb06c45b49334598d858c08be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be32dbfc52d4ab3bef56de81da70e21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f4de158e56453ea2b40d32946b5324_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02f22e84df6a45609376bb4bbce1cf8e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e2f16409934c59b4f8cb94a706dc14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96bdb26537c44cc6b5fef08200c07e6f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9261483f2cf444697023aae54718727_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa36cac814f44a06a730eb8daf40ca38_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b6af31fbcb4cb5b587df488ccd9a82_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5ead454a5844d28a4260c4149d6b73_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7691a4cd4aca428e882b620433db6759_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f634c57178e427b9ece243062defb9c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2a38c35f7048949286b849f4126c2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i898bf7e1b82b4fd3a5c551aa4879fb16_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b60ec582530407797a99033b53bbf05_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9f105ca63d4c1090d6168b48daf166_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide58e19786fb437497710ff2a2f106c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8363a6e4996490fac437219786a762d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib22aebb1a2f448a8b5e073383b0f94c1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a5e18c117b491dab5190737229f0a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776bb75da13044258dd0d043f2083674_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c5737320f84dbb81a3529e36798635_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73b1bb54137c4111b70b6f8e573b2d33_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3dfaa6dfa1240039de2e6dff373a711_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3af9929d68c2470ba7dce232ee415fde_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eafc73607f5454aafd32bc87073240c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43034ba78f184fed9391b7aa159e7b94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15739e828cad4e53af9937b4cf53b886_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1e15ed7bcf42019a3e50c393218b9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4dc31d7b404c919dfaf4a0a27a0aff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec4e19869fe24a178b94aa20a13f86b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia317542b2a494470b42249229135b47e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i097161875b3d423d84de836dca9e6e1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292cbc754afb4c849eda7b618d73c0a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib617d7e96fc14f90a5109fe4b4e42246_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65bc19c293874f40856a561cd84a8945_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e75a83dae34a3e81787449842b080d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18af5711da6640a097e5c4348ee46f60_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ddd1a458e84be0b45073c62a0600f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia77d73b036584e0f9d8fe145c72c60dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabeecd1debc54d2491b639ea1e2d971c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i714f475d443c449882547155cf8a8321_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac5eb7e48d214a51937b661bf27d5c25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e7d5628512b4a3e8635bfd28f644363_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6417dba8c0b47b8b32488655a275284_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a19a318f1bb483fa686deeaa2359f9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2189f4174640ff8254517903eb5f68_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7eaed297368425488f2206696292750_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262c5548fe9c44b8aa7a185ebe27e739_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0494276ab7c45fda83381f5dde00ce2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3326fe2dfeb408fa75e3dba728e3dc1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>pcrx:product</xbrli:measure></xbrli:unit><xbrli:context id="i97a72732ce3f4d6ca28e806af66ae46c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>pcrx:customer</xbrli:measure></xbrli:unit><xbrli:context id="i7ba25e639e904a9d80a76eefeea1ce89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7321b7b30b420f86d7944c99c15c52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380d3a4003e54e71815bb7db455f68c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bfeff53dc92453d8702a3c0ae51c52d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df8ab515900456b8b8748721140d7ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52bcafe560714f84b452f8d30131893d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice902dc371e243acbe67af152c1848da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0fe11f05a54770acc081985b4107dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic79b87819ddf45adb47f8de52f00559e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1b98464ce04367b1e114e9a4d74874_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c5bbc9ad9d4d038376f6d8ca847370_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e7c8ae84494cf49e1dc21ec2d425fa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9359bc477c664a09916c4119368c7808_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:CustomersOutsideUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33291270d39e439a99ab030eecef7f59_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:CustomersOutsideUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3861be95c084c30b8a15610c61c7be1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:CustomersOutsideUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d024abaafbd4d6e9cda562be11efadd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d54a85658be4c869764ca7b02d10225_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f8f41343e614090bd98a3129a5dcdc4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c66ebd062648669078e714c644cc79_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86add3d370c4395b397c37d521b6125_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>pcrx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72dde336ea2646239cd55a4c4c35744d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa17a81b38264f39b34ab843a76bdd7b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14320622ef29473cb23cce50b7da7f46_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57cd9faa19194a9c8470e9fe6d5218d4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4efcb358dc364ee385b99f35f75898ae_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8d9fd8299c410c8c9b5a06cf205cd2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i712922c8b31944bcb4ececbbd4ecb4a5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6fe451f5a2472a9296caa5f57011d7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie406c0d697dd4848bc04dae623fcce72_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b07dbdf7694f77bc022c7d7d9afa7c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d04eaeb562d4b64900de3e69bac3a78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a88692b931e4aef8edbc75ea1bf544e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06af3d3299684224a00de2d7598b92d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320c15f4336b4069b57910624e292a4c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd3c4592d3b415cba09402210cae28d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c16dbebfa7a404f8409b8c58ef412d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if63921146eb64ffe98b470ec795407f5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2e28fa586746b9821aa10826da495f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc25a5337c794bf8bd461563d5da11b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a8455031a245d78c33f94ce7a73d04_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c7f9a44c2e3462cb1305f9f59a302b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28deb21f2b4942ecb350c0910d65ebed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34a22ddc8218489080892a6cdaf5ebb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id683cf836c4e4f11916c047f28e031ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3462358bbe414ffbb1b57b6e9e01c5c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia92a3c6cd7d9435cb9eff94c7851d7f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ac5092cc3645d7bc0aef94ffd9cee5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57086efa37da41e998389e0480dd7425_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf91a2291efc4aa296367a3d8f467bd8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied14d59a15b74bf6b3ced695a67b49f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc0dc9d1d7b14f25ad8be83ef27a2350_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e8ea6a6bb646069500943f11b40bd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie03f2a211d40429ba9a8f59edb0f3814_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8787beaf97a040fc93e4271eaa597cf7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id086e74a59d7487d9c24f8b8d7361978_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42a9830d9b244758b1ed6841c20a7f8a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f568606f0c4823a905f91cf481d300_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736f64d4bbd849d7be2b019552be776c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c69cb4d02b34bbca69ebe9cac7ed74e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8edb95efe04b6799f90101e59f96cb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30fd1b228fa24cc99396d29a977444ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e0d7ce79dbc4e3789299398e8fce7f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de2811811e245db84f11e1e3de5d7e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if533c736fa2840fb9422c87e1310fa3a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d56d46c5c9a4e8a9f809b42b0655590_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec6610466d344f0fa088043b24569826_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02771c45dac74870b7443cd500921e8a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84613c0ab0204e27bfad217490c8e958_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356e2083084446a6b5546356a72bfb5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66cf7a1d0974accbfeaa215c9671c3a_D20211119-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcrx:RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb1a68217b5c4d4e873ece15e0f90135_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf250MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9218c1eec9ef41a4992bc55da182b205_D20211119-20301231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf250MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2030-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcdbdc73190942b1a864a717a9c9bcca_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf375MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e721f32c0054c3c80e74321a03292d4_D20211119-20301231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf375MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2030-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie03ed2c8aff24b4494f38ae68516f2ce_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf500MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i008e93128d4947408a9a2c78e9148223_D20211119-20301231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf500MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2030-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c856dbf51f94a28b261f6eecf123ef1_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfFDAApprovalOfFX201Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d300faae4fa47d5b99bd8a7e5282ce7_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfFDAApprovalOfFX301Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37470c5184194ea6bcf6c2946155189f_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936811b25a12408a9e9c474cd8eec9ba_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63aa112e385a4b169e514d953a28f982_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6aad501cb7243e887c49fac7690b6ca_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1eb92833ae9435a9ecf1d355bbcb009_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e8639429a9c49ba9041fee399c2357f_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf45bc62b484e8483fd1b35bcdd3bbd_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1807decbe80497fafb382a9fabc9899_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9797eb88784347c2ba91f649e7a89035_D20211119-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47f4eb49ec8441a9b58dbd98a28a2201_D20190409-20190409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-09</xbrli:startDate><xbrli:endDate>2019-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic017681e6bcd4a53adcb05dba9e3ceea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementofRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36eb9081f8f347b192a76fc04c03d19e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementofRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ebc2eb0427e4bb0850c72962f7e29e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementofRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3ab2a481794a02a175b6f16b61f237_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c2512b823f4ff3b209636ae4dcafac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eb5b42525974ef7a5b153a0d9d0073d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9863c66e56824ed29ccd21bb3ceabb02_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90f8785504d43449257cd196f4121b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i226f17bf85d347659a1ecbbcad647fc7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237836ce0fbe43459715133f0ac3bbcb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77820b7ad1054da597cf88e94c1572ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a8c9c388f348728c52ecd109ff1575_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dcb927188d04ed7a4fc660309e24cb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b2e96dbe6ff49688146016bf2c6b677_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a79447216ec4d1fbb7c60937d2de629_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i379f934d2a6348d0aa120e522eb186cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="location"><xbrli:measure>pcrx:location</xbrli:measure></xbrli:unit><xbrli:context id="ib93d52bc0a2448159425d955a92ad1b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:SkyePharmaHoldingIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5476241970e4bc8a69aaac752a07c87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponFirstCommercialSaleInMajorEUCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponAnnualNetSalesReachingDollar500.0MillionThresholdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616ccf441438422f96ae7988c62ac2d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0432a62d54346d4b0cc4ae20df8f3ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50f0a34fc053410586063c1b4fb4c582_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ae07bdfce9402a9e491efa689e082a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i893f93318f184b3b845f1b842931685c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied35346c8e384819b7401a314ca21029_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b03b72e8eb425dac2c21da48a1406e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9117c0cf9ab9426eb1181bbfdab3c069_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aa9720883ec4f3787f93c48c11dae98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02d7f7d8ef346e095ed28b213a41443_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i029b2fd1da9b426aa281eb6edf9c4164_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied606e7f1e9940e3acdfe0b049aa4169_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a522e9d6934acc9765ff247056057b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDueMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i438cb9109aec4c73bc3f0bbdd10be313_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDueMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531cf89254884fafb25ee2779d786c28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDueMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50f3b14c8eb24f87b8db39c9626146de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib156d0fef78446749f347f5513f5ceb7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca63f94b05a4f70aa9157c96a600b08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693f123fe4684339ab826c50fedd6ad7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i948cac0513e648dca715d8b2e62ccb32_I20211207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9859fe995b1b42efbfc4b581a85bb092_D20211207-20211207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-07</xbrli:startDate><xbrli:endDate>2021-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae2b3e809f41477ea25d6594d89a6967_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia39c7c0a086e4f0b8a4d0984865174c0_D20251231-20251231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-31</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad5e620d8a44d559404a2918c7529ee_I20261207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf747e09ae34640bae22f200d713217_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>pcrx:payment</xbrli:measure></xbrli:unit><xbrli:context id="i3c7058bed2db4a56b3c7e5e12b92460d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7747ee53e646437988e64e05cfd00fdd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3552408c5bb444cbf0eb6a3ab86a409_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88770a0f88374817ab71722879f70098_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a422b889ef4dc5a23b911b3aeae411_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ecb39da69d4d29a362f012fbbd432c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">pcrx:FederalReserveBankOfNYRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaccaba05dfea42d581595525b0cc244f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia017c092a2784b0ca8aab079c9e5fc54_I20200710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40835215f27548ddb0046f269d3d2d44_D20170313-20170313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-13</xbrli:startDate><xbrli:endDate>2017-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie208910c77e8415fa39a49e9cb6b2e10_I20200710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcab94fdef344be8b8d6fd587edd7388_D20200710-20200710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-10</xbrli:startDate><xbrli:endDate>2020-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i159db211f8284627a7227966896882fc_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i098824f172bb410fbf000b0dcf738b96_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide059616fdda44779b287a0527e1ddb3_I20200707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd176f4fa004e9e999ce2a50dcb9adb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtRedemptionTermsOnOrAfterAugust12023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i051d7dc66a2540279e60e320f1d3037d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad983f5646e34e94a2da8681ed807b5d_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a977c4be98547f98b6c05154f959739_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd1e05a128ed42ccac04aeee92248fef_D20211206-20220106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-06</xbrli:startDate><xbrli:endDate>2022-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43427f256a794c4db525f11b824c9893_I20220107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce055e93fcd43c293a47474e350a43f_I20220107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDueMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7bf6b02068a41e8a7ed404d1082e6b2_D20170313-20170313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-13</xbrli:startDate><xbrli:endDate>2017-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0533c1098374121979b41de75d1de0b_I20170313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb73217f94c444aa76dcd2a69b80870_D20170313-20170313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-13</xbrli:startDate><xbrli:endDate>2017-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib19dbd6e7ef04ec58b328d34732c899d_I20170313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icadb10d36c46455daf4bbf36c85eb041_I20170307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6d5ff5d3bd44ee1aeb5e1d291f7b120_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtRedemptionTermsonorafterApril12020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-13</xbrli:startDate><xbrli:endDate>2017-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-13</xbrli:startDate><xbrli:endDate>2017-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65dfbd8ff8d7419f9e7bcef5200f53b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292dc4ba96214be2a65fdd56033cc528_I20211206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1a4dffa829749ac815dd4fff21096ef_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie577d6c271bb4749abe1c1aa7b73462a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552e4370c49c488aaf644acf28100abb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01558abfceb343c1997fa09cb38e955a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib13ef9c89d3842a090b30092159c6baa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i833dd50b748e4f648ce8fbdc883c4185_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c6e342295e24ffeb5b662e536f55798_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47b1b32def64bc0a3609d407c471b13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia547c4173aba4e05a06d562cb5145105_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7d1ef1836341deb53748bf79ee7540_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife6537b40fcd40ed8ef4f547088d8dd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59aef1e9bd7c4844a54073f163e8a93d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12a42225481b4c039ba48e07565653d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if31bdc45af904ee791953adb58a89ea7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2492fc03ca40809334ee540cedfd2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i877fef10b449448bb4a9b1ae0125a699_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73430b1c7b5c48378305535b3e6241c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied69c02578864bbc9cb25cd5c9b8b3ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb164609df064575b1b1a48271b62b19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46eb669c6b164a9e8a7ea3de4a9b62c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b76248be1d04ab7999d2ad496cd6c18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec8af6ae83c4cc5bb12c9babddf9666_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9513fc7cbbc24c9e8fd0a64ddc87b87a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib73e9b252a7f4625a0d9d5c279a031a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAndMyoscienceAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0b1b1bfd3a47be9e86153acff8ab26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAndMyoscienceAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79da6badc4ce4c8b87bad102f47d53f7_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd6c594f1a8d4d8198e32bc0c6d23237_D20211119-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d56f0f495b24f6292ed813d0fcfc838_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i596b14391d784004ad234ae361b60952_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e8a2f34478940948a4fc588e36055b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i688afa6b83624546a44f01cdc4648f16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iead150b687d149c184bc55655b3b10d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb7c445d56a64eec9a36a2231a41ca72_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df54267e2fb4ca08078fb42498c07b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed6c7cb25774dc791f211ce4f75f33a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide37340a89bb45a5b51beeb5442b41a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27fc0a4268ea499a866f36779e8349ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i453db66839f342d1b1291f445f8934ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a617a44b744a1596fff6fde2d5e5bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc9c5bceef24a519258f36b731eed51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7f2bb5426e04cc795ae3e950506e652_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id05c5a2e9e2a4674adef676d95ad516e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc6c788ace5a4a8fb5b0dde94e57c31f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6b31f4d2144d96b895a72c1ba86cb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i738a868b4ee144f2a08a48f1517a777b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8f291f33e434735b4f02c49878fd653_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:CodaBioTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d3e7bf6be84c83bf7d2041a67fdae2_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pcrx:SpineBioPharmaLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ec4a3b4cc1240d59d30b940f203ee7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:TELABioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb990da9e674a18bd073cb528fb1809_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:TELABioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i157d8e808cd54ff090acb94b024df9d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:TELABioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if556affba80d4a378bf1f3922edc8edf_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:GenascenceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie89711155ad84669abf871469c5aeeb0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b8974e2c7e4284b062762071958be9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d3af74affd441a79ce03b62daff7be3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a4df30aaf1c498ba552279f52d650f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b2394034c140f6a4694ff381035b4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ec2f1d36a341c69f0baa5aa111d33a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i396fdd45737f4f0b9bed95c0ddbc0622_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7a7512ce0f40b38a5bd571e54d9751_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d1942e618045a69aca1ec725725e2e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1b427d124e645ad81dfc92d5d66b207_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i268f623dedfe45ef8b32af260bc0891d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic646097fbe734ac9b8fd68d466e50d82_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e8c703d659b483fba7961601663c1bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0434aab27f55421b84d92aaa462e4576_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9491f3f75e24aaeb616d1274815af74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38819c0324594ec1b66a4ffa3fcf3f56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2612fd9b7b754b8cbaeace3e57620704_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b80643a294b465ea2661625af1ab96f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie41ce2db25d34febb04acbf253c2bfcd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e72dd91549146e4b77f296c7d373601_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f5d2774f94c4c19a034c9d35c8cf659_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3a1799953e4b7a9a6fe4c6d61c6c82_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74c8757d0944c88a8cd93d9a4b8cf53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:StockIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc17ef4c747949b48269bf0b8a76060c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:StockIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a5d9635bc2e455f8966f9f3b2bb58fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99a2df6ef1594ed0900053be4381bced_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i744090d10596403bb55779bf5925f19e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:EmployeeStockPurchasePlanESPP2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6806d31d7c914f92a84099b441fe66bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:EmployeeStockPurchasePlanESPP2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7da9c9dd8294201950b3c55f7f72c5e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ef046de56d45b6a564367b687cd904_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f8cb56d1ea45d9b5ddb5495a729cee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa85351b13540518354d61849bb9f7d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c86356bbbe45f6bfe831911514b73d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e8fd43a94a74dafbc22852d9e58719c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f91b2bb657745cc992ed2a4e6446bd4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddb7c0b3d882467292232e9502359bf3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i432c6966dd144c3991144693194ff39e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd01dc35d06044bb97b415c6c22acd17_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13fcb2c445c04b488b8969b4514b4362_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice16f3771e3e4ef983ae97345cb147d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917c4f0133de471d87fe63c0cf97feec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida3a6c4fe85b491991fb0aa639cee538_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca373b6b867452b83d716b6422dc258_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1c7481893dd4af497518d21d834ab65_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfa96bfa146c401bafdd7c90c8ba2c6e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib38eaa600b8e42a9851a181401b7e23e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8686eb39d5c4df494e9414f7b85eb73_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d0fc32d88804baaab656363bb728911_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c23ac5a7584fcfbb011f898d04aa74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab19655e67644e4a974aac9a1311b637_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefedf24a9a184d26b9444aa1d2768efd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddd1835957aa4542b486125e347c2dff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6be8009e772e4e3ba8f05b461e089043_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:ConversionPremiumOn2022NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id414a99ec0d0409883eb8b2bdee4eb13_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a963ed83400446a9515a4a04cf232b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a7bb9e5e6343258f6bed68cd00465f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1826d05ddc2f4352b6b5b4681a620e28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e541832bfb246b2a8efc0f7289d4bd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib770abe7bb5740aab0aa7d6eab698b4a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654e613b80f445abb2eaf1e762ad8cd3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c2116fd2ce647d29354014822fa3386_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ccac5f6e0624be1b654c50898619041_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia52e5d1054ac4b44a90054d80c6509a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f9b7c2524840cca0b7ffd47db88684_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4141a4b22784eb593c98bb5aca5ba58_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if331b6039ef04e5f968fc0addfc10181_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i119369de4e404fe3857119778cfab5ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f5ba37ffe97491eaff119eb51ec361a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc3b655165947618391e9bed60d7390_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82f093ad3c8b4abb848c3099f207cc6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9b29e19572b4bbaa5c8f9cdba9c2d35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cb2b41bd3004482921ace6f9b9f7baa_I20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5bb0c9c97f24e95b1c6936b67f583e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1346b922bbbc489fa1c57f1775c4d743_I20251231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifda9345b7dc64e9cbe52d2c5cb3bfc6d_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9893ef209dd044118e3a2ae603b1bb78_I20261231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i890f49a134e34776a700270d248f7c7d_I20271231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2027-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f2c982cd5b4bb8a9925e4a655e2c4b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d452fa4ecb406494b3046bb05e2386_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">pcrx:ForeignNetDeferredTaxAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14837e0e58ba4784b70f1121737d5625_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133d2578be2a4e5082559c610543604b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pcrx:AcquisitionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe2ba44a6d94addb0eb76d116d51d55_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pcrx:AcquisitionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i572235a599364bd3ade9416211dca6cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pcrx:AcquisitionRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b2886444d644925b435f39f13c30af4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i308c4a2c1d0642d5a4d9505955982379_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c466ffc9152473caa0acde1e894a6ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce4e7bdc7aa4d8ab4e06a6aa84c37ad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3233de79e7a2425eb18155c86074f1e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:NuanceBiotechCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3578ef27098d49db9276c9f493f654da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:NuanceBiotechCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9541d5a561504d64b4e108f280a3faa5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:NuanceBiotechCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8de97bb7b224ffbaf4d4572322a126e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:DepoCyteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia33a2f9e6ae84d97990e9334c7002dac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:DepoCyteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ae7b32599b43238324567b6549cb9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:DepoCyteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i130fb5352c624061a38b0f4e0e96ed76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pcrx:LegalFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i866ca805578348a1a7b549671e9b226d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pcrx:AdvisoryCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c5f7765b4224a9a8bd7a15b9a2f9b85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pcrx:SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id747d21ec2fe432ca5314f7a469d8620_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:NuanceBiotechCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dbbded270634aa69782055b700085d7_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:EurofarmaLabatoriesSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5b01a051b66415ba958a05fbf10d319_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:EurofarmaLabatoriesSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe450ec25c44c338992024884646e70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pcrx:CoPromotionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:DePuySynthesSalesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cda3779624d47cca8d9a4fd84dbdcdc_I20121205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:AratanaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45f29cdfecdd48d8b8c24cf61151d641_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:AratanaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib670284875d746c498df6bb492cd4f90_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:HongKongPharmaTainuoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id496bf8b482742cfbd9725d700e95fab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:HongKongPharmaTainuoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9733ef5993044559a5405d6f38d59438_D20120401-20120430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pcrx:FirstPriceOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-04-01</xbrli:startDate><xbrli:endDate>2012-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5828f75d0ba48dbb5d995070ffaf73a_D20120401-20120430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pcrx:SecondPriceOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-04-01</xbrli:startDate><xbrli:endDate>2012-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba035b436915468c957402bf102c1460_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:FortisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b894792258e44c8853a730b680cff6c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b28091853f41199ae71d31aea5bf87_I20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia16d04ef54124f998b23dcd9e5efc8ce_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:XenonPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a74aaba5c5b4ccaa7925c2b5333a951_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:XenonPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfSalesRelatedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2728c786372940b3a47b33099bff7244_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b7f38fb2f94964a96e1740885b526e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001396814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i284a0cec603b490382d0f8422359e7e8_1"></div><div style="min-height:31.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.109%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF84Nw_f30ef2b5-c55b-4cd3-8573-e40ba65b14fe">10-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.109%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:16pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6ODM0MDI3ZjM0MDgxNGQ2ZmJhYzliYzEwMDYyMGNmNmMvdGFibGVyYW5nZTo4MzQwMjdmMzQwODE0ZDZmYmFjOWJjMTAwNjIwY2Y2Y18xLTAtMS0xLTA_f0af5d7e-288d-4755-b4c1-28319eb6abfa">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Fiscal Year Ended: <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8xMjQ_7e924e2c-1858-4897-8f1b-f523258606cf"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8xMjQ_cfe32fdf-3b9c-4467-84fe-95bba38e6f82">December 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Or</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:16pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6NDMwZWZjOTEzYjA3NGRlZWFlOWU0NTBhNmUxYzI3ZWQvdGFibGVyYW5nZTo0MzBlZmM5MTNiMDc0ZGVlYWU5ZTQ1MGE2ZTFjMjdlZF8wLTAtMS0xLTA_110bf69a-28de-4ef9-bbfa-c26a1136f88d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160; to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8yMDE_d41b5ec2-9b94-4f4c-9fdd-c13a7e3ff983">001-35060</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="pcrx-20211231_g1.jpg" alt="pcrx-20211231_g1.jpg" style="height:78px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8yMDk_e3d3196c-e940-4dfb-834c-06be3881acc3">PACIRA BIOSCIENCES,&#160;INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.459%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl8wLTAtMS0xLTA_2152db2f-2acf-4f15-b385-475ebee7c3c9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl8wLTEtMS0xLTA_11b38465-9890-407f-82cc-2a6d3ed50fd3">51-0619477</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>&#160;Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl8zLTAtMS0xLTA_2410ccf1-2e00-4004-a289-0ee8bdd579f1">5401 West Kennedy Boulevard, Suite 890</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl80LTAtMS0xLTA_f9d3b769-3ef2-4b08-97fd-da8c35948a1f">Tampa,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl80LTEtMS0xLTA_9f95a823-8617-4f2a-a957-5e763a831ae9">Florida</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl81LTAtMS0xLTA_79a93b57-2dcd-40fa-913e-7dc45016314e">33609</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address and Zip Code of Principal Executive Offices)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl84LTAtMS0xLTA_81952df8-be47-4a78-9468-b7fb6b1d0e39">(813)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl84LTEtMS0xLTA_eed13a66-ce17-4f0e-b462-2355bc42badb">553-6680</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s Telephone Number,&#160;Including Area Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YmJiOGEwYjRhYzdlNDFmMjllYmExYzQ4NzBkMzE4NDEvdGFibGVyYW5nZTpiYmI4YTBiNGFjN2U0MWYyOWViYTFjNDg3MGQzMTg0MV8xLTAtMS0xLTA_59c8a938-fa36-4aad-acef-8f114e40f591">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YmJiOGEwYjRhYzdlNDFmMjllYmExYzQ4NzBkMzE4NDEvdGFibGVyYW5nZTpiYmI4YTBiNGFjN2U0MWYyOWViYTFjNDg3MGQzMTg0MV8xLTItMS0xLTA_f9c73ade-b183-4ce0-b2a4-0d1f5d866bc2">PCRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YmJiOGEwYjRhYzdlNDFmMjllYmExYzQ4NzBkMzE4NDEvdGFibGVyYW5nZTpiYmI4YTBiNGFjN2U0MWYyOWViYTFjNDg3MGQzMTg0MV8xLTQtMS0xLTA_6522ca42-5423-4d13-a86d-87fdf16aa201">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF81MjU_e609718e-89f7-45e8-8a1e-b51041bf60a9">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF82NzI_cb7b5038-26b6-45d2-a26a-fbbb35f5f61e">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8xMDIx_774ffd4a-2775-4d9c-8993-a45f533d6399">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8xMzQz_9e8e2b1e-d2e7-453a-a205-c38c3dfcfe53">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.862%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6MmNjZDk4M2FlZWVkNGJkM2JmNGM3MzZhYzllMmQ2YWMvdGFibGVyYW5nZToyY2NkOTgzYWVlZWQ0YmQzYmY0YzczNmFjOWUyZDZhY18wLTAtMS0xLTA_e3601c90-a9b8-4aeb-8dac-e4de1efa4530">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6MmNjZDk4M2FlZWVkNGJkM2JmNGM3MzZhYzllMmQ2YWMvdGFibGVyYW5nZToyY2NkOTgzYWVlZWQ0YmQzYmY0YzczNmFjOWUyZDZhY18xLTMtMS0xLTA_4c42f9b6-225a-48ca-80e2-0213929e9361">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6MmNjZDk4M2FlZWVkNGJkM2JmNGM3MzZhYzllMmQ2YWMvdGFibGVyYW5nZToyY2NkOTgzYWVlZWQ0YmQzYmY0YzczNmFjOWUyZDZhY18yLTMtMS0xLTA_4196e8fd-6e7b-4dbe-9608-553ea2700e1f">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8zNjE0_9e1999ae-2c66-4a5e-a3fb-0cfab5f466dd">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8yNDE3_daa6b485-6cfc-4ecf-8944-03740998caa3">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s voting stock held by non-affiliates of the registrant, based upon the closing sale price of the common stock as reported on the Nasdaq Global Select Market on June&#160;30, 2021, the last trading day of the registrant&#8217;s most recently completed second fiscal quarter, of $60.68 per share was approximately $<ix:nonFraction unitRef="usd" contextRef="ib9f5b792563940c3a6ac3952c900baba_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8yNzc1_a9d0957a-7050-43cd-bfde-3b1e8c836810">1.6</ix:nonFraction> billion. Shares of common stock held by each director and executive officer (and their respective affiliates) and by each person who owns 10&#160;percent or more of the outstanding common stock or who is otherwise believed by the registrant to be in a control position have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;27, 2022, <ix:nonFraction unitRef="shares" contextRef="ib74a5ff7f32a4742bb95a41a5c1e0be2_I20220227" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8zMTg0_b256871d-ec7c-4887-b2a6-f92e12fe4b49">44,847,728</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.001 par value per share, were outstanding.</span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8zODQ4MjkwNzAxNjMx_33ffc948-14b1-4ee9-b00f-e1a56e05fcdf" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;III of this Annual Report on Form&#160;10-K incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission no later than 120&#160;days after the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021.</span></div></ix:nonNumeric><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_2125"></div><hr style="page-break-after:always"/><div style="min-height:31.43pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This risk factor summary includes those risks most material to our business, financial condition, results of operations or prospects. A full discussion of the risks outlined in this summary, as well as those risks not outlined below, appear in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_16">Part I, Item 1A. </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_16">Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this Annual Report.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our success depends primarily on our ability to successfully commercialize EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bupivacaine liposome injectable suspension) and ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(triamcinolone acetonide extended-release injectable suspension).</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our efforts to successfully commercialize EXPAREL and ZILRETTA are subject to many internal and external challenges.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That the commercial success of our products may be severely hindered if we are unable to achieve and maintain adequate levels of third-party payer coverage and reimbursement for the products we offer, on reasonable pricing terms.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The significant competition we face from other pharmaceutical, medical device and biotechnology companies. </span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The regulatory approval for any approved product being limited to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and risks related to allegations of our failure to comply with such approved indications.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    If we are unable to establish and maintain effective marketing and sales capabilities or enter into agreements with third parties to market and sell our products.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our reliance on third parties to perform many essential services for EXPAREL, ZILRETTA and iovera&#176;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the fact that we will rely on third parties for any other products that we commercialize. </span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That we may need to increase the size of our organization and effectively manage our sales force, and we may experience difficulties in managing such growth.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our inability to manage our business effectively if we are unable to attract and retain key personnel.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The potential product liability exposure we may face.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our failure to manufacture our products in sufficient quantities and at acceptable quality and pricing levels, or to fully comply with CGMP (as defined below).</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That we may need to expand our manufacturing operations or outsource such operations to third parties.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our inability to continue manufacturing adequate supplies of our products.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That our co-production and other agreements with Thermo Fisher (as defined below) may involve unanticipated expenses and delays.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our reliance on third parties for the timely supply of specified raw materials and equipment for the manufacture of EXPAREL, ZILRETTA and iovera&#176;.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That our future growth depends on our ability to identify, develop, acquire or in-license products.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That we make substantial investments in research and development and if those investments are unsuccessful, it could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The use of hazardous materials in our business and that we must comply with environmental laws and regulations.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The risk of system failures.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That any collaboration arrangements that we may enter into in the future may not be successful.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The expense, length and uncertain outcomes of our trials and if our trials fail to demonstrate the safety and efficacy of our drug products or medical devices, it could prevent or significantly delay obtaining regulatory approvals.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our dependence on contract research organizations.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our dependence on clinical investigators and clinical sites to enroll patients in our clinical trials and sometimes other third parties to manage the trials and to perform related data collection and analysis.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Guidelines and recommendations published by various organizations could reduce the demand for or use of our products.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Periodic litigation, which could result in losses or unexpected expense of time and resources. </span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    If a regulatory or enforcement agency determines that we are promoting or have in the past promoted the &#8220;off-label&#8221; use of our products.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That we may not receive regulatory approval for any of our product candidates, or the approval may be delayed for various reasons.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The regulatory clearance process, which may result in substantial delays, unexpected or additional costs and other unforeseen factors and limitations on the types and uses of products we would be able to commercialize.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That a regulatory authority may determine that our products or any of our product candidates have undesirable side effects.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The substantial penalties we could face if we do not comply with federal, state and foreign laws and regulations relating to the healthcare business.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The highly regulated and technically complex design, development, manufacture, supply and distribution of our products.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our failure to comply with the extensive regulatory requirements to which we and our products are subject.</span></div><div style="height:31.43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.43pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    If the government or third-party payers fail to provide adequate coverage and payment rates for EXPAREL, ZILRETTA, iovera&#176; or any future products, or if hospitals or ASCs (as defined below) choose to use therapies that are less expensive.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Public concern regarding the safety of drug products such as EXPAREL and ZILRETTA and medical device products such as iovera&#176;.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That the patents and the patent applications that we have covering our pMVL (as defined below) products are limited to specific injectable formulations, processes and uses of drugs encapsulated in our pMVL drug delivery technology and our market opportunity for our product candidates may be limited by the lack of patent protection for the active ingredient itself and other formulations and delivery technology and systems that may be developed by competitors.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That the patents and the patent applications that we have covering iovera&#176; are primarily limited to specific handheld cryogenic needle devices that are cooled by a cryogen and methods for applying cryotherapy to nerve tissue using the cryogenic devices. </span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our inability ensure the protection of our proprietary rights and that all patents will eventually expire.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    If we are sued for infringing intellectual property rights of third parties.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That we may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Servicing our indebtedness, which requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial indebtedness.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That our Credit Agreement and the Indentures (each as defined below) each impose significant operating and financial restrictions on us and certain of our subsidiaries, which may prevent us from capitalizing on business opportunities. </span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That we may not have the ability to raise the funds necessary to settle conversions of the Notes (as defined below) in cash to the extent elected or to repurchase the Notes upon a fundamental change, and our future indebtedness may contain limitations on our ability to pay cash upon conversion of the Notes or limitations on our ability to repurchase the Notes.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That our indebtedness could adversely affect our business, financial condition, and results of operations, as well as the ability to meet payment obligations under our Credit Agreement and the Notes.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The risk that despite our current level of indebtedness, we may be able to incur substantially more debt.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The provisions of our charter documents and Delaware law that may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That our common stock price may be subject to significant fluctuations and volatility.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our intention to not pay dividends on our common stock for the foreseeable future.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That future sales in the public market or issuances of our common stock could lower the market price for our common stock.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That raising additional funds by issuing securities would cause dilution to existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    A pandemic, epidemic or outbreak of a contagious disease (such as the novel coronavirus (COVID-19) pandemic), or fear of such an event.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our failure to maintain the privacy and security of personal and business information.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That we may face risks related to environmental, social and corporate governance, or ESG, issues.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The significant losses we have incurred since our inception and that we may incur additional losses in the future.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    That we may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The potential significant fluctuations in our quarterly operating results.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our inability to successfully integrate the businesses and personnel of acquired companies and businesses, and inability to realize the anticipated synergies and benefits of such acquisitions.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our inability to realize the benefits from the Flexion Acquisition (as defined below) being substantially dependent on the commercial success of ZILRETTA and the cost savings resulting from the timely and effective integration of the operations of Pacira and Flexion (as defined below).</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    The use of our net operating loss carryforwards and research and development tax credits being limited.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Changes in data privacy and protection laws and regulations, particularly in Europe and the State of California.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Risks related to cybersecurity threats and incidents.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Significant changes in the global climate, extreme weather conditions and water availability.</span></div><div style="margin-bottom:1.5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;    Our international operations, which expose us to numerous and sometimes conflicting legal and regulatory requirements.</span></div><div style="height:31.43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 2</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_7"></div><hr style="page-break-after:always"/><div style="min-height:31.43pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOR THE YEAR ENDED DECEMBER 31, 2021</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page #</span></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_10">PART I</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:0 1pt"></td><td colspan="3" style="background-color:#f9f9f9;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_10">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_13">Item&#160;1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_13">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_16">Item&#160;1A.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_16">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_16">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_19">Item&#160;1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_19">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_22">Item&#160;2.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_22">Properties</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_22">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_25">Item&#160;3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_25">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_25">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_28">Item&#160;4.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_28">66</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_31">PART II</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:0 1pt"></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_31">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_34">Item&#160;5.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_34">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_37">Item&#160;6.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_37">Reserved</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_37">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_40">Item&#160;7.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_40">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_70">Item&#160;7A.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_70">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_70">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_73">Item&#160;8.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_73">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_73">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_76">Item&#160;9.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_76">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_76">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_79">Item&#160;9A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_79">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_79">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_82">Item&#160;9B.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_82">Other Information</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_82">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_2087">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_2087">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_2087">83</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#f9f9f9;padding:0 1pt"></td><td colspan="3" style="background-color:#f9f9f9;padding:0 1pt"></td><td colspan="3" style="background-color:#f9f9f9;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_85">PART III</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_85">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_88">Item&#160;10.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_88">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_88">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_91">Item&#160;11.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_91">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_91">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_94">Item&#160;12.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_94">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_94">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_97">Item&#160;13.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_97">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_97">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_100">Item&#160;14.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_100">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_100">83</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_103">PART IV</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:0 1pt"></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_103">84</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_106">Item&#160;15.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_106">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_106">84</a></span></div></td></tr><tr><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_112">Item 16.</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_112">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_112">87</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:31.43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.43pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K (the &#8220;Annual Report&#8221;) and certain other communications made by us contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the Flexion Acquisition (as defined below) and the costs and benefits thereof, our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, anticipated product portfolio, development programs, patent terms, development of products, strategic alliances and intellectual property. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We often use the words &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;can&#8221; and similar expressions to help identify forward-looking statements. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks related to future opportunities and plans for Flexion and its products, including uncertainty of the expected financial performance of Flexion and its products; the possibility that if we do not achieve the perceived benefits of the Flexion Acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of our shares could decline; the impact of the COVID-19 pandemic on elective surgeries, our manufacturing and supply chain, global and United States, or U.S., economic conditions; and our business, including our revenues, financial condition and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bupivacaine liposome injectable suspension), iovera&#176;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide extended-release injectable suspension) the rate and degree of market acceptance of EXPAREL, ZILRETTA and  iovera&#176;; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera&#176; and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera&#176; to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera&#176;; the commercial success of EXPAREL, ZILRETTA and iovera&#176;; the related timing and success of United States Food and Drug Administration, or FDA, supplemental New Drug Applications, or sNDAs, and premarket notification 510(k)s; the related timing and success of European Medicines Agency, or EMA, Marketing Authorization Applications, or MAA; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome, or pMVL, drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities and our ability to successfully construct an additional EXPAREL manufacturing suite in San Diego, California; the outcome of any litigation; the ability to successfully integrate Flexion or any future acquisitions into our existing business; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; and factors discussed in Part I-Item 1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the forward-looking statements included in this Annual Report represent our views as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on the forward-looking statements as representing our views as of any date subsequent to the date of the filing of this Annual Report.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in Part I-Item 1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:31.43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 4</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:center"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_13"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Business</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">References</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira BioSciences,&#160;Inc., a Delaware corporation, is the holding company for our California operating subsidiary named Pacira Pharmaceuticals, Inc. In March 2007, we acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings,&#160;Inc. (now a subsidiary of Vectura Group plc), or Skyepharma (referred to herein as the &#8220;Skyepharma Acquisition&#8221;). In April 2019, we acquired MyoScience, a privately held medical technology company (referred to herein as the &#8220;MyoScience Acquisition&#8221;) and in November 2021, we acquired Flexion Therapeutics, Inc., a publicly traded biopharmaceutical company (referred to herein as the &#8220;Flexion Acquisition&#8221;). Unless the context requires otherwise, references to &#8220;Pacira,&#8221; &#8220;we,&#8221; the &#8220;Company,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this Annual Report refers to Pacira BioSciences,&#160;Inc., a Delaware corporation, and its subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware under the name Blue Acquisition Corp. in December 2006 and changed our name to Pacira,&#160;Inc. in June 2007. In October 2010, we changed our name to Pacira Pharmaceuticals,&#160;Inc. and in April 2019, we changed our name to Pacira BioSciences, Inc. Our principal executive offices are located in Tampa, Florida.</span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks and Service Marks</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, iovera&#176;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Pacira logo and other trademarks or service marks of Pacira appearing in this Annual Report are the property of Pacira, and when first used in each part of this report, include the &#174; symbol.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains additional trade names, trademarks and service marks of other companies, which may or may not appear with the &#174; or &#8482; symbol. The absence of these symbols does not in any way imply that the respective owner(s) will not assert their rights to such marks to the fullest extent under applicable law. Our use of trademarks or trade names of other companies should not suggest any endorsement, sponsorship or other relationship with or by such companies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the industry leader in our commitment to non-opioid pain management and providing a non-opioid option to as many patients as possible to redefine the role of opioids as a rescue therapy only. We are advancing a pipeline of unique, safe, best-in-class products across a variety of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis, or OA, pain of the knee; low back and other areas; spasticity and stellate ganglion block of the sympathetic nerves. We have three commercialized non-opioid treatments: EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bupivacaine liposome injectable suspension), a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and iovera&#176;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Flexion Acquisition</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, we completed the Flexion Acquisition pursuant to an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated as of October 11, 2021, by and among us, Oyster Acquisition Company Inc., a Delaware corporation and wholly owned subsidiary of Pacira (&#8220;Purchaser&#8221;), and Flexion Therapeutics, Inc., a Delaware corporation (&#8220;Flexion&#8221;). Following the completion of a successful tender offer for the shares of Flexion&#8217;s common stock, and pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, Purchaser merged with and into Flexion with Flexion surviving as a wholly owned subsidiary of Pacira. We changed the name of Flexion to Pacira Therapeutics, Inc. after completing the merger. As part of the Flexion Acquisition, we acquired ZILRETTA, the first and only extended-release, intra-articular, or IA (meaning in the joint), injection indicated for the management of OA knee pain. ZILRETTA is a non-opioid therapy that employs a proprietary microsphere technology to provide pain relief. The addition of ZILRETTA to our innovative non-opioid product portfolio directly aligns with our mission to provide an opioid alternative to as many patients as possible and address medical needs along the neural pain pathway.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration for the Acquisition was approximately $578.8&#160;million consisting of (i) $448.5 million of cash paid to Flexion shareholders and to settle restricted stock units and certain stock options; (ii) an $85.1 million cash payment of Flexion debt not to be assumed by us and (iii) $45.2&#160;million of estimated fair value of contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders in conjunction with the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexion Acquisition. The consideration is subject to adjustments based on the estimated fair value of the potential milestone payments. We funded the cash portion of the purchase price with cash on hand. For more information, see Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve our goal of global leadership in non-opioid pain management and regenerative health solutions, we are advancing a three-pronged strategy: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Expanding the use of our opioid-free commercial assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The COVID pandemic and opioid crises have intensified the need for opioid alternatives. In the U.S., EXPAREL is the only opioid-free, long-acting local and regional analgesic approved for infiltration, field blocks and interscalene brachial plexus nerve block to produce local or regional postsurgical analgesia. EXPAREL is also approved for infiltration in pediatric patients aged six years and older in the U.S. In Europe, EXPAREL is approved as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults. Anesthesia-driven postsurgical management with long-acting field and nerve blocks utilizing EXPAREL are enabling the migration of complex, painful surgeries to outpatient sites of care. ZILRETTA is the first and only extended-release, intra-articular therapy that can provide major relief for OA knee pain for three months and has the potential to become an alternative to hyaluronic acid, or HA, and platelet rich plasma, or PRP, injections or other early intervention treatments. With the iovera&#176; system, healthcare providers can replace narcotics and radiofrequency ablation with an innovative drug-free nerve block. We believe the iovera&#176; system is also highly complementary to ZILRETTA. In addition to our current commercial opportunities, we are advancing label expansion activities. For EXPAREL, we are advancing two Phase 3 studies in lower extremity nerve block procedures, as well as a development program for pediatric patients under six years of age. For ZILRETTA, we plan to initiate a Phase 3 study in shoulder OA and we are defining label expansion studies to include safety superiority in patients with Type 2 diabetes and repeat dosing for OA knee pain. For iovera&#176;, we are developing new iovera&#176; Smart Tips for chronic lower back pain and spine procedures. We are also advancing plans to develop iovera&#176; as a treatment for spasticity.</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Advancing our clinical-stage pipeline within multiple areas of unmet need.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are advancing our pipeline of clinical-stage assets that utilize our proprietary multivesicular liposome (pMVL) technology. The pMVL carrier matrix consists of microscopic, spherical, lipid-based particles composed of a honeycomb of numerous, non-concentric, internal aqueous chambers containing the encapsulated active agent. Each chamber is separated from adjacent chambers by lipid membranes. Following injection, the pMVL particles release the active agent over an extended period as the lipid membranes erode or reorganize. We are preparing to launch a Phase 2 study of Dexamethosone-pMVL for low back pain (&#8220;PCRX-401&#8221;), a Phase 2 study of high-dose bupivacaine-pMVL for five or more days of pain relief (&#8220;PCRX-501&#8221;), and a Phase 2 study of low-dose bupivacaine-pMVL for epidural analgesia. </span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Accessing complementary innovative assets using a combination of strategic investment, in-licensing, or acquisition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe EXPAREL, ZILRETTA, iovera&#176; and our pMVL drug delivery technology offer a strong foundation to address the opioid epidemic. Building on these proprietary assets, we have also made investments in the musculoskeletal and chronic pain spaces. We plan to continue to advance these two key areas with a focus on the knee and spine continuums of care and chronic pain. We are using a combination of strategic investments to support promising early stage platforms, as well as in-licensing or acquisition transactions to build-out a pipeline of innovation to improve patients&#8217; journeys along the neural pain pathway.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Opioid Epidemic</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opioid addiction in the U.S. has reached epidemic proportions, with the U.S. Centers for Disease Control and Prevention, or CDC, reporting that overdose deaths rose by 29 percent to an unprecedented amount of more than 100,000 in the U.S. in the 12-months ending April 2021. This represents a worsening of the drug overdose epidemic in the U.S. and is the largest number of drug overdoses for a 12-month period ever recorded. The recent increase in drug overdose mortality began in 2019 and continued into 2020, prior to the declaration of the COVID-19 National Emergency in the U.S. The increases in drug overdose deaths appear to have accelerated during the COVID-19 pandemic. Synthetic opioids are the primary driver of the increases in overdose deaths, with deaths from synthetic opioids and psychostimulants also increasing in the 12-months ending April 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, new research showed that patients received nearly 100 to 200 opioid pills to help manage pain from four common procedures ranging from rotator cuff repair and hip replacement to knee replacement and sleeve gastrectomy. Further, one-quarter of orthopedic surgery patients were prescribed a daily dose of opioids equal to 90 milligrams of morphine or more, which are doses so potent that the CDC says they put patients at high risk for overdose. A 2017 report shows that across the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seven orthopedic and soft tissue surgical procedures examined, patients were prescribed an average of 82 opioid pills each to help manage postsurgical pain. The research also indicates that close to nine percent of surgical patients became newly persistent users in 2017, continuing to take these opioids at least three to six months after their procedure. Among patients having knee replacement surgery or a colectomy, newly persistent opioid users climbed as high as 15 percent and 17 percent, respectively. Further, women were 40 percent more likely to become persistent opioid users than men; and among persistent users, females were prescribed 15 percent more opioids than their male counterparts. These findings come from the report, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States for Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on an analysis of 2016 adjudicated medical and pharmacy claims data conducted by QuintilesIMS.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Portfolio and Product Candidate Pipeline</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current product portfolio and product candidate pipeline, along with anticipated milestones over the next 12 to 18 months, are summarized in the table below:</span></div><div style="margin-top:8pt"><img src="pcrx-20211231_g2.jpg" alt="pcrx-20211231_g2.jpg" style="height:715px;margin-bottom:5pt;vertical-align:text-bottom;width:715px"/></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Pediatric FDA action date of March 22, 2021 was for infiltration in patients aged 6 to 17 years old. Study designs have not been finalized for pediatric populations in infiltration or nerve block in patients aged 0 to less than 6 years old.</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-  TAP block is a transversus abdominis plane field block</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-  NOCITA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is a registered trademark of Aratana Therapeutics, Inc., a wholly owned subsidiary of Elanco Animal Health, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Products</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">EXPAREL (bupivacaine liposome injectable suspension)</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL was approved by the FDA in October 2011 and was commercially launched in April 2012. In the U.S., EXPAREL is currently indicated in patients six years of age and older for single-dose infiltration to produce postsurgical local analgesia, and in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. In November 2020, the European Commission, or EC, granted marketing authorization for EXPAREL as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults. We launched EXPAREL in the United Kingdom, or U.K., and select European Union, or E.U., countries in November 2021. Since its initial approval in 2011, more than 10 million patients have been treated with EXPAREL.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in our pMVL drug delivery technology, which delivers bupivacaine over time for extended analgesia. We believe that EXPAREL addresses a significant medical need for a safe and effective long-acting non-opioid postsurgical analgesic and plays a significant role in opioid minimization strategies. EXPAREL is designed for recovery with minimal opioid use by (i) delivering targeted local analgesia at the surgical site; (ii) reliably releasing bupivacaine over time for prolonged analgesia; (iii) eliminating the need for catheters and pumps that may hinder recovery; and (iv) providing long-lasting pain control while reducing the need for opioids.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net product sales of EXPAREL in 2021 were $506.5 million. For the years ended December 31, 2021, 2020 and 2019, net product sales of EXPAREL accounted for 94%, 96% and 98% of our total revenues, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ZILRETTA (triamcinolone acetonide extended-release injectable suspension)</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILRETTA was approved by the FDA in October 2017 and launched in the U.S. shortly thereafter. We market ZILRETTA through our ZILRETTA and iovera&#176; sales force of approximately 50 Treatment Solutions Mangers who are providing clinicians with two unique OA treatment options to individualize patient care. ZILRETTA is the first and only extended-release, intra-articular therapy for patients confronting OA knee pain. ZILRETTA employs a proprietary microsphere technology combining triamcinolone acetonide, or TA, a commonly administered, immediate-release corticosteroid, with a poly lactic-co-glycolic acid, or PLGA, matrix to provide extended pain relief. PLGA is a proven extended-release delivery vehicle that is metabolized to carbon dioxide and water as it releases drug in the IA space and is used in other approved drug products and surgical devices. The ZILRETTA microspheres slowly and continuously release triamcinolone acetonide into the knee to provide significant pain relief for 12 weeks, with some people experiencing pain relief through 16 weeks.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We added ZILRETTA to our commercial offering with the completion of the Flexion Acquisition in November 2021. ZILRETTA net product sales were $102.7 million for the year ended December 31, 2021. The vast majority of the 2021 ZILRETTA sales occurred prior to the completion of the Flexion Acquisition and prior to our ownership of Flexion. We recognized ZILRETTA net product sales of $12.7 million during</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the post-closing period of November 19, 2021 to December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">iovera&#176; system</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The iovera&#176; system is an FDA-approved, non-opioid handheld cryoanalgesia device used to produce precise, controlled doses of cold temperature only to targeted nerves. It has been FDA 510(k) cleared for use in pain applications since March 2014. We believe the iovera&#176; system is highly complementary to EXPAREL and ZILRETTA as a non-opioid therapy that alleviates pain using a non-pharmacological nerve block to disrupt pain signals being transmitted to the brain from the site of injury or surgery. For the year ended December 31, 2021, our net product sales of iovera&#176; were $16.2 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EXPAREL Clinical Benefits</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe EXPAREL can replace the use of bupivacaine delivered via elastomeric pumps as the foundation of a multimodal regimen for long-acting postsurgical pain management. Based on our clinical data, EXPAREL:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provides long-lasting local or regional analgesia;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">is a ready-to-use formulation;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expands easily with saline or lactated Ringer&#8217;s solution to reach a desired volume;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">leverages existing interscalene brachial plexus nerve block, field block and infiltration administration techniques; and</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilitates treatment of a variety of surgical sites.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe EXPAREL is a key component of long-acting postsurgical pain management regimens that reduce the need for opioids. Based on the clinical data from our Phase&#160;3 and Phase 4 clinical studies as well as data from retrospective health outcomes studies, EXPAREL significantly reduces opioid usage while improving postsurgical pain management.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Phase&#160;3 hemorrhoidectomy trial, EXPAREL:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delayed the median time to rescue analgesic use (opioids) to 15&#160;hours for patients treated with EXPAREL versus one hour for patients treated with placebo;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">significantly increased the percentage of patients requiring no opioid rescue medication through 72 hours post-surgery to 28%, compared to 10% for placebo;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">resulted in 45% less opioid usage through 72 hours post-surgery compared to placebo; and</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increased the percentage of patients who were pain free at 24&#160;hours post-surgery compared to placebo.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Phase&#160;3 trial as an interscalene brachial plexus nerve block for upper extremity surgeries, EXPAREL:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">decreased total opioid consumption by 78% (p&lt;0.0001) from zero to 48 hours after surgery;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduced pain scores by 46% versus placebo (p&lt;0.0001); and</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">allowed 13% of patients who received EXPAREL to remain opioid-free for 48 hours after surgery (p&lt;0.01) compared to one opioid-free patient in the placebo arm.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL can improve patient satisfaction and outcomes. We believe EXPAREL:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provides effective pain control without the need for expensive and difficult-to-use delivery technologies that extend the duration of action for bupivacaine, such as elastomeric pumps, or opioids administered through patient-controlled analgesia, or PCA, when used as part of a multimodal postsurgical pain regimen;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduces the need for patients to be constrained by elastomeric pumps and PCA systems, which are barriers to earlier ambulation and may introduce catheter-related issues, including infection; and</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">promotes maintenance of early postsurgical pain management, which may reduce the time spent in the intensive care unit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key EXPAREL Markets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL-based enhanced recovery after surgery, or ERAS, protocols are becoming a cornerstone of opioid-sparing postsurgical pain management and enabling the shifting of many complex, painful orthopedic procedures to the 23-hour stay environment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orthopedics</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total joint arthroplasties are expected to grow rapidly in the coming years with a significant migration of these procedures from the inpatient hospital setting to outpatient sites of care. EXPAREL-based regional analgesia as part of multimodal pain management protocols in enhanced ERAS pathways is supporting this surgical migration. The clinical and economic benefits of EXPAREL in total joint arthroplasty procedures have been demonstrated in clinical studies with EXPAREL use associated with significant reductions in opioid consumption, well-controlled pain management, shorter recovery time, same-day discharge to home and high patient satisfaction.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL is being adopted in an increasing number of spine surgeries as a key component of a multimodal pain management solution enabling rapid recovery after surgery and a reduced reliance on opioids, which have been the mainstay in postsurgical pain control in the spine area for decades. Two important patient groups are driving the spine market: first, pediatric cases, like adolescent scoliosis patients, who are undergoing highly invasive surgeries and who until very recently only had opioids available to treat their pain, and second, adult degenerative patients who are often coming into surgery opioid-tolerant and who may have already had multiple back surgeries. Managing postsurgical pain in these adult degenerative patients </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">can be challenging due to their established opioid tolerance, but with EXPAREL, healthcare providers can control their pain with a non-opioid approach, and when feasible based on surgical intervention and patient characteristics, move many historical inpatient procedures to the 23-hour stay environment. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL administered as a brachial plexus nerve block is a key and growing part of our business. An EXPAREL brachial plexus block provides pain coverage for the upper quadrant for use in rotator cuff, shoulder arthroplasty, elbow, wrist, and hand procedures. Like other regional field blocks, our anesthesiologist customers see the strong advantages of using brachial plexus blocks as a vehicle for shifting procedures to the outpatient setting by replacing antiquated pumps and catheters, which often become dislodged and prevent a procedure from taking place in a 23-hour site of care. Additionally, EXPAREL reimbursement is consistently improving as payers and self-insured employers continue to drive the shift from inpatient to outpatient care for a variety of surgeries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Abdominal and Colorectal</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of truncal blocks have emerged for use in abdominal and colorectal procedures. Transversus abdominis plane, or TAP, and erector spine plane blocks represent a significant market where EXPAREL is providing long-acting pain control in the abdominal region and supporting the migration of these procedures to the 23-hour setting. We expect the expanding use of EXPAREL field blocks as the foundation of enhanced recovery protocols across various abdominal and colorectal procedures to continue to be a significant growth driver.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Women&#8217;s Health</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a significant and growing demand among women for managing pain with non-opioid options. Opioid addiction in women is growing at an alarming rate and studies have shown that women are 40% more likely than men to become newly persistent users of opioids following surgery. Women&#8217;s Health continues to be an important source of growth as anesthesia-driven EXPAREL-based TAP and pectoralis blocks take hold as institutional protocol for C-section, abdominoplasty, gynecologic oncology, mastectomy and breast reconstruction procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cardiothoracic </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiothoracic surgery is considered one of the most painful types of surgical procedures for both open and minimally invasive procedures. As a result, opioids are widely used, but are often inadequate. Poorly controlled postoperative pain leads to the development of chronic persistent pain in as many as 40% of these patients and persistent opioid use after surgery is seen in over 10% of such patients. Regional anesthesia approaches have been evolving, with EXPAREL replacing thoracic epidurals as an alternative method of producing long-lasting analgesia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatrics</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the FDA approved our sNDA to expand the EXPAREL label to include use in patients six years of age and older for single-dose infiltration to produce postsurgical local analgesia. EXPAREL is the first and only FDA-approved long-acting local analgesic for the pediatric population as young as age six. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opioids, short-acting local anesthetics and catheter-based devices have been the historical mainstay in pediatric postsurgical pain management despite safety implications and limited studies in children. The risks and complications of adult-based pain management approaches may be magnified in children with 50 percent of children reporting moderate to severe pain in the hospital after surgery and 20 percent of children reporting chronic pain 12 months after surgery.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL is redefining the paradigm of care for postsurgical pain management in children as the market&#8217;s only clinically proven safe alternative for long-acting, non-opioid postsurgical pain control in children aged 6 and over. There are approximately one million pediatric procedures per year in the U.S. We are working with prominent thought leaders who are providing a rapid transfer of best-practice for establishing EXPAREL-based protocols as the new standard of care. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Molar (Wisdom Tooth) Procedures</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third molar (wisdom tooth) extractions are among the most common dental procedures in the U.S. and are performed in up to 5 million patients every year. Oral surgery, including third molar extraction, is associated with a defined period of pain and discomfort that traditionally leads to prescriptions for opioids. A large retrospective review of the Medicaid database found that of 2.8 million patients who underwent surgical tooth extraction, 1.2 million, or roughly 42 percent, filled a prescription for opioids within seven days after surgery, with a median of 120 morphine milligram equivalents dispensed per patient. A study of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the effect of EXPAREL on postoperative opioid prescribing after third molar extraction showed that patients who received EXPAREL were prescribed significantly fewer opioids, including refills, compared to those who did not receive EXPAREL. The study, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A Retrospective Cross-Sectional Study of the Effect of Liposomal Bupivacaine on Postoperative Opioid Prescribing After Third Molar Extraction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was published in The Journal of Oral and Maxillofacial Surgery in July 2021. In this retrospective analysis, researchers reviewed data from 600 patients who underwent third molar extractions between 2012 and 2018. De-identified data from 300 patients who received EXPAREL were compared to data from 300 patients who did not receive an infiltration of EXPAREL. Data from two outpatient oral surgery centers were included in this analysis. Patients in the EXPAREL treatment group received:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">59 percent fewer opioids, including refills, compared to patients in the non-EXPAREL group (p&lt;0.0001)</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Fewer additional opioid prescriptions compared to the non-EXPAREL group (3.3% of patients required a refill vs. 7.7% of patients, respectively)</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we announced a collaboration with Aetna, one of the nation&#8217;s leading diversified health care benefits companies, with the support of the American Association of Oral and Maxillofacial Surgeons (AAOMS). This national program aims to reduce the number of opioid tablets dispensed to patients undergoing impacted third molar extractions by at least 50 percent through the utilization of EXPAREL to provide prolonged non-opioid postsurgical pain control. Aetna now includes the cost of EXPAREL as a covered expense for impacted third molar extractions performed by surgeons who have completed training on use of the product.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZILRETTA Clinical Benefits</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILRETTA combines a commonly administered steroid, TA, with PLGA, delivering a 32 milligram dose of TA to provide extended therapeutic concentrations in the joint and persistent analgesic effect.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the strength of its pivotal and other clinical trials, we believe that ZILRETTA represents an important treatment option for the millions of patients in the U.S. in need of safe and effective extended relief from OA knee pain. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pivotal Phase 3 trial, on which the approval of ZILRETTA was based, showed that ZILRETTA significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through Week 16. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the magnitude and duration of pain relief provided by ZILRETTA in clinical trials were clinically meaningful with the magnitude of pain relief amongst the largest seen to date in OA clinical trials. The overall frequency of treatment-related adverse events in these trials was similar to those observed with placebo, and no drug-related serious adverse events were reported. We believe that ZILRETTA holds the potential to become the corticosteroid of choice given its safety and efficacy profile, and the fact that it is the first and only extended-release corticosteroid on the market. In September 2021, the American Association of Orthopaedic Surgeons, or AAOS, updated its evidence-based clinical practice guidelines, finding ZILRETTA can improve patient outcomes over traditional immediate-release corticosteroids.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">iovera&#176; Clinical Benefits</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a growing body of clinical data demonstrating success with iovera&#176; treatment for OA of the knee. Surgical intervention is typically a last resort for patients suffering from OA of the knee. In one study, the majority of the patients suffering from OA of the knee experienced pain relief up to 150 days after being treated with iovera&#176;.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary findings demonstrated reductions in opioids, including:</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The daily morphine equivalent consumption in the per protocol group analysis was significantly lower at 72 hours (p&lt;0.05), 6 weeks (p&lt;0.05) and 12 weeks (p&lt;0.05).</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients who were administered iovera&#176; were far less likely to take opioids six weeks after surgery. The number of patients taking opioids six weeks after TKA in the control group was three times the number of patients taking opioids in the cryoanalgesia group (14% vs. 44%, p&lt;0.01).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients in the iovera&#176; group demonstrated a statistically significant reduction in pain scores from their baseline pain scores at 72 hours (p&lt;0.05) and at 12 weeks (p&lt;0.05).</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these data validate iovera&#176; as a clinically meaningful non-opioid alternative for patients undergoing TKA, and that iovera&#176; offers the opportunity to provide patients with non-opioid pain control well in advance of any necessary surgical intervention through a number of key product attributes:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">iovera&#176; is safe and effective with immediate pain relief that can last for months as the nerve regenerates over time;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">iovera&#176; is repeatable;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The iovera&#176; technology does not risk damage to the surrounding tissue;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">iovera&#176; is a convenient handheld device with a single-use procedure-specific Smart Tip; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">iovera&#176; can be delivered precisely using ultrasound guidance or an anatomical landmark.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the AAOS updated its evidence-based clinical practice guidelines, reporting that denervation therapy&#8212;including cryoneurolysis&#8212;may reduce knee pain and improve function in patients with symptomatic OA of the knee.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Osteoarthritis Market</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OA is the most common form of arthritis. It is also called degenerative joint disease and occurs most frequently in the hands, hips and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work. According to the CDC, OA affects over 32.5 million adults in the U.S.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lifetime risk of developing symptomatic knee OA is 45 percent. The prevalence of symptomatic knee OA increases with each decade of life, with the annual incidence of knee OA being highest between age 55 and 64 years old. There are 14 million individuals in the U.S. who have symptomatic knee OA, and nearly two million are under the age of 45. Surgical intervention is typically a last resort for patients suffering from OA of the knee.</span></div><div><span><br/></span></div><div style="text-indent:22.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the addition of ZILRETTA to our product offering, we can now offer clinicians the flexibility to individualize OA knee pain treatment with either ZILRETTA or a drug-free nerve block with iovera&#176; based on patient factors and preference, physician training, site of care and reimbursement considerations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Label and Global Expansion Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EXPAREL</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pediatrics. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working with the FDA to finalize a regulatory pathway to expand the EXPAREL label for patients under six years of age, as well as the administration of EXPAREL as a nerve block in the pediatric setting. We are working with both the FDA and the European Medicines Agency, or EMA, to harmonize our pediatric clinical studies as much as possible between the two regions.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lower extremity nerve block. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing two Phase 3 studies of EXPAREL as a nerve block in lower extremity surgeries. One is a popliteal sciatic nerve block for bunionectomy and the second is an adductor canal block for TKA. We believe positive results from these studies will form the basis for an sNDA submission seeking label expansion to include lower extremity nerve blocks. We believe the addition of this indication is significant as anesthesia-driven regional approaches using nerve and field blocks continue to expand as institutional protocols.</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stellate ganglion block. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe a long-acting stellate ganglion block with EXPAREL has the potential to be an effective approach for managing ventricular tachycardia (commonly referred to as &#8220;electrical storm&#8221;), a life-threatening clinical condition characterized by the recurrence of hemodynamically unstable ventricular tachycardia and/or ventricular fibrillation. We are planning pilot studies that will separately evaluate long-acting stellate ganglion blocks with EXPAREL and iovera&#176; for managing electrical storm.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Global expansion. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prioritized the European and Latin American markets for global expansion. In Europe, we were granted marketing authorization by the EC in November 2020 for EXPAREL as a brachial plexus block or femoral nerve block for treatment of post-operating pain in adults and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults. We launched EXPAREL in the U.K. and targeted E.U. countries in the fourth quarter of 2021. In Latin America, we have a distribution agreement with Eurofarma Laboratories S.A., or Eurofarma, for the development and commercialization of EXPAREL. Eurofarma has the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia and Mexico. In addition, Eurofarma will be responsible for regulatory filings for EXPAREL in these countries. We will receive royalties and are also eligible to receive regulatory- and commercial-based milestone payments that are triggered by the achievement of certain events.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ZILRETTA </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe ZILRETTA&#8217;s extended-release profile may also provide effective treatment for OA pain of the shoulder, and we intend to initiate a Phase 3 trial investigating ZILRETTA in shoulder OA in 2022. In addition, we are planning a comparative safety study of ZILRETTA in patients with Type 2 diabetes and are evaluating a repeat dosing study.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The iovera&#176; System</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently launched a next-generation iovera&#176; handheld device, which we believe is more efficient, easier to use and more durable. We are also developing new iovera&#176; Smart Tips for certain procedures and are developing a specific tip for a medial branch block for treating chronic low-back pain, as well as spine procedures. We are also seeking a label expansion for the treatment of spasticity, which we believe is a significant long-term opportunity for iovera&#176;. Additionally, we expect to begin selling iovera&#176; in the E.U. through a contracted sales force in the first quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Development Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PCRX-201 and PCRX-301 (Formerly FX-201 and FX-301)</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PCRX-201 and PCRX-301 were added to our portfolio as part of the Flexion Acquisition. PCRX-201 is a gene therapy product candidate designed to provide &#8220;on demand&#8221; production of an anti-inflammatory protein, interleukin-1 receptor antagonist (IL-1Ra) whenever inflammation is detected in the joint. PCRX-301, is a locally administered Na</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 inhibitor, known as funapide, formulated for extended release in a thermosensitive hydrogel. The initial development of PCRX-301 was intended to support administration as a peripheral analgesic lower extremity nerve block for management of post-operative pain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">pMVL-Based Clinical Programs</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the proven safety, flexibility and customizability of our pMVL drug delivery technology platform for acute, sub-acute and chronic pain applications, we have several pMVL-based products in clinical development. Following data readouts from preclinical and feasibility studies for these candidates, we have prioritized three programs for clinical development: (i) PCRX-401, a dexamethasone-pMVL for low back pain; (ii) PCRX-501, a high-dose bupivacaine-pMVL for extended pain relief and (iii) a low-dose bupivacaine-pMVL for intrathecal analgesia. We are planning to initiate a Phase 2 study for low-dose bupivacaine-pMVL for intrathecal analgesia in late 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">External Innovation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In parallel to our internal clinical programs, our business development team continues to pursue innovative acquisition targets that are complementary to EXPAREL, ZILRETTA and iovera&#176; and are of great interest to the surgical and anesthesia audiences we are already calling on today. We are using a combination of strategic investments, in-licensing and acquisition transactions to buildout a pipeline of innovation to improve patients&#8217; journeys along the neural pain pathway. Select strategic investments we have made to support promising early stage platforms are summarized below.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#eaeaea;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company</span></td><td colspan="3" style="background-color:#eaeaea;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Development Stage</span></td><td colspan="3" style="background-color:#eaeaea;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of Platform Technology</span></td><td colspan="3" style="background-color:#eaeaea;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Potential Therapeutic Areas</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coda Therapeutics, Inc.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Chemogenetic platform to reverse the aberrant neuronal activity underlying neurological disorders using optimized adeno-associated virus (AAV) vectors</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuropathic pain</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genascence Corporation</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Adeno-Associated Vector (AAV)-based gene therapy targeting Interleukin 1 Receptor Antagonist (IL-1Ra)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Knee OA</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GeneQuine Biotherapeutics GmbH</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Next-generation gene transfer vehicles that enter joint cells to confer multi-year gene expression</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OA and other musculoskeletal disorders</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spine BioPharma, LLC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3-ready</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Remedisc 7-amino acid chain peptide that binds to and induces down regulation of transforming growth factor, beta 1 (TGF&#946;1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Degenerative disc disease</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built our sales and marketing organization to commercialize our products. Our primary target audiences are healthcare practitioners who influence pain management decisions including anesthesiologists, surgeons, pharmacists and physician extenders (including physician assistants, nurse practitioners and registered nurses).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our field team, consisting of sales representatives, account managers, scientific and medical affairs personnel and reimbursement and market access professionals, executes on a full range of activities to broaden the use of our non-opioid products for pain management, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">providing publications and abstracts showing clinical efficacy and safety, health outcomes and review articles;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">working in tandem with hospital staff, such as anesthesiologists, surgeons, heads of quality, pharmacists, executives and registered nurses, to provide access and resources for drug utilization or medication use evaluations and health outcomes studies, which provide retrospective and prospective analyses for our hospital customers using their own hospital data to demonstrate the true cost of opioid-based postsurgical pain control;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">working with Key Opinion Leaders (KOLs) and advisory boards to address topics of best practice techniques as well as guidelines and protocols for the use of our products, meeting the educational and training needs of our physician, surgeon, anesthesiologist, pharmacist and registered nurse customers</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">undertaking education initiatives such as center of excellence programs; preceptorship programs; opioid-sparing and ERAS pain protocols and predictive models for enhanced patient care; interactive discussion forums; patient education platforms leveraging public relations, advocacy partnerships and public affairs efforts where appropriate; web-based training and virtual launch programs;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collaborating with healthcare providers towards improving the knowledge and management of pain in surgical and OA patients with a focus on opioid risk and non-opioid alternatives and engaging our field-based medical teams in system-wide partnerships to address the national opioid epidemic, with a goal of studying alternative postsurgical pain management options that focus on optimization and opioid alternative strategies; and</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilitating reimbursement and the shift of procedures to hospital outpatient and ambulatory surgical center, or ASC, sites of care.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pacira Innovation and Training Center of Tampa</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we opened the Pacira Innovation and Training center of Tampa (the &#8220;PITT&#8221;). We designed this facility to help advance clinician understanding of the latest local, regional and field block approaches for managing pain. The PITT provides an unparalleled training environment for healthcare providers working to reduce or eliminate patient exposure to opioids. The PITT supports a full range of educational events to advance clinician understanding of the latest local, regional, and field block approaches for managing pain and reducing or eliminating exposure to opioids. Our corporate headquarters are also located at the PITT.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PITT consists of approximately 13,000 square-feet of fully adaptable space and is equipped with state-of-the-art technology and audio/visual capabilities and features several distinct training spaces including a simulation lab equipped with seven ultrasound scanning stations; a lecture hall featuring a 4&#189;-foot tall by 24-foot wide liquid crystal display video wall to support live, virtual and even global presentations; and a green-screen broadcast studio designed to livestream content with single or multiple hosts.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our EXPAREL programs, we are hosting ongoing workshops to train new users on best practice techniques for iovera&#176; administration at the PITT. Led by healthcare professionals, these labs include didactic lectures and hands-on trainings including live model nerve scanning and identification using ultrasound and peripheral nerve stimulation.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PITT also serves as a venue for national anesthesia provider organizations to host their own workshops and training sessions.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have started the process for opening a second innovation and training center that will be located in Houston, Texas.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DePuy Synthes Sales Inc.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we announced the conclusion of a co-promotion agreement with DePuy Synthes Sales, Inc., or DePuy Synthes, part of the Johnson &amp; Johnson family of companies to market and promote the use of EXPAREL for orthopedic procedures in the U.S. market. The collaboration began in January 2017 and concluded in January 2021. During that time </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DePuy Synthes field representatives collaborated with the Pacira field teams to support EXPAREL use and education in orthopedic surgical settings. In addition to partnering with DePuy Synthes in support of orthopedic surgical procedures, Pacira field representatives remained the overall EXPAREL account managers and commercial leads for soft tissue surgeons, anesthesiologists and ASCs. Through this collaboration we significantly expanded the use of EXPAREL and solidified its role in opioid-sparing protocols across a range of orthopedic procedures. Our decision to conclude the partnership was due to the evolution of orthopedic practice from an inpatient hospital experience to the ambulatory setting with anesthesia-driven regional approaches playing an increasingly essential role. This growing market is already served by our field-based teams.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Agreements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MyoScience Acquisition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we completed the MyoScience Acquisition. The consideration included an initial cash payment of $120.0 million, reduced by $1.0 million for post-closing purchase price adjustments and indemnification obligations incurred to date, plus contingent milestone payments up to an aggregate of $100.0 million of which $43.0&#160;million is available at December 31, 2021. Upon the completion of the MyoScience Acquisition, we renamed MyoScience Pacira CryoTech, Inc. For more information on the MyoScience Acquisition, refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein.</span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SkyePharma Holdings, Inc. (Now a Subsidiary of Vectura Group plc)</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the stock purchase agreement related to the Skyepharma Acquisition, we agreed to certain earn-out and milestone payments. Milestones were based on net sales of DepoBupivacaine products collected, including EXPAREL, and certain other yet-to-be-developed products. The milestones were as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$10.0 million upon the first commercial sale in the U.S. (met April 2012);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$4.0 million upon the first commercial sale in the U.K., France, Germany,&#160;Italy or Spain (met November 2021); </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$8.0 million when annual net sales collected reach $100.0 million (met September 2014);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$8.0 million when annual net sales collected reach $250.0 million (met June 2016); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$32.0 million when annual net sales collected reach $500.0 million (met December 2021).</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we met both remaining milestones: $4.0 million upon the first commercial sale in the U.K., France, Germany, Italy or Spain which was paid in the fourth quarter of 2021; and $32.0 million when annual net sales collected reached $500.0 million, which was paid in the first quarter of 2022. See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein for further information related to the Skyepharma Acquisition.</span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Development Foundation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an agreement with the Research Development Foundation, or RDF, we were required to pay RDF a low single-digit royalty on the collection of revenues from certain products for as long as certain patents assigned to us under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by us, in connection with our bankruptcy or insolvency or if we directly or indirectly oppose or dispute the validity of the assigned patent rights.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. Patent No. 11,033,495 issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends our royalty obligations under the agreement until 2041. We disagreed and explained that the royalty period under the agreement was set to end on December 24, 2021 with the expiration of our U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, we filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit seeks a declaration from the court that we owe no royalties to RDF with respect to our EXPAREL product after December 24, 2021. During the pendency of the lawsuit, we will continue to pay royalties to RDF under protest. We are unable to predict the outcome of this action at this time.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aratana Therapeutics, Inc.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2012, we entered into an Exclusive License, Development and Commercialization Agreement and related Supply Agreement with Aratana Therapeutics,&#160;Inc., a wholly owned subsidiary of Elanco Animal Health, Inc., or Aratana. Under the agreements, we granted Aratana an exclusive royalty-bearing license, including the limited right to grant sublicenses, for the development and commercialization of our bupivacaine liposome injectable suspension product for use in animals. In August 2016, the FDA&#8217;s Center for Veterinary Medicine, or CVM, approved NOCITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bupivacaine liposome injectable suspension), as a local post-operative analgesia for cranial cruciate ligament surgery in dogs (NOCITA is a registered trademark of Aratana). In August 2018, the CVM expanded the NOCITA label to include its use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy in cats. In June 2019, the CVM approved a 10mL vial size for NOCITA. Aratana began purchasing our bupivacaine liposome injectable suspension product in 2016.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are eligible to receive up to $40.0 million upon the achievement of commercial milestones. Aratana is required to pay us a tiered double-digit royalty on certain net sales made in the U.S. If the product is approved by foreign regulatory agencies for sale outside of the U.S., Aratana will be required to pay us a tiered double-digit royalty on such net sales. Royalty rates will be reduced by a certain percentage upon the entry of a generic competitor for animal health indications into certain jurisdictions or if Aratana must pay royalties to third parties under certain circumstances.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party has the right to terminate the license agreement in connection with (i)&#160;an insolvency event involving the other party that is not discharged in a specified period of time; (ii)&#160;a material breach of the agreement by the other party that remains uncured for a specified cure period or (iii)&#160;the failure to achieve a minimum annual revenue as set forth in the agreement, all on specified notice. We may terminate the agreement in connection with (i)&#160;Aratana&#8217;s failure to pay any amounts due under the agreement; (ii)&#160;Aratana&#8217;s failure to achieve regulatory approval in a particular jurisdiction with respect to such jurisdiction or (iii)&#160;Aratana&#8217;s failure to achieve its first commercial sale within a certain amount of time on a country by country basis after receiving regulatory approval, all on specified notice. Aratana may terminate the license agreement (i)&#160;upon the entry of a generic competitor for animal health indications on a country by country basis or (ii)&#160;at any time on a country by country basis except with respect to the U.S. and any country in the E.U., all on specified notice. The parties may also terminate the license agreement by mutual consent. The license agreement will terminate automatically if we terminate the supply agreement. In the event that the license agreement is terminated, all rights to the product (on a jurisdiction by jurisdiction basis) will be terminated and returned to us. Unless terminated earlier pursuant to its terms, the license agreement is effective until July 2033, after which Aratana has the option to extend the agreement for an additional five-year term, subject to certain requirements.</span></div><div style="margin-bottom:12pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eurofarma Laboratories S.A.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a distribution agreement with Eurofarma for the development and commercialization of EXPAREL in Latin America. Under the terms of the agreement, Eurofarma obtained the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia, and Mexico. In addition, Eurofarma is responsible for regulatory filings for EXPAREL in these countries. We will receive royalties based on Eurofarma&#8217;s future commercialization of the product and are also eligible to receive milestone payments that are triggered by the achievement of certain regulatory and commercial events.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Verve Medical Products, Inc.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a licensing agreement with Verve Medical Products, Inc. for the distribution of iovera&#176; in Canada. We began selling iovera&#176; in Canada in the fourth quarter of 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hong Kong Pharma Tainuo Ltd.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Flexion entered into an exclusive license agreement with Hong Kong Pharma Tainuo Ltd., or HK Tainuo, and Jiangsu Tainuo Pharmaceutical Co. Ltd., or Jiangsu Tainuo, a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd., for the development and commercialization (other than manufacturing) of ZILRETTA in Greater China (consisting of mainland China, Hong Kong, Macau and Taiwan). Under the terms of the agreement, HK Tainuo made upfront payments to Flexion in 2020. We are eligible to receive up to $32.5 million in aggregate development, regulatory and commercial sales milestone payments. All payments received from HK Tainuo are subject to applicable Hong Kong withholding taxes. HK Tainuo is responsible for the clinical development, product registration and commercialization of ZILRETTA in Greater China and Jiangsu Tainuo serves as the guarantor of HK Tainuo&#8217;s obligations and responsibilities under the agreement. We are solely responsible for the manufacture and supply of ZILRETTA to HK Tainuo for all clinical and commercial activities. The terms related to product manufacturing and supply, including pricing and minimum purchase requirements agreed to in the license </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, will be covered by a separate supply agreement. All amounts owed to us are nonrefundable and non-creditable once paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Customers</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December&#160;31, 2021: Cardinal Health, Inc., McKesson Drug Company and AmerisourceBergen Health Corporation, which accounted for 31%, 28% and 26% of our total revenues, respectively. These wholesalers process orders for EXPAREL under a drop-ship program. EXPAREL is delivered directly to end-users without the wholesalers ever taking physical possession of the product. None of our customers of ZILRETTA or iovera&#176; accounted for 10 percent or more of our total revenue for the year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Research Facilities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Internal Facilities</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture EXPAREL and iovera&#176; handpieces at our facility in San Diego, California. We also have a mixed-use research and development, manufacturing and office facility which sits adjacent to our EXPAREL and iovera&#176; manufacturing facility, and a warehouse located within five miles of these facilities. We refer to these three buildings as the Science Center Campus, and together they consist of approximately 195,000 square feet. Our manufacturing facilities are inspected regularly and approved by the FDA, EMA, Medicines and Healthcare Products Regulatory Agency, or MHRA, and the Environmental Protection Agency (EPA). Our iovera&#176; facility in Fremont, California, consists of approximately 20,000 square feet of mixed-use manufacturing, research and development and office space.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase raw materials and components from third-party suppliers to manufacture EXPAREL, ZILRETTA and  iovera&#176;. In most instances, alternative sources of supply are available, although switching to an alternative source would, in some instances, take time and could lead to delays in manufacturing our product candidates. While we have not experienced shortages of our raw materials in the past, such suppliers may not sell these raw materials to us at the times that we need them or on commercially reasonable terms and we do not have direct control over the availability of these raw materials from our suppliers.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All manufacturing of products, initial product release and stability testing are conducted by us and our manufacturing partners in accordance with Current Good Manufacturing Practices, or CGMP.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our EXPAREL manufacturing facility at the Science Center Campus is an approximately 84,000 square foot structure located on a five-acre site. It was custom built as a pharmaceutical research and development and manufacturing facility. Activities in this facility include the manufacture of EXPAREL bulk product on dedicated production lines and its fill/finish into vials, microbiological and quality control testing, product storage, development of analytical methods and manufacturing of development products. We are expanding our EXPAREL manufacturing capacity at our Science Center Campus as we expect the demand for EXPAREL will increase.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 90,000 square-foot mixed-use research and development, manufacturing and office facility is located adjacent to our EXPAREL manufacturing facility and was completely renovated in 2020 to meet our specifications. This building houses our Science Center related research and development activities and general and administrative functions, as it includes both laboratories and the building infrastructure necessary to support the formulation, analytical testing, clinical and process development activities for manufacturing additional commercial product indications and new pipeline products. Our pilot plant suite for early stage clinical product production is located in this building and there is additional space for future expansion opportunities.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have an approximately 21,000 square foot warehouse that serves as the main CGMP warehouse for our San Diego operations, primarily being used for the storage of production materials. It contains ambient as well as cold temperature CGMP warehouse storage and also features a quality control clean room for sampling incoming materials.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Fremont, California facility has been leased since 2015. It is dedicated to the iovera&#176; product line and consists of approximately 20,000 square feet of space for manufacturing, quality control, research and development and the warehousing of raw materials and finished goods. We have expanded our iovera&#176; manufacturing capacity through a third party, Providien Device Assembly, LLC, or Providien, as explained below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution of our pMVL products, including EXPAREL, requires cold-chain distribution, whereby a product must be maintained between specified temperatures. We have validated processes for continuous monitoring of temperature from manufacturing through delivery to the end-user.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Production Facilities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Thermo Fisher Scientific Pharma Services</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 2014, we and Thermo Fisher entered into a Strategic Co-Production Agreement, Technical Transfer and Service Agreement and Manufacturing and Supply Agreement (the &#8220;EXPAREL Manufacturing and Supply Agreement&#8221;) to collaborate in the manufacture of EXPAREL. Thermo Fisher undertook certain technical transfer activities and construction services needed to prepare Thermo Fisher&#8217;s Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. We provided Thermo Fisher with the equipment necessary to manufacture EXPAREL and pay fees to Thermo Fisher based on Thermo Fisher&#8217;s achievement of certain technical transfer and construction milestones. We also reimburse Thermo Fisher for certain nominal expenses and additional services. In February 2019, we announced that commercial production of EXPAREL was underway at the first Thermo Fisher suite. We developed a second dedicated suite that is expected to enable another doubling of EXPAREL manufacturing capacity. We began commercial production of EXPAREL out of that second suite in August 2021.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the EXPAREL Manufacturing and Supply Agreement is 10 years from the date of FDA approval of the first manufacturing suite, which was received in May 2018. We pay fees to Thermo Fisher for their operation of the manufacturing suites and the amount of EXPAREL produced by Thermo Fisher. We also reimburse Thermo Fisher for purchases made on our behalf, certain nominal expenses and additional services. We may terminate this agreement upon one month&#8217;s notice if a regulatory authority causes the withdrawal of EXPAREL from the U.S. or any other market that represents 80 percent of our overall sales, or at any time for convenience by providing between 18 and 36 months&#8217; notice (depending on the number of years after the FDA approval date). Either party may terminate the EXPAREL Manufacturing and Supply Agreement in the event of the breach or bankruptcy of the other party.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in July 2015, Flexion and Thermo Fisher entered into a Manufacturing and Supply Agreement (the &#8220;ZILRETTA Manufacturing and Supply Agreement&#8221;) and a Technical Transfer and Service Agreement related to the manufacture of ZILRETTA at the same Thermo Fisher site in Swindon, England where our EXPAREL suites are located. Thermo Fisher agreed to undertake certain transfer activities and construction services needed to prepare its facility for the commercial manufacture of ZILRETTA in dedicated manufacturing suites. Flexion provided Thermo Fisher with certain equipment and materials necessary to manufacture ZILRETTA. We make monthly payments to Thermo Fisher for such activities and reimburse Thermo Fisher for certain material, equipment and miscellaneous expenses and additional services.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the ZILRETTA Manufacturing Agreement that we assumed as part of the Flexion Acquisition expires in October 2027. We pay a monthly base fee to Thermo Fisher for the operation of the manufacturing suites and a per product fee for each vial of ZILRETTA based upon a forecast of commercial demand. We also reimburse Thermo Fisher for purchases of materials and equipment made on our behalf, certain nominal expenses and additional services. The ZILRETTA Manufacturing Agreement will remain in full effect unless and until it expires or is terminated. Upon termination of the ZILRETTA Manufacturing Agreement (other than termination by us in the event that Thermo Fisher does not meet the construction and manufacturing milestones or for a breach by Thermo Fisher), we will be obligated to pay for the costs incurred by Thermo Fisher associated with the removal of our manufacturing equipment and for Thermo Fisher&#8217;s termination costs up to a specified capped amount.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Providien Device Assembly</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we and Providien entered into a Manufacturing and Supply Agreement (the &#8220;Providien Agreement&#8221;) to collaborate in the manufacture of iovera&#176; Smart Tips at Providien&#8217;s Tijuana, Mexico facility. The initial term of the Providien Agreement is five years. We will pay fees based on the amount of iovera&#176; Smart Tips delivered by Providien. The Providien Agreement may be terminated by either party upon one years&#8217; written notice without cause. We may terminate the Providien Agreement upon thirty days&#8217; written notice in the event that iovera&#176; is withdrawn from the market or no longer sold by us. Either party may terminate the Providien Agreement in the event of the breach or bankruptcy of the other party.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property and Exclusivity</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our products, our product candidates and our technologies through a combination of patents, trade secrets, proprietary know-how, regulatory exclusivity and contractual restrictions on disclosure. We note that the patents and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications described below are only examples intended to highlight the variety of coverage provided by our existing and constantly developing portfolio.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents and Patent Applications</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect the proprietary position of our products and product candidates by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. As of December&#160;31, 2021, there are over 13 families of patents and patent applications relating to various aspects of the pMVL drug delivery technology and 25 families of patents and patent applications relating to various aspects of the technology used by iovera&#176;. There is one family of patents and patent applications relating to various aspects of the technology used by ZILRETTA. Patents have been issued in numerous countries, with an emphasis on the North American, European and Japanese markets. These patents generally have a term of 20&#160;years from the date of the non-provisional filing unless referring to an earlier filed application. Some of our expired U.S. patents had a term of 17&#160;years from the grant date. Our issued patents expire at various dates in the future, as discussed below, with the last currently issued patent for the pMVL drug delivery technology expiring in 2041, the last currently issued patent for ZILRETTA expiring in 2031 and the last currently issued patent for the iovera&#176; technology expiring in 2040.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents and Patent Applications for our pMVL and pMVL Products</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent relating to product-by-process and process in connection with the production of multivesicular liposomes was issued on March 7, 2017. This patent is listed in the Orange Book for EXPAREL and includes a patent term adjustment that equates to an expiration date of December 24, 2021. Several Track One patent applications directed to various aspects of an improved EXPAREL manufacturing process were filed in January 2021 and, if granted, would provide patent protection through 2041. Additionally, we have filed several patent applications directed to other important aspects of the EXPAREL technology which, if granted, would provide additional patent protection through 2040 and beyond.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the United States Patent and Trademark Office, or USPTO, issued U.S. Patent No. 11,033,495 related to EXPAREL. The patent, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing of Bupivacaine Multivesicular Liposomes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; claims composition of EXPAREL prepared by the improved manufacturing process. In November 2021, the USPTO issued U.S. Patent Nos. 11,185,506 and 11,179,336, claiming the improved EXPAREL manufacturing process and EXPAREL composition, respectively. All three patents will have an expiration date of January 22, 2041. U.S. Patent Nos. 11,033,495 and 11,179,336 are currently listed in the FDA&#8217;s &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; (the &#8220;Orange Book&#8221;). Additionally, we recently received four Notices of Allowance from the USPTO for four EXPAREL patents that have been examined and will issue. Two patents claim chemical composition of EXPAREL and two claim product-by-process. After issuance, we will submit these patents for listing in the Orange Book. After listing, the Orange Book would have a total of six EXPAREL patents each with an expiration date of January 22, 2041.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued patents for EXPAREL in the U.S. relating to methods for modifying the rate of drug release of the product candidate and the composition of the product candidate expired in January 2017 and September 2018, respectively. In the U.S., a patent relating to the composition of the product was issued in September 2014 and expired in September 2018. A patent relating to the method of treatment using EXPAREL was issued in December 2015 and expired in September 2018. In Europe, granted patent(s) related to the composition of EXPAREL expired in September 2018. A patent relating to methods of modifying the rate of drug release of the product candidate expired in January 2018. In addition, a patent relating to the process for making the product candidate expired in November 2018.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2010, a provisional patent was filed relating to an alternative process to manufacture EXPAREL and other pMVL-based products. The process offers many advantages, including larger scale production and lower manufacturing costs. In April 2011, we filed an international patent application providing the basis for several national phase patent applications, for example in Europe, China, Japan, Israel and India which, if granted, could potentially prevent others from using this process until at least 2031. In the U.S., we also filed a series of patent applications directed to the alternative manufacturing process. Eight of the patent applications were issued as patents as of December 2020. Patents that claim the process and apparatus will expire at the latest in November 2033. One of the patents claims a product made by the process and expires in April 2031. As of December 31, 2021, we have four granted patents in China, one granted patent in Europe, one granted patent in Japan and one granted patent in Israel, protecting various aspects of the alternative process, including the methods of using the apparatus and the apparatus itself.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents and Patent Applications for ZILRETTA</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A composition of matter patent has been issued by the USPTO for ZILRETTA, with a patent term into 2031. The USPTO has also issued two patents directed at the methods of manufacturing and using ZILRETTA with patent terms into 2031. Considerable expertise and effort were required to carry out the large body of original work underlying the formulation of ZILRETTA, including experimenting with, and observing the effects of over 50 steroid and PLGA formulations. We believe our extensive know-how and trade secrets relating to the manufacturing process for ZILRETTA, including those that relate to precise pharmaceutical release profiles, represent a meaningful entry barrier.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own three U.S. ZILRETTA patents as well as counterpart foreign patents and patent applications covering composition of matter, methods of manufacture, and methods of use. Our U.S. ZILRETTA patents have expiration dates in 2031. The ZILRETTA composition of matter invention is the result of several unique discoveries relating to a narrow drug load specification, a certain release profile of polymers, specific polymer weights and ratios, and clinical efficacy observed within a dose-range. The U.S. patents directed to ZILRETTA&#8217;s composition of matter and methods of use are listed in the FDA Orange Book. We also have two U.S. patents directed at compositions of matter similar to ZILRETTA, as well as methods of making and using the same, with patent terms into 2031.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we had one patent granted in Hong Kong, further expanding our global intellectual property portfolio, which includes patents in the U.S., Australia, Canada, China, E.U., Indonesia, India, Japan, Malaysia, Mexico, New Zealand, the Philippines, the Russian Federation, Saudi Arabia, Singapore, South Africa, South Korea, Taiwan and Ukraine. These foreign patents cover the composition of matter, methods of manufacturing, and methods of using ZILRETTA and are similar in scope to the protection in the U.S. described above.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also in-licensed intellectual property, owned by the Southwest Research Institute, or SwRI, which gives us exclusive rights to SwRI patents covering our proprietary microsphere manufacturing technology used in the production of ZILRETTA. These patents are scheduled to expire in 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCRX-201 (Formerly FX-201)</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, Flexion acquired the global rights to PCRX-201 from GeneQuine, including a direct exclusive license of certain foundational patents, patent applications, and other proprietary rights owned by the Baylor College of Medicine, or Baylor, that are related to PCRX-201 for human applications. These patents generally cover the composition of matter and method of use of PCRX-201 in the treatment of OA. In 2019, the USPTO issued patent number 10,301,647, which covers the composition of matter and method of use of PCRX-201 in the treatment of OA with a term through January 2033. In addition, the Baylor patents related to PCRX-201 are issued in Europe, with an expiry date in 2032, and in Australia, Japan, China, India and Eurasia with expiry dates in 2033. We are continuing to prosecute one U.S. Baylor patent application related to PCRX-201. Further, we have a pending Patent Cooperation Treaty, or PCT, application covering composition of matter and effective dosages of PCRX-201 in the treatment of OA in humans, which, if granted, is expected to provide protection until 2040.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a U.S. provisional application covering composition of matter and method of use of PCRX-201 for the treatment of degenerative disc disease (DDD), which, if granted, is expected to provide protection until 2042. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCRX-301 (Formerly FX-301)</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, Flexion acquired the global rights to develop and commercialize funapide from Xenon Pharmaceuticals, Inc., or Xenon, which we have formulated for extended release with our proprietary thermosensitive hydrogel as PCRX-301. As part of the transaction with Xenon, we acquired foundational patents and patent applications covering the composition of matter, methods of use, and methods of manufacture related to funapide. We own patents directed to funapide granted in the U.S. as well as Australia, Canada, China, Europe, Hong Kong, Mexico and New Zealand with expiry dates in 2030. In addition, we have a PCT patent application covering composition of matter, method of use, and method of manufacture for PCRX-301, which, if granted, is expected to provide protection until 2040.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a U.S. provisional application covering a composition of matter, method of use, and method of manufacture for PCRX-301 with different amounts of polar organic solvent and solubility enhancer, which if converted and granted, is expected to provide protection until 2042.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents and Patent Applications for iovera&#176;</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued patents in the U.S. afford us a wide range of coverage of various aspects of the iovera&#176; technology. For example, several of our earliest filed patents cover the structural aspects of a handheld cryogenic device with single needle and needle arrays, tissue-penetrating needle probes that may be detachable, fused silica tubing fluid delivery paths, methods of applying cryotherapy using the cryogenic device and methods for using replaceable needle probes. These patents are set to expire between 2025 and 2032. An important patent family specifically directed to systems and methods of treating pain offers both broad and variable coverage of cryogenic device features and methods of using the same for pain management, including single-use needle probes, particular needle sizes and shapes. Patents in this family are set to expire between 2025 and 2028. Another important patent family has broad disclosure and coverage of a variety of indications for treatment by cryogenic devices, including joint function and stiffness, OA, occipital neuralgia, spasticity, neuroma and other nerve entrapment indications and is set to expire between 2033 and 2037.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are several patents and pending patent applications directed to other important aspects of the iovera&#176; technology. For example, patents covering the probe filtration system are set to expire in 2033 and patents on the Smart Tip technology are set to expire between 2034 and 2037. Other patents and applications cover methods of using needles with blunt tips and aspects of cryogenic devices coupled with a neurostimulator for locating nerves.&#160;We also have three design patent families that cover the current handheld cryogenic device, its charging station dock and combinations thereof. To obtain coverage of our developing next-generation technology, we filed eight new non-provisional and PCT applications in 2020, which if granted, could potentially prevent others from using this next-generation technology until at least 2040. In addition, we filed four new design patent families in 2021 in the U.S. and foreign jurisdictions covering ornamental aspects of our next-generation cryogenic device.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Intellectual Property</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a provisional application covering composition of matter, method of use, and method of manufacture for formulations of an anesthetic drug of amino amide group (lidocaine, bupivacaine and ropivacaine) formulated in a triblock copolymer component (one or more PLGA-polyethylene glycol-PLGA triblock copolymers), which if converted and granted, is expected to provide protection until 2042.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets and Proprietary Information</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets play an important role in protecting our pMVL-based products and pipeline, ZILRETTA and iovera&#176; and provide protection beyond patents and regulatory exclusivity. The scale-up and commercial manufacture of pMVL-based and iovera&#176; products involve processes, custom equipment and in-process and release analytical techniques that we believe are unique to us. The expertise and knowledge required to understand the critical aspects of our pMVL manufacturing steps requires knowledge of both traditional and non-traditional emulsion processing and traditional pharmaceutical production, overlaid with all of the challenges presented by aseptic manufacturing. ZILRETTA is also manufactured using custom equipment and proprietary processes with respect to certain of the formulation and manufacturing techniques related to the TA-formulated PLGA microspheres in ZILRETTA, including those that relate to its precise pharmaceutical release profile. The iovera&#176; system relies on manufacturing techniques that are able to provide the precision and tight tolerances required for a self-contained handheld cryogenic device. Additionally, the iovera&#176; device includes proprietary software for device operations during cryotherapy treatments.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants and other advisors to execute proprietary information and confidentiality agreements upon the commencement of their employment or engagement. These agreements generally provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not be disclosed to third parties except in specific circumstances. In the case of our employees, the agreements also typically provide that all inventions resulting from work performed for us, utilizing our property or relating to our business and conceived or completed during employment shall be our exclusive property to the extent permitted by law. Where appropriate, agreements we obtain with our consultants also typically contain similar assignment of invention obligations. Further, we require confidentiality agreements from third parties that receive our confidential data or materials.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EXPAREL</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Our competitors include organizations such as major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and generic drug companies. Many of our competitors have greater financial and other resources than we have, such as more commercial resources, larger research and development staffs and more extensive marketing and manufacturing organizations. As a result, these companies may obtain marketing approval more rapidly than we are able and may be more effective in developing, selling and marketing their products. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may succeed in developing, acquiring or licensing on an exclusive basis technologies and drug products that are more effective or less costly than EXPAREL or any other products that we are currently selling through partners or developing or that we may develop, which could render our products obsolete and noncompetitive. We expect any products that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price and the availability of reimbursement from government and other third-party payers. </span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL competes with well-established products with similar indications. Competing products available for postsurgical pain management include opioids such as morphine, fentanyl, meperidine and hydromorphone, each of which is available generically from several manufacturers, and several of which are available as proprietary products using novel delivery systems. Ketorolac, a non-steroidal anti-inflammatory drug, or NSAID, is also available generically in the U.S. from several manufacturers, and Caldolor (ibuprofen for injection), an NSAID, has been approved by the FDA for pain management and fever in adults. EXPAREL also competes with currently marketed non-opioid products such as bupivacaine, marcaine, ropivacaine and other anesthetics/analgesics, all of which are also used in the treatment of postsurgical pain and are available as either oral tablets, injectable dosage forms or administered using novel delivery systems. Additional products may be developed for the treatment of acute pain, including new injectable NSAIDs, novel opioids, new formulations of currently available opioids and NSAIDs, long-acting local anesthetics and new chemical entities as well as alternative delivery forms of various opioids and NSAIDs. Currently EXPAREL also competes with elastomeric pumps/catheter devices intended to provide bupivacaine over several days and with off-label combinations of other approved analgesics, called &#8220;cocktails&#8221;, that are physician-combined in an attempt to extend the duration of pain control.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZILRETTA</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediate-release steroids and HA injections are currently the two marketed classes of IA products that compete directly with ZILRETTA. Also available are stem cell and PRP injections, but these require on-site preparation from tissue or blood taken from the patient and have generated questionable efficacy in controlled clinical trials. Because these are minimally manipulated autologous therapies, they do not require and have not received FDA review or approval. For that reason, they are generally not reimbursed by payers, and patients must pay out of pocket to receive these therapies. Furthermore, the American Association of Hip &amp; Knee Surgeons (AAHKS) issued a position statement indicating that it cannot recommend biologic therapies, including stem cell and PRP injections, for the treatment of advanced hip or knee arthritis.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">iovera&#176;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is intensely competitive and subject to rapid and significant technological change. The cryotherapy pain management field in particular is a growing industry due to increased attention on opioid usage for pain, which has created a rapidly emerging market and has fueled an increased interest in opioid alternatives. Many of our competitors in our space have greater financial and other resources than we have, such as more commercial resources, larger research and development staffs and more extensive marketing and manufacturing organizations. As a result, these companies may obtain marketing approval more rapidly than we are able and may be more effective in developing, selling and marketing their products.&#160;The rise of various small and early stage companies in the cryotherapy pain management field may also prove to be significant competitors, particularly if they enter into collaborative arrangements with large, established companies.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors are continuously engaged in trials and attempts to develop new products or approaches in hopes of capturing the pain management market. They may succeed in developing, acquiring or licensing on an exclusive basis, technologies that are more effective or less costly than the iovera&#176; system, which could render the iovera&#176; system obsolete and noncompetitive. As a result, it is critical that we continue to innovate and to increase marketing efforts in our primary markets. We expect any products that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convenience of administration and delivery, price and the availability of reimbursement from government and other third-party payers.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Besides pharmaceutical products for pain management, iovera&#176; competes with medical devices that ablate or degenerate peripheral nerves to treat indications such as joint pain, neuralgia and OA pain. Competing products include cryotherapy devices as well as other devices such as cooled radio-frequency ablation devices that block or degenerate peripheral nerves involved in conducting pain signals. Avanos Medical, Inc. markets these medical devices in the U.S. Additional non-opioid products or entirely different approaches may also be developed for pain management by one or more of our competitors.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., prescription drug and medical device products are subject to extensive pre- and post-market regulation by the FDA, including regulations that govern the research, development, testing, manufacturing, distribution, safety, efficacy, approval, labeling, storage, record keeping, reporting, advertising and promotion of such products under the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations. Outside the U.S., prescription drug and medical device products are regulated by comparable agencies (including the EMA and MHRA in the E.U. and U.K. as well as authorities in Canada and Latin America), laws and regulations. Failure to comply with applicable regulatory requirements may result in, among other things, refusal to approve pending applications, withdrawal of an approval, warning letters, clinical holds, civil or criminal penalties, recall or seizure of products, injunction, debarment, partial or total suspension of production or withdrawal of the product from the market. Any agency or judicial enforcement action could have a material adverse effect on the Company.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Environment</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceuticals</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., generally the FDA must approve any new drug, including a new use of a previously approved drug, before marketing of the drug occurs in the U.S. This process generally involves:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">completion of preclinical laboratory and animal testing and formulation studies in compliance with the FDA&#8217;s Good Laboratory Practice regulations;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin for unapproved use in the U.S.;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">approval by an independent Institutional Review Board, or IRB, at each clinical trial site before each trial may be initiated;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s Good Clinical Practices, or GCP, to establish the safety and efficacy of the proposed drug product for each intended use;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">completion of process validation, quality product release and stability;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission of a New Drug Application, or NDA, to the FDA;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">satisfactory completion of an FDA pre-approval inspection of the product&#8217;s manufacturing facility or facilities to assess compliance with CGMP requirements and to ensure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, quality and purity;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">satisfactory completion of an FDA advisory committee review, if applicable; and</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">review and approval by the FDA of the NDA.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that the FDA will grant approvals for any of our product candidates on a timely basis, if at all. Preclinical tests include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals. The results of preclinical tests, together with manufacturing information, analytical data and a proposed clinical trial protocol and other information, are submitted as part of an IND application to the FDA. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA places the trial on a clinical hold because of, among other things, concerns about the conduct of the clinical trial or about exposure of human research subjects to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Thus, submission of an IND does not by itself automatically result in FDA authorization to commence a clinical trial. In addition, the FDA requires us to amend an existing IND for each successive clinical trial conducted during product development. Further, an IRB covering each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial along with informed consent information for subjects before the clinical trial commences at that center. The IRB also must monitor the clinical trial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until it is completed. The FDA, the IRB or the sponsor may suspend a clinical trial at any time, on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. We may also suspend or terminate a clinical trial based on evolving business objectives and/or the competitive climate.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the product candidate to healthy volunteers or patients having the disease being studied under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Sponsors of clinical trials generally must register at the National Institutes of Health (NIH)-maintained website (www.clinicaltrials.gov) and report key findings and parameters. For purposes of an NDA submission and approval, typically, the conduct of human clinical trials occurs in the following three pre-market sequential phases, which may overlap or be combined:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Phase&#160;1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors initially conduct clinical trials in a limited population, either patients or healthy volunteers, to test the product candidate for safety, dose tolerance, absorption, metabolism, distribution, excretion and clinical pharmacology, and, if possible, to gain early evidence of effectiveness. In the cases of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing often is conducted only on patients having the specific disease. </span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Phase&#160;2: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors conduct clinical trials generally in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted indications and to determine dose tolerance, optimal dosage and dosing schedule. Sponsors may conduct multiple Phase&#160;2 clinical trials to obtain information prior to beginning larger and more extensive Phase&#160;3 clinical trials.</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Phase&#160;3: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These include expanded controlled and uncontrolled trials, including pivotal clinical trials. When Phase&#160;2 evaluations suggest the effectiveness of a dose range of the product and acceptability of such product&#8217;s safety profile, sponsors undertake Phase&#160;3 clinical trials in larger patient populations to obtain additional information needed to evaluate the overall benefit and risk balance of the drug and to provide an adequate basis to develop labeling.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some clinical trials may be overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial. The process of completing clinical testing and obtaining FDA approval for a new drug is likely to take a number of years and requires the expenditure of substantial resources. If an application is submitted, there can be no assurance that the FDA will review and approve the NDA. In addition, sponsors may elect to conduct, or be required by the FDA to, conduct post-approval clinical trials to further assess the drug&#8217;s safety or effectiveness after NDA approval, generate new data and best-practice administration techniques. Studies in an indication after approval are typically referred to as Phase&#160;4 clinical trials.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements for drug approval and the clinical trials that approvals are based on are similar in other countries, however each regulatory agency will have differing policies, procedures and processes that we must comply with in each market we wish to sell our products in. There also can be no assurance that approval or utilization of our products will be identical in different jurisdictions. For example, EXPAREL is approved in femoral nerve block for treatment of post-operative pain in adults in Europe, but the FDA has not approved this indication in the U.S.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Medical Device Amendments of 1976 to the FDCA and its subsequent amendments regulate the design, manufacture and marketing of medical devices. Medical devices that require notification submitted as a 510(k) clearance request must be reviewed and cleared by the FDA before we can begin marketing them. To request 510(k) clearance, we must be able to demonstrate that the medical device is substantially equivalent to a previously cleared and legally marketed 510(k) medical device. Medical devices require extensive clinical testing which consists of safety and efficacy studies, followed by pre-market approval, or PMA, applications for specific surgical indications. The FDA&#8217;s Quality System Regulations, or QSRs, set forth standards for our product design and manufacturing processes, require the maintenance of certain records and provide for inspections of our facilities by the FDA. There are also certain requirements of state, local and foreign governments that must be complied with in the manufacture and marketing of our products. A new indication for 510(k) clearance may or may not require a clinical trial&#8212;for instance, expanding the use of iovera&#176; to treat spasticity will, and we expect to commence a clinical trial in 2022.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval Process</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceuticals</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, sponsors submit the results of product development, preclinical studies and clinical trials to the FDA as part of an NDA requesting approval to market the product for one or more indications. NDAs must also contain extensive information relating to the product&#8217;s pharmacology, chemistry, manufacture, controls and proposed labeling, among other things. In addition, 505(b)(2) applications must contain a patent certification for each patent listed in the FDA&#8217;s Orange Book that covers the drug referenced in the application and upon which the third-party studies were conducted. For some drugs, the FDA may require Risk Evaluation and Mitigation Strategies, or REMS, which could include medication guides, physician communication plans or restrictions on distribution and use, such as limitations on who may prescribe the drug or where it may be dispensed or administered. Currently, the FDA does not require a REMS for EXPAREL but the EMA and MHRA do.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA accepts a submission for substantive review, the FDA typically reviews the NDA in accordance with established timeframes. Under PDUFA, the FDA establishes goals for NDA review time through a two-tiered classification system: Priority Review and Standard Review. A Priority Review designation is given to drugs that address an unmet medical need by offering major advances in treatment or providing a treatment where no adequate therapy currently exists. Standard Review applies to all applications that are not eligible for Priority Review. The FDA aims to complete Standard Reviews of NDAs within 12 months of submission (ten months after the Day 60 filing date) and Priority Reviews within eight months of submission (six months after the Day 60 filing date). For an sNDA, the FDA aims to complete its Standard Review within 10 months of submission and Priority Reviews within six months of submission. Review processes may sometimes extend beyond these target completion dates due to FDA requests for additional information or clarification, difficulties scheduling an advisory committee meeting, negotiations regarding REMS or FDA workload issues, but in general under PDUFA the FDA is supposed to complete its reviews within the target timeframes despite these factors. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to the application&#8217;s approval. The recommendations of an advisory committee do not bind the FDA, but the FDA generally follows such recommendations.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under PDUFA, NDA applicants must pay significant NDA user fees upon submission. In addition, manufacturers of approved prescription drug products must pay annual program fees.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with CGMP requirements and are adequate to ensure consistent production of the product within required specifications. Additionally, the FDA will typically inspect one or more clinical sites to ensure compliance with GCP before approving an NDA.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA and the manufacturing facilities, it may issue an approval letter or a Complete Response Letter, or CRL, to indicate that the review cycle for an application is complete and that the application is not ready for approval. CRLs generally outline the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than we do. If the FDA requires a REMS plan, it could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may approve an NDA contingent on, among other things, changes to proposed labeling, a commitment to conduct one or more post-market studies or clinical trials and the correction of identified manufacturing deficiencies, including the development of adequate controls and specifications. If and when the deficiencies have been addressed to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., although timelines vary as do specific regulatory procedures, the same general principals hold including the potential for a REMS plan which could entail other requirements, including but not limited to patient registries and risk minimization tools.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., authorization to bring a medical device to market is generally obtained in one of two ways. The first pathway, a pre-market notification (the 510(k) process), requires demonstration that the new device is substantially equivalent to an already legally marketed medical device. The second pathway, a PMA, requires an independent demonstration that a medical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">device is safe and effective for its intended use. In general, PMAs require a much longer time horizon and can be much more expensive than obtaining clearance through the 510(k) process. A PMA must be submitted to the FDA if it is determined that the device is not eligible for the 510(k) clearance process. A PMA must be supported by extensive data including, but not limited to, technical, preclinical and clinical trials, manufacturing and labeling to demonstrate reasonable evidence of the device&#8217;s safety and efficacy to the FDA&#8217;s satisfaction.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain 510(k) clearance, we must file with the FDA a pre-market notification demonstrating that our proposed device is substantially equivalent to a previously cleared and legally marketed 510(k) device or a device that was in commercial distribution before May&#160;28, 1976 for which the FDA has not yet called for the submission of a PMA. 510(k) clearance for a predecessor device to iovera&#176; was first obtained in March 2009 when the focus of MyoScience was cosmetic applications (i.e. facial wrinkle reduction). The MyoScience business focus shifted to pain management in 2014, and since then there have been a number of advancements that led to three additional 510(k) submissions and clearances to support iovera&#176; and the subsequent growth of the iovera&#176; product line.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device receives 510(k) clearance or a PMA approval, it may be changed or modified. Any modification that could significantly affect its safety or effectiveness, or that would constitute a significant change in its intended use, will require a new clearance or approval. Regulations provide that the manufacturer initially determines when a specific modification requires notification to FDA. The FDA has issued draft guidance that, if finalized and implemented, will result in manufacturers needing to seek a significant number of new clearances for changes made to legally marketed devices. The FDA reviews the manufacturer&#8217;s decision to file&#160;a 510(k) or PMA for modifications during facility audits.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section&#160;505(b)(2) New Drug Applications</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For pharmaceutical products, as an alternate path to FDA approval, particularly for modifications to drug products previously approved by the FDA, an applicant may submit an NDA under Section&#160;505(b)(2) of the FDCA. Section&#160;505(b)(2) was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, and permits the submission of an NDA where at least some of the information required for approval comes from preclinical and/or clinical trials not conducted by or for the applicant. The FDA interprets Section&#160;505(b)(2) of the FDCA to permit the applicant to rely upon the FDA&#8217;s previous findings of safety and effectiveness for an approved product. The FDA may also require companies to perform additional clinical trials or measurements to support any change from the previously approved product. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section&#160;505(b)(2) applicant.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applications under Section&#160;505(b)(2) are subject to any non-patent exclusivity period applicable to the referenced product, which may delay approval of the 505(b)(2) application even if the FDA has completed its substantive review and determined the drug should be approved. In addition, 505(b)(2) applications must include patent certifications to any patents listed in the FDA&#8217;s Orange Book as covering the referenced product. If the 505(b)(2) applicant seeks to obtain approval before the expiration of an applicable listed patent, the 505(b)(2) applicant must provide notice to the patent owner and NDA holder of the referenced product. If the patent owner or NDA holder brings a patent infringement lawsuit within 45&#160;days of such notice, the 505(b)(2) application cannot be approved for 30&#160;months or until the 505(b)(2) applicant prevails, whichever is sooner. If the 505(b)(2) applicant loses the patent infringement suit, the FDA may not approve the 505(b)(2) application until the patent expires, plus any period of pediatric exclusivity.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any future NDA submissions for our product candidates, we intend to follow the development and approval pathway permitted under the FDCA that we believe will maximize the commercial opportunities for these product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceuticals</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After approval, the NDA sponsor must comply with comprehensive requirements governing, among other things, drug listing, recordkeeping, manufacturing, marketing activities, product sampling, distribution and annual reporting. Additionally, adverse events must be reported to the FDA in a timely fashion, and pharmacovigilance programs to proactively look for adverse events are mandated by the FDA. An adverse event is any undesirable experience associated with the use of a medical product in a patient. A serious adverse event is an adverse event that results in death, is life-threatening or results in hospitalization or disability, among other things. If the events suggest a new safety signal for the drug in question, that could lead to the need for additional safety statements in the labeling of the product or additional REMS. Additionally, adverse events found in other drugs could also mean that we have to abide by additional safety measures and include warnings in our labeling. Similar reporting and pharmacovigilance obligations exist with regulatory agencies outside the U.S.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If new safety issues are identified following approval, the FDA can require the NDA sponsor to revise the approved labeling to reflect the new safety information; conduct post-market studies or clinical trials to assess the new safety information and implement a REMS program to mitigate newly identified risks. The FDA may also require post-approval testing, including Phase&#160;4 trials, and surveillance programs to monitor the effect of approved products which have been commercialized, and the FDA has the authority to prevent or limit further marketing of a product based on the results of these post-marketing programs. Drugs may be marketed only for approved indications and in accordance with the provisions of the FDA-approved label. Further, if we modify a drug, including any changes in indications, labeling or manufacturing processes or facilities, the FDA may require us to submit and obtain FDA approval of a new or supplemental NDA, which may require us to develop additional data or conduct additional preclinical studies and clinical trials.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with CGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from CGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If after approval the FDA determines that the product does not meet applicable regulatory requirements or poses unacceptable safety risks, the FDA may take other regulatory actions, including initiating suspension or withdrawal of the NDA approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. While physicians may prescribe for off-label uses, manufacturers may only promote for the approved indications and in accordance with the provisions of the approved label. The FDA has very broad enforcement authority under the FDCA, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing entities to correct deviations from FDA standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA, and state and federal civil and criminal investigations and prosecutions.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution, including a drug pedigree which tracks the distribution of prescription drugs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad post&#8209;market and regulatory obligations that we must adhere to. We are subject to unannounced inspections by the FDA to determine our compliance with QSRs and other rules and regulations. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a medical device is placed on the market, numerous regulatory requirements apply. These include, but are not limited to:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">QSRs, which require manufacturers, including third&#8209;party manufacturers, to follow stringent design, testing, documentation and other quality assurance procedures during product design and throughout the manufacturing process;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off&#8209;label uses; and</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential withdrawal of 510(k) clearance or other approvals that were previously granted; </span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products;</span></div><div style="margin-bottom:5pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties; or</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">requiring us to repair, replace and/or refund the cost of any medical device we have manufactured or distributed.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, they could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we are subject to a variety of foreign regulations governing clinical trials and the commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process and requirements vary from country to country, and the time may be longer or shorter than that necessary for FDA approval. </span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in Europe, there are several tracks for marketing approval for pharmaceuticals, for product approval and post-approval regulatory processes, depending on the type of product for which approval is sought. Under the centralized procedure, a company submits a single application to the EMA. The marketing application is similar to the NDA in the U.S. and is evaluated by the Committee for Medicinal Products for Human Use, or CHMP, the expert scientific committee of the EMA. If the CHMP determines that the marketing application fulfills the requirements for quality, safety and efficacy, it will submit a favorable opinion to the EC. The CHMP opinion is not binding, but is typically adopted by the EC. A marketing application approved by the EC is valid in all E.U. member states and is recognized by the MHRA. The centralized procedure is required for all biological products, orphan medicinal products and new treatments for neurodegenerative disorders, and it is available for certain other products, including those which constitute a significant therapeutic, scientific or technical innovation.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with FDA, EMA or MHRA approval, we may not be able to secure additional regulatory approvals in a timely manner, if at all. Additionally, as in the U.S., post-approval regulatory requirements, such as those regarding product manufacture, marketing or distribution would apply to any product that is approved in Europe, the U.K., Canada and Latin America, and failure to comply with such obligations could have a material adverse effect on our ability to successfully commercialize any product.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in Europe and the U.S., we will be subject to regulations governing clinical trials, product approvals, and commercial distribution in the U.K, Canada, Latin America and any other jurisdictions in which EXPAREL, ZILRETTA, iovera&#176; or any other future product is approved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-Party Payer Coverage and Reimbursement</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our products and product candidates will depend, in part, upon the availability of coverage and reimbursement from third-party payers at the federal, state and private levels. Government payer programs, including Medicare and Medicaid, private health care insurance companies and managed care plans may deny coverage or reimbursement for a product or therapy in whole or in part if they determine that the product or therapy is not medically appropriate or necessary. Also, third-party payers have attempted to control costs by limiting coverage and the amount of reimbursement for particular procedures, medical devices or drug treatments. The U.S. Congress and state legislatures from time to time propose and adopt </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiatives aimed at cost containment that could impact our ability to sell our products at a price level high enough to realize an appropriate return on our investment, which would materially impact our results of operations.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the &#8220;Affordable Care Act&#8221;), a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Affordable Care Act revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates owed to states by pharmaceutical manufacturers for covered outpatient drugs. The Affordable Care Act also established a new Medicare Part&#160;D coverage gap discount program, in which drug manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand name drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Substantial new provisions affecting compliance have also been enacted, which may require us to modify our business practices with healthcare practitioners. There have been proposed in Congress a number of legislative initiatives regarding healthcare, including possible repeal of the Affordable Care Act. At this time, it remains unclear whether there will be any changes made to the Affordable Care Act. The full impact that the Affordable Care and other new laws will have on our business is uncertain. However, such laws appear likely to continue the pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. Moreover, in the coming years, additional changes could be made to governmental healthcare programs that could significantly impact the success of our products.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of our products may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the U.S. has increased, and we expect will continue to increase, the pressure on pharmaceutical and medical device pricing. Some third-party payers require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers that use such therapies, or place limits on the amount of reimbursement. Coverage policies and third-party payer reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for our products, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. There can be no assurance that our products will be considered medically reasonable and necessary for a specific indication, that our products will be considered cost-effective by third-party payers or that an adequate level of reimbursement will be available so that the third-party payers&#8217; reimbursement policies will not adversely affect our ability to sell our products profitably.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing/Data Exclusivity</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity provisions under the FDCA can delay the submission or approval of certain applications of other companies seeking to reference another company&#8217;s NDA. The FDA may grant three or five years of marketing exclusivity in the U.S. for the approval of new or supplemental NDAs, including Section&#160;505(b)(2) NDAs, for, among other things, new indications, dosages or dosage forms of an existing drug, if new clinical investigations that were conducted or sponsored by the applicant are essential to the approval of the application. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, or a Section 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. Additionally, six months of marketing exclusivity in the U.S. is available under Section&#160;505A of the FDCA if, in response to a written request from the FDA, a sponsor submits and the agency accepts requested information relating to the use of the approved drug in the pediatric population. This six-month pediatric exclusivity period is not a standalone exclusivity period, but rather is added to any existing patent or non-patent exclusivity period for which the drug product is eligible. In the past, based on our clinical trial program for EXPAREL, the FDA granted three years of marketing exclusivity to EXPAREL, which expired in October 2014. In Europe, manufacturers qualify for 8 years of data exclusivity upon marketing authorization approval and an additional two years of market exclusivity, for a total of 10 years of regulatory exclusivity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Requirements</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with the FDA&#8217;s CGMP requirements and comparable regulations in other countries. The CGMP provisions include requirements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our products must meet CGMP requirements to the satisfaction of the FDA and other authorities pursuant to a pre-approval inspection before we can use them to manufacture our products. We and any third-party manufacturers we engage or with which we partner are also subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations. Failure to comply with these and other statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Adverse experiences with the product or product complaints must be reported and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations Pertaining to Sales and Marketing</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a prescription drug or medical device manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug or device. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. There is therefore a possibility that our practices might be challenged under the anti-kickback or similar laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third-party payers (including Medicare and Medicaid) claims for reimbursed drugs, procedures or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical and medical device industries and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the federal civil False Claims Act. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical and medical device manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers or require disclosure to the government and public of such interactions. The laws include the federal Physician Payment Sunshine Act, or &#8220;sunshine&#8221; provisions, enacted in 2010 as part of the Affordable Care Act. The sunshine provisions apply to pharmaceutical and medical device manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments made to physicians and certain other healthcare practitioners or to teaching hospitals. State laws may also require disclosure of pharmaceutical and medical device pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements. Given the lack of clarity in laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. Outside the U.S., other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regenerative Medicine Advanced Therapies</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the 21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Century Cures Act, Congress amended the FDCA to create the regenerative medicine advanced therapies, or RMAT, designation. The RMAT designation is intended to facilitate efficient development and expedite review of regenerative medicine advanced therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. RMAT covers cell therapies, gene therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. A sponsor may request that the FDA designate a regenerative medicine advanced therapy concurrently with or at any time after submission of an IND. The FDA has 60 calendar days to determine whether the criteria are met, including whether there is preliminary clinical evidence indicating the potential to address unmet medical needs for a serious or life-threatening disease or condition. A Biologics License Application (BLA) for a regenerative medicine advanced therapy may be eligible for priority review or accelerated approval through surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of clinical trial sites. Benefits of such designation also include early interactions with the FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine advanced therapy that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Privacy and Security Laws</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to, or our marketing activities may be limited by, the Health Insurance Portability and Accountability Act, or HIPAA and its implementing regulations, which established uniform standards for certain &#8220;covered entities&#8221; (healthcare providers, health plans and healthcare clearinghouses) governing the conduct of certain electronic healthcare transactions and protecting the security and privacy of protected health information. The American Recovery and Reinvestment Act of 2009, commonly referred to as the economic stimulus package, included sweeping expansion of HIPAA&#8217;s privacy and security standards called the Health Information Technology for Economic and Clinical Health Act, or HITECH, which became effective in February 2010. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates&#8221;&#8212;independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes and our manufacturing processes involve the controlled use of hazardous materials and chemicals and produce waste products, including pharmaceutical residues. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials and waste products, including those related to pharmaceutical residues. While we believe we are in compliance with applicable environmental regulations, the failure to fully comply with any such regulations could result in the imposition of penalties, fines and/or sanctions which could have a material adverse effect on our business. It is possible, however, that environmental issues may arise in the future which we cannot now predict.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working towards improving our sustainable footprint through key practices like waste reduction, water recycling, and using energy efficient equipment where possible. We have a focus on raising awareness and educating associates on reducing our internal use of consumables and natural resources. In addition, we have a broad range of recycling and waste management initiatives at our manufacturing facilities and corporate offices. For example, at our internal manufacturing facilities we have addressed our use and recycling of paper products, aluminum cans, glass, electronics and plastic, as well as disposal of non-recyclables and effective water management.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a risk-based cybersecurity program dedicated to protecting the confidentiality, integrity and availability of our information. We utilize a layered approach in protecting against, and the detection of, cyber-attacks, and leverage outside partnerships to gain intelligence on threats and continue to adjust our protection mechanisms to be effective. All employees receive information security training (including data protection and fraud awareness) on an annual basis, and we use state-of-the-art technology to monitor systems for anomalous behavior. In the event an incident were to occur, a Security Incident Response Team would be convened that consists of members from many functions, including legal counsel. Additionally, we carry a Cyber Insurance policy to help cover investigation and mitigation expenses.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have numerous controls to protect against common attacks, some attacks may still be effective. Our controls are designed to detect, triage and eradicate these attacks. Over the past three years, there have been no known material breaches, and no expenses related to the investigation of such breaches.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Citizenship</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the industry leader in our commitment to non-opioid pain management and providing a non-opioid option to as many patients as possible to redefine the role of opioids as a rescue therapy only. We are dedicated to the principles of social responsibility and good corporate governance. Our Board of Directors is comprised of industry leaders with extensive and diverse experience spanning business and scientific leadership. We hold ourselves to the highest standards and our Code of Business Conduct and Ethics reflects the business practices and principles of behavior that support this commitment. We are deeply invested in the welfare of our patients and employees, the environment and the communities where we live and work. We conduct our operations and manage our product and pipeline programs in a responsible manner and strive to comply with applicable laws, rules and regulations.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we provided support for charitable medical missions in Honduras and Ghana by donating EXPAREL to help support surgeries for patients in need and have also supported the Louisiana State University Opioid Minimization Initiative as well as made a commitment to donate EXPAREL to not-for-profit children&#8217;s hospitals each year over the next three years.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacira Core Values</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a team of dedicated and highly talented professionals focused on driving improved patient outcomes with opioid-reducing strategies. We are an organization built on high ethical standards, an unwavering commitment to patients and transparent communications. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities and society.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The six core values that underpin everything we do are:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Patients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Their safety and welfare are our top priority at all times</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">People</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our greatest asset</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Passion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We are passionate about what we do</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Think</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our thoughts are shared generously</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Trust</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Building trust is essential</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">Teamwork</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The cornerstone of our business success</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Rewards</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to attract and retain talent, we maintain broad-based benefits that are provided to all employees, including our 401(k) retirement plan with an employer matching contribution, employee stock purchase plan, flexible spending accounts, medical, dental and vision care plans, healthcare and dependent care savings accounts, life insurance, short- and long-term disability policies, paid vacation, paid sick time and paid company holidays. Additionally, we reward employees driving significant value creation with a variety of long-term and short-term incentives including a recognition platform, annual performance bonuses, stock options, restricted stock units and a long-term performance cash incentive. We also offer our executives the opportunity to participate in a deferred compensation plan with an employer match. We encourage our employees to give back in their communities and offer one paid day off per year to volunteer. We regularly benchmark our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rewards programs, adjusting as needed, to ensure our total rewards are competitive. We are committed to paying all our employees a fair and living wage.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Management</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a desire to cultivate and develop our future leaders. We regularly assess and identify our emerging talent and support their development with programs including leadership development, executive coaching and mentoring. We track turnover and employee engagement among other metrics, and conduct stay and exit interviews to ensure our talent strategy serves our goal of attracting, developing and retaining top talent to serve as our future leaders and stewards of our vision. We offer targeted selection training for interviewers to ensure a consistent methodology applied in identifying and hiring the best candidates for open positions. We offer a number of critical skills programs including management skills training for people managers, as well as project management and communications training.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Wellbeing, Health and Safety</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira is committed to the total wellbeing of our employees and their families. We offer a range of benefits designed to meet individual needs and help employees and their families live healthy lives. This includes a variety of tools to promote total wellbeing in the areas of health, wealth, work and life to keep our employees and their families healthy, lower their healthcare costs and reduce stress. For example, we provide access to free biometric screenings, an employee assistance program, or EAP, and host in-person and webinar trainings on stress management and other EAP benefits, access to telemedicine including mental health visits, a health advocate service to help employees and their families navigate the healthcare system, activity challenges and more. We offer our eligible employees flexible work arrangements&#8212;including remote working opportunities, flexible schedules and reduced schedules to help achieve an appropriate work/life balance. Benefits that protect financial wellbeing are also provided, including but not limited to: a paid parental leave benefit, insurance to help protect assets during times of short- and long-term disability, life insurance and accidental death and dismemberment insurance, financial education seminars on savings, debt and other financial topics, access to discounts on a variety of products and services and incentives to engage in a new or maintain a wellbeing activity. In addition, we maintain a recognition program based on our core values, known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celebrate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, through which we recognize each other&#8217;s commitment to making a meaningful difference for our patients and communities and create a shared culture where everyone is responsible for living up to and sustaining our core values.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a formal Environmental Health and Safety (EHS) Program. It is our policy that everyone is entitled to a safe and healthful place to work. We recognize that accident prevention, employee wellness and efficiency of operations are directly related to quality, production and cost. Pacira operates its facilities in a manner that protects the health of its employees and minimizes the impact of its operations on the environment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Equity and Inclusion</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to intentionally cultivating a culture of inclusion where all feel welcomed and valued for their backgrounds, perspectives and experiences. We hold one another accountable to promote trust and transparency in support of our communities and collective purpose. In support of this diversity, equity and inclusion vision, we have developed a strategy and multi-year roadmap, prioritizing education and training, and have also developed a global labor and human rights policy. Our executive team and senior leaders have received training on Unconscious Bias and Inclusive Leadership. We list our job postings on state job banks and distribute them to community engaged veteran, minority, women and diversity organizations. We are committed to evaluating our people processes to ensure we are attracting, developing, promoting and retaining diverse talent.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we established P.O.W.E.R. (Preparing Our Women for Excellence and Results), an employee resource group open to all Pacira colleagues, focused on promoting leadership values, fostering a community of support and the advancement of women through professional development and networking opportunities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we established a cross-functional diversity, equity and inclusion employee council to serve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as an advisory board, comprised of employees who lead, advocate for, inform and communicate our corporate diversity, equity and inclusion strategic initiatives around four key areas: leadership development, diversity recruiting, culture and communications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health and safety of our employees has always been important to us, which is why we took responsible action in response to the COVID-19 pandemic. We covered the cost of COVID-19 testing and treatment for our employees and covered family members under our benefit plans and extended our paid sick leave for COVID-related absences. We amended our 401(k) </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">savings plan to enhance loan eligibility and repayment terms and to permit certain distributions. We implemented additional safety protocols and guidelines at our manufacturing sites and required our non-manufacturing personnel to work from home, including our field sales force and clinical education teams which continue to support our customers remotely. With the reopening of many states, the ability of our sales representatives to renew their in-person engagement efforts, in conjunction with these remote efforts, has occurred across all sites of care, with more focus on physician offices and ASCs. Our offices have since re-opened with strict safety, social distancing and hygiene guidelines implemented, and we continue to support remote working as appropriate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employees</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 697 employees, all of which are full-time. 30 of these employees are Flexion employees who remain with us on a transitional basis of up to eight months. All of our employees are based in the U.S. except for nine located in England and one located in the Netherlands. None of our employees are represented by a labor union, and we consider our current employee relations to be good.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate website is located at www.pacira.com. We file reports and other information with the United States Securities and Exchange Commission, or SEC, as required by the Exchange Act, which are accessible on the SEC&#8217;s website at www.sec.gov. We also make available free of charge through our website our Annual Report, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, proxy statements and any amendments to those reports filed or furnished pursuant to Sections&#160;13(a) and 15(d) of the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. In addition, we regularly use our corporate website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the sections entitled &#8220;Investors&#8221; and &#8220;News,&#8221; as a source of information about us. The foregoing references to our corporate website are not intended to, nor shall they be deemed to, incorporate information on our corporate website into this Annual Report by reference, and the inclusion of our website address in this Annual Report is an inactive textual reference only and is not intended to be an active link to our website.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information in this Annual Report, any of the factors set forth below could significantly and negatively affect our business, financial condition, results of operations or prospects. The trading price of our common stock may decline due to these risks. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements beginning on page&#160;1 of this Annual Report. These risk factors are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development and Commercialization of our Products and Product Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends primarily on our ability to successfully commercialize EXPAREL and ZILRETTA.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested a significant portion of our efforts and financial resources in the development and commercialization of our lead product, EXPAREL, which was first approved by the FDA on October&#160;28, 2011 and commercially launched in April 2012. EXPAREL was approved by the EC on November 16, 2020. During 2021, sales of EXPAREL accounted for 94% of our total revenue, and we expect EXPAREL sales will remain of primary importance for the foreseeable future. We added ZILRETTA to our product portfolio upon completing the Flexion Acquisition in November 2021 and it accounted for 2% of our total revenue in 2021, all of which was recognized during the six weeks after the acquisition. Our success primarily depends on our ability to continue to effectively commercialize EXPAREL and ZILRETTA. Our ability to effectively generate revenues from EXPAREL and ZILRETTA will depend on our ability to, among other things:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create market demand for EXPAREL and ZILRETTA through our marketing and sales activities and other arrangements established for their promotion;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">train, deploy and support a qualified sales force;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">secure formulary approvals for EXPAREL at a substantial number of targeted hospitals and ASCs;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture EXPAREL and ZILRETTA in sufficient quantities in compliance with requirements of regulatory agencies and at acceptable quality and pricing levels in order to meet commercial demand;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implement and maintain agreements with wholesalers and distributors on commercially reasonable terms;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive adequate levels of coverage and reimbursement for EXPAREL and ZILRETTA from commercial health plans and governmental health programs;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain compliance with regulatory requirements;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain regulatory approvals for additional indications and geographic expansion for the use of EXPAREL and ZILRETTA;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensure that our entire supply chain efficiently and consistently delivers EXPAREL and ZILRETTA to our customers; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain and defend our patent protection and regulatory exclusivity for EXPAREL and ZILRETTA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption in our ability to generate revenues from the sale of EXPAREL and ZILRETTA will have a material and adverse impact on our results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our efforts to successfully commercialize EXPAREL and ZILRETTA are subject to many internal and external challenges and if we cannot overcome these challenges in a timely manner, our future revenues and profits could be materially and adversely impacted.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL has been a commercialized drug since 2012. We continue to expend significant time and resources to train our sales force to be credible and persuasive in convincing physicians, hospitals and ASCs to use EXPAREL. In addition, we also must train our sales force to ensure that a consistent and appropriate message about EXPAREL is delivered to our potential customers. If we are unable to effectively train our sales force and equip them with effective materials, including medical and sales literature to help them inform and educate potential customers about the benefits and risks of EXPAREL and its proper administration, our efforts to successfully commercialize EXPAREL could be put in jeopardy, which could have a material adverse effect on our future revenues and profits.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our extensive internal efforts, the successful commercialization of EXPAREL will require many third parties, over whom we have no control, to choose to utilize EXPAREL. These third parties include physicians and hospital pharmacy and therapeutics committees (&#8220;P&amp;T committees&#8221;). Generally, before we can attempt to sell EXPAREL in a hospital, EXPAREL must be approved for addition to that hospital&#8217;s list of approved drugs, or formulary list, by the hospital&#8217;s P&amp;T committee. A hospital&#8217;s P&amp;T committee typically governs all matters pertaining to the use of medications within the institution, including the review of medication formulary data and recommendations for the appropriate use of drugs within the institution </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the medical staff. The frequency of P&amp;T committee meetings at hospitals varies considerably, and P&amp;T committees often require additional information to aid in their decision-making process. Therefore, we may experience substantial delays in obtaining formulary approvals. Additionally, hospital pharmacists may be concerned that the cost of acquiring EXPAREL for use in their institutions will adversely impact their overall pharmacy budgets, which could cause pharmacists to resist efforts to add EXPAREL to the formulary, or to implement restrictions on the usage of EXPAREL or to encourage use of a lower cost dose than a surgeon or anesthesiologist would otherwise choose in order to control costs. We cannot guarantee that we will be successful in obtaining the approvals we need from enough P&amp;T committees quickly enough to optimize hospital sales of EXPAREL. Even if we obtain hospital formulary approval for EXPAREL, physicians must still prescribe EXPAREL for its commercialization to be successful.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If EXPAREL does not achieve broader market acceptance, the revenues that we generate from its sales will be limited. The degree of market acceptance of EXPAREL also depends on a number of other factors, including:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care for the targeted indications for EXPAREL, which could reduce the marketing impact of any claims that we can make;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative efficacy, convenience and ease of administration of EXPAREL;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse events associated with EXPAREL;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment versus economic and clinical benefit, both in absolute terms and in relation to alternative treatments;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payers, and by government healthcare programs, including Medicare and Medicaid;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent and strength of our marketing and distribution of EXPAREL;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety, efficacy and other potential advantages over, and availability of, alternative treatments, including, in the case of EXPAREL, a number of products already used to treat pain in the hospital setting; and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution and use restrictions imposed by regulatory agencies or to which we agree as part of a mandatory risk evaluation and mitigation strategy or voluntary risk management plan.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to effectively promote and sell EXPAREL and any product candidates that we may develop, license or acquire in the hospital or ASC marketplace will also depend on pricing and cost effectiveness, including our ability to produce a product at a competitive price and therefore achieve acceptance of the product onto hospital formularies, and our ability to obtain sufficient third-party coverage or reimbursement. We will also need to demonstrate acceptable evidence of safety and efficacy, as well as relative convenience and ease of administration. Market acceptance could be further limited depending on the prevalence and severity of any expected or unexpected adverse side effects associated with our product candidates.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our approved labels for EXPAREL do not contain claims that EXPAREL is safer or more effective than competitive products and do not permit us to promote EXPAREL as being superior to competing products. Further, the availability of inexpensive generic forms of postsurgical pain management products may also limit acceptance of EXPAREL among physicians, patients and third-party payers. If EXPAREL does not achieve a broader level of acceptance among physicians, patients and third-party payers, we may not generate meaningful revenues from EXPAREL, and we may not remain profitable.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILRETTA is only approved for the management of OA pain of the knee for patients in the U.S. Successful commercialization of ZILRETTA is subject to many risks. Market acceptance of ZILRETTA will depend on a number of factors, including:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety as demonstrated in clinical trials;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to demonstrate the impact of real-world evidence;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and market introduction of competitive products;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product label and clinical indications for which the product is approved;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, the medical community and patients of the product as a safe and effective treatment;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to distinguish safety and efficacy from existing, less expensive generic alternative therapies;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience of prescribing, administrating and initiating patients on the product;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential and perceived advantages or value of the product over alternative treatments;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the economics of a buy-and-bill product and discounts and rebates we offer;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement by third-party payers and government authorities to support pricing;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of sales and marketing efforts.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If ZILRETTA does not achieve a broader level of acceptance among physicians, patients and third-party payers, we may not generate meaningful revenues from ZILRETTA, and our business, financial condition and results of operations may suffer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to achieve and maintain adequate levels of third-party payer coverage and reimbursement for any product we may offer, on reasonable pricing terms, that product&#8217;s commercial success may be severely hindered.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILRETTA is a physician-administered product, and therefore physicians are required to purchase and manage the inventory of ZILRETTA, prior to administering the product to patients. Physicians obtain reimbursement for ZILRETTA from the applicable third-party payer, such as Medicare or a health insurance company, only after it has been administered to patients. This is called a &#8220;buy and bill&#8221; process. Because physicians are at financial risk for the cost of a &#8220;buy and bill&#8221; product until they have been reimbursed, concerns about reimbursement can impact a physician&#8217;s decision to use the product. The future growth of ZILRETTA depends on the availability of coverage and adequate reimbursement from third-party payers, including commercial payers, governmental healthcare programs, such as Medicare and Medicaid and managed care organizations, among others. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payers to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from third-party payers are critical to product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. The resulting reimbursement payment rates for ZILRETTA might not be adequate or may require co-payments that patients find unacceptably high. If coverage and reimbursement for ZILRETTA are not available or only available at limited levels, we may not be able to successfully commercialize ZILRETTA, which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from other pharmaceutical, medical device and biotechnology companies. Our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical, medical device and biotechnology industries are intensely competitive and subject to rapid and significant technological change. Our major competitors include organizations such as major multinational pharmaceutical and medical device companies, established biotechnology companies and specialty pharmaceutical and generic drug companies. Many of our competitors have greater financial and other resources than we have, such as larger research and development staff, more extensive marketing, distribution, sales and manufacturing organizations and experience, more extensive clinical trial and regulatory experience, expertise in prosecution of intellectual property rights and access to development resources like personnel and technology. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis technologies, drug products and medical devices that are more effective or less costly than EXPAREL, ZILRETTA, iovera&#176; or any product candidate that we are currently developing or that we may develop, license or acquire, which could render our products obsolete and noncompetitive or significantly harm the commercial opportunity for EXPAREL, ZILRETTA, iovera&#176; or our product candidates.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, our competitors may obtain patent protection or other intellectual property rights that may limit our ability to develop other indications for, or commercialize, EXPAREL, ZILRETTA, iovera&#176; or our product candidates. Our competitors may also develop drugs or medical devices that are safer, more effective, useful or less costly than ours and may be more successful than us in manufacturing and marketing their products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL competes with well-established products with similar indications. Competing products available for postsurgical pain management include opioids such as morphine, fentanyl, meperidine and hydromorphone, each of which is available generically from several manufacturers, and several of which are available as proprietary products using novel delivery systems. Ketorolac, an NSAID is also available generically in the U.S. from several manufacturers, and Caldolor (ibuprofen for injection), an NSAID, has been approved by the FDA for pain management and fever in adults. EXPAREL also competes with currently marketed non-opioid products such as bupivacaine, marcaine, ropivacaine and other anesthetics/analgesics, all of which are also used in the treatment of postsurgical pain and are available as either oral tablets, injectable dosage forms or administered using novel delivery systems. Additional products may be developed for the treatment of acute pain, including new injectable NSAIDs, novel opioids, new formulations of currently available opioids and NSAIDs, long-acting local anesthetics and new chemical entities as well as alternative delivery forms of various opioids and NSAIDs. EXPAREL also competes with elastomeric bags/catheter devices intended to provide bupivacaine over several days. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILRETTA competes with immediate-release steroids and hyaluronic acid-containing products, as well as stem cell and PRP injections. Immediate-release TA and other injectable immediate-release steroids, which are the current IA standard of care for OA pain, are available in generic form and are therefore relatively inexpensive compared to the pricing for ZILRETTA. These generic steroids also have well-established market positions and familiarity with physicians, healthcare payers, and patients. Although we believe the proven and extended pain relief evidenced in clinical trials demonstrate that ZILRETTA represents a clinically meaningful and highly efficacious option, it is possible that we will receive data from additional clinical trials or in a post-marketing setting from physician and patient experiences with the commercial product that does not continue to support such interpretations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The iovera&#176; system competes with cryotherapy devices as well as other devices such as cooled radio-frequency ablation devices that block or degenerate peripheral nerves involved in conducting pain signals.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory approval for any approved product is limited to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and allegations of our failure to comply with such approved indications could limit our sales efforts and have a material adverse effect on our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, labeling, advertising and promotion of prescription drugs and medical devices is strictly regulated. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval granted is limited to those specific diseases and indications for which a product is deemed to be safe and effective by an appropriate regulatory agency. For example, the FDA-approved label for EXPAREL does not include an indication in obstetrical paracervical block anesthesia. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain regulatory approval for any desired future indications for our products and product candidates, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an example, in the U.S. and Europe, while physicians may choose, and are generally permitted to prescribe drugs, medical devices or treatments for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote the products is narrowly limited to those indications that are specifically approved by the FDA, EMA or MHRA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical and medical device companies on the subject of off-label use. In the U.S., although recent court decisions suggest that certain off-label promotional activities may be protected under the First Amendment of the U.S. Constitution, the scope of any such protection is unclear. If our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to issue warning letters or untitled letters, bring an enforcement action against us, suspend or withdraw an approved product from the market, require a recall or institute fines or civil fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our reputation and our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain effective marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may be unable to generate additional product revenues.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to build our commercial infrastructure for the marketing, sale and distribution of pharmaceutical products. In order to continue commercializing our products effectively, we must continue to build our marketing, sales and distribution capabilities. The establishment, development and training of our sales force and related compliance plans to market our products is expensive and time consuming. In the event we are not successful in further developing our marketing and sales infrastructure, we may not be able to continue to successfully commercialize our products, including outside the U.S., which would limit our ability to generate additional product revenues.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our internal marketing and sales efforts, we have entered into agreements with third-party distributors to promote and sell EXPAREL in certain territories. For example, we previously had a co-promotion agreement with DePuy Synthes to market and promote the use of EXPAREL for orthopedic procedures in the U.S. market which we terminated effective January 2021. Additionally, in March 2020, Flexion entered into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo for the development and commercialization (other than manufacturing) of ZILRETTA in Greater China. There can be no assurance that such distributors and promoters will be successful in marketing and promoting our products.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional distribution arrangements in the future, including arrangements with third-party distributors to commercialize and sell our products in certain foreign countries. The use of distributors involves certain risks, including risks that such distributors will:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not effectively distribute or support our products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not provide us with accurate or timely information regarding their inventories, the number of accounts using our products or complaints about our products;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to comply with their obligations to us;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to comply with laws and regulations to which they are subject, whether in the U.S. or in foreign jurisdictions;</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce or discontinue their efforts to sell or promote our products; or</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cease operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such failure may result in decreased sales, which would have an adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to perform many essential services for EXPAREL, ZILRETTA and iovera&#176; and will rely on third parties for any other products that we commercialize. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize EXPAREL, ZILRETTA and iovera&#176; will be significantly impacted and we may be subject to regulatory sanctions.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with third-party service providers to perform a variety of functions related to the sale and distribution of EXPAREL, ZILRETTA and iovera&#176;, key aspects of which are out of our direct control. These service providers provide key services related to customer service support, warehousing and inventory program services, distribution services, contract administration and chargeback processing services, accounts receivable management and cash application services, financial management and information technology services. In addition, our inventory is stored at two warehouses maintained by two service providers. We substantially rely on these providers as well as other third-party providers that perform services for us, including entrusting our inventories of products to their care and handling. If these third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines or otherwise do not carry out their contractual duties to us, or encounter physical or natural damage at their facilities, our ability to deliver product to meet commercial demand would be significantly impaired. In addition, we may engage third parties to perform various other services for us relating to adverse event reporting, safety database management, fulfillment of requests for medical information regarding our product candidates and related services. If the quality or accuracy of the data maintained by these service providers is insufficient, we could be subject to regulatory sanctions.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution of our pMVL-based products, including EXPAREL, requires cold-chain distribution provided by third parties, whereby the product must be maintained between specified temperatures. If a problem occurs in our cold-chain distribution processes, whether through our failure to maintain our products or product candidates between specified temperatures or because of a failure of one of our distributors or partners to maintain the temperature of the products or product candidates, the product or product candidate could be adulterated and rendered unusable. We have obtained limited inventory and cargo insurance coverage for our products. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. This could have a material adverse effect on our business, financial condition, results of operations and reputation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to increase the size of our organization and effectively manage our sales force, and we may experience difficulties in managing growth.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 697 employees. We may need to expand our personnel resources in order to manage our operations and sales of EXPAREL, ZILRETTA and iovera&#176;. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. In addition, we may not be able to recruit and retain qualified personnel in the future, particularly in marketing positions, due to competition for personnel among pharmaceutical and medical device businesses, and the failure to do so could have a significant negative impact on our future product revenues and business results. Our need to effectively manage our operations, growth and various projects requires that we:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the hiring and training of an effective commercial organization for the commercialization of EXPAREL, ZILRETTA and iovera&#176;, and establish appropriate systems, policies and infrastructure to support that organization;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to establish and maintain effective relationships with distributors and commercial partners for the promotion and sale of our products;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensure that our distributors, partners, suppliers, consultants and other service providers successfully carry out their contractual obligations, provide high quality results and meet expected deadlines;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our development efforts and clinical trials effectively;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our manufacturing capabilities and effectively manage our co-production arrangements with Thermo Fisher and Providien;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to carry out our own contractual obligations to our licensors and other third parties; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to improve our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our development and commercialization goals. Additionally, these tasks may impose a strain on our administrative and operational infrastructure. If we are unable to effectively manage our growth, our product sales and resulting revenues will be negatively impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manage our business effectively if we are unable to attract and retain key personnel.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified management and commercial, scientific and clinical personnel due to the intense competition for qualified personnel among biotechnology, pharmaceutical, medical device and other businesses, as well as universities, non-profit research organizations and government entities, particularly in Tampa, Florida; San Diego, California and northern New Jersey. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the development and manufacturing expertise for our products and pMVL drug delivery technology and the commercialization expertise of certain members of our senior management. In particular, we are highly dependent on the skills and leadership of our senior management team. If we lose one or more of these key employees, our ability to successfully implement our business strategy could be seriously harmed. Replacing key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully. Competition to hire from this limited talent pool is intense, and we may be unable to hire, train, retain or motivate additional key personnel.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for EXPAREL, ZILRETTA, iovera&#176; or product candidates that we may develop and may have to limit their commercialization.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of EXPAREL, ZILRETTA, iovera&#176; and any product candidates that we may develop, license or acquire in clinical trials and the sale of any products for which we obtain regulatory approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers or others using, administering or selling our products. We have been a party of these suits in the past and may be again in the future. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue from decreased demand for our products and/or product candidates;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation or financial stability;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management attention;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our products and/or product candidates.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained limited product liability insurance coverage for our products and our clinical trials with a $10.0&#160;million annual aggregate coverage limit. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer, including our indemnification obligations to other parties. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage on acceptable terms, at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include the sale of additional commercial products upon regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing, or at all. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical devices that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause the price of our common stock to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to manufacture our products in sufficient quantities and at acceptable quality and pricing levels, or to fully comply with CGMP regulations, we may face delays in the commercialization of these products or be unable to meet market demand, and may lose potential revenues.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of EXPAREL and ZILRETTA requires significant expertise and capital investment, including the development of advanced manufacturing techniques, process controls and the use of specialized processing equipment. We must comply with federal, state and foreign regulations, including the FDA&#8217;s regulations governing CGMP, enforced by the FDA through its facilities inspection program and by similar regulatory authorities in other jurisdictions where we do business. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The FDA or similar foreign regulatory authorities at any time may implement new standards or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of our products. Any failure by us or our manufacturing partner to comply with applicable regulations may result in fines and civil penalties, suspension of production, product seizure or recall, operating restrictions, imposition of a consent decree, modification or withdrawal of product approval or criminal prosecution and would limit the availability of our product. Any manufacturing defect or error discovered after products have been produced and distributed also could result in significant consequences, including costly recall procedures, re-stocking costs, damage to our reputation and potential for product liability claims.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA requires manufacturers of medical devices to adhere to certain regulations, including the FDA&#8217;s QSRs, which requires periodic audits, design controls, quality control testing and documentation procedures, as well as complaint evaluations and investigations. Regulations regarding the development, manufacture and sale of medical products are evolving and are subject to change in the future.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to produce the required commercial quantities of our products to meet market demand those products on a timely basis or at all, or if we fail to comply with applicable laws for the manufacturing of our products, we will suffer damage to our reputation and commercial prospects, we will lose potential revenues and we may be required to expend significant resources to resolve any such issues.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to expand our manufacturing operations or outsource such operations to third parties.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To successfully meet future customer demand for EXPAREL, ZILRETTA and iovera&#176;, we may need to expand our existing commercial manufacturing facilities or establish large-scale commercial manufacturing capabilities. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. As a result, we must continue to improve our manufacturing processes to allow us to reduce our production costs. We may not be able to manufacture our drugs and/or medical devices at a cost or in quantities necessary to be commercially successful.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The build-up or other expansion of our internal manufacturing capabilities for EXPAREL production in San Diego, California and co-production capabilities for EXPAREL and ZILRETTA at Thermo Fisher&#8217;s Swindon, England site, exposes us to significant up-front fixed costs. If market demand for our products does not align with our expanded manufacturing capacity, we may be unable to offset these costs and to achieve economies of scale, and our operating results may be adversely affected as a result of high operating expenses. Alternatively, if we experience demand for our products in excess of our estimates, our facilities may be insufficient to support higher production volumes, which could harm our customer relationships and overall reputation. Our ability to meet such excess demand could also depend on our ability to raise additional capital and effectively scale our manufacturing operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the procurement time for the equipment that we use to manufacture EXPAREL and ZILRETTA requires long lead times. Therefore, we may experience delays, additional or unexpected costs and other adverse events in connection with our capacity expansion projects, including those associated with potential delays in the procurement of manufacturing equipment required to manufacture EXPAREL or ZILRETTA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to expanding our internal manufacturing facilities, we may enter into arrangements with third parties to supply, manufacture, package, test and/or store EXPAREL, ZILRETTA, iovera&#176; or our other products, such as our manufacturing arrangements with Thermo Fisher and Providien. Entering into such arrangements requires testing and compliance inspections, regulatory agency approvals and development of the processes and facilities necessary for the production of our products. Such arrangements also involve additional risks, many of which would be outside of our control. Such risks include disruptions or delays in production, manufactured products that do not meet our required specifications, the failure of such third-party manufacturers to comply with CGMP regulations or other regulatory requirements, protection of our intellectual property and manufacturing process, loss of control of our complex manufacturing process, inabilities to fulfill our commercial needs and financial risks in connection with our investment in setting up a third-party manufacturing process, such as the substantial capital outlays that were required by us to assist in setting up our manufacturing process at Thermo Fisher&#8217;s facility.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to timely achieve and maintain satisfactory production yields and quality, whether through our internal manufacturing capabilities or arrangements with contract manufacturers, our relationships with potential customers and overall reputation may be harmed and our revenues could decrease.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our inability to continue manufacturing adequate supplies of our products could result in a disruption in the supply to our customers and partners, which could have a material adverse impact on our business and results of operations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL is currently manufactured at our facilities in San Diego, California; both EXPAREL and ZILRETTA are currently manufactured at the Thermo Fisher facility in Swindon, England and iovera&#176; is currently manufactured at our facilities in San Diego, California; Fremont, California and at the Providien facility in Tijuana, Mexico. These facilities are the only currently approved sites for manufacturing EXPAREL, ZILRETTA and iovera&#176; in the world. We may experience temporary or prolonged suspensions in production of our products due to issues in our manufacturing process that must be remediated or in response to inspections conducted by the FDA or similar foreign regulatory authorities, which could have a material adverse effect on our business, financial position and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our San Diego and Fremont facilities in California, the Thermo Fisher facility in Swindon, England and the Providien facility in Tijuana, Mexico are also subject to the risks of a natural or man-made disaster, including earthquakes, floods and fires, or other business disruptions. In addition, we have obtained limited property and business interruption insurance coverage for our manufacturing sites in San Diego, Fremont, England and Mexico. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. There can be no assurance that we would be able to meet our requirements for EXPAREL, ZILRETTA or iovera&#176; if there were a catastrophic event or failure of our current manufacturing systems. If we are required to change or add a new manufacturer or supplier, the process would likely require prior FDA and/or equivalent foreign regulatory authority approval and would be very time consuming. An inability to continue manufacturing adequate supplies of EXPAREL, ZILRETTA or iovera&#176; at our facilities could result in a disruption in the supply of these products to our customers and partners and a breach of our contractual obligations to such counterparties.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our co-production and other agreements with Thermo Fisher may involve unanticipated expenses and delays.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Thermo Fisher have entered into a Co-Production Agreement, Technical Transfer and Service Agreement and Manufacturing and Supply Agreement. Under these agreements, Thermo Fisher undertook certain technical transfer activities and construction services to prepare Thermo Fisher&#8217;s Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites, of which the first suite received FDA approval in May 2018 and began commercial production in February 2019. In August 2021, the second EXPAREL suite received FDA approval and began commercial production. We agreed with Thermo Fisher, among other things, to provide them with the process equipment necessary to manufacture EXPAREL in these suites.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, Flexion and Thermo Fisher entered into the ZILRETTA Manufacturing and Supply Agreement and the ZILRETTA Technical Transfer and Service Agreement related to the manufacture of ZILRETTA at the same Thermo Fisher site in Swindon, England where our EXPAREL suites are located. Thermo Fisher agreed to undertake certain transfer activities and construction services needed to prepare its facility for the commercial manufacture of ZILRETTA in dedicated manufacturing suites. Flexion provided Thermo Fisher with certain equipment and materials necessary to manufacture ZILRETTA.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Thermo Fisher facilities require regulatory approval prior to any production and manufacturing of EXPAREL and ZILRETTA. While we have anticipated and budgeted for additional capital expenditures associated with the Thermo Fisher suites for both EXPAREL and ZILRETTA, if the Thermo Fisher suites do not maintain their regulatory approvals (or fail to receive any additional regulatory approvals that may be needed in the future), this could have a material adverse effect on our business, financial position and results of operations.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the production under these agreements involve additional risks, many of which would be outside of our control, such as disruptions or delays in production, manufactured products that do not meet our required specifications, the failure of Thermo Fisher to comply with CGMP regulations or other regulatory requirements, protection of our intellectual property and manufacturing processes, loss of control of our complex manufacturing processes and inabilities to fulfill our commercial needs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties for the timely supply of specified raw materials and equipment for the manufacture of EXPAREL, ZILRETTA and iovera&#176;. Although we actively manage these third-party relationships to provide continuity and quality, some events which are beyond our control could result in the complete or partial failure of these goods and services. Any such failure could have a material adverse effect on our financial condition and operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase certain raw materials and equipment from various suppliers in order to manufacture our products. The acquisition of certain of these materials may require considerable lead times, and our ability to source such materials is also dependent on logistics providers. If we are unable to source the required raw materials and equipment from our suppliers on a timely basis and in accordance with our specifications, we may experience delays in manufacturing and may not be able to meet our customers&#8217; or partners&#8217; demands for our products. Additionally, we have some sole sources of supply for certain materials </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and equipment used in our manufacturing processes. Should the need arise to qualify additional suppliers or change suppliers, we could bear substantial costs and could fail to maintain adequate production levels to meet demand for our products. In addition, we and our third-party suppliers must comply with federal, state and foreign regulations, including CGMP regulations, and any failure to comply with applicable regulations, or failure of government agencies to provide necessary authorizations, may harm our ability to manufacture and commercialize our products on a timely and competitive basis, which could result in decreased product sales and lower revenues.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the global impact of COVID-19 continues, we may experience additional disruptions that could severely impact our supply chain, which would disrupt our clinical trials and commercialization efforts. To the extent that our vendors are unable to comply with their obligations under our agreements or cannot deliver goods or services timely, our ability to continue meeting commercial demand for our products or advancing development of our product candidates may become impaired.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could incur higher costs for certain goods or services due to inflation or increased freight costs. While </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">global industry-wide logistics challenges did not negatively impact us during the year ended December 31, 2021, we may experience such challenges in 2022. We also rely on international shipping to transport our products to their various geographic markets. During the year ended December 31, 2021, international shipping to the U.S. was disrupted and delayed due to congestion in west coast ports. Continued or additional delays in shipping may cause us to have to use more costly methods to ship our products. In addition, global inflation may contribute to higher incremental freight costs and such inflation may result in higher freight costs. Failure to adequately produce and timely ship our products to customers could lead to lost potential revenue, failure to meet customer demand, strained relationships with customers, including wholesales, and diminished brand loyalty. Despite our actions to mitigate these impacts, we may still be impacted by global logistics challenges in 2022.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth depends on our ability to identify, develop, acquire or in-license products and if we do not successfully identify, develop, acquire or in-license related product candidates or integrate them into our operations, we may have limited growth opportunities.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important part of our business strategy is to continue to develop a pipeline of product candidates by developing, acquiring or in-licensing products, businesses or technologies that we believe are a strategic fit with our focus on the hospital marketplace. However, these business activities may entail numerous operational and financial risks, including:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant capital expenditures;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty or inability to secure financing to fund development activities for such development, acquisition or in-licensed products or technologies;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for development, acquisition or in-licensing of new products;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the successful integration of acquired products, businesses or technologies into our operations, and achieving the expected benefits and synergies from such acquisitions;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management&#8217;s time and attention;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected development, acquisition or in-license and integration costs;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty entering markets in which we have limited or no direct experience;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in managing multiple product development programs; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to successfully develop new products or clinical failure.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited resources to identify and execute the development, acquisition or in-licensing of products, businesses and technologies and integrate them into our current infrastructure. We may compete with larger pharmaceutical and medical device companies and other competitors, including public and private research organizations, academic institutions and government agencies, in our efforts to establish new collaborations and in-licensing opportunities. These competitors may have access to greater financial resources, research and development staffs and facilities than us and may have greater expertise in identifying and evaluating new opportunities. We may not be successful in locating and acquiring or in-licensing additional desirable product candidates on acceptable terms or at all. We may also not be successful in developing or commercializing our current product candidates. Such efforts may require the dedication of significant financial and personnel resources, and any diversion of resources may also disrupt our management from expanding on EXPAREL, ZILRETTA or iovera&#176; sales. Moreover, we may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">devote resources to potential development, acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We make substantial investments in research and development and unsuccessful investments could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The industry in which we compete is characterized by rapid technological change, changes in customer requirements, frequent new product introductions and enhancements and evolving industry standards, and new delivery methods. In order to remain competitive, we have made, and expect to continue to make, significant investments in research and development. If we fail to develop new and enhanced products and technologies, if we focus on products and technologies that do not become widely adopted, or if new competitive products and technologies that we do not support become widely accepted, demand for our products may be reduced. Increased investments in research and development or unsuccessful research and development efforts could cause our cost structure to fall out of alignment with demand for our products, which would have a negative impact on our financial results.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing activities involve the controlled storage, use and disposal of hazardous materials, including the components of our products, product candidates and other hazardous compounds. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling, release and disposal of, and exposure to, these hazardous materials. Violation of these laws and regulations could lead to substantial fines and penalties. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials or unintended failure to comply with these laws and regulations. In the event of an accident or failure to comply with these laws and regulations, state or federal authorities may curtail our use of these materials and interrupt our business operations. In addition, we could become subject to potentially material liabilities relating to the investigation and cleanup of any contamination, whether currently unknown or caused by future releases.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems are vulnerable to damage from computer viruses, human error, unauthorized access, natural disasters, intentional acts of vandalism, terrorism, war and network, telecommunication and electrical failures. Any system failure, accident or security breach that causes interruptions in our operations could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed clinical trials for our products could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability, reputation damage and harm to our business operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is to commercialize our products in the U.S. and abroad, occasionally seeking collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of our products in other countries. Accordingly, we may enter into collaboration arrangements in the future on a selective basis. Any future collaboration arrangements that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaboration arrangements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations with pharmaceutical and/or medical device companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials are expensive, lengthy and have uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results. Clinical trials may fail to demonstrate the safety and efficacy of our drug products or medical devices, which could prevent or significantly delay obtaining regulatory approval.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to receiving approval to commercialize any of our drug products or medical devices, we must demonstrate with scientifically appropriate and statistically sound evidence from well-controlled clinical trials, and to the satisfaction of the FDA and other regulatory authorities, that each of the products are both safe and effective. For each drug product, we will need to demonstrate its efficacy and monitor its safety throughout the process. Clinical trials are expensive and can take many years to complete, and their outcomes are inherently uncertain. If such development is unsuccessful, our business and reputation would be harmed and our stock price would be adversely affected.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our drug and medical device products are prone to the risks of failure inherent in development. Clinical trials of new drug and medical device products sufficient to obtain regulatory approval are expensive and take years to complete. We may not be able to successfully complete clinical testing within the time frame we have planned, or at all. We may experience numerous unforeseen events during, or as a result of, the clinical trial process which could delay or prevent us from receiving regulatory approval or commercializing our products. In addition, the results of pre-clinical studies and early stage clinical trials of our products do not necessarily predict the results of later-stage clinical trials. Later-stage clinical trials may fail to demonstrate that a product is safe and effective despite having progressed through initial clinical testing. Even if we believe the data collected from clinical trials of our products is promising, such data may not be sufficient to support approval by regulatory agencies. Pre-clinical and clinical data can be interpreted in different ways, and results generated in our completed clinical trials do not ensure that any future clinical trials will be successful or consistent with the results generated in previous trials.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, regulatory authorities could interpret such data in different ways than we or our partners do, which could delay, limit or prevent regulatory approval. Regulatory authorities, our institutional review boards, our contract research organizations or we ourselves may suspend or terminate our clinical trials for our drug products and medical devices. Any failure or significant delay in completing clinical trials for our drug products or medical devices, or in receiving regulatory approval for the sale of any drugs or medical devices resulting from our products, may severely harm our business and reputation. Even if we receive regulatory approvals, our drug and medical device products may later exhibit adverse effects that may limit or prevent their widespread use, may cause the regulatory authority to revoke, suspend or limit their approval, or may force us to withdraw products derived from those drug or medical device products from the market.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our dependence on contract research organizations could result in delays in and additional costs for our drug development efforts.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely on contract research organizations, or CROs, to perform preclinical testing and clinical trials for drug candidates that we choose to develop without a collaborator. If the CROs that we hire to perform our preclinical testing and clinical trials or our collaborators or licensees do not meet deadlines, do not follow proper procedures or a conflict arises between us and our CROs, our preclinical testing and clinical trials may take longer than expected, may be delayed or may be terminated. If we were forced to find a replacement CRO to perform any of our preclinical testing or clinical trials, we may not be able to find a suitable replacement on favorable terms, if at all. Even if we were able to find another CRO to perform a preclinical test or clinical trial, any material delay in a test or clinical trial may result in significant additional expenditures that could adversely affect our operating results. Events such as these may also delay regulatory approval for our drug candidates or our ability to commercialize our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on clinical investigators and clinical sites to enroll patients in our clinical trials and sometimes other third parties to manage the trials and to perform related data collection and analysis, and, as a result, we may face costs and delays outside of our control.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on clinical investigators and clinical sites to enroll patients and sometimes third parties to manage our trials and to perform related data collection and analysis. However, we may be unable to control the amount and timing of resources that the clinical sites which conduct the clinical testing may devote to our clinical trials. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials may be delayed or terminated due to the inability of our clinical investigators to enroll enough patients. Patient enrollment depends on many factors, including the size of the patient population, the nature of the trial protocol, the proximity of patients to clinical sites and the eligibility criteria for the trial. If our clinical investigators and clinical sites fail to enroll a sufficient number of patients in our clinical trials or fail to enroll them on our planned schedule, we may face increased costs, delays or termination of the trials, which could delay or prevent us from obtaining regulatory approvals for our product candidates. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreements with clinical investigators and clinical sites for clinical testing and for trial management services place substantial responsibilities on these parties, which could result in delays in, or termination of, our clinical trials if these parties fail to perform as expected. For example, if any of our clinical trial sites fail to comply with FDA-approved GCPs, we may be unable to use the data gathered at those sites. If these clinical investigators, clinical sites or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, our clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approval for, or successfully commercialize, our product candidates.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to periodic litigation, which could result in losses or unexpected expense of time and resources. </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are called upon to defend ourselves against lawsuits relating to our business. Due to the inherent uncertainties of litigation, we cannot accurately predict the ultimate outcome of any such proceedings. See Note 21, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein for information about our legal proceedings. An unfavorable outcome in these or other proceedings could have an adverse impact on our business, financial condition and results of operations. In addition, any significant litigation in the future, regardless of its merits, could divert management&#8217;s attention from our operations and result in substantial legal fees. In addition, if our stock price is volatile, we may become involved in additional securities class action lawsuits in the future. Any litigation could result in substantial costs and a diversion of management&#8217;s attention and resources that are needed to successfully run our business.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guidelines and recommendations published by various organizations could reduce the demand for or use of our products.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies promulgate regulations and guidelines directly applicable to us and to our products and product candidates. In addition, professional societies, practice management groups, private health and science foundations and other organizations from time to time may publish papers, guidelines or recommendations to the healthcare and patient communities with respect to specific products or classes of products. Recommendations of government agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines that do not recognize a product, suggest limitations or inadequacies of a product or suggest the use of competitive or alternative products as the standard of care to be followed by patients and healthcare providers could result in decreased use or adoption of any of our products which could have an adverse impact on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Risks</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be materially adversely affected if a regulatory or enforcement agency determines that we are promoting or have in the past promoted the &#8220;off-label&#8221; use of our products.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, labeling, advertising and promotion of prescription drugs and medical devices is strictly regulated. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. According to these regulations, companies may not promote drugs or medical devices for &#8220;off-label&#8221; uses&#8212;that is, uses that are not consistent with the product&#8217;s labeling and that differ from those that were approved by the FDA, EMA, MHRA or other regulatory agency. For example, the FDA-approved label for EXPAREL does not include an indication in obstetrical paracervical block anesthesia. In addition to the FDA approval required for new formulations or device enhancements, any new indication for an approved product also requires FDA approval. If we are not able to obtain regulatory approval for any desired future indications for our products and product candidates, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an example, while physicians may choose, and are generally permitted to prescribe drugs and/or medical devices for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by a regulatory authority, our ability to promote the products is narrowly limited to those indications that are approved by the FDA or other regulatory agency. &#8220;Off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical and medical device companies on the subject of off-label use. Although recent court decisions suggest that certain off-label promotional activities may be protected under the First Amendment of the U.S. Constitution, the scope of such protection is unclear. Moreover, while we promote our products consistent with what we believe to be the approved indication for our drugs and medical devices, regulators may disagree. If a regulatory agency determines that our promotional activities fail to comply with their regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow rules and guidelines relating to promotion and advertising may cause a regulatory body to issue warning letters or untitled letters, bring an enforcement action against us, suspend or withdraw an approved product from the market, require a recall or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institute fines or civil fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our reputation and our business.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, we received a warning letter from the FDA&#8217;s Office of Prescription Drug Promotion (OPDP) pertaining to certain promotional aspects of EXPAREL. We took actions to immediately address the FDA&#8217;s concerns and minimize further disruption to our business. Ultimately, however, in September 2015, we, along with two independent physicians, filed a lawsuit in federal court against the FDA and other governmental defendants seeking to exercise our lawful rights to communicate truthful and non-misleading information about EXPAREL. The complaint outlined our belief that the FDA&#8217;s warning letter received in September 2014 and regulations restricting our truthful and non-misleading speech about EXPAREL violated the Administrative Procedure Act and the First and Fifth Amendments of the U.S. Constitution. The lawsuit sought a declaration and injunctive relief to permit us to promote EXPAREL consistent with its approved indication and pivotal trials that supported FDA approval. On December 15, 2015, we announced that the FDA had formally withdrawn the September 2014 Warning Letter via a &#8220;Rescission Letter,&#8221; and that the FDA and Pacira had reached an amicable resolution of the lawsuit. As part of the resolution of this matter, the FDA confirmed that EXPAREL was broadly approved for &#8220;administration into the surgical site to produce postsurgical analgesia&#8221; in a variety of surgeries not limited to those studied in its pivotal trials. The FDA also approved a labeling supplement for EXPAREL that further clarified that EXPAREL was not limited to any specific surgery type or site, that the proper dosage and administration of EXPAREL is based on various patient and procedure-specific factors, that there was a significant treatment effect for EXPAREL compared to placebo over the first 72 hours in the pivotal hemorrhoidectomy trial and that EXPAREL may be admixed with bupivacaine, provided certain medication ratios are observed. The Warning Letter and labeling supplement only applied to the infiltration indication that was approved at that time, and does not apply to the interscalene brachial plexus nerve block indication subsequently approved in April 2018. We and the FDA agreed that, in future interactions, the parties will deal with each other in an open, forthright and fair manner.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2015, we received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to EXPAREL. In July 2020, we formally entered into settlement agreements that resolved all outstanding investigations and claims by the U.S. Department of Justice, the U.S. of Health and Human Services, various States Attorneys&#8217; General and a private plaintiff (the &#8220;Plaintiffs&#8221;). This agreement concluded a five-year investigation related to the sale and marketing of EXPAREL. Under the various settlement agreements, we paid a global settlement of $3.5 million. As part of the settlement, we admitted to no wrongdoing and explicitly denied the Plaintiffs&#8217; allegations. We have been given assurances that this concluded the investigation that originated from the U.S. Department of Justice subpoena in April 2015.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict whether any future regulatory actions will have an effect on our product sales, and even if such actions are ultimately resolved favorably, our sales may suffer due to reputational or other concerns. We can make no assurances that we will not receive warning letters in the future from the FDA or other regulatory authority or be subject to other regulatory action. As noted above, any regulatory violation or allegations of a violation may have a material adverse effect on our reputation and business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not receive regulatory approval for any of our product candidates, or the approval may be delayed for various reasons, including successful challenges to the FDA&#8217;s interpretation of Section&#160;505(b)(2), which would have a material adverse effect on our business and financial condition.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in our efforts to obtain regulatory approval from the FDA for any of our product candidates, and there can be no assurance that such approval will not be delayed, or that the FDA will ultimately approve these product candidates. Although the FDA&#8217;s longstanding position has been that the agency may rely upon prior findings of safety or effectiveness to support approval of a 505(b)(2) application, this policy has been controversial and subject to challenge in the past. If the FDA&#8217;s policy is successfully challenged administratively or in court, we may be required to seek approval of our products via full NDAs that contain a complete data package demonstrating the safety and effectiveness of our product candidates, which would be time-consuming, expensive and would have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, as a condition of the EXPAREL NDA approval on October&#160;28, 2011, has required us to study EXPAREL in pediatric patients as a post-marketing requirement. We have agreed to a trial timeline where we will study successive pediatric patient subpopulations. In December 2019, we announced positive results for our extended pharmacokinetic and safety study for local analgesia in children aged 6 to 17 undergoing cardiovascular or spine surgeries. Those positive results provided the foundation for an sNDA submission which was approved by the FDA in March 2021. Additionally, we are in negotiations with the FDA and EMA for clarity on other pediatric study obligations for children aged zero to less than six years old. These trials will be expensive and time consuming and we are required to meet the timelines for submission of protocols and data and for completion as agreed with the FDA and EMA, and we may be delayed in meeting such timelines. We are required to conduct </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these trials even if we believe that the costs and potential benefits of conducting the trials are not warranted from a scientific or financial perspective. The failure to conduct these pediatric trials or to meet applicable deadlines could result in the imposition of sanctions, including, among other things, issuance of warnings letters or imposition of seizures or injunctions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For iovera&#176; and any other potential medical device, we must obtain clearance or approval from the FDA or other regulatory authorities prior to introducing a new product or a modification to an existing product. The regulatory clearance process may result in substantial delays, unexpected or additional costs and other unforeseen factors and limitations on the types and uses of products we would be able to commercialize, any of which could have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., before we are able to market a new medical device, or a new use, claim for or significant modification to an existing medical device, we generally must first receive clearance or approval from the FDA and certain other regulatory authorities. Many foreign jurisdictions outside the U.S. also require clearance, approval or compliance with certain standards before a medical device or other product can be marketed. The process of obtaining regulatory clearances and approvals to market a medical device can be costly, time consuming, involve rigorous pre-clinical and clinical testing, require changes in products or result in limitations on the indicated uses of products. There can be no assurance that these clearances and approvals will be granted on a timely basis, if at all. In addition, once a medical device has been cleared or approved, a new clearance or approval may be required before the medical device may be modified, its labeling changed or marketed for a different use. Medical devices are cleared or approved for one or more specific intended uses and promoting a device for an off-label use could result in government enforcement action. Furthermore, a product approval or clearance can be withdrawn or limited due to unforeseen problems with the medical device or issues relating to its application. The regulatory clearance and approval process may result in, among other things, delayed, if at all, realization of product net sales, substantial additional costs and limitations on the types of products we may bring to market or their indicated uses, any one of which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A regulatory authority may determine that our products or any of our product candidates have undesirable side effects.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If concerns are raised regarding the safety of a new product candidate as a result of undesirable side effects identified during clinical testing, a regulatory authority may decline to approve the drug or medical device or issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve the product. Undesirable side effects caused by our products or any product candidate could also result in the inclusion of unfavorable information in our product labeling, imposition of distribution or use restrictions, a requirement to conduct post-market studies or to implement a risk evaluation and mitigation strategy, denial, suspension or withdrawal of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing and generating revenues from the sale of EXPAREL, ZILRETTA, iovera&#176; or any product candidate.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the side effects observed in the EXPAREL clinical trials completed to date include nausea and vomiting. In addition, the class of drugs that EXPAREL belongs to has been associated with nervous system and cardiovascular toxicities at high doses. We cannot be certain that these side effects and others will not be observed in the future, or that regulatory authorities will not require additional trials or impose more severe labeling restrictions due to these side effects or other concerns. The active component of EXPAREL is bupivacaine and bupivacaine infusions have been associated with the destruction of articular cartilage, or chondrolysis. Chondrolysis has not been observed in clinical trials of EXPAREL, but we cannot be certain that this side effect will not be observed in the future.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of EXPAREL, ZILRETTA, iovera&#176; or any of our product candidates, if we or others later identify previously unknown undesirable side effects caused by such products, if known side effects are more frequent or severe than in the past, or if we or others detect unexpected safety signals for such products or any products perceived to be similar to such products:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of unfavorable labeling statements, specific warnings or contraindications (including boxed warnings);</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend or withdraw their approval of the product, or require it to be removed from the market;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may impose restrictions on the distribution or use of the product;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, conduct additional clinical trials, reformulate the product, change the labeling of the product or change or obtain re-approvals of manufacturing facilities;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the product may be significantly decreased from projected sales;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to government investigations, product liability claims and litigation; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of our products or any of our product candidates and could substantially increase our commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from its sale.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with federal, state and foreign laws and regulations relating to the health care business, we could face substantial penalties.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which we may conduct our business. In the U.S., the laws that directly or indirectly affect our ability to operate our business include the following:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Anti-Kickback Law, which prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce either the referral of an individual or furnishing or arranging for a good or service for which payment may be made under federal health care programs such as Medicare and Medicaid;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other Medicare laws and regulations that prescribe the requirements for coverage and payment for services performed by our customers, including the amount of such payment;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal False Claims Act, which imposes civil and criminal liability on individuals and entities who submit, or cause to be submitted, false or fraudulent claims for payment to the government;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal False Statements Act, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with delivery of or payment for health care benefits, items or services; and</span></div><div style="margin-bottom:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">various state laws that impose similar requirements and liability with respect to state healthcare reimbursement and other programs.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws and regulations described above or any other law or governmental regulation to which we or our customers are or will be subject, we may be subject to civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment or restructuring of our operations. Similarly, if our customers are found to be non-compliant with applicable laws, they may be subject to sanctions, which could also have a negative impact on us. Any penalties, damages, fines, curtailment or restructuring of our operations would adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#8217;s attention from the operation of our business and damage our reputation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The design, development, manufacture, supply and distribution of our products are highly regulated and technically complex.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design, development, manufacture, supply and distribution of our products are all highly regulated. We, along with our third-party providers, must comply with all applicable regulatory requirements of the FDA and foreign regulatory authorities. In addition, the facilities used to manufacture, store and distribute our products are subject to inspection by regulatory authorities at any time to determine compliance with applicable regulations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing techniques and facilities used for the manufacture and supply of our products must be operated in conformity with CGMP and other FDA, EMA and MHRA regulations, including potentially prior regulatory approval. In addition, any expansion of our existing manufacturing facilities or the introduction of any new manufacturing facilities, including the manufacturing suites at the Thermo Fisher and Providien facilities, also require conformity with CGMP and other FDA, EMA and MHRA regulations. In complying with these requirements, we, along with our co-production partners and suppliers, must continually expend time, money and effort in production, record keeping and quality assurance and control to ensure that our products meet applicable specifications and other requirements for safety, efficacy and quality. In addition, we, along with our co-production partners and suppliers, are subject to unannounced inspections by the FDA, EMA, MHRA and other regulatory authorities.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to comply with regulatory and other legal requirements applicable to the manufacture, supply and distribution of our products could lead to remedial action (such as recalls), civil and criminal penalties and delays in manufacture, supply and distribution of our products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design, development, manufacture, supply and distribution of our products are all highly complex. If we are unable to manufacture our products in compliance with our highly complex specifications in the future, we may be subject to product exchanges, significant costs and charges, supply constraints or other corrective measures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive regulatory requirements to which we and our products are subject, such products could be subject to restrictions or withdrawal from the market and we could be subject to penalties.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing, manufacturing, quality control, labeling, safety, effectiveness, advertising, promotion, storage, sales, distribution, import, export and marketing, among other things, of EXPAREL, ZILRETTA, iovera&#176; and our product candidates are subject to extensive regulation by governmental authorities in the U.S. and elsewhere throughout the world. Quality control and manufacturing procedures regarding our products and product candidates must conform to CGMP. Regulatory authorities, including but not limited to the FDA, EMA and MHRA, periodically inspect manufacturing facilities to assess compliance with CGMP. Our failure, or the failure of any contract manufacturers with whom we may work in the future, to comply with the laws administered by the FDA, EMA, the MHRA or other governmental authorities could result in, among other things, any of the following:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recall or seizure;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of an approved product from the market;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of production;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reputational concerns of our customers or the medical community;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit import or export of an approved product;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">denial of permission to file an application or supplement in a jurisdiction;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or termination of ongoing clinical trials;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines and other monetary penalties;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecutions; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated expenditures.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the government or third-party payers fail to provide adequate coverage and payment rates for EXPAREL, ZILRETTA, iovera&#176; or any future products, or if hospitals or ASCs choose to use therapies that are less expensive, our revenue and prospects for profitability will be limited.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of our existing products and any future products will depend in part upon the availability of coverage and reimbursement from third-party payers. Such third-party payers include government health programs such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Assuming coverage is approved, the resulting reimbursement payment rates might not be adequate. In particular, many U.S. hospitals and ASCs receive a fixed reimbursement amount per procedure for certain surgeries and other treatment therapies they perform. Because this amount may not be based on the actual expenses the hospital or ASC incurs, these sites may choose to use therapies which are less expensive when compared to our product candidates. Although hospitals and ASCs may receive separate reimbursement for EXPAREL, ZILRETTA, iovera&#176; or any product candidates that we may develop, in-license or acquire, if approved, will face competition from other therapies and drugs for these limited hospital and ASC financial resources. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to the satisfaction of hospitals, ASCs, other target customers and their third-party payers. Such studies might require us to commit a significant amount of management time, financial and other resources. Our future products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. For example, third-party payers may limit the indications for which our products will be reimbursed to a smaller set of indications than we believe is appropriate or limit the circumstances under which our products will be reimbursed to a smaller set of circumstances than we believe is appropriate. In addition, in the U.S., no uniform policy of coverage and reimbursement for drug or medical device products exists among third-party payers. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we believe that future coverage and reimbursement will likely be subject to increased restrictions both in the U.S. and in international markets, as federal, state and foreign governments continue to propose and pass new legislation designed to reduce or contain the cost of healthcare. Third-party coverage and reimbursement for our products or product candidates for which we receive regulatory approval may not be available or adequate in either the U.S. or international markets, which could have a negative effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public concern regarding the safety of drug products such as EXPAREL and ZILRETTA and medical device products such as iovera&#176; could result in the inclusion of unfavorable information in our labeling, or require us to undertake other activities that may entail additional costs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of widely publicized events concerning the safety risk of certain drug products, the FDA, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug and medical device safety issues. These events have resulted in the withdrawal of drug and medical device products, revisions to labeling that further limits use of the drug and medical device products and the establishment of risk management programs that may, for example, restrict distribution of drug or medical device products after approval. The Food and Drug Administration Amendments Act of 2007, or FDAAA, grants significant expanded authority to the FDA, much of which is aimed at improving the safety of drug and medical device products before and after approval. In particular, the FDAAA authorizes the FDA to, among other things, require post-approval studies and clinical trials, mandate changes to product labeling to reflect new safety information and require risk evaluation and mitigation strategies for certain drugs and medical devices, including certain currently approved drugs and medical devices. The FDAAA also significantly expands the federal government&#8217;s clinical trial registry and results databank, which we expect will result in significantly increased government oversight of clinical trials. Under the FDAAA, companies that violate these and other provisions of the new law are subject to substantial civil monetary penalties, among other regulatory, civil and criminal penalties. The increased attention to drug safety issues may result in a more cautious approach by the FDA in its review of data from our clinical trials. Data from clinical trials may receive greater scrutiny, particularly with respect to safety, which may make the FDA or other regulatory authorities more likely to require additional preclinical studies or clinical trials. If the FDA or any other regulatory agency requires us to provide additional clinical or preclinical data for EXPAREL, ZILRETTA or iovera&#176;, the indications for which these products were approved may be limited or there may be specific warnings or limitations on dosing, and our efforts to commercialize EXPAREL, ZILRETTA or iovera&#176; may be otherwise adversely impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patents and the patent applications that we have covering our pMVL products are limited to specific injectable formulations, processes and uses of drugs encapsulated in our pMVL drug delivery technology and our market opportunity for our product candidates may be limited by the lack of patent protection for the active ingredient itself and other formulations and delivery technology and systems that may be developed by competitors.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The active ingredient in EXPAREL is bupivacaine. Patent protection for the bupivacaine molecules themselves has expired and generic immediate-release products are available. As a result, competitors who obtain the requisite regulatory approval can offer products with the same active ingredient as EXPAREL so long as the competitors do not infringe any process, use or formulation patents that we have developed for drugs encapsulated in our pMVL drug delivery technology.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we are aware of at least one FDA-approved long-acting instillable bupivacaine product on the market which utilizes an alternative delivery system to EXPAREL. Such a product is similar to EXPAREL in that it also extends the duration of effect of bupivacaine, but achieves this clinical outcome using a completely different drug delivery system as compared to our pMVL drug delivery technology.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of patents and patent applications covering products in the same field as EXPAREL indicates that competitors have sought to develop and may seek to market competing formulations that may not be covered by our patents and patent applications. The commercial opportunity for EXPAREL could be significantly harmed if competitors are able to develop and commercialize alternative formulations of bupivacaine that are long-acting but outside the scope of our patents.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, because EXPAREL has been approved by the FDA, one or more third parties may challenge the patents covering this product, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. For example, if a third-party files an ANDA for a generic drug product containing bupivacaine and relies in whole or in part on studies conducted by or for us, the third-party will be required to certify to the FDA that either: (i)&#160;there is no patent information listed in the FDA&#8217;s Orange Book with respect to our NDA for EXPAREL; (ii)&#160;the patents listed in the Orange Book have expired; (iii)&#160;the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration or (iv)&#160;the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third-party&#8217;s generic drug product. A certification that the new product will not infringe the Orange Book-listed patents for EXPAREL, or that such patents are invalid, is called a paragraph&#160;IV certification. If the third-party submits a paragraph&#160;IV certification to the FDA, a notice of the paragraph&#160;IV certification must also be sent to us once the third-party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within 45&#160;days of receipt of the notice automatically prevents the FDA from approving the third-party&#8217;s ANDA until the earliest of 30&#160;months or the date on which the patent expires, the lawsuit is settled or the court reaches a decision in the infringement lawsuit in favor of the third-party. If we do not file&#160;a patent infringement lawsuit within the required 45-day period, the third-party&#8217;s ANDA will not be subject to the 30-month stay. Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our products.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a Notice Letter advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an ANDA with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,033,495 (the &#8217;495 patent).</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we filed a patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (21-cv-19829) asserting infringement of the &#8217;495 patent. This triggered an automatic 30-month stay of final approval of the eVenus ANDA. On January 6, 2022, eVenus filed an Answer with counterclaims to the Complaint, alleging the &#8217;495 patent is invalid and/or not infringed through the manufacture, sale, or offer for sale of the product described in product described in eVenus&#8217;s ANDA submission.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we received a second Notice Letter advising that eVenus submitted to the FDA an amendment to its ANDA with a Paragraph IV Certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (133 mg/10 mL) in the U.S. prior to the expiration of the &#8217;495 patent. In the Notice Letter, eVenus also advised that it submitted a Paragraph IV Certification to the FDA seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL and 133 mg/10 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,179,336 (the &#8217;336 patent). eVenus further alleges in the Notice Letter that both the &#8217;495 patent and the &#8217;366 patent are invalid and/or not infringed.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we filed a second patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (22-cv-00718) asserting that the 133 mg/10 mL ANDA product will infringe the &#8217;495 and &#8217;336 patents and that the 266 mg/20 mL ANDA product will infringe the &#8217;336 patent. This filing triggered a second automatic 30-month stay of final approval for the 133 mg/10 mL ANDA product.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These litigations are in their infancy, and we are unable to predict the outcome of this action at this time.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patents and the patent applications that we have covering our iovera&#176; products are primarily limited to specific handheld cryogenic needle devices that are cooled by a cryogen and methods for applying cryotherapy to nerve tissue using the cryogenic devices. Our market opportunity for our product candidates may be limited by gaps in patent coverage for the cryogenic devices, methods of use and other cryotherapy technology and systems that may be developed by competitors.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The iovera&#176; cryogenic device is a compact, self-contained handheld device with a replaceable cryogen cartridge that delivers a cryogen through internal supply tubes to needle lumens of a replaceable needle probe, so as to cool the needle probe and thereby cool a surrounding target nerve tissue. We also have secured patents covering particular cryotherapy methods and pain treatments that provide what we deem to be optimal treatment using the iovera&#176; cryogenic device. </span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have patents that are broad enough to cover various alternative designs and methods, much of our patent coverage is tailored to cover the iovera&#176; device and methods of use. It is thus possible that competitors may attempt to design around many of our patents. For example, we are aware of competitors developing cryogenic systems that are not self-contained handheld devices, or cryogenic systems that deliver cryotherapy through different mechanisms. It is also possible that competitors may attempt to develop and market cryotherapy devices and methods not covered by our patents, for example, basic cryotherapy treatment systems that are off-patent or cryoanalgesia for other nerve entrapment treatments.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial opportunity for iovera&#176; could be significantly harmed if competitors are able to develop and commercialize alternative designs and methods outside the scope of our patents.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our earliest patent family is scheduled to expire in 2025, thereby opening the door for competitors to copy some of our early technology. This early patent family is primarily focused on treating cosmetic defects that are no longer the focus of iovera&#176;, but the underlying technology is nonetheless relevant enough for there to be appreciable overlap.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, one or more third parties may challenge the patents covering the iovera&#176; product, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. Litigation or other proceedings to defend or enforce intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management&#8217;s attention from our core business and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because it is difficult and costly to protect our proprietary rights, we may not be able to ensure their protection and all patents will eventually expire.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for EXPAREL, ZILRETTA, iovera&#176;, our pMVL drug delivery technology and for any product candidates that we may develop, license or acquire and the methods we use to manufacture them, as well as successfully defending these patents and trade secrets against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical, medical device and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical, medical device or biotechnology patents has emerged to date in the U.S. Patent positions and policies outside the U.S. are even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have been the first to make the inventions covered by each of our pending patent applications and issued patents;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have been the first to file patent applications for these inventions;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our product candidates or technologies;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that none of the pending patent applications will result in issued patents;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our product candidates may not provide a basis for commercially viable active products, may not provide us with any competitive advantages, may not have sufficient scope or strength to protect the technologies they were intended to protect or may be challenged by third parties;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may design around our patent claims to produce competitive products that fall outside the scope of our patents;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or in-license additional proprietary technologies that are patentable;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents of others may have an adverse effect on our business; or</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may infringe our patents and we may not have adequate resources to enforce our patents.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent applications in the U.S. are maintained in confidence for at least 18&#160;months after their earliest effective filing date. Consequently, we cannot be certain we were the first to invent or the first to file patent applications on EXPAREL, ZILRETTA, iovera&#176;, our pMVL drug delivery technology or any product candidates that we may develop, license or acquire. In the event that a third-party has also filed a U.S. patent application relating to our product candidates or a similar invention, we may have to participate in interference proceedings declared by the United States Patent and Trademark Office, or USPTO, to determine priority of invention in the U.S. The costs of these proceedings could be substantial and it is possible that our efforts would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. Furthermore, we may not have identified all U.S. and foreign patents or published applications that affect our business either by blocking our ability to commercialize our drugs or medical devices or by covering similar technologies that affect our drug or medical device markets.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some countries, including many in Europe, do not grant patent claims directed to methods of treating humans, and in these countries patent protection may not be available at all to protect our product candidates. Even if patents are issued, we cannot guarantee that the claims of those patents will be valid and enforceable or provide us with any significant protection against competitive products, or otherwise be commercially valuable to us. Furthermore, while we generally apply for patents in those countries where we intend to make, have made, use or sell patented products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file&#160;a patent application in any such country, we may be precluded from doing so at a later date. We also cannot assure you that the patents issuing as a result of our foreign patent applications will have the same scope of coverage as our U.S. patents.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our older patents have already expired. In the case of EXPAREL, the European and U.S. patents protecting the formulation of EXPAREL expired in 2018. An existing formulation patent for EXPAREL expired in November 2013. An existing formulation patent for EXPAREL expired in the U.S. in 2013 and its equivalents in Canada, Germany, France, Spain, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Italy and the U.K. expired in 2014. In Europe, manufacturers qualify for 8 years of data exclusivity upon marketing authorization approval and an additional two years of market exclusivity, for a total of 10 years of regulatory exclusivity. Our earliest patent family for iovera&#176; is scheduled to expire in 2025. Once our patents covering EXPAREL, ZILRETTA and iovera&#176; have expired, we will be more reliant on trade secrets to protect against generic competition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets to protect our technology, particularly where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. While we use reasonable efforts to protect our trade secrets through confidentiality and non-disclosure agreements, our licensors, employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Policing unauthorized use of our trade secrets or enforcing a claim that a third-party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, trade secret laws in other countries may not be as protective as they are in the U.S. Thus, courts outside the U.S. are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to protect the goodwill associated with our company and product names, we rely on trademark protection for our marks. We have registered the &#8220;Pacira&#8221;, &#8220;EXPAREL&#8221;, "ZILRETTA" and &#8220;iovera&#176;&#8221; marks with the USPTO. A third-party may assert a claim that one of our marks is confusingly similar to its mark, and such claims or the failure to timely register a mark or objections by the FDA or other regulatory agency could force us to select a new name for one of our product candidates, which could cause us to incur additional expense or delay the commercialization of such product.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to obtain or maintain patent, trade secret and/or trademark protection for EXPAREL, ZILRETTA, iovera&#176;, our pMVL drug delivery technology or any product candidate that we may develop, license or acquire, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and achieve profitability.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in any litigation would harm our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop, manufacture, market and sell EXPAREL, ZILRETTA, iovera&#176;, our pMVL drug delivery technology or any product candidates that we may develop, license or acquire depends upon our ability to avoid infringing the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the general fields of pain management and cancer treatment and cover the use of numerous compounds, formulations and medical devices in our targeted markets. Because of the uncertainty inherent in any patent or other litigation involving proprietary rights, we and our licensors may not be successful in defending intellectual property claims by third parties, which could have a material adverse effect on our results of operations. Regardless of the outcome of any litigation, defending the litigation may be expensive, time-consuming and distracting to management. In addition, because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that EXPAREL, ZILRETTA or iovera&#176; may infringe. There could also be existing patents of which we are not aware that EXPAREL, ZILRETTA or iovera&#176; may inadvertently infringe.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology, biopharmaceutical and medical device industries in general. If a third-party claims that we infringe on their products or technology, we could face a number of issues, including:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">infringement and other intellectual property claims which, with or without merit, can be expensive and time consuming to litigate and can divert management&#8217;s attention from our core business;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial damages for past infringement which we may have to pay if a court decides that our product infringes on a competitor&#8217;s patent;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a court prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us, which it would not be required to do;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a license is available from a patent holder, we may have to pay substantial royalties or grant cross licenses to our patents; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redesigning our processes so they do not infringe, which may not be possible or could require substantial funds and time.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology, pharmaceutical and medical device industries, we employ individuals who were previously employed at other biotechnology, pharmaceutical and medical device companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Indebtedness and our Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servicing our indebtedness requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial indebtedness.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make payments of the principal of, to pay interest on or to refinance our indebtedness, including the Term Loan (as defined below), the 2.375% convertible senior notes due 2022, or 2022 Notes, issued in our private offering completed on March 13, 2017, the 0.750% convertible senior notes due 2025, or 2025 Notes, issued in our private offering completed on July 10, 2020, and Flexion&#8217;s 3.375% Convertible Senior Notes due 2024, or Flexion 2024 Notes and, together with the 2022 Notes and the 2025 Notes, the Notes, each as described below, or to make cash payments in connection with any conversion of the 2022 Notes, 2025 Notes or Flexion 2024 Notes (if applicable) depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our indebtedness and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring indebtedness or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021, we entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with JP Morgan Chase Bank, N.A., as administrative agent and the initial lender. The Credit Agreement provides for a single-advance term loan B facility in the principal amount of $375.0 million (the &#8220;Term Loan&#8221;), which is secured by substantially all of our and any subsidiary guarantor&#8217;s assets and is scheduled to mature on December 7, 2026, subject to certain exceptions set forth in the Credit Agreement. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 10, 2020, we completed a private placement of $402.5 million in aggregate principal amount of 2025 Notes, and entered into an indenture, or 2025 Indenture, with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per year, payable semiannually in arrears on February 1 and August 1 of each year. The 2025 Notes mature on August 1, 2025.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2017, we completed a private placement of $345.0 million in aggregate principal amount of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our 2022 Notes, and entered into an indenture, or 2022 Indenture, with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of 2.375% per year, payable semiannually in arrears on April 1 and October 1 of each year. We used a portion of the net proceeds from the 2025 Notes to repurchase $185.0 million in aggregate principal amount of the 2022 Notes. The 2022 Notes mature on April 1, 2022. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 2, 2017, Flexion issued an aggregate of $201.3 million principal amount of Flexion 2024 Notes, and entered into an indenture, or Flexion 2024 Notes Indenture, as supplemented to date, or Flexion 2024 Notes Indenture and, together with the 2025 Indenture and the 2022 Indenture, the Indentures, with respect to the 2024 Flexion Notes. The Flexion 2024 Notes accrue interest at a fixed rate of 3.375% per year, payable semiannually in arrears on May 1 and November 1 of each year. As a result of the Flexion Acquisition, holders of the Flexion 2024 Notes became entitled to certain Flexion Acquisition-related conversion and repurchase rights, as discussed in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein. Following the expiration of the offer to purchase, there were $8.6 million aggregate principal amount of Flexion 2024 Notes outstanding. In addition, as a result of the Flexion Acquisition and as discussed in more detail below, any future conversion rights are subject to the occurrence of any future events giving rise to such conversion rights under the Flexion 2024 Notes Indenture. The Flexion 2024 Notes mature on May 1, 2024.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our total consolidated gross indebtedness was $1.1 billion, which consisted of $402.5 million of principal outstanding on the 2025 Notes, $160.0 million of principal outstanding on the 2022 Notes, $375.0 million of principal outstanding on the Term Loan and $201.5 million of principal outstanding on the Flexion 2024 Notes. As of February&#160;28, 2022, our total consolidated gross indebtedness was $946.1&#160;million, which reflects the January 2022 repurchase of $192.6 million aggregate principal amount of the Flexion 2024 Notes, as discussed in more detail in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein. Additionally, our subsidiaries had no indebtedness (excluding trade payables, intercompany liabilities and income tax-related liabilities).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Credit Agreement and the Indentures each impose significant operating and financial restrictions on us and certain of our subsidiaries, which may prevent us from capitalizing on business opportunities. A breach of any of those restrictive covenants may cause us to be in default under the Credit Agreement and/or the Indentures, and our lenders could foreclose on our assets.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Credit Agreement requires us to maintain certain financial covenants. A decline in our operating performance could negatively impact our ability to meet these financial covenants. If we breach any of these restrictive covenants, the lenders could either refuse to lend funds to us or accelerate the repayment of any outstanding borrowings under the Credit Agreement. We may not have sufficient funds to repay such indebtedness upon a default or be unable to receive a waiver of the default from the lenders. If we are unable to repay the indebtedness, the lenders could initiate a bankruptcy proceeding or collection proceedings with respect to our assets, all of which secure our indebtedness under the Credit Agreement.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement and the Indentures also contain certain restrictive covenants that limit, and in some circumstances prohibit, our ability to, among other things: incur additional debt or issue preferred stock; sell, lease or transfer our assets; pay dividends on, and make other distributions on, or redeem or repurchase, our common stock; make certain capital expenditures and investments; guarantee debt or obligations; create certain liens; enter into transactions with our affiliates; and enter into certain merger, consolidation or other reorganization transactions. These restrictions could limit our ability to obtain future financing, incur or guarantee additional debt, incur certain liens, enter into transactions with affiliates, transfer or sell certain assets, make acquisitions or needed capital expenditures, withstand potential downturns in our business, or the economy in general, conduct operations or otherwise take advantage of business opportunities that may arise, any of which could place us at a competitive disadvantage relative to our competitors. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that we will be able to maintain compliance with these covenants in the future and, if we fail to do so, that we will be able to obtain waivers from the lenders and/or amend the covenants. Our failure to comply with the restrictive covenants described above as well as other terms of our indebtedness could result in an event of default, which, if not cured or waived, could result in our being required to repay these borrowings before their due date. If we are forced to refinance these borrowings on less favorable terms or cannot refinance these borrowings, our results of operations and financial condition could be adversely affected.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash to the extent elected or to repurchase the Notes upon a fundamental change, and our future indebtedness may contain limitations on our ability to pay cash upon conversion of the Notes or limitations on our ability to repurchase the Notes.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes will have the right to require us to repurchase their Notes upon the occurrence of a fundamental change at a repurchase price equal to 100% of their principal amount, plus accrued and unpaid interest, if any. We have the option to pay the principal in cash, shares of our common stock, or any combination thereof. While it is our intention to pay the principal in cash, upon conversion of the Notes we will be required to make cash payments for each $1,000 in principal amount of Notes converted of at least the lesser of $1,000 and the sum of the daily conversion values. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered therefor or Notes being converted. The Credit Agreement limits, and any credit facility or other agreement that we may enter into may limit, our ability to make cash payments at the time of a fundamental change or upon conversion of the Notes. Further, our ability to repurchase the Notes or to pay cash upon conversions of the Notes may be limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase Notes at a time when the repurchase is required by the applicable indenture or to pay any cash payable on future conversions of the Notes as required by the Indenture would constitute a default under the applicable indenture. A default under the applicable indenture or the fundamental change itself could also lead to a default under agreements governing our Credit Agreement or future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or make cash payments upon conversions thereof.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business, financial condition, and results of operations, as well as the ability to meet payment obligations under our Credit Agreement and the Notes.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our total consolidated gross indebtedness was $1.1 billion, which consisted of $402.5 million of principal outstanding on the 2025 Notes, $160.0 million of principal outstanding on the 2022 Notes, $375.0 million of principal outstanding on the Term Loan, and $201.5 million of principal outstanding on the Flexion 2024 Notes. As of February&#160;28, 2022, our total consolidated gross indebtedness was $946.1&#160;million, which reflects the January 2022 repurchase of $192.6 million aggregate principal amount of the Flexion 2024 Notes, as discussed in more detail in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein. Subject to the limits contained in the Credit Agreement and the Indentures, we may be able to incur substantial additional debt from time to time. If we do so, the risks related to our level of debt could increase. Specifically, our level of debt could have important consequences, including the following:</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;   making it more difficult for us to meet our obligations with respect to our debt;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;   reducing the availability of cash flow to fund future working capital, capital expenditures, acquisitions or other general corporate purposes;</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;   limiting our ability to obtain additional financing to fund future working capital, capital expenditures, acquisitions or other general corporate purposes;</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;   requiring a substantial portion of our cash flows to be dedicated to debt service payments instead of other purposes, thereby reducing the amount of cash flows available for working capital, capital expenditures, acquisitions or other general corporate purposes;</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;   increasing our vulnerability to general adverse economic and industry conditions;</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;   exposing us to the risk of increased interest rates as certain of our borrowings are at variable rates of interest;</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;   placing us at a disadvantage compared to other, less leveraged competitors;</span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;   increasing our cost of borrowing; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;   limiting our flexibility in planning for changes in our business and reacting to changes in the industry in which we compete.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we are unable to meet our debt service obligations or should we fail to comply with our financial and other negative covenants contained in the agreements governing our indebtedness, we may be required to refinance all or part of our debt, sell important strategic assets at unfavorable prices, incur additional indebtedness or issue common stock or other equity securities. We may not be able to, at any given time, refinance our debt, sell assets, incur additional indebtedness or issue equity securities on terms acceptable to us, in amounts sufficient to meet our needs. If we are able to raise additional funds through the issuance of equity securities, such issuance would also result in dilution to our stockholders. Our inability to service our obligations or refinance our debt could have a material and adverse effect on our business, financial condition or operating results. In addition, our debt obligations may limit our ability to make required investments in capacity, technology, or other areas of our business, which could have a material adverse effect on our business, financial condition, or operating results.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could have an adverse effect on our business, financial condition and results of operations and our ability to meet our debt payment obligations.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Despite our current level of indebtedness, we may be able to incur substantially more debt, which could increase the risks to our financial condition described above.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be able to incur substantial additional indebtedness in the future. Although certain of the agreements governing our existing indebtedness contain restrictions on the incurrence of additional indebtedness and entering into certain types of other transactions, these restrictions are subject to a number of qualifications and exceptions, including compliance with various financial conditions. Additional indebtedness incurred in compliance with our existing debt instruments could be substantial. To the extent new debt is added to our current debt levels, the substantial leverage risks described in the immediately preceding risk factor would increase.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our total consolidated gross indebtedness was $1.1 billion, which consisted of $402.5 million of principal outstanding on the 2025 Notes, $160.0 million of principal outstanding on the 2022 Notes, $375.0 million of principal outstanding on the Term Loan, and $201.5 million of principal outstanding on the Flexion 2024 Notes. As of February&#160;28, 2022, our total consolidated gross indebtedness was $946.1&#160;million, which reflects the January 2022 repurchase of $192.6 million aggregate principal amount of the Flexion 2024 Notes, as discussed in more detail in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our restated certificate of incorporation and our bylaws, as well as provisions of the Delaware General Corporation Law, or DGCL, could make it more difficult for a third-party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions include:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminating the ability of stockholders to call a special meeting of stockholders; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section&#160;203 of the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our common stock price may be subject to significant fluctuations and volatility.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile, and from February&#160;3, 2011, the first day of trading of our common stock, to February&#160;28, 2022, the trading prices of our stock have ranged from $6.16 to $121.95 per share.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock could be subject to wide fluctuations in price in response to various factors, including the following:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of EXPAREL, ZILRETTA and iovera&#176;;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials of our products, product candidates or those of our competitors;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or developments in laws or regulations applicable to our products or product candidates;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of competitive products or technologies;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial projections we provide to the public;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed the estimates and projections of the investment community;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of the pharmaceutical and medical device industry by the public, legislatures, regulators and the investment community;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory concerns or government actions;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions and overall fluctuations in U.S. equity markets;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning our sources of manufacturing supply;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to patents or other proprietary rights;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in products, businesses and technologies;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuances of debt, equity or convertible securities;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Fluctuations in our stock price could, among other things, adversely impact the trading price of our shares.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock for the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common stock. We currently intend to retain our future earnings to finance the future development and expansion of our business, and as such we do not expect to pay any cash dividends on our common stock in the foreseeable future. The payment of future dividends, if any, will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in future financing instruments, provisions of applicable law and any other factors our board of directors deems relevant.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales in the public market or issuances of our common stock could lower the market price for our common stock.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may sell additional shares of our common stock to raise capital. Except under limited circumstances, we are not restricted from issuing additional common stock, including securities that are convertible into or exchangeable for, or that represent the right to receive, common stock. The issuance of additional shares of our common stock or convertible securities, including upon exercise of our outstanding options, vesting of our restricted stock units or otherwise, will dilute the ownership interest of our common stockholders. In addition, our greater than 5% stockholders may sell a substantial number of their shares in the public market, which could also affect the market price for our common stock. We cannot predict the size of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future sales or issuances of our common stock or the effect, if any, that they may have on the market price for our common stock. The issuance and/or sale of substantial amounts of common stock, or the perception that such issuances and/or sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity or debt securities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional funds by issuing securities would cause dilution to existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#8217; ownership would be diluted. If we raise additional funds through licensing arrangements, it may be necessary to relinquish potentially valuable rights to our potential products or proprietary technologies, or grant licenses on terms that are not favorable to us. Any debt financing we enter into may involve covenants that restrict our operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A pandemic, epidemic or outbreak of a contagious disease (such as the novel coronavirus (COVID-19) pandemic), or fear of such an event, could have a material adverse effect on our business, operating results and financial condition.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A pandemic, epidemic or outbreak of an infectious disease, including the current COVID-19 pandemic, or other public health crisis, could have a material adverse effect on our business, financial condition and operations, including but not limited to our revenue and cash flows, including potential decreases in sales, manufacturing issues, supply issues and delays in payments by our customers. For example, during 2020, our net product sales were negatively impacted by the COVID-19 pandemic due to the significant postponement or suspension in the scheduling of elective surgical procedures resulting from public health guidance and government directives. Elective surgery restrictions began to lift on a state-by-state basis in April 2020, allowing our net product sales to return to year-over-year growth in June 2020. However, while many restrictions have since eased with COVID-19 vaccines now widely available, the elective surgery market faced additional pandemic-related challenges in August and September 2021 due to regional surges in COVID-19 Delta variant cases, staffing shortages and fatigue from care teams addressing significant procedure backlogs, and in December 2021, the COVID-19 Omicron variant prompted some government restrictions on elective procedures and surgical staffing challenges which began to ease in January 2022. While these challenges have recently began to subside, it is unknown how long it will take the elective surgery market to normalize, or if restrictions on elective procedures will recur due to COVID-19 variant strains or otherwise. We do not know if, and how, future restrictions may affect the surgical communities&#8217; return to, or redefining of, normal operations, whether due to governmental restrictions, institutional, patient or clinical decisions or general economic conditions. New or prolonged suspensions of elective surgeries by governmental restrictions or action would cause net sales of our products to decrease. In addition, due to health concerns from the COVID-19 pandemic or negative economic conditions, patients and clinicians could cancel or defer elective procedures or otherwise avoid medical treatment, which would result in reduced patient volumes and revenues, which could potentially continue over an extended period of time.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business disruptions could include disruptions or restrictions to our workforce, including the ability of our sales teams to interact with our customers and healthcare professionals to educate them on the benefits of our products and perform typical sales activities. For example, the ongoing COVID-19 pandemic had significantly impacted the ability of our sales representatives to access customers and healthcare professionals through personal interactions within the healthcare setting, including hospitals and ASCs. With the reopening of many states, the ability of our sales representatives to renew their in-person engagement efforts, in conjunction with remote efforts, has occurred across all sites of care, with more focus on physician offices and ASCs. In addition, any temporary closures of our manufacturing facilities or the facilities of our suppliers and contract manufacturers (and the resulting impact on production or our products) or the workforce at such facilities, could cause delays in the shipment or production of our products. If our customers experience disruptions to their businesses and cash flows, we could experience delays or difficulties with the collection of our accounts receivable. Any sustained impacts and business disruptions to our facilities or workforce, our customers, our suppliers, or our contract manufacturers would likely adversely impact our cash flows, sales and operating results.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant increase in the number of our employees who are working remotely as a result of the pandemic, and an extended period of remote work arrangements and subsequent reintroduction into the workplace could introduce operational risk, strain our business continuity plans, negatively impact productivity and/or collaboration, and give rise to claims by employees or otherwise adversely affect our business. Additionally, the COVID-19 pandemic could require new or modified processes, procedures and controls to respond to changes in our business environment. We may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers and business partners. There is no certainty that such measures will be sufficient to mitigate the risks posed by COVID-19.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, the extent to which COVID-19 or other public health crises could continue to impact our business is difficult to predict and will depend on many factors beyond our control, including the speed of contagion, the development and implementation of effective preventative measures and possible treatments, the scope of governmental and other restrictions on elective surgeries, travel and other activity through quarantines/social distancing and other measures, the timing of effective vaccines becoming widely available and accepted by the public, public reactions to these factors and more.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts our business, revenues and results of operations will depend on future developments, which are highly uncertain, constantly changing and cannot be predicted. This includes new information that may emerge concerning the severity of COVID-19, the spread and proliferation of COVID-19 around the world, the duration of the outbreak and the actions taken to contain COVID-19 or treat its impact, among others.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not maintain the privacy and security of personal and business information, we could damage our reputation with customers and employees, incur substantial additional costs and become subject to litigation.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive, retain and transmit personal information about our customers and employees and entrust that information to third-party suppliers, including cloud service-providers that perform activities for us. Our business depends upon the secure transmission of encrypted confidential information over public networks, including information permitting payments. A compromise of our security systems or defects within our hardware or software, or those of our suppliers, that results in our customers&#8217; or employees&#8217; information being obtained by unauthorized persons, could adversely affect our reputation with our customers and others, as well as our operations, results of operations, financial condition and liquidity, and could result in litigation, government actions, or the imposition of penalties. In addition, a breach could require that we expend significant additional resources related to the security of information systems and could disrupt our operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of data by our business is regulated at the national and state or local level in all of our operating countries.&#160;Privacy and information-security laws and regulations change, and compliance with them may result in cost increases due to, among other things, systems changes and the development of new processes. If we or those with whom we share information fail to comply with these laws and regulations, our reputation could be damaged, possibly resulting in lost future business, and we could be subjected to additional legal risk as a result of non-compliance.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have security measures and controls to protect personal and business information and continue to make investments to secure access to our information technology network. These measures may be undermined, however, due to the actions of outside parties, employee error, internal or external malfeasance, or otherwise, and, as a result, an unauthorized party may obtain access to our data systems and misappropriate business and personal information. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these techniques, timely discover or counter them, or implement adequate preventative measures. Any such breach or unauthorized access could result in significant legal and financial exposure, damage to our reputation, and potentially have an adverse effect on our business and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental, social and corporate governance, or ESG, issues may have an adverse effect on our business, financial condition and results of operations and damage our reputation.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increasing focus from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet regulatory requirements or investor, customer, consumer, employee or other stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation, brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with us.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not adapt to or comply with new regulations, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding ESG issues, investors may reconsider their decision to invest in our Company, and customers and consumers may choose to stop purchasing our products, which could have a material adverse effect on our reputation, business or financial condition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulatively, we have incurred significant losses since our inception and may incur additional losses in the future.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have focused primarily on developing and commercializing EXPAREL. We recorded net income of $42.0 million and $145.5 million for the years ended December&#160;31, 2021 and 2020, respectively, and a net loss of $11.0 million for the year ended December 31, 2019. As of December&#160;31, 2021, we had an accumulated deficit of $211.9 million. Losses, among other things, have had an adverse effect on stockholders&#8217; equity and working capital. We incurred significant pre-commercialization expenses as we prepared for the commercial launch of EXPAREL, and we incur significant sales, marketing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and manufacturing expenses, as well as continued development expenses related to the commercialization of EXPAREL, ZILRETTA and iovera&#176;. As a result, we had not been profitable prior to 2015 and were not again until 2020. Because of the numerous risks and uncertainties associated with developing pharmaceutical products and medical devices, we are unable to predict the extent of future losses, if any.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing and commercializing products for use in the hospital or ASC settings, conducting clinical trials, establishing outsourced manufacturing relationships and successfully manufacturing and marketing drugs and medical devices that we may develop is expensive. We may need to raise additional capital to:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to fund our operations;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our efforts to hire additional personnel and build a commercial infrastructure to commercialize EXPAREL, ZILRETTA and iovera&#176;;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualify, outsource or build additional commercial-scale manufacturing of our products under CGMP;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license and develop additional product candidates; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refinance our Notes and Term Loan.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial resources to continue our operations or meet all of our objectives, which could require us to postpone, scale back or eliminate some, or all, of these objectives. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of maintaining a commercial organization to sell, market and distribute EXPAREL, ZILRETTA and iovera&#176;;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of the commercialization of EXPAREL, ZILRETTA and iovera&#176;;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of manufacturing sufficient supplies of EXPAREL, ZILRETTA and iovera&#176; to meet customer demand, including the cost of expanding our manufacturing facilities to produce EXPAREL, ZILRETTA and iovera&#176;;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress and costs of our efforts to prepare for the submission of an NDA, sNDA or 510(k) pre-market notification for any product candidates that we may in-license or acquire in the future, and the potential that we may need to conduct additional clinical trials to support applications for regulatory approval;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with our product candidates, including any such costs we may be required to expend if our licensors are unwilling or unable to do so;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we may establish; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential that we may be required to file&#160;a lawsuit to defend our patent rights or regulatory exclusivities from challenges by companies seeking to market generic versions of extended-release liposome injections of bupivacaine or a cryoanalgesic device that infringes on the various patents covering iovera&#176;.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary businesses, products and technologies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we can generate sufficiently more product revenue, if ever, we expect to finance or supplement future cash needs through public or private equity offerings, debt financings, stock option exercises, royalties, collaboration and licensing arrangements, as well as through interest income earned on cash and investment balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our development programs or our commercialization efforts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our operating results will be affected by numerous factors, including:</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of underlying hospital and ASC demand for EXPAREL, ZILRETTA and iovera&#176; and end-user buying patterns;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining our existing manufacturing facilities for EXPAREL, ZILRETTA and iovera&#176; and expanding their manufacturing capacities;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of other collaborative, licensing, distribution, manufacturing or similar arrangements and the timing of payments we may make or receive under these arrangements;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our future development programs;</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any product liability or intellectual property infringement lawsuit in which we may become involved; and</span></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments, lawsuits and investigations affecting EXPAREL, ZILRETTA, iovera&#176; or the product candidates of our competitors.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly or annual operating results fall below the expectations of our investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to successfully integrate the businesses and personnel of acquired companies and businesses, and may not realize the anticipated synergies and benefits of such acquisitions.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may complete acquisitions of companies and certain businesses of companies, and we may not realize the expected benefits from such acquisitions because of integration difficulties or other challenges. For example, in April 2019, we completed the MyoScience Acquisition and in November 2021, we completed the Flexion Acquisition.</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of any acquisitions will depend, in part, on our ability to realize all or some of the anticipated synergies and other benefits from integrating the acquired businesses with our existing businesses. The integration process may be complex, costly and time-consuming. The potential difficulties we may face in integrating the operations of our acquisitions include, among others:</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to implement our business plans for the combined businesses and consolidation or expansion of production capacity as planned and where applicable;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected losses of key employees, customers or suppliers of our acquired companies and businesses;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated issues in conforming our acquired companies&#8217; and businesses&#8217; standards, processes, procedures and internal controls with our operations;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordinating new product and process development;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing the scope, geographic diversity and complexity of our operations;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management&#8217;s attention from other business concerns;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse effects on our or our acquired companies&#8217; and businesses&#8217; existing business relationships;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated changes in applicable laws and regulations;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks inherent in our acquired companies&#8217; and businesses&#8217; industry and operations;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated expenses and liabilities;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential unfamiliarity with our acquired companies and businesses technology, products and markets, which may place us at a competitive disadvantage; and</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other difficulties in the assimilation of our acquired companies and businesses operations, technologies, products and systems.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If MyoScience, Flexion, or any other acquired companies and businesses have unanticipated or larger than anticipated liabilities for patent and trademark infringement claims, violations of laws, commercial disputes, taxes and other known and unknown types of liabilities, there may be liabilities that we underestimated or did not discover in the course of performing our due diligence investigation of our acquired companies and businesses. We may have no recourse or limited recourse under the applicable acquisition-related agreement to recover damages relating to the liabilities of our acquired companies and businesses.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to maintain or increase the levels of revenue, earnings or operating efficiency that each of the acquired companies and businesses and us had historically achieved or might achieve separately. In addition, we may not accomplish the integration of any acquired companies and businesses smoothly, successfully or within the anticipated costs or timeframe. If we experience difficulties with the integration process or if the business of any acquired companies or businesses deteriorates, the anticipated cost savings, growth opportunities and other synergies of any acquired companies and businesses may not be realized fully or at all, or may take longer to realize than expected. If any of the above risks occur, our business, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial condition, results of operations and cash flows may be materially and adversely impacted, we may fail to meet the expectations of investors or analysts, and our stock price may decline as a result.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to realize the benefits from the Flexion Acquisition is substantially dependent on the commercial success of ZILRETTA and the cost savings resulting from the timely and effective integration of the operations of Pacira and Flexion.</span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to realize the benefits from the Flexion Acquisition is substantially dependent on our ability to successfully commercialize ZILRETTA. Combining with Pacira may not accelerate the growth and success of ZILRETTA. If we are unsuccessful at convincing health care providers to increase their rate of adoption of ZILRETTA, our sales could be adversely affected, and our business could suffer.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our ability to realize the benefits from the Flexion Acquisition is substantially dependent on the cost savings resulting from the timely and effective integration of the operations Pacira and Flexion. The process of integrating the operations of Pacira and Flexion could encounter unexpected costs and delays, which include but are not limited to: the loss of key personnel; the loss of key customers; the loss of key suppliers; integrating the products, services and related assets, as well as internal controls into our business operations; and unanticipated issues in integrating sales, marketing and administrative functions. If we are unable to timely and effectively integrate the operations of Pacira and Flexion, our results of operations could be adversely affected, and our business could suffer. Further, even if the integration is timely and effective, we may never realize the cost savings expected from the integration of the operations of the two companies.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The use of our net operating loss carryforwards and research and development tax credits will be limited.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have significant federal and state net operating loss, or NOL, carryforwards and federal and state research and development tax credit carryforwards. Our NOL carryforwards and research and development tax credits may expire and not be used. Our Federal and state NOL carryforwards will begin expiring in 2032 and 2028, respectively, if we have not used them prior to that time. For any federal NOLs generated after December 31, 2017, the NOLs will have an indefinite life and utilization will be subject to a limitation of 80% of taxable income. The non-U.S. NOLs do not expire. Additionally, our ability to use certain NOLs and credit carryforwards to offset taxable income or tax, respectively, in the future will be limited under Internal Revenue Code Sections&#160;382 and 383 because we experienced cumulative changes in ownership of more than 50% within a three-year period. Such ownership changes were triggered by the cumulative ownership changes arising as a result of the initial acquisition of the Company&#8217;s stock in 2007 and the completion of our initial public offering and our other financing transactions. Additionally, on November 19, 2021, we completed the Flexion Acquisition which also triggered an ownership change. Because of these ownership changes, we will be limited regarding the amount of NOL carryforwards and research tax credits that we can utilize annually in the future to offset taxable income or tax, respectively. Such an annual limitation may significantly reduce the utilization of the NOLs and research tax credits before they expire. Accordingly, we have not recognized a benefit in our consolidated financial statements for the NOLs and tax credits which may expire unused.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in data privacy and protection laws and regulations, particularly in Europe and the State of California, or any failure to comply with such laws and regulations, could adversely affect our business and financial results.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a variety of continuously evolving and developing laws and regulations globally regarding privacy, data protection and data security, including those related to the collection, storage, handling, use, disclosure, transfer and security of personal data. Significant uncertainty exists as privacy and data protection laws may be interpreted and applied differently from country to country and may create inconsistent or conflicting requirements. These laws apply to transfers of information among our affiliates, as well as to transactions we enter into with third-party vendors.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the E.U. adopted a comprehensive General Data Privacy Regulation, or GDPR, in May 2016 that replaced the then-current E.U. Data Protection Directive and related country-specific legislation in May 2018. GDPR requires companies to satisfy new requirements regarding the handling of personal and sensitive data, including its use, protection and the ability of persons whose data is stored to correct or delete such data about themselves. Failure to comply with GDPR requirements could result in penalties of up to 4% of total worldwide revenue.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the California Consumer Privacy Act, or CCPA, became effective in January 2020 and imposed new responsibilities on us for the handling, disclosure and deletion of personal information for our employees and consumers who reside in California. The CCPA permits California to assess potentially significant fines for violating CCPA and creates a right for individuals to bring class action suits seeking damages for violations. In addition, we will be required to implement more stringent privacy regulations by January 1, 2023 as the California Privacy Rights Act passed in November 2020.</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, legislators and regulators in the U.S. are proposing new and more robust cybersecurity rules in light of the recent broad-based cyberattacks at a number of companies. Our efforts to comply with GDPR, the CCPA and other privacy and data protection laws may impose significant costs and challenges that are likely to increase over time and may require us to revise certain of our business practices. These and similar initiatives around the world could increase the cost of developing, implementing or securing our servers and require us to allocate more resources to improved technologies, adding to our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information technology and compliance costs. In addition, enforcement actions and investigations by regulatory authorities related to data security incidents and privacy violations continue to increase. The enactment of more restrictive laws, rules, regulations, or future enforcement actions or investigations could impact us through increased costs or restrictions on our business, and noncompliance could result in substantial regulatory penalties and significant legal liability or litigation related to violation of existing or future data privacy laws and regulations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to cybersecurity threats and incidents.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly face attempts by others to gain unauthorized access through the internet, or to introduce malicious software, to our Information Technology, or IT, systems. Individuals or organizations, including malicious hackers and insider threats including employees and third-party service providers, or intruders into our physical facilities, at times attempt to gain unauthorized access to our software and services. We could also be a target of malicious attackers who attempt to gain access to our network or data centers; steal proprietary information related to our business, products, employees, suppliers and customers; interrupt our systems and services or those of our suppliers, customers, or others; or demand ransom to return control of such systems and services. Such attempts, including but not limited to &#8220;phishing&#8221; attempts, are increasing in number and in technical sophistication, and if successful, expose us and any affected parties to risk of loss or misuse of proprietary or confidential information or disruptions of our business operations, including our manufacturing operations. Our IT infrastructure also includes services provided by third parties, and these service providers can experience breaches of their systems and products that impact the security of our systems and our proprietary or confidential information. A substantial breach of our or one of our service providers&#8217; systems could damage our reputation and result in the loss of revenues or the misuse of confidential data, and we may incur significant expenses to resolve such issues.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant changes in the global climate, extreme weather conditions and water availability could adversely affect our business or operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could experience adverse impacts to our business if climate change, other extreme weather conditions and/or water availability challenges adversely affect our operations or the operations of our suppliers, distributors and customers. There is mounting scientific evidence, as well as concern from the general public, that emissions of greenhouse gases and contributing human activities have caused and will continue to cause significant changes in global temperatures and weather patterns and increase the frequency or severity of weather events, extreme heat, wildfires and flooding. While such conditions cannot be predicted, if such conditions were to impact our manufacturing sites or otherwise alter production schedules, including those of our third-party suppliers of raw materials, our manufacturing equipment, or our distributors, we could experience a disruption in the supply of EXPAREL, ZILRETTA or iovera&#176; to our customers and partners, or we could see an unfavorable impact on the cost or availability of our raw or packaging materials. Disruptions to the operations of our customers could also adversely impact the demand for our products. Regulations in response to climate change could result in increased manufacturing costs associated with increased compliance and water and energy costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international operations expose us to numerous and sometimes conflicting legal and regulatory requirements, the compliance of which could be costly and time consuming and violation of these regulations could adversely affect our business or operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous, and sometimes conflicting, legal requirements on matters as diverse as pharmaceutical and medical device marketing, product liability, anti-corruption, data protection and privacy, compliance, taxation, accounting and financial reporting, employment laws, wage-and-hour standards, labor relations and human rights. The global nature of our operations may increase the difficulty and cost of compliance with various regulations and laws, as compliance with diverse legal requirements is costly, time-consuming and requires significant resources. Violations of one or more of these regulations in the conduct of our business could result in significant fines, enforcement actions or criminal sanctions against us and/or our employees, prohibitions on doing business and damage to our reputation.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these legal and regulatory requirements, there are risks inherent in doing business internationally, including but not limited to:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different or more restrictive privacy, data protection, data localization, and other laws that could require us to make changes to our products, services and operations, such as mandating that certain types of data collected in a particular country be stored and/or processed within that country;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in developing, staffing, and simultaneously managing our foreign operations as a result of distance, language, and cultural differences;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stringent local labor laws and regulations;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">profit repatriation restrictions, and foreign currency exchange restrictions;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical events, including natural disasters, acts of war and terrorism, and public health emergencies, including divergent governmental responses thereto across the jurisdictions in which we operate;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">import or export regulations;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and laws and regulations of other jurisdictions prohibiting corrupt payments to government officials and other third parties;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">antitrust and competition regulations;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax developments;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade barriers and changes in trade regulations;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political or social unrest, economic instability, repression, or human rights issues; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to other government regulation or required compliance with local laws.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_19"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_22"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Properties</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy three facilities totaling approximately 195,000 square feet at our Science Center Campus in San Diego, California. We use these facilities for research and development, manufacturing, general and administrative purposes and the storage of inventory and raw materials. Our EXPAREL and iovera&#176; handpieces manufacturing facility and mixed-use research and development property leases both expire in June 2030 and our warehouse lease expires in August 2030. Our iovera&#176; facility in Fremont, California, consists of approximately 20,000 square feet of mixed-use manufacturing, research and development and office space, and its lease currently expires in June 2022 with operations moving to both the Science Center Campus and Providien facility. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacira Innovation and Training center at Tampa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (known as the &#8220;PITT&#8221;) in Tampa, Florida, is an approximately 13,000 square-foot facility that supports a full range of educational events to advance clinician understanding of the latest local, regional and field block approaches for managing pain and reducing or eliminating exposure to opioids. Our corporate headquarters are also located at the PITT, and our lease expires in December 2026. In addition, we have an administrative, commercial and business development office in Parsippany, New Jersey, where we occupy approximately 53,000 square feet under a lease expiring in March 2028. As part of the Flexion Acquisition, we assumed leases for approximately 42,000 square feet of office space in Burlington, Massachusetts under a lease that expires in April 2025 and approximately 5,300 square feet of laboratory space in Woburn, Massachusetts under a lease that expires in February 2024.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our research and development and manufacturing facilities at our Science Center Campus, Thermo Fisher, Fremont and Providien sites (as discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1&#8212;Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above) will be sufficient for our commercial and pipeline development needs. We also may add new facilities or expand existing facilities as we add employees, expand our geographic markets and if demand for EXPAREL, ZILRETTA and iovera&#176; increases and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_25"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information related to Item 3. Legal Proceedings, refer to Note 21, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_28"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 66</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_34"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.    Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed and traded under the ticker symbol &#8220;PCRX&#8221; on the Nasdaq Global Select Market. As of February 27, 2022, we had eleven holders of record of our common stock. The number of record holders is based on the actual number of holders registered on the books of our transfer agent and does not reflect a substantially greater amount of holders of shares in &#8220;street name&#8221;, whose shares are held of record by banks, brokers and other financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows the value of an investment of $100.00 made on December 31, 2016, in each of Pacira BioSciences, Inc. (PCRX), the Nasdaq Composite Index (&#94;IXIC), the Nasdaq Biotechnology Index (&#94;NBI) and the S&amp;P Pharmaceuticals Select Index (&#94;SPSIPH). The three indices included are for comparative purposes only and do not necessarily reflect management&#8217;s opinion that such indices are an appropriate measure of the relative performance of our common stock. All results assume the reinvestment of dividends, if any, and are calculated as of December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. The historical stock price performance of our common stock and the indices shown in this performance graph is not necessarily indicative of future stock price performance.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Comparison of Five-Year Cumulative Total Returns</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Among Pacira BioSciences, Inc., the Nasdaq Composite Index,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">the Nasdaq Biotechnology Index and the S&amp;P Pharmaceuticals Select Index</span></div><div style="padding-right:-9pt;text-align:center"><img src="pcrx-20211231_g3.jpg" alt="pcrx-20211231_g3.jpg" style="height:342px;margin-bottom:5pt;vertical-align:text-bottom;width:708px"/></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Total Return as of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira BioSciences, Inc. (PCRX)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Composite Index (&#94;IXIC)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Biotechnology Index (&#94;NBI)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P Pharmaceuticals Select Index (&#94;SPSIPH)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common stock. We currently intend to retain our future earnings to finance the future development and expansion of our business, and as such we do not expect to pay any cash dividends on our common stock in the foreseeable future. The payment of future dividends, if any, will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in the agreements governing our indebtedness, provisions of applicable law and any other factors our board of directors deems relevant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 67</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Reserved</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_40"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based upon our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC. We operate and report our financial information in one segment. The following discussion of our financial condition and results of operations should be read in conjunction with the other sections of this Annual Report, including our consolidated financial statements and the notes to those consolidated financial statements appearing in Part IV, Item 15, of this Annual Report. This discussion contains forward-looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth under &#8220;Risk Factors&#8221; in Part I, Item&#160;1A. of this Annual Report, our actual results may differ materially from those anticipated in these forward-looking statements. Certain defined terms have been brought forward from Part I of this Annual Report.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section of this Annual Report discusses year-to-year comparisons between 2021 and 2020, as well as other discussions of 2021 and 2020 items. We have&#160;omitted&#160;discussion&#160;of the year ended December&#160;31, 2019 (the earliest of the three years covered by our consolidated financial statements presented in this Annual Report) as permitted by SEC regulations.&#160;The complete Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for year-to-year comparisons between 2020 and 2019 and other discussions of 2019 items can be found within Part II, Item 7, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1396814/000139681421000014/pcrx-20201231.htm">to our Annual Report for the year ended December 31, 2020, filed with the SEC on March 1, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is available free of charge on the SEC&#8217;s website at www.sec.gov and our corporate website at www.pacira.com.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_43"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira is the industry leader in our commitment to non-opioid pain management and providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Our long-acting, local analgesic EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bupivacaine liposome injectable suspension) was commercially launched in April 2012. EXPAREL utilizes our unique pMVL drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. In the U.S., EXPAREL is the only opioid-free, long-acting local and regional analgesic approved for infiltration, field blocks and interscalene brachial plexus nerve block to produce local or regional postsurgical analgesia. EXPAREL is also approved for infiltration in pediatric patients aged six years and older in the U.S. In Europe, EXPAREL is approved as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults. Since its initial approval in 2011, more than ten million patients have been treated with EXPAREL. We drop-ship EXPAREL directly to the end-user based on orders placed to wholesalers or directly to us, and there is no product held by wholesalers. With the MyoScience Acquisition in April 2019, we acquired iovera&#176;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature only to targeted nerves, which we sell directly to end users. The iovera&#176; system is highly complementary to EXPAREL as a non-opioid therapy that alleviates pain by disrupting pain signals being transmitted to the brain from the site of injury or surgery. With the Flexion Acquisition in November 2021, we acquired ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular therapy that can provide major relief for OA knee pain for three months and has the potential to become an alternative to hyaluronic acid, or HA, and platelet rich plasma, or PRP, injections or other early intervention treatments. We believe ZILRETTA is highly complementary to iovera&#176;.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to pursue the expanded use of EXPAREL, ZILRETTA and iovera&#176; in additional procedures; progress our earlier-stage product candidate pipeline; advance regulatory activities for EXPAREL, ZILRETTA, iovera&#176; and other product candidates; invest in sales and marketing resources for EXPAREL, ZILRETTA and iovera&#176;; expand and enhance our manufacturing capacity for EXPAREL, ZILRETTA and iovera&#176;; invest in products, businesses and technologies; and support legal matters.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Flexion Acquisition</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, we completed the Flexion Acquisition pursuant to the Merger Agreement, under which Flexion became our wholly owned subsidiary and added ZILRETTA, a non-opioid corticosteroid that employs a proprietary microsphere technology to provide extended pain relief, to our commercial offering. The addition of ZILRETTA to our innovative non-opioid product portfolio directly aligns with our mission to provide an opioid alternative to as many patients as possible and address medical needs along the neural pain pathway.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration of $<ix:nonFraction unitRef="usd" contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80My9mcmFnOjBiYzY1ZGNjZmY0MzRhMTlhODljZTNmZjM4MzA3MjdjL3RleHRyZWdpb246MGJjNjVkY2NmZjQzNGExOWE4OWNlM2ZmMzgzMDcyN2NfMjE5OTAyMzI2NTYxNA_95a70d4f-3ee4-4335-82b9-a5b2075e49ac">578.8</ix:nonFraction>&#160;million included an initial payment of $428.3 million which represented $8.50 in cash per share of Flexion common stock, $20.2 million paid to settle restricted stock units and in-the-money stock options, an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-5" name="pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80My9mcmFnOjBiYzY1ZGNjZmY0MzRhMTlhODljZTNmZjM4MzA3MjdjL3RleHRyZWdpb246MGJjNjVkY2NmZjQzNGExOWE4OWNlM2ZmMzgzMDcyN2NfMjE5OTAyMzI2ODU5NQ_472087cc-5097-4251-ad31-12659399458b">85.1</ix:nonFraction>&#160;million cash payment of Flexion debt not to be assumed by us and $<ix:nonFraction unitRef="usd" contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119" decimals="-5" name="pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80My9mcmFnOjBiYzY1ZGNjZmY0MzRhMTlhODljZTNmZjM4MzA3MjdjL3RleHRyZWdpb246MGJjNjVkY2NmZjQzNGExOWE4OWNlM2ZmMzgzMDcyN2NfMjE5OTAyMzI2ODcwNg_35e13d74-af23-4202-845b-42bcd2823211">45.2</ix:nonFraction>&#160;million in contingent consideration representing the fair value of contingent value rights, or CVRs, that were issued in conjunction with the Flexion acquisition. The Merger Agreement provided for one non-tradeable CVR per share of Flexion common stock as well as one CVR per share for certain Flexion equity awards. Each CVR entitles Flexion shareholders to contingent milestone payments of up to an aggregate of $8.00 in cash per share of Flexion common stock if certain milestones are met on or prior to December 31, 2030. We estimate that up to an additional $380.2 million in the aggregate may be payable to holders of the CVRs if each of the applicable milestones are achieved. For more information, see Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Highlights</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2021, we closed on the $375.0 million Term Loan. Proceeds of the Term Loan were used to replenish a portion of our funds that were used to pay the purchase price and transaction costs of the Flexion Acquisition and related transactions. For more information, see Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recently received four Notices of Allowance from the USPTO for four EXPAREL patents that have been examined and will issue. Two patents claim chemical composition of EXPAREL and two claim product-by-process. After issuance, Pacira will submit these patents for listing in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;). After listing, the Orange Book would have a total of six EXPAREL patents each with an expiration date of January 22, 2041.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coronavirus (COVID-19) Pandemic</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since early 2020, our revenues have been impacted by COVID-19 and pandemic-related challenges that included the significant postponement or suspension in the scheduling of elective surgical procedures due to public health guidance and government directives. While the degree of impact has diminished during the course of the pandemic due to the introduction of vaccines and the lessening of elective surgery restrictions, certain pandemic-related operational challenges persist. It remains unclear how long it will take the elective surgery market to normalize or if restrictions on elective procedures will recur due to future COVID-19 variants or otherwise. For instance, while many restrictions have since eased with COVID-19 vaccines now widely available, the elective surgery market faced additional pandemic-related challenges in August and September 2021 due to regional surges in COVID-19 Delta variant cases, staffing shortages and fatigue from care teams addressing significant procedure backlogs, and in December 2021, the COVID-19 Omicron variant prompted some government restrictions on elective procedures and surgical staffing challenges which began to ease in January 2022.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to actively monitor the situation and implement measures recommended by federal, state or local authorities, or that we determine are in the best interests of our patients, employees, partners, suppliers, shareholders and stakeholders. For a description of risks facing the Company that relate to the COVID-19 pandemic or any other future pandemic, epidemic or outbreak of contagious disease, see Item 1A. &#8220;Risk Factors&#8221; in this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 69</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of (i) EXPAREL in the U.S., E.U. and U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera&#176; in the U.S. and Canada; and (iv) sales of, and royalties on, our bupivacaine liposome injectable suspension, primarily to Aratana for veterinary use. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our revenues during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXPAREL</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZILRETTA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iovera&#176;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bupivacaine liposome injectable suspension</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative licensing and milestone revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) ZILRETTA net product sales are attributable to the period beginning November 19, 2021, the date of the Flexion Acquisition.</span></div><div style="margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXPAREL net product sales grew 23% in 2021 compared to 2020, primarily due to increases of 21% in gross vial volume and increases of 4% in gross selling price per unit, partially offset by the sales mix of EXPAREL vial sizes. Although the demand for EXPAREL has continued to increase primarily as a result of ASCs and anesthesiologists broadening the use of long-acting EXPAREL regional approaches as a foundation of multimodal opioid-minimization strategies that enable shifting inpatient procedures to 23-hour sites of care, the elective surgery market faced additional pandemic-related challenges from August through December 2021 due to regional surges in COVID-19 Delta and Omicron variant cases, staffing shortages and fatigue from care teams addressing significant procedure backlogs. In 2020, we were also impacted by the suspension of elective surgeries due to the COVID-19 pandemic. EXPAREL utilization remains above the overall sharp decline in elective surgical procedures relative to pre-pandemic baseline levels due to increased utilization in outpatient settings and emergent procedures.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bupivacaine liposome injectable suspension revenue and the related royalty revenue both decreased 19% in 2021 versus 2020 due to the timing of orders placed by Aratana for veterinary use.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Flexion Acquisition, we acquired ZILRETTA in November 2021, which is an extended-release corticosteroid treatment for OA knee pain. We recognized net product sales of $12.7 million for the year ended December 31, 2021, which are attributable to the period beginning on November 19, 2021, the closing date of the Flexion Acquisition. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales of iovera&#176; increased 83% in 2021 versus 2020 primarily due to an increased iovera&#176; sales force, new customers and the impact that the COVID-19 pandemic had in 2020. We have seen the greatest iovera&#176; demand as a pain relief for patients in advance of TKA procedures and in chronic pain management, particularly for people with mild to severe OA of the knee.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaborative licensing and milestone revenue recognized in 2021 was the result of a portion of an upfront payment recognized under our distribution agreement with Eurofarma for the development and commercialization of EXPAREL in Latin America. For more information, see Note 19, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Partners,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included herein.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any renewed government suspension of, or reluctance of patients to have, elective procedures would impact our future sales of EXPAREL, ZILRETTA and iovera&#176; during the ongoing COVID-19 pandemic.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily relates to the costs to produce, package and deliver our products to customers. These expenses include labor, raw materials, manufacturing overhead and occupancy costs, depreciation of facilities, royalty payments, quality control and engineering.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding cost of goods sold and gross margin during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin increased one percentage point in 2021 versus 2020 primarily due to downtime that occurred in 2020, including planned time to prepare our manufacturing suite for a new EXPAREL capacity expansion project at our Science Center Campus in San Diego, California and to a lesser extent an EXPAREL price increase.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses primarily consist of costs related to clinical trials and related outside services, product development and other research and development costs, including trials that we are conducting to generate new data for EXPAREL, ZILRETTA and iovera&#176; and stock-based compensation expense. Clinical and preclinical development expenses include costs for clinical personnel, clinical trials performed by third-parties, toxicology studies, materials and supplies, database management and other third-party fees. Product development and manufacturing capacity expansion expenses include development costs for our products, which include personnel, equipment, materials and contractor costs for process development and product candidates, development costs related to significant scale-ups of our manufacturing capacity and facility costs for our research space. Regulatory and other expenses include regulatory activities related to unapproved products and indications, medical information expenses and related personnel. Stock-based compensation expense relates to the costs of stock option grants, awards of restricted stock units, or RSUs, and our employee stock purchase plan, or ESPP.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a breakout of our research and development expenses during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and preclinical development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product development and manufacturing capacity expansion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expense decreased 7% in 2021 versus 2020.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical and preclinical development expense increased 4% due to increased activities in our iovera&#176; and EXPAREL TKA (&#8220;PREPARE&#8221;) trial, activities related to two EXPAREL lower extremity nerve block trials in bunionectomy and TKA and ongoing trials for products acquired from the Flexion Acquisition in November 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development and manufacturing capacity expansion expense decreased 18% in 2021 versus 2020 mainly attributable to the completion of the significant scale-up of our manufacturing capacity at the Thermo Fisher site in Swindon, England.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory and other expenses decreased 13% in 2021 versus 2020. Regulatory expenses decreased due to the completion of our regulatory review and approval of our MAA in the E.U. Other research and development expenses decreased with lower spend for EXPAREL and iovera&#176; publications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation increased 5% in 2021 versus 2020 primarily due to an increase in the number of equity awards granted to research and development personnel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that research and development will increase in 2022 due to the addition of ZILRETTA, PCRX-201 and PCRX-301 to our product portfolio and pipeline. We believe ZILRETTA&#8217;s extended-release profile may provide effective treatment for OA pain of the shoulder, and we intend to initiate a Phase 3 trial investigating ZILRETTA in shoulder OA in 2022. In addition, we are planning a comparative safety study of ZILRETTA in patients with Type 2 diabetes and are evaluating a repeat dosing study.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses primarily consist of compensation and benefits for our sales force and personnel that support our sales, marketing, medical and scientific affairs operations, payments to our marketing partners for the promotion and sale of our products, expenses related to communicating the health outcome benefits of our products, investments in provider-level market access and patient reimbursement support and educational programs for our customers. General and administrative expenses consist of compensation and benefits for legal, finance, regulatory activities related to approved products and indications, compliance, information technology, human resources, business development, executive management and other supporting personnel. It also includes professional fees for legal, audit, tax and consulting services. Stock-based compensation expense relates to the costs of stock option grants, RSU awards and our ESPP.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding selling, general and administrative expenses during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,516&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of total revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total selling, general and administrative expenses increased 3% in 2021 versus 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing decreased 6% in 2021 versus 2020 driven by the termination of our co-promotion agreement with DePuy Synthes Sales, Inc. effective January 2021. This was partially offset by compensation expenses due to an expanded sales force for EXPAREL and iovera&#176;, the addition of a sales force to support ZILRETTA and set-up costs for our new contracted sales force in Europe. We are continuing our marketing investment in EXPAREL and iovera&#176;, which includes educational initiatives and programs related to the impact of opioids and postsurgical pain management and our national advocacy campaign designed to educate patients about non-opioid treatment options. Additionally, we continue our investment in clinician training in the use of EXPAREL and iovera&#176; at our PITT training facility in Tampa, Florida. We also incurred launch expenses for EXPAREL in connection with our label expansion for use in pediatric populations as young as age six. We expect that the addition of ZILRETTA to our commercial portfolio will increase our sales and marketing spend in 2022 as we increase the size of our ZILRETTA and iovera&#176; sales force which is providing clinicians with two unique OA treatment options to individualize patient care and patient reimbursement support for ZILRETTA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased 26% in 2021 versus 2020 due to increased legal costs, which includes an insurance recovery of $2.1&#160;million in 2020 for legal expenditures related to a since-resolved Department of Justice inquiry and additional administrative and integration costs related to the Flexion Acquisition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation increased 6% in 2021 versus 2020, primarily due to an increase in the number of grants outstanding to selling, general and administrative personnel. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization of Acquired Intangible Assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the amortization of acquired intangible assets during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets increased 72% in 2021 versus 2020 due to the acquisition of Flexion in November 2021. As part of the acquisition, we acquired a developed technology intangible asset for ZILRETTA for OA knee pain, which is being amortized over a useful life of approximately ten years. For more information, see Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included herein.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Charges, Product Discontinuation and Other</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the costs related to the Flexion Acquisition, MyoScience Acquisition, our DepoCyt(e) discontinuation and other activities during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% +</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product discontinuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition-related charges, product discontinuation and other</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100% +</span></td></tr></table></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recognized acquisition-related charges of $39.9 million. These charges are primarily driven by severance and other employee related costs, investment banking, legal and other professional fees, third-party services and other one-time charges associated with the Flexion Acquisition and were partially offset by a gain from changes in fair value associated with the contingent consideration related to the MyoScience Acquisition. In 2020, we recognized charges related to the MyoScience Acquisition primarily due to changes in the fair value of contingent consideration. For more information, see Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Charges, Product Discontinuation and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we agreed to a mutual termination of our agreement with Nuance to advance the development and commercialization of EXPAREL in China due to the lack of a viable regulatory pathway that adequately safeguards our intellectual property against the risk of a generic product. Dissolution costs of $3.0 million were included in other operating expenses in the consolidated statements of operations for the year ended December 31, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we recorded a product discontinuation gain of $0.2 million related to the final settlement of the lease agreement for the site of the former DepoCyt(e) manufacturing activities. The foregoing references to DepoCyt(e) mean DepoCyt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when discussed in the context of the U.S. and Canada and DepoCyte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when discussed in the context of the E.U.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense, Net </span></div><div style="margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding other expense, net during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,071)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,520)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,261)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net increased 28% in 2021 versus 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 24% increase in interest expense was due to the increase in outstanding debt from the entry into the $375.0 million Term Loan in December 2021, the issuance of $402.5&#160;million aggregate principal amount of our 2025 Notes in July 2020 and the assumed $201.3 million principal amount of the Flexion 2024 Notes in connection with the Flexion Acquisition. This increase was partially offset by a decrease of interest expense associated with our 2022 Notes as a result of the $185.0 million repurchase of principal in July 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the issuance of the 2025 Notes, in July 2020, we incurred an $8.1&#160;million loss on early extinguishment of debt recognized due to the retirement of $185.0&#160;million aggregate principal of our existing 2022 Notes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased 81% in 2021 versus 2020 primarily due to lower interest rates and to a lesser extent the sale of available-for-sale investments in 2021 used to fund the cash portion of the purchase price consideration associated with the Flexion Acquisition.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net expense for 2021 included a realized loss on the sale of our equity investment in TELA Bio, Inc., or TELA Bio, in the amount of $2.6&#160;million. In 2020, Other, net income included $1.1 million of U.K. research and development tax credits and a $1.6 million unrealized gain on our equity investment in TELA Bio.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense (Benefit)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our income tax expense (benefit) during the periods indicated, including percent changes (dollar amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Increase / (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,434)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)% +</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded income tax expense of $14.4 million for the year ended December 31, 2021 and an income tax benefit of $125.4 million for the year ended December 31, 2020. The effective tax rate of 26% for the year ended December 31, 2021 differed from the U.S. statutory tax rate of 21% due to non-deductible expenses and valuation allowances recorded against capital loss carryforwards, partially offset by stock-based compensation deductions and tax credits.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit for the year ended December 31, 2020 represented the full release of a $126.6 million valuation allowance on net domestic deferred assets as we determined that there was sufficient positive evidence to conclude that it was more likely than not that domestic deferred taxes were realizable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 74</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2006, we have devoted most of our cash resources to manufacturing, research and development and selling, general and administrative activities related to the development and commercialization of EXPAREL. In addition, we acquired ZILRETTA as part of the Flexion Acquisition in November 2021 and iovera&#176; as part of the MyoScience Acquisition in April 2019. We are primarily dependent on the commercial success of EXPAREL and ZILRETTA. We have financed our operations primarily with the proceeds from the sale of convertible senior notes and other debt, common stock, product sales and collaborative licensing and milestone revenue. As of December&#160;31, 2021, we had an accumulated deficit of $211.9 million, cash and cash equivalents and short-term available-for-sale investments of $656.4 million and working capital of $344.9 million. The net cash proceeds from the Term Loan was $359.2 million after deducting fees and financing costs. For more information, see Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could continue to result in a reduction of certain commercial and clinical expenditures which could offset a portion of the potential revenue declines caused by the COVID-19 pandemic. We currently expect that our cash, short-term and long-term investments on hand will be adequate to cover any potential short-term liquidity needs, and that we would be able to access other sources of financing should the need arise.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was signed into law in response to the COVID-19 pandemic. The CARES Act, among other things, allows for certain measures to increase liquidity for businesses such as the deferral of employer payroll taxes, a tax credit for retaining employees and other provisions. We benefited from the provision to defer the payment of certain employer payroll taxes in the amount of $2.8 million for the year ended December 31, 2020 and remitted $1.4 million in December 2021. The remaining $1.4 million is due by December 31, 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Cash Flows</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows from operating, investing and financing activities for the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Statements of Cash Flows Data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,607)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, net cash provided by operating activities was&#160;$125.7 million&#160;compared to&#160;$77.0 million&#160;in 2020. The increase&#160;of&#160;$48.7 million&#160;was primarily attributable to a 26% increase in total revenues, which was partially offset by expenditures related to the Flexion Acquisition including severance, legal fees and third-party services. For more information, see Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Charges, Product Discontinuation and Other, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements. In addition, in 2021 there were contingent consideration payments to MyoScience securityholders of $12.0 million, of which $6.8 million has been classified as an operating cash outflow and $5.2 million as a financing cash outflow.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, net cash used in investing activities was&#160;$20.8 million, which was primarily driven by the $420.0 million cash portion of the purchase price consideration, net of cash received, associated with the Flexion Acquisition and $45.9 million of capital expenditures, largely for equipment for our new 200-liter EXPAREL capacity expansion project at our Science Center Campus in San Diego, California. These uses of cash were partially offset by the net sale of available-for-sale investments of $457.2 million to fund the cash portion of the purchase price consideration associated with the Flexion Acquisition.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, net cash used in investing activities was&#160;$277.6 million, which reflected $238.6 million of short-term and long-term investment purchases (net of maturities) and purchases of fixed assets of $37.8 million. Major fixed asset purchases included equipment for the new 200-liter EXPAREL capacity expansion project at our Science Center Campus and expenditures for expanding our EXPAREL manufacturing capacity in Swindon, England. In addition, we made a $1.2 million equity investment.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, net cash provided by financing activities was $380.7 million, which consisted of net proceeds from the Term Loan of $359.2 million, the exercise of stock options of $23.8 million and $2.8 million from the issuance of shares through our ESPP. We also made contingent consideration payments to MyoScience securityholders, of which $5.2 million was classified as financing activities based on the recognition at the time of the MyoScience Acquisition.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, net cash provided by financing activities was $222.3 million, which consisted of gross proceeds from the issuance of the 2025 Notes of $402.5 million, the exercise of stock options of $45.2 million and $2.5 million from the issuance of shares through our ESPP. In conjunction with the issuance of the 2025 Notes, we paid $211.1 million of cash (including $1.2 million of accrued interest classified as an operating outflow) to retire $185.0 million of our 2022 Notes in privately negotiated transactions and $12.5 million in financing costs. We also made contingent consideration payments to MyoScience securityholders, of which $5.6 million was classified as financing activities based on their recognition at the time of the MyoScience Acquisition.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.52pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From our inception through December&#160;31, 2021, we have raised $344.5&#160;million of net proceeds from the sale of common stock and other equity securities via public offerings.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2026 Term Loan B Facility</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the $375.0 million Term Loan which is secured by substantially all of the Company&#8217;s and any subsidiary guarantor&#8217;s assets and is scheduled to mature on December 7, 2026, subject to certain exceptions set forth in the Credit Agreement. The Company may elect to borrow either alternate base rate borrowings or term benchmark borrowings. Each term loan borrowing which is an alternate base rate borrowing bears interest at a variable rate per annum equal to the Alternate Base Rate (as defined in the Credit Agreement) subject to a 1.75% floor, plus 6.00%. Each term loan borrowing which is a term benchmark borrowing bears interest at a variable rate per annum equal to (i) the Adjusted Term SOFR Rate (as defined in the Credit Agreement) subject to a 0.75% floor plus (ii) 7.00%.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement requires us to, among other things, maintain (i) a first lien net leverage ratio, determined as of the last day of any fiscal quarter, of no greater than 1.75 to 1.00 and (ii) liquidity, at any time, of at least $150.0 million. The Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of December 31, 2021, the Company was in compliance with all financial covenants under the Credit Agreement.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, we had $375.0 million in outstanding borrowings under the Term Loan. As a result of our entry into the Term Loan, we expect our interest to increase in 2022. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein for further discussion of the Term Loan.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Convertible Senior Notes</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we completed a private placement of $402.5 million in aggregate principal amount of our 2025 Notes and entered into an indenture with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per annum, payable semiannually in arrears on February&#160;1 and August 1 of each year. The 2025 Notes mature on August 1, 2025. At December&#160;31, 2021, the outstanding principal on the 2025 Notes was $402.5 million. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein for further discussion of the 2025 Notes, including information on convertibility factors, redemption, timeframes and balance sheet classification.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Convertible Senior Notes</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, as part of the Flexion Acquisition, we assumed $201.3 million in aggregate principal amount of the Flexion 2024 Notes. The Flexion 2024 Notes have a maturity date of May 1, 2024, are unsecured, and accrue interest at a rate of 3.375% per annum, payable semi-annually on May 1 and November 1 of each year. At December&#160;31, 2021, the outstanding principal on the Flexion 2024 Notes was $201.3 million. In January 2022, we repurchased $192.6 million aggregate principal amount of the Flexion 2024 Notes. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein for further discussion of the Flexion 2024 Notes.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Convertible Senior Notes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, we completed a private placement of $345.0 million in aggregate principal amount of our 2022 Notes and entered into an indenture with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of 2.375% per annum, payable semiannually in arrears on April&#160;1 and October&#160;1 of each year. The 2022 Notes mature on April 1, 2022, and since October 1, 2020, holders may convert their 2022 Notes at any time. In July 2020, we used part of the net proceeds from the issuance of the 2025 Notes discussed above to repurchase $185.0 million aggregate principal of the 2022 Notes in privately negotiated transactions for an aggregate of approximately $211.1 million in cash, including accrued interest. At December&#160;31, 2021, the outstanding principal on the 2022 Notes was $160.0 million and we intend to repay the principal with cash on hand upon maturity on April 1, 2022. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein for further discussion of the 2022 Notes, including information on convertibility factors, redemption, timeframes and balance sheet classification.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents, available-for-sale investments and cash received from product sales will be sufficient to enable us to fund our operating expenses, capital expenditure requirements and payment of the interest and principal on our Term Loan and our Notes, and any conversions of our Notes through the next 12 months. Our future use of operating cash and capital requirements will depend on many forward-looking factors, including, but not limited to, the following:</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of successfully integrating Flexion into our existing business and expanding the commercialization of ZILRETTA;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of the potential Flexion milestone payments under the CVR Agreement, which could be up to an aggregate of $425.5&#160;million if certain regulatory and commercial milestones are met (See Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein for more information);</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic, including the amounts and delays of suspended elective surgical procedures, clinical trials and general economic conditions;</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and extent to which the holders of our Notes elect to convert their Notes and the timing of principal and interest payments on our Term Loan;</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and our ability to successfully continue to expand the commercialization of EXPAREL, ZILRETTA and iovera&#176;, including outside of the U.S.;</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of expanding and maintaining our manufacturing facilities, including the current EXPAREL capacity expansion project at our Science Center Campus in San Diego, California;</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of potential remaining milestone payments to MyoScience security holders, which could be up to an aggregate of $43.0&#160;million if certain regulatory and commercial milestones are met (See Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included herein for more information);</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of additional strategic investments, including additional investments under existing agreements;</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to legal and regulatory issues;</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of performing additional clinical trials for our products, including the additional pediatric trials required by the FDA and EMA as a condition of approval of EXPAREL;</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs for the development and commercialization of other product candidates;</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future payments under our employee benefit plans, including but not limited to our cash long-term incentive plan and non-qualified deferred compensation plan; and</span></div><div style="margin-bottom:8pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in products, businesses and technologies.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional debt or equity financing to meet our future operating and capital requirements. We have no committed external sources of funds, and additional equity or debt financing may not be available on acceptable terms, if at all. Capital market disruptions or negative economic conditions, especially in light of the COVID-19 pandemic, may hinder our access to capital.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_58"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had three convertible senior notes outstanding as of December&#160;31, 2021. $160.0 million in aggregate principal amount is due on our 2022 Notes in April 2022, $8.7 million in aggregate principal amount is due on the Flexion 2024 Notes in May 2024, and $402.5 million in aggregate principal amount is due on our 2025 Notes in August 2025. There was $201.5 million in aggregate principal amount of Flexion 2024 Notes outstanding as of December 31, 2021 of which $192.6 million in aggregate principal amount was repurchased on January 7, 2022 following an offer to purchase the Flexion 2024 Notes. The remaining interest payments on our Notes is $17.9 million, of which an estimated $5.3 million is due in 2022. We also have a $375.0 million Term Loan with contractually obligated principal payments of $28.1 million in 2022, $37.5 million in each of 2023 and 2024, $42.2 million in 2025 and $229.7 million in 2026. The remaining interest payments on the our Term Loan is approximately $115.9 million, based on the current interest rate.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into various lease agreements for manufacturing, research and development and corporate activities, which are typically classified as operating leases under the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2021, we had net minimum commitments of $104.2 million, of which $13.2 million is due in 2022.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have approximately $<ix:nonFraction unitRef="usd" contextRef="ib97087953997481c9eb9531b2899f6a0_I20211231" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF81OC9mcmFnOmQxZDJjYTM2NTQ4NzQ4MTBiOTZkZGVkNGY0NTkyNTQyL3RleHRyZWdpb246ZDFkMmNhMzY1NDg3NDgxMGI5NmRkZWQ0ZjQ1OTI1NDJfMTE1NDQ4NzIwOTg1MDA_1e79b6fa-0ab6-4463-93b8-757005d3b481">50.3</ix:nonFraction> million of minimum, non-cancelable contractual commitments for contract manufacturing services as of&#160;December&#160;31, 2021, of which $18.5&#160;million is due within one year, and the remaining $31.8 million is due within one to three years. We have approximately $<ix:nonFraction unitRef="usd" contextRef="ia919a337f89e4501a657825c42e3742f_I20211231" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF81OC9mcmFnOmQxZDJjYTM2NTQ4NzQ4MTBiOTZkZGVkNGY0NTkyNTQyL3RleHRyZWdpb246ZDFkMmNhMzY1NDg3NDgxMGI5NmRkZWQ0ZjQ1OTI1NDJfMTE1NDQ4NzIwOTg1OTU_97fd1254-4398-456e-b264-8b821edc034c">9.2</ix:nonFraction> million of minimum, non-cancelable contractual commitments for the purchase of certain raw materials as of&#160;December&#160;31, 2021, of which $4.7&#160;million is due within one year, and the remaining $4.5 million is due within one to three years.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the MyoScience Acquisition, upon the achievement of certain regulatory and commercial milestones, there are up to $<ix:nonFraction unitRef="usd" contextRef="i18f0515519fd468ea2893c1d1449bb1e_I20211231" decimals="-5" name="pcrx:ContingentConsiderationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF81OC9mcmFnOmQxZDJjYTM2NTQ4NzQ4MTBiOTZkZGVkNGY0NTkyNTQyL3RleHRyZWdpb246ZDFkMmNhMzY1NDg3NDgxMGI5NmRkZWQ0ZjQ1OTI1NDJfMTE1NDQ4NzIxMDgwNzU_d3c591bd-a30b-40dd-849e-0b43212ccf85">43.0</ix:nonFraction>&#160;million in potential milestone payments available as of December 31, 2021. As part of the Flexion Acquisition there are up to $425.5&#160;million in potential payments if all the regulatory and commercial milestones are met. For more information, see Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein.</span></div><div style="margin-bottom:1pt;margin-top:1pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_61"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our management&#8217;s discussion and analysis of our financial condition and results of operations on our financial statements that have been prepared in accordance with GAAP in the U.S. The preparation of these financial statements requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, contingent consideration, purchase price adjustments, inventory costs, liabilities and accruals, clinical trial expenses, stock-based compensation and the valuation of deferred tax assets. We base our estimates on historical experience, contract terms and on other factors we believe to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are more fully discussed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein. The following accounting policies, which may include significant judgments and estimates, were used in the preparation of our consolidated financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved. The calculation of some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis. If our assessments, experiences or judgments are not accurate estimates of future results, our results could be affected. The sensitivity of our estimates varies by program. Estimates associated with chargebacks and government programs have the greatest risk of being subject to adjustment because of the time delay between recording the accrual and the final settlement. Historically, adjustments to these estimates to reflect actual results or updated expectations have not been material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary of activity with respect to our sales related allowances and accruals for the years ended December 31, 2021, 2020 and 2019 appears in Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to an acquisition, we measure contingent consideration arrangements at fair value for each period with changes in fair value recognized in the consolidated statements of operations as acquisition-related charges. Changes in contingent consideration can result from changes in the assumed achievement and timing of estimated sales, costs of goods sold and regulatory approvals. In the absence of new information, changes in fair value reflect the impact of the passage of time towards the potential achievement of the milestones.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the key assumptions used in the valuation of our contingent consideration milestones:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Flexion Ranges Utilized as of <br/>December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MyoScience Ranges Utilized as of <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d43a54915fb471a881eb7c22d53ebb8_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMS0yLTEtMS02NDI0Ni90ZXh0cmVnaW9uOmQxYjEwMjAwNWQ0MjQwYzg5ZjU1YzZkMzk3NTU2ZGY3XzQ_e555f7a3-3e52-42a8-ad4a-6c6ed1a7c635">11.39</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if920c61660554030b10993e6540fa419_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMS0yLTEtMS02NDI0Ni90ZXh0cmVnaW9uOmQxYjEwMjAwNWQ0MjQwYzg5ZjU1YzZkMzk3NTU2ZGY3XzEw_2a15cb68-0421-41f3-b50c-db0f7ea3d8f2">12.92</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2cf381db5a940f290c4b8ce845a8a32_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMS00LTEtMS02NDI0Ni90ZXh0cmVnaW9uOmM1N2U4OTgxMGUyZjRlOWRiNWRlMjNkZTBlMDNiYWY5XzQ_2ca0d2ec-c0d0-4e6b-8447-a757e658091b">11.42</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7c32d4b9517d48699bd04bc765bd4313_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMS00LTEtMS02NDI0Ni90ZXh0cmVnaW9uOmM1N2U4OTgxMGUyZjRlOWRiNWRlMjNkZTBlMDNiYWY5XzEw_f13747bb-7642-4c87-ac29-1e5df3a3e4d8">12.13</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achieving regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34416a5edad84520b386d27a329de124_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMi0yLTEtMS02NDI0Ni90ZXh0cmVnaW9uOmVhZDk2OTA4ODIxNjQ3NGRiMDJiZjRkZDYzZjIyNTA1XzQ_965b0cac-5a10-4e1c-ae3d-a5eadef7be9f">10.00</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i5b952c5725b44f818a3a4608b206c6b4_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMi0yLTEtMS02NDI0Ni90ZXh0cmVnaW9uOmVhZDk2OTA4ODIxNjQ3NGRiMDJiZjRkZDYzZjIyNTA1XzEw_a82055ca-7bd3-4987-a0d3-f13a2ff29d18">15.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87676acfa0004a61af3790653d502de3_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMi00LTEtMS02NDI0Ni90ZXh0cmVnaW9uOmIwYjk3OTBmZGU4NDQyY2ZiNjg5ZjlhMGNkN2U4MTY4XzQ_3f397d69-62ad-4b9a-bc48-4dc2c9924c9a">1.00</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of achieving regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 to 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum remaining potential payments related to contingent consideration from the Flexion Acquisition and MyoScience Acquisition are $<ix:nonFraction unitRef="usd" contextRef="i6d4add3e8085457381bf09ffb890926b_I20211231" decimals="-5" name="pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RleHRyZWdpb246MGE1NWNjMWRiZTE4NGVmOGJmNzM2MDFlNzgyODM3NWVfMTY0OTI2NzQ0MzQ3OTM_26c62d9f-df6c-4b85-b8b4-99afb072cb05">425.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i18f0515519fd468ea2893c1d1449bb1e_I20211231" decimals="-5" name="pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RleHRyZWdpb246MGE1NWNjMWRiZTE4NGVmOGJmNzM2MDFlNzgyODM3NWVfMTY0OTI2NzQ0MzQ4MDE_a496e354-721c-44e7-919d-16c11b42f6ad">43.0</ix:nonFraction> million, respectively, as of December&#160;31, 2021. Small changes to these assumptions may result in a material impact to the calculated amounts. Additionally, the forecasted revenue annual growth rates are key assumptions in the contingent consideration valuations associated with our commercial milestones. The impact of a hypothetical 10 percent increase in the forecasted annual growth rates would have increased the value of our contingent consideration liability as of December 31, 2021 by $10.1&#160;million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Price Accounting</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an acquisition, we determine the fair value of the assets acquired and liabilities assumed on the date of acquisition, which may include a significant amount of intangible assets, as well as goodwill. When determining the fair values of the acquired intangible assets, we consider, among other factors, analyses of historical financial performance and an estimate of the future performance of the acquired business. The fair values of the acquired intangible assets are primarily calculated using an income approach that relies on discounted cash flows. This method is computed utilizing a forecast of the expected future net cash flows for the asset adjusted to present value by applying a discount rate that reflects the risk factors associated with the net cash flows. We consider this approach to be the most appropriate valuation technique because the inherent value of an acquired intangible asset is its ability to generate future income. In a typical acquisition, we engage a third-party valuation expert to assist us with the fair value analyses for acquired intangible assets.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair values of acquired intangible assets requires us to exercise significant judgment. We select reasonable estimates and assumptions based on evaluating a number of factors, including, but not limited to, marketplace participants, consumer awareness and brand history. Additionally, there are significant judgments inherent in discounted cash flows such as estimating the amount and timing of projected future cash flows and the discount rates. Regarding the Flexion Acquisition, the following assumptions were utilized to determine the fair value of our ZILRETTA product:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Flexion Acquisition Ranges Utilized as of December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range of discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5% - 18.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forecasted annual sales growth rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0% - 50.0%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small changes to these assumptions may result in a material impact to the calculated amounts.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_64"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements for further discussion of recent accounting pronouncements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 79</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our cash equivalents and investment activities is to preserve principal while at the same time maximizing the income that we receive from our investments without significantly increasing risk. We invest in corporate bonds, commercial paper, asset-backed securities and U.S. Treasury and other government agency notes, which are reported at fair value. These securities are subject to interest rate risk and credit risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the interest rate later rises, we expect that the fair value of our investment will decline. A hypothetical 100 basis point increase in interest rates would have reduced the fair value of our available-for-sale securities at&#160;December&#160;31, 2021&#160;by approximately $0.6&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our 2022 Notes and 2025 Notes are impacted by both the fair value of our common stock and interest rate fluctuations. As of&#160;December&#160;31, 2021, the estimated fair value of the 2025 Notes was $1,113 per $1,000 principal amount and the estimated fair value of the 2022 Notes was $1,039 per $1,000 principal amount. See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein for further discussion of our 2022 Notes and 2025 Notes, which bear interest at fixed rates. At December&#160;31, 2021, all $402.5 million of principal remains outstanding on the 2025 Notes, and $160.0 million of principal remains outstanding on the 2022 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan provided for a single-advance term loan in the principal amount of $375.0&#160;million and is scheduled to mature on December 7, 2026. Each term loan borrowing which is an alternate base rate borrowing bears interest at a variable rate per annum equal to the Alternate Base Rate (as defined in the Credit Agreement) subject to a 1.75% floor, plus 6.00%. Each term loan borrowing which is a term benchmark borrowing bears interest at a variable rate per annum equal to (i) the Adjusted Term SOFR rate (as defined in the Credit Agreement) subject to a 0.75% floor plus (ii) 7.00%. At December&#160;31, 2021, we had $375.0&#160;million in outstanding borrowings under the Term Loan. A hypothetical 100 basis point increase in interest rates would have increased interest expense during the year ended December&#160;31, 2021 by approximately $0.3&#160;million, which considers that the Term Loan was outstanding for less than one month during 2021. The impact of a hypothetical 100 basis point increase in interest rates would increase interest expense by $3.0&#160;million in 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Flexion Acquisition and as discussed in more detail in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein, any future conversion rights for the Flexion 2024 Notes are subject to the occurrence of any future events giving rise to such conversion rights under the indenture governing the Flexion 2024 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with certain vendors and partners that operate in foreign jurisdictions. The more significant transactions are primarily denominated in the U.S. Dollar, subject to an annual adjustment based on changes in currency exchange rates.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our accounts receivable are primarily concentrated with four large wholesalers of pharmaceutical products. In the event of non-performance or non-payment, there may be a material adverse impact on our financial condition, results of operations or net cash flow.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_73"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="text-indent:23.44pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements required by this item, together with the report of our independent registered public accounting firm, begin on page&#160;F-1 of this Annual Report.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_76"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_79"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, as such term is defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act, which are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chairman and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, we acquired Flexion (now Pacira Therapeutics, Inc., or Pacira Therapeutics). As such, the scope of our assessment of the effectiveness of our disclosure controls and procedures did not include the internal controls over </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial reporting of Pacira Therapeutics. These exclusions are consistent with the SEC Staff&#8217;s guidance that an assessment of a recently acquired business may be omitted from the scope of our assessment of the effectiveness of disclosure controls and procedures that are also part of internal controls over financial reporting in the 12 months following the acquisition. Pacira Therapeutics (excluding goodwill and intangible assets, which are included within the scope of the assessment) accounted for 13% of our total assets and 2% of our total revenue as of and for the year ended December 31, 2021.</span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on their evaluation as of December&#160;31, 2021, our Chief Executive Officer and Chairman and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December&#160;31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chairman and Chief Financial Officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December&#160;31, 2021, based on the criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based upon the results of the evaluation, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2021 was audited by KPMG&#160;LLP, our independent registered public accounting firm, as stated in their report appearing below, which expressed an unqualified opinion on the effectiveness of our internal control over financial reporting as of December&#160;31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Flexion Acquisition, we have commenced a project to evaluate the processes and procedures of Pacira Therapeutics&#8217; internal control over financial reporting into our internal control over financial reporting framework. Except for the activities described above, there have been no changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 81</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_2074"></div><hr style="page-break-after:always"/><div style="min-height:42.7pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.:</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Pacira BioSciences, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021and 2020, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements), and our report dated February&#160;28, 2022 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired Flexion Therapeutics, Inc. during 2021, and management excluded from its assessment of the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021, Flexion Therapeutics, Inc.&#8217;s internal control over financial reporting associated with total assets of 13% (excluding goodwill and intangible assets, which are included in the scope of the assessment) and total revenues of 2% included in the consolidated financial statements of the Company as of and for the year ended December 31, 2021. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Flexion Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ KPMG LLP</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short Hills, New Jersey</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 82</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_2087"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_85"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_88"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be included in the proxy statement for our 2022 annual stockholders&#8217; meeting and is incorporated by reference into this report.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_91"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be included in the proxy statement for our 2022 annual stockholders&#8217; meeting and is incorporated by reference into this report.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_94"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Authorized For Issuance Under Equity Compensation Plans</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information, as of December 31, 2021, concerning shares of our common stock authorized for issuance under our equity compensation plans. We have two equity compensation plans under which shares are currently authorized for issuance, our Amended and Restated 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;) and our 2014 Employee Stock Purchase Plan (the &#8220;2014 ESPP&#8221;). The 2011 Plan and the 2014 ESPP were approved by stockholders. In April 2014, our board of directors adopted (without stockholder approval) the 2014 Inducement Plan, which authorized 175,000 shares of common stock to be granted as equity awards to new employees.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(c)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price of Outstanding<br/>Options and Rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,020,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation plans</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,050,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Awards issuable under our 2011 Plan include common stock, stock options, restricted stock, restricted stock units and other incentive awards.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Does not include 955,277 unvested shares outstanding as of December 31, 2021 in the form of restricted stock units under our 2011 Plan, which do not require the payment of any consideration by the recipients.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;See Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Stock Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, to our consolidated financial statements included herein for further descriptions of our equity compensation plans.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information required by this item will be included in the proxy statement for our 2022 annual stockholders&#8217; meeting and is incorporated by reference into this report.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_97"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be included in the proxy statement for our 2022 annual stockholders&#8217; meeting and is incorporated by reference into this report.</span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_100"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be included in the proxy statement for our 2022 annual stockholders&#8217; meeting and is incorporated by reference into this report.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-top:8pt;text-indent:22.5pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_103"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:center"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_106"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;Exhibits, Financial Statement Schedules</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Documents filed as part of this Annual Report on Form&#160;10-K:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     Financial Statements</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_124">Consolidated Balance Sheets</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_127">Consolidated Statements of Operations</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_130">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_133">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_136">Consolidated Statements of Cash Flows</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_139">Notes to Consolidated Financial Statements</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The report of our independent registered accounting firm, KPMG LLP, with respect to the above-referenced financial statements and their report on internal control over financial reporting are included in this Form 10-K. Their consent appears as </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="pcrx-12312021xex231.htm">Ex</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="pcrx-12312021xex231.htm">hibit 23.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Form 10-K. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_121">Report of Registered Independent Accounting Firm on the Consolidated Financial Statements</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_2074">Report of Registered Independent Accounting Firm on Internal Control over Financial Reporting</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)     Schedules</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not required, are not applicable or the information is included in the consolidated financial statements or related notes thereto.</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)     Exhibits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:9.54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed with, or incorporated by reference in this Form&#160;10-K.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 84</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Incorporation By Reference From</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date<br/>Filed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465919012708/a19-5831_1ex2d1.htm">2.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated March 4, 2019, by and among Pacira Pharmaceuticals, Inc., PS Merger, Inc., MyoScience, Inc., and Fortis Advisors LLC, as the securityholders&#8217; representative. # &#8224;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/5/2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465921124889/tm2129703d1_ex2-1.htm">2.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc., Pacira BioSciences, Inc. and Oyster Acquisition Company Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/12/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312511032911/dex31.htm">3.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/11/2011</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465919020471/a19-7968_1ex3d1.htm">3.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, dated April 9, 2019.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/9/2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465919020471/a19-7968_1ex3d2.htm">3.3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amended and Restated Bylaws.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/9/2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681419000014/pcrx-3312019xex41.htm">4.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specimen Certificate Evidencing Shares of Common Stock.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465920082725/tm2024106d5_ex4-1.htm">4.2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture (including form of 0.750% Convertible Senior Notes due 2025), dated July 10, 2020, between the Registrant and Wells Fargo Bank, National Association, as trustee.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/10/2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465917016145/a17-8213_1ex4d1.htm">4.3</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture (including form of 2.375% Convertible Senior Notes due 2022), dated March 13, 2017, between the Registrant and Wells Fargo Bank, National Association, as trustee.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/13/2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex44.htm">4.4</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1419600/000119312517154081/d384951dex41.htm">Indenture (including form of 3.375% Convertible Senior Notes due 2024), dated as of May 2, 2017, by and between Flexion Therapeutics, Inc. and Wells Fargo Bank, National Association, as trustee</a>.*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex45.htm">4.5</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1419600/000110465921141653/tm2133207d11_ex4-1.htm">First Supplemental Indenture, dated as of November 19, 2021, by and between Flexion Therapeutics, Inc. and Wells Fargo Bank, National Association, as trustee.</a>*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681420000008/pcrx-12312019xex43.htm">4.6</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Securities.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/21/2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465921080152/tm2119430d1_ex10-1.htm">10.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated 2011 Stock Incentive Plan.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/11/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465914044018/a14-14761_1ex10d3.htm">10.2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Nonstatutory Stock Option Agreement under the Amended and Restated 2011 Stock Incentive Plan for grants made prior to February 1, 2022.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/4/2014</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex103.htm">10.3</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Nonstatutory Stock Option Agreement (Employees) under the Amended and Restated 2011 Stock Incentive Plan for grants made on or after February 1, 2022.*   ***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex104.htm">10.4</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Nonstatutory Stock Option Agreement (Non-Employee Directors) under the Amended and Restated 2011 Stock Incentive Plan for grants made on or after February 1, 2022.*   ***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit106.htm">10.3</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Restricted Stock Unit Award Agreement (Employees) under the Amended and Restated 2011 Stock Incentive Plan.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/30/2015</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit107.htm">10.4</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Restricted Stock Unit Award Agreement (Non-Employee Directors) under the Amended and Restated 2011 Stock Incentive Plan.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/30/2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000006/pcrx-33114xex101.htm">10.5</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Inducement Plan.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465914044018/a14-14761_1ex10d2.htm">10.6</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Employee Stock Purchase Plan.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/4/2014</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex104.htm">10.7</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assignment Agreement, dated February&#160;9, 1994, amended April&#160;15, 2004, between the Registrant and Research Development Foundation.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/3/2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex105.htm">10.8</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Purchase Agreement, dated January 8, 2007, between SkyePharma, Inc. and the Registrant.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/3/2010</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312510273776/dex1021.htm">10.9</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement between the Registrant and David Stack.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/3/2010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465913021811/a13-7707_1ex99d3.htm">10.10</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to Executive Employment Agreement, dated March 13, 2013, between the Registrant and David Stack.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/18/2013</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit105.htm">10.11</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 2 to Executive Employment Agreement, dated June 30, 2015, between the Registrant and David Stack.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/30/2015</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000006/pcrx-33115xex102.htm">10.12</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, dated November 29, 2012, between the Registrant and Kristen Williams.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000006/pcrx-33115xex103.htm">10.13</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to Employment Agreement, dated March 13, 2013, between the Registrant and Kristen Williams.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2015</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Incorporation By Reference From</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date<br/>Filed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit105.htm">10.14</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 2 to Employment Agreement, dated June 30, 2015, between the Registrant and Kristen Williams.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/30/2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681416000023/pcrx-63016xex101.htm">10.15</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Employment Agreement, dated May 2, 2016, between the Registrant and Charles A. Reinhart, III.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/4/2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681420000020/pcrx-3312020xex101.htm">10.16</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Employment Agreement, dated June 19, 2019, between the Registrant and Max Reinhardt.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/7/2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681420000020/pcrx-3312020xex102.htm">10.17</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Employment Agreement, dated April 24, 2017, between the Registrant and Roy Winston.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/7/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000119312511006874/dex1032.htm">10.18</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Registrant and its directors and officers.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/13/2011</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465911059158/a11-26671_1ex10d1.htm">10.19</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Outsourcing Services Agreement entered into as of August&#160;25, 2011 by the Registrant and Integrated Commercialization Solutions,&#160;Inc.&#8224;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/25/2011</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000144530513002604/pcrx-9302013xex101.htm">10.20</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to Commercial Outsourcing Services Agreement, dated August 1, 2013, between the Registrant and Integrated Commercialization Solutions, Inc.&#8224;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/31/2013</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000013/pcrx-93014xex101.htm">10.21</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment to Commercial Outsourcing Services Agreement, dated August 25, 2014, between the Registrant and Integrated Commercialization Solutions, Inc.&#8224;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/30/2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681415000009/exhibit101.htm">10.22</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Amendment to Commercial Outsourcing Services Agreement, dated April 29, 2015, between the Registrant and Integrated Commercialization Solutions, Inc.&#8224;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/30/2015</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681420000020/pcrx-3312020xex103.htm">10.23</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth through Eleventh Amendments to Commercial Outsourcing Services Agreement, between the Registrant and Integrated Commercialization Solutions, Inc.&#8224;&#8224;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/7/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465920072223/tm2022374d1_ex10-1.htm">10.24</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira BioSciences, Inc. Deferred Compensation Plan.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/11/2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681420000052/pcrx-ltip.htm">10.25</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira BioSciences, Inc. Long-Term Incentive Plan.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/7/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000009/pcrx-63014xex101.htm">10.26</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic Co-Production Agreement dated April 4, 2014, by and between the Registrant and Patheon UK Limited.&#8224;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000009/pcrx-63014xex102.htm">10.27</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and Supply Agreement dated April 4, 2014, by and between the Registrant and Patheon UK Limited.&#8224;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681414000009/pcrx-63014xex103.htm">10.28</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technical Transfer and Service Agreement dated April 4, 2014, by and between the Registrant and Patheon UK Limited.&#8224;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465912034943/a12-8876_1ex10d1.htm">10.29</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Consulting Agreement, dated April&#160;3, 2012, between the Registrant and Gary Pace.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/9/2012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465912073140/a12-20102_1ex10d1.htm">10.30</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amended and Restated Consulting Agreement, dated August&#160;17, 2012, between the Registrant and Gary Pace.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/1/2012</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000144530513002604/pcrx-9302013xex103.htm">10.31</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Amendment to Consulting Agreement, dated September 11, 2013, between the Registrant and Gary Pace.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/31/2013</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000162828016011728/pcrx-12312015xex1057.htm">10.32</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth Amendment to Consulting Agreement, dated November 25, 2015, between the Registrant and Gary Pace.***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000139681419000014/pcrx-3312019xex101.htm">10.33</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Employment Agreement, dated May 29, 2017, between the Registrant and Dennis McLoughlin.***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465921141652/tm2129703d9_ex10-1.htm">10.34</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Value Right Agreement, dated as of November 19, 2021, by and between Pacira BioSciences, Inc. and American Stock Transfer &amp; Trust Company, LLC.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/19/2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1396814/000110465921147891/tm2134794d1_ex10-1.htm">10.35</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement, dated as of December 7, 2021, by and among Pacira BioSciences, Inc., the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.##</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex1036.htm">10.36</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and Supply Agreement dated July 31, 2015, between Flexion Therapeutics, Inc. and Patheon UK Limited, as amended to date.&#8224;&#8224;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex1037.htm">10.37</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technical Transfer and Service Agreement dated July 31, 2015, between Flexion Therapeutics, Inc. and Patheon UK Limited, as amended to date.&#8224;&#8224;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex1038.htm">10.38</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Side Letter to the Manufacturing and Supply Agreement between Flexion Therapeutics, Inc. and Patheon UK Limited, dated as of April 8, 2020.&#8224;&#8224;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Incorporation By Reference From</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date<br/>Filed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex211.htm">21.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiaries of the Registrant.*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex231.htm">23.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of KPMG LLP.*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex311.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer and Chairman pursuant to Exchange Act Rule&#160;13a-14(a).*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex312.htm">31.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer pursuant to Exchange Act Rule&#160;13a-14(a).*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pcrx-12312021xex321.htm">32.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer and Chairman and Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Schema Document.*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Calculation Linkbase Document.*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Label Linkbase Document.*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Presentation Linkbase Document.*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101).</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">* &#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-top:8pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="margin-top:8pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Denotes management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Confidential treatment has been requested or granted as to certain portions, which portions were omitted and filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#8224;&#160;&#160;&#160;&#160;Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.</span></div><div style="margin-top:8pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Certain schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K under the Securities Exchange Act of 1934, as amended. The Company hereby undertakes to supplementally furnish copies of any omitted schedules to the Securities and Exchange Commission upon request.</span></div><div style="margin-top:8pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">##      Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to supplementally furnish copies of any omitted schedules and exhibits to the Securities and Exchange Commission upon request.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_112"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 87</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.066%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PACIRA BIOSCIENCES,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;DAVID STACK</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stack</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;DAVID STACK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Chief Executive Officer and Chairman<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stack</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;CHARLES A. REINHART, III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles A. Reinhart, III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;LAUREN RIKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Finance<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lauren Riker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;LAURA BREGE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laura Brege</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ CHRISTOPHER J. CHRISTIE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher J. Christie</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ MARK FROIMSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Froimson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ YVONNE GREENSTREET</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yvonne Greenstreet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ MARK KRONENFELD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Kronenfeld</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JOHN LONGENECKER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Longenecker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;GARY PACE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gary Pace</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;ANDREAS WICKI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andreas Wicki</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;PAUL HASTINGS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lead Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul Hastings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page 88</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEAR ENDED DECEMBER 31, 2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page #</span></td></tr><tr><td colspan="12" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_121">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_121">F-2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditor Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMTgvZnJhZzphMjQ3NmJlMDg2MGY0MDFkYjA0YTNlMjg5OWE5OWU2Yy90YWJsZTpkYjhiYmQzOTRiNjI0OTE4OTNmZGFhZGIzODMzYzM0NS90YWJsZXJhbmdlOmRiOGJiZDM5NGI2MjQ5MTg5M2ZkYWFkYjM4MzNjMzQ1XzItMi0xLTEtNTAzNDg_b57323fd-4e6a-431f-9a07-48a76825d62e">KPMG LLP</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditor Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMTgvZnJhZzphMjQ3NmJlMDg2MGY0MDFkYjA0YTNlMjg5OWE5OWU2Yy90YWJsZTpkYjhiYmQzOTRiNjI0OTE4OTNmZGFhZGIzODMzYzM0NS90YWJsZXJhbmdlOmRiOGJiZDM5NGI2MjQ5MTg5M2ZkYWFkYjM4MzNjMzQ1XzMtMi0xLTEtNTAzNDg_2eab0fee-a006-46f1-9c3b-03a2fa09a49e">Short Hills, NJ</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditor Firm ID:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMTgvZnJhZzphMjQ3NmJlMDg2MGY0MDFkYjA0YTNlMjg5OWE5OWU2Yy90YWJsZTpkYjhiYmQzOTRiNjI0OTE4OTNmZGFhZGIzODMzYzM0NS90YWJsZXJhbmdlOmRiOGJiZDM5NGI2MjQ5MTg5M2ZkYWFkYjM4MzNjMzQ1XzQtMi0xLTEtNTAzNDg_c22dd209-1784-4afd-8d5e-ed45d4362353">185</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_124">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_124">F-4</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_127">Consolidated Statements of Operations for the years ended December&#160;31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_127">F-5</a></span></div></td></tr><tr><td colspan="12" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_130">Consolidated Statements of Comprehensive Income (Loss) for the years ended December&#160;31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_130">F-6</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_133">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_133">F-7</a></span></div></td></tr><tr><td colspan="12" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_136">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#f9f9f9;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_136">F-8</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_139">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_139">F-10</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-1</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.:</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Pacira BioSciences, Inc. and subsidiaries (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 28, 2022 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Initial fair value measurement of intangible assets acquired in connection with the acquisition of</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flexion Therapeutics, Inc.</span></div><div style="text-indent:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 5 and 9 to the consolidated financial statements, the Company acquired Flexion Therapeutics, Inc. (Flexion) on November 19, 2021 for consideration of approximately $578.8 million. The Company measured the assets acquired and the liabilities assumed at fair value, which resulted in the recognition of $541.0 million of intangible assets, comprised of $480.0 million of developed technology and $61.0 million of in-process research and development.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of the initial fair value measurement of the developed technology and in-process research and development intangible assets acquired in connection with the acquisition of Flexion as a critical audit matter. Evaluating the initial fair value measurement of those intangible assets was complex and required significant auditor judgment due to the high degree of subjectivity in evaluating certain assumptions used to estimate fair value. In particular, the fair value measurement was sensitive to management&#8217;s forecasts of revenue and the discount rate. In </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, the audit effort associated with the evaluation of the Company&#8217;s discount rate involved the use of valuation professionals with specialized skills and knowledge.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company&#8217;s acquisition-date valuation process, including controls related to the development of assumptions for forecasted revenues and discount rate. We performed sensitivity analyses over the forecasted revenues to assess the impact of changes in that assumption on the Company&#8217;s determination of the fair value of the developed technology and in-process intangible assets. We evaluated the future revenue growth rates used by the Company to determine forecasted revenues, by comparing them to industry data that was assessed to be relevant and reliable. We involved valuation professionals with specialized skills and knowledge, who assisted in evaluating the Company's discount rate assumption, by comparing the inputs to that assumption to publicly available market data, and assessing the resulting discount rate.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair value measurement of the contingent consideration liabilities associated with the acquisitions of Flexion Therapeutics, Inc. and MyoScience, Inc.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 5 and 12 to the consolidated financial statements, the Company recognized contingent consideration liabilities at their estimated fair value on the acquisition date, in connection with applying the acquisition method of accounting for business combinations. Subsequent changes to the fair value of the contingent consideration liabilities were recorded in the consolidated statement of operations in the period of change. The initial fair value of the contingent consideration liability related to the acquisition of Flexion was $45.2 million. The fair value of the Flexion and MyoScience, Inc. (MyoScience) contingent consideration as of December 31, 2021 was $46.4 million and $11.2 million, respectively.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of the fair value measurement of the contingent consideration liabilities related to achieving commercial and regulatory milestones associated with the acquisitions of Flexion and MyoScience as a critical audit matter. Evaluating the fair value measurement of the contingent consideration liabilities required significant auditor judgment, due to the high degree of subjectivity inherent in certain assumptions with unobservable inputs that were used in the simulation model. In particular, the fair value measurement was sensitive to management&#8217;s forecasts of revenues, estimated probabilities and timing related to the achievement of certain commercial and regulatory milestones, volatility, and discount rates. In addition, the audit effort associated with the evaluation of the Company&#8217;s volatility and discount rates involved the use of valuation professionals with specialized skills and knowledge.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company&#8217;s initial and ongoing fair value measurement process for contingent consideration liabilities related to achieving commercial and regulatory milestones. This included controls related to the development of the assumptions for forecasted revenues, estimated probabilities and timing related to the achievement of certain milestones, volatility, and discount rates. We evaluated the forecasted revenue and certain commercial and regulatory milestone assumptions used in the Company&#8217;s models by comparing them to industry benchmarks and other third-party market data that were assessed to be relevant and reliable. We involved valuation professionals with specialized skills and knowledge, who assisted in evaluating the Company&#8217;s volatility and discount rates, by comparing the inputs to those assumptions to publicly available market data for the comparable entities used by the Company, and assessing the resulting volatility and discount rates.</span></div><div style="padding-left:31.5pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.194%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ KPMG LLP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company&#8217;s auditor since 2015.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short Hills, New Jersey</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-3</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:2pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQtMS0xLTEtMA_c9d54283-006f-4283-a410-3f479795186a">585,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQtMy0xLTEtMA_dc0dc3a4-b20c-46fe-9d05-768e72dcd0c3">99,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term available-for-sale investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzUtMS0xLTEtMA_160db8e3-26cc-4fa1-99e5-1c94fc0689ca">70,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzUtMy0xLTEtMA_b5798f55-1338-4775-9268-7287b4cce391">421,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzYtMS0xLTEtMA_7f4bcef8-9a00-4831-b496-40a61e88896b">96,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzYtMy0xLTEtMA_620e1f52-ee2f-4ee3-89da-0d2c44197f9b">53,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzctMS0xLTEtMA_b276ce3b-7d5d-4c80-a76c-8d2ab19b4aeb">98,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzctMy0xLTEtMA_892a23c9-9540-43ef-a34d-a61387912aa4">64,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzgtMS0xLTEtMA_a5342c41-0ad2-4d53-8cf3-2c25a710bf1a">14,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzgtMy0xLTEtMA_c8ca09a3-ac28-467e-a455-266612bca0cf">12,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzktMS0xLTEtMA_e203f17b-0190-4cdc-94c6-141fd797cb16">866,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzktMy0xLTEtMA_f70ad391-a310-467e-9184-de3733a4a63d">651,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEwLTEtMS0xLTA_392430f5-d8c5-4de6-b362-4d7e272ec312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEwLTMtMS0xLTA_f20dab3b-aea8-4e8f-9cfb-4ab4f9fc643a">95,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzExLTEtMS0xLTA_4e459d03-457f-45d6-8646-225ae30c0d49">188,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzExLTMtMS0xLTA_b3d19b8c-8fe4-4755-8a9f-14245876aeac">136,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEyLTEtMS0xLTA_e8346d37-4b80-4f85-95ee-2dfed0b681f1">76,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEyLTMtMS0xLTA_336c56dc-e6fa-4c29-8585-454d13280dd3">74,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEzLTEtMS0xLTA_af7b1dbf-1899-4326-8859-175767b0c9b1">145,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEzLTMtMS0xLTA_0c62b2c9-8066-4a0d-aaf6-8f880fad9b9d">99,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE0LTEtMS0xLTA_9c48a815-2e73-474e-aa6d-3e3fc3bb2e04">623,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE0LTMtMS0xLTA_0e67dbb6-400b-47e8-945c-bf886e0b6fed">96,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE1LTEtMS0xLTA_271ae3fd-f22c-4ea0-a181-2b5b55347061">153,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE1LTMtMS0xLTA_22d71192-c368-41a7-a9ff-26ef8e204798">106,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:InvestmentsAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE2LTEtMS0xLTA_0d621534-47ed-4db3-838b-eb84b1f30bca">21,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:InvestmentsAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE2LTMtMS0xLTA_51455de4-7714-464a-86ba-404f6ec32113">14,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE4LTEtMS0xLTA_1fb4a76b-ba4a-4195-872f-6ef9422be855">2,075,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE4LTMtMS0xLTA_57c5f35a-588e-4a37-8b96-952de51426cf">1,274,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzIyLTEtMS0xLTA_3e2ffa2b-6742-41a1-a882-74ef069ee21a">10,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzIyLTMtMS0xLTA_dcb0017b-6c58-402b-9024-100cb97bc79b">10,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzIzLTEtMS0xLTA_02dbc05b-6fb2-4b31-8028-5d44c3789d67">127,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzIzLTMtMS0xLTA_20637da9-1bf9-4749-883a-a958be94b77f">70,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI0LTEtMS0xLTA_c7af4f54-b1e1-4b1f-b315-04660c6457de">7,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI0LTMtMS0xLTA_8230851d-17e6-4a56-9e43-35a2501fb286">7,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI1LTEtMS0xLTA_eada0951-939d-4466-95dd-c46c55652a1c">350,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:ConvertibleDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI1LTMtMS0xLTA_9b2a4a10-dcd8-40a4-a3a1-3cd2ba94afd4">149,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:ContingentConsiderationCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI2LTEtMS0xLTA_ec90a190-ad27-4959-b7e4-2251ae0301c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:ContingentConsiderationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI2LTMtMS0xLTA_810d455e-4622-4ca1-b13a-b07b59b13ede">14,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:SecuredDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI3LTEtMS0xLTMyMjg3_f4f6e64b-2ab0-4814-8a80-db33a9e6ad1b">24,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:SecuredDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI3LTMtMS0xLTMyMjg3_e9fcc3fa-6ee0-4d3c-9692-9a298c7e3944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI4LTEtMS0xLTA_c27e0bcd-f443-444f-ab31-79b81a1b5d0a">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI4LTMtMS0xLTA_af0e1780-cd14-45c1-8419-ebba84f8a068">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI5LTEtMS0xLTA_763c8a4a-55ed-4409-aa15-d4711fe32996">521,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI5LTMtMS0xLTA_7f8fb454-ba93-49a7-8a88-288dee9ae0c2">253,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMwLTEtMS0xLTA_c6e12eb3-cf53-41f9-b3b5-d495caf046c6">339,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMwLTMtMS0xLTA_1a6a56f9-8616-43cf-9b31-1465eb723dbd">313,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMxLTEtMS0xLTA_f96e94ee-e920-417f-bda2-6e05974c8517">71,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMxLTMtMS0xLTA_97125463-b4c9-4f1d-a868-81011c46d784">71,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTEtMS0xLTQ1OTY1_0b800a53-1832-4507-8ea1-95317613f811">10,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTMtMS0xLTQ1OTY1_11d42253-9d75-417e-950b-b98479e88965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTEtMS0xLTMyMjk5_c606b44f-1770-4fa6-aee8-05eb22559946">335,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTMtMS0xLTMyMjk5_bb649467-5f75-4ccd-b154-c19e765bb4b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:ContingentConsiderationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMyLTEtMS0xLTA_7f13b3ef-a890-40b4-b9cd-21b878ddfe3d">57,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:ContingentConsiderationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMyLTMtMS0xLTA_21fc3ead-d92d-4fbd-acba-814f84937f7c">13,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTEtMS0xLTA_39272d3e-6941-41bd-a724-a3f25f228fe0">9,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTMtMS0xLTA_85b07d92-f140-431a-9cf0-bdeac851603b">3,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM0LTEtMS0xLTA_26e3572b-9f8e-43f5-a324-3235e06e0872">1,344,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM0LTMtMS0xLTA_fbe00f5b-c004-4990-8e0d-c93e44972ec7">654,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 21)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM1LTEtMS0xLTA_4d10a810-03f5-4bdc-9b77-2a0c02ccf9e1"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM1LTMtMS0xLTA_89b72709-db8d-424e-8a9a-afc6aed53340"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl8zMQ_5dd6a07c-5454-46f4-a96a-371a652f6a1f"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl8zMQ_847cc73a-2480-45ba-bf25-5c4bea4a5f6e">0.001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl8zNQ_d10834c7-96cb-4e8f-8919-fdb622faa412"><ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl8zNQ_da68ab9b-c6c0-4c30-a7f8-01864f4f44bc">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl81Nw_1e18375b-d111-4e08-92ab-74fc41d74706"><ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl81Nw_772f0162-08e2-469c-bfd8-cfdc1c0056d2"><ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl81Nw_ce346380-336c-47e6-aa31-40eb653f048b"><ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl81Nw_f8c1fa0b-a96f-49f1-9cce-3dfafc89704f">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at December&#160;31, 2021 and 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTEtMS0xLTA_a0b1a614-0330-4188-9fb5-25895b16260d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTMtMS0xLTA_14610879-dd67-49a3-a98b-1aa0738a2930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18yOA_30283716-8b2b-4ccc-bfaa-cc653c12610c"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18yOA_d801be9e-ab5d-4890-afad-a6a666513f89">0.001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18zMg_6328e4bc-d92b-4d3f-b016-8f94be3fc785"><ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18zMg_849ee73d-e0bb-470e-af07-4f9f2b7980d3">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y181NA_084d571f-0755-4973-bb6e-260cda39c742"><ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y181NA_9ebc5d82-18b6-4387-84d1-e0dea8895e9a">44,734,308</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18xMTU0NDg3MjA5MTc4Ng_47ecbdc0-9b9f-4bac-bbaa-94c1f2a9586d"><ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18xMTU0NDg3MjA5MTc4Ng_a9457dfb-99c9-44f4-ae68-d460e069acee">43,636,929</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTEtMS0xLTA_6316a543-d746-4fd3-8efe-7ebd1bb666dd">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTMtMS0xLTA_e5347749-5045-4572-be91-ff108e0dcb09">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM5LTEtMS0xLTA_d6d7ea45-4c8a-4f99-8572-0ebf4f3b63a3">942,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM5LTMtMS0xLTA_00106451-0467-4306-88a3-2646b567e761">873,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQwLTEtMS0xLTA_367fb10d-8f6d-492d-85ec-8327bb090332">211,895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQwLTMtMS0xLTA_b366b4d6-648d-4da8-9fac-4b4eef844740">253,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQxLTEtMS0xLTA_3d38d6a3-aa34-4ea5-a406-2ff79f622bfd">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQxLTMtMS0xLTA_b8243e81-d597-49da-9d4d-36671e4f3921">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQyLTEtMS0xLTA_285bd67a-5345-4d3f-945e-adc43ffb4c56">730,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQyLTMtMS0xLTA_f212b7a0-5479-4d03-93ab-d78b8e4ff015">619,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQzLTEtMS0xLTA_d287b103-3af7-47e7-9f12-08c08cf659d9">2,075,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQzLTMtMS0xLTA_312084c8-8703-4c9d-a344-7cc5d98d1cdf">1,274,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-4</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f38afdcb06c45b49334598d858c08be_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMtMS0xLTEtMA_ff434858-b7cf-4d7e-9f33-1be7547f4e5f">538,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be32dbfc52d4ab3bef56de81da70e21_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMtMy0xLTEtMA_5026bad6-f0d2-4623-a385-db45e2160bb0">426,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f4de158e56453ea2b40d32946b5324_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMtNS0xLTEtMA_d82c15ab-edcc-4d3c-bbc4-e35b7a529e41">418,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f22e84df6a45609376bb4bbce1cf8e_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtMS0xLTEtNTc0MzY_3a286d0c-734f-4728-a8c4-14882a0eec1a">2,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e2f16409934c59b4f8cb94a706dc14_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtMy0xLTEtNTc0MzY_844cc4b3-7f5f-4440-8c3c-f9858227deba">3,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96bdb26537c44cc6b5fef08200c07e6f_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtNS0xLTEtNTc0MzY_f3cc0367-f3be-4e3e-a2f4-1fd3d4584896">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative licensing and milestone revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtMS0xLTEtMA_c82c4cbf-3ce4-460f-a287-932aad57d392">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtMy0xLTEtMA_c112b114-b899-4c04-8749-40f3ed315905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtNS0xLTEtMA_aac38bd0-a7df-425a-8939-1a442167569c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzYtMS0xLTEtMA_f66bea6e-c42b-483b-84c5-337a1a25a77a">541,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzYtMy0xLTEtMA_6880b0e7-24a2-45ac-98dc-b5ad38d0796d">429,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzYtNS0xLTEtMA_d3544e70-a7c7-49c2-971c-b99187326970">421,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzgtMS0xLTEtMA_103242ff-340d-4284-993a-8acf0de140e6">140,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzgtMy0xLTEtMA_c6e93a56-0dd7-47a1-bc5b-4687595ee24d">117,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzgtNS0xLTEtMA_7a575ae6-4279-4d51-acb0-2cb54bb50d6a">106,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzktMS0xLTEtMA_c8a85cb3-34fd-4d85-a8d6-abccc007c5c0">55,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzktMy0xLTEtMA_f79031a8-d6d2-4d9c-b33a-54e3bc6ec882">59,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzktNS0xLTEtMA_ccdd5495-e250-476e-9c09-28e84c338473">72,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEwLTEtMS0xLTA_34863e6e-da60-4107-ac80-8348a6e3b10e">199,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEwLTMtMS0xLTA_949c5780-ee59-480a-9f18-23648cff11fd">193,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEwLTUtMS0xLTA_fff0f5ad-3efc-4254-91ed-d5f35bc72ecf">200,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzExLTEtMS0xLTA_7e08705a-bc77-45c5-b632-a478e169319f">13,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzExLTMtMS0xLTA_10d749bb-a9b5-4915-b056-b44b5f210997">7,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzExLTUtMS0xLTA_5e7dfee7-36f0-4d56-ae51-346b3ca2030f">5,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related charges, product discontinuation and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEyLTEtMS0xLTA_eb945dc1-745b-4757-9c18-18994911443f">42,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEyLTMtMS0xLTA_5c0ebb54-e72b-468f-a6f0-037dac470bff">5,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEyLTUtMS0xLTA_8f19f6b9-88d9-4025-a296-03f10bf9c787">25,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEzLTEtMS0xLTA_48699cfb-73cb-430a-abac-71dea2ec9533">451,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEzLTMtMS0xLTA_6fd3e199-5f16-4c12-b609-90941c89f5c5">383,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEzLTUtMS0xLTA_eb80c356-df55-4ea6-b378-1d69d55963e5">410,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE0LTEtMS0xLTA_ebf0e855-2201-49e6-bd45-b940200b08ed">89,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE0LTMtMS0xLTA_780b066b-ab0e-4874-9b8e-a551d16f9837">46,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE0LTUtMS0xLTA_255dbcf9-a899-4415-b9c4-e47b340ddfed">10,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE2LTEtMS0xLTA_64a53399-3c6e-4c0a-beba-befe6fc49656">896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE2LTMtMS0xLTA_eda10b8d-85a4-4147-bbc7-cdc03f44e13b">4,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE2LTUtMS0xLTA_e74053f9-1079-42b8-90c9-9593ae06b094">7,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE3LTEtMS0xLTA_0c663c96-cb29-4f0f-b909-de0eb331383b">31,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE3LTMtMS0xLTA_7b0c0b36-a24e-4fe6-908d-9032face97ca">25,671</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE3LTUtMS0xLTA_ee7528f8-a0a8-4852-b43f-60bf88632ee5">23,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE4LTEtMS0xLTA_ee0fcf0a-b0a8-4cea-ad59-01693247775b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE4LTMtMS0xLTA_25e966f8-e7e8-4b5a-9436-68cda6f9a969">8,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE4LTUtMS0xLTA_0f434b1a-4bd1-4002-bb3a-bc21c6b2cafe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE5LTEtMS0xLTA_f3b69531-0277-4d70-a993-7b247c1ef5ff">2,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE5LTMtMS0xLTA_035a24ea-c4fa-49bb-9f10-51ce66e0970f">2,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE5LTUtMS0xLTA_ec429b4c-4eb8-457f-a870-c6f3d7287cbc">4,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIwLTEtMS0xLTA_a0af78f6-636b-4fc9-a28b-0d3a8e31b045">33,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIwLTMtMS0xLTA_259d7fcd-d1ae-42b5-acd7-6c6115321ca6">26,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIwLTUtMS0xLTA_4bac6488-7e8b-4ff8-8aa6-58db020e2ad6">21,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIxLTEtMS0xLTA_bbe2d531-9ae9-4982-bdd2-a361d1e4bd79">56,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIxLTMtMS0xLTA_76b4ace6-4708-4dff-8b53-afd395d17c50">20,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIxLTUtMS0xLTA_0d9b9b4f-e902-4e3d-8850-7053d00fae3d">10,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIyLTEtMS0xLTA_d15c8807-78c7-4d3b-9dd5-0c3f136ebe98">14,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIyLTMtMS0xLTA_95fd118f-e164-407e-bea2-9188bf996e0d">125,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIyLTUtMS0xLTA_4b2ca59f-aeac-4889-a971-09f0c5ada969">268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIzLTEtMS0xLTA_c8a5c961-52e4-430a-9cca-c76b345364d4">41,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIzLTMtMS0xLTA_80e95b83-0dd7-4d0b-9ae1-3571f1d0a348">145,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIzLTUtMS0xLTA_6b85ac3c-cac9-4da6-bddc-f269d7c9c37f">11,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI2LTEtMS0xLTA_dd63ca6c-5ce4-4109-a606-63ed161e91dd">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI2LTMtMS0xLTA_e133da78-b813-4565-a283-3803dbf782a8">3.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI2LTUtMS0xLTA_5c01ea1e-4b02-443e-8b68-1562eea07f62">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI3LTEtMS0xLTA_c364a475-f5c2-457a-b4ee-2aeac54e1a9d">0.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI3LTMtMS0xLTA_83a9b3ee-a3d6-4181-9074-7cc70decfb25">3.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI3LTUtMS0xLTA_c4406b57-b65c-4aa7-857f-96a655cac517">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI5LTEtMS0xLTA_58210cd9-30bf-46a0-aff4-2fbf233a0abd">44,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI5LTMtMS0xLTA_22cce838-b683-4b45-b308-664a91f13da6">42,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI5LTUtMS0xLTA_ff53cc04-f9dc-45d5-99f8-fac98108ba44">41,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMwLTEtMS0xLTA_15f861c4-fb94-453e-a72d-c87ff36b22e7">45,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMwLTMtMS0xLTA_94afddfc-82f5-4102-95e6-8a01d79e41ac">43,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMwLTUtMS0xLTA_96f07b1b-eaa8-43b0-87f6-5e4f9a615a3d">41,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-5</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzItMS0xLTEtMA_54479c2e-6333-4abf-acdb-55caea0f5f36">41,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzItMy0xLTEtMA_6367fc46-38e9-4837-8b41-c0fee18192a8">145,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzItNS0xLTEtMA_2fa8a915-4933-421d-aa1e-b3ccdff58474">11,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net unrealized gain (loss) on investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzQtMS0xLTEtMA_8365989e-17ac-4022-8bf3-45aca598781b">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzQtMy0xLTEtMA_007f7862-4390-4149-91f3-44ceacd90c0f">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzQtNS0xLTEtMA_aab5d478-2e97-41ad-b08f-cd439fbfa5ae">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzUtMS0xLTEtMA_0b403ca9-1898-4e4a-aa56-da01e5b9363a">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzUtMy0xLTEtMA_504142d3-d286-439c-8d7e-442d934d3838">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzUtNS0xLTEtMA_a0263c3a-e111-46ee-a12a-69578928ae9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzYtMS0xLTEtMA_d968880b-4b8f-49db-a239-814a32b4f850">151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzYtMy0xLTEtMA_b5aff1a2-9b4d-4079-8b44-830dd4bebc89">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzYtNS0xLTEtMA_74abeb56-7fe0-4dd0-9743-001195177eec">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzctMS0xLTEtMA_33fbde8d-e771-4d88-8e65-06e1cc79681a">41,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzctMy0xLTEtMA_df2df453-dd45-4a22-b1f4-5f962142464b">145,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzctNS0xLTEtMA_1b68340e-94d7-476f-b272-c0cd8d5d1d07">10,414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-6</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER&#160;31, 2021, 2020 AND 2019</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa36cac814f44a06a730eb8daf40ca38_I20181231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTEtMS0xLTA_96f80547-6d92-45a3-bdc7-20acb13104fd">41,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa36cac814f44a06a730eb8daf40ca38_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTMtMS0xLTA_709fd4ef-e5c5-4644-a17d-40b6e6d1a8ca">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b6af31fbcb4cb5b587df488ccd9a82_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTUtMS0xLTA_b1a215a6-8cd6-4881-9861-5e30809d7597">709,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice5ead454a5844d28a4260c4149d6b73_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTctMS0xLTA_c75a979b-d864-4d84-9daa-1d998b67e6ca">388,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7691a4cd4aca428e882b620433db6759_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTktMS0xLTA_32a3c8ea-60e5-4ffe-aa77-50f3f7674784">280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f634c57178e427b9ece243062defb9c_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTExLTEtMS0w_7a6d2b44-77a5-4791-9f7c-5d520c10db86">321,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEyLTAtMS0xLTA_54d63146-003c-4c28-a1fa-c0f426679644">Cumulative effect adjustment of the adoption<br/>&#160;&#160;&#160;&#160;&#160;of Accounting Standards Update 2016-02<br/>&#160;&#160;&#160;&#160;&#160;(Note 3)</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f2a38c35f7048949286b849f4126c2b_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEyLTctMS0xLTA_9952a073-e509-40b1-ae9b-1fc5a35a7bac">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i898bf7e1b82b4fd3a5c551aa4879fb16_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEyLTExLTEtMS0w_13951035-1e68-4a80-a3de-0949c2b9e4b6">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b60ec582530407797a99033b53bbf05_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEzLTEtMS0xLTA_70bbbec7-cd08-4d82-8e5b-c6b7c101d1fc">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b60ec582530407797a99033b53bbf05_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEzLTMtMS0xLTA_57257a4f-4739-4263-a896-2dfc8d9d0f67">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9f105ca63d4c1090d6168b48daf166_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEzLTUtMS0xLTA_07be5900-3b85-4b53-a894-c6f328f53d4a">8,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEzLTExLTEtMS0w_c9e9a4b6-6c18-4fc7-b29a-0a97979f2d5b">8,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b60ec582530407797a99033b53bbf05_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE0LTEtMS0xLTA_8e0fbfb4-39b3-4956-9e81-572e64050da5">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Common stock issued under employee stock<br/>&#160;&#160;&#160;&#160;&#160;purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b60ec582530407797a99033b53bbf05_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE1LTEtMS0xLTA_cdee91a1-5491-4953-b036-d7656ce4c138">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9f105ca63d4c1090d6168b48daf166_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE1LTUtMS0xLTA_6fbb2453-8a10-451f-9e80-8d0c0ffb0385">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE1LTExLTEtMS0w_49addf94-3736-4bba-98bf-40804fc5033c">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9f105ca63d4c1090d6168b48daf166_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE2LTUtMS0xLTA_458768d1-4b2d-456c-99d4-22f0b7266efc">33,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE2LTExLTEtMS0w_4f3e0f77-fbeb-47dc-8433-ba8f1ed936b9">33,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Retirement of equity component<br/>&#160;&#160;&#160;&#160;&#160;of 2019 convertible senior notes (Note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide58e19786fb437497710ff2a2f106c9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE3LTUtMS0xLTA_49103684-a31e-423b-bfd1-f0ad149ac1d6">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8363a6e4996490fac437219786a762d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE3LTExLTEtMS0w_c5999c4d-1c24-4f72-8297-e8019badbe37">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other comprehensive income (Note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib22aebb1a2f448a8b5e073383b0f94c1_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE4LTktMS0xLTA_5fcc1397-c27b-496a-8bee-5645cb128a4f">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE4LTExLTEtMS0w_6804a112-7690-43c4-813d-be085ba7bec2">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4a5e18c117b491dab5190737229f0a1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIwLTctMS0xLTA_c799a227-e561-4cbe-829b-daacbefaffd8">11,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIwLTExLTEtMS0w_ecde1b5e-63f4-4b02-be19-36dd18605e14">11,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i776bb75da13044258dd0d043f2083674_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTEtMS0xLTA_71d9f2cf-eeb6-4104-9f1c-4d3c98677d6d">41,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776bb75da13044258dd0d043f2083674_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTMtMS0xLTA_4f4e2dd3-7d23-4c00-a982-b433644f307b">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c5737320f84dbb81a3529e36798635_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTUtMS0xLTA_933187e7-50a6-466f-ac41-a0884f2c9600">753,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73b1bb54137c4111b70b6f8e573b2d33_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTctMS0xLTA_2a9c3344-dd94-4df7-a998-07823d540874">399,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3dfaa6dfa1240039de2e6dff373a711_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTktMS0xLTA_fbf02a28-9db2-40b1-a17e-7e7d7c630b56">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTExLTEtMS0w_1975b186-74ab-45ee-8809-2891baa33795">354,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIyLTEtMS0xLTA_77291e57-8f5b-4520-84bc-ffe34e74141f">1,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIyLTMtMS0xLTA_81c176e7-6afa-448c-9797-4a7ce4fefbda">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3af9929d68c2470ba7dce232ee415fde_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIyLTUtMS0xLTA_89a9e065-dca4-4abd-bf79-e0ef15f7dae7">45,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIyLTExLTEtMS0w_9fe2f3c3-944b-424f-8f99-2b9ed7064817">45,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTEtMS0xLTA_80ea4dd5-79f7-4d32-ba3e-bf91b1cda4f2">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock<br/>&#160;&#160;&#160;&#160;&#160;purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI0LTEtMS0xLTA_7ec527f8-1840-4e31-9d42-5053870c6e0b">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3af9929d68c2470ba7dce232ee415fde_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI0LTUtMS0xLTA_81093cc6-6c6d-4f1a-b9b3-3b029471e5c3">2,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI0LTExLTEtMS0w_e2342704-09ed-4c8b-9651-12965286d63a">2,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3af9929d68c2470ba7dce232ee415fde_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTUtMS0xLTA_24733611-f1ae-4591-9fb2-310cb29ae4a5">39,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTExLTEtMS0w_4d31de44-7bd8-476e-a129-651faa54b5c8">39,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Retirement of equity component<br/>&#160;&#160;&#160;&#160;&#160;of 2022 convertible senior notes (Note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eafc73607f5454aafd32bc87073240c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI3LTUtMS0xLTA_2dfbb9b2-792b-4f90-a7b7-f3bc6753a247">33,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43034ba78f184fed9391b7aa159e7b94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI3LTExLTEtMS0w_87fecc51-4ca9-4ae8-96cf-2147b61a086f">33,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Equity component of 2025 convertible</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;senior notes issued, net of deferred taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;of $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="pcrx:DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpiMWUzYjNkZTliMjM0YTJiOGY1NzNjZGQ2Y2MwZDBhYl85OQ_876e9b3c-3081-4138-a74f-247a74ec6d7a">20,450</ix:nonFraction> (Note 11)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15739e828cad4e53af9937b4cf53b886_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI4LTUtMS0xLTA_8297ba5c-eac9-4bca-8ab9-639f8beb665a">64,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1e15ed7bcf42019a3e50c393218b9f_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI4LTExLTEtMS0w_cdaf25a1-4ac0-4b06-bcfc-95c480aa1b3e">64,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Other comprehensive loss (Note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e4dc31d7b404c919dfaf4a0a27a0aff_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI5LTktMS0xLTA_6fdd848c-9fbf-43fe-bc6f-e50d32458e74">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI5LTExLTEtMS0w_777f6576-b65c-493e-b4c5-f97b3df043a4">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec4e19869fe24a178b94aa20a13f86b3_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMwLTctMS0xLTA_46f59dee-4f91-44e4-9ace-7ce4b8afe8db">145,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMwLTExLTEtMS0w_acd0bcfc-0e2e-4ffa-9ecf-870f64787ef3">145,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia317542b2a494470b42249229135b47e_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTEtMS0xLTA_eec5809d-70f4-4647-a700-242afa265aea">43,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia317542b2a494470b42249229135b47e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTMtMS0xLTA_dd296fb4-601f-465e-9a31-596bf39c9fdd">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097161875b3d423d84de836dca9e6e1b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTUtMS0xLTA_c5aaec30-0a99-487c-b9b4-031a06a38772">873,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292cbc754afb4c849eda7b618d73c0a2_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTctMS0xLTA_bb6e01ca-17b9-401c-8153-06d5437565ea">253,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib617d7e96fc14f90a5109fe4b4e42246_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTktMS0xLTA_9ae263b3-1cdf-46a5-a18c-ef58788b72cd">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTExLTEtMS0w_ad805b7f-dc75-412c-8567-cec8360ccca0">619,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65bc19c293874f40856a561cd84a8945_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTEtMS0xLTI3MDIy_a34fc0f5-987e-46ef-bfeb-38dc161a6ea7">732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65bc19c293874f40856a561cd84a8945_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTMtMS0xLTI3MDIy_71402ad5-0380-4e7a-8ce4-8eff22a86fb3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e75a83dae34a3e81787449842b080d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTUtMS0xLTI3MDIy_e97b1dac-3621-4169-aca7-c170610c9d90">23,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTExLTEtMS0yNzAyMg_b7eddbc6-c9d2-4928-99c7-1ec95da266e4">23,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65bc19c293874f40856a561cd84a8945_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI0LTEtMS0xLTI3MDIy_c5ee3f7f-f600-4036-a5b8-ac102b961d07">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under employee stock<br/>&#160;&#160;&#160;&#160;&#160;purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65bc19c293874f40856a561cd84a8945_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTEtMS0xLTI3MDIy_c190f2c8-ff65-4502-937a-b4b196536b20">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e75a83dae34a3e81787449842b080d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTUtMS0xLTI3MDIy_d6aa86a2-1117-4c01-8d5b-0736aa1cb24b">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTExLTEtMS0yNzAyMg_9bc5b292-fccc-45c7-baa1-d3ffb9e09c5b">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e75a83dae34a3e81787449842b080d_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI2LTUtMS0xLTI3MDIy_2f79daff-ceb1-4fc9-8044-21ab68c34a59">42,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI2LTExLTEtMS0yNzAyMg_d020f36d-e054-4b1a-809b-81c85238dd41">42,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss (Note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18af5711da6640a097e5c4348ee46f60_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMwLTktMS0xLTI3MDIy_f88314e6-e5af-4597-83a3-62c8b77ee12a">151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMwLTExLTEtMS0yNzAyMg_c3f86b1c-1d1d-43c6-a186-966c9dbdcb08">151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ddd1a458e84be0b45073c62a0600f8_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTctMS0xLTI3MDIy_a5eab808-0fb6-4589-8da4-6ed1a8dac7b2">41,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTExLTEtMS0yNzAyMg_8bfc7bc2-6438-46e8-b8a2-e04c96f9b739">41,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia77d73b036584e0f9d8fe145c72c60dd_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTEtMS0xLTI3MDIy_8243c07d-6bbf-4a6e-b6fb-8f2a6f64980c">44,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77d73b036584e0f9d8fe145c72c60dd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTMtMS0xLTI3MDIy_c3d015c1-9cfd-44a3-acb1-c3a0805a9ded">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabeecd1debc54d2491b639ea1e2d971c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTUtMS0xLTI3MDIy_d895b274-b7fe-45f2-a78d-ffe93857324b">942,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i714f475d443c449882547155cf8a8321_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTctMS0xLTI3MDIy_50a12979-4656-431e-b4d4-4d1fb2c315a9">211,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5eb7e48d214a51937b661bf27d5c25_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTktMS0xLTI3MDIy_6641e0ea-a182-4eec-ae8b-5be8d50fc65b">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTExLTEtMS0yNzAyMg_590af16b-d33b-40aa-a3c6-a2990bb1f0a7">730,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-7</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMtMS0xLTEtMA_0508775d-23e6-4372-a756-c2ee4607a266">41,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMtMy0xLTEtMA_ca2c6e60-80a5-4f18-a8e3-4597c883966f">145,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMtNS0xLTEtMA_d5787de1-810a-4f8c-8e7b-845d755a60dc">11,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzUtMS0xLTEtMA_95603aee-b18b-4ad8-9f9e-54427e708cbe">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzUtMy0xLTEtMA_dafe0aef-f6a7-410a-b51e-61666cab3cec">126,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzUtNS0xLTEtMA_4df84c37-0b33-4399-b3be-5a6985bc8d2d">1,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of fixed assets and amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYtMS0xLTEtMA_dda4f9f6-3ff7-4036-8d6b-9589f34b18ee">28,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYtMy0xLTEtMA_3127f1ef-fcd5-4116-aac2-1cb512027216">19,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYtNS0xLTEtMA_af463acb-0aed-4e03-a4ba-fc77cd6946de">19,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization&#160;of&#160;debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzctMS0xLTEtMA_6b54bc95-2eba-44a8-bf55-8cbfd9c96479">2,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzctMy0xLTEtMA_cbfdb3a0-dab5-462d-9426-3db13beb74c4">2,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzctNS0xLTEtMA_44facc6a-0fdb-4e0a-8786-7fcd3d32a73e">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzgtMS0xLTEtMA_dd21ce36-dd18-45c3-ab12-4e89ef62466f">23,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzgtMy0xLTEtMA_62da9a06-fe22-4ef4-8ace-1df0e1717ac1">18,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzgtNS0xLTEtMA_53f50da5-3861-462b-8047-93cc8808681a">13,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on disposal and impairment of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzktMS0xLTEtMA_3f074ddb-65d0-4e6e-9732-50a282fbc2ba">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzktMy0xLTEtMA_0749c7b4-453f-4898-ae68-2a8652d7e3f7">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzktNS0xLTEtMA_c1dfe359-6bf2-4229-9167-ed14216bdc36">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEwLTEtMS0xLTA_40b54c87-2c64-4d45-9974-36dff5b6424f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEwLTMtMS0xLTA_6aead1b8-d071-4138-b235-b50772b8313d">8,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEwLTUtMS0xLTA_d2f1bc2c-64b9-4526-8663-59bc4dca2e31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzExLTEtMS0xLTA_8d8596ef-ab23-45ff-9061-3a586c08abc5">42,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzExLTMtMS0xLTA_7e2fd854-6503-4a85-9ca8-720d6850aff4">39,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzExLTUtMS0xLTA_89e5cefd-56b3-4061-80e3-5a3f0503f374">33,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in contingent consideration (after an acquisition)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEyLTEtMS0xLTA_98ff8fdb-953a-4368-a8da-288a56b91799">989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEyLTMtMS0xLTA_9871e014-929e-4abe-896e-e688dc9612ee">5,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEyLTUtMS0xLTA_a9fcc764-448c-4777-bff8-748df518403f">16,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on investment (net of stock dividend) and other non-operating income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEzLTEtMS0xLTA_532d9046-b66f-4ba3-9390-51d6c6b976bf">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEzLTMtMS0xLTA_1c675691-9907-47fe-bb96-50f370831edd">1,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEzLTUtMS0xLTA_31292130-6154-47c1-aa6a-b7a9abbd2fee">4,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities (net of acquisitions):</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE1LTEtMS0xLTA_544ad83b-93bc-47e5-a66a-5f46cf5107dd">10,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE1LTMtMS0xLTA_e678c3e1-50eb-4568-87d1-a1c360d00eeb">5,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE1LTUtMS0xLTA_a1920c56-5f22-470c-b981-b0c624240ab8">8,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE2LTEtMS0xLTA_f3e2e426-07f1-4d1b-a274-1324ed6fc43e">4,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE2LTMtMS0xLTA_bb52085e-b297-4bf8-951f-20886e1e8289">6,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE2LTUtMS0xLTA_c82566b4-a405-4dfa-a19b-ce4f2b4daa61">8,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE3LTEtMS0xLTA_dbd4bb2c-296e-48ac-9b87-3be61315a88c">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE3LTMtMS0xLTA_386343f7-866a-486d-8039-aedc8b0c8b13">739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE3LTUtMS0xLTA_cebf94ba-be01-4c9b-a7b0-7c0d01549b5c">3,885</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE4LTEtMS0xLTA_edf94146-57cb-4fd8-ac82-7759a9513646">10,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE4LTMtMS0xLTA_8035cde1-2af1-404a-bc85-494002c01dea">3,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE4LTUtMS0xLTA_dab27fc1-5145-4263-822e-d719343e54d5">1,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE5LTEtMS0xLTA_dd9fb587-7a66-41a6-a755-061e4d135a0c">5,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE5LTMtMS0xLTA_78324b28-9984-4518-b0c7-bfc7002b06cc">5,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE5LTUtMS0xLTA_d0ba98a9-d2e6-4158-a0c1-bc0522630d80">22,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIwLTEtMS0xLTA_63c557e6-c1e7-48fd-9dbd-fb0812442d86">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIwLTMtMS0xLTA_c59615b4-b36a-480b-9d31-a6cf6c300b1c">2,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIwLTUtMS0xLTA_a694ab17-27ca-4154-83c4-981c020ee4ad">6,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIxLTEtMS0xLTA_4482d60b-6733-4e8e-8de1-d6b9f7b8613e">6,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIxLTMtMS0xLTA_b93484e2-de7a-48aa-85bd-51b1d9605d3c">9,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIxLTUtMS0xLTA_4ca9a32d-6d6e-466e-9064-ba6dbcdb4064">370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIyLTEtMS0xLTA_8d3e7e7a-bb70-4de0-bf2c-ed66ad5eb044">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIyLTMtMS0xLTA_b594bdbd-483f-4679-bce3-e71a0803f0a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIyLTUtMS0xLTA_a0eabcc2-1c30-46ab-9ff4-bdd3b830944c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIzLTEtMS0xLTA_b26206aa-ede3-414e-bcab-504babaec88d">125,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIzLTMtMS0xLTA_2f1c754e-0831-4429-ae48-02c13f083287">77,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIzLTUtMS0xLTA_83ee874d-f8b9-4215-ae63-a00367c252dc">70,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Flexion Therapeutics, Inc. (net of cash acquired)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTEtMS0xLTI3MTMx_d16d9b62-b833-428a-bd96-a22f72a434c3">420,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTMtMS0xLTI3MTMx_2262ee2d-7264-47f9-96ec-27cb7bc75153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTUtMS0xLTI3MTMx_db8af365-6008-4a0c-a047-fb0506863b19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of MyoScience, Inc. (net of cash acquired)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTEtMS0xLTA_1e170d9e-ba0f-4e14-b530-d753351f08f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTMtMS0xLTA_0bc7d5ac-5c12-4d11-bfe6-96eccdf330bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTUtMS0xLTA_ef62bd1e-985d-4bda-986d-98f9831c261a">117,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI2LTEtMS0xLTA_ba7ec147-a47a-4c7b-bc17-2b235944b443">45,866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI2LTMtMS0xLTA_cf9a2821-6955-4e82-a551-54aaa7157c96">37,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI2LTUtMS0xLTA_7d4e4f0d-c52a-4858-8fa7-0cc2c10cced4">10,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI3LTEtMS0xLTA_5ab41d74-9edd-4bc7-848f-4e914698b00c">611,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI3LTMtMS0xLTA_6dba3d5d-0187-451f-9965-b16d17e219a0">546,516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI3LTUtMS0xLTA_1f7dab28-b878-45f6-8f24-49dd649804db">318,484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of available-for-sale investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI4LTEtMS0xLTA_314a5ffe-172e-4399-8f79-b6f550ea5bb0">1,068,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI4LTMtMS0xLTA_606ebf9a-eb5c-43fa-b5fb-522da35a588f">307,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI4LTUtMS0xLTA_bbf3c75c-ea67-46d5-8667-e9021b5117e9">319,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="pcrx:PaymentOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI5LTEtMS0xLTA_531ee18c-fa5f-4b89-899f-2cf759a2408f">4,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="pcrx:PaymentOfContingentConsideration" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI5LTMtMS0xLTA_0212284d-e35d-4e0a-ba52-2b9a207262ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="pcrx:PaymentOfContingentConsideration" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI5LTUtMS0xLTA_a30952a2-a856-4a49-8191-9d5f30c58768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of equity investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMyLTEtMS0xLTU4OTEz_a8518944-9b42-4329-a98c-9cf26bae3522">9,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMyLTMtMS0xLTU4OTEz_d3eb748b-f84b-45fb-946b-dc136206c95f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMyLTUtMS0xLTU4OTEz_2bfb9e5e-9dec-4bab-a982-9354150ec440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of equity and debt investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMwLTEtMS0xLTA_536eb2f8-01a0-4640-b5bb-5d010a5d2a7c">17,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMwLTMtMS0xLTA_023315e3-7290-456f-a038-bfffb8b30ff0">1,160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMwLTUtMS0xLTA_c421c4b5-1555-42fc-befa-19c9c1cde35d">1,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMxLTEtMS0xLTA_1d6ca790-913b-4268-ab21-514d09338c4a">20,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMxLTMtMS0xLTA_a027986d-a7b0-4245-8ef5-3b99079c10c3">277,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMxLTUtMS0xLTA_4e3be820-f2a8-4f95-b07f-310728051bb0">128,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMzLTEtMS0xLTA_c120e662-ac95-41d5-810c-f6b49b372715">23,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMzLTMtMS0xLTA_3610bbf5-af8d-4db2-8683-4a0d7aa2dd58">45,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMzLTUtMS0xLTA_0b2d70ff-fb86-4ce2-9077-1cc09edd563c">8,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM0LTEtMS0xLTA_e8a1df40-4be2-42f0-a0cd-60a019d8ee75">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM0LTMtMS0xLTA_ea282cf5-91ba-4415-80d2-efebca01bbb0">2,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM0LTUtMS0xLTA_b7806fa4-ba7d-4a67-950b-185575cd760b">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from term loan B credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM3LTEtMS0xLTU4OTAx_5f28510e-f226-49f4-a777-0ed4cbcfba4b">363,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM3LTMtMS0xLTU4OTAx_087d4196-6869-4c4d-8b86-49ae20121b33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM3LTUtMS0xLTU4OTAx_2ed0e026-fe73-4d1b-b5e5-f1b3767f10be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from debt component of the 2025 convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7d5628512b4a3e8635bfd28f644363_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM1LTEtMS0xLTA_2986ca31-5450-44a4-b404-6455448d5ca4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6417dba8c0b47b8b32488655a275284_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM1LTMtMS0xLTA_f4104aa9-596f-4ee2-a087-e2771f3427f8">314,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a19a318f1bb483fa686deeaa2359f9c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM1LTUtMS0xLTA_50fad56b-55e6-4ecc-9d7e-136ed738284b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from equity component of the 2025 convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7d5628512b4a3e8635bfd28f644363_D20210101-20211231" decimals="-3" name="pcrx:ProceedsFromConvertibleOptionComponentOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM2LTEtMS0xLTA_d002cea2-a8c0-4f76-8d1f-9940d17b89b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6417dba8c0b47b8b32488655a275284_D20200101-20201231" decimals="-3" name="pcrx:ProceedsFromConvertibleOptionComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM2LTMtMS0xLTA_ef834358-2a1c-4b9a-8ad4-e8d182b3e2b3">87,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a19a318f1bb483fa686deeaa2359f9c_D20190101-20191231" decimals="-3" name="pcrx:ProceedsFromConvertibleOptionComponentOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM2LTUtMS0xLTA_58bf9b16-33f7-47a7-9ded-8510645edd10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of 2019 convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2189f4174640ff8254517903eb5f68_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM4LTEtMS0xLTA_3905b32d-501a-4ee9-8626-a0a0bc9648c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7eaed297368425488f2206696292750_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM4LTMtMS0xLTA_7744c982-14bb-4471-8580-33e75d390007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8363a6e4996490fac437219786a762d_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM4LTUtMS0xLTA_b2b4e4ad-5c2b-4291-9510-be852f6f034a">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of 2022 convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262c5548fe9c44b8aa7a185ebe27e739_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM5LTEtMS0xLTA_c493c4bf-3a44-4703-b429-251d6781ab59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43034ba78f184fed9391b7aa159e7b94_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM5LTMtMS0xLTA_322dcb1e-aebe-4145-b832-f4317a4aac1a">176,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0494276ab7c45fda83381f5dde00ce2_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM5LTUtMS0xLTA_004c695f-7cf2-44de-8ea1-303c66627e46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement of equity component of the 2022 convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262c5548fe9c44b8aa7a185ebe27e739_D20210101-20211231" decimals="-3" name="pcrx:RetirementOfEquityComponentOfConvertibleSeniorNotes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQwLTEtMS0xLTA_c29d4299-fceb-4771-a3ec-d159b7b0181a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43034ba78f184fed9391b7aa159e7b94_D20200101-20201231" decimals="-3" name="pcrx:RetirementOfEquityComponentOfConvertibleSeniorNotes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQwLTMtMS0xLTA_f137ec7f-6e3f-4a3a-a3df-4a1d22cd5ee4">33,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0494276ab7c45fda83381f5dde00ce2_D20190101-20191231" decimals="-3" name="pcrx:RetirementOfEquityComponentOfConvertibleSeniorNotes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQwLTUtMS0xLTA_31ad0f2d-fa62-42eb-86e2-5aebd1baeeb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion premium on 2019 convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="pcrx:PaymentsForDebtConversionPremiums" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQxLTEtMS0xLTA_80d0a13c-50ea-458d-b1ff-73ee496afa55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="pcrx:PaymentsForDebtConversionPremiums" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQxLTMtMS0xLTA_4e61fe47-74fd-46ce-a3e0-4a17a2937d24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="pcrx:PaymentsForDebtConversionPremiums" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQxLTUtMS0xLTA_79a54459-d241-449f-a769-4481251a4f63">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance and financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQyLTEtMS0xLTA_2a831aa3-a21b-47a1-a3f5-c49b6582f9d5">4,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQyLTMtMS0xLTA_c323ddcb-5d77-4247-9415-6179d5964c03">12,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQyLTUtMS0xLTA_7400afd3-6b9f-4f5b-934f-7d99c2f16c0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQzLTEtMS0xLTA_71f42119-0280-4252-a211-bcb70c92096d">5,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQzLTMtMS0xLTA_0848d8f7-f694-43a2-8e5c-5452fbcf85cb">5,591</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQzLTUtMS0xLTA_361abe8d-b4df-4e20-9ee7-2628acd9800a">6,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ1LTEtMS0xLTA_845a12db-7276-4c4d-9ce1-14148ad30eb5">380,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ1LTMtMS0xLTA_9f8a6367-d662-4240-8955-95a81744606a">222,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ1LTUtMS0xLTA_5919cab2-ca58-4136-a543-34f24bcbcda6">3,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ2LTEtMS0xLTA_6b9fde27-1461-4f24-838b-a3b7d022202e">485,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ2LTMtMS0xLTA_c8f81c4c-1cea-4fb4-a64d-cea44a4b9094">21,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ2LTUtMS0xLTA_f1fc2504-16e9-424b-bc59-12fb3276c9de">54,298</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ3LTEtMS0xLTA_554b9b8c-e98b-4074-9b8e-e3e524dbf67e">99,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ3LTMtMS0xLTA_1bbaeb61-f762-4d2a-9b04-eb4ac8a7195b">78,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f634c57178e427b9ece243062defb9c_I20181231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ3LTUtMS0xLTA_b2f8fe38-7ac8-4218-aca9-3f17569c35d1">132,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ4LTEtMS0xLTA_d37603c5-e582-4df0-9bb6-284caa4f16f5">585,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ4LTMtMS0xLTA_14ebfe9a-8056-460d-99f2-5d0e255944f1">99,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ4LTUtMS0xLTA_e28f158e-644f-4ccd-90e2-f688e790711c">78,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">See accompanying notes to consolidated financial statements.</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PACIRA BIOSCIENCES, INC.</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU4LTEtMS0xLTA_45dcb941-6c07-4874-9dbd-d0376a1317ae">6,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU4LTMtMS0xLTA_da936d97-399c-4162-89e5-75dca7abd780">7,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU4LTUtMS0xLTA_dea32c25-5697-4d06-89cc-c82a6fdc1fda">8,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes, net of refunds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU5LTEtMS0xLTA_c9b9dcfa-8822-43ec-9f39-8d85db55c890">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU5LTMtMS0xLTA_769c3989-43e2-4eb3-ad3c-4f7eac824f86">2,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU5LTUtMS0xLTA_18f844cf-5033-4185-9151-7fd89b5ed03c">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYzLTEtMS0xLTA_b269e777-d08f-4483-8dfb-e84a0a42710c">6,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYzLTMtMS0xLTA_5df1cb21-0b44-4074-b818-995e8e0fc121">9,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYzLTUtMS0xLTA_bdad7e5e-85f4-44d5-ab21-08917acb5ba9">3,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="pcrx:IncreaseDecreaseInContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzY0LTEtMS0xLTA_0a7e85c3-6666-45c9-8344-46c13fd7513f">45,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="pcrx:IncreaseDecreaseInContingentConsideration" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzY0LTMtMS0xLTA_1522f72a-bea3-432f-8394-87356b37d993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="pcrx:IncreaseDecreaseInContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzY0LTUtMS0xLTA_4ef2aafb-17d2-4635-9823-409bd06b5076">28,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-9</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"> </span></div><div id="i284a0cec603b490382d0f8422359e7e8_142"></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDIvZnJhZzoyMDEyYzhmYjQxYWQ0MzhiODQ0MmFkOWJhOGY4MDg5ZC90ZXh0cmVnaW9uOjIwMTJjOGZiNDFhZDQzOGI4NDQyYWQ5YmE4ZjgwODlkXzI2NDE_22609ecd-90df-4aa5-846d-cb9fa5734f80" continuedAt="iacc7495a238d4fe4be9f8d25268a8ada" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="iacc7495a238d4fe4be9f8d25268a8ada"><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira BioSciences,&#160;Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Pacira&#8221;) is the industry leader in its commitment to non-opioid pain management and providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The Company&#8217;s long-acting, local analgesic, EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom in November 2021. EXPAREL utilizes the Company&#8217;s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the Company added iovera&#176;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to its commercial offering with the acquisition of MyoScience, Inc., or MyoScience. The iovera&#176; system is a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature to only targeted nerves.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion, and added ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. For more information, see Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies, reliance on revenue from <ix:nonFraction unitRef="product" contextRef="if3326fe2dfeb408fa75e3dba728e3dc1_D20210101-20211231" decimals="INF" name="pcrx:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDIvZnJhZzoyMDEyYzhmYjQxYWQ0MzhiODQ0MmFkOWJhOGY4MDg5ZC90ZXh0cmVnaW9uOjIwMTJjOGZiNDFhZDQzOGI4NDQyYWQ5YmE4ZjgwODlkXzExNDU_cb43f16d-b4da-4dde-be81-546fa8bd7236">three</ix:nonFraction> products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coronavirus (COVID-19) Pandemic</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since early 2020, the Company&#8217;s revenues have been impacted by the global pandemic caused by a novel strain of coronavirus (COVID-19) and pandemic-related challenges that included the significant postponement or suspension in the scheduling of elective surgical procedures due to public health guidance and government directives. While the degree of impact has diminished during the course of the pandemic due to the introduction of vaccines and the lessening of elective surgery restrictions, certain pandemic-related operational challenges persist. It remains unclear how long it will take the elective surgery market to normalize or if restrictions on elective procedures will recur due to future COVID-19 variants or otherwise. For instance, while many restrictions have since eased with COVID-19 vaccines now widely available, the elective surgery market faced additional pandemic-related challenges in August and September 2021 due to regional surges in COVID-19 Delta variant cases, staffing shortages and fatigue from care teams addressing significant procedure backlogs, and in December 2021, the COVID-19 Omicron variant prompted some government restrictions on elective procedures and surgical staffing challenges which began to ease in January 2022. The Company&#8217;s manufacturing sites are operational and have safety protocols and guidelines as recommended by federal, state and local governments. To date, there have been no material impacts to the Company&#8217;s supply chain. The situation remains dynamic and subject to rapid and possibly material changes. Additional negative impacts may also arise from the COVID-19 pandemic that the Company is unable to foresee. The nature and extent of such impacts will depend on future developments, which are highly uncertain and cannot be predicted.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_145"></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQ2_9115f335-13c7-42a5-b5c7-63e05278671c" continuedAt="i097669f2a4be4ae887247ed6d2a8c9ba" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i097669f2a4be4ae887247ed6d2a8c9ba" continuedAt="i11aedefe5dd04174b6989fdfce5e1535"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQx_431384fd-267c-4292-a9fa-deec85df8c9c" escape="true"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQx_c57ccb3f-560f-428c-a109-ca47823a03f7" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC. The accounts of the Company&#8217;s wholly owned subsidiaries are included in these consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.</span></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzAx_9b6ef44c-f864-4034-8408-ec762e51127c" continuedAt="i365cb57993954a72979f4993ec3c9187" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, purchase price allocation, stock-based compensation, inventory costs, impairments of equity investments, long-lived assets, goodwill, liabilities and accruals, including contingent consideration, </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i11aedefe5dd04174b6989fdfce5e1535" continuedAt="i73f5eda04ddb42c38dff68be120cf062"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i365cb57993954a72979f4993ec3c9187">convertible senior notes, and the valuation of deferred tax assets. The Company&#8217;s critical accounting policies are those that are both most important to the Company&#8217;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.</ix:continuation></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjUy_aee41559-f492-49d5-96dc-0207cbfa6469" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue From Contracts With Customers</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s sources of revenue include (i) sales of EXPAREL in the U.S., European Union, or E.U. and the United Kingdom, or U.K.; (ii) sales of ZILRETTA in the U.S.; (iii) sales of iovera&#176; in the U.S., and Canada; (iv) sales of, and royalties on, its bupivacaine liposome injectable suspension, including for veterinary use and (v) license fees and milestone payments. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further information on the Company&#8217;s accounting policies related to revenue from contracts with customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Licensing and Milestone Revenue</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements generally involve a license to the Company&#8217;s products. In determining how and when to recognize the revenue under a collaboration agreement, the Company must assess whether the license is distinct, which depends upon whether the customer can benefit from the license and whether the license is separate from other performance obligations in the agreement. If the license is distinct, the Company must further assess whether the customer has a right to access or a right to use the license depending on whether the functionality of the license is expected to substantively change over time. If the license is not expected to substantively change, the revenue is recognized at the point in time when the license is provided. If the license is expected to substantively change, the revenue is recognized over the license period.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (e.g. obtaining regulatory approval) represent variable consideration and would be included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third-party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales are incurred or the performance obligation to which the sales relate has been satisfied.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties are estimated and recognized as revenue when sales to the Company&#8217;s commercial partners occur, unless some constraint exists, as the royalties predominately relate to a supply agreement. Royalties are based on sales of the Company&#8217;s bupivacaine liposome injectable suspension product for veterinary use.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:MajorCustomersPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzIz_1bc92f6e-7a6c-439c-b323-75a6f6d49109" continuedAt="i1e131c1bca75479f831188b4ee7bc0ec" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Major Customers</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health,&#160;Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The Company also sells EXPAREL directly to ambulatory surgery centers and physicians. The Company sells ZILRETTA primarily to specialty distributors and a specialty pharmacy, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as Group Purchasing Organizations, or GPOs. The Company sells its bupivacaine liposome injectable suspension for veterinary use to a third-party licensee in the U.S. and sells iovera&#176; directly to end users.</span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzE2_bc652afc-8bf3-47d1-8c12-1354bffaff92" escape="true"><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes the percentage of revenues comprised by the Company&#8217;s <ix:nonFraction unitRef="customer" contextRef="i97a72732ce3f4d6ca28e806af66ae46c_D20210101-20211231" decimals="INF" name="pcrx:ConcentrationRiskNumberofCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzUxNzE_df0a3092-7fc7-4bc2-aaf9-a4d15088f0df">three</ix:nonFraction> largest wholesalers in each period presented:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Largest wholesaler</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ba25e639e904a9d80a76eefeea1ce89_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzItMS0xLTEtMA_2aefbfc4-ea7c-4092-b5dc-3999ac017a63">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7321b7b30b420f86d7944c99c15c52_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzItMy0xLTEtMA_ff3652f8-ddde-4e97-ac42-24d86f3bc996">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i380d3a4003e54e71815bb7db455f68c9_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzItNS0xLTEtMA_5fbf8324-9742-41a9-b092-6ebdc11014a6">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second largest wholesaler</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4bfeff53dc92453d8702a3c0ae51c52d_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzMtMS0xLTEtMA_69b92880-ad12-4d14-8917-5a91ad713ab1">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1df8ab515900456b8b8748721140d7ff_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzMtMy0xLTEtMA_0a6fb97b-b352-4541-aa7d-27122a05bc88">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52bcafe560714f84b452f8d30131893d_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzMtNS0xLTEtMA_3f58932d-18b7-436c-9002-048fed00ce3b">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third largest wholesaler</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice902dc371e243acbe67af152c1848da_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzQtMS0xLTEtMA_dbf583bf-dec4-4793-9ef5-382889b50711">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e0fe11f05a54770acc081985b4107dd_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzQtMy0xLTEtMA_c6694b74-fa3a-4ecb-ae42-02c1dbb43b54">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic79b87819ddf45adb47f8de52f00559e_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzQtNS0xLTEtMA_af942492-3a00-4877-85ab-344db7464b76">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d1b98464ce04367b1e114e9a4d74874_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzUtMS0xLTEtMA_0129883f-5ad2-47f1-bcd3-6571331e8b40">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i71c5bbc9ad9d4d038376f6d8ca847370_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzUtMy0xLTEtMA_8a4ec756-897e-4278-9a51-a57ad5a88567">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7e7c8ae84494cf49e1dc21ec2d425fa_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzUtNS0xLTEtMA_9d72175a-d11d-47bd-8034-6f83eb581a0f">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i73f5eda04ddb42c38dff68be120cf062" continuedAt="ic77e7767f53c4971a2d4a24282810697"><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1e131c1bca75479f831188b4ee7bc0ec">Revenue from outside the U.S. accounted for less than <ix:nonFraction unitRef="number" contextRef="i9359bc477c664a09916c4119368c7808_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzE2NDkyNjc0NjQ3MDM_93fbc0c0-09d5-4ba5-9620-2d919ee85f0b">1</ix:nonFraction>% of the Company&#8217;s total revenue for the year ended December 31, 2021. The Company began selling EXPAREL in the E.U. and U.K. and iovera&#176; in Canada in the fourth quarter of 2021. The Company had <ix:nonFraction unitRef="number" contextRef="i33291270d39e439a99ab030eecef7f59_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzUyMzg_1162ce6f-265e-441b-864f-690c52b69012"><ix:nonFraction unitRef="number" contextRef="ie3861be95c084c30b8a15610c61c7be1_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzUyMzg_6db29f1b-02d3-417d-a8ce-b0b28d872fee">no</ix:nonFraction></ix:nonFraction> revenue from outside the U.S. during the years ended December&#160;31, 2020 and 2019.</ix:continuation></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQz_2ac34396-0cb1-4175-a157-25f8f3608d72" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. These include both internal and external costs, of which a significant portion of development activities are outsourced to third parties, including contract research organizations. Clinical trial costs are accrued over the service periods specified in contracts and adjusted as necessary based on an ongoing review of the level of effort and actual costs incurred. Research and development costs are presented net of reimbursements from commercial partners.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQ4_fe932ed3-c950-4a37-a5db-37397be16275" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues interest and penalties, if any, on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in its consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQ5_9fcf20ba-496a-493f-8305-4c6834256c39" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation consists of grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors, in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&#8217;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value in addition to the closing price of the Company&#8217;s common stock on the date of grant:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Expected term of the option</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Expected volatility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Expected dividends</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Risk-free interest rate</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes its historical volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option activity. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero-coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&#8217;s common stock is estimated to be zero as the Company has not declared or paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. Additionally, the Company&#8217;s ability to declare and pay a dividend in the future could be limited per the agreements governing its indebtedness. The Company records forfeitures as they occur rather than estimating forfeitures during each reporting period.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzA0_df14701d-f515-4e3c-86d3-d35ef0d4f136" continuedAt="i61861195318d4409972a878e9ceb831c" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i61861195318d4409972a878e9ceb831c">All highly liquid investments with maturities of 90 days or less when purchased are considered cash equivalents. Cash equivalents include corporate debt securities, asset backed securities and money market funds.</ix:continuation> As of December&#160;31, 2021, the carrying value of money market funds was $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzExNTQ0ODcyMTE3NTIx_215963d5-6ec7-4f29-8bf5-2773c778cf4c">223.0</ix:nonFraction>&#160;million, commercial paper was $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="us-gaap:CommercialPaperAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzExNTQ0ODcyMTE3NTM1_d256895d-a345-4cf9-8800-8315a996c5e5">19.0</ix:nonFraction>&#160;million and asset backed securities was $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="us-gaap:AssetBackedSecuritiesAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzExNTQ0ODcyMTE3NjM5_0eba4039-fff3-488a-abc1-beae9a087b09">2.6</ix:nonFraction>&#160;million. As of December 31, 2020, the carrying value of money market funds was $<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-5" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzg3Nzg_c9578227-3495-422c-a2ab-bc5aae331aff">51.8</ix:nonFraction> million and commercial paper was $<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-5" name="us-gaap:CommercialPaperAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzg4MDY_b37f54b6-93a5-47dc-83fa-2f5e32f2a3a3">6.5</ix:nonFraction> million. The carrying values approximate fair value as of December&#160;31, 2021 and 2020.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ic77e7767f53c4971a2d4a24282810697" continuedAt="i0e46c996d2b44ed5a908e0c88efcadff"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjkx_36bbc4b5-8852-42ca-b55e-d89b7f60c735" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term and Long-Term Available-For-Sale Investments</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term available-for-sale investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper, corporate and government bonds, and other bonds issued in the U.S. (and denominated in the U.S. dollar) by foreign entities, all with maturities of greater than three months, but less than one year. Long-term available-for-sale investments consist of corporate and government agency bonds with maturities greater than one year. The Company evaluates the classification of its investments at the time of purchase and re-evaluates such determination at each balance sheet date, which includes an assessment of the intent to hold the available-for-sale securities. The Company&#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. The Company classifies its investments as available-for-sale. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities (except for credit losses) are excluded from net income (loss) and are reported as a separate component of accumulated other comprehensive income (loss) until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. The Company evaluates whether a credit loss exists, and in the event a credit loss does exist, the credit loss is recognized in the consolidated statements of operations, based on the amount that the fair value is less than the amortized cost.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzEz_f3ec2759-c5de-49ed-b5ad-bc8aa378d6f9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value, and is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzI3_52f6fc42-14ca-434a-a184-9271f77a6fac" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fixed Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQ0_1c174195-3b0c-499f-a5a2-f48e8a5d322d" continuedAt="i0311ded8922b4ec5a04f2511204998eb" escape="true">Useful lives by asset category are as follows:</ix:nonNumeric></span></div><div><ix:continuation id="i0311ded8922b4ec5a04f2511204998eb" continuedAt="i86020fac96b04837b604f97fcf5683ec"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d024abaafbd4d6e9cda562be11efadd_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzEtMi0xLTEtMC90ZXh0cmVnaW9uOmEyNzAxZDZhNDcwYzRmMzVhOGEwNmFkNThlZjU0NDc2XzQ_fe369b86-4ea3-4c35-88c6-07cb7b996e4c">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i7d54a85658be4c869764ca7b02d10225_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzEtMi0xLTEtMC90ZXh0cmVnaW9uOmEyNzAxZDZhNDcwYzRmMzVhOGEwNmFkNThlZjU0NDc2XzEw_33e1d7f5-520b-467f-a3f3-33de42744721">3</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6f8f41343e614090bd98a3129a5dcdc4_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzItMi0xLTEtMA_fbd14764-a226-4ef0-8963-ddbb781850ad">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i45c66ebd062648669078e714c644cc79_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmFmNDBmNzJiNWUwODRkMjNiOGViZDFjOTY2ZDMxMDM1XzQ_75b78d6c-35fe-49db-af76-4d596bc0439b">5</ix:nonNumeric> to <ix:nonNumeric contextRef="ie86add3d370c4395b397c37d521b6125_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmFmNDBmNzJiNWUwODRkMjNiOGViZDFjOTY2ZDMxMDM1XzEw_c514bd8d-3359-4c74-a407-0a4ad4937eef">10</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:AssetRetirementObligationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjcz_f659d819-45b1-4555-a020-a11184e07c1c" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Retirement Obligations</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of such lease agreements. The Company records its asset retirement obligations, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records expense to accrete the ARO to its full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzA1_cd2c06fc-d886-4162-8c1c-a1781d17033f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes right-of-use, or ROU, assets and lease liabilities at the commencement of its lease agreements. The leases are evaluated at commencement to determine whether they should be classified as operating or financing leases. Lease costs associated with operating leases are recognized on a straight-line basis, while lease costs for financing leases are recognized over the lease term using the effective interest method. The Company does not have any financing leases. The amount of ROU assets and lease liabilities to be recognized is impacted by the type of lease payments, the lease term and the incremental borrowing rate. Variable lease payments are not included at commencement and are recognized in the period in which they are incurred. The lease term is based on the contractual term and is adjusted for any renewal options or termination rights that are reasonably certain to be exercised. The incremental borrowing rate is based on the rate the Company estimates it would pay on a collateralized basis over a similar term in a similar economic environment.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i0e46c996d2b44ed5a908e0c88efcadff" continuedAt="ibd6f29d51bb94be5a999fe497d93d3fc"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjcw_11b3b995-e196-4b7c-8767-d781eb0bfef3" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values, with some exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value can be determined, the asset or liability is recognized; if fair value is not determinable, then no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. </span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development, or IPR&amp;D, is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is recorded as an expense at the acquisition date.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="pcrx:ContingentConsiderationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjk5_902bcc09-a1ae-488b-894d-c926a69b9dc5" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to an acquisition, the Company measures contingent consideration arrangements at fair value each period, with changes in fair value recognized in the consolidated statements of operations as acquisition-related charges. Changes in contingent consideration can result from changes in the assumed achievement and timing of estimated sales, costs of goods sold and regulatory approvals. In the absence of new information, changes in fair value reflect the passage of time towards achievement of the milestones, and are accreted to the period in which payments are expected to be made.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjQx_7bf57b7c-1f04-40f7-8686-d330037d6149" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired in a business combination and is not amortized, but is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzE3_31fd808a-903e-42c1-bf67-3373ac6e012a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their estimated useful lives and are recorded at cost, net of accumulated amortization.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjQ1_846727e5-70f4-4029-935c-8548974833d9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in equity securities without a readily determinable fair value. In the fourth quarter of 2019, the equity investment then held became publicly traded and thereafter, was recognized at its fair value at each reporting period with any unrealized holding gains (losses) included in other income (expense). The equity method investments without a readily determinable fair value are recognized at cost less any impairments, plus or minus any changes resulting from observable price changes in orderly transactions for a similar investment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjc0_aa589d47-0750-45cf-b6ba-4a968061ee2b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjkz_5279eb43-82d9-49b5-a685-df1de1e9aa91" continuedAt="ifd42c1f84ced4d24bbd4d8bd15a7396f" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Debt Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ibd6f29d51bb94be5a999fe497d93d3fc"><ix:continuation id="ifd42c1f84ced4d24bbd4d8bd15a7396f"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the expected impact of Accounting Standards Update 2020-06 on accounting for convertible debt, which is effective January 1, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement of the convertible debt, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the retirement of the equity component and is recognized as a reduction of additional paid-in capital.</span></div></ix:continuation><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzE4_1d249f0e-9696-44eb-9810-fb90fd895d83" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Per Share Data</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the RSUs expected to vest, the shares to be purchased under the Company&#8217;s employee stock purchase plan (using the treasury stock method), and the excess conversion value on the Company&#8217;s convertible senior notes. See Note 3,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the expected impact of Accounting Standards Update 2020-06 on the calculation of dilutive shares for convertible debt, which is effective January 1, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQw_a8c36767-3b9d-4eec-8437-8ae91acf38d5" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currencies</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet accounts of the Company&#8217;s foreign subsidiaries with functional currencies other than the U.S. Dollar are translated using the exchange rate at each respective balance sheet date.&#160;Revenues and expenses are translated using average exchange rates for each calendar month during the year.&#160;Translation&#160;adjustments are recorded as a component of accumulated other comprehensive income (loss) in the consolidated financial statements. Gains or losses from foreign currency exchanges are recorded in other, net in the consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzA3_cbcb1c3a-5187-4e72-bb19-d17f13ff98c9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer manages and allocates resources at a consolidated level. Accordingly, the Company views its business as <ix:nonFraction unitRef="segment" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNDk3_c23dc9a8-bdb9-49a8-aad7-43c8d5b973ff">one</ix:nonFraction> reportable operating segment to evaluate performance, allocate resources, set operational targets and forecast its future financial results.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_148"></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzgwNzc_1e47d44e-cecf-4f30-bf06-eb24aec811cf" continuedAt="i5c432078344f4ab5985fb6cf805758b1" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><ix:continuation id="i5c432078344f4ab5985fb6cf805758b1" continuedAt="iee64c119e3fd42e9b0268fd70e4c9f34"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzgwODI_75063aff-3ca9-405e-ada2-ad49164be8c8" continuedAt="icbc3d50f792a46fdbae30c2325814032" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:0.5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2021-08,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amends Accounting Standards Codification, or ASC, 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. As a result of the amendments made by the ASU, it is expected that an acquirer will generally recognize and measure acquired contract assets and contract liabilities in a manner consistent with how the acquiree recognized and measured them in its pre-acquisition financial statements. The ASU&#8217;s amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (i) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (ii) prospectively to all business combinations that occur </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="iee64c119e3fd42e9b0268fd70e4c9f34"><ix:continuation id="icbc3d50f792a46fdbae30c2325814032"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on or after the date of initial application. The Company has decided to early adopt this standard and will apply it to the valuation of a Flexion deferred revenue contract.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amended the approaches and methodologies in accounting for income taxes during interim periods and makes changes to certain income tax classifications. The standard allows for certain exceptions, including the exception to the use of the incremental approach for intra-period tax allocations, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to-date loss exceeds the anticipated loss for the year. The standard also required franchise or similar taxes partially based on income to be reported as income tax and to reflect the effects of enacted changes in tax laws or rates in the annual effective tax rate computation from the date of enactment. Lastly, in future acquisitions, the Company will be required to evaluate when the step-up in the tax basis of goodwill is part of the business combination and when it should be considered a separate transaction. The standard became effective for the Company beginning January 1, 2021, and there were no material impacts to the consolidated financial statements upon adoption.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2021</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which limits the number of convertible instruments that require separate accounting to (i) those with embedded conversion features that are not clearly and closely related to the debt, that meet the definition of a derivative, and that do not qualify for the scope exception from derivative accounting and (ii) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid in capital. In addition, the new guidance requires diluted earnings per share calculations to be prepared using the if-converted method, instead of the treasury stock method. The guidance must be applied in fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted no earlier than for fiscal years beginning after December 15, 2020. The Company has elected to adopt the new guidance using a modified retrospective method of transition, which would be applied to transactions outstanding at January 1, 2022. As a result, after adopting the ASU&#8217;s guidance, the Company will not separately present in equity an embedded conversion feature for its convertible debt. Instead, the Company will account for a convertible debt instrument wholly as debt. In addition, the Company will not record interest expense on the previously recorded discount on convertible debt. The impact on the balance sheet at January 1, 2022 increased net debt by approximately $<ix:nonFraction unitRef="usd" contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231" decimals="-5" name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzE2NDkyNjc0NTkxMTQ_e9025800-3da5-427a-9e5d-f8417ee81b63">64.9</ix:nonFraction>&#160;million, reduced accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231" decimals="-5" sign="-" name="pcrx:IncreaseDecreaseInRetainedEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzE2NDkyNjc0NTkwOTk_7f423f49-7ba9-4aad-a8ea-a735faf61807">47.2</ix:nonFraction>&#160;million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzE2NDkyNjc0NTkxMjk_e06d333f-25fd-430f-943c-877facbc2cf3">96.5</ix:nonFraction>&#160;million and decreased deferred tax liabilities by $<ix:nonFraction unitRef="usd" contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzM4NDgyOTA3MTQ3MDU_30447b48-c1c3-4162-b532-9a86b92b255e">15.7</ix:nonFraction>&#160;million. The impact on the consolidated statement of operations will reduce interest expense by approximately $<ix:nonFraction unitRef="usd" contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231" decimals="-5" sign="-" name="pcrx:IncreaseDecreaseInInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzE2NDkyNjc0NTkwNzk_5d1447fd-6d09-4606-8d21-cbd1268a79ca">18.0</ix:nonFraction>&#160;million in 2022, with a resultant impact on basic and diluted income (loss) per share.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_151"></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzQ0MDg_3a40f2d9-09c5-49df-a0a4-ea38ae2dd4bb" continuedAt="ib7b8a297ba864acfb52a431f83345fe7" escape="true">REVENUE</ix:nonNumeric></span></div><ix:continuation id="ib7b8a297ba864acfb52a431f83345fe7" continuedAt="i45878521c88f4cc98a06acaf7a0d0d1f"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist of (i) EXPAREL in the U.S., the E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera&#176; in the U.S. and Canada and (iv) sales of, and royalties on, its bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are from the Company&#8217;s collaborative licensing agreements. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure only relates to revenue associated with net EXPAREL and ZILRETTA product sales. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and a specialty pharmacy, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as GPOs. Product revenue is recognized when control of the promised goods are transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the product is delivered to the customer. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i45878521c88f4cc98a06acaf7a0d0d1f" continuedAt="ic101fc835c2f46a8b03fa65932fd0ce1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved. The calculation of some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.</span></div><div style="margin-top:9pt"><span><br/></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="pcrx:MovementinValuationandQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzQ0MDM_3846accd-1572-4f9f-9183-8a7e1d266147" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of activity with respect to the Company&#8217;s sales related allowances and accruals related to EXPAREL for the years ended December&#160;31, 2021, 2020 and 2019, as well as ZILRETTA for the year ended December 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:25.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Returns Allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prompt Payment Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Service Fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Volume Rebates and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72dde336ea2646239cd55a4c4c35744d_I20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtMS0xLTEtMA_1a909324-bc49-4ece-b055-1a16ba40590c">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa17a81b38264f39b34ab843a76bdd7b_I20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtMy0xLTEtMA_be8b02cd-a88b-4018-b658-caa5a49eef8f">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14320622ef29473cb23cce50b7da7f46_I20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtNS0xLTEtMA_4b6ac98e-b3b3-4dff-afbf-676aa020ca9c">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57cd9faa19194a9c8470e9fe6d5218d4_I20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtNy0xLTEtMA_efc9051f-e18b-4494-9677-5663ea2ea7e9">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efcb358dc364ee385b99f35f75898ae_I20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtOS0xLTEtNDk2OTI_411f7d24-c06d-44a6-ad7c-1ea9a1d00518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f634c57178e427b9ece243062defb9c_I20181231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtOS0xLTEtMA_d345a8f3-05a0-4b3a-8b64-e06af2f29081">3,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8d9fd8299c410c8c9b5a06cf205cd2_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItMS0xLTEtMA_19ec6ca1-6435-43e2-9787-dd506bbeef88">783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i712922c8b31944bcb4ececbbd4ecb4a5_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItMy0xLTEtMA_2714b3ad-e8e0-4e0e-8987-dfb00f1a2037">8,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6fe451f5a2472a9296caa5f57011d7_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItNS0xLTEtMA_33e9326f-ef7f-4fea-964e-bb6d9f2e9ccc">6,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie406c0d697dd4848bc04dae623fcce72_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItNy0xLTEtMA_bf4fc4c8-dd4b-4bca-b2f9-645177e73d1e">11,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b07dbdf7694f77bc022c7d7d9afa7c_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItOS0xLTEtNDk2OTI_5c107048-90ed-4564-bbf4-5ddf66edd83f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItOS0xLTEtMA_3a406063-51be-435a-ade5-64c358dc06d9">26,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Payments/Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee8d9fd8299c410c8c9b5a06cf205cd2_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtMS0xLTEtMA_deea0882-39c8-4733-9d5c-26ec29e407e4">587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i712922c8b31944bcb4ececbbd4ecb4a5_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtMy0xLTEtMA_6ee4838e-05c3-4efd-aa0e-f3ef07ff9296">8,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6fe451f5a2472a9296caa5f57011d7_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtNS0xLTEtMA_272ae72f-e38e-4f5e-9ef7-e53293c63768">5,948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie406c0d697dd4848bc04dae623fcce72_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtNy0xLTEtMA_92312eb8-89c3-4696-870a-a77da606762e">10,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b07dbdf7694f77bc022c7d7d9afa7c_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtOS0xLTEtNDk2OTI_a27936ba-c3b1-4d80-bce0-ace9731bc028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtOS0xLTEtMA_0c07e501-6f0f-4b2e-96de-a55f2cf4dcc3">25,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d04eaeb562d4b64900de3e69bac3a78_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtMS0xLTEtMA_796c43ab-a7ab-4799-8664-1608aea677c2">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a88692b931e4aef8edbc75ea1bf544e_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtMy0xLTEtMA_0a0e273d-72f2-4d2a-a240-fef4cf54c41d">962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06af3d3299684224a00de2d7598b92d9_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtNS0xLTEtMA_1d388501-dcd2-4ef4-920b-850ec51c9c30">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320c15f4336b4069b57910624e292a4c_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtNy0xLTEtMA_b599e1b2-6af6-4665-9a66-a8835ae8bf6d">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd3c4592d3b415cba09402210cae28d_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtOS0xLTEtNDk2OTI_19d88f29-f873-4bc6-937e-61f4c8d518ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtOS0xLTEtMA_047e8db4-c603-4352-95ef-f511e60bb438">4,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c16dbebfa7a404f8409b8c58ef412d3_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtMS0xLTEtMA_116f69d2-a25b-4e3b-94b1-5400b2e47f02">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63921146eb64ffe98b470ec795407f5_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtMy0xLTEtMA_aa0b26d3-eede-4e5a-8567-89c1d8cfb0ee">8,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2e28fa586746b9821aa10826da495f_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtNS0xLTEtMA_b477da64-1107-416d-89fe-3dd9d5641caf">6,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc25a5337c794bf8bd461563d5da11b9_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtNy0xLTEtMA_4649a051-66bd-490e-96bd-719a9167ce03">12,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a8455031a245d78c33f94ce7a73d04_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtOS0xLTEtNDk2OTI_c74b0c54-d351-4f0d-aa5f-ac14b567ff5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtOS0xLTEtMA_8016700f-6a46-4bc9-a682-8ceb31e16daf">28,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Payments/Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c16dbebfa7a404f8409b8c58ef412d3_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtMS0xLTEtMA_d2892bbe-35ca-4046-8b1e-d18b9dacc3cc">311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if63921146eb64ffe98b470ec795407f5_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtMy0xLTEtMA_bcbcf622-b88a-4175-949a-9f5c62d46518">8,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b2e28fa586746b9821aa10826da495f_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtNS0xLTEtMA_e8c148dd-7f3c-4f70-b236-52c433e4dd38">6,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc25a5337c794bf8bd461563d5da11b9_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtNy0xLTEtMA_05ebc114-2b00-4ef8-8051-deaefcc5b735">12,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a8455031a245d78c33f94ce7a73d04_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtOS0xLTEtNDk2OTI_c01f7f43-d3ca-4a1c-aa34-7e1db314543c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtOS0xLTEtMA_d58fb902-b4ac-41b3-99f9-c7c0fe168938">28,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c7f9a44c2e3462cb1305f9f59a302b6_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctMS0xLTEtMA_ced163a9-6a8c-4f1d-b765-c0b40165f3fa">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28deb21f2b4942ecb350c0910d65ebed_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctMy0xLTEtMA_0c23cdb1-ba94-40ab-8378-2fc7dc1fd1a8">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a22ddc8218489080892a6cdaf5ebb4_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctNS0xLTEtMA_2754205f-5351-4be2-865c-a6764cc2908e">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id683cf836c4e4f11916c047f28e031ba_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctNy0xLTEtMA_b3411ef6-6213-4291-a6a9-4c910ea7c8cf">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3462358bbe414ffbb1b57b6e9e01c5c9_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctOS0xLTEtNDk2OTI_3d9d7b03-415a-4da2-8420-a64ce5990e24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctOS0xLTEtMA_5f36ae32-015e-40c4-a012-7fb03164e6df">4,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92a3c6cd7d9435cb9eff94c7851d7f4_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtMS0xLTEtMA_708afd36-8382-4a49-9af8-39143ada0a81">3,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ac5092cc3645d7bc0aef94ffd9cee5_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtMy0xLTEtMA_e81d6b19-7f93-41f4-a7a4-cf985ec8e6ae">10,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57086efa37da41e998389e0480dd7425_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtNS0xLTEtMA_6770c488-f927-4cc0-8a35-d4968d0465ec">10,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf91a2291efc4aa296367a3d8f467bd8_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtNy0xLTEtMA_267bb377-991d-4047-b6cf-d69c984a74ae">17,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied14d59a15b74bf6b3ced695a67b49f0_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtOS0xLTEtNDk2OTI_3b743bda-806d-4601-9d4d-af309fb711d7">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtOS0xLTEtMA_26fa42c6-79ce-4a0b-8751-8be1bd88d6ed">41,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Payments/Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia92a3c6cd7d9435cb9eff94c7851d7f4_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktMS0xLTEtMA_08eccdd5-1ad9-4dac-9840-c816e5c99865">757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63ac5092cc3645d7bc0aef94ffd9cee5_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktMy0xLTEtMA_fe629d58-2842-481c-aaec-2e8e883ca27a">10,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57086efa37da41e998389e0480dd7425_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktNS0xLTEtMA_4f8ad989-2022-49df-9da6-e456301da545">7,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf91a2291efc4aa296367a3d8f467bd8_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktNy0xLTEtMA_e98a1fc2-4637-41db-8480-81b7d4bfd404">15,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied14d59a15b74bf6b3ced695a67b49f0_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktOS0xLTEtNDk2OTI_faf2ced1-09f1-4a52-b55c-fc223255157e">378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktOS0xLTEtMA_df9f6bc9-4e21-431f-999d-ecb6ebe2297d">34,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc0dc9d1d7b14f25ad8be83ef27a2350_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTEtMS0xLTA_0f7199a3-fe94-4a2e-9505-09043393ea6d">3,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e8ea6a6bb646069500943f11b40bd6_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTMtMS0xLTA_11d1468f-b2d4-4ce8-83f0-5935beea00d9">1,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie03f2a211d40429ba9a8f59edb0f3814_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTUtMS0xLTA_691ab117-7e3c-4e9b-bcb9-cd34a620e78b">3,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8787beaf97a040fc93e4271eaa597cf7_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTctMS0xLTA_9552b9a7-62af-49d0-8cab-aa3a954a4c19">3,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id086e74a59d7487d9c24f8b8d7361978_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTktMS0xLTQ5Njky_d77ba691-657a-44ee-886f-6ac43a4716fb">761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTktMS0xLTA_ab4b9673-99d1-4f55-9db9-61d815a536f1">12,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Licensing and Milestone Revenue</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements generally involve a license to the Company&#8217;s products. In determining how and when to recognize the revenue under a collaboration agreement, the Company must assess whether the license is distinct, which depends upon whether the customer can benefit from the license and whether the license is separate from other performance obligations in the agreement. If the license is distinct, the Company must further assess whether the customer has a right to access or a right to use the license depending on whether the functionality of the license is expected to substantively change over time. If the license is not expected to substantively change, the revenue is recognized at the point in time when the license is provided. If the license is expected to substantively change, the revenue is recognized over the license period.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (e.g. obtaining regulatory approval) represent variable consideration and are included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third-party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales are incurred or the performance obligation to which the sales relate has been satisfied.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacy, GPOs and doctors. Payment terms generally range from&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzI3NzA_1d583239-02d3-4c41-bc38-abbb200a0e6b">zero</span>&#160;to&#160;<ix:nonNumeric contextRef="i74f568606f0c4823a905f91cf481d300_D20210101-20211231" name="pcrx:AccountsReceivablePaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzI3NzY_0e3cbab0-19d0-4e12-ae0b-6bab942e4d49">97</ix:nonNumeric>&#160;days from the date of the transaction, and accordingly, there is no significant financing component. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ic101fc835c2f46a8b03fa65932fd0ce1"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company&#8217;s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company&#8217;s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenue</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzQ0MDY_dc2e0190-9144-4107-83b9-bcebd7e4df70" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregated net product sales in the periods presented as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;EXPAREL</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736f64d4bbd849d7be2b019552be776c_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzMtMS0xLTEtMA_ea9861dc-e273-47bd-821b-794ad71eff32">506,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c69cb4d02b34bbca69ebe9cac7ed74e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzMtMy0xLTEtMA_b94a9c34-5846-4abe-b0f4-d468e0390172">413,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8edb95efe04b6799f90101e59f96cb_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzMtNS0xLTEtMA_09f8afce-b503-4f69-9309-afabfb94b28b">407,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;ZILRETTA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30fd1b228fa24cc99396d29a977444ca_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtMS0xLTEtMjY2OTU_6cd556ea-f6c0-4f79-b501-9ac93f8e2af8">12,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0d7ce79dbc4e3789299398e8fce7f1_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtMy0xLTEtMjY2OTU_5c3d1ba7-aa37-4c27-9d1c-26fbd1f0d282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de2811811e245db84f11e1e3de5d7e6_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtNS0xLTEtMjY2OTU_e1bd8dfc-2c64-4d2d-93f3-28db23c8b104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;iovera&#176;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if533c736fa2840fb9422c87e1310fa3a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtMS0xLTEtMA_b2cb4592-faa0-4fea-b42c-bd43abdb1e38">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d56d46c5c9a4e8a9f809b42b0655590_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtMy0xLTEtMA_30ac8236-2ff7-45e9-a5c0-7b3ec0f32ab1">8,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6610466d344f0fa088043b24569826_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtNS0xLTEtMA_802a0914-49e0-4904-a3bc-73ccc7b7d68a">7,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Bupivacaine liposome injectable suspension</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02771c45dac74870b7443cd500921e8a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtMS0xLTEtNjU4NjE_16b0c844-9544-48e8-9ec6-fd734e675f23">3,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84613c0ab0204e27bfad217490c8e958_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtMy0xLTEtNjU4NjE_27897a0c-bd95-4227-ab3f-fa2a327d854b">4,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356e2083084446a6b5546356a72bfb5d_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtNS0xLTEtNjU4NjE_4d458412-112a-4e1a-915a-4e65b39e6daa">3,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total net product sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtMS0xLTEtMA_ba5297c6-1a06-4903-9daf-f9beed917611">538,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtMy0xLTEtMA_35e62d18-d0ed-4d2c-b833-d5382bbd65e0">426,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtNS0xLTEtMA_59444c62-03f6-470f-b76d-fcdcd0a6f903">418,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began recognizing revenue from net product sales of ZILRETTA on November 19, 2021, the date of the Flexion Acquisition.</span></div></ix:continuation><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_154"></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzI5NDk_07a854fa-4543-4841-98b6-a77ed8a46d58" continuedAt="ib85b848b64604ee0abe4a29dc731542a" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="ib85b848b64604ee0abe4a29dc731542a" continuedAt="i8e07e683e20243ffa328ba635f0eed8d"><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Flexion Therapeutics, Inc.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, the Company acquired Flexion (the &#8220;Flexion Acquisition&#8221;), a biopharmaceutical company focused on the discovery, development, and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis, pursuant to an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated as of October 11, 2021, by and among the Company, Oyster Acquisition Company Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#8220;Purchaser&#8221;), and Flexion. Following the completion of a successful tender offer for the shares of Flexion&#8217;s common stock, and pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, Purchaser merged with and into Flexion with Flexion surviving as a wholly owned subsidiary of the Company. The Company changed the name of Flexion to Pacira Therapeutics, Inc. after completing the merger.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The total consideration for the Flexion Acquisition was approximately $<ix:nonFraction unitRef="usd" contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NjY1MzU_95a70d4f-3ee4-4335-82b9-a5b2075e49ac">578.8</ix:nonFraction>&#160;million consisting of: (i) $<ix:nonFraction unitRef="usd" contextRef="if66cf7a1d0974accbfeaa215c9671c3a_D20211119-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDc5NDA_d94313da-6c09-487c-908b-9533130f4751">448.5</ix:nonFraction>&#160;million of cash paid to former Flexion stockholders and to settle restricted stock units and in-the-money stock options; (ii) an $<ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-5" name="pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NjY1MDI_472087cc-5097-4251-ad31-12659399458b">85.1</ix:nonFraction>&#160;million cash payment of Flexion debt not to be assumed by the Company and (iii) $<ix:nonFraction unitRef="usd" contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119" decimals="-5" name="pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NjY1MTc_35e13d74-af23-4202-845b-42bcd2823211">45.2</ix:nonFraction>&#160;million of estimated contingent consideration related to contingent value rights, or CVRs, that were issued to Flexion shareholders and certain equity award holders in conjunction with the Flexion Acquisition. The consideration is subject to adjustments based on the achievement of certain potential milestone payments. The Company estimates that up to an additional $<ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0ODgxMDU_cac9ff12-aca6-4b56-8d32-57920d8280db">380.2</ix:nonFraction>&#160;million in the aggregate may be payable to holders of the CVRs if each of the applicable milestones are achieved, as follows:</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb1a68217b5c4d4e873ece15e0f90135_I20211119" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk0NjQ_b5b74f6f-bb32-479e-acd7-7dca91cf39f5">1.00</ix:nonFraction> per CVR the first time that net sales of ZILRETTA in any calendar year equal or exceed $<ix:nonFraction unitRef="usd" contextRef="i9218c1eec9ef41a4992bc55da182b205_D20211119-20301231" decimals="-5" name="pcrx:ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk0NzE_ea614d9e-194f-4469-9e2d-29c47838a8da">250.0</ix:nonFraction>&#160;million;</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) $<ix:nonFraction unitRef="usdPerShare" contextRef="ifcdbdc73190942b1a864a717a9c9bcca_I20211119" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk0OTk_d0e75032-688b-481c-a272-8cc7a75b62c3">2.00</ix:nonFraction> per CVR, the first time that net sales of ZILRETTA in any calendar year equal or exceed $<ix:nonFraction unitRef="usd" contextRef="i1e721f32c0054c3c80e74321a03292d4_D20211119-20301231" decimals="-5" name="pcrx:ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1MDY_af295f0e-3369-4ba3-a3da-7f954f177fc8">375.0</ix:nonFraction>&#160;million;</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) $<ix:nonFraction unitRef="usdPerShare" contextRef="ie03ed2c8aff24b4494f38ae68516f2ce_I20211119" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1MjI_53af68b4-42d6-40ae-996f-da2ec043f250">3.00</ix:nonFraction> per CVR, the first time that net sales of ZILRETTA in any calendar year equal or exceed $<ix:nonFraction unitRef="usd" contextRef="i008e93128d4947408a9a2c78e9148223_D20211119-20301231" decimals="-5" name="pcrx:ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1Mjk_be49662b-d984-4c0a-a218-be268394d331">500.0</ix:nonFraction>&#160;million;</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) $<ix:nonFraction unitRef="usdPerShare" contextRef="i0c856dbf51f94a28b261f6eecf123ef1_I20211119" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1NDU_cbf51b59-d83a-4c12-8038-d6a9f0e4800e">1.00</ix:nonFraction> per CVR upon approval by the U.S. Food and Drug Administration, or FDA, of a Biologics License Application (BLA) for PCRX-201 (formerly FX-201), a clinical stage gene therapy product candidate; and</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i8e07e683e20243ffa328ba635f0eed8d" continuedAt="i7f465c6b990749f990d36d923b306a55"><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v) $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d300faae4fa47d5b99bd8a7e5282ce7_I20211119" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1NTI_025748db-336f-45c3-888f-3eeb189a6644">1.00</ix:nonFraction> per CVR upon approval by the FDA of a new drug application, or NDA, for PCRX-301 (formerly FX-301), an investigational product candidate.</span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzQzOTgwNDY1Mjk5MjQ_240811b1-0c88-4e26-ae41-8c36dd98b2e1" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration for the Flexion Acquisition was $<ix:nonFraction unitRef="usd" contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NTE5Nzc_5beeaff7-31fa-49ca-ad10-20825a0d5a72">578.8</ix:nonFraction>&#160;million, which consisted of the following (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value of Purchase Price Consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of purchase consideration paid at closing:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for all outstanding shares of Flexion&#8217;s common stock (50,392 shares of common stock acquired at $8.50 per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37470c5184194ea6bcf6c2946155189f_D20211119-20211119" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzItMi0xLTEtNDY4OTQ_f6c78222-8132-4ff7-9313-c5976a2e2c32">428,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration paid to settle RSUs and in-the-money options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i936811b25a12408a9e9c474cd8eec9ba_D20211119-20211119" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzMtMi0xLTEtNDY4OTQ_9ff9d72e-9747-44a3-8464-320fb90dbed8">20,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid to settle Flexion debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63aa112e385a4b169e514d953a28f982_I20211119" decimals="-3" name="pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzctMi0xLTEtNDY4OTQ_8696bfbb-ba4d-4743-8ce7-8386a6479b46">85,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzctMi0xLTEtNjQ5OTI_4978d741-c696-4618-a93b-983ca6cc151c">533,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent value rights (CVRs)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119" decimals="-3" name="pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzEwLTItMS0xLTQ2ODk0_5ca29eb1-2519-4639-bd36-b04cb6fe9fd1">45,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzEyLTItMS0xLTQ2ODk0_91ae51e1-b8b8-4e0d-a42b-d2b18aaf339e">578,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the Flexion Acquisition using the acquisition method of accounting and, accordingly, has included the assets acquired, liabilities assumed and results of operations in its consolidated financial statements from the acquisition date of November 19, 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary purchase price allocation is based on estimates, assumptions, valuations and other studies which have not yet been finalized. Prior to the finalization of the purchase price allocation, if information becomes available that would indicate it is probable that unknown events had occurred and the amounts can be reasonably estimated, such items will be included in the final purchase price allocation and may change the carrying value of goodwill. The Company is finalizing its valuation of intangible assets, tangible assets, liabilities and tax analyses, and anticipates finalizing the purchase price allocation as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i7f465c6b990749f990d36d923b306a55" continuedAt="iaf188000297046de99e5966b8e15a372"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzQzOTgwNDY1Mjk5MjU_09cceeb9-e03f-44d2-b31a-17065c26d9b0" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the preliminary allocation of the Flexion Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts Recognized at the Acquisition Date</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS ACQUIRED</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzItMi0xLTEtNDcwMjA_86cba975-6a6c-4c5d-ac3c-54dd726681a8">113,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzMtMi0xLTEtNDcwMjA_e048cc56-8cc5-490d-a8ec-b9f88e50ac20">11,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzQtMi0xLTEtNDcwMjA_cd254922-e3f3-484d-9c02-5b20bfc34dbd">32,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzUtMi0xLTEtNDcwMjA_c31af945-f35d-41c3-a609-964d5602a5e8">29,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzYtMi0xLTEtNDcwMjA_64f1c695-53a9-4129-bbaf-43d65d28c6f7">4,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzctMi0xLTEtNDcwMjA_b145b51b-93af-4474-9534-feb2dfd4e0d6">23,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzgtMi0xLTEtNDcwMjA_e8cb8aac-f3e7-4f36-ac1a-0d2fb6e0e640">58,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="pcrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzktMi0xLTEtNDcwMjA_3d80657c-9ceb-4900-8ba8-5ad0c34e0714">6,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzEwLTItMS0xLTQ3MDIw_51715947-2ee5-4709-b819-a0c8cabe0f38">480,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development (IPR&amp;D) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzExLTItMS0xLTQ3MDIw_f0ce067b-a4f8-4300-822e-3098efc161bc">61,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzEyLTItMS0xLTUzODcw_21b7125c-2484-4249-8b0b-0ff6533cefeb">820,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES ASSUMED</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzEyLTItMS0xLTQ3MDIw_2b8748f7-502f-4069-85d2-cc3a9836d120">9,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="pcrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzEzLTItMS0xLTQ3MDIw_a9c849a2-4aca-4097-b84c-b90ab3cc748e">22,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE0LTItMS0xLTQ3MDIw_367f689e-743a-4983-b036-67874d580ebf">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE1LTItMS0xLTQ3MDIw_847f9cbb-7ce3-499a-8130-c0b5719bf7b8">6,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE2LTItMS0xLTQ3MDIw_7ab45e7e-f78d-4ffd-acfb-595f9c0bd525">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE4LTItMS0xLTQ3MDIw_fcaedf31-b3e7-4226-9cd0-4308b145a49f">201,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6aad501cb7243e887c49fac7690b6ca_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzIwLTItMS0xLTUzODc5_1a43533a-6471-4eb0-935e-2af84d751c1f">251,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE5LTItMS0xLTQ3MDIw_641fc68e-a67e-40b6-ac77-a9e800614f65">569,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzIwLTItMS0xLTQ3MDIw_1075d997-8684-43eb-ba1d-a5ece01cea0d">9,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzIxLTItMS0xLTQ3MDIw_cc8c56a2-ef6a-4343-b773-1a17917b9655">578,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired identifiable intangible assets and IPR&amp;D assets were valued from a market participants&#8217; perspective using a multi-period excess earnings methodology (income approach). The identifiable finite-lived intangible asset, ZILRETTA, is a developed technology for OA knee pain with a value of $<ix:nonFraction unitRef="usd" contextRef="ic1eb92833ae9435a9ecf1d355bbcb009_D20211119-20211119" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTQ1OTA4_dd92b0ac-2e2a-4a1b-af64-7bdab96c2b5f">480.0</ix:nonFraction>&#160;million and a useful life of <ix:nonNumeric contextRef="ic1eb92833ae9435a9ecf1d355bbcb009_D20211119-20211119" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTI3MDY1_600ce2a3-4fd8-4777-a86d-32b9c57aa4c3">9.7</ix:nonNumeric> years. A discount rate of <ix:nonFraction unitRef="number" contextRef="i2e8639429a9c49ba9041fee399c2357f_D20211119-20211119" decimals="3" name="pcrx:FiniteLivedIntangibleAssetsMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTQ1OTIy_aae83938-49d7-406a-9a6c-ac4d44b61bbb">17.5</ix:nonFraction>% was used in calculating the fair value of this technology. The IPR&amp;D asset relates to the use of ZILRETTA for the treatment of OA pain of the shoulder and was valued at $<ix:nonFraction unitRef="usd" contextRef="i8bf45bc62b484e8483fd1b35bcdd3bbd_D20211119-20211119" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTQ1OTM2_4476cfee-f53d-430e-8822-5b9ead69232d">60.0</ix:nonFraction>&#160;million. The projected cash flows for this asset were adjusted for the probability of successful development and commercialization, and were discounted at <ix:nonFraction unitRef="number" contextRef="ic1807decbe80497fafb382a9fabc9899_D20211119-20211119" decimals="2" name="us-gaap:AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTQ1OTI5_52af5c43-c267-4326-9d8c-9f891d19af3b">18.0</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the purchase price over the fair value of identifiable net assets acquired represents goodwill. This goodwill is primarily attributable to the value of combining ZILRETTA with iovera&#176; and EXPAREL as a safe and effective non-opioid multimodal regimen for pain management, as well as the synergies of merging operations. The acquired goodwill and intangible assets are currently not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of acquired goodwill and intangible assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzQzOTgwNDY1Mjk5MjY_7bf3864b-dfd9-43d6-ba74-504541c5c200" continuedAt="if7247c354b6948638b341526ac7234a0" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexion results from the acquisition date of November 19, 2021 through December 31, 2021, which are included in the consolidated statements of operations, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification in Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisition Date Through <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9797eb88784347c2ba91f649e7a89035_D20211119-20211231" decimals="-3" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTphNTc1NTkxNzI5NmU0Yjk0OTJmNzk4ZDFmZjdjNTA4MC90YWJsZXJhbmdlOmE1NzU1OTE3Mjk2ZTRiOTQ5MmY3OThkMWZmN2M1MDgwXzEtMi0xLTEtMzA5MzU_0e596014-816b-4d6a-87b6-986799deb6be">12,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9797eb88784347c2ba91f649e7a89035_D20211119-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTphNTc1NTkxNzI5NmU0Yjk0OTJmNzk4ZDFmZjdjNTA4MC90YWJsZXJhbmdlOmE1NzU1OTE3Mjk2ZTRiOTQ5MmY3OThkMWZmN2M1MDgwXzItMi0xLTEtMzA5NDM_2a5d2167-4912-4aab-9aed-5e8f262d01de">25,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Charges Product Discontinuation and Other,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on costs incurred related to the Flexion Acquisition.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="iaf188000297046de99e5966b8e15a372"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Pro Forma Summary of Operations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the unaudited pro forma summary of operations for the years ended December 31, 2021 and 2020, as if the Flexion Acquisition had occurred on January 1, 2020. <ix:continuation id="if7247c354b6948638b341526ac7234a0" continuedAt="i9001d3728e3c4e3a938537583eb7e438">This pro forma information does not purport to represent what the Company&#8217;s actual results would have been if the acquisition had occurred as of January 1, 2020, and is not indicative of what such results would be expected for any future period (in thousands, except per share amounts):</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:9pt"><ix:continuation id="i9001d3728e3c4e3a938537583eb7e438"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended&#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzItMi0xLTEtNDcxNjE_44c4b53b-6967-4d24-b50f-bc3fba5bdc28">630,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzItNC0xLTEtNDcxNjE_b6071a10-3f51-4e13-adb3-339578450f9e">515,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzMtMi0xLTEtNDcxNjE_ef172aa2-a752-4e48-a2bc-f1cdccf12bda">67,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzMtNC0xLTEtNDcxNjE_b2c3db5d-3146-48bf-a924-8dc43bfa6aed">19,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzQtMi0xLTEtNDcxNjE_1add562e-1c11-4b1f-aca5-4a2cbd04ebd5"><ix:nonFraction unitRef="usdPerShare" contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzQtMi0xLTEtNDcxNjE_feab8940-83a1-429f-b806-0304d9b01047">1.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzQtNC0xLTEtNDcxNjE_44f57d22-1b6e-4529-a7b2-54faa8fc7788"><ix:nonFraction unitRef="usdPerShare" contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzQtNC0xLTEtNDcxNjE_a27a9c20-3812-4899-9a68-a5687781c51b">0.46</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of the Company and Flexion. The summary pro forma financial information primarily reflects the following pro forma adjustments:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Removal of the acquisition-related transaction fees and costs, including certain stock-based compensation and other compensation expenses related to the acquisition, from the years ended December 31, 2021 and 2020;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Removal of the income tax benefit resulting from the Company decreasing its existing valuation allowance on deferred tax assets from the years ended December 31, 2021 and 2020;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Removal of Flexion&#8217;s interest expense and associated deferred financing cost amortization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Adjustments to the Company&#8217;s interest income for the cash used to acquire Flexion; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Additional cost of goods sold related to the step-up value in inventory;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Additional amortization expense from the acquired developed technology intangible assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Additional depreciation of fixed assets; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Additional lease expense on the ROU assets.</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all of the above adjustments were adjusted for the applicable tax impact.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MyoScience, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2019, the Company acquired MyoScience (the &#8220;MyoScience Acquisition&#8221;), a privately held medical device company, in which MyoScience became a wholly owned subsidiary of the Company and was renamed Pacira CryoTech, Inc. The total consideration was $<ix:nonFraction unitRef="usd" contextRef="i47f4eb49ec8441a9b58dbd98a28a2201_D20190409-20190409" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMxODY5_0d4b6f3d-f02e-4c68-8984-c1e24ab9d30b">147.5</ix:nonFraction>&#160;million, which included a cash payment of $<ix:nonFraction unitRef="usd" contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMxOTA3_ab3eb7ce-f178-4352-83fd-4845fcb368c4">119.0</ix:nonFraction> million and the fair value of contingent consideration in the amount of $<ix:nonFraction unitRef="usd" contextRef="i47f4eb49ec8441a9b58dbd98a28a2201_D20190409-20190409" decimals="-5" name="pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMxOTc1_059c293e-e154-416c-816a-18f6d82a20db">28.5</ix:nonFraction> million. The contingent consideration consisted of contingent milestone payments up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231" decimals="-5" name="pcrx:ContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyMDc0_58ef2319-fca9-4a7d-a0bb-3d464ac0680e">100.0</ix:nonFraction> million upon the achievement of certain regulatory and commercial milestones, of which $<ix:nonFraction unitRef="usd" contextRef="i18f0515519fd468ea2893c1d1449bb1e_I20211231" decimals="-5" name="pcrx:ContingentConsiderationCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyMTU3_d3c591bd-a30b-40dd-849e-0b43212ccf85">43.0</ix:nonFraction>&#160;million are available as of December 31, 2021. The Company&#8217;s obligation to make milestone payments is limited to those milestones achieved through December 31, 2023, with any such milestones payable within <ix:nonNumeric contextRef="i47f4eb49ec8441a9b58dbd98a28a2201_D20190409-20190409" name="pcrx:ContingentConsiderationPaymentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyMzQ1_a677ffa9-9705-4e4d-88cc-b7c6124871e1">60</ix:nonNumeric> days of the end of the fiscal quarter of achievement. During the years ended December 31, 2021, 2020 and 2019, the Company made $<ix:nonFraction unitRef="usd" contextRef="ic017681e6bcd4a53adcb05dba9e3ceea_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTM0OTUy_33a7f606-6f00-4ae0-a6e6-e999780d5ba7">12.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i36eb9081f8f347b192a76fc04c03d19e_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyNDcx_0e0a625f-0b5c-4d00-b195-376ced319670">15.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4ebc2eb0427e4bb0850c72962f7e29e3_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyNDc5_f2c43332-175a-4c6f-95b6-e93fbbe6296c">7.0</ix:nonFraction>&#160;million of cash payments for the achievement of certain milestones, respectively. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information on the measurement and amounts recognized in the Company&#8217;s consolidated financial statements for contingent consideration. See Note 21, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information on a dispute regarding the achievement of certain milestone payments.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-21</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90ZXh0cmVnaW9uOjRjYTM5MjM3NzcyMjRkN2ZiOTRlYTA3ZGNhMGViNGEzXzU4Ng_3a50ee90-f014-45b5-b93f-0fef62d11c11" continuedAt="i3970e6df66c3428fbea20272a813f61c" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i3970e6df66c3428fbea20272a813f61c"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90ZXh0cmVnaW9uOjRjYTM5MjM3NzcyMjRkN2ZiOTRlYTA3ZGNhMGViNGEzXzU5Mw_5f0e35c7-8af6-46eb-88a5-f0ce17afb701" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzItMS0xLTEtMA_d433ff50-9407-4d25-9e8a-ef44838e4bba">36,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzItMy0xLTEtMA_d2bc3753-79c2-4e99-8ece-20746f72dd75">26,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzMtMS0xLTEtMA_7ec4d404-4392-4ca7-b5bc-4051db2a4cf5">35,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzMtMy0xLTEtMA_f966a0e4-cdfd-4af8-a1b6-8cc28806d2d9">16,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzQtMS0xLTEtMA_43dbcccc-3c32-4421-aa61-a06955e6be07">27,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzQtMy0xLTEtMA_c7c995f2-bafa-43aa-8bbf-9bc5a95ad97a">21,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzUtMS0xLTEtMA_8a8d38b6-5cc3-432b-96c3-da08ddb999c0">98,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzUtMy0xLTEtMA_b2f79065-15d2-4276-8f09-0515e71d26fd">64,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:22.5pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_160"></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzExMTg_a9394f6f-f6dd-4935-98e2-e67accd38add" continuedAt="i92b28b9ce14742f4ad7c673cfa4bf6f8" escape="true">FIXED ASSETS</ix:nonNumeric></span></div><ix:continuation id="i92b28b9ce14742f4ad7c673cfa4bf6f8" continuedAt="ife29bd4d9e6d4cbeb80dbb7f40540275"><ix:continuation id="i86020fac96b04837b604f97fcf5683ec"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net, summarized by major category, consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3ab2a481794a02a175b6f16b61f237_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzItMS0xLTEtMA_2d05fa4e-bc6c-4a3f-8f04-11662be36f16">117,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c2512b823f4ff3b209636ae4dcafac_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzItMy0xLTEtMA_c78178d3-5c75-411f-ac88-a14dfb10df2d">74,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eb5b42525974ef7a5b153a0d9d0073d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzMtMS0xLTEtMA_843fc739-a36f-43da-b298-5758b862aec6">59,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9863c66e56824ed29ccd21bb3ceabb02_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzMtMy0xLTEtMA_50521e4f-af4c-416a-bfbe-422fceb305ed">54,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90f8785504d43449257cd196f4121b2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzQtMS0xLTEtMA_8eb26e72-a3b0-4e14-8853-461f7131f735">13,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226f17bf85d347659a1ecbbcad647fc7_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzQtMy0xLTEtMA_def9d2c1-4b8d-4265-8ef1-aced1d5aeca4">12,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237836ce0fbe43459715133f0ac3bbcb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzUtMS0xLTEtMA_063a28f0-78c1-45c1-9d61-535a38f03315">2,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77820b7ad1054da597cf88e94c1572ef_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzUtMy0xLTEtMA_82b80d48-2adb-4580-8ef1-d1304ce8d7fe">2,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a8c9c388f348728c52ecd109ff1575_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzYtMS0xLTEtMA_0e1f33e2-8f55-43bb-bca9-dd8ef868ab15">80,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dcb927188d04ed7a4fc660309e24cb6_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzYtMy0xLTEtMA_ec006727-0e49-4c99-9f9f-15c05241c776">71,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzctMS0xLTEtMA_27f4aec6-a746-4c32-bfde-5cb9b7f293a3">273,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzctMy0xLTEtMA_67b1af6c-dea5-4b88-9f61-2d0304ab181d">215,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzgtMS0xLTEtMA_560e461e-0ecf-4611-b4ca-a3131d1fe71b">85,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzgtMy0xLTEtMA_8b01fdc1-40e3-4d04-97a7-1b8dc3717336">78,360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzktMS0xLTEtMA_1d42ba3d-f1ee-45d5-a301-5bdb97b54409">188,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzktMy0xLTEtMA_55df09a4-0e59-4ae2-856c-8b1377e03e2c">136,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on useful lives by asset category, refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzEyMDk0NjI3OTA4NzI1_4f040d19-9005-47ce-8363-724b73c69054">15.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzI5Mg_cfed417a-9779-4797-881f-1c25199e269e">12.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzI5OQ_374f6f2b-3cb3-4978-92f7-f18d8ab5c798">14.0</ix:nonFraction> million, respectively. During the years ended December&#160;31, 2021, 2020 and 2019, the Company capitalized interest of $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzM5MQ_57c3dee1-65a4-4901-b246-2ae75329af2d">3.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-5" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzQwNQ_24e55c1f-7b3e-4f7d-9a9e-44ebce2f65ee">2.4</ix:nonFraction> million and less than $0.1 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021&#160;and&#160;2020, total fixed assets, net, includes leasehold improvements and manufacturing process equipment located outside of the U.S. in the amount of $<ix:nonFraction unitRef="usd" contextRef="i7b2e96dbe6ff49688146016bf2c6b677_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzU3NQ_fea60f97-f844-4d19-82a9-d98682729e07">65.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9a79447216ec4d1fbb7c60937d2de629_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzU4Mg_6928a8fc-5152-452b-a548-b3a09ee98b55">67.5</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ife29bd4d9e6d4cbeb80dbb7f40540275">As of December&#160;31, 2021 and 2020, the Company had AROs of $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="us-gaap:AssetRetirementObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzY0MQ_1716f9cf-60d0-422b-bce7-45597913351d">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-5" name="us-gaap:AssetRetirementObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzY0OA_a12f619d-ca55-489a-895e-380266ed9bb7">2.0</ix:nonFraction> million, respectively, included in accrued expenses and other liabilities on its consolidated balance sheet, for costs associated with returning leased space to its original condition upon the termination of certain lease agreements.</ix:continuation> </span></div><div style="margin-top:3pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_163"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzE2MDI_f23235dc-2a92-4ea1-9041-28118f21cc1c" continuedAt="i671ce7587ffb4b4092433ed81264d9dd" escape="true">LEASES</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i671ce7587ffb4b4092433ed81264d9dd" continuedAt="i518add55a76d4795bda373183e7299f7">The Company leases all of its facilities, including its EXPAREL manufacturing facility in San Diego, California and its iovera&#176; manufacturing facility in Fremont, California. These leases have remaining terms up to <ix:nonNumeric contextRef="i379f934d2a6348d0aa120e522eb186cb_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzIzNA_832ffe35-f3e9-49ce-86d1-a464c52fcb01">8.7</ix:nonNumeric> years, some of which provide renewal options at the then-current market value. The Company also has an embedded lease with Thermo Fisher Scientific Pharma Services for the use of their manufacturing facility in Swindon, England. A portion of the associated monthly base fees has been allocated to the lease component based on a relative fair value basis. As a result of the Flexion Acquisition, the Company recorded new operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzE0MjkzNjUxMTYzNTMw_1fa3a912-bb32-4f0c-a18d-494ddbdbf577">6.6</ix:nonFraction>&#160;million arising from obtaining ROU lease assets for <ix:nonFraction unitRef="location" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="0" name="pcrx:NumberOfLocationsNewOperatingLeaseLiability" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzcxNDY4MjU1ODMzNDY_940bac01-4746-45cc-a516-26c494951583">three</ix:nonFraction> locations.</ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i518add55a76d4795bda373183e7299f7"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzE2MDM_7c3603d4-9647-4b80-8a7a-3357d70c9ab3" continuedAt="ie1e78e5046b349a79f712d8d78864a14" escape="true">Total operating lease costs are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="ie1e78e5046b349a79f712d8d78864a14" continuedAt="i9b1ba89196224abb8d34597a2b89546f"><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Lease Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzItMi0xLTEtMA_fd16c6f1-dc78-42b1-8013-1fefb117dc23">11,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzItNC0xLTEtMA_0f7be6ea-55ca-4ad3-8db2-b47fc27c89a3">10,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzItNi0xLTEtMA_81412e44-18bc-4651-876e-1d234dfe3fab">6,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzMtMi0xLTEtMA_ff54b213-63b3-49e4-bbe7-0ee7b1bdfb10">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzMtNC0xLTEtMA_730dfcaa-b22c-4c2f-a7bf-513bbb959381">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzMtNi0xLTEtMA_cdc3ef03-36f2-4202-acb3-a568368f10c5">1,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzQtMi0xLTEtMA_7cb38841-f0ae-47fc-99d7-d3ec22480636">13,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzQtNC0xLTEtMA_87f3ef99-48a5-415c-965a-9690a4c0492d">12,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzQtNi0xLTEtMA_ae75fc0d-8aa2-4d1c-944c-1a4bb4f9e5f9">7,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, net of lease incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzItMi0xLTEtMA_109ef761-abe8-4a13-ba01-1419f9dbfade">12,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzItNC0xLTEtMA_2f6e0dd7-b055-46eb-8f72-ad504f3d1c3f">14,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzItNi0xLTEtMjgwMjA_85287be3-312b-4163-b0fa-56c1118c5ff1">7,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recorded in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzMtMi0xLTEtMA_4b614c4a-a273-4806-942e-e8da40636616">8,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzMtNC0xLTEtMA_cc96e7f7-7e37-467d-8087-6b441fa7413d">42,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzMtNi0xLTEtMjgwMjA_22ac5a37-264b-49c3-9bfb-d23d59562f98">41,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to net the amortization of the ROU asset and the reduction of the lease liability principal in other liabilities in the consolidated statement of cash flows.</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. <ix:continuation id="i9b1ba89196224abb8d34597a2b89546f" continuedAt="i9d13ba9d37a24bbd8479adc610eca3c4">The weighted average remaining lease term and the weighted average discount rate are summarized as follows:</ix:continuation></span></div><div><ix:continuation id="i9d13ba9d37a24bbd8479adc610eca3c4"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTo1Yjg2MTY4NTliZDk0NWNlYTQwYTM5ZmVhZjdmMGM3Yi90YWJsZXJhbmdlOjViODYxNjg1OWJkOTQ1Y2VhNDBhMzlmZWFmN2YwYzdiXzItMi0xLTEtMA_9a2841cb-96cc-4ab5-8360-89230393720f">7.77</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTo1Yjg2MTY4NTliZDk0NWNlYTQwYTM5ZmVhZjdmMGM3Yi90YWJsZXJhbmdlOjViODYxNjg1OWJkOTQ1Y2VhNDBhMzlmZWFmN2YwYzdiXzItNC0xLTEtMA_8e9cfc80-13ff-47cd-bb79-d05905a994e9">9.18</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTo1Yjg2MTY4NTliZDk0NWNlYTQwYTM5ZmVhZjdmMGM3Yi90YWJsZXJhbmdlOjViODYxNjg1OWJkOTQ1Y2VhNDBhMzlmZWFmN2YwYzdiXzMtMi0xLTEtMA_ec98642c-19df-4a15-b601-03ffc918467e">6.96</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTo1Yjg2MTY4NTliZDk0NWNlYTQwYTM5ZmVhZjdmMGM3Yi90YWJsZXJhbmdlOjViODYxNjg1OWJkOTQ1Y2VhNDBhMzlmZWFmN2YwYzdiXzMtNC0xLTEtMA_04e68910-d6cc-4b74-b0d9-fd6c8d57d0c3">6.87</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzE2MDY_83cc1299-76e0-44bd-b66e-2398300bafcc" escape="true"><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, maturities of the Company&#8217;s operating lease liabilities are as follows (in thousands): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Payments Due</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzEtMi0xLTEtMA_cfcb1e5d-6a23-44c2-99be-e55f1f4d54a6">13,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzItMi0xLTEtMA_35b0961d-611a-4a3f-8f9f-cd827e14305e">13,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzMtMi0xLTEtMA_1d51b141-81d1-4782-9246-7a9f779f34b0">13,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzQtMi0xLTEtMA_825e26da-6071-4064-a3a7-ef2109a7feb2">12,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzUtMi0xLTEtMA_ec743647-6aba-4499-bfd3-8923c0d7cc05">12,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzYtMi0xLTEtMA_5f68ae82-67d8-45c2-a708-4d473bf67a95">39,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzctMi0xLTEtMA_78181bc2-11c5-4eb9-b88a-1a05931236ed">104,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzktMi0xLTEtMA_7f11f4b2-8eac-448e-b684-4059be28b0b2">24,547</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzEwLTItMS0xLTA_6b5d1573-b960-4030-a49b-c8098c408984">79,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-23</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIyNTA_e8408a7b-5e16-4c99-998a-728b30951438" continuedAt="i013b04f04737438591155b18fedba574" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i013b04f04737438591155b18fedba574" continuedAt="ib6444790aafd4ce1af5877910daedfa8"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s goodwill results from the acquisition of Pacira Pharmaceuticals, Inc. from SkyePharma Holding, Inc. (now a subsidiary of Vectura Group plc), or Skyepharma in 2007 (the &#8220;Skyepharma Acquisition&#8221;), the MyoScience Acquisition in 2019 and the Flexion Acquisition in 2021. <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIyNDU_c3cf0cf1-e115-4543-a7b0-5d3e3d4c29b6" continuedAt="iad408c3485684bf7809dfd60cb614f86" escape="true">The change in the carrying value of the Company&#8217;s goodwill is summarized as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:9pt"><ix:continuation id="iad408c3485684bf7809dfd60cb614f86"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:83.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.026%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzMtMi0xLTEtMA_d303f97e-4716-4ae5-bdcd-0d315934aeb8">99,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 accumulated adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzQtMi0xLTEtMA_8327a564-d977-489c-8c8e-563bb6ad61d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzUtMi0xLTEtMA_c2af3114-2c4e-4220-966a-bdb022a452e0">99,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill arising from milestones achieved under the Skyepharma Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib93d52bc0a2448159425d955a92ad1b3_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzQtMi0xLTEtNDg5MTM_689822ce-8751-4d3d-a875-c1a9e79cdf37">36,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill arising from the Flexion Acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzYtMi0xLTEtMA_a635956f-925b-4f89-a120-eb3cc72392b9">9,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzctMi0xLTEtMA_416223ea-0ec0-441c-bfd4-4deab3371168">145,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skyepharma Acquisition was accounted for under Statement of Financial Accounting Standards 141, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was the effective GAAP standard at the date of acquisition. In connection with the Skyepharma Acquisition, the Company agreed to certain milestone payments for DepoBupivacaine products, including EXPAREL. In the fourth quarter of 2021, the Company met both of its two remaining milestones due to Skyepharma: $<ix:nonFraction unitRef="usd" contextRef="id5476241970e4bc8a69aaac752a07c87_I20211231" decimals="-5" name="pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzgyMQ_21c7ce82-09e5-41b3-9c43-9d9762302b68">4.0</ix:nonFraction> million upon the first commercial sale in the U.K., France, Germany, Italy or Spain which was paid in the fourth quarter of 2021; and $<ix:nonFraction unitRef="usd" contextRef="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231" decimals="-5" name="pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzkxNQ_978c81a3-cf5d-4329-96c3-ecd6afeef23a">32.0</ix:nonFraction> million when annual net sales collected reached $<ix:nonFraction unitRef="usd" contextRef="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231" decimals="-5" name="pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0Xzk1Ng_959041a7-c397-447f-8f1c-88fc29eeba4c">500.0</ix:nonFraction> million, which was paid in the first quarter of 2022. These milestone payments were treated as additions to the Skyepharma Acquisition and, therefore, recorded as goodwill. The Company made a tax election that allows the acquired goodwill and intangible assets associated with the MyoScience Acquisition to be tax deductible.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Flexion Acquisition, the Company recorded goodwill totaling $<ix:nonFraction unitRef="usd" contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzEzMTk0MTM5NTQwMzYw_303ac9c3-75a4-4a80-b37f-fbef3cd35e4a">9.6</ix:nonFraction>&#160;million. The acquired goodwill and intangible assets are currently not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of acquired goodwill and intangible assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIyNTI_a3635b39-8b4a-4aa2-94fb-6345391cc20b" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consist of the IPR&amp;D and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible<br/>Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average <br/>Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616ccf441438422f96ae7988c62ac2d7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEtMi0xLTEtMjY0MTA_779b37d7-2754-4d5e-8a71-5372b5c69ca5">590,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616ccf441438422f96ae7988c62ac2d7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEtNC0xLTEtMjY0MTA_65a37386-f5be-4b6d-8257-84b1d6b88ad4">27,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616ccf441438422f96ae7988c62ac2d7_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEtNi0xLTEtMjY0MTA_a8f2af03-4808-47af-90a7-85c548c49cc6">562,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib0432a62d54346d4b0cc4ae20df8f3ee_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEtOC0xLTEtMjY0MTA_a195b9a3-24ae-4d9a-9c96-ec0dd69c2170">10 years, 5 months</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f0a34fc053410586063c1b4fb4c582_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzItMi0xLTEtMjY0MTA_e9669f39-a714-4d6e-941c-4ee3fffe6473">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50f0a34fc053410586063c1b4fb4c582_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzItNC0xLTEtMjY0MTA_d9da8e4d-45bd-45b8-9dbf-53691b01187f">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f0a34fc053410586063c1b4fb4c582_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzItNi0xLTEtMjY0MTA_00e16a23-1252-47e9-bde0-4da2fa814ebf">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5ae07bdfce9402a9e491efa689e082a_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzItOC0xLTEtMjY0MTA_5f562c0b-7d37-4315-a471-c5a58df0c0dc">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzMtMi0xLTEtMjY0MTA_24179817-cc98-4478-9a65-d3da9783271d">590,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzMtNC0xLTEtMjY0MTA_0c38439c-e9bd-4da7-83b0-1cb9b6d12a8b">27,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzMtNi0xLTEtMjY0MTA_d623c91b-1b73-4225-8d72-89582e3411eb">562,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i893f93318f184b3b845f1b842931685c_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzQtMi0xLTEtMjY0MTA_21044c03-02b5-476f-a2c2-717ae8b06dc9">61,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i893f93318f184b3b845f1b842931685c_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzQtNi0xLTEtMjY0MTA_68d3f133-8648-4606-943c-04e5844a935c">61,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzUtMi0xLTEtMjY0MTA_3d276c45-ddeb-436d-86fc-c098a1975ff9">651,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzUtNC0xLTEtMjY0MTA_b4d8fc8d-9fd7-4fbb-96ae-4912920ed954">27,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzUtNi0xLTEtMjY0MTA_4bc2e97e-47d3-45fd-bb0a-4ea8cf365393">623,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible<br/>Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average <br/>Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied35346c8e384819b7401a314ca21029_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEwLTItMS0xLTI2NDEw_399576a8-1a82-4c98-8ff2-334aa5804fc8">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied35346c8e384819b7401a314ca21029_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEwLTQtMS0xLTI2NDEw_9b05a399-67ec-44c6-b922-b9ec1171605b">13,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied35346c8e384819b7401a314ca21029_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEwLTYtMS0xLTI2NDEw_4f2d2ab6-7383-41a8-82c3-ab5a8794cd95">96,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7b03b72e8eb425dac2c21da48a1406e_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEwLTgtMS0xLTI2NDEw_93849fa0-2ee2-4961-b7db-b3fa7e29ee97">14</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9117c0cf9ab9426eb1181bbfdab3c069_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzExLTItMS0xLTI2NDEw_c7e69050-8855-4c42-ac19-2834ca88db37">90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9117c0cf9ab9426eb1181bbfdab3c069_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzExLTQtMS0xLTI2NDEw_d4359292-7df6-4a45-a6c8-1687e6e6120e">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9117c0cf9ab9426eb1181bbfdab3c069_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzExLTYtMS0xLTI2NDEw_62f7cace-10c8-4f34-a4c3-6f5e90fa037a">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2aa9720883ec4f3787f93c48c11dae98_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzExLTgtMS0xLTI2NDEw_2d926d12-0808-46a7-8261-784e29ee5611">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEyLTItMS0xLTI2NDEw_aee4b0db-1f76-4ead-917e-47f9c0d18afa">110,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEyLTQtMS0xLTI2NDEw_d6b621f8-b492-4ca2-91fd-0685e36356d7">13,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEyLTYtMS0xLTI2NDEw_360ef478-ef1f-4cc7-b51c-b8758bea003c">96,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets for the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIwMjY_b7776617-065e-44ef-9ca6-43e8d07087fe">13.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIwMzM_9faa8088-7f0e-40af-a3a6-b7fb5a0c2418">7.9</ix:nonFraction> million, respectively. Assuming no changes in the gross carrying amount of these intangible assets, the future estimated </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib6444790aafd4ce1af5877910daedfa8">amortization expense on the finite-lived intangible assets will be $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NDk2_c5c08bfd-6cbf-4bda-b576-bea82bcf11c3">57.4</ix:nonFraction>&#160;million through 2028, $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTEx_48666d0b-1b14-459e-9ccd-ee00a06b9a88"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTEx_7ceec1e9-4007-4b6c-9947-d532bfd9c8a2">57.3</ix:nonFraction></ix:nonFraction>&#160;million in 2029 and 2030, $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTI2_36efebec-8457-4eac-898e-5b9284de2c13">36.9</ix:nonFraction>&#160;million in 2031, $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTQx_4336f521-81fc-424a-bdc9-00ae30f97321">7.9</ix:nonFraction>&#160;million in 2032 and $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTU1_ffca26dc-b5aa-4b40-be32-fbbce288e716">2.2</ix:nonFraction>&#160;million in 2033.</ix:continuation></span></div><div id="i284a0cec603b490382d0f8422359e7e8_169"></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90ZXh0cmVnaW9uOjY5NzhlMzkwYzZmYTQwY2JhOGJiZTNhNTY3MGY3MzI0Xzk1_79e7691c-0bc1-4cd6-b8db-faab6946bfce" continuedAt="i0f696ce052d6439ab20e1783765c617d" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i0f696ce052d6439ab20e1783765c617d"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90ZXh0cmVnaW9uOjY5NzhlMzkwYzZmYTQwY2JhOGJiZTNhNTY3MGY3MzI0Xzky_38098a34-8462-47d6-9b32-c38a3608758d" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:Accruedsellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzItMS0xLTEtMA_d9b40d3a-2680-4f65-bdb8-1169e4c791ef">12,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:Accruedsellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzItMy0xLTEtMA_7a892e45-eadc-4b24-b4dc-d386824bb97a">23,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:Accruedresearchanddevelopmentexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzMtMS0xLTEtMA_9d81bfe4-5324-44bd-9b98-53c4f6a5a26b">5,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:Accruedresearchanddevelopmentexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzMtMy0xLTEtMA_57a11a7a-a942-4ad5-bfd5-ba9da96895b1">6,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:AccruedOperatingExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzQtMS0xLTEtMA_54950d2f-3ec4-4844-8cfc-c7ae8e773591">14,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:AccruedOperatingExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzQtMy0xLTEtMA_855f429a-36d4-4f5f-8adc-31877ff20ca8">11,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzUtMS0xLTEtMA_ad8b681f-ae42-4bbf-924b-a8164c79d9f9">45,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzUtMy0xLTEtMA_e439e6b7-2fbf-41d5-b8e6-7fefa0342701">22,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzYtMS0xLTEtMA_5a9bbd23-9f84-43ee-8eb5-f6608137eda5">35,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzYtMy0xLTEtMA_900d88dd-b07a-4828-8557-6b37aa0add72">3,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:AccruedEndOfTermFeeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzctMS0xLTEtMA_2bd2c0bc-8fb9-4546-b08b-d7759dac716e">5,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:AccruedEndOfTermFeeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzctMy0xLTEtMA_877e96fb-ed5a-40c7-afa7-07af5abbddda">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and wholesaler service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:ProductReturnsRebatesandOtherFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzgtMS0xLTEtMA_6072fbcd-2207-4ca0-8d2e-2b46a4781681">8,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:ProductReturnsRebatesandOtherFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzgtMy0xLTEtMA_96ad750b-029a-4389-ae57-b4ba6377f8a6">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzktMS0xLTEtMA_416a3784-4b85-484b-bdf9-cddd24583ece">127,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzktMy0xLTEtMA_b4e47925-69db-4548-aee2-47a347c27624">70,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) At December 31, 2021, accrued royalties included a $<ix:nonFraction unitRef="usd" contextRef="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231" decimals="-5" name="pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90ZXh0cmVnaW9uOjY5NzhlMzkwYzZmYTQwY2JhOGJiZTNhNTY3MGY3MzI0XzQzOTgwNDY1MTE4MDE_75f46010-bedb-4509-b5ec-f96b2259772c">32.0</ix:nonFraction>&#160;million milestone payment to Skyepharma that was met in the fourth quarter of 2021 for achieving annual net sales collected of $<ix:nonFraction unitRef="usd" contextRef="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231" decimals="-5" name="pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90ZXh0cmVnaW9uOjY5NzhlMzkwYzZmYTQwY2JhOGJiZTNhNTY3MGY3MzI0XzE2NDkyNjc0NDMyOTU_959041a7-c397-447f-8f1c-88fc29eeba4c">500.0</ix:nonFraction> million on the Company&#8217;s DepoBupivacaine products, including EXPAREL. This milestone was subsequently paid in the first quarter of 2022. See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, for more information.</span></div></ix:continuation><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_172"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MzY3_279db591-fd67-4960-ab3c-53c677c5538d" continuedAt="ic2c87d5a58954dfaa3c87d8fa3425cde" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="ic2c87d5a58954dfaa3c87d8fa3425cde" continuedAt="i919cb349fec448c9b5efab09950c010e"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3NTMzNTA_4c7cf203-c3cf-403d-9772-6305eaba7e75" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s outstanding debt is summarized as follows (amounts in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan B facility maturing December 2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzEtMS0xLTEtMzMwMzE_014237fc-079f-4abe-a095-171f5c9ede7d">359,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02d7f7d8ef346e095ed28b213a41443_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzEtMy0xLTEtMzMwMzE_e4cb5946-5292-4129-be3b-4c81a5e9488c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i029b2fd1da9b426aa281eb6edf9c4164_I20211231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzMtMC0xLTEtMzMwMzEvdGV4dHJlZ2lvbjo3OTkxNThmZmJjMjI0NWRkYmI0ODAxNDA5YTAyODdjN18xNjQ5MjY3NDQxNzIx_60e9839d-a2e6-485f-9edb-a616aa4762d2">0.750</ix:nonFraction>% Convertible senior notes due August 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzMtMS0xLTEtMzMwMzE_4be2f9b7-c49c-4530-9425-c6c3a2a7fc12">330,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzMtMy0xLTEtMzMwMzE_78df11ad-79e7-4109-b583-9e5bb6cb249d">313,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0a522e9d6934acc9765ff247056057b_I20211231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzQtMC0xLTEtMzMwMzEvdGV4dHJlZ2lvbjpkMjNmMzVhNTRkNzE0NDkxYmFlNzYyZGNjYjMwYzc5MV8xNjQ5MjY3NDQxNzQ0_b46fe979-da29-45e1-9fee-9e33277210f3">3.375</ix:nonFraction>% Convertible senior notes due May 2024 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438cb9109aec4c73bc3f0bbdd10be313_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzQtMS0xLTEtMzMwMzE_3ae2e70b-5aec-4f14-99bf-746e110741a1">201,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531cf89254884fafb25ee2779d786c28_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzQtMy0xLTEtMzMwMzE_afe0eeee-9404-46fc-a582-bc7db64b8c27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50f3b14c8eb24f87b8db39c9626146de_I20211231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzYtMC0xLTEtNTM0MzIvdGV4dHJlZ2lvbjo5YzhhMTcxMmQzYWQ0NjUwOWZkZTk3YjM1Y2Q0YjBlMF8xNjQ5MjY3NDQxNzIw_6f8800f7-84ea-4cd3-a70e-41de4abb0020">2.375</ix:nonFraction>% Convertible senior notes due April 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzYtMS0xLTEtNTM0MzI_37f2ca1c-c36b-4448-ac37-c2d9fd49af3b">157,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzYtMy0xLTEtNTM0MzI_0416366b-6202-49eb-94c0-e7aec64ddee9">149,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca63f94b05a4f70aa9157c96a600b08_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzUtMS0xLTEtMzMwMzE_cf67553c-b12a-40d6-a14f-216517deb66e">1,049,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693f123fe4684339ab826c50fedd6ad7_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzUtMy0xLTEtMzMwMzE_519439e6-b2c1-4756-a55c-84dcabfd5845">462,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loan B Facility</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021, the Company entered into a term loan credit agreement (the &#8220;Credit Agreement&#8221;) with JP Morgan Chase Bank, N.A., as administrative agent and the initial lender. The term loan issued under the Credit Agreement (the &#8220;Term Loan&#8221;), which was issued at a <ix:nonFraction unitRef="number" contextRef="i948cac0513e648dca715d8b2e62ccb32_I20211207" decimals="2" name="pcrx:DebtInstrumentDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5MjU_b821852b-1e9c-4c43-9d1c-4a39e9316ee9">3</ix:nonFraction>% discount and allows for a single-advance term loan B facility in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="i948cac0513e648dca715d8b2e62ccb32_I20211207" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTc2NTQz_e61c8336-0c36-450a-ae13-255fc9baf4b9">375.0</ix:nonFraction>&#160;million, which is secured by substantially all of the Company&#8217;s and each subsidiary guarantor&#8217;s assets. Subject to certain conditions, the Company may, at any time, on one or more occasions, add one or more new classes of term facilities and/or increase the principal amount of the loans of any existing class by requesting one or more incremental term facilities. The net proceeds of the Term Loan were approximately $<ix:nonFraction unitRef="usd" contextRef="i9859fe995b1b42efbfc4b581a85bb092_D20211207-20211207" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTc2NzE3_f102ff88-3d89-4198-9817-3eb77db59dda">363.8</ix:nonFraction>&#160;million after deducting an original issue discount of $<ix:nonFraction unitRef="usd" contextRef="i948cac0513e648dca715d8b2e62ccb32_I20211207" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTc2NzYx_9bdc13c5-8e1b-4873-8575-caed3cdacce9">11.2</ix:nonFraction>&#160;million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3NzYzNzY_eaaaa060-298f-46ad-a668-66449ad2a216" continuedAt="i0ce762f0ffd244aead3cc2ca90c0ea35" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the Term Loan is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.181%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan maturing December 2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkM2E3NTgwMzMxMzE0ZDljYTUzZDBjYjU3MTJkYTVmNi90YWJsZXJhbmdlOmQzYTc1ODAzMzEzMTRkOWNhNTNkMGNiNTcxMmRhNWY2XzItMS0xLTEtNTgwODc_8b32de92-0e4e-420b-bd86-faba9bc7c8c8">375,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkM2E3NTgwMzMxMzE0ZDljYTUzZDBjYjU3MTJkYTVmNi90YWJsZXJhbmdlOmQzYTc1ODAzMzEzMTRkOWNhNTNkMGNiNTcxMmRhNWY2XzMtMS0xLTEtNTgwODc_70a53352-2e39-4ee9-90ac-0e9282920578">4,443</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkM2E3NTgwMzMxMzE0ZDljYTUzZDBjYjU3MTJkYTVmNi90YWJsZXJhbmdlOmQzYTc1ODAzMzEzMTRkOWNhNTNkMGNiNTcxMmRhNWY2XzQtMS0xLTEtNTgwODc_872cb0e8-d106-4228-89bb-6d60de3a327b">11,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total debt, net of debt discount and deferred financing costs</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkM2E3NTgwMzMxMzE0ZDljYTUzZDBjYjU3MTJkYTVmNi90YWJsZXJhbmdlOmQzYTc1ODAzMzEzMTRkOWNhNTNkMGNiNTcxMmRhNWY2XzUtMS0xLTEtNTQ2Njk_014237fc-079f-4abe-a095-171f5c9ede7d">359,497</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan matures on December 7, 2026 and requires quarterly repayments of principal in the amount of $<ix:nonFraction unitRef="usd" contextRef="iae2b3e809f41477ea25d6594d89a6967_D20220630-20220630" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MTU0_ad3b7803-5541-4e37-b70b-ae8a01aa825f">9.4</ix:nonFraction>&#160;million. commencing June 30, 2022, and increasing to $<ix:nonFraction unitRef="usd" contextRef="ia39c7c0a086e4f0b8a4d0984865174c0_D20251231-20251231" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MTY4_d5c26865-3954-4f29-81ba-e42ca1fd60d0">14.1</ix:nonFraction>&#160;million commencing December 31, 2025, with a remaining balloon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i9ad5e620d8a44d559404a2918c7529ee_I20261207" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MTgz_23ab7fee-6588-4e69-8df3-58333a7c0b34">188.0</ix:nonFraction>&#160;million due at maturity. During 2022, the Company will be required to make <ix:nonFraction unitRef="payment" contextRef="iaaf747e09ae34640bae22f200d713217_I20221231" decimals="INF" name="pcrx:DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA4MDI0MjU_839bf3ee-3621-46a9-b0d0-92abe9ea1d1f">three</ix:nonFraction> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i919cb349fec448c9b5efab09950c010e" continuedAt="i1661aac5e77145d09ce8743f9f67312b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarterly payments totaling $<ix:nonFraction unitRef="usd" contextRef="i3c7058bed2db4a56b3c7e5e12b92460d_D20220101-20221231" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MTk3_b68ff39f-4aef-4f5a-adfd-7f68fd83a8dc">28.1</ix:nonFraction>&#160;million. The Company is also required to make mandatory prepayments of principal from (i) commencing with the fiscal year ending December 31, 2022, the Company&#8217;s excess cash flow (as defined in the Credit Agreement) existing in any fiscal year and if the Senior Secured Leverage Ratio (as defined in the Credit Agreement) for such fiscal year exceeds certain predetermined limits (ii) net proceeds (as defined in the Credit Agreement) of non-ordinary course assets sales and casualty events and (iii) debt issuance proceeds (other than permitted debt under the Credit Agreement). No mandatory prepayments are due for 2021. Prepayment penalties for the Term Loan are <ix:nonFraction unitRef="number" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="2" name="pcrx:DebtInstrumentPrepaymentPenaltyPercentYear1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5Mjk_8fbf7de0-dcd1-467d-bf01-cc08c9a3579b">3</ix:nonFraction>% in loan year 1, <ix:nonFraction unitRef="number" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="2" name="pcrx:DebtInstrumentPrepaymentPenaltyPercentYear2" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5MzM_deba1c94-c5f0-48f7-9185-3f4784cc494b">2</ix:nonFraction>% in loan year 2, <ix:nonFraction unitRef="number" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="2" name="pcrx:DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5Mzc_d9fc7c49-5e5d-4345-815b-b05fb3f6354d">1</ix:nonFraction>% in loan year 3 and no prepayment penalties thereafter. Prepayment penalties generally do not apply to mandatory prepayment obligations under the Credit Agreement, such as prepayments due in connection with excess cash flow.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan requires the Company to, among other things, maintain (i) a first lien net leverage ratio, determined as of the last day of any fiscal quarter, of no greater than <ix:nonFraction unitRef="number" contextRef="i7747ee53e646437988e64e05cfd00fdd_I20211231" decimals="INF" name="pcrx:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MjM3_0960647a-6458-4a07-8d22-73eb3b98cc74">1.75</ix:nonFraction> to 1.00 and (ii) liquidity, at any time, of at least $<ix:nonFraction unitRef="usd" contextRef="i7747ee53e646437988e64e05cfd00fdd_I20211231" decimals="-5" name="pcrx:DebtInstrumentCovenantLeverageRatioMaximumValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MjI4_a54042d3-3120-48c4-a857-60b85fff329c">150.0</ix:nonFraction>&#160;million. The Term Loan also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of December&#160;31, 2021, the Company was in compliance with all financial covenants under the Credit Agreement.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company may elect to borrow either term benchmark borrowings or alternate base rate borrowings. Term benchmark borrowings bear interest at a variable rate per annum equal to the Adjusted Term SOFR Rate (as defined in the Credit Agreement) (subject to a <ix:nonFraction unitRef="number" contextRef="ic3552408c5bb444cbf0eb6a3ab86a409_D20210101-20211231" decimals="INF" name="pcrx:DebtInstrumentVariableRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NDY_bc1d6ea0-2588-4a40-b7c4-a231c124ddbb">75</ix:nonFraction> basis points floor) plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="i88770a0f88374817ab71722879f70098_D20210101-20211231" decimals="INF" name="pcrx:DebtInstrumentBasisSpreadTwoOnVariableRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NDE_cef95651-69cc-4442-bd4c-12009bba375e">700</ix:nonFraction> basis points. Alternate base rate borrowings bear interest at a variable rate per annum determined using a base rate (subject to a <ix:nonFraction unitRef="number" contextRef="ie1a422b889ef4dc5a23b911b3aeae411_D20210101-20211231" decimals="INF" name="pcrx:DebtInstrumentVariableRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NTA_fc396b3b-b773-4a11-baa4-a5624c5e711f">175</ix:nonFraction> basis points floor) equal to the greatest of (i) Prime Rate (as defined in the Credit Agreement) in effect on such day, (ii) NYFRB Rate (as defined in the Credit Agreement) plus <ix:nonFraction unitRef="number" contextRef="ib5ecb39da69d4d29a362f012fbbd432c_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NjU_29411368-d6d0-403d-8340-d7e842d28a69">50</ix:nonFraction> basis points or (iii) the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus <ix:nonFraction unitRef="number" contextRef="i88770a0f88374817ab71722879f70098_D20210101-20211231" decimals="INF" name="pcrx:DebtInstrumentBasisSpreadOneOnVariableRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NTU_3854d5cf-9864-4f56-8439-213528c798ee">100</ix:nonFraction> basis points, subject to certain exceptions, plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="iaccaba05dfea42d581595525b0cc244f_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NjA_bd2185fe-96cd-4e51-95e6-d2ca5f1cd28f">600</ix:nonFraction> basis points. As of December 31, 2021, borrowings under the Term Loan consisted entirely of term benchmark borrowings at a rate of <ix:nonFraction unitRef="number" contextRef="i7747ee53e646437988e64e05cfd00fdd_I20211231" decimals="INF" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTkwMzUw_42dc4c16-7092-4111-9ce3-fb6d666c0184">7.75</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2025</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="ia017c092a2784b0ca8aab079c9e5fc54_I20200710" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNQ_e470450d-3643-4da3-8b37-956214cc6b80">402.5</ix:nonFraction>&#160;million in aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="ia017c092a2784b0ca8aab079c9e5fc54_I20200710" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE1NQ_9ecde54c-e27e-4d00-a3bd-7ab4f5f6a800">0.750</ix:nonFraction>% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture, or 2025 Indenture, with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of <ix:nonFraction unitRef="number" contextRef="ia017c092a2784b0ca8aab079c9e5fc54_I20200710" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM0MA_4e1d09d8-ea03-448f-8cbe-568fec6eb7fc">0.750</ix:nonFraction>% per year, payable semiannually in arrears on February 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and August 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year, beginning on February 1, 2021. The 2025 Notes mature on August 1, 2025. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i0ce762f0ffd244aead3cc2ca90c0ea35" continuedAt="i7062b9aab38846e39ff6877e6c6d7a3d"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2025 Notes is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmJjODhiZDg2ZjY0ZjQ4NjE4YjcwZjY1ODEwNjJjYjhjXzQ_97d7b466-f0c7-45c6-845a-37165a14e3fc">0.750</ix:nonFraction>% Convertible senior notes due August 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzItMS0xLTEtMA_b0d8e076-21eb-45d1-b72d-ea4d4561ea89">402,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzItMy0xLTEtMA_2bc1824f-7cd8-45a7-8383-e9b9289139de">402,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzMtMS0xLTEtMA_510dff06-291a-4434-ba81-63c2759acfee">7,155</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzMtMy0xLTEtMA_a7b7023a-15f4-4632-a123-ed4009db4358">8,940</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzQtMS0xLTEtMA_0df17d0d-11be-4280-94e1-9e0600551030">64,718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzQtMy0xLTEtMA_f7ecbca7-3d45-4e9b-a1f8-f7522df36079">80,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of debt discount and deferred financing costs</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzUtMS0xLTEtMA_330238d3-3e31-4781-84b8-209917767cf3">330,627</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzUtMy0xLTEtMA_b74e8464-1c26-4c1e-9733-455a44b60b43">313,030</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from the issuance of the 2025 Notes was approximately $<ix:nonFraction unitRef="usd" contextRef="i40835215f27548ddb0046f269d3d2d44_D20170313-20170313" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzY1Mw_27bc4dd4-eb37-40f1-addc-16a800c0af19">390.0</ix:nonFraction>&#160;million, after deducting commissions and the offering expenses paid by the Company. A portion of the net proceeds from the 2025 Notes was used by the Company to repurchase $<ix:nonFraction unitRef="usd" contextRef="ie208910c77e8415fa39a49e9cb6b2e10_I20200710" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzgyMQ_ac88fc5e-4113-483c-abfe-a5fff3046570">185.0</ix:nonFraction>&#160;million in aggregate principal amount of its outstanding <ix:nonFraction unitRef="number" contextRef="ie208910c77e8415fa39a49e9cb6b2e10_I20200710" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzg3Mw_56d2f2bb-5828-4a82-a8b7-c37eb26d3002">2.375</ix:nonFraction>% convertible senior notes due 2022 in privately negotiated transactions for a total of $<ix:nonFraction unitRef="usd" contextRef="ibcab94fdef344be8b8d6fd587edd7388_D20200710-20200710" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzk2Mg_ac6aa033-55d4-41d0-82fb-b13ac93008ab">211.1</ix:nonFraction>&#160;million of cash (including accrued interest).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert the 2025 Notes at any time prior to the close of business on the business day immediately preceding February 3, 2025, only under the following circumstances:</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least <ix:nonFraction unitRef="segment" contextRef="i159db211f8284627a7227966896882fc_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzMzE_d90a753a-33f0-492a-ae25-f107e1fc9f0e">20</ix:nonFraction> trading days (whether or not consecutive) during a period of <ix:nonFraction unitRef="segment" contextRef="i159db211f8284627a7227966896882fc_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzOTU_51838f38-42e0-4ab4-b7c3-1bf632bd75d6">30</ix:nonFraction> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i159db211f8284627a7227966896882fc_D20211001-20211231" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE1Mjg_7530340d-8bfa-496a-be8f-ad0ac58d0903">130</ix:nonFraction>% of the conversion price on each applicable trading day;</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) during the five-business day period immediately after any five consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2025 Indenture) per $1,000 principal amount of notes for each trading day </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i1661aac5e77145d09ce8743f9f67312b" continuedAt="ieebec4d82c544c2c98a30162d02a84ca"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i098824f172bb410fbf000b0dcf738b96_D20211001-20211231" decimals="2" name="pcrx:DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4Njg_1cfc9f6d-33e1-4c44-a26f-148f676bec20">98</ix:nonFraction>% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of the Company&#8217;s assets; or</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) if the Company calls the 2025 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after February 3, 2025, until the close of business on the second scheduled trading day immediately preceding August 1, 2025, holders may convert their 2025 Notes at any time.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of these conditions for conversion were met during the quarter ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2025 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="pcrx:SettlementPeriodConvertibleDebtConversionRequest" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzI3NDU_7ebaac6e-611a-4545-8ad4-0718d092dde6">40</ix:nonNumeric> consecutive trading days during the observation period (as more fully described in the 2025 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option. The initial conversion rate for the 2025 Notes is 13.9324 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ide059616fdda44779b287a0527e1ddb3_I20200707" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzMyMTQ_7815c598-faf1-4835-b0c7-95522ab4142a">71.78</ix:nonFraction> per share of the Company&#8217;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2025 Notes represents a premium of approximately <ix:nonFraction unitRef="number" contextRef="ide059616fdda44779b287a0527e1ddb3_I20200707" decimals="3" name="pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM0NzA_63a6b8a3-76f5-48df-95a2-e34b023b50e4">32.5</ix:nonFraction>% to the closing sale price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ide059616fdda44779b287a0527e1ddb3_I20200707" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM1MDI_f779965c-9dc4-4a12-b0d9-2aa96a2fb92f">54.17</ix:nonFraction> per share of the Company&#8217;s common stock on the Nasdaq Global Select Market on July 7, 2020, the date that the Company priced the private offering of the 2025 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the 2025 Notes had a market price of $1,113 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the $<ix:nonFraction unitRef="usd" contextRef="i0fd176f4fa004e9e999ce2a50dcb9adb_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzQxMzk_7782f3fa-1466-473a-a11c-d81266eb94b6">402.5</ix:nonFraction>&#160;million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&#8217;s option).</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to August 1, 2023, the Company may not redeem the 2025 Notes. On or after August 1, 2023 (but, in the case of a redemption of less than all of the outstanding 2025 Notes, no later than the 40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> scheduled trading day immediately before the maturity date), the Company may redeem for cash all or part of the 2025 Notes if the last reported sale price (as defined in the 2025 Indenture) of the Company&#8217;s common stock has been at least <ix:nonFraction unitRef="number" contextRef="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzQ3MTI_67249430-ccf9-4d78-82b1-0abdcc220031">130</ix:nonFraction>% of the conversion price then in effect for (i) each of at least <ix:nonFraction unitRef="segment" contextRef="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzQ3Nzk_bbe72f91-80d1-4b5d-8240-253da946070a">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="segment" contextRef="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzQ4MzU_60d2f7c6-f94a-4647-9521-3d05364cdad1">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of redemption and (ii) the trading day immediately before the date the Company sends such notice. The redemption price will equal the sum of (i) <ix:nonFraction unitRef="number" contextRef="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231" decimals="2" name="pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzUxMTU_26b89364-06fa-4538-8ae2-146e0e6f495d">100</ix:nonFraction>% of the principal amount of the 2025 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2025 Notes for redemption will constitute a &#8220;make-whole fundamental change&#8221; (as defined in the 2025 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2025 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, as defined in the 2025 Indenture, subject to certain conditions, holders of the 2025 Notes may require the Company to repurchase for cash all or part of their 2025 Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i098824f172bb410fbf000b0dcf738b96_D20211001-20211231" decimals="2" name="pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzU4ODk_6e2316bc-0647-4c79-8809-7fb57096e020">100</ix:nonFraction>% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change occurs prior to August 1, 2025, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes are the Company&#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2025 Notes, and equal in right of payment to the Company&#8217;s unsecured indebtedness. The 2025 Notes are also effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to any debt or other liabilities (including trade payables) of the Company&#8217;s subsidiaries.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ieebec4d82c544c2c98a30162d02a84ca" continuedAt="i97e5df3bc0d34db881dac37d3c848165"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the 2025 Notes are currently classified on the Company&#8217;s consolidated balance sheet at December&#160;31, 2021 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company&#8217;s common stock during the prescribed measurement periods. In the event that the holders of the 2025 Notes have the election to convert the 2025 Notes at any time during the prescribed measurement period, the 2025 Notes would then be considered a current obligation and classified as such.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2025 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $<ix:nonFraction unitRef="usd" contextRef="i051d7dc66a2540279e60e320f1d3037d_I20211231" decimals="-5" name="pcrx:DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzgwNDc_2e77a5eb-d414-4193-b890-d6852469ad43">314.7</ix:nonFraction>&#160;million was calculated using a <ix:nonFraction unitRef="number" contextRef="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231" decimals="4" name="pcrx:DebtInstrumentConvertibleAssumedBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzgwNzM_230fbbc9-07ec-4c44-987f-0bbf8429d96c">5.78</ix:nonFraction>% assumed borrowing rate. The equity component of $<ix:nonFraction unitRef="usd" contextRef="i051d7dc66a2540279e60e320f1d3037d_I20211231" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzgxMjQ_b0690f23-620f-4364-9aba-d2e9cba84ded">87.8</ix:nonFraction>&#160;million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2025 Notes and is recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. The equity component is treated as a discount on the liability component of the 2025 Notes, which is amortized over the <ix:nonNumeric contextRef="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MzY5_083b7311-af9a-4726-963f-952e431022df">five-year</ix:nonNumeric> term of the 2025 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. A deferred tax liability was recognized in the amount of $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="pcrx:DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzg3Mzc_0308086c-e32b-4ddf-84c4-3b8d32dcd383">20.5</ix:nonFraction>&#160;million, with the offsetting amount recorded in additional paid-in capital. See Note 16,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information regarding the Company&#8217;s deferred taxes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total transaction costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzg5NTk_be46589d-9d25-43c2-b26e-1997b819e672">12.5</ix:nonFraction>&#160;million related to the issuance of the 2025 Notes to the liability and equity components of the 2025 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="pcrx:AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4Mzcx_3ca3f248-8014-41fe-9b5d-c15735af1ef9">five-year</ix:nonNumeric> term of the 2025 Notes, and transaction costs attributable to the equity component totaling $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="pcrx:TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzkyOTQ_1f4e93e2-6a00-4e86-aaa0-48ed8fed7f86">2.7</ix:nonFraction> million are netted with the equity component in stockholders&#8217; equity. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2025 Indenture contains customary events of default with respect to the 2025 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2025 Notes will automatically become due and payable.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2024 Assumed from the Flexion Acquisition</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, on May 2, 2017, Flexion issued an aggregate of $<ix:nonFraction unitRef="usd" contextRef="iad983f5646e34e94a2da8681ed807b5d_I20170502" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTUwODEw_47b73d04-3060-4ee2-a6f2-3704e62e946a">201.3</ix:nonFraction>&#160;million principal amount of <ix:nonFraction unitRef="number" contextRef="iad983f5646e34e94a2da8681ed807b5d_I20170502" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTUwODM0_4c9a841c-e07e-4d58-a766-1472f514d5ee">3.375</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Flexion 2024 Notes&#8221;), pursuant to the indenture, dated as of May 2, 2017 (the &#8220;Original Flexion Indenture&#8221;), between Flexion and Wells Fargo Bank, National Association, as trustee (the &#8220;Flexion Trustee&#8221;), as supplemented by the First Supplemental Indenture, dated as of November 19, 2021, between Flexion and the Flexion Trustee (the &#8220;First Supplemental Flexion Indenture&#8221; and, together with the Original Flexion Indenture, the &#8220;Flexion Indenture&#8221;). The Flexion 2024 Notes have a maturity date of May 1, 2024, are unsecured, and accrue interest at a rate of <ix:nonFraction unitRef="number" contextRef="iad983f5646e34e94a2da8681ed807b5d_I20170502" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTUxNDM2_4c003aae-ffa0-4912-ac46-83471497f1ce">3.375</ix:nonFraction>% per annum, payable semi-annually on May 1 and November 1 of each year. Upon the Flexion Acquisition, the principal was assumed and recorded at fair value by the Company. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the Flexion 2024 Notes, at the election of each holder thereof, each Flexion 2024 Note was convertible into cash, shares of Flexion&#8217;s common stock, or a combination thereof, at Flexion&#8217;s election, at a conversion rate of approximately 37.3413 shares of Flexion common stock per $1,000 principal amount of the Flexion 2024 Notes, which corresponded to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i5a977c4be98547f98b6c05154f959739_I20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTU0MzA4_4ed99183-a9c7-4865-8301-41c28f184707">26.78</ix:nonFraction> per share of Flexion&#8217;s common stock. As a result of the Flexion Acquisition, and in connection with the Notice (as defined below), holders of the Flexion 2024 Notes became entitled to certain Flexion Acquisition-related conversion and repurchase rights, as discussed below. In addition, as a result of the Flexion Acquisition and as discussed in more detail below, any future conversion rights are subject to the occurrence of any future events giving rise to such conversion rights under the Flexion Indenture.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2021, as a result of the Flexion Acquisition and in accordance with the Flexion Indenture, Flexion provided a Fundamental Change Company Notice and Offer to Purchase (the &#8220;Notice&#8221;) to the holders of the Flexion 2024 Notes and offered to repurchase for cash all of the outstanding Flexion 2024 Notes, at a repurchase price in cash equal to <ix:nonFraction unitRef="number" contextRef="icd1e05a128ed42ccac04aeee92248fef_D20211206-20220106" decimals="2" name="pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTYxMTc0_5f4c8128-4342-4026-9204-ab57351387c2">100</ix:nonFraction>% of the principal amount of the Flexion 2024 Notes being repurchased, plus accrued and unpaid interest thereon to, but excluding, January 7, 2022, subject to the terms and conditions set forth therein. The offer to purchase expired at 5:00 p.m., New York City time, on January 6, 2022, as scheduled. </span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i97e5df3bc0d34db881dac37d3c848165" continuedAt="i6f5614fcddba4b74b4adec20d5e072a8"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any holder that did not exercise its repurchase right in accordance with the terms of the Notice retained the conversion rights associated with such holder&#8217;s Flexion 2024 Notes under the Flexion Indenture. For conversion of Flexion 2024 Notes in connection with the Fundamental Change and the Make-Whole Fundamental Change (each as defined in the Flexion Indenture) resulting from the Flexion Acquisition, each $1,000 principal amount of the Flexion 2024 Notes was convertible into (i) $317.40 in cash and (ii) 37.3413 CVRs, based on the conversion rate of 37.3413, prior to 5:00 p.m., New York City time, on January 7, 2022. Alternatively, holders could retain their Flexion 2024 Notes and such Flexion 2024 Notes would remain outstanding subject to their existing terms, including with respect to a holder&#8217;s right to receive interest payments on the Flexion 2024 Notes and exercise any future conversion rights that may arise under the Flexion Indenture.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 7, 2022, following the expiration of the offer to purchase, the Company accepted the $<ix:nonFraction unitRef="usd" contextRef="i43427f256a794c4db525f11b824c9893_I20220107" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTYyNTIw_5867885e-67f5-4b1c-a581-e43a3862e2dd">192.6</ix:nonFraction>&#160;million aggregate principal amount of Flexion 2024 Notes that were validly tendered (and not validly withdrawn). No Flexion 2024 Notes were converted in connection with the Notice. The remaining principal outstanding is $<ix:nonFraction unitRef="usd" contextRef="i0ce055e93fcd43c293a47474e350a43f_I20220107" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE2NDkyNjc1MjEzODU_82283adb-9689-4ed4-8f45-ed30ccc0976d">8.6</ix:nonFraction>&#160;million as of the date of this report.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2022</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="if7bf6b02068a41e8a7ed404d1082e6b2_D20170313-20170313" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzk5MjA_270a6730-b015-4702-a803-4906e5ade9c5">345.0</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ia0533c1098374121979b41de75d1de0b_I20170313" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzk5NTY_1334ed54-8893-4b96-abb2-52162129c611">2.375</ix:nonFraction>% convertible senior notes due 2022, or 2022 Notes, and entered into an indenture, or 2022 Indenture, with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of <ix:nonFraction unitRef="number" contextRef="ia0533c1098374121979b41de75d1de0b_I20170313" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEwMTQx_956c016f-4334-4422-91b1-6764b6ac4a0a">2.375</ix:nonFraction>% per year, payable semiannually in arrears on April 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. The 2022 Notes mature on April 1, 2022. As discussed above, in July 2020, the Company used part of the net proceeds from the issuance of the 2025 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="ie208910c77e8415fa39a49e9cb6b2e10_I20200710" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEwMzk1_654e9d4c-a707-4f75-8d1f-63a6122e3bc6">185.0</ix:nonFraction>&#160;million aggregate principal amount of the 2022 Notes in privately negotiated transactions for an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ibcab94fdef344be8b8d6fd587edd7388_D20200710-20200710" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEwNTAw_c233a4a6-3631-4dca-9c14-c7c838bc4657">211.1</ix:nonFraction>&#160;million in cash (including accrued interest). The partial repurchase of the 2022 Notes resulted in an $<ix:nonFraction unitRef="usd" contextRef="ibcab94fdef344be8b8d6fd587edd7388_D20200710-20200710" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEwNTk3_21d77a29-3e83-47aa-85ae-c2fe767e6bea">8.1</ix:nonFraction>&#160;million loss on early extinguishment of debt during the year ended December 31, 2020.</span></div><div><span><br/></span></div><ix:continuation id="i7062b9aab38846e39ff6877e6c6d7a3d"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2022 Notes is as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzItMC0xLTEtMC90ZXh0cmVnaW9uOjcxZmY0YTQ5YjA0YzRiOGJiMDU0Y2Y4YzI2ZDc2ZjgwXzQ_8c528764-8469-467a-8c18-79d5c3bf2f4b">2.375</ix:nonFraction>% Convertible senior notes due April 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzItMS0xLTEtMA_21100c00-2e83-4d9b-947d-7f8e3f0d2ddc">160,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzItMy0xLTEtMA_08eaf71e-181f-47ca-9c8c-b0e735a86f56">160,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzMtMS0xLTEtMA_8765afeb-d46f-4826-8cac-aa1260932eb7">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzMtMy0xLTEtMA_326f2546-02fa-40ba-b7f7-d76354d68a65">1,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzQtMS0xLTEtMA_697fec61-5102-422e-ac7a-065ec8402d2b">1,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzQtMy0xLTEtMA_d0ad547e-ad62-4283-94b5-73dcd1c30de7">9,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of debt discount and deferred financing costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzUtMS0xLTEtMA_3aab89e5-8b3d-4f3b-b8bc-5fbb9253cb1c">157,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzUtMy0xLTEtMA_260e100c-d9db-4f24-9c1b-fa3f829cc89a">149,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2022 Notes at any time through the close of business on the second scheduled trading day immediately preceding April 1, 2022. Upon conversion, holders will receive the principal amount of their 2022 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the <ix:nonNumeric contextRef="i4fb73217f94c444aa76dcd2a69b80870_D20170313-20170313" name="pcrx:SettlementPeriodConvertibleDebtConversionRequest" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTM3_74c6ebde-3eba-4cd9-b100-57fdb91a658a">40</ix:nonNumeric> consecutive trading days during the observation period (as more fully described in the 2022 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option. The initial conversion rate for the 2022 Notes is 14.9491 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib19dbd6e7ef04ec58b328d34732c899d_I20170313" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEyMDA2_e5b07736-630d-4b14-91f1-ae1e9150e90b">66.89</ix:nonFraction> per share of the Company&#8217;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2022 Notes represents a premium of approximately <ix:nonFraction unitRef="number" contextRef="ib19dbd6e7ef04ec58b328d34732c899d_I20170313" decimals="3" name="pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEyMjYy_e642df66-de2a-4329-8fc3-ff2b95b6bdcd">37.5</ix:nonFraction>% to the closing sale price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icadb10d36c46455daf4bbf36c85eb041_I20170307" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEyMjk0_e02b6d23-62af-4676-a9c5-dcf3471ac3fb">48.65</ix:nonFraction> per share of the Company&#8217;s common stock on the Nasdaq Global Select Market on March 7, 2017, the date that the Company priced the private offering of the 2022 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the 2022 Notes had a market price of $1,039 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2022 Notes will be paid pursuant to the terms of the 2022 Indenture. In the event that all of the 2022 Notes are settled, the Company would be required to repay the remaining $<ix:nonFraction unitRef="usd" contextRef="ia6d5ff5d3bd44ee1aeb5e1d291f7b120_D20210101-20211231" decimals="-5" name="pcrx:RemainingPaymentRequiredUponFullSettlementOfNotes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEyOTMy_fc0dccf4-1f52-4ed1-8ce3-344e43a547b4">160.0</ix:nonFraction> million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&#8217;s option).</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 1, 2020, the Company may redeem for cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option, all or part of the 2022 Notes if the last reported sale price (as defined in the 2022 Indenture) of the Company&#8217;s common stock has been at least <ix:nonFraction unitRef="number" contextRef="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313" decimals="2" name="pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzMzk1_d8e729d1-8108-4abb-b8c3-4102ed2a8096">130</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313" name="pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzNDUw_587aec42-dbd2-4202-90a7-5fcafba75d47">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313" name="pcrx:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzNTA2_09058a80-9082-4bce-938b-054cfa0947c2">30</ix:nonNumeric> consecutive trading-day period ending within five </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i6f5614fcddba4b74b4adec20d5e072a8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trading days prior to the date on which the Company provides notice of redemption. This condition was not met during the quarter ended December&#160;31, 2021. The redemption price will equal the sum of (i) <ix:nonFraction unitRef="number" contextRef="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313" decimals="2" name="pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzNzQz_04bff6a4-fa05-4f59-a6f0-7004afb5c800">100</ix:nonFraction>% of the principal amount of the 2022 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2022 Notes for redemption will constitute a &#8220;make-whole fundamental change&#8221; (as defined in the 2022 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2022 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, as defined in the 2022 Indenture, subject to certain conditions, holders of the 2022 Notes may require the Company to repurchase for cash all or part of their 2022 Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313" decimals="2" name="pcrx:DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE0NTE3_e94990dd-9115-4bf7-9a33-3c219ab5d5e9">100</ix:nonFraction>% of the principal amount of the 2022 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change occurs prior to April 1, 2022, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Notes are the Company&#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2022 Notes, and equal in right of payment to the Company&#8217;s unsecured indebtedness. The 2022 Notes are also effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to any debt or other liabilities (trade payables) of the Company&#8217;s subsidiaries.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2022 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $<ix:nonFraction unitRef="usd" contextRef="ib19dbd6e7ef04ec58b328d34732c899d_I20170313" decimals="-5" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE2Njc2_934a665d-70ff-4cd5-b44a-82dd866f7171">274.1</ix:nonFraction> million was calculated using a <ix:nonFraction unitRef="number" contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313" decimals="4" name="pcrx:DebtInstrumentConvertibleAssumedBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE2NzAy_6ced58a1-3010-4763-ab3b-2ce8826846ba">7.45</ix:nonFraction>% assumed borrowing rate. The equity component of $<ix:nonFraction unitRef="usd" contextRef="ib19dbd6e7ef04ec58b328d34732c899d_I20170313" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE2NzUz_6aeafa86-332a-4e42-bf84-7d20343754b4">70.9</ix:nonFraction> million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2022 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2022 Notes, which is amortized over the <ix:nonNumeric contextRef="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MzY1_bedef99f-0a36-4194-86a7-cc7cef5cc0a0">five-year</ix:nonNumeric> term of the 2022 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313" decimals="-5" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE3MzY1_a7b7ebe8-7867-4f1e-89f8-da755cc3d139">11.0</ix:nonFraction> million related to the issuance of the 2022 Notes to the liability and equity components of the 2022 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the <ix:nonNumeric contextRef="i262c5548fe9c44b8aa7a185ebe27e739_D20210101-20211231" name="pcrx:AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4Mzcw_d0e645ce-a291-4447-bad5-dc3e80174970">five-year</ix:nonNumeric> term of the 2022 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2022 Indenture contains customary events of default with respect to the 2022 Notes, including that upon certain events of default, <ix:nonFraction unitRef="number" contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313" decimals="2" name="pcrx:DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MTAw_5114ae20-02f5-457a-9fd6-a599c18c9b0a">100</ix:nonFraction>% of the principal and accrued and unpaid interest on the 2022 Notes will automatically become due and payable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="pcrx:ScheduleOfInterestExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MzYy_233f698b-79d6-45cb-aa6d-942244632efd" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:55.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual and other interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzItMS0xLTEtMA_e0200c98-4562-4800-9c2c-e1e5d0d1ddc3">9,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzItMy0xLTEtMA_d1657ee7-b1a7-4738-92bf-8f8f9d91a484">7,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzItNS0xLTEtMA_2da6bdaa-9c1a-414e-813f-29219aad9f9d">8,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzMtMS0xLTEtMA_5630fb36-714d-4b8a-8326-b9c698f85ddf">2,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzMtMy0xLTEtMA_83b3854d-3e59-4684-a0dd-115d3c5fe3eb">2,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzMtNS0xLTEtMA_43feee95-40d5-4a0b-a448-c814717a15b7">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzQtMS0xLTEtMA_52ad8c05-7ff9-437e-84e2-88c24c2ebcec">23,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzQtMy0xLTEtMA_f6386de5-4469-4060-9334-b32a70a147c7">18,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzQtNS0xLTEtMA_a50690c6-abd5-494f-adb2-4f9ef7533632">13,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized interest (Note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzUtMS0xLTEtMA_ab0eee79-8dd3-4789-85f8-4d548de5625b">3,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzUtMy0xLTEtMA_c055d6c8-a7f1-4a8a-8cc0-1d66cd9095f6">2,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzUtNS0xLTEtMA_b8aacab9-00e8-407d-ae94-0f7a5fb2c238">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzYtMS0xLTEtMA_289caee2-ccb1-4e82-a3ee-ba8626c6deb2">31,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzYtMy0xLTEtMA_d77aa662-c2c1-4686-9359-344615e2833a">25,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzYtNS0xLTEtMA_3b57b5f8-04fe-4f12-81e3-3ad523552122">23,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate on total debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzgtMS0xLTEtMA_3e194f61-5e98-4e31-aa08-8325e8e7d78c">6.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzgtMy0xLTEtMA_147c118e-fd25-4c38-9154-36eb65ffa2c9">7.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzgtNS0xLTEtMA_06551389-664a-4d90-8c71-67aa206ad5f2">7.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-30</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_178"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NDc_6b622d0c-8434-41ab-9840-3ac9a1cae619" continuedAt="i95eeb6113afd4bf98117810a1b447912" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i95eeb6113afd4bf98117810a1b447912" continuedAt="ife5dd46896cc4f3fad120bb2229e326b"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Level&#160;1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Level&#160;2: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Level&#160;3: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company&#8217;s equity investment with a readily determinable fair value was calculated utilizing market quotations from a major American stock exchange (Level 1). The fair value of the Company&#8217;s convertible senior notes are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company&#8217;s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amounts of equity investments and convertible notes receivable without readily determinable fair values have not been adjusted for either impairments or upward or downward adjustments based on observable transactions. <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NDg_1e8cffc8-17ca-4067-ac64-090346fc057c" continuedAt="i1256c6671a8b4bfeb4fa88ccc0b05bc9" escape="true">The carrying values and fair values of the Company&#8217;s financial assets and liabilities at December&#160;31, 2021 are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i1256c6671a8b4bfeb4fa88ccc0b05bc9"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Asset:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie577d6c271bb4749abe1c1aa7b73462a_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtMi0xLTEtNjY0Mjc_2e966169-1447-450e-8103-6979060803d5">14,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552e4370c49c488aaf644acf28100abb_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtNC0xLTEtNjY0Mjc_5212d7dd-578c-42fe-ba97-d6bec5e33c1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01558abfceb343c1997fa09cb38e955a_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtNi0xLTEtNjY0Mjc_3b83c6c9-fee2-4476-82f9-ee803be1d07c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13ef9c89d3842a090b30092159c6baa_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtOC0xLTEtNjY0Mjc_b718ac30-229d-45be-87ae-6131568de79d">14,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Convertible notes receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie577d6c271bb4749abe1c1aa7b73462a_I20211231" decimals="-3" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtMi0xLTEtMA_8aee037e-6026-469b-bdea-b1c18635920c">4,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552e4370c49c488aaf644acf28100abb_I20211231" decimals="-3" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtNC0xLTEtMA_7c565663-7386-4e80-b0bd-3fc3a5a6bf09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01558abfceb343c1997fa09cb38e955a_I20211231" decimals="-3" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtNi0xLTEtMA_38ac5b0a-9a1b-4e35-ac79-2a28ab7e6fd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13ef9c89d3842a090b30092159c6baa_I20211231" decimals="-3" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtOC0xLTEtMA_feb81200-c22b-4adb-9f03-cbcebd8983d6">4,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Acquisition-related contingent consideration </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie577d6c271bb4749abe1c1aa7b73462a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzYtMi0xLTEtMA_1a3a7b01-2dcb-4911-b9d0-2353946a855b">57,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552e4370c49c488aaf644acf28100abb_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzYtNC0xLTEtMA_369d2eda-880b-4cb8-a58f-e00234b030b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01558abfceb343c1997fa09cb38e955a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzYtNi0xLTEtMA_63e32a7e-d256-45de-8ad5-1a6634c9df9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13ef9c89d3842a090b30092159c6baa_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzYtOC0xLTEtMA_93fb2a2f-2443-4e86-abb6-19f96806ca6d">57,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Liabilities Measured at Amortized Cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facility due December 2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833dd50b748e4f648ce8fbdc883c4185_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktMi0xLTEtNTQ5NzQ_0fcb011d-c085-4bd3-a698-7cbfa84941fd">359,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6e342295e24ffeb5b662e536f55798_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktNC0xLTEtNTQ5NzQ_5adc79e0-3162-42d9-a783-65604a428e70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie47b1b32def64bc0a3609d407c471b13_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktNi0xLTEtNTQ5NzQ_fffa7f6f-c5a3-48c8-a53a-d6d01be1f6b2">371,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia547c4173aba4e05a06d562cb5145105_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktOC0xLTEtNTQ5NzQ_415be574-6fd8-47cb-aca1-ac3a37a5cb46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2.375% convertible senior notes due 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7d1ef1836341deb53748bf79ee7540_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTItMS0xLTU0OTM2_3d8ee0f5-bc3a-487c-bb9a-72583f92667c">157,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife6537b40fcd40ed8ef4f547088d8dd6_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTQtMS0xLTU0OTM2_8e6f707e-b299-487d-a0f5-4b38c0722b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59aef1e9bd7c4844a54073f163e8a93d_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTYtMS0xLTU0OTM2_c4184d89-4e68-4d14-8100-33c6a3d3ac01">166,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a42225481b4c039ba48e07565653d6_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTgtMS0xLTU0OTM2_821e2c1b-12df-45f0-ba6c-9ea23c1046ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% convertible senior notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31bdc45af904ee791953adb58a89ea7_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktMi0xLTEtMA_2797df26-a663-474d-aae4-c568f99d7e36">330,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2492fc03ca40809334ee540cedfd2d_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktNC0xLTEtMA_b99852f8-0eb4-4b10-9d2a-6c8220ac1fb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877fef10b449448bb4a9b1ae0125a699_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktNi0xLTEtMA_e1d96aac-94b6-4da6-9bd0-251e0ec075eb">447,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73430b1c7b5c48378305535b3e6241c4_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktOC0xLTEtMA_f3647a1c-551d-45bc-b8d6-f855df8ad8d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% convertible senior notes due 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied69c02578864bbc9cb25cd5c9b8b3ae_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTItMS0xLTA_081be044-d398-48eb-bbc2-fbad2fe32a5d">201,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb164609df064575b1b1a48271b62b19_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTQtMS0xLTA_46ef4ed9-973b-4610-9f31-c684d90867b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46eb669c6b164a9e8a7ea3de4a9b62c3_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTYtMS0xLTA_1f999354-64cf-4183-a69a-977c5da76cdd">201,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b76248be1d04ab7999d2ad496cd6c18_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTgtMS0xLTA_c5f22cc3-eeb4-4110-a604-b75219698ebd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The closing price of the Company&#8217;s common stock as reported on the Nasdaq Global Select Market was $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzIxMjQ_58664097-526b-409d-baae-f54bdba621db">60.17</ix:nonFraction> per share at December&#160;31, 2021 compared to a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i50f3b14c8eb24f87b8db39c9626146de_I20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzIxNzc_ec3e41f7-cd42-4e27-92de-369ebf369206">66.89</ix:nonFraction> per share for the 2022 Notes and a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i029b2fd1da9b426aa281eb6edf9c4164_I20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzIyMzU_ad25d7b8-830a-4c5b-9acc-1182a238bd31">71.78</ix:nonFraction> per share for the 2025 Notes. Therefore, at December&#160;31, 2021, the conversion prices were above the stock price. The maximum conversion premium that could have been due on the 2022 Notes and 2025 Notes at December&#160;31, 2021 was&#160;approximately <ix:nonFraction unitRef="shares" contextRef="ibec8af6ae83c4cc5bb12c9babddf9666_D20210101-20211231" decimals="-5" name="pcrx:DebtInstrumentConvertibleConversionPremiumShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzI0Mzk_8ee64e1f-8030-4f35-96e2-1846308af471">2.4</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i9513fc7cbbc24c9e8fd0a64ddc87b87a_D20210101-20211231" decimals="-5" name="pcrx:DebtInstrumentConvertibleConversionPremiumShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzI0NDY_1605e867-0c4a-4c53-92c1-2eb4f5e5ba85">5.6</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock, respectively. These figures assume no increases in the conversion rate for certain corporate events.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">(2) Relates to the Flexion 2024 Notes. For more information, See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">.</span></div></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a non-recurring basis, including assets and liabilities acquired in a business combination and long-lived assets, which would be recognized at fair value if deemed impaired or if reclassified as assets held for sale. The fair value in these instances would be determined using Level 3 inputs.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ife5dd46896cc4f3fad120bb2229e326b" continuedAt="ie5fbbd7add5b405698fb315f7ddd4a09"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recognized contingent consideration related to the Flexion Acquisition and the MyoScience Acquisition in the amount of $<ix:nonFraction unitRef="usd" contextRef="ib73e9b252a7f4625a0d9d5c279a031a2_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzQzOTgwNDY1MzcwOTc_9e949033-18b5-4834-9bd7-f04d2eea59ea">57.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8a0b1b1bfd3a47be9e86153acff8ab26_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzMxMjU_84aa081b-0bcd-4e9c-b25b-e12a553848c8">28.3</ix:nonFraction>&#160;million as of December&#160;31, 2021 and 2020, respectively. Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Charges, Product Discontinuation and Other,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a probability-weighted discounted cash flow approach that is based on unobservable inputs and a Monte Carlo simulation. These inputs include, as applicable, estimated probabilities and the timing of achieving specified commercial and regulatory milestones, estimated forecasts of revenue and costs and the discount rate used to calculate the present value of estimated future payments. Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, as part of the purchase price consideration related to the Flexion Acquisition, the Company recorded contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i79da6badc4ce4c8b87bad102f47d53f7_D20211119-20211119" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDMyNDM1_009b26f6-36e4-4691-9a7c-88ce8004d162">45.2</ix:nonFraction>&#160;million, which represents the Company&#8217;s achievement of meeting regulatory and sales-based milestones. For the period of acquisition through December&#160;31, 2021, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="ifd6c594f1a8d4d8198e32bc0c6d23237_D20211119-20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDMyNTc3_4e162951-3fc2-416d-b6b6-23810d782380">1.2</ix:nonFraction>&#160;million liability due to an estimated $<ix:nonFraction unitRef="usdPerShare" contextRef="i2d56f0f495b24f6292ed813d0fcfc838_I20211119" decimals="2" name="pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDMzMDUy_76009083-04e9-4077-984d-9110eb847b1f">0.02</ix:nonFraction> increase to contingent consideration per CVR fair value, which was included in acquisition-related charges in the consolidated statements of operations. At December&#160;31, 2021, the weighted average discount rate was 12.2% and the weighted average probability of success for regulatory milestones was <ix:nonFraction unitRef="number" contextRef="i596b14391d784004ad234ae361b60952_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQwMTQ2_f32bc13e-973e-49e0-8e49-7763484e5eee">12.7</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an acquisition-related gain of $<ix:nonFraction unitRef="usd" contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDM3NzEy_edd1c870-a71a-492f-984a-a90458a812fc">2.2</ix:nonFraction>&#160;million and for the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2019, the Company recognized acquisition-related charges of&#160;$<ix:nonFraction unitRef="usd" contextRef="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzExNTQ0ODcyMTE5NTUz_ab61dec5-e8b0-48cb-b561-c786d5f4cbf1">5.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzExNTQ0ODcyMTE5NTgx_df952203-e36f-4e33-8280-7507b82365bb">16.7</ix:nonFraction>&#160;million, respectively, related to the MyoScience Acquisition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a result of revisions to the probabilities of regulatory milestones being met and future projections, which have been included in acquisition-related charges in the consolidated statements of operations. At December&#160;31, 2021, the weighted average discount rate was <ix:nonFraction unitRef="number" contextRef="i5e8a2f34478940948a4fc588e36055b6_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzQ1NTE_8e3f119b-ed2f-407f-9308-a9e8f5048cd1">11.8</ix:nonFraction>% and the weighted average probability of success for regulatory milestones was <ix:nonFraction unitRef="number" contextRef="i688afa6b83624546a44f01cdc4648f16_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzQ2MzI_775fc3de-a801-4675-ac8c-c60ec94b91ca">1</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NTM_03c599a0-2e13-477f-aae2-b434dca29c92" escape="true"><div style="margin-bottom:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the key assumptions used in the valuation of the Company&#8217;s contingent consideration:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Flexion Ranges Utilized as of <br/>December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MyoScience Ranges Utilized as of <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d43a54915fb471a881eb7c22d53ebb8_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzEtMi0xLTEtNTUzNTgvdGV4dHJlZ2lvbjo3MDJjZDM4NGZiZGM0N2Q5YTc5ZjhmNWJmNDgwNjJlNF8xNjQ5MjY3NDQxNjY2Mw_e555f7a3-3e52-42a8-ad4a-6c6ed1a7c635">11.39</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if920c61660554030b10993e6540fa419_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzEtMi0xLTEtNTUzNTgvdGV4dHJlZ2lvbjo3MDJjZDM4NGZiZGM0N2Q5YTc5ZjhmNWJmNDgwNjJlNF8xNjQ5MjY3NDQxNjY3MQ_2a15cb68-0421-41f3-b50c-db0f7ea3d8f2">12.92</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2cf381db5a940f290c4b8ce845a8a32_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzEtMi0xLTEtMC90ZXh0cmVnaW9uOmRhZjFiZWUwOTM3NjQ1MDM5Nzk2MDAwMTIzMjI5OTY2XzQ_2ca0d2ec-c0d0-4e6b-8447-a757e658091b">11.42</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7c32d4b9517d48699bd04bc765bd4313_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzEtMi0xLTEtMC90ZXh0cmVnaW9uOmRhZjFiZWUwOTM3NjQ1MDM5Nzk2MDAwMTIzMjI5OTY2XzEw_f13747bb-7642-4c87-ac29-1e5df3a3e4d8">12.13</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achieving regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34416a5edad84520b386d27a329de124_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzItMi0xLTEtNTUzNTgvdGV4dHJlZ2lvbjpiMjIwYWI2M2VlYTQ0NDA2OTNkZTcxNDViZmUwMGFkMV8xNjQ5MjY3NDQxNjY1Ng_965b0cac-5a10-4e1c-ae3d-a5eadef7be9f">10.00</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i5b952c5725b44f818a3a4608b206c6b4_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzItMi0xLTEtNTUzNTgvdGV4dHJlZ2lvbjpiMjIwYWI2M2VlYTQ0NDA2OTNkZTcxNDViZmUwMGFkMV8xNjQ5MjY3NDQxNjY2Mw_a82055ca-7bd3-4987-a0d3-f13a2ff29d18">15.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87676acfa0004a61af3790653d502de3_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzItMi0xLTEtMC90ZXh0cmVnaW9uOjAyOGQ3NDIxYWYwNjRkNTZiNzk1ZDRiMGRiMmJlYTE4XzQ_3f397d69-62ad-4b9a-bc48-4dc2c9924c9a">1.00</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of achieving regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 to 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum remaining potential payments related to the contingent consideration from the Flexion Acquisition and MyoScience Acquisition are $<ix:nonFraction unitRef="usd" contextRef="i6d4add3e8085457381bf09ffb890926b_I20211231" decimals="-5" name="pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQwMTkz_26c62d9f-df6c-4b85-b8b4-99afb072cb05">425.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i18f0515519fd468ea2893c1d1449bb1e_I20211231" decimals="-5" name="pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzQ4NzE_a496e354-721c-44e7-919d-16c11b42f6ad">43.0</ix:nonFraction> million, respectively, as of December&#160;31, 2021.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NTg_62a825f7-50b0-4b37-b152-0d100f37c676" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the Company&#8217;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent<br/>Consideration<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead150b687d149c184bc55655b3b10d9_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzEtMi0xLTEtMA_42fedad8-8e90-4b83-bbbb-a826332ec199">28,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to the Flexion Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7c445d56a64eec9a36a2231a41ca72_D20210101-20211231" decimals="-3" name="pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzItMi0xLTEtNTU1NTI_7fe25c02-feb5-42a4-b41c-837e731e3c29">45,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb7c445d56a64eec9a36a2231a41ca72_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzItMi0xLTEtMA_4c49799f-d63f-4140-b4d6-5d06ac76820d">989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Payments made or offset against amounts due </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb7c445d56a64eec9a36a2231a41ca72_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzMtMi0xLTEtMA_29c67eef-ff48-4edf-8429-11979a2a7eed">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5df54267e2fb4ca08078fb42498c07b7_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzQtMi0xLTEtMA_38700a06-4a30-4679-9add-8d43fa7ec136">57,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate and government bonds with maturities greater than three months, but less than one year. Long-term investments consist of government bonds with maturities greater than one year but less than three years. Net unrealized gains and losses (excluding credit losses, if any) from the Company&#8217;s short-term and long-term investments are reported in other comprehensive income (loss). At December&#160;31, 2021, all of the Company&#8217;s short-term investments are classified as </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ie5fbbd7add5b405698fb315f7ddd4a09" continuedAt="i5297e2b237394c028fd720a9a4615bd8"><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available-for-sale investments and are determined to be Level 2 instruments, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. At the time of purchase, all short-term and long-term investments had an &#8220;A&#8221; or better rating by Standard&#160;&amp; Poor&#8217;s.</span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NjQ_e8188446-755b-4766-ac2b-de673f722b99" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company&#8217;s investments at December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021 Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>(Level&#160;2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed6c7cb25774dc791f211ce4f75f33a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzItMi0xLTEtNjY0ODI_c1c9d7a4-d5da-49df-9df1-49bfbb7b7140">3,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed6c7cb25774dc791f211ce4f75f33a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzItNC0xLTEtNjY0ODI_ef9b0b22-8436-4cac-8034-2f31ecc7042a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed6c7cb25774dc791f211ce4f75f33a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzItNi0xLTEtNjY0ODI_f4f07946-01dd-46ba-a12a-43556913a00c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed6c7cb25774dc791f211ce4f75f33a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzItOC0xLTEtNjY0ODI_10c2465c-3790-47c0-a5ca-75deac7e6961">3,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide37340a89bb45a5b51beeb5442b41a0_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzMtMi0xLTEtNjY0ODI_5f1d1e28-9f3a-4acd-bd44-b4a291cbaa2e">57,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide37340a89bb45a5b51beeb5442b41a0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzMtNC0xLTEtNjY0ODI_d9e9cdd1-2e07-4386-a6c8-a05e0a1bd421">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide37340a89bb45a5b51beeb5442b41a0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzMtNi0xLTEtNjY0ODI_4ac1a5d1-b279-42a3-a691-4b3e81fb62fa">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide37340a89bb45a5b51beeb5442b41a0_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzMtOC0xLTEtNjY0ODI_151f7d8e-6454-4133-8d52-f846de7dcce2">57,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fc0a4268ea499a866f36779e8349ff_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzQtMi0xLTEtNjY0ODI_b822af01-0be0-4680-8fcf-e64fb3cc5390">9,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fc0a4268ea499a866f36779e8349ff_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzQtNC0xLTEtNjY0ODI_8afebb5f-4d22-4142-8f14-c6702d364d3e">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fc0a4268ea499a866f36779e8349ff_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzQtNi0xLTEtNjY0ODI_d950af92-8397-4748-b713-4c8115fbd997">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fc0a4268ea499a866f36779e8349ff_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzQtOC0xLTEtNjY0ODI_1566e015-32db-4944-a88b-ddb28f19c04b">10,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzEyLTItMS0xLTY2NDgy_11ae7d69-e11a-4b3f-bf2f-3b855cdc0547">70,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzEyLTQtMS0xLTY2NDgy_2172caff-5bd6-4d91-8f7b-446ab7560a6a">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzEyLTYtMS0xLTY2NDgy_58dc7f74-5939-49e2-8cf8-bc79547a484e">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzEyLTgtMS0xLTY2NDgy_6ed8f19e-c671-428a-85ab-99439df3dae1">70,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020 Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level&#160;2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzItMi0xLTEtMA_5f288b47-6486-42b0-8c61-4c462ded2f83">34,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzItNC0xLTEtMA_447855a0-8e5b-4119-87e0-34d852a8cbbc">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzItNi0xLTEtMA_e8bfa041-ed57-49fc-8ce4-16c97838fad2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzItOC0xLTEtMA_a1125823-86ed-4c1e-9c77-f1b074df6e3b">35,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453db66839f342d1b1291f445f8934ed_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzMtMi0xLTEtMA_3b2918be-8fce-4d2b-83f1-20ebac39619c">221,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453db66839f342d1b1291f445f8934ed_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzMtNC0xLTEtMA_bd134389-86dc-4bc3-bd17-306ba1816672">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i453db66839f342d1b1291f445f8934ed_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzMtNi0xLTEtMA_208ced8d-e655-4650-8c98-766098a7e41d">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453db66839f342d1b1291f445f8934ed_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzMtOC0xLTEtMA_d01f6b84-e907-4f6b-9d58-fe827bf9a3b3">221,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a617a44b744a1596fff6fde2d5e5bf_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzQtMi0xLTEtMA_a1ba4760-4a49-4f67-8dfe-e435ea138f2f">120,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a617a44b744a1596fff6fde2d5e5bf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzQtNC0xLTEtMA_e38429b2-cedd-4ef6-beac-f1df9a07b4dd">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9a617a44b744a1596fff6fde2d5e5bf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzQtNi0xLTEtMA_2a9606b6-4f5b-419a-a198-8afcd55760fb">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a617a44b744a1596fff6fde2d5e5bf_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzQtOC0xLTEtMA_c1d8a701-6a06-4b17-abf1-7d869d01c9c0">120,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;U.S. Government bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzUtMi0xLTEtMA_4417005c-6d5a-4aba-ac5a-a8b3352302fc">44,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzUtNC0xLTEtMA_6bb9ae3f-e566-40ba-ba5a-a5a2cfb2ad88">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzUtNi0xLTEtMA_475c757d-f5b5-45a0-b490-0f9baa9e16d5">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzUtOC0xLTEtMA_079e7e29-db96-4bbd-a5f5-eaf72061e78d">44,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc9c5bceef24a519258f36b731eed51_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzYtMi0xLTEtMA_03af6bee-761d-47f4-8d9f-32cd7662b960">421,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc9c5bceef24a519258f36b731eed51_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzYtNC0xLTEtMA_2e3a7750-62ff-4198-8356-cc8d1a389c25">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafc9c5bceef24a519258f36b731eed51_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzYtNi0xLTEtMA_da85ec75-2ac7-4794-9c83-776af9e7e012">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc9c5bceef24a519258f36b731eed51_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzYtOC0xLTEtMA_4118dda4-4e33-463d-ab8a-2e48fbe04455">421,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;U.S. Government bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f2bb5426e04cc795ae3e950506e652_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzgtMi0xLTEtMA_efb78a80-56fd-455a-aa1a-3139a6267d9f">95,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f2bb5426e04cc795ae3e950506e652_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzgtNC0xLTEtMA_1abfe47e-d1b1-4727-87eb-1dc9e185b1e8">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f2bb5426e04cc795ae3e950506e652_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzgtNi0xLTEtMA_d329bc8d-a31d-4adb-a58a-972f6d6c43c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f2bb5426e04cc795ae3e950506e652_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzgtOC0xLTEtMA_7cebbab7-2337-4d8c-83ff-4b1d9d984802">95,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05c5a2e9e2a4674adef676d95ad516e_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzktMi0xLTEtMA_ffdbcd59-6cc4-4f51-b984-d3663d34d3eb">95,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05c5a2e9e2a4674adef676d95ad516e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzktNC0xLTEtMA_69774d85-2420-493d-9ae9-11670161b763">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05c5a2e9e2a4674adef676d95ad516e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzktNi0xLTEtMA_f4966b83-36dd-44d6-a9ea-93b704183c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05c5a2e9e2a4674adef676d95ad516e_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzktOC0xLTEtMA_fb392359-23cf-4724-b6b0-85094d11bacd">95,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzEwLTItMS0xLTA_134553ab-2067-4a22-98c9-978c678d5fd5">516,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzEwLTQtMS0xLTA_faf76099-739f-47cb-b0c9-ebb3f69057c2">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzEwLTYtMS0xLTA_8ec1419f-6455-46a4-9742-a5b086de8b67">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzEwLTgtMS0xLTA_6ee78b01-543f-4abc-944e-3a99646d5f66">517,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, there were no investments available for sale that were materially less than their amortized cost.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elects to recognize its interest receivable separate from its available-for-sale investments. At December&#160;31, 2021 and December&#160;31, 2020, the interest receivable recognized in prepaid expenses and other current assets was $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="us-gaap:AccruedInvestmentIncomeReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzY4MzA_7538ceb9-a9ac-4bd7-ac60-d7dd799d7f65">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-5" name="us-gaap:AccruedInvestmentIncomeReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzY4Mzc_a4800c4a-50a6-43d7-a650-b523aff8b653">1.6</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity and Convertible Note Investments</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, the Company held an equity investment of $<ix:nonFraction unitRef="usd" contextRef="ibc6c788ace5a4a8fb5b0dde94e57c31f_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ0ODc_fac94768-5076-4865-931e-a24be758713c">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8e6b31f4d2144d96b895a72c1ba86cb0_I20201231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1MDE_743a9c9f-ff33-45f5-91b5-eadf66d48c53">1.2</ix:nonFraction>&#160;million, respectively, in GeneQuine Biotherapeutics GmbH, or GeneQuine, a privately held biopharmaceutical company headquartered in Hamburg, Germany. This investment has no readily determinable fair value and is recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments. During 2021, the Company purchased a convertible note from GeneQuine in the amount of $<ix:nonFraction unitRef="usd" contextRef="i738a868b4ee144f2a08a48f1517a777b_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1MTU_d91623f3-ebd7-420b-969f-e2945c502ec6">1.2</ix:nonFraction>&#160;million and invested an additional $<ix:nonFraction unitRef="usd" contextRef="i738a868b4ee144f2a08a48f1517a777b_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1MzE_807a285d-be72-4629-b339-103599ed2fe8">3.0</ix:nonFraction>&#160;million in equity investments. During the year ended December&#160;31, 2021, the valuation of the convertible note was reduced by less than $<ix:nonFraction unitRef="usd" contextRef="i738a868b4ee144f2a08a48f1517a777b_D20210101-20211231" decimals="-5" name="us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1ODE_a6c010bb-6f9c-4b4e-b904-a44f75e43edb">0.1</ix:nonFraction>&#160;million due to changes in foreign currency exchange rates. The Company has the right to make additional investments in debt securities of $<ix:nonFraction unitRef="usd" contextRef="ibc6c788ace5a4a8fb5b0dde94e57c31f_I20211231" decimals="-5" name="pcrx:PotentialAdditionalInvestmentUponAchievingMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1OTU_09f19e3d-7302-4ab6-827b-a976f5149778">1.7</ix:nonFraction>&#160;million predicated upon GeneQuine achieving certain prespecified near-term milestones.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company purchased preferred shares in Coda BioTherapeutics, Inc., a privately held preclinical stage biopharmaceutical company that is developing a gene-therapy platform to treat neurological disorders and diseases for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="if8f291f33e434735b4f02c49878fd653_D20210401-20210430" decimals="-5" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTMzMzQ_9d488e1f-e3ad-480b-9121-c6a66fd3484e">10.0</ix:nonFraction>&#160;million. There were no adjustments to this investment during the year ended December 31, 2021.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company purchased a convertible note in the amount of $<ix:nonFraction unitRef="usd" contextRef="i53d3e7bf6be84c83bf7d2041a67fdae2_I20210430" decimals="-5" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTM0MDA_d9a165aa-daad-4d56-9233-7be6b50f4efc">3.0</ix:nonFraction>&#160;million from Spine BioPharma, LLC, a preclinical stage biopharmaceutical company. There were no adjustments to this investment during the year ended December 31, 2021.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i5297e2b237394c028fd720a9a4615bd8"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company held an equity investment in TELA Bio, Inc., or TELA Bio, in its consolidated balance sheets in the amount of $<ix:nonFraction unitRef="usd" contextRef="i6ec4a3b4cc1240d59d30b940f203ee7b_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxMjY1_0cbe1456-273c-48e1-a41d-2ffa374751a4">11.6</ix:nonFraction> million. During the year ended December 31, 2021, the Company sold its investment in TELA Bio for net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0cb990da9e674a18bd073cb528fb1809_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxMzgw_9fbe2551-fc09-4686-a0f9-9371ca229071">9.1</ix:nonFraction>&#160;million and recognized a realized loss of $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxNDE4_b696edcc-de02-41ad-9bcc-db53dc66a373">2.6</ix:nonFraction>&#160;million, which was recorded in other, net in the consolidated statements of operations. In 2020, the fair value of TELA Bio increased by $<ix:nonFraction unitRef="usd" contextRef="i0cb990da9e674a18bd073cb528fb1809_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxNTUx_2e4635d1-d366-4c67-af74-c46e8ff078d2">1.6</ix:nonFraction> million, which was recorded in other, net in the consolidated statement of operations and in 2019, the Company also recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i157d8e808cd54ff090acb94b024df9d4_D20200101-20201231" decimals="-5" name="us-gaap:ImpairmentOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxNjk2_5ef6bfb5-fe2e-499b-b075-a0bde2885d58">5.7</ix:nonFraction> million in other, net related to its investment in TELA Bio. The fair values of TELA Bio at December 31, 2020 and 2019 were based on Level 1 inputs.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2021, in January 2022, the Company purchased preferred shares in the privately-held Genascence Corporation, a preclinical stage biopharmaceutical company, for $<ix:nonFraction unitRef="usd" contextRef="if556affba80d4a378bf1f3922edc8edf_I20220131" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzExNTQ0ODcyMTE5MTI5_f3abe938-e5fc-44af-b650-4b3a8d93e53b">7.5</ix:nonFraction>&#160;million, recorded as an equity investment. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally insured limits.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, <ix:nonFraction unitRef="customer" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="INF" name="pcrx:NumberOfMajorCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg1NTg_50b7bdf7-c94a-4cac-94a0-7986a6d2a5ec">four</ix:nonFraction> wholesalers each accounted for over 10% of the Company&#8217;s accounts receivable at <ix:nonFraction unitRef="number" contextRef="ie89711155ad84669abf871469c5aeeb0_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg2NDA_55694e70-9d17-41b8-ac65-62e767db79af">30</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ie9b8974e2c7e4284b062762071958be9_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE0MjkzNjUxMTg3MDU5_8467880b-e37c-4f5a-a114-dd337ee0de03">20</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i6d3af74affd441a79ce03b62daff7be3_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg2NDQ_6965a7a0-21df-42f5-9afb-60e7272e70af">17</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5a4df30aaf1c498ba552279f52d650f3_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg2NTE_f7901a57-174d-412a-b545-2985e76a80ab">11</ix:nonFraction>%. At December&#160;31, 2020, <ix:nonFraction unitRef="customer" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="INF" name="pcrx:NumberOfMajorCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg2NjI_c1878d0a-701f-4af3-97ac-cd4bbd6c694e">three</ix:nonFraction> wholesalers each accounted for over 10% of the Company&#8217;s accounts receivable at <ix:nonFraction unitRef="number" contextRef="i06b2394034c140f6a4694ff381035b4e_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg3NDQ_b12e836d-70b5-40ee-9423-ee614e306091">36</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i41ec2f1d36a341c69f0baa5aa111d33a_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg3NDg_b7b8d5c5-54f7-4239-9255-59295ee642ad">28</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i396fdd45737f4f0b9bed95c0ddbc0622_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg3NTU_6471e7d7-49e6-49b5-84fd-cff17f4ee75c">23</ix:nonFraction>%. For additional information regarding the Company&#8217;s wholesalers, see Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. EXPAREL revenues are primarily derived from major wholesalers that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company&#8217;s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of December&#160;31, 2021 and 2020, the Company did not deem any allowances for credit losses on its accounts receivable necessary.</span></div></ix:continuation><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_181"></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzU1NQ_1dc32877-5eb0-441c-89af-2aa23092c8ca" continuedAt="ia1b2084e1e5c43418502f6f06eb2835d" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ia1b2084e1e5c43418502f6f06eb2835d"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzg4_063d3417-410f-438c-995c-dff32128b09d"><ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzg4_e5d0fcb3-5773-4a2c-a5bf-f5827589971b">250,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, of which <ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzExNTQ0ODcyMDkyMjM4_4e72a445-7e63-48ef-9e24-7e22d18d79e3"><ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzExNTQ0ODcyMDkyMjM4_a5c6d96d-af5b-4be7-b753-1fd56609bf79">44,734,308</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzEzMQ_76dafe87-2470-4e6f-bd94-9eaaa542b445"><ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzEzMQ_f3c174b3-cae6-46ec-9c68-624b0636f091">43,636,929</ix:nonFraction></ix:nonFraction> were issued and outstanding at December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI0Nw_16ce46fd-d0cb-422e-b56c-b6f1dc6a3052"><ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI0Nw_88c83f87-98bd-4052-90ad-b57ae046b893">5,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock. <ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI3Nw_0221a050-48d2-4da3-b2a2-f502f29a00e4"><ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI3Nw_0289b23a-ef6c-4f5d-90a8-668573de9f25"><ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI3Nw_443a56ae-8d8f-48a4-a6f3-82baaee8ab52"><ix:nonFraction unitRef="shares" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI3Nw_9b6af2d5-bc66-4b14-94eb-5c95c95753c5">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preferred stock was issued or outstanding at either December&#160;31, 2021 or 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzU2NA_c1d102ee-fd02-4f91-be03-6db1edb1499f" continuedAt="i14ea9ffc11a6491c9cf48141011b13e9" escape="true">The following table illustrates the changes in the balances of the Company&#8217;s accumulated other comprehensive income (loss) for the periods presented (in thousands):</ix:nonNumeric></span></div><div><ix:continuation id="i14ea9ffc11a6491c9cf48141011b13e9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gains<br/>(Losses) From Available<br/>For Sale Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81d1942e618045a69aca1ec725725e2e_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEtMi0xLTEtNTE5MTc_9084f0ff-1d0b-4f88-94ed-d87f1f750412">280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b427d124e645ad81dfc92d5d66b207_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEtNC0xLTEtNTE5MTc_672c0344-25a3-40cf-a120-9c96fb40453e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7691a4cd4aca428e882b620433db6759_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzQtMS0xLTEtMA_b414ca2f-5a63-410e-81b3-038f38ff29e5">280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on investments, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268f623dedfe45ef8b32af260bc0891d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzItMi0xLTEtNTE5MTc_46a7d9d8-6755-4e06-83f8-f6770c0013b1">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib22aebb1a2f448a8b5e073383b0f94c1_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzUtMS0xLTEtMA_0c82f689-9b0b-4be9-bfcf-fbea176ceb61">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic646097fbe734ac9b8fd68d466e50d82_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzQtMi0xLTEtNTE5MTc_e568960d-cd37-404f-8402-b3a3cbf4f103">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8c703d659b483fba7961601663c1bb_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzQtNC0xLTEtNTE5MTc_a12e1066-5505-4a5b-82ab-36701cc1b410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3dfaa6dfa1240039de2e6dff373a711_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzctMS0xLTEtMA_40ffbdbc-cbc7-42d2-a00c-5eb60ccfe0eb">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on investments, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0434aab27f55421b84d92aaa462e4576_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzUtMi0xLTEtNTE5MTc_ef952758-2466-44f2-bdf7-31c75fa56751">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e4dc31d7b404c919dfaf4a0a27a0aff_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzgtMS0xLTEtMA_c1104e58-5757-4c64-ab22-a81134caf65e">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9491f3f75e24aaeb616d1274815af74_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzYtNC0xLTEtNTE5MTc_77a3defe-ac44-4fc4-974a-3c97c42e7bc3">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e4dc31d7b404c919dfaf4a0a27a0aff_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzktMS0xLTEtMA_707f6ec2-a936-4ec6-b622-20ddef9b5c6b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38819c0324594ec1b66a4ffa3fcf3f56_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzgtMi0xLTEtNTE5MTc_dd9c84c6-5893-45c4-900f-62ef0bc0c817">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2612fd9b7b754b8cbaeace3e57620704_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzgtNC0xLTEtNTE5MTc_fac153de-bd44-498f-8b0e-36eaabce1c43">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib617d7e96fc14f90a5109fe4b4e42246_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzExLTEtMS0xLTA_c7cccae5-8ed4-4271-8ed6-1ff5543c99dc">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on investments, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b80643a294b465ea2661625af1ab96f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzktMi0xLTEtNTE5MTc_47d96e22-a478-48ed-81db-41f3ad64d95a">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18af5711da6640a097e5c4348ee46f60_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzktMS0xLTEtMjg3MTU_63e1b5cc-d771-4efe-aa0c-14786b0d77ef">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie41ce2db25d34febb04acbf253c2bfcd_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEwLTQtMS0xLTUxOTE3_a5175733-d7a7-45ca-9920-f0b94c6a92de">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18af5711da6640a097e5c4348ee46f60_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEwLTEtMS0xLTI4NzE1_695adacb-3d65-4d3e-bfc0-c69fdaa30f3e">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e72dd91549146e4b77f296c7d373601_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEyLTItMS0xLTUxOTE3_ea291408-b782-4f23-a09a-d6fcd0d7f7dd">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f5d2774f94c4c19a034c9d35c8cf659_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEyLTQtMS0xLTUxOTE3_0622c732-4966-486c-8460-d514bde13b83">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5eb7e48d214a51937b661bf27d5c25_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEyLTEtMS0xLTI4NzE1_ec68424f-8cca-4b8e-8eda-ee080bc01e1e">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-34</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2ODM_27aaebdc-8208-4c46-b410-b7ba23dace8b" continuedAt="i1d7eaabb29f74af9a44498638a5219a8" escape="true">STOCK PLANS</ix:nonNumeric></span></div><ix:continuation id="i1d7eaabb29f74af9a44498638a5219a8" continuedAt="ie58b09acbe7749ffb5155ee95ede3e5d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Incentive Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s amended and restated 2011 stock incentive plan, or 2011 Plan, was originally adopted by its board of directors and approved by its stockholders in June 2011 and was amended in June 2014, June 2016, June 2019 and June 2021. The June 2021 amendment and approval by the Company&#8217;s stockholders increased the number of shares of common stock authorized for issuance as equity awards under the plan by&#160;<ix:nonFraction unitRef="shares" contextRef="i0b3a1799953e4b7a9a6fe4c6d61c6c82_D20210601-20210630" decimals="INF" name="pcrx:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ0Ng_be353a57-4b63-4c1d-b951-4f0342cadce6">1,500,000</ix:nonFraction>&#160;shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2011 Plan allows the granting of incentive stock options, non-statutory stock options, restricted stock awards and other stock-based awards. In April 2014, the Company&#8217;s board of directors also adopted the 2014 Inducement Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock option grants have an exercise price equal to the closing price of the Company&#8217;s common stock on the date of grant, generally have a <ix:nonNumeric contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2NzA_b550ad66-365f-486d-8cbc-7393ac438a00">10-year</ix:nonNumeric> contractual term and vest in increments (typically over <ix:nonNumeric contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzkxMw_f3923737-e39a-4e06-b9f6-bebd4907240e">four years</ix:nonNumeric> from the date of grant, although the Company may occasionally grant options with different vesting terms, including grants made to its non-employee directors). The Company also grants RSUs to employees and non-employee directors generally vesting in increments over <ix:nonNumeric contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzExODI_122f3eac-c2b4-48a3-ba6d-c8095ffb1cbf">four years</ix:nonNumeric> from the date of grant, except for such grants made to non-employee directors. The Company uses authorized but unissued shares of its common stock to satisfy its obligations under these plans.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2014 Employee Stock Purchase Plan, or ESPP, was adopted by its board of directors in April 2014 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved by the Company&#8217;s stockholders in June 2014. The purpose of the ESPP is to provide a vehicle for eligible employees to purchase shares of the Company&#8217;s common stock at a discounted price and to help retain and motivate current employees as well as attract new talent. Under the ESPP, up to <ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="pcrx:EmployeeStockPurchasePlanESPPSharesinESPP" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzE4MjQ_9141dbc3-197c-4856-9b32-20a5fdfb7397">500,000</ix:nonFraction> shares of common stock may be sold. The plan expires in June 2024. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 of the Internal Revenue Code, or IRC. The maximum fair market value of stock which can be purchased by a participant in a calendar year is $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:MaximumFairMarketValuePurchaseofESPPShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzIxMzc_2613c726-4538-48de-b72c-42cef3f2e645">25,000</ix:nonFraction>. Six-month offering periods begin on January 1 and July 1 of each year. During an offering period, eligible employees have the opportunity to elect to purchase shares of the Company&#8217;s common stock on the purchase dates of June 30 and December 31 (or the last trading day of an offering period). The per share purchase price will be equal to the lesser of <ix:nonFraction unitRef="number" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="2" name="pcrx:EmployeeStockPurchasePlanfairvalue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzI0OTU_722559e5-f6bd-4259-876f-c1fccc82c7b6">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on either the offering date or the purchase date. During the year ended December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="INF" name="pcrx:StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzI2Mjk_a3b7e96b-b535-4385-ae2b-9e2f2bbb2f24">55,483</ix:nonFraction> shares were purchased and issued through the ESPP.</span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="pcrx:ScheduleOfSharesAvailableForIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2Nzg_f45e70fc-5273-40d3-abb0-4e68dd4dc55b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain information about the Company&#8217;s stock incentive plans at December&#160;31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Incentive Plan</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards Reserved For Issuance</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards<br/>Issued</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards Available For Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011 Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic74c8757d0944c88a8cd93d9a4b8cf53_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzEtMi0xLTEtMA_150e0e12-03a4-4779-b4e2-4aa9f31c63c6">14,431,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc17ef4c747949b48269bf0b8a76060c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzEtNC0xLTEtMA_5007cd05-2e20-46e6-91a1-a72f68dfdbc5">12,425,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic74c8757d0944c88a8cd93d9a4b8cf53_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzEtNi0xLTEtMA_4b1a4507-ca44-4bd1-86d3-13558c863875">2,006,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Inducement Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a5d9635bc2e455f8966f9f3b2bb58fa_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzItMi0xLTEtMA_3cb596c6-485c-447a-9a80-51c3577e6b17">175,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99a2df6ef1594ed0900053be4381bced_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzItNC0xLTEtMA_98dc6e74-9620-48b6-9e0c-3651d833bdf5">36,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a5d9635bc2e455f8966f9f3b2bb58fa_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzItNi0xLTEtMA_950bee9f-4ea0-4b0e-9348-b443f5e81675">138,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzMtMi0xLTEtMA_2cadf40b-efed-474c-b620-726eb56ed084">14,606,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzMtNC0xLTEtMA_3c7c2e6a-7b8c-45ad-812e-eeb7441d3be9">12,461,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzMtNi0xLTEtMA_c2948800-0b5d-474f-9d39-86f272f91fd5">2,145,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Reserved<br/>For Purchase</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Purchased</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Available<br/>For Purchase</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i744090d10596403bb55779bf5925f19e_I20211231" decimals="INF" name="pcrx:EmployeeStockPurchasePlanNumberofSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzYtMi0xLTEtMA_ab68bfdc-6eaf-47d9-9e0e-44e059d94f3a">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6806d31d7c914f92a84099b441fe66bb_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzYtNC0xLTEtMA_7c5654ec-eea0-4041-b009-04beb7222e04">409,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i744090d10596403bb55779bf5925f19e_I20211231" decimals="INF" name="pcrx:EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzYtNi0xLTEtMA_29cb0fbc-b3e5-4d97-882a-9b60e26e8d4c">90,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for stock options and RSUs is based on the estimated grant date fair value of an award recognized over the requisite service period on a straight-line expense attribution method. Compensation expense for ESPP share options is based on the estimated grant date fair value of the ESPP shares and the grant date number of shares that can be purchased, which is recognized as expense over the length of an offering period.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ie58b09acbe7749ffb5155ee95ede3e5d" continuedAt="i6879f7777a2f454b9850b6539cc44939"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2ODY_55b7f7d3-c0f0-4f98-b4b0-467234d5e39e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense in its consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7da9c9dd8294201950b3c55f7f72c5e_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzItMi0xLTEtMA_32f6232a-8d71-45dd-b52e-b048fe968896">5,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75ef046de56d45b6a564367b687cd904_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzItNC0xLTEtMA_1eb99795-0f9e-4a09-a0b6-6bfacb4a88a4">5,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f8cb56d1ea45d9b5ddb5495a729cee_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzItNi0xLTEtMA_cf55c29c-11c0-40af-9732-2916b214064e">4,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa85351b13540518354d61849bb9f7d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzMtMi0xLTEtMA_3b208e81-15c5-4903-9a0f-09c6d4b1d34a">5,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6c86356bbbe45f6bfe831911514b73d_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzMtNC0xLTEtMA_cfe03b8a-049f-4477-a6f0-2c7e55f717e9">5,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e8fd43a94a74dafbc22852d9e58719c_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzMtNi0xLTEtMA_db392dbb-bf94-4c32-a1e6-0fb9f9d9be83">5,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f91b2bb657745cc992ed2a4e6446bd4_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzQtMi0xLTEtMA_74d4ab04-1b1f-40b2-9488-61cdf6ad45f0">30,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb7c0b3d882467292232e9502359bf3_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzQtNC0xLTEtMA_5aaa325c-666c-401f-b667-c0c7201fdea4">29,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i432c6966dd144c3991144693194ff39e_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzQtNi0xLTEtMA_5e6e1965-4144-476b-95c1-2049f43cbb93">23,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzUtMi0xLTEtMA_2958880e-4037-489e-9120-50dc0189a7d3">42,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzUtNC0xLTEtMA_094fce51-6cbb-48bd-b02e-2f0969c34942">39,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzUtNi0xLTEtMA_29be7123-45f8-4d9a-b5e8-3828ca2b244d">33,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzgtMi0xLTEtMA_23ede54f-c756-4398-ab46-ccb19a379ba0">25,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzgtNC0xLTEtMA_5e6868f5-da52-4d8b-a434-8ca81eadcb6e">26,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzgtNi0xLTEtMA_b98dc5a3-6d17-4266-9d5c-f10e7a9dca4b">23,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzktMi0xLTEtMA_38558eff-16ac-4583-95c1-63c75014402c">15,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzktNC0xLTEtMA_28775741-fe48-492d-ad06-2615b7420200">12,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzktNi0xLTEtMA_7f525dd2-ad0a-4251-a7cc-20934cba46f0">9,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEwLTItMS0xLTA_cd3d6934-c4d0-493b-a9ba-5fe93785b86e">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEwLTQtMS0xLTA_799f5046-aaae-4214-b0f0-9c590280af2b">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEwLTYtMS0xLTA_95fab4f8-8045-4a9b-a954-8d003211190a">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzExLTItMS0xLTA_ce81877d-24e1-48cf-80c3-1c3bb0999470">42,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzExLTQtMS0xLTA_d8511963-5642-4c59-b617-d516bbb4afb7">39,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzExLTYtMS0xLTA_5886359f-0f83-4ac7-a16a-deb7593a153a">33,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEzLTItMS0xLTA_e9631ace-4b60-4de9-b493-8221b1146ea7">8,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEzLTQtMS0xLTA_30b0e637-31f1-4824-bf25-e75b6693eb03">8,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEzLTYtMS0xLTA_4d67807c-e594-4938-9fc7-223c21fab6f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2ODE_89cd3882-5a4f-4895-9a25-57a3447c0bb1" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity and related information for the period from December 31, 2018 to December&#160;31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price (Per Share)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value<br/>(in Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd01dc35d06044bb97b415c6c22acd17_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEtMS0xLTEtMA_77602727-7f6a-4cc2-bf3b-c56443fcbb92">5,722,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd01dc35d06044bb97b415c6c22acd17_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEtMy0xLTEtMA_56b2dbbc-08ef-488e-bb2d-721566ef06b0">41.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i13fcb2c445c04b488b8969b4514b4362_D20180101-20181231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEtNS0xLTEtMA_208f4ae1-a997-4b0d-85f7-d2eb6c730655">7.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd01dc35d06044bb97b415c6c22acd17_I20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEtNy0xLTEtMA_67c3eecd-fb81-4af0-991c-959d8045ca90">49,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzItMS0xLTEtMA_faf4b94a-2b3a-4e19-9d29-7d104dfb31d5">1,872,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzItMy0xLTEtMA_7644f7ee-7152-4ecd-88d6-8d607c85d579">42.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzMtMS0xLTEtMA_a600ca69-693a-4974-9f39-54d7975e57e7">425,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzMtMy0xLTEtMA_a543ce18-c27e-494a-939a-2476dc52855c">19.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzMtNy0xLTEtMA_461c4186-80a5-4ae5-9f32-801fb35c995c">9,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzQtMS0xLTEtMA_4b591907-2a11-400f-b67e-c2236e1df534">286,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzQtMy0xLTEtMA_955bdae9-5ab2-409b-9615-a18b1a656d45">39.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzUtMS0xLTEtMA_f9d7e1f2-2c6b-4da2-8c3e-c915ae915e6d">176,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzUtMy0xLTEtMA_30054414-e691-43b6-a72b-6675a5a703af">63.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice16f3771e3e4ef983ae97345cb147d7_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzYtMS0xLTEtMA_63eb9599-a18f-4f1a-aae7-b78fb79cad9b">6,706,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice16f3771e3e4ef983ae97345cb147d7_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzYtMy0xLTEtMA_24aa9f1e-6de5-4a29-9f19-5fb3a498877e">42.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzYtNS0xLTEtMA_7555be59-bae5-419c-b8d1-2a5106b3e84c">7.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice16f3771e3e4ef983ae97345cb147d7_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzYtNy0xLTEtMA_bf1574ae-bae5-483c-b944-2a343e951af0">50,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzctMS0xLTEtMA_270f1b4d-c0f9-42b3-be09-60a1758db33e">1,502,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzctMy0xLTEtMA_fc774e6f-1a72-4b94-bd0d-aef3c5be7d63">47.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzgtMS0xLTEtMA_7e8b1a02-0057-4be5-8cf9-588b7bc084e1">1,428,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzgtMy0xLTEtMA_b1aefad7-0d6b-4937-b4d4-4a6e64a675b3">31.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzgtNy0xLTEtMA_4d52ff90-7b6b-467b-b0b8-0a206fb08e14">34,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzktMS0xLTEtMA_b657c7de-29e1-4964-9d97-7c93a77f2189">426,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzktMy0xLTEtMA_d52d3bd1-e9a3-4a9b-a2f3-2dba1de4a7df">42.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEwLTEtMS0xLTA_62ffda7e-6956-4469-977a-e0562998bb06">119,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEwLTMtMS0xLTA_e2651c63-6e10-4870-8123-6b7e20108453">71.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i917c4f0133de471d87fe63c0cf97feec_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzExLTEtMS0xLTA_30d03322-b89a-43ca-9d2a-15010ba00a05">6,235,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i917c4f0133de471d87fe63c0cf97feec_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzExLTMtMS0xLTA_29a1a510-2820-4952-94f9-f102ed811557">45.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzExLTUtMS0xLTA_5d447fa7-3e46-469f-8c01-51caa1d876eb">6.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917c4f0133de471d87fe63c0cf97feec_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzExLTctMS0xLTA_9d3f00d9-7f59-4def-b7ce-4eaa0aff673c">102,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEyLTEtMS0xLTA_8695ea19-90dc-4621-9e93-7d97e10fa0a3">890,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEyLTMtMS0xLTA_ba8e560e-b86f-4fef-beaa-255cb18918fc">60.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEzLTEtMS0xLTA_b0d9eaa5-3ca7-483f-a9a1-3bcd61b82029">732,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEzLTMtMS0xLTA_e445cf12-f4e2-4b4e-aa3a-dce5fd99d276">32.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEzLTctMS0xLTA_21049f2e-5d06-4172-9a2e-32d3e47d5b2b">23,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE0LTEtMS0xLTA_5a772a84-534d-4b3f-90af-a08d525be030">278,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE0LTMtMS0xLTA_203163e8-cc72-44ae-8ca3-16eba2575088">46.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE1LTEtMS0xLTA_f5da98bd-3027-46f2-a0e0-7b3c8b19bc48">64,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE1LTMtMS0xLTA_ce10c102-f09d-4f60-a504-28b94af67cca">80.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE2LTEtMS0xLTA_2b37c758-9522-45f6-b2dc-b5a63163153b">6,050,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE2LTMtMS0xLTA_64fc7c68-903f-426d-95c3-4787068a1355">49.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE2LTUtMS0xLTA_66d88ded-312e-40cc-92bb-1e00b2dda65d">6.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE2LTctMS0xLTA_dc00acce-0a37-4d5b-b804-038ea52bf0dc">81,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE3LTEtMS0xLTA_b0b4067a-5488-4ac1-bf1a-01c408fc14a3">3,826,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE3LTMtMS0xLTA_8dc92cf1-6d60-464c-bbea-792fb51bb1c6">48.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE3LTUtMS0xLTA_35ef4a1d-68b3-4d0f-a3dc-cd4030505e7e">5.49</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE3LTctMS0xLTA_f7fecb92-2800-42f1-b472-16533ef4a263">59,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE4LTEtMS0xLTA_29e7d870-e255-4536-8f54-40fb19ae7132">6,050,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE4LTMtMS0xLTA_763883cf-8abe-43e8-a8d1-6057fb1430bb">49.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE4LTUtMS0xLTA_5beeecab-81fb-4962-a644-cfc80419a538">6.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE4LTctMS0xLTA_785060da-6b68-4557-9981-fbbc36552393">81,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM1NTA_afffb74e-91b7-48b2-b373-7c365419f88c">47.3</ix:nonFraction> million of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM2OTI_76ea6c45-f863-4bee-9c63-b4bfcce1718e">2.6</ix:nonNumeric> years. The Company&#8217;s stock options have a maximum expiration date of <ix:nonNumeric contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM3NTg_86ef79e3-90b4-4750-ae25-594fbd2a05d8">ten years</ix:nonNumeric> from the date of grant. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of stock options granted for the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM4ODE_a7489be8-a356-4afc-8a08-ce37983f2a86">26.74</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM4ODU_75905af0-e66a-4846-a407-d573fa3c404b">22.40</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM4OTI_3ff7b523-1838-4134-af2a-f2fb03368108">20.92</ix:nonFraction> per share, respectively. <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2ODk_af649082-109b-4d7d-8101-18c027b22ca6" continuedAt="ic65787ac1a1e4b87ae79809db9d6f0a3" escape="true">The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:</ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i6879f7777a2f454b9850b6539cc44939"><div style="margin-bottom:6pt;margin-top:8pt"><ix:continuation id="ic65787ac1a1e4b87ae79809db9d6f0a3"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzItMi0xLTEtMA_232eec0d-5b70-4636-b1ca-abf2e30af949">None</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzItNC0xLTEtMA_f8f629f6-e8a6-41fb-8921-6f2eb8f41ccf">None</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzItNi0xLTEtMA_2b36dd3a-e46e-4f9a-8af4-9e2e89c8dbb2">None</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmI3ZThmMWJmNTkyNTQ1YjRiODM5MzM2ZDBlMDc1NDc2XzQ_3a09fc7b-cc64-4b0b-be1c-589eecf54cc0">0.43</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmI3ZThmMWJmNTkyNTQ1YjRiODM5MzM2ZDBlMDc1NDc2Xzk_81769dc4-58ce-498f-b74a-c8131629045b">1.21</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtNC0xLTEtMC90ZXh0cmVnaW9uOmEyZWNjOTA4NTJjZTQ0MDk5N2MyN2JkZWJkYTg1Zjk2XzQ_2d54a666-2cf5-42ea-90e6-c9d822279ef9">0.22</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtNC0xLTEtMC90ZXh0cmVnaW9uOmEyZWNjOTA4NTJjZTQ0MDk5N2MyN2JkZWJkYTg1Zjk2Xzk_faea1877-3ef5-49b6-83fd-27c9c0cb16d0">1.60</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtNi0xLTEtMC90ZXh0cmVnaW9uOmFmZDgzYTE3MWJkMTQxYzNiOWUyOWM1YjBlZmY2N2NiXzQ_6624df72-a3ab-4db8-a555-fb87b441c77c">1.33</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtNi0xLTEtMC90ZXh0cmVnaW9uOmFmZDgzYTE3MWJkMTQxYzNiOWUyOWM1YjBlZmY2N2NiXzk_5820542b-4958-4938-8187-530ba73e6d2c">2.54</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzQtMi0xLTEtMA_ded4f82b-b8ac-41ff-98cb-f1679f002140">49.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzQtNC0xLTEtMA_87d4edf6-ad85-4944-b4a2-829e346276c8">53.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzQtNi0xLTEtMA_a7607165-c281-4a8f-82de-83d597b89ac8">53.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzUtMi0xLTEtMA_91f8bd3a-b5a1-45ee-b272-080c8432f78f">5.36</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzUtNC0xLTEtMA_4a8c36dd-1f0b-4657-a850-9afcaf8a0c8b">5.36</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzUtNi0xLTEtMA_9f3e9c8d-a24f-4429-b5af-8b3c62085d77">5.22</ix:nonNumeric> years</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2Njg_7520f11d-55e2-4d1b-b29d-2a3d4d2942e5" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSU activity and related information for the period from December 31, 2018 to December&#160;31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair Value (Per Share)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value<br/>(in Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaca373b6b867452b83d716b6422dc258_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEtMS0xLTEtMA_6a9206e7-20e0-4614-83ba-36804e9c317e">577,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaca373b6b867452b83d716b6422dc258_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEtMy0xLTEtMA_a075ab55-489a-417c-bf47-3ff0b85376d0">42.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaca373b6b867452b83d716b6422dc258_I20181231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEtNS0xLTEtMA_1c3e3663-f7f8-4c59-a1ad-2fbe5391ecdc">24,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzItMS0xLTEtMA_d340fcfd-8171-4b51-bf09-224919fa5753">305,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzItMy0xLTEtMA_404651d0-d962-415f-83d9-f8fc719597fe">43.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzMtMS0xLTEtMA_18d6932b-3afc-4a41-b751-a57cc5396a46">192,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzMtMy0xLTEtMA_0df2d80f-d08a-43ed-b655-0f4537fb7d6f">45.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzQtMS0xLTEtMA_1f373228-ba15-4d53-aa85-1afdc3319c62">59,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzQtMy0xLTEtMA_1d5bba08-f043-4dac-9fe5-756524d4239b">41.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1c7481893dd4af497518d21d834ab65_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzUtMS0xLTEtMA_74658b1f-01a1-4968-9f2e-b888117469d7">631,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1c7481893dd4af497518d21d834ab65_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzUtMy0xLTEtMA_77e96d67-56c7-405e-b93e-88270e75ddcf">41.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c7481893dd4af497518d21d834ab65_I20191231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzUtNS0xLTEtMA_8f0d2aff-f78e-4fa3-8a19-77bdde89a478">28,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzYtMS0xLTEtMA_75154cad-80ba-4065-94df-04aea3d9d6de">665,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzYtMy0xLTEtMA_d628e667-813d-4711-a2d7-275a2a9c62c3">48.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzctMS0xLTEtMA_d6ec11f8-59a4-479e-9d73-98ddd1d9b823">239,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzctMy0xLTEtMA_f7af9948-0f85-44f3-bc37-fdc83ef142a1">41.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzgtMS0xLTEtMA_d25b10eb-1dcd-415a-96a8-bd8d935b7244">100,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzgtMy0xLTEtMA_a5a3c555-08f9-4807-96dc-dca7d6413e58">44.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfa96bfa146c401bafdd7c90c8ba2c6e_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzktMS0xLTEtMA_8aae10a4-c82f-49f7-a842-0fa83310fa02">957,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfa96bfa146c401bafdd7c90c8ba2c6e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzktMy0xLTEtMA_fb1c025b-ef19-4798-ba52-f2b617ab8aa4">46.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa96bfa146c401bafdd7c90c8ba2c6e_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzktNS0xLTEtMA_106df534-51fd-42a5-90dc-b389e22c7123">57,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEwLTEtMS0xLTA_c1c00dff-c05b-4940-9115-8af90e25265f">446,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEwLTMtMS0xLTA_7f533598-4741-4572-87ee-9e687069e8fc">60.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzExLTEtMS0xLTA_cfb410f9-de1d-4e1b-b0bd-265646d69e8b">309,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzExLTMtMS0xLTA_56890cbe-daeb-4f49-9484-17b52da7fadc">45.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEyLTEtMS0xLTA_8e85e84a-0c7d-4c89-be95-56d802cbfe30">138,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEyLTMtMS0xLTA_ce7d8c2b-f254-42da-8bdd-bf86c8b66d83">50.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and expected to vest at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib38eaa600b8e42a9851a181401b7e23e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEzLTEtMS0xLTA_73eb40a9-783f-48c5-af5f-25bd8e7e0307">955,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib38eaa600b8e42a9851a181401b7e23e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEzLTMtMS0xLTA_da4173cf-1e18-4759-979c-35181de0de66">52.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38eaa600b8e42a9851a181401b7e23e_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEzLTUtMS0xLTA_62f0bd94-660f-4d3a-8673-d5130b7a2e38">57,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ib38eaa600b8e42a9851a181401b7e23e_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQxOTU_e96bb34f-817e-4a2d-990d-0d6cac8b7e50">41.0</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQzMjg_33eb1ca6-6922-4b57-8492-0d5aa4f5d025">2.9</ix:nonNumeric> years. The Company&#8217;s RSUs have a maximum vest date of <ix:nonNumeric contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQzNzk_a32e4e66-db68-4d8e-9ca3-bae2ef4f57a2">four years</ix:nonNumeric> from the date of grant. The fair values of RSUs awarded are equal to the closing price of the Company&#8217;s common stock on the date of grant.</span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2Njk_505b4daf-e80d-41d0-87b6-7875dfcf78cf" escape="true"><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the ESPP share options granted were estimated using the Black-Scholes model with the following weighted average assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share option fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie8686eb39d5c4df494e9414f7b85eb73_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItMi0xLTEtMC90ZXh0cmVnaW9uOjNhZTE0OGY1NjZkZTRkN2Y5ZDk5ZGIxYzRmYTVkODVkXzQ_83f089c0-ec0d-4471-b46c-11e879ea864c">15.16</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d0fc32d88804baaab656363bb728911_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItMi0xLTEtMC90ZXh0cmVnaW9uOjNhZTE0OGY1NjZkZTRkN2Y5ZDk5ZGIxYzRmYTVkODVkXzk_45789999-7eb6-436a-b925-8b34ef2749ad">15.23</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i70c23ac5a7584fcfbb011f898d04aa74_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItNC0xLTEtMC90ZXh0cmVnaW9uOjU1YTIxYTA3YmY0YzQ5YWI4NTZlZGY1ZWU1OTEwZmRhXzQ_122aa965-33b9-4c2e-b119-b7d58a4717f7">11.02</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="iab19655e67644e4a974aac9a1311b637_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItNC0xLTEtMC90ZXh0cmVnaW9uOjU1YTIxYTA3YmY0YzQ5YWI4NTZlZGY1ZWU1OTEwZmRhXzk_6bf17ebc-e5f3-4feb-98b7-be9f1b82f924">17.54</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iefedf24a9a184d26b9444aa1d2768efd_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItNi0xLTEtMC90ZXh0cmVnaW9uOjQxZDAyZDNhNGI4ZDQzZDE4ZGNjMTM2OGM1MTI0MmZkXzQ_5ff4677f-a0d8-45c2-ba6d-8e2ec02d0983">11.13</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="iddd1835957aa4542b486125e347c2dff_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItNi0xLTEtMC90ZXh0cmVnaW9uOjQxZDAyZDNhNGI4ZDQzZDE4ZGNjMTM2OGM1MTI0MmZkXzk_d6d3e38f-9b2d-46e4-adf1-a0bc7a917fcb">11.36</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzMtMi0xLTEtMA_53f0c2f7-5ca5-4634-bc40-d820ce8eb6f6">None</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzMtNC0xLTEtMA_106c290f-fef1-40e0-8751-439464f55939">None</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzMtNi0xLTEtMA_66c5b60c-548b-4ea2-8fd8-3ed9de93068b">None</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtMi0xLTEtMC90ZXh0cmVnaW9uOjI5ZjU5Mjg5MjM2NTQzNmRhNTU0MDZkOGExNjM1Y2U3XzQ_08d9a99e-fa2a-4022-a738-2606bac7ec1e">0.50</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtMi0xLTEtMC90ZXh0cmVnaW9uOjI5ZjU5Mjg5MjM2NTQzNmRhNTU0MDZkOGExNjM1Y2U3Xzk_734a51b3-6069-44eb-b1a4-b5c508d1768b">0.90</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtNC0xLTEtMC90ZXh0cmVnaW9uOmYzMDhkOTgwNTZkYjQ2MmE5NGNhYWNmODIzODVkOTJmXzQ_5769ca0c-6ced-4ce1-9545-c0a84009de1c">0.14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtNC0xLTEtMC90ZXh0cmVnaW9uOmYzMDhkOTgwNTZkYjQ2MmE5NGNhYWNmODIzODVkOTJmXzk_74c2fc47-ce27-4eb1-9083-6ee8ae34f817">1.57</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtNi0xLTEtMC90ZXh0cmVnaW9uOmQ1NjkzMmE3ZWIzZDRkMWZiM2M4NGE0NDIxMDZiZGEwXzQ_5dd57f43-db44-4238-b7c9-1bd9ce739628">2.10</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtNi0xLTEtMC90ZXh0cmVnaW9uOmQ1NjkzMmE3ZWIzZDRkMWZiM2M4NGE0NDIxMDZiZGEwXzk_8984efe1-06de-418a-9741-100a458dfd37">2.56</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzUtMi0xLTEtMA_928dd558-4300-4f8c-b906-721b0d90c11e">37.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzUtNC0xLTEtMA_b5a1a47b-270d-4821-85d0-eed043936472">44.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzUtNi0xLTEtMA_103665b7-bef4-4c88-bb87-62eb2a93d359">40.2</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of ESPP share options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzYtMi0xLTEtMA_389b7a9d-2f68-4a08-8ff2-198c5c193baa">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzYtNC0xLTEtMA_d9f01ef9-1e82-4ef1-abfd-5633b16488a5">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzYtNi0xLTEtMA_9f16f2df-a026-4483-b95b-665a1c44516e">6</ix:nonNumeric> months</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-37</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90ZXh0cmVnaW9uOjQ0NTczYjMxODhmYTQ1NTI4NGJiZWQ3ODQwOGZkZDUxXzEyNTI_60c22994-46b5-4148-a34c-f19ae8eb4d09" continuedAt="ie8264d7992f84b14837968053ec0ee09" escape="true">NET INCOME (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ie8264d7992f84b14837968053ec0ee09"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential common shares are excluded from the diluted net income (loss) per share computation to the extent that they would be antidilutive. Because the Company reported a net loss for the year ended December 31, 2019, no potentially dilutive securities were included in the computation of diluted net loss per share for that period. As discussed in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has the option to pay cash for the aggregate principal amount due upon the conversion of its 2022 Notes and 2025 Notes. Since it is the Company&#8217;s intent to settle the principal amount of its 2022 Notes and 2025 Notes in cash, the potentially dilutive effect of such notes on net income (loss) per share is computed under the treasury stock method. As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU 2020-06 will require the Company to use the if-converted method upon adoption; this new accounting pronouncement was not adopted as of December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90ZXh0cmVnaW9uOjQ0NTczYjMxODhmYTQ1NTI4NGJiZWQ3ODQwOGZkZDUxXzEyNTU_ba7bbb84-13f4-4e76-8b3e-ebcdd3756664" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income (loss) per common share for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzMtMS0xLTEtMA_fbd77b7e-a5ae-4f19-84d4-aedfa75877d9">41,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzMtMy0xLTEtMA_0bf17b3f-3869-4b19-89a9-4c6094cb9a82">145,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzMtNS0xLTEtMA_b58e627b-86cc-4273-9a20-6fd7e3f7f065">11,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEwLTEtMS0xLTA_0b9387ec-3bef-494b-bbed-054d64c19342">44,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEwLTMtMS0xLTA_ed7b3151-0c96-4b6a-aa28-e2d2c6009392">42,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEwLTUtMS0xLTA_b884636f-3ee7-461a-a94e-10ec7992c823">41,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computation of diluted securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEyLTEtMS0xLTA_dbb379ed-bf6c-4b04-8c85-6aa2bf80d926">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEyLTMtMS0xLTA_063ae7c4-00c4-47a7-a1a8-4f73a49a2bf9">783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEyLTUtMS0xLTA_48a8aacc-1ee5-402b-94a6-505dfb86ea36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEzLTEtMS0xLTA_142550e5-7708-4ab7-af3b-7000b499ad1c">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEzLTMtMS0xLTA_68f2bfcf-d987-49a2-bc1a-12d8a9c79d45">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEzLTUtMS0xLTA_cafef63c-6de0-49fb-a72c-ea15030073b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of conversion premium on the 2022 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6be8009e772e4e3ba8f05b461e089043_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE0LTEtMS0xLTA_9f077e8f-f8da-4d01-a0f5-a9f2039b6b00">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of ESPP purchase options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE1LTEtMS0xLTA_e56e3256-3394-48d2-bc58-04d22b371ff5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE1LTMtMS0xLTA_dc2b22b7-0f17-4f99-a990-fa46c399442e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE1LTUtMS0xLTA_1ef389cc-1a47-44d8-ada0-d316175688c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE2LTEtMS0xLTA_db0ea1a8-22a7-4968-8771-7a2bd428d712">45,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE2LTMtMS0xLTA_be4ae750-060c-4dfe-aaca-b7bc4c696e76">43,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE2LTUtMS0xLTA_d85bc99f-0ad7-4410-b2de-6648dd62970e">41,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE4LTEtMS0xLTA_0471bcba-00e2-4fea-8e38-aff8e667b5f7">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE4LTMtMS0xLTA_8efa565c-c9b3-4e82-8609-f5737833b833">3.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE4LTUtMS0xLTA_170a7dde-0fb1-4231-9bff-a90e5902e5a9">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE5LTEtMS0xLTA_cc5ef349-c246-4faf-8802-21ad9b268035">0.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE5LTMtMS0xLTA_7f269cfa-bf9c-4c83-ae05-47b20fa2ecb2">3.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE5LTUtMS0xLTA_e825d9a4-4ee4-410a-a2dc-0e2eb213d2ce">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90ZXh0cmVnaW9uOjQ0NTczYjMxODhmYTQ1NTI4NGJiZWQ3ODQwOGZkZDUxXzEyNTk_d6fdd7a5-f53c-410f-b0f7-547c859e22db" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the outstanding stock options, RSUs and ESPP purchase options that were excluded from the diluted net income (loss) per common share calculation because the effect of including these potential shares were antidilutive in the periods presented (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id414a99ec0d0409883eb8b2bdee4eb13_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzItMS0xLTEtMA_59925f5a-313f-440c-b1aa-52c892530a60">2,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a963ed83400446a9515a4a04cf232b9_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzItMy0xLTEtMA_18e78e4a-be7a-4b04-b1e4-1002ddf50b6d">4,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82a7bb9e5e6343258f6bed68cd00465f_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzItNS0xLTEtMA_623c6ab8-62fd-444f-8362-48cb4654839a">6,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1826d05ddc2f4352b6b5b4681a620e28_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzMtMS0xLTEtMA_ff49db7a-6ebc-4e7f-9ce0-e16dbb00de9e">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e541832bfb246b2a8efc0f7289d4bd7_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzMtMy0xLTEtMA_0da2627d-5b9c-4d84-a69b-3ef5e5cbf4d2">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib770abe7bb5740aab0aa7d6eab698b4a_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzMtNS0xLTEtMA_36d1dd5c-df47-4cb1-af62-427ea0e36701">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ESPP purchase options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i654e613b80f445abb2eaf1e762ad8cd3_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzYtMS0xLTEtMA_7523dc09-130d-4f67-aeaf-22589cb2c31b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c2116fd2ce647d29354014822fa3386_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzYtMy0xLTEtMA_2b2e48e2-769e-4ffe-bf09-bc3a738e827b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ccac5f6e0624be1b654c50898619041_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzYtNS0xLTEtMA_6ea1a71c-ff6a-4aef-ab31-26a1d7eb69df">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzctMS0xLTEtMA_c5e6418c-ee5e-43a2-90e0-9b36f0050e15">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzctMy0xLTEtMA_e0719f75-c766-4ecc-8dc7-4652423df5ef">4,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzctNS0xLTEtMA_7a53b706-0f4f-4217-adcf-493681ccbb04">7,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-38</span></div></div></div><div id="i284a0cec603b490382d0f8422359e7e8_190"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcwOTE_c06fc5a7-6616-4501-b28e-3bd0be748940" continuedAt="i9a4741fb0e544db6869c0b8cfbc8477c" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i9a4741fb0e544db6869c0b8cfbc8477c" continuedAt="i3d713723db7441bfacd9616bb6409672"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcwOTY_17d6eebe-995b-4d65-ba08-259e6f07a0ae" escape="true"><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes and the related tax expense (benefit) is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzMtMS0xLTEtMA_1faeaaab-74bc-4923-b2b2-ba233721d4c1">64,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzMtMy0xLTEtMA_3de36bc2-ad59-4d68-ad11-c16052674b5a">17,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzMtNS0xLTEtMA_fce436cc-a445-4407-bdd3-382a91d59c71">7,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzQtMS0xLTEtMA_55b9341d-25f3-4302-9a17-cefd118826eb">8,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzQtMy0xLTEtMA_418d1262-081c-4069-9403-df8e732e5567">3,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzQtNS0xLTEtMA_682cc15c-202a-4fa2-a769-486b9b8af637">3,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzUtMS0xLTEtMA_8e592a46-af6d-4d1f-b000-c19b19075191">56,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzUtMy0xLTEtMA_47733d6e-c7e8-43f9-86d3-2ca0d858ca68">20,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzUtNS0xLTEtMA_85cb5d51-41ae-410b-a870-96a6dce2a453">10,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzgtMS0xLTEtMA_22d411bd-5626-489c-b88b-9779e46adec6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzgtMy0xLTEtMA_a8ee941f-c3ae-470c-996c-4227afaaec5c">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzgtNS0xLTEtMA_83acbe05-fd99-40be-98b7-ca4c3de7970c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzktMS0xLTEtMA_e31132b8-ac80-45e1-89f6-6dfecb0572a5">3,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzktMy0xLTEtMA_d0c50562-37fb-42f5-ac1c-149a2b452e42">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzktNS0xLTEtMA_caeb82f6-88c8-46fd-9362-7e18d4692fb5">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEwLTEtMS0xLTA_d002d806-4640-4e21-81d9-2bbe7f9c64e3">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEwLTMtMS0xLTA_27cb1f9f-ef7d-4cb2-a45a-9de64d9f3472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEwLTUtMS0xLTA_90e46171-af9e-4eb6-9d35-78a4f7743fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total current taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzExLTEtMS0xLTA_e5abadac-8a82-4ff4-a782-0bd5e02707c8">3,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzExLTMtMS0xLTA_02981d8e-b53f-4bc2-9e23-c09d5a66e807">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzExLTUtMS0xLTA_8dbb881a-8d54-4205-b74d-45e8beda4255">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEzLTEtMS0xLTA_acd4e4a3-70ca-4f4f-84ba-c114c5f9bcc9">12,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEzLTMtMS0xLTA_6f4832e4-f75b-4bd0-a303-495648986bea">99,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEzLTUtMS0xLTA_965c6ca5-f51b-4626-a23e-6b92e6e4acda">1,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE0LTEtMS0xLTA_004a4cc8-9f4e-4c39-8e42-77f04d2524b6">1,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE0LTMtMS0xLTA_c63cfa7b-f0c9-4350-9ffb-40aab4e9127e">27,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE0LTUtMS0xLTA_bece58f8-c217-438e-b1c6-107c0728409a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE2LTEtMS0xLTA_c9626555-8998-4d0f-9a3b-b771d76f6a98">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE2LTMtMS0xLTA_8132a528-be5e-48a9-aa92-4f58f9433fc5">126,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE2LTUtMS0xLTA_c81bbcd3-bf76-4fe9-b16b-bf00c00cfa9c">1,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE4LTEtMS0xLTA_bb6b14a5-8de5-4df2-8fdb-e2d4a4fd37ed">14,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE4LTMtMS0xLTA_12c47e6a-b1ab-4071-95bd-c55da722e942">125,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE4LTUtMS0xLTA_19ee932d-4473-42ef-a192-d082e9212732">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense of $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTcyMDEw_58400ae8-5077-4a9b-b95a-5ff68a7ccf40">14.4</ix:nonFraction>&#160;million for the year ended December 31, 2021 represents the effective tax rate applied to domestic operating results adjusted for certain discrete tax items including deductible stock-based compensation, non-deductible capital losses and tax credits. For the year ended December 31, 2020, the Company had an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzIwNw_3ae1a7cc-6c2a-4f0e-96fe-fa379c71a493">125.4</ix:nonFraction>&#160;million primarily related to the release of a valuation allowance on its domestic net deferred assets. The income tax expense for the year ended December 31, 2019 consists primarily of state income taxes in jurisdictions where the availability of carryforward losses are either limited or fully utilized as well as state taxes on the one-time gain from the deemed sale of assets resulting from an IRC section 338(g) tax election made by the Company related to the MyoScience Acquisition. This was partially offset by a reduction in the Company&#8217;s valuation allowance on its deferred tax assets due to the MyoScience Acquisition. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i3d713723db7441bfacd9616bb6409672" continuedAt="ied557353d1c24449bcf109751c47bbac"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcwODg_590321df-48cb-4657-9d1d-31d3feb14717" escape="true"><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzItMS0xLTEtMA_c152eaf0-4fc6-4a34-8f87-21e7c952e7aa">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzItMy0xLTEtMA_6f2c3064-c408-4d35-bb6e-921e1be02837">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzItNS0xLTEtMA_6dd95444-f2cb-4367-a0cf-94deab493930">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzMtMS0xLTEtMA_11fa6ccb-eda4-44b0-bade-d5df729b50b5">3.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzMtMy0xLTEtMA_d939f98f-4b16-463b-b3a1-15222f8226a2">3.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzMtNS0xLTEtMA_2b177fd0-3589-4561-b7c1-76742effb556">7.33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" sign="-" name="pcrx:EffectiveIncomeTaxRateReconciliationForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzQtMS0xLTEtMA_f40e0115-dd38-4339-91af-391d2b3097d6">1.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" name="pcrx:EffectiveIncomeTaxRateReconciliationForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzQtMy0xLTEtMA_c445560d-e213-4210-9436-8ac6632b5469">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="pcrx:EffectiveIncomeTaxRateReconciliationForeign" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzQtNS0xLTEtMA_c695c1c6-9e84-454d-b846-e15ed840ecc8">3.95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzUtMS0xLTEtMA_1d35d8b5-6bbb-4530-a39b-0cbdf469d0da">6.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzUtMy0xLTEtMA_a9a09b71-c60c-40a1-9b88-91775fa56790">647.87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzUtNS0xLTEtMA_676c18bb-e987-42af-8c72-e7df527b5e14">19.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzYtMS0xLTEtMA_1c7b27d0-e5e8-488a-962c-968a89c45296">3.80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzYtMy0xLTEtMA_9cfb1dd5-56cd-4e0a-b235-31e0f6b59c74">1.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzYtNS0xLTEtMA_58296c51-0706-436e-9088-ef7668baf1cc">10.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzctMS0xLTEtMA_bc6c6655-d075-48b3-adc3-5b6728318733">3.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzctMy0xLTEtMA_71bc1e06-d81b-44b5-bac7-e1000525b7c5">7.92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzctNS0xLTEtMA_25e13eb9-2542-4a1b-945e-7d7236765bdd">19.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="pcrx:EffectOfStateBlendedTaxRateChangesExpenseBenefit" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzktMS0xLTEtMA_dd6d7e13-c5bd-439c-b4cb-7fd6e5c20cb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" name="pcrx:EffectOfStateBlendedTaxRateChangesExpenseBenefit" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzktMy0xLTEtMA_14696b30-0592-4fbc-a05a-9c588c1bc835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="pcrx:EffectOfStateBlendedTaxRateChangesExpenseBenefit" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzktNS0xLTEtMA_ccf83774-2ac9-4748-8046-80263a765891">0.42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes refinancing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEwLTEtMS0xLTA_26841687-7ddc-430c-9fde-e38fb2713d6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" sign="-" name="pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEwLTMtMS0xLTA_7814a698-d74e-4fb5-ab5c-76ae4cef90a3">5.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" name="pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEwLTUtMS0xLTA_c539eaaf-60d2-4525-aae1-440c7f2b435c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzExLTEtMS0xLTA_afa0cf50-fafd-48b5-9639-39bde6183895">5.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzExLTMtMS0xLTA_a83b2091-5aec-4b70-87a6-dacbcbe5b799">4.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzExLTUtMS0xLTA_ab5e433b-ff90-4db2-8b1f-c0a15af37c6a">13.58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" sign="-" name="pcrx:EffectiveIncomeTaxRateReconciliationTaxReservesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEyLTEtMS0xLTA_8700ab1e-4012-4b0c-be98-3bbffd79861b">1.31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" name="pcrx:EffectiveIncomeTaxRateReconciliationTaxReservesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEyLTMtMS0xLTA_31a70e52-a0be-47a3-93d0-9caedbcf5915">7.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="pcrx:EffectiveIncomeTaxRateReconciliationTaxReservesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEyLTUtMS0xLTA_67336ff3-1416-4d72-8d8e-edd4ddf4d41b">15.41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338(g) tax election</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="pcrx:EffectiveIncomeTaxRateReconciliation338gElectionPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEzLTEtMS0xLTA_3ed59150-75c7-42ba-8ee9-9acd108859b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" name="pcrx:EffectiveIncomeTaxRateReconciliation338gElectionPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEzLTMtMS0xLTA_4d6ffc46-7b9a-4b70-9abc-f117369131d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="pcrx:EffectiveIncomeTaxRateReconciliation338gElectionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEzLTUtMS0xLTA_3cdd8821-2cd4-4aed-b6c2-756987004a12">9.61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE1LTEtMS0xLTA_2d81ba0d-ab8e-462c-b670-160b843fec2b">1.67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE1LTMtMS0xLTA_9dbef1ef-9eb4-462c-8373-7d204b6e98bd">1.84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE1LTUtMS0xLTA_dcf612b3-7aa1-45bc-8b43-5b73fa2c72bf">2.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE2LTEtMS0xLTA_92d1d2a9-f55c-4fe3-a791-f2dfac697f51">25.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE2LTMtMS0xLTA_60997e57-c956-4d4b-89e6-b21fb6c57ee8">624.39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE2LTUtMS0xLTA_dbe8af20-2dc4-4815-917c-2974b99b22bc">2.49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rates of <ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEwODk_726151b5-5fc9-40a8-99d6-9a0077e52ab2">25.57</ix:nonFraction>%, (<ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEwOTM_4ce15b44-9f41-4ba7-b825-1db61df2f615">624.39</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzExMDA_e7f09974-ad03-4742-a7de-57c1e0b0d5b9">2.49</ix:nonFraction>)% for the years ended December&#160;31, 2021, 2020 and 2019, respectively, differed from the expected U.S. statutory tax rate of <ix:nonFraction unitRef="number" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEyMDY_4e262664-18c3-480c-817b-fa06f928ccaf"><ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEyMDY_642816ac-66d4-4602-8eeb-0f9abbe28326"><ix:nonFraction unitRef="number" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEyMDY_7d2690f9-15e0-4ccb-beda-c15dcf60fa41">21.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>%. The difference in tax rates for the year ended December 31, 2021 was primarily driven by non-deductible expenses and valuation allowances recorded against capital loss carryforwards, partially offset by stock-based compensation deductions and tax credits. The difference in tax rates for the year ended December 31, 2020 was primarily due to the release of a domestic valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEzMzU_422909fa-afdc-42ff-a0ae-e861d75e996e">126.6</ix:nonFraction>&#160;million as discussed below. The difference for the year ended December 31, 2019 was primarily driven by pretax losses for which the Company concluded that a majority of its tax benefits are not more-likely-than-not to be realized, resulting in the recording of a full valuation allowance.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. At each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. During the year ended December 31, 2020, the Company determined there was sufficient positive evidence to conclude that it was more-likely-than-not the domestic deferred taxes of $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzI2MDA_654b3aa9-2652-4bb8-b3f9-6de69ab18b06">126.6</ix:nonFraction>&#160;million were realizable and, therefore, the domestic valuation allowance was released. The Company maintains a full valuation allowance on its foreign net deferred tax balances as it is more-likely-than-not the tax benefits are not realizable.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ied557353d1c24449bcf109751c47bbac" continuedAt="i5ff3c157ba0f46afb23eb3708d339367"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcxMDM_07532f00-015d-4155-8a6b-a86bed209765" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities at December&#160;31, 2021 and 2020 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzMtMS0xLTEtMA_c6f6a5a6-5218-4e72-8f5f-344d9935ba54">174,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzMtMy0xLTEtMA_da833b39-dc74-4bff-b306-2d7a3c7a7654">66,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzQtMS0xLTEtMA_54d9ba8a-0d37-4f1f-af34-ef365fd47254">35,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzQtMy0xLTEtMA_ba97ba7d-ba03-406c-95c6-0c48fa38343d">17,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzYtMS0xLTEtMA_f670cdab-34cb-4eeb-a982-afad12c581e0">80,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzYtMy0xLTEtMA_08c9db29-62d6-4115-8e9c-2eaf5a1da9e9">7,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:DeferredTaxAssetsStockBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzYtMS0xLTEtNjQ1OTM_304a4600-deb0-420d-8e67-a4bb3a904049">24,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:DeferredTaxAssetsStockBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzYtMy0xLTEtNjQ1OTM_88d7739c-9ecf-4019-846f-a56c43f59a71">21,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzctMS0xLTEtMA_5846852e-39f6-40d8-8cac-b1db3fabae3f">2,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzctMy0xLTEtMA_7a98a1cd-6cec-447b-8bea-41f8cc22cadc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzktMS0xLTEtMA_3f9ab73f-6703-44db-af34-6a09e217333c">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzktMy0xLTEtMA_b2079fe3-e33b-4eee-a6ad-229d941e8436">1,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEwLTEtMS0xLTA_c3907348-995b-43cb-b2f7-7f1e2ef850c1">2,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEwLTMtMS0xLTA_104553a4-ec78-4ac3-a3ef-bc83cae36aa8">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzExLTEtMS0xLTA_45cf4437-2003-4149-b6e9-9a7e0d16c486">319,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzExLTMtMS0xLTA_57badd26-8303-4181-9961-df16dc6e33e2">116,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" sign="-" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEzLTEtMS0xLTY0NTcw_db15d161-4e07-4ce5-9757-23f0941e4801">131,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEzLTMtMS0xLTY0NTcw_f364ee55-d495-4dcd-b726-6c5940a3f695">13,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEzLTEtMS0xLTA_87b53ee8-50b6-4cc8-856c-cefdd4afe410">15,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEzLTMtMS0xLTA_8c9bb6da-de8f-4e33-8f29-c51b1dd2af29">20,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE0LTEtMS0xLTY0NjI5_1642e4ba-8114-4268-a151-66caef97e999">147,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE0LTMtMS0xLTY0NjI5_efff02a4-89bb-4e51-ac40-df55557184e7">7,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE0LTEtMS0xLTA_11364ee3-b3aa-4b06-92b0-0c9a8f13aa50">172,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE0LTMtMS0xLTA_2f446f22-4db7-45ab-bac6-62384cc757ad">108,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE1LTEtMS0xLTA_ac3c3342-1359-45a8-96ac-27453304ffce">18,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE1LTMtMS0xLTA_bfd219ae-37ea-44d3-a2be-e1ffbe8612d4">2,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE2LTEtMS0xLTA_2a3bbe68-e755-42b9-a3ce-b2612e418284">153,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE2LTMtMS0xLTA_bccee682-d138-4610-897a-e11f86fc777c">106,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company&#8217;s federal net operating losses, or NOLs, and federal tax credit carryforwards totaled $<ix:nonFraction unitRef="usd" contextRef="ia52e5d1054ac4b44a90054d80c6509a1_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzMyNjM_4d047ab8-c8b2-4643-8c86-9733afc09372">662.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i46f9b7c2524840cca0b7ffd47db88684_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzMyNzA_03890fed-1bb6-44db-91ad-cf712e383ce2">25.9</ix:nonFraction> million, respectively. The Company also had state NOLs and state tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="id4141a4b22784eb593c98bb5aca5ba58_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzMzNTg_9e65f0fc-37bd-48f5-b7a1-10c4006e45a1">171.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if331b6039ef04e5f968fc0addfc10181_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzMzNjU_e162991f-53c4-4c15-9f8d-df3f735aa4a1">9.5</ix:nonFraction> million, respectively, which are subject to change on an annual basis due to variations in the Company&#8217;s annual state apportionment factors. The Company&#8217;s federal and state NOLs carryforwards include $<ix:nonFraction unitRef="usd" contextRef="i119369de4e404fe3857119778cfab5ec_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTc2Mjk2_94913fe6-c400-4d12-8e35-bf5a2b29ee45">538.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0f5ba37ffe97491eaff119eb51ec361a_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTc2Mjc4_d18ef879-8ea9-4c5a-88f7-28cf77f8c8df">28.6</ix:nonFraction>&#160;million, respectively, attributed to the Flexion Acquisition. Additionally, the Company&#8217;s federal and state tax credits include $<ix:nonFraction unitRef="usd" contextRef="i5fc3b655165947618391e9bed60d7390_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTc5MjE3_cc537304-ec5e-48a9-8042-b19a2d0a8c40">11.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i82f093ad3c8b4abb848c3099f207cc6a_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTc5MjMy_6c03aa63-f2ba-4bcc-a25d-f5df601b957a">3.6</ix:nonFraction>&#160;million, respectively, as a result of the Flexion Acquisition. The federal and state NOLs will begin to expire in 2032 and 2028, respectively. The Company had non-U.S. tax NOLs of $<ix:nonFraction unitRef="usd" contextRef="id9b29e19572b4bbaa5c8f9cdba9c2d35_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzM1Mzg_81c4fc5a-573e-43f0-9c38-472368933894">10.3</ix:nonFraction> million at December&#160;31, 2021. The non-U.S. NOLs do not expire.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company had cumulative changes in ownership of more than <ix:nonFraction unitRef="number" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="INF" name="pcrx:MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzM3NjY_6f8bd538-7c5d-4e33-9a19-e24cb7c51b2f">50</ix:nonFraction>% within a three-year period, under IRC sections 382 and 383, the Company&#8217;s ability to use certain net operating losses, tax attributes and credit carryforwards to offset taxable income or tax will be limited. Such ownership changes were triggered by the initial acquisition of the Company&#8217;s stock in 2007 as well as cumulative ownership changes arising as a result of the completion of the Company&#8217;s initial public offering and other financing transactions. Additionally, on November 19, 2021, the Company completed the Flexion Acquisition which also triggered an ownership change. As a result of these ownership changes, the Company estimates $<ix:nonFraction unitRef="usd" contextRef="ia52e5d1054ac4b44a90054d80c6509a1_I20211231" decimals="-5" name="pcrx:NetOperatingLossSubjecttoLimitation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQyODk_2f623f61-291c-454c-8d9b-c4d9bd802b7e">531.7</ix:nonFraction> million of federal net operating losses and $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="pcrx:OtherTaxAttributesSubjectToLimitation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzExNTQ0ODcyMTIwMDg0_1bc3ef47-a8f3-4535-9d95-94a83683d548">21.2</ix:nonFraction>&#160;million of other tax attributes are subject to annual limitations. At December&#160;31, 2021, all of these federal net operating losses and other tax attributes were available. The Company estimates that an additional $<ix:nonFraction unitRef="usd" contextRef="i1cb2b41bd3004482921ace6f9b9f7baa_I20241231" decimals="-5" name="pcrx:ExpectedAdditionalNetOperatingLossesInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ0NjQ_295d3f0d-baf7-4473-822f-275a8936d6f7"><ix:nonFraction unitRef="usd" contextRef="if5bb0c9c97f24e95b1c6936b67f583e4_I20221231" decimals="-5" name="pcrx:ExpectedAdditionalNetOperatingLossesInYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ0NjQ_618f9b60-0033-403a-8e30-7b9791b6e178"><ix:nonFraction unitRef="usd" contextRef="i1346b922bbbc489fa1c57f1775c4d743_I20251231" decimals="-5" name="pcrx:ExpectedAdditionalNetOperatingLossesInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ0NjQ_abde5851-6511-4c74-9f41-3241f5420168"><ix:nonFraction unitRef="usd" contextRef="ifda9345b7dc64e9cbe52d2c5cb3bfc6d_I20231231" decimals="-5" name="pcrx:ExpectedAdditionalNetOperatingLossesInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ0NjQ_d2dd1a11-d29b-4642-bde7-2e53d3af5bd2">35.4</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million will come available in each of 2022 to 2025, $<ix:nonFraction unitRef="usd" contextRef="i9893ef209dd044118e3a2ae603b1bb78_I20261231" decimals="-5" name="pcrx:ExpectedAdditionalNetOperatingLossesInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ1MTM_2e1b5c16-3594-4ada-b52a-49e373fa41d8">30.8</ix:nonFraction> million in 2026 and $<ix:nonFraction unitRef="usd" contextRef="i890f49a134e34776a700270d248f7c7d_I20271231" decimals="-5" name="pcrx:ExpectedAdditionalNetOperatingLossesInYearSix" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ1Mjg_140022ac-ed28-4d21-941c-6c639a34c519"><ix:nonFraction unitRef="usd" contextRef="i890f49a134e34776a700270d248f7c7d_I20271231" decimals="-5" name="pcrx:ExpectedAdditionalNetOperatingLossesInYearAfterYearSix" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ1Mjg_d4c0771d-eac0-4b3f-97a0-40000c6cf1a8">6.9</ix:nonFraction></ix:nonFraction> million in 2027 and thereafter.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 740, the Company establishes a valuation allowance for deferred tax assets that, in its judgment, are not more-likely-than-not realizable. These judgments are based on projections of future income, including tax-planning strategies, by individual tax jurisdictions. In each reporting period, the Company assesses the likelihood that its deferred tax assets will be realized and determines if adjustments to its valuation allowance are appropriate. The Company had a net increase in its valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzUzNzM_50748069-cdbc-448d-8c5b-ea2e53041191">16.5</ix:nonFraction> million and a net reduction in its valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzUzOTU_653afeb4-2ceb-40b5-873a-0306170ddb33">126.6</ix:nonFraction> million for the years ended December&#160;31, 2021 and December 31, 2020, respectively. The current year net increase in The Company&#8217;s valuation allowance includes $<ix:nonFraction unitRef="usd" contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgxNTEy_52802af6-30b2-4682-b409-5700f6367228">12.5</ix:nonFraction>&#160;million as a result of the Flexion Acquisition, $<ix:nonFraction unitRef="usd" contextRef="ic0f2c982cd5b4bb8a9925e4a655e2c4b_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgxNTI3_f7125949-ac19-4167-8016-a5e0811934ff">2.2</ix:nonFraction>&#160;million against U.S. capital loss carryforwards and $<ix:nonFraction unitRef="usd" contextRef="ib3d452fa4ecb406494b3046bb05e2386_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgxNTQx_69421328-d1b7-4b33-856c-345530e1d1c0">1.8</ix:nonFraction>&#160;million against foreign net deferred tax assets. The Company continues to maintain a full valuation allowance against foreign net deferred tax assets since it is more-likely-than-not the tax benefit related to the foreign losses are not realizable. During the year ended December 31, 2020, the Company determined that there was sufficient positive evidence to conclude that it is more likely than not that additional domestic deferred taxes of $<ix:nonFraction unitRef="usd" contextRef="i14837e0e58ba4784b70f1121737d5625_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzU2MzU_fb27fa61-e1c7-4759-a47a-5781a4e33559">126.6</ix:nonFraction>&#160;million are realizable and, therefore, reduced the valuation allowance accordingly.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i5ff3c157ba0f46afb23eb3708d339367"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded a reserve of $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzU5MTY_80cbe41f-1fd1-426e-824e-a633957e7de7">2.9</ix:nonFraction> million related to unrecognized tax benefits, or UTBs of which $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgyMTg1_1f0f8643-739e-4f43-b38c-e8ec9e031352">4.3</ix:nonFraction>&#160;million related to tax credit positions taken during the year, offset by a $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgyMTk5_fd4f17aa-487a-4d69-9505-ae9d58b928df">1.4</ix:nonFraction>&#160;million reduction for prior year tax credit positions. The Company&#8217;s UTB liability at December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzYwNTc_1043a79b-94b3-463c-aed1-347b577509dd">9.0</ix:nonFraction> million. <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcxMDQ_495eb794-f83a-4270-89a1-40b2e29c87af" continuedAt="ic2c56863c6b64b25b741ef14869c850f" escape="true">The change in the Company&#8217;s UTBs for the year ended December&#160;31, 2021 is summarized as follows (in thousands):</ix:nonNumeric></span></div><div><ix:continuation id="ic2c56863c6b64b25b741ef14869c850f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrecognized<br/>Tax Benefit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozNjVhNDQ2MGYzYTQ0NDQ3OWZiOWM1NmI4NzYyODk3MS90YWJsZXJhbmdlOjM2NWE0NDYwZjNhNDQ0NDc5ZmI5YzU2Yjg3NjI4OTcxXzEtMi0xLTEtMA_4382028c-ba54-4a12-9804-4947fb59d177">6,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions for current year positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozNjVhNDQ2MGYzYTQ0NDQ3OWZiOWM1NmI4NzYyODk3MS90YWJsZXJhbmdlOjM2NWE0NDYwZjNhNDQ0NDc5ZmI5YzU2Yjg3NjI4OTcxXzUtMi0xLTEtMA_ab6a9da3-238d-4da9-8594-f7a1da0e5fe2">4,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction for prior year positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozNjVhNDQ2MGYzYTQ0NDQ3OWZiOWM1NmI4NzYyODk3MS90YWJsZXJhbmdlOjM2NWE0NDYwZjNhNDQ0NDc5ZmI5YzU2Yjg3NjI4OTcxXzYtMi0xLTEtNjA3Njg_a9a06d4d-f28f-4b98-bc88-32f44840d443">1,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozNjVhNDQ2MGYzYTQ0NDQ3OWZiOWM1NmI4NzYyODk3MS90YWJsZXJhbmdlOjM2NWE0NDYwZjNhNDQ0NDc5ZmI5YzU2Yjg3NjI4OTcxXzctMi0xLTEtMA_16946294-945d-40f4-befa-0bdd84467a69">9,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses the likelihood of additional tax assessments by jurisdiction and, if necessary, adjusts its reserve for UTBs based on new information or developments. Due to the Company&#8217;s tax credit carryforwards, the reserve was recorded as a reduction of the Company&#8217;s deferred tax assets, and any potential deficiency would not result in a tax liability. Therefore, no interest or penalties were recognized in income tax expense for the years ended December&#160;31, 2021, 2020 and 2019. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently subject to audit by the U.S. Internal Revenue Service, or IRS, for the years 2018 through 2021, and state tax jurisdictions for the years 2017 through 2021. However, the IRS or states may still examine and adjust an NOL arising from a closed year to the extent it is utilized in a year that remains subject to audit. The Company&#8217;s previously filed income tax returns are not presently under audit by the IRS or state tax authorities.</span></div></ix:continuation><div style="margin-bottom:8pt;text-indent:22.5pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_193"></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE2NjI_c1d4ba65-8f22-4cb3-8f4f-49444dffd1f5" continuedAt="ife4433ceff484f249f3ccdb55b8acc43" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="ife4433ceff484f249f3ccdb55b8acc43" continuedAt="i03059543549648ef8b7e79af2eda582a"><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">401(k) Plan</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 401(k) plan is a deferred salary arrangement under section 401(k) of the IRC. Under the 401(k) plan, participating U.S. employees may defer a portion of their pre-tax earnings which are eligible for a discretionary percentage match as defined in the 401(k) plan and determined by the Company&#8217;s board of directors (up to the maximum amount permitted by the IRC). The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzQ0Nw_6c7df40f-5e86-480d-a38a-d6e95040fa09">2.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzQ1MQ_92270ff8-ebe0-4fc6-abf4-4db2efdded40">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzQ1OA_c298bc1c-2fd0-4a38-b2af-5f9f7204bac2">2.6</ix:nonFraction> million of related compensation expense for its 401(k) discretionary match for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Compensation Plan</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company&#8217;s board of directors adopted the Company&#8217;s Deferred Compensation Plan, or DCP. The Company intends that the DCP constitute, and be construed and administered as, an unfunded plan of deferred compensation within the meaning of the Employee Retirement Income Security Act of 1974, as amended, and the IRC of 1986, as amended, under which eligible participants may elect to defer the receipt of current compensation. Eligible participants include select management and highly compensated employees of the Company, including the Company&#8217;s named executive officers. Pursuant to the DCP, subject to any minimum and maximum deferral requirements that the administrator of the DCP may establish, participants may elect to defer their base salary and annual incentive awards. In addition to elective deferrals, the DCP permits the Company to make matching and certain other discretionary contributions to the participants. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE1Njk_b24b634b-d4e8-4c3a-b7e1-8af8f60ee3d3"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE1Njk_d4acbca6-f98e-43d9-9347-4b2bdb7adcbc">0.2</ix:nonFraction></ix:nonFraction>&#160;million of related compensation expense for its DCP discretionary match for each of the years ended December&#160;31, 2021 and 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Long-Term Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company&#8217;s board of directors adopted a cash long-term incentive plan, or LTIP, commencing in 2021, focused on pre-determined, objective performance goals. The LTIP provides cash awards to participants based on the achievement of certain performance goals during each applicable performance period from January 1 through December 31 of each calendar year. Award amounts ranging from <ix:nonFraction unitRef="number" contextRef="i42a9830d9b244758b1ed6841c20a7f8a_D20210101-20211231" decimals="2" name="pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE2NDkyNjc0NDYwOTY_151a1681-27a3-4470-8828-dc182c33b8d9">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i74f568606f0c4823a905f91cf481d300_D20210101-20211231" decimals="2" name="pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE2NDkyNjc0NDYxMDA_733c2d67-c4f4-4f91-87af-0e93c19dd050">225</ix:nonFraction>% of the target cash award are earned based on achievement of two equally weighted financial metrics: net revenue and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), with a relative total shareholder return modifier based on the Company&#8217;s stock price performance relative to the companies comprising the S&amp;P Pharmaceuticals Select Industry Index. The performance period for these metrics is <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzM4NDgyOTA3MDQ2NzA_f3dbfd46-79c8-49bd-a77a-bce714211527">one year</ix:nonNumeric>, with an additional <ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzM4NDgyOTA3MDQ2Njk_c5aabe31-bd2f-49fd-9b30-acd80c8e5158">three years</ix:nonNumeric> of time-vesting following the performance period. The first performance period began on January </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i03059543549648ef8b7e79af2eda582a">1, 2021, and for the year ended December&#160;31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-5" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE2NDkyNjc0NDU3MDg_437aa854-747a-4204-8938-2002ec341f7f">1.1</ix:nonFraction>&#160;million of related compensation expense under the LTIP, which is payable to participants in January 2025 after the three-year vesting period concludes.</ix:continuation></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_196"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 18&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzI1NTI_aa0988a5-49ff-4946-b407-b98264777f02" continuedAt="i46ae4c2415bb4ae292bcbe3ff2b611b5" escape="true">ACQUISITION&#8211;RELATED CHARGES, PRODUCT DISCONTINUATION AND OTHER</ix:nonNumeric></span></div><ix:continuation id="i46ae4c2415bb4ae292bcbe3ff2b611b5" continuedAt="ifee8a95cf6fe4954aeecf969d46f3a6e"><ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzM4NDgyOTA3MTc5NDI_a048b8d4-1a77-4570-a6a1-77fbb5f2c025" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related charges, product discontinuation and other for the years ended December&#160;31, 2021, 2020 and 2019 are summarized below (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance-related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzItMS0xLTEtNjU2NjU_784fc264-3a09-4dad-a918-ba311e923231">26,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzItMy0xLTEtNjU2NjU_a4636b6e-743c-46dd-a1a8-039fc365fcef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzItNS0xLTEtNjU2NjU_30446c84-15ae-45cd-9978-347a7d2e78ad">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133d2578be2a4e5082559c610543604b_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzMtMS0xLTEtNjU2NjU_d5f2f8fb-28c3-488e-bf34-bfad44b330a0">10,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe2ba44a6d94addb0eb76d116d51d55_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzMtMy0xLTEtNjU2NjU_167cce43-24b7-4030-a6fd-01266549b539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i572235a599364bd3ade9416211dca6cd_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzMtNS0xLTEtNjU2NjU_e64bb37f-12d4-4658-a5cf-d31cbb76affd">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other acquisition expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2886444d644925b435f39f13c30af4_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzQtMS0xLTEtNjU2NjU_d471854c-4d84-4413-84cb-02a2cd365e84">3,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308c4a2c1d0642d5a4d9505955982379_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzQtMy0xLTEtNjU2NjU_0d81e819-8706-4a5b-aaf1-5266a5cbc40a">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c466ffc9152473caa0acde1e894a6ef_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzQtNS0xLTEtNjU2NjU_b79f6356-2324-4d93-81f9-81feedbe393f">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition-related charges</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="pcrx:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzUtMS0xLTEtNjU2NjU_33de8d30-97be-452d-ae3d-0a612bbbeeec">40,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="pcrx:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzUtMy0xLTEtNjU2NjU_e5ded562-d9ee-4c24-b8ef-e1aee6ac2e9a">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="pcrx:BusinessCombinationAcquisitionAndIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzUtNS0xLTEtNjU2NjU_98a6d3bd-7856-40c3-9270-e8a59b4a2023">4,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzYtMS0xLTEtNjU2NjU_65ecbab9-cc26-44bd-a944-8705c39648c6">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzYtMy0xLTEtNjU2NjU_cba4016c-5e1d-4e49-be47-c543bafefadf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce4e7bdc7aa4d8ab4e06a6aa84c37ad_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzYtNS0xLTEtNjU2NjU_c67489a9-4bd9-4f9f-8f22-a53e7da890a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyoScience contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzctMS0xLTEtNjU2NjU_6c516c4b-7ff4-4408-adb8-8ae23fa68ae7">2,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzctMy0xLTEtNjU2NjU_d161b7cb-d065-47d2-942c-09bd166b828c">5,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzctNS0xLTEtNjU2NjU_bcb47172-d826-4b83-a1e6-0f50e441c6fa">16,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination of Nuance agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3233de79e7a2425eb18155c86074f1e9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnContractTermination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzgtMS0xLTEtNjU2NjU_5ee8008a-6d67-4b81-9c07-970f73c45685">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3578ef27098d49db9276c9f493f654da_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnContractTermination" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzgtMy0xLTEtNjU2NjU_776285af-ead9-4244-bc42-56425d0982f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9541d5a561504d64b4e108f280a3faa5_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnContractTermination" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzgtNS0xLTEtNjU2NjU_aec30112-873f-4909-91c8-9bc4284b01d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinuation of DepoCyt(e)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8de97bb7b224ffbaf4d4572322a126e_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnContractTermination" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzktMS0xLTEtNjU2NjU_d633167f-64ba-41d5-988b-fb8751095eb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia33a2f9e6ae84d97990e9334c7002dac_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnContractTermination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzktMy0xLTEtNjU2NjU_9fed1a46-ab9d-4699-9704-b1b30b31b586">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ae7b32599b43238324567b6549cb9b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnContractTermination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzktNS0xLTEtNjU2NjU_a527d81f-0820-4880-addc-21e07f98e50b">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Department of Justice settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzEwLTEtMS0xLTY1NjY1_ac6bba07-eb5f-44e5-a52f-381b296d8d8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzEwLTMtMS0xLTY1NjY1_07f24cc5-a608-4d8d-9607-1a7d2d865f17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzEwLTUtMS0xLTY1NjY1_191cb866-6bda-4907-8b74-35fa8666d5d2">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition-related charges, product discontinuation and other</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231" decimals="-3" name="pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzExLTEtMS0xLTY1NjY1_fac6b30f-9571-4181-a26a-616f9a217a9e">42,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231" decimals="-3" name="pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzExLTMtMS0xLTY1NjY1_d31b1a56-dca1-4ec9-bc35-9603067c9f42">5,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231" decimals="-3" name="pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzExLTUtMS0xLTY1NjY1_323aca70-c8b0-48f1-849d-c8b7004d4b96">25,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flexion Acquisition</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized acquisition-related costs of $<ix:nonFraction unitRef="usd" contextRef="i130fb5352c624061a38b0f4e0e96ed76_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMDk4ODky_3c4f332f-3c32-4513-b2b8-d080f53524aa">40.2</ix:nonFraction>&#160;million, primarily</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> severance, legal fees, third-party services and other one-time charges</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the year ended December 31,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2021 related to the Flexion Acquisition.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, as part of the purchase price consideration related to the Flexion Acquisition, the Company recorded a contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i79da6badc4ce4c8b87bad102f47d53f7_D20211119-20211119" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDI5MDYx_87150661-aaaf-4fd7-9647-da51e438f936">45.2</ix:nonFraction>&#160;million, which represents the Company&#8217;s achievement of meeting regulatory and sales-based milestones. From the date of the acquisition through December&#160;31, 2021, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="ifd6c594f1a8d4d8198e32bc0c6d23237_D20211119-20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDI5MDg5_bc2ff866-dddc-425a-8c88-a7d66fe78a7e">1.2</ix:nonFraction>&#160;million charge due to an estimated $<ix:nonFraction unitRef="usdPerShare" contextRef="i2d56f0f495b24f6292ed813d0fcfc838_I20211119" decimals="2" name="pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDI5MTA5_92d55d0f-4632-45de-905a-d3c96f30abc7">0.02</ix:nonFraction> per CVR increase to the fair value of contingent consideration, which was included in acquisition-related charges in the consolidated statements of operations. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Flexion Acquisition, the Company initiated a restructuring through a headcount reduction in the sales and administrative functions. </span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MyoScience Acquisition</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized acquisition-related and other charges of $<ix:nonFraction unitRef="usd" contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEyMzgx_c4e3de8d-0034-494e-8990-7dbff8ac93a4">0.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzYyNQ_540e2749-408f-44cc-abf4-116010276065">0.2</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction unitRef="usd" contextRef="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzMDk4_525f90cc-c2e2-4fcf-bfc0-da82af08dcb3">4.9</ix:nonFraction>&#160;million during the years ended December 31, 2021, 2020 and 2019, respectively, related to the MyoScience Acquisition. The 2021 charges relate to one-time termination benefits in the event of a facility closure. For more information see Note 21, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2020 charges relate to acquisition-related accounting services. The 2019 charges include $<ix:nonFraction unitRef="usd" contextRef="i866ca805578348a1a7b549671e9b226d_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzMDgz_93ee9516-2526-4262-8b88-39ea609427cf">4.2</ix:nonFraction> million for advisory costs, including legal, financial, accounting and tax services and $<ix:nonFraction unitRef="usd" contextRef="i9c5f7765b4224a9a8bd7a15b9a2f9b85_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzkyNQ_7bd77987-3de9-429d-ad56-df623cc6eef4">0.7</ix:nonFraction> million for separation costs, asset write-downs and other restructuring charges. In addition, the Company recognized a contingent consideration credit of $<ix:nonFraction unitRef="usd" contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzNTc5_edd1c870-a71a-492f-984a-a90458a812fc">2.2</ix:nonFraction>&#160;million in 2021 and contingent consideration charges of $<ix:nonFraction unitRef="usd" contextRef="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzODUz_5c52d502-4063-4416-bc1e-186ea959394a">5.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzODY3_e60b2334-270b-4963-84fd-e2c7eb7fccc8">16.7</ix:nonFraction>&#160;million in 2020 and 2019, respectively. See Note 12, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the MyoScience Acquisition, the Company initiated a restructuring through a headcount reduction in the sales and administrative functions. In addition, the Company terminated a number of existing distributor agreements that were maintained by MyoScience.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ifee8a95cf6fe4954aeecf969d46f3a6e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nuance Biotech Co. Ltd.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered an agreement with Nuance Biotech Co. Ltd., or Nuance, a China-based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL in China. Under the terms of the agreement, the Company had granted Nuance the exclusive rights to develop and commercialize EXPAREL. In April 2021, the Company and Nuance agreed to a mutual termination of the agreement due to the lack of a viable regulatory pathway that adequately safeguards the Company&#8217;s intellectual property against the risk of a generic product. Dissolution costs of $<ix:nonFraction unitRef="usd" contextRef="id747d21ec2fe432ca5314f7a469d8620_D20210101-20211231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTA2NTcw_cfdc1818-e2d9-46b2-9e6d-fcc92ff51a6f">3.0</ix:nonFraction>&#160;million were included in acquisition-related charges, product discontinuation and other in the consolidated statements of operations during the year ended December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DepoCyt(e) Discontinuation</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company received formal notice of the termination of a Supply Agreement and a Distribution Agreement (and all related agreements as subsequently amended) from Mundipharma International Corporation Limited and Mundipharma Medical Company, respectively (collectively, &#8220;Mundipharma&#8221;). In November 2019, the Company reached a settlement with Mundipharma and made a $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDY2OTk_08e6fda9-c6b7-4680-a54b-496b38c9d664">5.3</ix:nonFraction> million payment related to the DepoCyt(e) discontinuation which had previously been accrued.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231" decimals="-5" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE0NjA_f2f48f3f-31cc-4bc1-b1f7-20f9b0487e04">0.2</ix:nonFraction> million during the year ended December 31, 2020, and a charge of $<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-5" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE1MTk_18ee0ac6-fb7a-474b-9701-41cf8ce4b34b">0.2</ix:nonFraction> million in the year ended December 31, 2019, respectively, related to the discontinuation of its DepoCyt(e) manufacturing activities in June 2017 due to persistent technical issues specific to the DepoCyt(e) manufacturing process. <ix:nonFraction unitRef="usd" contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" decimals="-5" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDU2NjY_9583e615-0c5f-4ce1-b34c-d9e59e5f3407">No</ix:nonFraction> costs related to the Company&#8217;s DepoCyt(e) discontinuation were recognized in the year ended December&#160;31, 2021 as the lease of the idle DepoCyt(e) manufacturing facility expired in August 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Inquiry Settlement</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEyMzQy_cc09eff2-e955-4835-9ed3-e318d36f0c20">3.5</ix:nonFraction>&#160;million for the settlement of a U.S. Department of Justice inquiry. Refer to Note 21, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further information surrounding our legal proceedings.</span></div></ix:continuation><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_199"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 19&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="pcrx:CommercialPartnersAndAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzQ2MjQ_9a268541-1ef8-4bf5-8308-27087db8abe1" continuedAt="idc66b6ec58534bd5b26e2d2076a845f4" escape="true">COMMERCIAL PARTNERS AND OTHER AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="idc66b6ec58534bd5b26e2d2076a845f4" continuedAt="ie760b43249dd45f4af11a2091668648d"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Thermo Fisher Scientific Pharma Services</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2014, the Company and Thermo Fisher entered into a Strategic Co-Production Agreement, a Technical Transfer and Service Agreement (the &#8220;EXPAREL Technical Transfer and Service Agreement&#8221;) and a Manufacturing and Supply Agreement to collaborate in the manufacture of EXPAREL. Under the terms of the EXPAREL Technical Transfer and Service Agreement, Thermo Fisher agreed to undertake certain technical transfer activities and construction services needed to prepare its Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. The Company contracted to purchase EXPAREL from Thermo Fisher, beginning with FDA approval of the first suite, which occurred in May 2018. Commercial production began in February 2019. Under these agreements, the Company makes monthly base fee payments to Thermo Fisher. Unless earlier terminated by giving notice of up to three years (other than termination by the Company in the event of a material breach by Thermo Fisher), this agreement will expire in May 2028.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in July 2015, Flexion and Thermo Fisher entered into a Manufacturing and Supply Agreement (the &#8220;ZILRETTA Manufacturing and Supply Agreement&#8221;) and a Technical Transfer and Service Agreement related to the manufacture of ZILRETTA at the same Thermo Fisher site in Swindon, England where the Company&#8217;s EXPAREL suites are located. Thermo Fisher agreed to undertake certain transfer activities and construction services needed to prepare its facility for the commercial manufacture of ZILRETTA in dedicated manufacturing suites. Flexion provided Thermo Fisher with certain equipment and materials necessary to manufacture ZILRETTA. The Company makes monthly payments to Thermo Fisher for such activities and reimburses Thermo Fisher for certain material, equipment and miscellaneous expenses and additional services.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the ZILRETTA Manufacturing and Supply Agreement that the Company assumed as part of the Flexion Acquisition expires in October 2027. The Company pays a monthly base fee to Thermo Fisher for the operation of the manufacturing suites and a per product fee for each vial of ZILRETTA based upon a forecast of commercial demand. The Company also reimburses Thermo Fisher for purchases of materials and equipment made on its behalf, certain nominal expenses and additional services. The ZILRETTA Manufacturing and Supply Agreement will remain in full effect unless and </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ie760b43249dd45f4af11a2091668648d" continuedAt="ib7e9f05f15494af4b2d6354b853de6fb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until it expires or is terminated. Upon termination of the ZILRETTA Manufacturing and Supply Agreement (other than termination by the Company in the event that Thermo Fisher does not meet the construction and manufacturing milestones or for a breach by Thermo Fisher), the Company will be obligated to pay for the costs incurred by Thermo Fisher associated with the removal of its manufacturing equipment and for Thermo Fisher&#8217;s termination costs up to a specified capped amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eurofarma Laboratories S.A.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a distribution agreement with Eurofarma Laboratories S.A., or Eurofarma, for the development and commercialization of EXPAREL in Latin America. Under the terms of the agreement, Eurofarma obtained the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia and Mexico. In addition, Eurofarma is responsible for regulatory filings for EXPAREL in these countries. The Company received a $<ix:nonFraction unitRef="usd" contextRef="i0dbbded270634aa69782055b700085d7_D20210601-20210630" decimals="-5" name="pcrx:CollaborativeArrangementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzExNTQ0ODcyMTI1MzY0_638e4fcb-1f8e-4834-b2d9-c9870d72d281">0.3</ix:nonFraction>&#160;million upfront payment that is partially refundable upon certain circumstances and will receive royalties based on Eurofarma&#8217;s future commercialization of the product and is also eligible to receive milestone payments that are triggered by the achievement of certain regulatory and commercial events. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="id5b01a051b66415ba958a05fbf10d319_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzExNTQ0ODcyMTI1Njg1_df6fdab5-e837-4ca2-b14d-1967c83c9364">0.1</ix:nonFraction>&#160;million of collaborative licensing and milestone revenue in its consolidated statements of operations during the year ended December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Verve Medical Products, Inc.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a licensing agreement with Verve Medical Products, Inc. for the distribution of iovera&#176; in Canada. The Company began selling iovera&#176; in Canada in the fourth quarter of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DePuy Synthes Sales, Inc.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company announced a Co-Promotion Agreement with DePuy Synthes Sales, Inc., or DePuy Synthes, part of the Johnson &amp; Johnson family of companies, to market and promote the use of EXPAREL for orthopedic procedures in the U.S. DePuy Synthes field representatives, specializing in joint reconstruction, spine, sports medicine, trauma and cranio-maxillofacial (CMF) procedures, collaborated with and supplemented the Company&#8217;s field teams by expanding the reach and frequency of EXPAREL education in the hospital surgical suite and ambulatory surgery center settings.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company notified DePuy Synthes that the Co-Promotion Agreement would terminate on January 2, 2021. The Company recorded termination-related costs of $<ix:nonFraction unitRef="usd" contextRef="i1fe450ec25c44c338992024884646e70_D20210101-20211231" decimals="-5" name="pcrx:PaymentOfEarlyTerminationFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzE4NTY_a8eaf430-9ad5-41e6-8312-8f8c4373b60c">8.8</ix:nonFraction>&#160;million which were recorded in selling, general and administrative expense during the year ended December 31, 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aratana Therapeutics,&#160;Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2012, the Company entered into a worldwide license, development and commercialization agreement with Aratana Therapeutics,&#160;Inc., a wholly owned subsidiary of Elanco Animal Health, Inc., or Aratana. Under the agreement, the Company granted Aratana an exclusive royalty-bearing license, including the limited right to grant sublicenses, for the development and commercialization of the Company&#8217;s bupivacaine liposome injectable suspension product for veterinary use. Under the agreement, Aratana developed and obtained FDA approval for the use of the product in veterinary surgery to manage postsurgical pain. The Company is eligible to receive from Aratana up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i0cda3779624d47cca8d9a4fd84dbdcdc_I20121205" decimals="-5" name="pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzI2OTE_448f10c9-df02-425e-b7f3-834a42d48608">40.0</ix:nonFraction> million upon the achievement of commercial milestones. Aratana is required to pay the Company a tiered double-digit royalty on certain net sales made in the U.S. If the product is approved by foreign regulatory agencies for sale outside of the U.S., Aratana will be required to pay the Company a tiered double-digit royalty on such net sales. Royalty rates will be reduced by a certain percentage upon the entry of a generic competitor for animal health indications into certain jurisdictions or if Aratana must pay royalties to third parties under certain circumstances. Unless terminated earlier pursuant to its terms, the license agreement is effective until July 2033, after which Aratana has the option to extend the agreement for an additional <ix:nonNumeric contextRef="i45f29cdfecdd48d8b8c24cf61151d641_D20210101-20211231" name="pcrx:CollaborativeArrangementOptionToExtendTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzQ2MjU_2f0d33a6-f1b9-48cb-8a3f-2026da28927a">five-year</ix:nonNumeric> term, subject to certain requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aratana began purchasing bupivacaine liposome injectable suspension product in 2016, which they market under the trade name NOCITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a registered trademark of Aratana) for veterinary use.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="ib7e9f05f15494af4b2d6354b853de6fb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hong Kong Pharma Tainuo Ltd.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in March 2020, Flexion entered into an exclusive license agreement with Hong Kong Tainuo Pharma Ltd., or HK Tainuo, and Jiangsu Tainuo Pharmaceutical Co. Ltd., or Jiangsu Tainuo, a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd., for the development and commercialization of ZILRETTA in Greater China (consisting of mainland China, Hong Kong, Macau and Taiwan). Under the terms of the agreement, HK Tainuo paid Flexion an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib670284875d746c498df6bb492cd4f90_D20210101-20211231" decimals="-5" name="pcrx:CollaborativeArrangementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzE0MjkzNjUxMTg2Njgw_63860214-0634-4c6a-bbc5-2c2e9adabf9a">10.0</ix:nonFraction>&#160;million during the year ended December 31, 2020 which was recorded as deferred revenue as of December 31, 2021. The Company is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="id496bf8b482742cfbd9725d700e95fab_I20211231" decimals="-5" name="pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzE0MjkzNjUxMTg2Njk1_da554c29-d00b-4a43-a167-2c3db8570304">32.5</ix:nonFraction>&#160;million in aggregate development, regulatory and commercial sales milestone payments. HK Tainuo is responsible for the clinical development, product registration and commercialization of ZILRETTA in Greater China. The Company is solely responsible for the manufacture and supply of ZILRETTA to HK Tainuo for all clinical and commercial activities. The terms related to product manufacturing and supply, including pricing and minimum purchase requirements agreed to in the license agreement, will be covered by a separate supply agreement, which has not yet been finalized. Unless terminated earlier in accordance with its terms, the license agreement continues in effect in perpetuity or as long as HK Tainuo or Jiangsu Tainuo continue to sell ZILRETTA in Greater China. The proceeds associated with the upfront payment have been recorded in long-term deferred revenue on the consolidated balance sheet, as there is uncertainty around the timing of when the revenue will be recognized.</span></div></ix:continuation><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_202"></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 20&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzU2MQ_1b1f5dac-6261-4bcb-977d-9bccb3c0bae7" continuedAt="i735887a10db548b189b153452553edb6" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i735887a10db548b189b153452553edb6">In April 2012, the Company entered into a consulting agreement with Dr. Gary Pace, a director of the Company. In connection with the consulting agreement, Dr. Pace received an option to purchase <ix:nonFraction unitRef="shares" contextRef="i9733ef5993044559a5405d6f38d59438_D20120401-20120430" decimals="INF" name="pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzIzNQ_169e3a18-ad0c-4546-89e4-096d20895fb6">20,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9733ef5993044559a5405d6f38d59438_D20120401-20120430" decimals="INF" name="pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzI4NQ_7bb1077e-58c7-4653-a8fb-f865935b5556">11.02</ix:nonFraction> per share and an option to purchase <ix:nonFraction unitRef="shares" contextRef="id5828f75d0ba48dbb5d995070ffaf73a_D20120401-20120430" decimals="INF" name="pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzMyNA_e2827088-5024-4b13-8ab8-a7db07d90a3d">70,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id5828f75d0ba48dbb5d995070ffaf73a_D20120401-20120430" decimals="INF" name="pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzM3NA_a12317e1-231a-4ef4-a39e-7015add500d6">16.67</ix:nonFraction> per share, the latter of which were fully exercised in 2020. No services were provided under the consulting agreement in the years ended December&#160;31, 2021, 2020, or 2019, and as of December&#160;31, 2021 and 2020, there was nothing payable to Dr. Pace for consulting services.</ix:continuation></span></div><div><span><br/></span></div><div id="i284a0cec603b490382d0f8422359e7e8_205"></div><div style="margin-bottom:5pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 21&#8212;<ix:nonNumeric contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzU4OTk_d2ebdac5-50bc-48e2-b996-7c2e875f2a74" continuedAt="iadc42b4c100643deadce012688afc2ad" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="iadc42b4c100643deadce012688afc2ad" continuedAt="i9dbda53a02be4cdbacd261b0b10a0376"><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to patents, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings that it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MyoScience Milestone Litigation</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company and its subsidiary, Pacira CryoTech, Inc. (&#8220;Pacira CryoTech&#8221;), filed a lawsuit in the Court of Chancery of the State of Delaware against Fortis Advisors LLC (&#8220;Fortis&#8221;), solely in its capacity as representative for the former securityholders of MyoScience, and certain other defendants, seeking declaratory judgment with respect to certain terms of the merger agreement for the MyoScience Acquisition (the &#8220;Merger Agreement&#8221;), specifically related to the achievement of certain milestone payments under the Merger Agreement. In addition, the Company and Pacira CryoTech sought general, special and compensatory damages against the other defendants related to breach of fiduciary duties in connection with the purported achievement of milestone payments under the Merger Agreement, and breach of the Merger Agreement and certain other agreements with the defendants. In October 2020, Fortis filed an answer and counterclaim against the Company and Pacira CryoTech seeking to recover certain milestone payments under the Merger Agreement. The total remaining value of these milestones is $<ix:nonFraction unitRef="usd" contextRef="iba035b436915468c957402bf102c1460_D20201001-20201031" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzE3Mzc_3d16a164-9db9-443a-bfb8-6d38e1d41db2">30.0</ix:nonFraction>&#160;million, plus attorneys&#8217; fees. The Company believes that the counterclaim from Fortis is without merit and intends to vigorously defend against all claims. The Company is unable to predict the outcome of this action at this time.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">eVenus Pharmaceutical Laboratories Litigations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company received a Notice Letter advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,033,495 (the &#8217;495 patent).</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i9dbda53a02be4cdbacd261b0b10a0376" continuedAt="i0792806b32654229a8957544a5f982ea"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company filed a patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (21-cv-19829) asserting infringement of the &#8217;495 patent. This triggered an automatic 30-month stay of final approval of the eVenus ANDA. On January 6, 2022, eVenus filed an Answer with counterclaims to the Complaint, alleging the &#8217;495 patent is invalid and/or not infringed through the manufacture, sale, or offer for sale of the product described in product described in eVenus&#8217;s ANDA submission.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received a second Notice Letter advising that eVenus submitted to the FDA an amendment to its ANDA with a Paragraph IV Certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (133 mg/10 mL) in the U.S. prior to the expiration of the &#8217;495 patent. In the Notice Letter, eVenus also advised that it submitted a Paragraph IV Certification to the FDA seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL and 133 mg/10 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,179,336 (the &#8217;336 patent). eVenus further alleges in the Notice Letter that both the &#8217;495 patent and the &#8217;366 patent are invalid and/or not infringed.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company filed a second patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (22-cv-00718) asserting that the 133 mg/10 mL ANDA product will infringe the &#8217;495 and &#8217;336 patents and that the 266 mg/20 mL ANDA product will infringe the &#8217;336 patent. This filing triggered a second automatic 30-month stay of final approval for the 133 mg/10 mL ANDA product.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These litigations are in their infancy, and the Company is unable to predict the outcome of this action at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Development Foundation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an agreement with the Research Development Foundation, or RDF, the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products, for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company&#8217;s U.S. Patent No. 11,033,495 issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company&#8217;s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement was set to end on December 24, 2021 with the expiration of its U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit seeks a declaration from the court that the Company owes no royalties to RDF with respect to its EXPAREL product after December 24, 2021. During the pendency of the lawsuit, the Company will continue to pay royalties to RDF under protest, however, the Company is unable to predict the outcome of this action at this time.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Inquiry Settlement</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2015, the Company received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of New Jersey pertaining to marketing and promotional practices related to EXPAREL. In July 2020, the Company formally entered into settlement agreements that resolved all outstanding investigations and claims by the United States Department of Justice, the United States Department of Health and Human Services, various States Attorneys&#8217; General and a private plaintiff. This agreement concluded a <ix:nonNumeric contextRef="i7b894792258e44c8853a730b680cff6c_D20190101-20190331" name="pcrx:LitigationInvestigationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzU4OTc_4b7f680e-73c2-47e9-ac8d-1fd2ac678715">five-year</ix:nonNumeric> investigation related to the sale and marketing of EXPAREL. Under the various settlement agreements, the Company paid a global settlement of $<ix:nonFraction unitRef="usd" contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzI2NzY_31c71c7e-f531-4dfe-b9db-cb0068d99151">3.5</ix:nonFraction>&#160;million, which was recorded in acquisition-related charges, product discontinuation and other in the consolidated financial statements for the year ended December 31, 2019. The Company expressly denies all allegations and contentions and has admitted no wrongdoing in connection with the settlement agreements. The Company has been given assurances that this concluded the investigation that originated from the U.S. Department of Justice subpoena in April 2015.</span></div><div><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Obligations</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately $<ix:nonFraction unitRef="usd" contextRef="ib97087953997481c9eb9531b2899f6a0_I20211231" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzMxODY_1e79b6fa-0ab6-4463-93b8-757005d3b481">50.3</ix:nonFraction> million of minimum, non-cancelable contractual commitments for contract manufacturing services and $<ix:nonFraction unitRef="usd" contextRef="ia919a337f89e4501a657825c42e3742f_I20211231" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzMyODA_97fd1254-4398-456e-b264-8b821edc034c">9.2</ix:nonFraction> million of minimum, non-cancelable contractual commitments for the purchase of certain raw materials as of&#160;December&#160;31, 2021.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i284a0cec603b490382d0f8422359e7e8_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PACIRA BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><ix:continuation id="i0792806b32654229a8957544a5f982ea"><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Trial Commitments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL in pediatric patients, as well as the administration of EXPAREL as a nerve block in the pediatric setting. The Company was granted a deferral for the required pediatric trials until after the indications were approved in adults. Similarly, in Europe, the Company agreed with the European Medicines Agency, or EMA, on a Pediatric Investigation Plan as a prerequisite for submitting a Marketing Authorization Application (MAA) in the E.U. Despite the U.K.&#8217;s withdrawal from the E.U., the agreed pediatric plan is applicable in the U.K.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company announced positive results for its extended pharmacokinetic and safety study (&#8220;PLAY&#8221;) for local analgesia in children aged six to 17 undergoing cardiovascular or spine surgeries. Those positive results were the basis for the submission of a supplemental New Drug Application, or sNDA, in the U.S. and Type II variations in the E.U. and U.K. to expand the EXPAREL label to include use in patients six years of age and older for single-dose infiltration to produce postsurgical local analgesia. In March 2021, the Company announced that the FDA approved the submission of the sNDA in the U.S. The EMA and the Medicines and Healthcare Products Regulatory Agency, or MHRA, are still reviewing the Type II variations.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is working with the FDA, MAA and MHRA to finalize the regulatory pathway for its remaining pediatric commitments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Milestone Payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information on potential contingent milestone payments related to the MyoScience and Flexion acquisitions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCRX-201 and PCRX-301 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PCRX-201 (formerly FX-201) and PCRX-301 (formerly FX-301) were added to the Company&#8217;s portfolio as part of the Flexion Acquisition. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in February 2017, Flexion entered into an agreement with GeneQuine to acquire the global rights to PCRX-201, a gene therapy product candidate. As part of the agreement, up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ib6b28091853f41199ae71d31aea5bf87_I20170228" decimals="-5" name="pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzExNTQ0ODcyMTQ1MDEw_df217975-8cea-4a97-9651-484ada6fa1bf">56.0</ix:nonFraction>&#160;million of payments could become due upon the achievement of certain development and regulatory milestones.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in September 2019, Flexion entered into a definitive agreement with Xenon Pharmaceuticals, Inc. to acquire the global rights to PCRX-301, a locally administered Na</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 inhibitor. As part of the agreement, up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ia16d04ef54124f998b23dcd9e5efc8ce_I20190930" decimals="-5" name="pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzExNTQ0ODcyMTQ1MDI1_6cf43382-5be9-4eaf-a088-6df73a7c3bfa">45.8</ix:nonFraction>&#160;million of payments could become due upon the achievement of certain development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i3a74aaba5c5b4ccaa7925c2b5333a951_I20190930" decimals="-5" name="pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzExNTQ0ODcyMTQ1MDQw_eb237727-a2f1-4339-aea5-6ec52c1e6a03">75.0</ix:nonFraction>&#160;million of payments could become due for sales-related milestones.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One-Time Termination Benefits</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has communicated to a select number of employees a commitment to provide one-time termination benefits in the event that a facility closure occurs. The Company is recognizing these expenses ratably over the remaining service period required. The Company currently estimates the total cost of these one-time benefits to be approximately $<ix:nonFraction unitRef="usd" contextRef="i2728c786372940b3a47b33099bff7244_I20211231" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzE2NDkyNjc0NTY0MzI_b5a8f2bb-abaa-4570-945f-2ef8f617d2d5">1.1</ix:nonFraction>&#160;million. During the year ended December 31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i12b7f38fb2f94964a96e1740885b526e_D20210101-20211231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzE2NDkyNjc0NTY1NDk_7ef9b8ee-5b48-4c99-93ef-c19708596d6e">0.7</ix:nonFraction>&#160;million in one-time termination charges, which are included in acquisition-related (gains) charges, product discontinuation and other in the consolidated statements of operations.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc.  |  2021 Form 10-K  |  Page F-48</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>pcrx-12312021xex44.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iab6c0e53b1c64d81bd1664dbe897a59e_33"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.4</font></div></div><div style="text-align:right"><font><br></font></div><div id="iab6c0e53b1c64d81bd1664dbe897a59e_57"></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXECUTION VERSION </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AND </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WELLS FARGO BANK, NATIONAL ASSOCIATION, </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as Trustee </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INDENTURE </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated as of May 2, 2017 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible Senior Notes due 2024</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </font></div><div style="padding-left:0.47pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">AGE</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EFINITIONS</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definitions</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">References to Interest</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">SSUE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ESCRIPTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">XECUTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EGISTRATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">XCHANGE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OTES</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designation and Amount</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Form of Notes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Date and Denomination of Notes&#59; Payments of Interest and Defaulted Amounts</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Execution, Authentication and Delivery of Notes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exchange and Registration of Transfer of Notes&#59; Restrictions on Transfer&#59; Depositary</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mutilated, Destroyed, Lost or Stolen Notes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Temporary Notes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.08. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cancellation of Notes Paid, Converted, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.09. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">CUSIP Numbers</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Additional Notes&#59; Repurchases</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ATISFACTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ISCHARGE</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satisfaction and Discharge</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ARTICULAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OVENANTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OMPANY</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Payment of Principal and Interest</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Maintenance of Office or Agency</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Appointments to Fill Vacancies in Trustee&#8217;s Office</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Provisions as to Paying Agent</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Existence</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rule 144A Information Requirement and Annual Reports</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Stay, Extension and Usury Laws</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.08. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Compliance Certificate&#59; Statements as to Defaults</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.09. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Further Instruments and Acts</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:95.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 5</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ISTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OLDERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EPORTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">RUSTEE</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 5.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lists of Holders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 5.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Preservation and Disclosure of Lists</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 6</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EFAULTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EMEDIES</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Events of Default</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Acceleration&#59; Rescission and Annulment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Additional Interest</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Payments of Notes on Default&#59; Suit Therefor</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Application of Monies Collected by Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Proceedings by Holders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Proceedings by Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.08. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Remedies Cumulative and Continuing</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.09. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Direction of Proceedings and Waiver of Defaults by Majority of Holders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notice of Defaults</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Undertaking to Pay Costs</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 7</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONCERNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">RUSTEE</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Duties and Responsibilities of Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reliance on Documents, Opinions, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">No Responsibility for Recitals, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trustee, Paying Agents, Conversion Agents, Bid Solicitation Agent or Note Registrar May Own Notes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Monies and Shares of Common Stock to Be Held in Trust</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Compensation and Expenses of Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Officer&#8217;s Certificate and Opinion of Counsel as Evidence</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.08. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eligibility of Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.09. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Resignation or Removal of Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Acceptance by Successor Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Succession by Merger, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:95.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.12. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trustee&#8217;s Application for Instructions from the Company</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 8</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONCERNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OLDERS</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Action by Holders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Proof of Execution by Holders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Who Are Deemed Absolute Owners</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Company-Owned Notes Disregarded</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revocation of Consents&#59; Future Holders Bound</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="padding-left:0.42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:95.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 9</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OLDERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217; M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EETINGS</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Purpose of Meetings</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Call of Meetings by Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Call of Meetings by Company or Holders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Qualifications for Voting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Regulations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Voting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">No Delay of Rights by Meeting</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 10</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">UPPLEMENTAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NDENTURES</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental Indentures Without Consent of Holders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Supplemental Indentures with Consent of Holders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effect of Supplemental Indentures</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notation on Notes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Evidence of Compliance of Supplemental Indenture to Be Furnished Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 11</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONSOLIDATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ERGER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ALE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONVEYANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EASE</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 11.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Company May Consolidate, Etc. on Certain Terms</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 11.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Successor Corporation to Be Substituted</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 11.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Opinion of Counsel to Be Given to Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 12</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:95.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">MMUNITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NCORPORATORS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">TOCKHOLDERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">FFICERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">IRECTORS</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 12.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indenture and Notes Solely Corporate Obligations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 13</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NTENTIONALLY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">MITTED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 14</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONVERSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OTES</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conversion Privilege</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conversion Procedure&#59; Settlement Upon Conversion</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole</font></div><div style="margin-bottom:1pt;text-indent:60pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Fundamental Changes or Notice of Redemption</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustment of Conversion Rate</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments of Prices</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Shares to Be Fully Paid</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="padding-left:0.42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effect of Recapitalizations, Reclassifications and Changes of the Common Stock</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.08. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Certain Covenants</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.09. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Responsibility of Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notice to Holders Prior to Certain Actions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Stockholder Rights Plans</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.12. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#91;Intentionally Omitted&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.13. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exchange in Lieu of Conversion</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 15</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EPURCHASE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OTES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OLDERS</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#91;Intentionally Omitted&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Repurchase at Option of Holders Upon a Fundamental Change</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Withdrawal of Fundamental Change Repurchase Notice</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Deposit of Fundamental Change Repurchase Price</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Covenant to Comply with Applicable Laws Upon Repurchase of Notes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 16</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PTIONAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EDEMPTION</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Optional Redemption</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notice of Optional Redemption&#59; Selection of Notes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Payment of Notes Called for Redemption</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Restrictions on Redemption</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 17</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ISCELLANEOUS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ROVISIONS</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Provisions Binding on Company&#8217;s Successors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Official Acts by Successor Corporation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Addresses for Notices, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Governing Law&#59; Jurisdiction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Evidence of Compliance with Conditions Precedent&#59; Certificates and Opinions of Counsel to Trustee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Legal Holidays</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">No Security Interest Created</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.08. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Benefits of Indenture</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.09. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Table of Contents, Headings, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Authenticating Agent</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Execution in Counterparts</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.12. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Severability</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.13. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Waiver of Jury Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.14. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Force Majeure</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.15. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Calculations</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.16. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">USA PATRIOT Act</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBITS </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.287%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit A</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INDENTURE dated as of May 2, 2017 between Flexion Therapeutics, Inc., a Delaware corporation, as issuer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; as more fully set forth in Section 1.01) and Wells Fargo Bank, National Association, a national banking association organized under the laws of the United States of America, as trustee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; as more fully set forth in Section 1.01).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">W I T N E S S E T H&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, for its lawful corporate purposes, the Company has duly authorized the issuance of its 3.375% Convertible Senior Notes due 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), initially in an aggregate principal amount not to exceed $201,250,000 and in order to provide the terms and conditions upon which the Notes are to be authenticated, issued and delivered, the Company has duly authorized the execution and delivery of this Indenture&#59; and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, the Form of Note, the certificate of authentication to be borne by each Note, the Form of Notice of Conversion, the Form of Fundamental Change Repurchase Notice and the Form of Assignment and Transfer to be borne by the Notes are to be substantially in the forms hereinafter provided&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, all acts and things necessary to make the Notes, when executed by the Company and authenticated and delivered by the Trustee or a duly authorized authenticating agent, as in this Indenture provided, the valid, binding and legal obligations of the Company, and this Indenture a valid agreement according to its terms, have been done and performed, and the execution of this Indenture and the issuance hereunder of the Notes have in all respects been duly authorized. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOW, THEREFORE, THIS INDENTURE WITNESSETH&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">That in order to declare the terms and conditions upon which the Notes are, and are to be, authenticated, issued and delivered, and in consideration of the premises and of the purchase and acceptance of the Notes by the Holders thereof, the Company covenants and agrees with the Trustee for the benefit of each other and for the equal and proportionate benefit of the respective Holders from time to time of the Notes (except as otherwise provided below), as follows&#58; </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 1 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EFINITIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The terms defined in this Section 1.01 (except as herein otherwise expressly provided or unless the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section 1.01. The words &#8220;herein,&#8221; &#8220;hereof,&#8221; &#8220;hereunder&#8221; and words of similar import refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. The terms defined in this Article include the plural as well as the singular. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means all amounts, if any, payable pursuant to Section 4.06(d), Section 4.06(e) and Section 6.03, as applicable.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.03(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of any specified Person means any other Person directly or indirectly controlling or controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, &#8220;control,&#8221; when used with respect to any specified Person means the power to direct or cause the direction of the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise&#59; and the terms &#8220;controlling&#8221; and &#8220;controlled&#8221; have meanings correlative to the foregoing. Notwithstanding anything to the contrary herein, the determination of whether one Person is an &#8220;Affiliate&#8221; of another Person for purposes of this Indenture shall be made based on the facts at the time such determination is made or required to be made, as the case may be, hereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any Registrar, Paying Agent, Conversion Agent, or Custodian.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any matter at any time relating to a Global Note, the rules, policies and procedures of the Depositary applicable to such matter. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bid Solicitation Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Company or the Person appointed by the Company to solicit bids for the Trading Price of the Notes in accordance with Section 14.01(b)(i). The Company shall initially act as the Bid Solicitation Agent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the board of directors of the Company or a committee of such board duly authorized to act for it hereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of Directors, and to be in full force and effect on the date of such certification, and delivered to the Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Note, any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York is authorized or required by law or executive order to close or be closed. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, for any entity, any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) stock issued by that entity, but shall not include any debt securities convertible into or exchangeable for any securities otherwise constituting Capital Stock pursuant to this definition.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.02(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clause A Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.04(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clause B Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.04(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clause C Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.04(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">close of business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means 5&#58;00 p.m. (New York City time).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Combination Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.02(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities and Exchange Commission.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of any Person means Capital Stock of such Person that is generally entitled (a) to vote in the election of directors of such Person or (b) if such Person is not a corporation, to vote or otherwise participate in the selection of the governing body, partners, managers or others that will control the management or policies of such Person.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the common stock of the Company, par value $0.001 per share, at the date of this Indenture, subject to Section 14.07.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in the first paragraph of this Indenture, and subject to the provisions of Article 11, shall include its successors and assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a written order of the Company, signed by one of its Officers and delivered to the Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 4.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.02(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.01(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means as of any time, $1,000, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">divided by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the Conversion Rate as of such time.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.01(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate Trust Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the office of the Trustee at which at any time its corporate trust business in respect of this Indenture shall be administered, which office is located at (i) subject to clauses (ii) and (iii), 333 S. Grand Avenue, 5th Floor, Suite 5A, MAC&#58; E2064-05A, Los Angeles, CA 90071, Attention&#58; Corporate, Municipal and Escrow Services, (ii) subject to clause (iii), with respect to Agent services, such office shall also mean the office or agency of the Trustee located on the date hereof at Corporate Trust Operations, MAC N9300-070, 600 South Fourth Street, Minneapolis, MN 55415, or (iii) such other address as the Trustee may designate from time to time by notice to the Holders and the Company, or the principal corporate trust office of any successor trustee (or such other address as such successor trustee may designate from time to time by notice to the Holders and the Company).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Custodian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Trustee, as custodian for The Depository Trust Company, with respect to the Global Notes, or any successor entity thereto.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daily Conversion Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, for each of the 40 consecutive Trading Days during the Observation Period, one-fortieth (1&#47;40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of the product of (a) the Conversion Rate on such Trading Day and (b) the Daily VWAP for such Trading Day.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daily Measurement Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Specified Dollar Amount (if any), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">divided by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 40.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daily Settlement Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; for each of the 40 consecutive Trading Days during the Observation Period, shall consist of&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) cash in an amount equal to the lesser of (i) the Daily Measurement Value and (ii) the Daily Conversion Value on such Trading Day&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) if the Daily Conversion Value on such Trading Day exceeds the Daily Measurement Value, a number of shares of Common Stock equal to (i) the difference between the Daily Conversion Value and the Daily Measurement Value, divided by (ii) the Daily VWAP for such Trading Day. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daily VWAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, for each of the 40 consecutive Trading Days during the relevant Observation Period, the per share volume-weighted average price as displayed under the heading &#8220;Bloomberg VWAP&#8221; on Bloomberg page &#8220;FLXN &#60;equity&#62; AQR&#8221; (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such Trading Day (or if such volume-weighted average price is unavailable, the market value of one share of the Common Stock on such Trading Day determined, using a volume-weighted average method, by a nationally recognized independent investment banking firm retained for this purpose by the Company). The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daily VWAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall be determined without regard to after-hours trading or any other trading outside of the regular trading session trading hours.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any event that is, or after notice or passage of time, or both, would be, an Event of Default.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Default Settlement Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, initially, Physical Settlement. Other than during any period (i) after the date the Company issues a Notice of Redemption in accordance with Article 16 and prior to the related Redemption Date or (ii) on or after February 1, 2024, the Company may change the Default Settlement Method by delivering to the Trustee, the Conversion Agent (if other than the Trustee) and the Holders a written notice specifying a new Default Settlement Method selected by the Company. Such new Default Settlement Method shall apply to all conversions of Notes with respect to which the Default Settlement Method applies and the relevant Conversion Date occurs on or after the Scheduled Trading Day following the date on which such notice is delivered.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Defaulted Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any amounts on any Note (including, without limitation, the Redemption Price, the Fundamental Change Repurchase Price, principal and interest) that are payable but are not punctually paid or duly provided for.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to each Global Note, the Person specified in Section 2.05(c) as the Depositary with respect to such Notes, until a successor shall have been appointed and become such pursuant to the applicable provisions of this Indenture, and thereafter, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depositary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean or include such successor.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distributed Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.04(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.03(c), except that, as used in Section 14.04 and Section 14.05, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the first date on which shares of the Common Stock trade on the applicable exchange or in the applicable market, regular way, reflecting the relevant share split or share combination, as applicable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 6.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ex-Dividend Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the first date on which shares of the Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive the issuance, dividend or distribution in question, from the Company or, if applicable, from the seller of Common Stock on such exchange or market (in the form of due bills or otherwise) as determined by such exchange or market.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form of Assignment and Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the &#8220;Form of Assignment and Transfer&#8221; attached as Attachment 3 to the Form of Note attached hereto as Exhibit A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form of Fundamental Change Repurchase Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the &#8220;Form of Fundamental Change Repurchase Notice&#8221; attached as Attachment 2 to the Form of Note attached hereto as Exhibit A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form of Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the &#8220;Form of Note&#8221; attached hereto as Exhibit A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form of Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the &#8220;Form of Notice of Conversion&#8221; attached as Attachment 1 to the Form of Note attached hereto as Exhibit A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Freely Tradable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means that the Notes are eligible for sale and transfer without registration under the Securities Act pursuant to Rule 144 (without being subject to limitations on volume or manner of sale pursuant to Rule 144).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred at the time after the Notes are originally issued if any of the following occurs&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) a &#8220;person&#8221; or &#8220;group&#8221; within the meaning of Section 13(d) of the Exchange Act, other than the Company, its direct or indirect Wholly Owned Subsidiaries and the employee benefit plans of the Company and its direct or indirect Wholly Owned Subsidiaries, files a Schedule TO or any schedule, form or report under the Exchange Act disclosing that such person or group has become the direct or indirect &#8220;beneficial owner,&#8221; as defined in Rule 13d-3 under the Exchange Act, of the Company&#8217;s Common Equity representing more than 50% of the voting power of the Company&#8217;s Common Equity&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) the consummation of (A) any recapitalization, reclassification or change of the Common Stock (other than changes resulting from a subdivision or combination) as a result of which the Common Stock would be converted into, or exchanged for, stock,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other securities, other property or assets&#59; (B) any share exchange, consolidation or merger of the Company pursuant to which the Common Stock will be converted into cash, securities or other property or assets&#59; or (C) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken as a whole, to any Person other than one of the Company&#8217;s direct or indirect Wholly Owned Subsidiaries&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that a transaction described in clause (B) in which the holders of all classes of the Company&#8217;s Common Equity immediately prior to such transaction own, directly or indirectly, more than 50% of all classes of Common Equity of the continuing or surviving corporation or transferee or the parent thereof immediately after such transaction in substantially the same proportions (relative to each other) as such ownership immediately prior to such transaction shall not be a Fundamental Change pursuant to this clause (b)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) the stockholders of the Company approve any plan or proposal for the liquidation or dissolution of the Company&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) the Common Stock (or other common stock underlying the Notes) ceases to be listed or quoted on any of The New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or any of their respective successors)&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that a transaction or transactions described in clause (a) or clause (b) above shall not constitute a Fundamental Change, if at least 90% of the consideration received or to be received by holders of the Common Stock, excluding cash payments for fractional shares and cash payments made in respect of dissenters&#8217; rights, in connection with such transaction or transactions consists of shares of common stock that are listed or quoted on any of The New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or any of their respective successors) or will be so listed or quoted when issued or exchanged in connection with such transaction or transactions and as a result of such transaction or transactions the Notes become convertible into such consideration, excluding cash payments for fractional shares and cash payments made in respect of dissenters&#8217; rights (subject to the provisions of Section 14.02(a)). For purposes of the definition of &#8220;Fundamental Change,&#8221; any transaction that constitutes a Fundamental Change pursuant to both clause (a) and clause (b) of the definition thereof shall be deemed a Fundamental Change solely under clause (b) of the definition thereof. If any transaction occurs in which the Common Stock is converted into, or exchanged for, Reference Property consisting of common equity of another entity, following completion of any related Make-Whole Fundamental Change Period (or, in the case of a transaction that would have been a Fundamental Change or a Make-Whole Fundamental Change but for the proviso immediately following clause (d) of the definition thereof, following the effective date of such transaction), references to the Company in this definition shall instead be references to such other entity.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Change Company Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 15.02(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Change Repurchase Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 15.02(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Change Repurchase Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 15.02(b)(i).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Change Repurchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 15.02(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">given</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">mailed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">notify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">sent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; with respect to any notice to be given to a Holder pursuant to this Indenture, shall mean notice (x) given to the Depositary (or its designee) pursuant to the standing instructions from the Depositary or its designee, including by electronic mail in accordance with accepted practices or procedures at the Depositary (in the case of a Global Note) or (y) mailed to such Holder by first class mail, postage prepaid, at its address as it appears on the Note Register (in the case of a Physical Note), in each case, in accordance with Section 17.03. Notice so &#8220;given&#8221; shall be deemed to include any notice to be &#8220;mailed&#8221; or &#8220;delivered,&#8221; as applicable, under this Indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Global Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 2.05(b).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; as applied to any Note, or other similar terms (but excluding the term &#8220;beneficial holder&#8221;), means any Person in whose name at the time a particular Note is registered on the Note Register.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means this instrument as originally executed or, if amended or supplemented as herein provided, as so amended or supplemented.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means each May 1 and November 1 of each year, beginning on November 1, 2017.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Last Reported Sale Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of the Common Stock (or other security for which a closing sale price must be determined) on any date means the closing sale price per share (or if no closing sale price is reported, the average of the bid and ask prices or, if more than one in either case, the average of the average bid and the average ask prices) on that date as reported in composite transactions for the principal U.S. national or regional securities exchange on which the Common Stock (or such other security) is traded. If the Common Stock (or such other security) is not listed for trading on a U.S. national or regional securities exchange on the relevant date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Last Reported Sale Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall be the last quoted bid price for the Common Stock (or such other security) in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. or a similar organization. If the Common Stock (or such other security) is not so quoted, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Last Reported Sale Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall be the average of the mid-point of the last bid and ask prices for the Common Stock (or such other security) on the relevant date from each of at least three nationally recognized independent investment banking firms selected by the Company for this purpose.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Make-Whole Fundamental Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any transaction or event that constitutes a Fundamental Change (as defined above and determined after giving effect to any exceptions to or exclusions from such definition, but without regard to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">proviso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in clause (b) of the definition thereof).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Make-Whole Fundamental Change Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.03(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Disruption Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, for the purposes of determining amounts due upon conversion (a) a failure by the primary U.S. national or regional securities exchange or market on which the Common Stock is listed or admitted for trading to open for trading during its regular trading session or (b) the occurrence or existence prior to 1&#58;00 p.m., New York City time, on any Scheduled Trading Day for the Common Stock for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in the Common Stock or in any options contracts or futures contracts relating to the Common Stock.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means May 1, 2024.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Measurement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.01(b)(i).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Merger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.07(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in the first paragraph of the recitals of this Indenture.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 2.05(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note Registrar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 2.05(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.02(b).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notice of Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 16.02(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; with respect to any Note surrendered for conversion means&#58; (i) subject to clause (ii), if the relevant Conversion Date occurs prior to February 1, 2024, the 40 consecutive Trading Day period beginning on, and including, the third Trading Day immediately succeeding such Conversion Date&#59; (ii) if the relevant Conversion Date occurs on or after the date of the Company&#8217;s issuance of a Notice of Redemption with respect to the Notes pursuant to Article 16 and prior to the relevant Redemption Date, the 40 consecutive Trading Day period beginning on, and including, the 42nd Scheduled Trading Day immediately preceding such Redemption Date&#59; and (iii) subject to clause (ii), if the relevant Conversion Date occurs on or after February 1, 2024, the 40 consecutive Trading Day period beginning on, and including, the 42nd Scheduled Trading Day immediately preceding the Maturity Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Offering Memorandum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the preliminary offering memorandum dated April 25, 2017, as supplemented by the related pricing term sheet dated April 26, 2017, relating to the offering and sale of the Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Company, the President, the Chief Executive Officer, the Chief Financial Officer, the Chief Accounting Officer, the Treasurer, the Assistant Treasurer, the General Counsel, the Secretary, any Executive or Senior Vice President or any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President (whether or not designated by a number or numbers or word or words added before or after the title &#8220;Vice President&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Officer&#8217;s Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; when used with respect to the Company, means a certificate that is delivered to the Trustee and that is signed by any Officer of the Company. Each such certificate shall include the statements provided for in Section 17.05 if and to the extent required by the provisions of such Section. The Officer giving an Officer&#8217;s Certificate pursuant to Section 4.08 shall be the principal executive, financial or accounting officer of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">open of business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means 9&#58;00 a.m. (New York City time).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion of Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Company, an opinion in writing signed by legal counsel, who may be an employee of or counsel to the Company, that is delivered and acceptable to the Trustee, which opinion may contain customary exceptions and qualifications as to the matters set forth therein. Each such opinion shall include the statements provided for in Section 17.05 if and to the extent required by the provisions of such Section 17.05.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Optional Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 16.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">outstanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; when used with reference to Notes, shall, subject to the provisions of Section 8.04, mean, as of any particular time, all Notes authenticated and delivered by the Trustee under this Indenture, except&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Notes theretofore canceled by the Trustee or accepted by the Trustee for cancellation&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Notes, or portions thereof, that have become due and payable and in respect of which monies in the necessary amount shall have been deposited in trust with the Trustee or with any Paying Agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own Paying Agent)&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Notes that have been paid pursuant to Section 2.06 or Notes in lieu of which, or in substitution for which, other Notes shall have been authenticated and delivered pursuant to the terms of Section 2.06 unless proof satisfactory to the Trustee is presented that any such Notes are held by protected purchasers in due course&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Notes converted pursuant to Article 14 and required to be cancelled pursuant to Section 2.08&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Notes redeemed pursuant to Article 16&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Notes repurchased by the Company pursuant to the penultimate sentence of Section 2.10. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paying Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 4.02.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an individual, a corporation, a limited liability company, an association, a partnership, a joint venture, a joint stock company, a trust, an unincorporated organization or a government or an agency or a political subdivision thereof.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physical Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means permanent certificated Notes in registered form issued in denominations of $1,000 principal amount and integral multiples thereof.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physical Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.02(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Predecessor Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of any particular Note means every previous Note evidencing all or a portion of the same debt as that evidenced by such particular Note&#59; and, for the purposes of this definition, any Note authenticated and delivered under Section 2.06 in lieu of or in exchange for a mutilated, lost, destroyed or stolen Note shall be deemed to evidence the same debt as the mutilated, lost, destroyed or stolen Note that it replaces.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any dividend, distribution or other transaction or event in which the holders of Common Stock (or other applicable security) have the right to receive any cash, securities or other property or in which the Common Stock (or such other security) is exchanged for or converted into any combination of cash, securities or other property, the date fixed for determination of holders of the Common Stock (or such other security) entitled to receive such cash, securities or other property (whether such date is fixed by the Board of Directors, by statute, by contract or otherwise).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 16.02(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, for any Notes to be redeemed pursuant to Section 16.01, 100% of the principal amount of such Notes, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> accrued and unpaid interest, if any, to, but excluding, the Redemption Date (unless the Redemption Date falls after a Regular Record Date but on or prior to the immediately succeeding Interest Payment Date, in which case interest accrued to the Interest Payment Date will be paid to Holders of record of such Notes on such Regular Record Date, and the Redemption Price will be equal to 100% of the principal amount of such Notes).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reference Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.07(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regular Record Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; with respect to any Interest Payment Date, means the April 15 or October 15 (whether or not such day is a Business Day) immediately preceding the applicable May 1 or November 1 Interest Payment Date, respectively.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Resale Restriction Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 2.05(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Responsible Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, when used with respect to the Trustee, any officer within the corporate trust department of the Trustee, including any vice president, assistant vice president, assistant secretary, assistant treasurer, trust officer or any other officer of the Trustee who customarily performs functions similar to those performed by the Persons who at the time shall be such officers that have direct responsibility for the administration of this Indenture, </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">respectively, and also means, with respect to a particular corporate trust matter, any other officer to whom such matter is referred because of such person&#8217;s knowledge of and familiarity with the particular subject. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 2.05(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rule 144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Rule 144 as promulgated under the Securities Act.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rule 144A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Rule 144A as promulgated under the Securities Act.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a day that is scheduled to be a Trading Day on the principal U.S. national or regional securities exchange or market on which the Common Stock is listed or admitted for trading. If the Common Stock is not so listed or admitted for trading, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a Business Day.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Settlement Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in Section 14.02(a)(iv). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Settlement Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any conversion of Notes, Physical Settlement, Cash Settlement or Combination Settlement, as elected (or deemed to have been elected) by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Settlement Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning specified in Section 14.02(a)(iii).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a Subsidiary of the Company that meets the definition of &#8220;significant subsidiary&#8221; in Rule 1-02(w) of Regulation S-X under the Exchange Act&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that, in the case of a Subsidiary of the Company that meets the criteria of clause (3) of the definition thereof but not clause (1) or clause (2) of the definition thereof, such Subsidiary shall not be deemed to be a Significant Subsidiary unless such Subsidiary&#8217;s income (or loss) from continuing operations before income taxes, extraordinary items and cumulative effect of a change in accounting principles exclusive of amounts attributable to any non-controlling interests for the last completed fiscal year prior to the date of such determination exceeds $5,000,000.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Specified Dollar Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the maximum cash amount per $1,000 principal amount of Notes to be received upon conversion as specified in the Settlement Notice (or deemed specified as provided in Section 14.02(a)(iii)) related to any converted Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Spin-Off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.04(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.03(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any corporation, association, partnership or other business entity of which more than 50% of the total voting power of shares of Capital Stock or other interests (including partnership interests) entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, general partners or </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">trustees thereof is at the time owned or controlled, directly or indirectly, by (i) such Person&#59; (ii) such Person and one or more Subsidiaries of such Person&#59; or (iii) one or more Subsidiaries of such Person. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Successor Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 11.01(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a day on which (i) trading in the Common Stock (or other security for which a closing sale price must be determined) generally occurs on The NASDAQ Global Market or, if the Common Stock (or such other security) is not then listed on The NASDAQ Global Market, on the principal other U.S. national or regional securities exchange on which the Common Stock (or such other security) is then listed or, if the Common Stock (or such other security) is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock (or such other security) is then traded and (ii) a Last Reported Sale Price for the Common Stock (or closing sale price for such other security) is available on such securities exchange or market&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that if the Common Stock (or such other security) is not so listed or traded, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a Business Day&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that for purposes of determining amounts due upon conversion only, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a day on which (x) there is no Market Disruption Event and (y) trading in the Common Stock generally occurs on The NASDAQ Global Market or, if the Common Stock is not then listed on The NASDAQ Global Market, on the principal other U.S. national or regional securities exchange on which the Common Stock is then listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock is then listed or admitted for trading, except that if the Common Stock is not so listed or admitted for trading, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a Business Day. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of the Notes on any date of determination means the average of the secondary market bid quotations obtained by the Bid Solicitation Agent for $2,000,000 principal amount of Notes at approximately 3&#58;30 p.m., New York City time, on such determination date from three independent nationally recognized securities dealers the Company selects for this purpose&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that if three such bids cannot reasonably be obtained by the Bid Solicitation Agent but two such bids are obtained, then the average of the two bids shall be used, and if only one such bid can reasonably be obtained by the Bid Solicitation Agent, that one bid shall be used. If the Bid Solicitation Agent cannot reasonably obtain at least one bid for $2,000,000 principal amount of Notes from a nationally recognized securities dealer on any determination date, then the Trading Price per $1,000 principal amount of Notes on such determination date shall be deemed to be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 2.05(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trigger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.04(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trust Indenture Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Trust Indenture Act of 1939, as amended, as it was in force at the date of execution of this Indenture&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that in the event the Trust Indenture Act of 1939 is amended after the date hereof, the term &#8220;Trust Indenture Act&#8221; shall mean, to the extent required by such amendment, the Trust Indenture Act of 1939, as so amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Person named as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; in the first paragraph of this Indenture until a successor trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean or include each Person who is then a Trustee hereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">unit of Reference Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.07(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall have the meaning specified in Section 14.04(c).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wholly Owned Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any Subsidiary of such Person, except that, solely for purposes of this definition, the reference to &#8220;more than 50%&#8221; in the definition of &#8220;Subsidiary&#8221; shall be deemed replaced by a reference to &#8220;100%&#8221;, the calculation of which shall exclude nominal amounts of the voting power of shares of Capital Stock or other interests in the relevant Subsidiary as may be required to satisfy local minority interest requirements outside of the United States.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. References to Interest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Unless the context otherwise requires, any reference to interest on, or in respect of, any Note in this Indenture shall be deemed to include Additional Interest if, in such context, Additional Interest is, was or would be payable pursuant to any of Section 4.06(d), Section 4.06(e) and Section 6.03. Unless the context otherwise requires, any express mention of Additional Interest in any provision hereof shall not be construed as excluding Additional Interest in those provisions hereof where such express mention is not made.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 2 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">SSUE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ESCRIPTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">XECUTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EGISTRATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">XCHANGE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OTES</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Designation and Amount.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Notes shall be designated as the &#8220;3.375% Convertible Senior Notes due 2024.&#8221; The aggregate principal amount of Notes that may be authenticated and delivered under this Indenture is initially limited to $201,250,000, subject to Section 2.10 and except for Notes authenticated and delivered upon registration or transfer of, or in exchange for, or in lieu of other Notes to the extent expressly permitted hereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Form of Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Notes and the Trustee&#8217;s certificate of authentication to be borne by such Notes shall be substantially in the respective forms set forth in Exhibit A, the terms and provisions of which shall constitute, and are hereby expressly incorporated in and made a part of this Indenture. To the extent applicable, the Company and the Trustee, by their execution and delivery of this Indenture, expressly agree to such terms and provisions and to be bound thereby. In the case of any conflict between this Indenture and a Note, the provisions of this Indenture shall control and govern to the extent of such conflict.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any Global Note may be endorsed with or have incorporated in the text thereof such legends or recitals or changes not inconsistent with the provisions of this Indenture as may be required by the Custodian or the Depositary, or as may be required to comply with any applicable law or any regulation thereunder or with the rules and regulations of any securities exchange or automated quotation system upon which the Notes may be listed or traded or </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designated for issuance or to conform with any usage with respect thereto, or to indicate any special limitations or restrictions to which any particular Notes are subject. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any of the Notes may have such letters, numbers or other marks of identification and such notations, legends or endorsements as the Officers executing the same may approve (execution thereof to be conclusive evidence of such approval) and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange or automated quotation system on which the Notes may be listed or designated for issuance, or to conform to usage or to indicate any special limitations or restrictions to which any particular Notes are subject. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each Global Note shall represent such principal amount of the outstanding Notes as shall be specified therein and shall provide that it shall represent the aggregate principal amount of outstanding Notes from time to time endorsed thereon and that the aggregate principal amount of outstanding Notes represented thereby may from time to time be increased or reduced to reflect redemptions, repurchases, cancellations, conversions, transfers, exchanges or issuances of additional Notes (to the extent such issuances are fungible with the Notes represented by such Global Note for U.S. federal income tax and securities law purposes) permitted hereby. Any endorsement of a Global Note to reflect the amount of any increase or decrease in the amount of outstanding Notes represented thereby shall be made by the Trustee or the Custodian, at the direction of the Trustee, in such manner and upon instructions given by the Holder of such Notes in accordance with this Indenture. Payment of principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, a Global Note shall be made to the Holder of such Note on the date of payment, unless a record date or other means of determining Holders eligible to receive payment is provided for herein. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Date and Denomination of Notes&#59; Payments of Interest and Defaulted Amounts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) The Notes shall be issuable in registered form without coupons in denominations of $1,000 principal amount and integral multiples thereof. Each Note shall be dated the date of its authentication and shall bear interest from the date specified on the face of such Note. Accrued interest on the Notes shall be computed on the basis of a 360-day year composed of twelve 30-day months and, for partial months, on the basis of the number of days actually elapsed in a 30-day month.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) The Person in whose name any Note (or its Predecessor Note) is registered on the Note Register at the close of business on any Regular Record Date with respect to any Interest Payment Date shall be entitled to receive the interest payable on such Interest Payment Date. The principal amount of any Note (x) in the case of any Physical Note, shall be payable at the office or agency of the Company maintained by the Company for such purposes in the continental United States of America, which shall initially be the Corporate Trust Office and (y) in the case of any Global Note, shall be payable by wire transfer of immediately available funds to the account of the Depositary or its nominee. The Company shall pay, or cause the Paying Agent to pay, interest (i) on any Physical Notes (A) to Holders holding Physical Notes having an aggregate principal amount of $5,000,000 or less, by check mailed to the Holders of these Notes at their address as it appears in the Note Register and (B) to Holders holding Physical Notes having an aggregate principal amount of more than $5,000,000, either by check mailed to each </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holder or, upon application by such a Holder to the Note Registrar not later than the relevant Regular Record Date, by wire transfer in immediately available funds to that Holder&#8217;s account within the United States if such Holder has provided the Company, the Trustee, the Registrar or the Paying Agent with the requisite information necessary to make such wire transfer, which application shall remain in effect until the Holder notifies, in writing, the Note Registrar to the contrary or (ii) on any Global Note by wire transfer of immediately available funds to the account of the Depositary or its nominee. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Any Defaulted Amounts shall forthwith cease to be payable to the Holder on the relevant payment date but shall accrue interest per annum at the rate borne by the Notes, subject to the enforceability thereof under applicable law, from, and including, such relevant payment date, and such Defaulted Amounts, together with such interest thereon, shall be paid by the Company, at its election in each case, as provided in clause (i) or (ii) below&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) The Company may elect to make payment of any Defaulted Amounts to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on a special record date for the payment of such Defaulted Amounts, which shall be fixed in the following manner. The Company shall notify the Trustee in writing of the amount of the Defaulted Amounts proposed to be paid on each Note and the date of the proposed payment (which shall be not less than 25 days after the receipt by the Trustee of such notice, unless the Trustee shall consent to an earlier date), and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount to be paid in respect of such Defaulted Amounts or shall make arrangements satisfactory to the Trustee for such deposit on or prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Amounts as in this clause provided. Thereupon the Company shall fix a special record date for the payment of such Defaulted Amounts which shall be not more than 15 days and not less than 10 days prior to the date of the proposed payment, and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment (unless the Trustee shall consent to an earlier date). The Company shall promptly notify the Trustee of such special record date, and the Trustee, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Amounts and the special record date therefor to be delivered to each Holder not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted Amounts and the special record date therefor having been so delivered, such Defaulted Amounts shall be paid to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on such special record date and shall no longer be payable pursuant to the following clause (ii) of this Section 2.03 (c). The Trustee shall have no responsibility whatsoever for the calculation of any Defaulted Amounts. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) The Company may make payment of any Defaulted Amounts in any other lawful manner not inconsistent with the requirements of any securities exchange or automated quotation system on which the Notes may be listed or designated for issuance, and upon such notice as may be required by such exchange or automated quotation system, if, after notice given by the Company to the Trustee of the proposed payment </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Execution, Authentication and Delivery of Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Notes shall be signed in the name and on behalf of the Company by the manual or facsimile signature of its Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary or any of its Executive or Senior Vice Presidents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Notes executed by the Company to the Trustee for authentication, together with a Company Order for the authentication and delivery of such Notes, and the Trustee in accordance with such Company Order shall authenticate and deliver such Notes, without any further action by the Company hereunder&#59; provided that the Trustee shall be entitled to receive an Officer&#8217;s Certificate and an Opinion of Counsel of the Company addressing such matters as the Trustee may reasonably request. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Only such Notes as shall bear thereon a certificate of authentication substantially in the form set forth on the Form of Note attached as Exhibit A hereto, executed manually by an authorized officer of the Trustee (or an authenticating agent appointed by the Trustee as provided by Section 17.10), shall be entitled to the benefits of this Indenture or be valid or obligatory for any purpose. Such certificate by the Trustee (or such an authenticating agent) upon any Note executed by the Company shall be conclusive evidence that the Note so authenticated has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits of this Indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In case any Officer of the Company who shall have signed any of the Notes shall cease to be such Officer before the Notes so signed shall have been authenticated and delivered by the Trustee, or disposed of by the Company, such Notes nevertheless may be authenticated and delivered or disposed of as though the person who signed such Notes had not ceased to be such Officer of the Company&#59; and any Note may be signed on behalf of the Company by such persons as, at the actual date of the execution of such Note, shall be the Officers of the Company, although at the date of the execution of this Indenture any such person was not such an Officer. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Exchange and Registration of Transfer of Notes&#59; Restrictions on Transfer&#59; Depositary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) The Company shall cause to be kept at the Corporate Trust Office a register (the register maintained in such office or in any other office or agency of the Company designated pursuant to Section 4.02, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide for the registration of Notes and of transfers of Notes. Such register shall be in written form or in any form capable of being converted into written form within a reasonable period of time. The Trustee is hereby initially appointed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Note Registrar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; for the purpose of registering Notes and transfers of Notes as herein provided. The Company may appoint one or more co-Note Registrars in accordance with Section 4.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon surrender for registration of transfer of any Note to the Note Registrar or any co-Note Registrar, and satisfaction of the requirements for such transfer set forth in this Section 2.05, the Company shall execute, and the Trustee shall authenticate and deliver, in the name of the designated transferee or transferees, one or more new Notes of any authorized denominations </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and of a like aggregate principal amount and bearing such restrictive legends as may be required by this Indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes may be exchanged for other Notes of any authorized denominations and of a like aggregate principal amount, upon surrender of the Notes to be exchanged at any such office or agency maintained by the Company pursuant to Section 4.02. Whenever any Notes are so surrendered for exchange, the Company shall execute, and the Trustee shall authenticate and deliver, the Notes that the Holder making the exchange is entitled to receive, bearing registration numbers not contemporaneously outstanding. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Notes presented or surrendered for registration of transfer or for exchange, repurchase or conversion shall be duly endorsed, or be accompanied by a written instrument or instruments of transfer in form satisfactory to the Company and duly executed by the Holder thereof or its attorney-in-fact duly authorized in writing. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No service charge shall be imposed by the Company, the Trustee, the Note Registrar, any co-Note Registrar or the Paying Agent for any exchange or registration of transfer of Notes, but the Company may require a Holder to pay a sum sufficient to cover any documentary, stamp or similar issue or transfer tax required in connection therewith as a result of the name of the Holder of new Notes issued upon such exchange or registration of transfer being different from the name of the Holder of the old Notes surrendered for exchange or registration of transfer. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None of the Company, the Trustee, the Note Registrar or any co-Note Registrar shall be required to exchange or register a transfer of (i) any Notes surrendered for conversion or, if a portion of any Note is surrendered for conversion, such portion thereof surrendered for conversion, (ii) any Notes, or a portion of any Note, surrendered for repurchase (and not withdrawn) in accordance with Article 15 or (iii) any Notes selected for redemption in accordance with Article 16, except the unredeemed portion of any Note being redeemed in part. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Notes issued upon any registration of transfer or exchange of Notes in accordance with this Indenture shall be the valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under this Indenture as the Notes surrendered upon such registration of transfer or exchange. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) So long as the Notes are eligible for book-entry settlement with the Depositary, unless otherwise required by law, subject to the fourth paragraph from the end of Section 2.05(c) all Notes shall be represented by one or more Notes in global form (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Global Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) registered in the name of the Depositary or the nominee of the Depositary. Each Global Note shall bear the legend required on a Global Note set forth in Exhibit A hereto. The transfer and exchange of beneficial interests in a Global Note that does not involve the issuance of a Physical Note shall be effected through the Depositary (but not the Trustee or the Custodian) in accordance with this Indenture (including the restrictions on transfer set forth herein) and the Applicable Procedures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Every Note that bears or is required under this Section 2.05(c) to bear the legend set forth in this Section 2.05(c) (together with any Common Stock issued upon conversion of the Notes that is required to bear the legend set forth in Section 2.05(d), collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall be subject to the restrictions on transfer set forth in this Section 2.05(c) (including the legend set forth below), unless such restrictions on transfer shall be eliminated or otherwise waived by written consent of the Company, and the Holder of each such Restricted Security, by such Holder&#8217;s acceptance thereof, agrees to be bound by all such restrictions on transfer. As used in this Section 2.05(c) and Section 2.05(d), the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; encompasses any sale, pledge, transfer or other disposition whatsoever of any Restricted Security.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until the date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Resale Restriction Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) that is the later of (1) the date that is one year after the last date of original issuance of the Notes, or such shorter period of time as permitted by Rule 144 or any successor provision thereto, and (2) such later date, if any, as may be required by applicable law, any certificate evidencing such Note (and all securities issued in exchange therefor or substitution thereof, other than Common Stock, if any, issued upon conversion thereof, which shall bear the legend set forth in Section 2.05(d), if applicable) shall bear a legend in substantially the following form (unless such Notes have been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer, or sold pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, or unless otherwise agreed by the Company in writing, with notice thereof to the Trustee)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THIS SECURITY AND THE COMMON STOCK, IF ANY, ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECURITIES ACT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A &#8220;QUALIFIED INSTITUTIONAL BUYER&#8221; (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) AGREES FOR THE BENEFIT OF FLEXION THERAPEUTICS, INC. (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) THAT IT WILL NOT OFFER, SELL, PLEDGE OR OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE DATE THAT IS THE LATER OF (X) ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE HEREOF OR SUCH SHORTER PERIOD OF TIME AS PERMITTED BY RULE 144 UNDER THE SECURITIES ACT OR ANY SUCCESSOR PROVISION THERETO AND (Y) SUCH LATER DATE, IF ANY, AS MAY BE REQUIRED BY APPLICABLE LAW, EXCEPT&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, OR </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT, OR </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, OR </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH CLAUSE (2)(D) ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE THAT THE PROPOSED TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No transfer of any Note prior to the Resale Restriction Termination Date will be registered by the Note Registrar unless the applicable box on the Form of Assignment and Transfer has been checked. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any Note (or security issued in exchange or substitution therefor) (i) as to which such restrictions on transfer shall have expired in accordance with their terms, (ii) that has been transferred pursuant to a registration statement that has become effective or been declared effective under the Securities Act and that continues to be effective at the time of such transfer or (iii) that has been sold pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, may, upon surrender of such Note for exchange to the Note Registrar in accordance with the provisions of this Section 2.05, be exchanged for a new Note or Notes, of like tenor and aggregate principal amount, which shall not bear the restrictive legend required by this Section 2.05(c) and shall not be assigned a restricted CUSIP number. The Company shall be entitled to instruct the Custodian in writing to so surrender any Global Note as to which any of the conditions set forth in clause (i) through (iii) of the immediately preceding sentence have been satisfied, and, upon such instruction, the Custodian shall so surrender such Global Note for exchange&#59; and any new Global Note so exchanged therefor shall not bear the restrictive legend specified in this Section 2.05(c) and shall not be assigned a restricted CUSIP number. The Company shall promptly notify the Trustee upon the occurrence of the Resale Restriction Termination Date and promptly after a registration statement, if any, with respect to the Notes or any Common Stock issued upon conversion of the Notes has been declared effective under the Securities Act. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any other provisions of this Indenture (other than the provisions set forth in this Section 2.05(c)), a Global Note may not be transferred as a whole or in part except (i) by the Depositary to a nominee of the Depositary or by a nominee of the Depositary to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a successor Depositary or a nominee of such successor Depositary and (ii) for exchange of a Global Note or a portion thereof for one or more Physical Notes in accordance with the second immediately succeeding paragraph. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Depositary shall be a clearing agency registered under the Exchange Act. The Company initially appoints The Depository Trust Company to act as Depositary with respect to each Global Note. Initially, each Global Note shall be issued to the Depositary, registered in the name of Cede &#38; Co., as the nominee of the Depositary, and deposited with the Trustee as custodian for Cede &#38; Co. The Company has entered into a letter of representations with the Depositary in the form provided by the Depositary, and the Trustee and each Agent are hereby authorized to act in accordance with such letter and Applicable Procedures. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If (i) the Depositary notifies the Company at any time that the Depositary is unwilling or unable to continue as depositary for the Global Notes and a successor depositary is not appointed within 90 days, (ii) the Depositary ceases to be registered as a clearing agency under the Exchange Act and a successor depositary is not appointed within 90 days or (iii) an Event of Default with respect to the Notes has occurred and is continuing and a beneficial owner of any Note requests that its beneficial interest therein be issued as a Physical Note, the Company shall execute, and the Trustee, upon receipt of an Officer&#8217;s Certificate and a Company Order for the authentication and delivery of Notes, shall authenticate and deliver (x) in the case of clause (iii), a Physical Note to such beneficial owner in a principal amount equal to the principal amount of such Note corresponding to such beneficial owner&#8217;s beneficial interest and (y) in the case of clause (i) or (ii), Physical Notes to each beneficial owner of the related Global Notes (or a portion thereof) in an aggregate principal amount equal to the aggregate principal amount of such Global Notes in exchange for such Global Notes, and upon delivery of the Global Notes to the Trustee such Global Notes shall be canceled. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physical Notes issued in exchange for all or a part of the Global Note pursuant to this Section 2.05(c) shall be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, or, in the case of clause (iii) of the immediately preceding paragraph, the relevant beneficial owner, shall instruct the Trustee. Upon execution and authentication, the Trustee shall deliver such Physical Notes to the Persons in whose names such Physical Notes are so registered. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At such time as all interests in a Global Note have been converted, canceled, repurchased, redeemed or transferred, such Global Note shall be, upon receipt thereof, canceled by the Trustee in accordance with standing procedures and existing instructions between the Depositary and the Custodian. At any time prior to such cancellation, if any interest in a Global Note is exchanged for Physical Notes, converted, canceled, repurchased, redeemed or transferred to a transferee who receives Physical Notes therefor or any Physical Note is exchanged or transferred for part of such Global Note, the principal amount of such Global Note shall, in accordance with the standing procedures and instructions existing between the Depositary and the Custodian, be appropriately reduced or increased, as the case may be, and an endorsement shall be made on such Global Note, by the Trustee or the Custodian, at the direction of the Trustee, to reflect such reduction or increase. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None of the Company, the Trustee or any agent of the Company or the Trustee shall have any responsibility or liability for any act or omission of the Depositary, or for any aspect of the records relating to or payments made on account of beneficial ownership interests of a Global Note or maintaining, supervising or reviewing any records of the Depositary relating to such beneficial ownership interests.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Until the Resale Restriction Termination Date, any stock certificate representing Common Stock issued upon conversion of a Note shall bear a legend in substantially the following form (unless such Common Stock has been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer, or pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, or such Common Stock has been issued upon conversion of a Note that has been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer, or pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, or unless otherwise agreed by the Company with written notice thereof to the Trustee and any transfer agent for the Common Stock)&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECURITIES ACT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A &#8220;QUALIFIED INSTITUTIONAL BUYER&#8221; (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) AGREES FOR THE BENEFIT OF FLEXION THERAPEUTICS, INC. (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) THAT IT WILL NOT OFFER, SELL, PLEDGE OR OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE DATE THAT IS THE LATER OF (X) ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE OF THE SERIES OF NOTES UPON THE CONVERSION OF WHICH THIS SECURITY WAS ISSUED OR SUCH SHORTER PERIOD OF TIME AS PERMITTED BY RULE 144 UNDER THE SECURITIES ACT OR ANY SUCCESSOR PROVISION THERETO AND (Y) SUCH LATER DATE, IF ANY, AS MAY BE REQUIRED BY APPLICABLE LAW, EXCEPT&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, OR </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT, OR </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, OR </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH CLAUSE (2)(D) ABOVE, THE COMPANY AND THE TRANSFER AGENT FOR THE COMPANY&#8217;S COMMON STOCK RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE THAT THE PROPOSED TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any such Common Stock (i) as to which such restrictions on transfer shall have expired in accordance with their terms, (ii) that has been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer or (iii) that has been sold pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, may, upon surrender of the certificates representing such shares of Common Stock for exchange in accordance with the procedures of the transfer agent for the Common Stock, be exchanged for a new certificate or certificates for a like aggregate number of shares of Common Stock, which shall not bear the restrictive legend required by this Section 2.05(d). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Any Note or Common Stock issued upon the conversion or exchange of a Note that is purchased or owned by any Affiliate of the Company (or any Person who was an Affiliate of the Company at any time during the three months preceding) may not be resold by such Affiliate (or such Person, as the case may be) unless registered under the Securities Act or resold pursuant to an exemption from the registration requirements of the Securities Act in a transaction that results in such Note or Common Stock, as the case may be, no longer being a &#8220;restricted security&#8221; (as defined under Rule 144). The Company shall cause any Note that is repurchased or owned by it or any of its Subsidiaries to be surrendered to the Trustee for cancellation in accordance with Section 2.08. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) The Trustee shall have no obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Note (including any transfers between or among depositary participants or beneficial owners of interests in any Global Note) other than to require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Indenture, and to examine the same to determine substantial compliance as to form with the express requirements hereof. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mutilated, Destroyed, Lost or Stolen Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In case any Note shall become mutilated or be destroyed, lost or stolen, the Company in its discretion may execute, and upon its written request the Trustee or an authenticating agent appointed by the Trustee shall authenticate and deliver, a new Note, bearing a registration number not contemporaneously outstanding, in exchange and substitution for the mutilated Note, or in lieu of and in substitution for the Note so destroyed, lost or stolen. In every case the applicant for a substituted Note shall furnish to the Company, to the Trustee and, if applicable, to such authenticating agent such security or indemnity as may be required by each of them to save each of them harmless from any loss,</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">liability, cost or expense caused by or connected with such substitution, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company, to the Trustee and, if applicable, to such authenticating agent evidence to their satisfaction of the destruction, loss or theft of such Note and of the ownership thereof. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Trustee or such authenticating agent may authenticate any such substituted Note and deliver the same upon the receipt of such security or indemnity as the Trustee, the Company and, if applicable, such authenticating agent may require. No service charge shall be imposed by the Company, the Trustee, the Note Registrar, any co-Note Registrar or the Paying Agent upon the issuance of any substitute Note, but the Company may require a Holder to pay a sum sufficient to cover any documentary, stamp or similar issue or transfer tax required in connection therewith as a result of the name of the Holder of the new substitute Note being different from the name of the Holder of the old Note that became mutilated or was destroyed, lost or stolen. In case any Note that has matured or is about to mature or has been surrendered for required repurchase or is about to be converted in accordance with Article 14 shall become mutilated or be destroyed, lost or stolen, the Company may, in its sole discretion, instead of issuing a substitute Note, pay or authorize the payment of or convert or authorize the conversion of the same (without surrender thereof except in the case of a mutilated Note), as the case may be, if the applicant for such payment or conversion shall furnish to the Company, to the Trustee and, if applicable, to such authenticating agent such security or indemnity as may be required by each of them to save each of them harmless for any loss, liability, cost or expense caused by or connected with such substitution, and, in every case of destruction, loss or theft, evidence satisfactory to the Company, the Trustee and, if applicable, any Paying Agent or Conversion Agent of the destruction, loss or theft of such Note and of the ownership thereof. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Every substitute Note issued pursuant to the provisions of this Section 2.06 by virtue of the fact that any Note is destroyed, lost or stolen shall constitute an additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Note shall be found at any time, and shall be entitled to all the benefits of (but shall be subject to all the limitations set forth in) this Indenture equally and proportionately with any and all other Notes duly issued hereunder. To the extent permitted by law, all Notes shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement, payment, redemption, conversion or repurchase of mutilated, destroyed, lost or stolen Notes and shall preclude any and all other rights or remedies notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement, payment, redemption, conversion or repurchase of negotiable instruments or other securities without their surrender. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Temporary Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Pending the preparation of Physical Notes, the Company may execute and the Trustee or an authenticating agent appointed by the Trustee shall, upon written request of the Company, authenticate and deliver temporary Notes (printed or lithographed). Temporary Notes shall be issuable in any authorized denomination, and substantially in the form of the Physical Notes but with such omissions, insertions and variations as may be appropriate for temporary Notes, all as may be determined by the Company. Every such temporary Note shall be executed by the Company and authenticated by the Trustee or such authenticating agent upon the same conditions and in substantially the same manner, and with the same effect, as the Physical Notes. Without unreasonable delay, the Company shall execute and deliver to the Trustee or such authenticating agent Physical Notes (other than any Global </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note) and thereupon any or all temporary Notes (other than any Global Note) may be surrendered in exchange therefor, at each office or agency maintained by the Company pursuant to Section 4.02 and the Trustee or such authenticating agent shall authenticate and deliver in exchange for such temporary Notes an equal aggregate principal amount of Physical Notes. Such exchange shall be made by the Company at its own expense and without any charge therefor. Until so exchanged, the temporary Notes shall in all respects be entitled to the same benefits and subject to the same limitations under this Indenture as Physical Notes authenticated and delivered hereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Cancellation of Notes Paid, Converted, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company shall cause all Notes surrendered for the purpose of payment, repurchase, redemption, registration of transfer or exchange or conversion, if surrendered to any Person other than the Trustee (including any of the Company&#8217;s agents, Subsidiaries or Affiliates), to be surrendered to the Trustee for cancellation. All Notes delivered to the Trustee shall be canceled promptly by it, and, except as expressly permitted by the provisions of this Indenture, no Notes shall be authenticated in exchange thereof. The Trustee shall dispose of canceled Notes in accordance with its customary procedures. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. CUSIP Numbers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company in issuing the Notes may use &#8220;CUSIP&#8221; numbers (if then generally in use), and, if so, the Trustee shall use &#8220;CUSIP&#8221; numbers in all notices issued to Holders as a convenience to such Holders&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Notes or on such notice and that reliance may be placed only on the other identification numbers printed on the Notes. The Company shall promptly notify the Trustee in writing of any change in the &#8220;CUSIP&#8221; numbers. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Additional Notes&#59; Repurchases.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company may, without the consent of, or notice to, the Holders and notwithstanding Section 2.01, reopen this Indenture and issue additional Notes hereunder with the same terms and with the same CUSIP number as the Notes initially issued hereunder (other than differences in the issue date, the issue price and interest accrued prior to the issue date of such additional Notes and, if applicable, restrictions on transfer in respect of such additional Notes) in an unlimited aggregate principal amount&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that if any such additional Notes are not fungible with the Notes initially issued hereunder for U.S. federal income tax purposes or securities law purposes, such additional Notes shall have one or more separate CUSIP numbers. Prior to the issuance of any such additional Notes, the Company shall deliver to the Trustee a Company Order, an Officer&#8217;s Certificate and an Opinion of Counsel, such Officer&#8217;s Certificate and Opinion of Counsel to cover such matters, in addition to those required by Section 17.05, as the Trustee shall reasonably request. In addition, the Company may, to the extent permitted by law, and directly or indirectly (regardless of whether such Notes are surrendered to the Company), repurchase Notes in the open market or otherwise, whether by the Company or its Subsidiaries or through a private or public tender or exchange offer or through counterparties to private agreements, including by cash-settled swaps or other derivatives, in each case, without prior notice to the Holders of the Notes. The Company shall cause any Notes so repurchased (other than Notes repurchased pursuant to cash-settled swaps or other derivatives) to be surrendered to the Trustee for cancellation in accordance with Section 2.08, and such Notes shall no longer be considered outstanding under this Indenture upon their repurchase. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 3 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ATISFACTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ISCHARGE</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Satisfaction and Discharge.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) This Indenture and the Notes shall cease to be of further effect when (i) all Notes theretofore authenticated and delivered (other than Notes which have been destroyed, lost or stolen and which have been replaced, paid or converted as provided in Section 2.06) have been delivered to the Trustee for cancellation&#59; or (ii) the Company has deposited with the Trustee or delivered to Holders, as applicable, after all of the Notes have become due and payable, whether on the Maturity Date, any Redemption Date, any Fundamental Change Repurchase Date, upon conversion or otherwise, cash or cash, shares of Common Stock or a combination thereof, as applicable, solely to satisfy the Company&#8217;s Conversion Obligation, sufficient to pay all of the outstanding Notes and all other sums due and payable under this Indenture by the Company&#59; and (b) the Trustee, upon request of the Company contained in an Officer&#8217;s Certificate and at the expense of the Company, shall execute proper instruments acknowledging such satisfaction and discharge of this Indenture and the Notes, when the Company has delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the satisfaction and discharge of this Indenture and the Notes have been complied with. Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the Trustee under Section 7.06 shall survive.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 4 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ARTICULAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OVENANTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OMPANY</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Payment of Principal and Interest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company covenants and agrees that it will pay or cause to be paid the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, each of the Notes at the places, at the respective times and in the manner provided herein and in the Notes. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Maintenance of Office or Agency.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company will maintain in the continental United States of America an office or agency where the Notes may be surrendered for registration of transfer or exchange or for presentation for payment or repurchase (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paying Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or for conversion (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and where notices and demands to or upon the Company in respect of the Notes and this Indenture may be served. The Company will give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency. If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office or the office or agency of the Trustee in the continental United States of America.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may also from time to time designate as co-Note Registrars one or more other offices or agencies where the Notes may be presented or surrendered for any or all such purposes and may from time to time rescind such designations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency in the continental United States of America for such purposes. The Company will give </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office or agency. The terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paying Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; include any such additional or other offices or agencies, as applicable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company hereby initially designates the Trustee as the Paying Agent, Note Registrar, Custodian and Conversion Agent and the Corporate Trust Office as the office or agency in the continental United States of America where Notes may be surrendered for registration of transfer or exchange or for presentation for payment or repurchase or for conversion. Notices and demands to or upon the Company in respect of the Notes and this Indenture may be served on the Company as provided in Section 17.03. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Appointments to Fill Vacancies in Trustee&#8217;s Office.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.09, a Trustee, so that there shall at all times be a Trustee hereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Provisions as to Paying Agent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) If the Company shall appoint a Paying Agent other than the Trustee, the Company will cause such Paying Agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section 4.04&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) that it will hold all sums held by it as such agent for the payment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes in trust for the benefit of the Holders of the Notes&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) that it will give the Trustee prompt written notice of any failure by the Company to make any payment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes when the same shall be due and payable&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) that at any time during the continuance of an Event of Default, upon request of the Trustee, it will forthwith pay to the Trustee all sums so held in trust. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company shall, on or before each due date of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, the Notes, deposit with the Paying Agent a sum sufficient to pay such principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) or accrued and unpaid interest, and (unless such Paying Agent is the Trustee) the Company will promptly notify the Trustee in writing of any failure to take such action&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that if such deposit is made on the due date, such deposit must be received by the Paying Agent by 11&#58;00 a.m., New York City time, on such date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) If the Company shall act as its own Paying Agent, it will, on or before each due date of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes, set aside, segregate and hold in trust for the benefit of the Holders of the Notes a sum sufficient to pay such principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and accrued and unpaid interest so becoming due and will promptly notify the Trustee in writing of any failure to take such action and of any failure by the Company to make any payment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, the Notes when the same shall become due and payable. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Anything in this Section 4.04 to the contrary notwithstanding, the Company may, at any time, for the purpose of obtaining a satisfaction and discharge of this Indenture, or for any other reason, pay, cause to be paid or deliver to the Trustee all sums or amounts held in trust by the Company or any Paying Agent hereunder as required by this Section 4.04, such sums or amounts to be held by the Trustee upon the trusts herein contained and upon such payment or delivery by the Company or any Paying Agent to the Trustee, the Company or such Paying Agent shall be released from all further liability but only with respect to such sums or amounts. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Subject to any escheatment laws, any money and shares of Common Stock deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, accrued and unpaid interest on and the consideration due upon conversion of any Note and remaining unclaimed for two years (or as of any common law escheatment date) after such principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable), interest or consideration due upon conversion has become due and payable shall be paid to the Company on request of the Company contained in an Officer&#8217;s Certificate, or (if then held by the Company) shall be discharged from such trust&#59; and the Holder of such Note shall thereafter, as an unsecured general creditor, look only to the Company for payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money and shares of Common Stock, and all liability of the Company as trustee thereof, shall thereupon cease. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Existence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject to Article 11, the Company shall do or cause to be done all things necessary to preserve and keep in full force and effect its corporate existence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Rule 144A Information Requirement and Annual Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) At any time the Company is not subject to Section 13 or 15(d) of the Exchange Act, the Company shall, so long as any of the Notes or any shares of Common Stock issuable upon conversion thereof shall, at such time, constitute &#8220;restricted securities&#8221; within the meaning of Rule 144(a)(3) under the Securities Act, promptly provide to the Trustee and, upon written request, any Holder, beneficial owner or prospective purchaser of such Notes or any shares of Common Stock issuable upon conversion of such Notes, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act to facilitate the resale of such Notes or shares of Common Stock pursuant to Rule 144A. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) The Company shall file with the Trustee, within 15 days after the same are required to be filed with the Commission (giving effect to any grace period provided by Rule 12b-25 or any successor rule under the Exchange Act), copies of any annual or quarterly reports (on Form 10-K or 10-Q or any respective successor form) that the Company is required to file with the Commission pursuant to Section 13 or 15(d) of the Exchange Act (excluding any information, documents or reports, or portions thereof, subject to confidential treatment and any </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">correspondence with the Commission). Any such document or report that the Company files with the Commission via the Commission&#8217;s EDGAR system (or any successor thereto) shall be deemed to be filed with the Trustee for purposes of this Section 4.06(b) at the time such documents are filed via the EDGAR system (or any successor thereto), it being understood that the Trustee shall not be responsible for determining whether such filings have been made. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Delivery of the reports, information and documents described in subsection (a) or subsection (b) above to the Trustee is for informational purposes only, and the information and the Trustee&#8217;s receipt of such shall not constitute constructive notice of any information contained therein, or determinable from information contained therein, including the Company&#8217;s compliance with any of its covenants hereunder (as to which the Trustee is entitled to conclusively rely on an Officer&#8217;s Certificate). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) If, at any time during the six-month period beginning on, and including, the date that is six months after the last date of original issuance of the Notes, the Company fails to timely file any document or report that it is required to file with the Commission pursuant to Section 13 or 15(d) of the Exchange Act, as applicable (after giving effect to all applicable grace periods thereunder and other than reports on Form 8-K), or the Notes are not otherwise Freely Tradable by Holders other than the Company&#8217;s Affiliates or Holders that were the Company&#8217;s Affiliates at any time during the three months preceding (as a result of restrictions pursuant to U.S. securities laws or the terms of this Indenture or the Notes), the Company shall pay Additional Interest on the Notes. Such Additional Interest shall accrue on the Notes at the rate of 0.50% per annum of the principal amount of the Notes outstanding for each day during such period for which the Company&#8217;s failure to file has occurred and is continuing or the Notes are not otherwise Freely Tradable by Holders other than the Company&#8217;s Affiliates (or Holders that have been the Company&#8217;s Affiliates at any time during the three months preceding) without restrictions pursuant to U.S. securities laws or the terms of this Indenture or the Notes. As used in this Section 4.06(d), documents or reports that the Company is required to &#8220;file&#8221; with the Commission pursuant to Section 13 or 15(d) of the Exchange Act do not include documents or reports that the Company furnishes to the Commission pursuant to Section 13 or 15(d) of the Exchange Act. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) If, and for so long as, the restrictive legend on the Notes specified in Section 2.05(c) has not been removed, the Notes are assigned a restricted CUSIP number or the Notes are not otherwise Freely Tradable by Holders other than the Company&#8217;s Affiliates or Holders that were the Company&#8217;s Affiliates at any time during the three months preceding (without restrictions pursuant to U.S. securities laws or the terms of this Indenture or the Notes) as of the 380th day after the last date of original issuance of the Notes, the Company shall pay Additional Interest on the Notes at a rate equal to 0.50% per annum of the principal amount of Notes outstanding until the restrictive legend on the Notes has been removed in accordance with Section 2.05(c), the Notes are assigned an unrestricted CUSIP number and the Notes are Freely Tradable by Holders other than the Company&#8217;s Affiliates (or Holders that were the Company&#8217;s Affiliates at any time during the three months preceding) without restrictions pursuant to U.S. securities laws or the terms of this Indenture or the Notes. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Additional Interest will be payable in arrears on each Interest Payment Date following accrual in the same manner as regular interest on the Notes. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) Subject to the immediately succeeding sentence, the Additional Interest that is payable in accordance with Section 4.06 (d) or Section 4.06 (e) shall be in addition to, and not in lieu of, any Additional Interest that may be payable as a result of the Company&#8217;s election pursuant to Section 6.03. However, in no event shall any Additional Interest that may accrue as a result of the Company&#8217;s failure to comply with its obligations pursuant to Section 4.06(d) and Section 4.06(e), together with any Additional Interest payable at the Company&#8217;s election pursuant to Section 6.03 as the remedy for an Event of Default relating to its failure to comply with its obligations as set forth in Section 4.06(b), accrue at a rate in excess of 0.50% per annum, regardless of the number of events or circumstances giving rise to the requirement to pay such Additional Interest. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) If Additional Interest is payable by the Company pursuant to Section 4.06 (d) or Section 4.06 (e), the Company shall deliver to the Trustee an Officer&#8217;s Certificate to that effect stating (i) the amount of such Additional Interest that is payable and (ii) the date on which such Additional Interest is payable. Unless and until a Responsible Officer of the Trustee receives at the Corporate Trust Office such a certificate, the Trustee may assume without inquiry that no such Additional Interest is payable. If the Company has paid Additional Interest directly to the Persons entitled to it, the Company shall deliver to the Trustee an Officer&#8217;s Certificate setting forth the particulars of such payment. Neither the Trustee nor the Paying Agent shall have any responsibility for the determination, verification or calculation of any Additional Interest. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Stay, Extension and Usury Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law that would prohibit or forgive the Company from paying all or any portion of the principal of or interest on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or that may affect the covenants or the performance of this Indenture&#59; and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law had been enacted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Compliance Certificate&#59; Statements as to Defaults.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company shall deliver to the Trustee within 120 days after the end of each fiscal year of the Company (beginning with the fiscal year ending on December 31, 2017) an Officer&#8217;s Certificate that need not comply with Section 17.05 stating whether the signer thereof has knowledge of any Event of Default or Default that occurred during the previous fiscal year.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the Company shall deliver to the Trustee, within 30 days after the occurrence of any Event of Default or Default, an Officer&#8217;s Certificate setting forth the details of such Event of Default or Default, its status and the action that the Company is taking or proposing to take in respect thereof. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 4.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Further Instruments and Acts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Upon request of the Trustee, the Company will execute and deliver such further instruments and do such further acts as may be reasonably necessary or proper to carry out more effectively the purposes of this Indenture.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 5 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ISTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OLDERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EPORTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">RUSTEE</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Lists of Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company covenants and agrees that it will furnish or cause to be furnished to the Trustee, semi-annually, not more than 15 days after each April 15 and October 15 in each year beginning with October 15, 2017, and at such other times as the Trustee may request in writing, within 30 days after receipt by the Company of any such request (or such lesser time as the Trustee may reasonably request in order to enable it to timely provide any notice to be provided by it hereunder), a list in such form as the Trustee may reasonably require of the names and addresses of the Holders as of a date not more than 15 days (or such other date as the Trustee may reasonably request in order to so provide any such notices) prior to the time such information is furnished, except that no such list need be furnished so long as the Trustee is acting as Note Registrar.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Preservation and Disclosure of Lists.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the Holders contained in the most recent list furnished to it as provided in Section 5.01 or maintained by the Trustee in its capacity as Note Registrar, if so acting. The Trustee may destroy any list furnished to it as provided in Section 5.01 upon receipt of a new list so furnished.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 6 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EFAULTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EMEDIES</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Events of Default.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Each of the following events shall be an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; with respect to the Notes&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) default in any payment of interest on any Note when due and payable, and the default continues for a period of 30 days&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) default in the payment of principal of any Note when due and payable on the Maturity Date, upon Optional Redemption, upon any required repurchase, upon declaration of acceleration or otherwise&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) failure by the Company to comply with its obligation to convert the Notes in accordance with this Indenture upon exercise of a Holder&#8217;s conversion right, and such failure continues for a period of five Business Days&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) failure by the Company to issue a Fundamental Change Company Notice in accordance with Section 15.02(c), notice of the Effective Date of a Make-Whole Fundamental Change in accordance with Section 14.03(b) or notice of a specified corporate event in accordance with Section 14.01(b)(ii) or Section 14.01(b)(iii), in each case, when due&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) failure by the Company to comply with its obligations under Article 11&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) failure by the Company for 60 days after written notice has been received by the Company from the Trustee or by the Company and the Trustee from the Holders of at least 25% </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in principal amount of the Notes then outstanding to comply with any of its other agreements contained in the Notes or this Indenture&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) default by the Company or any Significant Subsidiary of the Company with respect to any mortgage, agreement or other instrument under which there may be outstanding, or by which there may be secured or evidenced, any indebtedness for money borrowed in excess of $15,000,000 (or its foreign currency equivalent) in the aggregate of the Company and&#47;or any such Significant Subsidiary, whether such indebtedness now exists or shall hereafter be created (i) resulting in such indebtedness becoming or being declared due and payable or (ii) constituting a failure to pay the principal or interest of any such indebtedness when due and payable at its stated maturity, upon required repurchase, upon declaration of acceleration or otherwise, if such default is not cured or waived, or such acceleration is not rescinded, within 30 days after written notice to the Company by the Trustee or to the Company and the Trustee by Holders of at least 25% in aggregate principal amount of the Notes then outstanding&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) the Company or any Significant Subsidiary shall commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to the Company or any such Significant Subsidiary or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of the Company or any such Significant Subsidiary or any substantial part of its property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally to pay its debts as they become due&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) an involuntary case or other proceeding shall be commenced against the Company or any Significant Subsidiary seeking liquidation, reorganization or other relief with respect to the Company or such Significant Subsidiary or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of the Company or such Significant Subsidiary or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of 90 consecutive days&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j) a final judgment or judgments for the payment of $15,000,000 (or its foreign currency equivalent) or more (excluding any amounts covered by insurance) in the aggregate rendered against the Company or any Significant Subsidiary, which judgment is not discharged, bonded, paid, waived or stayed within 60 days after (i) the date on which the right to appeal thereof has expired if no such appeal has commenced, or (ii) the date on which all rights to appeal have been extinguished. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Acceleration&#59; Rescission and Annulment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If one or more Events of Default shall have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body), then, and in each and every such case (other than an Event of Default specified in Section 6.01(h) or Section 6.01(i) with respect to the Company), unless the principal of all of the Notes shall have already become due and payable, either the Trustee or the Holders </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of at least 25% in aggregate principal amount of the Notes then outstanding determined in accordance with Section 8.04, by notice in writing to the Company (and to the Trustee if given by Holders), may declare 100% of the principal of, and accrued and unpaid interest on, all the Notes to be due and payable immediately, and upon any such declaration the same shall become and shall automatically be immediately due and payable, anything contained in this Indenture or in the Notes to the contrary notwithstanding. If an Event of Default specified in Section 6.01(h) or Section 6.01(i) with respect to the Company occurs and is continuing, 100% of the principal of, and accrued and unpaid interest, if any, on, all Notes shall become and shall automatically be immediately due and payable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The immediately preceding paragraph, however, is subject to the conditions that if, at any time after the principal of the Notes shall have been so declared due and payable, and before any judgment or decree for the payment of the monies due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum sufficient to pay installments of accrued and unpaid interest upon all Notes and the principal of any and all Notes that shall have become due otherwise than by acceleration (with interest on overdue installments of accrued and unpaid interest to the extent that payment of such interest is enforceable under applicable law, and on such principal at the rate borne by the Notes at such time) and amounts due to the Trustee pursuant to Section 7.06, and if (1) rescission would not conflict with any judgment or decree of a court of competent jurisdiction and (2) any and all existing Events of Default under this Indenture, other than the nonpayment of the principal of and accrued and unpaid interest, if any, on Notes that shall have become due solely by such acceleration, shall have been cured or waived pursuant to Section 6.09 and all amounts owing to the Trustee have been paid, then and in every such case (except as provided in the immediately succeeding sentence) the Holders of a majority in aggregate principal amount of the Notes then outstanding, by written notice to the Company and to the Trustee, may waive all Defaults or Events of Default with respect to the Notes and rescind and annul such declaration and its consequences and such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured for every purpose of this Indenture&#59; but no such waiver or rescission and annulment shall extend to or shall affect any subsequent Default or Event of Default, or shall impair any right consequent thereon. Notwithstanding anything to the contrary herein, no such waiver or rescission and annulment shall extend to or shall affect any Default or Event of Default resulting from (i) the nonpayment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, any Notes, (ii) a failure to repurchase any Notes when required or (iii) a failure to pay or deliver, as the case may be, the consideration due upon conversion of the Notes. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Additional Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding anything in this Indenture or in the Notes to the contrary, to the extent the Company elects, the sole remedy for an Event of Default relating to the Company&#8217;s failure to comply with its obligations as set forth in Section 4.06(b) shall (i) for the first 180 days after the occurrence of such an Event of Default (which, for the avoidance of doubt, shall not commence until the 60-day period described in Section 6.01(f) has passed), consist exclusively of the right to receive Additional Interest on the Notes at a rate equal to 0.25% per annum of the principal amount of the Notes outstanding for each day during such 180-day period on which such Event of Default is continuing and (ii) for the period from, and including, the 181st day after the occurrence of such an Event of Default to, and including, the</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360th day after the occurrence of such an Event of Default, consist exclusively of the right to receive Additional Interest on the Notes at a rate equal to 0.50% per annum of the principal amount of the Notes outstanding for each day during such additional 180-day period on which such an Event of Default is continuing. Subject to the last paragraph of this Section 6.03, Additional Interest payable pursuant to this Section 6.03 shall be in addition to, not in lieu of, any Additional Interest payable pursuant to Section 4.06(d) or Section 4.06(e). If the Company so elects, such Additional Interest shall be payable in the same manner and on the same dates as the stated interest payable on the Notes. On the 361st day after such Event of Default (if the Event of Default relating to the Company&#8217;s failure to comply with its obligations as set forth in Section 4.06(b) is not cured or waived prior to such 361st day), the Notes shall be immediately subject to acceleration as provided in Section 6.02. The provisions of this paragraph will not affect the rights of Holders of Notes in the event of the occurrence of any Event of Default other than the Company&#8217;s failure to comply with its obligations as set forth in Section 4.06(b). In the event the Company does not elect to pay Additional Interest following an Event of Default in accordance with this Section 6.03 or the Company elects to make such payment but does not pay the Additional Interest when due, the Notes shall be immediately subject to acceleration as provided in Section 6.02. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In order to elect to pay Additional Interest as the sole remedy during the first 360 days after the occurrence of any Event of Default described in the immediately preceding paragraph, the Company must notify all Holders of the Notes, the Trustee and the Paying Agent of such election prior to the beginning of such 360-day period (which, for the avoidance of doubt, shall not commence until the 60-day period described in Section 6.01(f) has passed). Upon the failure to timely give such notice, the Notes shall be immediately subject to acceleration as provided in Section 6.02. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In no event shall Additional Interest payable at the Company&#8217;s election as the remedy for an Event of Default relating to its failure to comply with its obligations under Section 4.06(b) as set forth in this Section 6.03, together with any interest that may accrue as a result of the Company&#8217;s failure to comply with its obligations as described in Section 4.06(d) and Section 4.06(e), accrue at a rate in excess of 0.50% per annum, regardless of the number of events or circumstances giving rise to the requirement to pay such Additional Interest. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Payments of Notes on Default&#59; Suit Therefor.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If an Event of Default described in clause (a) or (b) of Section 6.01 shall have occurred, the Company shall, upon demand of the Trustee, pay to the Trustee, for the benefit of the Holders of the Notes, the whole amount then due and payable on the Notes for principal and interest, if any, with interest on any overdue principal and interest, if any, at the rate borne by the Notes at such time, and, in addition thereto, such further amount as shall be sufficient to cover any amounts due to the Trustee under Section 7.06. If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon the Notes and collect the moneys adjudged or decreed to be payable in the manner provided by law out of the property of the Company or any other obligor upon the Notes, wherever situated.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event there shall be pending proceedings for the bankruptcy or for the reorganization of the Company or any other obligor on the Notes under Title 11 of the United States Code, or any other applicable law, or in case a receiver, assignee or trustee in bankruptcy or reorganization, liquidator, sequestrator or similar official shall have been appointed for or taken possession of the Company or such other obligor, the property of the Company or such other obligor, or in the event of any other judicial proceedings relative to the Company or such other obligor upon the Notes, or to the creditors or property of the Company or such other obligor, the Trustee, irrespective of whether the principal of the Notes shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any demand pursuant to the provisions of this Section 6.04, shall be entitled and empowered, by intervention in such proceedings or otherwise, to file and prove a claim or claims for the whole amount of principal and accrued and unpaid interest, if any, in respect of the Notes, and, in case of any judicial proceedings, to file such proofs of claim and other papers or documents and to take such other actions as it may deem necessary or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceedings relative to the Company or any other obligor on the Notes, its or their creditors, or its or their property, and to collect and receive any monies or other property payable or deliverable on any such claims, and to distribute the same after the deduction of any amounts due to the Trustee under Section 7.06&#59; and any receiver, assignee or trustee in bankruptcy or reorganization, liquidator, custodian or similar official is hereby authorized by each of the Holders to make such payments to the Trustee, as administrative expenses, and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due it for reasonable compensation, expenses, advances and disbursements, including agents and counsel fees, and including any other amounts due to the Trustee under Section 7.06, incurred by it up to the date of such distribution. To the extent that such payment of reasonable compensation, expenses, advances and disbursements out of the estate in any such proceedings shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all distributions, dividends, monies, securities and other property that the Holders of the Notes may be entitled to receive in such proceedings, whether in liquidation or under any plan of reorganization or arrangement or otherwise. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting such Holder or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All rights of action and of asserting claims under this Indenture, or under any of the Notes, may be enforced by the Trustee without the possession of any of the Notes, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for the payment of the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Notes. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In any proceedings brought by the Trustee (and in any proceedings involving the interpretation of any provision of this Indenture to which the Trustee shall be a party) the Trustee shall be held to represent all the Holders of the Notes, and it shall not be necessary to make any Holders of the Notes parties to any such proceedings. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In case the Trustee shall have proceeded to enforce any right under this Indenture and such proceedings shall have been discontinued or abandoned because of any waiver pursuant to Section 6.09 or any rescission and annulment pursuant to Section 6.02 or for any other reason or shall have been determined adversely to the Trustee, then and in every such case the Company, the Holders and the Trustee shall, subject to any determination in such proceeding, be restored respectively to their several positions and rights hereunder, and all rights, remedies and powers of the Company, the Holders and the Trustee shall continue as though no such proceeding had been instituted. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Application of Monies Collected by Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any money or property collected by the Trustee pursuant to this Article 6, and after an Event of Default any money or other property distributable in respect of the Company&#8217;s obligations under this Indenture, shall be applied in the following order, at the date or dates fixed by the Trustee for the distribution of such monies, upon presentation of the several Notes, and stamping thereon the payment, if only partially paid, and upon surrender thereof, if fully paid&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, to the payment of all amounts due the Trustee under this Indenture&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, in case the principal of the outstanding Notes shall not have become due and be unpaid, to the payment of interest on, and any cash due upon conversion of, the Notes in default in the order of the date due of the payments of such interest and cash due upon conversion, as the case may be, with interest (to the extent that such interest has been collected by the Trustee) upon such overdue payments at the rate borne by the Notes at such time, such payments to be made ratably to the Persons entitled thereto&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, in case the principal of the outstanding Notes shall have become due, by declaration or otherwise, and be unpaid to the payment of the whole amount (including, if applicable, the payment of the Redemption Price, the Fundamental Change Repurchase Price and any cash due upon conversion) then owing and unpaid upon the Notes for principal and interest, if any, with interest on the overdue principal and, to the extent that such interest has been collected by the Trustee, upon overdue installments of interest at the rate borne by the Notes at such time, and in case such monies shall be insufficient to pay in full the whole amounts so due and unpaid upon the Notes, then to the payment of such principal (including, if applicable, the Redemption Price, the Fundamental Change Repurchase Price and the cash due upon conversion) and interest without preference or priority of principal over interest, or of interest over principal or of any installment of interest over any other installment of interest, or of any Note over any other Note, ratably to the aggregate of such principal (including, if applicable, the Redemption Price, the Fundamental Change Repurchase Price and any cash due upon conversion) and accrued and unpaid interest&#59; and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, to the payment of the remainder, if any, to the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Proceedings by Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Except to enforce the right to receive payment of principal (including, if applicable, the Redemption Price and the Fundamental Change Repurchase Price) or interest when due, or the right to receive payment or delivery of the consideration due upon conversion, no Holder of any Note shall have any right by virtue of or by availing of any provision of this Indenture to institute any suit, action or proceeding in equity or at law upon or under or with respect to this Indenture, or for the appointment of a receiver, trustee, liquidator, custodian or other similar official, or for any other remedy hereunder, unless&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) such Holder previously shall have given to the Trustee written notice of an Event of Default and of the continuance thereof, as herein provided&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Holders of at least 25% in aggregate principal amount of the Notes then outstanding shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) such Holders shall have offered to the Trustee such security or indemnity reasonably satisfactory to it against any loss, cost, liability or expense to be incurred therein or thereby&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) the Trustee for 60 days after its receipt of such notice, request and offer of such security or indemnity, shall have neglected or refused to institute any such action, suit or proceeding&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) no written direction that, in the opinion of the Trustee, is inconsistent with such written request shall have been given to the Trustee by the Holders of a majority of the aggregate principal amount of the Notes then outstanding within such 60-day period pursuant to Section 6.09, </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">it being understood and intended, and being expressly covenanted by the taker and Holder of every Note with every other taker and Holder and the Trustee that no one or more Holders shall have any right in any manner whatever by virtue of or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of any other Holder, or to obtain or seek to obtain priority over or preference to any other such Holder, or to enforce any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all Holders (except as otherwise provided herein). For the protection and enforcement of this Section 6.06, each and every Holder and the Trustee shall be entitled to such relief as can be given either at law or in equity. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any other provision of this Indenture and any provision of any Note, the right of any Holder to receive payment or delivery, as the case may be, of (x) the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, (y) accrued and unpaid interest, if any, on, and (z) the consideration due upon conversion of, such Note, on or after the respective due dates expressed or provided for in such Note or in this Indenture, or to institute suit for the enforcement of any such payment or delivery, as the case may be, on or after such respective dates against the Company shall not be impaired or affected without the consent of such Holder. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Proceedings by Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In case of an Event of Default, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as are necessary to protect and enforce any of such rights, either by suit in equity or by action at law or by proceeding in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in this Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture or by law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Remedies Cumulative and Continuing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Except as provided in the last paragraph of Section 2.06, all powers and remedies given by this Article 6 to the Trustee or to the Holders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any thereof or of any other powers and remedies available to the Trustee or the Holders of the Notes, by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture, and no delay or omission of the Trustee or of any Holder of any of the Notes to exercise any right or power accruing upon any Default or Event of Default shall impair any such right or power, or shall be construed to be a waiver of any such Default or Event of Default or any acquiescence therein&#59; and, subject to the provisions of Section 6.06, every power and remedy given by this Article 6 or by law to the Trustee or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Direction of Proceedings and Waiver of Defaults by Majority of Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Holders of a majority of the aggregate principal amount of the Notes at the time outstanding determined in accordance with Section 8.04 shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee with respect to the Notes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that (a) such direction shall not be in conflict with any rule of law or with this Indenture, and (b) the Trustee may take any other action deemed proper by the Trustee that is not inconsistent with such direction. The Trustee may refuse to follow any direction that it determines is unduly prejudicial to the rights of any other Holder (it being understood that the Trustee does not have an affirmative duty to ascertain whether or not any such directions are unduly prejudicial to such Holders) or that would involve the Trustee in personal liability. The Holders of a majority in aggregate principal amount of the Notes at the time outstanding determined in accordance with Section 8.04 may on behalf of the Holders of all of the Notes waive any past Default or Event of Default hereunder and its consequences except (i) a default in the payment of accrued and unpaid interest, if any, on, or the principal (including any Redemption Price and any Fundamental Change Repurchase Price) of, the Notes when due that has not been cured pursuant to the provisions of Section 6.01, (ii) a failure by the Company to pay or deliver, as the case may be, the consideration due upon conversion of the Notes or (iii) a default in respect of a covenant or provision hereof which under Section 10.02 cannot be modified or amended without the consent of each Holder of an outstanding Note affected. Upon any such waiver the Company, the Trustee and the Holders of the Notes shall be restored to their former positions and rights hereunder&#59; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon. Whenever any Default or Event of Default hereunder shall have been waived as permitted by this Section 6.09, said Default or Event of Default shall for all purposes of the Notes and this Indenture be deemed to have been cured and</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to be not continuing&#59; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Notice of Defaults.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Trustee shall deliver to all Holders notice of all Defaults actually known to a Responsible Officer that have occurred and are continuing within 90 days after a Responsible Officer receives written notice thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that, except in the case of a Default in the payment of the principal of (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable), or accrued and unpaid interest on, any of the Notes or a Default in the payment or delivery of the consideration due upon conversion, the Trustee shall be protected in withholding such notice if and so long as the Trustee in good faith determines that the withholding of such notice is in the interests of the Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Undertaking to Pay Costs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All parties to this Indenture agree, and each Holder of any Note by its acceptance thereof shall be deemed to have agreed, that any court may, in its discretion, require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit and that such court may in its discretion assess reasonable costs, including reasonable attorneys&#8217; fees and expenses, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that the provisions of this Section 6.11 (to the extent permitted by law) shall not apply to any suit instituted by the Trustee, to any suit instituted by any Holder, or group of Holders, holding in the aggregate more than 10% in principal amount of the Notes at the time outstanding determined in accordance with Section 8.04, or to any suit instituted by any Holder for the enforcement of the payment of the principal of or accrued and unpaid interest, if any, on any Note (including, but not limited to, the Redemption Price and the Fundamental Change Repurchase Price, if applicable) on or after the due date expressed or provided for in such Note or to any suit for the enforcement of the right to convert any Note, or receive the consideration due upon conversion, in accordance with the provisions of Article 14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 7 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONCERNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">RUSTEE</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Duties and Responsibilities of Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Trustee, prior to the occurrence of an Event of Default and after the curing or waiver of all Events of Default that may have occurred, undertakes to perform such duties and only such duties as are specifically set forth in this Indenture. In the event an Event of Default has occurred and is continuing, the Trustee shall exercise such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in its exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person&#8217;s own affairs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that if an Event of Default occurs and is continuing, the Trustee will be under no obligation to exercise any of the rights or powers under this Indenture at the request or direction of any of the Holders unless such Holders have offered to the Trustee indemnity or security reasonably satisfactory to it against any loss, cost, liability or expense that might be incurred by it in compliance with such request or direction.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No provision of this Indenture shall be construed to relieve the Trustee from liability for its own grossly negligent action, its own grossly negligent failure to act or its own willful misconduct, except that&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) prior to the occurrence of an Event of Default and after the curing or waiving of all Events of Default that may have occurred&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) the duties and obligations of the Trustee shall be determined solely by the express provisions of this Indenture, and the Trustee shall not be liable except for the performance of such duties and obligations as are specifically set forth in this Indenture and no implied covenants or obligations shall be read into this Indenture against the Trustee&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) in the absence of bad faith and willful misconduct on the part of the Trustee, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture&#59; but, in the case of any such certificates or opinions that by any provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of any mathematical calculations or other facts stated therein)&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Officers of the Trustee, unless it shall be proved that the Trustee was grossly negligent in ascertaining the pertinent facts&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the Holders of not less than a majority of the aggregate principal amount of the Notes at the time outstanding determined as provided in Section 8.04 relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) whether or not therein provided, every provision of this Indenture relating to the conduct or affecting the liability of, or affording protection to, the Trustee shall be subject to the provisions of this Section&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) the Trustee shall not be liable in respect of any payment (as to the correctness of amount, entitlement to receive or any other matters relating to payment) or notice effected by the Company or any Paying Agent or any records maintained by any co-Note Registrar with respect to the Notes&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) if any party fails to deliver a notice relating to an event the fact of which, pursuant to this Indenture, requires notice to be sent to the Trustee, the Trustee may conclusively rely on its failure to receive such notice as reason to act as if no such event occurred, unless a Responsible Officer of the Trustee had actual knowledge of such event&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) in the absence of written investment direction from the Company, all cash received by the Trustee shall be placed in a non-interest bearing trust account, and in no event shall the Trustee be liable for the selection of investments or for investment losses incurred thereon or for losses incurred as a result of the liquidation of any such investment prior to its maturity date or the failure of the party directing such investments prior to its maturity date or the failure of the party directing such investment to provide timely written investment direction, and the Trustee shall have no obligation to invest or reinvest any amounts held hereunder in the absence of such written investment direction from the Company&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) in the event that the Trustee is also acting as Custodian, Note Registrar, Paying Agent, Conversion Agent or transfer agent hereunder, the rights and protections afforded to the Trustee pursuant to this Article 7 shall also be afforded to such Custodian, Note Registrar, Paying Agent, Conversion Agent or transfer agent. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal financial liability in the performance of any of its duties or in the exercise of any of its rights or powers. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reliance on Documents, Opinions, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as otherwise provided in Section 7.01&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) before the Trustee acts or refrains from acting, it may require an Officer&#8217;s Certificate, an Opinion of Counsel or both, and the Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on such certificate or opinion&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) the Trustee may conclusively rely and shall be fully protected in acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, bond, note, coupon or other paper or document (whether in its original or facsimile form) believed by it in good faith to be genuine and to have been signed or presented by the proper party or parties&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by an Officer&#8217;s Certificate (unless other evidence in respect thereof be herein specifically prescribed)&#59; and any Board Resolution may be evidenced to the Trustee by a copy thereof certified by the Secretary or an Assistant Secretary of the Company&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) the Trustee may consult with counsel of its election and require an Opinion of Counsel, and any advice of such counsel or Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken or omitted by it hereunder in good faith and in accordance with such advice or Opinion of Counsel&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) the Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the Company, personally or by agent or</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">attorney at the expense of the Company and shall incur no liability of any kind by reason of such inquiry or investigation&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) the Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents, custodians, nominees or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent, custodian, nominee or attorney appointed by it with due care hereunder&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) the permissive rights of the Trustee enumerated herein shall not be construed as duties&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) under no circumstances shall the Trustee be liable in its individual capacity for the obligations evidenced by the Notes&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) the rights, privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its right to be compensated, reimbursed and indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and each agent, custodian and other Person employed to act hereunder&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j) the Trustee shall not be required to give any bond or surety in respect of the performance of its powers and duties hereunder&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k) the Trustee may request that the Company deliver a certificate setting forth the names of individuals and&#47;or titles of officers authorized at such time to take specified actions pursuant to this Indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In no event shall the Trustee be liable for any consequential, punitive, indirect or special loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action. The Trustee shall not be charged with knowledge of any Default or Event of Default with respect to the Notes, unless either (1) a Responsible Officer shall have actual knowledge of such Default or Event of Default or (2) written notice of such Default or Event of Default shall have been given to the Trustee by the Company or by any Holder of the Notes at the Corporate Trust Office and such notice references the Notes and this Indenture. The Trustee shall not be liable for any action it takes or omits to take in good faith that it believes to be authorized or within the rights or powers conferred upon it by this Indenture, unless it shall be proved that the Trustee was grossly negligent in ascertaining the pertinent facts. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. No Responsibility for Recitals, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The recitals contained herein and in the Notes (except in the Trustee&#8217;s certificate of authentication) shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the same. The Trustee makes no representations as to and shall not be responsible for the validity or sufficiency of this Indenture or of the Notes. The Trustee shall not be accountable for the use or application by the Company of any Notes or the proceeds of any Notes authenticated and delivered by the Trustee in conformity with the provisions of this Indenture or any money paid to the Company or upon the Company&#8217;s direction under any provision of this Indenture. The Trustee shall not be bound to ascertain or inquire as to the performance, observance, or breach of any covenants,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">conditions, representations, warranties or agreements on the part of the Company, but the Trustee may require full information and advice as to the performance of the aforementioned covenants. The Trustee makes no representation as to and shall not be responsible for any statement or recital herein or any statement in the Offering Memorandum or any other document in connection with the sale of the Notes. The Trustee shall have no obligation to independently determine or verify if any Fundamental Change, Make Whole Fundamental Change, Merger Event, or any other event has occurred or notify the Holders of any such event. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Trustee, Paying Agents, Conversion Agents, Bid Solicitation Agent or Note Registrar May Own Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Trustee, any Paying Agent, any Conversion Agent, Bid Solicitation Agent (if other than the Company) or Note Registrar, in its individual or any other capacity, may become the owner or pledgee of Notes with the same rights it would have if it were not the Trustee, Paying Agent, Conversion Agent and may become a creditor of, or otherwise deal with, the Company or any of its Affiliates with the same rights it would have if it were not Trustee, Bid Solicitation Agent or Note Registrar.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Monies and Shares of Common Stock to Be Held in Trust.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All monies and shares of Common Stock received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received. Money and shares of Common Stock held by the Trustee in trust hereunder need not be segregated from other funds except to the extent required by law. The Trustee shall be under no liability for interest on any money or shares of Common Stock received by it hereunder except as may be agreed in writing from time to time by the Company and the Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Compensation and Expenses of Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company covenants and agrees to pay to the Trustee from time to time, and the Trustee shall receive, such compensation for all services rendered by it hereunder in any capacity (which shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust) as mutually agreed to in writing between the Trustee and the Company, and the Company will pay or reimburse the Trustee upon its request for all reasonable expenses, disbursements and advances reasonably incurred or made by the Trustee in accordance with any of the provisions of this Indenture in any capacity thereunder (including the reasonable compensation and the expenses and disbursements of its agents and counsel and of all Persons not regularly in its employ) except any such expense, disbursement or advance as shall have been caused by its gross negligence or willful misconduct as finally adjudicated by a court of competent jurisdiction. The Company also covenants to indemnify the Trustee in any capacity under this Indenture and any other document or transaction entered into in connection herewith and its agents and any authenticating agent for, and to hold them harmless against, any loss, claim (whether asserted by the Company, a Holder or any other Person), damage, liability, cost or expense incurred without gross negligence or willful misconduct as finally adjudicated by a court of competent jurisdiction on the part of the Trustee, its officers, directors, agents or employees, or such agent or authenticating agent, as the case may be, and arising out of or in connection with the acceptance or administration of this Indenture or in any other capacity hereunder, including the costs and expenses of defending themselves against any claim of liability in the premises. The obligations of the Company under this Section 7.06 to compensate or indemnify the Trustee and to pay or reimburse the Trustee for expenses, disbursements and advances shall be secured by a senior claim to which the Notes are hereby made subordinate on all money or property held or collected</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by the Trustee, except, subject to the effect of Section 6.05, funds held in trust herewith for the benefit of the Holders of particular Notes, and for the avoidance of doubt, such lien shall not be extended in a manner that would conflict with the Company&#8217;s obligations to its other creditors. The Trustee&#8217;s right to receive payment of any amounts due under this Section 7.06 shall not be subordinate to any other liability or indebtedness of the Company. The obligations of the Company under this Section 7.06 shall survive the satisfaction and discharge of this Indenture and the earlier resignation or removal of the Trustee. The Company need not pay for any settlement made without its consent, which consent shall not be unreasonably withheld. The indemnification provided in this Section 7.06 shall extend to the officers, directors, agents and employees of the Trustee. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Without prejudice to any other rights available to the Trustee under applicable law, when the Trustee and its agents and any authenticating agent incur expenses or render services after an Event of Default specified in Section 6.01(h) or Section 6.01(i) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any bankruptcy, insolvency or similar laws. &#8220;Trustee&#8221; for the purposes of this Section 7.06 shall include any predecessor Trustee and the Trustee in each of its capacities hereunder and each agent, custodian and other person employed to act hereunder&#59; provided, however, that the gross negligence or willful misconduct of any Trustee hereunder shall not affect the rights of any other Trustee hereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Officer&#8217;s Certificate and Opinion of Counsel as Evidence. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except as otherwise provided in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it necessary or desirable that a matter be proved or established prior to taking or omitting any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of gross negligence and willful misconduct on the part of the Trustee, be deemed to be conclusively proved and established by an Officer&#8217;s Certificate and Opinion of Counsel delivered to the Trustee, and such Officer&#8217;s Certificate and Opinion of Counsel, in the absence of gross negligence and willful misconduct on the part of the Trustee, shall be full warrant to the Trustee for any action taken or omitted by it under the provisions of this Indenture upon the faith thereof.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Eligibility of Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> There shall at all times be a Trustee hereunder which shall be a Person that is eligible pursuant to the Trust Indenture Act (as if the Trust Indenture Act were applicable hereto) to act as such and has a combined capital and surplus of at least $50,000,000. If such Person publishes reports of condition at least annually, pursuant to law or to the requirements of any supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such Person shall be deemed to be its combined capital and surplus as set forth in its most recent report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, it shall resign immediately in the manner and with the effect hereinafter specified in this Article.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Resignation or Removal of Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) The Trustee may at any time resign by giving 30 days&#8217; advance written notice of such resignation to the Company and by delivering notice thereof to the Holders. Upon receiving such notice of resignation, the Company shall promptly appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the resigning Trustee and </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted appointment within 30 days after the giving of such notice of resignation to the Holders, the resigning Trustee may, upon ten Business Days&#8217; advance written notice to the Company and the Holders, petition any court of competent jurisdiction at the expense of the Company for the appointment of a successor trustee, or any Holder who has been a bona fide holder of a Note or Notes for at least six months (or since the date of this Indenture) may, subject to the provisions of Section 6.11, on behalf of himself or herself and all others similarly situated, petition any such court for the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) In case at any time any of the following shall occur&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) the Trustee shall cease to be eligible in accordance with the provisions of Section 7.08 and shall fail to resign after written request therefor by the Company or by any such Holder, or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) the Trustee shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation, </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">then, in either case, the Company may by a Board Resolution remove the Trustee and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or, subject to the provisions of Section 6.11, any Holder who has been a bona fide holder of a Note or Notes for at least six months (or since the date of this Indenture) may, on behalf of himself or herself and all others similarly situated, petition any court of competent jurisdiction at the expense of the Company for the removal of the Trustee and the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) The Holders of a majority in aggregate principal amount of the Notes at the time outstanding, as determined in accordance with Section 8.04, may at any time on 30 days&#8217; advance written notice remove the Trustee and nominate a successor trustee that shall be deemed appointed as successor trustee unless, within ten days after notice to the Company of such nomination, the Company objects thereto, in which case the Trustee so removed or any Holder, upon the terms and conditions and otherwise as in Section 7.09(a) provided, may petition any court of competent jurisdiction for an appointment of a successor trustee. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Any resignation or removal of the Trustee and appointment of a successor trustee pursuant to any of the provisions of this Section 7.09 shall become effective upon acceptance of appointment by the successor trustee as provided in Section 7.10. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Acceptance by Successor Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any successor trustee appointed as provided in Section 7.09 shall execute, acknowledge and deliver to the Company and to its predecessor trustee an instrument accepting such appointment hereunder, and thereupon the resignation or removal of the predecessor trustee shall become effective and such successor </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, duties and obligations of its predecessor hereunder, with like effect as if originally named as Trustee herein&#59; but, nevertheless, on the written request of the Company or of the successor trustee, the trustee ceasing to act shall, upon payment of any amounts then due it pursuant to the provisions of Section 7.06, execute and deliver an instrument transferring to such successor trustee all the rights and powers of the trustee so ceasing to act. Upon request of any such successor trustee, the Company shall execute any and all instruments in writing for more fully and certainly vesting in and confirming to such successor trustee all such rights and powers. Any trustee ceasing to act shall, nevertheless, retain a senior claim to which the Notes are hereby made subordinate on all money or property held or collected by such trustee as such, except for funds held in trust for the benefit of Holders of particular Notes, to secure any amounts then due it pursuant to the provisions of Section 7.06. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No successor trustee shall accept appointment as provided in this Section 7.10 unless at the time of such acceptance such successor trustee shall be eligible under the provisions of Section 7.08. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon acceptance of appointment by a successor trustee as provided in this Section 7.10, each of the Company and the successor trustee, at the written direction and at the expense of the Company shall deliver or cause to be delivered notice of the succession of such trustee hereunder to the Holders. If the Company fails to deliver such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be delivered at the expense of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Succession by Merger, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any corporation or other entity into which the Trustee may be merged or converted or with which it may be consolidated, or any corporation or other entity resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation or other entity succeeding to all or substantially all of the corporate trust business of the Trustee (including the administration of this Indenture), shall be the successor to the Trustee hereunder without the execution or filing of any paper or any further act on the part of any of the parties hereto&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that in the case of any corporation or other entity succeeding to all or substantially all of the corporate trust business of the Trustee such corporation or other entity shall be eligible under the provisions of Section 7.08.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In case at the time such successor to the Trustee shall succeed to the trusts created by this Indenture, any of the Notes shall have been authenticated but not delivered, any such successor to the Trustee may adopt the certificate of authentication of any predecessor trustee or authenticating agent appointed by such predecessor trustee, and deliver such Notes so authenticated&#59; and in case at that time any of the Notes shall not have been authenticated, any successor to the Trustee or an authenticating agent appointed by such successor trustee may authenticate such Notes either in the name of any predecessor trustee hereunder or in the name of the successor trustee&#59; and in all such cases such certificates shall have the full force which it is anywhere in the Notes or in this Indenture provided that the certificate of the Trustee shall have&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that the right to adopt the certificate of authentication of any predecessor trustee or to authenticate Notes in the name of any predecessor trustee shall apply only to its successor or successors by merger, conversion or consolidation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 7.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Trustee&#8217;s Application for Instructions from the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any application by the Trustee for written instructions from the Company (other than with regard to any action proposed to be taken or omitted to be taken by the Trustee that affects the rights of the Holders of the Notes under this Indenture) may, at the option of the Trustee, set forth in writing any action proposed to be taken or omitted by the Trustee under this Indenture and the date on and&#47;or after which such action shall be taken or such omission shall be effective. The Trustee shall not be liable to the Company for any action taken by, or omission of, the Trustee in accordance with a proposal included in such application on or after the date specified in such application (which date shall not be less than three Business Days after the date any officer that the Company has indicated to the Trustee should receive such application actually receives such application, unless any such officer shall have consented in writing to any earlier date), unless, prior to taking any such action (or the effective date in the case of any omission), the Trustee shall have received written instructions in accordance with this Indenture in response to such application specifying the action to be taken or omitted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 8 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONCERNING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OLDERS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Action by Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Whenever in this Indenture it is provided that the Holders of a specified percentage of the aggregate principal amount of the Notes may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action, the Holders of such specified percentage have joined therein may be evidenced (a) by any instrument or any number of instruments of similar tenor executed by Holders in person or by agent or proxy appointed in writing, or (b) by the record of the Holders voting in favor thereof at any meeting of Holders duly called and held in accordance with the provisions of Article 9, or (c) by a combination of such instrument or instruments and any such record of such a meeting of Holders. Whenever the Company or the Trustee solicits the taking of any action by the Holders of the Notes, the Company or the Trustee may, but shall not be required to, fix in advance of such solicitation, a date as the record date for determining Holders entitled to take such action. The record date if one is selected shall be not more than fifteen days prior to the date of commencement of solicitation of such action.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Proof of Execution by Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject to the provisions of Section 7.01, Section 7.02 and Section 9.05, proof of the execution of any instrument by a Holder or its agent or proxy shall be sufficient if made in accordance with such reasonable rules and regulations as may be prescribed by the Trustee or in such manner as shall be satisfactory to the Trustee. The holding of Notes shall be proved by the Note Register or by a certificate of the Note Registrar. The record of any Holders&#8217; meeting shall be proved in the manner provided in Section 9.06.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Who Are Deemed Absolute Owners</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Company, the Trustee, any authenticating agent, any Paying Agent, any Conversion Agent and any Note Registrar may deem the Person in whose name a Note shall be registered upon the Note Register to be, and may treat it as, the absolute owner of such Note (whether or not such Note shall be overdue and </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">notwithstanding any notation of ownership or other writing thereon made by any Person other than the Company or any Note Registrar) for the purpose of receiving payment of or on account of the principal (including any Redemption Price and any Fundamental Change Repurchase Price) of and (subject to Section 2.03) accrued and unpaid interest on such Note, for conversion of such Note and for all other purposes&#59; and neither the Company nor the Trustee nor any Paying Agent nor any Conversion Agent nor any Note Registrar shall be affected by any notice to the contrary. The sole registered holder of a Global Note shall be the Depositary or its nominee. All such payments or deliveries so made to any Holder for the time being, or upon its order, shall be valid, and, to the extent of the sums or shares of Common Stock so paid or delivered, effectual to satisfy and discharge the liability for monies payable or shares deliverable upon any such Note. Notwithstanding anything to the contrary in this Indenture or the Notes following an Event of Default, any holder of a beneficial interest in a Global Note may directly enforce against the Company, without the consent, solicitation, proxy, authorization or any other action of the Depositary or any other Person, such holder&#8217;s right to exchange such beneficial interest for a Note in certificated form in accordance with the provisions of this Indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Company-Owned Notes Disregarded.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In determining whether the Holders of the requisite aggregate principal amount of Notes have concurred in any direction, consent, waiver or other action under this Indenture, Notes that are owned by the Company, by any Subsidiary thereof or by any Affiliate of the Company or any Subsidiary thereof shall be disregarded and deemed not to be outstanding for the purpose of any such determination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that for the purposes of determining whether the Trustee shall be protected in relying on any such direction, consent, waiver or other action, only Notes that a Responsible Officer knows are so owned shall be so disregarded. Notes so owned that have been pledged in good faith may be regarded as outstanding for the purposes of this Section 8.04 if the pledgee shall establish to the satisfaction of the Trustee the pledgee&#8217;s right to so act with respect to such Notes and that the pledgee is not the Company, a Subsidiary thereof or an Affiliate of the Company or a Subsidiary thereof. In the case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee. Upon request of the Trustee, the Company shall furnish to the Trustee promptly an Officer&#8217;s Certificate listing and identifying all Notes, if any, known by the Company to be owned or held by or for the account of any of the above described Persons&#59; and, subject to Section 7.01, the Trustee shall be entitled to accept such Officer&#8217;s Certificate as conclusive evidence of the facts therein set forth and of the fact that all Notes not listed therein are outstanding for the purpose of any such determination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 8.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Revocation of Consents&#59; Future Holders Bound.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> At any time prior to (but not after) the evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the Holders of the percentage of the aggregate principal amount of the Notes specified in this Indenture in connection with such action, any Holder of a Note that is shown by the evidence to be included in the Notes the Holders of which have consented to such action may, by filing written notice with the Trustee at its Corporate Trust Office and upon proof of holding as provided in Section 8.02, revoke such action so far as concerns such Note. Except as aforesaid, any such action taken by the Holder of any Note shall be conclusive and binding upon such Holder and upon all future Holders and owners of such Note and of any Notes issued in exchange or substitution therefor or upon registration of transfer thereof, irrespective of whether</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any notation in regard thereto is made upon such Note or any Note issued in exchange or substitution therefor or upon registration of transfer thereof.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OLDERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217; M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EETINGS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Purpose of Meetings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A meeting of Holders may be called at any time and from time to time pursuant to the provisions of this Article 9 for any of the following purposes&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) to give any notice to the Company or to the Trustee or to give any directions to the Trustee permitted under this Indenture, or to consent to the waiving of any Default or Event of Default hereunder (in each case, as permitted under this Indenture) and its consequences, or to take any other action authorized to be taken by Holders pursuant to any of the provisions of Article 6&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) to remove the Trustee and nominate a successor trustee pursuant to the provisions of Article 7&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) to consent to the execution of an indenture or indentures supplemental hereto pursuant to the provisions of Section 10.02&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) to take any other action authorized to be taken by or on behalf of the Holders of any specified aggregate principal amount of the Notes under any other provision of this Indenture or under applicable law. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Call of Meetings by Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Trustee may at any time call a meeting of Holders to take any action specified in Section 9.01, to be held at such time and at such place as the Trustee shall determine. Notice of every meeting of the Holders, setting forth the time and the place of such meeting and in general terms the action proposed to be taken at such meeting and the establishment of any record date pursuant to Section 8.01, shall be delivered to Holders of such Notes. Such notice shall also be delivered to the Company. Such notices shall be delivered not less than 20 nor more than 90 days prior to the date fixed for the meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any meeting of Holders shall be valid without notice if the Holders of all Notes then outstanding are present in person or by proxy or if notice is waived before or after the meeting by the Holders of all Notes then outstanding, and if the Company and the Trustee are either present by duly authorized representatives or have, before or after the meeting, waived notice. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Call of Meetings by Company or Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In case at any time the Company, pursuant to a Board Resolution, or the Holders of at least 10% of the aggregate principal amount of the Notes then outstanding, shall have requested the Trustee to call a meeting of Holders, by written request setting forth in reasonable detail the action proposed to be taken at the meeting, and the Trustee shall not have delivered the notice of such meeting within 20 days after receipt of such request, then the Company or such Holders may determine the time and the place for such meeting and may call such meeting to take any action authorized in Section 9.01, by delivering notice thereof as provided in Section 9.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Qualifications for Voting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To be entitled to vote at any meeting of Holders a Person shall (a) be a Holder of one or more Notes on the record date pertaining to such meeting or (b) be a Person appointed by an instrument in writing as proxy by a Holder of one or more Notes on the record date pertaining to such meeting. The only Persons who shall be entitled to be present or to speak at any meeting of Holders shall be the Persons entitled to vote at such meeting and their counsel and any representatives of the Trustee and its counsel and any representatives of the Company and its counsel.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Notwithstanding any other provisions of this Indenture, the Trustee may make such reasonable regulations as it may deem advisable for any meeting of Holders, in regard to proof of the holding of Notes and of the appointment of proxies, and in regard to the appointment and duties of inspectors of votes, the submission and examination of proxies, certificates and other evidence of the right to vote, and such other matters concerning the conduct of the meeting as it shall think fit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Trustee shall, by an instrument in writing, appoint a temporary chairman of the meeting, unless the meeting shall have been called by the Company or by Holders as provided in Section 9.03, in which case the Company or the Holders calling the meeting, as the case may be, shall in like manner appoint a temporary chairman. A permanent chairman and a permanent secretary of the meeting shall be elected by vote of the Holders of a majority in aggregate principal amount of the outstanding Notes represented at the meeting and entitled to vote at the meeting. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the provisions of Section 8.04, at any meeting of Holders each Holder or proxyholder shall be entitled to one vote for each $1,000 principal amount of Notes held or represented by him or her&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that no vote shall be cast or counted at any meeting in respect of any Note challenged as not outstanding and ruled by the chairman of the meeting to be not outstanding. The chairman of the meeting shall have no right to vote other than by virtue of Notes held by it or instruments in writing as aforesaid duly designating it as the proxy to vote on behalf of other Holders. Any meeting of Holders duly called pursuant to the provisions of Section 9.02 or Section 9.03 may be adjourned from time to time by the Holders of a majority of the aggregate principal amount of Notes represented at the meeting, whether or not constituting a quorum, and the meeting may be held as so adjourned without further notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.06.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The vote upon any resolution submitted to any meeting of Holders shall be by written ballot on which shall be subscribed the signatures of the Holders or of their representatives by proxy and the outstanding aggregate principal amount of the Notes held or represented by them. The permanent chairman of the meeting shall appoint two inspectors of votes who shall count all votes cast at the meeting for or against any resolution and who shall make and file with the secretary of the meeting their verified written reports in duplicate of all votes cast at the meeting. A record in duplicate of the proceedings of each meeting of Holders shall be prepared by the secretary of the meeting and there shall be attached to said record the original reports of the inspectors of votes on any vote by ballot taken thereat and affidavits by one or more Persons having knowledge of the facts setting forth a copy of the notice of the meeting and showing that said notice was delivered as provided in Section 9.02. The record shall show the aggregate principal amount of the Notes voting in favor of or against any resolution. The record shall be signed and verified by the affidavits of the permanent chairman </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and secretary of the meeting and one of the duplicates shall be delivered to the Company and the other to the Trustee to be preserved by the Trustee, the latter to have attached thereto the ballots voted at the meeting. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any record so signed and verified shall be conclusive evidence of the matters therein stated. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 9.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. No Delay of Rights by Meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Nothing contained in this Article 9 shall be deemed or construed to authorize or permit, by reason of any call of a meeting of Holders or any rights expressly or impliedly conferred hereunder to make such call, any hindrance or delay in the exercise of any right or rights conferred upon or reserved to the Trustee or to the Holders under any of the provisions of this Indenture or of the Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 10 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">UPPLEMENTAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NDENTURES</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Supplemental Indentures Without Consent of Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company, when authorized by the resolutions of the Board of Directors and the Trustee, at the Company&#8217;s expense, may from time to time and at any time enter into an indenture or indentures supplemental hereto for one or more of the following purposes&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) to cure any ambiguity, omission, defect or inconsistency, as set forth in an Officer&#8217;s Certificate&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) to provide for the assumption by a Successor Company of the obligations of the Company under the Notes and this Indenture pursuant to Article 11&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) to add guarantees with respect to the Notes&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) to secure the Notes&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) to add to the covenants or Events of Default of the Company for the benefit of the Holders or surrender any right or power conferred upon the Company under this Indenture&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) to make any change that does not adversely affect the rights of any Holder&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) to increase the Conversion Rate as provided in Article 14&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) to provide for the acceptance of appointment by a successor trustee or facilitate the administration of the trusts under this Indenture by more than one trustee&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) to provide that the Notes are convertible into Reference Property in connection with any Merger Event, subject to the provisions of Section 14.02, and make such related changes to the terms of the Notes in accordance with Section 14.07&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j) to conform the provisions of this Indenture or the Notes to the &#8220;Description of Notes&#8221; section of the Offering Memorandum, as set forth in an Officer&#8217;s Certificate&#59; or </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k) to irrevocably elect a Settlement Method (including a Default Settlement Method). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon the written request of the Company, the Trustee is hereby authorized to join with the Company in the execution of any such supplemental indenture, to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to, but may in its discretion, enter into any supplemental indenture that affects the Trustee&#8217;s own rights, duties or immunities under this Indenture or otherwise. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any supplemental indenture authorized by the provisions of this Section 10.01 may be executed by the Company and the Trustee without the consent of the Holders of any of the Notes at the time outstanding, notwithstanding any of the provisions of Section 10.02. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Supplemental Indentures with Consent of Holders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> With the consent (evidenced as provided in Article 8) of the Holders of at least a majority of the aggregate principal amount of the Notes then outstanding (determined in accordance with Article 8 and including, without limitation, consents obtained in connection with a repurchase of, or tender or exchange offer for, Notes), the Company, when authorized by the resolutions of the Board of Directors and the Trustee, at the Company&#8217;s expense, may from time to time and at any time enter into an indenture or indentures supplemental hereto for the purpose of adding any provisions to or changing in any manner, waiving or eliminating any of the provisions of this Indenture or the Notes or any supplemental indenture or of modifying in any manner the rights of the Holders&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that, without the consent of each Holder of an outstanding Note affected, no such supplemental indenture shall&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) reduce the amount of Notes whose Holders must consent to an amendment&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) reduce the rate of or extend the stated time for payment of interest on any Note&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) reduce the principal of or extend the Maturity Date of any Note&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) except as required by this Indenture, make any change that adversely affects the conversion rights of any Notes&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) reduce the Redemption Price or Fundamental Change Repurchase Price of any Note or amend or modify in any manner adverse to the Holders the Company&#8217;s obligation to make such payments, whether through an amendment or waiver of provisions in the covenants, definitions or otherwise&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) make any Note payable in a currency, or at a place of payment, other than that stated in the Note&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) change the ranking of the Notes&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) impair the right of any Holder to receive payment of principal and interest on such Holder&#8217;s Notes on or after the due dates therefor or to institute suit for the enforcement of any payment on or with respect to such Holder&#8217;s Notes&#59; or </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) make any change in this Article 10 that requires each Holder&#8217;s consent or in the waiver provisions in Section 6.02 or Section 6.09. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon the written request of the Company, and upon the filing with the Trustee of evidence satisfactory to it of the consent of Holders as aforesaid and subject to Section 10.05, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee&#8217;s own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion, but shall not be obligated to, enter into such supplemental indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders do not need under this Section 10.02 to approve the particular form of any proposed supplemental indenture. It shall be sufficient if such Holders approve the substance thereof. After any such supplemental indenture becomes effective, the Company shall send to the Holders a notice briefly describing such supplemental indenture. However, the failure to give such notice to all the Holders, or any defect in the notice, will not impair or affect the validity of the supplemental indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Effect of Supplemental Indentures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Upon the execution of any supplemental indenture pursuant to the provisions of this Article 10, this Indenture shall be and be deemed to be modified and amended in accordance therewith and the respective rights, limitation of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the Holders shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments and all the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture for any and all purposes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Notation on Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Notes authenticated and delivered after the execution of any supplemental indenture pursuant to the provisions of this Article 10 may, at the Company&#8217;s expense, bear a notation in form approved by the Trustee as to any matter provided for in such supplemental indenture. If the Company or the Trustee shall so determine, new Notes so modified as to conform, in the opinion of the Trustee and the Board of Directors, to any modification of this Indenture contained in any such supplemental indenture may, at the Company&#8217;s expense, be prepared and executed by the Company, authenticated by the Trustee (or an authenticating agent duly appointed by the Trustee pursuant to Section 17.10) and delivered in exchange for the Notes then outstanding, upon surrender of such Notes then outstanding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 10.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Evidence of Compliance of Supplemental Indenture to Be Furnished Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In addition to the documents required by Section 17.05, the Trustee shall receive an Officer&#8217;s Certificate and an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant hereto complies with the requirements of this Article 10, is permitted or authorized by this Indenture and is the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with such supplemental indenture&#8217;s terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 11 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONSOLIDATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ERGER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ALE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONVEYANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EASE</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 11.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Company May Consolidate, Etc. on Certain Terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject to the provisions of Section 11.02, the Company shall not consolidate with, merge with or into, or sell, convey, transfer or lease all or substantially all of the consolidated properties and assets of the Company and its Subsidiaries, taken as a whole, to, another Person, unless&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) the resulting, surviving or transferee Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Successor Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), if not the Company, shall be a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and the Successor Company (if not the Company) shall expressly assume, by supplemental indenture all of the obligations of the Company under the Notes and this Indenture&#59; and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) immediately after giving effect to such transaction, no Default or Event of Default shall have occurred and be continuing under this Indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 11.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Successor Corporation to Be Substituted.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In case of any such consolidation, merger, sale, conveyance, transfer or lease and upon the assumption by the Successor Company, by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the due and punctual payment of the principal of and accrued and unpaid interest on all of the Notes, the due and punctual delivery or payment, as the case may be, of any consideration due upon conversion of the Notes and the due and punctual performance of all of the covenants and conditions of this Indenture to be performed by the Company, such Successor Company (if not the Company) shall succeed to and, except in the case of a lease of all or substantially all of the consolidated properties and assets of the Company and its Subsidiaries, taken as a whole, shall be substituted for the Company, with the same effect as if it had been named herein as the party of the first part. Such Successor Company thereupon may cause to be signed, and may issue either in its own name or in the name of the Company any or all of the Notes issuable hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee&#59; and, upon the order of such Successor Company instead of the Company and subject to all the terms, conditions and limitations in this Indenture prescribed, the Trustee shall authenticate and shall deliver, or cause to be authenticated and delivered, any Notes that previously shall have been signed and delivered by the Officers of the Company to the Trustee for authentication, and any Notes that such Successor Company thereafter shall cause to be signed and delivered to the Trustee for that purpose. All the Notes so issued shall in all respects have the same legal rank and benefit under this Indenture as the Notes theretofore or thereafter issued in accordance with the terms of this Indenture as though all of such Notes had been issued at the date of the execution hereof. In the event of any such consolidation, merger, sale, conveyance or transfer (but not in the case of a lease), upon compliance with this Article 11 the Person named as the &#8220;Company&#8221; in the first paragraph of this Indenture (or any successor that shall thereafter have become such in the manner prescribed in this Article 11) may be dissolved, wound up and liquidated at any time thereafter and, except in the case of a lease, such Person shall be released from its liabilities as obligor and maker of the Notes and from its obligations under this Indenture and the Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In case of any such consolidation, merger, sale, conveyance, transfer or lease, such changes in phraseology and form (but not in substance) may be made in the Notes thereafter to be issued as may be appropriate. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 11.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Opinion of Counsel to Be Given to Trustee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If the Successor Company is not the Company, no such consolidation, merger, sale, conveyance, transfer or lease shall be effective unless the Trustee shall have received an Officer&#8217;s Certificate and an Opinion of Counsel certifying that any such consolidation, merger, sale, conveyance, transfer or lease and any such assumption and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture complies with this Indenture.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 12 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">MMUNITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NCORPORATORS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">TOCKHOLDERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">FFICERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">IRECTORS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 12.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Indenture and Notes Solely Corporate Obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> No recourse for the payment of the principal of or accrued and unpaid interest on any Note, nor for any claim based thereon or otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Company in this Indenture or in any supplemental indenture or in any Note, nor because of the creation of any indebtedness represented thereby, shall be had against any incorporator, stockholder, employee, agent, Officer or director or Subsidiary, as such, past, present or future, of the Company or of any successor corporation, either directly or through the Company or any successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise&#59; it being expressly understood that all such liability is hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issue of the Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 13 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">NTENTIONALLY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">MITTED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#93; </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 14 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ONVERSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OTES</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Conversion Privilege.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) Subject to and upon compliance with the provisions of this Article 14, each Holder of a Note shall have the right, at such Holder&#8217;s option, to convert all or any portion (if the portion to be converted is $1,000 principal amount or an integral multiple thereof) of such Note (i) subject to satisfaction of the conditions described in Section 14.01(b), at any time prior to the close of business on the Business Day immediately preceding February 1, 2024 under the circumstances and during the periods set forth in Section 14.01(b), and (ii) regardless of the conditions described in Section 14.01(b), on or after February 1, 2024 and prior to the close of business on the Business Day immediately preceding the Maturity Date, in each case, at an initial conversion rate of 37.3413 shares of Common Stock (subject to adjustment as provided in this Article 14, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) per $1,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">principal amount of Notes (subject to, and in accordance with, the settlement provisions of Section 14.02, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) (i) Prior to the close of business on the Business Day immediately preceding February 1, 2024, a Holder may surrender all or any portion of its Notes for conversion at any time during the five Business Day period immediately after any ten consecutive Trading Day period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Measurement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in which the Trading Price per $1,000 principal amount of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes, as determined following a request by a Holder of Notes in accordance with this subsection (b)(i), for each Trading Day of the Measurement Period was less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate on each such Trading Day. The Trading Prices shall be determined by the Bid Solicitation Agent pursuant to this subsection (b)(i) and the definition of Trading Price set forth in this Indenture. The Company shall provide written notice to the Bid Solicitation Agent (if other than the Company) of the three independent nationally recognized securities dealers selected by the Company pursuant to the definition of Trading Price, along with appropriate contact information for each. The Bid Solicitation Agent (if other than the Company) shall have no obligation to determine the Trading Price per $1,000 principal amount of Notes pursuant to this subsection (b)(i) and the definition of Trading Price set forth in this Indenture unless the Company has requested such determination in writing, and the Company shall have no obligation to make such request (or, if the Company is acting as Bid Solicitation Agent, the Company shall have no obligation to determine the Trading Price) or to determine the Trading Price per $1,000 principal amount of Notes unless a Holder of at least $2,000,000 aggregate principal amount of Notes provides the Company with reasonable evidence that the Trading Price per $1,000 principal amount of Notes would be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate, at which time the Company shall instruct the Bid Solicitation Agent (if other than the Company) to determine, or if the Company is acting as Bid Solicitation Agent, the Company shall determine, the Trading Price per $1,000 principal amount of Notes beginning on the next Trading Day and on each successive Trading Day until the Trading Price per $1,000 principal amount of Notes is greater than or equal to 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate. If (x) the Company is not acting as Bid Solicitation Agent, and the Company does not instruct the Bid Solicitation Agent, in writing, to obtain bids when obligated as provided in the immediately preceding sentence, or if the Company instructs the Bid Solicitation Agent, in writing, to obtain bids and the Bid Solicitation Agent fails to make such determination or (y) the Company is acting as Bid Solicitation Agent and the Company fails to make such determination when obligated as provided in the immediately preceding sentence, then, in each case, the Trading Price per $1,000 principal amount of Notes shall be deemed to be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate on each Trading Day of such failure. If the Trading Price condition set forth above has been met and the Notes are convertible pursuant to this Section 14.01(b)(i), the Company shall so notify the Holders, the Trustee and the Conversion Agent (if other than the Trustee) in writing. If, at any time after the Trading Price condition set forth above has been met, the Trading Price per $1,000 principal amount of Notes is greater than or equal to 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate for such date, the Company shall so notify the Holders of the Notes, the Trustee and the Conversion Agent (if other than the Trustee) in writing. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) If, prior to the close of business on the Business Day immediately preceding February 1, 2024, the Company elects to&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A) issue to all or substantially all holders of the Common Stock any rights, options or warrants (other than in connection with a stockholder rights plan prior to separation of the relevant rights) entitling them, for a period of not more than 60 calendar days after the declaration date for such issuance, to subscribe for or purchase shares of the Common Stock at a price per share that is less than the average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the declaration date for such issuance&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B) distribute to all or substantially all holders of the Common Stock the Company&#8217;s assets, securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the Board of Directors, exceeding 10% of the Last Reported Sale Price of the Common Stock on the Trading Day preceding the declaration date for such distribution, </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">then, in either case, the Company shall notify all Holders of the Notes, the Trustee and the Conversion Agent (if other than the Trustee) at least 50 Scheduled Trading Days prior to the Ex-Dividend Date for such issuance or distribution. Once the Company has given such notice, a Holder may surrender all or any portion of its Notes for conversion at any time until the earlier of (1) the close of business on the Business Day immediately preceding the Ex-Dividend Date for such issuance or distribution and (2) the Company&#8217;s announcement that such issuance or distribution will not take place, in each case, even if the Notes are not otherwise convertible at such time. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) If (A) a transaction or event that constitutes a Fundamental Change or a Make-Whole Fundamental Change occurs prior to the close of business on the Business Day immediately preceding February 1, 2024, regardless of whether a Holder has the right to require the Company to repurchase the Notes pursuant to Section 15.02, or (B) the Company is a party to a consolidation, merger, binding share exchange, or transfer or lease of all or substantially all of the consolidated assets of the Company and its Subsidiaries, taken as a whole, prior to the close of business on the Business Day immediately preceding February 1, 2024, in each case, pursuant to which the Common Stock would be converted into cash, securities or other assets, then, in the case of either (A) or (B), all or any portion of a Holder&#8217;s Notes may be surrendered for conversion at any time from or after the effective date of such transaction or event until 35 Trading Days after the effective date of such transaction or event (or, if the Company gives notice after the effective date of such transaction or event pursuant to the succeeding sentence, until the 35th Trading Day after the Company gives such notice) or, if such transaction or event also constitutes a Fundamental Change, until the related Fundamental Change Repurchase Date. The Company shall notify Holders, the Trustee and the Conversion Agent (if other than the Trustee) within three Business Days of the effective date of such transaction or event. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) Prior to the close of business on the Business Day immediately preceding February 1, 2024, a Holder may surrender all or any portion of its Notes for conversion at any time during any calendar quarter commencing after the calendar quarter ending on June 30, 2017 (and only during such calendar quarter), if the Last Reported Sale Price of the Common Stock for at least 20 Trading Days (whether or not consecutive) during the period of 30 consecutive Trading Days ending on the last Trading Day of the immediately preceding calendar quarter is greater than or equal to 130% of the Conversion Price on each applicable Trading Day. Neither the Trustee nor any Agent shall have any obligation to make any calculation or to determine whether the Notes may be surrendered for conversion, or to notify the Company, the Depositary or any of the Holders of the Notes if the Notes have become convertible. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v) If the Company delivers a Notice of Redemption in respect of any or all of the Notes pursuant to Article 16, then a Holder may surrender all or any portion of its Notes for conversion at any time prior to the close of business on the Business Day immediately preceding the relevant Redemption Date, even if the Notes are not otherwise convertible at such time. After that time, the right to convert on account of the Company&#8217;s delivery of the Notice of Redemption shall expire, unless the Company defaults in the payment of the Redemption Price, in which case a Holder of Notes may convert its Notes until the Business Day immediately preceding the date on which the Redemption Price has been paid or duly provided for. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Conversion Procedure&#59; Settlement Upon Conversion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Subject to this Section 14.02, Section 14.03(b) and Section 14.07(a), upon conversion of any Note, the Company shall pay or deliver, as the case may be, to the converting Holder, in respect of each $1,000 principal amount of Notes being converted, cash (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), shares of Common Stock, together with cash, if applicable, in lieu of delivering any fractional share of Common Stock in accordance with subsection (j) of this Section 14.02 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Physical Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) or a combination of cash and shares of Common Stock, together with cash, if applicable, in lieu of delivering any fractional share of Common Stock in accordance with subsection (j) of this Section 14.02 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Combination Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), at its election, as set forth in this Section 14.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) All conversions for which the relevant Conversion Date occurs on or after February 1, 2024, and all conversions for which the relevant Conversion Date occurs on or after the Company&#8217;s issuance of a Notice of Redemption with respect to the Notes and prior to the related Redemption Date, shall be settled using the same Settlement Method. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) Except for any conversions for which the relevant Conversion Date occurs on or after February 1, 2024, and any conversions for which the relevant Conversion Date occurs on or after the Company&#8217;s issuance of a Notice of Redemption with respect to the Notes but prior to the related Redemption Date, the Company shall use the same Settlement Method for all conversions with the same Conversion Date, but the Company shall not have any obligation to use the same Settlement Method with respect to conversions with different Conversion Dates.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) If, in respect of any Conversion Date (or one of the periods described in the third immediately succeeding set of parentheses, as the case may be), the Company elects to deliver a notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Settlement Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) of the relevant Settlement Method in respect of such Conversion Date (or such period, as the case may be), the Company, through the Trustee, shall deliver such Settlement Notice to converting Holders no later than the close of business on the Trading Day immediately following the relevant Conversion Date (or, in the case of any conversions for which the relevant Conversion Date occurs (x) after the date of issuance of a Notice of Redemption with respect to the Notes and prior to the related Redemption Date, in such Notice of Redemption, or (y) on or after February 1, 2024, no later than February 1, 2024). If the Company does not elect a Settlement Method prior to the deadline set forth in the immediately preceding sentence, the Company shall settle such conversions using the Default Settlement Method. Such Settlement Notice shall specify the relevant Settlement Method and, in the case of an election of Combination Settlement, the relevant Settlement Notice shall indicate the Specified Dollar Amount per $1,000 principal amount of Notes. If the Company delivers a Settlement Notice electing Combination Settlement in respect of its Conversion Obligation but does not indicate a Specified Dollar Amount per $1,000 principal amount of Notes in such Settlement Notice, or if Combination Settlement otherwise applies but the Company does not timely notify holders of the Specified Dollar Amount per $1,000 principal amount of Notes, the Specified Dollar Amount per $1,000 principal amount of Notes shall be deemed to be $1,000. At any time prior to February 1, 2024, the Company may irrevocably elect to settle all conversions occurring on or after the date the Company gives notice thereof to Holders, the Trustee and the Conversion Agent (if other than the Trustee) through Combination Settlement with a Specified Dollar Amount the Company elects. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) The cash, shares of Common Stock or combination of cash and shares of Common Stock in respect of any conversion of Notes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Settlement Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall be computed as follows&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A) if the Company elects (or is deemed to have elected) to satisfy its Conversion Obligation in respect of such conversion by Physical Settlement, the Company shall deliver to the converting Holder in respect of each $1,000 principal amount of Notes being converted a number of shares of Common Stock equal to the Conversion Rate in effect on the Conversion Date&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B) if the Company elects (or is deemed to have elected) to satisfy its Conversion Obligation in respect of such conversion by Cash Settlement, the Company shall pay to the converting Holder in respect of each $1,000 principal amount of Notes being converted cash in an amount equal to the sum of the Daily Conversion Values for each of the 40 consecutive Trading Days during the related Observation Period&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C) if the Company elects (or is deemed to have elected) to satisfy its Conversion Obligation in respect of such conversion by Combination Settlement, the Company shall pay or deliver, as the case may be, in respect of each $1,000 principal amount of Notes being converted, a Settlement Amount equal to the</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">sum of the Daily Settlement Amounts for each of the 40 consecutive Trading Days during the related Observation Period. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v) The Daily Settlement Amounts (if applicable) and the Daily Conversion Values (if applicable) shall be determined by the Company promptly following the last day of the Observation Period. Promptly after such determination of the Daily Settlement Amounts or the Daily Conversion Values, as the case may be, and the amount of cash payable in lieu of delivering any fractional share of Common Stock, the Company shall notify the Trustee and the Conversion Agent (if other than the Trustee) of the Daily Settlement Amounts or the Daily Conversion Values, as the case may be, and the amount of cash payable in lieu of delivering fractional shares of Common Stock. The Trustee and the Conversion Agent (if other than the Trustee) shall have no responsibility for any such determination. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Subject to Section 14.02(e), before any Holder of a Note shall be entitled to convert a Note as set forth above, such Holder shall (i) in the case of a Global Note, comply with the Applicable Procedures of the Depositary in effect at that time and, if required, pay funds equal to interest payable on the next Interest Payment Date to which such Holder is not entitled as set forth in Section 14.02(h) and (ii) in the case of a Physical Note (1) complete, manually sign and deliver an irrevocable notice to the Conversion Agent as set forth in the Form of Notice of Conversion (or a facsimile, PDF or other electronic transmission thereof) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notice of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) at the office of the Conversion Agent and state in writing therein the principal amount of Notes to be converted and the name or names (with addresses) in which such Holder wishes the certificate or certificates for any shares of Common Stock to be delivered upon settlement of the Conversion Obligation to be registered, (2) surrender such Notes, duly endorsed to the Company or in blank (and accompanied by appropriate endorsement and transfer documents), at the office of the Conversion Agent, (3) if required, furnish appropriate endorsements and transfer documents, (4) if required, pay all transfer and similar taxes as set forth in Section 14.02(d) and Section 14.02(e) and (5) if required, pay funds equal to interest payable on the next Interest Payment Date to which such Holder is not entitled as set forth in Section 14.02(h). The Trustee (and if different, the Conversion Agent) shall notify the Company of any conversion pursuant to this Article 14 on the Conversion Date for such conversion. No Notice of Conversion with respect to any Notes may be surrendered by a Holder thereof if such Holder has also delivered a Fundamental Change Repurchase Notice to the Company in respect of such Notes and has not validly withdrawn such Fundamental Change Repurchase Notice in accordance with Section 15.03.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If more than one Note shall be surrendered for conversion at one time by the same Holder, the Conversion Obligation with respect to such Notes shall be computed on the basis of the aggregate principal amount of the Notes (or specified portions thereof to the extent permitted thereby) so surrendered. Any exercise by a Holder of its conversion rights in respect of a Note shall be irrevocable. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) A Note shall be deemed to have been converted immediately prior to the close of business on the date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) that the Holder has complied with the requirements set forth in subsection (b) above. Except as set forth in Section 14.03(b) and Section 14.07(a), the Company shall pay or deliver, as the case may be, the consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">due in respect of the Conversion Obligation on the third Business Day immediately following the relevant Conversion Date, if the Company elects Physical Settlement, or on the third Business Day immediately following the last Trading Day of the Observation Period, in the case of any other Settlement Method. If any shares of Common Stock are due to converting Holders, the Company shall issue or cause to be issued, and deliver to the Conversion Agent or to such Holder, or such Holder&#8217;s nominee or nominees, certificates or a book-entry transfer through the Depositary for the full number of shares of Common Stock to which such Holder shall be entitled in satisfaction of the Company&#8217;s Conversion Obligation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) In case any Note shall be surrendered for partial conversion, the Company shall execute, and the Trustee shall authenticate and deliver to or upon the written order of the Holder of the Note so surrendered, a new Note or Notes in authorized denominations in an aggregate principal amount equal to the unconverted portion of the surrendered Note, without payment of any service charge by the converting Holder but, if required by the Company or Trustee, with payment of a sum sufficient to cover any documentary, stamp or similar issue or transfer tax or similar governmental charge required by law or that may be imposed in connection therewith as a result of the name of the Holder of the new Notes issued upon such conversion being different from the name of the Holder of the old Notes surrendered for such conversion. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) If a Holder submits a Note for conversion, the Company shall pay any documentary, stamp or similar issue or transfer tax due on the issue of any shares of Common Stock upon conversion, unless the tax is due because the Holder requests such shares to be issued in a name other than the Holder&#8217;s name, in which case the Holder shall pay that tax. The Conversion Agent may refuse to deliver the certificates representing the shares of Common Stock being issued in a name other than the Holder&#8217;s name until the Trustee receives a sum sufficient to pay any tax that is due by such Holder in accordance with the immediately preceding sentence. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Except as provided in Section 14.04, no adjustment shall be made for dividends on any shares of Common Stock issued upon the conversion of any Note as provided in this Article 14. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) Upon the conversion of an interest in a Global Note, the Trustee, or the Custodian (if other than the Trustee) at the direction of the Trustee, shall make a notation on such Global Note as to the reduction in the principal amount represented thereby. The Company shall notify the Trustee in writing of any conversion of Notes effected through any Conversion Agent other than the Trustee. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) Upon conversion, a Holder shall not receive any separate cash payment for accrued and unpaid interest, if any, except as set forth below. The Company&#8217;s settlement of the full Conversion Obligation shall be deemed to satisfy in full its obligation to pay the principal amount of the Note and accrued and unpaid interest, if any, to, but not including, the relevant Conversion Date. As a result, accrued and unpaid interest, if any, to, but not including, the relevant Conversion Date shall be deemed to be paid in full rather than cancelled, extinguished or forfeited. Upon a conversion of Notes into a combination of cash and shares of Common Stock, accrued and unpaid interest will be deemed to be paid first out of the cash paid upon such conversion. Notwithstanding the foregoing, if Notes are converted after the close of business on a Regular Record Date, Holders of such Notes as of the close of business on such Regular </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Record Date will receive the full amount of interest payable on such Notes on the corresponding Interest Payment Date notwithstanding the conversion. Notes surrendered for conversion during the period from the close of business on any Regular Record Date to the open of business on the immediately following Interest Payment Date must be accompanied by funds equal to the amount of interest payable on the Notes so converted&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that no such payment shall be required (1) for conversions following the Regular Record Date immediately preceding the Maturity Date&#59; (2) if the Company has specified a Redemption Date that is after a Regular Record Date and on or prior to the Business Day immediately following the corresponding Interest Payment Date&#59; (3) if the Company has specified a Fundamental Change Repurchase Date that is after a Regular Record Date and on or prior to the Business Day immediately following the corresponding Interest Payment Date&#59; or (4) to the extent of any Defaulted Amounts, if any Defaulted Amounts exists at the time of conversion with respect to such Note. Therefore, for the avoidance of doubt, all Holders of record on the Regular Record Date immediately preceding the Maturity Date, any Redemption Date described in clause (2) of the immediately preceding sentence and any Fundamental Change Repurchase Date described in clause (3) of the immediately preceding sentence shall receive the full interest payment due on the Maturity Date or other applicable Interest Payment Date regardless of whether their Notes have been converted following such Regular Record Date. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) The Person in whose name the shares of Common Stock shall be issuable upon conversion shall be treated as a stockholder of record as of the close of business on the relevant Conversion Date (if the Company elects to satisfy the related Conversion Obligation by Physical Settlement) or the last Trading Day of the relevant Observation Period (if the Company elects to satisfy the related Conversion Obligation by Combination Settlement), as the case may be. Upon a conversion of Notes, such Person shall no longer be a Holder of such Notes surrendered for conversion. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j) The Company shall not issue any fractional share of Common Stock upon conversion of the Notes and shall instead pay cash in lieu of delivering any fractional share of Common Stock issuable upon conversion based on the Daily VWAP for the relevant Conversion Date (in the case of Physical Settlement) or based on the Daily VWAP for the last Trading Day of the relevant Observation Period (in the case of Combination Settlement). For each Note surrendered for conversion, if the Company has elected Combination Settlement, the full number of shares that shall be issued upon conversion thereof shall be computed on the basis of the aggregate Daily Settlement Amounts for the relevant Observation Period, and any fractional shares remaining after such computation shall be paid in cash. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole Fundamental Changes or Notice of Redemption.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) If (x) the Effective Date of a Make-Whole Fundamental Change occurs prior to the Maturity Date or (y) the Company gives a Notice of Redemption with respect to any or all of the Notes in accordance with Article 16 and, in each case, a Holder elects to convert its Notes in connection with such Make-Whole Fundamental Change or Notice of Redemption, as applicable, the Company shall, under the circumstances described below, increase the Conversion Rate for the Notes so surrendered for conversion by a number of additional shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as described below. A conversion of Notes shall be deemed for these purposes to be &#8220;in connection with&#8221; such Make-Whole Fundamental Change if the relevant Notice of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion is received by the Conversion Agent from, and including, the Effective Date of the Make-Whole Fundamental Change up to, and including, the Business Day immediately prior to the related Fundamental Change Repurchase Date (or, in the case of a Make-Whole Fundamental Change that would have been a Fundamental Change but for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">proviso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in clause (b) of the definition thereof, the 35th Trading Day immediately following the Effective Date of such Make-Whole Fundamental Change) (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Make-Whole Fundamental Change Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). A conversion of Notes shall be deemed for these purposes to be &#8220;in connection with&#8221; a Notice of Redemption if the relevant Notice of Conversion is received by the Conversion Agent from, and including, the date of the Notice of Redemption until the close of business on the Business Day immediately preceding the corresponding Redemption Date. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Upon surrender of Notes for conversion in connection with a Make-Whole Fundamental Change or Notice of Redemption, the Company shall, at its option, satisfy the related Conversion Obligation by Physical Settlement, Cash Settlement or Combination Settlement in accordance with Section 14.02&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that if, at the effective time of a Make-Whole Fundamental Change described in clause (b) of the definition of Fundamental Change, the Reference Property following such Make-Whole Fundamental Change is composed entirely of cash, for any conversion of Notes following the Effective Date of such Make-Whole Fundamental Change, the Conversion Obligation shall be calculated based solely on the Stock Price for the transaction and shall be deemed to be an amount of cash per $1,000 principal amount of converted Notes equal to the Conversion Rate (including any adjustment for Additional Shares), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> such Stock Price. In such event, the Conversion Obligation shall be paid to Holders in cash on the third Business Day following the Conversion Date. The Company shall notify the Holders of Notes of the Effective Date of any Make-Whole Fundamental Change no later than five Business Days after such Effective Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) The number of Additional Shares, if any, by which the Conversion Rate shall be increased shall be determined by reference to the table below, based on the date on which the Make-Whole Fundamental Change occurs or becomes effective or the date of the relevant Notice of Redemption (in each case, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and the price paid (or deemed to be paid) per share of the Common Stock in the Make-Whole Fundamental Change or with respect to the Notice of Redemption, as the case may be (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). If the holders of the Common Stock receive in exchange for their Common Stock only cash in a Make-Whole Fundamental Change described in clause (b) of the definition of Fundamental Change, the Stock Price shall be the cash amount paid per share. Otherwise, the Stock Price shall be the average of the Last Reported Sale Prices of the Common Stock over the five consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Effective Date of the Make-Whole Fundamental Change or the date of the Notice of Redemption, as the case may be. The Board of Directors shall make appropriate adjustments to the Stock Price, in its good faith determination, to account for any adjustment to the Conversion Rate that becomes effective, or any event requiring an adjustment to the Conversion Rate where the Ex-Dividend Date, Effective Date (as such term is used in Section 14.04) or expiration date of the event occurs during such five consecutive Trading Day period. In the event that a conversion in connection with a Notice of Redemption would also be deemed to be in connection with a Make-Whole Fundamental Change, a Holder of the Notes to be converted shall be entitled solely to a single increase to the</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion Rate with respect to the first to occur of the applicable date of the Notice of Redemption or the Effective Date of the applicable Make-Whole Fundamental Change.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) The Stock Prices set forth in the column headings of the table below shall be adjusted as of any date on which the Conversion Rate of the Notes is otherwise adjusted. The adjusted Stock Prices shall equal the Stock Prices applicable immediately prior to such adjustment, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> a fraction, the numerator of which is the Conversion Rate immediately prior to such adjustment giving rise to the Stock Price adjustment and the denominator of which is the Conversion Rate as so adjusted. The number of Additional Shares set forth in the table below shall be adjusted in the same manner and at the same time as the Conversion Rate as set forth in Section 14.04.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) The following table sets forth the number of Additional Shares of Common Stock by which the Conversion Rate shall be increased per $1,000 principal amount of Notes pursuant to this Section 14.03 for each Stock Price and Effective Date set forth below&#58; </font></div><div style="padding-left:0.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="63" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Price</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$20.60</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$23.00</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$26.78</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$30.00</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$34.81</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$40.00</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$50.00</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$60.00</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$70.00</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$80.00</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$100.00</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8pt;text-indent:-8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2, 2017</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2965</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1669</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8903</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5412</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5443</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3392</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6148</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1307</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7825</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3094</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8pt;text-indent:-8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 1, 2018</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0265</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8577</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5787</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2514</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2905</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1580</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4942</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0577</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7469</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3094</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8pt;text-indent:-8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 1, 2019</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7465</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5127</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2227</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9138</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9920</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9406</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3452</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9621</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6926</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3094</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8pt;text-indent:-8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 1, 2020</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4426</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1072</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7943</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5027</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6270</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6742</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1595</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8373</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6140</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3094</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8pt;text-indent:-8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 1, 2021</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0726</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5870</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2403</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9747</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1643</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3422</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9277</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6769</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5054</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2788</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8pt;text-indent:-8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 1, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.5896</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8704</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4807</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2700</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5685</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9378</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6507</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4824</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3674</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2142</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8pt;text-indent:-8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 1, 2023</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8796</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7293</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3067</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2735</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8028</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4712</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3378</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2576</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2005</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1222</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8pt;text-indent:-8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 1, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1370</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0000</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The exact Stock Prices and Effective Dates may not be set forth in the table above, in which case&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) if the Stock Price is between two Stock Prices in the table above or the Effective Date is between two Effective Dates in the table, the number of Additional Shares shall be determined by a straight-line interpolation between the number of Additional Shares set forth for the higher and lower Stock Prices and the earlier and later Effective Dates, as applicable, based on a 365-day year&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) if the Stock Price is greater than $100.00 per share (subject to adjustment in the same manner as the Stock Prices set forth in the column headings of the table above pursuant to subsection (d) above), no Additional Shares shall be added to the Conversion Rate&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) if the Stock Price is less than $20.60 per share (subject to adjustment in the same manner as the Stock Prices set forth in the column headings of the table above pursuant to subsection (d) above), no Additional Shares shall be added to the Conversion Rate. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in no event shall the Conversion Rate per $1,000 principal amount of Notes exceed 48.5436 shares of Common Stock, subject to adjustment in the same manner as the Conversion Rate pursuant to Section 14.04. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Nothing in this Section 14.03 shall prevent an adjustment to the Conversion Rate pursuant to Section 14.04 in respect of a Make-Whole Fundamental Change. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Adjustment of Conversion Rate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Conversion Rate shall be adjusted from time to time by the Company if any of the following events occurs, except that the Company shall not make any adjustments to the Conversion Rate if Holders of the Notes participate (other than in the case of (x) a share split or share combination or (y) a tender or exchange offer), at the same time and upon the same terms as holders of the Common Stock and solely as a result of holding the Notes, in any of the transactions described in this Section 14.04, without having to convert their Notes, as if they held a number of shares of Common Stock equal to the Conversion Rate, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the principal amount (expressed in thousands) of Notes held by such Holder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) If the Company exclusively issues shares of Common Stock as a dividend or distribution on shares of the Common Stock, or if the Company effects a share split or share combination, the Conversion Rate shall be adjusted based on the following formula&#58;</font></div><div><font><br></font></div><div style="text-align:center"><img alt="image_69a.jpg" src="image_69a.jpg" style="height:37px;margin-bottom:5pt;vertical-align:text-bottom;width:109px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">where, </font></div><div style="padding-left:0.07pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date of such dividend or distribution, or immediately prior to the open of business on the Effective Date of such share split or share combination, as applicable&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately after the open of business on such Ex-Dividend Date or Effective Date&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the number of shares of Common Stock outstanding immediately prior to the open of business on such Ex-Dividend Date or Effective Date&#59; and</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the number of shares of Common Stock outstanding immediately after giving effect to such dividend, distribution, share split or share combination.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any adjustment made under this Section 14.04(a) shall become effective immediately after the open of business on the Ex-Dividend Date for such dividend or distribution, or immediately after the open of business on the Effective Date for such share split or share combination, as applicable. If any dividend or distribution of the type described in this Section 14.04(a) is declared but not so paid or made, the Conversion Rate shall be immediately readjusted, effective as of the date the Board of Directors determines not to pay such dividend or distribution, to the Conversion Rate that would then be in effect if such dividend or distribution had not been declared. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) If the Company issues to all or substantially all holders of the Common Stock any rights, options or warrants entitling them, for a period of not more than 60 calendar days after the</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">declaration date for such issuance, to subscribe for or purchase shares of the Common Stock at a price per share that is less than the average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the declaration date for such issuance, the Conversion Rate shall be increased based on the following formula&#58; </font></div><div><font><br></font></div><div style="text-align:center"><img alt="image_71a.jpg" src="image_71a.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:134px"></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">where, </font></div><div style="padding-left:0.07pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such issuance&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately after the open of business on such Ex-Dividend Date&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the number of shares of Common Stock outstanding immediately prior to the open of business on such Ex-Dividend Date&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the total number of shares of Common Stock issuable pursuant to such rights, options or warrants&#59; and</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Y</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the number of shares of Common Stock equal to the aggregate price payable to exercise such rights, options or warrants, divided by the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the declaration date for the issuance of such rights, options or warrants.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any increase made under this Section 14.04(b) shall be made successively whenever any such rights, options or warrants are issued and shall become effective immediately after the open of business on the Ex-Dividend Date for such issuance. To the extent that shares of the Common Stock are not delivered after the expiration of such rights, options or warrants, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect had the increase with respect to the issuance of such rights, options or warrants been made on the basis of delivery of only the number of shares of Common Stock actually delivered. If such rights, options or warrants are not so issued or if no such rights, options or warrants are exercised prior to their expiration, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect if such Ex-Dividend Date for such issuance had not occurred. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of this Section 14.04(b) and for the purpose of Section 14.01(b)(ii)(A), in determining whether any rights, options or warrants entitle the holders to subscribe for or purchase shares of the Common Stock at less than such average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the declaration date for such issuance, and in determining the aggregate offering price of such shares of Common Stock, there shall be taken into account any consideration received by the Company for such rights, options or warrants and any amount </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">payable on exercise or conversion thereof, the value of such consideration, if other than cash, to be determined by the Board of Directors. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) If the Company distributes shares of its Capital Stock, evidences of its indebtedness, other assets or property of the Company or rights, options or warrants (other than in connection with a stockholder rights plan prior to separation of the relevant rights) to acquire its Capital Stock or other securities, to all or substantially all holders of the Common Stock, excluding (i) dividends, distributions or issuances as to which an adjustment was effected pursuant to Section 14.04(a) or Section 14.04(b), (ii) dividends or distributions paid exclusively in cash as to which the provisions set forth in Section 14.04(d) shall apply, (iii) distributions of Reference Property in exchange for, or upon conversion of, Common Stock in a Merger Event, (iv) except as otherwise provided in Section 14.11, rights issued pursuant to a stockholder rights plan adopted by the Company and (v) Spin-Offs as to which the provisions set forth below in this Section 14.04(c) shall apply (any of such shares of Capital Stock, evidences of indebtedness, other assets or property or rights, options or warrants to acquire Capital Stock or other securities, the &#8220;Distributed Property&#8221;), then the Conversion Rate shall be increased based on the following formula&#58;</font></div><div><font><br></font></div><div style="text-align:center"><img alt="image_73a.jpg" src="image_73a.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:116px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">where, </font></div><div style="padding-left:0.02pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such distribution&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately after the open of business on such Ex-Dividend Date&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Ex-Dividend Date for such distribution&#59; and</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FMV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the fair market value (as determined by the Board of Directors) of the Distributed Property with respect to each outstanding share of the Common Stock on the Ex-Dividend Date for such distribution.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any increase made under the portion of this Section 14.04(c) above shall become effective immediately after the open of business on the Ex-Dividend Date for such distribution. If such distribution is not so paid or made or, in the case of a distribution of rights, options or warrants, such rights, options or warrants are not exercised prior to their expiration, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect if such distribution had not been declared. Notwithstanding the foregoing, if &#8220;FMV&#8221; (as defined above) is equal to or greater than &#8220;SP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; (as defined above), in lieu of the foregoing increase, each Holder of a Note shall receive, in respect of each $1,000 principal amount thereof, at the same time and upon the same terms as holders of the Common Stock receive the Distributed Property, the amount and kind of Distributed Property such Holder would have received if such Holder owned a number of </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares of Common Stock equal to the Conversion Rate in effect on the Ex-Dividend Date for the distribution. If the Board of Directors determines the &#8220;FMV&#8221; (as defined above) of any distribution for purposes of this Section 14.04(c) by reference to the actual or when-issued trading market for any securities, it shall in doing so consider the prices in such market over the same period used in computing the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Ex-Dividend Date for such distribution. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to an adjustment pursuant to this Section 14.04(c) where there has been a payment of a dividend or other distribution on the Common Stock of shares of Capital Stock of any class or series, or similar equity interest, of or relating to a Subsidiary or other business unit of the Company, that are, or, when issued, will be, listed or admitted for trading on a U.S. national securities exchange (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Spin-Off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Conversion Rate shall be increased based on the following formula&#58;</font></div><div><font><br></font></div><div style="text-align:center"><img alt="image_75a.jpg" src="image_75a.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:161px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">where, </font></div><div style="padding-left:0.04pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:7.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately prior to the end of the Valuation Period&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately after the end of the Valuation Period&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FMV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the average of the Last Reported Sale Prices of the Capital Stock or similar equity interest distributed to holders of the Common Stock applicable to one share of the Common Stock (determined by reference to the definition of Last Reported Sale Price as set forth in Section 1.01 as if references therein to Common Stock were to such Capital Stock or similar equity interest) over the first 10 consecutive Trading Day period after, and including, the Ex-Dividend Date of the Spin-Off (the &#8220;Valuation Period&#8221;)&#59; and</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the average of the Last Reported Sale Prices of the Common Stock over the Valuation Period.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The increase to the Conversion Rate under the preceding paragraph shall occur at the close of business on the last Trading Day of the Valuation Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that (x) in respect of any conversion of Notes for which Physical Settlement is applicable, if the relevant Conversion Date occurs during the Valuation Period, references in the portion of this Section 14.04(c) related to Spin-Offs with respect to 10 Trading Days shall be deemed to be replaced with such lesser number of Trading Days as have elapsed between the Ex-Dividend Date of such Spin-Off and the Conversion Date in determining the Conversion Rate, and (y) in respect of any conversion of Notes for which Cash Settlement or Combination Settlement is applicable, for any Trading Day that falls within the relevant Observation Period for such conversion and within the Valuation Period, the reference to &#8220;10&#8221; in the preceding paragraph shall be deemed replaced with such lesser number of Trading Days as have elapsed between the Ex-Dividend Date for such Spin-Off and such Trading Day in determining the Conversion Rate as of such Trading Day. In addition, if</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Ex-Dividend Date for such Spin-Off is after the 10th Trading Day immediately preceding, and including, the end of any Observation Period in respect of a conversion of Notes, references in the preceding paragraph to 10 Trading Days will be deemed to be replaced, solely in respect of that conversion of Notes, with such lesser number of Trading Days as have elapsed from, and including, the Ex-Dividend Date for the Spin-Off to, and including, the last Trading Day of such Observation Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of this Section 14.04(c) (and subject in all respect to Section 14.11), rights, options or warrants distributed by the Company to all holders of the Common Stock entitling them to subscribe for or purchase shares of the Company&#8217;s Capital Stock, including Common Stock (either initially or under certain circumstances), which rights, options or warrants, until the occurrence of a specified event or events (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trigger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#58; (i) are deemed to be transferred with such shares of the Common Stock&#59; (ii) are not exercisable&#59; and (iii) are also issued in respect of future issuances of the Common Stock, shall be deemed not to have been distributed for purposes of this Section 14.04(c) (and no adjustment to the Conversion Rate under this Section 14.04(c) will be required) until the occurrence of the earliest Trigger Event, whereupon such rights, options or warrants shall be deemed to have been distributed and an appropriate adjustment (if any is required) to the Conversion Rate shall be made under this Section 14.04(c). If any such right, option or warrant, including any such existing rights, options or warrants distributed prior to the date of this Indenture, are subject to events, upon the occurrence of which such rights, options or warrants become exercisable to purchase different securities, evidences of indebtedness or other assets, then the date of the occurrence of any and each such event shall be deemed to be the date of distribution and Ex-Dividend Date with respect to new rights, options or warrants with such rights (in which case the existing rights, options or warrants shall be deemed to terminate and expire on such date without exercise by any of the holders thereof). In addition, in the event of any distribution (or deemed distribution) of rights, options or warrants, or any Trigger Event or other event (of the type described in the immediately preceding sentence) with respect thereto that was counted for purposes of calculating a distribution amount for which an adjustment to the Conversion Rate under this Section 14.04(c) was made, (1) in the case of any such rights, options or warrants that shall all have been redeemed or purchased without exercise by any holders thereof, upon such final redemption or purchase (x) the Conversion Rate shall be readjusted as if such rights, options or warrants had not been issued and (y) the Conversion Rate shall then again be readjusted to give effect to such distribution, deemed distribution or Trigger Event, as the case may be, as though it were a cash distribution, equal to the per share redemption or purchase price received by a holder or holders of Common Stock with respect to such rights, options or warrants (assuming such holder had retained such rights, options or warrants), made to all holders of Common Stock as of the date of such redemption or purchase, and (2) in the case of such rights, options or warrants that shall have expired or been terminated without exercise by any holders thereof, the Conversion Rate shall be readjusted as if such rights, options and warrants had not been issued.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of Section 14.04(a), Section 14.04(b) and this Section 14.04(c), if any dividend or distribution to which this Section 14.04(c) is applicable also includes one or both of&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A) a dividend or distribution of shares of Common Stock to which Section 14.04(a) is applicable (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clause A Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B) a dividend or distribution of rights, options or warrants to which Section 14.04(b) is applicable (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clause B Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">then, in either case, (1) such dividend or distribution, other than the Clause A Distribution and the Clause B Distribution, shall be deemed to be a dividend or distribution to which this Section 14.04(c) is applicable (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clause C Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and any Conversion Rate adjustment required by this Section 14.04(c) with respect to such Clause C Distribution shall then be made, and (2) the Clause A Distribution and Clause B Distribution shall be deemed to immediately follow the Clause C Distribution and any Conversion Rate adjustment required by Section 14.04(a) and Section 14.04(b) with respect thereto shall then be made, except that, if determined by the Company (I) the &#8220;Ex-Dividend Date&#8221; of the Clause A Distribution and the Clause B Distribution shall be deemed to be the Ex-Dividend Date of the Clause C Distribution and (II) any shares of Common Stock included in the Clause A Distribution or Clause B Distribution shall be deemed not to be &#8220;outstanding immediately prior to the open of business on such Ex-Dividend Date or Effective Date&#8221; within the meaning of Section 14.04(a) or &#8220;outstanding immediately prior to the open of business on such Ex-Dividend Date&#8221; within the meaning of Section 14.04(b). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) If any cash dividend or distribution is made to all or substantially all holders of the Common Stock, the Conversion Rate shall be adjusted based on the following formula&#58;</font></div><div><font><br></font></div><div style="text-align:center"><img alt="image_78a.jpg" src="image_78a.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:131px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">where, </font></div><div style="padding-left:0.07pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:4.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such dividend or distribution&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately after the open of business on the Ex-Dividend Date for such dividend or distribution&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Last Reported Sale Price of the Common Stock on the Trading Day immediately preceding the Ex-Dividend Date for such dividend or distribution&#59; and</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the amount in cash per share the Company distributes to all or substantially all holders of the Common Stock.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any increase pursuant to this Section 14.04(d) shall become effective immediately after the open of business on the Ex-Dividend Date for such dividend or distribution. If such dividend or distribution is not so paid, the Conversion Rate shall be decreased, effective as of the date the Board of Directors determines not to make or pay such dividend or distribution, to be the Conversion Rate that would then be in effect if such dividend or distribution had not been declared. Notwithstanding the foregoing, if &#8220;C&#8221; (as defined above) is equal to or greater than &#8220;SP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; (as defined above), in lieu of the foregoing increase, each Holder of a Note shall receive, for each $1,000 principal amount of Notes, at the same time and upon the same terms as holders of shares of the Common Stock, the amount of cash that such Holder would have received if </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">such Holder owned a number of shares of Common Stock equal to the Conversion Rate on the Ex-Dividend Date for such cash dividend or distribution. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) If the Company or any of its Subsidiaries make a payment in respect of a tender or exchange offer for the Common Stock, to the extent that the cash and value of any other consideration included in the payment per share of the Common Stock exceeds the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the last date on which tenders or exchanges may be made pursuant to such tender or exchange offer, the Conversion Rate shall be increased based on the following formula&#58;</font></div><div><font><br></font></div><div style="text-align:center"><img alt="image_80a.jpg" src="image_80a.jpg" style="height:46px;margin-bottom:5pt;vertical-align:text-bottom;width:184px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">where, </font></div><div style="padding-left:0.07pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:4.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately prior to the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Conversion Rate in effect immediately after the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the aggregate value of all cash and any other consideration (as determined by the Board of Directors) paid or payable for shares of Common Stock purchased in such tender or exchange offer&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">0</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the number of shares of Common Stock outstanding immediately prior to the date such tender or exchange offer expires (prior to giving effect to the purchase of all shares of Common Stock accepted for purchase or exchange in such tender or exchange offer)&#59;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the number of shares of Common Stock outstanding immediately after the date such tender or exchange offer expires (after giving effect to the purchase of all shares of Common Stock accepted for purchase or exchange in such tender or exchange offer)&#59; and</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#61;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the date such tender or exchange offer expires.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The increase to the Conversion Rate under this Section 14.04(e) shall occur at the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that (x) in respect of any conversion of Notes for which Physical Settlement is applicable, if the relevant Conversion Date occurs during the 10 Trading Days immediately following, and including, the Trading Day next </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">succeeding the expiration date of any tender or exchange offer, references to &#8220;10&#8221; or &#8220;10th&#8221; in the preceding paragraph shall be deemed replaced with such lesser number of Trading Days as have elapsed between the expiration date of such tender or exchange offer and such Conversion Date in determining the Conversion Rate and (y) in respect of any conversion of Notes for which Cash Settlement or Combination Settlement is applicable, for any Trading Day that falls within the relevant Observation Period for such conversion and within the 10 Trading Days immediately following, and including, the Trading Day next succeeding the expiration date of any tender or exchange offer, references in this Section 14.04(e) with respect to 10 Trading Days shall be deemed replaced with such lesser number of Trading Days as have elapsed between the date that such tender or exchange offer expires and such Trading Day in determining the Conversion Rate as of such Trading Day. In addition, if the Trading Day next succeeding the date such tender or exchange offer expires is after the 10th Trading Day immediately preceding, and including, the end of any Observation Period in respect of a conversion of Notes, references in the preceding paragraph to 10 Trading Days shall be deemed to be replaced, solely in respect of that conversion of Notes, with such lesser number of Trading Days as have elapsed from, and including, the Trading Day next succeeding the date such tender or exchange offer expires to, and including, the last Trading Day of such Observation Period. If the Company is obligated to purchase shares of the Common Stock pursuant to any such tender or exchange offer described in this Section 14.04(e) but is permanently prevented by applicable law from effecting any such purchase or all such purchases are rescinded, the applicable Conversion Rate shall be decreased to be the Conversion Rate that would then be in effect if such tender or exchange offer had not been made or had been made only in respect of the purchases that have been effected. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Notwithstanding this Section 14.04 or any other provision of this Indenture or the Notes, if a Conversion Rate adjustment becomes effective on any Ex-Dividend Date, and a Holder that has converted its Notes on or after such Ex-Dividend Date and on or prior to the related Record Date would be treated as the record holder of the shares of Common Stock as of the related Conversion Date as described under Section 14.02(i) based on an adjusted Conversion Rate for such Ex-Dividend Date, then, notwithstanding the Conversion Rate adjustment provisions in this Section 14.04, the Conversion Rate adjustment relating to such Ex-Dividend Date shall not be made for such converting Holder. Instead, such Holder shall be treated as if such Holder were the record owner of the shares of Common Stock on an unadjusted basis and participate in the related dividend, distribution or other event giving rise to such adjustment. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) Except as stated herein, the Company shall not adjust the Conversion Rate for the issuance of shares of the Common Stock or any securities convertible into or exchangeable for shares of the Common Stock or the right to purchase shares of the Common Stock or such convertible or exchangeable securities. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) In addition to those adjustments required by clauses (a), (b), (c), (d) and (e) of this Section 14.04, and to the extent permitted by applicable law and subject to the applicable rules and&#47;or listing standards of any exchange on which any of the Company&#8217;s securities are then listed and The NASDAQ Global Market, the Company from time to time may increase the Conversion Rate by any amount for a period of at least 20 Business Days if the Board of Directors determines that such increase would be in the Company&#8217;s best interest. In addition, to the extent permitted by applicable law and subject to the applicable rules and&#47;or listing standards of any exchange on which any of the Company&#8217;s securities are then listed and The NASDAQ </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Market, the Company may (but is not required to) increase the Conversion Rate to avoid or diminish any income tax to holders of Common Stock or rights to purchase Common Stock in connection with a dividend or distribution of shares of Common Stock (or rights to acquire shares of Common Stock) or similar event. Whenever the Conversion Rate is increased pursuant to either of the preceding two sentences, the Company shall deliver to the Holder of each Note a notice of the increase at least 15 days prior to the date the increased Conversion Rate takes effect, and such notice shall state the increased Conversion Rate and the period during which it will be in effect. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) Notwithstanding anything to the contrary in this Article 14, the Conversion Rate shall not be adjusted&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) upon the issuance of any shares of Common Stock pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on the Company&#8217;s securities and the investment of additional optional amounts in shares of Common Stock under any plan&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) upon the issuance of any shares of Common Stock or options or rights to purchase those shares pursuant to any present or future employee, director or consultant benefit plan or program of or assumed by the Company or any of the Company&#8217;s Subsidiaries&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) upon the issuance of any shares of the Common Stock pursuant to any option, warrant, right or exercisable, exchangeable or convertible security not described in clause (ii) of this subsection and outstanding as of the date the Notes were first issued&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) upon the repurchase of any shares of the Common Stock pursuant to an open-market share repurchase program or other buy-back transaction that is not a tender offer or exchange offer of the nature described in Section 14.04(e)&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v) solely for a change in the par value of the Common Stock&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi) for accrued and unpaid interest, if any. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j) All calculations and other determinations under this Article 14 shall be made by the Company and shall be made to the nearest one-ten thousandth (1&#47;10,000th) of a share. The Company shall not adjust the Conversion Rate pursuant to clause (a), (b), (c), (d) or (e) of this Section 14.04 unless the adjustment would result in a change of at least 1% in the then-effective Conversion Rate. However, the Company shall carry forward any adjustment to the Conversion Rate that is less than 1% of the then-effective Conversion Rate and take that adjustment into account in any subsequent adjustment. Notwithstanding the foregoing, all such carried-forward adjustments shall be made (i) in connection with any subsequent adjustment to the Conversion Rate of at least 1%, (ii) on the Conversion Date for any Notes (in the case of Physical Settlement), (iii) on each Trading Day of any Observation Period (in the case of Cash Settlement or Combination Settlement) and (iv) on the Effective Date of any Make-Whole Fundamental Change, in each case, unless the adjustment has already been made.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k) Whenever the Conversion Rate is adjusted as herein provided, the Company shall promptly file with the Trustee (and the Conversion Agent if not the Trustee) an Officer&#8217;s Certificate setting forth the Conversion Rate after such adjustment and setting forth a brief statement of the facts requiring such adjustment. Unless and until a Responsible Officer of the Trustee shall have received such Officer&#8217;s Certificate, the Trustee shall not be deemed to have knowledge of any adjustment of the Conversion Rate and may assume without inquiry that the last Conversion Rate of which it has knowledge is still in effect. Promptly after delivery of such certificate, the Company shall prepare a notice of such adjustment of the Conversion Rate setting forth the adjusted Conversion Rate and the date on which each adjustment becomes effective and shall deliver such notice of such adjustment of the Conversion Rate to each Holder. Failure to deliver such notice shall not affect the legality or validity of any such adjustment. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l) For purposes of this Section 14.04, the number of shares of Common Stock at any time outstanding shall not include shares of Common Stock held in the treasury of the Company so long as the Company does not pay any dividend or make any distribution on shares of Common Stock held in the treasury of the Company, but shall include shares of Common Stock issuable in respect of scrip certificates issued in lieu of fractions of shares of Common Stock. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Adjustments of Prices. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Whenever any provision of this Indenture requires the Company to calculate the Last Reported Sale Prices, the Daily VWAPs, the Daily Conversion Values or the Daily Settlement Amounts over a span of multiple days (including an Observation Period and the period for determining the Stock Price for purposes of a Make-Whole Fundamental Change or Optional Redemption), the Board of Directors shall make appropriate adjustments to each to account for any adjustment to the Conversion Rate that becomes effective, or any event requiring an adjustment to the Conversion Rate where the Ex-Dividend Date, Effective Date or expiration date, as the case may be, of the event occurs, at any time during the period when the Last Reported Sale Prices, the Daily VWAPs, the Daily Conversion Values or the Daily Settlement Amounts are to be calculated. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Shares to Be Fully Paid.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company shall provide, free from preemptive rights, out of its authorized but unissued shares or shares held in treasury, sufficient shares of Common Stock to provide for conversion of the Notes from time to time as such Notes are presented for conversion (assuming delivery of the maximum number of Additional Shares pursuant to Section 14.03 and that at the time of computation of such number of shares, all such Notes would be converted by a single Holder and that Physical Settlement were applicable).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Effect of Recapitalizations, Reclassifications and Changes of the Common Stock.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) In the case of&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) any recapitalization, reclassification or change of the Common Stock (other than changes resulting from a subdivision or combination), </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) any consolidation, merger, combination or similar transaction involving the Company,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) any sale, lease or other transfer to a third party of the consolidated assets of the Company and the Company&#8217;s Subsidiaries substantially as an entirety or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) any statutory share exchange, </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in each case, as a result of which the Common Stock would be converted into, or exchanged for, stock, other securities, other property or assets (including cash or any combination thereof) (any such event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Merger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), then, at and after the effective time of such Merger Event, the right to convert each $1,000 principal amount of Notes shall be changed into a right to convert such principal amount of Notes into the kind and amount of shares of stock, other securities or other property or assets (including cash or any combination thereof) that a holder of a number of shares of Common Stock equal to the Conversion Rate immediately prior to such Merger Event would have owned or been entitled to receive (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reference Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; with each &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">unit of Reference Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; meaning the kind and amount of Reference Property that a holder of one share of Common Stock is entitled to receive) upon such Merger Event and, prior to or at the effective time of such Merger Event, the Company or the successor or purchasing Person, as the case may be, shall execute with the Trustee a supplemental indenture permitted under Section 10.01(i) providing for such change in the right to convert each $1,000 principal amount of Notes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that at and after the effective time of the Merger Event (A) the Company shall continue to have the right to determine the form of consideration to be paid or delivered, as the case may be, upon conversion of Notes in accordance with Section 14.02 and (B) (I) any amount payable in cash upon conversion of the Notes in accordance with Section 14.02 shall continue to be payable in cash, (II) any shares of Common Stock that the Company would have been required to deliver upon conversion of the Notes in accordance with Section 14.02 shall instead be deliverable in the amount and type of Reference Property that a holder of that number of shares of Common Stock would have been entitled to receive in such Merger Event and (III) the Daily VWAP shall be calculated based on the value of a unit of Reference Property.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Merger Event causes the Common Stock to be converted into, or exchanged for, the right to receive more than a single type of consideration (determined based in part upon any form of stockholder election), then (i) the Reference Property into which the Notes will be convertible shall be deemed to be (x) the weighted average of the types and amounts of consideration received by the holders of Common Stock that affirmatively make such an election or (y) if no holders of Common Stock affirmatively make such an election, the types and amounts of consideration actually received by the holders of Common Stock, and (ii) the unit of Reference Property for purposes of the immediately preceding paragraph shall refer to the consideration referred to in clause (i) attributable to one share of Common Stock. If the holders of the Common Stock receive only cash in such Merger Event, then for all conversions for which the relevant Conversion Date occurs after the effective date of such Merger Event (A) the consideration due upon conversion of each $1,000 principal amount of Notes shall be solely cash in an amount equal to the Conversion Rate in effect on the Conversion Date (as may be increased by any Additional Shares pursuant to Section 14.03), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the price paid per share of Common Stock in such Merger Event and (B) the Company shall satisfy the Conversion Obligation by paying cash to converting Holders on the third Business Day immediately following the relevant Conversion Date. The Company shall notify Holders, the Trustee and the Conversion Agent (if other than the Trustee) of such weighted average as soon as practicable after such determination is made.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Reference Property in respect of any such Merger Event includes shares of common equity, such supplemental indenture described in the second immediately preceding paragraph shall provide for anti-dilution and other adjustments that shall be as nearly equivalent as is possible to the adjustments provided for in this Article 14. If, in the case of any Merger Event, the Reference Property includes shares of stock, securities or other property or assets (other than cash and&#47;or cash equivalents) of a Person other than the Company or the successor or purchasing corporation, as the case may be, then, if such Person is an Affiliate of the Company or an Affiliate of the successor or purchasing corporation, such supplemental indenture shall also be executed by such other Person and shall contain such additional provisions to protect the interests of the Holders of the Notes as the Company shall reasonably consider necessary or appropriate. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) When the Company executes a supplemental indenture pursuant to subsection (a) of this Section 14.07, the Company shall promptly file with the Trustee an Officer&#8217;s Certificate briefly stating the reasons therefor, the kind or amount of cash, securities or property or asset that will comprise a unit of Reference Property after any such Merger Event, any adjustment to be made with respect thereto and that all conditions precedent have been complied with, and shall promptly deliver notice thereof to all Holders. The Company shall cause notice of the execution of such supplemental indenture to be delivered to each Holder within 20 days after execution thereof. Failure to deliver such notice shall not affect the legality or validity of such supplemental indenture. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) The Company shall not become a party to any Merger Event unless its terms are consistent with this Section 14.07. None of the foregoing provisions shall affect the right of a holder of Notes to convert its Notes into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, as set forth in Section 14.01 and Section 14.02, prior to the effective date of such Merger Event. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) The above provisions of this Section shall similarly apply to successive Merger Events. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.08. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Certain Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (a) The Company covenants that all shares of Common Stock issued upon conversion of Notes will be fully paid and non-assessable by the Company and free from all taxes, liens and charges with respect to the issue thereof. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) The Company covenants that, if any shares of Common Stock to be provided for the purpose of conversion of Notes hereunder require registration with or approval of any governmental authority under any federal or state law before such shares of Common Stock may be validly issued upon conversion, the Company will, to the extent then permitted by the rules and interpretations of the Commission, secure such registration or approval, as the case may be. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) The Company further covenants that if at any time the Common Stock shall be listed on any national securities exchange or automated quotation system the Company will list and keep listed, so long as the Common Stock shall be so listed on such exchange or automated quotation system, any Common Stock issuable upon conversion of the Notes. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.09. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Responsibility of Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Trustee and any other Conversion Agent shall not at any time be under any duty or responsibility to any Holder to determine the Conversion Rate (or any adjustment thereto) or whether any facts exist that may require any adjustment (including any increase) of the Conversion Rate, or with respect to the nature or extent or calculation of any such adjustment when made, or with respect to the method employed, or herein or in any supplemental indenture provided to be employed, in making the same. The Trustee and any other Conversion Agent shall not be accountable with respect to the validity or value (or the kind or amount) of any shares of Common Stock, or of any securities, property or cash that may at any time be issued or delivered upon the conversion of any Note&#59; and the Trustee and any other Conversion Agent make no representations with respect thereto. Neither the Trustee nor any Conversion Agent shall be responsible for any failure of the Company to issue, transfer or deliver any shares of Common Stock or stock certificates or other securities or property or cash upon the surrender of any Note for the purpose of conversion or to comply with any of the duties, responsibilities or covenants of the Company contained in this Article. Without limiting the generality of the foregoing, neither the Trustee nor any Conversion Agent shall be under any responsibility to determine the correctness of any provisions contained in any supplemental indenture entered into pursuant to Section 14.07 relating either to the kind or amount of shares of stock or securities or property (including cash) receivable by Holders upon the conversion of their Notes after any event referred to in such Section 14.07 or to any adjustment to be made with respect thereto, but, subject to the provisions of Section 7.01, may accept (without any independent investigation) as conclusive evidence of the correctness of any such provisions, and shall be protected in relying upon, the Officer&#8217;s Certificate (which the Company shall be obligated to file with the Trustee prior to the execution of any such supplemental indenture) with respect thereto. Neither the Trustee nor the Conversion Agent shall be responsible for determining whether any event contemplated by Section 14.01(b) has occurred that makes the Notes eligible for conversion or no longer eligible therefor until the Company has delivered to the Trustee and the Conversion Agent the notices referred to in Section 14.01(b) with respect to the commencement or termination of such conversion rights, on which notices the Trustee and the Conversion Agent may conclusively rely, and the Company agrees to deliver such notices to the Trustee and the Conversion Agent immediately after the occurrence of any such event or at such other times as shall be provided for in Section 14.01(b). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notice to Holders Prior to Certain Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In case of any&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) action by the Company or one of its Subsidiaries that would require an adjustment in the Conversion Rate pursuant to Section 14.04 or Section 14.11&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Merger Event&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) voluntary or involuntary dissolution, liquidation or winding-up of the Company&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">then, in each case (unless notice of such event is otherwise required pursuant to another provision of this Indenture), the Company shall cause to be filed with the Trustee and the Conversion Agent (if other than the Trustee) and to be delivered to each Holder, as promptly as possible but in any event at least 10 days prior to the applicable date hereinafter specified, a notice stating (i) the date on which a record is to be taken for the purpose of such action by the Company or one of its Subsidiaries or, if a record is not to be taken, the date as of which the </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">holders of Common Stock of record are to be determined for the purposes of such action by the Company or one of its Subsidiaries, or (ii) the date on which such Merger Event, dissolution, liquidation or winding-up is expected to become effective or occur, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their Common Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding-up. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such action by the Company or one of its Subsidiaries, Merger Event, dissolution, liquidation or winding-up. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Stockholder Rights Plans.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If the Company has a stockholder rights plan in effect upon conversion of the Notes, each share of Common Stock, if any, issued upon such conversion shall be entitled to receive the appropriate number of rights, if any, and the certificates representing the Common Stock issued upon such conversion shall bear such legends, if any, in each case as may be provided by the terms of any such stockholder rights plan, as the same may be amended from time to time. However, if, prior to any conversion of Notes, the rights have separated from the shares of Common Stock in accordance with the provisions of the applicable stockholder rights plan, the Conversion Rate shall be adjusted at the time of separation as if the Company distributed to all or substantially all holders of the Common Stock Distributed Property as provided in Section 14.04(c), subject to readjustment in the event of the expiration, termination or redemption of such rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.12. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#91;Intentionally Omitted&#93;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 14.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Exchange in Lieu of Conversion. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding anything herein to the contrary, when a Holder surrenders Notes for conversion, the Company may, at its election (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), direct the Conversion Agent to surrender, on or prior to the second Trading Day following the Conversion Date, such Notes to one or more financial institutions designated by the Company for exchange in lieu of conversion. In order to accept any Notes surrendered for conversion, the designated financial institution(s) must agree to timely pay and&#47;or deliver, in exchange for such Notes, the cash, shares of Common Stock or combination thereof due upon conversion, all as provided in this Article 14. If the Company makes an Exchange Election, by the close of business on the second Trading Day following the relevant Conversion Date, (i) the Company shall notify the Holder surrendering Notes for conversion that the Company has made the Exchange Election and shall notify the designated financial institution(s) of the Settlement Method the Company has elected with respect to such conversion and the relevant deadline for payment and&#47;or delivery of the cash, shares of Common Stock or combination thereof due upon conversion, and (ii) such designated financial institution(s) shall notify the Conversion Agent whether it will pay and&#47;or deliver the consideration due upon conversion upon exchange.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the designated financial institution(s) accepts any such Notes, it (or they) shall pay and&#47;or deliver the cash, shares of Common Stock or combination thereof due upon conversion to the Conversion Agent and the Conversion Agent shall pay and&#47;or deliver such cash, shares of Common Stock or combination thereof to the relevant Holder. Any Notes exchanged by the designated financial institution(s) shall remain outstanding, subject to the Applicable Procedures. If the designated financial institution(s) agrees to accept any Notes for exchange but does not timely pay and&#47;or deliver the cash, shares of Common Stock or combination thereof due upon</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">conversion, or if such designated financial institution(s) does not accept the Notes for exchange, the Company shall pay and&#47;or deliver the cash, shares of Common Stock or combination thereof due upon conversion to the converting Holder at the time and in the manner provided in this Article 14 as if the Company had not made an Exchange Election. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s designation of a financial institution(s) to which Notes may be submitted for exchange does not require the financial institution(s) to accept any Notes. The Company may, but is not obligated to, pay any consideration to, or otherwise enter into any agreement with, any designated financial institution(s) for or with respect to such designation. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 15 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EPURCHASE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OTES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">AT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">OLDERS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#91;Intentionally Omitted&#93;.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Repurchase at Option of Holders Upon a Fundamental Change.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) If a Fundamental Change occurs at any time prior to the Maturity Date, each Holder shall have the right, at such Holder&#8217;s option, to require the Company to repurchase for cash all of such Holder&#8217;s Notes, or any portion thereof that is equal to $1,000 or an integral multiple of $1,000, on the date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Change Repurchase Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) specified by the Company that is not less than 20 Business Days or more than 35 Business Days following the date of the Fundamental Change Company Notice at a repurchase price equal to 100% of the principal amount thereof, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> accrued and unpaid interest thereon to, but excluding, the Fundamental Change Repurchase Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Change Repurchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), unless the Fundamental Change Repurchase Date falls after a Regular Record Date but on or prior to the Interest Payment Date to which such Regular Record Date relates, in which case the Company shall instead pay the full amount of accrued and unpaid interest to Holders of record as of such Regular Record Date, and the Fundamental Change Repurchase Price shall be equal to 100% of the principal amount of Notes to be repurchased pursuant to this Article 15. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Repurchases of Notes under this Section 15.02 shall be made, at the option of the Holder thereof, upon&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) delivery to the Paying Agent by a Holder of a duly completed notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Change Repurchase Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in the form set forth in Attachment 2 to the Form of Note attached hereto as Exhibit A, if the Notes are Physical Notes, or in compliance with the Applicable Procedures for surrendering interests in Global Notes, if the Notes are Global Notes, in each case on or before the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) delivery of the Notes, if the Notes are Physical Notes, to the Paying Agent at any time after delivery of the Fundamental Change Repurchase Notice (together with all necessary endorsements for transfer) at the Corporate Trust Office of the Paying Agent, or book-entry transfer of the Notes, if the Notes are Global Notes, in compliance with the Applicable Procedures, in each case such delivery being a condition to receipt by the Holder of the Fundamental Change Repurchase Price therefor.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Fundamental Change Repurchase Notice in respect of any Notes to be repurchased shall state&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) in the case of Physical Notes, the certificate numbers of the Notes to be delivered for repurchase&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) the portion of the principal amount of Notes to be repurchased, which must be $1,000 or an integral multiple thereof&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) that the Notes are to be repurchased by the Company pursuant to the applicable provisions of the Notes and this Indenture&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that if the Notes are Global Notes, the Fundamental Change Repurchase Notice must comply with the Applicable Procedures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding anything herein to the contrary, any Holder delivering to the Paying Agent the Fundamental Change Repurchase Notice contemplated by this Section 15.02 shall have the right to withdraw, in whole or in part, such Fundamental Change Repurchase Notice at any time prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date by delivery of a written notice of withdrawal to the Paying Agent in accordance with Section 15.03. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Paying Agent (if other than the Company) shall promptly notify the Company of the receipt by it of any Fundamental Change Repurchase Notice or written notice of withdrawal thereof. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) On or before the 20th calendar day after the occurrence of the effective date of a Fundamental Change, the Company shall provide to all Holders of Notes and the Trustee, the Conversion Agent (if other than the Trustee) and the Paying Agent (in the case of a Paying Agent other than the Trustee) a written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fundamental Change Company Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) of the occurrence of the effective date of the Fundamental Change and of the repurchase right at the option of the Holders arising as a result thereof. In the case of Physical Notes, such notice shall be by first class mail or, in the case of Global Notes, such notice shall be delivered in accordance with the Applicable Procedures. Each Fundamental Change Company Notice shall specify&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) the events causing the Fundamental Change&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) the date of the Fundamental Change&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) the last date on which a Holder may exercise the repurchase right pursuant to this Article 15&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) the Fundamental Change Repurchase Price&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v) the Fundamental Change Repurchase Date&#59;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi) the name and address of the Paying Agent and the Conversion Agent, if applicable&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii) if applicable, the Conversion Rate and any adjustments to the Conversion Rate&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii) that the Notes with respect to which a Fundamental Change Repurchase Notice has been delivered by a Holder may be converted only if the Holder withdraws the Fundamental Change Repurchase Notice in accordance with the terms of this Indenture&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix) the procedures that Holders must follow to require the Company to repurchase their Notes. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No failure of the Company to give the foregoing notices and no defect therein shall limit the Holders&#8217; repurchase rights or affect the validity of the proceedings for the repurchase of the Notes pursuant to this Section 15.02. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At the Company&#8217;s request, the Trustee shall give such notice in the Company&#8217;s name and at the Company&#8217;s expense&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that, in all cases, the text of such Fundamental Change Company Notice shall be prepared by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Notwithstanding the foregoing, no Notes may be repurchased by the Company on any date at the option of the Holders upon a Fundamental Change if the principal amount of the Notes has been accelerated, and such acceleration has not been rescinded, on or prior to such date (except in the case of an acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Notes). The Paying Agent will promptly return to the respective Holders thereof any Physical Notes held by it during the acceleration of the Notes (except in the case of an acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Notes), or any instructions for book-entry transfer of the Notes in compliance with the Applicable Procedures shall be deemed to have been cancelled, and, upon such return or cancellation, as the case may be, the Fundamental Change Repurchase Notice with respect thereto shall be deemed to have been withdrawn. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Withdrawal of Fundamental Change Repurchase Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) A Fundamental Change Repurchase Notice may be withdrawn (in whole or in part) by means of a written notice of withdrawal delivered to the Corporate Trust Office of the Paying Agent in accordance with this Section 15.03 at any time prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date, specifying&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) the principal amount of the Notes with respect to which such notice of withdrawal is being submitted, </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) if Physical Notes have been issued, the certificate number of the Note in respect of which such notice of withdrawal is being submitted, and </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) the principal amount, if any, of such Note that remains subject to the original Fundamental Change Repurchase Notice, which portion must be in principal amounts of $1,000 or an integral multiple of $1,000&#59; </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that if the Notes are Global Notes, the notice must comply with Applicable Procedures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Deposit of Fundamental Change Repurchase Price.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a) The Company will deposit with the Trustee (or other Paying Agent appointed by the Company, or if the Company is acting as its own Paying Agent, set aside, segregate and hold in trust as provided in Section 4.04) on or prior to 11&#58;00 a.m., New York City time, on the Fundamental Change Repurchase Date an amount of money sufficient to repurchase all of the Notes to be repurchased at the appropriate Fundamental Change Repurchase Price. Subject to receipt of funds and&#47;or Notes by the Trustee (or other Paying Agent appointed by the Company), payment for Notes surrendered for repurchase (and not withdrawn prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date) will be made on the later of (i) the Fundamental Change Repurchase Date (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the Holder has satisfied the conditions in Section 15.02) and (ii) the time of book-entry transfer or the delivery of such Note to the Trustee (or other Paying Agent appointed by the Company) by the Holder thereof in the manner required by Section 15.02 by mailing checks for the amount payable to the Holders of such Notes entitled thereto as they shall appear in the Note Register&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that payments to the Depositary shall be made by wire transfer of immediately available funds to the account of the Depositary or its nominee. The Trustee shall, promptly after such payment and upon written demand by the Company, return to the Company any funds in excess of the Fundamental Change Repurchase Price.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) If by 11&#58;00 a.m. New York City time, on the Fundamental Change Repurchase Date, the Trustee (or other Paying Agent appointed by the Company) holds money sufficient to make payment on all the Notes or portions thereof that are to be repurchased on such Fundamental Change Repurchase Date, then, with respect to the Notes that have been properly surrendered for repurchase and have not been validly withdrawn, (i) such Notes will cease to be outstanding, (ii) interest will cease to accrue on such Notes (whether or not book-entry transfer of the Notes has been made or the Notes have been delivered to the Trustee or Paying Agent) and (iii) all other rights of the Holders of such Notes will terminate (other than the right to receive the Fundamental Change Repurchase Price and, if applicable, accrued and unpaid interest). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Upon surrender of a Note that is to be repurchased in part pursuant to Section 15.02, the Company shall execute and the Trustee shall authenticate and deliver to the Holder a new Note in an authorized denomination equal in principal amount to the unrepurchased portion of the Note surrendered. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 15.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Covenant to Comply with Applicable Laws Upon Repurchase of Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In connection with any repurchase offer upon a Fundamental Change pursuant to this Article 15, the Company will, if required&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) comply with the provisions of Rule 13e-4, Rule 14e-1 and any other tender offer rules under the Exchange Act that may then be applicable&#59; </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) file a Schedule TO or any other required schedule under the Exchange Act&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) otherwise comply with all federal and state securities laws in connection with any offer by the Company to repurchase the Notes&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in each case, so as to permit the rights and obligations under this Article 15 to be exercised in the time and in the manner specified in this Article 15. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 16 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">PTIONAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">EDEMPTION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Optional Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. No sinking fund is provided for the Notes. The Notes shall not be redeemable by the Company prior to May 6, 2020. On or after May 6, 2020, the Company may redeem (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Optional Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), for cash, all or any portion of the Notes, at the Redemption Price, if the Last Reported Sale Price of the Common Stock has been at least 130% of the Conversion Price then in effect for at least 20 Trading Days (whether or not consecutive), including the Trading Day immediately preceding the date on which the Company provides the Notice of Redemption in accordance with Section 16.02, during any 30 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date on which the Company provides the Notice of Redemption in accordance with Section 16.02. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notice of Optional Redemption&#59; Selection of Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (a) In case the Company exercises its Optional Redemption right to redeem all or, as the case may be, any part of the Notes pursuant to Section 16.01, it shall fix a date for redemption (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and it shall deliver or cause to be delivered a notice of such Optional Redemption (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notice of Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) not less than 50 nor more than 60 Scheduled Trading Days prior to the Redemption Date to the Trustee, the Paying Agent (if other than the Trustee) and each Holder of Notes. The Redemption Date must be a Business Day. The Company shall not specify a Redemption Date that falls on or after the 42nd Scheduled Trading Day immediately preceding the Maturity Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Each Notice of Redemption shall identify the provision of this Indenture permitting redemption and shall specify&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) the Redemption Date&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) the Redemption Price&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) that on the Redemption Date, the Redemption Price will become due and payable upon each Note to be redeemed, and that interest thereon, if any, shall cease to accrue on and after the Redemption Date unless the Company defaults in the payment of the Redemption Price&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) the place or places where such Notes are to be surrendered for payment of the Redemption Price&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v) that Holders may surrender their Notes for conversion at any time prior to the close of business on the Business Day immediately preceding the Redemption Date (unless the Company fails to pay the Redemption Price, in which case a Holder may convert such Notes until the Business Day immediately preceding the date on which the Redemption Price has been paid or duly provided for)&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi) the procedures a converting Holder must follow to convert its Notes and the Settlement Method and Specified Cash Amount, if applicable&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii) the Conversion Rate and, if applicable, the number of Additional Shares added to the Conversion Rate in accordance with Section 14.03&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii) the CUSIP, ISIN or other similar numbers, if any, assigned to such Notes and that no representation is made as to the correctness or accuracy of the CUSIP or ISIN number listed in such notice or printed on the Notes&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix) in case any Note is to be redeemed in part only, the portion of the principal amount thereof to be redeemed and on and after the Redemption Date, and that upon surrender of such Note, a new Note in principal amount equal to the unredeemed portion thereof shall be issued. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Notice of Redemption shall be irrevocable. At the Company&#8217;s prior written request, the Trustee shall give the Notice of Redemption in the Company&#8217;s name and at its expense&#59; provided, however, that the Company shall have delivered to the Trustee not later than the close of business the Business Day prior to the date the Notice of Redemption is to be sent (unless a shorter period shall be satisfactory to the Trustee), an Officer&#8217;s Certificate and a Company Order requesting that the Trustee give such Notice of Redemption together with the Notice of Redemption to be given setting forth the information to be stated therein as provided in the preceding paragraph. The Notice of Redemption, if given in the manner herein provided, shall be conclusively presumed to have been duly given, whether or not the Holder receives such notice. In any case, failure to give such Notice of Redemption or any defect in the Notice of Redemption to the Holder of any Note designated for redemption as a whole or in part shall not affect the validity of the proceedings for the Optional Redemption of any other Note. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) If fewer than all of the outstanding Notes are to be redeemed, (i) if the Notes to be redeemed are Physical Notes, the Trustee shall select the Notes or portions thereof to be redeemed (in principal amounts of $1,000 or integral multiples of $1,000 in excess thereof) by a method the Trustee considers to be fair, and (ii) if the Notes to be redeemed are Global Notes, the Notes to be redeemed will be selected in accordance with the Applicable Procedures. If any Note selected for partial redemption is submitted for conversion in part after such selection, the portion of the Note submitted for conversion shall be deemed (so far as may be possible) to be the portion selected for redemption. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16.03. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Payment of Notes Called for Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (a) If any Notice of Redemption has been given in respect of the Notes in accordance with Section 16.02, the Notes shall become due and payable on the Redemption Date at the place or places stated in the Notice of Redemption and at the applicable Redemption Price. On presentation and surrender of the </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes at the place or places stated in the Notice of Redemption, the Notes shall be paid and redeemed by the Company at the applicable Redemption Price. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Prior to 11&#58;00 a.m., New York City time, on the Redemption Date, the Company shall deposit with the Paying Agent or, if the Company or a Subsidiary of the Company is acting as the Paying Agent, shall segregate and hold in trust as provided in Section 7.05 an amount of cash (in immediately available funds if deposited on the Redemption Date), sufficient to pay the Redemption Price of all of the Notes to be redeemed on such Redemption Date. Subject to receipt of funds by the Paying Agent, payment for the Notes to be redeemed shall be made on the Redemption Date for such Notes. The Paying Agent shall, promptly after such payment and upon written demand by the Company, return to the Company any funds in excess of the Redemption Price. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 16.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Restrictions on Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Company may not redeem any Notes on any date if the principal amount of the Notes has been accelerated in accordance with the terms of this Indenture, and such acceleration has not been rescinded on or prior to the Redemption Date (except in the case of an acceleration resulting from a Default by the Company in the payment of the Redemption Price with respect to such Notes).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 17 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ISCELLANEOUS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ROVISIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Provisions Binding on Company&#8217;s Successors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All the covenants, stipulations, promises and agreements of the Company contained in this Indenture shall bind its successors and assigns whether so expressed or not.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Official Acts by Successor Corporation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or Officer of the Company shall and may be done and performed with like force and effect by the like board, committee or officer of any corporation or other entity that shall at the time be the lawful sole successor of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Addresses for Notices, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any notice or demand that by any provision of this Indenture is required or permitted to be given or served by the Trustee or by the Holders on the Company shall be deemed to have been sufficiently given or made, for all purposes if given or served by overnight courier or by being deposited postage prepaid by registered or certified mail in a post office letter box addressed (until another address is filed by the Company with the Trustee) to Flexion Therapeutics, Inc., 10 Mall Road, Suite 301, Burlington, MA 01803, Attention&#58; General Counsel. Any notice, direction, request or demand hereunder to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or served by being deposited postage prepaid by registered or certified mail in a post office letter box addressed to the Corporate Trust Office or sent electronically in PDF format.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Trustee, by notice to the Company, may designate additional or different addresses for subsequent notices or communications. The Trustee shall have the right, but shall not be required, to rely upon and comply with instructions and directions sent by e-mail, facsimile </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and other similar unsecured electronic methods by persons believed by the Trustee to be authorized to give instructions and directions on behalf of the Company or any Person. The Trustee shall have no duty or obligation to verify or confirm that the Person who sent such instructions or directions is, in fact, a Person authorized to give instructions or directions on behalf of the Company&#59; and the Trustee shall have no liability for any losses, liabilities, costs or expenses incurred or sustained by the Company as a result of such reliance upon or compliance with such instructions or directions. The Company agrees to assume all risks arising out of the use of such electronic methods to submit instructions and directions to the Trustee, including, without limitation, the risk of the Trustee acting on unauthorized instructions, and the risk of interception and misuse by third parties. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any notice or communication delivered or to be delivered to a Holder of Physical Notes shall be mailed to it by first class mail, postage prepaid, at its address as it appears on the Note Register and shall be sufficiently given to it if so mailed within the time prescribed. Any notice or communication delivered or to be delivered to a Holder of Global Notes shall be delivered in accordance with the Applicable Procedures and shall be sufficiently given to it if so delivered within the time prescribed. Notwithstanding any other provision of this Indenture or any Note, where this Indenture or any Note provides for notice of any event (including any Notice of Redemption or Fundamental Change Company Notice) to a Holder of a Global Note (whether by mail or otherwise), such notice shall be sufficiently given if given to the Depositary (or its designee) pursuant to the standing instructions from the Depositary or its designee, including by electronic mail in accordance with Applicable Procedures. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Failure to mail or deliver a notice or communication to a Holder or any defect in it shall not affect its sufficiency with respect to other Holders. If a notice or communication is mailed or delivered, as the case may be, in the manner provided above, it is duly given, whether or not the addressee receives it. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In case by reason of the suspension of regular mail service or by reason of any other cause it shall be impracticable to give such notice to Holders by mail, then such notification as shall be made with the approval of the Trustee shall constitute a sufficient notification for every purpose hereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Governing Law&#59; Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> THIS INDENTURE AND EACH NOTE, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS INDENTURE AND EACH NOTE, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICTS OF LAWS PROVISIONS THEREOF).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company irrevocably consents and agrees, for the benefit of the Holders from time to time of the Notes and the Trustee, that any legal action, suit or proceeding against it with respect to obligations, liabilities or any other matter arising out of or in connection with this Indenture or the Notes may be brought in the courts of the State of New York or the courts of the United States located in the Borough of Manhattan, New York City, New York and, until amounts due and to become due in respect of the Notes have been paid, hereby irrevocably consents and submits to the non-exclusive jurisdiction of each such court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> in personam</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, generally</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and unconditionally with respect to any action, suit or proceeding for itself in respect of its properties, assets and revenues. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company irrevocably and unconditionally waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any of the aforesaid actions, suits or proceedings arising out of or in connection with this Indenture brought in the courts of the State of New York or the courts of the United States located in the Borough of Manhattan, New York City, New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Evidence of Compliance with Conditions Precedent&#59; Certificates and Opinions of Counsel to Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Upon any application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each stating that such action is permitted by the terms of this Indenture&#59; provided that no Opinion of Counsel shall be required to be delivered in connection with (x) the original issuance of Notes on the date hereof under this Indenture or (y) an Optional Redemption pursuant to Article 16. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each Officer&#8217;s Certificate and Opinion of Counsel provided for, by or on behalf of the Company in this Indenture and delivered to the Trustee with respect to compliance with this Indenture (other than the Officer&#8217;s Certificates provided for in Section 4.08) shall include (a) a statement that the person signing such certificate is familiar with the requested action and this Indenture&#59; (b) a brief statement as to the nature and scope of the examination or investigation upon which the statement contained in such certificate is based&#59; (c) a statement that, in the judgment of such person, he or she has made such examination or investigation as is necessary to enable him or her to express an informed judgment as to whether or not such action is permitted by this Indenture&#59; and (d) a statement as to whether or not, in the judgment of such person, such action is permitted by this Indenture and all conditions precedent have been complied with. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Legal Holidays</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In any case where any Interest Payment Date, any Redemption Date, any Fundamental Change Repurchase Date or the Maturity Date is not a Business Day, then any action to be taken on such date need not be taken on such date, but may be taken on the next succeeding Business Day with the same force and effect as if taken on such date, and no interest shall accrue in respect of the delay. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">No Security Interest Created</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Nothing in this Indenture or in the Notes, expressed or implied, shall be construed to constitute a security interest under the Uniform Commercial Code or similar legislation, as now or hereafter enacted and in effect, in any jurisdiction. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.08. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Benefits of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Nothing in this Indenture or in the Notes, expressed or implied, shall give to any Person, other than the Holders, the parties hereto, any Paying Agent, any Conversion Agent, any authenticating agent, any Note Registrar and their successors hereunder, any benefit or any legal or equitable right, remedy or claim under this Indenture. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.09. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Table of Contents, Headings, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The table of contents and the titles and headings of the articles and sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Authenticating Agent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Trustee may appoint an authenticating agent that shall be authorized to act on its behalf and subject to its direction in the authentication and delivery of Notes in connection with the original issuance thereof and transfers and exchanges of Notes hereunder, including under Section 2.04, Section 2.05, Section 2.06, Section 2.07, Section 10.04 and Section 15.04 as fully to all intents and purposes as though the authenticating agent had been expressly authorized by this Indenture and those Sections to authenticate and deliver Notes. For all purposes of this Indenture, the authentication and delivery of Notes by the authenticating agent shall be deemed to be authentication and delivery of such Notes &#8220;by the Trustee&#8221; and a certificate of authentication executed on behalf of the Trustee by an authenticating agent shall be deemed to satisfy any requirement hereunder or in the Notes for the Trustee&#8217;s certificate of authentication. Such authenticating agent shall at all times be a Person eligible to serve as trustee hereunder pursuant to Section 7.08.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any corporation or other entity into which any authenticating agent may be merged or converted or with which it may be consolidated, or any corporation or other entity resulting from any merger, consolidation or conversion to which any authenticating agent shall be a party, or any corporation or other entity succeeding to the corporate trust business of any authenticating agent, shall be the successor of the authenticating agent hereunder, if such successor corporation or other entity is otherwise eligible under this Section 17.10, without the execution or filing of any paper or any further act on the part of the parties hereto or the authenticating agent or such successor corporation or other entity. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any authenticating agent may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time terminate the agency of any authenticating agent by giving written notice of termination to such authenticating agent and to the Company. Upon receiving such a notice of resignation or upon such a termination, or in case at any time any authenticating agent shall cease to be eligible under this Section, the Trustee may appoint a successor authenticating agent (which may be the Trustee), shall give written notice of such appointment to the Company and shall deliver notice of such appointment to all Holders. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company agrees to pay to the authenticating agent from time to time reasonable compensation for its services although the Company may terminate the authenticating agent, if it determines such agent&#8217;s fees to be unreasonable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Section 7.02, Section 7.03, Section 7.04, Section 8.03 and this Section 17.10 shall be applicable to any authenticating agent. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an authenticating agent is appointed pursuant to this Section 17.10, the Notes may have endorsed thereon, in addition to the Trustee&#8217;s certificate of authentication, an alternative certificate of authentication in the following form&#58; </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________________________, </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as Authenticating Agent, certifies that this is one of the Notes described </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in the within-named Indenture. </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; ___________________________ </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized Signatory </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Execution in Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. The exchange of copies of this Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In the event any provision of this Indenture or in the Notes shall be invalid, illegal or unenforceable, then (to the extent permitted by law) the validity, legality or enforceability of the remaining provisions shall not in any way be affected or impaired.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Waiver of Jury Trial.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Force Majeure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services or other unavailability of the Federal Reserve Bank wire or facsimile or other wire or communication facility&#59; it being understood that the Trustee shall use reasonable efforts that are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">. Calculations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as otherwise provided herein, the Company shall be responsible for making all calculations called for under the Notes. These calculations include, but are not limited to, determinations of the Trading Price of the Notes, determinations of whether the Notes are convertible and determinations of the Last Reported Sale Prices of the Common Stock, the Daily VWAPs, the Daily Conversion Values, the Daily Settlement Amounts, accrued interest payable on the Notes and the Conversion Rate of the Notes. The Company shall make all these calculations in good faith and, absent manifest error, the Company&#8217;s calculations shall be final and binding on Holders of Notes. The Company shall provide a schedule of its calculations to each of the Trustee and the Conversion Agent, and each of the Trustee and Conversion Agent is entitled to rely conclusively upon the accuracy of the Company&#8217;s calculations without independent verification. The Trustee will forward the Company&#8217;s</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">calculations to any Holder of Notes upon the written request of that Holder at the sole cost and expense of the Company. The Trustee (including in its capacities as Note Registrar, Paying Agent and Conversion Agent, as the case may be) shall have no responsibility to determine the sale price of the Notes, Trading Price of the Notes, any Settlement Amount, any adjustment or increase to the Conversion Rate or any circumstance under which any adjustment to the Conversion Rate is required, whether any Fundamental Change has occurred, or whether the Notes are convertible pursuant to Article 14. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 17.16. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">USA PATRIOT Act. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The parties hereto acknowledge that in accordance with Section 326 of the USA PATRIOT Act, the Trustee, like all financial institutions and in order to help fight the funding of terrorism and money laundering, is required to obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture agree that they will provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the USA PATRIOT Act.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Remainder of page intentionally left blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the date first written above. </font></div><div style="padding-left:280.95pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.346%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael D. Clayman, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Michael D. Clayman, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:280.95pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WELLS FARGO BANK, NATIONAL<br>ASSOCIATION, as Trustee</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Maddy Hughes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Maddy Hughes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Vice President</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT A </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;FORM OF FACE OF NOTE&#93; </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;INCLUDE FOLLOWING LEGEND IF A GLOBAL NOTE&#93; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (&#8220;DTC&#8221;), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE &#38; CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT HEREUNDER IS MADE TO CEDE &#38; CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE &#38; CO., HAS AN INTEREST HEREIN.&#93; </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;INCLUDE FOLLOWING LEGEND IF A RESTRICTED SECURITY&#93; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;THIS SECURITY AND THE COMMON STOCK, IF ANY, ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A &#8220;QUALIFIED INSTITUTIONAL BUYER&#8221; (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2) AGREES FOR THE BENEFIT OF FLEXION THERAPEUTICS, INC. (THE &#8220;COMPANY&#8221;) THAT IT WILL NOT OFFER, SELL, PLEDGE OR OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE DATE THAT IS THE LATER OF (X) ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE HEREOF OR SUCH SHORTER PERIOD OF TIME AS PERMITTED BY RULE 144 UNDER THE SECURITIES ACT OR ANY SUCCESSOR PROVISION THERETO AND (Y) SUCH LATER DATE, IF ANY, AS MAY BE REQUIRED BY APPLICABLE LAW, EXCEPT&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, OR </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT, OR </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-1 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, OR </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH CLAUSE (2)(D) ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER TO DETERMINE THAT THE PROPOSED TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.&#93; </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-2</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible Senior Note due 2024 </font></div><div style="padding-left:0.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No. &#91; &#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Initially&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> $&#91; &#93;</font></div></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CUSIP No. &#91; &#93; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion Therapeutics, Inc., a corporation duly organized and validly existing under the laws of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; which term includes any successor corporation or other entity under the Indenture referred to on the reverse hereof), for value received hereby promises to pay to &#91;CEDE &#38; CO.&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#91; &#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, or registered assigns, the principal sum &#91;as set forth in the &#8220;Schedule of Exchanges of Notes&#8221; attached hereto&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#91;of $&#91; &#93;&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, which amount, taken together with the principal amounts of all other outstanding Notes, shall not, unless permitted by the Indenture, exceed $201,250,000 in aggregate at any time, in accordance with the rules and procedures of the Depositary, on May 1, 2024, and interest thereon as set forth below. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Note shall bear interest at the rate of 3.375% per year from May 2, 2017, or from the most recent date to which interest had been paid or provided for to, but excluding, the next scheduled Interest Payment Date until May 1, 2024. Interest is payable semi-annually in arrears on each May 1 and November 1, commencing on November 1, 2017, to Holders of record at the close of business on the preceding April 15 and October 15 (whether or not such day is a Business Day), respectively. Accrued interest on the Notes shall be computed on the basis of a 360-day year composed of twelve 30-day months and, for partial months, on the basis of the number of days actually elapsed in a 30-day month. Additional Interest will be payable as set forth in Section 4.06(d), Section 4.06(e) and Section 6.03 of the within-mentioned Indenture, and any reference to interest on, or in respect of, any Note therein shall be deemed to include Additional Interest if, in such context, Additional Interest is, was or would be payable pursuant to any of such Section 4.06(d), Section 4.06(e) or Section 6.03, and any express mention of the payment of Additional Interest in any provision therein shall not be construed as excluding Additional Interest in those provisions thereof where such express mention is not made. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any Defaulted Amounts shall accrue interest per annum at the rate borne by the Notes, subject to the enforceability thereof under applicable law, from, and including, the relevant payment date to, but excluding, the date on which such Defaulted Amounts shall have been paid by the Company in accordance with Section 2.03(c) of the Indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company shall pay the principal of and interest on this Note, if and so long as such Note is a Global Note, in immediately available funds to the Depositary or its nominee, as the case may be, as the registered Holder of such Note. As provided in and subject to the provisions of the Indenture, the Company shall pay the principal of any Notes (other than Notes that are</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________ </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Include if a global note.</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Include if a global note.</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Include if a physical note.</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Include if a global note.</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Include if a physical note.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-3 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Notes) at the office or agency designated by the Company for that purpose. The Company has initially designated the Trustee as its Paying Agent, Note Registrar, Custodian and Conversion Agent in respect of the Notes and its agency in the continental United States of America as a place where Notes may be presented for payment or for registration of transfer and exchange. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to the further provisions of this Note set forth on the reverse hereof, including, without limitation, provisions giving the Holder of this Note the right to convert this Note into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, on the terms and subject to the limitations set forth in the Indenture. Such further provisions shall for all purposes have the same effect as though fully set forth at this place. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">This Note, and any claim, controversy or dispute arising under or related to this Note, shall be construed in accordance with and governed by the laws of the State of New York (without regard to the conflicts of laws provisions thereof). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the case of any conflict between this Note and the Indenture, the provisions of the Indenture shall control and govern. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Note shall not be valid or become obligatory for any purpose until the certificate of authentication hereon shall have been signed manually by the Trustee or a duly authorized authenticating agent under the Indenture. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Remainder of page intentionally left blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-4 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Company has caused this Note to be duly executed. </font></div><div style="padding-left:280.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.307%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.628%"><tr><td style="width:1.0%"></td><td style="width:57.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRUSTEE&#8217;S CERTIFICATE OF AUTHENTICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee, certifies that this is one of the Notes described in the within-named Indenture.</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;  ___________________________________</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Authorized Signatory</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-5 </font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;FORM OF REVERSE OF NOTE&#93; </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible Senior Note due 2024 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Note is one of a duly authorized issue of Notes of the Company, designated as its 3.375% Convertible Senior Notes due 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), limited to the aggregate principal amount of $201,250,000 all issued or to be issued under and pursuant to an Indenture dated as of May 2, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), between the Company and Wells Fargo Bank, National Association (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), to which Indenture and all indentures supplemental thereto reference is hereby made for a description of the rights, limitations of rights, obligations, duties and immunities thereunder of the Trustee, the Company and the Holders of the Notes. Additional Notes may be issued in an unlimited aggregate principal amount, subject to certain conditions specified in the Indenture. Capitalized terms used in this Note and not defined in this Note shall have the respective meanings set forth in the Indenture.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In case certain Events of Default shall have occurred and be continuing, the principal of, and interest on, all Notes may be declared, by either the Trustee or Holders of at least 25% in aggregate principal amount of Notes then outstanding, and upon said declaration shall become, due and payable, in the manner, with the effect and subject to the conditions and certain exceptions set forth in the Indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the terms and conditions of the Indenture, the Company will make all payments and deliveries in respect of the Fundamental Change Repurchase Price on the Fundamental Change Repurchase Date (if applicable), the Redemption Price on any Redemption Date (if applicable) and the principal amount on the Maturity Date, as the case may be, to the Holder who surrenders a Note to a Paying Agent to collect such payments in respect of the Note. The Company will pay cash amounts in money of the United States that at the time of payment is legal tender for payment of public and private debts. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Indenture contains provisions permitting the Company and the Trustee, in certain circumstances without the consent of the Holders of the Notes, and in certain other circumstances with the consent of the Holders of not less than a majority in aggregate principal amount of the Notes at the time outstanding, evidenced as in the Indenture provided, to execute supplemental indentures modifying the terms of the Indenture and the Notes as described therein. It is also provided in the Indenture that, subject to certain exceptions, the Holders of a majority in aggregate principal amount of the Notes at the time outstanding may on behalf of the Holders of all of the Notes waive any past Default or Event of Default under the Indenture and its consequences. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay or deliver, as the case may be, the principal (including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, accrued and unpaid interest on, and the consideration due upon conversion of, this Note at the place, at the respective times, at the rate and in the lawful money and&#47;or shares of Common Stock, as the case may be, herein prescribed.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-6 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes are issuable in registered form without coupons in denominations of $1,000 principal amount and integral multiples thereof. At the office or agency of the Company referred to on the face hereof, and in the manner and subject to the limitations provided in the Indenture, Notes may be exchanged for a like aggregate principal amount of Notes of other authorized denominations, without payment of any service charge but, if required by the Company or Trustee, with payment of a sum sufficient to cover any transfer or similar tax that may be imposed in connection therewith as a result of the name of the Holder of the new Notes issued upon such exchange of Notes being different from the name of the Holder of the old Notes surrendered for such exchange. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Notes are not subject to redemption prior to May 6, 2020. The Notes shall be redeemable at the Company&#8217;s option on or after May 6, 2020 in accordance with the terms and subject to the conditions specified in the Indenture. No sinking fund is provided for the Notes. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon the occurrence of a Fundamental Change, the Holder has the right, at such Holder&#8217;s option, to require the Company to repurchase for cash all of such Holder&#8217;s Notes or any portion thereof (in principal amounts of $1,000 or integral multiples thereof) on the Fundamental Change Repurchase Date at a price equal to the Fundamental Change Repurchase Price. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the provisions of the Indenture, the Holder hereof has the right, at its option, during certain periods and upon the occurrence of certain conditions specified in the Indenture, prior to the close of business on the Business Day immediately preceding the Maturity Date, to convert any Notes or portion thereof that is $1,000 or an integral multiple thereof, into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, at the Conversion Rate specified in the Indenture, as adjusted from time to time as provided in the Indenture. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company shall furnish to any Holder upon written request and without charge a copy of the Indenture. Requests may be made to&#58; Flexion Therapeutics, Inc., 10 Mall Road, Suite 301, Burlington, MA 01803, Attention&#58; General Counsel. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-7 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABBREVIATIONS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following abbreviations, when used in the inscription of the face of this Note, shall be construed as though they were written out in full according to applicable laws or regulations&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEN COM &#61; as tenants in common </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UNIF GIFT MIN ACT &#61; Uniform Gifts to Minors Act </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CUST &#61; Custodian </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEN ENT &#61; as tenants by the entireties </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JT TEN &#61; joint tenants with right of survivorship and not as tenants in common </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional abbreviations may also be used though not in the above list.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A-8</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SCHEDULE A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHEDULE OF EXCHANGES OF NOTES </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible Senior Notes due 2024 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The initial principal amount of this Global Note is DOLLARS ($&#91; &#93;). The following increases or decreases in this Global Note have been made&#58; </font></div><div style="padding-left:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:15.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.440%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date of exchange</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of<br>decrease in<br>principal amount<br>of this Global Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of<br>increase in<br>principal amount<br>of this Global Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount<br>of this Global Note<br>following such<br>decrease or<br>increase</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Signature of<br>authorized<br>signatory of<br>Trustee or<br>Custodian</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________________</font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Include if a global note.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A-9 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ATTACHMENT 1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;FORM OF NOTICE OF CONVERSION&#93; </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible Senior Notes due 2024 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To&#58; Wells Fargo Corporate Trust-DAPS Reorg </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 Fourth Street South, 7th Floor </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAC N9300-070 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minneapolis, MN 55415 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phone&#58; 1-800-344-5128 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fax&#58; 1-866-969-1290 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; dapsreorg&#64;wellsfargo.com </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned registered owner of this Note hereby exercises the option to convert this Note, or the portion hereof (that is $1,000 principal amount or an integral multiple thereof) below designated, into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, in accordance with the terms of the Indenture referred to in this Note, and directs that any cash payable and any shares of Common Stock issuable and deliverable upon such conversion, together with any cash for any fractional share, and any Notes representing any unconverted principal amount hereof, be issued and delivered to the registered Holder hereof unless a different name has been indicated below. If any shares of Common Stock or any portion of this Note not converted are to be issued in the name of a Person other than the undersigned, the undersigned will pay all documentary, stamp or similar issue or transfer taxes, if any in accordance with Section 14.02(d) and Section 14.02(e) of the Indenture. Any amount required to be paid to the undersigned on account of interest accompanies this Note. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Indenture. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature(s)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </font></div><div style="padding-left:0.25pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.410%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature Guarantee</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature(s) must be guaranteed by an eligible Guarantor Institution (banks, stock brokers, savings and loan associations and credit unions) with membership in an approved signature guarantee medallion program pursuant to Securities and Exchange Commission Rule 17Ad-15 if shares of Common Stock are to be issued, or Notes are to be delivered, other than to and in the name of the registered holder.</font></div><div><font><br></font></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fill in for registration of shares if to be issued, and Notes if to be delivered, other than to and in the name of the registered holder&#58;</font></div></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Name)</font></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Street Address)</font></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(City, State and Zip Code)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Please print name and address</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:280.85pt;text-indent:-45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.974%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount to be converted (if less than all)&#58; $      ,000</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOTICE&#58; The above signature(s) of the Holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever.</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Social Security or Other Taxpayer Identification Number</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ATTACHMENT 2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;FORM OF FUNDAMENTAL CHANGE REPURCHASE NOTICE&#93; </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible Senior Notes due 2024 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To&#58; Wells Fargo Corporate Trust-DAPS Reorg </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 Fourth Street South, 7th Floor </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MAC N9300-070 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minneapolis, MN 55415 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phone&#58; 1-800-344-5128 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fax&#58; 1-866-969-1290 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; dapsreorg&#64;wellsfargo.com </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned registered owner of this Note hereby acknowledges receipt of a notice from Flexion Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) as to the occurrence of a Fundamental Change with respect to the Company and specifying the Fundamental Change Repurchase Date and requests and instructs the Company to pay to the registered holder hereof in accordance with Section 15.02 of the Indenture referred to in this Note (1) the entire principal amount of this Note, or the portion thereof (that is $1,000 principal amount or an integral multiple thereof) below designated, and (2) if such Fundamental Change Repurchase Date does not fall during the period after a Regular Record Date and on or prior to the corresponding Interest Payment Date, accrued and unpaid interest, if any, thereon to, but excluding, such Fundamental Change Repurchase Date. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Indenture.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the case of Physical Notes, the certificate numbers of the Notes to be repurchased are as set forth below&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; _____________________ </font></div><div style="padding-left:280.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature(s)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Social Security or Other Taxpayer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification Number</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.878%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount to be repaid (if less than all)&#58; $      ,000</font></div><div style="text-indent:-31.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOTICE&#58; The above signature(s) of the Holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever.</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ATTACHMENT 3 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;FORM OF ASSIGNMENT AND TRANSFER&#93; </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible Senior Notes due 2024 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For value received hereby sell(s), assign(s) and transfer(s) unto (Please insert social security or Taxpayer Identification Number of assignee) the within Note, and hereby irrevocably constitutes and appoints attorney to transfer the said Note on the books of the Company, with full power of substitution in the premises. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with any transfer of the within Note occurring prior to the Resale Restriction Termination Date, as defined in the Indenture governing such Note, the undersigned confirms that such Note is being transferred&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To Flexion Therapeutics, Inc. or a subsidiary thereof&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Pursuant to a registration statement that has become or been declared effective under the Securities Act of 1933, as amended&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Pursuant to and in compliance with Rule 144A under the Securities Act of 1933, as amended&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Pursuant to and in compliance with Rule 144 under the Securities Act of 1933, as amended, or any other available exemption from the registration requirements of the Securities Act of 1933, as amended.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; ________________________</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature(s)</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature Guarantee</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature(s) must be guaranteed by an eligible Guarantor Institution (banks, stock brokers, savings and loan associations and credit unions) with membership in an approved signature guarantee medallion program pursuant to Securities and Exchange Commission Rule 17Ad-15 if Notes are to be delivered, other than to and in the name of the registered holder.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOTICE&#58; The signature on the assignment must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>3
<FILENAME>pcrx-12312021xex45.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idb0516ac8fc64eba9d906e55ebc983a9_33"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.5</font></div></div><div><font><br></font></div><div id="idb0516ac8fc64eba9d906e55ebc983a9_39"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WELLS FARGO BANK, NATIONAL ASSOCIATION,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as Trustee</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FIRST SUPPLEMENTAL INDENTURE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated as of November 19, 2021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible Senior Notes due 2024</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FIRST SUPPLEMENTAL INDENTURE, dated as of November 19, 2021 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), between Flexion Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as issuer, and Wells Fargo Bank, National Association, a national banking association organized under the laws of the United States of America, as trustee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), to the Indenture, dated as of May 2, 2017 (as supplemented or otherwise modified prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), between the Company and the Trustee.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, the Company has heretofore executed and delivered the Indenture, pursuant to which the Company issued its 3.375% Convertible Senior Notes due 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in the original aggregate principal amount of $201,250,000&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, the Company has entered into an Agreement and Plan of Merger, dated as of October 11, 2021 (as amended, supplemented, restated, or otherwise modified, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Merger Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), by and among the Company&#59; Pacira BioSciences, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; and Oyster Acquisition Company Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Merger Sub</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Merger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) on the date hereof, with the Company as the surviving entity in the Merger, becoming a wholly owned subsidiary of Parent as of the date hereof&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, the Merger constitutes a Merger Event under the Indenture&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, Section 14.07(a) of the Indenture provides that prior to or at the effective time of any Merger Event, the Company shall execute with the Trustee a supplemental indenture permitted under Section 10.01(i) of the Indenture providing for the right to convert each $1,000 principal amount of Notes into the kind and amount of shares of stock, other securities, or other property or assets (including cash or any combination thereof) that a holder of a number of shares of Common Stock equal to the Conversion Rate immediately prior to such Merger Event would have owned or been entitled to receive (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reference Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) upon such Merger Event&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, in connection with the Merger, each outstanding share of Common Stock prior to the effective time (other than certain shares of Common Stock as set forth in the Merger Agreement) shall be converted into the right to receive&#58; (a) an amount in cash equal to $8.50 per share, in cash, net of applicable withholding taxes and without interest, plus (b) one non-transferable contingent value right per share (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CVR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), which will represent the right to receive one or more contingent payments up to $8.00 per share in the aggregate, in cash, if the specified milestones are achieved on or prior to December 31, 2030, pursuant to the terms of the Contingent Value Right Agreement, dated as of November 19, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CVR Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), by and between Parent and American Stock Transfer &#38; Trust Company, LLC, as rights agent, in accordance with the terms of the Merger Agreement&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, Section 10.01 of the Indenture provides that the Company and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental thereto without the consent of any Holder to, among other things, (i) provide that the Notes are convertible into Reference Property in connection with any Merger Event, subject to the provisions of Section 14.02 of the Indenture, and make such related changes to the terms of the Notes in accordance with Section 14.07 of the Indenture&#59; or (ii) make any change that does not adversely affect the rights of any Holder&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, in connection with the execution and delivery of this Supplemental Indenture, the Trustee has received an Officer&#8217;s Certificate and an Opinion of Counsel as contemplated by Sections 10.05 and 17.05 of the Indenture&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, the Company has requested that the Trustee execute and deliver this Supplemental Indenture and has satisfied all requirements necessary to make this Supplemental Indenture a valid instrument in accordance with its terms.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WITNESSETH&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company covenants and agrees with the Trustee as follows for the equal and ratable benefit of the Holders&#58;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEFINITIONS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 1.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definitions in the Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Unless otherwise specified herein or the context otherwise requires&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) a term defined in the Indenture has the same meaning when used in this Supplemental Indenture unless the definition of such term is amended or supplemented pursuant to this Supplemental Indenture&#59;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) the terms defined in this Supplemental Indenture include the plural as well as the singular&#59; and</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) unless otherwise stated, a reference to a Section or Article is to a Section or Article of this Supplemental Indenture.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EFFECT OF MERGER ON CONVERSION</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 2.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conversion Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In accordance with and subject to Section 14.07 of the Indenture, at and after the effective time of the Merger, (a) the right to convert each $1,000 principal amount of Notes shall be changed into a right to convert such principal amount of Notes into the number of units of Reference Property that a holder of a number of shares of Common Stock equal to the Conversion Rate immediately prior to such Merger Event would have owned or been entitled to receive upon such Merger, and (b) a &#8220;unit of Reference Property&#8221; shall mean $8.50 in cash, plus one (1) CVR, plus&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if the Milestone 1 Amount (as defined in the CVR Agreement) has been paid to the Rights Agent pursuant to the terms of the CVR Agreement prior to the applicable Conversion Date, $1.00, plus</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if the Milestone 2 Amount (as defined in the CVR Agreement) has been paid to the Rights Agent pursuant to the terms of the CVR Agreement prior to the applicable Conversion Date, $2.00, plus</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if the Milestone 3 Amount (as defined in the CVR Agreement) has been paid to the Rights Agent pursuant to the terms of the CVR Agreement prior to the applicable Conversion Date, $3.00, plus</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if the Milestone 4 Amount (as defined in the CVR Agreement) has been paid to the Rights Agent pursuant to the terms of the CVR Agreement prior to the applicable Conversion Date, $1.00, plus</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if the Milestone 5 Amount (as defined in the CVR Agreement) has been paid to the Rights Agent pursuant to the terms of the CVR Agreement prior to the applicable Conversion Date, $1.00.</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE 3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MISCELLANEOUS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.01. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Ratification of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Indenture, as supplemented by this Supplemental Indenture, is in all respects ratified and confirmed, and this Supplemental Indenture shall be deemed part of the Indenture in the manner and to the extent herein and therein provided.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.02. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trustee Not Responsible for Recitals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The recitals herein contained are made by the Company and not by the Trustee, and the Trustee assumes no responsibility for the correctness thereof. The Trustee makes no representation as to and shall not be responsible for the validity or sufficiency of this Supplemental Indenture, the Merger, or the Reference Property. All of the provisions contained in the Indenture in respect of the rights, privileges, immunities, powers, and duties of the Trustee shall be applicable in respect of the Supplemental Indenture as fully and with like force and effect as though set forth in full herein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.03 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All agreements of the Company and the Trustee in this Supplemental Indenture will bind their respective successors.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.04. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. THIS SUPPLEMENTAL INDENTURE AND ANY CLAIM, CONTROVERSY, OR DISPUTE ARISING UNDER OR RELATED TO THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.05. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Headings, Etc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The titles and headings of the articles and sections of this Supplemental Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.06. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Execution in Counterparts&#59; Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Supplemental Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. This Supplemental Indenture and any certificate, agreement, or other document to be signed in connection with this Indenture shall be valid, binding, and enforceable against a party when executed and delivered by an authorized individual on behalf of the party by means of (i) an original manual signature&#59; (ii) a faxed, scanned, or photocopied manual signature&#59; or (iii) any other electronic signature permitted by the federal Electronic Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic Transactions Act, and&#47;or any other relevant electronic signatures law, including any relevant provisions of the UCC (collectively, &#8220;Signature Law&#8221;), in each case to the extent applicable. Each faxed, scanned, or photocopied manual signature, or other electronic signature, shall for all purposes have the same validity, legal effect, and admissibility in evidence as an original manual signature. Each party hereto shall be entitled to conclusively rely upon, and shall have no liability with respect to, any faxed, scanned, or photocopied manual signature, or other electronic signature, of any other party and shall have no duty to investigate, confirm, or otherwise verify the validity or authenticity thereof. For the avoidance of doubt, original manual signatures shall be used for execution or indorsement of writings when required under the UCC or other Signature Law due to the character or intended character of the writings.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.07. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In the event that any provision of this Supplemental Indenture shall be invalid, illegal, or unenforceable, then (to the extent permitted by law) the validity, legality, or enforceability of the remaining provisions shall not in any way be affected or impaired.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.08. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS SUPPLEMENTAL INDENTURE OR THE TRANSACTIONS CONTEMPLATED HEREBY.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 3.09. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Supplemental Indenture shall become effective upon, without further action by the parties hereto, the effective time of the Merger.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the day and year first above written.</font></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLEXION THERAPEUTICS, INC.</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael D. Clayman, MD</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Michael D. Clayman, MD</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#8239;&#8239;&#8239;President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; Computershare Trust Company, N.A., as attorney-in-fact</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott Little</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Scott Little</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#8239;&#8239;&#8239;Vice President</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE PAGE TO SUPPLEMENTAL INDENTURE</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>pcrx-12312021xex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia0604c28b1864072b4cd4ddec78adc4a_33"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">PACIRA BIOSCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Nonstatutory Stock Option Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Granted Under Amended and Restated 2011 Stock Incentive Plan</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This agreement evidences the grant by Pacira BioSciences, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), on &#91;GRANT DATE&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) to &#91;PARTICIPANT NAME&#93;, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), of an option to purchase, in whole or in part, on the terms provided herein and in the Company&#8217;s Amended and Restated 2011 Stock Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), a total of &#91;NUMBER OF AWARDS GRANTED&#93; shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) of common stock, $0.001</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">par value per share, of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) at $&#91;GRANT PRICE&#93; per Share.  Unless earlier terminated, this option shall expire at 5&#58;00 p.m., Pacific time, on &#91;EXPIRATION DATE&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Final Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">It is intended that the option evidenced by this agreement shall not be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).  Except as otherwise indicated by the context, the term &#8220;Participant&#8221;, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The option shares vest as follows&#58; 25% of the option shares vest upon the one-year anniversary of the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Vesting Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; and 6.25% of the option shares vest every three-months thereafter.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Form of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Each election to exercise this option shall be in writing, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, and payment in full in the manner provided in the Plan.  The Participant may purchase less than the number of Shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for the lesser of  (i) fifty (50) whole shares or (ii) the amount of unexercised option shares remaining under this option.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Continuous Relationship with the Company Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Except as otherwise provided in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, officer or director of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Eligible Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination of Relationship with the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">three months after such cessation (but in no event after the Final Exercise Date), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation.  Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise Period Upon Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for &#8220;cause&#8221; as specified in paragraph (e) below, this option shall be exercisable, within the period of three years following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If, prior to the Final Exercise Date, the Participant&#8217;s employment or other relationship with the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other relationship.  If, prior to the Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or other termination is subsequent to the date of the delivery of such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#8217;s employment or other relationship shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the preceding sentence, terminate upon the effective date of such termination of employment or other relationship).  If the Participant is party to an employment, consulting or severance agreement with the Company that contains a definition of &#8220;cause&#8221; for termination of employment or other relationship, &#8220;Cause&#8221; shall have the meaning ascribed to such term in such agreement.  Otherwise, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive.  The Participant&#8217;s employment or other relationship shall be considered to have been terminated for &#8220;Cause&#8221; if the Company determines, within 30 days after the Participant&#8217;s resignation, that termination for Cause was warranted.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant&#59; provided, however, that the Participant may transfer this option gratuitously to or for the benefit of any immediate family member of the Participant, family trust or other entity established for the benefit of the Participant and&#47;or an immediate family member of the Participant if the Company would be eligible to use a Form S-8 under the Securities Act for the registration of the sale of the Shares to such proposed transferee&#59; provided further, that the Company will not be required to recognize any such permitted transfer until such time as such permitted transferee, as a condition to such transfer, delivers to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee will be bound by all the terms and conditions of this option.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.</font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the Company has caused this option to be executed under its corporate seal by its duly authorized officer. This option shall take effect as a sealed instrument.</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">PACIRA BIOSCIENCES, INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; ___________________________________</font></div><div style="text-align:justify;text-indent:234pt"><font><br></font></div><div style="text-align:justify;text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; ________________________________</font></div><div style="text-align:justify;text-indent:234pt"><font><br></font></div><div style="text-align:justify;text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; _________________________________</font></div><div><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt of a copy of the Company&#8217;s Amended and Restated 2011 Stock Incentive Plan.</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">PARTICIPANT&#58;</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; ___________________________________</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; _________________________________</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SIGNATURE PAGE TO NONSTATUTORY STOCK OPTION AGREEMENT</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>pcrx-12312021xex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4cafccb81367496e8fdd0001573ce2df_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.4</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">PACIRA BIOSCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Nonstatutory Stock Option Agreement for Non-Employee Directors</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Granted Under Amended and Restated 2011 Stock Incentive Plan</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This agreement evidences the grant by Pacira BioSciences, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), on &#91;GRANT DATE&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) to &#91;PARTICIPANT NAME&#93;, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), of an option to purchase, in whole or in part, on the terms provided herein and in the Company&#8217;s Amended and Restated 2011 Stock Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), a total of &#91;NUMBER OF AWARDS GRANTED&#93; shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) of common stock, $0.001</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">par value per share, of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) at $&#91;GRANT PRICE&#93; per Share.  Unless earlier terminated, this option shall expire at 5&#58;00 p.m., Pacific time, on &#91;EXPIRATION DATE&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Final Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">It is intended that the option evidenced by this agreement shall not be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).  Except as otherwise indicated by the context, the term &#8220;Participant&#8221;, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The option shares vest as follows&#58; 25% of the option shares vest upon the one-year anniversary of the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Vesting Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; and 6.25% of the option shares vest every three-months thereafter.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Form of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Each election to exercise this option shall be in writing, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, and payment in full in the manner provided in the Plan.  The Participant may purchase less than the number of Shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for the lesser of  (i) fifty (50) whole shares or (ii) the amount of unexercised option shares remaining under this option.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Continuous Relationship with the Company Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Except as otherwise provided in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, officer or director of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Eligible Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination of Relationship with the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">three months after such cessation (but in no event after the Final Exercise Date), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation.  Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise Period Upon Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for &#8220;cause&#8221; as specified in paragraph (e) below, this option shall be exercisable, within the period of three years following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(e) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination of Relationship After Five Years of Service on the Board.  If the Participant  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ceases to be an Eligible Participant after completing five years of service on the Board (measured from the Participant&#8217;s date of commencement as a director on the Board), the right to exercise this option shall terminate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">three years after such cessation (but in no event after the Final Exercise Date), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation.  Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If, prior to the Final Exercise Date, the Participant&#8217;s employment or other relationship with the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other relationship.  If, prior to the Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or other termination is subsequent to the date of the delivery of such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#8217;s employment or other relationship shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the preceding sentence, terminate upon the effective date of such termination of employment or other relationship).  If the Participant is party to an employment, consulting or severance agreement with the Company that contains a definition of &#8220;cause&#8221; for termination of employment or other relationship, &#8220;Cause&#8221; shall have the meaning ascribed to such term in such agreement.  Otherwise, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean willful misconduct by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive.  The Participant&#8217;s employment or other relationship shall be considered to have been terminated for &#8220;Cause&#8221; if the Company determines, within 30 days after the Participant&#8217;s resignation, that termination for Cause was warranted.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant&#59; provided, however, that the Participant may transfer this option gratuitously to or for the benefit of any immediate family member of the Participant, family trust or other entity established for the benefit of the Participant and&#47;or an immediate family member of the Participant if the Company would be eligible to use a Form S-8 under the Securities Act for the registration of the sale of the Shares to such proposed transferee&#59; provided further, that the Company will not be required to recognize any such permitted transfer until such time as such permitted transferee, as a condition to such transfer, delivers to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee will be bound by all the terms and conditions of this option.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.</font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the Company has caused this option to be executed under its corporate seal by its duly authorized officer. This option shall take effect as a sealed instrument.</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">PACIRA BIOSCIENCES, INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; ___________________________________</font></div><div style="text-align:justify;text-indent:234pt"><font><br></font></div><div style="text-align:justify;text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; ________________________________</font></div><div style="text-align:justify;text-indent:234pt"><font><br></font></div><div style="text-align:justify;text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; _________________________________</font></div><div><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt of a copy of the Company&#8217;s Amended and Restated 2011 Stock Incentive Plan.</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">PARTICIPANT&#58;</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; ___________________________________</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; _________________________________</font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-indent:234pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SIGNATURE PAGE TO NONSTATUTORY STOCK OPTION AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(NON-EMPLOYEE DIRECTORS)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>6
<FILENAME>pcrx-12312021xex1036.htm
<DESCRIPTION>EX-10.36
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5081908fd9284096b8bcede89479a529_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 10.36</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANUFACTURING AND SUPPLY AGREEMENT</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">***Text Omitted and Filed Separately </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">with the Securities and Exchange Commission. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confidential Treatment Requested </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Under 17 C.F.R. Sections 200.80(b)(4) </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">and 240.24b-2. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANUFACTURING AND SUPPLY AGREEMENT </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANUFACTURING AND SUPPLY AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) dated as of July 31, 2015 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is made by and between Flexion Therapeutics, Inc., a Delaware corporation having its principal place of business at 10 Mall Road, Suite 301, Burlington, Massachusetts, United States (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and Patheon UK Limited, a company incorporated in England and Wales having its principal place of business at Kingfisher Drive, Covingham, Swindon, SN35BZ, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Flexion, and Patheon are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECITALS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, Flexion has a commercial interest in the Manufacture (as defined herein) and commercialization of FX006 drug product, an extended-release formulation of triamcinolone acetonide (TCA) which is manufactured using the Flexion Manufacturing Process (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, Patheon has expertise and experience in manufacturing and packaging pharmaceutical products and is interested in providing Manufacturing services to Flexion in connection with the Product&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, in anticipation of this Agreement and the goods and services that Patheon will supply hereunder, the Parties are executing an agreement pursuant to which Patheon would undertake certain technical transfer and construction services in order to validate and scale up Flexion&#8217;s technology package and prepare Patheon&#8217;s facilities for the Manufacture of the Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Technical Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, in consideration of the foregoing, the mutual promises and covenants of the Parties contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE I. DEFINITIONS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following terms shall have the meanings set forth below. Unless the context indicates otherwise, the singular shall include the plural and the plural shall include the singular. Any term not defined hereunder shall have the meaning ascribed to such term in the Technical Transfer Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any services requested and approved by Flexion that supplement Patheon&#8217;s regular performance of the Services, as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. For the purposes of this Section 1.2 only, a Person will be regarded as in control of another Person if such Person owns, or directly or indirectly controls, more than 50% of the voting securities (or comparable equity interests) or other </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ownership interests of the other Person, or if such Person directly or indirectly possesses the power to direct or cause the direction of the management or policies of the other Person, whether through the ownership of voting securities, by contract, or any other means whatsoever. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Agreed Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.3(d). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble hereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">API</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the active pharmaceutical ingredient Triamcinolone Acetonide, Micronised. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means applicable United States, Canadian, English and other foreign federal, state, and local laws, orders, rules, regulations, guidelines, standards, customs and ordinances, including, without limitation, those (to the extent they are applicable) of the FDA, Health Canada, the Medicines and Healthcare Products Regulatory Agency in the United Kingdom and other comparable foreign Regulatory Authorities, including the FDA Act. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Base Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the monthly fee paid by Flexion in consideration for the Services, as more specifically set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of this Agreement. For the avoidance of doubt, Base Fees do not include Capital Expenditures (as defined in the Technical Transfer Agreement), Product Fees, Material Costs, or charges for Bill Back Items or Additional Services. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bill Back Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the items and services set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that are used or necessary in connection with the Manufacture of the Products and which result in a nominal cost to Flexion. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Analysis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a certificate evidencing the analytical tests conducted on a specific batch of Product or Material and setting forth, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">inter alia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the items tested, specifications, and test results. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a certificate stating that a specific batch of Product complies with the warranty set forth in Section 6.3. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.11 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.5A. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.3(a). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means ownership or the right by a Party to assign or grant a license or sublicense under intellectual property rights to the other Party of the scope set forth herein, without breaching the terms of any agreement with a Third Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Diligent and Reasonable Steps</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 6.4(a). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Deficiency Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.8(a).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 2 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.90. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Discretionary Manufacturing Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.9(c). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble hereto </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the European Medicines Agency. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any equipment used in the Manufacture of the Product as more fully set forth in Section 2.9 herein. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Flexion Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Patheon Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(b). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expected Yield Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.8(f). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.8(e). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means to make, have made, import, use, sell, offer for sale, receive or otherwise dispose of a product or process, including the research, development (including the conduct of clinical trials), registration, modification, enhancement, improvement, Manufacture, storage, formulation, optimization, export, transport, distribution, promotion, or marketing of a product or process. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the facility of Patheon located at Kingfisher Drive, Swindon, Wiltshire SN3 5BZ, United Kingdom, or such other facility approved in accordance with Section 3.3(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.27 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Food and Drug Administration and any successor organization thereto and all agencies under its direct control. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">FDA Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Federal Food, Drug, and Cosmetic Act, as amended. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">FDA Approval Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date of receipt of FDA approval allowing for Patheon&#8217;s manufacturing, testing, and packaging for the Product from the Phase I Filling Space and Phase II Manufacturing Space. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Filing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.15(a). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.31 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble hereto. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.32 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Assignors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(m).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 3 -</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(e)(ii). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.2. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.35 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Manufacturing Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.9(a). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.36 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Manufacturing Equipment Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(e)(i). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion&#8217;s Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the proprietary process owned or Controlled by Flexion for Manufacturing the Product, as disclosed by Flexion to Patheon, and each intermediate of the Product, as established as of the Effective Date, including without limitation, as set forth in the investigational new drug application filed with the FDA, and, when applicable, as set forth in the NDA as may be filed with, and approved by, the FDA. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion&#8217;s Manufacturing Process Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(e)(i). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion On Site Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.4. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Product Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(e)(i). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Specification Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(e)(i). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Specific Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(e)(i) </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion-Supplied Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.3(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the current good manufacturing practices applicable from time to time to the Manufacturing of the Product, or any intermediate of the Product, pursuant to Applicable Law, including those promulgated under the FDA Act at 21 C.F.R. (chapters 210 and 211), and those promulgated under EC Directive 2003&#47;94&#47;EC, together with the latest FDA and EMA guidance documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.3(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.3(a).</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 4 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.3(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Draft</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.15(b). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Key Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.1(f). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.51 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Late Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.7(b). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Letter Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Letter Agreement between the Parties dated 1 May 2015. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Long Term Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.3(b). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any claims, lawsuits, losses, damages, liabilities, penalties, costs, and expenses (including reasonable attorneys&#8217; fees and disbursements). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the maintenance of Equipment and Facilities in satisfactory operating condition, including the performance of systematic inspection and service of Equipment pursuant to the applicable Standard Operating Procedures of Patheon, as reviewed and agreed to by Flexion (the &#8220;Equipment Standard Operating Procedures&#8221;), or the manufacturer&#8217;s terms of operation and recommended procedures. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Make Good Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.3(e). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the manufacturing, processing, formulating, filling, sterilization, packaging, labelling, storage, handling, and quality control testing of Materials or of the Product. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Suite IOQ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the completion of the Phase I Filling Space and Phase II Manufacturing Space, including without limitation, the installation, qualification and operational qualification of the Equipment in each of the Phase I Filling Space and the Phase II Manufacturing Space, including the computer systems, utilities and manufacturing area enabling the initiations of technical transfer activities, as agreed to by the Parties and indicated by the delivery by Patheon to Flexion of the interim IOQ report for the Phase I Filling Space and Phase II Manufacturing Space. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Services Termination Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.3(g). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Suite</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the manufacturing suite at the Facility capable of Manufacturing the Product pursuant to Flexion&#8217;s Manufacturing Process, whose footprint is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, together with the areas identified in the plan attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> as the areas for the bulk powder Manufacture and bulk vial filling, and, pursuant to the terms of Section 2.10, the Phase I Filling Space. The footprint of the Manufacturing Suite is diagrammatic in nature and is intended to generally depict the location </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 5 - </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and approximate size of current and future spaces allocated to Flexion. Such footprint may be amended during the Term of and pursuant to the Technical Transfer Agreement to be specifically adapted to the Manufacture of the Product, and the Parties shall agree upon the definitive footprint, taking into account parameters such as the exact design of the space, space classifications, code requirements, equipment, material, personnel, waste stream process flows, equipment sizing and utility requirements. For purposes of clarity, prior to the Phase III Manufacturing Suite Clearance Date (as defined in Section 2.10 herein), the definition of Manufacturing Suite shall include the Phase I Filling Space. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Marketing Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an approved New Drug Application as defined in the FDA Act and the regulations promulgated thereunder, or any corresponding foreign application, registration, or certification, necessary or reasonably useful to market any Product in a country or regulatory jurisdiction other than the United States, including applicable pricing and reimbursement approvals, and all supplements and amendments thereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means all API, excipients and processing aids, and processing, filling and packaging components, used in connection with the Manufacture of the Product and listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, as amended prior to Product launch, based on the Parties&#8217; most recent usage experience rate, and to reflect changes to the Specifications. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Material Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(a). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Maximum Manufacturing Services Termination Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.3(g). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66 Not used. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the new drug application for a product, including the Product, requesting permission to place a drug on the market in accordance with 21 C.F.R. Part 314, and all supplements filed pursuant to the requirements of the FDA, including all documents, data, and other information filed concerning such product that are necessary for FDA approval to market such product in the Territory. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Conforming Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (a) a batch of Product that fails, or is aborted during processing&#59; or (b) a Product Manufactured by Patheon that fails to &#91;&#8230;***&#8230;&#93;. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Filing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.15(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Specific Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(e)(ii) </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PAI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.8. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 6 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; have the meanings set forth in the Preamble hereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.72 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble hereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.73 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Assignors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(l). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(f)(ii). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.1. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Independent Manufacturing Equipment Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(f)(i). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Manufacturing Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.9(a)(ii). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Non-Applicable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1(f)(ii). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Nonconformance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.8(c). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon-Supplied Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81 Not used. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.82 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture, or other similar entity or organization, including a government or political subdivision, department, or agency of a government. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Phase I Filling Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Phase II Manufacturing Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Phase III Manufacturing Suite</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall each be as represented in Schedule 1.60. After the Phase III Manufacturing Suite Clearance Date, the Phase II Manufacturing Space shall be incorporate into the Phase III Manufacturing Suite. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Phase I Filling Space Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Schedule 2.1(a) at section II. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Phase III Manufacturing Suite Clearance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in section 2.10(d). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.86 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Phase III Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in section 2.10 (b). </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 7 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Recitals hereto in finished, unpackaged form, according to the Specifications, as the same may be amended from time to time. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.4. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Project Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; have the meaning set forth in Section 3.4. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any information disclosed hereunder by one Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) to another Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) (whether disclosed in oral, written, electronic or visual form) that is non-public, confidential or proprietary including, without limitation, information relating to the Disclosing Party&#8217;s patent and trademark applications, process designs, process models, drawings, plans, designs, data, databases and extracts therefrom, formulae, methods, know-how and other intellectual property, its clients or client confidential information, finances, marketing, products and processes and all price quotations, manufacturing or professional service proposals and information relating to composition and proprietary technology. In addition, all analyses, compilations, studies, reports or other documents prepared by any Party&#8217;s directors, officers, employees, advisers, agents, consultants, subcontractors, service partners, professional advisors, or representatives (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) containing the Proprietary Information will be deemed to be Proprietary Information. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a written purchase order that sets forth (a) the quantities of each presentation of Product to be delivered by Patheon to Flexion, (b) the requested delivery dates therefor, and (c) the size of the vials and bulk packaging to be used for such Product. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.90. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all approvals (including pricing and reimbursement approvals), licenses, registrations, or authorizations of any Regulatory Authority necessary to Exploit the Product in any country in the Territory, including any (a) approval of a Product, Marketing Authorization and supplements and amendments thereto&#59; (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto)&#59; (c) labelling approval&#59; and (d) technical, medical, and scientific licenses. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any applicable supra-national, federal, national, regional, state, provincial, or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities regulating or otherwise exercising authority with respect to the Exploitation of a Product in the Territory. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.15.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 8 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.15. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Remediation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2(a)(iii). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.100 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Replacement Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.3(f). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.101 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.11. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.102 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Required Manufacturing Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.9(b). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.103 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Scheduled Production Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.3(d). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.104 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the (a) Manufacturing Services performed by Patheon under this Agreement and (b) the Transfer Services performed by Patheon pursuant to the Technical Transfer Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.105 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Shipment Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.8(c). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.106 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Specifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the specifications for each presentation of Product (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the dosage forms in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) given by Flexion to Patheon relating to the specifications of the Materials&#59; the manufacturing specifications, directions and processes&#59; the storage requirements&#59; all environmental, health and safety information for the Product including material safety data sheets and the finished Product specifications, specifications for bulk and primary packaging and shipping requirements for the Product, as amended, modified, or supplemented from time to time. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.107 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Technical Transfer Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.108 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Supplies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means various consumables &#47; disposables used in small quantities for gowning, cleaning of Equipment and Manufacturing Suite, and in quality control testing of Materials and Product. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.109 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means all forms of taxation and statutory, governmental, state, federal, provincial, local, government or municipal charges, duties, imposts, contributions, levies, withholding or liabilities wherever chargeable and whether of the United Kingdom or any other jurisdiction (including for the avoidance of doubt, national insurance contributions in the United Kingdom) and any penalty, fine, surcharge, interest, charge, charges or costs thereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.110 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Technical Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Recitals. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.111 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 9 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.112 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;&#8230;***&#8230;&#93; and other territories agreed by the Parties pursuant to Section 2.2(h) from time to time. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.113 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a Person who is neither a Party nor an Affiliate of a Party. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.114 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Losses incurred as a result of claims brought by Third Parties. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.115 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.64 of the Technical Transfer Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.116 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">TUPE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.3(f). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.117 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.4(c). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.118 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Yield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.8(f). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.119 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Yield Reimbursement Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.8(f). </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE II. MANUFACTURING SERVICES </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Supply Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Subject to the terms and conditions hereof and in consideration for the payments set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Patheon shall provide the Manufacturing Services and shall supply the Product &#91;&#8230;***&#8230;&#93; to Flexion. Flexion agrees to purchase from Patheon such quantities of Product as Flexion may order, in its discretion, in accordance with the terms herein during the Term. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Pursuant to the Technical Transfer Agreement, Flexion will develop and Patheon will confirm Flexion&#8217;s Manufacturing Process. Flexion&#8217;s Manufacturing Process is the Proprietary Information of Flexion, as further clarified in Article V. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Patheon shall Manufacture all Products delivered hereunder (i) in accordance with the Specifications, this Agreement, the Quality Agreement, and (ii) in compliance with GMP and all other Applicable Law. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Patheon shall ensure that sufficient numbers of adequately educated and experienced staff are retained at the Facility in order to Manufacture evenly throughout the year the volumes of Product set out in the Forecast. Patheon shall perform all activities necessary to maintain a GMP compliant status of the </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 10 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">manufacturing lines and areas of the Facility applicable to the Manufacture of the Product. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Flexion reserves the right to request replacement of any personnel assigned by Patheon to perform the Services hereunder. If Patheon disagrees with such request and the Parties cannot reach resolution on Flexion&#8217;s request for replacement, such request will be discussed by the Steering Committee pursuant to the procedures set forth in Exhibit 2.7 of the Technology Transfer and Services Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Patheon shall perform the Services under the direction of key personnel of Patheon to a project for the duration of the project (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Key Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Key Personnel include the Project Manager, Operational Manager, Quality Manager or other personnel reasonably agreed-to by the Parties. Patheon shall provide information on the qualifications and background of all proposed Key Personnel prior to such Key Personnel&#8217;s commencement of activities under this Agreement on Patheon&#8217;s behalf. Patheon will not remove Key Personnel without Flexion&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed) except in the event of such Key Personnel&#8217;s promotion, resignation, incapacity or death, or termination for cause. Patheon will use commercially reasonable efforts to minimize turnover in Key Personnel, and will provide &#91;&#8230;***&#8230;&#93; business days&#8217; notice to Flexion, whenever practical, of any changes to the Key Personnel, at which point, both Parties shall discuss and reasonable agree on a suitable replacement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Materials, Bill Back Items and Additional Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) All Materials necessary for the Manufacture of the Product are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon shall source all of the Materials set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> under the heading &#8220;Patheon Supplied Materials (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon-Supplied Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and such Materials will be invoiced to Flexion monthly at the time of purchase by Patheon, at cost plus an &#91;&#8230;***&#8230;&#93;% handling fee, in accordance with the invoicing procedure set forth in ARTICLE IV (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Material Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Flexion will purchase, and ship to Patheon in accordance with Schedule 1.62 under the heading &#8220;Flexion Supplied Materials&#8221; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion-Supplied Materials&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) unless otherwise agreed to by the Parties. Patheon shall store, handle, and protect the Materials with a reasonable level of care, which shall include taking all reasonable precautions to ensure that the Materials are not subject to contamination, deterioration, destruction, or theft. Patheon shall keep adequate records of its usage of the Materials during the Term. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Flexion acknowledges that Patheon is required under GMP to follow certain verification and approval processes for all vendors used by </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 11 -</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patheon in the procurement of Materials. In the event that Flexion requests Patheon to procure Materials from a vendor that is not currently verified by Patheon, Flexion will be liable for Patheon&#8217;s fees for the performance of the initial audit and verification activities by Patheon under this Section 2.2(b) as an Additional Service. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Flexion will, at its sole cost and expense, deliver to Patheon the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion-Supplied Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to the Facility DDP (Incoterms 2010) at no cost to Patheon at least &#91;&#8230;***&#8230;&#93; days before the Scheduled Production Date, in sufficient quantities for Patheon to Manufacture the desired quantities of Product and to ship Product by the Agreed Delivery Date. If the Flexion-Supplied Materials are not received &#91;&#8230;***&#8230;&#93; days before the Scheduled Production Date, Patheon may delay the shipment of Product for a period of time proportionate to such delay. All shipments of Flexion-Supplied Materials, if required, will be accompanied by Certificate(s) of Analysis from the Material manufacturer or Flexion, confirming its compliance with the Material&#8217;s specifications. Flexion will obtain the proper release of the Flexion-Supplied Materials from the applicable customs agency and&#47;or Regulatory Authority. Flexion or Flexion&#8217;s designated broker will be the &#8220;Importer of Record&#8221; for Flexion-Supplied Materials imported to the Facility. Flexion-Supplied Materials will be held by Patheon on behalf of Flexion as set forth in this Agreement. Title to Flexion-Supplied Materials will at all times remain the property of Flexion. Any Flexion-Supplied Materials received by Patheon will only be used by Patheon to perform the Manufacturing Services or associated activities necessary to perform the Manufacturing Services (e.g. media fills or validation runs). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Flexion and Patheon will agree upon a minimum inventory level of Patheon-Supplied Materials required to support the Manufacture of the Product based on the last Forecast received by Patheon from Flexion. Patheon will keep on hand all Materials necessary to support the Manufacture of the Product based on such agreed-upon minimum inventory levels. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Patheon will provide sufficient storage capacity to support storage of the required quantity of Materials pursuant to Section 2.2 of this Agreement for up to the longer of &#91;&#8230;***&#8230;&#93; or the amount of time set forth next to the applicable Material on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> herein. Patheon will also provide sufficient storage capacity to support storage of Product for up to &#91;&#8230;***&#8230;&#93; post Manufacture &#91;&#8230;***&#8230;&#93;. Any additional storage, or storage of Materials (either Flexion-Supplied Materials or Patheon-Supplied Materials) or Product beyond the applicable period stated herein, will be subject to the mutual agreement of the Parties. For any such additional storage, Flexion will pay Patheon &#163;&#91;&#8230;***&#8230;&#93; per pallet, per month for storing any Materials or Product. Storage of Materials or Product that contain controlled substances or require refrigeration will be charged at &#163;&#91;&#8230;***&#8230;&#93; per pallet per month. Storage fees are subject to a one pallet minimum </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 12 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">charge per month. &#91;&#8230;***&#8230;&#93; will be liable for all risk or loss of damage to stored Materials or Product to the extent such damage was caused by &#91;&#8230;***&#8230;&#93;&#8217;s, or its subcontractor&#8217;s or vendors&#8217;, &#91;&#8230;***&#8230;&#93;. Patheon shall store the Product according to GMP, any applicable storage guidelines stipulated by Flexion and agreed by Patheon and the provisions under the Quality Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Bill Back Items will be charged to Flexion at Patheon&#8217;s cost plus a &#91;&#8230;***&#8230;&#93;% handling fee. Patheon shall invoice Flexion monthly for any Bill Back Items used in connection with the Manufacture of the Products during the preceding month in accordance with ARTICLE IV. Patheon may only invoice Bill Back Items that have been quoted to and approved in writing by Flexion&#8217;s Project Manager, or otherwise mutually agreed to by the Parties in advance. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) If Flexion is interested in having Patheon perform Additional Services, Flexion will provide Patheon with a written request containing sufficient detail to enable Patheon to provide Flexion with a quote and proposal to provide such Additional Services. Patheon may only invoice for Additional Services that have been quoted to and approved in writing by an authorized person of Flexion and that have been agreed in writing by the Parties in a Change of Scope Agreement. Where a rate for Additional Services has been specified in Schedule 2.1 (a), such rates are calculated as at 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> January, 2015. These fees will be adjusted on 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> January of each year (first review &#91;&#8230;***&#8230;&#93;) to reflect any increase in the UK Consumer Price Index&#58; All Items Index published by the Office for National Statistics (as published at www.ons.gov.uk, specific details are located at http&#58;&#47;&#47;www.ons.gov.uk&#47;ons&#47;rel&#47;cpi&#47;consumer-price-indices during the previous 12 months (based on the average of the monthly changes over the 12-month period). Patheon shall invoice Flexion monthly for any Additional Services performed by Patheon during the preceding month in accordance with ARTICLE IV. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) If Flexion decides to have Patheon perform Manufacturing Services for the Product for a Territory outside the &#91;&#8230;***&#8230;&#93;, then Flexion will inform Patheon of the additional requirements for each new country and Patheon will prepare a quotation for consideration by Flexion of any additional costs for the Product destined for each new country. The agreed additional requirements and change over fees will be set out in a written amendment to this Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon-Supplied Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) Patheon will purchase all Patheon-Supplied Materials. Flexion understands and acknowledges that Patheon will rely on Flexion&#8217;s Purchase Orders and Forecasts in ordering the Patheon-Supplied Materials required to meet the Purchase Orders. In addition, Flexion understands that to ensure an orderly </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 13 -</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">supply of Patheon-Supplied Materials, Patheon may want to purchase Patheon-Supplied Materials in sufficient volumes to meet the production requirements for Products during part or all of the Forecast or to meet the production requirements of any longer period agreed to by Patheon and Flexion. Accordingly, Flexion authorizes Patheon to purchase Patheon-Supplied Materials to satisfy the Manufacturing Services requirements for Products for the first &#91;&#8230;***&#8230;&#93; contemplated in the most recent Forecast. Patheon may make other purchases of Patheon-Supplied Materials to meet Manufacturing Services requirements for longer periods if agreed to in writing by the Parties. Flexion will give Patheon written authorization to order Patheon Supplied Materials for any launch quantities of Product request by Flexion which will be considered a Purchase Order when accepted by Patheon. Flexion will reimburse Patheon for any destruction costs, as mutually agreed to in good faith, of any Patheon-Supplied Material ordered by Patheon under Purchase Orders or under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that are not included in finished Products Manufactured for Flexion within &#91;&#8230;***&#8230;&#93; after the forecasted month for which the purchases have been made (or for a longer period as the Parties may agree). If any non-expired Patheon-Supplied Materials are used in Products subsequently manufactured for Flexion, Flexion will receive credit for any costs of those Patheon-Supplied Materials previously paid to Patheon by Flexion. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Forecasting, Order, and Delivery of Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) No later than &#91;&#8230;***&#8230;&#93; prior to the anticipated FDA Approval Date and thereafter at least &#91;&#8230;***&#8230;&#93; prior to the &#91;&#8230;***&#8230;&#93; of each &#91;&#8230;***&#8230;&#93; during the Term, Flexion shall deliver to Patheon a written good faith &#91;&#8230;***&#8230;&#93; month forecast, calculated by month, estimating the quantities of each presentation of Product that Flexion expects to purchase from Patheon during such period (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). If Patheon is unable to accommodate any portion of the Forecast, it will notify Flexion and the Parties will agree on any revisions to the Forecast. Flexion shall update the Forecast on or before the &#91;&#8230;***&#8230;&#93; of each &#91;&#8230;***&#8230;&#93; on a rolling forward basis. Flexion shall use commercially reasonable efforts to also update the Forecast prior to the next &#91;&#8230;***&#8230;&#93; deadline if it determines that the volumes estimated in the most recent Forecast have changed by more than &#91;&#8230;***&#8230;&#93; percent &#91;&#8230;***&#8230;&#93;%). The most recent Forecast will prevail. Except as set forth in Section 2.3(c) below, each Forecast shall be non-binding and shall be used by Patheon for planning purposes only. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Commencing on &#91;&#8230;***&#8230;&#93;, Flexion will give Patheon a written non-binding &#91;&#8230;***&#8230;&#93;-year forecast for strategic purposes, of the volume of Product Flexion then anticipates to purchase from Patheon for each year during such period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Long Term Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). The Long Term Forecast will thereafter be updated every six months (as of June 1 and December 1) during the </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 14 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term. If Patheon is unable to accommodate any portion of the Long Term Forecast, it will notify Flexion and the Parties will agree on any revisions to the Long Term Forecast. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) &#91;&#8230;***&#8230;&#93;. Flexion will issue Purchase Order(s) to purchase and, when accepted by Patheon, for Patheon to Manufacture and deliver the forecasted quantity or a quantity greater than the forecasted quantity of the Product for each such &#91;&#8230;***&#8230;&#93; period, provided that the delivery lead time must be at least &#91;&#8230;***&#8230;&#93; days from the date of Patheon&#8217;s acceptance of the Purchase Order pursuant to clause (d) below. The quantities of Products ordered in Purchase Orders will be firm and binding on Flexion and may not be reduced by Flexion. Unless otherwise stated herein, expedited Purchase Orders will be subject to additional fees. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Patheon shall accept all Purchase Orders for Product that are issued consistent with the terms of this Agreement. Patheon shall accept in writing any Purchase Order by sending an acknowledgement to Flexion within &#91;&#8230;***&#8230;&#93; business days of its receipt of the Purchase Order. The acknowledgement will include, subject to confirmation from Flexion, the delivery date for the Product ordered which shall be approximately &#91;&#8230;***&#8230;&#93; days from the date of Patheon&#8217;s acceptance of the Purchase Order (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Agreed Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and the scheduled date of production for such Products (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Scheduled Production Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for the purposes of Section 2.2(c). The Agreed Delivery Date may be amended by agreement of the Parties or as set forth in Section 2.2(c). If Patheon fails to acknowledge receipt of a Purchase Order within the &#91;&#8230;***&#8230;&#93; business day period, the Purchase Order will be deemed to have been accepted by Patheon. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Patheon shall deliver Product to Flexion &#91;&#8230;***&#8230;&#93; the Facility (as defined in Incoterms 2010) by the Agreed Delivery Date. All Product shall be packed for shipping in accordance with the Specifications. Title and risk of loss to Product shall pass to Flexion (or a designated Flexion Affiliate) &#91;&#8230;***&#8230;&#93;. Each delivery of Product shall be accompanied by a Certificate of Analysis and a Certificate of Compliance and such other documents as may be required pursuant to the Quality Agreement. The costs of all freight, insurance, handling fees, taxes, and other costs associated with the shipment of Product, as well as export licenses, import license, and customs formalities for the import and export of goods will be borne by &#91;&#8230;***&#8230;&#93;. Patheon shall endeavour to make all deliveries of Product hereunder utilizing stock rotation based on expiration dating, with Product expiring earliest delivered first, save that a failure to comply with this requirement shall not be grounds for Flexion to reject any Product. Flexion shall collect shipments reasonably promptly from the Facility following notification of availability for </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 15 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">delivery from Patheon. Storage of Product will be as described in Section 2.2(e). Patheon will, in accordance with Flexion&#8217;s instructions and as agent for Flexion, at Flexion&#8217;s risk, arrange for shipping to be paid by Flexion. Flexion will arrange for insurance and will select the freight carrier used by Patheon to ship Products and may monitor Patheon&#8217;s shipping and freight practices as they pertain to this Agreement.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) If Flexion cancels any Purchase Order after receipt thereof by Patheon, Flexion will pay Patheon &#91;&#8230;***&#8230;&#93;% of the Product Fee for the Purchase Order. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The purchase price for all Products Manufactured hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall be as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon shall invoice Flexion for all quantities of Product Manufactured and ready for collection by Flexion not previously invoiced in accordance with Purchase Orders. All Product Fees will be due and payable in accordance with the invoicing procedures set forth in ARTICLE IV. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Base Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon will invoice Flexion monthly in advance for the Base Fee and any Phase I Filling Space Fee set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. All Base Fees and Phase I Filling Space Fees will be due and payable in accordance with the invoicing procedures set forth in ARTICLE IV. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product Fee Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Parties shall use commercially reasonable efforts to reduce, through operating efficiencies, the cost of Manufacture of the Products during the Term and the benefits of such reduction in costs shall be shared equally by the Parties. The Product Fee stated herein is calculated as at the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> January 2015. Starting on the &#91;&#8230;***&#8230;&#93;, the Product Fee shall be adjusted annually to reflect any increase in the UK Consumer Price Index&#58; All Items Index published by the Office for National Statistics (as published at www.ons.gov.uk, specific details are located at http&#58;&#47;&#47;www.ons.gov.uk&#47;ons&#47;rel&#47;cpi&#47;consumer-price-indices&#47;) during the preceding twelve (12) months (based on the average of the monthly changes over the 12-month period). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall be deemed amended pursuant to the terms hereof. The Product Fee is subject to adjustment if, after &#91;&#8230;***&#8230;&#93; from the FDA Approval Date, (i) Flexion does not submit Purchase Orders for at least &#91;&#8230;***&#8230;&#93; vials of Product per calendar year, in which case the Product Fee may increase by an amount reasonably sufficient for Patheon to absorb its increased costs, and (ii) Flexion submits Purchase Orders for more than &#91;&#8230;***&#8230;&#93; vials of Product per calendar year, in which case the Product Fee may decrease for the volumes of Product exceeding &#91;&#8230;***&#8230;&#93; vials per calendar year as reasonably agreed-on by the Parties in order to adjust for additional volume discounts and economies of scale. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 16 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Failure or Inability to Supply Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Patheon shall ensure that Product is Manufactured and delivered to Flexion on a timely basis consistent with the terms of this Agreement (including the Forecast and Purchase Order procedures set forth in Section 2.3). In the event that Patheon, at any time during the Term, shall have reason to believe that it will be unable to supply Flexion with the full quantity of Product forecasted to be ordered or actually ordered by Flexion in a timely manner and in conformity with the warranty set forth in Section 6.3 (whether by reason of force majeure or otherwise), Patheon shall notify Flexion thereof within &#91;&#8230;***&#8230;&#93; business days. Promptly thereafter, the Parties shall meet to discuss how Flexion shall obtain such full quantity of conforming Product. Compliance by Patheon with this Section 2.7(a) shall not relieve Patheon of any other obligation or liability under this Agreement, including any obligation or liability under clause (b) below. If Patheon&#8217;s inability is partial, Patheon shall fulfill Purchase Orders with such quantities of Product as are available. In the event Patheon&#8217;s inability to meet Purchase Orders or forecasts is due to a shortage of production capacity in the Manufacturing Suite, Patheon shall in addition to the foregoing requirements, promptly notify Flexion of such shortage of production capacity and the estimated date such shortage of production capacity is to end. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) If Patheon fails to Manufacture the full quantity of Product specified in a Purchase Order by the Agreed Delivery Date and in conformity with the warranty set forth in Section 6.3 (and such failure is directly due to the acts or omissions of Patheon where such acts or omission does not constitute a force majeure event pursuant to the terms of Section 10.2) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Late Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and Patheon is unable to cure such failure within &#91;&#8230;***&#8230;&#93; days, in full and final settlement of such failure, Flexion, at its option, may (i) cancel the unfulfilled portion of such Purchase Order, in which event Flexion shall have no liability with respect to the portion of such Purchase Order so cancelled, or (ii) accept late delivery of all or any portion of the Product specified in such Purchase Order, in which event (A) Patheon shall pay all reasonable documented shipping costs for the expedited shipment of Product that are required in addition to the shipping costs for a non-expedited shipment (which shall be the responsibility of Flexion), and (B) the Product Fee otherwise payable by Flexion with respect to all Product delivered late but accepted by Flexion under such Purchase Order shall be reduced by &#91;&#8230;***&#8230;&#93;% per day for each day of delay after such Agreed Delivery Date, but not to exceed in aggregate an amount equal to &#91;&#8230;***&#8230;&#93;% of the Product Fees of the Product delivered late (i.e., &#91;&#8230;***&#8230;&#93; days) per Purchase Order&#59; provided that, sub-Section (ii) shall only apply after the Manufacture and delivery of the first &#91;&#8230;***&#8230;&#93; batches of commercial Product (including validation batches) pursuant to this Agreement, following which, if the Parties agree that the Manufacturing process is sufficiently robust to allow the Product to be delivered in a timely manner, this sub-Section (ii) </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 17 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shall be implemented. Any Product which is delivered to Flexion with less than &#91;&#8230;***&#8230;&#93; of expiry, assuming a product shelf life of &#91;&#8230;***&#8230;&#93;, shall be considered Non-Conforming Product subject the provisions of Section 2.8(c)&#59; provided that, if the Product shelf life is not &#91;&#8230;***&#8230;&#93; (as set forth in the FDA approved label for the Product), the Parties shall mutually agree in good faith on the reasonably appropriate minimum amount of expiry a Product should have when delivered. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 A. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Batch Numbering and Expiration Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; Each batch of the Product manufactured by Patheon will bear a unique lot number using Patheon batch numbering system. This number will be printed on the aluminium cap of the vial and will appear on all documents relating to the particular batch of Product and shall identify the date of manufacture for the batch of Product. Patheon will calculate the expiration date for the Product for each batch by adding the expiration period of the Product supplied by Flexion to the date of manufacture of each batch. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Conforming Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) In the event Patheon discovers a potential Non-Conforming Product prior to delivery of such Product to Flexion, Patheon shall provide written notice to Flexion as soon as practicable describing in detail the Non-Conforming Product and the potential cause of such Non-Conforming Product. Flexion (or its shipping carrier) will perform a customary inspection of the Products Manufactured by Patheon on receipt. For the avoidance of doubt, such inspection will be limited to a visual inspection of the shipment-ready packaged Products (and associated shipping documentation) and Flexion will not be obliged to perform any testing of the Product. Flexion shall within (i) &#91;&#8230;***&#8230;&#93; days after delivery thereof by Patheon or (ii) within &#91;&#8230;***&#8230;&#93; days after Flexion discovers or is informed of a discovery of nonconformity that could not reasonably have been detected by the customary inspection on delivery (but not after the expiration date of the Product), give Patheon notice of any Non-Conforming Product (including a sample of such Non-Conforming Product, if applicable) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Deficiency Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Subject to Flexion&#8217;s rights under 3.10 and 3.12, should Flexion fail to give Patheon the Deficiency Notice within the applicable &#91;&#8230;***&#8230;&#93; day period, then the delivery will be deemed to have been accepted by Flexion on the &#91;&#8230;***&#8230;&#93; day after delivery or discovery, as applicable. Patheon shall have no liability under this Section 2.8 for Nonconforming Product for which it has not received a Deficiency Notice within such applicable &#91;&#8230;***&#8230;&#93; day period. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Patheon shall conduct a root-cause analysis to verify whether a Product constitutes a Non-Conforming Product and, if found, to determine the cause of such Non-Conforming Product (including by undertaking an appropriate evaluation of a Non-Conforming Product sample, as applicable). </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 18 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion shall provide reasonable cooperation to Patheon in connection with any such root-cause analysis. Patheon shall notify Flexion in writing of its determination regarding whether the Product constitutes a Non-Conforming Product within &#91;&#8230;***&#8230;&#93; days after either discovery of the Non-Conforming Product or receipt of such Deficiency Notice from Flexion, as applicable. Such notification shall include Patheon&#8217;s good faith determination of the cause of the Non-Conforming Product. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Nonconformance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean (i) Patheon&#8217;s failure to perform &#91;&#8230;***&#8230;&#93; pursuant to Section &#91;&#8230;***&#8230;&#93;, and (ii) Patheon&#8217;s failure to provide the &#91;&#8230;***&#8230;&#93; in accordance with the &#91;&#8230;***&#8230;&#93;. In the event of a Non-Conforming Product caused by a Patheon Nonconformance, Patheon, at Flexion&#8217;s option, promptly shall (x) supply Flexion with a conforming quantity of Product at Patheon&#8217;s expense (subject to Flexion supplying Patheon with Flexion-Supplied Materials and Patheon reimbursing Flexion for the actual costs of &#91;&#8230;***&#8230;&#93;) and reimburse Flexion for any incurred shipment costs in the event that the Non-Conforming Product was shipped from the Facility at the time of the discovery of the Patheon Nonconformance (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Shipment Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;))&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (y) reimburse Flexion for the applicable Product Fee (including the cost of any Patheon-Supplied Materials), the actual costs of the &#91;&#8230;***&#8230;&#93; and Shipment Costs with respect to such Non-Conforming Product (in each case, to the extent already paid by Flexion). For each of (x) and (y) above, Patheon&#8217;s obligation to reimburse &#91;&#8230;***&#8230;&#93; shall be subject to the limitation of liability in Section 9.5(a) herein but Section 9.5(a) (1) shall not apply in relation to the internal expenses incurred by Patheon to supply conforming Product to Flexion pursuant to (x), including the cost of any Patheon-Supplied Materials or any Shipment Costs, and (2) shall not apply to the reimbursement of the Product Fee pursuant to (y). For the avoidance of doubt, Flexion will not be liable for Product Fees for Non-Conforming Product caused by a Patheon Nonconformance. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) If the Non-Conforming Product was caused by any reason other than a Patheon Nonconformance or the cause of such non-conformance is not due to Patheon Nonconformance (where applicable, as may be determined by an Expert in accordance with 2.8(e), Flexion shall be liable for all expected Product Fees for such Non-Conforming Product, to the extent not already paid. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) If, following the root-cause analysis described in Section 2.8(b), Patheon notifies Flexion that it does not believe the Product is a Non-Conforming Product, or if the Parties disagree as to the cause of a Non-Conforming Product, the Parties shall first submit such dispute to the Project Managers for prompt resolution. If the Project Managers cannot resolve the dispute, the Parties </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 19 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shall submit the dispute to an independent expert or (if mutually agreed to by the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) a testing lab, each as agreed by the Parties (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) for evaluation, provided that both Parties shall be entitled to observe and obtain copies of all results of such evaluation. The Expert shall determine (i) whether the Product is a Non-Conforming Product and (ii) the cause of the Non-Conforming Product&#59; provided that, if the cause of the Non-Conforming Product is undeterminable the Expert shall give an opinion as to the likely cause. Both Parties shall cooperate with the Expert&#8217;s reasonable requests for assistance in connection with its evaluation hereunder. The findings of the Expert shall be binding on the Parties, absent fraud or manifest error. The expenses of the Expert shall be borne (x) by Patheon if the testing confirms the Non-Conforming Product and the cause or likely cause is found to be a Patheon Nonconformance&#59; (y) by Flexion if the testing confirms the Non-Conforming Product and the cause or likely cause is found not to be a Patheon Nonconformance or the cause or likely cause of such non-conformance is not identifiable&#59; and (z) by the Party stating the Product was Non-Conforming in the event the testing concludes that the Product meets the warranty set forth in Section 6.3. Costs of dealing with Product Complaints and Inquiries will be dealt with in accordance with Section 3.10. Costs of recalls will be dealt with in accordance with Section 3.12. Patheon shall have no liability for any Non-conforming Product unless such Non-conforming Product is identified as being due to a Patheon Nonconformance (where applicable, as may be determined by an Expert in accordance with 2.8(e). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) During its performance of the Manufacturing Services, Patheon is expected to produce a certain percentage of saleable batches of Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Yield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). For the avoidance of doubt, Nonconforming Product arising from anything other than a Patheon Nonconformance is treated as good and saleable Product for the purposes of this Section 2.8(f). The Parties shall calculate and mutually agree on the expected Yield after each anniversary of the initial batch of commercial Manufacture of Product and based on at least &#91;&#8230;***&#8230;&#93; batches of Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expected Yield Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). In the event the actual Yield in any calendar year is more than &#91;&#8230;***&#8230;&#93;% lower than the then-current Expected Yield Rate for such calendar year, (i) Patheon and Flexion will engage in good faith discussions to agree to a remediation plan describing the steps to be taken to achieve the then-current Expected Yield Rate and (ii) Patheon will reimburse Flexion for &#91;&#8230;***&#8230;&#93; used by Patheon as a result of Patheon&#8217;s failure to meet the Expected Yield Rate in such batches (i.e., a pro-rated refund of &#91;&#8230;***&#8230;&#93; paid by Flexion and&#47;or reimbursement to Flexion for the costs of any &#91;&#8230;***&#8230;&#93;) subject to the limitation of liability in Section 9.5(a) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Yield Reimbursement Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). In the event the actual Yield in any calendar year is more than &#91;&#8230;***&#8230;&#93;% greater than the then-current Expected Yield Rate for such calendar year, Patheon shall be entitled to reduce any Yield Reimbursement Payment to be made in the next calendar year by an amount equal to the excess Materials that would have been </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 20 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">used by Patheon if the Yield for such calendar year was equal to the then-current Expected Yield Rate in such batches. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Equipment and Amendment of Product Specifications, Manufacturing Process, Equipment and Formulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Equipment. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Manufacturing Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean process equipment necessary to Manufacture the bulk Product and shall consist of equipment for the bulk Manufacturing, vial preparation, fill&#47;finish, and in-process control testing of the Product and its intermediates as more fully set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> attached hereto which must comply with all EU mandatory requirements including without limitation, Supply of Machinery (Safety) Regulations 2008 (UK Regulations, Secondary UK Legislation), Electrical equipment of machines (General requirements BS EN 60204-1&#58;2006+A1&#58;2009) (British Product Standards), Machinery Directive 2006&#47;42&#47;EC (European Union Directive), Low Voltage Directive (LVD) 2006&#47;95&#47;EC (European Union Directive), and Electromagnetic Compatibility (EMC) Directive 2004&#47;108&#47;EC (European Union Directive). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Manufacturing Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean any equipment, other than the Flexion Manufacturing Equipment, necessary to Manufacture the Product including as more fully set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> attached hereto, waste handling systems and all building infrastructure and any and all improvements or additions made thereto, as approved in writing by Flexion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) Patheon, acting as Flexion&#8217;s agent, shall purchase the Flexion Manufacturing Equipment on Flexion&#8217;s behalf and pursuant to Flexion&#8217;s written instruction. The inclusion of items of Flexion Manufacturing Equipment in Schedule 2.9, as may be amended by agreement from time to time, shall constitute written instruction to purchase. Title to all Flexion Manufacturing Equipment will be held by Flexion unless otherwise set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Title to all Patheon Manufacturing Equipment will be held by Patheon. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) Patheon is authorized to use the Flexion Manufacturing Equipment solely for the purposes of performing the Manufacturing Services for Flexion. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v) During the Term, Flexion shall be responsible for additions and replacement cost of any Flexion Manufacturing Equipment and Patheon Manufacturing Equipment. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi) During the Term, Patheon shall, at its sole cost and expense, subject to this subsection (vi), provide all Maintenance for the Equipment and Facilities. Notwithstanding the foregoing, with respect to the Flexion Manufacturing Equipment and Patheon Manufacturing Equipment, Maintenance does not include (A) the cost of spare parts, (B) Equipment breakdowns caused by any reason outside of Patheon&#8217;s reasonable control (other than breakdowns caused </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 21 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by Patheon&#8217;s negligence or failure to maintain the Equipment in accordance with the applicable Equipment Standard Operating Procedures of Patheon or the manufacturer&#8217;s terms of operation and recommended procedures), or (C) specialized maintenance services not within Patheon&#8217;s technical expertise or that requires specialist equipment, in each case where Patheon is required to utilize a Third Party contractor. Patheon&#8217;s costs associated with such spare parts and Third Party contractors will be reimbursed by Flexion as a Bill Back Item. Patheon shall not be liable for ordinary wear and tear of the Flexion Manufacturing Equipment or Patheon Manufacturing Equipment&#59; Patheon shall only be liable for the repair or replacement of any damage caused to such Equipment where such damage arises due to its negligence or willful misconduct or its failure to maintain Equipment pursuant the applicable Equipment Standard Operating Procedures of Patheon or the manufacturer&#8217;s terms of operation and recommended procedures. Throughout the Term of this Agreement, Patheon shall maintain property insurance on Flexion Manufacturing Equipment in the amount equal to the replacement value of such Equipment. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) For changes to the Specifications, Quality Agreement, Flexion&#8217;s Manufacturing Process, the Equipment, the Services to be provided pursuant hereto or the formulation of the Product that are required by Applicable Law (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Required Manufacturing Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), Patheon and Flexion shall cooperate to promptly make such changes within the required timeline. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) For changes to the Specifications, Quality Agreement, Flexion&#8217;s Manufacturing Process, the Equipment, the Services to be provided hereto or the formulation of the Product that are not Required Manufacturing Changes (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Discretionary Manufacturing Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), Patheon and Flexion must each agree to any Discretionary Manufacturing Changes and shall cooperate in making such changes, and each agrees that it shall not unreasonably withhold, condition or delay its consent to such Discretionary Manufacturing Changes. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Notwithstanding the foregoing, all internal and external costs, including, without limitation, costs of obsolete Materials, work-in-process and Product (i) associated with Required Manufacturing Changes shall be borne by Flexion, and (ii) all such costs associated with Discretionary Manufacturing Changes shall be agreed between the Parties&#59; provided that, in each case, all such costs shall be commensurate with costs common in the industry for the types of changes being made. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) In the event that Flexion changes the Specifications, Quality Agreement, Flexion&#8217;s Manufacturing Process, the Equipment, the Services to be provided hereto or the formulation of the Product, or consents to any change by Patheon, Patheon shall provide to Flexion at Flexion&#8217;s cost as an Additional Service any such documentation or other information with respect thereto as they relate to the Manufacturing Services as Flexion may reasonably request in order to obtain or maintain any Regulatory Approval or comply with GMP or other Applicable Law. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 22 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Phase I Filling Space Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Prior to the Phase III Manufacturing Suite Clearance Date, Patheon shall provide the Manufacturing Services utilizing the Phase I Filling Space and Phase II Manufacturing Space. During this period, the Phase I Filling Space Fee set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall be payable if a period of &#91;&#8230;***&#8230;&#93; has elapsed after the date on which Flexion submitted for approval to the FDA or other applicable Regulatory Authority for the Manufacture of Product in the Phase III Manufacturing Suite for commercial sale in the Territory. The Phase I Filling Space Fee shall cease to be payable on the Phase III Manufacturing Suite Clearance Date unless Flexion exercises the Phase I Option. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) After the Phase III Manufacturing Suite Clearance Date, (1) Patheon will provide the Manufacturing Services set forth herein utilizing the Phase II Manufacturing Space and Phase III Manufacturing Suite and (2) Flexion shall have the option to elect to have Patheon continue to provide the Manufacturing Services utilizing the Phase I Filling Space for all or any portion of the remaining Term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Phase I Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), provided that, (i) Flexion pays the Phase I Filling Space Fee set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) commencing after election of the Phase I Option, and (ii) the Phase I Option shall cease to be applicable if Flexion does not exercise the Phase I Option within &#91;&#8230;***&#8230;&#93; from Patheon&#8217;s notice to Flexion that &#91;&#8230;***&#8230;&#93;. After the Phase III Manufacturing Suite Clearance Date, Patheon shall have no obligation to provide the Manufacturing Services utilizing the Phase I Filling Space unless Flexion has exercised the Phase I Option in accordance with this Section 2.10(b). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) The extent of the use of the Phase I Filling Space for the Manufacturing Services shall be at Flexion&#8217;s sole discretion both prior to and after the Phase III Manufacturing Suite Clearance Date except that the Parties acknowledge that the Phase I Filling Space will &#91;&#8230;***&#8230;&#93; after the Phase III Manufacturing Suite Clearance Date. The Parties shall discuss and agree &#91;&#8230;***&#8230;&#93; in good faith but any associated costs or fees would be payable by &#91;&#8230;***&#8230;&#93;. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) For purposes of this Section 2.10, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Phase III Manufacturing Suite Clearance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the date upon which, in Flexion&#8217;s sole discretion, the FDA or other applicable Regulatory Authority, has approved or will allow the Product to be Manufactured in the Phase III Manufacturing Suite for commercial sale in the applicable Territory.</font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 23 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE III. REGULATORY, ACCESS, AND OTHER MATTERS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Within &#91;&#8230;***&#8230;&#93; of the Effective Date, the Parties shall enter into a mutually agreed upon quality agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). If the is any inconsistency between this Agreement and the Quality Agreement, the terms of the Quality Agreement shall control solely with respect to quality issues, and this Agreement shall control with respect to all other issues. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. All Product shall be released in accordance with the terms of the Quality Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Maintenance of Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Patheon shall Manufacture the Product &#91;&#8230;***&#8230;&#93; at the Facility, unless Flexion has granted prior written consent to Manufacture the Product at any other facility, such consent to be granted by Flexion in its sole discretion. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Subject to Section 2.9(b)-(d), Patheon shall ensure that any and all necessary licenses, registrations, and Regulatory Authority approvals have been obtained in connection with the Facility and Equipment used in connection with the Manufacture of the Product by Patheon. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Subject to Section 2.9, Patheon shall maintain the Facility and Equipment in a state of repair and operating efficiency consistent with the requirements of the Specifications, the Regulatory Approvals, Flexion&#8217;s Manufacturing Process, GMP, and all other Applicable Law. Prior to each use of Equipment in Manufacturing the Product, Patheon shall ensure that such Equipment is cleaned and consistent with any procedures reasonably established by Flexion and notified to Patheon, the Specifications, the Regulatory Approvals, Flexion&#8217;s Manufacturing Process, GMP, and all other Applicable Law. Without limitation of the foregoing, Patheon agrees to implement, in connection with the Manufacture of the Product, quality assurance and quality control procedures, including validation protocols and process change procedures that are reasonably satisfactory to Flexion. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Patheon shall maintain in the Facility an adequate GMP and temperature controlled area for the Product, all intermediates thereof, and Materials used in Manufacturing the Product in accordance with the Specifications, the Regulatory Approvals, Flexion&#8217;s Manufacturing Process, any risk mitigation plan, the Quality Agreement, GMP, and all Applicable Law. All Product, intermediates and Materials (as applicable) shall be held by Patheon in a GMP and temperature controlled area (on a separate pallet and SAP reference from other products) until delivery to Flexion. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 24 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Patheon shall only use qualified disposal services or sites that have appropriate environmental and operating permits and are in compliance with the Quality Agreement and Applicable Law. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion On Site Representatives&#59; Project Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. For so long as Patheon is obliged to Manufacture and supply the Products for Flexion, Flexion shall have the right at all times throughout the Term to have &#91;&#8230;***&#8230;&#93; representatives present (or other number as reasonably requested by Flexion after discussion by the members of the Steering Committee) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion On Site Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in that portion of Patheon&#8217;s Manufacturing facilities that is being used to Manufacture the Product or store Materials to observe the procedures and processes used to Manufacture the Product. Subject to the following sentence, such representatives shall have full access to the Manufacturing Suite and to all non-financial records that relate to the Product, the Materials and Bill Back Items. Patheon shall provide reasonable (semi-permanent) on-site accommodations at the Facility for the Flexion On Site Representatives (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, office space). For the avoidance of doubt, the term &#8220;non-financial records&#8221; as used in this Agreement does not include the Reports (defined in Section 3.11 below). Flexion On Site Representatives shall be appropriately trained by Flexion (e.g. GMP training) and shall observe at all times Patheon&#8217;s policies and procedures (as amended from time-to-time) as they pertain to the Facility, including policies relating to health and safety and compliance with GMP, and comply with all reasonable directions of Patheon in relation to the same&#59; provided that Flexion is given notice of such policies and given a reasonable period of time to review and implement such policies. Patheon may refuse or limit in its sole discretion at any time admission to the Facility by any Flexion On Site Representative who fails to observe such policies or comply with such reasonable directions. For the avoidance of doubt, Flexion On Site Representatives shall have (i) no management authority over any Patheon employee and (ii) no authority to conclude contracts on behalf of Flexion. Patheon and Flexion will each appoint a project manager (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and, together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Project Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), who will meet as needed to resolve any issues or problems arising in the performance of this Agreement. Flexion&#8217;s Project Manager may be one of the Flexion On Site Representatives. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notification of Regulatory Inspections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon shall notify Flexion by telephone within &#91;&#8230;***&#8230;&#93;, and in writing within &#91;&#8230;***&#8230;&#93;, after learning of any proposed or unannounced visit or inspection of any part of the Facility by any Regulatory Authority, including the Occupational Safety and Health Administration or any equivalent governmental agencies of the country of Manufacture, and shall permit Flexion or its agents to be present at the Facility to support Patheon during such visit or inspection if it, directly or indirectly relates to the Product or Manufacturing Suite or may reasonably be expected to adversely affect the Product or the Manufacturing Suite. For the avoidance of doubt the responsibility for conducting the inspection rests with Patheon. Flexion personnel will be permitted to take part in the inspection where this participation is directly requested either by the authorized agent of the Regulatory Authority or by Patheon. Patheon shall provide to Flexion in so far as it, directly or indirectly, affects the Product or the Manufacturing Suite or may reasonably be expected to adversely affect the Product or the</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 25 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing Suite, either a copy of any report and other written communications received from such Regulatory Authority in connection with any visit or inspection, including the Form 483 observations and responses or any equivalent form under Applicable Law. Such copy or summary shall be provided to Flexion within &#91;&#8230;***&#8230;&#93; business days of Patheon&#8217;s receipt thereof (and may be redacted as Patheon acting reasonably deems necessary to protect the confidentiality of matters not affecting, or not reasonably likely to affect, the Product or the Manufacturing Suite which are confidential to Patheon or to other clients of Patheon). Flexion shall have the right to review and comment on any communications with such Regulatory Authority pertaining to such inspection as set forth in Section 3.15. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon shall maintain, or cause to be maintained, (a) all records necessary to comply with GMP and all other Applicable Law relating to the Manufacture of Product, (b) all Manufacturing records, standard operating procedures, equipment log books, batch records, laboratory notebooks, and all raw data relating to the Manufacturing of the Product, and (c) such other records as Flexion may reasonably require in order to ensure compliance by Patheon with the terms of this Agreement. The template, form and style of all records referred to herein are the exclusive property of Patheon&#59; Flexion Proprietary Information and all Product-specific related information contained in these records shall be deemed Proprietary Information of Flexion and be retained for such period as may be required by GMP and all other Applicable Law or for such longer period as Flexion may reasonably require. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon shall comply and shall cause each of subcontractors and its Materials and Bill Back Items suppliers to comply with the Quality Agreement, GMP and Applicable Law in carrying out the Manufacturing of the Product and its other duties and obligations under this Agreement. Should during the Term of this Agreement a change or changes in Applicable Law lead to Patheon (a) providing services not originally contemplated by Patheon, or (b) incurring increased costs in order to comply with said change or changes, any such services or costs (to the extent pertaining to the Product or related to Flexion&#8217;s Manufacturing Process or Flexion Manufacturing Equipment) shall constitute an Additional Service subject to mutual written agreement of the Parties. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Flexion and its designated representatives shall have the right to audit all applicable non-financial records of Patheon for the purpose of determining Patheon&#8217;s compliance with the obligations set forth in this Agreement and the Technical Transfer Agreement, including Sections 2.2(a) and 6.2 of this Agreement, and the terms of any Purchase Order. Such audit right shall include the right to inspect&#58; (a) the Materials used in the Manufacture of the Product, (b) the holding facilities for such Materials and Product, (c) the Equipment used in the Manufacture of the Product, (d) all non-financial records relating to the Manufacturing Suite and the Manufacturing of the Product (subject to any other restrictions set forth in this Agreement) and (e) all other documentation set forth in the Quality Agreement. Flexion shall provide Patheon with reasonable prior advance notice of its intention to conduct such audit and the Parties will determine a mutually agreeable date for such audit.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 26 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion shall include no more than &#91;&#8230;***&#8230;&#93; of Flexion&#8217;s representatives in each such audit, with each such audit lasting no more than &#91;&#8230;***&#8230;&#93; days without Patheon&#8217;s prior written consent. Flexion may exercise its audit rights under this Section 3.8 no more than &#91;&#8230;***&#8230;&#93; per calendar year&#59; provided that, in the event any of the following circumstances arise, Flexion may elect and Patheon shall permit Flexion to conduct additional audits in a timely manner&#58; (i) where there is the occurrence of a condition or event relating to the Materials or any Product which constitutes a serious health risk&#59; (ii) where either Party has received correspondence or a report from a Regulatory Authority pointing out a deficiency in the Product by or on behalf of Patheon&#59; (iii) where the Specifications have not been complied with or there is otherwise evidence that compliance with the Specifications is at risk&#59; or (iv) in the event of a recall related to the Product. The Steering Committee will discuss the findings of any audit conducted by Flexion under this Section 3.8 and shall mutually agree upon a plan to remedy any issues identified by Flexion in such audit and Patheon shall use commercially reasonable efforts to implement such plan in a timely manner. Patheon will support the first Product approval, including its inspection if required, of the FDA or equivalent regulatory launch for other jurisdictions (where applicable) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PAI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) (including one mock-readiness review and efforts conducted with Flexion representatives in advance of such inspection). Patheon will be prepared for the successful completion of the PAI with respect to the Manufacturing of the Product at the Facility a minimum of &#91;&#8230;***&#8230;&#93; in advance of the anticipated date of the PAI and Patheon will cooperate with Flexion to prepare for and to complete the PAI in accordance with guidelines and requirements set forth by the applicable Regulatory Authority. Additional support (including, without limitation, subsequent regulatory launches or Product approval inspections&#47;resulting reports for other jurisdictions) will be subject to additional fees. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Inventory Reviews</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Without limiting the foregoing, Flexion shall have the right, with Patheon&#8217;s assistance, to conduct an annual inventory count of the Materials and of the Products. Following an audit or inventory, Flexion may discuss its observations and conclusions with Patheon, and Patheon shall promptly implement such corrective actions after notification thereof by Flexion. In the event the Parties are unable to agree upon whether or not corrective actions are necessary, such dispute shall be resolved pursuant to the terms of Section 10.9. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product Inquiries and Complaints</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) With respect to Products Manufactured by Patheon, each Party will promptly (as may be further defined in the Quality Agreement) submit to the other Party any Product safety and efficacy inquiries, Product quality complaints, and adverse drug event reports received by such Party, together with all available evidence and other information relating thereto, in accordance with procedures to be agreed upon by the Parties. Except as otherwise required by, or to comply with, Applicable Law or the terms of this Agreement, Flexion, as the Party holding the applicable Regulatory Approval, will be responsible for investigating </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 27 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and responding to all such inquiries, complaints, and adverse events regarding the Product, and reporting to the FDA or any other Regulatory Authority. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Pursuant to a reported complaint or adverse drug event pertaining to the Products Manufactured by Patheon, if the nature of the reported complaint or adverse drug event requires testing, Patheon will, upon Flexion&#8217;s request and approval, perform analytical testing of corresponding Product complaint or retention samples and provide the results thereto to Flexion as soon as reasonably practicable, but no later than &#91;&#8230;***&#8230;&#93; days after Flexion&#8217;s request. Such testing shall be performed using approved testing procedures as set forth in the applicable Regulatory Approval or the Quality Agreement. If such analytical testing concludes that the reported complaint or adverse drug event was the result of a Patheon Nonconformance, Patheon shall reimburse Flexion for &#91;&#8230;***&#8230;&#93; associated with such complaint or adverse drug event and incurred by Flexion with respect to such nonconforming Product, including &#91;&#8230;***&#8230;&#93;. Costs of recalls will be dealt with in accordance with Section 3.12. If such analytical testing concludes that the reported complaint or adverse drug event was not the result of a Patheon Nonconformance, Flexion shall compensate Patheon for all costs associated with such complaint or adverse drug event and incurred by Patheon with respect to such nonconforming Product, including costs of recalls, market withdrawals, returns, and destruction. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) If the Parties disagree as to which Party is responsible, Patheon and Flexion representatives shall attempt to resolve such dispute. If the representatives cannot resolve such dispute within &#91;&#8230;***&#8230;&#93; days, the retention samples shall be submitted by Patheon and Flexion to an Expert and Section 2.8 shall apply. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Prior to the start of Patheon&#8217;s commercial Manufacture of the Product (or as reasonably requested by Flexion prior to such date), Patheon and Flexion will work together in good faith to develop and agree upon Patheon&#8217;s ordinary course reporting obligations. Such reports (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) will include those reports as necessary for Flexion to (a) manage Product inventory&#59; (b) manage its financial close and reporting&#59; (c) monitor on-going Product and process performance for its internal analysis and reporting&#59; and (d) comply with Applicable Law. Patheon will deliver such reports via electronic delivery methods, including by utilizing Patheon&#8217;s existing IT systems as practicable. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) In the event (i) any Regulatory Authority issues a request, directive, or order that Product be recalled, (ii) a court of competent jurisdiction orders such a recall, or (iii) Flexion as holder of the applicable Regulatory Approval shall reasonably determine that Product should be recalled, withdrawn, or a field </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 28 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">correction issued, the Parties shall take all appropriate corrective actions, and shall cooperate in the investigations surrounding the recall. In the event that Flexion determines that Product should be recalled, to the extent reasonably possible, Flexion shall consult with Patheon prior to taking any corrective actions. In the event of any Product recall, withdrawal, or field correction resulting from a Patheon Nonconformance, Patheon shall bear &#91;&#8230;***&#8230;&#93; associated with such recall, withdrawal, or field correction, which shall include &#91;&#8230;***&#8230;&#93; of the recalled Product and all other &#91;&#8230;***&#8230;&#93; incurred in connection with such recall, plus &#91;&#8230;***&#8230;&#93; incurred by Flexion with respect to such Product. In all other circumstances, all costs associated with any Product recall, withdrawal, or field correction shall be borne by Flexion. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) If there is any dispute concerning which Party&#8217;s acts or omissions gave rise to such recall of Product, Patheon and Flexion representatives shall attempt to resolve such dispute. If the representatives cannot resolve such dispute within &#91;&#8230;***&#8230;&#93; days, the matter shall be submitted by Patheon and Flexion to an Expert and Section 2.8 shall apply. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Upon &#91;&#8230;***&#8230;&#93; days&#8217; prior written notice, Flexion may audit any Third Party invoices subsequently invoiced to Flexion pertaining to Patheon&#8217;s provision of Equipment, Materials, Bill Back Items and Additional Services hereunder&#59; provided, however, that Flexion will not be entitled to more than one audit during any &#91;&#8230;***&#8230;&#93; period. Such audits will be conducted during normal business hours, without undue disruption to Patheon&#8217;s business, and may be conducted by Flexion, or by an independent public accounting firm designated by Flexion who is bound by confidentiality obligations at least as stringent as those set forth in the Confidentiality Agreement. Except as hereinafter set forth, Flexion will bear the full cost of the performance of any such audit. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) If, as a result of any audit described in Section 3.13(a), it is shown that the payments or credits from one Party to the other under this Agreement with respect to the period of time audited were less than or more than the amount that should have been paid or credited, then the Parties will reconcile the amounts owed by each Party to the other. In addition, if such audit demonstrates that Patheon has overcharged Flexion hereunder by more than &#91;&#8230;***&#8230;&#93;% for the period audited, then Patheon will also reimburse Flexion for its documented reasonable out-of-pocket costs and expenses incurred in connection with the audit. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 29 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Prior to subcontracting any of Patheon&#8217;s obligations hereunder, Patheon will notify Flexion (1) in advance of engaging a proposed subcontractor that directly relates to the Manufacture of the Product and will obtain Flexion&#8217;s prior written approval of each such subcontractor, and (2) within six (6) months, of all other subcontractors so engaged. The terms of any subcontract directly relating to the Manufacture of the Product will be in writing and will be consistent with this Agreement, including (i) the confidentiality obligations set forth in Article VII, (ii) the representations and warranties of Patheon in Section 6.3, and (iii) compliance with Applicable Law as required hereunder. No subcontracting will release Patheon from its responsibility for its obligations under this Agreement and Patheon will be responsible for the work and activities of each such subcontractor as they relate to performance of Patheon&#8217;s obligations under this Agreement, including compliance with the terms of this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Filing Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as otherwise set forth in this Agreement or the Technical Transfer Agreement, each Party will be responsible for all routine filings and communications with Regulatory Authorities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) required with respect to such Party&#8217;s Regulatory Obligations hereunder. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean&#58; (i) with respect to Flexion, any Regulatory Filings pertaining to the Product, Flexion&#8217;s Manufacturing Process, and filling and packaging processes and procedures&#59; and (ii) with respect to Patheon, any Regulatory Filings pertaining to the Facility, including in connection with a Facility inspection by a Regulatory Authority (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, those described in Section 3.5). For the avoidance of doubt, Flexion shall have the sole responsibility and Regulatory Obligation for the filing of all documents with all applicable Regulatory Authorities, and to take any other actions that may be required, for the receipt of Regulatory Approval for the development or commercial manufacture of the Product. Flexion shall provide Patheon with a copy of any Regulatory Approval directly relevant to this Agreement on request including any Regulatory Approval required for the storage, receipt or distribution of the Product by Flexion or its designee. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Filing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) will provide reasonable assistance and cooperation to the other Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Filing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in the connection with the Filing Party&#8217;s Regulatory Obligations consistent with the terms of this Section 3.15 and the Non-Filing Party&#8217;s obligations under this Agreement. The Filing Party shall notify the Non-Filing Party in writing of any written communications received by the Filing Party from a Regulatory Authority related to the other Party&#8217;s Regulatory Obligations within &#91;&#8230;***&#8230;&#93; business days after receipt thereof. The Filing Party shall consult with the Non-Filing Party concerning the response of the Filing Party to each such communication, unless such filing is not relevant to the Non-Filing Party&#8217;s Regulatory Obligations. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Verification of Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Prior to filing any documents or communications with a Regulatory Authority that incorporate or uses data generated by the Non-Filing Party or otherwise relate to the Non-Filing Party&#8217;s Regulatory Obligations, the Filing Party will give the Non-Filing Party a draft of </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 30 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">such document or communication (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Draft</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) to give the Non-Filing Party the opportunity to verify the accuracy and regulatory validity of such Initial Draft. The Non-Filing Party shall be given a minimum of &#91;&#8230;***&#8230;&#93; calendar days to review the Initial Draft, but the Parties may mutually agree to a different time for the review as needed under the circumstances. The Initial Draft may be redacted by the Filing Party as reasonably deems necessary to protect the confidentiality of matters not affecting the Non-Filing Party or which are confidential to the Filing Party or to other clients or customers of the Non-Filing Party. The Parties agree that in reviewing the Initial Draft, the Non-Filing Party&#8217;s role will be limited to verifying the accuracy of the description of its Regulatory Filing Obligations or accuracy of its data or information in the Initial Draft. Notwithstanding the forgoing, nothing in this Section 3.15(b) shall be deemed to limit a Party&#8217;s ability to make any filing with, or otherwise communicate with, any Regulatory Authority if such Party reasonably determines that such filing or communication is legally required and must be made in an expedited manner and consultation with the other Party as provided herein is not reasonably possible. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Inaccuracies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the Non-Filing Party determines that any of its data or information in the Initial Draft is inaccurate or any other errors relating to the Non-Filing Party&#8217;s Regulatory Obligations, the Non-Filing Party will notify Filing Party in writing of such inaccuracy and provide a recommendation to remediate the Initial Draft. Such notice shall also include documentation and data sufficient to substantiate the Non-Filing Party&#8217;s claim that the Initial Draft is inaccurate to the Filing Party&#8217;s reasonable satisfaction. The Non-Filing Party shall provide comments to the Initial Draft no later than &#91;&#8230;***&#8230;&#93; days prior to the required filing date with the applicable Regulatory Authority. If the Non-Filing Party does not provide comments or notify the Filing Party of inaccuracies within such &#91;&#8230;***&#8230;&#93; day period, the Non-Filing Party will be deemed to have approved any data or language related to its Regulatory Obligations in the Initial Draft. The Filing Party shall be required to incorporate the Non-Filing Party&#8217;s recommendations to the extent they directly relate to an error in the Non-Filing Party&#8217;s data or information or the Non-Filing Party&#8217;s Regulatory Filing Obligations. The Parties will work together in good faith to resolve any inaccuracies contained in the Initial Draft as soon as practicable under the circumstances to prevent a delay or postponement of such filing (or any related inspections by such Regulatory Authority to which the filing relates). Any on-going disagreement regarding the Deficiencies shall be escalated to the Steering Committee for resolution on an expedited basis. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon shall deliver a copy of the final version of the filing to Flexion at least &#91;&#8230;***&#8230;&#93; days prior to the required filing date. Flexion shall deliver a copy of the final version of the filing to Patheon promptly after the required filing date. Subject to the foregoing, the Non-Filing </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 31 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Party will not assume any responsibility for the accuracy of any other materials submitted by the Filing Party to a Regulatory Authority in connection with this Agreement. Except as otherwise set forth in this Agreement or the Technical Transfer Agreement, the Filing Party is solely responsible for the preparation and filing of any materials required by a Regulatory Authority with respect to such Party&#8217;s Regulatory Filing Obligations hereunder and any relevant costs will be borne by the Filing Party. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE IV. FEES AND INVOICING </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. (a) Patheon shall invoice Flexion for all applicable fees and charges incurred by Patheon as set out in this Agreement or the Technical Transfer Agreement. (b) All invoices shall be sent electronically to &#91;&#8230;***&#8230;&#93;. Payment shall be due thirty (30) days after receipt by Flexion of an undisputed invoice. All payments from Flexion to Patheon hereunder shall be in British Pounds (GBP). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Late Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In relation to all invoices issued by Patheon pursuant to this Agreement, if Flexion fails to make any payment due to Patheon by the due date for payment, then, without limiting Patheon&#8217;s remedies under ARTICLE VIII or at law, Patheon may charge interest on past due accounts at &#91;&#8230;***&#8230;&#93;% per month which is equal to an annual rate of &#91;&#8230;***&#8230;&#93;%. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Disputed Invoices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If Flexion disputes any portion of an invoice, (a) Flexion shall provide Patheon with written notice of the disputed portion within &#91;&#8230;***&#8230;&#93; business days of receipt by Flexion of Patheon&#8217;s invoice and its reasons therefor and shall not be obliged to pay such disputed portion unless and until such disputed portion is determined to be due and owing, and (b) Patheon shall cancel such invoice and issue a new invoice reflecting the undisputed invoiced amount, which shall be paid by Flexion within &#91;&#8230;***&#8230;&#93; days. The Parties shall use good faith efforts to resolve the dispute regarding the disputed amount promptly, and if the Parties agree that a balance is due, Patheon shall issue an invoice for such balance, and payment shall be due &#91;&#8230;***&#8230;&#93; days after receipt of such invoice. In the event of any inconsistency between an invoice and this Agreement, the terms of this Agreement shall control. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Subject to (b) and (c) below, Patheon will bear all Taxes however designated as a result of the provision of the Services under this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Flexion acknowledges that it will be responsible for all Taxes that arise in respect of the following&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) The acquisition of the Flexion-Supplied Materials. </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 32 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) The acquisition of the Flexion Manufacturing Equipment. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Any payment due under this Agreement for the provision of Services to Flexion by Patheon is exclusive of value added or equivalent tax in any other jurisdiction, including any related interest and penalties (hereinafter all referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). If any VAT is payable on a Service supplied by Patheon to Flexion under this Agreement, this VAT will be added to the invoice amount and will be for the account of (and reimbursable to Patheon by) Flexion. Where applicable, Patheon will use its reasonable commercial efforts to ensure that its invoices to Flexion are issued in such a way that these invoices meet the requirements for deduction of input VAT by Flexion, to the extent permitted by law to do so. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Flexion acknowledges that all amounts due in respect of any fees payable by Flexion under this Agreement shall be paid in full without any set-off, counterclaim, deduction or withholding in respect of any Tax liabilities. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE V. INTELLECTUAL PROPERTY </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Flexion shall maintain ownership and Control of all of its technology and intellectual property rights existing prior to the Effective Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Flexion Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Patheon shall maintain ownership and Control of all of its technology and intellectual property rights existing prior to the Effective Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Patheon Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Existing Flexion Intellectual Property shall include and Flexion shall own all right, title, and interest in and to (i) the Product, (ii) the Specifications, and (iii) Flexion&#8217;s Manufacturing Process. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Existing Patheon Intellectual Property shall include and Patheon shall own all right, title, and interest in and to the Patheon Manufacturing Equipment as of the Effective Date. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Flexion shall own all right, title, and interest in and to, all intellectual property (specifically including inventions and patents and patent applications therefor) with respect to, and any data with respect to&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) (A) any improvement of, modification of, change of, enhancement of, new indication for, new formula for, new formulation for, new ingredients for, new dosage for, new dosage strength for, new means of delivery for, or new labelling or packaging for, the Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Product Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; (B) any improvement of, modification of, change of, or enhancement of the Specifications (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Specification Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; (C) any improvement of, modification of, change of, enhancement of, new process for, new procedure for, or new step related to Flexion&#8217;s Manufacturing Process (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Manufacturing Process Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; and (D) any improvements of, modification of, change </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 33 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of or enhancement of Flexion Manufacturing Equipment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Manufacturing Equipment Improvements&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in each of case (A), (B), (C) and (D) , (1) that is developed, conceived, or created after the Effective Date specifically as a result of or in connection with this Agreement, including Patheon&#8217;s Manufacturing of the Product hereunder, (2) whether or not patentable, (3) whether developed, conceived, or created by employees of, or consultants to, Flexion or Patheon, alone or jointly with each other or with permitted Third Parties (including permitted sublicensees and subcontractors), and (4) that has specific applicability, meaning it does not have applicability to products other than the Product, to the Product, Specifications, Flexion&#8217;s Manufacturing Process or the Flexion Manufacturing Equipment as applicable (together the Flexion Specification Improvements, Flexion Product Improvements, Flexion&#8217;s Manufacturing Process Improvements and the Flexion Manufacturing Equipment Improvements shall be referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Specific Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) any improvement of, modification of, change of, enhancement of manufacturing, processing, formulating, filling, labelling or packaging technology or equipment which is (x) developed, conceived, created, generated or derived after the Effective Date by Patheon, alone or jointly with Flexion or other permitted Third Parties (including permitted sublicensees) specifically as a result of or in connection with this Agreement, and (y) of generic application to the Product, meaning it has application to or utility in relation to a range of products which includes the Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Specific Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)(the Flexion Specific Improvements and the Non-Specific Improvements are together &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) any inventions, know how or other intellectual property developed, conceived, or created by Flexion, alone or jointly with Third Parties (other than Patheon or its Affiliates, or their respective employees and consultants), in the course of conducting activities outside the scope of this Agreement and without any use of any Existing Patheon Intellectual Property, Patheon Independent Manufacturing Equipment Improvements and&#47;or Patheon Non-Applicable Inventions (as defined hereunder). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Patheon shall own all right, title, and interest in and to, all intellectual property (specifically including inventions and patents and patent applications therefor) with respect to, and any data with respect to&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) any improvement of, modification of, change of, enhancement of Patheon&#8217;s Manufacturing Equipment, (1) that is developed, conceived, or created as a result of or in connection with this Agreement, including Patheon&#8217;s Manufacturing of the Product hereunder, (2) whether or not patentable, (3) whether developed, conceived, or created by employees of, or consultants to, Flexion or Patheon, alone or jointly with each other or with permitted Third Parties (including permitted sublicensees), and (4) that is of generic application rather than a specific solution that only has applicability to the Product, (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Independent Manufacturing Equipment Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 34 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) any inventions, know how or other intellectual property developed, conceived, or created by Patheon, alone or jointly with Flexion or other permitted Third Parties (including permitted sub-licensees), in the course of conducting activities under the scope of this Agreement where such inventions know how or other intellectual property have no applicability to the Product, the Specifications, Flexion&#8217;s Manufacturing Process or the Flexion Manufacturing Equipment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Non-Applicable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) (together the Patheon Independent Manufacturing Equipment Improvements and the Patheon Non-Applicable Inventions are together &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) any inventions, know how or other intellectual property developed, conceived, or created by Patheon, alone or jointly with Third Parties, in the course of conducting activities outside the scope of this Agreement and without any use of any Existing Flexion Intellectual Property or Flexion Specific Improvements. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) Patheon shall, and shall cause its Affiliates to, promptly disclose in writing and in reasonable detail to Flexion any Flexion Improvements developed, conceived, or created by employees, consultants, or subcontractors of Patheon or its Affiliates, alone or jointly with employees, consultants or subcontractors of Flexion or its Affiliates. Such written notice will be treated as the Proprietary Information of Flexion hereunder. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) Flexion shall, and shall cause its Affiliates to promptly disclose in writing and in reasonable detail to Patheon any potential Patheon Improvement and any Flexion Non-Specific Improvements developed, conceived, or created by employees, consultants, or subcontractors of Flexion or its Affiliates, alone or jointly with employees, consultants, or subcontractors of Patheon or its Affiliates. Such written notice in relation to Patheon Improvements will be treated as the Proprietary Information of Patheon hereunder. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) The Specifications, Flexion&#8217;s Manufacturing Process, and any and all information or material related to the Existing Flexion Intellectual Property, and Flexion Improvements shall constitute Proprietary Information of Flexion, which shall be deemed the disclosing Party with respect to such Proprietary Information and shall be subject to the provisions of Article VII of this Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j) Patheon&#8217;s Manufacturing Equipment and any and all information or material related to the Existing Patheon Intellectual Property and Patheon Improvements shall constitute Proprietary Information of Patheon, which shall be deemed the disclosing Party with respect to such Proprietary Information. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k) Patheon shall, and shall cause its Affiliates, to disclose in writing and in reasonable detail to Flexion prior to the implementation of any such Patheon Improvement or Non-Specific Improvement into the Manufacturing Services or any potential Patheon Improvements or Non-Specific Improvements and Flexion shall, in its sole discretion, decide whether such improvement shall be </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 35 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">used in the Manufacture of the Product. Such written notice will be treated as the Proprietary Information of Patheon hereunder. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l) Patheon agrees to, and hereby does, and shall cause each of its employees, consultants, and Affiliates (collectively with Patheon, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Assignors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) to assign to Flexion all right, title and interest in and to the Flexion Improvements developed, conceived or created by such Patheon Assignors, alone or jointly with others including all intellectual property rights associated therewith. Upon Flexion&#8217;s request and at Flexion&#8217;s sole expense, Patheon shall, and shall use commercially reasonable efforts to cause each Patheon Assignor to, assist Flexion or anyone Flexion reasonably designates in preparing, filing, prosecuting, obtaining, enforcing or defending patent, copyright or other intellectual property application or grant of right issuing therefrom in any and all countries in the world. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m) Flexion agrees to, and hereby does, and shall cause each of its employees, consultants, and Affiliates (collectively with Flexion, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Assignors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) to assign to Patheon all right, title and interest in and to the Patheon Improvements developed, conceived or created by such Flexion Assignors, alone or jointly with others including all intellectual property rights associated therewith. Upon Patheon&#8217;s request and at Patheon&#8217;s sole expense, Flexion shall, and shall use commercially reasonable efforts to cause each Flexion Assignor to, assist Patheon or anyone Patheon reason ably designates in preparing, filing, prosecuting, obtaining, enforcing or defending patent, copyright or other intellectual property application or grant of right issuing therefrom in any and all countries in the world. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Flexion hereby grants to Patheon a fully paid-up worldwide, non-exclusive license, under Flexion&#8217;s entire right, title, and interest in and to the Existing Flexion Intellectual Property for Patheon to Manufacture the Products solely pursuant to the terms of this Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Flexion hereby grants to Patheon a fully paid-up worldwide, non-exclusive license, under Flexion&#8217;s entire right, title, and interest in and to the Flexion Improvements, in each case to make Products solely pursuant to the terms of this Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Flexion hereby grants to Patheon a perpetual, irrevocable, fully paid-up worldwide, exclusive license, with the right to grant sub-licences, under Flexion&#8217;s entire right, title, and interest in and to the Non-Specific Improvements for the manufacture, use, sale or supply of any and all products, except Excluded Products or any and all products which, at any time, are owned by or exclusively licensed to Flexion. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, Flexion grants to Patheon a perpetual, irrevocable, fully paid-up worldwide, co-exclusive license, with the right to grant sub-licences, under Flexion&#8217;s entire right, title, and interest in and to the Non-Specific Improvements </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 36 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for the manufacture, use, sale or supply of any and all products which, at any time, are owned by or exclusively licensed (in terms of the right of Flexion to sell such products) to Flexion except Excluded Products. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accordingly, notwithstanding anything to the contrary herein, Flexion retains&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) co-exclusively with Patheon, rights to the Non-Specific Improvements for the manufacture, use, sale or supply of any and all products which, at any time, are owned by or exclusively licensed (in terms of the right of Flexion to sell such products) to Flexion, and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) exclusively, any and all rights to the Non-Specific Improvements for the manufacture, use, sale or supply of Excluded Products&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">provided that, in either case (i) or (ii), </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion may only sublicense its rights to Non-Specific Improvements to a Third Party in conjunction with the license or assignment by Flexion of rights to manufacture, use, sell or supply a therapeutic product that is, or were prior to the assignment, owned by or exclusively license (in terms of the right of Flexion to sell such products) to Flexion&#59; and</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other than with respect to permitted assignments of this Agreement under Section 10.5A herein Flexion shall not assign or otherwise transfer its right to Non-Specific Improvements without the prior written consent of Patheon. In the event that Flexion wishes to assign any Non-Specific Improvement(s) to an Affiliate, Patheon and Flexion shall enter into a novation agreement with that Flexion Affiliate, to novate the rights and obligations hereunder in respect of such Non-Specific Improvement(s) only.</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the purposes of this Section 5.2(c), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any product which comprises as its active agent &#91;&#8230;***&#8230;&#93;. For the avoidance of doubt, co-exclusive means that only Patheon (and its authorised sub-licensees) and Flexion (and its authorised sub-licensees) has rights in relation to the Non-Specific Improvements, such rights and the scope and nature of authorised sub-licensees being as expressly set out in this clause 5.2(c) and no wider. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 37 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Upon the request of Flexion at any time during the &#91;&#8230;***&#8230;&#93; period prior to expiry of this Agreement, Patheon shall, at Flexion&#8217;s cost (i) promptly disclose to Flexion or its designee any Patheon Improvement, (ii) have its representatives meet with representatives of Flexion or its designee to enable Flexion or such designee to Manufacture the Product, and (iii) provide such other assistance as Flexion may reasonably request to enable Flexion or such designee to Manufacture the Product. Flexion shall reimburse Patheon for its fees and all documented out-of-pocket expenses reasonably incurred by Patheon in connection with such technology transfer. Patheon will provide a quotation for the services which Flexion requires pursuant to this Section 5.3 as Additional Services and on acceptance by Flexion of the same, Patheon will provide the services stated therein. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In the event that, during the Term, any Third Party institutes against Patheon any action that alleges that the Manufacture of the Product hereunder in accordance with the terms hereof infringes the intellectual property rights held by such Third Party, then, as between Patheon and Flexion, and subject to Flexion indemnifying and defending and holding harmless Patheon in relation to such action pursuant Section 9.1(a)(iv) herein, Flexion, at its sole expense, shall have the sole obligation to contest and assume discretion and control of the defense of such action, including the right to settle such action on terms determined by Flexion&#59; provided, however, that in no event may Flexion agree to the entry of any equitable or injunctive relief that is binding on Patheon and its Affiliates without Patheon&#8217;s prior written consent, not to be unreasonably withheld or delayed. Patheon, at Flexion&#8217;s expense, shall use all commercially reasonable efforts to assist and cooperate with Flexion as reasonably request by Flexion in such action. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Licenses of Rights to Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The licenses granted by the Parties hereunder shall be deemed to be licenses of rights to &#8220;intellectual property&#8221; as defined Section 101 of the United States Bankruptcy Code and, in connection therewith, each Party shall have the rights set forth in Section 365(n) of the United States Bankruptcy Code in the event of any rejection or proposed rejection of this Agreement in any bankruptcy proceeding. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE VI. REPRESENTATIONS AND WARRANTIES </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Representations and Warranties of Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Party hereby represents and warrants to the other Party as follows&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Such Party (i) is duly formed and in good standing under the laws of the jurisdiction of its formation, (ii) has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, and (iii) has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid, and binding obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 38 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">insolvency, or other similar laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Except for the FDA&#8217;s approval of Patheon&#8217;s manufacturing, testing, and packaging for the Product from the Manufacturing Suite, all necessary consents, approvals, and authorizations of all Regulatory Authorities, other governmental authorities, and other Persons required to be obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) The execution and delivery of this Agreement and the performance of such Party&#8217;s obligations hereunder (i) do not and will not conflict with or violate any requirement of Applicable Law or any provision of the articles of incorporation, bylaws limited partnership agreement, or other constituent document of such Party and (ii) do not and will not conflict with, violate, or breach, or constitute a default or require any consent under, any contractual obligation or court or administrative order by which such Party is bound. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Representations, Warranties and Covenants, of Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon warrants, represents and covenants, that&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) (i) it has facilities, personnel, experience, and expertise sufficient in quality and quantity to perform the obligations hereunder, (ii) it shall perform its obligations in conformity with GMPs where applicable, (iii) it will comply with the Quality Agreement and comply with all agreed upon quality assurance, quality controls, and review procedures in the performance of its obligations hereunder and (iv) during the Term, the Facility will remain operational and qualified for the purpose of the Manufacture of Product under the terms of this Agreement&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) it has, as of the Effective Date observed and complied, and shall, during the Term and at its cost (subject to Sections 2.9(b)-(d) and Section 3.7), observe and comply, with all then-current Applicable Laws, including federal, state, and local laws, orders, regulations, rules, customs, and ordinances now in force or that may hereafter be in force, pertaining to the Facility and the performance of the Manufacturing Services and including, without limitation, (i) labor laws, orders, regulations, rules, customs, and ordinances of the country of Manufacture and (ii) those issued by the FDA pertaining to the Manufacturing Services and the Facility (but not those pertaining solely to non-Manufacturing matters relating to the Product, compliance with which shall be the responsibility of Flexion), and any laws, orders, regulations, rules, or ordinances issued in addition to, as a supplement to or as a replacement of Applicable Laws&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) none of it, its Affiliates, nor any Person under its direction or control, has ever been, nor will it engage suppliers which have to its actual </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 39 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">knowledge, after due inquiry, been, (i) debarred or convicted of a crime for which a person can be debarred, under Section 335(a) or 335(b) of the FDA Act, or any equivalent Applicable Law of the country of Manufacture, (ii) threatened to be debarred under the FDA Act or any equivalent Applicable Law of the country of Manufacture or (iii) indicted for a crime or otherwise (to its actual knowledge after due inquiry) engaged in conduct for which a person can be debarred under the FDA or any equivalent Applicable Law of the country of Manufacture, and Patheon agrees that it will, within &#91;&#8230;***&#8230;&#93;, notify Flexion in the event it receives notification of any such debarment, conviction, threat or indictment. Should Patheon become aware of any actual or suspected noncompliance with the foregoing, Patheon will notify Flexion in writing of such issue within &#91;&#8230;***&#8230;&#93;. For the purpose of this Section 6.2, suppliers and subcontractors engaged by Patheon to undertake the Manufacture of the Product shall be deemed to be under Patheon&#8217;s direction or control&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) none of it, its Affiliates, nor any Person under its direction or control is currently excluded from a federal or state health care program under Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. &#167;&#167; 1320a-7, 1320c-5 or any equivalent Applicable Law of the country of Manufacture, as may be amended or supplemented&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) none of it, its Affiliates, nor any Person under its direction or control is otherwise currently excluded from contracting with the U.S. federal government or the government of the country of Manufacture&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) none of it, its Affiliates, nor any Person under its direction or control is otherwise currently excluded, suspended, or debarred from any U.S. or foreign governmental program&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) it shall immediately notify Flexion if, at any time during the Term, Patheon, its Affiliates, or any Person under its direction or control is convicted of an offense that would subject it or Flexion to exclusion, suspension, or debarment from any U.S. or foreign governmental program&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) agrees to keep the Equipment free form all liens and encumbrances. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) it will not enter into any agreement or arrangement with any other Person that would prevent its ability to perform its obligations hereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Warranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon warrants that, at the time of delivery of Product to Flexion&#58; (a) such Product will have been Manufactured in accordance with the &#91;&#8230;***&#8230;&#93;&#59; (b) such Product will be in conformity with the</font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 40 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; in accordance with the &#91;&#8230;***&#8230;&#93; set out therein and will conform with the &#91;&#8230;***&#8230;&#93; therefor provided pursuant to Section &#91;&#8230;***&#8230;&#93;&#59; (c) title to such Product will pass to Flexion as provided herein free and clear of any security interest, lien, or other encumbrance&#59; (d) such Product will not be adulterated or misbranded within the meaning of the FDA Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> a result of a Patheon Nonconformance&#59; and (e) such Product will not be articles that, under the provisions of the FDA Act, may not be introduced into interstate commerce as a result of a Patheon Nonconformance. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Representations and Warranties of Flexion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Flexion warrants and represents that&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) (1) as of the Effective Date, it or its Affiliates Control all issued patents and pending patent applications set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 6.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, which patents and applications are necessary for performance of the Manufacturing Services&#59; and (2) it has the right to authorize Patheon to use and exploit such issued patents and pending patent applications to perform the Manufacturing Services in accordance with the terms and conditions hereof&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) as of the Effective Date, to the actual knowledge of Flexion&#8217;s management team, having taken all Diligent and Reasonable Steps to ascertain the same, that there are no facts or circumstances that would cause Flexion to conclude that the performance of the Manufacturing Services, in accordance with the terms and conditions hereof and using Flexion&#8217;s Manufacturing Process, or the manufacture, use, supply or other disposition of the Product by Patheon as may be required to perform its obligations under this Agreement, will result, in the infringement or misappropriation of any Third Party&#8217;s intellectual property rights&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) as of the Effective Date, Flexion or its Affiliates Control and have the right to lawfully disclose the Specifications to Patheon and to authorize Patheon to use the Specification to perform the Manufacturing Services&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) as of the Effective Date, there are no actions or other legal proceedings pending against Flexion and&#47;or its Affiliates concerning the infringement of Third Party intellectual property rights related to any of the Specifications, Flexion&#8217;s Manufacturing Process, any of the Materials, or the sale, use, or other disposition by Flexion of any Product made in accordance with the Specifications. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the purposes of part (ii) above, &#8220;Diligent and Reasonable Steps&#8221; means such steps as would normally be taken by a company of the same size and nature as Flexion for a product of </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 41 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">similar market potential at a similar stage of its product life, when utilizing sound and reasonable business practice. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Quality and Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) during the Term, the Specifications for all Products conform to all applicable GMPs and Applicable Laws&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) during the Term, the Products, if labelled and manufactured in accordance with the Specifications and in compliance with the Quality Agreement, applicable GMPs and Applicable Laws may be lawfully sold and distributed in every jurisdiction in which Flexion markets the Products&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) during the Term, on the date of shipment to Patheon, any Flexion-Supplied Materials will conform to the specifications for the Flexion-Supplied Materials that Flexion has given to Patheon and the Flexion-Supplied Materials will be adequately contained, packaged, and labelled and will conform to the affirmations of fact on the container. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Flexion agrees that, as a pre-condition to the adding of any country to the Territory pursuant to section 2.2(h), Flexion shall repeat the warranties above as at the date on which the country is added to the Territory. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DISCLAIMER. THE FOREGOING EXPRESS WARRANTIES SET FORTH IN THIS ARTICLE VI ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT, AND ALL OTHER WARRANTIES ARE HEREBY DISCLAIMED AND EXCLUDED BY EACH PARTY.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Patheon confirms that all licences, registrations and Regulatory Authority approvals to be obtained by Patheon pursuant to this Agreement and the Technical Transfer Agreement shall be obtained in a lawful and ethical manner. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Patheon has not and shall not cause Flexion or its subsidiaries or affiliates to be in violation of any applicable U.S. export or import control or customs law or regulation, U.S. sanctions or embargoes, the U.S. Foreign Corrupt Practices Act of 1977 (as amended) (&#8220;FCPA&#8221;), the U.S. Travel Act, the UK Bribery Act of 2010 (the &#8220;UK Bribery Act&#8221;), anti-corruption and anti-kickback laws and regulations, any applicable anti-corruption laws or regulations of another country, or any other applicable law or regulation. In relation to Flexion&#8217;s business, Patheon has not and shall not directly or indirectly offer, pay, solicit, or accept any bribes, kickbacks, or other improper payments&#47;benefits to or from any party, including, but not limited to, any employee, representative, or official of the Flexion, any government, or any state-affiliated entity. Patheon has not and shall not offer, pay, solicit, or accept any rebates or refunds in connection with the Product </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 42 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or Flexion&#8217;s business without informing and obtaining the written approval of Flexion in advance and ensuring that such rebate&#47;refund is compliant with all applicable laws and regulations. Patheon has in good faith provided to Flexion accurate and complete due diligence information and materials regarding Patheon and its employees and Affiliates in response to requests by Flexion. In relation to the performance of this Agreement, Patheon shall fully cooperate with Flexion in ensuring compliance with the FCPA, the UK Bribery Act and all other applicable laws and regulations.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Flexion may suspend its performance under this Agreement if Flexion reasonably suspects that Patheon has or will violate the FCPA, the UK Bribery Act or any other applicable law or regulation. Patheon shall reasonably cooperate with Flexion with any audit or questioning related thereto.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Patheon understands and acknowledges that a violation of the FCPA, the UK Bribery Act or any of the terms of this Section 6.6 by Patheon or its employees, agents, or contractors shall constitute a &#91;&#8230;***&#8230;&#93; for the purpose of Section &#91;&#8230;***&#8230;&#93; of this Agreement. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE VII. CONFIDENTIALITY </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Subject to the provisions of clauses (b), (c) and (d) below, at all times during the Term and for seven (7) years following the expiration or termination thereof, the Receiving Party (i) shall keep completely confidential and shall not publish or otherwise disclose any Proprietary Information furnished to it by the Disclosing Party, except to those of the Receiving Party&#8217;s Representatives or Affiliates to perform such Party&#8217;s obligations hereunder (and who shall be advised of the Receiving Party&#8217;s obligations hereunder and who are bound by confidentiality obligations with respect to such Proprietary Information no less onerous than those set forth in this Agreement) and (ii) shall not use Proprietary Information of the Disclosing Party directly or indirectly for any purpose other than performing its obligations or exercising its rights hereunder. The Receiving Party shall be jointly and severally liable for any breach by any of its Representatives of the restrictions set forth in this Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) The Receiving Party&#8217;s obligations set forth in this Agreement shall not extend to any Proprietary Information of the Disclosing Party&#58; </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 43 -</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) that is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no wrongful act, fault or negligence on the part of a Receiving Party or its Representatives or Affiliates&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) that is received from a Third Party without restriction and without breach of any agreement between such Third Party and the Disclosing Party&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) that the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation on use or disclosure prior to its receipt from the Disclosing Party&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) that is generally made available to Third Parties by the Disclosing Party without restriction on disclosure&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v) that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party without reference to the Proprietary Information of the Disclosing Party. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Each Party may disclose Proprietary Information to the extent that such disclosure is&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) made in response to a valid order of a court of competent jurisdiction or other governmental body of a country or any political subdivision thereof of competent jurisdiction&#59; provided, however, that the Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash such order and to obtain a protective order requiring that the Proprietary Information and&#47;or documents that are the subject of such order be held in confidence by such court or governmental body or, if disclosed, be used only for the purposes for which the order was issued&#59; and provided further that if a disclosure order is not quashed or a protective order is not obtained, the Proprietary Information disclosed in response to such court or governmental order shall be limited to that information which is legally required to be disclosed in such response to such court or governmental order&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) otherwise required by law or regulation, including the rules and regulations of any securities authority or stock exchange on which such Party&#8217;s or its Affiliate&#8217;s securities are traded, as determined in good faith by counsel for the Receiving Party and acting in accordance with Section 10.10&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) made in connection with the filing or prosecution of patent rights as permitted by this Agreement&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv) made in connection with the enforcement of such Party&#8217;s rights under this Agreement and in performing its obligations under this Agreement&#59; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v) made in connection with the prosecution or defense of litigation as permitted by this Agreement&#59; </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 44 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi) made to Affiliates, actual and potential licensees and sublicensees, employees, consultants or agents of the Receiving Party who have a need to know such information in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement, provided, in each case, that any such Affiliate, actual or potential licensee or sublicensee, employee, consultant or agent agrees to be bound by terms of confidentiality and non-use comparable in scope to those set forth herein&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii) made to Third Parties in connection with due diligence or similar investigations by such Third Parties, and disclosure to potential Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by reasonable obligations of confidentiality and non-use&#59; and </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii) with respect to disclosure by Flexion, made to Regulatory Authorities in connection with obtaining and maintaining any Marketing Authorization. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) The Parties rights and obligations regarding the filing of this Agreement with any securities authority or with any stock exchange on which securities issued by a Party or its Affiliate are traded are set forth in Section 10.10. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Subject to Patheon&#8217;s obligations with any Regulatory Authority, upon expiration or termination of this Agreement, each Party, at the request of the other, shall return all data, files, records and other materials in its possession or control containing or comprising the other Party&#8217;s Proprietary Information&#59; provided that each Party may retain a copy of any Proprietary Information of the other Party required in order to permit a Party to exercise its rights pursuant to clause (c) above. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Party acknowledges that a breach by either Party of the this ARTICLE VII may not reasonably or adequately be compensated in damages in an action at law and that such a breach may cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party may be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to apply for preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of this ARTICLE VII&#59; provided, however, that no specification in this Agreement of a specific legal or equitable remedy will be construed as a waiver or prohibition against the pursuing of other legal or equitable remedies in the event of such a breach. Each Party agrees that the existence of any claim, demand, or cause of action of it against the other Party, whether predicated upon this Agreement, or otherwise, will not constitute a defense to the enforcement by the other Party, or its successors or assigns, of the covenants contained in this ARTICLE VII. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 45 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE VIII. TERM AND TERMINATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement shall commence as of the Effective Date and, unless earlier terminated in accordance with the terms hereof, shall expire on the tenth (10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) anniversary of the FDA Approval Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding, by mutual agreement the Parties may commence discussions three (3) years prior to the end of the Initial Term with a view to extending the Initial Term for such period or periods as may be agreed (collectively, the Initial Term and any extensions thereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In addition to any other provision of this Agreement expressly providing for termination of this Agreement, this Agreement may be terminated as follows&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Flexion may terminate this Agreement&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) at any time by giving Patheon one (1) month prior written notice in the event that for efficacy or safety reasons the Product is withdrawn permanently or, if not yet approved, the Product is barred from further development (in either case for reasons outside of the reasonable control of Flexion) in the United States or any other market in a country or countries of the Territory that represent eighty percent (80%) or more of Flexion&#8217;s overall Product sales including without limitation&#58; (A) if any Regulatory Authority causes the clinical hold or permanent withdrawal of the Product, (B) failure to receive Marketing Authorization in the United States, (C) failure of the Product to achieve its primary endpoint or key secondary endpoints with respect to either of the ongoing (as of the Effective Date) Phase 2(b) and Phase 3 clinical trials, or (D) safety data which Flexion determines may have a materially adverse impact on use of the Product. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) for convenience, at any time (x) prior to the FDA Approval Date, with three (3) months written notice to Patheon, and (y) after the FDA Approval Date, by giving twenty four (24) months prior written notice to Patheon&#59; or </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) at any time upon written notice in the event of any material default by Patheon in the performance of any of its obligations hereunder, which material default has not been cured by Patheon within ninety (90) days after receiving written notice thereof (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Remediation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), provided that Patheon shall continue performing hereunder pursuant to the terms of Section 8.4 below. Flexion&#8217;s right to terminate this Agreement for a particular breach under this Section 8.2(a)(iii) may only be exercised for a period of one hundred twenty (120) days following the expiry of the Remediation Period (where the breach has not been remedied) and, if the termination right is not exercised during this period, then Flexion will be deemed to have waived its right to terminate this Agreement for such breach. For purposes of clarity, the Parties agree that a &#8220;material default&#8221; of Patheon shall have occurred if (A) Patheon shall have delivered Non-Conforming Product caused by Patheon Nonconformance with respect to three (3) batches in any one calendar year, or (B) the Facility and&#47;or the Manufacturing</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 46 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suite violates GMP or other Applicable Law preventing the ability to continue the Manufacturing of Product for at least six (6) months. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Patheon may terminate this Agreement at any time upon written notice in the event of (i) any material default by Flexion in the performance of any of its obligations hereunder, which default has not been cured by Flexion within ninety (90) days after receiving written notice thereof&#59; or (ii) Flexion&#8217;s default of its payment obligations in accordance with ARTICLE IV which default has not been cured by Flexion within fifteen (15) days after receiving written notice thereof&#59; provided, however, that, if Flexion fails to cure such payment default, Patheon may not terminate without first providing a second notice to the attention of Flexion&#8217;s Chief Executive Officer and an additional fifteen (15) day cure period. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) This Agreement may be terminated at any time by either Party immediately upon written notice to the other Party (A) pursuant to Section 10.2 in the event of a force majeure that remains uncured for the period provided in Section 10.2, or (B) if the other Party shall file in any court or agency, pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for arrangement or for the appointment of a receiver or trustee of the other Party or of its assets, or if the other Party proposes a written agreement of composition of its debts, or if the other Party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is consented to by such Party or is not dismissed within sixty (60) days after the filing thereof, or if the other Party shall propose or be a Party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of its creditors. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Either Party may terminate this Agreement by giving three (3) months&#8217; notice to the other Party if a permanent injunction is granted pursuant to a Third Party claim for intellectual property infringement in either the United Kingdom and&#47;or the United States preventing the further sale, promotion or marketing of the Product in such country as applicable. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) This Agreement will automatically terminate should either Flexion or Patheon exercise its right to terminate the Technical Transfer Agreement (but not in the event of an expiration of such agreement as set forth in Section 8.2 thereof) prior to the FDA Approval Date, in which case, any payment to Patheon will be made in accordance with the Technical Transfer Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The expiration or termination of this Agreement shall be without prejudice to any rights or obligations of the Parties that may have accrued prior to such termination, and the provisions of Sections 2.8 (in respect of Product on the market at the date of termination of this Agreement), 3.5, 3.6, 3.8, 3.10, 3.12, 3.13, 5.1, 5.2(c), 5.5, 6.3, 6.5, 8.3 and 8.4 and ARTICLE I (to the extent definitions are used in other surviving sections pursuant to this Section 8.3(a)), ARTICLE IV, </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 47 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARTICLE VII, ARTICLE IX, and ARTICLE X&#59; provided that, Section 3.8 shall only survive for a period of &#91;&#8230;***&#8230;&#93; days after expiration or termination of this Agreement in respect of deviations that occurred before termination or expiration and continue to be relevant shall survive the expiration or termination of this Agreement. Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Upon expiration or termination of this Agreement, subject to the Parties&#8217; obligations under Section 8.4 below, each Party, at the request of the other, shall return all data, files, records, and other materials in its possession or control containing or comprising the other Party&#8217;s Proprietary Information. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Upon expiration or termination of this Agreement for any reason, subject to the Parties&#8217; obligations under Section 8.4 below, (i) all submitted but unfilled Purchase Orders with respect to which Patheon has (1) not begun Manufacture of Product shall be cancelled, or (2) begun Manufacture of the Product shall be completed, unless otherwise agreed (ii) Flexion shall remove all Flexion Manufacturing Equipment and Materials from the Facility within &#91;&#8230;***&#8230;&#93; days of such termination under all sections other than Section 8.2(a)(iii) and within &#91;&#8230;***&#8230;&#93; days &#91;&#8230;***&#8230;&#93; of a termination by Flexion pursuant to Section 8.2(a)(iii) that is not reasonably disputed by Patheon, failing which Flexion will pay a fee equivalent to the aggregate monthly Base Fee for the Manufacturing Suite for each month or part month the Flexion Manufacturing Equipment or Materials remain at the Facility after &#91;&#8230;***&#8230;&#93; days or &#91;&#8230;***&#8230;&#93; days, as applicable, from such termination. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Upon expiration or termination of this Agreement, subject to the Parties&#8217; obligations under Section 8.4 below, (i) Flexion shall purchase from Patheon at Patheon&#8217;s cost, all unpaid Material Costs and Bill Back Items which were ordered, purchased, produced or maintained by Patheon in contemplation of the Manufacture of the Product in accordance with Section 2.2&#59; (ii) Flexion shall pay Patheon any earned but unpaid Product Fees, including those under any outstanding Purchase Order as described in Section 8.3(c)&#59; (iii) Flexion shall pay for any earned (through the month of such expiration or termination) but undisputed and unpaid Base Fees, Phase I Filling Space Fees or Additional Services&#59; and (iv) Flexion shall pay all due and outstanding invoices under ARTICLE IV. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Upon expiration or termination of this Agreement for any reason other than by &#91;&#8230;***&#8230;&#93; pursuant to Section &#91;&#8230;***&#8230;&#93; that is not reasonably disputed by &#91;&#8230;***&#8230;&#93;, subject to the Parties&#8217; obligations under Section 8.4 below, Flexion shall pay to Patheon all and any removal and Make Good Costs associated with the removal of the Flexion Manufacturing Equipment </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 48 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">from the Facility as agreed to in good faith by the Parties. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Make Good Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the reasonable costs required to repair the Facility and return it to a clean, safe and useable area based on the repair of damage caused by the installation or removal of Flexion Manufacturing Equipment. In relation to termination of this Agreement by &#91;&#8230;***&#8230;&#93; pursuant to Section &#91;&#8230;***&#8230;&#93;, Flexion shall pay any Make Good Costs that are required in relation to and to the extent that any damage that is caused to the Facility as a result of the negligence of Flexion or its agent or a failure to materially comply with the reasonable written instructions of Patheon in the removal of Flexion Manufacturing Equipment. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) The Parties understand and believe that the expiration or termination of this Agreement for any reason shall not constitute a &#8220;relevant transfer&#8221; as defined by and pursuant to Regulation 3(1)(b) of the Transfer of Undertakings (Protection of Employment) Regulations 2006 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">TUPE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). If, contrary to the Parties&#8217; understanding and belief, TUPE does apply on the expiration or termination of this Agreement to the transfer of any employee or subcontractor of Patheon to Flexion or to any person who, after expiration or termination of this Agreement, provides to Flexion services similar to the Manufacturing Services and&#47;or the Additional Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Replacement Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) then&#58; </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">without prejudice to Flexion&#8217;s obligations under Section 8.3(g) below, following termination or expiry of this Agreement other than by &#91;&#8230;***&#8230;&#93; pursuant to Section &#91;&#8230;***&#8230;&#93;, Flexion shall indemnify Patheon for and against all claims, costs, expenses or liabilities arising, incurred or suffered by Patheon in relation to any claim made by or in respect of any person employed or formerly employed by Patheon for which it is alleged Flexion and&#47;or any Replacement Entity may be liable by virtue of TUPE, provided that this indemnity shall not apply if and to the extent that, (A) the aggregate amount payable by Flexion pursuant to this Section 8.3(f)(i) and Section 8.3(g) exceeds the Maximum Manufacturing Services Termination Costs&#59; or (B) any such claim, cost, expense or liability arises as a result of a failure by Patheon to comply with its applicable obligations under TUPE.</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">if (A) this Agreement has been terminated by &#91;&#8230;***&#8230;&#93; pursuant to Section &#91;&#8230;***&#8230;&#93;, or (B) this Agreement terminates or expires under any other circumstances and the aggregate amount payable by Flexion pursuant to Section 8.3(f)(i) and Section 8.3(g) exceeds the Maximum Manufacturing Services Termination Costs, Patheon shall indemnify Flexion for and against all claims, costs, expenses or liabilities arising, incurred or suffered by Flexion and&#47;or any Replacement Entity in relation to any claim</font></td></tr></table></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 49 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">made by or in respect of any person employed or formerly employed by Patheon for which it is alleged Flexion and&#47;or any Replacement Entity may be liable by virtue of TUPE provided that this indemnity shall not apply if and to the extent that any such claim, cost, expense or liability arises as a result of a failure by Flexion or the Replacement Entity to comply with its applicable obligations under TUPE.</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) Subject to the Parties&#8217; obligations under Section 8.4 below, Flexion shall pay to Patheon the following costs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Services Termination Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#58; (i) upon expiration or termination of this Agreement, all reasonable actual costs incurred by Patheon to complete activities associated with such completion, expiry or termination including, without limitation, disposal fees that may be payable for any Materials and supplies owned by Flexion to be disposed of by Patheon&#59; and (ii) upon expiration or termination of this Agreement other than by &#91;&#8230;***&#8230;&#93; pursuant to Section &#91;&#8230;***&#8230;&#93;, all and any direct costs and expenses or termination or cancellation fees payable by Patheon as a consequence of or arising from the termination of this Agreement, to include but not limited to, all and any reasonable redundancy costs of employees employed by Patheon to work solely or mainly in providing the Services and&#47;or Manufacturing the Product, all and any termination costs in relation to subcontractors and agency staff working solely or mainly in providing the Services and&#47;or Manufacturing the Product and any termination or cancellation fees payable to Third Party suppliers. Patheon will use commercially reasonable efforts to mitigate the Manufacturing Services Termination Costs and reallocate available resources. Patheon will further provide Flexion with documentation in order to substantiate the Manufacturing Services Termination Costs. Notwithstanding anything in this Section 8.3(g), Flexion&#8217;s aggregate liability for the Manufacturing Services Termination Costs (under both this Agreement and the Technical Transfer Agreement combined) shall be limited to the payment to Patheon of the first &#163;&#91;&#8230;***&#8230;&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Maximum Manufacturing Services Termination Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) Flexion acknowledges that no Patheon Competitor (being a Person that derives greater than &#91;&#8230;***&#8230;&#93;% of its revenues from performing contract pharmaceutical or biopharmaceutical development or commercial manufacturing services) will be permitted access to the Facility. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) In relation to any representatives of Flexion that are permitted access to the Facility pursuant to Section 8.3 or 8.4, Flexion shall ensure that such representatives are appropriately trained by Flexion (e.g. GMP training) and shall </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 50 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">observe at all times Patheon&#8217;s policies and procedures (as amended from time-to-time) as they pertain to the Facility, including policies relating to health and safety and compliance with GMP, and comply with all reasonable directions of Patheon in relation to the same&#59; provided that Flexion is given notice of such policies and given a reasonable period of time to review and implement such policies. Patheon may refuse or limit in its sole discretion at any time admission to the Facility by any of Flexion&#8217;s representatives who fail to observe such policies or comply with such reasonable directions. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j) The Parties agree that if any fees or charges are duplicated under Section 8.11 of the Technical Transfer Agreement, Flexion shall only be obligated to make such payment once. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Transition Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Upon the delivery by either Party of a notice of termination of this Agreement for any reason, upon the request of Flexion, and subject to terms set forth in this Agreement including this Section 8.4(a), (i) Patheon shall provide Flexion with the reasonable assistance of its staff and reasonable access to its other internal resources to provide Flexion with a reasonable level of technical assistance and consultation to transfer the Manufacture and the regulatory qualification of the Product to a supplier of Flexion&#8217;s election, provided that Flexion will reimburse Patheon for its fees and all documented costs and out-of-pocket expenses incurred in connection with such assistance (Patheon would provide a quotation for the services which Flexion requires pursuant to this Section 8.4 as Additional Services and on acceptance by Flexion of the same, Patheon will provide the services stated therein) and (ii) Patheon will provide the deliverables set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto subject to payment of the fees and costs to be paid by Flexion as described above. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Upon the delivery by &#91;&#8230;***&#8230;&#93; of a notice of termination of this Agreement pursuant to Section &#91;&#8230;***&#8230;&#93; (but not including the giving of notice of termination following an extension to this Agreement pursuant to this Section 8.4(b)), if requested by Flexion in writing given at the same time as the giving of such notice of termination including the term of such additional supply, Patheon shall supply the Products pursuant to the terms of this Agreement for a period not to exceed a maximum of &#91;&#8230;***&#8230;&#93; from the delivery of a notice of termination. For the avoidance of doubt, the termination date of this Agreement shall be deemed the date upon which the Parties have completed their obligations under this Section 8.4. Flexion acknowledges that, during such transition assistance period, no Patheon Competitor (being a Person that derives greater than &#91;&#8230;***&#8230;&#93;% of its revenues from performing contract pharmaceutical or biopharmaceutical development or commercial manufacturing services) will be permitted access to portions of the Facility other than those dedicated to the Manufacture of the Product.</font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 51 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE IX. INDEMNIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Indemnification Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Flexion shall indemnify Patheon, its Affiliates, and their respective directors, officers, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and defend and save each of them harmless, from and against any and all (a) Third Party Losses incurred by any of them in connection with, arising from, or occurring as a result of (i) the breach by Flexion of any of its obligations under this Agreement&#59; (ii) the breach or inaccuracy of any representation or warranty made by Flexion in this Agreement, (iii) any negligence or willful misconduct by Flexion or any of its Affiliates, (iv) any claim made by any Person that the Manufacture and supply of the Product in accordance with the terms hereof infringes or misappropriates the patent, trademark, or other intellectual property rights of such Person, and (v) any product liability claim made by any Person with respect to any Product Manufactured in accordance with the terms hereof, except to the extent liability is based on a Patheon Nonconformance or (b) any Loss incurred by any of them as a direct result of and to the extent of the negligence or willful misconduct of the Flexion On Site Representatives at the Facility except, in each case, for those Losses for which Patheon has an obligation to indemnify the Flexion Indemnified Parties pursuant to Section 9.2, as to which Losses each Party shall indemnify the other to the extent of their respective liability for such Losses and provided, however, that Flexion will not be required to indemnify the Patheon Indemnified Parties with respect to any such Loss hereunder to the extent the same is caused by any breach of contract, negligent act or omission, or intentional misconduct by any Patheon Indemnified Parties. For the avoidance of doubt, the parties acknowledge that Patheon has not and will not conduct any freedom to operate searches in relation to the Product and&#47;or Flexion&#8217;s Manufacturing Process nor reviewed any third party patents in relation thereto and that Patheon&#8217;s failure or omission to do so will not be considered negligence for the purposes of excluding or limiting a claim under this indemnity. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Indemnification Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon shall indemnify Flexion, its Affiliates, and their respective directors, officers, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and defend and save each of them harmless, from and against any and all (a) Third Party Losses incurred by any of them resulting from, or relating to, any claim of personal injury or property damage to the extent that the injury or damage is in connection with, arising from, or occurring as a result of (i) the breach or inaccuracy of any representation or warranty made by Patheon in this Agreement, (ii) any negligence or willful misconduct by Patheon or any of its Affiliates&#59; and (iii) any product liability claim made by any Person with respect to any Product Manufactured by Patheon to the extent any such liability is based on or caused by a Patheon Nonconformance&#59; (b) Third Party Losses incurred by any of them in connection with, arising from, or occurring as a result of a claim that any Existing Patheon Intellectual Property or Patheon Improvement used by Patheon in its Manufacture of the Product infringes or misappropriates the patent, trademark, or other intellectual property rights of such Person&#59; except, in each case, for which Flexion has an obligation to indemnify the Patheon Indemnified Parties pursuant to Section 9.1, as to which Losses each Party shall indemnify the other to the extent of their respective liability for such Losses and provided, however, that Patheon will not be required to indemnify the Flexion Indemnified Parties with respect to any </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 52 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">such Loss hereunder to the extent the same is caused by any breach of contract, negligent act or omission, or intentional misconduct by Flexion Indemnified Parties. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The indemnified Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall give the indemnifying Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) prompt written notice (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) of any Loss, action, or discovery of facts upon which such Indemnified Party intends to base a request for indemnification under Section 9.1 or 9.2 (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), but in no event shall the Indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses upon which it intends to seek indemnification. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Control of Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. At its option, the Indemnifying Party may assume the defense of any Claims by giving written notice to the Indemnified Party within &#91;&#8230;***&#8230;&#93; days after the Indemnifying Party&#8217;s receipt of an Indemnification Claim Notice&#59; provided that the assumption of the defense of a Claim by the Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify any Indemnified Party in respect of the Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party&#8217;s Claim. Upon assuming the defense of a Claim, the Indemnifying Party may appoint as lead counsel in the defense of such Claim any legal counsel selected by the Indemnifying Party. In the event the Indemnifying Party assumes the defense of a Claim, the Indemnified Party shall immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by any Indemnified Party in connection with the Claim. Subject to clause (c) below, if the Indemnifying Party assumes the defense of a Claim, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense, or settlement of such Claim. In the event that it is ultimately determined that the Indemnifying Party is not obliged to indemnify, defend, or hold harmless an Indemnified Party from and against any Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including attorneys&#8217; fees and costs of suit) and any Losses incurred by the Indemnifying Party in its defense of such Claim. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Right to Participate in Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Without limiting Section 9.3(b), any Indemnified Party shall be entitled to participate in, but not control, the defense of a Claim and to employ counsel of its choice for such purpose&#59; provided, </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 53 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">however, that such employment shall be at the Indemnified Party&#8217;s own expense unless (i) the employment thereof has been specifically authorized by the Indemnifying Party in writing, (ii) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 9.3(b) (in which case the Indemnified Party shall control the defense), or (iii) the interests of the Indemnified Party and the Indemnifying Party with respect to such Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules, or equitable principles. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. With respect to any Losses (i) relating solely to the payment of money damages in connection with a Claim, (ii) that will not result in the Indemnified Party becoming subject to injunctive or other relief or otherwise adversely affect the business or reputation of the Indemnified Party in any manner, and (iii) as to which the Indemnifying Party has acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement, or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Claims, where the Indemnifying Party has assumed the defense of the Claim in accordance with Section 9.3(b), the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement, or otherwise dispose of such Loss&#59; provided that it obtains the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed. The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, agree to any settlement or acquiesce to any judgment with respect to a Claim that obligates the Indemnified Party to pay any amount subject to indemnification by the Indemnifying Party or causes the Indemnified Party to admit to any civil or criminal liability. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the Indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party shall cooperate in the defense or prosecution thereof and shall, at the Indemnifying Party&#8217;s expense, furnish such records, information, and testimony, provide such witnesses, and attend such conferences, discovery proceedings, hearings, trials, and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party shall reimburse the Indemnified Party for all its time and reasonable out-of-pocket expenses in connection therewith. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Claim shall be reimbursed on a monthly basis in arrears by the Indemnifying Party, without prejudice to the </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 54 - </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnifying Party&#8217;s right to contest the Indemnified Party&#8217;s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obliged to indemnify the Indemnified Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. During the Term and for &#91;&#8230;***&#8230;&#93; thereafter, each Party shall procure and maintain at its own expense from a qualified and licensed insurer liability insurance or indemnity policies, in an amount not less than $&#91;&#8230;***&#8230;&#93; in the aggregate with respect to public and products liability, subject to such deductible or self-retention limits as either Party in its business discretion may elect. Such policies shall insure against liability on the part of each Party and any of its Affiliates, as their interests may appear, due to injury, disability, or death of any person or persons, or injury to property, arising from the distribution of the Products. Each Party will either (a) include the other Party and its officers and employees and consultants as additional insureds on such policies, or (b) ensure that such policy contains an indemnity to principal clause. Promptly following the execution of this Agreement, each Party shall provide to the other a certificate of insurance (i) summarizing the insurance coverage and (ii) identifying any exclusions. Each Party shall promptly notify the other of any material adverse alterations to the terms of this policy or decreases in the amounts for which insurance is provided. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation on Damages</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Maximum Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except with respect to (i) &#91;&#8230;***&#8230;&#93; of Patheon or (ii) for damages incurred by Flexion arising from, or occurring as a result of a claim by a Third Party that any &#91;&#8230;***&#8230;&#93; used by Patheon in its Manufacture of the Product &#91;&#8230;***&#8230;&#93; or (iii) breaches of &#91;&#8230;***&#8230;&#93;, Patheon&#8217;s maximum liability to Flexion under this Agreement for any reason whatsoever, including, without limitation, any liability arising under Sections 2.7, 2.8, 3.10, 3.12 or 9.2 hereof or resulting from any and all breaches of its representations, warranties, or any other obligations under this Agreement in each calendar year (liability cap pro-rated for part calendar years) will not exceed &#91;&#8230;***&#8230;&#93;% of the revenues received by Patheon pursuant to this Agreement in the &#91;&#8230;***&#8230;&#93; period prior to the month in which the underlying event occurred that gave rise to the liability (e.g. the date of the incident or manufacture). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR (I) ANY (DIRECT OR INDIRECT) LOSS OF PROFITS, OF PRODUCTION, OF ANTICIPATED SAVINGS, OF BUSINESS, OF GOODWILL OR OF USE OF THE PRODUCT OR COSTS OF ANY SUBSTITUTE SERVICES OR (II) ANY OTHER LIABILITY, DAMAGE, COST OR EXPENSE OF ANY KIND INCURRED BY THE OTHER PARTY OF AN INDIRECT OR CONSEQUENTIAL NATURE, REGARDLESS OF ANY </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 55 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOTICE OF THE POSSIBILITY OF THE DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT DAMAGES AVAILABLE FOR &#91;&#8230;***&#8230;&#93;. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) The limitations set forth in Sections 9.5(a) and 9.5(b) shall not act to exclude or limit either Party&#8217;s liability for (i) personal injury or death caused by the negligence of that Party, or for (ii) fraudulent misrepresentation. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Sole &#38; Exclusive Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding anything in this Article IX to the contrary&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) Except as described in Section 9.5(c) above and except for Patheon&#8217;s indemnification obligations set forth in Section 9.2, Patheon&#8217;s sole liability and Flexion&#8217;s sole and exclusive remedy whether in contract, tort, equity or otherwise for Non-Conforming Product based on or caused by a Patheon Nonconformance shall be the rights and remedies set forth in Section 2.8, 3.10 and 3.12 of this Agreement and in Section 8.2(a)(iii) of this Agreement. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) Patheon&#8217;s sole liability and Flexion&#8217;s sole and exclusive remedy whether in contract, tort, equity or otherwise for Patheon&#8217;s failure to Manufacture the full quantity of Product specified in a Purchase Order by the Agreed Delivery Date shall be the rights and remedies set forth in Section 2.7 and Section 8.2(a)(iii) of this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product Liability Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. As soon as it becomes aware, each Party will give the other prompt written notice of any defect or alleged defect in a Product, any injury alleged to have occurred as a result of the use or application of the Product, and any circumstances that may give rise to litigation or recall of a Product or regulatory action that may affect the sale or Manufacture of a Product, specifying, to the extent the Party has such information, the time, place, and circumstances thereof and the names and addresses of the persons involved. Each Party will also furnish promptly to the other copies of all papers received in respect of any claim, action, or suit arising out of such alleged defect, injury, or regulatory action. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Allocation of Risk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement (including, without limitation, this ARTICLE IX) is reasonable and creates a reasonable allocation of risk for the relative profits the Parties each expect to derive from the Products. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE X. MISCELLANEOUS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding that advance notification of any notices or other communications may be given by electronic mail transmission, all notices or other communications that shall or may be given pursuant to this Agreement shall be in writing </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 56 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(including by confirmed receipt electronic mail) and shall be deemed to be effective (a) when delivered if sent by registered or certified mail, return receipt requested, or (b) on the next business day, if sent by overnight courier, (c) when sent if sent by electronic mail provided that receipt is confirmed, in each case to the Parties at the following addresses (or at such other addresses as shall be specified by like notice) with postage or delivery charges prepaid&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to Flexion&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion Therapeutics, Inc. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Michael Clayman, MD </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Telephone&#58; &#91;&#8230;***&#8230;&#93; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a copy to&#58; Legal </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to Patheon&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attention&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patheon UK Limited </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Director &#38; General Manager </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kingfisher Drive, Covingham </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swindon, Wiltshire SN3 5BZ </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;&#8230;***&#8230;&#93; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with copy to </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Director. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Neither Party shall be liable for delay in delivery, performance or nonperformance, in whole or in part, nor shall the other Party have the right to terminate this Agreement except as otherwise specifically provided in this Section 10.2 where such delay in delivery, performance or nonperformance results from acts beyond the reasonable control and without the fault or negligence of such Party including, but not limited to, the following conditions&#58; fires, floods, storms, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotion, or acts, omissions, or delays in acting by any governmental authority&#59; provided that the Party affected by such a condition shall, within five (5) days of its occurrence, give notice to the other Party stating the nature of the condition, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is reasonably required, and the nonperforming Party shall use its commercially reasonable efforts to remedy its inability to perform&#59; provided, however, that in the event the suspension of performance continues for &#91;&#8230;***&#8230;&#93; days after the date of the occurrence, and such failure to perform would constitute a material breach of this Agreement in the absence of such force majeure event, the non-affected Party may terminate this Agreement immediately by written notice to the affected Party. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 57 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Parties to this Agreement are independent contractors. Nothing contained in this Agreement shall be construed to place the Parties in the relationship of employer and employee, partners, principal, and agent or a joint venture. Neither Party shall have the power to bind or obligate the other Party nor shall either Party hold itself out as having such authority. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Save where expressly stated in Sections 2.8 and 8.2(a)(iii), no waiver by either Party of any provision or breach of this Agreement shall constitute a waiver by such Party of any other provision or breach, and no such waiver shall be effective unless made in writing and signed by an authorized representative of the Party against whom waiver is sought. No course of conduct or dealing between the Parties will act as a modification or waiver of any provision of this Agreement. Either Party&#8217;s consent to or approval of any act of the other Party shall not be deemed to render unnecessary the obtaining of that Party&#8217;s consent to or approval of any subsequent act by the other Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement (together with all Exhibits and Schedules hereto, which are hereby incorporated by reference), the Quality Agreement, and the Technical Transfer Agreement constitute the final, complete, and exclusive agreement between the Parties relating to the subject matter hereof and supersede all prior conversations, understandings, promises, and agreements relating to the subject matter hereof, including without limitation that (i) certain Confidentiality Agreement dated September 22, 2014 between Flexion and Patheon and the Letter Agreement, and (ii) that certain Patheon Partner External User Account&#47;Access Form, Client Agreement and Authorization signed by Flexion on June 5, 2015. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neither Party has relied upon any communications, representations, terms or promises, verbal or written, not set forth herein. No terms, provisions or conditions of any purchase order or other business form or written authorization used by Flexion or Patheon will have any effect on the rights, duties, or obligations of the Parties under or otherwise modify this Agreement, regardless of any failure of Flexion or Patheon to object to the terms, provisions, or conditions unless the document specifically refers to this Agreement and is signed by both Parties. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment&#59; Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement may not be assigned by Patheon without the prior written consent of Flexion. Notwithstanding the foregoing, either Party may assign this Agreement to an Affiliate or to an acquirer or successor in interest in connection with a Change of Control of such Party without the prior written consent of the other Party, provided that such Party provides the other Party with written notice of any such assignment. This Agreement shall be binding upon and inure to the benefit of Flexion and Patheon and their respective successors, heirs, executors, administrators, and permitted assigns. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the closing of (a) a merger, consolidation or similar transaction providing for the acquisition of the direct or indirect ownership of more than fifty percent (50%) of a Party&#8217;s shares or similar equity interests or voting power of the outstanding voting securities or that represents the power to direct the management and policies of such Party (including any acquisition arising through the offering of any shares of Patheon or any of its Affiliates on any securities or stock exchange), or (b) the sale of all or substantially all of a Party&#8217;s assets related to the subject matter of the Agreement. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 58 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment&#59; Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement may not be amended, modified, altered, or supplemented except by a writing signed by both Parties. No modification of any nature to this Agreement and no representation, agreement, arrangement, or other communication shall be binding on the Parties unless such is expressly contained in writing and executed by the Parties as an amendment to this Agreement. This Agreement may not be amended in any respect by any purchase order, invoice, acknowledgment, or other similar printed document issued by either Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The laws of &#91;&#8230;***&#8230;&#93;, whether procedural or substantive (but excluding application of any choice of law provisions contained therein) shall apply to all matters pertaining only to (a) title to and ownership of Materials, Equipment or the Facility, and its appurtenances including, without limitation, all rights therein and the creation, exercise and extinction of such rights, obligations and liabilities or (b) employment law matters. In relation to such matters, both Parties shall submit to the exclusive jurisdiction of the &#91;&#8230;***&#8230;&#93; Courts. For the avoidance of doubt, the Parties agree that nothing in this Agreement shall (i) grant Flexion any property ownership rights in the Facility or (ii) shall constitute a lease to the Facility. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) In all other respects, this Agreement shall be construed under and governed by the laws of &#91;&#8230;***&#8230;&#93; without regard to the application of principles of conflicts of law. In relation to such matters, both Parties shall submit to the exclusive jurisdiction of &#91;&#8230;***&#8230;&#93;. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Any preliminary issue over which of sub-section 10.7(a) or (b) applies to a particular claim or dispute shall be determined in accordance with provisions of 10.7(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) The Parties expressly exclude the application of the United Nations Convention on Contracts for the International Sale of Goods, if applicable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Party and its Affiliates, and their respective representatives, shall comply with all applicable laws, rules and regulations in the performance of their obligations under this Agreement. Without limiting the foregoing, each Party and its Affiliates, and their respective representatives, shall comply with export control laws and regulations of the country of Manufacture and of the United States. Neither Party nor its Affiliates (or representatives) shall, directly or indirectly, without prior U.S. government authorization, export, re-export, or transfer the Product to any country subject to a U.S. trade embargo, to any resident or national of any country subject to a U.S. trade embargo, or to any person or entity listed on the &#8220;Entity List&#8221; or &#8220;Denied Persons List&#8221; maintained by the </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 59 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Commerce or the list of &#8220;Specifically Designated Nationals and Blocked Persons&#8221; maintained by the U.S. Department of Treasury. In so far as the same applies to a Party or its Affiliates, each Party and its Affiliates and respective representatives shall comply with the requirements of the Foreign Corrupt Practices Act of 1977 (15 U.S.C. &#167; 78dd-1, et seq.). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The Parties recognize that disputes may arise from time to time during the Term of this Agreement. It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes arising under this Agreement in an expedient manner by mutual cooperation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Section 10.9 if and when a dispute arises under this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Unless otherwise specifically recited in the Agreement, disputes between the Parties under this Agreement will be first referred to the Project Manager of each Party as soon as reasonably possible after such dispute has arisen. If the Project Managers are unable to resolve such a dispute within fifteen (15) days of being requested by a Party to resolve such dispute, either Party may, by written notice to the other, have such dispute referred to the Steering Committee. If the Steering Committee is unable to resolve such dispute within thirty (30) days of being requested by a Party to resolve such dispute, each Party shall have the right, pursuant to written notice, to refer such dispute to the &#91;&#8230;***&#8230;&#93; of each Party for attempted resolution by negotiations within thirty (30) days after such written notice is received. If the &#91;&#8230;***&#8230;&#93; are unable to resolve such dispute within thirty (30) days of being requested by a Party to resolve such dispute, each Party shall have the right to pursue any remedies available to it at law or in equity. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Authorities and Stock Exchange Filings&#59; Press Releases&#59; Use of Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The Parties shall coordinate in advance with each other in connection with (i) a Party&#8217;s decision to file this Agreement with any securities authority or with any stock exchange on which securities issued by a Party or its Affiliate are traded, or (ii) any other disclosure of information pertaining to this Agreement as otherwise required by the rules and regulations of the Securities and Exchange Commission or any other securities authority or stock exchange on which securities issued by a Party or its Affiliates are traded, and, in each such instance, (a) the filing Party will provide the other Party at least ten (10) business days to review a draft redacted version of this Agreement, and (b) both Parties shall work together in good faith to agree on the disclosure to be made, having due and proper regard to their legal obligations&#59; provided that the filing Party subject to such rules and regulations shall ultimately retain control over what information to disclose to any securities authority or stock exchange. Each filing Party shall use reasonable efforts to seek confidential treatment for terms proposed to be redacted&#59; provided that the Parties shall use their reasonable efforts to file redacted versions with any governing bodies which are consistent with redacted versions previously filed with any other governing bodies. </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 60 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other than such obligations, neither Party (nor any of its Affiliates) shall be obligated to consult with or obtain approval from the other Party with respect to any filings to any securities authority or stock exchange. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Except for the filings described in Section 10.10(a) above, the Parties agree not to disclose in any press release or other public statement any terms or conditions of this Agreement to any Third Party without the prior consent of the other Party. Neither Party shall (a) issue a press release or make any other public statement that references this Agreement or (b) use the other Party&#8217;s or the other Party&#8217;s Affiliates&#8217; names or trademarks for publicity or advertising purposes, except with the prior written consent of the other Party. Each Party agrees that it shall cooperate fully and in a timely manner with the other with respect to all disclosures to the Securities and Exchange Commission or any other governmental or regulatory agencies, including requests for confidential treatment of Proprietary Information of either Party included in any such disclosure. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If any provision of this Agreement is found by a proper authority to be unenforceable, that provision to the extent it is found to be unenforceable or invalid shall be severed and the remainder of the provision and this Agreement will continue in full force and effect. The Parties shall use their best efforts to agree upon a valid and enforceable provision as a substitute for any invalid or unenforceable provision, taking in to account the Parties&#8217; original intent of this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Unless the context of this Agreement otherwise requires&#58; (a) words of any gender include each other gender&#59; (b) words using the singular or plural number also include the plural or singular number, respectively&#59; (c) the terms &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; and derivative or similar words refer to this entire Agreement&#59; (d) the terms &#8220;Article,&#8221; &#8220;Section,&#8221; &#8220;Exhibit,&#8221; &#8220;Schedule,&#8221; or &#8220;clause&#8221; refer to the specified Article, Section, Exhibit, Schedule, or clause of this Agreement&#59; (e) &#8220;or&#8221; is disjunctive but not necessarily exclusive&#59; and (f) the term &#8220;including&#8221; or &#8220;includes&#8221; means &#8220;including without limitation&#8221; or &#8220;includes without limitation.&#8221; Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless business days are specified. The captions and headings of this Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties, and no rule of strict construction shall be applied against either Party hereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement is not intended to confer upon any non-party rights or remedies hereunder, except as may be received or created as part of a valid assignment. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each of the Parties agrees to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such additional assignments, agreements, documents, and instruments, that may be necessary or as the other Party hereto may at any time and from time to time reasonably request in connection with this Agreement or to </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 61 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party its rights and remedies under, this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement may be signed in counterparts, each and every one of which shall be deemed an original. Electronic or Facsimile signatures shall be treated as original signatures. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16 &#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;The remainder of this page is left blank intentionally.&#93; </font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 62 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first written above. </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PATHEON UK LIMITED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FLEXION THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.M. Botterill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael D. Clayman, M.D.</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.M. Botterill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael D. Clayman, M.D.</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exec. Dir. &#38; Gen. Manager</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEO</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93;</font></td></tr></table></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- 63 - </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 2.9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 64-65. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64-65 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 1.60 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 66-71. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66-71 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 1.62 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 1.82 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 2.1(a) </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93;</font></td></tr></table></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 74-80. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74-80 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 6.4(a) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 81-83. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81-83 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 8.4(a) </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 84-85. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84-85 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AMENDMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">First Amendment to the Manufacturing and Supply Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is between Flexion Therapeutics, Inc., having its principal office at 10 Mall Road, Burlington MA, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Patheon UK Limited, having a principal place of business at Kingfisher Drive, Covingham, Swindon, Wiltshire SN35BZ, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#59; individually, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This Amendment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is dated 8 May 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Flexion and Patheon entered into a Manufacturing and Supply Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing and Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on 31 July 2015, pursuant to which Patheon provides manufacturing services for Flexion&#8217;s FX006 drug product (ZILRETTA) (an extended-release formulation of triamcinolone acetonide).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have agreed to initiate construction of the area referred to as the Phase III manufacturing suite at Patheon&#8217;s facility and to incur certain capital expenditures to facilitate the manufacture of Flexion&#8217;s product in this manufacturing suite.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing and the mutual promises, covenants and agreements set forth below and in the Manufacturing and Supply Agreement, and for other good and valuable consideration, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties hereto, intending to be legally bound, do hereby agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.Definitions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Defined terms in this Amendment Agreement shall have the same meaning as those in the Manufacturing and Supply Agreement as applicable unless otherwise indicated.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.Amendments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Manufacturing and Supply Agreement shall be amended such that the following Schedules or parts of Schedules to the Manufacturing and Supply Agreement shall be replaced as set out in the Exhibits attached to this Amendment Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 2.9 (Equipment)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Phase III and Combined Phases I, II and III of Schedule 1.60 (Footprint)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.Effectiveness of Amendments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The amendments to the Manufacturing and Supply Agreement set forth herein shall be effective as of the Amendment Effective Date. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.Integration</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except for the sections of the Manufacturing and Supply Agreement specifically amended hereunder, all terms and conditions of the Manufacturing and Supply Agreement remain and shall remain in full force and effect. This Amendment Agreement shall hereafter be incorporated into and deemed part of the Manufacturing and Supply Agreement and any future reference to the Manufacturing and Supply Agreement shall include the terms and conditions of this Amendment Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.Governing Law and Jurisdiction</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the laws that govern the Manufacturing and Supply Agreement, and the Parties submit to the jurisdiction and dispute resolution provisions as set forth in the Manufacturing and Supply Agreement.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have caused this Amendment Agreement to be executed by their duly authorized representatives, effective as of the date of the last signature.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:45.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FLEXION THERAPEUTICS, INC.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Michael D. Clayman, M.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PATHEON UK LTD.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Luca Andretta</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael D. Clayman, M.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Luca Andretta</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CEO</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">May 9, 2019</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">May 12, 2019</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 1 of the Amendment Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 2 of the Amendment Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AMENDMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Second Amendment to the Manufacturing and Supply Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is between Flexion Therapeutics, Inc., having its principal office at 10 Mall Road, Burlington MA, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Patheon UK Limited, having a principal place of business at Kingfisher Drive, Covingham, Swindon, Wiltshire SN35BZ, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#59; individually, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This Amendment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is dated 17 June 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Flexion and Patheon entered into a Manufacturing and Supply Agreement on 31 July 2015 as amended by the First Amendment Agreement dated 8 May 2019, (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing and Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to which Patheon provides manufacturing services for Flexion&#8217;s FX006 drug product (ZILRETTA) (an extended-release formulation of triamcinolone acetonide).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have agreed to amend certain pricing terms and other related terms of the Manufacturing and Supply Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing and the mutual promises, covenants and agreements set forth below and in the Manufacturing and Supply Agreement, and for other good and valuable consideration, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties hereto, intending to be legally bound, do hereby agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.Definitions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Defined terms in this Amendment Agreement shall have the same meaning as those in the Manufacturing and Supply Agreement as applicable unless otherwise indicated.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.Amendments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Manufacturing and Supply Agreement shall be amended such that the original Schedule 2.1(a) to the Manufacturing and Supply Agreement shall be deleted and replaced in its entirety with new Schedule 2.1(a), as set forth in Exhibit 1 to this Amendment Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.Memorialization of Understanding. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For additional clarity, the Parties understand and agree that the definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patheon Nonconformance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for the purposes of the Agreement, is inclusive of (i) Patheon&#8217;s &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in connection with performing (or failing to perform), &#91;***&#93; pursuant to Section &#91;***&#93;, and (ii) Patheon&#8217;s &#91;***&#93; &#91;***&#93; in connection with providing (or failing to provide), the &#91;***&#93; in accordance with the &#91;***&#93;. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.Effectiveness of Amendments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The amendments to the Manufacturing and Supply Agreement set forth herein shall be effective as of the Amendment Effective Date. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.Integration&#59; Counterparts</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except for the sections or schedules of the Manufacturing and Supply Agreement specifically amended hereunder, all terms and conditions of the Manufacturing and Supply Agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remain and shall remain in full force and effect. This Amendment Agreement shall hereafter be incorporated into and deemed part of the Manufacturing and Supply Agreement and any future reference to the Manufacturing and Supply Agreement shall include the terms and conditions of this Amendment Agreement. This Amendment Agreement may be executed in counterparts, each of which is deemed an original, but all of which together are deemed to be one and the same agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.Governing Law and Jurisdiction</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the laws that govern the Manufacturing and Supply Agreement, and the Parties submit to the jurisdiction and dispute resolution provisions as set forth in the Manufacturing and Supply Agreement.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have caused this Amendment Agreement to be executed by their duly authorized representatives, effective as of the date of the last signature.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:45.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FLEXION THERAPEUTICS, INC.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Michael D. Clayman, M.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PATHEON UK LTD.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Luca Andretta</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael D. Clayman, M.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Luca Andretta</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CEO</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">June 21, 2019</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">June 21, 2019</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 1 of the Amendment Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>7
<FILENAME>pcrx-12312021xex1037.htm
<DESCRIPTION>EX-10.37
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i07702cdc63324ab492b180a344ef1ef2_33"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.37</font></div></div><div><font><br></font></div><div id="i07702cdc63324ab492b180a344ef1ef2_60"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TECHNICAL TRANSFER AND SERVICE AGREEMENT </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">***Text Omitted and Filed Separately </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">with the Securities and Exchange Commission. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confidential Treatment Requested </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Under 17 C.F.R. Sections 200.80(b)(4) </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">and 240.24b-2. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TECHNICAL TRANSFER AND SERVICE AGREEMENT </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TECHNICAL TRANSFER AND SERVICE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), dated as of July 31, 2015 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), is made by and between Flexion Therapeutics, Inc., a Delaware corporation having its principal place of business at 10 Mall Road, Suite 301, Burlington, Massachusetts, United States (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and Patheon UK Limited, a company incorporated in England and Wales having its principal place of business at Kingfisher Drive, Covingham, Swindon, SN35BZ, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Flexion and Patheon are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECITALS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, Flexion has a commercial interest in the Manufacture (as defined herein) and commercialization of FX006 drug product, an extended-release formulation of triamcinolone acetonide (TCA) which is manufactured using Flexion&#8217;s Manufacturing Process (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, concurrently herewith, the Parties are executing a manufacturing and supply agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing and Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) pursuant to which Patheon would be a manufacturer and supplier of the Product&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, in anticipation of the Manufacturing and Supply Agreement and the goods and services that Patheon will supply thereunder, the Parties desire to enter into a binding agreement pursuant to which Patheon would undertake certain technical transfer and construction services in order to validate and scale up portions of Flexion&#8217;s technology package and prepare Patheon&#8217;s facilities for the Manufacture of the Product&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing, the mutual promises and covenants of the Parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows&#58; </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DEFINITIONS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following terms will have the meanings set forth below. Unless the context indicates otherwise, the singular will include the plural and the plural will include the singular. Any term not defined hereunder shall have the meaning ascribed to such term in the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Federal Food, Drug and Cosmetic Act, as amended. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any services requested and approved by Flexion that supplement Patheon&#8217;s regular performance of the Services as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">control with, such Person. For the purposes of this Section 1.3 only, a Person will be regarded as in control of another Person if such Person owns, or directly or indirectly controls, more than 50% of the voting securities (or comparable equity interests) or other ownership interests of the other Person, or if such Person directly or indirectly possesses the power to direct or cause the direction of the management or policies of the other Person, whether through the ownership of voting securities, by contract, or any other means whatsoever. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble hereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">API</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the active pharmaceutical ingredient triamcinolone acetonide, micronized. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means applicable United States, Canadian, English and other foreign federal, state, and local laws, orders, rules, regulations, guidelines, standards, customs and ordinances, including, without limitation, those (to the extent they are applicable) of the FDA, Health Canada, the Medicines and Healthcare Products Regulatory Agency in the United Kingdom and other comparable foreign Regulatory Authorities, including the Food Drug and Cosmetic Act. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Base Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the monthly fee paid by Flexion in consideration for the Services, as more specifically set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of the Manufacturing and Supply Agreement. For the avoidance of doubt, Base Fees do not include Capital Expenditures, Product Fees (as defined in the Manufacturing and Supply Agreement), Material Costs (as defined in the Manufacturing and Supply Agreement), or charges for Bill Back Items or Additional Services. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bill Back Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means items and services set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of the Manufacturing and Supply Agreement that are used or necessary in connection with the Manufacture of the Products and which result in a nominal cost to Flexion. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Capital Expenditures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Analysis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 1.8a of the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.11 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.6. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.3(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Completion of the Tech Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means ownership or the right by a Party to assign or grant a license or sublicense under intellectual property rights to the other Party of the scope set forth herein, without breaching the terms of any agreement with a Third Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Discretionary Manufacturing Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Exhibit 2.1-F. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the European Medicines Agency. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any equipment used in the Manufacture of the Product as more fully set forth in Section 2.9 of the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means to make, have made, import, use, sell, offer for sale, receive or otherwise dispose of the Product or process, including the research, development (including the conduct of clinical trials), registration, modification, enhancement, improvement, Manufacture, storage, formulation, optimization, export, transport, distribution, promotion, or marketing of the Product or process. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Facility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the facility of Patheon located at Kingfisher Drive, Swindon, Wiltshire SN3 5BZ, United Kingdom. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the United States Food and Drug Administration and any successor organization thereto and all agencies under its direct control. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.2. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Manufacturing Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion&#8217;s Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the proprietary process owned or Controlled by Flexion for Manufacturing the Product as disclosed by Flexion to Patheon, and each intermediate of the Product, as established as of the Effective Date, including, without limitation, as set forth in the investigational new drug application filed with the FDA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and, when applicable, as set forth in the NDA as may be filed with, and approved by, the FDA. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion On Site Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 0(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.27 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the current good manufacturing practices applicable from time to time to the Manufacturing of the Product, or any intermediate of the Product, pursuant to Applicable Law, including those promulgated under the Act at 21 C.F.R. (chapters 210 and 211), and those promulgated under EC Directive 2003&#47;94&#47;EC, together with the latest FDA and EMA guidance documents pertaining to manufacturing and quality control practices, all as updated, amended and revised from time to time. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.3(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.3(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.3(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.31 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Key Technical Assumptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.32 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any claims, lawsuits, losses, damages, liabilities, penalties, costs, and expenses (including reasonable attorneys&#8217; fees and disbursements). </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the maintenance of Equipment and Facilities in satisfactory operating condition, including the performance of systematic inspection and service of Equipment pursuant to the applicable Standard Operating Procedures of Patheon, as reviewed and agreed to by Flexion (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Equipment Standard Operating Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), or the manufacturer&#8217;s terms of operation and recommended procedures. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Make Good Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.11(c). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.35 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the manufacturing, processing, formulating, sterilization, filling, packaging, labelling, storage, handling, and quality control testing of Materials or the Product as more particularly set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.36 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing and Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Recitals. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Suite</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the manufacturing suite at the Facility capable of Manufacturing the Product pursuant to Flexion&#8217;s Manufacturing Process, whose footprint is attached as Exhibit 2.1-A, together with the areas identified in the plan attached as Exhibit 2.1-A as the areas for the bulk powder Manufacture and bulk vial filling and, pursuant to the terms of Section 2.10 of the Manufacturing and Supply Agreement, the Phase I Filling Space. The footprint of the Manufacturing Suite and the engineering approach shall be revised by the Parties in order to adapt the Manufacturing Suite to Flexion&#8217;s Manufacturing Process, as set forth in Section 2.1 hereto. Such footprint is diagrammatic in nature and is intended to generally depict the location and approximate size of current and future spaces allocated to Flexion. Such footprint may be amended to be specifically adapted to the Manufacture of the Product, and the Parties shall agree upon the definitive footprint, taking into account parameters such as the exact design of the space, space classifications, code requirements, equipment, materials, personnel, waste stream process flows, equipment sizing and utility requirements. For purposes of clarity, prior to the Phase III Manufacturing Suite Clearance Date (as defined in Section 2.10 of the Manufacturing and Supply Agreement), the definition of Manufacturing Suite shall include the Phase I Filling Space. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means all API, excipients and processing aids, and processing, filling and packaging components, used in connection with the Manufacture of the Product and listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of the Manufacturing and Supply Agreement, as amended prior to Product launch, based on the Parties&#8217; most recent usage experience rate, and to reflect changes to the Specifications. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the new drug application for a product, including the Product, requesting permission to place a drug on the market in accordance with 21 C.F.R. Part 314, and all supplements filed pursuant to the requirements of the FDA, including all documents, data, and other information filed concerning such product that are necessary for FDA approval to market such product in the Territory. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">NDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#8220;national drug code,&#8221; a unique three-segment number, which is a universal product identifier for human drugs. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Preamble. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 7.1. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Manufacturing Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture, or other similar entity or organization, including a government or political subdivision, department, or agency of a government. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.46 Not used. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the Recitals hereto, in finished, unpackaged form, according to the Specifications. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.7(c). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning given in the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1 of the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.51 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any and all approvals (including pricing and reimbursement approvals), licenses, registrations, or authorizations of any Regulatory Authority necessary to Exploit the Product in any country in the Territory, including any (a) approval of a Product, Marketing Authorization and supplements and amendments thereto&#59; (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto)&#59; (c) labelling approval&#59; and (d) technical, medical, and scientific licenses. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any applicable supra-national, federal, national, regional, state, provincial, or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities regulating or otherwise exercising authority with respect to the Exploitation of the Product in the Territory. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Remediation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.5. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Required Manufacturing Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Exhibit 2.1-F. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the (a) Manufacturing Services performed by Patheon pursuant to the Manufacturing and Supply Agreement&#59; and (b) the Transfer Services performed by Patheon under this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Specifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the specifications for each presentation of Product (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the dosage forms in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of the Manufacturing and Supply Agreement) given by </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion to Patheon relating to the specifications of the Materials&#59; the manufacturing specifications, directions and processes&#59; the storage requirements&#59; all environmental, health and safety information for the Product including material safety data sheets and the finished Product specifications, specifications for bulk and primary packaging and shipping requirements for the Product, as amended, modified, or supplemented from time to time. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.7(e). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means all forms of taxation and statutory, governmental, state, federal, provincial, local, government or municipal charges, duties, imposts, contributions, levies, withholding or liabilities wherever chargeable and whether of the United Kingdom or any other jurisdiction (including for the avoidance of doubt, national insurance contributions in the United Kingdom) and any penalty, fine, surcharge, interest, charge, charges or costs thereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means &#91;&#8230;***&#8230;&#93; and other territories agreed by the Parties pursuant to Section 2.2(h) of the Manufacturing and Supply Agreement from time to time. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a Person who is neither a Party nor an Affiliate of a Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Losses incurred as a result of claims brought by Third Parties. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Timeline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.1. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the services rendered under this Agreement, as described in Section 2.1 and in the Exhibits attached to this Agreement, based on the Key Technical Assumptions stated therein. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.15(c). </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE 2 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">TRANSFER SERVICES </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description of Transfer Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon will (a) provide engineering and construction services, directly or using third parties (pursuant to Section 9.8 hereto), to construct the Manufacturing Suite in accordance with the engineering approach and the footprints set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of this Agreement, as it may be amended by mutual written agreement of the Parties, and the projected capital requirements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, (b) procure and&#47;or validate the Equipment necessary to Manufacture the Product in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and perform the Transfer Services set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, and (c) provide other services set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in order to validate and implement Flexion&#8217;s Manufacturing Process for the Product in compliance with the Quality Agreement, GMP, all other Applicable Law and the Specifications and register the Facility to Manufacture the Product (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Patheon will perform the Transfer Services, (i) to facilitate the Regulatory Approval of the Manufacturing Suite as the manufacturing, testing, and packaging sites for the Product, (ii) so that the Product is Manufactured and tested using Flexion&#8217;s Manufacturing Process including testing and releasing (pursuant to the terms of the Quality Agreement) all Materials according to the Specifications and test methods, including the Specifications set forth in the NDA when approved. Patheon will use its commercially reasonable efforts to complete the Transfer Services in a timely fashion in accordance with the schedule set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Timeline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). The Parties will cooperate with one another in the performance of this Agreement in good faith. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Payments for Transfer Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Parties acknowledge and agree that Patheon&#8217;s consideration for the Transfer Services performed hereunder is (a) the payment of the Base Fees, as set forth in Schedule 2.1(a) of the Manufacturing and Supply Agreement, (b) the payments associated with the Equipment, Manufacturing Suite construction and related process and support and validation services, each in accordance with the capital requirements set forth in Exhibit 2.1-B (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Capital Expenditures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; (c) charges for Bill Back Items&#59; and (d) charges for Additional Services. All payments from Flexion to Patheon hereunder shall be in British Pounds (GBP) and will be due and payable in accordance with the invoicing procedures set forth in ARTICLE IV of the Manufacturing and Supply Agreement. All invoices from Patheon to Flexion for Capital Expenditures shall include all (if any) applicable invoices from vendors for the supply, transportation, installation, and commissioning of the Equipment that pertain to the Transfer Services invoiced by Patheon. Flexion acknowledges that the amounts of Capital Expenditures are estimates and are subject to review once manufacturing details and process specification requirements have been confirmed, any necessary machine trials performed and upon receipt of formal quotations from the equipment suppliers&#59; provided however that, in no event shall the Capital Expenditures exceed the amount set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> by more than &#91;&#8230;***&#8230;&#93; percent (&#91;&#8230;***&#8230;&#93;%) unless otherwise mutually agreed by the Parties in writing. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Parties may modify and agree upon the definitive engineering approach, footprint of the Manufacturing Suite, or the Timeline, taking into account parameters such as the exact design of the space, space classifications, code requirements, Equipment, </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">materials, personnel, waste stream process flows, equipment sizing and utility requirements. Any such modifications shall be discussed by the Parties and agreed to in writing including as to any consequential fees and costs or savings relating thereto, duly executed by the Parties. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion&#8217;s Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) To assist Patheon in its performance of the Transfer Services under this Agreement, Flexion shall (i) at its expense provide Patheon in a timely fashion with relevant information, documentation, and data relating to (1) Flexion&#8217;s Manufacturing Process, (2) the Equipment necessary to Manufacture the Product in accordance with Flexion&#8217;s Manufacturing Process, and (3) Product safety and information, documentation, and data, including any applicable NDA numbers, NDC codes, &#8220;CMC&#8221; sections of NDAs, validation protocols, validation reports, method validation protocols, method validation reports, and other documents necessary or reasonably requested by Patheon for Patheon to Manufacture the Product, provide the Transfer Services or otherwise necessary for Patheon&#8217;s performance hereunder, and (ii) provide Flexion-Supplied Materials pursuant to Section 2.10. If requested by Patheon to provide support or information, Flexion shall use commercially reasonable efforts to provide such reasonable and necessary support or information in order to enable Patheon to perform the Transfer Services under this Agreement as soon as reasonably possible and in any event within &#91;&#8230;***&#8230;&#93; business days of Patheon&#8217;s request (or will provide an explanation of the legitimate reason for any delay and a projected date by which such support or information will be provided). In the event Flexion is to review or approve any information, documentation, data, or samples prepared or supplied by or on behalf of Patheon, it will complete such review and approval process as soon as reasonably possible and in any event within &#91;&#8230;***&#8230;&#93; business days of Patheon&#8217;s request. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) It is understood and acknowledged by the Parties that Flexion will retain ownership of the IND and NDA to the Product, and any supplements thereto, and is responsible for the NDA submission documents and all correspondence with the FDA and other competent Regulatory Authority concerning the Product, other than submission documents and correspondence associated with GMP inspections of the Facility&#59; provided, however, that Section 2.9 of this Agreement and Sections 3.6 and 5.1 of the Manufacturing and Supply Agreement will govern the ownership of the intellectual property rights described or disclosed in such NDA and supplements. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Flexion shall have the sole responsibility for the filing of all documents with all applicable Regulatory Authorities, and to take any other actions that may be required for the receipt of Regulatory Approval for the development or commercial manufacture of the Product (other than the licences, registrations and Regulatory Authority approvals to be obtained by Patheon pursuant to Section 3.3(b) of the Manufacturing and Supply Agreement). Flexion will, at its expense and in cooperation with Patheon, use commercially reasonable efforts to diligently and proactively pursue Regulatory Approval for Patheon&#8217;s Manufacture of the Product at the Facility in a timely fashion in accordance with the Timeline. Without limiting such obligation, Flexion shall be responsible for filing the NDA submission documents, drug listing the Product, </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and completing correspondence with the FDA concerning the Product. All documentation and data provided by Patheon in support of the NDA filing shall be accurate and true and will reflect the current processes and procedures in place at Patheon. Flexion shall provide Patheon with a copy of any Regulatory Approval relevant to this Agreement on request including any Regulatory Approval required for the storage, receipt or distribution of the Product by Flexion or its designee. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Where documents or data generated by Patheon in relation to the Transfer Services are to be filed by Flexion with any Regulatory Authority and such filing includes data or information pertaining to a Patheon Regulatory Obligation within the meaning of Section 3.15 of the Manufacturing and Supply Agreement, prior to filing any such documents and data with the Regulatory Authority, Flexion shall provide Patheon with a copy of the documents incorporating such data so as to give Patheon the opportunity to review the accuracy of such documents as it relates to the Patheon Regulatory Obligation in accordance with the review and comment procedures set forth in Section 3.15 of the Manufacturing and Supply Agreement (including the process for resolution of inaccuracies set forth in Section 3.15(c) thereto). Notwithstanding anything in Section 3.15 of the Manufacturing and Supply Agreement to the contrary&#58; (i) at least &#91;&#8230;***&#8230;&#93; calendar days prior to filing with the Regulatory Authority any documentation which is or is equivalent to the Quality document portion (Drug Product section) of the U.S. Investigational New Drug application, the EU Clinical Trial application and Investigational Medicinal Product Dossier, the Common Technical Document module 3 (Drug Product section) of the US New Drug Application, U.S. Biological License Application, or the EU Marketing Authorization Application, as the case may be, Flexion shall provide Patheon with a copy of the Initial Draft (as defined in the Manufacturing and Supply Agreement) of such portion so as to permit Patheon to verify that the Initial Draft accurately describes the development and validation work Patheon has performed and the manufacturing and control processes that Patheon will perform pursuant to this Agreement&#59; (ii) Patheon shall provide comments regarding such Initial Draft no later than &#91;&#8230;***&#8230;&#93; days prior to the required filing date with the applicable Regulatory Authority (including notifying Flexion of any identified inaccuracies)&#59; and (iii) Flexion shall deliver a copy of the final version of the filing promptly after the required filing date. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon&#8217;s Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon will, at its expense, in consideration for the payments and reimbursements set forth in Section 2.2, provide the Transfer Services and use its commercially reasonable efforts to complete the Transfer Services in a timely fashion in accordance with the Timeline. Patheon will provide to Flexion all data and documentation necessary or reasonably useful to support Flexion&#8217;s submissions to the FDA, or any responses to questions raised by the FDA with respect to those Transfer Services, that are necessary or reasonably useful for Regulatory Approval of the Facility as the manufacturing, testing, and packaging site for the Product. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon, acting as Flexion&#8217;s agent, shall purchase the Flexion Manufacturing Equipment on Flexion&#8217;s behalf. Title to all Flexion Manufacturing Equipment will be held by Flexion. The Parties shall procure, supply, install, commission and validate the </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment in compliance with (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; (b) the capital requirements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and (c) the &#8220;Qualification and Validation&#8221; process set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon is authorized to use the Flexion Manufacturing Equipment pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> solely for the purposes of performing the Transfer Services and for the Manufacturing Services as set forth in the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion On Site Representatives&#59; Reporting of Results&#59; Project Managers&#59; Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Flexion shall have the right at all times throughout the Term to have &#91;&#8230;***&#8230;&#93; representatives (or other number as reasonably requested by Flexion after discussion by the members of the Steering Committee) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion On Site Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) present in that portion of the Facility that is being constructed or used to Manufacture the Product or store Materials, to observe the procedures and processes used to Manufacture the Product or to perform the activities associated with the transfer of Flexion&#8217;s Technology hereunder. The Flexion On Site Representatives shall have full access to the Manufacturing Suite and to the non-financial records that relate to the Product, and all records pertaining to any Materials and to Third Party invoices specifically invoiced by Patheon to Flexion as a Capital Expenditure or Bill Back Item. For the avoidance of doubt, the term &#8220;non-financial records&#8221; as used in this Agreement does not include the Reports (defined in Section 3.11 of the Manufacturing and Supply Agreement). Patheon shall provide reasonable (semi-permanent) on-site accommodations at the Facility for the Flexion On Site Representatives (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, office space). Flexion On Site Representatives shall be appropriately trained by Flexion (e.g. GMP training) and shall observe at all times Patheon&#8217;s policies and procedures (as amended from time to time) as they pertain to the Facility, including policies relating to health and safety and compliance with GMP&#59; provided that Flexion is given notice of such policies and given a reasonable period of time to review and implement such policies. Flexion will comply with all reasonable directions of Patheon in relation to the same. Patheon may refuse or limit in its sole discretion at any time admission to the Facility by any Flexion On Site Representative who fails to observe such policies or comply with such reasonable directions. For the avoidance of doubt, Flexion On Site Representatives shall have (i) no management authority over any Patheon employee and (ii) no authority to conclude contracts on behalf of Flexion. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Patheon will respond to Flexion&#8217;s inquiries regarding the status of the Transfer Services on an ongoing basis, and Patheon will endeavor to keep Flexion informed of interim results of the Transfer Services. Patheon will provide copies of all analytical, cleaning, and process validation protocols, data summaries, reports and all batch records, test methods, and specifications for Flexion&#8217;s review, comment, and approval prior to implementation and execution. Once such protocols, data summaries, reports, records, methods, and specifications have been approved and executed, Patheon will provide copies to Flexion. Patheon will provide Flexion with information relating to the Equipment to be used in connection with the Manufacture of the Product, which Equipment will be subject to Flexion&#8217;s review and approval (not to be unreasonably withheld or delayed). Within five (5) business days after Flexion&#8217;s </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">request, Patheon will provide to Flexion documentation that summarizes the implementation efforts of the Transfer Services at the Facility. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Patheon and Flexion will each appoint a project manager (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and, together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Project Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), who will meet as needed to resolve any issues or problems associated with the Transfer Services. Flexion&#8217;s Project Manager may be one of the Flexion On Site Representatives. Flexion reserves the right to request replacement of any personnel assigned by Patheon to perform the Transfer Services hereunder. If Patheon disagrees with such request and the Parties cannot reach resolution on Flexion&#8217;s request for replacement, such request will be discussed by the Steering Committee pursuant to the procedures set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Patheon shall ensure that sufficient numbers of adequately educated and experienced staff are retained at the Facility in order to provide the Transfer Services. Patheon shall perform the Transfer Services under the direction of key personnel of Patheon to a project for the duration of the project (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Key Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Key Personnel include the Project Manager, Operational Manager, Quality Manager or other personnel reasonably agreed-to by the Parties. Patheon shall provide information on the qualifications and background of all proposed Key Personnel prior to such Key Personnel&#8217;s commencement of activities under this Agreement on Patheon&#8217;s behalf. Patheon will not remove Key Personnel without Flexion&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed) except in the event of such Key Personnel&#8217;s promotion, resignation, incapacity or death, or termination for cause. Patheon will use commercially reasonable efforts to minimize turnover in Key Personnel, and will provide &#91;&#8230;***&#8230;&#93; business days&#8217; notice to Flexion, whenever practical, of any changes to the Key Personnel, at which point, both Parties shall discuss and reasonable agree on a suitable replacement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) The Parties desire to establish a steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The Parties recognize that disputes may arise from time to time during the term of this Agreement that relate to whether either Party has fulfilled its obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes arising under this Agreement in an expedient manner by mutual cooperation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Section 2.8 if and when a dispute arises under this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Unless otherwise specifically recited in the Agreement, disputes between the Parties under this Agreement will be first referred to the Project Manager of each Party as soon as reasonably possible after such dispute has arisen. If the Project Managers are unable to resolve such a dispute within &#91;&#8230;***&#8230;&#93; days of being requested by a Party to resolve such dispute, either Party may, by written notice to the other, have such dispute referred to the </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steering Committee. If the Steering Committee is unable to resolve such a dispute within &#91;&#8230;***&#8230;&#93; day of being requested by a Party to resolve such dispute, either Party may, by written notice to the other, have such dispute referred to the &#91;&#8230;***&#8230;&#93; of each Party for attempted resolution by negotiations within &#91;&#8230;***&#8230;&#93; days after such notice received. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Parties&#8217; intellectual property ownership rights relating to the subject matter of this Agreement shall be governed by ARTICLE V of the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon will purchase all Patheon-Supplied Materials (as defined in the Manufacturing and Supply Agreement) for the Transfer Services as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of the Manufacturing and Supply Agreement. Flexion shall purchase all Flexion-Supplied Materials (as defined in the Manufacturing and Supply Agreement) for the Transfer Services and ship such Flexion-Supplied Materials to Patheon in accordance with this Section 2.10 (except as otherwise mutually agreed to by the Parties in writing, in which case such Materials shall be considered Bill Back Items hereunder). All shipments from Flexion to Patheon will be made DDP (Incoterms 2010) the Facility unless otherwise agreed. All shipments of Flexion-Supplied Materials, if required, will be accompanied by Certificate(s) of Analysis from the Material manufacturer or Flexion, confirming its compliance with the Material&#8217;s specifications. Flexion will obtain the proper release of the Flexion-Supplied Materials from the applicable customs agency and Regulatory Authority. Flexion or Flexion&#8217;s designated broker will be the &#8220;Importer of Record&#8221; for Flexion-Supplied Materials imported to the Facility. Flexion-Supplied Materials will be held by Patheon on behalf of Flexion as set forth in this Agreement. Title to Flexion-supplied Materials will at all times remain the property of Flexion or a Flexion Affiliate. Any Flexion-Supplied Materials received by Patheon will only be used by Patheon to perform the Transfer Services or associated activities necessary to perform the Transfer Services (e.g., media fills or validation runs). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bill Back Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Bill Back Items will be charged to Flexion at Patheon&#8217;s cost plus a &#91;&#8230;***&#8230;&#93;% handling fee. Patheon shall invoice Flexion monthly for any Bill Back Items used in connection with the Transfer Services during the preceding month in accordance with ARTICLE IV of the Manufacturing and Supply Agreement. Patheon may only invoice Bill Back Items that have been quoted to and approved in writing by Flexion&#8217;s Project Manager, or otherwise mutually agreed to by the parties in advance. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If Flexion is interested in having Patheon perform Additional Services, Flexion will provide Patheon with a written request containing sufficient detail to enable Patheon to provide Flexion with a quote and proposal to provide such Additional Services. Patheon may only invoice for Additional Services that have been quoted to and approved in writing by Flexion&#8217;s Project Manager and that have been agreed in writing by the Parties in a Change of Scope Agreement. Patheon shall invoice Flexion monthly for any Additional Services performed by Patheon during the preceding month in accordance with ARTICLE IV of the Manufacturing and Supply Agreement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Storage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon will provide storage capacity to support storage of the required quantity of Materials necessary for Transfer Services which will be governed by Section 2.2(e) of the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Shipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except to the extent set forth otherwise in this Agreement, any shipment from Patheon to Flexion, whether of Product, Materials or otherwise, shall be made pursuant to Section 2.3(e) of the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Changes in Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Should during the Term of this Agreement, a change or changes in Applicable Law lead to Patheon (a) providing services not originally contemplated by Patheon, or (b) incurring increased costs in order to comply with said change or changes, any such services or costs (to the extent pertaining to the Product or related to Flexion&#8217;s Manufacturing Process or the Flexion Manufacturing Equipment) shall constitute an Additional Service subject to mutual written agreement of the Parties&#59; provided that, if such services or costs relate generically to the entire Facility then such costs to Flexion shall be prorated as applicable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Base Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon will invoice Flexion monthly in advance for the Base Fees, and such Base Fees will be due and payable, in accordance with the provisions and invoicing procedures set forth in ARTICLE IV of the Manufacturing and Supply Agreement. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE 3 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CONFIDENTIALITY </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Parties agree that the terms of ARTICLE VII of the Manufacturing and Supply Agreement shall govern the confidentiality obligations of the Parties and are incorporated herein by this reference. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE 4 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">FLEXION&#8217;S REPRESENTATIONS, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">WARRANTIES, AND COVENANTS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except where specifically stated to the contrary in this Agreement otherwise, Flexion will use its commercially reasonable efforts to perform Flexion&#8217;s obligations hereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Representations, Warranties, and Covenants of Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Flexion warrants, represents, and covenants that as of the Effective Date the warranties, representations and covenants set out in Sections 6.4(a) of the Manufacturing and Supply Agreement shall apply to the performance of the Transfer Services. </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">PATHEON&#8217;S REPRESENTATIONS, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">WARRANTIES, AND COVENANTS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patheon represents, warrants, and covenants to Flexion as follows&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except where specifically stated to the contrary in this Agreement otherwise, Patheon will use its commercially reasonable efforts to perform the Transfer Services in accordance with the agreed upon Timeline. In the event Patheon is not able to meet the Timeline, Patheon will provide written notice to Flexion of such inability as soon as practical, but in any event within &#91;&#8230;***&#8230;&#93; of discovering such inability. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Personnel and Transfer Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon will engage and employ professionally qualified personnel to perform the Transfer Services contemplated hereunder. Patheon represents and warrants that there is no claim, suit, proceeding, or other investigation issued on Patheon, or to the knowledge of Patheon (after due inquiry), pending or threatened against Patheon, which is likely to prevent or materially adversely affect the rights and interests of Flexion hereunder or keep Patheon from performing its obligations hereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Representations, Warranties, and Covenants of Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon warrants, represents, and covenants that&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) (i) it has facilities, personnel, experience, and expertise sufficient in quality and quantity to perform the obligations hereunder, (ii) it shall so perform in conformity with GMPs where applicable, and (iii) its management shall establish, and Patheon shall observe and comply with, appropriate quality assurance, quality controls, and review procedures for implementation of the Transfer Services&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) it has at the Effective Date and shall during the Term observe and comply with, at (subject to Section 2.14) its sole cost and expense, all Applicable Laws now in force or that may hereafter be in force, including federal, state, and local laws, orders, regulations, rules, customs, and ordinances now in force or that may hereafter be in force pertaining to Patheon&#8217;s performance of the Transfer Services and the Facility and including, without limitation, (i) labor laws, orders, regulations, rules, customs, and ordinances and (ii) those of the FDA pertaining to Patheon&#8217;s performance of the Transfer Services and the Facility, and any laws, orders, regulations, rules, or ordinances issued in addition to, as a supplement to or as a replacement of Applicable Laws. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) none of it, its Affiliates, nor any Person under its direction or control has ever been, nor will it engage suppliers which have to its actual knowledge, after due inquiry, been, (i) debarred or convicted of a crime for which a person can be debarred, under Section 335(a) or 335(b) of the Act, or any equivalent Applicable Law of the country of Manufacture, (ii) threatened to be debarred under the Act or any equivalent Applicable Law of the country of Manufacture or (iii) indicted for a crime or otherwise (to its actual knowledge after due inquiry) </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">engaged in conduct for which a person can be debarred under the FDA or any equivalent Applicable Law of the country of Manufacture, and Patheon agrees that it will, within &#91;&#8230;***&#8230;&#93;, notify Flexion in the event it receives notification of any such debarment, conviction, threat or indictment. Should Patheon become aware of any actual or suspected noncompliance with the foregoing, Patheon will notify Flexion in writing of such issue within &#91;&#8230;***&#8230;&#93;. For the purpose of this Section 5.3, suppliers and subcontractors engaged by Patheon to undertake the Manufacture of the Product shall be deemed to be under Patheon&#8217;s direction or control&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) none of it, its Affiliates, nor any Person under its direction or control is currently excluded from a federal or state health care program under Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. &#167;&#167; 1320a-7, 1320c-5 or any equivalent Applicable Law of the country of Manufacture, as may be amended or supplemented&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) none of it, its Affiliates, nor any Person under its direction or control is otherwise currently excluded from contracting with the U.S. federal government or the government of the country of Manufacture&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) none of it, its Affiliates, nor any Person under its direction or control is otherwise currently excluded, suspended, or debarred from any U.S. or foreign governmental program&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g) it shall immediately notify Flexion if, at any time during the Term, Patheon, its Affiliates, or any Person under its direction or control is convicted of an offense that would subject it or Flexion to exclusion, suspension, or debarment from any U.S. or foreign governmental program&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h) it will not enter into any agreement or arrangement with any other Person that would prevent its ability to perform its obligations hereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Section 6.6 of the Manufacturing and Supply Agreement shall apply to this Agreement and any violation thereof by Patheon or its employees, agents, or contractors in the performance of this Agreement shall constitute a material default for the purpose of Section 8.5 of this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. THE FOREGOING EXPRESS WARRANTIES AND THOSE IN ARTICLE 4 and ARTICLE 6 ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT, AND ALL OTHER WARRANTIES ARE HEREBY DISCLAIMED AND EXCLUDED BY EACH PARTY. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE 6 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">GENERAL REPRESENTATION AND WARRANTIES </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each Party represents, warrants, and covenants to the other as follows&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Power and Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Such Party (a) is duly formed and in good standing under the laws of the jurisdiction of its formation, (b) has the power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder, and (c) has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid, and binding obligation of such Party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other similar laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity. Except for the FDA&#8217;s approval of Patheon&#8217;s manufacturing, testing, and packaging for the Product from the Manufacturing Suite, all necessary consents, approvals, and authorizations of all Regulatory Authorities, other governmental authorities, and other Persons required to be obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The execution and delivery of this Agreement and the performance of such Party&#8217;s obligations hereunder (a) do not and will not conflict with or violate any requirement of Applicable Law or any provision of the articles of incorporation, bylaws, limited partnership agreement, or other constituent document of such Party and (b) do not and will not conflict with, violate, or breach, or constitute a default or require any consent under, any contractual obligation or court or administrative order by which such Party is bound. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Party and its Affiliates, and their respective representatives, shall comply with all Applicable Laws in the performance of their obligations under this Agreement. Without limiting the foregoing, each Party and its Affiliates, and their respective representatives, shall comply with export control laws and regulations of the country of Manufacture and of the United States. Neither Party nor its Affiliates (or representatives) shall, directly or indirectly, without prior U.S. government authorization, export, re-export, or transfer the Product to any country subject to a U.S. trade embargo, to any resident or national of any country subject to a U.S. trade embargo, or to any person or entity listed on the &#8220;Entity List&#8221; or &#8220;Denied Persons List&#8221; maintained by the U.S. Department of Commerce or the list of &#8220;Specifically Designated Nationals and Blocked Persons&#8221; maintained by the U.S. Department of Treasury. In so far as the same applies to a Party or its Affiliates, each Party and its Affiliates and respective representatives shall comply with the requirements of the Foreign Corrupt Practices Act of 1977 (15 U.S.C. &#167; 78dd-1, et seq.). </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">INDEMNIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Flexion will indemnify Patheon, its Affiliates, and their respective directors, officers, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Patheon Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and defend and save each of them harmless from and against any and all (i) Third Party Loss incurred by any of them in connection with, arising from, or occurring as a result of (a) any claim of personal injury or property damage to the extent that the injury or damage is the result of or arises other than from a breach of this Agreement by Patheon, (b) a claim that the Transfer Services performed by Patheon hereunder, in accordance with the terms and conditions of this Agreement, infringes or misappropriates a patent or any other intellectual property rights, if it is a claim related to the use of Flexion Manufacturing Equipment, Existing Flexion Intellectual Property (as defined in the Manufacturing and Supply Agreement), Flexion Improvements (as defined in the Manufacturing and Supply Agreement) or the Manufacturing Process or the Product, (c) any negligence or willful misconduct by Flexion or any of its Affiliates, or (d) any breach by Flexion of any of its obligations or any inaccuracy of any of Flexion&#8217;s warranties under this Agreement, or (ii) any Loss incurred by any of them as a direct result of and to the extent of the negligence or willful misconduct of the Flexion On Site Representatives at the Facility, except, in each case, for those Losses for which Patheon has an obligation to indemnify the Flexion Indemnified Parties pursuant to Section 7.2 below, as to which Losses each Party shall indemnify the other to the extent of their respective liability for such Losses&#59; and provided, however, that Flexion will not be required to indemnify the Patheon Indemnified Parties with respect to any such Loss hereunder to the extent the same is caused by any breach of contract, negligent act or omission, or intentional misconduct by Patheon or any or its Affiliates. For the avoidance of doubt, the parties acknowledge that Patheon has not and will not conduct any freedom to operate searches in relation to the Product and&#47;or Flexion&#8217;s Manufacturing Process nor reviewed any third party patents in relation thereto and that Patheon&#8217;s failure or omission to do so will not be considered negligence for the purposes of excluding or limiting a claim under this indemnity. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Patheon will indemnify Flexion, its Affiliates, and their respective directors, officers, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and defend and save each of them harmless from and against any and all Third Party Loss incurred by any of them in connection with, arising from, or occurring as a result of (a) any claim of personal injury or property damage to the extent that the injury or damage is the result of a failure by Patheon to perform the Transfer Services in accordance with the terms of this Agreement&#59; (b) a claim that any Existing Patheon Intellectual Property (as defined in the Manufacturing and Supply Agreement) or other intellectual property of Patheon employed by Patheon in providing the Transfer Services infringes or misappropriates a United States patent or any other intellectual property rights except to the extent such claim is based on the use of Existing Flexion Intellectual Property, Flexion Improvements, the Manufacturing Process or the Product in accordance with the terms and conditions of this Agreement, (c) any claim of personal injury or property damage to the extent that the injury or damage is the result of any negligence or willful misconduct by Patheon or any of its Affiliates, or (d) any claim of personal injury or property damage to the extent that the injury or damage is the result of any breach by Patheon of any of its obligations or any inaccuracy of any of Patheon&#8217;s warranties under this Agreement&#59; except, in each case, for those Losses for which Flexion has an obligation to indemnify the </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patheon Indemnified Parties pursuant to Section 7.1 above, as to which Losses each Party shall indemnify the other to the extent of their respective liability for such Losses&#59; and provided, however, that Patheon will not be required to indemnify the Flexion Indemnified Parties with respect to any such Loss hereunder to the extent the same is caused by any breach of contract, negligent act or omission, or intentional misconduct by Flexion or any or its Affiliates. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The indemnified Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall give the indemnifying Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) prompt written notice (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification Claim Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) of any Loss, action, or discovery of facts upon which such Indemnified Party intends to base a request for indemnification under Section 7.1 or 7.2 (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), but in no event shall the Indemnifying Party be liable for any Loss that results from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the Claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Loss upon which it intends to seek indemnification. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Control of Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. At its option, the Indemnifying Party may assume the defense of any Claims by giving written notice to the Indemnified Party within &#91;&#8230;***&#8230;&#93; days after the Indemnifying Party&#8217;s receipt of an Indemnification Claim Notice&#59; provided that the assumption of the defense of a Claim by the Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify any Indemnified Party in respect of the Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party&#8217;s Claim. Upon assuming the defense of a Claim, the Indemnifying Party may appoint as lead counsel in the defense of such Claim any legal counsel selected by the Indemnifying Party. In the event the Indemnifying Party assumes the defense of a Claim, the Indemnified Party shall immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by any Indemnified Party in connection with the Claim. Subject to clause (c) below, if the Indemnifying Party assumes the defense of a Claim, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense, or settlement of such Claim. In the event that it is ultimately determined that the Indemnifying Party is not obliged to indemnify, defend, or hold harmless an Indemnified Party from and against any Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including reasonable attorneys&#8217; fees and costs of suit) and any Loss incurred by the Indemnifying Party in its defense of such Claim. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Right to Participate in Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Without limiting Section 7.3(b), any Indemnified Party shall be entitled to participate in, but not control, the defense of a Claim and to employ counsel of its choice for such purpose&#59; provided, however, that such employment shall be at the Indemnified Party&#8217;s own expense unless (i) the employment thereof has been specifically authorized by the Indemnifying Party in writing, (ii) the Indemnifying Party has failed to assume </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the defense and employ counsel in accordance with Section 7.3(b) (in which case the Indemnified Party shall control the defense), or (iii) the interests of the Indemnified Party and the Indemnifying Party with respect to such Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules, or equitable principles. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. With respect to any Loss relating solely to the payment of money damages in connection with a Claim and that will not result in the Indemnified Party&#8217;s becoming subject to injunctive or other relief or otherwise adversely affect the business or reputation of the Indemnified Party in any manner, and as to which the Indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement, or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Claims, where the Indemnifying Party has assumed the defense of the Claim in accordance with Section 7.3(b), the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement, or otherwise dispose of such Loss&#59; provided that it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld or delayed). The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, agree to any settlement or acquiesce to any judgment with respect to a Claim that obligates the Indemnified Party to pay any amount subject to indemnification by the Indemnifying Party or causes the Indemnified Party to admit to any civil or criminal liability. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the Indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party shall cooperate in the defense or prosecution thereof and shall, at the Indemnifying Party&#8217;s expense, furnish such records, information, and testimony, provide such witnesses, and attend such conferences, discovery proceedings, hearings, trials, and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of records and information that are reasonably relevant to such Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party shall reimburse the Indemnified Party for all its reasonable time and out-of-pocket expenses in connection therewith. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Claim shall be reimbursed on a monthly basis in arrears by the Indemnifying Party, without prejudice to the Indemnifying Party&#8217;s right to, contest the Indemnified Party&#8217;s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obliged to indemnify the Indemnified Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) SUBJECT TO SECTION 7.4(b) BELOW, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR (I) ANY (DIRECT OR INDIRECT) LOSS OF PROFITS, OF PRODUCTION, OF ANTICIPATED SAVINGS, OF BUSINESS, OF GOODWILL OR OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USE OF THE PRODUCT OR COSTS OF ANY SUBSTITUTE SERVICES OR (II) FOR ANY OTHER LIABILITY, DAMAGE, COST OR EXPENSE OF ANY KIND INCURRED BY THE OTHER PARTY OF AN INDIRECT OR CONSEQUENTIAL NATURE, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF THE DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE DAMAGES AVAILABLE FOR BREACHES OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 3. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Nothing in this Agreement is intended to limit either Party&#8217;s liability for&#58; (i) death or personal injury caused by its negligence&#59; or (ii) fraud or fraudulent misrepresentation. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) If any part of the Transfer Services provided or procured by Patheon is not materially performed in accordance with the terms of this Agreement, then Flexion&#8217;s sole remedy whether in contract, tort, equity or otherwise (in addition to those expressly set forth in ARTICLE 8) will be for Patheon to repeat that part of the Transfer Service at Patheon&#8217;s cost (provided that where the Transfer Services to be repeated requires Flexion-Supplied Materials, Flexion will provide such Flexion-Supplied Materials and Patheon shall reimburse Flexion for the actual costs for such Flexion-Supplied Materials, including associated shipment costs)&#59; provided that, (i) Patheon shall only be liable to reimburse the costs of any Flexion-Supplied Materials and associated shipment costs &#91;&#8230;***&#8230;&#93;, and (ii) Patheon&#8217;s aggregate liability in each calendar year (liability cap to be pro-rated for partial calendar years) to reimburse the costs of any Flexion-Supplied Materials shall not exceed &#91;&#8230;***&#8230;&#93;% of the &#91;&#8230;***&#8230;&#93; received by Patheon in the &#91;&#8230;***&#8230;&#93; period prior to the month in which the underlying event occurred that gave rise to the liability (e.g. the date of the incident or manufacture) up to a maximum of &#163;&#91;&#8230;***&#8230;&#93;. Patheon shall not be liable to reimburse the cost of any Flexion-Supplied Materials under any other circumstances. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. During the Term and for &#91;&#8230;***&#8230;&#93; thereafter, each Party shall procure and maintain at its own expense from a qualified and licensed insurer liability insurance or indemnity policies, in an amount not less than $&#91;&#8230;***&#8230;&#93; in the aggregate with respect to public and products liability, subject to such deductible or self-retention limits as either Party in its business discretion may elect. Such policies shall insure against liability on the part of each Party and any of its Affiliates, as their interests may appear, due to injury, disability, or death of any person or persons, or injury to property, arising from the distribution of the Products. Each Party will either (a) include the other Party and its officers, employees and consultants as additional insureds on such policies, or (b) ensure that such policy contains an indemnity to principal clause. Promptly following the execution of this Agreement, each Party shall provide to the other a certificate of insurance (i) summarizing the insurance coverage and (ii) identifying any exclusions. Each Party shall promptly notify the other of any material adverse alterations to the terms of this policy or decreases in the amounts for which insurance is provided. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE 8 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">TERM AND TERMINATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement will remain in full force and effect unless and until it expires or is terminated in accordance with the provisions of this ARTICLE 8 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement will expire upon completion of the Transfer Services as described herein or until the Parties agree that the Transfer Services have been completed (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Completion of the Tech Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination by Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Flexion may terminate this Agreement in its entirety (a) prior to the FDA Approval Date by giving Patheon ninety (90) days&#8217; written notice for convenience, in which case, Section 8.11(f) shall apply, or (b) by giving Patheon thirty (30) days written notice if Patheon (due primarily to its acts or omissions) fails to complete Manufacturing Suite construction by the date stated in the Timeline </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> due solely to such failure, Patheon has not Manufactured registration batches in the Manufacturing Suite by &#91;&#8230;***&#8230;&#93;. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination by Mutual Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement may be terminated at any time upon mutual written agreement between the Parties. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Termination for Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Party will have the right to terminate this Agreement at any time upon written notice to the other Party, if such other Party (a) breaches any of the representations, warranties, covenants, or agreements set forth in this Agreement or (b) otherwise defaults in the performance of any of its duties or obligations under this Agreement, which in either case has a material effect on the other Party, and which breach or default is not cured within ninety (90) days after written notice is given to the breaching Party specifying the breach or default (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Remediation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). The aggrieved Party&#8217;s right to terminate this Agreement for a particular breach under this Section 8.5 may only be exercised for a period of one hundred and twenty (120) days following the expiry of the Remediation Period (where the breach has not been remedied) and, if the termination right is not exercised during this period, then the aggrieved Party will be deemed to have waived its right to terminate this Agreement for such breach. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy&#59; Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. To the extent permitted by law, each Party will have the right to terminate this Agreement immediately upon notice to the other Party, if the other Party shall file in any court or agency, pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for arrangement or for the appointment of a receiver or trustee of the other Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof, or if the other Party shall propose or be a party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of its creditors. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cross Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Should either Flexion or Patheon exercise its right to terminate this Agreement or the Manufacturing and Supply Agreement in its entirety (but not in the event of an expiration of this Agreement as set forth in Section 8.2) prior to the FDA Approval Date, then the Manufacturing and Supply Agreement, this Agreement and the Quality Agreement will concurrently and automatically terminate. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Neither the termination nor expiration of this Agreement will release or operate to discharge either Party from any liability or obligation that may have accrued prior to such termination or expiration, including any obligation to pay to the other Party any amounts accrued under this Agreement with respect to the period prior to the effective date of such expiration or termination. Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof will not limit remedies that may otherwise be available in law or equity. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding the giving of any notice of termination pursuant to this ARTICLE 8, each Party will continue to fulfill its obligations under this Agreement at all times until the effective date of any such termination or expiration. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The expiration or termination of this Agreement shall be without prejudice to any rights or obligations of the Parties that may have accrued prior to such termination, and the provisions of Sections 2.2 (as it may relate to any unpaid amounts due and owing), 2.6 (as it may relate to the use to which Patheon may put the Flexion Manufacturing Equipment), 2.8, 2.9 and ARTICLE 1, ARTICLE 3, ARTICLE 7, ARTICLE 8, and ARTICLE 9 shall survive the expiration or termination of this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Rights and Duties Upon Termination.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Upon termination of this Agreement, Patheon will, as promptly as practicable, (i) cease work on the Transfer Services, and (ii) make available for collection by Flexion, &#91;&#8230;***&#8230;&#93; (Incoterms 2010) the Facility, all Materials and results and information resulting from the Transfer Services (whether in written or electronic form) that are then in Patheon&#8217;s or its subcontractors&#8217; possession and that are the property of Flexion in accordance with Section 2.9 of this Agreement, including all Flexion Proprietary Information. Flexion shall return to Patheon all Patheon Proprietary Information. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Upon termination of this Agreement, Flexion will (i) pay all earned but unpaid fees and charges for the Transfer Services, including Material Costs, Capital Expenditures, Bill Back Items, Additional Services, Base Fees (through the month of such termination) to reflect Transfer Services performed as of the date of such termination by Patheon&#59; and (ii) pay all due and outstanding invoices in accordance with ARTICLE IV of the Manufacturing and Supply Agreement, including those for Bill Back Items or Additional Services performed as of the date of such expiration and termination&#59; provided that, the Parties agree that if any fees or charges are duplicated under Section 8.3 of the Manufacturing and Supply Agreement, Flexion shall only be obligated to make such payment once. </font></div><div><font><br></font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Upon termination of this Agreement, Flexion will pay to Patheon all and any removal and Make Good Costs associated with the removal of the Flexion Manufacturing Equipment from the Facility as agreed to in good faith by the Parties in writing. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Make Good Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the reasonable costs required to repair the Facility and return it to a clean, safe and useable area based on the repair of damage caused by the installation or removal of Flexion Manufacturing Equipment. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Upon termination of this Agreement prior to termination of the Manufacturing and Supply Agreement, Flexion will, as promptly as practicable, pay to Patheon the Manufacturing Services Termination Costs pursuant to the provisions of Sections 8.3(f) and 8.3(g) of the Manufacturing and Supply Agreement to the extent applicable to this Agreement or the Transfer Services. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e) Upon termination of this Agreement, in the event that Patheon will not be Manufacturing the Product for Flexion pursuant to the Manufacturing and Supply Agreement, Flexion shall remove all Flexion Manufacturing Equipment and Materials from the Facility within &#91;&#8230;***&#8230;&#93; days of said termination under all sections other than Section 8.5 and within &#91;&#8230;***&#8230;&#93; days &#91;&#8230;***&#8230;&#93; of a termination by Flexion pursuant to Section 8.5 that is not reasonably disputed by Patheon, failing which Flexion will pay a fee equivalent to the aggregate monthly Base Fee for each month or part month the Flexion Manufacturing Equipment or Materials remain at the Facility post-termination. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) Upon termination of this Agreement by Flexion pursuant to Section 8.3(a), in addition to any other obligation of Flexion under Section 8.11, Flexion shall also pay Patheon compensation of &#163;1,300,000 (one million, three hundred thousand British Pounds). The Parties confirm that this sum represents a genuine pre-estimate of Patheon&#8217;s loss in such circumstances. </font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARTICLE 9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">MISCELLANEOUS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding that advance notification of any notices or other communications may be given by electronic mail transmission, all notices or other communications that shall or may be given pursuant to this Agreement shall be in writing (including by confirmed receipt electronic mail) and shall be deemed to be effective (a) when delivered if sent by registered or certified mail, return receipt requested, or (b) on the next business day, if sent by overnight courier, (c) when sent if sent by electronic mail provided that receipt is confirmed, in each case to the Parties at the following addresses (or at such other addresses as shall be specified by like notice) with postage or delivery charges prepaid. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to Flexion&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion Therapeutics, Inc. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Michael Clayman, MD </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Telephone&#58; &#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With a copy to&#58; Legal </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to Patheon&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attention&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Director &#38; General Manager </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patheon UK Limited </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kingfisher Drive, Covingham </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swindon, Wiltshire SN3 5BZ </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with copy to </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Director. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Neither Party shall be liable for delay in delivery, performance or nonperformance, in whole or in part, nor shall the other Party have the right to terminate this Agreement except as otherwise specifically provided in this Section 9.2 where such delay in delivery, performance or nonperformance results from acts beyond the reasonable control and without the fault or negligence of such Party including, but not limited to, the following conditions&#58; fires, floods, storms, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotion, or acts, omissions, or delays in acting by any governmental authority&#59; provided that the Party affected by such a condition shall, within five (5) days of its occurrence, give notice to the other Party stating the nature of the condition, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is reasonably required, and the nonperforming Party shall use its commercially reasonable efforts to remedy its inability to perform&#59; provided, however, that in the event the suspension of performance continues for &#91;&#8230;***&#8230;&#93; days after the date of the occurrence, and such failure to perform would constitute a material breach of this Agreement in the absence of such force majeure event, the non-affected Party may terminate this Agreement immediately by written notice to the affected Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Parties to this Agreement are independent contractors. Nothing contained in this Agreement will be construed to place the Parties in the relationship of employer and employee, partners, principal, and agent or a joint venture. Neither Party will have the power to bind or obligate the other Party nor will either Party hold itself out as having such authority. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Save where expressly stated to the contrary in this Agreement, no waiver by either Party of any provision or breach of this Agreement will constitute a waiver by such </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Party of any other provision or breach, and no such waiver will be effective unless made in writing and signed by an authorized representative of the Party against whom waiver is sought. No course of conduct or dealing between the Parties will act as a modification or waiver of any provision of this Agreement. Either Party&#8217;s consent to or approval of any act of the other Party will not be deemed to render unnecessary the obtaining of that Party&#8217;s consent to or approval of any subsequent act by the other Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement (together with all Exhibits hereto, which are hereby incorporated by reference), the Manufacturing and Supply Agreement and the Quality Agreement, constitute the final, complete, and exclusive agreement between the Parties relating to the subject matter hereof and supersede all prior conversations, understandings, promises, and agreements relating to the subject matter hereof, including without limitation that (i) certain Confidentiality Agreement dated September 22, 2014 between Flexion and Patheon and the Letter Agreement between the Parties dated 1 May 2015, and (ii) that certain Patheon Partner External User Account&#47;Access Form, Client Agreement and Authorization signed by Flexion on June 5, 2015. Neither Party has relied upon any communication, representation, term, or promise, verbal or written, not set forth herein. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment&#59; Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Agreement may not be assigned by Patheon without the prior written consent of Flexion. Notwithstanding the foregoing, either Party may assign this Agreement to an Affiliate or to an acquirer or successor in interest in connection with a Change of Control of such Party without the prior written consent of the other Party, provided that such Party provides the other Party with written notice of any such assignment. This Agreement shall be binding upon and inure to the benefit of Flexion and Patheon and their respective successors, heirs, executors, administrators, and permitted assigns. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the closing of (a) a merger, consolidation or similar transaction providing for the acquisition of the direct or indirect ownership of more than fifty percent (50%) of a Party&#8217;s shares or similar equity interests or voting power of the outstanding voting securities or that represents the power to direct the management and policies of such Party (including any acquisition arising through the offering of any shares of Patheon or any of its Affiliates on any securities or stock exchange), or (b) the sale of all or substantially all of a Party&#8217;s assets related to the subject matter of the Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment&#59; Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement may not be amended, modified, altered, or supplemented except by a writing signed by both Parties. No modification of any nature to this Agreement and no representation, agreement, arrangement, or other communication will be binding on the Parties unless such is expressly contained in writing and executed by the Parties as an amendment to this Agreement. This Agreement may not be amended in any respect by any purchase order, invoice, acknowledgment, or other similar printed document issued by either Party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Prior to subcontracting any of Patheon&#8217;s obligations hereunder, Patheon will notify Flexion (1) in advance of engaging a proposed subcontractor that directly relates to the Manufacture of the Product and will obtain Flexion&#8217;s prior written approval of each such subcontractor, and (2) within six (6) months of all other subcontractors so engaged. The terms of any subcontract will be in writing and will not be materially inconsistent with this </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agreement or the Manufacturing and Supply Agreement, including Section 3.14 of the Manufacturing and Supply Agreement. No subcontracting will release Patheon from its responsibility for its obligations under this Agreement. Patheon will be responsible for the work and activities of each subcontractor as they relate to performance of Patheon&#8217;s obligations under this Agreement, including compliance with the terms of this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) The laws of &#91;&#8230;***&#8230;&#93;, whether procedural or substantive (but excluding application of any choice of law provisions contained therein) shall apply to all matters pertaining only to (a) title to and ownership of Materials, Equipment or the Facility, and its appurtenances including, without limitation, all rights therein and the creation, exercise and extinction of such rights, obligations and liabilities or (b) employment law matters. In relation to such matters, both Parties shall submit to the exclusive jurisdiction of the &#91;&#8230;***&#8230;&#93; Courts. For the avoidance of doubt, the Parties agree that nothing in this Agreement shall (i) grant Flexion any property ownership rights in the Facility or (ii) shall constitute a lease to the Facility. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) In all other respects, this Agreement shall be construed under and governed by the laws of &#91;&#8230;***&#8230;&#93; without regard to the application of principles of conflicts of law. In relation to such matters, both Parties shall submit to the exclusive jurisdiction of the &#91;&#8230;***&#8230;&#93;. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Any preliminary issue over which of sub-section 9.9(a) or (b) applies to a particular claim or dispute shall be determined in accordance with provisions of 9.9(a). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) The Parties expressly exclude the application of the United Nations Convention on Contracts for the International Sale of Goods, if applicable. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If any provision of this Agreement is found by a proper authority to be unenforceable, that provision to the extent it is found to be unenforceable or invalid will be severed and the remainder of the provision and this Agreement will continue in full force and effect. The Parties shall use their best efforts to agree upon a valid and enforceable provision as a substitute for any invalid or unenforceable provision, taking in to account the Parties&#8217; original intent of this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Unless the context of this Agreement otherwise requires&#58; (a) words of any gender include each other gender&#59; (b) words using the singular or plural number also include the plural or singular number, respectively&#59; (c) the terms &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; and derivative or similar words refer to this entire Agreement&#59; (d) the terms &#8220;Article,&#8221; &#8220;Section,&#8221; </font></div><div style="margin-top:2pt;text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Exhibit,&#8221; or &#8220;clause&#8221; refer to the specified Article, Section, Exhibit, or clause of this Agreement&#59; (e) &#8220;or&#8221; is disjunctive but not necessarily exclusive&#59; and (f) the term &#8220;including&#8221; or &#8220;includes&#8221; means &#8220;including without limitation&#8221; or &#8220;includes without limitation.&#8221; Whenever this Agreement refers to a number of days, such number will refer to calendar days unless business days are specified. The captions and headings of this Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The language of this Agreement will be deemed to be the language mutually chosen by the Parties, and no rule of strict construction will be applied against either Party hereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement is not intended to confer upon any non-party any right or remedy hereunder, except as may be received or created as part of a valid assignment. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each of the Parties agrees to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such additional assignments, agreements, documents, and instruments, that may be necessary or as the other Party hereto may at any time and from time to time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party its rights and remedies under, this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement may be signed in counterparts, each and every one of which will be deemed an original. Facsimile or PDF signatures will be treated as original signatures. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Subject to (b) and (c) below, Patheon will bear all Taxes however designated as a result of the provision of the Transfer Services under this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) Flexion acknowledges that it will be responsible for all Taxes that arise in respect of the following&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) The acquisition of the Flexion-Supplied Materials. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) The acquisition of the Flexion Manufacturing Equipment. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c) Any payment due under this Agreement for the provision of Transfer Services to Flexion by Patheon is exclusive of value added or equivalent tax in any other jurisdiction, including any related interest and penalties (hereinafter all referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). If any VAT is payable on a Transfer Service supplied by Patheon to Flexion under this Agreement, this VAT will be added to the invoice amount and will be for the account of (and reimbursable to Patheon by) Flexion. Where applicable, Patheon will use its reasonable commercial efforts to ensure that its invoices to Flexion are issued in such a way that these invoices meet the requirements for deduction of input VAT by Flexion, to the extent permitted by law to do so. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Flexion acknowledges that all amounts due in respect of any fees payable by Flexion under this Agreement shall be paid in full without any set-off, counterclaim, deduction or withholding in respect of any Tax liabilities. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The remainder of this page is left blank intentionally. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, this Technical Transfer and Service Agreement has been executed by the Parties hereto as of the day and year first written above. </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PATHEON UK LIMITED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FLEXION THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.M. Botterill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael D. Clayman, M.D.</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.M. Botterill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael D. Clayman, M.D.</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exec. Dir. &#38; Gen. Manager</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEO</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature Page of Technical Transfer and Service Agreement </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-A </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 30-36. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-36 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-B </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 37-43. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37-43 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-C </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-D </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 45-50. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45-50 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-E </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 51-52. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51-52 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.1-F </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;&#8230;***&#8230;&#93; </font></div><div style="margin-top:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Confidential Treatment Requested for pages 53-55. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omitted pages have been filed separately with the Commission. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53-55</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 2.7 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Steering Committee </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The purpose of the Steering Committee shall be to oversee the Technical Transfer and Service Agreement, the Manufacturing and Supply Agreement and the Quality Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and to facilitate communications between the Parties with respect thereto. The Steering Committee shall have the responsibilities and authority allocated to it in this Exhibit 2.7. The Steering Committee shall have the obligation to exercise its authority consistent with the respective purpose for the Steering Committee as stated herein and any such decisions shall be made in good faith. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Formation and Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Promptly following the Effective Date, the Parties shall confer and then create a Steering Committee. The Steering Committee shall have authority, subject to Paragraph 5, to oversee the priorities and budgets (not less than on a quarterly basis), to oversee manufacturing and controls for the Products, to review and approve all associated regulatory filings and correspondence under the Agreements (including reviewing and approving itemized budgets with respect to the foregoing), to approve the projects and plans of any subcommittee it establishes consistent with this authority and to review any concerns either Party may have concerning key employees employed by the Parties to provide the Transfer Services under the Technical Transfer Agreement and the Services under the Manufacturing and Supply Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">General Steering Committee Membership and Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Party shall designate an equal number of representatives (not to exceed three (3) for each Party) to the Steering Committee with appropriate expertise to serve as members of the Steering Committee. The Steering Committee representatives must all be employees of such Party or an Affiliate of such Party, with the caveat that each Party may designate for the Steering Committee up to one (1) representative who is not an employee if&#58; (i) such non-employee representative agrees in writing to be bound to the terms of this Agreement for the treatment and ownership of confidential information of the Parties, and (ii) the other Party consents to the designation of such non-employee representative, which consent shall not be unreasonably withheld. Each Party may replace its Steering Committee representatives at any time upon written notice to the other Party. The Steering Committee shall have a chairperson which shall be appointed by Flexion. The chairperson of the Steering Committee shall be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of the Steering Committee, and preparing and issuing minutes of each meeting within fifteen (15) days thereafter. </font></div></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Steering Committee shall be constituted and the first meeting of the Steering Committee shall be held within sixty (60) days following the Effective Date, with the Steering Committee considering finalization and approval of workplans prepared by the Parties for inclusion and commencement under the Agreements. Otherwise, the Steering Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held less </font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">frequently than once every six (6) months. Meetings of the Steering Committee may be held in person or by means of telecommunication (telephone, video, or web conferences). To the extent that the Steering Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with Flexion selecting the first meeting location for the Steering Committee. A reasonable number of additional representatives of a Party may attend meetings of the Steering Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in the Steering Committee.</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Meeting Agendas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Party will disclose to the other proposed agenda items along with appropriate information at least three (3) business days in advance of each meeting of the Steering Committee&#59; provided, that a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for the Steering Committee meeting. </font></div></td></tr></table></div><div><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations of Steering Committee Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Steering Committee shall have only such powers as are specifically delegated to it hereunder or from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, the Steering Committee shall not have any power to amend the Agreements. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 9.7 above. Additionally, no member of the Steering Committee shall be able to vote in the Steering Committee and thereby bind its respective Party on any material matter except as otherwise properly authorized, approved, or delegated by such Party in accord with Paragraph 5. </font></div></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Neither Party shall exercise its right to finally resolve a dispute at the Steering Committee in accordance with this Paragraph 4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this Agreement&#59; (ii) expands the obligations of the other Party under this Agreement&#59; (iii) negates any consent rights or other rights specifically allocated to the other Party under this Agreement&#59; (iv) purports to resolve any dispute involving the breach or alleged breach of this Agreement&#59; (v) resolves a matter if the provisions of this Agreement specify that mutual agreement is required for such matter&#59; or (vi) would require the other Party to perform any act that is inconsistent with applicable law. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Authorization of Steering Committee Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each representative serving on the Steering Committee shall be responsible for ensuring that he or she acts only as duly authorized by its respective Party and obtains any advance approvals, delegations, or other authorizations from his or her respective Party in advance of making any Steering Committee votes. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AMENDMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">First Amendment to the Technical Transfer and Service Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is between Flexion Therapeutics, Inc., having its principal office at 10 Mall Road, Burlington MA, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Patheon UK Limited, having a principal place of business at Kingfisher Drive, Covingham, Swindon, Wiltshire SN35BZ, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#59; individually, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This Amendment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is dated 8 May 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Flexion and Patheon entered into a Technical Transfer and Service Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Technical Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on 31 July 2015, pursuant to which Patheon provides certain technical transfer and construction services in order to validate and scale up portions of Flexion&#8217;s technology package and prepare Patheon&#8217;s facilities for the manufacture of Flexion&#8217;s FX006 drug product (ZILRETTA) (an extended-release formulation of triamcinolone acetonide).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have agreed to initiate construction of the area referred to as the Phase III manufacturing suite at Patheon&#8217;s facility and to incur certain capital expenditures to facilitate the manufacture of Flexion&#8217;s product in this manufacturing suite.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing and the mutual promises, covenants and agreements set forth below and in the Technical Transfer Agreement, and for other good and valuable consideration, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties hereto, intending to be legally bound, do hereby agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.Definitions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Defined terms in this Amendment Agreement shall have the same meaning as those in the Technical Transfer Agreement as applicable unless otherwise indicated.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.Amendments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Technical Transfer Agreement shall be amended such that the following Paragraphs or parts of the Exhibits to the Technical Transfer Agreement shall be replaced as set out in the Schedules attached to this Amendment Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.Effectiveness of Amendments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The amendments to the Technical Transfer Agreement set forth herein shall be effective as of the Amendment Effective Date. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.Integration</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except for the sections of the Technical Transfer Agreement specifically amended hereunder, all terms and conditions of the Technical Transfer Agreement remain and shall remain in full force and effect. This Amendment Agreement shall hereafter be incorporated into and deemed part of the Technical Transfer Agreement and any future reference to the Technical Transfer Agreement shall include the terms and conditions of this Amendment Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.Governing Law and Jurisdiction</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the laws that govern the Technical Transfer Agreement, and the Parties submit to the jurisdiction and dispute resolution provisions as set forth in the Technical Transfer Agreement.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have caused this Amendment Agreement to be executed by their duly authorized representatives, effective as of the date of the last signature.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:45.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FLEXION THERAPEUTICS, INC.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Michael D. Clayman, M.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PATHEON UK LTD.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Luca Andretta</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael D. Clayman, M.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Luca Andretta</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CEO</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">May 9, 2019</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">May 12, 2019</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1 of the Amendment Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2 of the Amendment Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 3 of the Amendment Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>8
<FILENAME>pcrx-12312021xex1038.htm
<DESCRIPTION>EX-10.38
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic91c1347330a4a1991fdbdb12abdc438_33"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.38</font></div></div><div><font><br></font></div><div id="ic91c1347330a4a1991fdbdb12abdc438_38"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK &#8220;&#91;***&#93;&#8221;.</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 8, 2020</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIA ELECTRONIC MAIL</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patheon UK Ltd</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Director &#38; General Manager</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kingfisher Drive, Covingham </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swindon, Wiltshire SN3 5 BZ</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Re&#58; Side Letter to the Manufacturing and Supply Agreement by and between Flexion Therapeutics, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Flexion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and Patheon UK Limited (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dear Mr. McLean&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is hereby made to the Manufacturing and Supply Agreement by and between Flexion and Patheon effective as of 31 July 2015, as amended by the First Amendment Agreement dated 8 May 2019 and by the Second Amendment Agreement dated 17 June 2019 (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Manufacturing and Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), pursuant to which Patheon provides manufacturing services for Flexion&#8217;s FX006 drug product (ZILRETTA) (an extended-release formulation of triamcinolone acetonide) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Schedule 2.1(a) of the Manufacturing and Supply Agreement, Flexion&#8217;s minimum annual volume commitment for 2020 is &#91;***&#93; units. However, Flexion has requested to reduce its own volume commitment for the calendar year 2020 and Patheon has agreed to accommodate such request at the conditions reported hereinafter. Therefore, each of Flexion and Patheon hereby agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined terms in this Side Letter shall have the same meaning as those in the Manufacturing and Supply Agreement as applicable unless otherwise indicated.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.For calendar year 2020&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)the manufacturing services for Flexion&#8217;s Product will be stopped for an extended period, starting from the end of the production activities for the batch &#91;***&#93; and until further notice by Flexion. It is understood that, in accordance with the current provisions of the Manufacturing and Supply Agreement, Flexion shall provide not less than three (3) months&#8217; notice if it wishes Patheon to resume Manufacture at the Manufacturing Suite.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)Patheon will not require Flexion &#91;***&#93;. For the sake of clarity, any additional batch of Product that Flexion should require Patheon to manufacture after batch &#91;***&#93;, will be invoiced by Patheon at the Product Fee set out in the Manufacturing and Supply Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)Flexion will continue to pay the Base Fee due for the remainder months of 2020 &#91;***&#93;, in 2020, pursuant to the Manufacturing and Supply Agreement.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.Additional Provisions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties agree that, on or about the end of the Q3 2020, good faith discussions will start concerning (i) Parties&#8217; business needs &#91;***&#93;. Nothing in this Section 3 shall be construed as an obligation for either Party to do anything or to amend the Manufacturing and Supply Agreement unless the Parties otherwise agree in writing.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.Effectiveness of Amendments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Side Letter constitutes the full, complete, final and integrated agreement between Flexion and Patheon relating to the subject matter hereof and supersedes all previous written or oral negotiations, commitments, agreements, transactions or understandings with respect to the subject matter hereof. This Side Letter shall be effective as of the date of the last signature entered below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Side Letter Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.Integration&#59; Counterparts</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except for the sections or schedules of the Manufacturing and Supply Agreement specifically amended hereunder, all terms and conditions of the Manufacturing and Supply Agreement remain and shall remain in full force and effect. This Side Letter shall be incorporated into and deemed part of the Manufacturing and Supply Agreement as of the Side Letter Effective Date and any future reference to the Manufacturing and Supply Agreement shall include </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the terms and conditions of this Side Letter. This Side Letter may be executed in counterparts, each of which is deemed an original, but all of which together are deemed to be one and the same agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.Governing Law and Jurisdiction</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Side Letter and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the laws that govern the Manufacturing and Supply Agreement, and the Parties submit to the jurisdiction and dispute resolution provisions as set forth in the Manufacturing and Supply Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the Parties have caused this Side Letter to be executed by their duly authorized representatives, on the dates shown below and will take effect from the Side Letter Effective Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:24pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FLEXION THERAPEUTICS, INC.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Clayman</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Michael Clayman</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> CEO</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> April 8, 2020</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:24pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PATHEON UK LTD.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jim McLean</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Jim McLean</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> General Manager</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> April 9, 2020</font></div></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>pcrx-12312021xex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib6695943e92742ebbcdc87cc2b23bcd2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;21.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF THE REGISTRANT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a listing of the subsidiaries of Pacira BioSciences, Inc., a Delaware corporation&#58;</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of<br>Incorporation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Domestic Subsidiaries</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira CryoTech, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira Pharmaceuticals International, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira Therapeutics, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion Therapeutics Securities Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International Subsidiaries</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira Ireland Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacira Canada, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>pcrx-12312021xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i85e14649e5fb4940be26ca53b5f7cf29_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23.1 </font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements (Nos. 333-175101, 333-181986, 333-196542, 333-212098, 333-233141 and 333-258410) on Form S-8 of our reports dated February 28, 2022, with respect to the consolidated financial statements of Pacira BioSciences, Inc. and the effectiveness of internal control over financial reporting.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#47;s&#47; KPMG LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short Hills, NJ</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>pcrx-12312021xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2e8769170aca4e669befacf36d214c0d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Stack, certify that&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Pacira BioSciences,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;DAVID STACK</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stack</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>pcrx-12312021xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i273eb42c507b4474b935e51bb17ee0c2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles A. Reinhart, III, certify that&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Pacira BioSciences,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;CHARLES A. REINHART, III</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles A. Reinhart, III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>pcrx-12312021xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5c4517432fea46c3a4bb8019dbe1ebfb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that this Annual Report on Form&#160;10-K of Pacira BioSciences,&#160;Inc. for the year ended December&#160;31, 2021, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Pacira BioSciences,&#160;Inc. at the dates and for the periods indicated.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;DAVID STACK</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stack</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;CHARLES A. REINHART, III</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles A. Reinhart, III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>pcrx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:66f2c054-d932-41b4-84f1-797b86c41d80,g:418797a4-960d-471e-b290-1e4b5463b147-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pcrx="http://www.pacira.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacira.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcrx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.pacira.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.pacira.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.pacira.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1006008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.pacira.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails">
        <link:definition>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails">
        <link:definition>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2109103 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTSDetails" roleURI="http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails">
        <link:definition>2410405 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUE" roleURI="http://www.pacira.com/role/REVENUE">
        <link:definition>2111104 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUETables" roleURI="http://www.pacira.com/role/REVENUETables">
        <link:definition>2312302 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESalesandValuationAccrualsDetails" roleURI="http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails">
        <link:definition>2413406 - Disclosure - REVENUE - Sales and Valuation Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUENarrativeDetails" roleURI="http://www.pacira.com/role/REVENUENarrativeDetails">
        <link:definition>2414407 - Disclosure - REVENUE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEDisaggregationDetails" roleURI="http://www.pacira.com/role/REVENUEDisaggregationDetails">
        <link:definition>2415408 - Disclosure - REVENUE- Disaggregation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.pacira.com/role/ACQUISITIONS">
        <link:definition>2116105 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.pacira.com/role/ACQUISITIONSTables">
        <link:definition>2317303 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.pacira.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>2418409 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails" roleURI="http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails">
        <link:definition>2419410 - Disclosure - ACQUISITIONS - Contingent Consideration Flexion Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails" roleURI="http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails">
        <link:definition>2420411 - Disclosure - ACQUISITIONS - Schedule of Assets and Liabilities Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSFlexionResultsDetails" roleURI="http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails">
        <link:definition>2421412 - Disclosure - ACQUISITIONS - Flexion Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSScheduleofProFormaInformationDetails" roleURI="http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails">
        <link:definition>2422413 - Disclosure - ACQUISITIONS - Schedule of Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.pacira.com/role/INVENTORIES">
        <link:definition>2123106 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.pacira.com/role/INVENTORIESTables">
        <link:definition>2324304 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESComponentsofInventoryDetails" roleURI="http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails">
        <link:definition>2425414 - Disclosure - INVENTORIES - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FIXEDASSETS" roleURI="http://www.pacira.com/role/FIXEDASSETS">
        <link:definition>2126107 - Disclosure - FIXED ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FIXEDASSETSTables" roleURI="http://www.pacira.com/role/FIXEDASSETSTables">
        <link:definition>2327305 - Disclosure - FIXED ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FIXEDASSETSScheduleofUsefulLivesDetails" roleURI="http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails">
        <link:definition>2428415 - Disclosure - FIXED ASSETS - Schedule of Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FIXEDASSETSNarrativeDetails" roleURI="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails">
        <link:definition>2429416 - Disclosure - FIXED ASSETS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.pacira.com/role/LEASES">
        <link:definition>2130108 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.pacira.com/role/LEASESTables">
        <link:definition>2331306 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.pacira.com/role/LEASESNarrativeDetails">
        <link:definition>2432417 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails" roleURI="http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails">
        <link:definition>2433418 - Disclosure - LEASES - Summary of operating lease cost and other operating lease information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails" roleURI="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails">
        <link:definition>2434419 - Disclosure - LEASES - Schedule of maturities of operating lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1" roleURI="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1">
        <link:definition>2434419 - Disclosure - LEASES - Schedule of maturities of operating lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETS" roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS">
        <link:definition>2135109 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSTables" roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables">
        <link:definition>2336307 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSGoodwillDetails" roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails">
        <link:definition>2437420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSNarrativeDetails" roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails">
        <link:definition>2438421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails">
        <link:definition>2439422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.pacira.com/role/ACCRUEDEXPENSES">
        <link:definition>2140110 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2341308 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>2442423 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.pacira.com/role/DEBT">
        <link:definition>2143111 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.pacira.com/role/DEBTTables">
        <link:definition>2344309 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTCarryingValueofDebtDetails" roleURI="http://www.pacira.com/role/DEBTCarryingValueofDebtDetails">
        <link:definition>2445424 - Disclosure - DEBT - Carrying Value of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://www.pacira.com/role/DEBTNarrativeDetails">
        <link:definition>2446425 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofDebtDetails" roleURI="http://www.pacira.com/role/DEBTScheduleofDebtDetails">
        <link:definition>2447426 - Disclosure - DEBT - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofInterestExpenseDetails" roleURI="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails">
        <link:definition>2448427 - Disclosure - DEBT - Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTS">
        <link:definition>2149112 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>2350310 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2451428 - Disclosure - FINANCIAL INSTRUMENTS - Fair Value of Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>2452429 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails">
        <link:definition>2453430 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Fair Value Inputs and Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails">
        <link:definition>2454431 - Disclosure - FINANCIAL INSTRUMENTS - Contingent Consideration Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails" roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails">
        <link:definition>2455432 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Investments at Amortized Cost and Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2156113 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2357311 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>2458433 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYAOCIDetails" roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails">
        <link:definition>2459434 - Disclosure - STOCKHOLDERS' EQUITY - AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANS" roleURI="http://www.pacira.com/role/STOCKPLANS">
        <link:definition>2160114 - Disclosure - STOCK PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSTables" roleURI="http://www.pacira.com/role/STOCKPLANSTables">
        <link:definition>2361312 - Disclosure - STOCK PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSNarrativeDetails" roleURI="http://www.pacira.com/role/STOCKPLANSNarrativeDetails">
        <link:definition>2462435 - Disclosure - STOCK PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSStockIncentivePlansDetails" roleURI="http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails">
        <link:definition>2463436 - Disclosure - STOCK PLANS - Stock Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSCompensationExpenseDetails" roleURI="http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails">
        <link:definition>2464437 - Disclosure - STOCK PLANS - Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSStockOptionActivityDetails" roleURI="http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails">
        <link:definition>2465438 - Disclosure - STOCK PLANS - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSValuationAssumptionsDetails" roleURI="http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails">
        <link:definition>2466439 - Disclosure - STOCK PLANS - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKPLANSRSUActivityDetails" roleURI="http://www.pacira.com/role/STOCKPLANSRSUActivityDetails">
        <link:definition>2467440 - Disclosure - STOCK PLANS - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERSHARE" roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHARE">
        <link:definition>2168115 - Disclosure - NET INCOME (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERSHARETables" roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHARETables">
        <link:definition>2369313 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERSHARECalculationDetails" roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails">
        <link:definition>2470441 - Disclosure - NET INCOME (LOSS) PER SHARE - Calculation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails" roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails">
        <link:definition>2471442 - Disclosure - NET INCOME (LOSS) PER SHARE - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.pacira.com/role/INCOMETAXES">
        <link:definition>2172116 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.pacira.com/role/INCOMETAXESTables">
        <link:definition>2373314 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.pacira.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2474443 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESCurrentandDeferredIncomeTaxesDetails" roleURI="http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails">
        <link:definition>2475444 - Disclosure - INCOME TAXES - Current and Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofEffectiveTaxRateDetails" roleURI="http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails">
        <link:definition>2476445 - Disclosure - INCOME TAXES - Reconciliation of Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2477446 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESUnrecognizedTaxBenefitsDetails" roleURI="http://www.pacira.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails">
        <link:definition>2478447 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.pacira.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>2179117 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSDetails" roleURI="http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails">
        <link:definition>2480448 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNET" roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNET">
        <link:definition>2181118 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables" roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables">
        <link:definition>2382315 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails" roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails">
        <link:definition>2483449 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Product Discontinuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails" roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails">
        <link:definition>2484450 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Flexion (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails" roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails">
        <link:definition>2485451 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - MyoScience (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails" roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails">
        <link:definition>2486452 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - NUANCE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepoCyteDiscontinuationDetails" roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepoCyteDiscontinuationDetails">
        <link:definition>2487453 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - DepoCyte Discontinuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepartmentofJusticeDetails" roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepartmentofJusticeDetails">
        <link:definition>2488454 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Department of Justice (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMERCIALPARTNERSANDOTHERAGREEMENTS" roleURI="http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTS">
        <link:definition>2189119 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails" roleURI="http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails">
        <link:definition>2490455 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.pacira.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2191120 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2492456 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2193121 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2494457 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.pacira.com/role/SUBSEQUENTEVENTS">
        <link:definition>2195122 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.pacira.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2496458 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" abstract="false" name="DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter" abstract="false" name="DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_WholesalerservicefeesMember" abstract="true" name="WholesalerservicefeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_PaymentOfContingentConsideration" abstract="false" name="PaymentOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AllowanceForVolumeRebatesandChargebacksMember" abstract="true" name="AllowanceForVolumeRebatesandChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_EmployeeStockPurchasePlanfairvalue" abstract="false" name="EmployeeStockPurchasePlanfairvalue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtRedemptionTermsonorafterApril12020Member" abstract="true" name="DebtRedemptionTermsonorafterApril12020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" abstract="false" name="DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" abstract="false" name="MovementinValuationandQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pcrx_MajorCustomerThreeMember" abstract="true" name="MajorCustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit" abstract="false" name="EffectOfStateBlendedTaxRateChangesExpenseBenefit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear" abstract="false" name="DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_FlexionAndMyoscienceAcquisitionMember" abstract="true" name="FlexionAndMyoscienceAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_Accruedsellinggeneralandadministrativeexpenses" abstract="false" name="Accruedsellinggeneralandadministrativeexpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_CoPromotionAgreementMember" abstract="true" name="CoPromotionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AchievementOfFDAApprovalOfFX201Member" abstract="true" name="AchievementOfFDAApprovalOfFX201Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain" abstract="true" name="MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ExpectedAdditionalNetOperatingLossesInYearFour" abstract="false" name="ExpectedAdditionalNetOperatingLossesInYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_PotentialAdditionalInvestmentUponAchievingMilestones" abstract="false" name="PotentialAdditionalInvestmentUponAchievingMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ConsultingAgreementMember" abstract="true" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_NuanceBiotechCo.Ltd.Member" abstract="true" name="NuanceBiotechCo.Ltd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_ForeignNetDeferredTaxAssetMember" abstract="true" name="ForeignNetDeferredTaxAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ThreeLargestCustomersMember" abstract="true" name="ThreeLargestCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ContingentConsiderationPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pcrx_MajorCustomerFourMember" abstract="true" name="MajorCustomerFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_MaximumFairMarketValuePurchaseofESPPShares" abstract="false" name="MaximumFairMarketValuePurchaseofESPPShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ExpectedAdditionalNetOperatingLossesInYearThree" abstract="false" name="ExpectedAdditionalNetOperatingLossesInYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_UponFirstCommercialSaleInMajorEUCountryMember" abstract="true" name="UponFirstCommercialSaleInMajorEUCountryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_CustomersOutsideUSMember" abstract="true" name="CustomersOutsideUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtInstrumentVariableRate" abstract="false" name="DebtInstrumentVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxReservesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_SettlementPeriodConvertibleDebtConversionRequest" abstract="false" name="SettlementPeriodConvertibleDebtConversionRequest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_AccruedOperatingExpensesCurrent" abstract="false" name="AccruedOperatingExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ConvertibleSeniorNotesDue2022Member" abstract="true" name="ConvertibleSeniorNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember" abstract="true" name="SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" abstract="false" name="ScheduleOfSharesAvailableForIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" abstract="false" name="DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_AdvisoryCostsMember" abstract="true" name="AdvisoryCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AllowanceForGovernmentRebatesMember" abstract="true" name="AllowanceForGovernmentRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_FederalReserveBankOfNYRateMember" abstract="true" name="FederalReserveBankOfNYRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ExpectedAdditionalNetOperatingLossesInYearFive" abstract="false" name="ExpectedAdditionalNetOperatingLossesInYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock" abstract="false" name="DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_IncreaseDecreaseInContingentConsideration" abstract="false" name="IncreaseDecreaseInContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_NetOperatingLossSubjecttoLimitation" abstract="false" name="NetOperatingLossSubjecttoLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member" abstract="true" name="DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" abstract="false" name="EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_FirstPriceOptionMember" abstract="true" name="FirstPriceOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" abstract="false" name="DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximumValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AchievementOfFDAApprovalOfFX301Member" abstract="true" name="AchievementOfFDAApprovalOfFX301Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_XenonPharmaceuticalsIncMember" abstract="true" name="XenonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_IncreaseDecreaseInRetainedEarnings" abstract="false" name="IncreaseDecreaseInRetainedEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member" abstract="true" name="DebtRedemptionTermsOnOrAfterAugust12023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_InducementPlan2014Member" abstract="true" name="InducementPlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AchievementOfZILRETTASalesOf250MillionMember" abstract="true" name="AchievementOfZILRETTASalesOf250MillionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1" abstract="false" name="DebtInstrumentPrepaymentPenaltyPercentYear1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_NumberOfMajorCustomers" abstract="false" name="NumberOfMajorCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_ConvertibleSeniorNotesDue2025Member" abstract="true" name="ConvertibleSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_GenascenceCorporationMember" abstract="true" name="GenascenceCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" abstract="false" name="MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes" abstract="false" name="RetirementOfEquityComponentOfConvertibleSeniorNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_LegalFeesMember" abstract="true" name="LegalFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AchievementofRegulatoryMilestoneMember" abstract="true" name="AchievementofRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ExpectedAdditionalNetOperatingLossesInYearSix" abstract="false" name="ExpectedAdditionalNetOperatingLossesInYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_CodaBioTherapeuticsIncMember" abstract="true" name="CodaBioTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" abstract="false" name="DebtInstrumentConvertibleAssumedBorrowingRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_DebtInstrumentMarketPrice" abstract="false" name="DebtInstrumentMarketPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pcrx_ScheduleOfInterestExpenseTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pcrx_ReserveForPromptPayDiscountMember" abstract="true" name="ReserveForPromptPayDiscountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_NumberOfLocationsNewOperatingLeaseLiability" abstract="false" name="NumberOfLocationsNewOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_SecondPriceOptionMember" abstract="true" name="SecondPriceOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ConvertibleSeniorNotes2019Member" abstract="true" name="ConvertibleSeniorNotes2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_LitigationInvestigationTerm" abstract="false" name="LitigationInvestigationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_FlexionTherapeuticsIncMember" abstract="true" name="FlexionTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" abstract="false" name="EmployeeStockPurchasePlanESPPSharesinESPP" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther" abstract="false" name="AcquisitionRelatedChargesProductDiscontinuationAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_PaymentsForDebtConversionPremiums" abstract="false" name="PaymentsForDebtConversionPremiums" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_GeneQuineMember" abstract="true" name="GeneQuineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo" abstract="false" name="ExpectedAdditionalNetOperatingLossesInYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" abstract="false" name="IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AchievementOfZILRETTASalesOf500MillionMember" abstract="true" name="AchievementOfZILRETTASalesOf500MillionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_EXPARELMember" abstract="true" name="EXPARELMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ContingentConsiderationNoncurrent" abstract="false" name="ContingentConsiderationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount" abstract="false" name="DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pcrx_Accruedresearchanddevelopmentexpenses" abstract="false" name="Accruedresearchanddevelopmentexpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtConversionAndRedemptionTermsDomain" abstract="true" name="DebtConversionAndRedemptionTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_SkyePharmaHoldingIncMember" abstract="true" name="SkyePharmaHoldingIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" abstract="false" name="COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" abstract="false" name="DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_FlexionAcquisitionMember" abstract="true" name="FlexionAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" abstract="true" name="AchievementOfDevelopmentAndCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" abstract="false" name="BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ContingentConsideration" abstract="false" name="ContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_MyoscienceAcquisitionMember" abstract="true" name="MyoscienceAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AchievementOfSalesRelatedMilestonesMember" abstract="true" name="AchievementOfSalesRelatedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_CommercialPartnersAndAgreementsTextBlock" abstract="false" name="CommercialPartnersAndAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pcrx_TELABioMember" abstract="true" name="TELABioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach" abstract="false" name="CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_IncomeTaxProvisionTable" abstract="true" name="IncomeTaxProvisionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_AcquisitionRelatedFeesMember" abstract="true" name="AcquisitionRelatedFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_SpineBioPharmaLLCMember" abstract="true" name="SpineBioPharmaLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ThirdLargestCustomerMember" abstract="true" name="ThirdLargestCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix" abstract="false" name="ExpectedAdditionalNetOperatingLossesInYearAfterYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_IncreaseDecreaseInInterestExpense" abstract="false" name="IncreaseDecreaseInInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ConvertibleSeniorNotesDue2024Member" abstract="true" name="ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" abstract="true" name="DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pcrx_FiniteLivedIntangibleAssetsMeasurementInput" abstract="false" name="FiniteLivedIntangibleAssetsMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" abstract="false" name="BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate" abstract="false" name="DebtInstrumentBasisSpreadTwoOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_ConcentrationRiskNumberofCustomers" abstract="false" name="ConcentrationRiskNumberofCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes" abstract="false" name="RemainingPaymentRequiredUponFullSettlementOfNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans" abstract="false" name="StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation" abstract="false" name="CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_AratanaTherapeuticsIncMember" abstract="true" name="AratanaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" abstract="false" name="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" abstract="false" name="ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pcrx_PaymentOfEarlyTerminationFees" abstract="false" name="PaymentOfEarlyTerminationFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt" abstract="false" name="ProceedsFromConvertibleOptionComponentOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AchievementOfMilestoneAxis" abstract="true" name="AchievementOfMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2" abstract="false" name="DebtInstrumentPrepaymentPenaltyPercentYear2" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_StockIncentivePlan2011Member" abstract="true" name="StockIncentivePlan2011Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_HongKongPharmaTainuoLtdMember" abstract="true" name="HongKongPharmaTainuoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DeferredTaxAssetsStockBasedCompensation" abstract="false" name="DeferredTaxAssetsStockBasedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_MajorCustomerTwoMember" abstract="true" name="MajorCustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ConvertibleSeniorNotes2025Member" abstract="true" name="ConvertibleSeniorNotes2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_IoveraMemberMember" abstract="true" name="IoveraMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ZILRETTAMember" abstract="true" name="ZILRETTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" abstract="false" name="AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" abstract="false" name="EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pcrx_FortisMember" abstract="true" name="FortisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_BupivacaineLiposomeInjectableSuspensionMember" abstract="true" name="BupivacaineLiposomeInjectableSuspensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ProductReturnsRebatesandOtherFees" abstract="false" name="ProductReturnsRebatesandOtherFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ContingentConsiderationCurrent" abstract="false" name="ContingentConsiderationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DePuySynthesSalesIncMember" abstract="true" name="DePuySynthesSalesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_CollaborativeArrangementUpfrontPayment" abstract="false" name="CollaborativeArrangementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" abstract="false" name="RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" abstract="false" name="ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_IncomeTaxProvisionLineItems" abstract="true" name="IncomeTaxProvisionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" abstract="false" name="TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" abstract="false" name="RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pcrx_EurofarmaLabatoriesSAMember" abstract="true" name="EurofarmaLabatoriesSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt" abstract="false" name="TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AchievementOfMilestoneDomain" abstract="true" name="AchievementOfMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_EffectiveIncomeTaxRateReconciliationForeign" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeign" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_ConvertibleSeniorNotesDueMay2024Member" abstract="true" name="ConvertibleSeniorNotesDueMay2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_OtherTaxAttributesSubjectToLimitation" abstract="false" name="OtherTaxAttributesSubjectToLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentDiscountRate" abstract="false" name="DebtInstrumentDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_ConversionPremiumOn2022NotesMember" abstract="true" name="ConversionPremiumOn2022NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" abstract="true" name="MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_CollaborativeArrangementOptionToExtendTerm" abstract="false" name="CollaborativeArrangementOptionToExtendTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_TermLoanBFacilityDue2026Member" abstract="true" name="TermLoanBFacilityDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtInstrumentConvertibleConversionPremiumShares" abstract="false" name="DebtInstrumentConvertibleConversionPremiumShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" abstract="false" name="AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_DepoCyteMember" abstract="true" name="DepoCyteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" abstract="false" name="AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent" abstract="false" name="DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentBasisSpreadOneOnVariableRate" abstract="false" name="DebtInstrumentBasisSpreadOneOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" abstract="false" name="BusinessCombinationAcquisitionAndIntegrationRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AccruedExpensesTable" abstract="true" name="AccruedExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_LargestCustomerMember" abstract="true" name="LargestCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember" abstract="true" name="RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ContingentConsiderationPaymentTerm" abstract="false" name="ContingentConsiderationPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_ExpectedAdditionalNetOperatingLossesInYearOne" abstract="false" name="ExpectedAdditionalNetOperatingLossesInYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliation338gElectionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" abstract="false" name="CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" abstract="true" name="UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" abstract="false" name="DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_MeasurementInputExpectedMilestonePaymentMember" abstract="true" name="MeasurementInputExpectedMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AchievementOfZILRETTASalesOf375MillionMember" abstract="true" name="AchievementOfZILRETTASalesOf375MillionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_DebtConversionAndRedemptionTermsAxis" abstract="true" name="DebtConversionAndRedemptionTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_AccountsReceivablePaymentTerms" abstract="false" name="AccountsReceivablePaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pcrx_MajorCustomerOneMember" abstract="true" name="MajorCustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AccruedEndOfTermFeeCurrent" abstract="false" name="AccruedEndOfTermFeeCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" abstract="false" name="DebtInstrumentConversionObligationPremiumOnCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_AccruedExpensesLineItems" abstract="true" name="AccruedExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" abstract="false" name="DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pcrx_EmployeeStockPurchasePlanESPP2014Member" abstract="true" name="EmployeeStockPurchasePlanESPP2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pcrx_SecondLargestCustomerMember" abstract="true" name="SecondLargestCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" abstract="false" name="AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pcrx_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" abstract="false" name="EmployeeStockPurchasePlanNumberofSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>pcrx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:66f2c054-d932-41b4-84f1-797b86c41d80,g:418797a4-960d-471e-b290-1e4b5463b147-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1f90e70a-8d4c-4f07-a698-4ccbee15a2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48582ddd-e6b5-43bb-a667-d3e9c6594302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1f90e70a-8d4c-4f07-a698-4ccbee15a2f9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48582ddd-e6b5-43bb-a667-d3e9c6594302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_9103691b-a7f5-4855-9f2d-98a2c0c33f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1f90e70a-8d4c-4f07-a698-4ccbee15a2f9" xlink:to="loc_us-gaap_ShortTermInvestments_9103691b-a7f5-4855-9f2d-98a2c0c33f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bf280bdf-a0b0-42ee-8dfd-21d04229b858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1f90e70a-8d4c-4f07-a698-4ccbee15a2f9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bf280bdf-a0b0-42ee-8dfd-21d04229b858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b0ddf942-e13f-42a7-9825-ed2a3af20bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1f90e70a-8d4c-4f07-a698-4ccbee15a2f9" xlink:to="loc_us-gaap_InventoryNet_b0ddf942-e13f-42a7-9825-ed2a3af20bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2f455c2-3fa5-4e7e-83e4-4709a874d968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1f90e70a-8d4c-4f07-a698-4ccbee15a2f9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2f455c2-3fa5-4e7e-83e4-4709a874d968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_624d95a6-e400-49bd-9ceb-2da3e4a17cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_aca19e49-6c03-47e9-9ea6-c0cae66e192e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_624d95a6-e400-49bd-9ceb-2da3e4a17cab" xlink:to="loc_us-gaap_PreferredStockValue_aca19e49-6c03-47e9-9ea6-c0cae66e192e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c0186891-596e-4299-8d0e-dc745c6d5916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_624d95a6-e400-49bd-9ceb-2da3e4a17cab" xlink:to="loc_us-gaap_CommonStockValue_c0186891-596e-4299-8d0e-dc745c6d5916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_820664b8-3079-4820-ac90-a13c74ec4918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_624d95a6-e400-49bd-9ceb-2da3e4a17cab" xlink:to="loc_us-gaap_AdditionalPaidInCapital_820664b8-3079-4820-ac90-a13c74ec4918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e4ba57a7-92f9-47da-a218-54e4026ce56d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_624d95a6-e400-49bd-9ceb-2da3e4a17cab" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e4ba57a7-92f9-47da-a218-54e4026ce56d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_86f3dee0-b7d4-49cb-8928-3f50646ef95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_624d95a6-e400-49bd-9ceb-2da3e4a17cab" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_86f3dee0-b7d4-49cb-8928-3f50646ef95d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2c2863c5-58e3-44b4-aaa6-104abc01ad7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9c43986f-bda3-40e5-a346-c42eb345173c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c2863c5-58e3-44b4-aaa6-104abc01ad7c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9c43986f-bda3-40e5-a346-c42eb345173c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_b911a427-caa3-415f-a4f8-13a3a5ef1df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c2863c5-58e3-44b4-aaa6-104abc01ad7c" xlink:to="loc_us-gaap_TaxesPayableCurrent_b911a427-caa3-415f-a4f8-13a3a5ef1df4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationCurrent_d200b05f-07f8-47d4-b830-8565bb606ab9" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c2863c5-58e3-44b4-aaa6-104abc01ad7c" xlink:to="loc_pcrx_ContingentConsiderationCurrent_d200b05f-07f8-47d4-b830-8565bb606ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_bf019dc7-e35a-4705-92c3-c77fc41796e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c2863c5-58e3-44b4-aaa6-104abc01ad7c" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_bf019dc7-e35a-4705-92c3-c77fc41796e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fa8814d9-43fe-49f2-b3d3-1289767b168b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c2863c5-58e3-44b4-aaa6-104abc01ad7c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fa8814d9-43fe-49f2-b3d3-1289767b168b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtCurrent_fbbd680c-73c0-4218-bb34-4d8a83f600e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c2863c5-58e3-44b4-aaa6-104abc01ad7c" xlink:to="loc_us-gaap_SecuredDebtCurrent_fbbd680c-73c0-4218-bb34-4d8a83f600e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eeb8ecc1-695e-4d34-9dc4-3a471ddd508c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c2863c5-58e3-44b4-aaa6-104abc01ad7c" xlink:to="loc_us-gaap_AccountsPayableCurrent_eeb8ecc1-695e-4d34-9dc4-3a471ddd508c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_77dedd9a-6e20-49d7-9d97-5a7a09f3915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationNoncurrent_67532086-9099-4ad8-936f-1d4c0deb0e5c" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77dedd9a-6e20-49d7-9d97-5a7a09f3915b" xlink:to="loc_pcrx_ContingentConsiderationNoncurrent_67532086-9099-4ad8-936f-1d4c0deb0e5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac7b4a31-7c1d-4ae5-98c8-25fe809c3f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77dedd9a-6e20-49d7-9d97-5a7a09f3915b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac7b4a31-7c1d-4ae5-98c8-25fe809c3f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_65bb9d5b-c27d-49b4-961f-a529c3aa19e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77dedd9a-6e20-49d7-9d97-5a7a09f3915b" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_65bb9d5b-c27d-49b4-961f-a529c3aa19e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4e367016-852e-427a-8210-12fae58a6f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77dedd9a-6e20-49d7-9d97-5a7a09f3915b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4e367016-852e-427a-8210-12fae58a6f36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_3591dcf7-3a4d-4f54-b1e5-63a251a30c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77dedd9a-6e20-49d7-9d97-5a7a09f3915b" xlink:to="loc_us-gaap_SecuredLongTermDebt_3591dcf7-3a4d-4f54-b1e5-63a251a30c6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7b11b54c-9a89-4a83-91cd-36bf2b4051c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77dedd9a-6e20-49d7-9d97-5a7a09f3915b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7b11b54c-9a89-4a83-91cd-36bf2b4051c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_37df1e07-5573-443a-b081-0d513ae0cddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77dedd9a-6e20-49d7-9d97-5a7a09f3915b" xlink:to="loc_us-gaap_LiabilitiesCurrent_37df1e07-5573-443a-b081-0d513ae0cddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3db80cc9-ef88-4630-b175-39c04e3d67b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e6962f2e-410f-4f06-bb84-e4df5508a406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3db80cc9-ef88-4630-b175-39c04e3d67b4" xlink:to="loc_us-gaap_AssetsCurrent_e6962f2e-410f-4f06-bb84-e4df5508a406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_b5dfdc98-2471-4074-932f-6e51c371b840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3db80cc9-ef88-4630-b175-39c04e3d67b4" xlink:to="loc_us-gaap_LongTermInvestments_b5dfdc98-2471-4074-932f-6e51c371b840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_26ed91b1-af6e-43d6-a02e-7d474a60b213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3db80cc9-ef88-4630-b175-39c04e3d67b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_26ed91b1-af6e-43d6-a02e-7d474a60b213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b6fb8920-2d8f-4b5c-ab4c-628ebf8c17e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3db80cc9-ef88-4630-b175-39c04e3d67b4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b6fb8920-2d8f-4b5c-ab4c-628ebf8c17e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1931f748-eccf-4b07-94df-bf14f571ecb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3db80cc9-ef88-4630-b175-39c04e3d67b4" xlink:to="loc_us-gaap_Goodwill_1931f748-eccf-4b07-94df-bf14f571ecb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f877bf6-1d82-460a-aeca-1b0c67995800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3db80cc9-ef88-4630-b175-39c04e3d67b4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f877bf6-1d82-460a-aeca-1b0c67995800" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_56a0999d-0238-4a22-af90-fa49f9308e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3db80cc9-ef88-4630-b175-39c04e3d67b4" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_56a0999d-0238-4a22-af90-fa49f9308e9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_34d2d20d-f2af-45be-87c4-260f94c781f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3db80cc9-ef88-4630-b175-39c04e3d67b4" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_34d2d20d-f2af-45be-87c4-260f94c781f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e811410c-1217-499f-8cdc-9828d6cde39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d984416d-092e-4dd3-9c92-347e498a0dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e811410c-1217-499f-8cdc-9828d6cde39b" xlink:to="loc_us-gaap_Liabilities_d984416d-092e-4dd3-9c92-347e498a0dcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f840e3ad-d37e-4c01-b068-0b3d79ea53d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e811410c-1217-499f-8cdc-9828d6cde39b" xlink:to="loc_us-gaap_StockholdersEquity_f840e3ad-d37e-4c01-b068-0b3d79ea53d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3edaa92c-5144-40f2-b1df-45b241e3948a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e811410c-1217-499f-8cdc-9828d6cde39b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3edaa92c-5144-40f2-b1df-45b241e3948a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2970f629-d4a1-42c8-bb4a-de1db1c085c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_d43f7c5f-e108-4db2-8d9b-ddd7e7439621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2970f629-d4a1-42c8-bb4a-de1db1c085c9" xlink:to="loc_us-gaap_CostOfRevenue_d43f7c5f-e108-4db2-8d9b-ddd7e7439621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ca3e8cef-1cc7-44c9-a47e-5a463ef93276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2970f629-d4a1-42c8-bb4a-de1db1c085c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ca3e8cef-1cc7-44c9-a47e-5a463ef93276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d3736b01-19a4-453a-a029-a9b8dcf36094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2970f629-d4a1-42c8-bb4a-de1db1c085c9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d3736b01-19a4-453a-a029-a9b8dcf36094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_72dad63e-87e3-42ad-9d1b-708183392cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2970f629-d4a1-42c8-bb4a-de1db1c085c9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_72dad63e-87e3-42ad-9d1b-708183392cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses_366ef5f3-fe6b-43c3-83b0-395d7baf7ba7" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2970f629-d4a1-42c8-bb4a-de1db1c085c9" xlink:to="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses_366ef5f3-fe6b-43c3-83b0-395d7baf7ba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_590f7e72-67a3-4ffe-9a25-76fef015525e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_634cac7c-ce3b-44bf-a249-2ce2c447c5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_590f7e72-67a3-4ffe-9a25-76fef015525e" xlink:to="loc_us-gaap_OperatingIncomeLoss_634cac7c-ce3b-44bf-a249-2ce2c447c5ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cef059e2-781c-4724-be93-58345aa695d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_590f7e72-67a3-4ffe-9a25-76fef015525e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cef059e2-781c-4724-be93-58345aa695d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46d592cf-a26c-475e-8654-18fba3eb6680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1203aa5d-98e6-4075-84b6-b0cf3b5289e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46d592cf-a26c-475e-8654-18fba3eb6680" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1203aa5d-98e6-4075-84b6-b0cf3b5289e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_84f86d47-1d59-48d8-9385-5ff2800fbcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46d592cf-a26c-475e-8654-18fba3eb6680" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_84f86d47-1d59-48d8-9385-5ff2800fbcf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_949a027a-1767-41d1-be4f-b1d0e938c60c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8d7c337e-fe28-42c4-8aef-395e580741b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_949a027a-1767-41d1-be4f-b1d0e938c60c" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8d7c337e-fe28-42c4-8aef-395e580741b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_31f12ce4-725a-41d8-9ab8-7342cae199b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_949a027a-1767-41d1-be4f-b1d0e938c60c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_31f12ce4-725a-41d8-9ab8-7342cae199b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c383e154-8413-49d3-8ae4-9fb07d9a3ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ba2102b5-d6f7-4c76-83f4-6c9d3cb6e69a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c383e154-8413-49d3-8ae4-9fb07d9a3ffa" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ba2102b5-d6f7-4c76-83f4-6c9d3cb6e69a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a2d33a78-a027-4fb9-a688-2cd95f223a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c383e154-8413-49d3-8ae4-9fb07d9a3ffa" xlink:to="loc_us-gaap_InterestExpense_a2d33a78-a027-4fb9-a688-2cd95f223a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6ffcd9df-56f9-4d5c-b403-df1c034f8195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c383e154-8413-49d3-8ae4-9fb07d9a3ffa" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6ffcd9df-56f9-4d5c-b403-df1c034f8195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3001f3e3-1d08-4585-bd33-5d5a8bda9688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c383e154-8413-49d3-8ae4-9fb07d9a3ffa" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3001f3e3-1d08-4585-bd33-5d5a8bda9688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2a770343-3015-4e6b-b0d6-3a97d14f5609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7da6d67c-f5d5-49f4-a209-fa44bb6d8c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a770343-3015-4e6b-b0d6-3a97d14f5609" xlink:to="loc_us-gaap_Revenues_7da6d67c-f5d5-49f4-a209-fa44bb6d8c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_76ba1b91-3b72-4d1d-8ba3-4fa2cab0b878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a770343-3015-4e6b-b0d6-3a97d14f5609" xlink:to="loc_us-gaap_CostsAndExpenses_76ba1b91-3b72-4d1d-8ba3-4fa2cab0b878" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1542d25-a79a-40b1-9cbd-1601f2e1cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_394dce8a-f40e-437f-bbb3-3a7aa82f4f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1542d25-a79a-40b1-9cbd-1601f2e1cd4f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_394dce8a-f40e-437f-bbb3-3a7aa82f4f53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b156f55b-e6f2-4d3d-850c-26a4dc3c70bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1542d25-a79a-40b1-9cbd-1601f2e1cd4f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b156f55b-e6f2-4d3d-850c-26a4dc3c70bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_08387582-79fc-4c0a-81ef-6a49763673aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9485c0e5-ea7c-4f96-84bc-538d417d6b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_08387582-79fc-4c0a-81ef-6a49763673aa" xlink:to="loc_us-gaap_NetIncomeLoss_9485c0e5-ea7c-4f96-84bc-538d417d6b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8186bb0f-42a5-4221-9209-43bc18a25fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_08387582-79fc-4c0a-81ef-6a49763673aa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8186bb0f-42a5-4221-9209-43bc18a25fcc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_05ca85bf-23a0-406d-a0be-4fb26e43a21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_394a4cb3-800a-46ef-ab34-af711c67fe83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_05ca85bf-23a0-406d-a0be-4fb26e43a21b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_394a4cb3-800a-46ef-ab34-af711c67fe83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_598878f9-2f6b-4178-8913-7605ce07072f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_05ca85bf-23a0-406d-a0be-4fb26e43a21b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_598878f9-2f6b-4178-8913-7605ce07072f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_946ee7d9-700c-4dab-b27f-b49daf38c20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_05ca85bf-23a0-406d-a0be-4fb26e43a21b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_946ee7d9-700c-4dab-b27f-b49daf38c20c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2050362c-c1db-40d2-a52b-b263a997241e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_cb6a4fc7-2fa0-4c55-aa73-b0a88ba67984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2050362c-c1db-40d2-a52b-b263a997241e" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_cb6a4fc7-2fa0-4c55-aa73-b0a88ba67984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f51c3d2f-ee3f-4f7f-98d0-cf6b84037756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2050362c-c1db-40d2-a52b-b263a997241e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f51c3d2f-ee3f-4f7f-98d0-cf6b84037756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_debe98b4-7f08-4976-bf98-b492e9c13ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2050362c-c1db-40d2-a52b-b263a997241e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_debe98b4-7f08-4976-bf98-b492e9c13ab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e8756471-4e54-4620-b17d-cf0966dfc0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2050362c-c1db-40d2-a52b-b263a997241e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e8756471-4e54-4620-b17d-cf0966dfc0b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d2906a47-dd48-4266-9b88-461df6ac5be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2050362c-c1db-40d2-a52b-b263a997241e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d2906a47-dd48-4266-9b88-461df6ac5be9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68a73d47-ff28-4e51-ad64-f2609e4d703f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2050362c-c1db-40d2-a52b-b263a997241e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68a73d47-ff28-4e51-ad64-f2609e4d703f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8f0a7ba6-a0d6-4f5b-aa4a-e60f836a6683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2050362c-c1db-40d2-a52b-b263a997241e" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8f0a7ba6-a0d6-4f5b-aa4a-e60f836a6683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentOfContingentConsideration_1fac6f1a-ef64-4fb3-a019-9d3eeb682bd6" xlink:href="pcrx-20211231.xsd#pcrx_PaymentOfContingentConsideration"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2050362c-c1db-40d2-a52b-b263a997241e" xlink:to="loc_pcrx_PaymentOfContingentConsideration_1fac6f1a-ef64-4fb3-a019-9d3eeb682bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_42c109f7-fd9d-480e-a791-17d4e7d4fea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_42c109f7-fd9d-480e-a791-17d4e7d4fea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_473b689f-92bf-466c-85db-d3fe38a23a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_473b689f-92bf-466c-85db-d3fe38a23a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes_97ccdf3c-939c-42d7-bc7c-a91eac4a173c" xlink:href="pcrx-20211231.xsd#pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes_97ccdf3c-939c-42d7-bc7c-a91eac4a173c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt_97c4ab27-12ae-4b46-8207-55028c303cf0" xlink:href="pcrx-20211231.xsd#pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt_97c4ab27-12ae-4b46-8207-55028c303cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_40f0b320-fd91-4efc-ae46-383bcee76b6c" xlink:href="pcrx-20211231.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_40f0b320-fd91-4efc-ae46-383bcee76b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_b4535c0e-6669-43e3-8792-f7752d9c9217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_b4535c0e-6669-43e3-8792-f7752d9c9217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_39e42fa3-08a2-4a17-afae-b40ec37dd16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_39e42fa3-08a2-4a17-afae-b40ec37dd16e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_c0ed21ce-2c99-48e1-b705-c6989e754f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_c0ed21ce-2c99-48e1-b705-c6989e754f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_fd580f71-1221-429c-afc5-c5a8137d4302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_fd580f71-1221-429c-afc5-c5a8137d4302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentsForDebtConversionPremiums_fc650955-ba02-4513-a556-590b9997440c" xlink:href="pcrx-20211231.xsd#pcrx_PaymentsForDebtConversionPremiums"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_36e204a0-04a1-44c7-9631-618c7fdc54b7" xlink:to="loc_pcrx_PaymentsForDebtConversionPremiums_fc650955-ba02-4513-a556-590b9997440c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c5e293e5-517c-4879-b856-58aa8eca2f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c5e293e5-517c-4879-b856-58aa8eca2f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_32f0e2b4-e838-4c71-ad38-c598111c0510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_32f0e2b4-e838-4c71-ad38-c598111c0510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8d7a25e5-7d07-4f56-b844-cc7e5f238cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_ShareBasedCompensation_8d7a25e5-7d07-4f56-b844-cc7e5f238cc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0c741d3a-d338-4eab-89d1-6cf93ff0f412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0c741d3a-d338-4eab-89d1-6cf93ff0f412" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c8cc838-232e-4583-8763-a639f5ad57c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c8cc838-232e-4583-8763-a639f5ad57c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73c52ec6-daf4-409a-aab8-803aa7c15bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73c52ec6-daf4-409a-aab8-803aa7c15bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8be5edeb-0f6b-4cb0-802d-5e3b9b568e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8be5edeb-0f6b-4cb0-802d-5e3b9b568e9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5680c2cd-3364-4edf-899b-c72bd0d048c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5680c2cd-3364-4edf-899b-c72bd0d048c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_34ac10d7-c6d4-4f34-87d1-40646c6fd8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_34ac10d7-c6d4-4f34-87d1-40646c6fd8b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_55d6fb7c-68c9-49c3-b735-28c6347d4381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_55d6fb7c-68c9-49c3-b735-28c6347d4381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_56451aa0-d11c-4bdb-9bf3-40c12d167f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_56451aa0-d11c-4bdb-9bf3-40c12d167f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_829a404a-60c4-4f03-9522-711acd813000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_829a404a-60c4-4f03-9522-711acd813000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_44d01b9d-0151-47d8-a157-ab80972be0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_44d01b9d-0151-47d8-a157-ab80972be0f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_24112d5b-e71b-4f81-882b-db36edc9309b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_24112d5b-e71b-4f81-882b-db36edc9309b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9635c684-d352-41de-a03c-d42a94e2fc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9635c684-d352-41de-a03c-d42a94e2fc25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0f900f7d-a1d9-4c26-8426-4a1bbac17851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0f900f7d-a1d9-4c26-8426-4a1bbac17851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_c002f092-3c51-4c5a-a006-de82d06a29e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_GainLossOnInvestments_c002f092-3c51-4c5a-a006-de82d06a29e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6f8aa912-df01-4a2a-9a4d-5b10dfc1f85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_520422a4-0361-4b7b-a681-258ee90e03ff" xlink:to="loc_us-gaap_NetIncomeLoss_6f8aa912-df01-4a2a-9a4d-5b10dfc1f85a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_51868339-f5cc-4383-92fa-fa61fbaaea06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e35e1a42-e6f1-4615-8de7-5f0a3e870235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_51868339-f5cc-4383-92fa-fa61fbaaea06" xlink:to="loc_us-gaap_Goodwill_e35e1a42-e6f1-4615-8de7-5f0a3e870235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c3194bee-85bf-4291-b8df-9f67abe395b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_51868339-f5cc-4383-92fa-fa61fbaaea06" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c3194bee-85bf-4291-b8df-9f67abe395b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_bc1cd7c3-22d9-4c47-ad0f-39a5e1dbf311" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_bc1cd7c3-22d9-4c47-ad0f-39a5e1dbf311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d3248c86-ffb1-494c-8a13-1b0691fa3396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d3248c86-ffb1-494c-8a13-1b0691fa3396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_26a48c5a-dc66-4328-ba18-3c581237cf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_26a48c5a-dc66-4328-ba18-3c581237cf6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_dd4e49e4-523c-48ef-9655-4fefbbd1b8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_dd4e49e4-523c-48ef-9655-4fefbbd1b8b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d0a6f2d8-4d6d-4f43-8737-613d97576687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d0a6f2d8-4d6d-4f43-8737-613d97576687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_394fc5b2-62fb-4ef8-a1bd-9594bbedbf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_394fc5b2-62fb-4ef8-a1bd-9594bbedbf1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_8a552c83-faeb-4b2c-aadc-c2126b2a68ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_8a552c83-faeb-4b2c-aadc-c2126b2a68ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b3c01cd5-cb52-4ad2-96db-4cf1f367ed55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b3c01cd5-cb52-4ad2-96db-4cf1f367ed55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2dfffc54-6009-4716-97b6-4c896ad55c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2dfffc54-6009-4716-97b6-4c896ad55c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_94e049b0-5d76-4ec6-b191-a17c57ce90b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_f48649e4-d631-433c-9f85-4458530b5a00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_94e049b0-5d76-4ec6-b191-a17c57ce90b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d92b27f4-81ca-4a70-988b-10f9db0702e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9c713ecc-b080-406b-a064-7cf15e38cb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d92b27f4-81ca-4a70-988b-10f9db0702e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_9c713ecc-b080-406b-a064-7cf15e38cb5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_8e710258-b5be-42c5-9fa8-fe7862790270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d92b27f4-81ca-4a70-988b-10f9db0702e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_8e710258-b5be-42c5-9fa8-fe7862790270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_a3b8ce92-49d3-480a-9a8d-846b4fe37f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d92b27f4-81ca-4a70-988b-10f9db0702e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_a3b8ce92-49d3-480a-9a8d-846b4fe37f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_0f10cac2-4717-40fb-a7e2-4ecbd17b3b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d92b27f4-81ca-4a70-988b-10f9db0702e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_0f10cac2-4717-40fb-a7e2-4ecbd17b3b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_c8fa4eea-a4d6-43e3-8cdb-eaabfd0a49a4" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d92b27f4-81ca-4a70-988b-10f9db0702e0" xlink:to="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_c8fa4eea-a4d6-43e3-8cdb-eaabfd0a49a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_99f66eaa-1224-4474-b64b-ff848d8c2b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_d92b27f4-81ca-4a70-988b-10f9db0702e0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_99f66eaa-1224-4474-b64b-ff848d8c2b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_85c7d758-752f-47eb-9398-2b098c325dc7" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_85c7d758-752f-47eb-9398-2b098c325dc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_20148b6d-270a-4af7-8b76-748638986283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_20148b6d-270a-4af7-8b76-748638986283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a03f392b-1289-47ce-96fc-ff474fad5358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a03f392b-1289-47ce-96fc-ff474fad5358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_36e618aa-c72f-4646-babf-8ff940492470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_36e618aa-c72f-4646-babf-8ff940492470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_58c639df-9147-464e-9993-43285f1ba218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_58c639df-9147-464e-9993-43285f1ba218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_4b651286-4ea0-49f4-97fe-a43c7fe1cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_4b651286-4ea0-49f4-97fe-a43c7fe1cc62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_496f8379-e7f6-4e71-af36-538dadee4154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_496f8379-e7f6-4e71-af36-538dadee4154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_e658b81f-eecc-4d11-8634-5cac7b044e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_e658b81f-eecc-4d11-8634-5cac7b044e2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a999cac6-2370-4a5b-ab10-906f470ffb70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a999cac6-2370-4a5b-ab10-906f470ffb70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cd4f77b9-0660-490b-b36d-a921b6826597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_cd4f77b9-0660-490b-b36d-a921b6826597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_601e4175-8a8c-4470-b240-5de04802b7ca" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_601e4175-8a8c-4470-b240-5de04802b7ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_238ea78f-ca37-4726-b3aa-732ecef2139a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_238ea78f-ca37-4726-b3aa-732ecef2139a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_868cb2de-1e44-49fb-8f0a-2a15a519192d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_868cb2de-1e44-49fb-8f0a-2a15a519192d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2337cf2d-d618-42ea-9cab-24a8546685af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2337cf2d-d618-42ea-9cab-24a8546685af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_df95c325-795d-4e29-a561-1ed33fd046a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_df95c325-795d-4e29-a561-1ed33fd046a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9defaeff-ada6-4755-90a5-90c17e8a5028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f52f8c71-6e60-4a81-8489-5178028a52ef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9defaeff-ada6-4755-90a5-90c17e8a5028" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INVENTORIESComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a775fe4e-007f-4529-8e84-3b0c9292c055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a19c8681-6da0-445c-9cde-868f47880212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a775fe4e-007f-4529-8e84-3b0c9292c055" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a19c8681-6da0-445c-9cde-868f47880212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_59565383-a759-4443-b7fc-35c7f579de8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a775fe4e-007f-4529-8e84-3b0c9292c055" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_59565383-a759-4443-b7fc-35c7f579de8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d0e94b13-b344-4284-b17c-713e68d8b12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a775fe4e-007f-4529-8e84-3b0c9292c055" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d0e94b13-b344-4284-b17c-713e68d8b12d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FIXEDASSETSScheduleofUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c8d164a1-0edb-4a22-bd7c-0e385ae5ace0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_945bd00a-d280-4031-a7c9-8f44542ec1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c8d164a1-0edb-4a22-bd7c-0e385ae5ace0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_945bd00a-d280-4031-a7c9-8f44542ec1a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9142e75f-229e-4a77-9eed-95afd6291f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c8d164a1-0edb-4a22-bd7c-0e385ae5ace0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9142e75f-229e-4a77-9eed-95afd6291f5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0097f3e3-f810-4098-96c2-7fd13f44605b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3d0ca146-e3b0-4202-aa7d-44bcd6ee2cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0097f3e3-f810-4098-96c2-7fd13f44605b" xlink:to="loc_us-gaap_OperatingLeaseCost_3d0ca146-e3b0-4202-aa7d-44bcd6ee2cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_d87f13a8-9cb8-4da5-a5bf-db0be69ee223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0097f3e3-f810-4098-96c2-7fd13f44605b" xlink:to="loc_us-gaap_VariableLeaseCost_d87f13a8-9cb8-4da5-a5bf-db0be69ee223" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_306c47e6-74ca-4b7a-94d1-953a704c7103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6e52b593-4156-4c43-82da-7f4861d63be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_306c47e6-74ca-4b7a-94d1-953a704c7103" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6e52b593-4156-4c43-82da-7f4861d63be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_290f1457-2e28-4252-8752-fc1b8bccff71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_306c47e6-74ca-4b7a-94d1-953a704c7103" xlink:to="loc_us-gaap_OperatingLeaseLiability_290f1457-2e28-4252-8752-fc1b8bccff71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_873f5f34-e9ce-4200-9475-8833d0ab3d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_34669473-60c2-4578-a70c-d090fd1848b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_873f5f34-e9ce-4200-9475-8833d0ab3d27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_34669473-60c2-4578-a70c-d090fd1848b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8395794c-1e40-44c1-b5d5-228ca812d715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_873f5f34-e9ce-4200-9475-8833d0ab3d27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8395794c-1e40-44c1-b5d5-228ca812d715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f1f1380f-4ed0-414c-89b6-de9518bb4dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_873f5f34-e9ce-4200-9475-8833d0ab3d27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f1f1380f-4ed0-414c-89b6-de9518bb4dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e2781d44-b363-4ecf-bee3-3a578ef16c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_873f5f34-e9ce-4200-9475-8833d0ab3d27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e2781d44-b363-4ecf-bee3-3a578ef16c71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fbc4101a-66b4-4d9f-8e97-81b5ba94b972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_873f5f34-e9ce-4200-9475-8833d0ab3d27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fbc4101a-66b4-4d9f-8e97-81b5ba94b972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_225f3bc5-ca5a-4e1e-b0d9-a81df21828a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_873f5f34-e9ce-4200-9475-8833d0ab3d27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_225f3bc5-ca5a-4e1e-b0d9-a81df21828a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ac66edc-bced-4f49-a128-6ad9161f8dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_68aec32e-76a4-4a84-9d76-45a17b990adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ac66edc-bced-4f49-a128-6ad9161f8dee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_68aec32e-76a4-4a84-9d76-45a17b990adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_680fa502-b44e-4a1d-b2a7-701e5c07c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ac66edc-bced-4f49-a128-6ad9161f8dee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_680fa502-b44e-4a1d-b2a7-701e5c07c3d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0ce9999b-332c-4016-b88f-34660278a6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_Accruedsellinggeneralandadministrativeexpenses_e2c6464e-9db6-4aa8-8b84-3978ef0ad9d6" xlink:href="pcrx-20211231.xsd#pcrx_Accruedsellinggeneralandadministrativeexpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ce9999b-332c-4016-b88f-34660278a6ce" xlink:to="loc_pcrx_Accruedsellinggeneralandadministrativeexpenses_e2c6464e-9db6-4aa8-8b84-3978ef0ad9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_Accruedresearchanddevelopmentexpenses_81216940-2b09-40b6-9c6a-1f3498272ebf" xlink:href="pcrx-20211231.xsd#pcrx_Accruedresearchanddevelopmentexpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ce9999b-332c-4016-b88f-34660278a6ce" xlink:to="loc_pcrx_Accruedresearchanddevelopmentexpenses_81216940-2b09-40b6-9c6a-1f3498272ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4691c29f-b894-4130-8d05-0533c9be91b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ce9999b-332c-4016-b88f-34660278a6ce" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4691c29f-b894-4130-8d05-0533c9be91b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedOperatingExpensesCurrent_6ecc8340-4d88-4c2c-b45b-a93b004db716" xlink:href="pcrx-20211231.xsd#pcrx_AccruedOperatingExpensesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ce9999b-332c-4016-b88f-34660278a6ce" xlink:to="loc_pcrx_AccruedOperatingExpensesCurrent_6ecc8340-4d88-4c2c-b45b-a93b004db716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_eb83a60d-7249-4733-8b71-41c32df8126c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ce9999b-332c-4016-b88f-34660278a6ce" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_eb83a60d-7249-4733-8b71-41c32df8126c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedEndOfTermFeeCurrent_f180eab3-f2ed-453e-a3e0-c9226f86fa34" xlink:href="pcrx-20211231.xsd#pcrx_AccruedEndOfTermFeeCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ce9999b-332c-4016-b88f-34660278a6ce" xlink:to="loc_pcrx_AccruedEndOfTermFeeCurrent_f180eab3-f2ed-453e-a3e0-c9226f86fa34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProductReturnsRebatesandOtherFees_42f57eba-9bac-432d-8da6-cf8a2983c576" xlink:href="pcrx-20211231.xsd#pcrx_ProductReturnsRebatesandOtherFees"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0ce9999b-332c-4016-b88f-34660278a6ce" xlink:to="loc_pcrx_ProductReturnsRebatesandOtherFees_42f57eba-9bac-432d-8da6-cf8a2983c576" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_62183fef-9311-4788-a260-94a347965f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0ed33bbd-ee2b-4667-ae2b-cae7a43d328b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_62183fef-9311-4788-a260-94a347965f97" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0ed33bbd-ee2b-4667-ae2b-cae7a43d328b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4daaaca9-5406-4e42-99fe-77039aa2bb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_62183fef-9311-4788-a260-94a347965f97" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4daaaca9-5406-4e42-99fe-77039aa2bb29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_89a3b0d9-f06c-4861-849b-15fcf7e7414f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_62183fef-9311-4788-a260-94a347965f97" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_89a3b0d9-f06c-4861-849b-15fcf7e7414f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_08fdd801-90d6-4cc5-a7fc-cd43e4376942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_3093f0b3-5d2e-4136-bcc7-856f5c85ad97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_08fdd801-90d6-4cc5-a7fc-cd43e4376942" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_3093f0b3-5d2e-4136-bcc7-856f5c85ad97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4c7fba96-be71-407a-b007-8e9c5925f897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_08fdd801-90d6-4cc5-a7fc-cd43e4376942" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4c7fba96-be71-407a-b007-8e9c5925f897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_124952be-cb29-4732-9b64-ab98427d983b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_08fdd801-90d6-4cc5-a7fc-cd43e4376942" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_124952be-cb29-4732-9b64-ab98427d983b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalizedAdjustment_9a300232-32a9-4fda-9b73-50e6ce9c8838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalizedAdjustment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_08fdd801-90d6-4cc5-a7fc-cd43e4376942" xlink:to="loc_us-gaap_InterestCostsCapitalizedAdjustment_9a300232-32a9-4fda-9b73-50e6ce9c8838" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba291b34-1046-4b54-9213-0dc78cb7a6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ea83a470-d818-4f3a-8833-95bd210961e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba291b34-1046-4b54-9213-0dc78cb7a6d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ea83a470-d818-4f3a-8833-95bd210961e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5875ba88-efa4-4956-b18c-a39e8b582660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba291b34-1046-4b54-9213-0dc78cb7a6d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5875ba88-efa4-4956-b18c-a39e8b582660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f4b0732d-7aa7-4c26-8b93-f7a47a7615bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba291b34-1046-4b54-9213-0dc78cb7a6d9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f4b0732d-7aa7-4c26-8b93-f7a47a7615bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESCurrentandDeferredIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_dd0f9433-5035-4728-89e8-94ce7b51529b" xlink:href="pcrx-20211231.xsd#pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5329d95a-da63-4247-a668-a3073d9a6548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_dd0f9433-5035-4728-89e8-94ce7b51529b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5329d95a-da63-4247-a668-a3073d9a6548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5df911e5-bbfc-403a-b382-26c915a2f56a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_dd0f9433-5035-4728-89e8-94ce7b51529b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5df911e5-bbfc-403a-b382-26c915a2f56a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d33fd95d-8543-49bc-be1e-30a11105c6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_45579536-6d43-4521-b180-d306c673e16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d33fd95d-8543-49bc-be1e-30a11105c6d8" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_45579536-6d43-4521-b180-d306c673e16f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_acee50f5-21e2-43b4-b19e-aae1d017c6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d33fd95d-8543-49bc-be1e-30a11105c6d8" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_acee50f5-21e2-43b4-b19e-aae1d017c6c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6d799db4-8cae-4cf5-9171-efee2dda5195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d33fd95d-8543-49bc-be1e-30a11105c6d8" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6d799db4-8cae-4cf5-9171-efee2dda5195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e9c20317-5703-471a-8fde-615a55cafeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d7e4924e-1711-456b-a7f1-f26c5ebb2e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e9c20317-5703-471a-8fde-615a55cafeb6" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d7e4924e-1711-456b-a7f1-f26c5ebb2e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_889d83f8-8bf8-4106-9e7c-9a8d943306b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e9c20317-5703-471a-8fde-615a55cafeb6" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_889d83f8-8bf8-4106-9e7c-9a8d943306b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4b9f11b4-2136-461c-8811-717fc9a8f41c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c7b5fea-5f0b-4398-bd18-057bc39b577b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4b9f11b4-2136-461c-8811-717fc9a8f41c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c7b5fea-5f0b-4398-bd18-057bc39b577b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e030ac63-3273-49b7-9405-ee841ed42375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4b9f11b4-2136-461c-8811-717fc9a8f41c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e030ac63-3273-49b7-9405-ee841ed42375" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESReconciliationofEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_183ec838-052a-41ec-916f-849430666e60" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_183ec838-052a-41ec-916f-849430666e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3703c232-b9b4-45cb-b78c-9f3368e169fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3703c232-b9b4-45cb-b78c-9f3368e169fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit_3fe5a953-4028-47c6-baca-b9d65baa1c39" xlink:href="pcrx-20211231.xsd#pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit_3fe5a953-4028-47c6-baca-b9d65baa1c39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_3054e817-afe1-4384-8dbf-645980e34375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_3054e817-afe1-4384-8dbf-645980e34375" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_c4195a9e-1159-4687-93ff-e352e24136a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_c4195a9e-1159-4687-93ff-e352e24136a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8babb2ed-6eaf-4f85-bfdb-818c15a2391e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8babb2ed-6eaf-4f85-bfdb-818c15a2391e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_eaa3b419-0e66-4d23-ab0f-84642166f1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_eaa3b419-0e66-4d23-ab0f-84642166f1e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent_836ae102-7131-4762-97fa-fecfe63015cc" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent_836ae102-7131-4762-97fa-fecfe63015cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_7c3e938c-d694-4bb4-9937-948ccafb190d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_7c3e938c-d694-4bb4-9937-948ccafb190d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_94c4d083-8a89-437d-a44d-c34940aaec85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_94c4d083-8a89-437d-a44d-c34940aaec85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_486c14e6-55d4-4ca3-9030-c399cb565fe5" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationForeign"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_486c14e6-55d4-4ca3-9030-c399cb565fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent_27707bd0-8341-414d-8c00-acc011e27157" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_32291b7e-ba6a-495f-8171-a42f4103a15a" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent_27707bd0-8341-414d-8c00-acc011e27157" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2afdecca-862a-41be-ab81-f783e392c313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_b1fc0d66-0f28-460f-b782-003a784880df" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2afdecca-862a-41be-ab81-f783e392c313" xlink:to="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_b1fc0d66-0f28-460f-b782-003a784880df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_da486fcf-de0f-472a-9183-18498e330e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2afdecca-862a-41be-ab81-f783e392c313" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_da486fcf-de0f-472a-9183-18498e330e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f1debab8-932d-4453-9964-65f90c5cf9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_f2102e76-fa96-4939-8220-d43e7c35a5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f1debab8-932d-4453-9964-65f90c5cf9bf" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_f2102e76-fa96-4939-8220-d43e7c35a5d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b08f50c7-e9a1-4303-a8bd-83804979a770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f1debab8-932d-4453-9964-65f90c5cf9bf" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b08f50c7-e9a1-4303-a8bd-83804979a770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_501e303f-acd5-4e3f-9894-ae6f0dc572f5" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5fb1eed3-5a2b-4e21-b1df-1d2e87a1d505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_501e303f-acd5-4e3f-9894-ae6f0dc572f5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5fb1eed3-5a2b-4e21-b1df-1d2e87a1d505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fa025829-de91-45db-b2bd-bb87a214dda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_501e303f-acd5-4e3f-9894-ae6f0dc572f5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fa025829-de91-45db-b2bd-bb87a214dda7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fe766f7e-43b3-450b-822a-16ba9f8a26fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c9aff3db-ff54-4e89-aa8c-a802ff3964ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe766f7e-43b3-450b-822a-16ba9f8a26fe" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c9aff3db-ff54-4e89-aa8c-a802ff3964ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_7b3a8d6c-4c48-46bf-8cd4-30d6f5032585" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxAssetsStockBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe766f7e-43b3-450b-822a-16ba9f8a26fe" xlink:to="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_7b3a8d6c-4c48-46bf-8cd4-30d6f5032585" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_9cbd7bf4-ffa9-4a46-a8fa-7340ba754de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe766f7e-43b3-450b-822a-16ba9f8a26fe" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_9cbd7bf4-ffa9-4a46-a8fa-7340ba754de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3b9cb865-ba54-4b0a-b6f1-3430330eb73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe766f7e-43b3-450b-822a-16ba9f8a26fe" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3b9cb865-ba54-4b0a-b6f1-3430330eb73f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8d84d2bb-dd6d-47a0-af99-27705e0a9e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe766f7e-43b3-450b-822a-16ba9f8a26fe" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8d84d2bb-dd6d-47a0-af99-27705e0a9e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_a17f76b9-2f46-4c9d-b42f-903085b8960a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe766f7e-43b3-450b-822a-16ba9f8a26fe" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_a17f76b9-2f46-4c9d-b42f-903085b8960a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e972987f-d20d-406c-9588-f2e5b3d7480b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe766f7e-43b3-450b-822a-16ba9f8a26fe" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e972987f-d20d-406c-9588-f2e5b3d7480b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>pcrx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:66f2c054-d932-41b4-84f1-797b86c41d80,g:418797a4-960d-471e-b290-1e4b5463b147-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="ida6733a33f8244a0844fa2e0cea1fde1_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b3837ff6-e020-4474-becd-c393eccef0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b3837ff6-e020-4474-becd-c393eccef0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3483ea00-9f4b-4788-a8ce-e6189da937b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3483ea00-9f4b-4788-a8ce-e6189da937b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_670b304e-f150-4964-8642-cefd3f32eae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:to="loc_us-gaap_Revenues_670b304e-f150-4964-8642-cefd3f32eae8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_e05544c5-266f-440c-8a76-55d49450a322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_CostOfRevenue_e05544c5-266f-440c-8a76-55d49450a322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c3d4f330-4eeb-4c27-a91d-b2d89dccac05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c3d4f330-4eeb-4c27-a91d-b2d89dccac05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5cc596ce-9de5-4804-b384-c2689e6ceb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5cc596ce-9de5-4804-b384-c2689e6ceb02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ec8b5be8-521f-4b3c-9105-b975da12b2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ec8b5be8-521f-4b3c-9105-b975da12b2b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses_7d8e1d0e-9c69-4a30-973b-884c482a7a2e" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses_7d8e1d0e-9c69-4a30-973b-884c482a7a2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_032970f7-16a1-4eaf-9579-f1765a8ad871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_CostsAndExpenses_032970f7-16a1-4eaf-9579-f1765a8ad871" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_58e1a98a-da7a-4c1b-b4e8-78165f2b5ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_OperatingIncomeLoss_58e1a98a-da7a-4c1b-b4e8-78165f2b5ca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f5ae023d-4813-4626-a812-d764131ed82e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f5ae023d-4813-4626-a812-d764131ed82e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_93bd879e-8299-4ba6-842d-a9c1769b15df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_InterestExpense_93bd879e-8299-4ba6-842d-a9c1769b15df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_40866da7-6eed-4f91-bc10-323e772e53e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_40866da7-6eed-4f91-bc10-323e772e53e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_12fc1f84-b878-405b-aebe-7f2cbae87def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_12fc1f84-b878-405b-aebe-7f2cbae87def" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fc82722e-37a9-464a-b44a-9e22fe628c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fc82722e-37a9-464a-b44a-9e22fe628c7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ad3ad7bf-a270-4442-bc60-7dad08b1d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ad3ad7bf-a270-4442-bc60-7dad08b1d96d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ec7ae3aa-136b-4f25-a9c4-d8ea1eb1241d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ec7ae3aa-136b-4f25-a9c4-d8ea1eb1241d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c57187c-353a-4aa0-bc86-97590ac7df15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_NetIncomeLoss_7c57187c-353a-4aa0-bc86-97590ac7df15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_676c5d2c-edd3-4568-bbcc-701641d40dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_EarningsPerShareAbstract_676c5d2c-edd3-4568-bbcc-701641d40dbd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_450a2391-cb29-42c3-ab8d-d7e52f7a8f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_676c5d2c-edd3-4568-bbcc-701641d40dbd" xlink:to="loc_us-gaap_EarningsPerShareBasic_450a2391-cb29-42c3-ab8d-d7e52f7a8f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b4000926-8862-47b0-93d5-e440efc97817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_676c5d2c-edd3-4568-bbcc-701641d40dbd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b4000926-8862-47b0-93d5-e440efc97817" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_035b560f-356c-47ba-bde8-4b15de48a688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_035b560f-356c-47ba-bde8-4b15de48a688" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1adf0aa1-60fe-45c4-9bc1-2fd7a3e52776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_035b560f-356c-47ba-bde8-4b15de48a688" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1adf0aa1-60fe-45c4-9bc1-2fd7a3e52776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61831a36-7ad5-471e-9832-85a2f5b0e72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_035b560f-356c-47ba-bde8-4b15de48a688" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61831a36-7ad5-471e-9832-85a2f5b0e72b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ead4f8ea-126b-4b45-91c7-1c988e66711d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_StatementTable_ead4f8ea-126b-4b45-91c7-1c988e66711d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7158d05-c70d-4891-ae46-2f96d01e5beb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ead4f8ea-126b-4b45-91c7-1c988e66711d" xlink:to="loc_srt_ProductOrServiceAxis_d7158d05-c70d-4891-ae46-2f96d01e5beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7158d05-c70d-4891-ae46-2f96d01e5beb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d7158d05-c70d-4891-ae46-2f96d01e5beb" xlink:to="loc_srt_ProductsAndServicesDomain_d7158d05-c70d-4891-ae46-2f96d01e5beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9f9a2b4b-9b56-4945-9815-d7fa2e455b2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d7158d05-c70d-4891-ae46-2f96d01e5beb" xlink:to="loc_srt_ProductsAndServicesDomain_9f9a2b4b-9b56-4945-9815-d7fa2e455b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9008c6a4-2854-4568-b8b1-d7e7ba9ec917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9f9a2b4b-9b56-4945-9815-d7fa2e455b2e" xlink:to="loc_us-gaap_ProductMember_9008c6a4-2854-4568-b8b1-d7e7ba9ec917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_16890daf-0773-43e5-8ca8-8a3c13e9728a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9f9a2b4b-9b56-4945-9815-d7fa2e455b2e" xlink:to="loc_us-gaap_RoyaltyMember_16890daf-0773-43e5-8ca8-8a3c13e9728a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i5e5febd3488f41a2a4f7aa1401937266_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e80546e5-8426-42b6-a816-394ee1ea4159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e80546e5-8426-42b6-a816-394ee1ea4159" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c3a212f6-5db3-4c41-a481-bf0950692b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_SharesOutstanding_c3a212f6-5db3-4c41-a481-bf0950692b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_140eb2c8-2d47-4ea5-b650-96ef099acbec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockholdersEquity_140eb2c8-2d47-4ea5-b650-96ef099acbec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_31403039-8a38-403e-9176-53da22ff0788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_31403039-8a38-403e-9176-53da22ff0788" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_03d6be1f-e210-427b-85a3-260b3f071484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_03d6be1f-e210-427b-85a3-260b3f071484" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_921c8154-00d2-4367-bbd3-bb718d836f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_921c8154-00d2-4367-bbd3-bb718d836f10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_47d6078f-09f2-4c49-a2c5-5e228a839784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_47d6078f-09f2-4c49-a2c5-5e228a839784" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0960a56d-1e37-4d1e-823a-a9984ab589cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0960a56d-1e37-4d1e-823a-a9984ab589cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_75527c45-1b26-41ec-903e-29d619dce9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_75527c45-1b26-41ec-903e-29d619dce9b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_738b8b3e-cf59-4b76-94f2-590b2e5b955a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_738b8b3e-cf59-4b76-94f2-590b2e5b955a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ddf976cd-1ca1-4381-8cb4-16271174f72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ddf976cd-1ca1-4381-8cb4-16271174f72c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b883746c-8c48-4137-8ebe-8c58f38c30e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_NetIncomeLoss_b883746c-8c48-4137-8ebe-8c58f38c30e1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_31bfbbdd-1076-43c3-b6de-0c84ffdbdfba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e5deb45a-3dd6-4213-8471-06b1fd2f56e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_06fc2081-fc5f-4220-8f9e-9fca680a7900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e80546e5-8426-42b6-a816-394ee1ea4159" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_06fc2081-fc5f-4220-8f9e-9fca680a7900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e80546e5-8426-42b6-a816-394ee1ea4159" xlink:to="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cf456df6-119d-4d17-ac1c-6cf8aa6a3352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cf456df6-119d-4d17-ac1c-6cf8aa6a3352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cf456df6-119d-4d17-ac1c-6cf8aa6a3352_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf456df6-119d-4d17-ac1c-6cf8aa6a3352" xlink:to="loc_us-gaap_EquityComponentDomain_cf456df6-119d-4d17-ac1c-6cf8aa6a3352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf456df6-119d-4d17-ac1c-6cf8aa6a3352" xlink:to="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1e55e5c-5ea6-469a-a7da-6b9ad02c50d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:to="loc_us-gaap_CommonStockMember_e1e55e5c-5ea6-469a-a7da-6b9ad02c50d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f08f55a8-798f-4bb6-8152-49a19eed82fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f08f55a8-798f-4bb6-8152-49a19eed82fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4f09514a-2a43-4ef6-ac36-470b154ef3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:to="loc_us-gaap_RetainedEarningsMember_4f09514a-2a43-4ef6-ac36-470b154ef3f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_887dd372-6acd-4799-8baa-3985537f5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_887dd372-6acd-4799-8baa-3985537f5cae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_86a381c0-6724-4e97-bfdf-9066d31243fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:to="loc_us-gaap_DebtInstrumentAxis_86a381c0-6724-4e97-bfdf-9066d31243fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86a381c0-6724-4e97-bfdf-9066d31243fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_86a381c0-6724-4e97-bfdf-9066d31243fd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86a381c0-6724-4e97-bfdf-9066d31243fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_86a381c0-6724-4e97-bfdf-9066d31243fd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotes2019Member_49865f45-1afc-4abe-ae8c-0d47d5727ca0" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotes2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:to="loc_pcrx_ConvertibleSeniorNotes2019Member_49865f45-1afc-4abe-ae8c-0d47d5727ca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_697616de-a762-47ae-8fd7-ea7e04faca29" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_697616de-a762-47ae-8fd7-ea7e04faca29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotes2025Member_781602a2-0f71-4099-bea3-a54cc5202ac9" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotes2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:to="loc_pcrx_ConvertibleSeniorNotes2025Member_781602a2-0f71-4099-bea3-a54cc5202ac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_15e23ba4-08fd-4861-bb8c-0bb080dd017a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_15e23ba4-08fd-4861-bb8c-0bb080dd017a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_15e23ba4-08fd-4861-bb8c-0bb080dd017a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_15e23ba4-08fd-4861-bb8c-0bb080dd017a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_15e23ba4-08fd-4861-bb8c-0bb080dd017a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5382fcba-23ed-45c8-8543-d0ad0a2e95d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_15e23ba4-08fd-4861-bb8c-0bb080dd017a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5382fcba-23ed-45c8-8543-d0ad0a2e95d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d516a62a-bdd4-4322-ba53-8fc9dc21c91c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5382fcba-23ed-45c8-8543-d0ad0a2e95d4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d516a62a-bdd4-4322-ba53-8fc9dc21c91c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i4c26b502b26a4b07afc86d96e005a3de_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b97fcaf-58c8-4cfa-8ca0-ba7f7e4c0ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:to="loc_us-gaap_NetIncomeLoss_7b97fcaf-58c8-4cfa-8ca0-ba7f7e4c0ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a298c8e-0336-40be-9f43-0924c83e3206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a298c8e-0336-40be-9f43-0924c83e3206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f2753f44-ef0d-4a47-923b-6db2d64439f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f2753f44-ef0d-4a47-923b-6db2d64439f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_69db47da-d456-45ff-889c-f39acf8dc48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_69db47da-d456-45ff-889c-f39acf8dc48d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8c858d5d-7ed2-44d2-9ac7-3f7eb1bf84b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8c858d5d-7ed2-44d2-9ac7-3f7eb1bf84b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_e8678519-dc7a-45e4-b2ec-73e24a2a51b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_e8678519-dc7a-45e4-b2ec-73e24a2a51b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed63d136-3a9c-45b0-b7e9-a30549ebc870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed63d136-3a9c-45b0-b7e9-a30549ebc870" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c925795d-3d57-4470-bf7d-93d726b32bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_ShareBasedCompensation_c925795d-3d57-4470-bf7d-93d726b32bf7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e27c4a8d-4235-478c-b9fd-35f8a6cf4de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e27c4a8d-4235-478c-b9fd-35f8a6cf4de6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_3616eead-4eb9-4f91-bbb3-6fe88278c665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_GainLossOnInvestments_3616eead-4eb9-4f91-bbb3-6fe88278c665" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2e20f2a2-8884-4af4-9fef-e079b48814be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2e20f2a2-8884-4af4-9fef-e079b48814be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8b3f0b31-2614-424f-ac6c-2ded07eacbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8b3f0b31-2614-424f-ac6c-2ded07eacbb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfe3502f-a7e7-46d1-9d95-9f57880501e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfe3502f-a7e7-46d1-9d95-9f57880501e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_56c917a1-4b3b-415f-a5ad-648e12ac30a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_56c917a1-4b3b-415f-a5ad-648e12ac30a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_71cda208-a98d-4866-a18d-7462111548d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_71cda208-a98d-4866-a18d-7462111548d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7c0053ae-f282-4a89-8ffd-a9bf9e80933a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7c0053ae-f282-4a89-8ffd-a9bf9e80933a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_489bdacf-c893-4568-97f0-ae2e524f53c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_489bdacf-c893-4568-97f0-ae2e524f53c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_415916f0-982a-4bdd-b6d3-b682c64e9471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_415916f0-982a-4bdd-b6d3-b682c64e9471" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bcfe4786-6905-4d5c-a575-5c30f195c0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bcfe4786-6905-4d5c-a575-5c30f195c0f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_a2261c0f-e041-45ba-b43d-850c9452d801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_a2261c0f-e041-45ba-b43d-850c9452d801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d5952428-0a88-4052-a04e-9e581f65786b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d5952428-0a88-4052-a04e-9e581f65786b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2b900db-97df-4990-98a8-7dce57a1a189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2b900db-97df-4990-98a8-7dce57a1a189" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a0bc03e5-8b92-4ce6-8c35-c3cca8fdba4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a0bc03e5-8b92-4ce6-8c35-c3cca8fdba4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_56a207ed-9894-47e3-bb30-58fb55c156c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_56a207ed-9894-47e3-bb30-58fb55c156c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentOfContingentConsideration_2b3c04bb-953f-4769-b097-4b66de099ccc" xlink:href="pcrx-20211231.xsd#pcrx_PaymentOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_pcrx_PaymentOfContingentConsideration_2b3c04bb-953f-4769-b097-4b66de099ccc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_572d7efc-608d-4da4-81c0-1cc8fe792d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_572d7efc-608d-4da4-81c0-1cc8fe792d82" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_e8819b9a-6e09-4904-bc38-3e7ddec69bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_e8819b9a-6e09-4904-bc38-3e7ddec69bd4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3edfa400-5a6f-44b4-81d6-f05e393c3ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3edfa400-5a6f-44b4-81d6-f05e393c3ee3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9084a709-85e1-4358-ba11-5bf92ae3b835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9084a709-85e1-4358-ba11-5bf92ae3b835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_8684f851-e44b-4a1f-aa64-005877bca6c7" xlink:href="pcrx-20211231.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_8684f851-e44b-4a1f-aa64-005877bca6c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_a79f351c-bcfb-4dcc-9962-3b7919a0093d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_a79f351c-bcfb-4dcc-9962-3b7919a0093d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_c2c147bc-673b-4039-9461-2d02cdaa7821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_c2c147bc-673b-4039-9461-2d02cdaa7821" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt_94b01ae3-45d8-49e6-8c0d-faf2c53a6cf3" xlink:href="pcrx-20211231.xsd#pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt_94b01ae3-45d8-49e6-8c0d-faf2c53a6cf3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_17037eca-98fd-49b9-b1d8-24a075edc3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_17037eca-98fd-49b9-b1d8-24a075edc3f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes_72c25c9b-c4a5-49df-8f2c-5baf1d789aaf" xlink:href="pcrx-20211231.xsd#pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes_72c25c9b-c4a5-49df-8f2c-5baf1d789aaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentsForDebtConversionPremiums_49571c8c-62ba-4d63-8f4b-fb5fc95a6217" xlink:href="pcrx-20211231.xsd#pcrx_PaymentsForDebtConversionPremiums"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_pcrx_PaymentsForDebtConversionPremiums_49571c8c-62ba-4d63-8f4b-fb5fc95a6217" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_16fadc20-99ee-4394-ae4d-66cf8dfd707a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_16fadc20-99ee-4394-ae4d-66cf8dfd707a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c208810f-5cc2-4f11-a3fe-ebc96d73fa47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c208810f-5cc2-4f11-a3fe-ebc96d73fa47" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17399872-3eca-4c8c-af6f-9bcd76f02a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17399872-3eca-4c8c-af6f-9bcd76f02a90" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cd07b807-e867-437f-b5d6-334b4728320f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cd07b807-e867-437f-b5d6-334b4728320f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_595c4a50-a05b-481a-9618-33f2f769b9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_595c4a50-a05b-481a-9618-33f2f769b9f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13a79f3d-04a0-4b55-9b58-e12bf7ec1d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9d88de7d-eab0-45cc-a834-c4b81c0ec4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9d88de7d-eab0-45cc-a834-c4b81c0ec4ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c165debd-0b29-4244-8711-9d5d6ddfa4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9d88de7d-eab0-45cc-a834-c4b81c0ec4ea" xlink:to="loc_us-gaap_InterestPaidNet_c165debd-0b29-4244-8711-9d5d6ddfa4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_e1fbca45-1c53-4ecb-af23-a87986883104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9d88de7d-eab0-45cc-a834-c4b81c0ec4ea" xlink:to="loc_us-gaap_IncomeTaxesPaid_e1fbca45-1c53-4ecb-af23-a87986883104" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ff050feb-5d0a-4a0f-ac14-3b7aa1699c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ff050feb-5d0a-4a0f-ac14-3b7aa1699c12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6a9d596-4cee-4b41-a3f2-7cbcd3f69cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ff050feb-5d0a-4a0f-ac14-3b7aa1699c12" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6a9d596-4cee-4b41-a3f2-7cbcd3f69cf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncreaseDecreaseInContingentConsideration_8bdf51a2-936d-49ff-9fb4-6638f95d10ac" xlink:href="pcrx-20211231.xsd#pcrx_IncreaseDecreaseInContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ff050feb-5d0a-4a0f-ac14-3b7aa1699c12" xlink:to="loc_pcrx_IncreaseDecreaseInContingentConsideration_8bdf51a2-936d-49ff-9fb4-6638f95d10ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0f7585fc-adae-4e59-b59c-732cfd4035af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_StatementTable_0f7585fc-adae-4e59-b59c-732cfd4035af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5ec9282-d540-4bcb-a8d1-8229d8a561ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0f7585fc-adae-4e59-b59c-732cfd4035af" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5ec9282-d540-4bcb-a8d1-8229d8a561ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b5ec9282-d540-4bcb-a8d1-8229d8a561ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5ec9282-d540-4bcb-a8d1-8229d8a561ca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b5ec9282-d540-4bcb-a8d1-8229d8a561ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5ec9282-d540-4bcb-a8d1-8229d8a561ca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_a7c67e2e-5076-4c7b-b8bb-fd2e00743f99" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_a7c67e2e-5076-4c7b-b8bb-fd2e00743f99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotes2019Member_da549052-0d2d-46a9-80a9-1e3d53ceaf53" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotes2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:to="loc_pcrx_ConvertibleSeniorNotes2019Member_da549052-0d2d-46a9-80a9-1e3d53ceaf53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_4e9f1357-4c17-4f29-a3ca-9e1a45a00994" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_4e9f1357-4c17-4f29-a3ca-9e1a45a00994" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended" id="i1b5eacba9192424e823375d94df33f9b_DESCRIPTIONOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6d825ac6-6352-4cee-b3b5-ad0640348d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberOfProducts_b408fb33-aa42-4436-9a8a-beebe0f9cc71" xlink:href="pcrx-20211231.xsd#pcrx_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6d825ac6-6352-4cee-b3b5-ad0640348d9e" xlink:to="loc_pcrx_ConcentrationRiskNumberOfProducts_b408fb33-aa42-4436-9a8a-beebe0f9cc71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_b942264e-1461-493c-a3ad-43d5800bfdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6d825ac6-6352-4cee-b3b5-ad0640348d9e" xlink:to="loc_us-gaap_ConcentrationRiskTable_b942264e-1461-493c-a3ad-43d5800bfdb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_be83a0e6-6513-4752-baa5-87280d393fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_b942264e-1461-493c-a3ad-43d5800bfdb7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_be83a0e6-6513-4752-baa5-87280d393fc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_be83a0e6-6513-4752-baa5-87280d393fc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_be83a0e6-6513-4752-baa5-87280d393fc5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_be83a0e6-6513-4752-baa5-87280d393fc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6d76175-104f-4c1e-b22e-6ea4cae709e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_be83a0e6-6513-4752-baa5-87280d393fc5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6d76175-104f-4c1e-b22e-6ea4cae709e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7faaa88c-762a-4376-bd97-73ed18294dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6d76175-104f-4c1e-b22e-6ea4cae709e5" xlink:to="loc_us-gaap_SalesRevenueNetMember_7faaa88c-762a-4376-bd97-73ed18294dbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_44300028-6d12-4acc-8de9-e832031283fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_b942264e-1461-493c-a3ad-43d5800bfdb7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_44300028-6d12-4acc-8de9-e832031283fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_44300028-6d12-4acc-8de9-e832031283fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_44300028-6d12-4acc-8de9-e832031283fa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_44300028-6d12-4acc-8de9-e832031283fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_89dd68be-152c-45f8-b415-4c673c9f12ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_44300028-6d12-4acc-8de9-e832031283fa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_89dd68be-152c-45f8-b415-4c673c9f12ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f3d82087-16fc-41e8-9a5d-9945f7c5d0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_89dd68be-152c-45f8-b415-4c673c9f12ae" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f3d82087-16fc-41e8-9a5d-9945f7c5d0b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails" xlink:type="extended" id="i981704ad990149609a14fbc9ee1dd632_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_79807502-f6ca-4a86-84a3-20a2d0b5c114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberofCustomers_268ad4e9-73f5-4dbd-8e4d-03ec636cdf55" xlink:href="pcrx-20211231.xsd#pcrx_ConcentrationRiskNumberofCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_79807502-f6ca-4a86-84a3-20a2d0b5c114" xlink:to="loc_pcrx_ConcentrationRiskNumberofCustomers_268ad4e9-73f5-4dbd-8e4d-03ec636cdf55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_240e5fdc-e47f-4e0b-a486-a6d7f81e2a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_79807502-f6ca-4a86-84a3-20a2d0b5c114" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_240e5fdc-e47f-4e0b-a486-a6d7f81e2a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_79807502-f6ca-4a86-84a3-20a2d0b5c114" xlink:to="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9a437536-0ad0-4092-89d3-dd503a4251a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9a437536-0ad0-4092-89d3-dd503a4251a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9a437536-0ad0-4092-89d3-dd503a4251a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9a437536-0ad0-4092-89d3-dd503a4251a6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9a437536-0ad0-4092-89d3-dd503a4251a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d61b6f93-df18-46c7-b794-20dc9210b602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9a437536-0ad0-4092-89d3-dd503a4251a6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d61b6f93-df18-46c7-b794-20dc9210b602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c8ab539f-0261-4e1a-92e7-fb98414905ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d61b6f93-df18-46c7-b794-20dc9210b602" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c8ab539f-0261-4e1a-92e7-fb98414905ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fbe1d311-16bc-402e-8efb-df102bb079b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:to="loc_srt_MajorCustomersAxis_fbe1d311-16bc-402e-8efb-df102bb079b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fbe1d311-16bc-402e-8efb-df102bb079b7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_fbe1d311-16bc-402e-8efb-df102bb079b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_fbe1d311-16bc-402e-8efb-df102bb079b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_fbe1d311-16bc-402e-8efb-df102bb079b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LargestCustomerMember_bf633c0f-e131-465f-8fac-6833d91af2a9" xlink:href="pcrx-20211231.xsd#pcrx_LargestCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:to="loc_pcrx_LargestCustomerMember_bf633c0f-e131-465f-8fac-6833d91af2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SecondLargestCustomerMember_963e197c-7315-488d-8a5b-1209c7c98876" xlink:href="pcrx-20211231.xsd#pcrx_SecondLargestCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:to="loc_pcrx_SecondLargestCustomerMember_963e197c-7315-488d-8a5b-1209c7c98876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThirdLargestCustomerMember_0c4249aa-f04e-4417-b4a7-dc8dfcf26c16" xlink:href="pcrx-20211231.xsd#pcrx_ThirdLargestCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:to="loc_pcrx_ThirdLargestCustomerMember_0c4249aa-f04e-4417-b4a7-dc8dfcf26c16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThreeLargestCustomersMember_380d1302-112b-4cda-a6c6-395927b60ee5" xlink:href="pcrx-20211231.xsd#pcrx_ThreeLargestCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:to="loc_pcrx_ThreeLargestCustomersMember_380d1302-112b-4cda-a6c6-395927b60ee5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f548d4d-bf34-4528-98c2-8ffbcb002d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f548d4d-bf34-4528-98c2-8ffbcb002d3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f548d4d-bf34-4528-98c2-8ffbcb002d3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f548d4d-bf34-4528-98c2-8ffbcb002d3b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f548d4d-bf34-4528-98c2-8ffbcb002d3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e493c41b-7dbd-46c8-95c0-fdb57f6e5309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f548d4d-bf34-4528-98c2-8ffbcb002d3b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e493c41b-7dbd-46c8-95c0-fdb57f6e5309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_28494cc4-ec73-47be-8c69-be6c38e5b296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e493c41b-7dbd-46c8-95c0-fdb57f6e5309" xlink:to="loc_us-gaap_SalesRevenueNetMember_28494cc4-ec73-47be-8c69-be6c38e5b296" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails" xlink:type="extended" id="i91774a03184042e48d876b52999f0de9_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7ca83158-c9ed-4ae7-9335-b1950eafde0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c3d2c0c1-d5f5-48aa-931a-566a4a6543ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7ca83158-c9ed-4ae7-9335-b1950eafde0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c3d2c0c1-d5f5-48aa-931a-566a4a6543ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_767adb67-1bb0-44b3-85cc-a08573b23803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7ca83158-c9ed-4ae7-9335-b1950eafde0a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_767adb67-1bb0-44b3-85cc-a08573b23803" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e43a406b-59ca-4d9c-96b7-2fce08aac39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_767adb67-1bb0-44b3-85cc-a08573b23803" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e43a406b-59ca-4d9c-96b7-2fce08aac39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e43a406b-59ca-4d9c-96b7-2fce08aac39e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e43a406b-59ca-4d9c-96b7-2fce08aac39e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e43a406b-59ca-4d9c-96b7-2fce08aac39e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e43a406b-59ca-4d9c-96b7-2fce08aac39e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_47fd6a5c-eb03-4631-bbe7-36af5c04df3f" xlink:href="pcrx-20211231.xsd#pcrx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_47fd6a5c-eb03-4631-bbe7-36af5c04df3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_31f108a0-acdd-4df8-b80c-d18f695150ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_31f108a0-acdd-4df8-b80c-d18f695150ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_9de3ac28-70ed-45e3-9253-e8cdea0117f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_9de3ac28-70ed-45e3-9253-e8cdea0117f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56d23d2b-d0ce-4db8-9dc9-01e8a1bcd8fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_767adb67-1bb0-44b3-85cc-a08573b23803" xlink:to="loc_srt_RangeAxis_56d23d2b-d0ce-4db8-9dc9-01e8a1bcd8fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56d23d2b-d0ce-4db8-9dc9-01e8a1bcd8fc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_56d23d2b-d0ce-4db8-9dc9-01e8a1bcd8fc" xlink:to="loc_srt_RangeMember_56d23d2b-d0ce-4db8-9dc9-01e8a1bcd8fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6842d8e2-66f2-4ff5-a51f-ed52cd4a3cba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_56d23d2b-d0ce-4db8-9dc9-01e8a1bcd8fc" xlink:to="loc_srt_RangeMember_6842d8e2-66f2-4ff5-a51f-ed52cd4a3cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4339385e-eead-47bf-a8fc-5a6dcb101309" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6842d8e2-66f2-4ff5-a51f-ed52cd4a3cba" xlink:to="loc_srt_MinimumMember_4339385e-eead-47bf-a8fc-5a6dcb101309" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_94426417-b3f3-4597-8673-5a1f9ccad2b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6842d8e2-66f2-4ff5-a51f-ed52cd4a3cba" xlink:to="loc_srt_MaximumMember_94426417-b3f3-4597-8673-5a1f9ccad2b4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="ic45121a940b5421da0b5cbc9fe20134f_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberofCustomers_e044899e-437a-43fc-85d3-f189d2b23cf1" xlink:href="pcrx-20211231.xsd#pcrx_ConcentrationRiskNumberofCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_pcrx_ConcentrationRiskNumberofCustomers_e044899e-437a-43fc-85d3-f189d2b23cf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_356d996b-8aaa-4948-8f25-2073c0afb3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_356d996b-8aaa-4948-8f25-2073c0afb3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_0d524fc6-056b-4972-aff0-8747185a5ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_0d524fc6-056b-4972-aff0-8747185a5ecf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperAtCarryingValue_86f348a0-8c8d-4db2-bce3-209f44f27509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_CommercialPaperAtCarryingValue_86f348a0-8c8d-4db2-bce3-209f44f27509" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_ea2995f6-45b4-4244-87f5-caf601e7d324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_ea2995f6-45b4-4244-87f5-caf601e7d324" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ccdf16d8-4031-4fdd-b154-40a5ea45a230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_NumberOfReportableSegments_ccdf16d8-4031-4fdd-b154-40a5ea45a230" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bf0b54ad-8d9a-4504-8ea9-f018844b11b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bf0b54ad-8d9a-4504-8ea9-f018844b11b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bf0b54ad-8d9a-4504-8ea9-f018844b11b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bf0b54ad-8d9a-4504-8ea9-f018844b11b5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bf0b54ad-8d9a-4504-8ea9-f018844b11b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3ffbd9b6-1883-4c2f-ac4f-a22dc54ad9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bf0b54ad-8d9a-4504-8ea9-f018844b11b5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3ffbd9b6-1883-4c2f-ac4f-a22dc54ad9a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0d0b8821-c78f-4822-9579-5beae7f66d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3ffbd9b6-1883-4c2f-ac4f-a22dc54ad9a6" xlink:to="loc_us-gaap_SalesRevenueNetMember_0d0b8821-c78f-4822-9579-5beae7f66d15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e368edc7-4fcc-47e8-b791-e82ec59ea6a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:to="loc_srt_MajorCustomersAxis_e368edc7-4fcc-47e8-b791-e82ec59ea6a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e368edc7-4fcc-47e8-b791-e82ec59ea6a6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e368edc7-4fcc-47e8-b791-e82ec59ea6a6" xlink:to="loc_srt_NameOfMajorCustomerDomain_e368edc7-4fcc-47e8-b791-e82ec59ea6a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_36928704-a4db-4bcd-be1d-4e23eb1b8239" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e368edc7-4fcc-47e8-b791-e82ec59ea6a6" xlink:to="loc_srt_NameOfMajorCustomerDomain_36928704-a4db-4bcd-be1d-4e23eb1b8239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CustomersOutsideUSMember_7de3a3f5-5ce6-4e77-9766-a7e6b2ebc7c4" xlink:href="pcrx-20211231.xsd#pcrx_CustomersOutsideUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_36928704-a4db-4bcd-be1d-4e23eb1b8239" xlink:to="loc_pcrx_CustomersOutsideUSMember_7de3a3f5-5ce6-4e77-9766-a7e6b2ebc7c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_095c2a1d-a34f-4f11-bd5e-3c52a11b862f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_095c2a1d-a34f-4f11-bd5e-3c52a11b862f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_095c2a1d-a34f-4f11-bd5e-3c52a11b862f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_095c2a1d-a34f-4f11-bd5e-3c52a11b862f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_095c2a1d-a34f-4f11-bd5e-3c52a11b862f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2a4226d4-7e26-4426-a0b1-3e7662b4b05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_095c2a1d-a34f-4f11-bd5e-3c52a11b862f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2a4226d4-7e26-4426-a0b1-3e7662b4b05f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4f6e17a3-3d95-47a9-b949-9c82ec24901e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2a4226d4-7e26-4426-a0b1-3e7662b4b05f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4f6e17a3-3d95-47a9-b949-9c82ec24901e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#RECENTACCOUNTINGPRONOUNCEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails" xlink:type="extended" id="ie53ecb38ee1e429fac5b2146332859c8_RECENTACCOUNTINGPRONOUNCEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_68482b08-6338-4753-a2d7-92c14fd3a756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_68482b08-6338-4753-a2d7-92c14fd3a756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncreaseDecreaseInRetainedEarnings_f592e3ab-ada8-4ec5-a581-deda3a66a29a" xlink:href="pcrx-20211231.xsd#pcrx_IncreaseDecreaseInRetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_pcrx_IncreaseDecreaseInRetainedEarnings_f592e3ab-ada8-4ec5-a581-deda3a66a29a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_94ce8021-7de7-4b74-8d11-a9066783b149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_94ce8021-7de7-4b74-8d11-a9066783b149" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b65e080f-f444-4011-8139-beb63880eaff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b65e080f-f444-4011-8139-beb63880eaff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncreaseDecreaseInInterestExpense_317b4b56-7ec1-4471-944f-a3c94d468aeb" xlink:href="pcrx-20211231.xsd#pcrx_IncreaseDecreaseInInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_pcrx_IncreaseDecreaseInInterestExpense_317b4b56-7ec1-4471-944f-a3c94d468aeb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_96df717a-76ba-41c9-b1d6-711e51b80300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_96df717a-76ba-41c9-b1d6-711e51b80300" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bc30731b-92b3-4d1b-bc19-f617042ae76e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_96df717a-76ba-41c9-b1d6-711e51b80300" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bc30731b-92b3-4d1b-bc19-f617042ae76e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_bc30731b-92b3-4d1b-bc19-f617042ae76e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bc30731b-92b3-4d1b-bc19-f617042ae76e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_bc30731b-92b3-4d1b-bc19-f617042ae76e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f9017b79-dfd8-44c7-8a2a-678b5658ac00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bc30731b-92b3-4d1b-bc19-f617042ae76e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f9017b79-dfd8-44c7-8a2a-678b5658ac00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_bef98612-7e0a-41b7-8efa-e99cf35ed2de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f9017b79-dfd8-44c7-8a2a-678b5658ac00" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_bef98612-7e0a-41b7-8efa-e99cf35ed2de" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#REVENUESalesandValuationAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails" xlink:type="extended" id="i6d414087adad49cc876a16f1206b1be2_REVENUESalesandValuationAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_31091354-31fd-4497-90fc-c94fba632b3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_31091354-31fd-4497-90fc-c94fba632b3c" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_7a74eb31-775d-4695-8bcd-699928322fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_7a74eb31-775d-4695-8bcd-699928322fe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c98aa610-74c5-451b-a45f-26aeb25a8863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c98aa610-74c5-451b-a45f-26aeb25a8863" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_ec04ee36-b6d8-4bc8-ba8c-44e8ed9489fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_ec04ee36-b6d8-4bc8-ba8c-44e8ed9489fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ead057a6-d30d-4743-98f6-85afbb30f928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f1cd2ccd-e1ee-4449-bab1-fddb95930d4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_31091354-31fd-4497-90fc-c94fba632b3c" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f1cd2ccd-e1ee-4449-bab1-fddb95930d4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_50e86665-e048-4262-ac04-4d50c03fb11c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f1cd2ccd-e1ee-4449-bab1-fddb95930d4b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_50e86665-e048-4262-ac04-4d50c03fb11c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_50e86665-e048-4262-ac04-4d50c03fb11c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_50e86665-e048-4262-ac04-4d50c03fb11c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_50e86665-e048-4262-ac04-4d50c03fb11c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_50e86665-e048-4262-ac04-4d50c03fb11c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_ccd80308-1092-4485-9556-4bb6bc4f9542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_ccd80308-1092-4485-9556-4bb6bc4f9542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ReserveForPromptPayDiscountMember_af4ff389-c894-4372-96ee-e5222e43f5c4" xlink:href="pcrx-20211231.xsd#pcrx_ReserveForPromptPayDiscountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_pcrx_ReserveForPromptPayDiscountMember_af4ff389-c894-4372-96ee-e5222e43f5c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_WholesalerservicefeesMember_e078f5da-0713-4396-9d97-9756372cae77" xlink:href="pcrx-20211231.xsd#pcrx_WholesalerservicefeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_pcrx_WholesalerservicefeesMember_e078f5da-0713-4396-9d97-9756372cae77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AllowanceForVolumeRebatesandChargebacksMember_77154fca-916a-405f-a23c-716404ec35c3" xlink:href="pcrx-20211231.xsd#pcrx_AllowanceForVolumeRebatesandChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_pcrx_AllowanceForVolumeRebatesandChargebacksMember_77154fca-916a-405f-a23c-716404ec35c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AllowanceForGovernmentRebatesMember_2412a74b-2092-4d3d-9827-5828af4b3e83" xlink:href="pcrx-20211231.xsd#pcrx_AllowanceForGovernmentRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_pcrx_AllowanceForGovernmentRebatesMember_2412a74b-2092-4d3d-9827-5828af4b3e83" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUENarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#REVENUENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/REVENUENarrativeDetails" xlink:type="extended" id="i0dc273a661ad4c53a400ef9767a78d4d_REVENUENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2ac60f7d-e287-440e-bea4-655f5dccca05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccountsReceivablePaymentTerms_50a0165b-3838-4538-9e1a-d0e3849c6b80" xlink:href="pcrx-20211231.xsd#pcrx_AccountsReceivablePaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2ac60f7d-e287-440e-bea4-655f5dccca05" xlink:to="loc_pcrx_AccountsReceivablePaymentTerms_50a0165b-3838-4538-9e1a-d0e3849c6b80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9488cf35-896c-44d7-82cd-093106ea1f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2ac60f7d-e287-440e-bea4-655f5dccca05" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9488cf35-896c-44d7-82cd-093106ea1f99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2efae54b-7969-4578-8207-f0cc6d102729" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9488cf35-896c-44d7-82cd-093106ea1f99" xlink:to="loc_srt_RangeAxis_2efae54b-7969-4578-8207-f0cc6d102729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2efae54b-7969-4578-8207-f0cc6d102729_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2efae54b-7969-4578-8207-f0cc6d102729" xlink:to="loc_srt_RangeMember_2efae54b-7969-4578-8207-f0cc6d102729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43632cc3-22cd-4051-8307-55c14758c895" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2efae54b-7969-4578-8207-f0cc6d102729" xlink:to="loc_srt_RangeMember_43632cc3-22cd-4051-8307-55c14758c895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_654233a0-1ee8-4339-98e7-b0fec9334eeb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43632cc3-22cd-4051-8307-55c14758c895" xlink:to="loc_srt_MinimumMember_654233a0-1ee8-4339-98e7-b0fec9334eeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_93df657a-12dd-4d1d-b9da-6209ea2790d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43632cc3-22cd-4051-8307-55c14758c895" xlink:to="loc_srt_MaximumMember_93df657a-12dd-4d1d-b9da-6209ea2790d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUEDisaggregationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#REVENUEDisaggregationDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/REVENUEDisaggregationDetails" xlink:type="extended" id="if53187772bfc43ebb7c326776b886770_REVENUEDisaggregationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_01db397f-d227-4407-acf9-09e31322235f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54da9eea-da83-4bc7-b301-710098a310c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_01db397f-d227-4407-acf9-09e31322235f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54da9eea-da83-4bc7-b301-710098a310c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_003ad31b-df5e-4ebd-af6e-bc0db9abaccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_01db397f-d227-4407-acf9-09e31322235f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_003ad31b-df5e-4ebd-af6e-bc0db9abaccc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c7cb836e-bdec-4c27-823c-569654ea9519" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_003ad31b-df5e-4ebd-af6e-bc0db9abaccc" xlink:to="loc_srt_ProductOrServiceAxis_c7cb836e-bdec-4c27-823c-569654ea9519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7cb836e-bdec-4c27-823c-569654ea9519_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c7cb836e-bdec-4c27-823c-569654ea9519" xlink:to="loc_srt_ProductsAndServicesDomain_c7cb836e-bdec-4c27-823c-569654ea9519_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c7cb836e-bdec-4c27-823c-569654ea9519" xlink:to="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EXPARELMember_e1a53925-284d-4981-95bb-6a98e781bdca" xlink:href="pcrx-20211231.xsd#pcrx_EXPARELMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:to="loc_pcrx_EXPARELMember_e1a53925-284d-4981-95bb-6a98e781bdca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ZILRETTAMember_12fd72da-a9d1-4189-b4ba-7ef257c43ff0" xlink:href="pcrx-20211231.xsd#pcrx_ZILRETTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:to="loc_pcrx_ZILRETTAMember_12fd72da-a9d1-4189-b4ba-7ef257c43ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMemberMember_a93588b5-05e4-47a9-aaa4-4aa394e111c3" xlink:href="pcrx-20211231.xsd#pcrx_IoveraMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:to="loc_pcrx_IoveraMemberMember_a93588b5-05e4-47a9-aaa4-4aa394e111c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember_23cd95cb-d4bb-4d5f-ae37-b2a111aa10f5" xlink:href="pcrx-20211231.xsd#pcrx_BupivacaineLiposomeInjectableSuspensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:to="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember_23cd95cb-d4bb-4d5f-ae37-b2a111aa10f5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="i5c7d271675e24e46bb44e0e12782a182_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e88eac97-1702-4887-b476-03d61edb012a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e88eac97-1702-4887-b476-03d61edb012a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_164170e7-1267-477c-ba8b-3728b9c2c2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_164170e7-1267-477c-ba8b-3728b9c2c2d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_6db1b8cc-754e-4422-9196-353ad9775a8d" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_6db1b8cc-754e-4422-9196-353ad9775a8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_4ff70de3-96bf-49ee-bb55-1a7e7441316b" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_4ff70de3-96bf-49ee-bb55-1a7e7441316b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5a653e07-7716-4a2f-b6ad-c11e26637772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5a653e07-7716-4a2f-b6ad-c11e26637772" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d284582d-6aa3-4380-a4fc-05623e2e32c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d284582d-6aa3-4380-a4fc-05623e2e32c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold_d84e7d44-913b-491f-8d04-e035671e906b" xlink:href="pcrx-20211231.xsd#pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold_d84e7d44-913b-491f-8d04-e035671e906b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsideration_4ed9da5a-6830-4b3c-a391-d8412359959e" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_ContingentConsideration_4ed9da5a-6830-4b3c-a391-d8412359959e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7b7fa2e1-7f53-40d3-aa2c-b8560ba0c486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7b7fa2e1-7f53-40d3-aa2c-b8560ba0c486" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88189605-63ba-4ab6-9829-4bb6848ef3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88189605-63ba-4ab6-9829-4bb6848ef3d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsMeasurementInput_e63bc76f-1543-4121-ae65-3b1adda5de48" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsMeasurementInput_e63bc76f-1543-4121-ae65-3b1adda5de48" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate_e15037a3-512c-4ca2-a1d9-4a30b6e604df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate_e15037a3-512c-4ca2-a1d9-4a30b6e604df" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationCurrent_94a0a9f7-7d09-4377-9714-3253bab99bd7" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_ContingentConsiderationCurrent_94a0a9f7-7d09-4377-9714-3253bab99bd7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationPaymentTerm_0f463d74-5969-43d0-9345-26fdfcf4c745" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_ContingentConsiderationPaymentTerm_0f463d74-5969-43d0-9345-26fdfcf4c745" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a9204dc-7159-4770-82a4-6f6bba3947a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a9204dc-7159-4770-82a4-6f6bba3947a1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_c1a756af-2c5d-4d66-9b01-c52301719f2a" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_c1a756af-2c5d-4d66-9b01-c52301719f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_c1a756af-2c5d-4d66-9b01-c52301719f2a_default" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_c1a756af-2c5d-4d66-9b01-c52301719f2a" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_c1a756af-2c5d-4d66-9b01-c52301719f2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_c1a756af-2c5d-4d66-9b01-c52301719f2a" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementofRegulatoryMilestoneMember_f2cfee7f-8afb-4f9e-92c7-50d9d2b09546" xlink:href="pcrx-20211231.xsd#pcrx_AchievementofRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementofRegulatoryMilestoneMember_f2cfee7f-8afb-4f9e-92c7-50d9d2b09546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfZILRETTASalesOf250MillionMember_a3603197-4bf5-48c9-96c5-08523e18461b" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfZILRETTASalesOf250MillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfZILRETTASalesOf250MillionMember_a3603197-4bf5-48c9-96c5-08523e18461b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfZILRETTASalesOf375MillionMember_786a37fe-890a-4e56-8745-f89a991d2041" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfZILRETTASalesOf375MillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfZILRETTASalesOf375MillionMember_786a37fe-890a-4e56-8745-f89a991d2041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfZILRETTASalesOf500MillionMember_6fdeb0c9-7300-4b0c-822c-0b2ce2d157f1" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfZILRETTASalesOf500MillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfZILRETTASalesOf500MillionMember_6fdeb0c9-7300-4b0c-822c-0b2ce2d157f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfFDAApprovalOfFX201Member_736123ad-7634-4950-ac7a-5e48f8d20b81" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfFDAApprovalOfFX201Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfFDAApprovalOfFX201Member_736123ad-7634-4950-ac7a-5e48f8d20b81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfFDAApprovalOfFX301Member_b6bdf62b-9183-45bf-84c5-e7b9cf922206" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfFDAApprovalOfFX301Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfFDAApprovalOfFX301Member_b6bdf62b-9183-45bf-84c5-e7b9cf922206" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_55ba84b3-e707-423e-b178-bd7e7e72c53f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_55ba84b3-e707-423e-b178-bd7e7e72c53f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55ba84b3-e707-423e-b178-bd7e7e72c53f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55ba84b3-e707-423e-b178-bd7e7e72c53f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55ba84b3-e707-423e-b178-bd7e7e72c53f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95386630-e6be-492d-a789-1040a311fbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55ba84b3-e707-423e-b178-bd7e7e72c53f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95386630-e6be-492d-a789-1040a311fbf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_fc79ccf5-1e77-447c-a041-2572b98eecaa" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95386630-e6be-492d-a789-1040a311fbf6" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_fc79ccf5-1e77-447c-a041-2572b98eecaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_7e0fbe2f-17ce-4e6f-b965-4f1eb4b68e33" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95386630-e6be-492d-a789-1040a311fbf6" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_7e0fbe2f-17ce-4e6f-b965-4f1eb4b68e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3c651ea9-c017-4769-88eb-28c0404ff776" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_srt_StatementScenarioAxis_3c651ea9-c017-4769-88eb-28c0404ff776" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3c651ea9-c017-4769-88eb-28c0404ff776_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3c651ea9-c017-4769-88eb-28c0404ff776" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3c651ea9-c017-4769-88eb-28c0404ff776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b7541cf3-4547-4597-8ceb-d9f17923f3d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3c651ea9-c017-4769-88eb-28c0404ff776" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b7541cf3-4547-4597-8ceb-d9f17923f3d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_918629ee-9060-42d0-aa89-e32c72553596" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b7541cf3-4547-4597-8ceb-d9f17923f3d2" xlink:to="loc_srt_ScenarioForecastMember_918629ee-9060-42d0-aa89-e32c72553596" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_001e3cea-3dd2-4720-9a32-b253993fa65d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_001e3cea-3dd2-4720-9a32-b253993fa65d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_001e3cea-3dd2-4720-9a32-b253993fa65d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_001e3cea-3dd2-4720-9a32-b253993fa65d" xlink:to="loc_us-gaap_ClassOfStockDomain_001e3cea-3dd2-4720-9a32-b253993fa65d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e136da1-6b5f-45f5-b935-01b063ddea9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_001e3cea-3dd2-4720-9a32-b253993fa65d" xlink:to="loc_us-gaap_ClassOfStockDomain_4e136da1-6b5f-45f5-b935-01b063ddea9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember_f88df07f-d09e-4d66-b84d-6a02d342d380" xlink:href="pcrx-20211231.xsd#pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4e136da1-6b5f-45f5-b935-01b063ddea9b" xlink:to="loc_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember_f88df07f-d09e-4d66-b84d-6a02d342d380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf824e20-5be7-4f73-a44d-c31ada9f56ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf824e20-5be7-4f73-a44d-c31ada9f56ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf824e20-5be7-4f73-a44d-c31ada9f56ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf824e20-5be7-4f73-a44d-c31ada9f56ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf824e20-5be7-4f73-a44d-c31ada9f56ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1bb671d-6878-43ea-b740-89a5a6eef86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf824e20-5be7-4f73-a44d-c31ada9f56ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1bb671d-6878-43ea-b740-89a5a6eef86b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cb72af4f-0be0-4bec-9015-668638cd8633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1bb671d-6878-43ea-b740-89a5a6eef86b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cb72af4f-0be0-4bec-9015-668638cd8633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8ca69768-2d05-473d-9f3f-aa6ab91bf7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1bb671d-6878-43ea-b740-89a5a6eef86b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8ca69768-2d05-473d-9f3f-aa6ab91bf7f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_bb6d3b0e-ab89-4468-bb96-6db1a86f1165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_bb6d3b0e-ab89-4468-bb96-6db1a86f1165" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bb6d3b0e-ab89-4468-bb96-6db1a86f1165_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bb6d3b0e-ab89-4468-bb96-6db1a86f1165" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bb6d3b0e-ab89-4468-bb96-6db1a86f1165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_08d63e0e-0aeb-47a1-90e9-01ae842e82d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bb6d3b0e-ab89-4468-bb96-6db1a86f1165" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_08d63e0e-0aeb-47a1-90e9-01ae842e82d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7b625527-8fa7-4ecd-9935-576403e39555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_08d63e0e-0aeb-47a1-90e9-01ae842e82d0" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7b625527-8fa7-4ecd-9935-576403e39555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a0b2a3b4-a555-4df0-bcf8-3870a1f66d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a0b2a3b4-a555-4df0-bcf8-3870a1f66d6b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a0b2a3b4-a555-4df0-bcf8-3870a1f66d6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a0b2a3b4-a555-4df0-bcf8-3870a1f66d6b" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a0b2a3b4-a555-4df0-bcf8-3870a1f66d6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_246a8ffb-50b5-48ce-ab42-0b1907dfa16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a0b2a3b4-a555-4df0-bcf8-3870a1f66d6b" xlink:to="loc_us-gaap_ValuationTechniqueDomain_246a8ffb-50b5-48ce-ab42-0b1907dfa16a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_bd8a9b71-4cd7-44b3-b2cf-de5f24dfc7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_246a8ffb-50b5-48ce-ab42-0b1907dfa16a" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_bd8a9b71-4cd7-44b3-b2cf-de5f24dfc7c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_4e7bfe6a-7254-4e5d-b35d-3f80825b16a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_246a8ffb-50b5-48ce-ab42-0b1907dfa16a" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_4e7bfe6a-7254-4e5d-b35d-3f80825b16a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails" xlink:type="extended" id="icf207c1216ee46a68de1a95c6fdb430e_ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_306e0fb1-40e9-4379-aa29-476496addb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_306e0fb1-40e9-4379-aa29-476496addb8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_a6b4a14a-7af7-4f15-a938-6db956929c36" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:to="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_a6b4a14a-7af7-4f15-a938-6db956929c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_93057605-c701-4149-8032-6f963d1b8960" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:to="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_93057605-c701-4149-8032-6f963d1b8960" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_670b782d-57a7-4be0-9ef9-6fc026127eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_670b782d-57a7-4be0-9ef9-6fc026127eb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cd9b90fb-9ad5-4071-9eb8-1bc407bfe4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cd9b90fb-9ad5-4071-9eb8-1bc407bfe4bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd9b90fb-9ad5-4071-9eb8-1bc407bfe4bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cd9b90fb-9ad5-4071-9eb8-1bc407bfe4bb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd9b90fb-9ad5-4071-9eb8-1bc407bfe4bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b15c45d-5d1c-4ee1-a32d-5698a51b51ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cd9b90fb-9ad5-4071-9eb8-1bc407bfe4bb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b15c45d-5d1c-4ee1-a32d-5698a51b51ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_24d320b5-cd8e-4163-8b2f-80fb8a313951" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b15c45d-5d1c-4ee1-a32d-5698a51b51ce" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_24d320b5-cd8e-4163-8b2f-80fb8a313951" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e6ebe861-670d-430d-a0d3-7dad9622db6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e6ebe861-670d-430d-a0d3-7dad9622db6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e6ebe861-670d-430d-a0d3-7dad9622db6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e6ebe861-670d-430d-a0d3-7dad9622db6c" xlink:to="loc_us-gaap_ClassOfStockDomain_e6ebe861-670d-430d-a0d3-7dad9622db6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b9967a7f-0b44-45ad-a4cf-647046b80a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e6ebe861-670d-430d-a0d3-7dad9622db6c" xlink:to="loc_us-gaap_ClassOfStockDomain_b9967a7f-0b44-45ad-a4cf-647046b80a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_52cdc1da-37f6-4a93-b35f-eb6c1771b33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9967a7f-0b44-45ad-a4cf-647046b80a51" xlink:to="loc_us-gaap_CommonStockMember_52cdc1da-37f6-4a93-b35f-eb6c1771b33c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_03119b30-d7da-427e-b5da-4036d44a419e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b9967a7f-0b44-45ad-a4cf-647046b80a51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_03119b30-d7da-427e-b5da-4036d44a419e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0cff462c-8d5b-4eb0-8ec4-6f2572ec46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0cff462c-8d5b-4eb0-8ec4-6f2572ec46d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0cff462c-8d5b-4eb0-8ec4-6f2572ec46d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0cff462c-8d5b-4eb0-8ec4-6f2572ec46d6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0cff462c-8d5b-4eb0-8ec4-6f2572ec46d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a67374bb-823b-44af-953b-42b6d7dfde7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0cff462c-8d5b-4eb0-8ec4-6f2572ec46d6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a67374bb-823b-44af-953b-42b6d7dfde7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtMember_4f5a2942-fe30-48b5-b246-63640c999671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a67374bb-823b-44af-953b-42b6d7dfde7f" xlink:to="loc_us-gaap_DebtMember_4f5a2942-fe30-48b5-b246-63640c999671" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails" xlink:type="extended" id="i3a340f32df2b456dbac3e98f152a26e0_ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_fa473f85-3619-49fb-b5bb-399c59593682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_fa473f85-3619-49fb-b5bb-399c59593682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_057527cd-20fa-43f0-96e4-6b3e60c981ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_057527cd-20fa-43f0-96e4-6b3e60c981ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_61dd249a-b800-4834-bfde-9b63e407fe27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_61dd249a-b800-4834-bfde-9b63e407fe27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e412a0b0-0038-4aa1-8122-b97b4d7ce064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e412a0b0-0038-4aa1-8122-b97b4d7ce064" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_23d7995c-33f9-49f1-9679-9cce96913b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_23d7995c-33f9-49f1-9679-9cce96913b2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ff38a469-6060-4af7-8d2e-98f87a483647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ff38a469-6060-4af7-8d2e-98f87a483647" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_2d841fd3-b19d-4636-b02d-59ab27e8f7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_2d841fd3-b19d-4636-b02d-59ab27e8f7fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_92df4175-dfad-46c3-b31f-fa487c9ce4c7" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_92df4175-dfad-46c3-b31f-fa487c9ce4c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85adcd38-2945-4994-9b6d-5ecd459c85c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85adcd38-2945-4994-9b6d-5ecd459c85c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6b02fe8a-1cd8-4631-ba92-fa70e1a39560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6b02fe8a-1cd8-4631-ba92-fa70e1a39560" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dd633326-6280-40e5-ba23-c8ba12c9ca9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dd633326-6280-40e5-ba23-c8ba12c9ca9b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6f02e44d-152a-4753-9cb0-373811724ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6f02e44d-152a-4753-9cb0-373811724ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_28ff9b58-86e9-46d6-8a6c-ec5eb014a444" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_28ff9b58-86e9-46d6-8a6c-ec5eb014a444" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ec37defe-516e-4efb-b868-fc8268dd28ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ec37defe-516e-4efb-b868-fc8268dd28ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_49312711-6c35-4f15-877d-b7c9661aa37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_49312711-6c35-4f15-877d-b7c9661aa37b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_601a4657-06c4-4dc2-b6ab-cc6f34a8a9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_601a4657-06c4-4dc2-b6ab-cc6f34a8a9c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_4686fda5-ecaa-4db5-bfdc-8147f1572306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_4686fda5-ecaa-4db5-bfdc-8147f1572306" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f7a3c7b7-b401-429a-9cfa-c5b13adf3fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f7a3c7b7-b401-429a-9cfa-c5b13adf3fd2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2bc65ff9-1158-4c89-ab5f-8c4cfbd222ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2bc65ff9-1158-4c89-ab5f-8c4cfbd222ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f161332d-ebfc-49b1-9052-9d4a979ce15b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_Goodwill_f161332d-ebfc-49b1-9052-9d4a979ce15b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0e583eed-e2bb-4fb3-beb7-ed84d5bbc682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0e583eed-e2bb-4fb3-beb7-ed84d5bbc682" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_708791d2-20be-4c0a-93de-172680ce50bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_708791d2-20be-4c0a-93de-172680ce50bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cce4ccc1-8106-454c-9574-e3fafe798d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_708791d2-20be-4c0a-93de-172680ce50bd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cce4ccc1-8106-454c-9574-e3fafe798d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cce4ccc1-8106-454c-9574-e3fafe798d5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cce4ccc1-8106-454c-9574-e3fafe798d5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cce4ccc1-8106-454c-9574-e3fafe798d5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_400dad88-4d50-405f-a998-4f74eb449ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cce4ccc1-8106-454c-9574-e3fafe798d5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_400dad88-4d50-405f-a998-4f74eb449ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_99b31066-d42e-4cfe-80cb-a05bc4702662" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_400dad88-4d50-405f-a998-4f74eb449ed2" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_99b31066-d42e-4cfe-80cb-a05bc4702662" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSFlexionResultsDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails" xlink:type="extended" id="ia03ea587a4f4486c8bc4a671cb43c68a_ACQUISITIONSFlexionResultsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_91c39040-dc4f-40dd-84f6-ca7d0f512a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_d0e112b5-36be-4296-af55-aa510ce90b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91c39040-dc4f-40dd-84f6-ca7d0f512a1e" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_d0e112b5-36be-4296-af55-aa510ce90b78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_ba0da800-363d-4926-b558-a9a59e3d430f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91c39040-dc4f-40dd-84f6-ca7d0f512a1e" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_ba0da800-363d-4926-b558-a9a59e3d430f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b3bedf38-7c73-458a-b521-3ff05ab3690c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91c39040-dc4f-40dd-84f6-ca7d0f512a1e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b3bedf38-7c73-458a-b521-3ff05ab3690c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_65689c0f-fd63-4f72-879d-edfbd02b7689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b3bedf38-7c73-458a-b521-3ff05ab3690c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_65689c0f-fd63-4f72-879d-edfbd02b7689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65689c0f-fd63-4f72-879d-edfbd02b7689_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_65689c0f-fd63-4f72-879d-edfbd02b7689" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65689c0f-fd63-4f72-879d-edfbd02b7689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d364217-ded9-460f-a95b-60e6fee55089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_65689c0f-fd63-4f72-879d-edfbd02b7689" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d364217-ded9-460f-a95b-60e6fee55089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_c7a98345-106d-4872-90b4-6f077a22f602" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d364217-ded9-460f-a95b-60e6fee55089" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_c7a98345-106d-4872-90b4-6f077a22f602" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSScheduleofProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails" xlink:type="extended" id="ic89f49b7320f4349ac3c858ceefb3332_ACQUISITIONSScheduleofProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ead43ebb-c88c-4f83-b820-62e28c33917b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ead43ebb-c88c-4f83-b820-62e28c33917b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_31206367-0902-4b53-9652-d854f3e72ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_31206367-0902-4b53-9652-d854f3e72ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_b5eb432d-8f53-49bb-a467-d77a1730ce97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_b5eb432d-8f53-49bb-a467-d77a1730ce97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_ac005158-4259-47b2-bb7a-2d656a3a9f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_ac005158-4259-47b2-bb7a-2d656a3a9f0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6e07ed-bab0-48e6-a894-9e462c062140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6e07ed-bab0-48e6-a894-9e462c062140" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_705b1be2-8be2-4a45-ac00-e35d42fc08cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6e07ed-bab0-48e6-a894-9e462c062140" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_705b1be2-8be2-4a45-ac00-e35d42fc08cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_705b1be2-8be2-4a45-ac00-e35d42fc08cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_705b1be2-8be2-4a45-ac00-e35d42fc08cf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_705b1be2-8be2-4a45-ac00-e35d42fc08cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dccccdb-8398-4251-bb5d-3f18834eec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_705b1be2-8be2-4a45-ac00-e35d42fc08cf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dccccdb-8398-4251-bb5d-3f18834eec2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_74c2220d-1915-4a0c-b127-0b999fa6c133" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dccccdb-8398-4251-bb5d-3f18834eec2e" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_74c2220d-1915-4a0c-b127-0b999fa6c133" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FIXEDASSETSScheduleofUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails" xlink:type="extended" id="i54df33b62edc4c31b0597f1fc4a0d386_FIXEDASSETSScheduleofUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7867e206-70a7-41f7-9442-06e498d29362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7867e206-70a7-41f7-9442-06e498d29362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45b41eca-94f2-4a76-a530-61834cd80745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45b41eca-94f2-4a76-a530-61834cd80745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b6439e63-9d3d-4e1c-b773-61ca0dc4a51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b6439e63-9d3d-4e1c-b773-61ca0dc4a51c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9946f908-258a-478e-9c6f-810f65c67c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9946f908-258a-478e-9c6f-810f65c67c3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79595806-d69e-4d93-aa46-78b6eeeea65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9946f908-258a-478e-9c6f-810f65c67c3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79595806-d69e-4d93-aa46-78b6eeeea65e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79595806-d69e-4d93-aa46-78b6eeeea65e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79595806-d69e-4d93-aa46-78b6eeeea65e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79595806-d69e-4d93-aa46-78b6eeeea65e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79595806-d69e-4d93-aa46-78b6eeeea65e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_26fb3bf0-5fec-487d-8d1c-5882bd91e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_26fb3bf0-5fec-487d-8d1c-5882bd91e9ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d0a26896-e57a-4d55-99af-88b02e24b144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d0a26896-e57a-4d55-99af-88b02e24b144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_e3a7bcdb-b495-4fef-9990-805c0f39dc45" xlink:href="pcrx-20211231.xsd#pcrx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_e3a7bcdb-b495-4fef-9990-805c0f39dc45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9a5d1061-1dfc-4b12-8ea0-84c8c658fd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9a5d1061-1dfc-4b12-8ea0-84c8c658fd80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_720a2453-c3a0-419a-8a8c-919cc400c6be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_us-gaap_ConstructionInProgressMember_720a2453-c3a0-419a-8a8c-919cc400c6be" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FIXEDASSETSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" xlink:type="extended" id="i1686499a8f5244c4bfaba0b2c454ad3f_FIXEDASSETSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8511fd6b-334d-40e4-b3fa-e27a9ad45305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:to="loc_us-gaap_Depreciation_8511fd6b-334d-40e4-b3fa-e27a9ad45305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_fc5e9e19-0639-48d7-a2c7-ce72ad46966f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:to="loc_us-gaap_InterestCostsCapitalized_fc5e9e19-0639-48d7-a2c7-ce72ad46966f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6f9b3049-a903-41b1-b62b-8821d0fb3906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6f9b3049-a903-41b1-b62b-8821d0fb3906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation_e3086050-8afa-4dab-9e19-fd0d2a038367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:to="loc_us-gaap_AssetRetirementObligation_e3086050-8afa-4dab-9e19-fd0d2a038367" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ac8fc279-1617-480d-b3b0-dc436996b196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ac8fc279-1617-480d-b3b0-dc436996b196" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ef843818-909f-46f7-a8c4-4885c99839a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ac8fc279-1617-480d-b3b0-dc436996b196" xlink:to="loc_srt_StatementGeographicalAxis_ef843818-909f-46f7-a8c4-4885c99839a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ef843818-909f-46f7-a8c4-4885c99839a1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ef843818-909f-46f7-a8c4-4885c99839a1" xlink:to="loc_srt_SegmentGeographicalDomain_ef843818-909f-46f7-a8c4-4885c99839a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_976f6009-2c8d-41b7-90de-5fa1e43a15dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ef843818-909f-46f7-a8c4-4885c99839a1" xlink:to="loc_srt_SegmentGeographicalDomain_976f6009-2c8d-41b7-90de-5fa1e43a15dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_477ad551-64f8-49b3-95eb-795627939562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_976f6009-2c8d-41b7-90de-5fa1e43a15dc" xlink:to="loc_us-gaap_NonUsMember_477ad551-64f8-49b3-95eb-795627939562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20bdd415-50b6-4e35-a918-ebafd3540eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ac8fc279-1617-480d-b3b0-dc436996b196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20bdd415-50b6-4e35-a918-ebafd3540eb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20bdd415-50b6-4e35-a918-ebafd3540eb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20bdd415-50b6-4e35-a918-ebafd3540eb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20bdd415-50b6-4e35-a918-ebafd3540eb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a5ff263-5737-494b-be3d-80a848b17b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20bdd415-50b6-4e35-a918-ebafd3540eb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a5ff263-5737-494b-be3d-80a848b17b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7f4b6074-d4e7-402c-b0d0-9c16911333fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a5ff263-5737-494b-be3d-80a848b17b03" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7f4b6074-d4e7-402c-b0d0-9c16911333fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/LEASESNarrativeDetails" xlink:type="extended" id="if7c25989c0ef43bdb497ebdb50c08a8d_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_48a111f3-ee39-4256-b55d-7caf3ee7b30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_48a111f3-ee39-4256-b55d-7caf3ee7b30d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e0e0320c-b5e0-47bf-9784-09e6f0f220dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:to="loc_us-gaap_OperatingLeaseLiability_e0e0320c-b5e0-47bf-9784-09e6f0f220dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfLocationsNewOperatingLeaseLiability_2cc6609e-b508-45ae-ab5f-303ae05fb210" xlink:href="pcrx-20211231.xsd#pcrx_NumberOfLocationsNewOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:to="loc_pcrx_NumberOfLocationsNewOperatingLeaseLiability_2cc6609e-b508-45ae-ab5f-303ae05fb210" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_dc3f2a85-34a0-47fb-9369-042673c3ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_dc3f2a85-34a0-47fb-9369-042673c3ed37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e2e4490-662d-49be-946a-90396076c826" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dc3f2a85-34a0-47fb-9369-042673c3ed37" xlink:to="loc_srt_RangeAxis_0e2e4490-662d-49be-946a-90396076c826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0e2e4490-662d-49be-946a-90396076c826_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0e2e4490-662d-49be-946a-90396076c826" xlink:to="loc_srt_RangeMember_0e2e4490-662d-49be-946a-90396076c826_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fbe2a5a9-1450-4d44-88cb-f4f64ad66707" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0e2e4490-662d-49be-946a-90396076c826" xlink:to="loc_srt_RangeMember_fbe2a5a9-1450-4d44-88cb-f4f64ad66707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aa21522a-15f4-4bc6-af83-b10da75ff87b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fbe2a5a9-1450-4d44-88cb-f4f64ad66707" xlink:to="loc_srt_MaximumMember_aa21522a-15f4-4bc6-af83-b10da75ff87b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9a2b1a00-d88d-47f3-a4ce-89299d9fe95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dc3f2a85-34a0-47fb-9369-042673c3ed37" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9a2b1a00-d88d-47f3-a4ce-89299d9fe95a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a2b1a00-d88d-47f3-a4ce-89299d9fe95a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9a2b1a00-d88d-47f3-a4ce-89299d9fe95a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a2b1a00-d88d-47f3-a4ce-89299d9fe95a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e0e06b4-c822-49b7-a93b-c8c77743c790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9a2b1a00-d88d-47f3-a4ce-89299d9fe95a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e0e06b4-c822-49b7-a93b-c8c77743c790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_cbe5cb4d-2b17-48de-b21a-6c38c4e6dd38" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e0e06b4-c822-49b7-a93b-c8c77743c790" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_cbe5cb4d-2b17-48de-b21a-6c38c4e6dd38" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#GOODWILLANDINTANGIBLEASSETSGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="extended" id="i617299fe9d2543d4b78fa59ddc5e5687_GOODWILLANDINTANGIBLEASSETSGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f6a233d1-6755-4af2-a83f-946d2911aecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_f6a233d1-6755-4af2-a83f-946d2911aecb" xlink:to="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a10e00d3-65b4-49ea-a841-9c9ed006f0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:to="loc_us-gaap_Goodwill_a10e00d3-65b4-49ea-a841-9c9ed006f0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_12a81ef3-3746-47f5-91be-784ac5f7565e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:to="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_12a81ef3-3746-47f5-91be-784ac5f7565e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2d08c200-40c7-4f33-90c9-b842b8a8cbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2d08c200-40c7-4f33-90c9-b842b8a8cbb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a3d3f618-cd00-4a19-94f1-b7ec16064d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_4f028abf-d979-4bca-87ae-163cf065fb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_f6a233d1-6755-4af2-a83f-946d2911aecb" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_4f028abf-d979-4bca-87ae-163cf065fb80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5e3ea676-6d14-4ed9-8c1e-6b18f33b9fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_4f028abf-d979-4bca-87ae-163cf065fb80" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5e3ea676-6d14-4ed9-8c1e-6b18f33b9fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5e3ea676-6d14-4ed9-8c1e-6b18f33b9fbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e3ea676-6d14-4ed9-8c1e-6b18f33b9fbf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5e3ea676-6d14-4ed9-8c1e-6b18f33b9fbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0bcebedf-f251-4318-8d5d-7af3d11ca007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e3ea676-6d14-4ed9-8c1e-6b18f33b9fbf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0bcebedf-f251-4318-8d5d-7af3d11ca007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SkyePharmaHoldingIncMember_b0755f58-f5c6-4572-a4db-d5b4ab0c00c5" xlink:href="pcrx-20211231.xsd#pcrx_SkyePharmaHoldingIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0bcebedf-f251-4318-8d5d-7af3d11ca007" xlink:to="loc_pcrx_SkyePharmaHoldingIncMember_b0755f58-f5c6-4572-a4db-d5b4ab0c00c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_332d4354-6872-43e2-82b1-fc8a60e916c1" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0bcebedf-f251-4318-8d5d-7af3d11ca007" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_332d4354-6872-43e2-82b1-fc8a60e916c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#GOODWILLANDINTANGIBLEASSETSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="extended" id="i71aec9f823824ebda4ab73ff1819f2e4_GOODWILLANDINTANGIBLEASSETSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_d5929913-88f6-478f-9c16-465bc3bffbde" xlink:href="pcrx-20211231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_d5929913-88f6-478f-9c16-465bc3bffbde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_ee64dec5-60a0-4af5-9569-ff39621d13f0" xlink:href="pcrx-20211231.xsd#pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_ee64dec5-60a0-4af5-9569-ff39621d13f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_68eae083-8570-4754-ad06-6a3bf6bf2109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_us-gaap_Goodwill_68eae083-8570-4754-ad06-6a3bf6bf2109" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f3b52912-9769-432a-bc23-a1bcce28a149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f3b52912-9769-432a-bc23-a1bcce28a149" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1_06f01ffe-2422-426d-a620-7daac0ddb702" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1_06f01ffe-2422-426d-a620-7daac0ddb702" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3_29017348-be05-4243-b5f1-c10ef95a5ca7" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3_29017348-be05-4243-b5f1-c10ef95a5ca7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2_e031e98b-4eb3-4410-8cba-08701fb2a95e" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2_e031e98b-4eb3-4410-8cba-08701fb2a95e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4_f70469dc-66c5-4e9c-9027-3eeb0440e160" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4_f70469dc-66c5-4e9c-9027-3eeb0440e160" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5_34ec66df-5142-4948-81ce-f7966a9e3127" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5_34ec66df-5142-4948-81ce-f7966a9e3127" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6_0f7335d0-faa7-45a5-9d33-f6735c4454dc" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6_0f7335d0-faa7-45a5-9d33-f6735c4454dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_12db2844-2f27-4029-9142-45158d2c38bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_12db2844-2f27-4029-9142-45158d2c38bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_4514a424-bdae-4b6d-a5c3-f1b93b1101a4" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_12db2844-2f27-4029-9142-45158d2c38bc" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_4514a424-bdae-4b6d-a5c3-f1b93b1101a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_4514a424-bdae-4b6d-a5c3-f1b93b1101a4_default" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_4514a424-bdae-4b6d-a5c3-f1b93b1101a4" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_4514a424-bdae-4b6d-a5c3-f1b93b1101a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_9af64e38-4ba1-45f3-898d-bf683f0b6ce2" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_4514a424-bdae-4b6d-a5c3-f1b93b1101a4" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_9af64e38-4ba1-45f3-898d-bf683f0b6ce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_106ff6c4-57ca-4679-a2fc-c74760af3b5a" xlink:href="pcrx-20211231.xsd#pcrx_UponFirstCommercialSaleInMajorEUCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_9af64e38-4ba1-45f3-898d-bf683f0b6ce2" xlink:to="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_106ff6c4-57ca-4679-a2fc-c74760af3b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_231bf1f2-81ef-405d-9443-46f4e64a1d17" xlink:href="pcrx-20211231.xsd#pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_9af64e38-4ba1-45f3-898d-bf683f0b6ce2" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_231bf1f2-81ef-405d-9443-46f4e64a1d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_df474720-fca4-412b-bd00-4c4f56f87004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_12db2844-2f27-4029-9142-45158d2c38bc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_df474720-fca4-412b-bd00-4c4f56f87004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df474720-fca4-412b-bd00-4c4f56f87004_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_df474720-fca4-412b-bd00-4c4f56f87004" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df474720-fca4-412b-bd00-4c4f56f87004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e775faa3-f952-4aea-bc8a-e5697b56935c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_df474720-fca4-412b-bd00-4c4f56f87004" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e775faa3-f952-4aea-bc8a-e5697b56935c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_bbb6ab71-fc4f-485e-ab58-fe31c67ec6f7" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e775faa3-f952-4aea-bc8a-e5697b56935c" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_bbb6ab71-fc4f-485e-ab58-fe31c67ec6f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" xlink:type="extended" id="idd21bd9e216842b1bad615d0496c7c45_GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bdd5ec08-fd0b-47e0-957c-1861a46758dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bdd5ec08-fd0b-47e0-957c-1861a46758dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fca902f6-ccbd-4311-a65b-46e156eeca41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fca902f6-ccbd-4311-a65b-46e156eeca41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aebb3257-648a-4f1a-b3dc-be4e3c9d73ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aebb3257-648a-4f1a-b3dc-be4e3c9d73ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_82d916f5-283d-4a12-a45c-3d664238b70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_82d916f5-283d-4a12-a45c-3d664238b70a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a39cbb92-ee32-4789-9f64-705efd42005d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_41a90974-142f-409a-925c-ac5701001857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_41a90974-142f-409a-925c-ac5701001857" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d13cd5a3-6f03-4df7-b414-dc78ff0537ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d13cd5a3-6f03-4df7-b414-dc78ff0537ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e5d01cdb-1871-4a6e-b985-4a61ca600a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e5d01cdb-1871-4a6e-b985-4a61ca600a52" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_a72af40a-6e0f-4658-a5af-98c5ed2e21a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_a72af40a-6e0f-4658-a5af-98c5ed2e21a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0858800-5018-4431-854d-d695bf201043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_a72af40a-6e0f-4658-a5af-98c5ed2e21a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0858800-5018-4431-854d-d695bf201043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0858800-5018-4431-854d-d695bf201043_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0858800-5018-4431-854d-d695bf201043" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0858800-5018-4431-854d-d695bf201043_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0858800-5018-4431-854d-d695bf201043" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e51c18f7-001c-4199-9a4d-387d6806ade3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e51c18f7-001c-4199-9a4d-387d6806ade3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_af6817e6-4dad-4fbb-bf9d-6a2208242c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:to="loc_us-gaap_CustomerRelationshipsMember_af6817e6-4dad-4fbb-bf9d-6a2208242c08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c343b729-0667-4abe-97ca-aaf62711f088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c343b729-0667-4abe-97ca-aaf62711f088" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACCRUEDEXPENSESDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended" id="ida6f58dcbb72455d9c6fa24e70b3f7d7_ACCRUEDEXPENSESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:href="pcrx-20211231.xsd#pcrx_AccruedExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_Accruedsellinggeneralandadministrativeexpenses_95a358e9-6a7b-4408-a917-d2f26dc97689" xlink:href="pcrx-20211231.xsd#pcrx_Accruedsellinggeneralandadministrativeexpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_Accruedsellinggeneralandadministrativeexpenses_95a358e9-6a7b-4408-a917-d2f26dc97689" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_Accruedresearchanddevelopmentexpenses_9ca9daa2-f86e-4426-ad67-149b153b7bac" xlink:href="pcrx-20211231.xsd#pcrx_Accruedresearchanddevelopmentexpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_Accruedresearchanddevelopmentexpenses_9ca9daa2-f86e-4426-ad67-149b153b7bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedOperatingExpensesCurrent_f3753220-cef3-4361-a116-31cf717dbabd" xlink:href="pcrx-20211231.xsd#pcrx_AccruedOperatingExpensesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_AccruedOperatingExpensesCurrent_f3753220-cef3-4361-a116-31cf717dbabd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f4708ba8-879b-403f-947d-398f60020135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f4708ba8-879b-403f-947d-398f60020135" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_44d078d1-60da-4415-b8a7-8cc37ad0649b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_44d078d1-60da-4415-b8a7-8cc37ad0649b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedEndOfTermFeeCurrent_a3df5888-34b3-4968-b216-5838ee111d0a" xlink:href="pcrx-20211231.xsd#pcrx_AccruedEndOfTermFeeCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_AccruedEndOfTermFeeCurrent_a3df5888-34b3-4968-b216-5838ee111d0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProductReturnsRebatesandOtherFees_0ad12dc2-9f23-46ee-a376-379608171176" xlink:href="pcrx-20211231.xsd#pcrx_ProductReturnsRebatesandOtherFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_ProductReturnsRebatesandOtherFees_0ad12dc2-9f23-46ee-a376-379608171176" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_50f4c57b-ceb9-46fe-8eaf-b06d00bd2d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_50f4c57b-ceb9-46fe-8eaf-b06d00bd2d3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_b54ca5b7-6976-43f5-bf03-d72cf57dbba7" xlink:href="pcrx-20211231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_b54ca5b7-6976-43f5-bf03-d72cf57dbba7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_067cbe5c-6ded-4675-b1b6-de4725b929b1" xlink:href="pcrx-20211231.xsd#pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_067cbe5c-6ded-4675-b1b6-de4725b929b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesTable_f759c4b5-b1b0-48aa-b2f3-db1d5746175b" xlink:href="pcrx-20211231.xsd#pcrx_AccruedExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_AccruedExpensesTable_f759c4b5-b1b0-48aa-b2f3-db1d5746175b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_204acf46-d7a2-4bb8-af81-8c4c8b556962" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_AccruedExpensesTable_f759c4b5-b1b0-48aa-b2f3-db1d5746175b" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_204acf46-d7a2-4bb8-af81-8c4c8b556962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_204acf46-d7a2-4bb8-af81-8c4c8b556962_default" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_204acf46-d7a2-4bb8-af81-8c4c8b556962" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_204acf46-d7a2-4bb8-af81-8c4c8b556962_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_0cae7b13-d9e9-4e4a-81e0-ede569b278bc" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_204acf46-d7a2-4bb8-af81-8c4c8b556962" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_0cae7b13-d9e9-4e4a-81e0-ede569b278bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_d5b43ba9-e559-4cbf-8be1-0aca968c6564" xlink:href="pcrx-20211231.xsd#pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_0cae7b13-d9e9-4e4a-81e0-ede569b278bc" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_d5b43ba9-e559-4cbf-8be1-0aca968c6564" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTCarryingValueofDebtDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTCarryingValueofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DEBTCarryingValueofDebtDetails" xlink:type="extended" id="i6c6776ecd91943b5b7ec22aa538eeb88_DEBTCarryingValueofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b8747c5f-8d5f-417d-84aa-abdc63ddf0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_708fb2f2-ce5f-4460-9ab7-24ad9c8ebda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8747c5f-8d5f-417d-84aa-abdc63ddf0e6" xlink:to="loc_us-gaap_LongTermDebt_708fb2f2-ce5f-4460-9ab7-24ad9c8ebda3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd07d55d-b6d8-47e3-bacb-a2505b3b3a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8747c5f-8d5f-417d-84aa-abdc63ddf0e6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd07d55d-b6d8-47e3-bacb-a2505b3b3a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8747c5f-8d5f-417d-84aa-abdc63ddf0e6" xlink:to="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3880dbf1-b046-4087-b944-b706a15951a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3880dbf1-b046-4087-b944-b706a15951a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3880dbf1-b046-4087-b944-b706a15951a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3880dbf1-b046-4087-b944-b706a15951a5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3880dbf1-b046-4087-b944-b706a15951a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_874527a4-46c0-43e3-a878-c9a979df1a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3880dbf1-b046-4087-b944-b706a15951a5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_874527a4-46c0-43e3-a878-c9a979df1a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_fcd22993-adae-4a08-bd57-7108add87321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_874527a4-46c0-43e3-a878-c9a979df1a5b" xlink:to="loc_us-gaap_SecuredDebtMember_fcd22993-adae-4a08-bd57-7108add87321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_8563bc8b-1505-47a3-bb07-1116c5f464a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_874527a4-46c0-43e3-a878-c9a979df1a5b" xlink:to="loc_us-gaap_UnsecuredDebtMember_8563bc8b-1505-47a3-bb07-1116c5f464a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bd8a4c54-0330-46bf-80ef-631f098c84c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:to="loc_us-gaap_DebtInstrumentAxis_bd8a4c54-0330-46bf-80ef-631f098c84c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bd8a4c54-0330-46bf-80ef-631f098c84c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bd8a4c54-0330-46bf-80ef-631f098c84c0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bd8a4c54-0330-46bf-80ef-631f098c84c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bd8a4c54-0330-46bf-80ef-631f098c84c0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanBFacilityDue2026Member_eb2252f4-827d-4ca2-8674-b87e1f550ac1" xlink:href="pcrx-20211231.xsd#pcrx_TermLoanBFacilityDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:to="loc_pcrx_TermLoanBFacilityDue2026Member_eb2252f4-827d-4ca2-8674-b87e1f550ac1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_4fea6ade-bfd3-40c9-9390-dcd31ad7e3d0" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_4fea6ade-bfd3-40c9-9390-dcd31ad7e3d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member_0b52128b-a956-45bc-a4f0-b94f3df6b2bb" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDueMay2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:to="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member_0b52128b-a956-45bc-a4f0-b94f3df6b2bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_7f8bd07e-b9cf-4957-acbc-985937c895d8" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_7f8bd07e-b9cf-4957-acbc-985937c895d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4b82574d-9f11-48d6-8cea-7ae9b8389c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4b82574d-9f11-48d6-8cea-7ae9b8389c39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4b82574d-9f11-48d6-8cea-7ae9b8389c39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4b82574d-9f11-48d6-8cea-7ae9b8389c39" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4b82574d-9f11-48d6-8cea-7ae9b8389c39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7d5e74eb-eb9e-4e25-902f-01330c93c34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4b82574d-9f11-48d6-8cea-7ae9b8389c39" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7d5e74eb-eb9e-4e25-902f-01330c93c34d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_fdeb64fe-49af-49d5-8ec2-7393930db95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7d5e74eb-eb9e-4e25-902f-01330c93c34d" xlink:to="loc_us-gaap_SubsequentEventMember_fdeb64fe-49af-49d5-8ec2-7393930db95c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DEBTNarrativeDetails" xlink:type="extended" id="i51db91d66ad4451b8b4a44d52981cdda_DEBTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentDiscountRate_2f2bae32-1772-4e90-a877-b49e8be4c3b8" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentDiscountRate_2f2bae32-1772-4e90-a877-b49e8be4c3b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_05d33297-7716-46d1-8111-c74efef7e933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_05d33297-7716-46d1-8111-c74efef7e933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_6d1d0a4e-3788-4bc6-aced-5d4465bec346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_6d1d0a4e-3788-4bc6-aced-5d4465bec346" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8452c2df-e342-4dba-9bd3-f76d57258d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8452c2df-e342-4dba-9bd3-f76d57258d03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_7097dcf4-7bca-44be-9e42-1d7115a7aee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_7097dcf4-7bca-44be-9e42-1d7115a7aee4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_a6e89b08-ca3b-4b14-8bff-dd9775409127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_a6e89b08-ca3b-4b14-8bff-dd9775409127" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear_d242ef46-3388-4b37-92e1-a7ea6011a7b0" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear_d242ef46-3388-4b37-92e1-a7ea6011a7b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1_e7842c84-1a4d-4c70-952c-244d898ab001" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1_e7842c84-1a4d-4c70-952c-244d898ab001" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2_02be755f-53c7-4317-964e-fa6fbeb0eb18" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2_02be755f-53c7-4317-964e-fa6fbeb0eb18" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter_29dc94bd-5c1c-4682-997d-ba21dd88fcb6" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter_29dc94bd-5c1c-4682-997d-ba21dd88fcb6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximum_52dd33b4-b343-4620-8632-15b0ce6c9a83" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximum_52dd33b4-b343-4620-8632-15b0ce6c9a83" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue_4b6c948c-5824-4e32-922c-ab0b4326597d" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue_4b6c948c-5824-4e32-922c-ab0b4326597d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentVariableRate_5f528fbd-f7c2-417e-bc01-50e67d810ca7" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentVariableRate_5f528fbd-f7c2-417e-bc01-50e67d810ca7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate_1f894b22-49f5-44ed-8686-f269c784b984" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentBasisSpreadOneOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate_1f894b22-49f5-44ed-8686-f269c784b984" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate_2d9b6f1f-c0dc-4658-8abc-794e1a997f4f" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate_2d9b6f1f-c0dc-4658-8abc-794e1a997f4f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0220190b-19fe-42ff-9fd2-d4be62242cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0220190b-19fe-42ff-9fd2-d4be62242cc8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_8c079de1-11cb-4367-8262-be196bd9b9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_8c079de1-11cb-4367-8262-be196bd9b9da" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0c410360-48cc-49f6-865d-5b522c06eb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0c410360-48cc-49f6-865d-5b522c06eb67" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62d1756d-8740-45b3-a26e-5f3ac0f8125e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62d1756d-8740-45b3-a26e-5f3ac0f8125e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_f90fd516-2ede-4fb9-b669-a07d6db93b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_f90fd516-2ede-4fb9-b669-a07d6db93b75" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_643e14c6-3873-4730-88f2-8679bce3e72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_643e14c6-3873-4730-88f2-8679bce3e72e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_3ec8e037-5dd9-4aa4-a1c8-6e31d7f47b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_RepaymentsOfDebt_3ec8e037-5dd9-4aa4-a1c8-6e31d7f47b9c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9d6ba207-1291-4be0-b5c5-203d8601c26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9d6ba207-1291-4be0-b5c5-203d8601c26e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_bdca59c3-2465-4733-9c67-40c516952b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_bdca59c3-2465-4733-9c67-40c516952b6b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_931fa367-fd91-472a-82e7-dd4501e9c7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_931fa367-fd91-472a-82e7-dd4501e9c7ad" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock_c2849d13-6094-486f-89cf-115b9cc39955" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock_c2849d13-6094-486f-89cf-115b9cc39955" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_8802f695-d712-4025-b7fe-74addc49360a" xlink:href="pcrx-20211231.xsd#pcrx_SettlementPeriodConvertibleDebtConversionRequest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_8802f695-d712-4025-b7fe-74addc49360a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_236d84b6-0747-4c63-b0b3-9c584aa39f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_236d84b6-0747-4c63-b0b3-9c584aa39f24" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_95c74678-34da-4b05-a317-a4edebadbcac" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_95c74678-34da-4b05-a317-a4edebadbcac" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_5c13fe68-6fa4-4987-9d22-3657c8110621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_SharePrice_5c13fe68-6fa4-4987-9d22-3657c8110621" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_bd038833-2882-4427-a009-0bcde7a1cac9" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_bd038833-2882-4427-a009-0bcde7a1cac9" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent_bd964500-e51b-4f53-a4fd-e9c70af154e2" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent_bd964500-e51b-4f53-a4fd-e9c70af154e2" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_e122f307-2780-43a9-929e-de2fe567558e" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConvertibleAssumedBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_e122f307-2780-43a9-929e-de2fe567558e" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_85b7f351-2237-49dc-a65c-fa547ff0dca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_85b7f351-2237-49dc-a65c-fa547ff0dca7" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_429b0abe-595d-4da6-baed-1cdce08333a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentTerm_429b0abe-595d-4da6-baed-1cdce08333a0" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt_2afd7f07-20ab-443f-b2c1-a7525a6d3fce" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt_2afd7f07-20ab-443f-b2c1-a7525a6d3fce" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_8375eca7-6195-4cbe-a577-23d9f12e6764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_8375eca7-6195-4cbe-a577-23d9f12e6764" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt_67483fdd-6b60-45ab-830d-155cba2100b4" xlink:href="pcrx-20211231.xsd#pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt_67483fdd-6b60-45ab-830d-155cba2100b4" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt_5a42f9ee-15b3-4505-a1d5-3031db6dffc4" xlink:href="pcrx-20211231.xsd#pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt_5a42f9ee-15b3-4505-a1d5-3031db6dffc4" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d03c1b0-6c22-49fc-afcf-76890c7907ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d03c1b0-6c22-49fc-afcf-76890c7907ca" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentMarketPrice_22901661-9063-4aa9-8e9b-7c07f65d832d" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentMarketPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentMarketPrice_22901661-9063-4aa9-8e9b-7c07f65d832d" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_2b56f829-75f8-447e-b9b7-d2b6a8b8ed7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_2b56f829-75f8-447e-b9b7-d2b6a8b8ed7b" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount_05f20dfd-ed02-44fc-bff2-d199d8b8c489" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount_05f20dfd-ed02-44fc-bff2-d199d8b8c489" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes_81dbbe71-0ee6-47e9-82ec-68306415a5cb" xlink:href="pcrx-20211231.xsd#pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes_81dbbe71-0ee6-47e9-82ec-68306415a5cb" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_265a5ba2-eb23-45a5-a504-4ac6520ae0bc" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_265a5ba2-eb23-45a5-a504-4ac6520ae0bc" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_4823e7d2-621c-4c4f-b0a5-420a353f26f5" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_4823e7d2-621c-4c4f-b0a5-420a353f26f5" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_20befad1-6e7d-41d2-9736-8573b4546574" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_20befad1-6e7d-41d2-9736-8573b4546574" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_ce325bf9-645c-4e27-a953-73e0f5136e08" xlink:href="pcrx-20211231.xsd#pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_ce325bf9-645c-4e27-a953-73e0f5136e08" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_610988d8-73c3-4d5c-85df-b7f5c0f515b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_ConvertibleDebt_610988d8-73c3-4d5c-85df-b7f5c0f515b0" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_28905931-c62d-44cd-98be-f8bcaf0ecddc" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_28905931-c62d-44cd-98be-f8bcaf0ecddc" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_ffeb111f-4675-4048-8420-1f603791a13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_ffeb111f-4675-4048-8420-1f603791a13a" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5e91e909-8327-44a9-a191-85472a55c10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_LongTermDebt_5e91e909-8327-44a9-a191-85472a55c10b" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b6490d7f-a48a-4cb3-9ca0-39248ebaafd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b6490d7f-a48a-4cb3-9ca0-39248ebaafd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b6490d7f-a48a-4cb3-9ca0-39248ebaafd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b6490d7f-a48a-4cb3-9ca0-39248ebaafd5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b6490d7f-a48a-4cb3-9ca0-39248ebaafd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b6490d7f-a48a-4cb3-9ca0-39248ebaafd5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_919464ca-c906-4e37-b5a8-737b996af647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:to="loc_us-gaap_SecuredDebtMember_919464ca-c906-4e37-b5a8-737b996af647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_90fb025f-446a-474e-a68d-08185c977c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:to="loc_us-gaap_UnsecuredDebtMember_90fb025f-446a-474e-a68d-08185c977c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_52656113-52cf-440f-a1ea-a27a3882b9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:to="loc_us-gaap_ConvertibleDebtMember_52656113-52cf-440f-a1ea-a27a3882b9d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c1e5776f-27ea-4cb7-91b6-31aed8a685fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_us-gaap_DebtInstrumentAxis_c1e5776f-27ea-4cb7-91b6-31aed8a685fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c1e5776f-27ea-4cb7-91b6-31aed8a685fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1e5776f-27ea-4cb7-91b6-31aed8a685fb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c1e5776f-27ea-4cb7-91b6-31aed8a685fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1e5776f-27ea-4cb7-91b6-31aed8a685fb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_fc0a3fc1-e4d7-493b-bacd-cb6090aa5148" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_fc0a3fc1-e4d7-493b-bacd-cb6090aa5148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_eda2e055-9173-4552-96f8-2f7910f1204b" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_eda2e055-9173-4552-96f8-2f7910f1204b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanBFacilityDue2026Member_7457de3c-e5f3-4f5f-90ac-3adb5ce78c4c" xlink:href="pcrx-20211231.xsd#pcrx_TermLoanBFacilityDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:to="loc_pcrx_TermLoanBFacilityDue2026Member_7457de3c-e5f3-4f5f-90ac-3adb5ce78c4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2024Member_91a6312b-8682-4d5d-a362-bcec92ff9542" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2024Member_91a6312b-8682-4d5d-a362-bcec92ff9542" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsAxis_0509d812-6982-4488-af98-538a55548aa4" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionAndRedemptionTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsAxis_0509d812-6982-4488-af98-538a55548aa4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0509d812-6982-4488-af98-538a55548aa4_default" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionAndRedemptionTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsAxis_0509d812-6982-4488-af98-538a55548aa4" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsDomain_0509d812-6982-4488-af98-538a55548aa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionAndRedemptionTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsAxis_0509d812-6982-4488-af98-538a55548aa4" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member_6f48e409-6204-4880-b3c7-743cbec2978b" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:to="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member_6f48e409-6204-4880-b3c7-743cbec2978b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member_8ea25d36-0814-4302-a43a-7b0c41745a70" xlink:href="pcrx-20211231.xsd#pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:to="loc_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member_8ea25d36-0814-4302-a43a-7b0c41745a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_2f35056d-3b03-446d-b436-a3c71a0fd6be" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:to="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_2f35056d-3b03-446d-b436-a3c71a0fd6be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_362c2b28-8945-4755-a496-fb068d9519db" xlink:href="pcrx-20211231.xsd#pcrx_DebtRedemptionTermsonorafterApril12020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:to="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_362c2b28-8945-4755-a496-fb068d9519db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_54746441-3a83-4e3f-be38-8e13097bbfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_us-gaap_VariableRateAxis_54746441-3a83-4e3f-be38-8e13097bbfcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_54746441-3a83-4e3f-be38-8e13097bbfcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_54746441-3a83-4e3f-be38-8e13097bbfcd" xlink:to="loc_us-gaap_VariableRateDomain_54746441-3a83-4e3f-be38-8e13097bbfcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_54746441-3a83-4e3f-be38-8e13097bbfcd" xlink:to="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_fe1a6b56-f389-4fbb-aa38-037e764c3ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_fe1a6b56-f389-4fbb-aa38-037e764c3ad4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_7f111b8c-952d-49ae-a26d-fd64d4d00225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:to="loc_us-gaap_BaseRateMember_7f111b8c-952d-49ae-a26d-fd64d4d00225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FederalReserveBankOfNYRateMember_a39e1982-26c8-4ed6-9946-1d1d3c6443ea" xlink:href="pcrx-20211231.xsd#pcrx_FederalReserveBankOfNYRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:to="loc_pcrx_FederalReserveBankOfNYRateMember_a39e1982-26c8-4ed6-9946-1d1d3c6443ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f3bc4d7e-0da7-4964-b59e-57bafd255e87" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_dei_LegalEntityAxis_f3bc4d7e-0da7-4964-b59e-57bafd255e87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f3bc4d7e-0da7-4964-b59e-57bafd255e87_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f3bc4d7e-0da7-4964-b59e-57bafd255e87" xlink:to="loc_dei_EntityDomain_f3bc4d7e-0da7-4964-b59e-57bafd255e87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_34b2e4bf-48b3-4d35-9b4c-1ca9a25cbbe0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f3bc4d7e-0da7-4964-b59e-57bafd255e87" xlink:to="loc_dei_EntityDomain_34b2e4bf-48b3-4d35-9b4c-1ca9a25cbbe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_2c3e4f85-cb93-4be6-8ec6-00ba8e78870a" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_34b2e4bf-48b3-4d35-9b4c-1ca9a25cbbe0" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_2c3e4f85-cb93-4be6-8ec6-00ba8e78870a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_39573b15-81fa-4b78-a255-deb38aa664da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_39573b15-81fa-4b78-a255-deb38aa664da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_39573b15-81fa-4b78-a255-deb38aa664da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_39573b15-81fa-4b78-a255-deb38aa664da" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_39573b15-81fa-4b78-a255-deb38aa664da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_edde2b3d-96d3-4785-94c3-a60a23901a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_39573b15-81fa-4b78-a255-deb38aa664da" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_edde2b3d-96d3-4785-94c3-a60a23901a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_82fbaac0-1850-43f3-a26f-19b4b193605a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_edde2b3d-96d3-4785-94c3-a60a23901a03" xlink:to="loc_us-gaap_SubsequentEventMember_82fbaac0-1850-43f3-a26f-19b4b193605a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ae691546-4462-45d4-92d6-e8002534781c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_srt_StatementScenarioAxis_ae691546-4462-45d4-92d6-e8002534781c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ae691546-4462-45d4-92d6-e8002534781c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ae691546-4462-45d4-92d6-e8002534781c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ae691546-4462-45d4-92d6-e8002534781c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a6602677-f8a9-4829-bd38-463a7dd88ce3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ae691546-4462-45d4-92d6-e8002534781c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a6602677-f8a9-4829-bd38-463a7dd88ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0f06c14a-ad67-4660-9fd4-ec87d41f176d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a6602677-f8a9-4829-bd38-463a7dd88ce3" xlink:to="loc_srt_ScenarioForecastMember_0f06c14a-ad67-4660-9fd4-ec87d41f176d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5404f5c-641d-4eab-855b-577ea075c8fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_srt_RangeAxis_a5404f5c-641d-4eab-855b-577ea075c8fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5404f5c-641d-4eab-855b-577ea075c8fb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a5404f5c-641d-4eab-855b-577ea075c8fb" xlink:to="loc_srt_RangeMember_a5404f5c-641d-4eab-855b-577ea075c8fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba9adca0-17f3-4e52-853c-66f350770119" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a5404f5c-641d-4eab-855b-577ea075c8fb" xlink:to="loc_srt_RangeMember_ba9adca0-17f3-4e52-853c-66f350770119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8063e018-b66e-4886-b842-e13ff7732236" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba9adca0-17f3-4e52-853c-66f350770119" xlink:to="loc_srt_MinimumMember_8063e018-b66e-4886-b842-e13ff7732236" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTScheduleofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="extended" id="i7c8cda2c2e984d689d4283f53b17feff_DEBTScheduleofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_81a454f3-01ac-42a7-af91-b05ae2d528fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_81a454f3-01ac-42a7-af91-b05ae2d528fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_999c13dc-9f7d-43cf-ad47-107b81c4627d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_999c13dc-9f7d-43cf-ad47-107b81c4627d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_f6ab7d26-088d-44c5-a925-ff03973a28ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_f6ab7d26-088d-44c5-a925-ff03973a28ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7677b968-ad07-4bb6-a1ad-fca31c1e39bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7677b968-ad07-4bb6-a1ad-fca31c1e39bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9a352577-a51c-4df2-95db-d3c61aceea8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_LongTermDebt_9a352577-a51c-4df2-95db-d3c61aceea8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_41f60605-3f73-4f22-af28-1511f5d2b84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_DebtInstrumentTable_41f60605-3f73-4f22-af28-1511f5d2b84f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_afb13fe8-2e81-4115-91fa-8fbb2a1f2b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41f60605-3f73-4f22-af28-1511f5d2b84f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_afb13fe8-2e81-4115-91fa-8fbb2a1f2b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_afb13fe8-2e81-4115-91fa-8fbb2a1f2b2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_afb13fe8-2e81-4115-91fa-8fbb2a1f2b2e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_afb13fe8-2e81-4115-91fa-8fbb2a1f2b2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7c7ab339-1b75-4a17-9add-235c18d949cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_afb13fe8-2e81-4115-91fa-8fbb2a1f2b2e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7c7ab339-1b75-4a17-9add-235c18d949cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_51a1a26f-ca3a-4561-aba4-d8b60011842e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c7ab339-1b75-4a17-9add-235c18d949cc" xlink:to="loc_us-gaap_UnsecuredDebtMember_51a1a26f-ca3a-4561-aba4-d8b60011842e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_415b83ba-2746-4a04-b744-ed9a6eb45319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c7ab339-1b75-4a17-9add-235c18d949cc" xlink:to="loc_us-gaap_SecuredDebtMember_415b83ba-2746-4a04-b744-ed9a6eb45319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_503e5934-f7b4-486a-8f2f-89d702242a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41f60605-3f73-4f22-af28-1511f5d2b84f" xlink:to="loc_us-gaap_DebtInstrumentAxis_503e5934-f7b4-486a-8f2f-89d702242a96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_503e5934-f7b4-486a-8f2f-89d702242a96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_503e5934-f7b4-486a-8f2f-89d702242a96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_503e5934-f7b4-486a-8f2f-89d702242a96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_503e5934-f7b4-486a-8f2f-89d702242a96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanBFacilityDue2026Member_b964b2f1-cb44-4209-bc62-879610508d17" xlink:href="pcrx-20211231.xsd#pcrx_TermLoanBFacilityDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:to="loc_pcrx_TermLoanBFacilityDue2026Member_b964b2f1-cb44-4209-bc62-879610508d17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_4ce8f766-d781-4978-847e-94a82bf0b093" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_4ce8f766-d781-4978-847e-94a82bf0b093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_a91aefcf-3ae9-4b36-94f3-045d020ac5af" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_a91aefcf-3ae9-4b36-94f3-045d020ac5af" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i3ca98a6db669428a8cb846eee6849be5_FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_01cf6411-122e-49c0-aec1-8895eff074a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_01cf6411-122e-49c0-aec1-8895eff074a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableFairValueDisclosure_93668fdb-acf7-46dd-81c2-5f6be66b644f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_NotesReceivableFairValueDisclosure_93668fdb-acf7-46dd-81c2-5f6be66b644f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ee5f84ea-b1d5-496c-ba7e-edd910e864d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ee5f84ea-b1d5-496c-ba7e-edd910e864d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_8f560563-0c94-4b69-900d-cdd02f43b509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_8f560563-0c94-4b69-900d-cdd02f43b509" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9d111405-486a-441a-aa94-a3ab3d367d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_SharePrice_9d111405-486a-441a-aa94-a3ab3d367d9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53701fed-d0d6-448e-ae32-171e05f7c35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53701fed-d0d6-448e-ae32-171e05f7c35d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_969624ba-0670-416b-a641-8da51db90d13" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConvertibleConversionPremiumShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_969624ba-0670-416b-a641-8da51db90d13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5e2793cb-e398-4c35-b2b7-1d2701633f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5e2793cb-e398-4c35-b2b7-1d2701633f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5e2793cb-e398-4c35-b2b7-1d2701633f51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5e2793cb-e398-4c35-b2b7-1d2701633f51" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5e2793cb-e398-4c35-b2b7-1d2701633f51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5e2793cb-e398-4c35-b2b7-1d2701633f51" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c3f5eba6-2f3a-49c2-95b2-67301a2fa61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c3f5eba6-2f3a-49c2-95b2-67301a2fa61f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ec683dc0-6115-4e11-b433-299aacd27c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ec683dc0-6115-4e11-b433-299aacd27c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bd607390-f782-47f0-99c5-d22dc38b1094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bd607390-f782-47f0-99c5-d22dc38b1094" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e69d87d3-79d7-4406-bf3b-61a88437270b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e69d87d3-79d7-4406-bf3b-61a88437270b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e69d87d3-79d7-4406-bf3b-61a88437270b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e69d87d3-79d7-4406-bf3b-61a88437270b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e69d87d3-79d7-4406-bf3b-61a88437270b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e69d87d3-79d7-4406-bf3b-61a88437270b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8b9fe693-7467-4c52-a94a-d76782b62c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8b9fe693-7467-4c52-a94a-d76782b62c23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8536bd1b-6026-4eab-9970-0e073a184ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8536bd1b-6026-4eab-9970-0e073a184ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_50834dd5-f7eb-4559-8052-d84465d5912d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_50834dd5-f7eb-4559-8052-d84465d5912d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d8c503d0-301e-4676-8c48-a33b36ae75de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_us-gaap_DebtInstrumentAxis_d8c503d0-301e-4676-8c48-a33b36ae75de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d8c503d0-301e-4676-8c48-a33b36ae75de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d8c503d0-301e-4676-8c48-a33b36ae75de" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d8c503d0-301e-4676-8c48-a33b36ae75de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d8c503d0-301e-4676-8c48-a33b36ae75de" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanBFacilityDue2026Member_ebb52dab-65f9-4583-b7ca-0b7f55d6a0b9" xlink:href="pcrx-20211231.xsd#pcrx_TermLoanBFacilityDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:to="loc_pcrx_TermLoanBFacilityDue2026Member_ebb52dab-65f9-4583-b7ca-0b7f55d6a0b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_678a8527-b2d6-4c53-8740-9dd7a4b99bad" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_678a8527-b2d6-4c53-8740-9dd7a4b99bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_f815fd0e-5f71-4c26-807f-feb0853bfb65" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_f815fd0e-5f71-4c26-807f-feb0853bfb65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2024Member_89f09130-1d3e-4265-9934-4ef660544ea0" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2024Member_89f09130-1d3e-4265-9934-4ef660544ea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4559a014-0e29-4a4c-8a1c-33524a9ec18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4559a014-0e29-4a4c-8a1c-33524a9ec18f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4559a014-0e29-4a4c-8a1c-33524a9ec18f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4559a014-0e29-4a4c-8a1c-33524a9ec18f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4559a014-0e29-4a4c-8a1c-33524a9ec18f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eadd58f2-7654-4f8f-8113-4c36ec2ba225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4559a014-0e29-4a4c-8a1c-33524a9ec18f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eadd58f2-7654-4f8f-8113-4c36ec2ba225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_ad62eaf3-0a04-480b-bcd3-dd33bafec364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eadd58f2-7654-4f8f-8113-4c36ec2ba225" xlink:to="loc_us-gaap_UnsecuredDebtMember_ad62eaf3-0a04-480b-bcd3-dd33bafec364" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_dd1a4657-2ce2-4832-8682-f41109fe5c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eadd58f2-7654-4f8f-8113-4c36ec2ba225" xlink:to="loc_us-gaap_SecuredDebtMember_dd1a4657-2ce2-4832-8682-f41109fe5c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2eba2cf5-da45-4090-97a0-b7a394a88acc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_srt_RangeAxis_2eba2cf5-da45-4090-97a0-b7a394a88acc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2eba2cf5-da45-4090-97a0-b7a394a88acc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2eba2cf5-da45-4090-97a0-b7a394a88acc" xlink:to="loc_srt_RangeMember_2eba2cf5-da45-4090-97a0-b7a394a88acc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_762bdec6-b59c-437a-bef9-1fffdce5b1e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2eba2cf5-da45-4090-97a0-b7a394a88acc" xlink:to="loc_srt_RangeMember_762bdec6-b59c-437a-bef9-1fffdce5b1e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_016e9cdf-81cd-480d-8f03-c04fc3ba9271" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_762bdec6-b59c-437a-bef9-1fffdce5b1e1" xlink:to="loc_srt_MaximumMember_016e9cdf-81cd-480d-8f03-c04fc3ba9271" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended" id="i07c410c750d940c9847822924f0a2e5a_FINANCIALINSTRUMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d1c34ac0-d546-4e86-b51f-a2571a05efcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d1c34ac0-d546-4e86-b51f-a2571a05efcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8d47d73d-a3d1-42eb-a854-ce6d2bdac7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8d47d73d-a3d1-42eb-a854-ce6d2bdac7a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_48c5f31a-41a1-41c6-bb40-e4eeb4b127f7" xlink:href="pcrx-20211231.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_48c5f31a-41a1-41c6-bb40-e4eeb4b127f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_11daba7b-a08d-4a2c-8956-7dc757d14903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_11daba7b-a08d-4a2c-8956-7dc757d14903" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1b142777-c7ad-4fe6-a70b-a88e6371c713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1b142777-c7ad-4fe6-a70b-a88e6371c713" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition_0fb77f85-b370-40b1-9b0b-2bafbeb02704" xlink:href="pcrx-20211231.xsd#pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition_0fb77f85-b370-40b1-9b0b-2bafbeb02704" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_11152142-09f4-4f03-b9c6-4911b5492493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_11152142-09f4-4f03-b9c6-4911b5492493" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7738775b-2730-47ed-aab4-739add88594c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7738775b-2730-47ed-aab4-739add88594c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_dfb32bd9-c750-47ea-8943-7cf693edcda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_dfb32bd9-c750-47ea-8943-7cf693edcda7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_27375dc9-e50e-4f11-9365-5ddfe911e44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_27375dc9-e50e-4f11-9365-5ddfe911e44d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_3c48fbf6-3704-427c-a619-93f58d1a85a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_3c48fbf6-3704-427c-a619-93f58d1a85a0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_8bf234e9-4195-4dc0-a1bb-f9649f176164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_8bf234e9-4195-4dc0-a1bb-f9649f176164" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones_23c88023-3d45-454c-a851-be558d11928e" xlink:href="pcrx-20211231.xsd#pcrx_PotentialAdditionalInvestmentUponAchievingMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones_23c88023-3d45-454c-a851-be558d11928e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_57689a61-9faa-44df-a1fa-ecccbf4d2e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_57689a61-9faa-44df-a1fa-ecccbf4d2e8f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_bea3b58b-7782-4412-a0e9-0a89abe90afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_ConvertibleNotesPayable_bea3b58b-7782-4412-a0e9-0a89abe90afa" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_69200929-e2c0-4d68-b185-3c089f026f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_69200929-e2c0-4d68-b185-3c089f026f96" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_8a57c874-7fa1-4cb8-a08b-6598e9e11336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_8a57c874-7fa1-4cb8-a08b-6598e9e11336" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_0cbae76b-5d4d-479a-9eb2-0dc82a667534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_0cbae76b-5d4d-479a-9eb2-0dc82a667534" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_2e35434f-04df-40fd-a33a-d9dc7ee0981a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_2e35434f-04df-40fd-a33a-d9dc7ee0981a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_a60ce9db-cd01-4413-bd82-cada17117452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_ImpairmentOfInvestments_a60ce9db-cd01-4413-bd82-cada17117452" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfMajorCustomers_01c90def-5987-47c4-a046-c2c59d7b974e" xlink:href="pcrx-20211231.xsd#pcrx_NumberOfMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_pcrx_NumberOfMajorCustomers_01c90def-5987-47c4-a046-c2c59d7b974e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9d57aa9f-d493-4177-8592-68fdc8dec417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9d57aa9f-d493-4177-8592-68fdc8dec417" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_636e3b14-98cd-429d-bfe6-970082ef8ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_636e3b14-98cd-429d-bfe6-970082ef8ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_636e3b14-98cd-429d-bfe6-970082ef8ddf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_636e3b14-98cd-429d-bfe6-970082ef8ddf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_636e3b14-98cd-429d-bfe6-970082ef8ddf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_636e3b14-98cd-429d-bfe6-970082ef8ddf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_31b5a1d1-4746-44e7-bd90-fab5d99d5653" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_31b5a1d1-4746-44e7-bd90-fab5d99d5653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_96cf4ba7-5707-4777-b34e-36f392232ef6" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:to="loc_pcrx_FlexionAcquisitionMember_96cf4ba7-5707-4777-b34e-36f392232ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAndMyoscienceAcquisitionMember_aafceee9-b6e4-4729-823d-5fa0811257b4" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAndMyoscienceAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:to="loc_pcrx_FlexionAndMyoscienceAcquisitionMember_aafceee9-b6e4-4729-823d-5fa0811257b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_279a6c52-b99e-4637-9929-bf49dfabc059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_279a6c52-b99e-4637-9929-bf49dfabc059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_279a6c52-b99e-4637-9929-bf49dfabc059_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_279a6c52-b99e-4637-9929-bf49dfabc059" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_279a6c52-b99e-4637-9929-bf49dfabc059_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3205f2df-03fd-4588-a6d0-cff07502672e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_279a6c52-b99e-4637-9929-bf49dfabc059" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3205f2df-03fd-4588-a6d0-cff07502672e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2f694432-9532-44d0-a749-c19f4601443d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3205f2df-03fd-4588-a6d0-cff07502672e" xlink:to="loc_us-gaap_UnsecuredDebtMember_2f694432-9532-44d0-a749-c19f4601443d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d787bbae-c7b1-42c2-85e2-641759e2d2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d787bbae-c7b1-42c2-85e2-641759e2d2c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d787bbae-c7b1-42c2-85e2-641759e2d2c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d787bbae-c7b1-42c2-85e2-641759e2d2c8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d787bbae-c7b1-42c2-85e2-641759e2d2c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d787bbae-c7b1-42c2-85e2-641759e2d2c8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4cb2bcd7-979a-47cc-887c-0ed862af26db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4cb2bcd7-979a-47cc-887c-0ed862af26db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_81325067-41a1-4470-9d08-e9cb127064e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_81325067-41a1-4470-9d08-e9cb127064e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4c5f978c-0a64-4256-a67b-6eb3f54f0b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4c5f978c-0a64-4256-a67b-6eb3f54f0b6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3b761a01-069b-47d3-93aa-1ca261c6b556" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_srt_MajorCustomersAxis_3b761a01-069b-47d3-93aa-1ca261c6b556" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3b761a01-069b-47d3-93aa-1ca261c6b556_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3b761a01-069b-47d3-93aa-1ca261c6b556" xlink:to="loc_srt_NameOfMajorCustomerDomain_3b761a01-069b-47d3-93aa-1ca261c6b556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3b761a01-069b-47d3-93aa-1ca261c6b556" xlink:to="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerOneMember_249f5186-51a9-4def-85cc-9e74fc2bbfed" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:to="loc_pcrx_MajorCustomerOneMember_249f5186-51a9-4def-85cc-9e74fc2bbfed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerTwoMember_0245b5d4-1c34-4481-aed1-5c4711536e27" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:to="loc_pcrx_MajorCustomerTwoMember_0245b5d4-1c34-4481-aed1-5c4711536e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerThreeMember_ca1ffcdb-cce4-4d38-bee6-6a24767487e9" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:to="loc_pcrx_MajorCustomerThreeMember_ca1ffcdb-cce4-4d38-bee6-6a24767487e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerFourMember_1dee0af2-4a2c-4d0a-b335-1d0be6c8e0b9" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:to="loc_pcrx_MajorCustomerFourMember_1dee0af2-4a2c-4d0a-b335-1d0be6c8e0b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5142fb59-2da2-4a01-9069-2db7fb323f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5142fb59-2da2-4a01-9069-2db7fb323f2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5142fb59-2da2-4a01-9069-2db7fb323f2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5142fb59-2da2-4a01-9069-2db7fb323f2b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5142fb59-2da2-4a01-9069-2db7fb323f2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9cf19efe-4fc3-471d-82f5-b4d77a091098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5142fb59-2da2-4a01-9069-2db7fb323f2b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9cf19efe-4fc3-471d-82f5-b4d77a091098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_81428518-805a-417b-aac5-66196fa1f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9cf19efe-4fc3-471d-82f5-b4d77a091098" xlink:to="loc_us-gaap_AccountsReceivableMember_81428518-805a-417b-aac5-66196fa1f0d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a86056ae-3b64-4110-bbc8-95467107837a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a86056ae-3b64-4110-bbc8-95467107837a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a86056ae-3b64-4110-bbc8-95467107837a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a86056ae-3b64-4110-bbc8-95467107837a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a86056ae-3b64-4110-bbc8-95467107837a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0c3385c7-9aa2-40be-b68f-4972553e1aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a86056ae-3b64-4110-bbc8-95467107837a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0c3385c7-9aa2-40be-b68f-4972553e1aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_88b75d7a-3583-428c-930b-663ca4c35c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0c3385c7-9aa2-40be-b68f-4972553e1aaf" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_88b75d7a-3583-428c-930b-663ca4c35c5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4549e6dc-b006-4ad5-966a-70964e78343c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_4549e6dc-b006-4ad5-966a-70964e78343c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4549e6dc-b006-4ad5-966a-70964e78343c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4549e6dc-b006-4ad5-966a-70964e78343c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4549e6dc-b006-4ad5-966a-70964e78343c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a1aa9c43-2e16-44ee-8e2f-cfdceb8a7189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4549e6dc-b006-4ad5-966a-70964e78343c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a1aa9c43-2e16-44ee-8e2f-cfdceb8a7189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_0952286d-f79b-48e9-afd3-6af812f3b192" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1aa9c43-2e16-44ee-8e2f-cfdceb8a7189" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_0952286d-f79b-48e9-afd3-6af812f3b192" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_806b4be9-0da5-4e17-b5cf-2a469615613a" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1aa9c43-2e16-44ee-8e2f-cfdceb8a7189" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_806b4be9-0da5-4e17-b5cf-2a469615613a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_6c8002b8-0317-4576-8502-88daf2054688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_6c8002b8-0317-4576-8502-88daf2054688" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c8002b8-0317-4576-8502-88daf2054688_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6c8002b8-0317-4576-8502-88daf2054688" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6c8002b8-0317-4576-8502-88daf2054688_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_efbeb1fd-0e69-4241-80df-b20c4370efc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6c8002b8-0317-4576-8502-88daf2054688" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_efbeb1fd-0e69-4241-80df-b20c4370efc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cdefbe76-7bd8-40bb-a02e-a2c9f9ea6e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_efbeb1fd-0e69-4241-80df-b20c4370efc3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cdefbe76-7bd8-40bb-a02e-a2c9f9ea6e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bf74a7d7-c274-4110-a355-2440d66af322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cdefbe76-7bd8-40bb-a02e-a2c9f9ea6e87" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bf74a7d7-c274-4110-a355-2440d66af322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_924c6daa-d948-4fc6-a148-c42fdafdc510" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_srt_RangeAxis_924c6daa-d948-4fc6-a148-c42fdafdc510" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_924c6daa-d948-4fc6-a148-c42fdafdc510_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_924c6daa-d948-4fc6-a148-c42fdafdc510" xlink:to="loc_srt_RangeMember_924c6daa-d948-4fc6-a148-c42fdafdc510_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7fe4800e-5e83-4448-b49b-5103cc1fcbd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_924c6daa-d948-4fc6-a148-c42fdafdc510" xlink:to="loc_srt_RangeMember_7fe4800e-5e83-4448-b49b-5103cc1fcbd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_84262af5-c94b-4e99-97a4-4a8d8889bc1d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7fe4800e-5e83-4448-b49b-5103cc1fcbd3" xlink:to="loc_srt_WeightedAverageMember_84262af5-c94b-4e99-97a4-4a8d8889bc1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3aa7e6d6-0e8c-4318-8e16-5cea4a3ffd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3aa7e6d6-0e8c-4318-8e16-5cea4a3ffd72" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aa7e6d6-0e8c-4318-8e16-5cea4a3ffd72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3aa7e6d6-0e8c-4318-8e16-5cea4a3ffd72" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aa7e6d6-0e8c-4318-8e16-5cea4a3ffd72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3228b595-9233-46b1-bcdf-befe27d2e384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3aa7e6d6-0e8c-4318-8e16-5cea4a3ffd72" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3228b595-9233-46b1-bcdf-befe27d2e384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_65b611e7-bfb2-40a9-9f2b-11f67c94bd8b" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3228b595-9233-46b1-bcdf-befe27d2e384" xlink:to="loc_pcrx_ContingentConsiderationMember_65b611e7-bfb2-40a9-9f2b-11f67c94bd8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d539b928-8be0-41bb-9bb2-f1b6a1472bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d539b928-8be0-41bb-9bb2-f1b6a1472bcd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d539b928-8be0-41bb-9bb2-f1b6a1472bcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d539b928-8be0-41bb-9bb2-f1b6a1472bcd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d539b928-8be0-41bb-9bb2-f1b6a1472bcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e28296e1-6f36-4f87-a8be-5fe942ca625b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d539b928-8be0-41bb-9bb2-f1b6a1472bcd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e28296e1-6f36-4f87-a8be-5fe942ca625b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_ec5ec89f-6353-4cd8-9ea3-ba3881202077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e28296e1-6f36-4f87-a8be-5fe942ca625b" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_ec5ec89f-6353-4cd8-9ea3-ba3881202077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_afd2bf50-e79a-4165-8abe-d5994b346d9b" xlink:href="pcrx-20211231.xsd#pcrx_MeasurementInputExpectedMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e28296e1-6f36-4f87-a8be-5fe942ca625b" xlink:to="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_afd2bf50-e79a-4165-8abe-d5994b346d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5af6ccfd-a6a6-4dc7-8633-72404434e73c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5af6ccfd-a6a6-4dc7-8633-72404434e73c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5af6ccfd-a6a6-4dc7-8633-72404434e73c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5af6ccfd-a6a6-4dc7-8633-72404434e73c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5af6ccfd-a6a6-4dc7-8633-72404434e73c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5af6ccfd-a6a6-4dc7-8633-72404434e73c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TELABioMember_1aa27621-9d96-4d00-9361-f5b4420d2eef" xlink:href="pcrx-20211231.xsd#pcrx_TELABioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:to="loc_pcrx_TELABioMember_1aa27621-9d96-4d00-9361-f5b4420d2eef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GeneQuineMember_73e5c4ee-360a-48d7-a921-7e0a39f4ad35" xlink:href="pcrx-20211231.xsd#pcrx_GeneQuineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:to="loc_pcrx_GeneQuineMember_73e5c4ee-360a-48d7-a921-7e0a39f4ad35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CodaBioTherapeuticsIncMember_9bc1af10-8b3e-493e-96c4-ff3f93510e54" xlink:href="pcrx-20211231.xsd#pcrx_CodaBioTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:to="loc_pcrx_CodaBioTherapeuticsIncMember_9bc1af10-8b3e-493e-96c4-ff3f93510e54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GenascenceCorporationMember_904a13c2-d0e0-4932-a379-4d468f8ccfbb" xlink:href="pcrx-20211231.xsd#pcrx_GenascenceCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:to="loc_pcrx_GenascenceCorporationMember_904a13c2-d0e0-4932-a379-4d468f8ccfbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2186024b-7836-4461-ac18-d107782509bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2186024b-7836-4461-ac18-d107782509bf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2186024b-7836-4461-ac18-d107782509bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2186024b-7836-4461-ac18-d107782509bf" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2186024b-7836-4461-ac18-d107782509bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a6f79266-58eb-4c99-942e-833d22d53113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2186024b-7836-4461-ac18-d107782509bf" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a6f79266-58eb-4c99-942e-833d22d53113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SpineBioPharmaLLCMember_c31a55ee-1ff0-4ca3-ab95-2d488ba10fa5" xlink:href="pcrx-20211231.xsd#pcrx_SpineBioPharmaLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a6f79266-58eb-4c99-942e-833d22d53113" xlink:to="loc_pcrx_SpineBioPharmaLLCMember_c31a55ee-1ff0-4ca3-ab95-2d488ba10fa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b8630f58-d8f1-411d-a3d2-662a1dc9b811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b8630f58-d8f1-411d-a3d2-662a1dc9b811" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b8630f58-d8f1-411d-a3d2-662a1dc9b811_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b8630f58-d8f1-411d-a3d2-662a1dc9b811" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b8630f58-d8f1-411d-a3d2-662a1dc9b811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_072e8bc0-fd06-4ba8-95dc-96fac69eeea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b8630f58-d8f1-411d-a3d2-662a1dc9b811" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_072e8bc0-fd06-4ba8-95dc-96fac69eeea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_c4dec7b0-44ea-49d9-8594-9083aec6fa73" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_072e8bc0-fd06-4ba8-95dc-96fac69eeea0" xlink:to="loc_pcrx_ContingentConsiderationMember_c4dec7b0-44ea-49d9-8594-9083aec6fa73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_030ad12f-bfe3-44d3-91df-818bbb35fbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_030ad12f-bfe3-44d3-91df-818bbb35fbc5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_030ad12f-bfe3-44d3-91df-818bbb35fbc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_030ad12f-bfe3-44d3-91df-818bbb35fbc5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_030ad12f-bfe3-44d3-91df-818bbb35fbc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1e8e4bac-6d1f-4324-bdb7-b5e5d058eeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_030ad12f-bfe3-44d3-91df-818bbb35fbc5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1e8e4bac-6d1f-4324-bdb7-b5e5d058eeb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0e09a7b8-c827-4d76-9c3a-ff1da0ca091d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1e8e4bac-6d1f-4324-bdb7-b5e5d058eeb8" xlink:to="loc_us-gaap_SubsequentEventMember_0e09a7b8-c827-4d76-9c3a-ff1da0ca091d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails" xlink:type="extended" id="iba5cbb85cdd242bca377ba644687b6f8_FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e581310e-a4c5-41d7-ad7a-5acf47533a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d39cdb7a-29dc-4d93-b5f1-12f7cc43ff2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e581310e-a4c5-41d7-ad7a-5acf47533a9f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d39cdb7a-29dc-4d93-b5f1-12f7cc43ff2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e581310e-a4c5-41d7-ad7a-5acf47533a9f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0abcff2-5996-4017-9c02-42b3ae3bb8d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_srt_RangeAxis_e0abcff2-5996-4017-9c02-42b3ae3bb8d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0abcff2-5996-4017-9c02-42b3ae3bb8d3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e0abcff2-5996-4017-9c02-42b3ae3bb8d3" xlink:to="loc_srt_RangeMember_e0abcff2-5996-4017-9c02-42b3ae3bb8d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63a96085-b8c9-4cfe-82e4-50284688ad1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e0abcff2-5996-4017-9c02-42b3ae3bb8d3" xlink:to="loc_srt_RangeMember_63a96085-b8c9-4cfe-82e4-50284688ad1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_67b5b335-084d-4136-aea2-dc9ee2ad0215" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_63a96085-b8c9-4cfe-82e4-50284688ad1c" xlink:to="loc_srt_MinimumMember_67b5b335-084d-4136-aea2-dc9ee2ad0215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ddaa8713-8ea0-44b7-93ab-24e464496307" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_63a96085-b8c9-4cfe-82e4-50284688ad1c" xlink:to="loc_srt_MaximumMember_ddaa8713-8ea0-44b7-93ab-24e464496307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a18448e7-fc15-457d-926d-a8e211f35a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a18448e7-fc15-457d-926d-a8e211f35a59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a18448e7-fc15-457d-926d-a8e211f35a59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a18448e7-fc15-457d-926d-a8e211f35a59" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a18448e7-fc15-457d-926d-a8e211f35a59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4c353a-e735-4513-b52a-4654e8e45d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a18448e7-fc15-457d-926d-a8e211f35a59" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4c353a-e735-4513-b52a-4654e8e45d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_4f441d7e-8c54-45e3-ae02-e436448acfb1" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4c353a-e735-4513-b52a-4654e8e45d7d" xlink:to="loc_pcrx_FlexionAcquisitionMember_4f441d7e-8c54-45e3-ae02-e436448acfb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_1ad63ffd-6849-4549-81ed-2b5cc0d1b159" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4c353a-e735-4513-b52a-4654e8e45d7d" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_1ad63ffd-6849-4549-81ed-2b5cc0d1b159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbe43290-a366-4b15-8b9f-e9c5217c945f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbe43290-a366-4b15-8b9f-e9c5217c945f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbe43290-a366-4b15-8b9f-e9c5217c945f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbe43290-a366-4b15-8b9f-e9c5217c945f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbe43290-a366-4b15-8b9f-e9c5217c945f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f55eb96-a8df-45fe-9018-390f667dc221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbe43290-a366-4b15-8b9f-e9c5217c945f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f55eb96-a8df-45fe-9018-390f667dc221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b26dc452-2ec8-471e-8ae3-14f44ef8bed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f55eb96-a8df-45fe-9018-390f667dc221" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b26dc452-2ec8-471e-8ae3-14f44ef8bed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4c4e0120-7428-48e3-b6b5-33748c6ea165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4c4e0120-7428-48e3-b6b5-33748c6ea165" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c4e0120-7428-48e3-b6b5-33748c6ea165_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4c4e0120-7428-48e3-b6b5-33748c6ea165" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c4e0120-7428-48e3-b6b5-33748c6ea165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2825e24-d763-4662-9776-45fce22c93c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4c4e0120-7428-48e3-b6b5-33748c6ea165" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2825e24-d763-4662-9776-45fce22c93c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_161b2544-b291-4a00-9d26-b7a352e33a15" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2825e24-d763-4662-9776-45fce22c93c1" xlink:to="loc_pcrx_ContingentConsiderationMember_161b2544-b291-4a00-9d26-b7a352e33a15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_46702c32-a455-496c-b03a-36e0f89e03f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_46702c32-a455-496c-b03a-36e0f89e03f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_46702c32-a455-496c-b03a-36e0f89e03f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_46702c32-a455-496c-b03a-36e0f89e03f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_46702c32-a455-496c-b03a-36e0f89e03f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fc0c034d-dab7-44db-b674-73c3172ddf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_46702c32-a455-496c-b03a-36e0f89e03f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fc0c034d-dab7-44db-b674-73c3172ddf75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_460c58b3-8288-43f5-a677-f5ab4ecf828a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fc0c034d-dab7-44db-b674-73c3172ddf75" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_460c58b3-8288-43f5-a677-f5ab4ecf828a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_9bfeb1dc-cfff-4766-96fa-5acd9318eb5b" xlink:href="pcrx-20211231.xsd#pcrx_MeasurementInputExpectedMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fc0c034d-dab7-44db-b674-73c3172ddf75" xlink:to="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_9bfeb1dc-cfff-4766-96fa-5acd9318eb5b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails" xlink:type="extended" id="ib64943ab1fd347f4832da087ca619a72_FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_b746a0b5-e4f4-4ce5-9479-8582642e528c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_b746a0b5-e4f4-4ce5-9479-8582642e528c" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e7f9b1c1-9472-429b-98e4-b877e54a08f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e7f9b1c1-9472-429b-98e4-b877e54a08f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice_3c838ea9-eda7-4ed4-b4ba-710f1003ec76" xlink:href="pcrx-20211231.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:to="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice_3c838ea9-eda7-4ed4-b4ba-710f1003ec76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_08e7456e-7e6b-4092-a8b0-fe8928ea4bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_08e7456e-7e6b-4092-a8b0-fe8928ea4bfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fac123ef-da2e-4d4b-8e2a-4d95789d4866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fac123ef-da2e-4d4b-8e2a-4d95789d4866" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1819bbf3-7345-4aae-bdaf-e44d2fe5301c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_90254c78-da1d-4330-b873-277a4ed9c3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_b746a0b5-e4f4-4ce5-9479-8582642e528c" xlink:to="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_90254c78-da1d-4330-b873-277a4ed9c3c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4b5938a3-f906-455e-ad14-24326c990b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_90254c78-da1d-4330-b873-277a4ed9c3c1" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4b5938a3-f906-455e-ad14-24326c990b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4b5938a3-f906-455e-ad14-24326c990b51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4b5938a3-f906-455e-ad14-24326c990b51" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4b5938a3-f906-455e-ad14-24326c990b51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f562837-e69b-4a16-8fcc-d71c9db7e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4b5938a3-f906-455e-ad14-24326c990b51" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f562837-e69b-4a16-8fcc-d71c9db7e0c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_ecab2b50-218c-4117-b4d0-f7783eb6b211" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f562837-e69b-4a16-8fcc-d71c9db7e0c0" xlink:to="loc_pcrx_ContingentConsiderationMember_ecab2b50-218c-4117-b4d0-f7783eb6b211" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails" xlink:type="extended" id="i5c2ea342be9f41ec811a30b9d2fc2a0e_FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b40910ed-d425-4e61-9eae-2dea5f8b104a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b40910ed-d425-4e61-9eae-2dea5f8b104a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e4ef61f-2e62-4b82-af67-1a143220de9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e4ef61f-2e62-4b82-af67-1a143220de9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8297e45-dd1f-4b9d-9f85-04bddb37b253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8297e45-dd1f-4b9d-9f85-04bddb37b253" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6f866cbf-09aa-4f35-a0f7-6c71beac9e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6f866cbf-09aa-4f35-a0f7-6c71beac9e7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3bcec3e3-cc2d-4096-9ac7-7ad93d28f951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3bcec3e3-cc2d-4096-9ac7-7ad93d28f951" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b9b6c0e0-3714-41b0-8bb5-6023bc7f7f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3bcec3e3-cc2d-4096-9ac7-7ad93d28f951" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b9b6c0e0-3714-41b0-8bb5-6023bc7f7f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9b6c0e0-3714-41b0-8bb5-6023bc7f7f82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b9b6c0e0-3714-41b0-8bb5-6023bc7f7f82" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9b6c0e0-3714-41b0-8bb5-6023bc7f7f82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b9b6c0e0-3714-41b0-8bb5-6023bc7f7f82" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7f525845-c492-465e-9090-9220a69c2536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7f525845-c492-465e-9090-9220a69c2536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_99ee3c98-3966-4163-b3aa-ea7a02273174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:to="loc_us-gaap_CommercialPaperMember_99ee3c98-3966-4163-b3aa-ea7a02273174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_55d6f637-4585-484f-b64b-8990d1e2abdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_55d6f637-4585-484f-b64b-8990d1e2abdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_54f956b6-35a0-487f-8610-0502a74a8d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_54f956b6-35a0-487f-8610-0502a74a8d5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4db78dd8-2107-47dd-8697-9563b408bb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3bcec3e3-cc2d-4096-9ac7-7ad93d28f951" xlink:to="loc_us-gaap_InvestmentTypeAxis_4db78dd8-2107-47dd-8697-9563b408bb7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4db78dd8-2107-47dd-8697-9563b408bb7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4db78dd8-2107-47dd-8697-9563b408bb7c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4db78dd8-2107-47dd-8697-9563b408bb7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5294875a-4931-4f3c-b640-ed2ddacdb67b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4db78dd8-2107-47dd-8697-9563b408bb7c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5294875a-4931-4f3c-b640-ed2ddacdb67b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_bc47fd0a-f241-4c50-bcd4-dac00fde33a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5294875a-4931-4f3c-b640-ed2ddacdb67b" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_bc47fd0a-f241-4c50-bcd4-dac00fde33a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LongTermInvestmentsMember_283804b4-0777-4b68-ae6a-e1c38a64a36b" xlink:href="pcrx-20211231.xsd#pcrx_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5294875a-4931-4f3c-b640-ed2ddacdb67b" xlink:to="loc_pcrx_LongTermInvestmentsMember_283804b4-0777-4b68-ae6a-e1c38a64a36b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKHOLDERSEQUITYAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails" xlink:type="extended" id="ic14bfc040293474984129f500d4e9ac6_STOCKHOLDERSEQUITYAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6f0756d1-c652-4fab-ba8d-8303c23b792c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:to="loc_us-gaap_StockholdersEquity_6f0756d1-c652-4fab-ba8d-8303c23b792c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9a13934-8720-45be-882e-30b9b9ba293e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9a13934-8720-45be-882e-30b9b9ba293e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8583f6f7-52de-431f-926d-8164f3fedac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8583f6f7-52de-431f-926d-8164f3fedac0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4b866a6-dead-472a-8cb2-630fa3815122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e51873bd-dccb-4ac3-a785-86a2f1379489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e51873bd-dccb-4ac3-a785-86a2f1379489" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e00bd098-5471-4f83-93f3-0756a037f3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e51873bd-dccb-4ac3-a785-86a2f1379489" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e00bd098-5471-4f83-93f3-0756a037f3eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e00bd098-5471-4f83-93f3-0756a037f3eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e00bd098-5471-4f83-93f3-0756a037f3eb" xlink:to="loc_us-gaap_EquityComponentDomain_e00bd098-5471-4f83-93f3-0756a037f3eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e00bd098-5471-4f83-93f3-0756a037f3eb" xlink:to="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_24a6c03f-188a-493f-b2af-8ab4e9a01fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_24a6c03f-188a-493f-b2af-8ab4e9a01fb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_23488c5d-1190-4c61-bb0e-9ea3190a65d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_23488c5d-1190-4c61-bb0e-9ea3190a65d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fad6a6f-1c1c-4481-9630-c5d886e314f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fad6a6f-1c1c-4481-9630-c5d886e314f3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSNarrativeDetails" xlink:type="extended" id="icdc809415f594f9da540213bc6889004_STOCKPLANSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_199cf1bd-30c8-4538-964e-a1a00549769e" xlink:href="pcrx-20211231.xsd#pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_199cf1bd-30c8-4538-964e-a1a00549769e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c339cd4b-b5a5-4700-8c81-53d1b3e16d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c339cd4b-b5a5-4700-8c81-53d1b3e16d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3191df18-7084-422d-91ae-0fcceab2d3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3191df18-7084-422d-91ae-0fcceab2d3f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_e6e903c3-e0de-477c-8fa3-13edbb942276" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanESPPSharesinESPP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_e6e903c3-e0de-477c-8fa3-13edbb942276" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_c1e56f4c-b17a-48ec-96f5-46426641689c" xlink:href="pcrx-20211231.xsd#pcrx_MaximumFairMarketValuePurchaseofESPPShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_c1e56f4c-b17a-48ec-96f5-46426641689c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanfairvalue_5c1fd3cb-83b9-47d1-94f5-1445f4011155" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanfairvalue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_EmployeeStockPurchasePlanfairvalue_5c1fd3cb-83b9-47d1-94f5-1445f4011155" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a8abf909-34ca-47fb-8621-9ace78827f02" xlink:href="pcrx-20211231.xsd#pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a8abf909-34ca-47fb-8621-9ace78827f02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_511624bd-1b3d-42b9-8224-f3ea20aa821b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_511624bd-1b3d-42b9-8224-f3ea20aa821b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_afcc6610-e43b-4edf-9f6b-ac8e9e1c8e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_afcc6610-e43b-4edf-9f6b-ac8e9e1c8e69" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67320ae3-a15f-4586-9b53-b5d7c8431027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67320ae3-a15f-4586-9b53-b5d7c8431027" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d746848a-2638-4e8f-bc0f-c1834a0875bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d746848a-2638-4e8f-bc0f-c1834a0875bb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21e27597-05a0-49b3-8d8c-f1a3525c6212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21e27597-05a0-49b3-8d8c-f1a3525c6212" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c8b35fd6-c7b5-46f8-a82a-7242c6654397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21e27597-05a0-49b3-8d8c-f1a3525c6212" xlink:to="loc_us-gaap_AwardTypeAxis_c8b35fd6-c7b5-46f8-a82a-7242c6654397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8b35fd6-c7b5-46f8-a82a-7242c6654397_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c8b35fd6-c7b5-46f8-a82a-7242c6654397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8b35fd6-c7b5-46f8-a82a-7242c6654397_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_224427ed-bcf1-4bd0-ae2c-afe344dc42e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c8b35fd6-c7b5-46f8-a82a-7242c6654397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_224427ed-bcf1-4bd0-ae2c-afe344dc42e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_404b0c18-e7fe-48e2-96aa-bc84bf526fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_224427ed-bcf1-4bd0-ae2c-afe344dc42e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_404b0c18-e7fe-48e2-96aa-bc84bf526fc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c454409c-dc48-4859-8d36-d5cfed19a46d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_224427ed-bcf1-4bd0-ae2c-afe344dc42e3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c454409c-dc48-4859-8d36-d5cfed19a46d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSStockIncentivePlansDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails" xlink:type="extended" id="ic6677f055d3e44cf98aeaa97d450392d_STOCKPLANSStockIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d66e2700-9374-4262-b516-541c83425811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d66e2700-9374-4262-b516-541c83425811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_23612975-8425-4328-abbd-2bdd71f56166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_23612975-8425-4328-abbd-2bdd71f56166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fefdff5b-e131-4082-8a0b-3e43461f3765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fefdff5b-e131-4082-8a0b-3e43461f3765" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_dc20e772-e053-4cb8-a0f0-83f9a822140a" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_dc20e772-e053-4cb8-a0f0-83f9a822140a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e00bb394-49a4-49cd-815f-53e5cb6315b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e00bb394-49a4-49cd-815f-53e5cb6315b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_a4811ee2-feca-42d4-bef5-eb507a5673b7" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_a4811ee2-feca-42d4-bef5-eb507a5673b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aaf6300-4c3e-461f-8d67-ce96e45bb8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aaf6300-4c3e-461f-8d67-ce96e45bb8a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a58119eb-2d4a-467b-a74d-62052a5d0d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aaf6300-4c3e-461f-8d67-ce96e45bb8a2" xlink:to="loc_us-gaap_PlanNameAxis_a58119eb-2d4a-467b-a74d-62052a5d0d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a58119eb-2d4a-467b-a74d-62052a5d0d90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a58119eb-2d4a-467b-a74d-62052a5d0d90" xlink:to="loc_us-gaap_PlanNameDomain_a58119eb-2d4a-467b-a74d-62052a5d0d90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a58119eb-2d4a-467b-a74d-62052a5d0d90" xlink:to="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_StockIncentivePlan2011Member_cafa28b5-c59b-4db6-9e92-09ac79bf48ce" xlink:href="pcrx-20211231.xsd#pcrx_StockIncentivePlan2011Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:to="loc_pcrx_StockIncentivePlan2011Member_cafa28b5-c59b-4db6-9e92-09ac79bf48ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InducementPlan2014Member_0c933f89-8bc3-4d79-a68c-35f55e0a3a33" xlink:href="pcrx-20211231.xsd#pcrx_InducementPlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:to="loc_pcrx_InducementPlan2014Member_0c933f89-8bc3-4d79-a68c-35f55e0a3a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanESPP2014Member_9298b26e-075c-4ea0-9ea9-2f03aa384e89" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanESPP2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:to="loc_pcrx_EmployeeStockPurchasePlanESPP2014Member_9298b26e-075c-4ea0-9ea9-2f03aa384e89" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails" xlink:type="extended" id="if2bbc544e2b649a492b69345fddc2081_STOCKPLANSCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3fac4245-f973-401b-ae29-fe4074f89de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27e00a78-6eb2-4488-919d-cf4680b6b37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3fac4245-f973-401b-ae29-fe4074f89de8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_27e00a78-6eb2-4488-919d-cf4680b6b37e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_11d63dd9-0b7d-4117-adbc-2d2bc5266952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3fac4245-f973-401b-ae29-fe4074f89de8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_11d63dd9-0b7d-4117-adbc-2d2bc5266952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6015e70b-bbff-4cf9-b178-13c52a0f2a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3fac4245-f973-401b-ae29-fe4074f89de8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6015e70b-bbff-4cf9-b178-13c52a0f2a81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cec9d3c0-3dcb-417e-bf83-6dc7e42b50ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6015e70b-bbff-4cf9-b178-13c52a0f2a81" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cec9d3c0-3dcb-417e-bf83-6dc7e42b50ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cec9d3c0-3dcb-417e-bf83-6dc7e42b50ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cec9d3c0-3dcb-417e-bf83-6dc7e42b50ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cec9d3c0-3dcb-417e-bf83-6dc7e42b50ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cec9d3c0-3dcb-417e-bf83-6dc7e42b50ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_44ba34e9-960d-4e6c-a79b-7a7c384d29c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:to="loc_us-gaap_CostOfSalesMember_44ba34e9-960d-4e6c-a79b-7a7c384d29c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c6ab7137-0b76-48e4-8f3d-21efbd7294d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c6ab7137-0b76-48e4-8f3d-21efbd7294d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f25ce240-b1b5-40f5-a04a-9544f2aca838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f25ce240-b1b5-40f5-a04a-9544f2aca838" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_62533053-9ae2-44e8-b5ac-3f1e408e38b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6015e70b-bbff-4cf9-b178-13c52a0f2a81" xlink:to="loc_us-gaap_AwardTypeAxis_62533053-9ae2-44e8-b5ac-3f1e408e38b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62533053-9ae2-44e8-b5ac-3f1e408e38b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_62533053-9ae2-44e8-b5ac-3f1e408e38b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62533053-9ae2-44e8-b5ac-3f1e408e38b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_62533053-9ae2-44e8-b5ac-3f1e408e38b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a9c5abd-1882-4db1-be92-fed9731c6119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a9c5abd-1882-4db1-be92-fed9731c6119" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9596a5d8-0c86-442e-b309-118161124dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9596a5d8-0c86-442e-b309-118161124dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_757ab5e1-826e-496d-9a8e-a22c41e3f70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:to="loc_us-gaap_EmployeeStockMember_757ab5e1-826e-496d-9a8e-a22c41e3f70a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails" xlink:type="extended" id="i862f9f78259e4c6fb5b1445bc88fab01_STOCKPLANSStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12ec806d-acd5-4975-8ea0-2815e950d408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12ec806d-acd5-4975-8ea0-2815e950d408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_965abe4f-33b0-4a9b-bbe7-97cd4630b6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_965abe4f-33b0-4a9b-bbe7-97cd4630b6f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_996073bf-cd97-4a31-a2a7-4d92b157552b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_996073bf-cd97-4a31-a2a7-4d92b157552b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eabbd885-6ac4-4cdf-8729-8d6fd8b3dff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eabbd885-6ac4-4cdf-8729-8d6fd8b3dff3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4eb9a2d5-fdd5-4fcf-8508-2c205925cb89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4eb9a2d5-fdd5-4fcf-8508-2c205925cb89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5d233a6-9a95-4762-acf8-c3b9a1b08e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_da8aec34-a28a-4525-8a87-f6063f008605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_da8aec34-a28a-4525-8a87-f6063f008605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c2f37eb1-b981-428c-a5bb-0313395bacc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c2f37eb1-b981-428c-a5bb-0313395bacc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16c79d28-6856-4608-9ca3-d014924f8976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16c79d28-6856-4608-9ca3-d014924f8976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8953ecef-f4da-4129-801f-7751386723b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8953ecef-f4da-4129-801f-7751386723b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4063c60d-f23f-45e1-a8fb-79a8c0ddb768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4063c60d-f23f-45e1-a8fb-79a8c0ddb768" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70d2ba8f-bfd8-4c58-8595-18bd3b639ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70d2ba8f-bfd8-4c58-8595-18bd3b639ed9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_686e0ddc-5042-4b24-bf75-0f22b7da22d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_686e0ddc-5042-4b24-bf75-0f22b7da22d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9864d15-d649-434e-b2ae-69ebafb59b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_45171097-3b36-4523-ad89-a5cff21f370a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_45171097-3b36-4523-ad89-a5cff21f370a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_002a728a-9cc9-493a-a099-2e3e140e8663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_002a728a-9cc9-493a-a099-2e3e140e8663" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e081909b-a70e-4e8e-988f-5740f40ea087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e081909b-a70e-4e8e-988f-5740f40ea087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0d413649-56d3-45b2-8989-f132f791e049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0d413649-56d3-45b2-8989-f132f791e049" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_760ef232-bbb5-4566-8594-2e85f661b562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_760ef232-bbb5-4566-8594-2e85f661b562" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6158f4b0-4060-4965-806c-f0a629320dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6158f4b0-4060-4965-806c-f0a629320dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d5f328c9-9342-4e35-9bc2-cca6c259184d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d5f328c9-9342-4e35-9bc2-cca6c259184d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_be24b06d-8313-44f1-919b-ae5cf020f825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_473117aa-e9f2-4403-bf43-746c48889b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_473117aa-e9f2-4403-bf43-746c48889b2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bf298077-52aa-4145-a8fa-6d8c0328853a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bf298077-52aa-4145-a8fa-6d8c0328853a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4de44145-e3c5-404b-b12f-0499a3871830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4de44145-e3c5-404b-b12f-0499a3871830" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b5cbd822-2b28-4658-893b-5d58d2a2385f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4de44145-e3c5-404b-b12f-0499a3871830" xlink:to="loc_us-gaap_AwardTypeAxis_b5cbd822-2b28-4658-893b-5d58d2a2385f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5cbd822-2b28-4658-893b-5d58d2a2385f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b5cbd822-2b28-4658-893b-5d58d2a2385f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5cbd822-2b28-4658-893b-5d58d2a2385f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_598ac405-0edf-440d-a376-0a2e9897436c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b5cbd822-2b28-4658-893b-5d58d2a2385f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_598ac405-0edf-440d-a376-0a2e9897436c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_82bb6f2f-04f6-4330-a644-dc0bc98bdbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_598ac405-0edf-440d-a376-0a2e9897436c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_82bb6f2f-04f6-4330-a644-dc0bc98bdbe0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails" xlink:type="extended" id="i0e5de40ce43f47458a09217f8d9dc394_STOCKPLANSValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21c4cebe-6209-47e5-b486-ebb86ff051a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21c4cebe-6209-47e5-b486-ebb86ff051a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a1306cdc-1b9e-4b2c-922d-081199a2a616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a1306cdc-1b9e-4b2c-922d-081199a2a616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a4c1e439-181a-491e-bf45-3caf56b108ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a4c1e439-181a-491e-bf45-3caf56b108ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_664aacce-efc3-4aa5-9476-b3f4d00c384b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_664aacce-efc3-4aa5-9476-b3f4d00c384b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2c322c86-cbed-4bc6-9260-ff08744cd9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2c322c86-cbed-4bc6-9260-ff08744cd9da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_841c29d3-8187-4a72-9da0-225c3e0417dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_841c29d3-8187-4a72-9da0-225c3e0417dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e4c6229-e389-42bd-9c7a-d774003d21b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e4c6229-e389-42bd-9c7a-d774003d21b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5e87e86-d268-4799-ab15-a59ae5c79968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21c4cebe-6209-47e5-b486-ebb86ff051a5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5e87e86-d268-4799-ab15-a59ae5c79968" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f012cfda-4aac-4a2f-b22c-5fa107fe174e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5e87e86-d268-4799-ab15-a59ae5c79968" xlink:to="loc_us-gaap_AwardTypeAxis_f012cfda-4aac-4a2f-b22c-5fa107fe174e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f012cfda-4aac-4a2f-b22c-5fa107fe174e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f012cfda-4aac-4a2f-b22c-5fa107fe174e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f012cfda-4aac-4a2f-b22c-5fa107fe174e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ece956-2083-4822-82d4-4dcf4e855477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f012cfda-4aac-4a2f-b22c-5fa107fe174e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ece956-2083-4822-82d4-4dcf4e855477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bf991497-760f-40f4-98c2-eca5526c66d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ece956-2083-4822-82d4-4dcf4e855477" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bf991497-760f-40f4-98c2-eca5526c66d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d7546412-dd00-484b-b139-0cac98f665ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ece956-2083-4822-82d4-4dcf4e855477" xlink:to="loc_us-gaap_EmployeeStockMember_d7546412-dd00-484b-b139-0cac98f665ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b70c5a79-e4d2-4f56-830a-0026e331f75b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5e87e86-d268-4799-ab15-a59ae5c79968" xlink:to="loc_srt_RangeAxis_b70c5a79-e4d2-4f56-830a-0026e331f75b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b70c5a79-e4d2-4f56-830a-0026e331f75b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b70c5a79-e4d2-4f56-830a-0026e331f75b" xlink:to="loc_srt_RangeMember_b70c5a79-e4d2-4f56-830a-0026e331f75b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f35a0d6-d9cc-46af-9eed-8d681fd95ff1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b70c5a79-e4d2-4f56-830a-0026e331f75b" xlink:to="loc_srt_RangeMember_5f35a0d6-d9cc-46af-9eed-8d681fd95ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b8447ed8-5981-4bd0-8fa0-0cb20f825cac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f35a0d6-d9cc-46af-9eed-8d681fd95ff1" xlink:to="loc_srt_MinimumMember_b8447ed8-5981-4bd0-8fa0-0cb20f825cac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb7749f6-6965-47db-b24a-0f94b777496a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f35a0d6-d9cc-46af-9eed-8d681fd95ff1" xlink:to="loc_srt_MaximumMember_bb7749f6-6965-47db-b24a-0f94b777496a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSRSUActivityDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/STOCKPLANSRSUActivityDetails" xlink:type="extended" id="idaa68ce8084740eda581c4cc923b701c_STOCKPLANSRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe2d6ab9-c86e-4b2d-b921-4edbaccbd20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe2d6ab9-c86e-4b2d-b921-4edbaccbd20d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fe82e8b8-66b6-4584-ba52-9befed6e18e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fe82e8b8-66b6-4584-ba52-9befed6e18e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22fdfe26-e9a8-491b-a9aa-8667045605c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22fdfe26-e9a8-491b-a9aa-8667045605c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_14ec297f-047f-45c0-ac48-ccf0638f7d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_14ec297f-047f-45c0-ac48-ccf0638f7d5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5780fa39-91c2-4c24-9271-e1f79e3f38ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad6742f4-767d-4104-8a4e-da173f860d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad6742f4-767d-4104-8a4e-da173f860d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67b134ac-3a6a-40fe-aa87-7328cf7a4fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67b134ac-3a6a-40fe-aa87-7328cf7a4fd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_513de0a3-7bbd-49c3-a31b-514dee984c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_513de0a3-7bbd-49c3-a31b-514dee984c99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ce8b7f23-f551-4008-a2d0-dd8b1cc5352c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ce8b7f23-f551-4008-a2d0-dd8b1cc5352c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c701756c-dfb4-40c5-a0f7-18114236e1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_f18693b1-f664-498b-9152-9f2691723212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_f18693b1-f664-498b-9152-9f2691723212" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2a0825d3-4910-4055-9b4c-3a76e057c43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_f18693b1-f664-498b-9152-9f2691723212" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2a0825d3-4910-4055-9b4c-3a76e057c43b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6833380-748b-4b31-902e-5ecdf8565397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6833380-748b-4b31-902e-5ecdf8565397" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6922abb9-c4da-4116-b4ea-d185c10740ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6833380-748b-4b31-902e-5ecdf8565397" xlink:to="loc_us-gaap_AwardTypeAxis_6922abb9-c4da-4116-b4ea-d185c10740ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6922abb9-c4da-4116-b4ea-d185c10740ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6922abb9-c4da-4116-b4ea-d185c10740ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6922abb9-c4da-4116-b4ea-d185c10740ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01278ee6-9e72-4ff8-a688-f38224f4a92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6922abb9-c4da-4116-b4ea-d185c10740ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01278ee6-9e72-4ff8-a688-f38224f4a92c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_befe4e69-9dc9-4972-944c-80647749786b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01278ee6-9e72-4ff8-a688-f38224f4a92c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_befe4e69-9dc9-4972-944c-80647749786b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#NETINCOMELOSSPERSHARECalculationDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails" xlink:type="extended" id="i5a7ce30d2ef448cea2200a3395cc783c_NETINCOMELOSSPERSHARECalculationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0e822013-325b-4ff9-b914-f0c6541568b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0e822013-325b-4ff9-b914-f0c6541568b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a9640409-79a9-4db8-bcb3-bcbd2d46febc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0e822013-325b-4ff9-b914-f0c6541568b9" xlink:to="loc_us-gaap_NetIncomeLoss_a9640409-79a9-4db8-bcb3-bcbd2d46febc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d37352a7-4e40-4388-9d65-5b6e5d4e55a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d37352a7-4e40-4388-9d65-5b6e5d4e55a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_71baf59a-bf7b-4275-958a-1bd69164da72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d37352a7-4e40-4388-9d65-5b6e5d4e55a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_71baf59a-bf7b-4275-958a-1bd69164da72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_430b108a-173e-4bcf-a226-67462881d85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_430b108a-173e-4bcf-a226-67462881d85f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_f0d372cd-65cf-4fbc-a1be-50395a17df21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_f0d372cd-65cf-4fbc-a1be-50395a17df21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ce1396bf-f8d4-4918-bd1f-e1b0a24a0e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ce1396bf-f8d4-4918-bd1f-e1b0a24a0e61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_987865d4-59f1-4d00-a526-5d5c26367e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_987865d4-59f1-4d00-a526-5d5c26367e10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bd55a8e6-cb05-4932-a385-d59ab0f45f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_987865d4-59f1-4d00-a526-5d5c26367e10" xlink:to="loc_us-gaap_EarningsPerShareBasic_bd55a8e6-cb05-4932-a385-d59ab0f45f29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7d1a6cc5-c7a7-4e2c-9d34-b6e83099d12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_987865d4-59f1-4d00-a526-5d5c26367e10" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7d1a6cc5-c7a7-4e2c-9d34-b6e83099d12b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d8d0d15-69a6-403e-b80f-4123197b6c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d8d0d15-69a6-403e-b80f-4123197b6c15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_485ccbf3-3fb2-451a-bf09-3279c577ecc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d8d0d15-69a6-403e-b80f-4123197b6c15" xlink:to="loc_us-gaap_AwardTypeAxis_485ccbf3-3fb2-451a-bf09-3279c577ecc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_485ccbf3-3fb2-451a-bf09-3279c577ecc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_485ccbf3-3fb2-451a-bf09-3279c577ecc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_485ccbf3-3fb2-451a-bf09-3279c577ecc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_485ccbf3-3fb2-451a-bf09-3279c577ecc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0e9534c-0edb-4c65-b320-dacfa2287bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0e9534c-0edb-4c65-b320-dacfa2287bf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7f599259-0dfd-4422-ad34-9c8ce4ed018f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7f599259-0dfd-4422-ad34-9c8ce4ed018f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConversionPremiumOn2022NotesMember_720d9c76-4368-4363-bd2a-b4ceb0896402" xlink:href="pcrx-20211231.xsd#pcrx_ConversionPremiumOn2022NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:to="loc_pcrx_ConversionPremiumOn2022NotesMember_720d9c76-4368-4363-bd2a-b4ceb0896402" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a371def3-8d03-4f1f-ae8b-78720c145643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:to="loc_us-gaap_EmployeeStockMember_a371def3-8d03-4f1f-ae8b-78720c145643" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="extended" id="ife2587fada794c7d831daadc8bbc081c_NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5e68f90c-bb53-480d-b8d5-b1663f6ae990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e149ee8d-936f-442a-a7aa-cccc74b78c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5e68f90c-bb53-480d-b8d5-b1663f6ae990" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e149ee8d-936f-442a-a7aa-cccc74b78c50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1769763-bcf8-4423-95ec-897ff2f2b38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5e68f90c-bb53-480d-b8d5-b1663f6ae990" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1769763-bcf8-4423-95ec-897ff2f2b38b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a679b5f-b017-4aad-938a-239678f9ecae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1769763-bcf8-4423-95ec-897ff2f2b38b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a679b5f-b017-4aad-938a-239678f9ecae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a679b5f-b017-4aad-938a-239678f9ecae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a679b5f-b017-4aad-938a-239678f9ecae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8a679b5f-b017-4aad-938a-239678f9ecae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a679b5f-b017-4aad-938a-239678f9ecae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_76b72f01-0d09-4256-9464-d2805779fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_76b72f01-0d09-4256-9464-d2805779fa98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2663bf50-77a8-4272-9e54-1e1ddcfa929a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2663bf50-77a8-4272-9e54-1e1ddcfa929a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_736c3436-37a2-450a-966a-dc61b6366100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:to="loc_us-gaap_EmployeeStockMember_736c3436-37a2-450a-966a-dc61b6366100" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="ic006bf82dbd64979b8fb48dafdd073ce_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:href="pcrx-20211231.xsd#pcrx_IncomeTaxProvisionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_23edc732-bec3-41e9-82c0-2d3ba85e1e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_23edc732-bec3-41e9-82c0-2d3ba85e1e86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5721e6fe-cca2-4fb4-9c02-8e2d6f604b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5721e6fe-cca2-4fb4-9c02-8e2d6f604b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_68bef483-1915-444b-ab56-4240834a4286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_68bef483-1915-444b-ab56-4240834a4286" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_723d4b96-d83c-449e-bcb9-b2eb848c8070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_723d4b96-d83c-449e-bcb9-b2eb848c8070" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_56aa8ce3-4b0a-4da9-8e34-8bb7913b01a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_OperatingLossCarryforwards_56aa8ce3-4b0a-4da9-8e34-8bb7913b01a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_3dc9d982-b8e8-4f90-a362-07d7dab429b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_3dc9d982-b8e8-4f90-a362-07d7dab429b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_4735c23a-7f0e-4c8d-a4c9-e28f61340942" xlink:href="pcrx-20211231.xsd#pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_4735c23a-7f0e-4c8d-a4c9-e28f61340942" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NetOperatingLossSubjecttoLimitation_de093115-8e92-4b05-813b-f9c14b6d7b40" xlink:href="pcrx-20211231.xsd#pcrx_NetOperatingLossSubjecttoLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_NetOperatingLossSubjecttoLimitation_de093115-8e92-4b05-813b-f9c14b6d7b40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_OtherTaxAttributesSubjectToLimitation_14918866-d2a3-43be-bd0f-844e7a05dc7e" xlink:href="pcrx-20211231.xsd#pcrx_OtherTaxAttributesSubjectToLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_OtherTaxAttributesSubjectToLimitation_14918866-d2a3-43be-bd0f-844e7a05dc7e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne_bf39d216-2697-436c-b098-0d0f367cd3e2" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne_bf39d216-2697-436c-b098-0d0f367cd3e2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo_341b0733-c14e-4a1b-984f-960aaf5a26b4" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo_341b0733-c14e-4a1b-984f-960aaf5a26b4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree_13c259bb-ef0c-4066-ba34-7d29604d47de" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree_13c259bb-ef0c-4066-ba34-7d29604d47de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour_4469b2c6-243b-460b-87b6-283b4369f85a" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour_4469b2c6-243b-460b-87b6-283b4369f85a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive_7debb8bb-8a4f-41f4-9f15-805beaf5d5d3" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive_7debb8bb-8a4f-41f4-9f15-805beaf5d5d3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix_60861b57-6db0-46ae-90bf-c8aa5428d688" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearSix"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix_60861b57-6db0-46ae-90bf-c8aa5428d688" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix_714ef61d-cd45-476a-8959-f2fc71eaa3e1" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix_714ef61d-cd45-476a-8959-f2fc71eaa3e1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f9d3f413-2991-457f-9742-7ec5b760a763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f9d3f413-2991-457f-9742-7ec5b760a763" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3e5ab358-88dc-4d1b-bab6-1ea07f219858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3e5ab358-88dc-4d1b-bab6-1ea07f219858" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b3935fcb-b35c-4426-a64c-1c13597b43e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b3935fcb-b35c-4426-a64c-1c13597b43e8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e810e5cf-62ec-419a-9ed3-835d3940bcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e810e5cf-62ec-419a-9ed3-835d3940bcab" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:href="pcrx-20211231.xsd#pcrx_IncomeTaxProvisionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_903f7d16-359f-45dd-9189-f08ff068b742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_903f7d16-359f-45dd-9189-f08ff068b742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_903f7d16-359f-45dd-9189-f08ff068b742_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_903f7d16-359f-45dd-9189-f08ff068b742" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_903f7d16-359f-45dd-9189-f08ff068b742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_903f7d16-359f-45dd-9189-f08ff068b742" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f1c3c69f-c8f2-4177-ad58-ff20ef192582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:to="loc_us-gaap_DomesticCountryMember_f1c3c69f-c8f2-4177-ad58-ff20ef192582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ccd38f30-6b3e-44c1-9fe5-66e9aa756e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ccd38f30-6b3e-44c1-9fe5-66e9aa756e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_3db0333a-d0db-445e-b0ea-588ac7fcfb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:to="loc_us-gaap_ForeignCountryMember_3db0333a-d0db-445e-b0ea-588ac7fcfb13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_b7848aa2-c13c-4b7f-b169-7b419f8fea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_b7848aa2-c13c-4b7f-b169-7b419f8fea3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_b7848aa2-c13c-4b7f-b169-7b419f8fea3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_b7848aa2-c13c-4b7f-b169-7b419f8fea3b" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_b7848aa2-c13c-4b7f-b169-7b419f8fea3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f595c288-ab75-4f53-bd96-c313b427885d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_b7848aa2-c13c-4b7f-b169-7b419f8fea3b" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f595c288-ab75-4f53-bd96-c313b427885d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_d71ec330-8a92-42bd-bf6a-b572faaa3324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f595c288-ab75-4f53-bd96-c313b427885d" xlink:to="loc_us-gaap_ResearchMember_d71ec330-8a92-42bd-bf6a-b572faaa3324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_9ec0010c-637b-4d0f-9ade-10b72666a4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f595c288-ab75-4f53-bd96-c313b427885d" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_9ec0010c-637b-4d0f-9ade-10b72666a4f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f7bca794-9017-433e-b609-7c99bce8caf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_srt_StatementScenarioAxis_f7bca794-9017-433e-b609-7c99bce8caf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f7bca794-9017-433e-b609-7c99bce8caf9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f7bca794-9017-433e-b609-7c99bce8caf9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f7bca794-9017-433e-b609-7c99bce8caf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fb2b4cf8-3ba0-4fe4-b96f-c6c00ac4318d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f7bca794-9017-433e-b609-7c99bce8caf9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fb2b4cf8-3ba0-4fe4-b96f-c6c00ac4318d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ccf95db4-ae1a-46f1-a600-a5669d06d4b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fb2b4cf8-3ba0-4fe4-b96f-c6c00ac4318d" xlink:to="loc_srt_ScenarioForecastMember_ccf95db4-ae1a-46f1-a600-a5669d06d4b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_18de3693-11af-482c-927f-8e12ae892c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_18de3693-11af-482c-927f-8e12ae892c15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_18de3693-11af-482c-927f-8e12ae892c15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_18de3693-11af-482c-927f-8e12ae892c15" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_18de3693-11af-482c-927f-8e12ae892c15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00764543-3138-4153-98be-7c5e05f3fc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_18de3693-11af-482c-927f-8e12ae892c15" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00764543-3138-4153-98be-7c5e05f3fc51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_d3c36f9c-152d-4718-b16e-c440a9923ee5" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00764543-3138-4153-98be-7c5e05f3fc51" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_d3c36f9c-152d-4718-b16e-c440a9923ee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_49c68bfc-a8c0-4a42-9899-090b0a27701e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_49c68bfc-a8c0-4a42-9899-090b0a27701e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_49c68bfc-a8c0-4a42-9899-090b0a27701e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_49c68bfc-a8c0-4a42-9899-090b0a27701e" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_49c68bfc-a8c0-4a42-9899-090b0a27701e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_13e8def3-ba11-483a-b563-fcfa075f8d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_49c68bfc-a8c0-4a42-9899-090b0a27701e" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_13e8def3-ba11-483a-b563-fcfa075f8d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ForeignNetDeferredTaxAssetMember_af7bbb90-8fbf-4809-8265-a6fc7eaaff08" xlink:href="pcrx-20211231.xsd#pcrx_ForeignNetDeferredTaxAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_13e8def3-ba11-483a-b563-fcfa075f8d3a" xlink:to="loc_pcrx_ForeignNetDeferredTaxAssetMember_af7bbb90-8fbf-4809-8265-a6fc7eaaff08" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended" id="ie003499c2623442582013c75c61692af_EMPLOYEEBENEFITPLANSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0a5109c8-74f5-4b83-a627-627a550db421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0a5109c8-74f5-4b83-a627-627a550db421" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_a8f239d2-90eb-4fc2-8c1a-d28b55da8d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_a8f239d2-90eb-4fc2-8c1a-d28b55da8d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage_e51ff1f1-22dd-4147-9071-b68d962be762" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage_e51ff1f1-22dd-4147-9071-b68d962be762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_538bbc58-c2db-494d-af3d-0dc31156744e" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_538bbc58-c2db-494d-af3d-0dc31156744e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_113e3b01-83be-4310-9876-c632450afb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_113e3b01-83be-4310-9876-c632450afb53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_4f158f14-4148-4bd1-9983-02e5f099a69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_4f158f14-4148-4bd1-9983-02e5f099a69e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b8c9ba3a-c6c2-468f-81bf-f62999350cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b8c9ba3a-c6c2-468f-81bf-f62999350cb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_861368b3-cb4c-43a0-9325-2edf11d33b0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b8c9ba3a-c6c2-468f-81bf-f62999350cb2" xlink:to="loc_srt_RangeAxis_861368b3-cb4c-43a0-9325-2edf11d33b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_861368b3-cb4c-43a0-9325-2edf11d33b0d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_861368b3-cb4c-43a0-9325-2edf11d33b0d" xlink:to="loc_srt_RangeMember_861368b3-cb4c-43a0-9325-2edf11d33b0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_475b493d-86cd-4264-943f-c5919783340c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_861368b3-cb4c-43a0-9325-2edf11d33b0d" xlink:to="loc_srt_RangeMember_475b493d-86cd-4264-943f-c5919783340c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7d60f5b7-f72c-4a7f-a2c4-ec1886f92b18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_475b493d-86cd-4264-943f-c5919783340c" xlink:to="loc_srt_MinimumMember_7d60f5b7-f72c-4a7f-a2c4-ec1886f92b18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8cf79a3a-1a7f-43b9-9a89-de3632ec7d9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_475b493d-86cd-4264-943f-c5919783340c" xlink:to="loc_srt_MaximumMember_8cf79a3a-1a7f-43b9-9a89-de3632ec7d9b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails" xlink:type="extended" id="i0e3461616ab54691a4864724ba328494_ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9944a168-ab5a-490a-a757-f31d6dc1f605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9944a168-ab5a-490a-a757-f31d6dc1f605" xlink:to="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_7bc71785-40c1-4e39-8a89-ef4835351505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_7bc71785-40c1-4e39-8a89-ef4835351505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c8f1c93f-e260-4ee6-9729-5406acecf977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c8f1c93f-e260-4ee6-9729-5406acecf977" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_4af75297-bf92-410d-966b-c0da443dede3" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_4af75297-bf92-410d-966b-c0da443dede3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e5ff4da1-0a54-4352-9556-1266a73090b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e5ff4da1-0a54-4352-9556-1266a73090b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_9535e3eb-fb65-45f8-8d77-94c05fd2911f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_GainLossOnContractTermination_9535e3eb-fb65-45f8-8d77-94c05fd2911f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_2e59915d-19e3-47b6-a147-4a0a7baea3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_LitigationSettlementExpense_2e59915d-19e3-47b6-a147-4a0a7baea3b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther_f8393677-27a7-4eec-b093-5ddd55533e51" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther_f8393677-27a7-4eec-b093-5ddd55533e51" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9944a168-ab5a-490a-a757-f31d6dc1f605" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7e09e48b-b026-4c0a-899b-d12be7c6007d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7e09e48b-b026-4c0a-899b-d12be7c6007d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_7e09e48b-b026-4c0a-899b-d12be7c6007d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7e09e48b-b026-4c0a-899b-d12be7c6007d" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_7e09e48b-b026-4c0a-899b-d12be7c6007d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_544d7b51-a8c5-427c-90b6-bd5087d39e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7e09e48b-b026-4c0a-899b-d12be7c6007d" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_544d7b51-a8c5-427c-90b6-bd5087d39e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedFeesMember_14d165a5-bd1d-4652-adcb-47388334f26e" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_544d7b51-a8c5-427c-90b6-bd5087d39e61" xlink:to="loc_pcrx_AcquisitionRelatedFeesMember_14d165a5-bd1d-4652-adcb-47388334f26e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_fc76ed72-df65-4932-9dd5-957709eb93b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_544d7b51-a8c5-427c-90b6-bd5087d39e61" xlink:to="loc_us-gaap_OtherRestructuringMember_fc76ed72-df65-4932-9dd5-957709eb93b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_85759717-2909-4823-ba8b-90322a01b3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_85759717-2909-4823-ba8b-90322a01b3c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85759717-2909-4823-ba8b-90322a01b3c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85759717-2909-4823-ba8b-90322a01b3c7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85759717-2909-4823-ba8b-90322a01b3c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91359536-56f2-42b9-b1bf-d6069c4b4465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85759717-2909-4823-ba8b-90322a01b3c7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91359536-56f2-42b9-b1bf-d6069c4b4465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_ba76950a-b384-410c-9b89-929f956a7eab" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91359536-56f2-42b9-b1bf-d6069c4b4465" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_ba76950a-b384-410c-9b89-929f956a7eab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_01e01b91-9e1a-4211-bb5a-5bc839618639" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91359536-56f2-42b9-b1bf-d6069c4b4465" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_01e01b91-9e1a-4211-bb5a-5bc839618639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7bc4f928-476c-4605-9d8d-dc296b555881" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:to="loc_srt_CounterpartyNameAxis_7bc4f928-476c-4605-9d8d-dc296b555881" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bc4f928-476c-4605-9d8d-dc296b555881_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7bc4f928-476c-4605-9d8d-dc296b555881" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bc4f928-476c-4605-9d8d-dc296b555881_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a69059c-2261-461c-8c72-da097307e4ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7bc4f928-476c-4605-9d8d-dc296b555881" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a69059c-2261-461c-8c72-da097307e4ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DepoCyteMember_07717aee-ad25-41d8-b0b7-740567f48529" xlink:href="pcrx-20211231.xsd#pcrx_DepoCyteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a69059c-2261-461c-8c72-da097307e4ba" xlink:to="loc_pcrx_DepoCyteMember_07717aee-ad25-41d8-b0b7-740567f48529" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NuanceBiotechCo.Ltd.Member_a1d580f0-99fd-475c-a34f-12312e32f75d" xlink:href="pcrx-20211231.xsd#pcrx_NuanceBiotechCo.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a69059c-2261-461c-8c72-da097307e4ba" xlink:to="loc_pcrx_NuanceBiotechCo.Ltd.Member_a1d580f0-99fd-475c-a34f-12312e32f75d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails" xlink:type="extended" id="i623be8e5c5a5409ca01eb994852950d5_ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_e08f4a7e-acec-42a0-8b7c-4627ff772865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_e08f4a7e-acec-42a0-8b7c-4627ff772865" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6d1168f8-e2d2-4ad0-b370-a5af1c650d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6d1168f8-e2d2-4ad0-b370-a5af1c650d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_344cb602-e25e-494b-a450-5dac81d8f67a" xlink:href="pcrx-20211231.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:to="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_344cb602-e25e-494b-a450-5dac81d8f67a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_696f7c6c-2b1e-40f8-bfd4-bd749730ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_696f7c6c-2b1e-40f8-bfd4-bd749730ccba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_696f7c6c-2b1e-40f8-bfd4-bd749730ccba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_696f7c6c-2b1e-40f8-bfd4-bd749730ccba" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_696f7c6c-2b1e-40f8-bfd4-bd749730ccba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d98fa4f3-440c-452d-b7dc-51f821d27e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_696f7c6c-2b1e-40f8-bfd4-bd749730ccba" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d98fa4f3-440c-452d-b7dc-51f821d27e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_33fee552-236b-4abb-befd-f1bcd99ce603" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d98fa4f3-440c-452d-b7dc-51f821d27e40" xlink:to="loc_pcrx_FlexionAcquisitionMember_33fee552-236b-4abb-befd-f1bcd99ce603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_752b177e-f8fa-4e54-b34c-1d77c3978c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_752b177e-f8fa-4e54-b34c-1d77c3978c55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_752b177e-f8fa-4e54-b34c-1d77c3978c55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_752b177e-f8fa-4e54-b34c-1d77c3978c55" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_752b177e-f8fa-4e54-b34c-1d77c3978c55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_29767b90-8124-4baa-8398-0c36378ef9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_752b177e-f8fa-4e54-b34c-1d77c3978c55" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_29767b90-8124-4baa-8398-0c36378ef9c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LegalFeesMember_25928d71-8d76-4262-9971-47c49ada7474" xlink:href="pcrx-20211231.xsd#pcrx_LegalFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29767b90-8124-4baa-8398-0c36378ef9c6" xlink:to="loc_pcrx_LegalFeesMember_25928d71-8d76-4262-9971-47c49ada7474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_452d5691-86d2-4a47-84a6-e8cd15c3fe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:to="loc_us-gaap_FinancialInstrumentAxis_452d5691-86d2-4a47-84a6-e8cd15c3fe15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_452d5691-86d2-4a47-84a6-e8cd15c3fe15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_452d5691-86d2-4a47-84a6-e8cd15c3fe15" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_452d5691-86d2-4a47-84a6-e8cd15c3fe15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d3dd6b-775d-45c9-8c30-b29312040833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_452d5691-86d2-4a47-84a6-e8cd15c3fe15" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d3dd6b-775d-45c9-8c30-b29312040833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_17199faf-7662-4764-bb14-86dd5ad5313f" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d3dd6b-775d-45c9-8c30-b29312040833" xlink:to="loc_pcrx_ContingentConsiderationMember_17199faf-7662-4764-bb14-86dd5ad5313f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_8197f256-8774-4a04-b668-f84b643716ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_8197f256-8774-4a04-b668-f84b643716ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8197f256-8774-4a04-b668-f84b643716ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8197f256-8774-4a04-b668-f84b643716ae" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8197f256-8774-4a04-b668-f84b643716ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ecb10705-209d-4d6e-976d-90c200171917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8197f256-8774-4a04-b668-f84b643716ae" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ecb10705-209d-4d6e-976d-90c200171917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_58e837ce-c866-44f4-91dd-be110af211d6" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ecb10705-209d-4d6e-976d-90c200171917" xlink:to="loc_pcrx_ContingentConsiderationMember_58e837ce-c866-44f4-91dd-be110af211d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails" xlink:type="extended" id="ic98bb2d1f01848e6b67917a50d968e45_ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_96c5176b-a5c9-499b-85c7-0f179836a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3f5aa526-a42e-4c78-97e8-83259def49e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96c5176b-a5c9-499b-85c7-0f179836a4ad" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3f5aa526-a42e-4c78-97e8-83259def49e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6a4434c1-0ade-4167-befa-bcdc74772bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96c5176b-a5c9-499b-85c7-0f179836a4ad" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6a4434c1-0ade-4167-befa-bcdc74772bd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_72f9313c-8cab-40b0-8793-55fc9b1dbcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96c5176b-a5c9-499b-85c7-0f179836a4ad" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_72f9313c-8cab-40b0-8793-55fc9b1dbcf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d23c3226-2af0-4c75-a1a1-bb796f2b508a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_72f9313c-8cab-40b0-8793-55fc9b1dbcf7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d23c3226-2af0-4c75-a1a1-bb796f2b508a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d23c3226-2af0-4c75-a1a1-bb796f2b508a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d23c3226-2af0-4c75-a1a1-bb796f2b508a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d23c3226-2af0-4c75-a1a1-bb796f2b508a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04254acc-6872-4ed1-8417-a27151332b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d23c3226-2af0-4c75-a1a1-bb796f2b508a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04254acc-6872-4ed1-8417-a27151332b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_980dd9a2-cdc8-4b57-9e12-80f5dd49eb44" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04254acc-6872-4ed1-8417-a27151332b48" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_980dd9a2-cdc8-4b57-9e12-80f5dd49eb44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_675be319-9822-4582-bdc2-41eb5e3d5aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_72f9313c-8cab-40b0-8793-55fc9b1dbcf7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_675be319-9822-4582-bdc2-41eb5e3d5aa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_675be319-9822-4582-bdc2-41eb5e3d5aa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_675be319-9822-4582-bdc2-41eb5e3d5aa8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_675be319-9822-4582-bdc2-41eb5e3d5aa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_655891ea-2416-43a7-9cb4-4eae6d39497e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_675be319-9822-4582-bdc2-41eb5e3d5aa8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_655891ea-2416-43a7-9cb4-4eae6d39497e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AdvisoryCostsMember_3cb39c45-1b07-4ae7-a9fa-266cbcacbb38" xlink:href="pcrx-20211231.xsd#pcrx_AdvisoryCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_655891ea-2416-43a7-9cb4-4eae6d39497e" xlink:to="loc_pcrx_AdvisoryCostsMember_3cb39c45-1b07-4ae7-a9fa-266cbcacbb38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember_a495bc53-5d3b-4260-8e7a-483359baa074" xlink:href="pcrx-20211231.xsd#pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_655891ea-2416-43a7-9cb4-4eae6d39497e" xlink:to="loc_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember_a495bc53-5d3b-4260-8e7a-483359baa074" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails" xlink:type="extended" id="icecf77377b4a4e969794fbd3a6b1f936_ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_05b86800-6c70-4267-9725-d008815f3239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_ee02ef31-5780-41f1-99cd-12901a435370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05b86800-6c70-4267-9725-d008815f3239" xlink:to="loc_us-gaap_LitigationSettlementExpense_ee02ef31-5780-41f1-99cd-12901a435370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef789cba-5a5c-43d9-bd9c-f98c75f894fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05b86800-6c70-4267-9725-d008815f3239" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef789cba-5a5c-43d9-bd9c-f98c75f894fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_11944ee2-df07-495a-b0a0-6e565e57d571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef789cba-5a5c-43d9-bd9c-f98c75f894fd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_11944ee2-df07-495a-b0a0-6e565e57d571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11944ee2-df07-495a-b0a0-6e565e57d571_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_11944ee2-df07-495a-b0a0-6e565e57d571" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11944ee2-df07-495a-b0a0-6e565e57d571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc2fead0-b706-4c1d-a24d-2771f84f60cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_11944ee2-df07-495a-b0a0-6e565e57d571" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc2fead0-b706-4c1d-a24d-2771f84f60cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NuanceBiotechCo.Ltd.Member_44b76998-08c9-4792-be98-8e3e1286c08e" xlink:href="pcrx-20211231.xsd#pcrx_NuanceBiotechCo.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc2fead0-b706-4c1d-a24d-2771f84f60cd" xlink:to="loc_pcrx_NuanceBiotechCo.Ltd.Member_44b76998-08c9-4792-be98-8e3e1286c08e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails" xlink:type="extended" id="i831b31279f9a40228a7cd6396ab5a625_COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentOfEarlyTerminationFees_1b1bf91f-1312-4b68-a10c-7adfb6724148" xlink:href="pcrx-20211231.xsd#pcrx_PaymentOfEarlyTerminationFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_PaymentOfEarlyTerminationFees_1b1bf91f-1312-4b68-a10c-7adfb6724148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_6653c81c-2c0f-44ee-af29-a2f29d899af1" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_6653c81c-2c0f-44ee-af29-a2f29d899af1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementOptionToExtendTerm_f961232b-b269-4c76-8841-000a94ec0d30" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementOptionToExtendTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementOptionToExtendTerm_f961232b-b269-4c76-8841-000a94ec0d30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementUpfrontPayment_d7c5b7cf-caed-4ace-9317-85dcb5ee0a39" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementUpfrontPayment_d7c5b7cf-caed-4ace-9317-85dcb5ee0a39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach_d16fe6ff-b342-419b-a6ec-fb063c3629ba" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach_d16fe6ff-b342-419b-a6ec-fb063c3629ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation_c0c8a12c-70a6-4fc8-a865-6ac1bfea99ae" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation_c0c8a12c-70a6-4fc8-a865-6ac1bfea99ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_606cfbdd-8f6c-4039-a00d-23999b255a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_606cfbdd-8f6c-4039-a00d-23999b255a46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8a644e2f-64a7-4c2c-93f7-667864b67f57" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_srt_CounterpartyNameAxis_8a644e2f-64a7-4c2c-93f7-667864b67f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8a644e2f-64a7-4c2c-93f7-667864b67f57_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8a644e2f-64a7-4c2c-93f7-667864b67f57" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8a644e2f-64a7-4c2c-93f7-667864b67f57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bc7b12f-6921-48a4-a3f9-183b6cc46059" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8a644e2f-64a7-4c2c-93f7-667864b67f57" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bc7b12f-6921-48a4-a3f9-183b6cc46059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DePuySynthesSalesIncMember_b29a9353-0fad-40a4-9430-b59c19d2bd66" xlink:href="pcrx-20211231.xsd#pcrx_DePuySynthesSalesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bc7b12f-6921-48a4-a3f9-183b6cc46059" xlink:to="loc_pcrx_DePuySynthesSalesIncMember_b29a9353-0fad-40a4-9430-b59c19d2bd66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_3cb7dcc5-e4d3-4cb7-b81f-500fb2838d71" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_3cb7dcc5-e4d3-4cb7-b81f-500fb2838d71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_3cb7dcc5-e4d3-4cb7-b81f-500fb2838d71_default" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_3cb7dcc5-e4d3-4cb7-b81f-500fb2838d71" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_3cb7dcc5-e4d3-4cb7-b81f-500fb2838d71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_60865e75-b3ba-4371-9bae-2541eddc6545" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_3cb7dcc5-e4d3-4cb7-b81f-500fb2838d71" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_60865e75-b3ba-4371-9bae-2541eddc6545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_bedf9c74-332a-405c-b6eb-2b82d28d4420" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_60865e75-b3ba-4371-9bae-2541eddc6545" xlink:to="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_bedf9c74-332a-405c-b6eb-2b82d28d4420" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98d0006b-74ea-4bf3-beb4-fd71cd0f3093" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_srt_RangeAxis_98d0006b-74ea-4bf3-beb4-fd71cd0f3093" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98d0006b-74ea-4bf3-beb4-fd71cd0f3093_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_98d0006b-74ea-4bf3-beb4-fd71cd0f3093" xlink:to="loc_srt_RangeMember_98d0006b-74ea-4bf3-beb4-fd71cd0f3093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17e91c72-8488-4378-a799-66676c9a6f38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_98d0006b-74ea-4bf3-beb4-fd71cd0f3093" xlink:to="loc_srt_RangeMember_17e91c72-8488-4378-a799-66676c9a6f38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4c2d5d4e-eed9-401a-97b5-b0c30027ee44" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17e91c72-8488-4378-a799-66676c9a6f38" xlink:to="loc_srt_MaximumMember_4c2d5d4e-eed9-401a-97b5-b0c30027ee44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8f5687e7-df49-4579-b101-f94b773f3146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8f5687e7-df49-4579-b101-f94b773f3146" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f5687e7-df49-4579-b101-f94b773f3146_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8f5687e7-df49-4579-b101-f94b773f3146" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f5687e7-df49-4579-b101-f94b773f3146_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8f5687e7-df49-4579-b101-f94b773f3146" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AratanaTherapeuticsIncMember_7371dfc1-fd93-4372-aea1-2a770641eba6" xlink:href="pcrx-20211231.xsd#pcrx_AratanaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:to="loc_pcrx_AratanaTherapeuticsIncMember_7371dfc1-fd93-4372-aea1-2a770641eba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EurofarmaLabatoriesSAMember_06f7496b-bf15-475a-8b31-dad60a739a37" xlink:href="pcrx-20211231.xsd#pcrx_EurofarmaLabatoriesSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:to="loc_pcrx_EurofarmaLabatoriesSAMember_06f7496b-bf15-475a-8b31-dad60a739a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_HongKongPharmaTainuoLtdMember_e1d80588-4a52-4e50-84e3-d34cff7ff89d" xlink:href="pcrx-20211231.xsd#pcrx_HongKongPharmaTainuoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:to="loc_pcrx_HongKongPharmaTainuoLtdMember_e1d80588-4a52-4e50-84e3-d34cff7ff89d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_8fd49963-8d3d-41b7-8f06-6cd70cbb88c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_us-gaap_TransactionTypeAxis_8fd49963-8d3d-41b7-8f06-6cd70cbb88c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_8fd49963-8d3d-41b7-8f06-6cd70cbb88c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_8fd49963-8d3d-41b7-8f06-6cd70cbb88c2" xlink:to="loc_us-gaap_TransactionDomain_8fd49963-8d3d-41b7-8f06-6cd70cbb88c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_59d01895-92c9-4fe2-9da6-c3e022117b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_8fd49963-8d3d-41b7-8f06-6cd70cbb88c2" xlink:to="loc_us-gaap_TransactionDomain_59d01895-92c9-4fe2-9da6-c3e022117b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CoPromotionAgreementMember_dcf4aeef-7c85-4d3a-98fb-5f0f41e0bba5" xlink:href="pcrx-20211231.xsd#pcrx_CoPromotionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_59d01895-92c9-4fe2-9da6-c3e022117b46" xlink:to="loc_pcrx_CoPromotionAgreementMember_dcf4aeef-7c85-4d3a-98fb-5f0f41e0bba5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i8e4f4329bfca44f4972c388cee1ecc16_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_70f07ba6-6a63-42c7-8a19-a46f422f1341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_c68902dd-3f00-4699-a689-8cca217ac821" xlink:href="pcrx-20211231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_70f07ba6-6a63-42c7-8a19-a46f422f1341" xlink:to="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_c68902dd-3f00-4699-a689-8cca217ac821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_9b6ab030-8a8d-4dd4-ac75-2a5654615c0f" xlink:href="pcrx-20211231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_70f07ba6-6a63-42c7-8a19-a46f422f1341" xlink:to="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_9b6ab030-8a8d-4dd4-ac75-2a5654615c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_70f07ba6-6a63-42c7-8a19-a46f422f1341" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6bc56adb-70c6-46a7-a51c-831f5f924b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6bc56adb-70c6-46a7-a51c-831f5f924b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6bc56adb-70c6-46a7-a51c-831f5f924b9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6bc56adb-70c6-46a7-a51c-831f5f924b9a" xlink:to="loc_us-gaap_RelatedPartyDomain_6bc56adb-70c6-46a7-a51c-831f5f924b9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_826fc324-51cc-452b-8b0e-011df2ea0cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6bc56adb-70c6-46a7-a51c-831f5f924b9a" xlink:to="loc_us-gaap_RelatedPartyDomain_826fc324-51cc-452b-8b0e-011df2ea0cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_eb53a898-82c3-4a6a-996b-aaa70c10d39a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_826fc324-51cc-452b-8b0e-011df2ea0cad" xlink:to="loc_srt_DirectorMember_eb53a898-82c3-4a6a-996b-aaa70c10d39a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EnergyAxis_20c0c964-5a38-4015-8a25-40e6c01f4579" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EnergyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:to="loc_srt_EnergyAxis_20c0c964-5a38-4015-8a25-40e6c01f4579" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EnergyDomain_20c0c964-5a38-4015-8a25-40e6c01f4579_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EnergyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_EnergyAxis_20c0c964-5a38-4015-8a25-40e6c01f4579" xlink:to="loc_srt_EnergyDomain_20c0c964-5a38-4015-8a25-40e6c01f4579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EnergyDomain_9dfd86a4-a051-4fa1-8982-1bc1c59df318" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EnergyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_EnergyAxis_20c0c964-5a38-4015-8a25-40e6c01f4579" xlink:to="loc_srt_EnergyDomain_9dfd86a4-a051-4fa1-8982-1bc1c59df318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConsultingAgreementMember_5dfc045b-213c-4744-a2e0-95376f545d40" xlink:href="pcrx-20211231.xsd#pcrx_ConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EnergyDomain_9dfd86a4-a051-4fa1-8982-1bc1c59df318" xlink:to="loc_pcrx_ConsultingAgreementMember_5dfc045b-213c-4744-a2e0-95376f545d40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eab3cd49-0a9c-4fa3-9fd2-f9853afc8df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eab3cd49-0a9c-4fa3-9fd2-f9853afc8df9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eab3cd49-0a9c-4fa3-9fd2-f9853afc8df9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eab3cd49-0a9c-4fa3-9fd2-f9853afc8df9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_eab3cd49-0a9c-4fa3-9fd2-f9853afc8df9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_99c75859-3879-43f0-82e8-5f4a8734f00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eab3cd49-0a9c-4fa3-9fd2-f9853afc8df9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_99c75859-3879-43f0-82e8-5f4a8734f00a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FirstPriceOptionMember_bcfd6eb0-c03e-45fb-90e6-add7011b2124" xlink:href="pcrx-20211231.xsd#pcrx_FirstPriceOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_99c75859-3879-43f0-82e8-5f4a8734f00a" xlink:to="loc_pcrx_FirstPriceOptionMember_bcfd6eb0-c03e-45fb-90e6-add7011b2124" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SecondPriceOptionMember_d839a6ca-c30d-4b3d-b8fe-9ea8b9ee852f" xlink:href="pcrx-20211231.xsd#pcrx_SecondPriceOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_99c75859-3879-43f0-82e8-5f4a8734f00a" xlink:to="loc_pcrx_SecondPriceOptionMember_d839a6ca-c30d-4b3d-b8fe-9ea8b9ee852f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="ifc612ac6b61647e9bc53b5394be7df39_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_da49e077-0c13-4829-b31a-663f0725a508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_da49e077-0c13-4829-b31a-663f0725a508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationInvestigationTerm_36da6ac7-8301-406e-85ff-df06ae776628" xlink:href="pcrx-20211231.xsd#pcrx_LitigationInvestigationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_pcrx_LitigationInvestigationTerm_36da6ac7-8301-406e-85ff-df06ae776628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_b906d770-42de-4b4b-be83-26f1ae9e5bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_b906d770-42de-4b4b-be83-26f1ae9e5bce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_c1f15db9-10e5-47a6-98cf-0b5def9fc39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_PurchaseObligation_c1f15db9-10e5-47a6-98cf-0b5def9fc39f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_0189944d-aac0-461a-982c-2546b3d662ad" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_0189944d-aac0-461a-982c-2546b3d662ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f7ced73e-f08e-47b2-b1e1-0159e09437ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f7ced73e-f08e-47b2-b1e1-0159e09437ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3352a335-854b-457b-9198-06f2d57bc9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_RestructuringCharges_3352a335-854b-457b-9198-06f2d57bc9b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1f10c4d1-9156-48e2-8408-58ac1cbf524a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_srt_CounterpartyNameAxis_1f10c4d1-9156-48e2-8408-58ac1cbf524a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f10c4d1-9156-48e2-8408-58ac1cbf524a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1f10c4d1-9156-48e2-8408-58ac1cbf524a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f10c4d1-9156-48e2-8408-58ac1cbf524a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1f10c4d1-9156-48e2-8408-58ac1cbf524a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FortisMember_47d5ab3a-db0b-46e2-a15a-fbe4a262da11" xlink:href="pcrx-20211231.xsd#pcrx_FortisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:to="loc_pcrx_FortisMember_47d5ab3a-db0b-46e2-a15a-fbe4a262da11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GeneQuineMember_ae7dfa82-0dc9-45ab-9fb3-255f105114d2" xlink:href="pcrx-20211231.xsd#pcrx_GeneQuineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:to="loc_pcrx_GeneQuineMember_ae7dfa82-0dc9-45ab-9fb3-255f105114d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_XenonPharmaceuticalsIncMember_ab7d4a49-8fb3-4d14-bdf5-6f991392a4ab" xlink:href="pcrx-20211231.xsd#pcrx_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:to="loc_pcrx_XenonPharmaceuticalsIncMember_ab7d4a49-8fb3-4d14-bdf5-6f991392a4ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fb2340fe-38b3-4eb7-b8c4-b684ee62e53a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_srt_ProductOrServiceAxis_fb2340fe-38b3-4eb7-b8c4-b684ee62e53a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb2340fe-38b3-4eb7-b8c4-b684ee62e53a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fb2340fe-38b3-4eb7-b8c4-b684ee62e53a" xlink:to="loc_srt_ProductsAndServicesDomain_fb2340fe-38b3-4eb7-b8c4-b684ee62e53a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_81e717a3-0786-4c4e-a3a1-ea322f00a009" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fb2340fe-38b3-4eb7-b8c4-b684ee62e53a" xlink:to="loc_srt_ProductsAndServicesDomain_81e717a3-0786-4c4e-a3a1-ea322f00a009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_4b4f8a74-d3ea-4211-b34d-33645b77fe86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81e717a3-0786-4c4e-a3a1-ea322f00a009" xlink:to="loc_us-gaap_ServiceMember_4b4f8a74-d3ea-4211-b34d-33645b77fe86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_a3ff15cb-95cd-4518-b7c4-abe1a0eeafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_81e717a3-0786-4c4e-a3a1-ea322f00a009" xlink:to="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_a3ff15cb-95cd-4518-b7c4-abe1a0eeafa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_5d4ab352-5d2e-4600-a6d4-f77678c36e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_5d4ab352-5d2e-4600-a6d4-f77678c36e39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_5d4ab352-5d2e-4600-a6d4-f77678c36e39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_5d4ab352-5d2e-4600-a6d4-f77678c36e39" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_5d4ab352-5d2e-4600-a6d4-f77678c36e39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e3b3c03c-2a80-4b54-8cc3-8edcccd8cca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_5d4ab352-5d2e-4600-a6d4-f77678c36e39" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e3b3c03c-2a80-4b54-8cc3-8edcccd8cca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_bac6c552-bf1a-430a-abcb-900ed013ad2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e3b3c03c-2a80-4b54-8cc3-8edcccd8cca8" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_bac6c552-bf1a-430a-abcb-900ed013ad2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_37885bfe-e4f8-40aa-8954-76f19aebb9e9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_dei_LegalEntityAxis_37885bfe-e4f8-40aa-8954-76f19aebb9e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_37885bfe-e4f8-40aa-8954-76f19aebb9e9_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_37885bfe-e4f8-40aa-8954-76f19aebb9e9" xlink:to="loc_dei_EntityDomain_37885bfe-e4f8-40aa-8954-76f19aebb9e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fa5bfcda-bccb-48f3-b35d-38cdc7c87b3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_37885bfe-e4f8-40aa-8954-76f19aebb9e9" xlink:to="loc_dei_EntityDomain_fa5bfcda-bccb-48f3-b35d-38cdc7c87b3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_ad17b305-5bbd-4bd3-b880-f88f46478831" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fa5bfcda-bccb-48f3-b35d-38cdc7c87b3d" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_ad17b305-5bbd-4bd3-b880-f88f46478831" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_1ab9f891-421b-471b-a9bb-ce3b1efca1b9" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_1ab9f891-421b-471b-a9bb-ce3b1efca1b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_1ab9f891-421b-471b-a9bb-ce3b1efca1b9_default" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_1ab9f891-421b-471b-a9bb-ce3b1efca1b9" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_1ab9f891-421b-471b-a9bb-ce3b1efca1b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_b26991b0-99f8-4926-9767-c89a53ea0da0" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_1ab9f891-421b-471b-a9bb-ce3b1efca1b9" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_b26991b0-99f8-4926-9767-c89a53ea0da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_38b199f6-ea25-4b2a-8188-1e5074f8dbed" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_b26991b0-99f8-4926-9767-c89a53ea0da0" xlink:to="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_38b199f6-ea25-4b2a-8188-1e5074f8dbed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfSalesRelatedMilestonesMember_c4ba6623-8fd5-4ba4-b6a4-769d63f13cf3" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfSalesRelatedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_b26991b0-99f8-4926-9767-c89a53ea0da0" xlink:to="loc_pcrx_AchievementOfSalesRelatedMilestonesMember_c4ba6623-8fd5-4ba4-b6a4-769d63f13cf3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.pacira.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="ib5b7f14d18f646759cdeec9d0d34fb36_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_9b2737da-b551-49d0-9b9b-7c27a5074bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_9b2737da-b551-49d0-9b9b-7c27a5074bca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f73f6cc-a8be-4ed9-8b9f-21eb70880205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f73f6cc-a8be-4ed9-8b9f-21eb70880205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_558386df-86a7-46d4-9959-bc7fba8e1263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:to="loc_us-gaap_LongTermDebt_558386df-86a7-46d4-9959-bc7fba8e1263" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:to="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d3171b33-240f-4aac-b416-94ccf27c7274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d3171b33-240f-4aac-b416-94ccf27c7274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d3171b33-240f-4aac-b416-94ccf27c7274_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d3171b33-240f-4aac-b416-94ccf27c7274" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d3171b33-240f-4aac-b416-94ccf27c7274_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2aabac43-87e3-4291-ad2b-481d9dd96293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d3171b33-240f-4aac-b416-94ccf27c7274" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2aabac43-87e3-4291-ad2b-481d9dd96293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c2780ef2-2b00-4ba9-8451-ed29413d72e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2aabac43-87e3-4291-ad2b-481d9dd96293" xlink:to="loc_us-gaap_SubsequentEventMember_c2780ef2-2b00-4ba9-8451-ed29413d72e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_98c248a8-04e0-43d8-a446-e2d778f14fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_98c248a8-04e0-43d8-a446-e2d778f14fad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98c248a8-04e0-43d8-a446-e2d778f14fad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_98c248a8-04e0-43d8-a446-e2d778f14fad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98c248a8-04e0-43d8-a446-e2d778f14fad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2991c461-9fac-42ca-b9db-ae126092bd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_98c248a8-04e0-43d8-a446-e2d778f14fad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2991c461-9fac-42ca-b9db-ae126092bd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member_e23947be-72b1-47dc-8f7d-0ae0a100ddac" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDueMay2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2991c461-9fac-42ca-b9db-ae126092bd63" xlink:to="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member_e23947be-72b1-47dc-8f7d-0ae0a100ddac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6f733ddb-d63e-4fd7-a0a7-107c32531481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6f733ddb-d63e-4fd7-a0a7-107c32531481" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6f733ddb-d63e-4fd7-a0a7-107c32531481_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6f733ddb-d63e-4fd7-a0a7-107c32531481" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6f733ddb-d63e-4fd7-a0a7-107c32531481_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dbd6d5fe-23c1-4366-b7d2-c32767fe5b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6f733ddb-d63e-4fd7-a0a7-107c32531481" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dbd6d5fe-23c1-4366-b7d2-c32767fe5b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_82ed85b1-2e72-43e6-aafd-39fc325b7518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dbd6d5fe-23c1-4366-b7d2-c32767fe5b2f" xlink:to="loc_us-gaap_UnsecuredDebtMember_82ed85b1-2e72-43e6-aafd-39fc325b7518" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>pcrx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:66f2c054-d932-41b4-84f1-797b86c41d80,g:418797a4-960d-471e-b290-1e4b5463b147-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_630827f0-2b43-4701-8145-fb21f6d5f157_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_dce11f68-fba1-433e-ada2-48767a153732_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f3d74dbb-1b3e-4e0f-92e6-2e1042980109_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Unrealized Gains (Losses) From Available For Sale Investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1283c749-30a9-4a87-8c8f-1529086bc493_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b9384126-8378-4b29-8b65-e7395a7e7d70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0e570056-0945-4a6c-ae64-d069ec1ca5cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_628c2d12-779b-4e13-93dc-acdf66814176_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccruedEndOfTermFeeCurrent_5a198900-f30a-4959-9ef4-94237abd595f_terseLabel_en-US" xlink:label="lab_pcrx_AccruedEndOfTermFeeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_pcrx_AccruedEndOfTermFeeCurrent_label_en-US" xlink:label="lab_pcrx_AccruedEndOfTermFeeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued End of Term Fee, Current</link:label>
    <link:label id="lab_pcrx_AccruedEndOfTermFeeCurrent_documentation_en-US" xlink:label="lab_pcrx_AccruedEndOfTermFeeCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for end of term fee. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedEndOfTermFeeCurrent" xlink:href="pcrx-20211231.xsd#pcrx_AccruedEndOfTermFeeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedEndOfTermFeeCurrent" xlink:to="lab_pcrx_AccruedEndOfTermFeeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_5e370634-cc94-4d83-8f15-a785016e2375_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma basic net loss per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_9e109be6-e83c-4ac7-806b-192e433c0a6b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2cc446b7-83f7-4682-90e8-add7c1a714a5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related fees</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f5d53dd3-8ddb-40c3-bb52-6f04dabf1c53_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_4ef9b961-99c2-422b-bad9-5545172eacc6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion price of notes into common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cda95dc4-347c-45f3-9d47-f5b9e37f75c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f272cafb-6e15-406f-b32b-a2772c86bb90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_be8a2b73-47d5-4beb-a89e-922b77e59e4c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_19de78a8-3654-4310-bb75-cf6cda5ddbdc_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bdb4263e-5555-46d0-a921-2eee263351f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_22033d69-4ed6-43ff-8ac5-cf51f045c537_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree_2ec24816-de9c-4364-8dca-7ce84c0ae0da_terseLabel_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional NOLs, year three</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree_label_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Three</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree_documentation_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree" xlink:to="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31c33af9-42b7-48fe-9538-41306a2ee64e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6c298da7-849e-48d5-b12c-4af449fdd6c7_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_56e4e369-3c52-4b89-bd19-8474915161a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan, awards available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_8f9d6d16-d3d3-4cc6-b18c-142b2143780d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Income Approach</link:label>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_label_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Income Approach [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:to="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_169543a9-b57a-428a-92e5-00c0e6ecff98_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_9025db6b-19e5-4b97-954e-2175bc612062_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2d0a516a-5b8a-4b72-964c-bb569a5e44b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0d1dbe31-71bc-45c8-b89e-2aaa3372a325_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4f77f3bf-a6f1-47f0-ade4-1ce68f87bee9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to acquisition</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c92f1dde-e4a1-4c06-afb6-3c8128f4b6af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments and accretion</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a9134123-0beb-4547-ad1a-41427edc6b57_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_a85db4ea-469d-4e00-ad7b-254a033a0f80_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5e14dfc2-ba44-479f-915b-5985432d75b8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CoPromotionAgreementMember_eb0f9470-6d8f-455e-83db-a572c98f959d_terseLabel_en-US" xlink:label="lab_pcrx_CoPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement</link:label>
    <link:label id="lab_pcrx_CoPromotionAgreementMember_label_en-US" xlink:label="lab_pcrx_CoPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement [Member]</link:label>
    <link:label id="lab_pcrx_CoPromotionAgreementMember_documentation_en-US" xlink:label="lab_pcrx_CoPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-Promotion Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CoPromotionAgreementMember" xlink:href="pcrx-20211231.xsd#pcrx_CoPromotionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CoPromotionAgreementMember" xlink:to="lab_pcrx_CoPromotionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5351c855-e69c-42c7-aaab-4f091c0898d8_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Useful Lives</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8fb58cd5-7093-47aa-870f-b7cab47c6145_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits resulting from prior tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d6ee6fa8-959d-4648-8e73-84209b5c5bf6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8dcf36ed-1e0e-4180-ab7c-70e7713108b0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5ce78a99-e164-4181-a8cb-0d17b2fa054b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5d249ba5-2ef4-42e2-8b18-c2869383ed32_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_293486cc-b57b-4f72-8932-b0482cb1cb75_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion terms prior to close of business on business day immediately proceeding October 1, 2021</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_label_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding October 1, 2021 [Member]</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_documentation_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding October 1, 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" xlink:to="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleSeniorNotes2019Member_978bfcc9-15af-47f1-a757-0fe7d31f0cf2_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotes2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes 2019</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotes2019Member_label_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotes2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes 2019 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotes2019Member_documentation_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotes2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the series 2019 senior convertible notes, which is a written promise to pay a note that can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotes2019Member" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotes2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleSeniorNotes2019Member" xlink:to="lab_pcrx_ConvertibleSeniorNotes2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_9475b559-4173-48d4-849d-f4ba9b88326e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_47021287-8f81-4c1a-9f48-70afa8064024_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_9db463ed-37f2-432d-947e-10e3187c70ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amount and Fair Value of the Long-term Debt</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes_d2fdacba-89df-4f81-ac19-33eff47e5158_negatedTerseLabel_en-US" xlink:label="lab_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of equity component of the 2022 convertible senior notes</link:label>
    <link:label id="lab_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes_label_en-US" xlink:label="lab_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of Equity Component of Convertible Senior Notes</link:label>
    <link:label id="lab_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes_documentation_en-US" xlink:label="lab_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of Equity Component of Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes" xlink:href="pcrx-20211231.xsd#pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes" xlink:to="lab_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_75723670-5a64-4484-9f51-bb47c84ffe03_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec3eb763-c5be-43af-a233-dc9382921d69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5962b4ed-3f75-4dd0-a9c1-d435913c9f3f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_169ae943-6f70-4d44-854d-58d17ef681ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7799aea7-f0ef-463d-bffc-eed6ca2ed426_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentDiscountRate_25705f73-9459-4670-a233-b312a933ed6a_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentDiscountRate_label_en-US" xlink:label="lab_pcrx_DebtInstrumentDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Discount Rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentDiscountRate_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentDiscountRate" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentDiscountRate" xlink:to="lab_pcrx_DebtInstrumentDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_58891b72-afc8-4800-873c-6d016e307460_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at December&#160;31, 2021 and 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_1602c1a9-26a0-4ebf-80ec-26540c52b7d8_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContingentConsiderationMember_4637e93c-3e9f-4e90-b292-fabdb26a4938_terseLabel_en-US" xlink:label="lab_pcrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationMember_label_en-US" xlink:label="lab_pcrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_pcrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentConsiderationMember" xlink:to="lab_pcrx_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther_de0eecbf-f6b1-4914-80d5-c2557507d6e7_terseLabel_en-US" xlink:label="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total acquisition-related charges, product discontinuation and other</link:label>
    <link:label id="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther_label_en-US" xlink:label="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-Related Charges, Product Discontinuation, And Other</link:label>
    <link:label id="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther_documentation_en-US" xlink:label="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-Related Charges, Product Discontinuation, And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther" xlink:to="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_5267c7da-e938-47fe-92dd-74a4023c19ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4c6d0ab2-9076-421e-be63-53a040a830de_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_c7c6c963-8b1f-42f0-bb6c-76a3fa47c325_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_c35cf68e-ca68-4a66-9d38-eb32f496e209_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6ded289-6584-4e40-87eb-9dcc71efb472_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_c2cc3d57-b365-45fc-bbb1-94cc32188524_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion obligation, number of trading days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum, Number of Trading Days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the minimum number of trading days within a period of 30 consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" xlink:to="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d24f8514-88a3-4197-a2a2-401c60e665ca_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2e612132-8fd4-4ac9-9e14-56c8a0c8f841_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_290abe3a-501e-4e7f-b97e-3c2652d2a1ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, repurchased face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_9ea61923-d4aa-4b85-8c4f-5791342453ec_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_37173649-3c3c-4c6a-9bc9-3a18c85c585c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FIXED ASSETS</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_2bb82fdb-03a3-4ff4-b21d-f909c74c4e6b_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_eb230c00-8cc9-4958-96ea-9240c500c6b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balloon payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_6dd546cf-85b7-4454-99b4-12621ce9ef97_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_02b54f1c-38dc-4697-8e12-94c5518b47e7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_992fdbc2-20db-4863-9f14-853d51c20bde_terseLabel_en-US" xlink:label="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity in Accrued Rebates and Chargebacks, Returns, Wholesaler Service Fees and Prompt Pay Discounts</link:label>
    <link:label id="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Valuation and Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Valuation and Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" xlink:href="pcrx-20211231.xsd#pcrx_MovementinValuationandQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" xlink:to="lab_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fa52cdd2-ed8e-4269-93a8-e03823330c50_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d6c03737-1a91-4fa3-bd4d-d8ffb3ca494d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income (loss) per common share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_GenascenceCorporationMember_5989b3e7-cd19-4734-ba68-3dfdecc46a77_terseLabel_en-US" xlink:label="lab_pcrx_GenascenceCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genascence Corporation</link:label>
    <link:label id="lab_pcrx_GenascenceCorporationMember_label_en-US" xlink:label="lab_pcrx_GenascenceCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genascence Corporation [Member]</link:label>
    <link:label id="lab_pcrx_GenascenceCorporationMember_documentation_en-US" xlink:label="lab_pcrx_GenascenceCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genascence Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GenascenceCorporationMember" xlink:href="pcrx-20211231.xsd#pcrx_GenascenceCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_GenascenceCorporationMember" xlink:to="lab_pcrx_GenascenceCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_c5025a58-6182-4db8-89ed-2dc38e8bb9c6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_be1c88d8-590f-4b3a-99ea-c5c2f34e9c41_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d05c2ff-bb24-4c56-ba78-009eb737691a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1355cd72-f591-4139-bc94-6d1ce1033167_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c462a4c8-5bc6-4731-9c28-d9edaa47c9b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_867b3d66-b6dc-46da-a9f8-32c6c051ce4a_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDueMay2024Member_e806edc6-809d-4f20-8166-e058462452ec_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDueMay2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDueMay2024Member_label_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDueMay2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due May 2024 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDueMay2024Member_documentation_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDueMay2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due May 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDueMay2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member" xlink:to="lab_pcrx_ConvertibleSeniorNotesDueMay2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_e9b8c353-ca2b-47db-862a-d15b6a7f080d_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfFDAApprovalOfFX301Member_bfbe2162-a5c0-4e77-88ff-e95a4dfc333f_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfFDAApprovalOfFX301Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of FDA Approval of FX-301</link:label>
    <link:label id="lab_pcrx_AchievementOfFDAApprovalOfFX301Member_label_en-US" xlink:label="lab_pcrx_AchievementOfFDAApprovalOfFX301Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of FDA Approval Of FX-301 [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfFDAApprovalOfFX301Member_documentation_en-US" xlink:label="lab_pcrx_AchievementOfFDAApprovalOfFX301Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of FDA Approval Of FX-301</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfFDAApprovalOfFX301Member" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfFDAApprovalOfFX301Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfFDAApprovalOfFX301Member" xlink:to="lab_pcrx_AchievementOfFDAApprovalOfFX301Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_5444d0c8-19e2-4477-9f78-6f3ec0de9698_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_82f1e19f-1f77-4a69-aef3-88a24ba2e3ac_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_0be6f3e5-6cf0-4671-8153-8472045c1eed_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_53970aa5-7b1e-4e1c-95e8-83d5ed5d6055_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_33d29fe9-223e-4ddf-bc70-9a457e2a0278_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_044f5468-bd4e-4d19-9a76-3bd1345a3deb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConcentrationRiskNumberofCustomers_68b94930-226a-4678-88bf-3a49cbeb706f_terseLabel_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberofCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, number of customers</link:label>
    <link:label id="lab_pcrx_ConcentrationRiskNumberofCustomers_label_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberofCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:label id="lab_pcrx_ConcentrationRiskNumberofCustomers_documentation_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberofCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number of Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberofCustomers" xlink:href="pcrx-20211231.xsd#pcrx_ConcentrationRiskNumberofCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConcentrationRiskNumberofCustomers" xlink:to="lab_pcrx_ConcentrationRiskNumberofCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_d96a72f9-a4f3-467c-9092-2afa61f7a414_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-recurring charge related to discontinuation</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6020f824-9dea-4ef4-b7b0-8f8dd5f9d888_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_97676841-1f3d-401b-8188-070bc53ba029_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt outstanding</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_efd322ba-5a31-467a-9634-2f129976680e_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt, net of debt discount and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6f7dc2e6-a1f0-4e0c-9acf-214deb1fcafe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FortisMember_2501600a-1f6e-4a50-94a4-421c56bc9dce_terseLabel_en-US" xlink:label="lab_pcrx_FortisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fortis</link:label>
    <link:label id="lab_pcrx_FortisMember_label_en-US" xlink:label="lab_pcrx_FortisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fortis [Member]</link:label>
    <link:label id="lab_pcrx_FortisMember_documentation_en-US" xlink:label="lab_pcrx_FortisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fortis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FortisMember" xlink:href="pcrx-20211231.xsd#pcrx_FortisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FortisMember" xlink:to="lab_pcrx_FortisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_25c6956c-5e0b-444f-9020-313494713b08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment Losses, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfInvestments" xlink:to="lab_us-gaap_ImpairmentOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_dbbb324e-5166-45ff-af3b-e8727ef1248b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_29edf5c7-3dd1-48ed-9008-885de2b8b848_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue_8a6066a2-b44f-4565-8d98-d4aa59b915b6_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage ratio maximum amount</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue_label_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum, Value</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue" xlink:to="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_412bda09-aca9-402e-983f-17a7d02faaef_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_OtherTaxAttributesSubjectToLimitation_bbd23acc-b994-491a-9f02-19cf9b2188d2_terseLabel_en-US" xlink:label="lab_pcrx_OtherTaxAttributesSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax attributes, subject to limitation</link:label>
    <link:label id="lab_pcrx_OtherTaxAttributesSubjectToLimitation_label_en-US" xlink:label="lab_pcrx_OtherTaxAttributesSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Attributes, Subject To Limitation</link:label>
    <link:label id="lab_pcrx_OtherTaxAttributesSubjectToLimitation_documentation_en-US" xlink:label="lab_pcrx_OtherTaxAttributesSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Attributes, Subject To Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_OtherTaxAttributesSubjectToLimitation" xlink:href="pcrx-20211231.xsd#pcrx_OtherTaxAttributesSubjectToLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_OtherTaxAttributesSubjectToLimitation" xlink:to="lab_pcrx_OtherTaxAttributesSubjectToLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_93ceb2ce-6680-4165-a8ab-111f01a85758_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for current year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligationsPolicy_369be2e6-b88f-4d8a-b2be-9e801f982209_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligations</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationsPolicy_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationsPolicy" xlink:to="lab_us-gaap_AssetRetirementObligationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CollaborativeArrangementOptionToExtendTerm_35a86a83-39ae-4104-87c6-9c8183f3d198_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeArrangementOptionToExtendTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, option to extend, term</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementOptionToExtendTerm_label_en-US" xlink:label="lab_pcrx_CollaborativeArrangementOptionToExtendTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option to Extend, Term</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementOptionToExtendTerm_documentation_en-US" xlink:label="lab_pcrx_CollaborativeArrangementOptionToExtendTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option to Extend, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementOptionToExtendTerm" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementOptionToExtendTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeArrangementOptionToExtendTerm" xlink:to="lab_pcrx_CollaborativeArrangementOptionToExtendTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionTypeAxis_fd3aaa9a-5fce-486c-8097-01aef5415aca_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TransactionTypeAxis_label_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_bce8f859-9171-434b-86e2-f8d516bc14d7_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_e67ce915-6ccc-4336-a695-a38357a96258_terseLabel_en-US" xlink:label="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments for EXPAREL agreed in connection with acquisition</link:label>
    <link:label id="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_label_en-US" xlink:label="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed Milestone Payments for Sale of Product in Connection with Acquisition</link:label>
    <link:label id="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_documentation_en-US" xlink:label="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the milestone payments agreed to be paid by the entity for the sale of the product, in connection with the acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:href="pcrx-20211231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:to="lab_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CollaborativeArrangementUpfrontPayment_b25fcc8f-ebb1-4116-ab81-a0a845845a8c_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, upfront payment</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementUpfrontPayment_label_en-US" xlink:label="lab_pcrx_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementUpfrontPayment_documentation_en-US" xlink:label="lab_pcrx_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementUpfrontPayment" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeArrangementUpfrontPayment" xlink:to="lab_pcrx_CollaborativeArrangementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_33b14914-9454-4f33-b95b-beafb18a7531_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ff0f80a0-31e9-40c2-a696-6c9ecd6df601_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d4e1716b-b0b5-46ef-8541-34e84ae5b28c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_InducementPlan2014Member_fd1dcc55-8972-4a99-911f-d402fd7f6a6a_terseLabel_en-US" xlink:label="lab_pcrx_InducementPlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Inducement Plan</link:label>
    <link:label id="lab_pcrx_InducementPlan2014Member_label_en-US" xlink:label="lab_pcrx_InducementPlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Plan 2014 [Member]</link:label>
    <link:label id="lab_pcrx_InducementPlan2014Member_documentation_en-US" xlink:label="lab_pcrx_InducementPlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InducementPlan2014Member" xlink:href="pcrx-20211231.xsd#pcrx_InducementPlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_InducementPlan2014Member" xlink:to="lab_pcrx_InducementPlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_55396767-0247-41b9-8951-0179df0483b0_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_e2fbdd5c-9609-4ef0-86b7-586e250d223c_terseLabel_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_label_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_documentation_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:to="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7a4e3d00-3529-420e-a182-719aa3d4eb18_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ec81f657-a5de-4e02-8446-7e8ea12efda5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_43ba299b-92dc-4b42-aca9-1ee1241d2b33_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContingentConsiderationPaymentTerm_14ea4a7b-e46b-4d89-b2a8-0f21d7f2e0ca_terseLabel_en-US" xlink:label="lab_pcrx_ContingentConsiderationPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, payment terms</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationPaymentTerm_label_en-US" xlink:label="lab_pcrx_ContingentConsiderationPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Payment Term</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationPaymentTerm_documentation_en-US" xlink:label="lab_pcrx_ContingentConsiderationPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationPaymentTerm" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentConsiderationPaymentTerm" xlink:to="lab_pcrx_ContingentConsiderationPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e23e458e-3272-4411-aace-f36c1a5cf61e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration (after an acquisition)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dc0b3bd5-7458-46c1-a80a-c2290a677990_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability payable to holders of CVRs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_33d997c3-ee21-4e3c-b45c-ad353926a845_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration (after an acquisition)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_4ee24e74-da36-41ae-b354-94d93cb894e3_terseLabel_en-US" xlink:label="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum fair market value of ESPP shares available for purchase</link:label>
    <link:label id="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_label_en-US" xlink:label="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Fair Market Value Purchase of ESPP Shares</link:label>
    <link:label id="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares_documentation_en-US" xlink:label="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Fair Market Value Purchase of ESPP Shares in a Calendar Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares" xlink:href="pcrx-20211231.xsd#pcrx_MaximumFairMarketValuePurchaseofESPPShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares" xlink:to="lab_pcrx_MaximumFairMarketValuePurchaseofESPPShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_8a9855f7-f86f-40ea-b774-132fb71cb29a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate of common stock per $1,000 of principal amount of notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_54916894-28fe-4c2a-aab1-c3ccf002e09f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8c60f3a5-af7b-4cb6-b084-66fc709c2c13_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at beginning of the period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_48fa4028-c40f-4316-9b39-a5f3ac359fb9_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at end of the period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c8895894-c2e6-4e58-956b-d52b2b643676_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_04451ff6-c9fc-43bd-ae7f-a9d156b033ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1a554f9f-56b8-484c-adf0-786a01d411f3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5672b905-9b03-4c61-bc4d-a65a76437410_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_70f8136e-e1a0-4b09-82ae-a1159fc0c98f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_3cd71ad3-385f-489a-9376-f6869427daaf_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_01b20f87-423d-4909-ab61-2ca03c063532_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government bonds</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_7dfe98ec-8585-426b-9a92-3683feb3e7b1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a69e58ca-b683-4b81-ac31-a4c9dad33cb8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_c3b15751-7dd6-4843-90f0-54d2e5216f19_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_f5b22c39-4e2f-449c-996c-87708301343b_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6ec76b2c-2159-45db-9b6f-8abf63004094_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_a9c82a3a-0b35-4274-b8bb-f58b0c786fa3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConcentrationRiskNumberOfProducts_498fe8c7-6b98-4d0f-9ea7-dd2cd72a13bc_terseLabel_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products</link:label>
    <link:label id="lab_pcrx_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_pcrx_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_pcrx_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberOfProducts" xlink:href="pcrx-20211231.xsd#pcrx_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConcentrationRiskNumberOfProducts" xlink:to="lab_pcrx_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DePuySynthesSalesIncMember_9fd66ffc-e056-4217-8536-8b455808d7c4_terseLabel_en-US" xlink:label="lab_pcrx_DePuySynthesSalesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy Synthes Sales Inc</link:label>
    <link:label id="lab_pcrx_DePuySynthesSalesIncMember_label_en-US" xlink:label="lab_pcrx_DePuySynthesSalesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy Synthes Sales Inc [Member]</link:label>
    <link:label id="lab_pcrx_DePuySynthesSalesIncMember_documentation_en-US" xlink:label="lab_pcrx_DePuySynthesSalesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy Synthes Sales Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DePuySynthesSalesIncMember" xlink:href="pcrx-20211231.xsd#pcrx_DePuySynthesSalesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DePuySynthesSalesIncMember" xlink:to="lab_pcrx_DePuySynthesSalesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_55143220-63c1-4468-b900-7b219ad4475c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a9563123-9877-42dd-ac70-6e843c74565c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term at the end of the period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_7593575e-e875-4239-9323-1197d47bde06_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_dd59145a-db42-4b56-937f-c3af0023dac4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0d33ba2c-d4f2-4e14-bed8-ec33ce4ece30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8fa98b04-792c-456d-977b-0b4551858dc2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_006f1b4b-b706-4fd8-9992-6d40d8b24fd3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.001; 250,000,000 shares authorized; 44,734,308 and 43,636,929 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1f6ba33e-8570-4322-bcfb-c0c31783f2dc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition of non-vested awards not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d75335d1-2343-4305-b7c9-c7257af25105_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance at the beginning of the period (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5dc76701-e594-49a9-9e93-58a3cf3a1e76_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance at the end of the period (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2b0a246a-c274-4c87-a5ab-35d608e3d1e1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_46b963c4-fa79-4888-9f54-b9b4d35fef77_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_13cfaf6d-d355-4a2c-9a2f-9243f321254a_verboseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right</link:label>
    <link:label id="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_59e2d587-ceb8-4b75-b9b5-4efc061135be_terseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent value rights (CVRs)</link:label>
    <link:label id="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_label_en-US" xlink:label="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred, Contingent Consideration</link:label>
    <link:label id="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_documentation_en-US" xlink:label="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" xlink:to="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_b5bda635-1cd0-46cd-94e4-cc852d288c2e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_139764c7-8b91-42fb-b91d-a8ea4f940bd4_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cd147215-2ead-4b62-bc82-ba990371258d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions Used to Estimate the Fair Values of Each Option Grant Using the Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation_12e235bc-4134-4b79-ab03-553c0e6a52bd_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Days from payment obligations, option to terminate</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation_label_en-US" xlink:label="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option To Terminate, Days From Payment Obligation</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation_documentation_en-US" xlink:label="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option To Terminate, Days From Payment Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation" xlink:to="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_ecfcf134-48f0-4d53-8424-4e26594c8289_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_fa729002-beec-436e-8b3b-65ef93763c79_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_60abd748-a133-44cf-8156-bacee23d04cc_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_39d692c1-7779-4cef-afad-f74754b58a7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of diluted securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_NumberOfLocationsNewOperatingLeaseLiability_811c3274-6c85-4c3a-aaa1-23cac76eb4b4_terseLabel_en-US" xlink:label="lab_pcrx_NumberOfLocationsNewOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of locations</link:label>
    <link:label id="lab_pcrx_NumberOfLocationsNewOperatingLeaseLiability_label_en-US" xlink:label="lab_pcrx_NumberOfLocationsNewOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Locations, New Operating Lease Liability</link:label>
    <link:label id="lab_pcrx_NumberOfLocationsNewOperatingLeaseLiability_documentation_en-US" xlink:label="lab_pcrx_NumberOfLocationsNewOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Locations, New Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfLocationsNewOperatingLeaseLiability" xlink:href="pcrx-20211231.xsd#pcrx_NumberOfLocationsNewOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NumberOfLocationsNewOperatingLeaseLiability" xlink:to="lab_pcrx_NumberOfLocationsNewOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_8e975fa1-9111-4d1c-9ed4-577cf9a47c64_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_4c222993-f12e-446c-8e1e-4d4fd46efa16_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_11896030-bc71-416f-bd80-4f4ef4472054_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term and Long-Term Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_e27dba3a-528c-4403-9e74-ae01c80ecc85_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_65bb310b-58eb-4d53-b566-621f273dc213_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_d2fbda19-9967-4e37-b9bf-a6bc21864409_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_a6914962-106c-45d7-bcfd-4f61138014da_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ProductReturnsRebatesandOtherFees_ee4a67f5-0125-4338-95f1-5008c7f96038_terseLabel_en-US" xlink:label="lab_pcrx_ProductReturnsRebatesandOtherFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns and wholesaler service fees</link:label>
    <link:label id="lab_pcrx_ProductReturnsRebatesandOtherFees_label_en-US" xlink:label="lab_pcrx_ProductReturnsRebatesandOtherFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns, Rebates and Other Fees</link:label>
    <link:label id="lab_pcrx_ProductReturnsRebatesandOtherFees_documentation_en-US" xlink:label="lab_pcrx_ProductReturnsRebatesandOtherFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns, Rebates and Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProductReturnsRebatesandOtherFees" xlink:href="pcrx-20211231.xsd#pcrx_ProductReturnsRebatesandOtherFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ProductReturnsRebatesandOtherFees" xlink:to="lab_pcrx_ProductReturnsRebatesandOtherFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_85157b78-cd25-4af9-a7a2-e3c6458bd4e2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ac409e5-97df-4dc4-945d-b2627ed9fb5b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_78500e78-0530-4de7-b770-0a32ade9f78a_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6a973eac-82ba-4c67-9d67-bc0a4db6c059_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4ebbaa25-b443-485d-a7b1-84ed310d283b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_508bee82-33ac-4995-a5d4-c0af51ecc84f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo_2df7eca5-087a-46ce-a39e-4dfab84ad291_terseLabel_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional NOLs, year two</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo_label_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Two</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo_documentation_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo" xlink:to="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_Accruedsellinggeneralandadministrativeexpenses_27505c14-a17f-4862-af35-526712a7da71_terseLabel_en-US" xlink:label="lab_pcrx_Accruedsellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued selling, general and administrative expenses</link:label>
    <link:label id="lab_pcrx_Accruedsellinggeneralandadministrativeexpenses_label_en-US" xlink:label="lab_pcrx_Accruedsellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued selling, general, and administrative expenses</link:label>
    <link:label id="lab_pcrx_Accruedsellinggeneralandadministrativeexpenses_documentation_en-US" xlink:label="lab_pcrx_Accruedsellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of liabilities incurred and payable to vendors for goods and services related to selling, general, and administrative activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_Accruedsellinggeneralandadministrativeexpenses" xlink:href="pcrx-20211231.xsd#pcrx_Accruedsellinggeneralandadministrativeexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_Accruedsellinggeneralandadministrativeexpenses" xlink:to="lab_pcrx_Accruedsellinggeneralandadministrativeexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7b8bed1d-f5a2-42f3-b2ab-f2ea349d8bca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS ACQUIRED</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ed90465b-6d34-481c-8fb6-e4edb6973a40_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_f5c74a82-cf7e-4181-a4a3-435917ddac51_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a8fd76c5-aa99-40ed-982a-87cda23d0cde_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_90a924e4-f44e-493e-a926-4b7dc51ee4c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_XenonPharmaceuticalsIncMember_537618ab-71bd-4afb-8c4e-bc818ea44b5f_terseLabel_en-US" xlink:label="lab_pcrx_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals, Inc</link:label>
    <link:label id="lab_pcrx_XenonPharmaceuticalsIncMember_label_en-US" xlink:label="lab_pcrx_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_pcrx_XenonPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_pcrx_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_XenonPharmaceuticalsIncMember" xlink:href="pcrx-20211231.xsd#pcrx_XenonPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_XenonPharmaceuticalsIncMember" xlink:to="lab_pcrx_XenonPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_aeb7a0ba-bf0f-4b66-aab6-23340f445c41_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_ac5c05df-959f-4372-8240-1332f93098cf_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_c51d44d8-19c6-415e-a81d-6d869138dd83_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note paid for investment</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_55f727b1-c7bf-4e83-9e49-8b8189296ccc_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, percentage of principal amount for computation of redemption price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_label_en-US" xlink:label="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percentage of Principal Amount for Computation of Redemption Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of principal amount used in computation of the redemption price to be paid on conversion of convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" xlink:to="lab_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_bd812d5e-6209-4088-b0be-1c15721553a1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice_835f955d-c6eb-4eb7-bb5f-3ec0d5232cd0_terseLabel_en-US" xlink:label="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration related to the Flexion Acquisition</link:label>
    <link:label id="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice_label_en-US" xlink:label="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchase Price</link:label>
    <link:label id="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice_documentation_en-US" xlink:label="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice" xlink:href="pcrx-20211231.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice" xlink:to="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_86a4fb65-6b7e-48f0-9add-ff4232a76b74_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_da6338d9-60a7-4a48-84d0-7b4bda42076b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c74b51c-455a-4057-b1e3-41b480fbda26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_201a36af-c447-4fc2-a17b-34b6587fd1e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9f03e6f5-ed6e-488a-857f-1949b70eb8f0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_1f9228ce-ea7d-4fcf-b33a-d6fb59d4f88a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_999e2dc7-4204-49c9-a38e-331702df2bee_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in additional equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_fb442ecb-a40b-4e7d-bf82-7d1f4a436b6d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e1a4ca06-7a14-4801-ba27-c5c07b95acd1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_a71d2f08-80f9-4006-9865-89f6bfbec59c_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_a54307ad-c538-41db-8b9a-7194c2ba1020_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_713797a3-28ce-4c7f-b595-a955d4785ebb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_2710c622-b3cf-4928-b021-14d794898dfe_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2ba04c38-8cb8-4eb6-8074-eb5551b553a3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_5b2fcedb-caf5-41c3-bdb0-6b0770d7d4ae_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_963bf37d-38ed-4a4c-8dd7-8977f5d3f1dc_terseLabel_en-US" xlink:label="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum cumulative percentage of change in ownership as condition to offset taxable income</link:label>
    <link:label id="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_label_en-US" xlink:label="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Cumulative Percentage of Change in Ownership as Condition to Offset Taxable Income or Tax</link:label>
    <link:label id="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_documentation_en-US" xlink:label="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents minimum cumulative percentage of change in ownership as a condition to offset taxable income or tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" xlink:href="pcrx-20211231.xsd#pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" xlink:to="lab_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_4b12e724-e920-4048-ab4d-9dc6c4810a7c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan B credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_a9525b44-48c5-4062-811a-088e63e02806_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_StockIncentivePlan2011Member_ceeb85e2-00fe-4bfb-9c85-b3764c6deaba_terseLabel_en-US" xlink:label="lab_pcrx_StockIncentivePlan2011Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan</link:label>
    <link:label id="lab_pcrx_StockIncentivePlan2011Member_label_en-US" xlink:label="lab_pcrx_StockIncentivePlan2011Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2011 [Member]</link:label>
    <link:label id="lab_pcrx_StockIncentivePlan2011Member_documentation_en-US" xlink:label="lab_pcrx_StockIncentivePlan2011Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information about the entity's 2011 stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_StockIncentivePlan2011Member" xlink:href="pcrx-20211231.xsd#pcrx_StockIncentivePlan2011Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_StockIncentivePlan2011Member" xlink:to="lab_pcrx_StockIncentivePlan2011Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_40fb19db-e1a9-41a2-a747-9c7b02e4f785_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_df17512b-5065-4229-b8b1-d274d447f7c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_12015e5f-bd52-4ad0-8dcb-22d9f183cce4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_38bc3e95-6ff3-408b-a59f-ab512b03aa28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfMilestoneAxis_1ccfb1ce-98ee-4f8d-87e0-eede2a4ef99a_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Milestone [Axis]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneAxis_label_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Milestone [Axis]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneAxis_documentation_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by categories of milestones achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfMilestoneAxis" xlink:to="lab_pcrx_AchievementOfMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_04bfa2ef-9412-4769-8d48-cf0ea8e293ef_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_91bbc5ca-5b63-4d28-a21f-c7583e268ac3_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_cda5e102-fc0a-4ea2-9bd0-7e612e4bfdf3_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, milestone payments to be received</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_label_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payments to be Received, Maximum</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_documentation_en-US" xlink:label="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:to="lab_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5c876b4a-ae9d-44fc-8c07-fc5c1bda5e32_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of income taxes at U.S. Federal statutory rate to the provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe27953f-82bb-44cf-bfde-585e7b67943b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_4616894a-ef44-46c3-aa82-38a367635422_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit) [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_ceeb8813-9534-4009-ac2c-67b6c0a50fb3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ee1e73d6-5331-4cd1-95a7-55ea54d90da9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b5eed0aa-213d-494a-95fd-852f20d3b70a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6629fe7c-74bd-4570-a964-b5c3cfdd96de_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bcb126c3-9373-406e-92b5-821cfc52e4f6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7ed6b660-b55e-4402-a379-beb8db33b55e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4250fa9f-e859-47c4-a749-e81c4651566c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConversionPremiumOn2022NotesMember_4b328abd-0cc2-4919-b6f7-d22eca6fe386_terseLabel_en-US" xlink:label="lab_pcrx_ConversionPremiumOn2022NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Premium on 2022 Notes</link:label>
    <link:label id="lab_pcrx_ConversionPremiumOn2022NotesMember_label_en-US" xlink:label="lab_pcrx_ConversionPremiumOn2022NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Premium on 2022 Notes [Member]</link:label>
    <link:label id="lab_pcrx_ConversionPremiumOn2022NotesMember_documentation_en-US" xlink:label="lab_pcrx_ConversionPremiumOn2022NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Premium on 2022 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConversionPremiumOn2022NotesMember" xlink:href="pcrx-20211231.xsd#pcrx_ConversionPremiumOn2022NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConversionPremiumOn2022NotesMember" xlink:to="lab_pcrx_ConversionPremiumOn2022NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0e4c4bdb-eeac-408c-af2f-065d6a3ef31c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c3af0d4c-457a-4f92-b469-6010f48cc5c3_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_86db27ee-57f9-4437-8ee5-9b3f972fc97c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e006735f-47a2-49cf-a048-cf37643d5d65_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SkyePharmaHoldingIncMember_02f95865-ca25-4c4d-a4e3-28c46153534f_terseLabel_en-US" xlink:label="lab_pcrx_SkyePharmaHoldingIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SkyePharma Holding, Inc.</link:label>
    <link:label id="lab_pcrx_SkyePharmaHoldingIncMember_label_en-US" xlink:label="lab_pcrx_SkyePharmaHoldingIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skye Pharma Holding Inc. [Member]</link:label>
    <link:label id="lab_pcrx_SkyePharmaHoldingIncMember_documentation_en-US" xlink:label="lab_pcrx_SkyePharmaHoldingIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to SkyePharma Holding, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SkyePharmaHoldingIncMember" xlink:href="pcrx-20211231.xsd#pcrx_SkyePharmaHoldingIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SkyePharmaHoldingIncMember" xlink:to="lab_pcrx_SkyePharmaHoldingIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_0e9e8291-f624-409a-824f-edd7e3e21243_terseLabel_en-US" xlink:label="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments for Product in Connection with Acquisition by Stage at which They are Payable [Axis]</link:label>
    <link:label id="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_label_en-US" xlink:label="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments for Product in Connection with Acquisition by Stage at which they are Payable [Axis]</link:label>
    <link:label id="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_documentation_en-US" xlink:label="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information pertaining to milestone payments for products by the stage at which they are payable, in connection with the acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" xlink:to="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_6e88c4c5-5457-47cf-926c-eb2a900eaca3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5621ca3-3e1b-4ac3-bff7-da12c13cd2db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_98e61568-dc09-4bdf-859e-c6312b8f788d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_966f7bac-39d8-4d26-956e-5bc7f3a58327_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix_9c89d787-80e6-45a0-86a1-7b60493bb13a_terseLabel_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional NOLs, year six</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix_label_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Six</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix_documentation_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix" xlink:to="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_b903298b-9c9c-49d1-bead-1cb33c6de1e4_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_482e2af0-c2ec-437c-ab7e-40e315ac0055_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AdvisoryCostsMember_dd34e124-6ac3-4aa7-8328-3458b27495b9_terseLabel_en-US" xlink:label="lab_pcrx_AdvisoryCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advisory Costs</link:label>
    <link:label id="lab_pcrx_AdvisoryCostsMember_label_en-US" xlink:label="lab_pcrx_AdvisoryCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advisory Costs [Member]</link:label>
    <link:label id="lab_pcrx_AdvisoryCostsMember_documentation_en-US" xlink:label="lab_pcrx_AdvisoryCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advisory Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AdvisoryCostsMember" xlink:href="pcrx-20211231.xsd#pcrx_AdvisoryCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AdvisoryCostsMember" xlink:to="lab_pcrx_AdvisoryCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_71b317d8-9a70-4781-af08-c913afa10ff9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related income tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_fc6fa150-9fca-4723-b738-6f68617f9cb2_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing sale price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfZILRETTASalesOf250MillionMember_9df7b3fa-8f2d-47eb-ba58-01a9a5e15735_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfZILRETTASalesOf250MillionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of ZILRETTA Sales of $250 Million</link:label>
    <link:label id="lab_pcrx_AchievementOfZILRETTASalesOf250MillionMember_label_en-US" xlink:label="lab_pcrx_AchievementOfZILRETTASalesOf250MillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of ZILRETTA Sales Of $250 Million [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfZILRETTASalesOf250MillionMember_documentation_en-US" xlink:label="lab_pcrx_AchievementOfZILRETTASalesOf250MillionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of ZILRETTA Sales Of $250 Million</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfZILRETTASalesOf250MillionMember" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfZILRETTASalesOf250MillionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfZILRETTASalesOf250MillionMember" xlink:to="lab_pcrx_AchievementOfZILRETTASalesOf250MillionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1747f17c-b962-43c3-b2b9-8ab6d91734b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_ace052a3-d1ea-4f21-b303-7d4fc995583b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, maximum term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_9bb983c0-ad27-48e8-bfca-eb1bb2fbe4a8_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed borrowing rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Assumed Borrowing Rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Assumed Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConvertibleAssumedBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" xlink:to="lab_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_041597d1-36b3-4df6-bc87-798d82a2dbc8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_535f7d83-015b-4485-b9b2-499ba3533bf4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_4c47db50-f1a4-4cc5-93a8-f7ed65b3c471_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0d38bdf6-2855-424b-a2dd-ef8ae7383dc8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FederalReserveBankOfNYRateMember_2af74199-2335-461e-bf3d-c1caddec3f74_terseLabel_en-US" xlink:label="lab_pcrx_FederalReserveBankOfNYRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NYFRB Rate</link:label>
    <link:label id="lab_pcrx_FederalReserveBankOfNYRateMember_label_en-US" xlink:label="lab_pcrx_FederalReserveBankOfNYRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Reserve Bank Of NY, Rate [Member]</link:label>
    <link:label id="lab_pcrx_FederalReserveBankOfNYRateMember_documentation_en-US" xlink:label="lab_pcrx_FederalReserveBankOfNYRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Reserve Bank Of NY, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FederalReserveBankOfNYRateMember" xlink:href="pcrx-20211231.xsd#pcrx_FederalReserveBankOfNYRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FederalReserveBankOfNYRateMember" xlink:to="lab_pcrx_FederalReserveBankOfNYRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_299c560e-98d7-4321-9c73-94cb833ce193_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_18b3f127-9e19-460a-9650-13a06cc62312_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_94998f52-b8b2-4d14-bef4-be8146541259_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_522f5042-871b-48b5-9f2b-ed8535757ce8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_122f45ea-67ce-4fe9-a51d-453ae0bebb4f_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant components of deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_20fee368-b396-4925-abe7-dbc42318bd98_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma diluted net loss per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_92ae8aec-a50f-4664-bd50-61cecaf81e48_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AcquisitionRelatedFeesMember_b339ccf1-ff2c-4ff5-8691-a9fdb0e81a4e_terseLabel_en-US" xlink:label="lab_pcrx_AcquisitionRelatedFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related fees</link:label>
    <link:label id="lab_pcrx_AcquisitionRelatedFeesMember_label_en-US" xlink:label="lab_pcrx_AcquisitionRelatedFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Related Fees [Member]</link:label>
    <link:label id="lab_pcrx_AcquisitionRelatedFeesMember_documentation_en-US" xlink:label="lab_pcrx_AcquisitionRelatedFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Related Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedFeesMember" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AcquisitionRelatedFeesMember" xlink:to="lab_pcrx_AcquisitionRelatedFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_1b1e2134-30c4-43a2-a7de-41b9450c38c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Adjustments</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_12651ed1-5bc0-46a6-8c27-a880b5837e3a_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ec3b16ac-7e59-4865-b380-e638a0a5aa83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ede2e9bb-4466-4246-8292-872adbf21b31_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0ed540e6-2662-48c4-ae95-00f3921fcb27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ead47f30-32a9-4456-b81d-328d6c80a6b2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_3542b979-e0d7-43c1-8e87-b2dd4484df17_terseLabel_en-US" xlink:label="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquisition-related Restructuring and Discontinuation Costs</link:label>
    <link:label id="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_label_en-US" xlink:label="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]</link:label>
    <link:label id="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_documentation_en-US" xlink:label="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" xlink:href="pcrx-20211231.xsd#pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" xlink:to="lab_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b3dccc81-5365-4a49-ad10-0f944d4c189b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_6b4598de-e4c2-4c1d-b4fb-e4bba878b357_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_878986c8-9b00-4faf-a46f-b026613f8891_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_582c2257-44ae-4989-8b20-80e8a02c1748_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1baea4ab-a671-41bc-9a74-ac3683a1a7c8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfZILRETTASalesOf375MillionMember_b79d89a6-96b2-495f-a8b0-3ae3cd6982cb_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfZILRETTASalesOf375MillionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of ZILRETTA Sales of $375 Million</link:label>
    <link:label id="lab_pcrx_AchievementOfZILRETTASalesOf375MillionMember_label_en-US" xlink:label="lab_pcrx_AchievementOfZILRETTASalesOf375MillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of ZILRETTA Sales Of $375 Million [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfZILRETTASalesOf375MillionMember_documentation_en-US" xlink:label="lab_pcrx_AchievementOfZILRETTASalesOf375MillionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of ZILRETTA Sales Of $375 Million</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfZILRETTASalesOf375MillionMember" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfZILRETTASalesOf375MillionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfZILRETTASalesOf375MillionMember" xlink:to="lab_pcrx_AchievementOfZILRETTASalesOf375MillionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_7cea8629-53a8-44a3-a5d0-e804acc6ddbe_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a80eea1f-e651-40dd-bcb2-20b4ad413678_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_634ee7a7-8ffb-4803-8420-8872c1cc4443_terseLabel_en-US" xlink:label="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments for Product in Connection with Acquisition by Stage at which they are Payable [Domain]</link:label>
    <link:label id="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_label_en-US" xlink:label="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments for Product in Connection with Acquisition by Stage at which they are Payable [Domain]</link:label>
    <link:label id="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_documentation_en-US" xlink:label="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments for Product in Connection with Acquisition by Stage at which they are Payable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain" xlink:to="lab_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_dbfaa02b-7ee0-4af2-b4d6-59b78cb479bb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ae29a4ff-2dd7-4c74-95da-23e65dc15ec7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_49270794-1b7c-44f9-98bb-ce7988b581d6_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ca531781-aa54-4943-940c-566cb9af15c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a735b346-d5d1-4b2d-9e33-ed698b10e4ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_4c1de4f5-9561-43dd-9a85-3610784145f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount_e01ee35d-1a01-4839-b738-73983802e12f_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVRs issued per principal amount</link:label>
    <link:label id="lab_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount_label_en-US" xlink:label="lab_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants Or Rights Issued, Per Principal Amount</link:label>
    <link:label id="lab_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount_documentation_en-US" xlink:label="lab_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants Or Rights Issued, Per Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount" xlink:to="lab_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fccbc495-d298-4b3a-9a25-4eeb53d42c64_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected recognition of non-vested stock options, not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_096080ad-b0aa-406e-aa65-7bb8d17488d7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_bf9f2339-3c61-459d-9f59-adacc7418441_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dde8dc4c-56b3-4226-93b5-7b3bdd29465a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_44e619c4-b59a-44ea-95eb-fc270181ca74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_1de02209-3093-436d-a5d6-0ec8b506b123_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8a7f5bd1-36c2-46e8-8079-0f414336d331_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP share option fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4a06110d-b70f-439d-88aa-d3b91ffacfd8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperAtCarryingValue_186061c6-3156-4d94-b645-19dcbf26b3bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CommercialPaperAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperAtCarryingValue" xlink:to="lab_us-gaap_CommercialPaperAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5e947dbc-f42a-4de5-9983-f084b4a5fd6c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_630ecd18-9f27-46dd-a7dd-a2710dbb299e_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_07cc658d-cd73-493c-bd6d-e654bd6cfc6c_terseLabel_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in Thousands)</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_label_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options, Outstanding Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_documentation_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:to="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_38b4e397-6749-4475-b562-53765feb1b92_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_Accruedresearchanddevelopmentexpenses_2c5a49b0-8848-46f8-b9df-502cb34ad554_terseLabel_en-US" xlink:label="lab_pcrx_Accruedresearchanddevelopmentexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_pcrx_Accruedresearchanddevelopmentexpenses_label_en-US" xlink:label="lab_pcrx_Accruedresearchanddevelopmentexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_pcrx_Accruedresearchanddevelopmentexpenses_documentation_en-US" xlink:label="lab_pcrx_Accruedresearchanddevelopmentexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of liabilities incurred and payable to vendors for goods and services related to research and development activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_Accruedresearchanddevelopmentexpenses" xlink:href="pcrx-20211231.xsd#pcrx_Accruedresearchanddevelopmentexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_Accruedresearchanddevelopmentexpenses" xlink:to="lab_pcrx_Accruedresearchanddevelopmentexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2024Member_d41b71a6-bc23-4552-a0d0-3c654caa4e39_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2024Member" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleSeniorNotesDue2024Member" xlink:to="lab_pcrx_ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_5140f9f9-92e8-4e82-8e3b-8b26009a4343_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_60c681ad-d3a5-4037-b2b3-4edd0a6e3b55_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_3099a0f7-2260-4717-aeac-be9ff062e49d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_091e0a3d-05b2-4b82-a9dd-43dc2796897a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_cb0c7df8-16f4-4e5d-a9d3-2fe65988da8c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_12d6fcd2-5f52-428f-bc5d-a6725be26e89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_53770f88-a362-4df1-b3bc-bf27b6930170_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3798d9ef-3d59-457f-9513-00ccc41f0323_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e2e92f83-46e5-44ba-adb4-d1501955fb7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_b2cdc862-b901-4e7f-b7d6-f633b14c753a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual and other interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_f5456bbb-7a8b-4435-aba6-4566b8638a10_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_166f1a9d-066d-4b0c-ae7f-dd2efa4c8baa_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_9595a243-70b0-4b5e-ac8a-3373f06ee24c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e565e697-f668-4081-a406-53add89f8d95_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FlexionAndMyoscienceAcquisitionMember_41da2898-02ef-4999-8dea-42f1d48f4014_terseLabel_en-US" xlink:label="lab_pcrx_FlexionAndMyoscienceAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flexion and Myoscience Acquisition</link:label>
    <link:label id="lab_pcrx_FlexionAndMyoscienceAcquisitionMember_label_en-US" xlink:label="lab_pcrx_FlexionAndMyoscienceAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flexion And Myoscience Acquisition [Member]</link:label>
    <link:label id="lab_pcrx_FlexionAndMyoscienceAcquisitionMember_documentation_en-US" xlink:label="lab_pcrx_FlexionAndMyoscienceAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flexion And Myoscience Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAndMyoscienceAcquisitionMember" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAndMyoscienceAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FlexionAndMyoscienceAcquisitionMember" xlink:to="lab_pcrx_FlexionAndMyoscienceAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_NetOperatingLossSubjecttoLimitation_43417d8b-81f3-461e-8084-e285bd192d02_terseLabel_en-US" xlink:label="lab_pcrx_NetOperatingLossSubjecttoLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss, subject to limitation</link:label>
    <link:label id="lab_pcrx_NetOperatingLossSubjecttoLimitation_label_en-US" xlink:label="lab_pcrx_NetOperatingLossSubjecttoLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss, Subject to Limitation</link:label>
    <link:label id="lab_pcrx_NetOperatingLossSubjecttoLimitation_documentation_en-US" xlink:label="lab_pcrx_NetOperatingLossSubjecttoLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Losses, Subject to Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NetOperatingLossSubjecttoLimitation" xlink:href="pcrx-20211231.xsd#pcrx_NetOperatingLossSubjecttoLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NetOperatingLossSubjecttoLimitation" xlink:to="lab_pcrx_NetOperatingLossSubjecttoLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1e618c47-7164-418e-8a25-7c782705cfa7_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c4bd73f7-adfa-4f36-8462-f17158d48b65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5524028a-74e8-4015-9ffd-be47c9791236_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9c8d3ad9-96a9-4958-ae6d-5a9a44cfe443_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss (Note 13)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_dbcd7d16-47ac-497a-a998-01c5389a45e6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 accumulated adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Translation and Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_e9f379cb-c4d7-4393-b9b7-e13bd2c8268d_terseLabel_en-US" xlink:label="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan, increased number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_label_en-US" xlink:label="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:href="pcrx-20211231.xsd#pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:to="lab_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fe0c1a46-eb34-4f12-b868-5d629523ac29_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_IncreaseDecreaseInInterestExpense_38c3c1cd-73fa-4b8b-a25c-6711fe5e018c_negatedTerseLabel_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in interest expense</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInInterestExpense_label_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Interest Expense</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInInterestExpense_documentation_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncreaseDecreaseInInterestExpense" xlink:href="pcrx-20211231.xsd#pcrx_IncreaseDecreaseInInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncreaseDecreaseInInterestExpense" xlink:to="lab_pcrx_IncreaseDecreaseInInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach_9d0d2c7e-e6b9-4e6c-bb71-5d3ac76fed65_terseLabel_en-US" xlink:label="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Days from material breach, option to terminate</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach_label_en-US" xlink:label="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option To Terminate, Days From Material Breach</link:label>
    <link:label id="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach_documentation_en-US" xlink:label="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Option To Terminate, Days From Material Breach</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach" xlink:to="lab_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_6e16f778-89a6-496a-aa55-6c4849946652_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_95520dc7-6c9a-4cdc-9cbe-3df7ad61b962_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5e3c7e9d-b36f-4d95-b32c-708cc6112d25_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ThirdLargestCustomerMember_db6cad0e-f462-4e49-b122-8de6609c5ccc_terseLabel_en-US" xlink:label="lab_pcrx_ThirdLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third largest wholesaler</link:label>
    <link:label id="lab_pcrx_ThirdLargestCustomerMember_label_en-US" xlink:label="lab_pcrx_ThirdLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Largest Customer [Member]</link:label>
    <link:label id="lab_pcrx_ThirdLargestCustomerMember_documentation_en-US" xlink:label="lab_pcrx_ThirdLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the third largest customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThirdLargestCustomerMember" xlink:href="pcrx-20211231.xsd#pcrx_ThirdLargestCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ThirdLargestCustomerMember" xlink:to="lab_pcrx_ThirdLargestCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0147db9b-7fbb-441f-a5f3-dca43c310849_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_64e7c232-b386-4152-855c-0adef11c94f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_51932fbf-3f00-4dad-ba4e-f2452589527c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_PaymentOfContingentConsideration_18b705fe-a6ac-4c08-96eb-c93118e415ef_negatedLabel_en-US" xlink:label="lab_pcrx_PaymentOfContingentConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_pcrx_PaymentOfContingentConsideration_label_en-US" xlink:label="lab_pcrx_PaymentOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Contingent Consideration</link:label>
    <link:label id="lab_pcrx_PaymentOfContingentConsideration_documentation_en-US" xlink:label="lab_pcrx_PaymentOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents earnout and milestone payment made which is associated with the acquisition of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentOfContingentConsideration" xlink:href="pcrx-20211231.xsd#pcrx_PaymentOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PaymentOfContingentConsideration" xlink:to="lab_pcrx_PaymentOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8f3a90d3-da57-4e90-a492-074801a4b3c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_d6317538-8737-44e6-9126-ab513ece51b7_terseLabel_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes refinancing</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_label_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Convertible Senior Notes Refinancing</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_documentation_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Convertible Senior Notes Refinancing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:to="lab_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f3273c69-c604-4df4-ba5f-cdf52fec16ee_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_ad619fe0-9982-4d2a-abf3-b2e53dadfb0c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a009fb78-e240-443f-b2aa-d4ecc053b3fe_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_9361aa91-1ba5-4a34-bff6-52fe56e12dfd_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_285fa52e-2a53-46dc-9e38-4edaf8641cff_terseLabel_en-US" xlink:label="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Redemption Terms on or after April 1, 2020</link:label>
    <link:label id="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_label_en-US" xlink:label="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Redemption Terms on or after April 1, 2020 [Member]</link:label>
    <link:label id="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member_documentation_en-US" xlink:label="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Redemption Terms on or after April 1, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member" xlink:href="pcrx-20211231.xsd#pcrx_DebtRedemptionTermsonorafterApril12020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member" xlink:to="lab_pcrx_DebtRedemptionTermsonorafterApril12020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c2e45a1c-5089-4f05-8fae-ac7cdc84bcf3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtMember_a597d2c8-eda1-4660-a22f-acd961da6595_terseLabel_en-US" xlink:label="lab_us-gaap_DebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtMember_label_en-US" xlink:label="lab_us-gaap_DebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtMember" xlink:to="lab_us-gaap_DebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_fb3a7e0c-d154-474d-92fb-d47a0605605b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_8eeb523a-2f49-4f14-9745-05beed9403fb_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_44137e08-e457-4fcb-a756-7a9095a3eaa5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate, at point in time</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_30761ecb-91fc-499b-81c3-9366fef8f936_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_e71a18aa-c07e-4d56-898a-c377d3cb4bb4_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion premium (in shares)</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Premium, Shares</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Premium, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConvertibleConversionPremiumShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares" xlink:to="lab_pcrx_DebtInstrumentConvertibleConversionPremiumShares" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_c07908fa-3281-47c4-b9fb-b199d91fc6a9_terseLabel_en-US" xlink:label="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual net sales threshold</link:label>
    <link:label id="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_label_en-US" xlink:label="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Net Sales Threshold for Determining Milestone Payments for Product in Connection with Acquisition</link:label>
    <link:label id="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_documentation_en-US" xlink:label="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the threshold amount of annual net sales considered to determine the stage at which a specified amount of milestone payments for product is agreed to be paid by the entity, in connection with the acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" xlink:href="pcrx-20211231.xsd#pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" xlink:to="lab_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ec342021-479e-40eb-85fc-84893e72db46_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_e910e6b7-b8c5-43c5-b3c4-5b77cdce016a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2022Member_335c5a60-1758-482f-ac2a-28ad95d894e4_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2022</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2022Member_6cb49b36-7760-4fd7-a58f-65c4f27c2ddb_verboseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.375% Convertible Senior Notes Due 2022</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2022Member_label_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2022 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2022Member_documentation_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleSeniorNotesDue2022Member" xlink:to="lab_pcrx_ConvertibleSeniorNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MajorCustomerFourMember_94a5a3ef-7a96-47ee-b6e1-c5073d0a3aaf_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customer four</link:label>
    <link:label id="lab_pcrx_MajorCustomerFourMember_label_en-US" xlink:label="lab_pcrx_MajorCustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Four [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerFourMember_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerFourMember" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerFourMember" xlink:to="lab_pcrx_MajorCustomerFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_WholesalerservicefeesMember_bb0022af-1783-4ba3-b0a1-2dbfcd69fb98_terseLabel_en-US" xlink:label="lab_pcrx_WholesalerservicefeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Fees</link:label>
    <link:label id="lab_pcrx_WholesalerservicefeesMember_label_en-US" xlink:label="lab_pcrx_WholesalerservicefeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler service fees [Member]</link:label>
    <link:label id="lab_pcrx_WholesalerservicefeesMember_documentation_en-US" xlink:label="lab_pcrx_WholesalerservicefeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler service fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_WholesalerservicefeesMember" xlink:href="pcrx-20211231.xsd#pcrx_WholesalerservicefeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_WholesalerservicefeesMember" xlink:to="lab_pcrx_WholesalerservicefeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_44eebc4c-041d-4d94-9137-ac15e45c9c8e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_37f3b245-da10-41f6-b162-e444e979ad71_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b9bed0c3-8c86-486c-9c38-ec22ac92dff6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_1e7de002-3447-4d68-b545-a615b9424eac_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_380b937d-c3cf-404e-bf07-50ff690a3db6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_b31edebe-3113-4baf-8a2a-90da4ec53be3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of Nuance agreement</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_dc53a9d2-b3f2-4a06-929e-93dffd35b376_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_ae678452-11fb-4390-96eb-f0fe09a44b71_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in convertible note, due to foreign currency exchange rates</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_7feccf82-7b72-4a40-b8ef-304f62b98607_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_bde782db-d899-425d-9025-92f3c9befe46_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_3e30e0dd-3490-4e99-90db-dd92f91c4144_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_1eea658e-1293-441c-935c-345392402a1f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt component of the 2025 convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_a5a77c97-f32c-4d45-8955-32dc8c047d32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total transaction costs</link:label>
    <link:label id="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_74aecfb5-30b1-49f6-956f-58c6e1445724_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_50c0a9f2-0de3-4dc3-951d-68c326170ee1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfZILRETTASalesOf500MillionMember_79fde649-111b-4995-bf9b-875ef397b5dd_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfZILRETTASalesOf500MillionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of ZILRETTA Sales of $500 Million</link:label>
    <link:label id="lab_pcrx_AchievementOfZILRETTASalesOf500MillionMember_label_en-US" xlink:label="lab_pcrx_AchievementOfZILRETTASalesOf500MillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of ZILRETTA Sales Of $500 Million [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfZILRETTASalesOf500MillionMember_documentation_en-US" xlink:label="lab_pcrx_AchievementOfZILRETTASalesOf500MillionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of ZILRETTA Sales Of $500 Million</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfZILRETTASalesOf500MillionMember" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfZILRETTASalesOf500MillionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfZILRETTASalesOf500MillionMember" xlink:to="lab_pcrx_AchievementOfZILRETTASalesOf500MillionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ZILRETTAMember_afa57cd0-caac-4a7f-b793-797ce9fd8092_terseLabel_en-US" xlink:label="lab_pcrx_ZILRETTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZILRETTA</link:label>
    <link:label id="lab_pcrx_ZILRETTAMember_label_en-US" xlink:label="lab_pcrx_ZILRETTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZILRETTA [Member]</link:label>
    <link:label id="lab_pcrx_ZILRETTAMember_documentation_en-US" xlink:label="lab_pcrx_ZILRETTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZILRETTA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ZILRETTAMember" xlink:href="pcrx-20211231.xsd#pcrx_ZILRETTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ZILRETTAMember" xlink:to="lab_pcrx_ZILRETTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_8fe591af-452f-4386-849b-6e9f3b270183_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_236e6165-c688-43bc-a6a6-f74325857f00_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentVariableRate_c270ca7f-4101-4873-ba3a-99e5fa072dfb_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentVariableRate_label_en-US" xlink:label="lab_pcrx_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentVariableRate_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentVariableRate" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentVariableRate" xlink:to="lab_pcrx_DebtInstrumentVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_124dd2e6-2e0f-4283-8e50-214fd295d325_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_IncomeTaxProvisionTable_7cbfebbe-2916-450a-a80a-a85ece4b4eed_terseLabel_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Provision [Table]</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvisionTable_label_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Provision [Table]</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvisionTable_documentation_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Provision [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncomeTaxProvisionTable" xlink:href="pcrx-20211231.xsd#pcrx_IncomeTaxProvisionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncomeTaxProvisionTable" xlink:to="lab_pcrx_IncomeTaxProvisionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b90665b5-2e54-482b-a8fa-a5ea2a5fc5bf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_47be6d7a-7b86-441b-b59d-2d28c7298e33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_daef96bc-6d42-4f4b-afe7-92f30fddefe2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c1199ccb-11c6-44d5-b4d6-7514c7707f2c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_3ce1056a-c258-4c5a-9258-0311ff19807f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns Allowances</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_16a8ff83-1d4b-486b-a9e5-f2e373f894d0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_b1c51049-594f-4eff-a04d-aa60c80ad89c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_label_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Investment Income Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInvestmentIncomeReceivable" xlink:to="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7c2742c5-7b2d-4397-8b9f-28c37b7c64b3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Useful Lives by Asset Category</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_80a74c81-8fbe-47ab-b980-417e475447f7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9991cf31-ef63-4e9f-905e-0efe78f25241_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_f991e4f6-511a-4969-b486-352974dac957_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period of equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_873b912a-765d-4422-9f33-e3b295931401_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6aaf4a4b-7a94-408d-ab51-a92629ad0a12_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_1e2e76c8-9864-4d4e-8138-d1194fb589ba_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix_2e177672-8694-4f35-a67e-0c9763af8e3b_terseLabel_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional NOLs, thereafter</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix_label_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year, After Year Six</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix_documentation_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year, After Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix" xlink:to="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e33ef4cb-fa92-4487-8c6c-e1f5114a552b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_68ef00cd-2398-4ab1-8657-c6d23a6d13a0_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentMarketPrice_98f78c55-fba1-4ce3-af40-d5f1ade515ba_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentMarketPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price per $1000 of principal amount of notes</link:label>
    <link:label id="lab_pcrx_DebtInstrumentMarketPrice_label_en-US" xlink:label="lab_pcrx_DebtInstrumentMarketPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Market Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentMarketPrice_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentMarketPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Market Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentMarketPrice" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentMarketPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentMarketPrice" xlink:to="lab_pcrx_DebtInstrumentMarketPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate_511fe1a2-b989-4668-8f04-c972ec3f18ba_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread two on variable rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate_label_en-US" xlink:label="lab_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread Two On Variable Rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread Two On Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate" xlink:to="lab_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_3f853b1f-f16e-4451-a3f3-25f620bc6ad6_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan (ESPP), maximum shares available for sale (in shares)</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP), Shares in ESPP</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP), Shares in ESPP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanESPPSharesinESPP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" xlink:to="lab_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsMeasurementInput_a9d0ea73-d836-40ad-854b-4b37f0ca85af_terseLabel_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate, measurement input</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsMeasurementInput_label_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Measurement Input</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsMeasurementInput_documentation_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsMeasurementInput" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FiniteLivedIntangibleAssetsMeasurementInput" xlink:to="lab_pcrx_FiniteLivedIntangibleAssetsMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_38179445-98bf-4cc1-9930-e855f1bf208e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsAxis_fea179c7-8469-425d-a83f-5b345eca41d9_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion and Redemption Terms [Axis]</link:label>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsAxis_label_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion and Redemption Terms [Axis]</link:label>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsAxis_documentation_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information regarding the conversion and redemption terms of the debt instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsAxis" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionAndRedemptionTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsAxis" xlink:to="lab_pcrx_DebtConversionAndRedemptionTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_3fa1da8e-41c2-4f23-9d02-12ad15f454f5_terseLabel_en-US" xlink:label="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement period - convertible debt conversion request</link:label>
    <link:label id="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_label_en-US" xlink:label="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Period - Convertible Debt Conversion Request</link:label>
    <link:label id="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest_documentation_en-US" xlink:label="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of trading days in a settlement period for convertible debt conversion requests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:href="pcrx-20211231.xsd#pcrx_SettlementPeriodConvertibleDebtConversionRequest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:to="lab_pcrx_SettlementPeriodConvertibleDebtConversionRequest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_5bd8592d-efe0-42cb-8565-24bcd2b0ef70_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_718829d8-5ebb-4997-81dc-5ab6bb4a0322_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_01bb6113-589e-4365-bc32-8c169273ba3a_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1df5e1b6-1992-4d2f-99a4-09e49bf8cbe4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4578fac9-257b-4763-8cbb-45fc14409ef7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition_c45c53c2-caf8-438e-811f-4e7903415124_terseLabel_en-US" xlink:label="lab_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential remaining milestone payments</link:label>
    <link:label id="lab_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition_label_en-US" xlink:label="lab_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Milestone Payments Yet To Be Paid in Connection, Acquisition</link:label>
    <link:label id="lab_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition_documentation_en-US" xlink:label="lab_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Milestone Payments Yet To Be Paid in Connection, Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" xlink:href="pcrx-20211231.xsd#pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" xlink:to="lab_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e3cb961-6cd1-45ad-af98-cd0433e29305_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_dfb3d5d3-6cc1-4044-be96-3e0297032d40_verboseLabel_en-US" xlink:label="lab_pcrx_CommercialPartnersAndAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMERCIAL PARTNERS AND OTHER AGREEMENTS</link:label>
    <link:label id="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_label_en-US" xlink:label="lab_pcrx_CommercialPartnersAndAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Partners and Agreements [Text Block]</link:label>
    <link:label id="lab_pcrx_CommercialPartnersAndAgreementsTextBlock_documentation_en-US" xlink:label="lab_pcrx_CommercialPartnersAndAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the entire disclosure of commercial agreement and arrangement with third parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CommercialPartnersAndAgreementsTextBlock" xlink:href="pcrx-20211231.xsd#pcrx_CommercialPartnersAndAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CommercialPartnersAndAgreementsTextBlock" xlink:to="lab_pcrx_CommercialPartnersAndAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter_9102ee73-70d0-442c-8bd7-e74a78c5404b_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty, year 4 and thereafter</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter_label_en-US" xlink:label="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Percent, Year 4 And Thereafter</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Percent, Year 4 And Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter" xlink:to="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ce6a53ae-090d-4c3d-9a9c-455b6fd7d481_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_72d88469-c1f2-4fa8-b522-0424c7f3528e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value (Per Share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5081409c-a9ed-4b69-97d6-2a53753e202a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_77ed5973-0d7d-416b-9cb2-b219b79a622e_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock_56a1a1af-615a-4d1a-894b-eab36530d085_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Integration, Restructuring and Other Related Costs [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_e02fc0f0-8751-4a46-92b2-faa915ea4208_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization&#160;of&#160;debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_beced92e-5e8d-4a98-8eda-d2ba75581219_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_d913c344-2d5d-4df9-8115-9302b746ba95_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_3c7c37f2-68e2-4f50-8708-674337e4745b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rates</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4836324d-8431-490e-aac3-93c38f1c1ea9_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Percentage of Revenue Comprised of the Three Largest Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_94945e6f-f512-4abf-8637-e9bf6a397f28_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt_b7436cf9-66bc-4658-bc3e-4049e697e547_terseLabel_en-US" xlink:label="lab_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs attributable to equity component of convertible debt</link:label>
    <link:label id="lab_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Attributable to the Equity Component of Convertible Debt</link:label>
    <link:label id="lab_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt_documentation_en-US" xlink:label="lab_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Attributable to the Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt" xlink:href="pcrx-20211231.xsd#pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt" xlink:to="lab_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_7b5f6756-2e0f-4fda-8b09-b3e17dac739f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_70c35def-9ba1-4f05-a7a0-baa734cf07a7_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5e9b98d6-bd51-4a23-a504-09e0b5b4386b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f81dfd0f-4fe5-405d-98e8-39ec5cb277f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b7cdf873-3681-4a33-91f6-bc398120354d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7a18eeb3-d08f-4f0b-9ff9-1322eae71039_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68169efc-75bd-4f9f-89f8-786f731c75cb_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e20bb7b2-8292-4080-bc08-9c466ebd6590_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_13f8bbba-8373-44e8-a904-fc255db0c5a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c14e016e-5159-46e9-a02f-c250f782bb9b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_5a654918-1446-4b90-91ca-ad889cbe6368_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_304c2081-55fd-4a35-b4cd-e64632f9d858_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Company's Stock Option Activity and Related Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_13bb1ee0-82e0-4646-88d0-55d58e3d41c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_3fbf2441-47fe-4502-85ff-f7cf2373113b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_a2e210e2-2504-4877-aca3-51caa571fc20_totalLabel_en-US" xlink:label="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income (loss) before income taxes</link:label>
    <link:label id="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_label_en-US" xlink:label="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Total</link:label>
    <link:label id="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_documentation_en-US" xlink:label="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The earnings or loss from continuing operations before income taxes for the entity as a whole, including domestic and foreign operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:href="pcrx-20211231.xsd#pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:to="lab_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d7f17236-53d2-4d16-a38f-6304f8e81949_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_8544b78f-39e7-4ceb-8095-f669bd711e9b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DepoCyteMember_984942d1-a43e-4b08-846c-3b39d332789a_terseLabel_en-US" xlink:label="lab_pcrx_DepoCyteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DepoCyte</link:label>
    <link:label id="lab_pcrx_DepoCyteMember_label_en-US" xlink:label="lab_pcrx_DepoCyteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DepoCyte [Member]</link:label>
    <link:label id="lab_pcrx_DepoCyteMember_documentation_en-US" xlink:label="lab_pcrx_DepoCyteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DepoCyte [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DepoCyteMember" xlink:href="pcrx-20211231.xsd#pcrx_DepoCyteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DepoCyteMember" xlink:to="lab_pcrx_DepoCyteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_8bc916b5-df8a-4cb3-9222-7f7d0ace8f96_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c51f7a28-3e97-485d-82cc-278e5f2dbff0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d01c984b-f904-44aa-9bf1-a72b298a85d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CustomersOutsideUSMember_6cc5cd83-e2df-414a-a8b0-e1370c130f0d_terseLabel_en-US" xlink:label="lab_pcrx_CustomersOutsideUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers outside U.S.</link:label>
    <link:label id="lab_pcrx_CustomersOutsideUSMember_label_en-US" xlink:label="lab_pcrx_CustomersOutsideUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers Outside US [Member]</link:label>
    <link:label id="lab_pcrx_CustomersOutsideUSMember_documentation_en-US" xlink:label="lab_pcrx_CustomersOutsideUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to customers outside U.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CustomersOutsideUSMember" xlink:href="pcrx-20211231.xsd#pcrx_CustomersOutsideUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CustomersOutsideUSMember" xlink:to="lab_pcrx_CustomersOutsideUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8b6994dd-7a08-47c3-897b-d2ab5bda43e5_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0850430d-aa66-40fb-b92b-3a3d6a0bf999_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_974fba51-ccaf-419e-9700-9c5d81573156_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a653e996-b970-4dc5-acdd-fea60d418680_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_53387111-3b1a-4357-a7ec-314946c40035_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4eff9f0f-26fe-4528-85f7-b750d2352031_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2978eb59-0ec9-4143-bb69-76357df86957_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_88223baf-6565-4728-badb-9c55826d3871_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember_6428e824-ed1f-49f2-80bc-eb70983a599a_terseLabel_en-US" xlink:label="lab_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs, In-The-Money Stock Options, and Common Stock</link:label>
    <link:label id="lab_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember_label_en-US" xlink:label="lab_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Money Stock Options, And Common Stock [Member]</link:label>
    <link:label id="lab_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember_documentation_en-US" xlink:label="lab_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Money Stock Options, And Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember" xlink:href="pcrx-20211231.xsd#pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember" xlink:to="lab_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccruedExpensesTable_adb46c03-85db-4724-8701-26e3949d1af5_terseLabel_en-US" xlink:label="lab_pcrx_AccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Table]</link:label>
    <link:label id="lab_pcrx_AccruedExpensesTable_label_en-US" xlink:label="lab_pcrx_AccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Table]</link:label>
    <link:label id="lab_pcrx_AccruedExpensesTable_documentation_en-US" xlink:label="lab_pcrx_AccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesTable" xlink:href="pcrx-20211231.xsd#pcrx_AccruedExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedExpensesTable" xlink:to="lab_pcrx_AccruedExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FirstPriceOptionMember_1260ff58-9cd5-40db-a311-fcbc0c88c5cd_terseLabel_en-US" xlink:label="lab_pcrx_FirstPriceOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Price Option</link:label>
    <link:label id="lab_pcrx_FirstPriceOptionMember_label_en-US" xlink:label="lab_pcrx_FirstPriceOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Price Option [Member]</link:label>
    <link:label id="lab_pcrx_FirstPriceOptionMember_documentation_en-US" xlink:label="lab_pcrx_FirstPriceOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Price Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FirstPriceOptionMember" xlink:href="pcrx-20211231.xsd#pcrx_FirstPriceOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FirstPriceOptionMember" xlink:to="lab_pcrx_FirstPriceOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_HongKongPharmaTainuoLtdMember_089c66a2-a2f4-4d62-bcb9-946b06b9f12a_terseLabel_en-US" xlink:label="lab_pcrx_HongKongPharmaTainuoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hong Kong Pharma Tainuo Ltd.</link:label>
    <link:label id="lab_pcrx_HongKongPharmaTainuoLtdMember_label_en-US" xlink:label="lab_pcrx_HongKongPharmaTainuoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hong Kong Pharma Tainuo Ltd. [Member]</link:label>
    <link:label id="lab_pcrx_HongKongPharmaTainuoLtdMember_documentation_en-US" xlink:label="lab_pcrx_HongKongPharmaTainuoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hong Kong Pharma Tainuo Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_HongKongPharmaTainuoLtdMember" xlink:href="pcrx-20211231.xsd#pcrx_HongKongPharmaTainuoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_HongKongPharmaTainuoLtdMember" xlink:to="lab_pcrx_HongKongPharmaTainuoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_31a4c017-46b4-49b9-8662-bc4f702575ff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3192947e-d9bd-4bdb-b73d-58c4c4b0d6ae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c9a011bf-6254-49e7-9870-d571124a8667_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_595e6d5c-0731-4496-858f-29c36f887ad2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8315daed-1b33-436f-816c-35c15a684783_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_74ec2dec-c458-4fd1-b335-3a94aef9a60b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_d396621d-dc70-407a-94e9-cc8d5b26263f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:to="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4e540cc9-c6aa-4f0e-9de6-52b4ab95ab7c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3646fffb-b0b3-48d1-9cb9-825823a9a471_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cb8796ed-0505-4352-a70a-36b3a3b1404b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_a1a89367-535d-4a36-96fd-4856d96999b1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1f888b66-7bf9-4328-b370-5e0f67b42089_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Assumptions Used to Estimate the Fair Values of Each Option Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_57f28dd4-52a8-4494-8a03-ac7597e183c0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected recognition of non-vested RSUs, not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MajorCustomerOneMember_c7d044b5-2f46-4fdf-8156-f25abe781522_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customer one</link:label>
    <link:label id="lab_pcrx_MajorCustomerOneMember_label_en-US" xlink:label="lab_pcrx_MajorCustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer One [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerOneMember_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerOneMember" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerOneMember" xlink:to="lab_pcrx_MajorCustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9675519d-c348-47cd-b053-3247b75a58ba_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement[Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_07ebb654-a32e-45fc-910a-576902ac0387_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e3a9f6d5-1cbe-4e32-957b-b2d15667dad3_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_22ca669c-0b48-4975-b44f-0a9eb16e0a3f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_6423edd0-7975-4f78-982c-29474adf34ab_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_fc4a33a1-1fe3-4eaf-92b2-c40d6744c148_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FlexionTherapeuticsIncMember_cfd8ede5-e31f-4833-ad9f-d0c47bf78902_terseLabel_en-US" xlink:label="lab_pcrx_FlexionTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flexion</link:label>
    <link:label id="lab_pcrx_FlexionTherapeuticsIncMember_label_en-US" xlink:label="lab_pcrx_FlexionTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flexion Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_pcrx_FlexionTherapeuticsIncMember_documentation_en-US" xlink:label="lab_pcrx_FlexionTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flexion Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FlexionTherapeuticsIncMember" xlink:to="lab_pcrx_FlexionTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_035dce22-cc34-4cba-b9c2-61fc6b9f53d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Change in Carrying Value of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_b2bf5dc5-7894-4bab-84e9-fe8d0c0cc5e0_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_eb2b2232-81b6-4a45-b24d-3855cdd2086e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_f90ec4d1-beb9-494b-b700-d848cc5e31a0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_200b58ff-6dab-4a19-9578-931ba005f4f6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ComputerEquipmentAndSoftwareMember_95f8c583-7a15-47ec-b764-341cd322263e_terseLabel_en-US" xlink:label="lab_pcrx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_pcrx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_pcrx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_pcrx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_pcrx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember" xlink:href="pcrx-20211231.xsd#pcrx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_pcrx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b596866c-1feb-4b0f-a17c-6af0b515f9c7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_944e4723-6347-4e19-a97e-a72846691c03_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a19e21-3ed2-4c35-b9ee-662f8ffcf417_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7e94b729-45f2-4864-928e-ac3ddbdf4cb5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b2fb6dbc-d497-40da-bb8d-2d802c39244c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term vested and expected to vest at the end of the period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_5d024705-baa5-4241-8d88-01f7855f0b4d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e7c07395-76c8-482f-901d-bfc0a3ba8414_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_CodaBioTherapeuticsIncMember_0dc25e30-4e01-4912-81c6-a7078f9a56ad_terseLabel_en-US" xlink:label="lab_pcrx_CodaBioTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coda BioTherapeutics, Inc</link:label>
    <link:label id="lab_pcrx_CodaBioTherapeuticsIncMember_label_en-US" xlink:label="lab_pcrx_CodaBioTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coda BioTherapeutics, Inc [Member]</link:label>
    <link:label id="lab_pcrx_CodaBioTherapeuticsIncMember_documentation_en-US" xlink:label="lab_pcrx_CodaBioTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coda BioTherapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CodaBioTherapeuticsIncMember" xlink:href="pcrx-20211231.xsd#pcrx_CodaBioTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_CodaBioTherapeuticsIncMember" xlink:to="lab_pcrx_CodaBioTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c21c817a-1de6-475c-91f0-5ab7a5454cea_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Share Data</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_5b805c49-24f4-45a2-98ec-18b43471dc03_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_172dc2f4-d835-4aa9-b766-bf1e11dde1de_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a4dab41-c58a-40dc-b138-6b00523c5ae9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5e703eb0-a6f4-4648-ba4e-bda80a17bbe7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_659b8423-e214-482c-9236-b4f2faa4dd68_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bf1da92e-9464-45d4-a034-c5e94808aad9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MajorCustomerTwoMember_3498ebff-5e0a-4d4f-9a3a-d733e41fc391_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customer two</link:label>
    <link:label id="lab_pcrx_MajorCustomerTwoMember_label_en-US" xlink:label="lab_pcrx_MajorCustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Two [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerTwoMember_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerTwoMember" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerTwoMember" xlink:to="lab_pcrx_MajorCustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_93adb9e2-4f59-46d4-ab0d-f9b071439cf7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_61fb87ea-dd08-427f-b300-ccda1df29243_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c15a808e-7b5e-423f-aa22-2068704651e8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c12faf0e-24c4-43b5-ad25-3083d7918845_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_88cbcd6f-e6ed-46fc-87b2-6c643528e04b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_78acdd62-06c1-4e64-91dc-9420033d28a9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f076a7b3-a14e-442e-8608-b83a7570e811_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_bbae5019-add1-41a4-b6bf-e0a922757886_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContingentConsideration_9201fa20-5806-46c5-b866-c0a31c612c56_terseLabel_en-US" xlink:label="lab_pcrx_ContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum total payments for contingent consideration possible</link:label>
    <link:label id="lab_pcrx_ContingentConsideration_label_en-US" xlink:label="lab_pcrx_ContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_pcrx_ContingentConsideration_documentation_en-US" xlink:label="lab_pcrx_ContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum amount of Contingent Consideration related to the acquisition of a business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsideration" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentConsideration" xlink:to="lab_pcrx_ContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7423e744-f272-4e02-b04a-c78026a6d426_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_48d2e87f-2775-4508-aec9-2ce5184f65b4_terseLabel_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits</link:label>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:to="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_580f469f-4a5b-48df-a4ea-5d4ffe6327cb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit_2f80b783-d6cc-4ef3-bc49-77d5fb6753ae_terseLabel_en-US" xlink:label="lab_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of rate changes</link:label>
    <link:label id="lab_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit_label_en-US" xlink:label="lab_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of State Blended Tax Rate Changes Expense (Benefit)</link:label>
    <link:label id="lab_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit_documentation_en-US" xlink:label="lab_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed as the result of changes in state blended tax rate changes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit" xlink:href="pcrx-20211231.xsd#pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit" xlink:to="lab_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember_1624b3ed-ad3c-4ffb-a112-74660adb26bd_terseLabel_en-US" xlink:label="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of achieving regulatory milestones</link:label>
    <link:label id="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember_label_en-US" xlink:label="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Milestone Payment [Member]</link:label>
    <link:label id="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember_documentation_en-US" xlink:label="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Milestone Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:href="pcrx-20211231.xsd#pcrx_MeasurementInputExpectedMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:to="lab_pcrx_MeasurementInputExpectedMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e5e32c84-0615-4563-8ea9-307c9537502a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_59d58b16-a53e-4964-b521-e0c7e19dfa5b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_67e6db57-da89-415b-b065-e112a4639eaa_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_71ee5323-93a8-463c-8f07-e7847d06dd5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of equity investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_2ef0d9b0-3c24-4c8e-a72b-c8acf9e8d17a_terseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_label_en-US" xlink:label="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</link:label>
    <link:label id="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_documentation_en-US" xlink:label="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:to="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d5fdd80c-47c3-485f-ae9a-4a00bef967c4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EnergyDomain_b885e712-e398-4b48-8b07-eca77dcb92a7_terseLabel_en-US" xlink:label="lab_srt_EnergyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument Type [Domain]</link:label>
    <link:label id="lab_srt_EnergyDomain_label_en-US" xlink:label="lab_srt_EnergyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Energy [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EnergyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EnergyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EnergyDomain" xlink:to="lab_srt_EnergyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_97dad613-a99b-432b-9ed8-a7480294a140_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_d09b5f51-7126-4970-a114-dd42b1d5be1d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Flexion Therapeutics, Inc. (net of cash acquired)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_790b2aeb-600d-45d5-853b-13892c789b2b_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_ad7dd1f5-275b-4a4e-8665-f716325f26f7_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionDomain_82e42129-6a12-448a-aa20-32663567eee0_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_TransactionDomain_label_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_a209f91c-0443-45ba-99de-4dee6f55241d_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Justice settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9ebd393-539d-4cc1-b8a9-b316859e2566_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_0aa49006-0f66-4450-80c9-c3ef5ae52d07_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_c875f55c-e44b-4ed1-a10a-94158973129c_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of conversion premium on the 2022 Notes (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_e8e24cb9-d525-4b6c-9439-822ea545f1c4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_4a9d9b60-a5d7-4375-8c23-0cc33c09a25a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in Thousands)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_4c32c16a-8549-4f9d-8b39-da53fb0f878f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_5c6b6a84-d1fc-4efd-a32c-322b18bc10db_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8f00af0e-abbb-45a5-80b4-8352ae065a20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_8b79f672-21f3-4672-b09f-c0030b144174_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Term SOFR Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_cfc3ae6f-6a2a-4058-8044-d09d9e9b2585_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_5119984a-0e25-4177-8046-a07874bf5632_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_00eaa35c-ddb1-4a6c-ade0-e8642a61c2cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Consideration for Flexion Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_95cb8a46-88e6-420a-85b7-222a03e08883_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_07242302-e13d-4389-b653-11edc85a2565_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_f0744041-9065-463e-bcba-5bcfe8ca7283_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_70e3c33d-11ed-4eae-9e85-df8fc7662852_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative licensing and milestone revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_340f6918-511f-4f86-ba78-045bda4b96be_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6977e2a1-38e4-47ce-872d-7b013e34e4c4_terseLabel_en-US" xlink:label="lab_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP shares purchased and issued during period (in shares)</link:label>
    <link:label id="lab_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchased And Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label id="lab_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchased And Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="pcrx-20211231.xsd#pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_15d7903e-971d-4697-b482-e0ba67825dc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f6c2db89-be61-4852-8b12-35607aa9d747_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue from customers to total revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_61c24f5f-453a-4f8e-bb08-473997065f34_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1f7bd70f-9690-4484-8d5c-8e138c234db4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f81441a4-8e09-4dc4-bb2e-3931a06b27ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7c7b323c-f1c8-4a72-ab50-9609ab028c14_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_435b26fc-bc35-4c79-ad6b-b46afc7cfcd5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e9214ba4-9fea-4b11-b18f-9b2d91bf6215_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_IncomeTaxProvisionLineItems_e7f7f19b-486f-4a51-8ec6-b102eb61bacf_terseLabel_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Provision [Line Items]</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvisionLineItems_label_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Provision [Line Items]</link:label>
    <link:label id="lab_pcrx_IncomeTaxProvisionLineItems_documentation_en-US" xlink:label="lab_pcrx_IncomeTaxProvisionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Income Tax Provision [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncomeTaxProvisionLineItems" xlink:href="pcrx-20211231.xsd#pcrx_IncomeTaxProvisionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems" xlink:to="lab_pcrx_IncomeTaxProvisionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4_0988168b-c711-454f-a328-0908a0b4478f_terseLabel_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization through 2031</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4_label_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 4</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4_documentation_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4" xlink:to="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3_85196cd3-8f79-4c35-b1d4-a145d594ecc5_terseLabel_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization through 2030</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3_label_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 3</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3_documentation_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3" xlink:to="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2_851a2ca3-a162-4fb1-80f4-08099797e6eb_terseLabel_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization, through 2029</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2_label_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 2</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2_documentation_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2" xlink:to="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1_8258d1d2-2fc8-408a-971f-e8b75afd41db_terseLabel_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization, through 2028</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1_label_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 1</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1_documentation_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1" xlink:to="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_21ffa6b6-ecaf-4f3a-9529-1f677ad59eb5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1fa9419c-6e1b-4920-98e8-7d1314be5658_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_47444596-5537-497d-bf92-384e8d59cec4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_2d3b01d2-40d1-4ba7-9ce9-d86f956501e8_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e4753c2a-716b-4c8f-b3fa-679a0f207f53_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets recorded in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_a69e30f8-e328-4aca-b6bb-8756c35593a4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_c808182d-26d1-4c51-a911-81e89152cde6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ReserveForPromptPayDiscountMember_3039bccb-4eb5-4bf2-b336-d7d2442c9eef_terseLabel_en-US" xlink:label="lab_pcrx_ReserveForPromptPayDiscountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prompt Payment Discounts</link:label>
    <link:label id="lab_pcrx_ReserveForPromptPayDiscountMember_label_en-US" xlink:label="lab_pcrx_ReserveForPromptPayDiscountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Prompt Pay Discount [Member]</link:label>
    <link:label id="lab_pcrx_ReserveForPromptPayDiscountMember_documentation_en-US" xlink:label="lab_pcrx_ReserveForPromptPayDiscountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Prompt Pay Discount [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ReserveForPromptPayDiscountMember" xlink:href="pcrx-20211231.xsd#pcrx_ReserveForPromptPayDiscountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ReserveForPromptPayDiscountMember" xlink:to="lab_pcrx_ReserveForPromptPayDiscountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9feb79ba-7c63-4051-9fa6-d3d31c4f3484_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of the Company's Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f8a1db1-1bfc-45d3-84d7-ed425df31624_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt_50eb148a-f241-45d1-a1a9-bb492203984e_terseLabel_en-US" xlink:label="lab_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity component of the 2025 convertible senior notes</link:label>
    <link:label id="lab_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt_label_en-US" xlink:label="lab_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Option Component of Convertible Debt</link:label>
    <link:label id="lab_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt_documentation_en-US" xlink:label="lab_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Option Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt" xlink:href="pcrx-20211231.xsd#pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt" xlink:to="lab_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_40a96ee7-650d-4577-8e54-ae2ba0411c55_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContingentConsiderationCurrent_d4d60598-967b-4db5-a63e-ccbb4099ad9e_terseLabel_en-US" xlink:label="lab_pcrx_ContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationCurrent_label_en-US" xlink:label="lab_pcrx_ContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Current</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationCurrent_documentation_en-US" xlink:label="lab_pcrx_ContingentConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationCurrent" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentConsiderationCurrent" xlink:to="lab_pcrx_ContingentConsiderationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_8d14b611-8163-4369-94f1-a457f09bb11e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_NumberOfMajorCustomers_b5c5c949-2540-4f88-80e4-04f53684b7e1_terseLabel_en-US" xlink:label="lab_pcrx_NumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major customers</link:label>
    <link:label id="lab_pcrx_NumberOfMajorCustomers_label_en-US" xlink:label="lab_pcrx_NumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Major Customers</link:label>
    <link:label id="lab_pcrx_NumberOfMajorCustomers_documentation_en-US" xlink:label="lab_pcrx_NumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of major customers of the reporting entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfMajorCustomers" xlink:href="pcrx-20211231.xsd#pcrx_NumberOfMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NumberOfMajorCustomers" xlink:to="lab_pcrx_NumberOfMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_eb988d55-3cb1-4cb8-a3f5-c01c56819178_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_29ce9efe-e708-453f-bb56-6f779ed89cb4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_47ccc04a-8018-42e0-8d17-d2b9123d5df9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33be8c26-0897-49a7-92ea-eec640916cb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f6ae28cd-ea91-48bf-8510-cf46e1452884_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_87ccfec4-0bca-4a83-90ad-c842db9436a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinuation of DepoCyt(e)</link:label>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnContractTermination" xlink:to="lab_us-gaap_GainLossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_eb52a754-e947-4318-a4b5-62ee31b6672e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4ef561cf-1bf4-4bac-9928-9dc47efebc19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan, awards reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_da2b4b81-04c0-4489-ac61-fd12adbd6c71_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities, net of lease incentive</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_TELABioMember_3adcf3a1-d41a-4fbd-9985-18746dbe5ac1_terseLabel_en-US" xlink:label="lab_pcrx_TELABioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TELA Bio</link:label>
    <link:label id="lab_pcrx_TELABioMember_label_en-US" xlink:label="lab_pcrx_TELABioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TELA Bio [Member]</link:label>
    <link:label id="lab_pcrx_TELABioMember_documentation_en-US" xlink:label="lab_pcrx_TELABioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TELA Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TELABioMember" xlink:href="pcrx-20211231.xsd#pcrx_TELABioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TELABioMember" xlink:to="lab_pcrx_TELABioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_24ff5b7b-8940-4ea0-b337-4558b44d5f48_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_a00b8ca4-952a-4db9-9d1f-d1b73a81d3cc_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_97ce598b-0af6-49f5-a057-84f31f75b322_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c4a95895-2c20-4ee8-ac21-27cbf0fa56a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_38cf2cbf-4954-4e0d-b845-d96ef9fcc707_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_e7b8aa41-f5fd-45de-9b4f-d65bf7281ad0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_cc2f1b06-b5d1-4f42-8772-a4d40e463a54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on convertible senior notes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8ced5e2f-daf9-4429-bba2-ce0b8d4100d8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_7bed858e-5b5e-4932-a0ea-ddb1d9217c9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_42746563-4db6-4523-b272-035220d6bb09_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6837c6de-5b52-431c-be11-426d8e3cc4c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_b26c38de-65cd-462a-a089-6d35b40d81d5_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b18dce5a-eacb-4639-9e78-063b4638a09e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_5d80b760-8089-4195-aa57-8fa9b69b54be_terseLabel_en-US" xlink:label="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon first commercial sale in a major EU country (United Kingdom, France, Germany, Italy and Spain)</link:label>
    <link:label id="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_label_en-US" xlink:label="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon First Commercial Sale in Major EU Country [Member]</link:label>
    <link:label id="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_documentation_en-US" xlink:label="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the stage for milestone payments upon the first commercial sale in a major EU country (UK, France, Germany, Italy or Spain).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember" xlink:href="pcrx-20211231.xsd#pcrx_UponFirstCommercialSaleInMajorEUCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember" xlink:to="lab_pcrx_UponFirstCommercialSaleInMajorEUCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_95c1a7a6-e072-451c-95c3-78e1b123fdc2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage_5925c117-9cdc-40a5-9a8c-111580405229_terseLabel_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance award (percent)</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage_label_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Award, Percentage</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage_documentation_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Award, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" xlink:to="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_47ad0c40-22a4-4e80-9750-7ab0b22bacc0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6_7545881c-32d9-40c2-8390-5208502bec92_terseLabel_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization through 2033</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6_label_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 6</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6_documentation_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 6</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6" xlink:to="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccruedOperatingExpensesCurrent_e6312a9d-13c8-4d04-a51c-f4b937ed8579_terseLabel_en-US" xlink:label="lab_pcrx_AccruedOperatingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued operating expenses</link:label>
    <link:label id="lab_pcrx_AccruedOperatingExpensesCurrent_label_en-US" xlink:label="lab_pcrx_AccruedOperatingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Operating Expenses, Current</link:label>
    <link:label id="lab_pcrx_AccruedOperatingExpensesCurrent_documentation_en-US" xlink:label="lab_pcrx_AccruedOperatingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedOperatingExpensesCurrent" xlink:href="pcrx-20211231.xsd#pcrx_AccruedOperatingExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedOperatingExpensesCurrent" xlink:to="lab_pcrx_AccruedOperatingExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5_9247b61d-a782-49c7-b00e-965202b30c87_terseLabel_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization through 2032</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5_label_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 5</link:label>
    <link:label id="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5_documentation_en-US" xlink:label="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5" xlink:to="lab_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_84f045ad-d458-4830-a1e0-ab5c7b5be759_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_6502bda4-2826-4fcc-84bb-085595326df8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4381d27f-a4d5-4dc6-8972-7b46d4ab5290_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_9b12a63d-04c3-4205-9677-876001d9c447_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2fa9233c-c2bd-4ebd-827a-a8ab884265b8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7755df2e-3feb-463a-88d9-f07e459fa442_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_0c2f3ead-5df2-4798-8978-6dc9c6509f6c_terseLabel_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">When annual net sales collected reach $500.0 million</link:label>
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_label_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon Annual Net Sales Reaching Dollar 500.0 Million Threshold [Member]</link:label>
    <link:label id="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_documentation_en-US" xlink:label="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the stage for milestone payments when the annual net sales reach 500.0 million dollars.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" xlink:href="pcrx-20211231.xsd#pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" xlink:to="lab_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_77b9af2f-ce31-4b39-84cd-734176cc49cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_5f6dc5ba-03cf-4dab-90f3-92cccc449d8a_terseLabel_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign taxes</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_label_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign_documentation_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to foreign operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:to="lab_pcrx_EffectiveIncomeTaxRateReconciliationForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_a54573d7-783e-4a34-8202-8944d575b319_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_57dbae05-90f9-4aef-801f-63626404a8ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8cae0471-ad02-48db-82aa-9bdff85f5e78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1a509ca1-e84a-4559-aaaa-aa4e4fef5055_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_6cbf5df8-4ac0-4943-9e35-ff9a816fed14_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_f90b477d-3885-4a77-b0cc-42b4e825a6ea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LargestCustomerMember_52319d4f-8877-4460-9e69-7d7f9f5cb63f_terseLabel_en-US" xlink:label="lab_pcrx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest wholesaler</link:label>
    <link:label id="lab_pcrx_LargestCustomerMember_label_en-US" xlink:label="lab_pcrx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Customer [Member]</link:label>
    <link:label id="lab_pcrx_LargestCustomerMember_documentation_en-US" xlink:label="lab_pcrx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the largest customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LargestCustomerMember" xlink:href="pcrx-20211231.xsd#pcrx_LargestCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LargestCustomerMember" xlink:to="lab_pcrx_LargestCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_52292f21-2fcd-4a27-a3e5-689f67cad6e1_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion obligation, stock closing price minimum as a percentage of conversion price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum as Percentage of Conversion Price</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of the conversion price that the closing sales price of the entity's common stock must exceed for at least 20 days within 30 consecutive trading days, in order for the notes to be convertible.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" xlink:to="lab_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_94cf1baa-5171-42ab-8541-c736c88fda4e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contracts With Customers</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanfairvalue_c14481cf-8f7b-4174-9b85-1d8bca86a2e5_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanfairvalue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP fair value (as percent)</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanfairvalue_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanfairvalue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan fair value</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanfairvalue_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanfairvalue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of fair value of common stock eligible employees can purchase common shares at through an employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanfairvalue" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanfairvalue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanfairvalue" xlink:to="lab_pcrx_EmployeeStockPurchasePlanfairvalue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_83f1073e-75e7-48fc-a031-31ed3aa8dc1d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of MyoScience, Inc. (net of cash acquired)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_7a08107b-8505-4f07-ba62-44b101203979_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_77b2381d-39fb-4565-aa25-09ba95300a6a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SpineBioPharmaLLCMember_0d30bf07-c8fc-4ea2-a9e6-c215a40a5d19_terseLabel_en-US" xlink:label="lab_pcrx_SpineBioPharmaLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spine BioPharma, LLC</link:label>
    <link:label id="lab_pcrx_SpineBioPharmaLLCMember_label_en-US" xlink:label="lab_pcrx_SpineBioPharmaLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spine BioPharma, LLC [Member]</link:label>
    <link:label id="lab_pcrx_SpineBioPharmaLLCMember_documentation_en-US" xlink:label="lab_pcrx_SpineBioPharmaLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spine BioPharma, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SpineBioPharmaLLCMember" xlink:href="pcrx-20211231.xsd#pcrx_SpineBioPharmaLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SpineBioPharmaLLCMember" xlink:to="lab_pcrx_SpineBioPharmaLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_5f28dc86-7ea8-4986-be11-29953213b1ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other acquisition expenses</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear_b48b7640-d0dc-4375-89c8-03e7ceff21d2_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payments</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear_label_en-US" xlink:label="lab_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal, Number Of Payments In Next Fiscal Year</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal, Number Of Payments In Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear" xlink:to="lab_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses_f298df4b-3a4d-4dc0-8730-dfd0f33f38cf_terseLabel_en-US" xlink:label="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related charges, product discontinuation and other</link:label>
    <link:label id="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses_label_en-US" xlink:label="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-Related Charges, Product Discontinuation And Other Expenses</link:label>
    <link:label id="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses_documentation_en-US" xlink:label="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-Related Charges, Product Discontinuation And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" xlink:to="lab_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c3e98fd7-1f1a-426f-b280-49bbe28278fb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_acde6577-df34-433a-87e5-61b12a1787c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_0c947e1a-9b3e-4f78-93b2-6284aee863cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock_a9c2ce21-dba2-4799-8d0a-c39a20381245_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of last sale price of common stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock_label_en-US" xlink:label="lab_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percentage of Last Reported Sale Price Of Common Stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percentage of Last Reported Sale Price Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock" xlink:to="lab_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5e76ed12-7499-469f-897c-a7d60797282a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_4344cbbc-754a-4ee9-8218-02a60c01341f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2025Member_798e3533-d937-4270-9e47-03e80cbcdd09_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2025Member_10f28093-c5b6-4f83-a593-278a242c7d54_verboseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.750% Convertible Senior Notes Due 2025</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2025Member_label_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:to="lab_pcrx_ConvertibleSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_a9d8fad2-154a-4091-bf83-d90e3d1b1e34_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0f81f75b-2893-41b6-8737-fd916a316a55_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_f2a88191-ed27-4c8e-90b0-67ef3c1abb22_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_bfd5abad-5604-4ff9-9990-945ae0a810bf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill arising from acquisition</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_11e6b9ce-4834-40db-a5c9-4817bc78f4a9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_80f52ac6-a908-4f38-a263-840cda1218ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 21)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanESPP2014Member_b587cad0-4c3e-4c77-9152-2d5ad0fa76f9_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanESPP2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 ESPP</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanESPP2014Member_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanESPP2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP) 2014 [Member]</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanESPP2014Member_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanESPP2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan (ESPP) 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanESPP2014Member" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanESPP2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanESPP2014Member" xlink:to="lab_pcrx_EmployeeStockPurchasePlanESPP2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_4272f84d-2bb4-4d37-80c7-5e3654e916d9_terseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of term loan</link:label>
    <link:label id="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_fb81be0d-a1a1-4b51-9606-04eaf9e2e870_verboseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to settle Flexion debt</link:label>
    <link:label id="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_label_en-US" xlink:label="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred, Debt</link:label>
    <link:label id="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_documentation_en-US" xlink:label="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" xlink:to="lab_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_1c959990-49f0-4828-9c34-710e0570eee7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6c266a3d-b685-448c-b1f8-c7be27004a11_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c568631f-d0b3-446d-b33f-8793f40e70c8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccruedExpensesLineItems_27dc13a8-f02f-4a10-afba-0aa9bb2266e9_terseLabel_en-US" xlink:label="lab_pcrx_AccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_pcrx_AccruedExpensesLineItems_label_en-US" xlink:label="lab_pcrx_AccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_pcrx_AccruedExpensesLineItems_documentation_en-US" xlink:label="lab_pcrx_AccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesLineItems" xlink:href="pcrx-20211231.xsd#pcrx_AccruedExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccruedExpensesLineItems" xlink:to="lab_pcrx_AccruedExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_087a6ce1-40ee-49cd-81bc-d198f1621d77_terseLabel_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_label_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Stock Based Compensation</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsStockBasedCompensation_documentation_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Stock Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxAssetsStockBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:to="lab_pcrx_DeferredTaxAssetsStockBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContingentConsiderationPolicyTextBlock_fee38053-768d-4d5b-a0e8-180ad131f489_terseLabel_en-US" xlink:label="lab_pcrx_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationPolicyTextBlock_label_en-US" xlink:label="lab_pcrx_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationPolicyTextBlock_documentation_en-US" xlink:label="lab_pcrx_ContingentConsiderationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationPolicyTextBlock" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentConsiderationPolicyTextBlock" xlink:to="lab_pcrx_ContingentConsiderationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_f3f2f6c9-15a7-4dd9-8f86-3856bf3c66f0_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_dcb15dce-da17-469a-9f66-2ffda22b1691_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance and financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_c7633879-75ff-42a0-bb31-c86e048297b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued in private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_b0382d86-e919-4941-b233-cd2fb4713173_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_29321ff2-b76f-4df8-9327-cc528c11526f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_2f1b8e88-2054-4315-95a5-34348480939f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtCurrent_b3c347d1-6d3f-4854-8e07-41322f1e45b0_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net</link:label>
    <link:label id="lab_us-gaap_SecuredDebtCurrent_label_en-US" xlink:label="lab_us-gaap_SecuredDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtCurrent" xlink:to="lab_us-gaap_SecuredDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6de0949b-0410-48a4-9bdb-a961a4892b15_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_e560a8d1-f466-474f-a7f7-81f2894da0f3_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_df16cc44-3a5e-4be3-80e6-187b93339dac_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_62652f25-3532-4fd0-82e4-1c41f5fae8d4_terseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total acquisition-related charges</link:label>
    <link:label id="lab_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_label_en-US" xlink:label="lab_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition And Integration Related Costs</link:label>
    <link:label id="lab_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_documentation_en-US" xlink:label="lab_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition And Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:to="lab_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SecondPriceOptionMember_0cfd0c65-1c24-44fd-b1e7-fa5d45956078_terseLabel_en-US" xlink:label="lab_pcrx_SecondPriceOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Price Option</link:label>
    <link:label id="lab_pcrx_SecondPriceOptionMember_label_en-US" xlink:label="lab_pcrx_SecondPriceOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Price Option [Member]</link:label>
    <link:label id="lab_pcrx_SecondPriceOptionMember_documentation_en-US" xlink:label="lab_pcrx_SecondPriceOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Price Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SecondPriceOptionMember" xlink:href="pcrx-20211231.xsd#pcrx_SecondPriceOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SecondPriceOptionMember" xlink:to="lab_pcrx_SecondPriceOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f711a627-b9d8-478f-8aa5-9670ca83c438_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConvertibleSeniorNotes2025Member_9faefa5c-5b2b-4a22-820a-746ca69b045e_terseLabel_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotes2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes 2025</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotes2025Member_label_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotes2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes 2025 [Member]</link:label>
    <link:label id="lab_pcrx_ConvertibleSeniorNotes2025Member_documentation_en-US" xlink:label="lab_pcrx_ConvertibleSeniorNotes2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotes2025Member" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotes2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConvertibleSeniorNotes2025Member" xlink:to="lab_pcrx_ConvertibleSeniorNotes2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member_50800975-b2cd-409c-b994-633661f68047_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding February 3, 2020</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member_label_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding February 3, 2020 [Member]</link:label>
    <link:label id="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member_documentation_en-US" xlink:label="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Terms Business Day Immediately Preceding February 3, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member" xlink:to="lab_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour_a3710aa4-4b67-424f-949a-355e3f1ec220_terseLabel_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional NOLs, year four</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour_label_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Four</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour_documentation_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour" xlink:to="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c47c44b7-37ab-4acd-ad02-eca5fe7edfd3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne_3fb9584b-c9c3-4060-b1a2-c6f19a97fa43_terseLabel_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional NOLs, year one</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne_label_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year One</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne_documentation_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne" xlink:to="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_627ac937-cfe3-4c06-b478-f08ca7e8562c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate_0d4993af-e506-43cd-bcf5-260394368796_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread one on variable rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate_label_en-US" xlink:label="lab_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread One On Variable Rate</link:label>
    <link:label id="lab_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread One On Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentBasisSpreadOneOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate" xlink:to="lab_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5f93edee-4984-4c3d-8c8a-e0b297aeee42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_1c11c8e5-a845-4ff0-b5ea-30b2349353b4_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customary events of default, percentage of principal and accrued and unpaid interest</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_label_en-US" xlink:label="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" xlink:to="lab_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximum_bdfdc3ef-23a3-4dd5-b371-bd9194f6e11e_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage ratio</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_pcrx_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AratanaTherapeuticsIncMember_f74a484a-b371-4a04-a597-930776de5d90_terseLabel_en-US" xlink:label="lab_pcrx_AratanaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aratana Therapeutics Inc</link:label>
    <link:label id="lab_pcrx_AratanaTherapeuticsIncMember_label_en-US" xlink:label="lab_pcrx_AratanaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aratana Therapeutics Inc [Member]</link:label>
    <link:label id="lab_pcrx_AratanaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_pcrx_AratanaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Aratana Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AratanaTherapeuticsIncMember" xlink:href="pcrx-20211231.xsd#pcrx_AratanaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AratanaTherapeuticsIncMember" xlink:to="lab_pcrx_AratanaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_f6d5f6a3-dd89-4c8c-be1d-8d6e979bc138_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9098e55d-36eb-4d1c-b2c4-df420591c4a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_685e045c-af40-40be-9383-705fbeef997b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_592d20b1-ac80-4bbf-8ad5-5ccf67fe93b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_04e883f2-2569-4ced-bdb4-3e708adacadb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_231bc5cb-b573-4182-aa11-4e3931a76524_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer discretionary contribution expense</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LongTermInvestmentsMember_dc6aca9c-f627-429c-b70a-83b258d4f236_terseLabel_en-US" xlink:label="lab_pcrx_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term:</link:label>
    <link:label id="lab_pcrx_LongTermInvestmentsMember_label_en-US" xlink:label="lab_pcrx_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments [Member]</link:label>
    <link:label id="lab_pcrx_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_pcrx_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LongTermInvestmentsMember" xlink:href="pcrx-20211231.xsd#pcrx_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LongTermInvestmentsMember" xlink:to="lab_pcrx_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_47deb99c-e8a4-4e05-8513-ff57c2b1a627_terseLabel_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares that can be purchased under option (in shares)</link:label>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_label_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Option to Purchase Shares of Common Stock Number of Shares</link:label>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_documentation_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares that can be purchased by the related party on exercise of option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" xlink:href="pcrx-20211231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" xlink:to="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_842592a9-dc27-4c53-a41c-05180e7fa54b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity and debt investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_f47ee34c-422b-43c7-a576-3b8bd472e4b4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cb3c01ad-1030-4ad9-8c7b-404b882528b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9f3f64a0-2f20-4182-b516-4a71c3e501dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_02b0afbd-1335-405a-a582-53fe55f4e724_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b608d9fb-fe65-4e67-ba71-4aff2a09a35b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1647da04-d3f7-4da1-8212-80dd573a820b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3d536ad-dc00-4f26-9581-604113475e66_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5d84ec37-447d-4cb5-962a-680642a81658_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LegalFeesMember_d2d0b4db-bcd4-4323-a0e1-007ef207ea79_terseLabel_en-US" xlink:label="lab_pcrx_LegalFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:label id="lab_pcrx_LegalFeesMember_label_en-US" xlink:label="lab_pcrx_LegalFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees [Member]</link:label>
    <link:label id="lab_pcrx_LegalFeesMember_documentation_en-US" xlink:label="lab_pcrx_LegalFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LegalFeesMember" xlink:href="pcrx-20211231.xsd#pcrx_LegalFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LegalFeesMember" xlink:to="lab_pcrx_LegalFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2a677683-ede7-4381-98c2-686e2c460127_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt_f878a4ec-30bf-4908-bdf5-797cb8440d71_terseLabel_en-US" xlink:label="lab_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period of transaction costs attributable to liability component of convertible debt</link:label>
    <link:label id="lab_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Period of Transaction Costs Attributable to Liability Component of Convertible Debt</link:label>
    <link:label id="lab_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt_documentation_en-US" xlink:label="lab_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Period of Transaction Costs Attributable to Liability Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" xlink:href="pcrx-20211231.xsd#pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" xlink:to="lab_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4bfff732-6201-4433-b7ac-33dce6789145_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d66b1cac-dc9d-42c5-8722-1753814584f1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_88714633-0c43-427c-8b14-1f8c00cd8a64_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire convertible note</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_134396e3-e8a4-4ff1-8aee-80cfae725e61_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_be66b4b4-82a2-4c0e-86fa-b57338fb64ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_fe9e42f2-1f4f-438d-ad4d-facf0a326ed6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes, net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate_5dd23dff-e1ad-46a0-ac33-06e45949da4b_terseLabel_en-US" xlink:label="lab_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected future cash flows discounted, rate</link:label>
    <link:label id="lab_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate_label_en-US" xlink:label="lab_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assumption, Date of Securitization or Asset-backed Financing Arrangement, Transferor's Continuing Involvement, Servicing Assets or Liabilities, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate" xlink:to="lab_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_64dce9b0-9a09-4eee-9ef9-c8b8a951a17b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d55e2145-f454-46c6-928d-6745e0738191_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_4d80b077-20b6-47c3-9281-f97c7d7965f7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ad412f09-afb4-4ffd-a9cf-1d66b0bd4881_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_LitigationInvestigationTerm_599a9ef7-f9c5-4eeb-9777-7383a15b9b4d_terseLabel_en-US" xlink:label="lab_pcrx_LitigationInvestigationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation investigation term</link:label>
    <link:label id="lab_pcrx_LitigationInvestigationTerm_label_en-US" xlink:label="lab_pcrx_LitigationInvestigationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Investigation, Term</link:label>
    <link:label id="lab_pcrx_LitigationInvestigationTerm_documentation_en-US" xlink:label="lab_pcrx_LitigationInvestigationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Investigation, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationInvestigationTerm" xlink:href="pcrx-20211231.xsd#pcrx_LitigationInvestigationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_LitigationInvestigationTerm" xlink:to="lab_pcrx_LitigationInvestigationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_ef9f3e8a-3a40-4ff6-a060-ca5d6c4e7305_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:to="lab_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_508d4c0d-9865-4bcb-b602-447acab10159_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2f9c77c9-3fc2-4711-86eb-9b66a2d60cdf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0852c0ca-845f-45f7-87f8-59971fe13189_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5f4d249f-9976-4099-ac28-a6cfc9e2055e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_e4164bb6-89de-4862-92bf-bb8bf15e6490_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_66f54ce5-d6bb-4e30-a8c4-afc477c8021f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0a878428-2558-4184-b66a-2f58d8b7392d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_577e8acd-0ac6-4d44-ba61-a46c6f3610d3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0b306e07-2275-4304-b49c-ce82f5957d15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made or offset against amounts due</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_931baaa0-72d2-4e98-9155-b1ac6087b31c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8118230c-4e26-476f-9e27-c2c55fcb1b6b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9528e6c8-c96f-4cbf-b273-b6b5b08b5bc4_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_927623b8-dd57-4033-89ff-6357abd8b2d1_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_14bcf8cd-defa-4dea-96a7-908169860b5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_bb322d63-26c3-4e8d-b2ea-50f192077d31_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent_9c2dbe35-a721-4780-a2b0-bad6e2b332ba_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt, carrying amount of liability component</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Liability Component</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Liability Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent" xlink:to="lab_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue_cecc49f8-f55b-44e4-a6f0-8ecdd10de1cc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue" xlink:to="lab_us-gaap_AssetBackedSecuritiesAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f78a2072-c105-4e90-aec9-5df0a2884610_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_06bdf3e5-551b-4e76-a930-eea0c6879386_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal retired</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c536413e-81c5-42fb-a84c-ae843615e16b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfFDAApprovalOfFX201Member_9869aefe-b367-4a22-9048-2384dc5ccb80_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfFDAApprovalOfFX201Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of FDA Approval of FX-201</link:label>
    <link:label id="lab_pcrx_AchievementOfFDAApprovalOfFX201Member_label_en-US" xlink:label="lab_pcrx_AchievementOfFDAApprovalOfFX201Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of FDA Approval Of FX-201 [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfFDAApprovalOfFX201Member_documentation_en-US" xlink:label="lab_pcrx_AchievementOfFDAApprovalOfFX201Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of FDA Approval Of FX-201</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfFDAApprovalOfFX201Member" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfFDAApprovalOfFX201Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfFDAApprovalOfFX201Member" xlink:to="lab_pcrx_AchievementOfFDAApprovalOfFX201Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1_dcb0793b-2f98-433c-8830-e721dd4c6739_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty, year 1</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1_label_en-US" xlink:label="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Percent, Year 1</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Percent, Year 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1" xlink:to="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2a011b0f-269d-479e-a166-60827944b45e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2_257de3e5-39bb-43f7-82e9-d433254ffea4_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty, year 2</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2_label_en-US" xlink:label="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Percent, Year 2</link:label>
    <link:label id="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Percent, Year 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2" xlink:to="lab_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_IncreaseDecreaseInRetainedEarnings_7a74be30-63aa-41a8-8ac1-e916bb845c1f_negatedTerseLabel_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInRetainedEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accumulated deficit</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInRetainedEarnings_label_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Retained Earnings</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInRetainedEarnings_documentation_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Retained Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncreaseDecreaseInRetainedEarnings" xlink:href="pcrx-20211231.xsd#pcrx_IncreaseDecreaseInRetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncreaseDecreaseInRetainedEarnings" xlink:to="lab_pcrx_IncreaseDecreaseInRetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_bab98f88-aa0f-4a50-ab63-73514f0b0867_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive_cdfbabcc-6e23-4f30-ae2b-97dae3ab3394_terseLabel_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional NOLs, year five</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive_label_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Five</link:label>
    <link:label id="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive_documentation_en-US" xlink:label="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Net Operating Losses In Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive" xlink:to="lab_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_af9caf56-d4fc-4e88-badd-d075f3443e07_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4e612c99-3fa2-43c7-89eb-7abae7ce83a4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligation_52156e01-5606-4461-88f7-2f5b681aea54_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset retirement obligation</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligation_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligation" xlink:to="lab_us-gaap_AssetRetirementObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7eb0c9d5-4cf6-47d0-a83d-9150c5d09484_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ccb2728-0637-40bd-bc0b-9ae254f07147_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_53ab9f4f-0dca-4b75-aaf6-ad3f9da9bab7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4e23c13e-3ae5-4457-ae52-ef9e135f4094_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7e8a37f0-4b75-4051-a611-eb929f92dfe0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP, shares purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9cdd2cb2-0737-42fb-b7bf-3941172afc54_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_d6088c76-5d6d-43e4-903b-4c674e0dd01b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on investment (net of stock dividend) and other non-operating income, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_01a9b1e2-5961-4386-8f48-c824f20742e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6da3aded-9671-43aa-b73b-62127082c9cb_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_afbf64b3-b53b-4cfa-978c-ec5b38452458_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold_1e6c37ff-5ee9-41fd-afba-c523f45cfc34_terseLabel_en-US" xlink:label="lab_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual product sales threshold</link:label>
    <link:label id="lab_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold_label_en-US" xlink:label="lab_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price, Annual Product Sales Threshold</link:label>
    <link:label id="lab_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold_documentation_en-US" xlink:label="lab_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price, Annual Product Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" xlink:href="pcrx-20211231.xsd#pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" xlink:to="lab_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalizedAdjustment_3bc628a8-5ff4-47be-a379-ea24cba6be69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalizedAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized interest (Note 7)</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalizedAdjustment_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalizedAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalizedAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalizedAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalizedAdjustment" xlink:to="lab_us-gaap_InterestCostsCapitalizedAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6bc5f98b-5489-43ed-8290-1b360f42dc71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_c7246702-87b6-4c8e-8f91-035928d5e2ac_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_34811bd3-b0dd-4153-a0ef-7976dc755549_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4dd79459-cbaa-4f62-a7f2-f4d8120b4f8b_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_68114831-fdf5-411d-987d-945f70f571c3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_237b401d-3d2b-47d4-8c44-49f0e1c39346_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e3291a48-3442-4b8b-9d96-f2c6d53a8a04_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_7344fc52-7702-4bbb-95a5-09268314ab20_terseLabel_en-US" xlink:label="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Shares Issued Under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Shares Issued Under Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" xlink:href="pcrx-20211231.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" xlink:to="lab_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_802ffd4a-fcb9-4ec2-8b9d-0d11817a7273_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b0226031-57c3-4129-99e9-e8dc39cc4dd5_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cbcfc8c2-3c51-4963-be05-2280e85844ee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ContingentConsiderationNoncurrent_0f8990fe-93c9-4f6a-b496-4774028dcc72_terseLabel_en-US" xlink:label="lab_pcrx_ContingentConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationNoncurrent_label_en-US" xlink:label="lab_pcrx_ContingentConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Noncurrent</link:label>
    <link:label id="lab_pcrx_ContingentConsiderationNoncurrent_documentation_en-US" xlink:label="lab_pcrx_ContingentConsiderationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationNoncurrent" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ContingentConsiderationNoncurrent" xlink:to="lab_pcrx_ContingentConsiderationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4396d358-3d30-4dea-88d0-36cb41995351_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9c499d60-5d69-4ff6-ba46-523f290ee882_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_562a1413-5066-4d7b-88cf-107710292787_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_d53780c5-9778-4541-8674-5a16f40ac4e1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_11945306-0a8e-49b0-a2a4-bd14ce5f9f9c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_35e7398b-e7e2-4b62-a9fc-fcca84572ccf_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_6ef51378-4812-4a97-b5e0-21455d4d842c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent_409c466a-24a7-4811-9649-8aa25f6380fc_terseLabel_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">338(g) tax election</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent_label_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, 338(g) Election, Percent</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent_documentation_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, 338(g) Election, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent" xlink:to="lab_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember_4e08715c-7d81-43b4-8e5f-3bdb9e1f7fab_terseLabel_en-US" xlink:label="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bupivacaine liposome injectable suspension</link:label>
    <link:label id="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember_label_en-US" xlink:label="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bupivacaine Liposome Injectable Suspension [Member]</link:label>
    <link:label id="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember_documentation_en-US" xlink:label="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bupivacaine Liposome Injectable Suspension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:href="pcrx-20211231.xsd#pcrx_BupivacaineLiposomeInjectableSuspensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:to="lab_pcrx_BupivacaineLiposomeInjectableSuspensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_23b33cd2-9420-4439-bff6-7863690d25a1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0c3047ed-5020-423e-8db4-28037d59310f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e7ef8d89-37b1-42a3-adae-1510eca7463a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_416afaae-8c29-4e7f-8ba8-3da8ecc3f4b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f281dd6d-f7aa-4e11-ae9d-d3455879e198_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_86209cb0-b708-49b0-b0d5-b6040098be6f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_IncreaseDecreaseInContingentConsideration_8031e38e-0267-4cbe-a688-ffb97609c86b_terseLabel_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in contingent consideration liabilities</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInContingentConsideration_label_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Contingent Consideration</link:label>
    <link:label id="lab_pcrx_IncreaseDecreaseInContingentConsideration_documentation_en-US" xlink:label="lab_pcrx_IncreaseDecreaseInContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncreaseDecreaseInContingentConsideration" xlink:href="pcrx-20211231.xsd#pcrx_IncreaseDecreaseInContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IncreaseDecreaseInContingentConsideration" xlink:to="lab_pcrx_IncreaseDecreaseInContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_317a9be9-0f2c-481d-b1c7-7a6b3205d23b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b67bb47b-bad2-4ff9-b145-c1385f051c8a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_0efd7093-d565-49c9-92d0-96e8770d77cd_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_43b8ad40-e06a-4ffc-bb0b-7212f94cc1ab_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EXPARELMember_2afba050-1f98-429e-8423-4aa9217beede_terseLabel_en-US" xlink:label="lab_pcrx_EXPARELMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EXPAREL</link:label>
    <link:label id="lab_pcrx_EXPARELMember_label_en-US" xlink:label="lab_pcrx_EXPARELMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EXPAREL [Member]</link:label>
    <link:label id="lab_pcrx_EXPARELMember_documentation_en-US" xlink:label="lab_pcrx_EXPARELMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EXPAREL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EXPARELMember" xlink:href="pcrx-20211231.xsd#pcrx_EXPARELMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EXPARELMember" xlink:to="lab_pcrx_EXPARELMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_cc8a2508-74f4-40e7-80fd-cf4580146e4f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32d00b39-fc6a-40e5-aa54-295b9ff9cb4c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MyoscienceAcquisitionMember_bb043068-2baa-41e3-9f17-de12de716d15_terseLabel_en-US" xlink:label="lab_pcrx_MyoscienceAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myoscience Acquisition</link:label>
    <link:label id="lab_pcrx_MyoscienceAcquisitionMember_label_en-US" xlink:label="lab_pcrx_MyoscienceAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myoscience Acquisition [Member]</link:label>
    <link:label id="lab_pcrx_MyoscienceAcquisitionMember_documentation_en-US" xlink:label="lab_pcrx_MyoscienceAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myoscience Acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MyoscienceAcquisitionMember" xlink:to="lab_pcrx_MyoscienceAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_8a0b2342-89f3-4029-9866-eecee78cb878_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan, awards issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_a2a4860a-79ab-47a8-af75-51c758148333_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f568db58-c271-4c30-bb82-9638894b0f4e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_47c05e36-a74a-4f46-8b8a-0e205753887a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6220744f-ae27-4cbc-bcf0-af7ddaeecf93_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_5a074d7d-dd51-49a6-afbe-117af7d643da_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on disposal and impairment of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_896c61e1-8b46-48e8-85af-5a5fa7882df6_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Justice settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4b9461f2-62cd-47b4-a826-a5b6b03161fc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fa27b2c2-f74d-48f7-8668-0335cd7d92aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (Per Share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_0177032e-9e92-418e-87e6-a636c613994d_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_GeneQuineMember_d94b37ce-d6b4-4e3f-a78c-33c088dfe665_terseLabel_en-US" xlink:label="lab_pcrx_GeneQuineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneQuine</link:label>
    <link:label id="lab_pcrx_GeneQuineMember_label_en-US" xlink:label="lab_pcrx_GeneQuineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneQuine [Member]</link:label>
    <link:label id="lab_pcrx_GeneQuineMember_documentation_en-US" xlink:label="lab_pcrx_GeneQuineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneQuine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GeneQuineMember" xlink:href="pcrx-20211231.xsd#pcrx_GeneQuineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_GeneQuineMember" xlink:to="lab_pcrx_GeneQuineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ee14ad9b-b603-44da-91a1-0e5969fdb991_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional amount payable to holders of the CVRs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b187de32-d829-44fe-a825-d79b9563eba9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableFairValueDisclosure_62a37ab8-5a47-4bc0-9a4d-f4342f3492fe_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes receivable</link:label>
    <link:label id="lab_us-gaap_NotesReceivableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesReceivableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableFairValueDisclosure" xlink:to="lab_us-gaap_NotesReceivableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec1f3777-d48b-47f0-b63c-c6ec22bfc18b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_34512e39-6cd4-4d4e-b493-2aa19549db0c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_237c7f45-d083-49c9-bdb1-1ad341d6c00e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_3c0f32c1-4633-4918-a410-8c7187876cd0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_334a3d82-43a0-4d34-9b41-5ba52909246b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_30b51f0a-6721-477e-be5b-f42ce3ce1c6f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_787f7ddc-20c3-4664-9180-f07f63599071_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_36c6275e-5037-4a37-adcc-83f779f073f2_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8ae092a9-0d2e-4a3b-ab9b-8893d0cc700e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Stock-based Compensation in Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_6168decf-63c7-464c-aae1-956caebdd2eb_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_635c438a-99c9-4e8f-a6c7-f08129bb20b7_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_640bb8c5-2fe0-4f43-a710-d59e55626724_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_f68566ac-81b8-4f8c-a07d-d22f6b108908_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9a4fa874-019c-4beb-adeb-9502c4fe9fdd_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_ec704fad-ba02-4f84-92ce-f31691c16694_verboseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member of board of directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_206311aa-dcfa-4141-91d2-b16422cf67cb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_6aea1fd1-f225-429a-9eb9-eda9eeeaaf30_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Major Customers</link:label>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:to="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_50866905-7fd5-451b-b252-0305d10d4916_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_4d17fb6a-21c1-4fcb-8e97-98b50fe25787_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs, of one-time benefits, estimate</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_58e0da33-7ec7-4a1e-892b-b13e7a0cdfa2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_f3e4ba74-e5ee-4f9c-ae04-9234a208bc0b_totalLabel_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of deferred tax liabilities</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_label_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross, Net of Deferred Tax Liabilities, Before Valuation Allowance</link:label>
    <link:label id="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_documentation_en-US" xlink:label="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Deferred Tax Liabilities, Before Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:to="lab_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_8ad5888c-4c9b-48da-91f0-92d68274b3cd_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP, shares available for purchase (in shares)</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Available For Purchase</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Available For Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" xlink:to="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0498493d-9463-4f77-b2d1-e219ce9fa464_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ThreeLargestCustomersMember_89deba99-220c-4b27-9ecf-98ce1b68f7cb_terseLabel_en-US" xlink:label="lab_pcrx_ThreeLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three largest customers</link:label>
    <link:label id="lab_pcrx_ThreeLargestCustomersMember_label_en-US" xlink:label="lab_pcrx_ThreeLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Customers [Member]</link:label>
    <link:label id="lab_pcrx_ThreeLargestCustomersMember_documentation_en-US" xlink:label="lab_pcrx_ThreeLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThreeLargestCustomersMember" xlink:href="pcrx-20211231.xsd#pcrx_ThreeLargestCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ThreeLargestCustomersMember" xlink:to="lab_pcrx_ThreeLargestCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_6e03b8cf-8c2d-4de0-9d2b-e6bed93e4bb8_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion obligation, number of consecutive trading days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Obligation Number of Consecutive Trading Days</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:to="lab_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ConsultingAgreementMember_842f2e40-1a62-406d-aa00-fe9b4e60e951_terseLabel_en-US" xlink:label="lab_pcrx_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting agreement</link:label>
    <link:label id="lab_pcrx_ConsultingAgreementMember_label_en-US" xlink:label="lab_pcrx_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:label id="lab_pcrx_ConsultingAgreementMember_documentation_en-US" xlink:label="lab_pcrx_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the consulting agreement entered into by the entity with a related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConsultingAgreementMember" xlink:href="pcrx-20211231.xsd#pcrx_ConsultingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ConsultingAgreementMember" xlink:to="lab_pcrx_ConsultingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_284fc526-d21c-4db3-93b7-fefa1fd410d0_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_d56cecbd-5984-4b88-99d2-f6f92c4f1265_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4eca7ce0-1dd2-4e74-a07b-517ca75c64bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_31a9155c-1fdd-4336-836e-5f1ad0d6739c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_2fc925f2-abdd-4523-b54f-98b327c6233f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of the Company's Debt and Financing Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_82d697eb-96af-4fe0-b9ff-5bf4db458511_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_59036010-619b-43cb-83a4-751525b71334_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_be3593a4-8ce1-4b05-a431-d574d5eaf3ae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member_78f9c682-ddc5-4c9b-ba7a-5828c10efa39_terseLabel_en-US" xlink:label="lab_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Redemption Terms on or after August 1, 2023</link:label>
    <link:label id="lab_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member_label_en-US" xlink:label="lab_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Redemption Terms on or after August 1, 2023 [Member]</link:label>
    <link:label id="lab_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member_documentation_en-US" xlink:label="lab_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Redemption Terms on or after August 1, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member" xlink:href="pcrx-20211231.xsd#pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member" xlink:to="lab_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_02b53cdd-0fec-44d6-85c6-d0d8ccc208f3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_8579db9b-e8c0-42a2-b36a-ce6caf38842c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3e888a4f-d8c2-427d-b71e-015d9ac6672f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1f7ef0e6-3a7a-40b7-88f5-14958a61c5ef_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9c0ea742-753f-4e21-b935-cb191e6fc0d0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (loss) per common share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_7b8778b9-2dbe-4437-8c38-25efbce40f64_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of diluted securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_f3ae7daf-40c5-4124-92d2-64e210ce9672_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_6444494f-9b76-49af-9ad2-e9ead34ea532_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_ceae81d3-3350-4122-b31a-b4c9e680b4a9_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cba1e19e-1d05-4181-8cbe-6db430aab872_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_cbc7a294-758b-4a32-99c4-dfe7ce590c89_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_826e91f9-3be1-4d22-8969-5e82f9588456_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9c2b3133-cb67-456d-a0ce-08b8f09ed3e8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AuditInformationAbstract_label_en-US" xlink:label="lab_pcrx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_pcrx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_pcrx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AuditInformationAbstract" xlink:href="pcrx-20211231.xsd#pcrx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AuditInformationAbstract" xlink:to="lab_pcrx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementofRegulatoryMilestoneMember_e7c717a5-eb1a-47f2-ab7d-edf04d10e0bc_terseLabel_en-US" xlink:label="lab_pcrx_AchievementofRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Regulatory Milestone</link:label>
    <link:label id="lab_pcrx_AchievementofRegulatoryMilestoneMember_label_en-US" xlink:label="lab_pcrx_AchievementofRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Regulatory Milestone [Member]</link:label>
    <link:label id="lab_pcrx_AchievementofRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_pcrx_AchievementofRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementofRegulatoryMilestoneMember" xlink:href="pcrx-20211231.xsd#pcrx_AchievementofRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementofRegulatoryMilestoneMember" xlink:to="lab_pcrx_AchievementofRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_b712cfb2-0270-425f-b9e5-ae6b11029020_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Transactions</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_928cad95-9f6b-41cf-93c3-4a8024721a49_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_797194f0-a660-4bd7-8ae9-4d72a96849f0_terseLabel_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of shares that can be purchased under option (in dollars per share)</link:label>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_label_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Option to Purchase Shares of Common Stock Exercise Price</link:label>
    <link:label id="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_documentation_en-US" xlink:label="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the exercise price of shares that can be purchased by the related party on exercise of option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" xlink:href="pcrx-20211231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" xlink:to="lab_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f1180062-e1a3-4622-8896-fa3d1e725af3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_c2b1a040-7c14-47ff-ac82-e30238b5dcb3_terseLabel_en-US" xlink:label="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="lab_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfMilestoneDomain_26262963-773e-4c81-9500-1c8059b15407_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Milestone [Domain]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneDomain_label_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Milestone [Domain]</link:label>
    <link:label id="lab_pcrx_AchievementOfMilestoneDomain_documentation_en-US" xlink:label="lab_pcrx_AchievementOfMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Different categories of achievement of milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfMilestoneDomain" xlink:to="lab_pcrx_AchievementOfMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_41e00c7c-ab9c-4fb9-b2b3-bced25983ded_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Income Taxes at the U.S. Federal Statutory Rate to the Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_880a9130-7458-425a-9ad9-8935dcb31ec8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_23744c0d-897a-45f4-877a-05da4745a397_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of fixed assets and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EnergyAxis_e8f42e61-a917-4094-a580-476b6478cd4b_terseLabel_en-US" xlink:label="lab_srt_EnergyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instrument [Axis]</link:label>
    <link:label id="lab_srt_EnergyAxis_label_en-US" xlink:label="lab_srt_EnergyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Energy [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EnergyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EnergyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EnergyAxis" xlink:to="lab_srt_EnergyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_b41049a2-48de-4692-ac26-fbf2bdb6f2f4_terseLabel_en-US" xlink:label="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt redemption price due to fundamental change as a percentage of principal</link:label>
    <link:label id="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Redemption Price Due to Fundamental Change as Percentage of Principal Amount</link:label>
    <link:label id="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the redemption price as a percentage of the principal amount at which the debt instrument may be required to be repurchased in the event of a fundamental change by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:href="pcrx-20211231.xsd#pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:to="lab_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FlexionAcquisitionMember_17951650-9b98-4832-891d-e38dcaa56981_terseLabel_en-US" xlink:label="lab_pcrx_FlexionAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flexion Acquisition</link:label>
    <link:label id="lab_pcrx_FlexionAcquisitionMember_label_en-US" xlink:label="lab_pcrx_FlexionAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flexion Acquisition [Member]</link:label>
    <link:label id="lab_pcrx_FlexionAcquisitionMember_documentation_en-US" xlink:label="lab_pcrx_FlexionAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flexion Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FlexionAcquisitionMember" xlink:to="lab_pcrx_FlexionAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones_b2ee16ff-ea8b-4935-813f-89ed24cced92_terseLabel_en-US" xlink:label="lab_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential additional investment upon achieving milestones</link:label>
    <link:label id="lab_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones_label_en-US" xlink:label="lab_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Additional Investment Upon Achieving Milestones</link:label>
    <link:label id="lab_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones_documentation_en-US" xlink:label="lab_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Additional Investment Upon Achieving Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones" xlink:href="pcrx-20211231.xsd#pcrx_PotentialAdditionalInvestmentUponAchievingMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones" xlink:to="lab_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_10ff62e9-082e-4842-b850-67834df986cf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_7c917310-4401-407d-85fe-f19b9dfadc70_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e2c214d8-dbc0-4107-96c1-e4570deaf732_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_04914e18-9bb5-4e48-8a9e-e5faccb75133_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_077660d6-bdc2-4eb1-b8d6-1ab2390fbd13_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_7639f897-9164-482b-8a27-7fb7272dc55b_terseLabel_en-US" xlink:label="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Information About the Plans</link:label>
    <link:label id="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_label_en-US" xlink:label="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Available for Issuance [Table Text Block]</link:label>
    <link:label id="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of shares available for issuance which includes information about awards reserved for issuance, awards issued and awards available for grant by plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" xlink:href="pcrx-20211231.xsd#pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" xlink:to="lab_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_NuanceBiotechCo.Ltd.Member_976b537a-8248-413d-aece-5ae7effdc005_terseLabel_en-US" xlink:label="lab_pcrx_NuanceBiotechCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance Biotech Co. Ltd.</link:label>
    <link:label id="lab_pcrx_NuanceBiotechCo.Ltd.Member_label_en-US" xlink:label="lab_pcrx_NuanceBiotechCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance Biotech Co. Ltd. [Member]</link:label>
    <link:label id="lab_pcrx_NuanceBiotechCo.Ltd.Member_documentation_en-US" xlink:label="lab_pcrx_NuanceBiotechCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance Biotech Co. Ltd. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NuanceBiotechCo.Ltd.Member" xlink:href="pcrx-20211231.xsd#pcrx_NuanceBiotechCo.Ltd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_NuanceBiotechCo.Ltd.Member" xlink:to="lab_pcrx_NuanceBiotechCo.Ltd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_48db1ff1-80f4-47a8-9015-c6e55f55bbb4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9313bb98-f81b-483c-8c55-9c78a3690957_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_ad51d9c8-7b73-42ac-8be2-a7a26f08f3cf_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_6f892a85-bc2d-4b26-af43-139c340bd184_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_574e0f19-d726-424a-9f2e-90381ec4a489_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:to="lab_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c1292c23-cd19-4d43-b31f-119df94c5b16_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current taxes:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_bf215a31-4380-4244-9818-2c0d8b1eb78d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction for prior year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_58104087-1692-4eee-adae-b645f5db05db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction for prior year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_ec82f3d5-3f75-4dc8-918a-6da24de8db7b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember_3b9fd565-2e2c-44f4-9ee5-ba25a4588b8f_terseLabel_en-US" xlink:label="lab_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs, Asset Write-downs, and Other Restructuring Charges</link:label>
    <link:label id="lab_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember_label_en-US" xlink:label="lab_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs, Asset Write-downs, And Other Restructuring Charges [Member]</link:label>
    <link:label id="lab_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember_documentation_en-US" xlink:label="lab_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs, Asset Write-downs, And Other Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember" xlink:href="pcrx-20211231.xsd#pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember" xlink:to="lab_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1ac20990-a892-491f-bfdd-810f6bb7ff66_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FIXED ASSETS</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_a84568db-a55a-4313-b187-2bed81bdf24e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_905e0184-1616-4200-af57-a3f952125a75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_e5e19b08-4164-4ea6-8ec3-1e527c137b96_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Development and Regulatory Milestones</link:label>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Development and Regulatory Milestones [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Development and Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0b267da7-631d-4a79-b394-55d024103fc7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_60fdf473-c812-4490-a68e-1aa1378b7a9c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_df8dc835-ea48-4352-b157-b373331dba9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_076b207e-b062-4943-96af-738786ce00ac_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT AND FINANCING OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e07296b2-0c60-4a94-a41d-892c696629cc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_fe88804d-391f-48f9-9f40-ab89ae3d8b43_terseLabel_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP, shares reserved for purchase (in shares)</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_label_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Authorized</link:label>
    <link:label id="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" xlink:to="lab_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AccountsReceivablePaymentTerms_94d278a3-0985-4866-94a4-9ecdfa951a24_terseLabel_en-US" xlink:label="lab_pcrx_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, payment terms</link:label>
    <link:label id="lab_pcrx_AccountsReceivablePaymentTerms_label_en-US" xlink:label="lab_pcrx_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:label id="lab_pcrx_AccountsReceivablePaymentTerms_documentation_en-US" xlink:label="lab_pcrx_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccountsReceivablePaymentTerms" xlink:href="pcrx-20211231.xsd#pcrx_AccountsReceivablePaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AccountsReceivablePaymentTerms" xlink:to="lab_pcrx_AccountsReceivablePaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_f52b5802-90ff-45ea-8e0f-27122c8d703c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3f611050-3301-4f69-ae5f-57e118a29b2b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_31e6b756-75ca-4e78-869f-43f399c01095_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b935aefc-8969-40ca-9e25-d71c7864194e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_61bcbbf5-6a8a-4c38-92fc-f1431fd42427_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets_1e84ae4e-a328-4763-874e-ff29292348fc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:to="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_c6075821-9f53-4367-a5d3-14164e58261f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_PaymentsForDebtConversionPremiums_299ed679-4a55-4606-a3ec-0adccea69d61_negatedLabel_en-US" xlink:label="lab_pcrx_PaymentsForDebtConversionPremiums" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion premium on 2019 convertible senior notes</link:label>
    <link:label id="lab_pcrx_PaymentsForDebtConversionPremiums_label_en-US" xlink:label="lab_pcrx_PaymentsForDebtConversionPremiums" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Debt Conversion Premiums</link:label>
    <link:label id="lab_pcrx_PaymentsForDebtConversionPremiums_documentation_en-US" xlink:label="lab_pcrx_PaymentsForDebtConversionPremiums" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Debt Conversion Premiums</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentsForDebtConversionPremiums" xlink:href="pcrx-20211231.xsd#pcrx_PaymentsForDebtConversionPremiums"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PaymentsForDebtConversionPremiums" xlink:to="lab_pcrx_PaymentsForDebtConversionPremiums" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_71549bbb-4add-423d-9ac9-8da2ef6383c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_IoveraMemberMember_1d0ccc88-4601-45ff-beda-493c44b6bbe0_terseLabel_en-US" xlink:label="lab_pcrx_IoveraMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">iovera&#176;</link:label>
    <link:label id="lab_pcrx_IoveraMemberMember_label_en-US" xlink:label="lab_pcrx_IoveraMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">iovera&#176; [Member] [Member]</link:label>
    <link:label id="lab_pcrx_IoveraMemberMember_documentation_en-US" xlink:label="lab_pcrx_IoveraMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">iovera&#176; [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMemberMember" xlink:href="pcrx-20211231.xsd#pcrx_IoveraMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_IoveraMemberMember" xlink:to="lab_pcrx_IoveraMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5db08702-d2de-4679-879b-fb87d3ab88d9_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_af6b715e-d502-49d5-8df9-230542c6051e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term exercisable at the end of the period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsDomain_2e9c5090-d7d5-4473-b73c-de0bd76fb933_terseLabel_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion and Redemption Terms [Domain]</link:label>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsDomain_label_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion and Redemption Terms [Domain]</link:label>
    <link:label id="lab_pcrx_DebtConversionAndRedemptionTermsDomain_documentation_en-US" xlink:label="lab_pcrx_DebtConversionAndRedemptionTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identification of the conversion and redemption terms of the debt instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsDomain" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionAndRedemptionTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain" xlink:to="lab_pcrx_DebtConversionAndRedemptionTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_d7e98992-1c42-4add-8d19-410014449944_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fea1815c-0bea-41bb-ae8e-e5fb95dca789_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AllowanceForVolumeRebatesandChargebacksMember_5d604c8c-cb7d-4ab6-a1d0-c284f2a0b939_terseLabel_en-US" xlink:label="lab_pcrx_AllowanceForVolumeRebatesandChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volume Rebates and Chargebacks</link:label>
    <link:label id="lab_pcrx_AllowanceForVolumeRebatesandChargebacksMember_label_en-US" xlink:label="lab_pcrx_AllowanceForVolumeRebatesandChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Volume Rebates and Chargebacks [Member]</link:label>
    <link:label id="lab_pcrx_AllowanceForVolumeRebatesandChargebacksMember_documentation_en-US" xlink:label="lab_pcrx_AllowanceForVolumeRebatesandChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Volume Rebates and Chargebacks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AllowanceForVolumeRebatesandChargebacksMember" xlink:href="pcrx-20211231.xsd#pcrx_AllowanceForVolumeRebatesandChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AllowanceForVolumeRebatesandChargebacksMember" xlink:to="lab_pcrx_AllowanceForVolumeRebatesandChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_ec2793ca-c3e6-46be-8c40-d342437c4e1b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_de54113d-c0fb-4785-a4c1-744edb70fce0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_4273b386-8136-4528-95c9-c4d35f78ea38_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_51e7b0a1-4471-4684-8c65-0f39f567a99f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ec0029e6-4f7e-4274-ab05-991cd81c91e4_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_608cae7b-526b-434d-ac6f-be1c69c971ac_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_SecondLargestCustomerMember_678db5a0-9f79-4535-83ee-b655f44cc754_terseLabel_en-US" xlink:label="lab_pcrx_SecondLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second largest wholesaler</link:label>
    <link:label id="lab_pcrx_SecondLargestCustomerMember_label_en-US" xlink:label="lab_pcrx_SecondLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Largest Customer [Member]</link:label>
    <link:label id="lab_pcrx_SecondLargestCustomerMember_documentation_en-US" xlink:label="lab_pcrx_SecondLargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the second largest customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SecondLargestCustomerMember" xlink:href="pcrx-20211231.xsd#pcrx_SecondLargestCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_SecondLargestCustomerMember" xlink:to="lab_pcrx_SecondLargestCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_aa9ee3ad-546c-497a-bb96-5f7c5daa83ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_896ff05a-2965-4203-9462-329fa5992128_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0cae18fc-1a98-4328-ade6-8705dfb59014_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fc871218-6919-4c61-ab60-351e53dc6c36_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_55c2140c-52b3-448e-ad89-eb6bddce8c05_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_cfaddbdb-1216-437f-92d8-0fb0a6c2e3b1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5832fa91-e9c6-4517-bba0-d058f4de3345_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_e1471a8f-1fa4-47e7-8140-04982f30025e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5a771f85-b2c9-4c71-9b42-44f9b02c8838_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c288b9ca-819a-4677-8408-fff3b8425290_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ForeignNetDeferredTaxAssetMember_a03cfbe9-7504-4f07-95eb-f16550e91ce4_terseLabel_en-US" xlink:label="lab_pcrx_ForeignNetDeferredTaxAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Net Deferred Tax Asset</link:label>
    <link:label id="lab_pcrx_ForeignNetDeferredTaxAssetMember_label_en-US" xlink:label="lab_pcrx_ForeignNetDeferredTaxAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Net Deferred Tax Asset [Member]</link:label>
    <link:label id="lab_pcrx_ForeignNetDeferredTaxAssetMember_documentation_en-US" xlink:label="lab_pcrx_ForeignNetDeferredTaxAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Net Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ForeignNetDeferredTaxAssetMember" xlink:href="pcrx-20211231.xsd#pcrx_ForeignNetDeferredTaxAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ForeignNetDeferredTaxAssetMember" xlink:to="lab_pcrx_ForeignNetDeferredTaxAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5b0b92ca-57a5-4ed2-8628-0d935beb778f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_50d40cc2-18c7-46b8-b8cc-ed9a4cd22591_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES ASSUMED</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_MajorCustomerThreeMember_aa09fe4c-dc59-4411-89f6-715866ede0df_terseLabel_en-US" xlink:label="lab_pcrx_MajorCustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major customer three</link:label>
    <link:label id="lab_pcrx_MajorCustomerThreeMember_label_en-US" xlink:label="lab_pcrx_MajorCustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customer Three [Member]</link:label>
    <link:label id="lab_pcrx_MajorCustomerThreeMember_documentation_en-US" xlink:label="lab_pcrx_MajorCustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerThreeMember" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_MajorCustomerThreeMember" xlink:to="lab_pcrx_MajorCustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b123a699-8c7b-4129-a3a1-d949735c66de_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_2945da8c-cf19-4926-a3b7-7274d07e757d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_48deb90d-aae0-4f6b-b580-ea58fbdc866e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Dilutive Effect of the Securities Excluded from the Calculation of Diluted Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_bec2c265-06ca-4c67-9389-fd7c24cdac29_terseLabel_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_label_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Options Outstanding Weighted A Average Remaining Contractual Term [Roll Forward]</link:label>
    <link:label id="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_documentation_en-US" xlink:label="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" xlink:to="lab_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_56f5935a-6c48-4f08-a3bf-706be0bc6ed1_terseLabel_en-US" xlink:label="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in CVR</link:label>
    <link:label id="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_label_en-US" xlink:label="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Per Share</link:label>
    <link:label id="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_documentation_en-US" xlink:label="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" xlink:href="pcrx-20211231.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" xlink:to="lab_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4ef3354b-5673-4946-b3e6-527a252d13f2_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_ec02ae50-e110-4588-87e4-bfc040ab9400_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_TermLoanBFacilityDue2026Member_428ce2b8-16d2-4665-aef5-15bbc0551a68_terseLabel_en-US" xlink:label="lab_pcrx_TermLoanBFacilityDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.000% Term Loan B Facility Maturing 2026</link:label>
    <link:label id="lab_pcrx_TermLoanBFacilityDue2026Member_label_en-US" xlink:label="lab_pcrx_TermLoanBFacilityDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due 2026 [Member]</link:label>
    <link:label id="lab_pcrx_TermLoanBFacilityDue2026Member_documentation_en-US" xlink:label="lab_pcrx_TermLoanBFacilityDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanBFacilityDue2026Member" xlink:href="pcrx-20211231.xsd#pcrx_TermLoanBFacilityDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_TermLoanBFacilityDue2026Member" xlink:to="lab_pcrx_TermLoanBFacilityDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_fe7e51ae-45d1-422f-8e6f-190e7ad0e400_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1e236a3b-0581-42ab-ac90-d1cb3abf694f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_9540b2ae-ec0e-4bee-8edb-324134beeb38_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fffa308a-94d6-4555-90a8-08592cbb9217_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities (net of acquisitions):</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_655684e7-8aa7-4254-a187-b51c856e353d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_94878815-fb29-4148-90bd-669ca34b50f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate on total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_692e7c15-e355-41ed-8c59-886d32570a07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in net debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_344fe2a3-245d-4b46-8119-5d03a27d5552_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_94c50380-1010-4252-9572-e84e44626d50_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_92eef5b1-acb5-4cbe-b997-33b661b30ec8_terseLabel_en-US" xlink:label="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Interest Expense Recognized Related to the Notes</link:label>
    <link:label id="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_label_en-US" xlink:label="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:label id="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock_documentation_en-US" xlink:label="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the amount of interest rate expenses related to convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:href="pcrx-20211231.xsd#pcrx_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:to="lab_pcrx_ScheduleOfInterestExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_8fd7aec3-c518-4a79-ad97-bc5976c3a0fc_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for settlement</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_1328a4dd-39cf-4d14-bb19-70e6d5b9b756_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_86bdd370-22b5-4fb4-894e-459a4887bbfd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_2d351557-e564-4edf-a83d-66faa334bff6_terseLabel_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt, premium on common stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_label_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion Obligation Premium on Common Stock</link:label>
    <link:label id="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_documentation_en-US" xlink:label="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:to="lab_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AllowanceForGovernmentRebatesMember_17dd68ff-87e1-4c0b-a384-119c4b19480d_terseLabel_en-US" xlink:label="lab_pcrx_AllowanceForGovernmentRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates</link:label>
    <link:label id="lab_pcrx_AllowanceForGovernmentRebatesMember_label_en-US" xlink:label="lab_pcrx_AllowanceForGovernmentRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Government Rebates [Member]</link:label>
    <link:label id="lab_pcrx_AllowanceForGovernmentRebatesMember_documentation_en-US" xlink:label="lab_pcrx_AllowanceForGovernmentRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Government Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AllowanceForGovernmentRebatesMember" xlink:href="pcrx-20211231.xsd#pcrx_AllowanceForGovernmentRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AllowanceForGovernmentRebatesMember" xlink:to="lab_pcrx_AllowanceForGovernmentRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_75d490b3-b5e8-4749-9512-890de59d53ac_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_PaymentOfEarlyTerminationFees_a3e8027e-6143-4026-bb50-a61cfed4577c_terseLabel_en-US" xlink:label="lab_pcrx_PaymentOfEarlyTerminationFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of early termination fees</link:label>
    <link:label id="lab_pcrx_PaymentOfEarlyTerminationFees_label_en-US" xlink:label="lab_pcrx_PaymentOfEarlyTerminationFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Early Termination Fees</link:label>
    <link:label id="lab_pcrx_PaymentOfEarlyTerminationFees_documentation_en-US" xlink:label="lab_pcrx_PaymentOfEarlyTerminationFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Early Termination Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentOfEarlyTerminationFees" xlink:href="pcrx-20211231.xsd#pcrx_PaymentOfEarlyTerminationFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_PaymentOfEarlyTerminationFees" xlink:to="lab_pcrx_PaymentOfEarlyTerminationFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0c413451-c308-4884-9636-e0920c727e8b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfSalesRelatedMilestonesMember_72531fe0-15a2-4843-90de-2e9da5d875da_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfSalesRelatedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Sales-Related Milestones</link:label>
    <link:label id="lab_pcrx_AchievementOfSalesRelatedMilestonesMember_label_en-US" xlink:label="lab_pcrx_AchievementOfSalesRelatedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Sales-Related Milestones [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfSalesRelatedMilestonesMember_documentation_en-US" xlink:label="lab_pcrx_AchievementOfSalesRelatedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Sales-Related Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfSalesRelatedMilestonesMember" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfSalesRelatedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfSalesRelatedMilestonesMember" xlink:to="lab_pcrx_AchievementOfSalesRelatedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_d123d576-acb4-41fa-aecf-2faa60490347_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent_23a55618-bba2-425d-bd49-080fa0ce35ac_terseLabel_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent_label_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Reserves, Percent</link:label>
    <link:label id="lab_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent_documentation_en-US" xlink:label="lab_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to tax reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent" xlink:to="lab_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_EurofarmaLabatoriesSAMember_266a6202-5623-40ea-9ef3-a827c850e828_terseLabel_en-US" xlink:label="lab_pcrx_EurofarmaLabatoriesSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurofarma Labatories S.A.</link:label>
    <link:label id="lab_pcrx_EurofarmaLabatoriesSAMember_label_en-US" xlink:label="lab_pcrx_EurofarmaLabatoriesSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurofarma Labatories S.A. [Member]</link:label>
    <link:label id="lab_pcrx_EurofarmaLabatoriesSAMember_documentation_en-US" xlink:label="lab_pcrx_EurofarmaLabatoriesSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurofarma Labatories S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EurofarmaLabatoriesSAMember" xlink:href="pcrx-20211231.xsd#pcrx_EurofarmaLabatoriesSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_EurofarmaLabatoriesSAMember" xlink:to="lab_pcrx_EurofarmaLabatoriesSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_8e20dc74-dd8c-4778-920b-2678ebf55a1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes_1b071202-ae1e-4405-bd6f-3ac008a53152_terseLabel_en-US" xlink:label="lab_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining payment required upon settlement of 2022 notes</link:label>
    <link:label id="lab_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes_label_en-US" xlink:label="lab_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Payment Required Upon Full Settlement of Notes</link:label>
    <link:label id="lab_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes_documentation_en-US" xlink:label="lab_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Payment Required Upon Full Settlement of Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes" xlink:href="pcrx-20211231.xsd#pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes" xlink:to="lab_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_7a0c29cb-6f34-4d61-a197-2f973940b049_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_87b66781-a76b-4117-8d31-96ca5233eb04_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_09e10c6d-9c64-4c0d-8ae2-912b6b65b2a1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt_5849c25e-da16-4956-8658-37d8ba2bacb0_terseLabel_en-US" xlink:label="lab_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax associated with equity component of convertible debt</link:label>
    <link:label id="lab_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Expense Associated to the Equity Component of Convertible Debt</link:label>
    <link:label id="lab_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt_documentation_en-US" xlink:label="lab_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Expense Associated to the Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" xlink:to="lab_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_87a101e6-1350-41ad-94d0-5b2650cd786b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_2c799346-1ac3-4177-82cd-51db27d4673b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_22e438e2-4d60-4464-9ab6-35f0dfdfd162_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technologies</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ab538ff8-80e8-4d25-8aa9-025cc0fe22ee_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_e5c45415-120e-44be-b023-5afc0b366b85_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_76ec9b01-8b64-4916-82d7-ad56fff60161_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_38ab92ac-4846-437e-bf60-ad1f662aa5e3_terseLabel_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Development and Commercial Milestones</link:label>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_label_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Development and Commercial Milestones [Member]</link:label>
    <link:label id="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_documentation_en-US" xlink:label="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the achievement of development and commercial events on the basis of which certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" xlink:to="lab_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_5928d295-8b11-4368-bd83-b54b744523af_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_d2d1658b-bd4a-44bd-a109-f4e5c0b658dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Used on ESPP Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>pcrx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:66f2c054-d932-41b4-84f1-797b86c41d80,g:418797a4-960d-471e-b290-1e4b5463b147-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacira.com/role/Cover" xlink:type="simple" xlink:href="pcrx-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1e50e15b-f840-4d48-ae89-0fee12be5e48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_DocumentType_1e50e15b-f840-4d48-ae89-0fee12be5e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_813239d9-c609-4be8-a428-d6c3dbe31bd7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_DocumentAnnualReport_813239d9-c609-4be8-a428-d6c3dbe31bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e66ab5be-55c9-49dd-8998-cbde8ba29c13" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_DocumentPeriodEndDate_e66ab5be-55c9-49dd-8998-cbde8ba29c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ae303773-89d0-4d0c-8954-7cd1dffd41a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_DocumentTransitionReport_ae303773-89d0-4d0c-8954-7cd1dffd41a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9a4a55a8-f9f2-4ba2-8de9-33675b8ccac0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityFileNumber_9a4a55a8-f9f2-4ba2-8de9-33675b8ccac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b2eda467-82d7-42d2-8e5a-98333155d195" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityRegistrantName_b2eda467-82d7-42d2-8e5a-98333155d195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ea729b4e-3109-47c5-a1ca-6f089f8e1d48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ea729b4e-3109-47c5-a1ca-6f089f8e1d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3dc35e25-db6f-45a5-9e18-1b3d587be95f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityTaxIdentificationNumber_3dc35e25-db6f-45a5-9e18-1b3d587be95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c169e59f-452b-4542-a645-c60340f66446" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityAddressAddressLine1_c169e59f-452b-4542-a645-c60340f66446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a9443df1-5f2f-4788-92b5-3c3b2f08cc40" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityAddressCityOrTown_a9443df1-5f2f-4788-92b5-3c3b2f08cc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_134f49fd-4cd6-4d7b-bf74-397936091cb7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityAddressStateOrProvince_134f49fd-4cd6-4d7b-bf74-397936091cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_de888356-b03f-492d-9a45-27190123c259" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityAddressPostalZipCode_de888356-b03f-492d-9a45-27190123c259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_05724a1d-7a42-4fab-921c-5ce461dd485d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_CityAreaCode_05724a1d-7a42-4fab-921c-5ce461dd485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1e3d514e-65fb-4d7f-a5e5-d18e07aaa68f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_LocalPhoneNumber_1e3d514e-65fb-4d7f-a5e5-d18e07aaa68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_491cb094-d6e4-4032-89e4-c011af3dfd85" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_Security12bTitle_491cb094-d6e4-4032-89e4-c011af3dfd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0a6ee923-a4d7-4d38-8fc5-cf757a8d32c3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_TradingSymbol_0a6ee923-a4d7-4d38-8fc5-cf757a8d32c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ecdadad8-118f-404b-9134-190dba5ce3a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_SecurityExchangeName_ecdadad8-118f-404b-9134-190dba5ce3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_4cc87e8a-8c42-45a5-88fc-00340f286e40" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_4cc87e8a-8c42-45a5-88fc-00340f286e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ce744260-401d-4195-8a41-331fceba4f4d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityVoluntaryFilers_ce744260-401d-4195-8a41-331fceba4f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_50d3efeb-ac5f-47f1-8ea0-79d942f02ae6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityCurrentReportingStatus_50d3efeb-ac5f-47f1-8ea0-79d942f02ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0bd794de-15fa-4924-8141-a79d6bbd0eae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityInteractiveDataCurrent_0bd794de-15fa-4924-8141-a79d6bbd0eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_26e3aefe-90fc-4b49-9c47-65d1fe4d4916" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityFilerCategory_26e3aefe-90fc-4b49-9c47-65d1fe4d4916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_82a5413c-7097-408c-8c0f-4d861fed87ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntitySmallBusiness_82a5413c-7097-408c-8c0f-4d861fed87ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_45a1bf43-d8c6-4d9c-80c4-ba021e9734d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityEmergingGrowthCompany_45a1bf43-d8c6-4d9c-80c4-ba021e9734d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_30fe3039-dcd4-4ad0-b59c-93ab7459475a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_30fe3039-dcd4-4ad0-b59c-93ab7459475a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_25a3e81d-b15d-4882-b82b-bc9bddc4fbbf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityShellCompany_25a3e81d-b15d-4882-b82b-bc9bddc4fbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_69cd0ecc-2a72-4aa4-802c-361283838cc4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityPublicFloat_69cd0ecc-2a72-4aa4-802c-361283838cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_57f5a6d3-051d-4924-8139-a6a463d9adcb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_57f5a6d3-051d-4924-8139-a6a463d9adcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3629f0bf-11dd-4357-8224-075c9e0217c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3629f0bf-11dd-4357-8224-075c9e0217c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_af69d8be-1880-4ef9-bd95-7d23ea37d8aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_EntityCentralIndexKey_af69d8be-1880-4ef9-bd95-7d23ea37d8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fa5611cb-8a57-4b5c-ad0b-e95f8d2362a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_AmendmentFlag_fa5611cb-8a57-4b5c-ad0b-e95f8d2362a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f6f4a841-90e1-4d0a-ad08-e4f8cefcef3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_CurrentFiscalYearEndDate_f6f4a841-90e1-4d0a-ad08-e4f8cefcef3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_08ea5ab7-6387-4323-9261-10e241b5385f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_DocumentFiscalYearFocus_08ea5ab7-6387-4323-9261-10e241b5385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b0a2dad9-b4ed-4cdf-9f6f-663abc5baeef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_01026a4f-5a2d-4924-ba36-fb2439d0f2c0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b0a2dad9-b4ed-4cdf-9f6f-663abc5baeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/AuditInformation" xlink:type="simple" xlink:href="pcrx-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AuditInformationAbstract_76dee90a-c003-4e3f-90c5-dac5d5026c40" xlink:href="pcrx-20211231.xsd#pcrx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_56228db3-3a4a-432f-a98c-bc81c8aa87e4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AuditInformationAbstract_76dee90a-c003-4e3f-90c5-dac5d5026c40" xlink:to="loc_dei_AuditorName_56228db3-3a4a-432f-a98c-bc81c8aa87e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_da910a42-4d9b-456a-a9dd-f0fbf77e9199" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AuditInformationAbstract_76dee90a-c003-4e3f-90c5-dac5d5026c40" xlink:to="loc_dei_AuditorLocation_da910a42-4d9b-456a-a9dd-f0fbf77e9199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_af9faedb-5484-49aa-bda1-488c8995dc8c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AuditInformationAbstract_76dee90a-c003-4e3f-90c5-dac5d5026c40" xlink:to="loc_dei_AuditorFirmId_af9faedb-5484-49aa-bda1-488c8995dc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5c69377d-7562-475b-a181-40e5368cc09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5c69377d-7562-475b-a181-40e5368cc09f" xlink:to="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_32e9cf90-767b-4083-a40b-2f95cd153951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_32e9cf90-767b-4083-a40b-2f95cd153951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_727448eb-b098-4777-af39-7113cb5be5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32e9cf90-767b-4083-a40b-2f95cd153951" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_727448eb-b098-4777-af39-7113cb5be5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_8e3c453f-d89a-4e9b-adaf-daf8ad09a6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32e9cf90-767b-4083-a40b-2f95cd153951" xlink:to="loc_us-gaap_ShortTermInvestments_8e3c453f-d89a-4e9b-adaf-daf8ad09a6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_373bf0f2-f38d-4972-b67c-6118108faa92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32e9cf90-767b-4083-a40b-2f95cd153951" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_373bf0f2-f38d-4972-b67c-6118108faa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0988b425-1c48-42d9-93f0-0133f725e1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32e9cf90-767b-4083-a40b-2f95cd153951" xlink:to="loc_us-gaap_InventoryNet_0988b425-1c48-42d9-93f0-0133f725e1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3df9c502-fe35-4906-a47c-60236e80dc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32e9cf90-767b-4083-a40b-2f95cd153951" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3df9c502-fe35-4906-a47c-60236e80dc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_634232f9-a6ae-4b23-a879-dcac8a1169ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32e9cf90-767b-4083-a40b-2f95cd153951" xlink:to="loc_us-gaap_AssetsCurrent_634232f9-a6ae-4b23-a879-dcac8a1169ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_bc651935-b5f7-44e2-8ba4-9dc5238926a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:to="loc_us-gaap_LongTermInvestments_bc651935-b5f7-44e2-8ba4-9dc5238926a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7c1c1e6c-1758-4b9d-a36a-da427c700aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7c1c1e6c-1758-4b9d-a36a-da427c700aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8a0606f1-87d9-4345-a9a0-f241839cbca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8a0606f1-87d9-4345-a9a0-f241839cbca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3826c3ff-9029-415f-9508-03532d104a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:to="loc_us-gaap_Goodwill_3826c3ff-9029-415f-9508-03532d104a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_19dd0ab4-c4fd-45ba-b3e8-7a6800416c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_19dd0ab4-c4fd-45ba-b3e8-7a6800416c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c3646a44-00bc-4c23-8e37-461ad53d834c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c3646a44-00bc-4c23-8e37-461ad53d834c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_72ef51e6-bee6-458d-832a-b77dc434e1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_72ef51e6-bee6-458d-832a-b77dc434e1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_989a2b5d-1412-4c6d-b679-0477175cf5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c84e9d1e-f5a7-41e8-a2e9-cb21630f0e3e" xlink:to="loc_us-gaap_Assets_989a2b5d-1412-4c6d-b679-0477175cf5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5c69377d-7562-475b-a181-40e5368cc09f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6c37930e-38a9-4cf1-9378-225fa98020c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:to="loc_us-gaap_AccountsPayableCurrent_6c37930e-38a9-4cf1-9378-225fa98020c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8f3fbb10-1ba2-44c3-b1c7-e7d23e6b0826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8f3fbb10-1ba2-44c3-b1c7-e7d23e6b0826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_942e6f2e-600e-4424-9479-c4b85270d3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_942e6f2e-600e-4424-9479-c4b85270d3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_7d731f9d-3de7-4146-8f67-5e06807e6fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_7d731f9d-3de7-4146-8f67-5e06807e6fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationCurrent_1958d888-4b41-4068-9afd-792a052755d2" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:to="loc_pcrx_ContingentConsiderationCurrent_1958d888-4b41-4068-9afd-792a052755d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtCurrent_7182fbfc-b7a2-4d5b-bf7f-91b539df50db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:to="loc_us-gaap_SecuredDebtCurrent_7182fbfc-b7a2-4d5b-bf7f-91b539df50db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_6fdbbdd1-fa61-4f8f-9e3d-1085685ca18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:to="loc_us-gaap_TaxesPayableCurrent_6fdbbdd1-fa61-4f8f-9e3d-1085685ca18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_edc3860e-76e5-4883-9b0d-fdd2c6cc55b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b29f4355-0e75-4c85-a74d-28761b843454" xlink:to="loc_us-gaap_LiabilitiesCurrent_edc3860e-76e5-4883-9b0d-fdd2c6cc55b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_45ef5ce2-d7cd-4f48-b534-b8e1b6f1a462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_45ef5ce2-d7cd-4f48-b534-b8e1b6f1a462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3e64841-5312-47cb-a4b6-c497c3a3299b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3e64841-5312-47cb-a4b6-c497c3a3299b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ef64ce36-569c-42c4-890f-1aa2406cabe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ef64ce36-569c-42c4-890f-1aa2406cabe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_be330a21-5f01-4574-88d0-1ea5a016693a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_SecuredLongTermDebt_be330a21-5f01-4574-88d0-1ea5a016693a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationNoncurrent_d34be3c9-1d2a-4d38-b042-594485ca232f" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_pcrx_ContingentConsiderationNoncurrent_d34be3c9-1d2a-4d38-b042-594485ca232f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f4e46cff-69ea-4d04-8e4c-d6f4d98c714d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f4e46cff-69ea-4d04-8e4c-d6f4d98c714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a2978c01-c571-44dc-90b9-144904e9f0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_Liabilities_a2978c01-c571-44dc-90b9-144904e9f0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fa3ac9e8-f657-4b14-b826-0816fa458dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fa3ac9e8-f657-4b14-b826-0816fa458dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0abddf7c-2243-4e65-8f02-5d278cc7f46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0abddf7c-2243-4e65-8f02-5d278cc7f46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a19ecd83-e5f8-4c0b-96b5-9d156d82794f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0abddf7c-2243-4e65-8f02-5d278cc7f46a" xlink:to="loc_us-gaap_PreferredStockValue_a19ecd83-e5f8-4c0b-96b5-9d156d82794f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e1259a45-198c-44f4-a95d-df300ec7ad1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0abddf7c-2243-4e65-8f02-5d278cc7f46a" xlink:to="loc_us-gaap_CommonStockValue_e1259a45-198c-44f4-a95d-df300ec7ad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4c1dc5b4-013e-4114-a9c1-c91d07c5d94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0abddf7c-2243-4e65-8f02-5d278cc7f46a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4c1dc5b4-013e-4114-a9c1-c91d07c5d94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9efebc32-3326-48a4-aba5-d4573630e35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0abddf7c-2243-4e65-8f02-5d278cc7f46a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9efebc32-3326-48a4-aba5-d4573630e35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7a5d8f6-6daf-4ca7-9b17-087ee8bc6b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0abddf7c-2243-4e65-8f02-5d278cc7f46a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f7a5d8f6-6daf-4ca7-9b17-087ee8bc6b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bb773ddb-a438-4976-8db4-3d986712292f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0abddf7c-2243-4e65-8f02-5d278cc7f46a" xlink:to="loc_us-gaap_StockholdersEquity_bb773ddb-a438-4976-8db4-3d986712292f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_46c8d572-f4f8-415c-a897-b88b2232392d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b20b6fb7-6957-44f5-ae57-50c3d3b9ac69" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_46c8d572-f4f8-415c-a897-b88b2232392d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_75b5a9a8-5586-4b5c-b104-990fc0b409d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a724a8b4-91a0-4094-8e6d-2171dbf61f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75b5a9a8-5586-4b5c-b104-990fc0b409d4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a724a8b4-91a0-4094-8e6d-2171dbf61f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b27d21c1-d23d-4dca-96cc-a2731aa9f2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75b5a9a8-5586-4b5c-b104-990fc0b409d4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b27d21c1-d23d-4dca-96cc-a2731aa9f2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_bc61d22a-1a5d-4b93-a252-f6d305779bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75b5a9a8-5586-4b5c-b104-990fc0b409d4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_bc61d22a-1a5d-4b93-a252-f6d305779bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a933c2b9-973a-4add-9001-5d2827d6945d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75b5a9a8-5586-4b5c-b104-990fc0b409d4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a933c2b9-973a-4add-9001-5d2827d6945d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_484ddc46-7b98-4776-9e67-bd29ac4beec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75b5a9a8-5586-4b5c-b104-990fc0b409d4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_484ddc46-7b98-4776-9e67-bd29ac4beec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_63786ee8-5a25-4a56-a1ca-824f3fcb9f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75b5a9a8-5586-4b5c-b104-990fc0b409d4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_63786ee8-5a25-4a56-a1ca-824f3fcb9f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a8f824da-69b3-4881-8c3d-db3514ac3e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75b5a9a8-5586-4b5c-b104-990fc0b409d4" xlink:to="loc_us-gaap_CommonStockSharesIssued_a8f824da-69b3-4881-8c3d-db3514ac3e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9aa89833-e01e-43f8-8b59-e2746fdbfa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75b5a9a8-5586-4b5c-b104-990fc0b409d4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9aa89833-e01e-43f8-8b59-e2746fdbfa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_20c2073f-558d-49c5-b727-8f712779c108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ead4f8ea-126b-4b45-91c7-1c988e66711d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_20c2073f-558d-49c5-b727-8f712779c108" xlink:to="loc_us-gaap_StatementTable_ead4f8ea-126b-4b45-91c7-1c988e66711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7158d05-c70d-4891-ae46-2f96d01e5beb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ead4f8ea-126b-4b45-91c7-1c988e66711d" xlink:to="loc_srt_ProductOrServiceAxis_d7158d05-c70d-4891-ae46-2f96d01e5beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9f9a2b4b-9b56-4945-9815-d7fa2e455b2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d7158d05-c70d-4891-ae46-2f96d01e5beb" xlink:to="loc_srt_ProductsAndServicesDomain_9f9a2b4b-9b56-4945-9815-d7fa2e455b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9008c6a4-2854-4568-b8b1-d7e7ba9ec917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9f9a2b4b-9b56-4945-9815-d7fa2e455b2e" xlink:to="loc_us-gaap_ProductMember_9008c6a4-2854-4568-b8b1-d7e7ba9ec917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_16890daf-0773-43e5-8ca8-8a3c13e9728a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9f9a2b4b-9b56-4945-9815-d7fa2e455b2e" xlink:to="loc_us-gaap_RoyaltyMember_16890daf-0773-43e5-8ca8-8a3c13e9728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ead4f8ea-126b-4b45-91c7-1c988e66711d" xlink:to="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b3837ff6-e020-4474-becd-c393eccef0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b3837ff6-e020-4474-becd-c393eccef0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3483ea00-9f4b-4788-a8ce-e6189da937b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3483ea00-9f4b-4788-a8ce-e6189da937b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_670b304e-f150-4964-8642-cefd3f32eae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6c461560-c7ca-48bc-83ba-f560921ce649" xlink:to="loc_us-gaap_Revenues_670b304e-f150-4964-8642-cefd3f32eae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_e05544c5-266f-440c-8a76-55d49450a322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_CostOfRevenue_e05544c5-266f-440c-8a76-55d49450a322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c3d4f330-4eeb-4c27-a91d-b2d89dccac05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c3d4f330-4eeb-4c27-a91d-b2d89dccac05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5cc596ce-9de5-4804-b384-c2689e6ceb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5cc596ce-9de5-4804-b384-c2689e6ceb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ec8b5be8-521f-4b3c-9105-b975da12b2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ec8b5be8-521f-4b3c-9105-b975da12b2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses_7d8e1d0e-9c69-4a30-973b-884c482a7a2e" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses_7d8e1d0e-9c69-4a30-973b-884c482a7a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_032970f7-16a1-4eaf-9579-f1765a8ad871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1b4e0ded-adca-4175-bdce-96be49f8dd60" xlink:to="loc_us-gaap_CostsAndExpenses_032970f7-16a1-4eaf-9579-f1765a8ad871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_58e1a98a-da7a-4c1b-b4e8-78165f2b5ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_OperatingIncomeLoss_58e1a98a-da7a-4c1b-b4e8-78165f2b5ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f5ae023d-4813-4626-a812-d764131ed82e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f5ae023d-4813-4626-a812-d764131ed82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_93bd879e-8299-4ba6-842d-a9c1769b15df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_InterestExpense_93bd879e-8299-4ba6-842d-a9c1769b15df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_40866da7-6eed-4f91-bc10-323e772e53e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_40866da7-6eed-4f91-bc10-323e772e53e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_12fc1f84-b878-405b-aebe-7f2cbae87def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_12fc1f84-b878-405b-aebe-7f2cbae87def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fc82722e-37a9-464a-b44a-9e22fe628c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c210b886-112c-48d6-ab6a-dfc3d54e79a8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fc82722e-37a9-464a-b44a-9e22fe628c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ad3ad7bf-a270-4442-bc60-7dad08b1d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ad3ad7bf-a270-4442-bc60-7dad08b1d96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ec7ae3aa-136b-4f25-a9c4-d8ea1eb1241d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ec7ae3aa-136b-4f25-a9c4-d8ea1eb1241d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c57187c-353a-4aa0-bc86-97590ac7df15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_NetIncomeLoss_7c57187c-353a-4aa0-bc86-97590ac7df15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_676c5d2c-edd3-4568-bbcc-701641d40dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_EarningsPerShareAbstract_676c5d2c-edd3-4568-bbcc-701641d40dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_450a2391-cb29-42c3-ab8d-d7e52f7a8f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_676c5d2c-edd3-4568-bbcc-701641d40dbd" xlink:to="loc_us-gaap_EarningsPerShareBasic_450a2391-cb29-42c3-ab8d-d7e52f7a8f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b4000926-8862-47b0-93d5-e440efc97817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_676c5d2c-edd3-4568-bbcc-701641d40dbd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b4000926-8862-47b0-93d5-e440efc97817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_035b560f-356c-47ba-bde8-4b15de48a688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1f752ee-11c4-4799-a74c-9ee99899a489" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_035b560f-356c-47ba-bde8-4b15de48a688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1adf0aa1-60fe-45c4-9bc1-2fd7a3e52776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_035b560f-356c-47ba-bde8-4b15de48a688" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1adf0aa1-60fe-45c4-9bc1-2fd7a3e52776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61831a36-7ad5-471e-9832-85a2f5b0e72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_035b560f-356c-47ba-bde8-4b15de48a688" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61831a36-7ad5-471e-9832-85a2f5b0e72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ba7ad13e-f8c9-450c-be55-6b65b799fd77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a5295f20-ed4a-4af6-91ab-184d7c7ad43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ba7ad13e-f8c9-450c-be55-6b65b799fd77" xlink:to="loc_us-gaap_NetIncomeLoss_a5295f20-ed4a-4af6-91ab-184d7c7ad43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_999865f1-dee9-480e-a14c-99fdf2ba5968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ba7ad13e-f8c9-450c-be55-6b65b799fd77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_999865f1-dee9-480e-a14c-99fdf2ba5968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4a5a8deb-bdc8-43e5-9b88-bf55df975ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_999865f1-dee9-480e-a14c-99fdf2ba5968" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4a5a8deb-bdc8-43e5-9b88-bf55df975ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9d106c7a-200d-4975-9d1a-405e83e32be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_999865f1-dee9-480e-a14c-99fdf2ba5968" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9d106c7a-200d-4975-9d1a-405e83e32be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cbdfe907-e34a-46f6-815d-b58ce5aa518c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_999865f1-dee9-480e-a14c-99fdf2ba5968" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_cbdfe907-e34a-46f6-815d-b58ce5aa518c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_871207d3-5f50-4fbf-a5b6-62f4807bd4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ba7ad13e-f8c9-450c-be55-6b65b799fd77" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_871207d3-5f50-4fbf-a5b6-62f4807bd4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b8f4ceb7-ee2c-4a0c-8016-bafcd272e45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b8f4ceb7-ee2c-4a0c-8016-bafcd272e45c" xlink:to="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cf456df6-119d-4d17-ac1c-6cf8aa6a3352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cf456df6-119d-4d17-ac1c-6cf8aa6a3352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf456df6-119d-4d17-ac1c-6cf8aa6a3352" xlink:to="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1e55e5c-5ea6-469a-a7da-6b9ad02c50d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:to="loc_us-gaap_CommonStockMember_e1e55e5c-5ea6-469a-a7da-6b9ad02c50d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f08f55a8-798f-4bb6-8152-49a19eed82fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f08f55a8-798f-4bb6-8152-49a19eed82fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4f09514a-2a43-4ef6-ac36-470b154ef3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:to="loc_us-gaap_RetainedEarningsMember_4f09514a-2a43-4ef6-ac36-470b154ef3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_887dd372-6acd-4799-8baa-3985537f5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6d60904-e263-416c-9d9e-c6fd6bfcea48" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_887dd372-6acd-4799-8baa-3985537f5cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_86a381c0-6724-4e97-bfdf-9066d31243fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:to="loc_us-gaap_DebtInstrumentAxis_86a381c0-6724-4e97-bfdf-9066d31243fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_86a381c0-6724-4e97-bfdf-9066d31243fd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotes2019Member_49865f45-1afc-4abe-ae8c-0d47d5727ca0" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotes2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:to="loc_pcrx_ConvertibleSeniorNotes2019Member_49865f45-1afc-4abe-ae8c-0d47d5727ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_697616de-a762-47ae-8fd7-ea7e04faca29" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_697616de-a762-47ae-8fd7-ea7e04faca29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotes2025Member_781602a2-0f71-4099-bea3-a54cc5202ac9" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotes2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bbbd3f92-9749-4487-bc4a-b0a78dc14a0a" xlink:to="loc_pcrx_ConvertibleSeniorNotes2025Member_781602a2-0f71-4099-bea3-a54cc5202ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_15e23ba4-08fd-4861-bb8c-0bb080dd017a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_15e23ba4-08fd-4861-bb8c-0bb080dd017a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5382fcba-23ed-45c8-8543-d0ad0a2e95d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_15e23ba4-08fd-4861-bb8c-0bb080dd017a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5382fcba-23ed-45c8-8543-d0ad0a2e95d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d516a62a-bdd4-4322-ba53-8fc9dc21c91c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5382fcba-23ed-45c8-8543-d0ad0a2e95d4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d516a62a-bdd4-4322-ba53-8fc9dc21c91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e80546e5-8426-42b6-a816-394ee1ea4159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8c4390a-e0e6-42db-80b6-3777566d1709" xlink:to="loc_us-gaap_StatementLineItems_e80546e5-8426-42b6-a816-394ee1ea4159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e80546e5-8426-42b6-a816-394ee1ea4159" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c3a212f6-5db3-4c41-a481-bf0950692b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_SharesOutstanding_c3a212f6-5db3-4c41-a481-bf0950692b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_140eb2c8-2d47-4ea5-b650-96ef099acbec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockholdersEquity_140eb2c8-2d47-4ea5-b650-96ef099acbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_31403039-8a38-403e-9176-53da22ff0788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_31403039-8a38-403e-9176-53da22ff0788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_03d6be1f-e210-427b-85a3-260b3f071484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_03d6be1f-e210-427b-85a3-260b3f071484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_921c8154-00d2-4367-bbd3-bb718d836f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_921c8154-00d2-4367-bbd3-bb718d836f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_47d6078f-09f2-4c49-a2c5-5e228a839784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_47d6078f-09f2-4c49-a2c5-5e228a839784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0960a56d-1e37-4d1e-823a-a9984ab589cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0960a56d-1e37-4d1e-823a-a9984ab589cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_75527c45-1b26-41ec-903e-29d619dce9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_75527c45-1b26-41ec-903e-29d619dce9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_738b8b3e-cf59-4b76-94f2-590b2e5b955a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_738b8b3e-cf59-4b76-94f2-590b2e5b955a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ddf976cd-1ca1-4381-8cb4-16271174f72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ddf976cd-1ca1-4381-8cb4-16271174f72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b883746c-8c48-4137-8ebe-8c58f38c30e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_NetIncomeLoss_b883746c-8c48-4137-8ebe-8c58f38c30e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_31bfbbdd-1076-43c3-b6de-0c84ffdbdfba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_SharesOutstanding_31bfbbdd-1076-43c3-b6de-0c84ffdbdfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e5deb45a-3dd6-4213-8471-06b1fd2f56e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cb3b6a4-c998-4c5a-ae82-3c644e30ec19" xlink:to="loc_us-gaap_StockholdersEquity_e5deb45a-3dd6-4213-8471-06b1fd2f56e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_06fc2081-fc5f-4220-8f9e-9fca680a7900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e80546e5-8426-42b6-a816-394ee1ea4159" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_06fc2081-fc5f-4220-8f9e-9fca680a7900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c72a7757-c306-463f-a2dc-72145627cfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt_c58d486f-2471-4eb0-837c-7feddc0c0e2d" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c72a7757-c306-463f-a2dc-72145627cfa2" xlink:to="loc_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt_c58d486f-2471-4eb0-837c-7feddc0c0e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8ebf2207-1c30-4b08-8743-186b344e0c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0f7585fc-adae-4e59-b59c-732cfd4035af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ebf2207-1c30-4b08-8743-186b344e0c7f" xlink:to="loc_us-gaap_StatementTable_0f7585fc-adae-4e59-b59c-732cfd4035af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b5ec9282-d540-4bcb-a8d1-8229d8a561ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0f7585fc-adae-4e59-b59c-732cfd4035af" xlink:to="loc_us-gaap_DebtInstrumentAxis_b5ec9282-d540-4bcb-a8d1-8229d8a561ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b5ec9282-d540-4bcb-a8d1-8229d8a561ca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_a7c67e2e-5076-4c7b-b8bb-fd2e00743f99" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_a7c67e2e-5076-4c7b-b8bb-fd2e00743f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotes2019Member_da549052-0d2d-46a9-80a9-1e3d53ceaf53" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotes2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:to="loc_pcrx_ConvertibleSeniorNotes2019Member_da549052-0d2d-46a9-80a9-1e3d53ceaf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_4e9f1357-4c17-4f29-a3ca-9e1a45a00994" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_303cbaf8-c3d5-4d93-badd-f3fe6abb2a13" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_4e9f1357-4c17-4f29-a3ca-9e1a45a00994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0f7585fc-adae-4e59-b59c-732cfd4035af" xlink:to="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b97fcaf-58c8-4cfa-8ca0-ba7f7e4c0ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:to="loc_us-gaap_NetIncomeLoss_7b97fcaf-58c8-4cfa-8ca0-ba7f7e4c0ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a298c8e-0336-40be-9f43-0924c83e3206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8a298c8e-0336-40be-9f43-0924c83e3206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f2753f44-ef0d-4a47-923b-6db2d64439f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f2753f44-ef0d-4a47-923b-6db2d64439f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_69db47da-d456-45ff-889c-f39acf8dc48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_69db47da-d456-45ff-889c-f39acf8dc48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8c858d5d-7ed2-44d2-9ac7-3f7eb1bf84b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8c858d5d-7ed2-44d2-9ac7-3f7eb1bf84b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_e8678519-dc7a-45e4-b2ec-73e24a2a51b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_e8678519-dc7a-45e4-b2ec-73e24a2a51b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed63d136-3a9c-45b0-b7e9-a30549ebc870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed63d136-3a9c-45b0-b7e9-a30549ebc870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c925795d-3d57-4470-bf7d-93d726b32bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_ShareBasedCompensation_c925795d-3d57-4470-bf7d-93d726b32bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e27c4a8d-4235-478c-b9fd-35f8a6cf4de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e27c4a8d-4235-478c-b9fd-35f8a6cf4de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_3616eead-4eb9-4f91-bbb3-6fe88278c665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d120cef6-d794-46ed-bfad-d7acc1f7e3c3" xlink:to="loc_us-gaap_GainLossOnInvestments_3616eead-4eb9-4f91-bbb3-6fe88278c665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ca7325b-dfd0-4e0b-bb25-70eac7c35539" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2e20f2a2-8884-4af4-9fef-e079b48814be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2e20f2a2-8884-4af4-9fef-e079b48814be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8b3f0b31-2614-424f-ac6c-2ded07eacbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8b3f0b31-2614-424f-ac6c-2ded07eacbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfe3502f-a7e7-46d1-9d95-9f57880501e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfe3502f-a7e7-46d1-9d95-9f57880501e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_56c917a1-4b3b-415f-a5ad-648e12ac30a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_56c917a1-4b3b-415f-a5ad-648e12ac30a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_71cda208-a98d-4866-a18d-7462111548d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_71cda208-a98d-4866-a18d-7462111548d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7c0053ae-f282-4a89-8ffd-a9bf9e80933a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7c0053ae-f282-4a89-8ffd-a9bf9e80933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_489bdacf-c893-4568-97f0-ae2e524f53c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_489bdacf-c893-4568-97f0-ae2e524f53c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_415916f0-982a-4bdd-b6d3-b682c64e9471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_415916f0-982a-4bdd-b6d3-b682c64e9471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bcfe4786-6905-4d5c-a575-5c30f195c0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8885e151-b80b-4309-9fb9-335980b2dd77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bcfe4786-6905-4d5c-a575-5c30f195c0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_a2261c0f-e041-45ba-b43d-850c9452d801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_a2261c0f-e041-45ba-b43d-850c9452d801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d5952428-0a88-4052-a04e-9e581f65786b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d5952428-0a88-4052-a04e-9e581f65786b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2b900db-97df-4990-98a8-7dce57a1a189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2b900db-97df-4990-98a8-7dce57a1a189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a0bc03e5-8b92-4ce6-8c35-c3cca8fdba4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a0bc03e5-8b92-4ce6-8c35-c3cca8fdba4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_56a207ed-9894-47e3-bb30-58fb55c156c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_56a207ed-9894-47e3-bb30-58fb55c156c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentOfContingentConsideration_2b3c04bb-953f-4769-b097-4b66de099ccc" xlink:href="pcrx-20211231.xsd#pcrx_PaymentOfContingentConsideration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_pcrx_PaymentOfContingentConsideration_2b3c04bb-953f-4769-b097-4b66de099ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_572d7efc-608d-4da4-81c0-1cc8fe792d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_572d7efc-608d-4da4-81c0-1cc8fe792d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_e8819b9a-6e09-4904-bc38-3e7ddec69bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_e8819b9a-6e09-4904-bc38-3e7ddec69bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3edfa400-5a6f-44b4-81d6-f05e393c3ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_237cb269-98b5-473e-b1d2-9fbad07f4160" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3edfa400-5a6f-44b4-81d6-f05e393c3ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9084a709-85e1-4358-ba11-5bf92ae3b835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9084a709-85e1-4358-ba11-5bf92ae3b835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_8684f851-e44b-4a1f-aa64-005877bca6c7" xlink:href="pcrx-20211231.xsd#pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan_8684f851-e44b-4a1f-aa64-005877bca6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_a79f351c-bcfb-4dcc-9962-3b7919a0093d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_a79f351c-bcfb-4dcc-9962-3b7919a0093d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_c2c147bc-673b-4039-9461-2d02cdaa7821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_c2c147bc-673b-4039-9461-2d02cdaa7821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt_94b01ae3-45d8-49e6-8c0d-faf2c53a6cf3" xlink:href="pcrx-20211231.xsd#pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt_94b01ae3-45d8-49e6-8c0d-faf2c53a6cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_17037eca-98fd-49b9-b1d8-24a075edc3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_17037eca-98fd-49b9-b1d8-24a075edc3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes_72c25c9b-c4a5-49df-8f2c-5baf1d789aaf" xlink:href="pcrx-20211231.xsd#pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes_72c25c9b-c4a5-49df-8f2c-5baf1d789aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentsForDebtConversionPremiums_49571c8c-62ba-4d63-8f4b-fb5fc95a6217" xlink:href="pcrx-20211231.xsd#pcrx_PaymentsForDebtConversionPremiums"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_pcrx_PaymentsForDebtConversionPremiums_49571c8c-62ba-4d63-8f4b-fb5fc95a6217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_16fadc20-99ee-4394-ae4d-66cf8dfd707a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_16fadc20-99ee-4394-ae4d-66cf8dfd707a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c208810f-5cc2-4f11-a3fe-ebc96d73fa47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c208810f-5cc2-4f11-a3fe-ebc96d73fa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17399872-3eca-4c8c-af6f-9bcd76f02a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7761edaa-fc85-4085-987e-952aec6c76d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_17399872-3eca-4c8c-af6f-9bcd76f02a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cd07b807-e867-437f-b5d6-334b4728320f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cd07b807-e867-437f-b5d6-334b4728320f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_595c4a50-a05b-481a-9618-33f2f769b9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_595c4a50-a05b-481a-9618-33f2f769b9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13a79f3d-04a0-4b55-9b58-e12bf7ec1d30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13a79f3d-04a0-4b55-9b58-e12bf7ec1d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9d88de7d-eab0-45cc-a834-c4b81c0ec4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9d88de7d-eab0-45cc-a834-c4b81c0ec4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c165debd-0b29-4244-8711-9d5d6ddfa4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9d88de7d-eab0-45cc-a834-c4b81c0ec4ea" xlink:to="loc_us-gaap_InterestPaidNet_c165debd-0b29-4244-8711-9d5d6ddfa4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_e1fbca45-1c53-4ecb-af23-a87986883104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9d88de7d-eab0-45cc-a834-c4b81c0ec4ea" xlink:to="loc_us-gaap_IncomeTaxesPaid_e1fbca45-1c53-4ecb-af23-a87986883104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ff050feb-5d0a-4a0f-ac14-3b7aa1699c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2dc50d16-4887-4c7c-ba44-709e64344ad0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ff050feb-5d0a-4a0f-ac14-3b7aa1699c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6a9d596-4cee-4b41-a3f2-7cbcd3f69cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ff050feb-5d0a-4a0f-ac14-3b7aa1699c12" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6a9d596-4cee-4b41-a3f2-7cbcd3f69cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncreaseDecreaseInContingentConsideration_8bdf51a2-936d-49ff-9fb4-6638f95d10ac" xlink:href="pcrx-20211231.xsd#pcrx_IncreaseDecreaseInContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ff050feb-5d0a-4a0f-ac14-3b7aa1699c12" xlink:to="loc_pcrx_IncreaseDecreaseInContingentConsideration_8bdf51a2-936d-49ff-9fb4-6638f95d10ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_04b890c8-5555-40a5-9259-68842bbf1f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bf05fe43-3363-4159-abb0-4215d94b2a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_04b890c8-5555-40a5-9259-68842bbf1f0c" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bf05fe43-3363-4159-abb0-4215d94b2a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd136673-be68-439c-adcf-1c01f0cdfd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_b942264e-1461-493c-a3ad-43d5800bfdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd136673-be68-439c-adcf-1c01f0cdfd52" xlink:to="loc_us-gaap_ConcentrationRiskTable_b942264e-1461-493c-a3ad-43d5800bfdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_be83a0e6-6513-4752-baa5-87280d393fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b942264e-1461-493c-a3ad-43d5800bfdb7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_be83a0e6-6513-4752-baa5-87280d393fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6d76175-104f-4c1e-b22e-6ea4cae709e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_be83a0e6-6513-4752-baa5-87280d393fc5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6d76175-104f-4c1e-b22e-6ea4cae709e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_7faaa88c-762a-4376-bd97-73ed18294dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6d76175-104f-4c1e-b22e-6ea4cae709e5" xlink:to="loc_us-gaap_SalesRevenueNetMember_7faaa88c-762a-4376-bd97-73ed18294dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_44300028-6d12-4acc-8de9-e832031283fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b942264e-1461-493c-a3ad-43d5800bfdb7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_44300028-6d12-4acc-8de9-e832031283fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_89dd68be-152c-45f8-b415-4c673c9f12ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_44300028-6d12-4acc-8de9-e832031283fa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_89dd68be-152c-45f8-b415-4c673c9f12ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f3d82087-16fc-41e8-9a5d-9945f7c5d0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_89dd68be-152c-45f8-b415-4c673c9f12ae" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f3d82087-16fc-41e8-9a5d-9945f7c5d0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_6d825ac6-6352-4cee-b3b5-ad0640348d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b942264e-1461-493c-a3ad-43d5800bfdb7" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_6d825ac6-6352-4cee-b3b5-ad0640348d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberOfProducts_b408fb33-aa42-4436-9a8a-beebe0f9cc71" xlink:href="pcrx-20211231.xsd#pcrx_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_6d825ac6-6352-4cee-b3b5-ad0640348d9e" xlink:to="loc_pcrx_ConcentrationRiskNumberOfProducts_b408fb33-aa42-4436-9a8a-beebe0f9cc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f4d490be-e6de-4760-8d37-16c76524881d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_401ee89f-7115-4b71-8a04-fc8c10a1381b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4d490be-e6de-4760-8d37-16c76524881d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_401ee89f-7115-4b71-8a04-fc8c10a1381b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_6b2f326a-f21b-471e-a569-f455dd1556b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_6b2f326a-f21b-471e-a569-f455dd1556b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0c864392-ee71-4bc5-bdc2-5192974b8ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0c864392-ee71-4bc5-bdc2-5192974b8ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_94944016-ea48-4575-8766-03c1a28ddbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_UseOfEstimates_94944016-ea48-4575-8766-03c1a28ddbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_41c5693c-ccef-44a3-9e3b-fa17a8708c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_41c5693c-ccef-44a3-9e3b-fa17a8708c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_8d1aee4d-a158-4029-90df-2090f9aaa27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_8d1aee4d-a158-4029-90df-2090f9aaa27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fb108435-e9f1-434a-962c-84f250f9c447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fb108435-e9f1-434a-962c-84f250f9c447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2d4361cf-bcea-426c-b637-d078c6582830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2d4361cf-bcea-426c-b637-d078c6582830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2b19014d-dd11-4bf2-a00c-e9fae425cb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2b19014d-dd11-4bf2-a00c-e9fae425cb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e68bcda0-1119-4247-b162-272379dec735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e68bcda0-1119-4247-b162-272379dec735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_68a7a07f-2832-46ea-9f71-6b805fc79fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_68a7a07f-2832-46ea-9f71-6b805fc79fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_b1b92329-862e-4669-ba3f-e63d01819673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_b1b92329-862e-4669-ba3f-e63d01819673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_39eaafa6-30df-485a-b535-4e0c1b57f7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_39eaafa6-30df-485a-b535-4e0c1b57f7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationsPolicy_79497931-a0ba-45d8-9381-7d02e05bb36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_AssetRetirementObligationsPolicy_79497931-a0ba-45d8-9381-7d02e05bb36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_aeff5d7d-0096-4854-911c-008a31e8a746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_aeff5d7d-0096-4854-911c-008a31e8a746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_a6f75c06-00ff-4412-a3a7-2c84089f4d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_a6f75c06-00ff-4412-a3a7-2c84089f4d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationPolicyTextBlock_c608967c-4cce-4a44-999f-2ad0c731bf4b" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_pcrx_ContingentConsiderationPolicyTextBlock_c608967c-4cce-4a44-999f-2ad0c731bf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1922ffae-7af2-4c4f-9637-1014b1950636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1922ffae-7af2-4c4f-9637-1014b1950636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_e42c6082-74f9-4842-98e7-011b8a469711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_e42c6082-74f9-4842-98e7-011b8a469711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_4b2847f9-cfe0-4f0b-babf-62736fb0d77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_4b2847f9-cfe0-4f0b-babf-62736fb0d77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9441dd6f-57d5-475a-a5ed-f9789168d3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9441dd6f-57d5-475a-a5ed-f9789168d3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_380d59b1-a15d-4dbb-8bc5-4ce2a64ee909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_DebtPolicyTextBlock_380d59b1-a15d-4dbb-8bc5-4ce2a64ee909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_75cda411-260b-489a-a205-c3dda64cf50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_75cda411-260b-489a-a205-c3dda64cf50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_be5f40d8-abd3-46e7-abc4-1b2826fa09b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_be5f40d8-abd3-46e7-abc4-1b2826fa09b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b08cef1d-30fc-4506-a5db-eb5c51e1dd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b08cef1d-30fc-4506-a5db-eb5c51e1dd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b3a0ca2f-54b3-4240-b5ab-9760a93bd9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b271b85-cd9b-4db8-9bcb-0e3653d5e45b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b3a0ca2f-54b3-4240-b5ab-9760a93bd9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ee042127-7ff8-4563-a1c5-e7fd68911524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e246355a-e502-4e21-9f7f-09e8c3bfeac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ee042127-7ff8-4563-a1c5-e7fd68911524" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e246355a-e502-4e21-9f7f-09e8c3bfeac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_82478179-8d06-460f-a2b4-d3c0c500245b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ee042127-7ff8-4563-a1c5-e7fd68911524" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_82478179-8d06-460f-a2b4-d3c0c500245b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2342604a-9552-4cbd-8b3c-9cb021308acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2342604a-9552-4cbd-8b3c-9cb021308acb" xlink:to="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9a437536-0ad0-4092-89d3-dd503a4251a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9a437536-0ad0-4092-89d3-dd503a4251a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d61b6f93-df18-46c7-b794-20dc9210b602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9a437536-0ad0-4092-89d3-dd503a4251a6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d61b6f93-df18-46c7-b794-20dc9210b602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c8ab539f-0261-4e1a-92e7-fb98414905ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_d61b6f93-df18-46c7-b794-20dc9210b602" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c8ab539f-0261-4e1a-92e7-fb98414905ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fbe1d311-16bc-402e-8efb-df102bb079b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:to="loc_srt_MajorCustomersAxis_fbe1d311-16bc-402e-8efb-df102bb079b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_fbe1d311-16bc-402e-8efb-df102bb079b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LargestCustomerMember_bf633c0f-e131-465f-8fac-6833d91af2a9" xlink:href="pcrx-20211231.xsd#pcrx_LargestCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:to="loc_pcrx_LargestCustomerMember_bf633c0f-e131-465f-8fac-6833d91af2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SecondLargestCustomerMember_963e197c-7315-488d-8a5b-1209c7c98876" xlink:href="pcrx-20211231.xsd#pcrx_SecondLargestCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:to="loc_pcrx_SecondLargestCustomerMember_963e197c-7315-488d-8a5b-1209c7c98876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThirdLargestCustomerMember_0c4249aa-f04e-4417-b4a7-dc8dfcf26c16" xlink:href="pcrx-20211231.xsd#pcrx_ThirdLargestCustomerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:to="loc_pcrx_ThirdLargestCustomerMember_0c4249aa-f04e-4417-b4a7-dc8dfcf26c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ThreeLargestCustomersMember_380d1302-112b-4cda-a6c6-395927b60ee5" xlink:href="pcrx-20211231.xsd#pcrx_ThreeLargestCustomersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cd40eed9-1e48-4091-80b4-71935450dd9d" xlink:to="loc_pcrx_ThreeLargestCustomersMember_380d1302-112b-4cda-a6c6-395927b60ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f548d4d-bf34-4528-98c2-8ffbcb002d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f548d4d-bf34-4528-98c2-8ffbcb002d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e493c41b-7dbd-46c8-95c0-fdb57f6e5309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f548d4d-bf34-4528-98c2-8ffbcb002d3b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e493c41b-7dbd-46c8-95c0-fdb57f6e5309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_28494cc4-ec73-47be-8c69-be6c38e5b296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e493c41b-7dbd-46c8-95c0-fdb57f6e5309" xlink:to="loc_us-gaap_SalesRevenueNetMember_28494cc4-ec73-47be-8c69-be6c38e5b296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_79807502-f6ca-4a86-84a3-20a2d0b5c114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d2d65939-3421-41a1-be82-1bb76d8a820b" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_79807502-f6ca-4a86-84a3-20a2d0b5c114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberofCustomers_268ad4e9-73f5-4dbd-8e4d-03ec636cdf55" xlink:href="pcrx-20211231.xsd#pcrx_ConcentrationRiskNumberofCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_79807502-f6ca-4a86-84a3-20a2d0b5c114" xlink:to="loc_pcrx_ConcentrationRiskNumberofCustomers_268ad4e9-73f5-4dbd-8e4d-03ec636cdf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_240e5fdc-e47f-4e0b-a486-a6d7f81e2a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_79807502-f6ca-4a86-84a3-20a2d0b5c114" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_240e5fdc-e47f-4e0b-a486-a6d7f81e2a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f839f834-69ab-4b5a-904a-e881cb12de6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_767adb67-1bb0-44b3-85cc-a08573b23803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f839f834-69ab-4b5a-904a-e881cb12de6b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_767adb67-1bb0-44b3-85cc-a08573b23803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e43a406b-59ca-4d9c-96b7-2fce08aac39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_767adb67-1bb0-44b3-85cc-a08573b23803" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e43a406b-59ca-4d9c-96b7-2fce08aac39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e43a406b-59ca-4d9c-96b7-2fce08aac39e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_47fd6a5c-eb03-4631-bbe7-36af5c04df3f" xlink:href="pcrx-20211231.xsd#pcrx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_47fd6a5c-eb03-4631-bbe7-36af5c04df3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_31f108a0-acdd-4df8-b80c-d18f695150ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_31f108a0-acdd-4df8-b80c-d18f695150ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_9de3ac28-70ed-45e3-9253-e8cdea0117f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1048ec38-5a06-45d8-8c1a-4692277ecc02" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_9de3ac28-70ed-45e3-9253-e8cdea0117f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56d23d2b-d0ce-4db8-9dc9-01e8a1bcd8fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_767adb67-1bb0-44b3-85cc-a08573b23803" xlink:to="loc_srt_RangeAxis_56d23d2b-d0ce-4db8-9dc9-01e8a1bcd8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6842d8e2-66f2-4ff5-a51f-ed52cd4a3cba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_56d23d2b-d0ce-4db8-9dc9-01e8a1bcd8fc" xlink:to="loc_srt_RangeMember_6842d8e2-66f2-4ff5-a51f-ed52cd4a3cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4339385e-eead-47bf-a8fc-5a6dcb101309" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6842d8e2-66f2-4ff5-a51f-ed52cd4a3cba" xlink:to="loc_srt_MinimumMember_4339385e-eead-47bf-a8fc-5a6dcb101309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_94426417-b3f3-4597-8673-5a1f9ccad2b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6842d8e2-66f2-4ff5-a51f-ed52cd4a3cba" xlink:to="loc_srt_MaximumMember_94426417-b3f3-4597-8673-5a1f9ccad2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7ca83158-c9ed-4ae7-9335-b1950eafde0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_767adb67-1bb0-44b3-85cc-a08573b23803" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7ca83158-c9ed-4ae7-9335-b1950eafde0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c3d2c0c1-d5f5-48aa-931a-566a4a6543ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7ca83158-c9ed-4ae7-9335-b1950eafde0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c3d2c0c1-d5f5-48aa-931a-566a4a6543ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7d76b449-2711-4849-b7b8-2958ec2b5fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7d76b449-2711-4849-b7b8-2958ec2b5fbe" xlink:to="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bf0b54ad-8d9a-4504-8ea9-f018844b11b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bf0b54ad-8d9a-4504-8ea9-f018844b11b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3ffbd9b6-1883-4c2f-ac4f-a22dc54ad9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bf0b54ad-8d9a-4504-8ea9-f018844b11b5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3ffbd9b6-1883-4c2f-ac4f-a22dc54ad9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0d0b8821-c78f-4822-9579-5beae7f66d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3ffbd9b6-1883-4c2f-ac4f-a22dc54ad9a6" xlink:to="loc_us-gaap_SalesRevenueNetMember_0d0b8821-c78f-4822-9579-5beae7f66d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e368edc7-4fcc-47e8-b791-e82ec59ea6a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:to="loc_srt_MajorCustomersAxis_e368edc7-4fcc-47e8-b791-e82ec59ea6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_36928704-a4db-4bcd-be1d-4e23eb1b8239" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e368edc7-4fcc-47e8-b791-e82ec59ea6a6" xlink:to="loc_srt_NameOfMajorCustomerDomain_36928704-a4db-4bcd-be1d-4e23eb1b8239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CustomersOutsideUSMember_7de3a3f5-5ce6-4e77-9766-a7e6b2ebc7c4" xlink:href="pcrx-20211231.xsd#pcrx_CustomersOutsideUSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_36928704-a4db-4bcd-be1d-4e23eb1b8239" xlink:to="loc_pcrx_CustomersOutsideUSMember_7de3a3f5-5ce6-4e77-9766-a7e6b2ebc7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_095c2a1d-a34f-4f11-bd5e-3c52a11b862f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_095c2a1d-a34f-4f11-bd5e-3c52a11b862f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2a4226d4-7e26-4426-a0b1-3e7662b4b05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_095c2a1d-a34f-4f11-bd5e-3c52a11b862f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2a4226d4-7e26-4426-a0b1-3e7662b4b05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4f6e17a3-3d95-47a9-b949-9c82ec24901e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2a4226d4-7e26-4426-a0b1-3e7662b4b05f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4f6e17a3-3d95-47a9-b949-9c82ec24901e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_701ddbda-8fc9-46a6-8c9f-32f2092c9a03" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConcentrationRiskNumberofCustomers_e044899e-437a-43fc-85d3-f189d2b23cf1" xlink:href="pcrx-20211231.xsd#pcrx_ConcentrationRiskNumberofCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_pcrx_ConcentrationRiskNumberofCustomers_e044899e-437a-43fc-85d3-f189d2b23cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_356d996b-8aaa-4948-8f25-2073c0afb3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_356d996b-8aaa-4948-8f25-2073c0afb3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_0d524fc6-056b-4972-aff0-8747185a5ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_0d524fc6-056b-4972-aff0-8747185a5ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperAtCarryingValue_86f348a0-8c8d-4db2-bce3-209f44f27509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_CommercialPaperAtCarryingValue_86f348a0-8c8d-4db2-bce3-209f44f27509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_ea2995f6-45b4-4244-87f5-caf601e7d324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_AssetBackedSecuritiesAtCarryingValue_ea2995f6-45b4-4244-87f5-caf601e7d324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ccdf16d8-4031-4fdd-b154-40a5ea45a230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_58f21935-4181-4074-94bc-6f34c7a7a0d0" xlink:to="loc_us-gaap_NumberOfReportableSegments_ccdf16d8-4031-4fdd-b154-40a5ea45a230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_03d3fdd4-edae-48ea-bb9d-51fdb8b5d103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_68507ca3-065d-4a5b-ab55-21b70c1505fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_03d3fdd4-edae-48ea-bb9d-51fdb8b5d103" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_68507ca3-065d-4a5b-ab55-21b70c1505fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#RECENTACCOUNTINGPRONOUNCEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_542e845d-654b-44b8-87be-05258f5cbdca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_96df717a-76ba-41c9-b1d6-711e51b80300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_542e845d-654b-44b8-87be-05258f5cbdca" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_96df717a-76ba-41c9-b1d6-711e51b80300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bc30731b-92b3-4d1b-bc19-f617042ae76e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_96df717a-76ba-41c9-b1d6-711e51b80300" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bc30731b-92b3-4d1b-bc19-f617042ae76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f9017b79-dfd8-44c7-8a2a-678b5658ac00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bc30731b-92b3-4d1b-bc19-f617042ae76e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f9017b79-dfd8-44c7-8a2a-678b5658ac00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_bef98612-7e0a-41b7-8efa-e99cf35ed2de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f9017b79-dfd8-44c7-8a2a-678b5658ac00" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_bef98612-7e0a-41b7-8efa-e99cf35ed2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_96df717a-76ba-41c9-b1d6-711e51b80300" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_68482b08-6338-4753-a2d7-92c14fd3a756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_68482b08-6338-4753-a2d7-92c14fd3a756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncreaseDecreaseInRetainedEarnings_f592e3ab-ada8-4ec5-a581-deda3a66a29a" xlink:href="pcrx-20211231.xsd#pcrx_IncreaseDecreaseInRetainedEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_pcrx_IncreaseDecreaseInRetainedEarnings_f592e3ab-ada8-4ec5-a581-deda3a66a29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_94ce8021-7de7-4b74-8d11-a9066783b149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_94ce8021-7de7-4b74-8d11-a9066783b149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b65e080f-f444-4011-8139-beb63880eaff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b65e080f-f444-4011-8139-beb63880eaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncreaseDecreaseInInterestExpense_317b4b56-7ec1-4471-944f-a3c94d468aeb" xlink:href="pcrx-20211231.xsd#pcrx_IncreaseDecreaseInInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_02604a2b-839b-4dac-a6ca-3c41832ac868" xlink:to="loc_pcrx_IncreaseDecreaseInInterestExpense_317b4b56-7ec1-4471-944f-a3c94d468aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUE" xlink:type="simple" xlink:href="pcrx-20211231.xsd#REVENUE"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/REVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_57aaeca8-bdc1-4c30-82b9-58b8fbfbf72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2d962d49-4864-40e2-96b7-53139c9d398f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_57aaeca8-bdc1-4c30-82b9-58b8fbfbf72d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2d962d49-4864-40e2-96b7-53139c9d398f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUETables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#REVENUETables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/REVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee6fe6f3-e5b3-4600-90a5-38f68fe22421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_d2462ca2-1951-4300-93d1-1327822e6118" xlink:href="pcrx-20211231.xsd#pcrx_MovementinValuationandQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee6fe6f3-e5b3-4600-90a5-38f68fe22421" xlink:to="loc_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock_d2462ca2-1951-4300-93d1-1327822e6118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6afd7068-59ea-4bfc-a1fb-d021b556fc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee6fe6f3-e5b3-4600-90a5-38f68fe22421" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6afd7068-59ea-4bfc-a1fb-d021b556fc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#REVENUESalesandValuationAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7b40d725-bb48-4a7a-a32c-9a44d65bfb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f1cd2ccd-e1ee-4449-bab1-fddb95930d4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7b40d725-bb48-4a7a-a32c-9a44d65bfb2b" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f1cd2ccd-e1ee-4449-bab1-fddb95930d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_50e86665-e048-4262-ac04-4d50c03fb11c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f1cd2ccd-e1ee-4449-bab1-fddb95930d4b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_50e86665-e048-4262-ac04-4d50c03fb11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_50e86665-e048-4262-ac04-4d50c03fb11c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_ccd80308-1092-4485-9556-4bb6bc4f9542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_ccd80308-1092-4485-9556-4bb6bc4f9542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ReserveForPromptPayDiscountMember_af4ff389-c894-4372-96ee-e5222e43f5c4" xlink:href="pcrx-20211231.xsd#pcrx_ReserveForPromptPayDiscountMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_pcrx_ReserveForPromptPayDiscountMember_af4ff389-c894-4372-96ee-e5222e43f5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_WholesalerservicefeesMember_e078f5da-0713-4396-9d97-9756372cae77" xlink:href="pcrx-20211231.xsd#pcrx_WholesalerservicefeesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_pcrx_WholesalerservicefeesMember_e078f5da-0713-4396-9d97-9756372cae77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AllowanceForVolumeRebatesandChargebacksMember_77154fca-916a-405f-a23c-716404ec35c3" xlink:href="pcrx-20211231.xsd#pcrx_AllowanceForVolumeRebatesandChargebacksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_pcrx_AllowanceForVolumeRebatesandChargebacksMember_77154fca-916a-405f-a23c-716404ec35c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AllowanceForGovernmentRebatesMember_2412a74b-2092-4d3d-9827-5828af4b3e83" xlink:href="pcrx-20211231.xsd#pcrx_AllowanceForGovernmentRebatesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8595058d-b85c-47c0-9e6e-54a3868bc8ac" xlink:to="loc_pcrx_AllowanceForGovernmentRebatesMember_2412a74b-2092-4d3d-9827-5828af4b3e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_31091354-31fd-4497-90fc-c94fba632b3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f1cd2ccd-e1ee-4449-bab1-fddb95930d4b" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_31091354-31fd-4497-90fc-c94fba632b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_31091354-31fd-4497-90fc-c94fba632b3c" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_7a74eb31-775d-4695-8bcd-699928322fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_7a74eb31-775d-4695-8bcd-699928322fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c98aa610-74c5-451b-a45f-26aeb25a8863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c98aa610-74c5-451b-a45f-26aeb25a8863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_ec04ee36-b6d8-4bc8-ba8c-44e8ed9489fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_ec04ee36-b6d8-4bc8-ba8c-44e8ed9489fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ead057a6-d30d-4743-98f6-85afbb30f928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_287b3f1a-b2ec-4825-b967-2fe74a54e9e7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ead057a6-d30d-4743-98f6-85afbb30f928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUENarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#REVENUENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/REVENUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c53deb1b-1229-4906-9da4-0d18cc3354df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9488cf35-896c-44d7-82cd-093106ea1f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c53deb1b-1229-4906-9da4-0d18cc3354df" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9488cf35-896c-44d7-82cd-093106ea1f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2efae54b-7969-4578-8207-f0cc6d102729" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9488cf35-896c-44d7-82cd-093106ea1f99" xlink:to="loc_srt_RangeAxis_2efae54b-7969-4578-8207-f0cc6d102729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43632cc3-22cd-4051-8307-55c14758c895" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2efae54b-7969-4578-8207-f0cc6d102729" xlink:to="loc_srt_RangeMember_43632cc3-22cd-4051-8307-55c14758c895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_654233a0-1ee8-4339-98e7-b0fec9334eeb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43632cc3-22cd-4051-8307-55c14758c895" xlink:to="loc_srt_MinimumMember_654233a0-1ee8-4339-98e7-b0fec9334eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_93df657a-12dd-4d1d-b9da-6209ea2790d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43632cc3-22cd-4051-8307-55c14758c895" xlink:to="loc_srt_MaximumMember_93df657a-12dd-4d1d-b9da-6209ea2790d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2ac60f7d-e287-440e-bea4-655f5dccca05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9488cf35-896c-44d7-82cd-093106ea1f99" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_2ac60f7d-e287-440e-bea4-655f5dccca05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccountsReceivablePaymentTerms_50a0165b-3838-4538-9e1a-d0e3849c6b80" xlink:href="pcrx-20211231.xsd#pcrx_AccountsReceivablePaymentTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2ac60f7d-e287-440e-bea4-655f5dccca05" xlink:to="loc_pcrx_AccountsReceivablePaymentTerms_50a0165b-3838-4538-9e1a-d0e3849c6b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/REVENUEDisaggregationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#REVENUEDisaggregationDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/REVENUEDisaggregationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7554e0b3-efe6-45ec-b8e0-c4f3469e42e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_003ad31b-df5e-4ebd-af6e-bc0db9abaccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7554e0b3-efe6-45ec-b8e0-c4f3469e42e0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_003ad31b-df5e-4ebd-af6e-bc0db9abaccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c7cb836e-bdec-4c27-823c-569654ea9519" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_003ad31b-df5e-4ebd-af6e-bc0db9abaccc" xlink:to="loc_srt_ProductOrServiceAxis_c7cb836e-bdec-4c27-823c-569654ea9519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c7cb836e-bdec-4c27-823c-569654ea9519" xlink:to="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EXPARELMember_e1a53925-284d-4981-95bb-6a98e781bdca" xlink:href="pcrx-20211231.xsd#pcrx_EXPARELMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:to="loc_pcrx_EXPARELMember_e1a53925-284d-4981-95bb-6a98e781bdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ZILRETTAMember_12fd72da-a9d1-4189-b4ba-7ef257c43ff0" xlink:href="pcrx-20211231.xsd#pcrx_ZILRETTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:to="loc_pcrx_ZILRETTAMember_12fd72da-a9d1-4189-b4ba-7ef257c43ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IoveraMemberMember_a93588b5-05e4-47a9-aaa4-4aa394e111c3" xlink:href="pcrx-20211231.xsd#pcrx_IoveraMemberMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:to="loc_pcrx_IoveraMemberMember_a93588b5-05e4-47a9-aaa4-4aa394e111c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember_23cd95cb-d4bb-4d5f-ae37-b2a111aa10f5" xlink:href="pcrx-20211231.xsd#pcrx_BupivacaineLiposomeInjectableSuspensionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8686acf-14ac-4dbb-91c1-45466aaff216" xlink:to="loc_pcrx_BupivacaineLiposomeInjectableSuspensionMember_23cd95cb-d4bb-4d5f-ae37-b2a111aa10f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_01db397f-d227-4407-acf9-09e31322235f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_003ad31b-df5e-4ebd-af6e-bc0db9abaccc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_01db397f-d227-4407-acf9-09e31322235f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54da9eea-da83-4bc7-b301-710098a310c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_01db397f-d227-4407-acf9-09e31322235f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54da9eea-da83-4bc7-b301-710098a310c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c3f0a477-48fc-48a9-8f14-7a63bf1ad861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_92eb9ccb-6abf-448a-87ae-d5953d8a2aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c3f0a477-48fc-48a9-8f14-7a63bf1ad861" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_92eb9ccb-6abf-448a-87ae-d5953d8a2aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4259b080-e5ee-44fe-9741-ad7cd8e696f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_71588455-507e-473c-965c-3b1534789620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4259b080-e5ee-44fe-9741-ad7cd8e696f2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_71588455-507e-473c-965c-3b1534789620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_861b9eee-4664-4838-8a63-3c6967dc559c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4259b080-e5ee-44fe-9741-ad7cd8e696f2" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_861b9eee-4664-4838-8a63-3c6967dc559c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_1c028a57-acea-496d-8ec2-0905814ccef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4259b080-e5ee-44fe-9741-ad7cd8e696f2" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_1c028a57-acea-496d-8ec2-0905814ccef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9bf7a49b-420c-4299-b990-e0fcc083c614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9bf7a49b-420c-4299-b990-e0fcc083c614" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_c1a756af-2c5d-4d66-9b01-c52301719f2a" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_c1a756af-2c5d-4d66-9b01-c52301719f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_c1a756af-2c5d-4d66-9b01-c52301719f2a" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementofRegulatoryMilestoneMember_f2cfee7f-8afb-4f9e-92c7-50d9d2b09546" xlink:href="pcrx-20211231.xsd#pcrx_AchievementofRegulatoryMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementofRegulatoryMilestoneMember_f2cfee7f-8afb-4f9e-92c7-50d9d2b09546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfZILRETTASalesOf250MillionMember_a3603197-4bf5-48c9-96c5-08523e18461b" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfZILRETTASalesOf250MillionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfZILRETTASalesOf250MillionMember_a3603197-4bf5-48c9-96c5-08523e18461b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfZILRETTASalesOf375MillionMember_786a37fe-890a-4e56-8745-f89a991d2041" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfZILRETTASalesOf375MillionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfZILRETTASalesOf375MillionMember_786a37fe-890a-4e56-8745-f89a991d2041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfZILRETTASalesOf500MillionMember_6fdeb0c9-7300-4b0c-822c-0b2ce2d157f1" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfZILRETTASalesOf500MillionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfZILRETTASalesOf500MillionMember_6fdeb0c9-7300-4b0c-822c-0b2ce2d157f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfFDAApprovalOfFX201Member_736123ad-7634-4950-ac7a-5e48f8d20b81" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfFDAApprovalOfFX201Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfFDAApprovalOfFX201Member_736123ad-7634-4950-ac7a-5e48f8d20b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfFDAApprovalOfFX301Member_b6bdf62b-9183-45bf-84c5-e7b9cf922206" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfFDAApprovalOfFX301Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_eb9eabaa-6dba-4dfa-b588-ddf365df3fd4" xlink:to="loc_pcrx_AchievementOfFDAApprovalOfFX301Member_b6bdf62b-9183-45bf-84c5-e7b9cf922206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_55ba84b3-e707-423e-b178-bd7e7e72c53f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_55ba84b3-e707-423e-b178-bd7e7e72c53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95386630-e6be-492d-a789-1040a311fbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55ba84b3-e707-423e-b178-bd7e7e72c53f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95386630-e6be-492d-a789-1040a311fbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_fc79ccf5-1e77-447c-a041-2572b98eecaa" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95386630-e6be-492d-a789-1040a311fbf6" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_fc79ccf5-1e77-447c-a041-2572b98eecaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_7e0fbe2f-17ce-4e6f-b965-4f1eb4b68e33" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95386630-e6be-492d-a789-1040a311fbf6" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_7e0fbe2f-17ce-4e6f-b965-4f1eb4b68e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3c651ea9-c017-4769-88eb-28c0404ff776" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_srt_StatementScenarioAxis_3c651ea9-c017-4769-88eb-28c0404ff776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b7541cf3-4547-4597-8ceb-d9f17923f3d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3c651ea9-c017-4769-88eb-28c0404ff776" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b7541cf3-4547-4597-8ceb-d9f17923f3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_918629ee-9060-42d0-aa89-e32c72553596" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b7541cf3-4547-4597-8ceb-d9f17923f3d2" xlink:to="loc_srt_ScenarioForecastMember_918629ee-9060-42d0-aa89-e32c72553596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_001e3cea-3dd2-4720-9a32-b253993fa65d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_001e3cea-3dd2-4720-9a32-b253993fa65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e136da1-6b5f-45f5-b935-01b063ddea9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_001e3cea-3dd2-4720-9a32-b253993fa65d" xlink:to="loc_us-gaap_ClassOfStockDomain_4e136da1-6b5f-45f5-b935-01b063ddea9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember_f88df07f-d09e-4d66-b84d-6a02d342d380" xlink:href="pcrx-20211231.xsd#pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4e136da1-6b5f-45f5-b935-01b063ddea9b" xlink:to="loc_pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember_f88df07f-d09e-4d66-b84d-6a02d342d380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf824e20-5be7-4f73-a44d-c31ada9f56ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf824e20-5be7-4f73-a44d-c31ada9f56ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1bb671d-6878-43ea-b740-89a5a6eef86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf824e20-5be7-4f73-a44d-c31ada9f56ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1bb671d-6878-43ea-b740-89a5a6eef86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cb72af4f-0be0-4bec-9015-668638cd8633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1bb671d-6878-43ea-b740-89a5a6eef86b" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cb72af4f-0be0-4bec-9015-668638cd8633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8ca69768-2d05-473d-9f3f-aa6ab91bf7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1bb671d-6878-43ea-b740-89a5a6eef86b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8ca69768-2d05-473d-9f3f-aa6ab91bf7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_bb6d3b0e-ab89-4468-bb96-6db1a86f1165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_bb6d3b0e-ab89-4468-bb96-6db1a86f1165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_08d63e0e-0aeb-47a1-90e9-01ae842e82d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bb6d3b0e-ab89-4468-bb96-6db1a86f1165" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_08d63e0e-0aeb-47a1-90e9-01ae842e82d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7b625527-8fa7-4ecd-9935-576403e39555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_08d63e0e-0aeb-47a1-90e9-01ae842e82d0" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7b625527-8fa7-4ecd-9935-576403e39555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a0b2a3b4-a555-4df0-bcf8-3870a1f66d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a0b2a3b4-a555-4df0-bcf8-3870a1f66d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_246a8ffb-50b5-48ce-ab42-0b1907dfa16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a0b2a3b4-a555-4df0-bcf8-3870a1f66d6b" xlink:to="loc_us-gaap_ValuationTechniqueDomain_246a8ffb-50b5-48ce-ab42-0b1907dfa16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_bd8a9b71-4cd7-44b3-b2cf-de5f24dfc7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_246a8ffb-50b5-48ce-ab42-0b1907dfa16a" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_bd8a9b71-4cd7-44b3-b2cf-de5f24dfc7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_4e7bfe6a-7254-4e5d-b35d-3f80825b16a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_246a8ffb-50b5-48ce-ab42-0b1907dfa16a" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_4e7bfe6a-7254-4e5d-b35d-3f80825b16a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cd93adbb-b5d0-4437-810c-25cdb0c426d4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e88eac97-1702-4887-b476-03d61edb012a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e88eac97-1702-4887-b476-03d61edb012a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_164170e7-1267-477c-ba8b-3728b9c2c2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_164170e7-1267-477c-ba8b-3728b9c2c2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_6db1b8cc-754e-4422-9196-353ad9775a8d" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_6db1b8cc-754e-4422-9196-353ad9775a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_4ff70de3-96bf-49ee-bb55-1a7e7441316b" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_4ff70de3-96bf-49ee-bb55-1a7e7441316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5a653e07-7716-4a2f-b6ad-c11e26637772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5a653e07-7716-4a2f-b6ad-c11e26637772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d284582d-6aa3-4380-a4fc-05623e2e32c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d284582d-6aa3-4380-a4fc-05623e2e32c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold_d84e7d44-913b-491f-8d04-e035671e906b" xlink:href="pcrx-20211231.xsd#pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold_d84e7d44-913b-491f-8d04-e035671e906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsideration_4ed9da5a-6830-4b3c-a391-d8412359959e" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsideration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_ContingentConsideration_4ed9da5a-6830-4b3c-a391-d8412359959e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7b7fa2e1-7f53-40d3-aa2c-b8560ba0c486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7b7fa2e1-7f53-40d3-aa2c-b8560ba0c486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88189605-63ba-4ab6-9829-4bb6848ef3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88189605-63ba-4ab6-9829-4bb6848ef3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsMeasurementInput_e63bc76f-1543-4121-ae65-3b1adda5de48" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsMeasurementInput"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsMeasurementInput_e63bc76f-1543-4121-ae65-3b1adda5de48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate_e15037a3-512c-4ca2-a1d9-4a30b6e604df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate_e15037a3-512c-4ca2-a1d9-4a30b6e604df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationCurrent_94a0a9f7-7d09-4377-9714-3253bab99bd7" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_ContingentConsiderationCurrent_94a0a9f7-7d09-4377-9714-3253bab99bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationPaymentTerm_0f463d74-5969-43d0-9345-26fdfcf4c745" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationPaymentTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_pcrx_ContingentConsiderationPaymentTerm_0f463d74-5969-43d0-9345-26fdfcf4c745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a9204dc-7159-4770-82a4-6f6bba3947a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dc11821d-48ae-4a05-9b15-b5c76b6a2f60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a9204dc-7159-4770-82a4-6f6bba3947a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2527816a-a854-4f9f-b0bd-5d880feeb6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2527816a-a854-4f9f-b0bd-5d880feeb6f7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cd9b90fb-9ad5-4071-9eb8-1bc407bfe4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cd9b90fb-9ad5-4071-9eb8-1bc407bfe4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b15c45d-5d1c-4ee1-a32d-5698a51b51ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cd9b90fb-9ad5-4071-9eb8-1bc407bfe4bb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b15c45d-5d1c-4ee1-a32d-5698a51b51ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_24d320b5-cd8e-4163-8b2f-80fb8a313951" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b15c45d-5d1c-4ee1-a32d-5698a51b51ce" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_24d320b5-cd8e-4163-8b2f-80fb8a313951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e6ebe861-670d-430d-a0d3-7dad9622db6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e6ebe861-670d-430d-a0d3-7dad9622db6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b9967a7f-0b44-45ad-a4cf-647046b80a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e6ebe861-670d-430d-a0d3-7dad9622db6c" xlink:to="loc_us-gaap_ClassOfStockDomain_b9967a7f-0b44-45ad-a4cf-647046b80a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_52cdc1da-37f6-4a93-b35f-eb6c1771b33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9967a7f-0b44-45ad-a4cf-647046b80a51" xlink:to="loc_us-gaap_CommonStockMember_52cdc1da-37f6-4a93-b35f-eb6c1771b33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_03119b30-d7da-427e-b5da-4036d44a419e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b9967a7f-0b44-45ad-a4cf-647046b80a51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_03119b30-d7da-427e-b5da-4036d44a419e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0cff462c-8d5b-4eb0-8ec4-6f2572ec46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0cff462c-8d5b-4eb0-8ec4-6f2572ec46d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a67374bb-823b-44af-953b-42b6d7dfde7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0cff462c-8d5b-4eb0-8ec4-6f2572ec46d6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a67374bb-823b-44af-953b-42b6d7dfde7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtMember_4f5a2942-fe30-48b5-b246-63640c999671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a67374bb-823b-44af-953b-42b6d7dfde7f" xlink:to="loc_us-gaap_DebtMember_4f5a2942-fe30-48b5-b246-63640c999671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ac4b05b-176f-412a-beb9-d3fdf1dfc22d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_306e0fb1-40e9-4379-aa29-476496addb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_306e0fb1-40e9-4379-aa29-476496addb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_a6b4a14a-7af7-4f15-a938-6db956929c36" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:to="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt_a6b4a14a-7af7-4f15-a938-6db956929c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_93057605-c701-4149-8032-6f963d1b8960" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:to="loc_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration_93057605-c701-4149-8032-6f963d1b8960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_670b782d-57a7-4be0-9ef9-6fc026127eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10c51c66-4045-422f-b838-7a7389a05cc0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_670b782d-57a7-4be0-9ef9-6fc026127eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f08f7071-8d2b-4355-a325-93ad841f149e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_708791d2-20be-4c0a-93de-172680ce50bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f08f7071-8d2b-4355-a325-93ad841f149e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_708791d2-20be-4c0a-93de-172680ce50bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cce4ccc1-8106-454c-9574-e3fafe798d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_708791d2-20be-4c0a-93de-172680ce50bd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cce4ccc1-8106-454c-9574-e3fafe798d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_400dad88-4d50-405f-a998-4f74eb449ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cce4ccc1-8106-454c-9574-e3fafe798d5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_400dad88-4d50-405f-a998-4f74eb449ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_99b31066-d42e-4cfe-80cb-a05bc4702662" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_400dad88-4d50-405f-a998-4f74eb449ed2" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_99b31066-d42e-4cfe-80cb-a05bc4702662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_708791d2-20be-4c0a-93de-172680ce50bd" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_fa473f85-3619-49fb-b5bb-399c59593682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_fa473f85-3619-49fb-b5bb-399c59593682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_057527cd-20fa-43f0-96e4-6b3e60c981ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_057527cd-20fa-43f0-96e4-6b3e60c981ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_61dd249a-b800-4834-bfde-9b63e407fe27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_61dd249a-b800-4834-bfde-9b63e407fe27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e412a0b0-0038-4aa1-8122-b97b4d7ce064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e412a0b0-0038-4aa1-8122-b97b4d7ce064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_23d7995c-33f9-49f1-9679-9cce96913b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_23d7995c-33f9-49f1-9679-9cce96913b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ff38a469-6060-4af7-8d2e-98f87a483647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ff38a469-6060-4af7-8d2e-98f87a483647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_2d841fd3-b19d-4636-b02d-59ab27e8f7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_2d841fd3-b19d-4636-b02d-59ab27e8f7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_92df4175-dfad-46c3-b31f-fa487c9ce4c7" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_92df4175-dfad-46c3-b31f-fa487c9ce4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85adcd38-2945-4994-9b6d-5ecd459c85c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_85adcd38-2945-4994-9b6d-5ecd459c85c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6b02fe8a-1cd8-4631-ba92-fa70e1a39560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6b02fe8a-1cd8-4631-ba92-fa70e1a39560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dd633326-6280-40e5-ba23-c8ba12c9ca9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_ce961dcc-7091-408b-b1e3-b32d5e5ba8c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dd633326-6280-40e5-ba23-c8ba12c9ca9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6f02e44d-152a-4753-9cb0-373811724ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6f02e44d-152a-4753-9cb0-373811724ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_28ff9b58-86e9-46d6-8a6c-ec5eb014a444" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_28ff9b58-86e9-46d6-8a6c-ec5eb014a444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ec37defe-516e-4efb-b868-fc8268dd28ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ec37defe-516e-4efb-b868-fc8268dd28ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_49312711-6c35-4f15-877d-b7c9661aa37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_49312711-6c35-4f15-877d-b7c9661aa37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_601a4657-06c4-4dc2-b6ab-cc6f34a8a9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_601a4657-06c4-4dc2-b6ab-cc6f34a8a9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_4686fda5-ecaa-4db5-bfdc-8147f1572306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_4686fda5-ecaa-4db5-bfdc-8147f1572306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f7a3c7b7-b401-429a-9cfa-c5b13adf3fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f7a3c7b7-b401-429a-9cfa-c5b13adf3fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2bc65ff9-1158-4c89-ab5f-8c4cfbd222ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2bc65ff9-1158-4c89-ab5f-8c4cfbd222ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f161332d-ebfc-49b1-9052-9d4a979ce15b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_b0745d14-407b-4257-93ac-3e9ebfc79bf2" xlink:to="loc_us-gaap_Goodwill_f161332d-ebfc-49b1-9052-9d4a979ce15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0e583eed-e2bb-4fb3-beb7-ed84d5bbc682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed7d6d15-3c38-4f8b-8de0-b75e4af6d29b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0e583eed-e2bb-4fb3-beb7-ed84d5bbc682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSFlexionResultsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_febf2ac5-d533-48fe-8526-2a8afeb6ee02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b3bedf38-7c73-458a-b521-3ff05ab3690c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_febf2ac5-d533-48fe-8526-2a8afeb6ee02" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b3bedf38-7c73-458a-b521-3ff05ab3690c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_65689c0f-fd63-4f72-879d-edfbd02b7689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b3bedf38-7c73-458a-b521-3ff05ab3690c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_65689c0f-fd63-4f72-879d-edfbd02b7689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d364217-ded9-460f-a95b-60e6fee55089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_65689c0f-fd63-4f72-879d-edfbd02b7689" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d364217-ded9-460f-a95b-60e6fee55089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_c7a98345-106d-4872-90b4-6f077a22f602" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d364217-ded9-460f-a95b-60e6fee55089" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_c7a98345-106d-4872-90b4-6f077a22f602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_91c39040-dc4f-40dd-84f6-ca7d0f512a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b3bedf38-7c73-458a-b521-3ff05ab3690c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_91c39040-dc4f-40dd-84f6-ca7d0f512a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_d0e112b5-36be-4296-af55-aa510ce90b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91c39040-dc4f-40dd-84f6-ca7d0f512a1e" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_d0e112b5-36be-4296-af55-aa510ce90b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_ba0da800-363d-4926-b558-a9a59e3d430f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91c39040-dc4f-40dd-84f6-ca7d0f512a1e" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_ba0da800-363d-4926-b558-a9a59e3d430f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONSScheduleofProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9767340b-f32c-42c4-92cf-d31e3edf2474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6e07ed-bab0-48e6-a894-9e462c062140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9767340b-f32c-42c4-92cf-d31e3edf2474" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6e07ed-bab0-48e6-a894-9e462c062140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_705b1be2-8be2-4a45-ac00-e35d42fc08cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6e07ed-bab0-48e6-a894-9e462c062140" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_705b1be2-8be2-4a45-ac00-e35d42fc08cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dccccdb-8398-4251-bb5d-3f18834eec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_705b1be2-8be2-4a45-ac00-e35d42fc08cf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dccccdb-8398-4251-bb5d-3f18834eec2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_74c2220d-1915-4a0c-b127-0b999fa6c133" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dccccdb-8398-4251-bb5d-3f18834eec2e" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_74c2220d-1915-4a0c-b127-0b999fa6c133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b6e07ed-bab0-48e6-a894-9e462c062140" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ead43ebb-c88c-4f83-b820-62e28c33917b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ead43ebb-c88c-4f83-b820-62e28c33917b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_31206367-0902-4b53-9652-d854f3e72ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_31206367-0902-4b53-9652-d854f3e72ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_b5eb432d-8f53-49bb-a467-d77a1730ce97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_b5eb432d-8f53-49bb-a467-d77a1730ce97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_ac005158-4259-47b2-bb7a-2d656a3a9f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5841392a-b1b5-4241-8be6-fe16044730b6" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_ac005158-4259-47b2-bb7a-2d656a3a9f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIES" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9f6106fb-8c70-4ede-a7ad-a66380e1e473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_91170f62-4f98-48f5-bef6-e4b8578d703f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9f6106fb-8c70-4ede-a7ad-a66380e1e473" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_91170f62-4f98-48f5-bef6-e4b8578d703f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_51106d75-fb63-4068-a671-b1e3710a3cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c4cd605d-3e09-489b-8424-eb368b59ef3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_51106d75-fb63-4068-a671-b1e3710a3cd2" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c4cd605d-3e09-489b-8424-eb368b59ef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INVENTORIESComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2efe3a61-5711-44f7-8929-92822710a3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_213aa2af-0046-4367-bb8c-b5fc77f6edcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2efe3a61-5711-44f7-8929-92822710a3f5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_213aa2af-0046-4367-bb8c-b5fc77f6edcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7fcf1c4a-8c11-4b1d-8a9e-db42151f3b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2efe3a61-5711-44f7-8929-92822710a3f5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7fcf1c4a-8c11-4b1d-8a9e-db42151f3b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_59bf7bdb-3ca7-4374-9c52-429c1ba73c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2efe3a61-5711-44f7-8929-92822710a3f5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_59bf7bdb-3ca7-4374-9c52-429c1ba73c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b2e817de-55b3-4c07-a9b7-8404f177cbef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2efe3a61-5711-44f7-8929-92822710a3f5" xlink:to="loc_us-gaap_InventoryNet_b2e817de-55b3-4c07-a9b7-8404f177cbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FIXEDASSETS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FIXEDASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_718c166a-5296-44ea-9065-0ef1e936691e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ca92d360-5ad0-4f48-ba64-cbe7adb86c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_718c166a-5296-44ea-9065-0ef1e936691e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ca92d360-5ad0-4f48-ba64-cbe7adb86c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FIXEDASSETSTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FIXEDASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_30f70b71-e575-472c-859a-0e27663a921b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1c898cf4-258a-4e2b-843b-1f8c42cefcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_30f70b71-e575-472c-859a-0e27663a921b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1c898cf4-258a-4e2b-843b-1f8c42cefcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FIXEDASSETSScheduleofUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_20efa40b-2bdf-4a67-8a26-b6ba62adb942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9946f908-258a-478e-9c6f-810f65c67c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_20efa40b-2bdf-4a67-8a26-b6ba62adb942" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9946f908-258a-478e-9c6f-810f65c67c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79595806-d69e-4d93-aa46-78b6eeeea65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9946f908-258a-478e-9c6f-810f65c67c3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79595806-d69e-4d93-aa46-78b6eeeea65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_79595806-d69e-4d93-aa46-78b6eeeea65e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_26fb3bf0-5fec-487d-8d1c-5882bd91e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_26fb3bf0-5fec-487d-8d1c-5882bd91e9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d0a26896-e57a-4d55-99af-88b02e24b144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d0a26896-e57a-4d55-99af-88b02e24b144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ComputerEquipmentAndSoftwareMember_e3a7bcdb-b495-4fef-9990-805c0f39dc45" xlink:href="pcrx-20211231.xsd#pcrx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_pcrx_ComputerEquipmentAndSoftwareMember_e3a7bcdb-b495-4fef-9990-805c0f39dc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9a5d1061-1dfc-4b12-8ea0-84c8c658fd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9a5d1061-1dfc-4b12-8ea0-84c8c658fd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_720a2453-c3a0-419a-8a8c-919cc400c6be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427ca4e5-608a-4e64-abce-815810352031" xlink:to="loc_us-gaap_ConstructionInProgressMember_720a2453-c3a0-419a-8a8c-919cc400c6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9946f908-258a-478e-9c6f-810f65c67c3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7867e206-70a7-41f7-9442-06e498d29362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7867e206-70a7-41f7-9442-06e498d29362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45b41eca-94f2-4a76-a530-61834cd80745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_45b41eca-94f2-4a76-a530-61834cd80745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b6439e63-9d3d-4e1c-b773-61ca0dc4a51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81877b60-6911-4421-a561-e9e7df354b57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b6439e63-9d3d-4e1c-b773-61ca0dc4a51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FIXEDASSETSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fa859f73-bfba-423d-b627-d7e2cc2eef41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ac8fc279-1617-480d-b3b0-dc436996b196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fa859f73-bfba-423d-b627-d7e2cc2eef41" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ac8fc279-1617-480d-b3b0-dc436996b196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ef843818-909f-46f7-a8c4-4885c99839a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ac8fc279-1617-480d-b3b0-dc436996b196" xlink:to="loc_srt_StatementGeographicalAxis_ef843818-909f-46f7-a8c4-4885c99839a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_976f6009-2c8d-41b7-90de-5fa1e43a15dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ef843818-909f-46f7-a8c4-4885c99839a1" xlink:to="loc_srt_SegmentGeographicalDomain_976f6009-2c8d-41b7-90de-5fa1e43a15dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_477ad551-64f8-49b3-95eb-795627939562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_976f6009-2c8d-41b7-90de-5fa1e43a15dc" xlink:to="loc_us-gaap_NonUsMember_477ad551-64f8-49b3-95eb-795627939562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20bdd415-50b6-4e35-a918-ebafd3540eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ac8fc279-1617-480d-b3b0-dc436996b196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20bdd415-50b6-4e35-a918-ebafd3540eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a5ff263-5737-494b-be3d-80a848b17b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20bdd415-50b6-4e35-a918-ebafd3540eb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a5ff263-5737-494b-be3d-80a848b17b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7f4b6074-d4e7-402c-b0d0-9c16911333fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a5ff263-5737-494b-be3d-80a848b17b03" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7f4b6074-d4e7-402c-b0d0-9c16911333fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ac8fc279-1617-480d-b3b0-dc436996b196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8511fd6b-334d-40e4-b3fa-e27a9ad45305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:to="loc_us-gaap_Depreciation_8511fd6b-334d-40e4-b3fa-e27a9ad45305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_fc5e9e19-0639-48d7-a2c7-ce72ad46966f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:to="loc_us-gaap_InterestCostsCapitalized_fc5e9e19-0639-48d7-a2c7-ce72ad46966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6f9b3049-a903-41b1-b62b-8821d0fb3906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6f9b3049-a903-41b1-b62b-8821d0fb3906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligation_e3086050-8afa-4dab-9e19-fd0d2a038367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetRetirementObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_abe1dc1d-deaa-4b47-a027-824b08569201" xlink:to="loc_us-gaap_AssetRetirementObligation_e3086050-8afa-4dab-9e19-fd0d2a038367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASES" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_51c62314-657e-46aa-904a-e123a49ae674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_10ed5132-307d-45a3-9b80-428eaea0c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_51c62314-657e-46aa-904a-e123a49ae674" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_10ed5132-307d-45a3-9b80-428eaea0c60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5640b0d6-fd87-4f98-a488-168453fd0881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_950029cc-a82e-4b91-bb1b-b704b7172831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5640b0d6-fd87-4f98-a488-168453fd0881" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_950029cc-a82e-4b91-bb1b-b704b7172831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c7d93ef2-8cb3-4354-975d-ccfce30a1314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5640b0d6-fd87-4f98-a488-168453fd0881" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c7d93ef2-8cb3-4354-975d-ccfce30a1314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_54f8d539-d8d4-4caf-a249-54ee8049c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_dc3f2a85-34a0-47fb-9369-042673c3ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_54f8d539-d8d4-4caf-a249-54ee8049c88c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_dc3f2a85-34a0-47fb-9369-042673c3ed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0e2e4490-662d-49be-946a-90396076c826" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dc3f2a85-34a0-47fb-9369-042673c3ed37" xlink:to="loc_srt_RangeAxis_0e2e4490-662d-49be-946a-90396076c826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fbe2a5a9-1450-4d44-88cb-f4f64ad66707" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0e2e4490-662d-49be-946a-90396076c826" xlink:to="loc_srt_RangeMember_fbe2a5a9-1450-4d44-88cb-f4f64ad66707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aa21522a-15f4-4bc6-af83-b10da75ff87b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fbe2a5a9-1450-4d44-88cb-f4f64ad66707" xlink:to="loc_srt_MaximumMember_aa21522a-15f4-4bc6-af83-b10da75ff87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9a2b1a00-d88d-47f3-a4ce-89299d9fe95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dc3f2a85-34a0-47fb-9369-042673c3ed37" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9a2b1a00-d88d-47f3-a4ce-89299d9fe95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e0e06b4-c822-49b7-a93b-c8c77743c790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9a2b1a00-d88d-47f3-a4ce-89299d9fe95a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e0e06b4-c822-49b7-a93b-c8c77743c790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_cbe5cb4d-2b17-48de-b21a-6c38c4e6dd38" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e0e06b4-c822-49b7-a93b-c8c77743c790" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_cbe5cb4d-2b17-48de-b21a-6c38c4e6dd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dc3f2a85-34a0-47fb-9369-042673c3ed37" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_48a111f3-ee39-4256-b55d-7caf3ee7b30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_48a111f3-ee39-4256-b55d-7caf3ee7b30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e0e0320c-b5e0-47bf-9784-09e6f0f220dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:to="loc_us-gaap_OperatingLeaseLiability_e0e0320c-b5e0-47bf-9784-09e6f0f220dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfLocationsNewOperatingLeaseLiability_2cc6609e-b508-45ae-ab5f-303ae05fb210" xlink:href="pcrx-20211231.xsd#pcrx_NumberOfLocationsNewOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bdd462f2-1a3b-481d-9e5e-10b52514731a" xlink:to="loc_pcrx_NumberOfLocationsNewOperatingLeaseLiability_2cc6609e-b508-45ae-ab5f-303ae05fb210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4cc99136-fe36-4719-a020-4ee129c68304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_ed212f32-819f-4efc-a62e-c0610e1841bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cc99136-fe36-4719-a020-4ee129c68304" xlink:to="loc_us-gaap_LeaseCostAbstract_ed212f32-819f-4efc-a62e-c0610e1841bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_24f0ac9e-d8b0-4ad3-8e09-f0d242b8a731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ed212f32-819f-4efc-a62e-c0610e1841bf" xlink:to="loc_us-gaap_OperatingLeaseCost_24f0ac9e-d8b0-4ad3-8e09-f0d242b8a731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_a6cfae75-e0c7-425c-84fa-afd903becee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ed212f32-819f-4efc-a62e-c0610e1841bf" xlink:to="loc_us-gaap_VariableLeaseCost_a6cfae75-e0c7-425c-84fa-afd903becee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_85f3ff2f-312c-4de4-bb1a-7b7ab92470dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_ed212f32-819f-4efc-a62e-c0610e1841bf" xlink:to="loc_us-gaap_LeaseCost_85f3ff2f-312c-4de4-bb1a-7b7ab92470dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_07159353-7ab4-4020-b2e4-c4a898982094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cc99136-fe36-4719-a020-4ee129c68304" xlink:to="loc_us-gaap_OperatingLeasePayments_07159353-7ab4-4020-b2e4-c4a898982094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c9664607-06f7-4216-a71e-380691f4f40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cc99136-fe36-4719-a020-4ee129c68304" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c9664607-06f7-4216-a71e-380691f4f40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_750ed896-040c-4c4d-bb0a-a063cbef64f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cc99136-fe36-4719-a020-4ee129c68304" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_750ed896-040c-4c4d-bb0a-a063cbef64f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fb2f879e-2115-4ea6-896b-da2b277fa30a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cc99136-fe36-4719-a020-4ee129c68304" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fb2f879e-2115-4ea6-896b-da2b277fa30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6af9378c-df3e-44d0-a5ce-70c87a81d69a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6af9378c-df3e-44d0-a5ce-70c87a81d69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d002ce12-8428-4b18-bbf6-38a5ffa5ef9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d002ce12-8428-4b18-bbf6-38a5ffa5ef9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_96292db5-49f6-483f-98dd-d6e0590c86ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_96292db5-49f6-483f-98dd-d6e0590c86ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9e295c6c-dbe1-4e1f-bd46-32c7e1534286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9e295c6c-dbe1-4e1f-bd46-32c7e1534286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_91731324-ea00-4026-9faf-5a78e668a271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_91731324-ea00-4026-9faf-5a78e668a271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dd299a03-e781-45ec-b0d7-34e9d20c5a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_dd299a03-e781-45ec-b0d7-34e9d20c5a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d102cec4-f4f6-48e9-833b-5530c60acc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d102cec4-f4f6-48e9-833b-5530c60acc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_14171954-d766-42a1-b7d2-7bb8191d0ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_14171954-d766-42a1-b7d2-7bb8191d0ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9c1963c3-50f7-48af-8117-fed933e3cdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e836d790-0591-4dda-b0fc-7fe713e865c6" xlink:to="loc_us-gaap_OperatingLeaseLiability_9c1963c3-50f7-48af-8117-fed933e3cdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="simple" xlink:href="pcrx-20211231.xsd#LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#GOODWILLANDINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_517b4f2f-1583-4f20-a7a9-479cf9534adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1e0681b1-0774-455c-af73-100d2f704f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_517b4f2f-1583-4f20-a7a9-479cf9534adf" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1e0681b1-0774-455c-af73-100d2f704f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_82cad198-36a1-4120-bd79-0322578b1a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_d31711b1-cd1c-47c6-9b0f-25438af69c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_82cad198-36a1-4120-bd79-0322578b1a69" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_d31711b1-cd1c-47c6-9b0f-25438af69c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a12497d6-9dc2-4ba7-ba3a-c07de32b1941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_82cad198-36a1-4120-bd79-0322578b1a69" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a12497d6-9dc2-4ba7-ba3a-c07de32b1941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#GOODWILLANDINTANGIBLEASSETSGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_743a5286-1d5d-46ab-93aa-75448c01d10f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_4f028abf-d979-4bca-87ae-163cf065fb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_743a5286-1d5d-46ab-93aa-75448c01d10f" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_4f028abf-d979-4bca-87ae-163cf065fb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5e3ea676-6d14-4ed9-8c1e-6b18f33b9fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_4f028abf-d979-4bca-87ae-163cf065fb80" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5e3ea676-6d14-4ed9-8c1e-6b18f33b9fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0bcebedf-f251-4318-8d5d-7af3d11ca007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e3ea676-6d14-4ed9-8c1e-6b18f33b9fbf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0bcebedf-f251-4318-8d5d-7af3d11ca007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SkyePharmaHoldingIncMember_b0755f58-f5c6-4572-a4db-d5b4ab0c00c5" xlink:href="pcrx-20211231.xsd#pcrx_SkyePharmaHoldingIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0bcebedf-f251-4318-8d5d-7af3d11ca007" xlink:to="loc_pcrx_SkyePharmaHoldingIncMember_b0755f58-f5c6-4572-a4db-d5b4ab0c00c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_332d4354-6872-43e2-82b1-fc8a60e916c1" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0bcebedf-f251-4318-8d5d-7af3d11ca007" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_332d4354-6872-43e2-82b1-fc8a60e916c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f6a233d1-6755-4af2-a83f-946d2911aecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_4f028abf-d979-4bca-87ae-163cf065fb80" xlink:to="loc_us-gaap_GoodwillLineItems_f6a233d1-6755-4af2-a83f-946d2911aecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_f6a233d1-6755-4af2-a83f-946d2911aecb" xlink:to="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a10e00d3-65b4-49ea-a841-9c9ed006f0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:to="loc_us-gaap_Goodwill_a10e00d3-65b4-49ea-a841-9c9ed006f0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_12a81ef3-3746-47f5-91be-784ac5f7565e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:to="loc_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_12a81ef3-3746-47f5-91be-784ac5f7565e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2d08c200-40c7-4f33-90c9-b842b8a8cbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2d08c200-40c7-4f33-90c9-b842b8a8cbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a3d3f618-cd00-4a19-94f1-b7ec16064d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b4a00d04-39e2-4617-8315-2a5f392d906a" xlink:to="loc_us-gaap_Goodwill_a3d3f618-cd00-4a19-94f1-b7ec16064d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#GOODWILLANDINTANGIBLEASSETSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9a537c52-f07b-42c8-9067-e92cc6094088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_12db2844-2f27-4029-9142-45158d2c38bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9a537c52-f07b-42c8-9067-e92cc6094088" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_12db2844-2f27-4029-9142-45158d2c38bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_4514a424-bdae-4b6d-a5c3-f1b93b1101a4" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_12db2844-2f27-4029-9142-45158d2c38bc" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_4514a424-bdae-4b6d-a5c3-f1b93b1101a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_9af64e38-4ba1-45f3-898d-bf683f0b6ce2" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_4514a424-bdae-4b6d-a5c3-f1b93b1101a4" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_9af64e38-4ba1-45f3-898d-bf683f0b6ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_106ff6c4-57ca-4679-a2fc-c74760af3b5a" xlink:href="pcrx-20211231.xsd#pcrx_UponFirstCommercialSaleInMajorEUCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_9af64e38-4ba1-45f3-898d-bf683f0b6ce2" xlink:to="loc_pcrx_UponFirstCommercialSaleInMajorEUCountryMember_106ff6c4-57ca-4679-a2fc-c74760af3b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_231bf1f2-81ef-405d-9443-46f4e64a1d17" xlink:href="pcrx-20211231.xsd#pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_9af64e38-4ba1-45f3-898d-bf683f0b6ce2" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_231bf1f2-81ef-405d-9443-46f4e64a1d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_df474720-fca4-412b-bd00-4c4f56f87004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_12db2844-2f27-4029-9142-45158d2c38bc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_df474720-fca4-412b-bd00-4c4f56f87004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e775faa3-f952-4aea-bc8a-e5697b56935c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_df474720-fca4-412b-bd00-4c4f56f87004" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e775faa3-f952-4aea-bc8a-e5697b56935c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_bbb6ab71-fc4f-485e-ab58-fe31c67ec6f7" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e775faa3-f952-4aea-bc8a-e5697b56935c" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_bbb6ab71-fc4f-485e-ab58-fe31c67ec6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_12db2844-2f27-4029-9142-45158d2c38bc" xlink:to="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_d5929913-88f6-478f-9c16-465bc3bffbde" xlink:href="pcrx-20211231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_d5929913-88f6-478f-9c16-465bc3bffbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_ee64dec5-60a0-4af5-9569-ff39621d13f0" xlink:href="pcrx-20211231.xsd#pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_ee64dec5-60a0-4af5-9569-ff39621d13f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_68eae083-8570-4754-ad06-6a3bf6bf2109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_us-gaap_Goodwill_68eae083-8570-4754-ad06-6a3bf6bf2109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f3b52912-9769-432a-bc23-a1bcce28a149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f3b52912-9769-432a-bc23-a1bcce28a149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1_06f01ffe-2422-426d-a620-7daac0ddb702" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1_06f01ffe-2422-426d-a620-7daac0ddb702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3_29017348-be05-4243-b5f1-c10ef95a5ca7" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3_29017348-be05-4243-b5f1-c10ef95a5ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2_e031e98b-4eb3-4410-8cba-08701fb2a95e" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2_e031e98b-4eb3-4410-8cba-08701fb2a95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4_f70469dc-66c5-4e9c-9027-3eeb0440e160" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4_f70469dc-66c5-4e9c-9027-3eeb0440e160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5_34ec66df-5142-4948-81ce-f7966a9e3127" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5_34ec66df-5142-4948-81ce-f7966a9e3127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6_0f7335d0-faa7-45a5-9d33-f6735c4454dc" xlink:href="pcrx-20211231.xsd#pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a8b17a60-6174-45b5-b094-bc8ef27dc194" xlink:to="loc_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6_0f7335d0-faa7-45a5-9d33-f6735c4454dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bc046d84-f431-4714-9abb-96de1366524f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_a72af40a-6e0f-4658-a5af-98c5ed2e21a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bc046d84-f431-4714-9abb-96de1366524f" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_a72af40a-6e0f-4658-a5af-98c5ed2e21a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0858800-5018-4431-854d-d695bf201043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_a72af40a-6e0f-4658-a5af-98c5ed2e21a4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0858800-5018-4431-854d-d695bf201043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0858800-5018-4431-854d-d695bf201043" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_e51c18f7-001c-4199-9a4d-387d6806ade3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_e51c18f7-001c-4199-9a4d-387d6806ade3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_af6817e6-4dad-4fbb-bf9d-6a2208242c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:to="loc_us-gaap_CustomerRelationshipsMember_af6817e6-4dad-4fbb-bf9d-6a2208242c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c343b729-0667-4abe-97ca-aaf62711f088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99237b87-88ce-4974-bc23-42de1513cafe" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c343b729-0667-4abe-97ca-aaf62711f088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_a72af40a-6e0f-4658-a5af-98c5ed2e21a4" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bdd5ec08-fd0b-47e0-957c-1861a46758dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bdd5ec08-fd0b-47e0-957c-1861a46758dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fca902f6-ccbd-4311-a65b-46e156eeca41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fca902f6-ccbd-4311-a65b-46e156eeca41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aebb3257-648a-4f1a-b3dc-be4e3c9d73ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aebb3257-648a-4f1a-b3dc-be4e3c9d73ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_82d916f5-283d-4a12-a45c-3d664238b70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_82d916f5-283d-4a12-a45c-3d664238b70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a39cbb92-ee32-4789-9f64-705efd42005d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a39cbb92-ee32-4789-9f64-705efd42005d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_41a90974-142f-409a-925c-ac5701001857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_41a90974-142f-409a-925c-ac5701001857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d13cd5a3-6f03-4df7-b414-dc78ff0537ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d13cd5a3-6f03-4df7-b414-dc78ff0537ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e5d01cdb-1871-4a6e-b985-4a61ca600a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_990857b9-f897-4022-8b7b-b4fa266b4536" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e5d01cdb-1871-4a6e-b985-4a61ca600a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_26f0ad53-38b1-4e54-bace-8a0a993f82b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1ad99c0c-642f-413d-96ae-011d67c25a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_26f0ad53-38b1-4e54-bace-8a0a993f82b7" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1ad99c0c-642f-413d-96ae-011d67c25a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a56e8e7c-1bfc-4a1e-b413-480bf89388e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fa29db36-866d-4b6e-8619-efad1f3ee6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a56e8e7c-1bfc-4a1e-b413-480bf89388e1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_fa29db36-866d-4b6e-8619-efad1f3ee6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8f125ed5-9bfb-4a43-a4cd-c8af3ca260a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesTable_f759c4b5-b1b0-48aa-b2f3-db1d5746175b" xlink:href="pcrx-20211231.xsd#pcrx_AccruedExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8f125ed5-9bfb-4a43-a4cd-c8af3ca260a5" xlink:to="loc_pcrx_AccruedExpensesTable_f759c4b5-b1b0-48aa-b2f3-db1d5746175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_204acf46-d7a2-4bb8-af81-8c4c8b556962" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesTable_f759c4b5-b1b0-48aa-b2f3-db1d5746175b" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_204acf46-d7a2-4bb8-af81-8c4c8b556962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_0cae7b13-d9e9-4e4a-81e0-ede569b278bc" xlink:href="pcrx-20211231.xsd#pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis_204acf46-d7a2-4bb8-af81-8c4c8b556962" xlink:to="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_0cae7b13-d9e9-4e4a-81e0-ede569b278bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_d5b43ba9-e559-4cbf-8be1-0aca968c6564" xlink:href="pcrx-20211231.xsd#pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain_0cae7b13-d9e9-4e4a-81e0-ede569b278bc" xlink:to="loc_pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember_d5b43ba9-e559-4cbf-8be1-0aca968c6564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:href="pcrx-20211231.xsd#pcrx_AccruedExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesTable_f759c4b5-b1b0-48aa-b2f3-db1d5746175b" xlink:to="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_Accruedsellinggeneralandadministrativeexpenses_95a358e9-6a7b-4408-a917-d2f26dc97689" xlink:href="pcrx-20211231.xsd#pcrx_Accruedsellinggeneralandadministrativeexpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_Accruedsellinggeneralandadministrativeexpenses_95a358e9-6a7b-4408-a917-d2f26dc97689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_Accruedresearchanddevelopmentexpenses_9ca9daa2-f86e-4426-ad67-149b153b7bac" xlink:href="pcrx-20211231.xsd#pcrx_Accruedresearchanddevelopmentexpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_Accruedresearchanddevelopmentexpenses_9ca9daa2-f86e-4426-ad67-149b153b7bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedOperatingExpensesCurrent_f3753220-cef3-4361-a116-31cf717dbabd" xlink:href="pcrx-20211231.xsd#pcrx_AccruedOperatingExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_AccruedOperatingExpensesCurrent_f3753220-cef3-4361-a116-31cf717dbabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f4708ba8-879b-403f-947d-398f60020135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f4708ba8-879b-403f-947d-398f60020135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_44d078d1-60da-4415-b8a7-8cc37ad0649b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_44d078d1-60da-4415-b8a7-8cc37ad0649b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AccruedEndOfTermFeeCurrent_a3df5888-34b3-4968-b216-5838ee111d0a" xlink:href="pcrx-20211231.xsd#pcrx_AccruedEndOfTermFeeCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_AccruedEndOfTermFeeCurrent_a3df5888-34b3-4968-b216-5838ee111d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ProductReturnsRebatesandOtherFees_0ad12dc2-9f23-46ee-a376-379608171176" xlink:href="pcrx-20211231.xsd#pcrx_ProductReturnsRebatesandOtherFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_ProductReturnsRebatesandOtherFees_0ad12dc2-9f23-46ee-a376-379608171176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_50f4c57b-ceb9-46fe-8eaf-b06d00bd2d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_50f4c57b-ceb9-46fe-8eaf-b06d00bd2d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_b54ca5b7-6976-43f5-bf03-d72cf57dbba7" xlink:href="pcrx-20211231.xsd#pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition_b54ca5b7-6976-43f5-bf03-d72cf57dbba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_067cbe5c-6ded-4675-b1b6-de4725b929b1" xlink:href="pcrx-20211231.xsd#pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AccruedExpensesLineItems_3ef8362c-1e8d-412a-8d3f-03fdc991afdf" xlink:to="loc_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition_067cbe5c-6ded-4675-b1b6-de4725b929b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBT" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ac8a357b-89b5-4ec5-a2e0-e165af706bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2b527263-96ce-44d8-9499-5293226ed951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ac8a357b-89b5-4ec5-a2e0-e165af706bbf" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2b527263-96ce-44d8-9499-5293226ed951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_21b89225-940b-465d-be4f-a3d42cb64490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_52733329-35fc-4e55-8f2c-d6ce383538e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_21b89225-940b-465d-be4f-a3d42cb64490" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_52733329-35fc-4e55-8f2c-d6ce383538e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_35fabba7-68cc-4d90-93c0-572556a4b6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_21b89225-940b-465d-be4f-a3d42cb64490" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_35fabba7-68cc-4d90-93c0-572556a4b6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock_b4ec7b50-64a7-4f00-8399-bbd72df6095e" xlink:href="pcrx-20211231.xsd#pcrx_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_21b89225-940b-465d-be4f-a3d42cb64490" xlink:to="loc_pcrx_ScheduleOfInterestExpenseTableTextBlock_b4ec7b50-64a7-4f00-8399-bbd72df6095e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTCarryingValueofDebtDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTCarryingValueofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTCarryingValueofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ce24547e-fa80-4f32-a3c1-a45f9cce3dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ce24547e-fa80-4f32-a3c1-a45f9cce3dca" xlink:to="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3880dbf1-b046-4087-b944-b706a15951a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3880dbf1-b046-4087-b944-b706a15951a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_874527a4-46c0-43e3-a878-c9a979df1a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3880dbf1-b046-4087-b944-b706a15951a5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_874527a4-46c0-43e3-a878-c9a979df1a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_fcd22993-adae-4a08-bd57-7108add87321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_874527a4-46c0-43e3-a878-c9a979df1a5b" xlink:to="loc_us-gaap_SecuredDebtMember_fcd22993-adae-4a08-bd57-7108add87321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_8563bc8b-1505-47a3-bb07-1116c5f464a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_874527a4-46c0-43e3-a878-c9a979df1a5b" xlink:to="loc_us-gaap_UnsecuredDebtMember_8563bc8b-1505-47a3-bb07-1116c5f464a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bd8a4c54-0330-46bf-80ef-631f098c84c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:to="loc_us-gaap_DebtInstrumentAxis_bd8a4c54-0330-46bf-80ef-631f098c84c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bd8a4c54-0330-46bf-80ef-631f098c84c0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanBFacilityDue2026Member_eb2252f4-827d-4ca2-8674-b87e1f550ac1" xlink:href="pcrx-20211231.xsd#pcrx_TermLoanBFacilityDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:to="loc_pcrx_TermLoanBFacilityDue2026Member_eb2252f4-827d-4ca2-8674-b87e1f550ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_4fea6ade-bfd3-40c9-9390-dcd31ad7e3d0" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_4fea6ade-bfd3-40c9-9390-dcd31ad7e3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member_0b52128b-a956-45bc-a4f0-b94f3df6b2bb" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDueMay2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:to="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member_0b52128b-a956-45bc-a4f0-b94f3df6b2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_7f8bd07e-b9cf-4957-acbc-985937c895d8" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_892b01e0-268e-40f3-ba10-2674191ef70c" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_7f8bd07e-b9cf-4957-acbc-985937c895d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4b82574d-9f11-48d6-8cea-7ae9b8389c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4b82574d-9f11-48d6-8cea-7ae9b8389c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7d5e74eb-eb9e-4e25-902f-01330c93c34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4b82574d-9f11-48d6-8cea-7ae9b8389c39" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7d5e74eb-eb9e-4e25-902f-01330c93c34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_fdeb64fe-49af-49d5-8ec2-7393930db95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7d5e74eb-eb9e-4e25-902f-01330c93c34d" xlink:to="loc_us-gaap_SubsequentEventMember_fdeb64fe-49af-49d5-8ec2-7393930db95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b8747c5f-8d5f-417d-84aa-abdc63ddf0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f39146b-cd69-43a4-b86b-22d34cbe34bd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b8747c5f-8d5f-417d-84aa-abdc63ddf0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_708fb2f2-ce5f-4460-9ab7-24ad9c8ebda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8747c5f-8d5f-417d-84aa-abdc63ddf0e6" xlink:to="loc_us-gaap_LongTermDebt_708fb2f2-ce5f-4460-9ab7-24ad9c8ebda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd07d55d-b6d8-47e3-bacb-a2505b3b3a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8747c5f-8d5f-417d-84aa-abdc63ddf0e6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd07d55d-b6d8-47e3-bacb-a2505b3b3a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_95906bc5-6dae-4354-a91e-f4276a718843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_95906bc5-6dae-4354-a91e-f4276a718843" xlink:to="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b6490d7f-a48a-4cb3-9ca0-39248ebaafd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b6490d7f-a48a-4cb3-9ca0-39248ebaafd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b6490d7f-a48a-4cb3-9ca0-39248ebaafd5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_919464ca-c906-4e37-b5a8-737b996af647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:to="loc_us-gaap_SecuredDebtMember_919464ca-c906-4e37-b5a8-737b996af647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_90fb025f-446a-474e-a68d-08185c977c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:to="loc_us-gaap_UnsecuredDebtMember_90fb025f-446a-474e-a68d-08185c977c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_52656113-52cf-440f-a1ea-a27a3882b9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_89603c5f-a160-4ce2-8f09-46f5918e6e8d" xlink:to="loc_us-gaap_ConvertibleDebtMember_52656113-52cf-440f-a1ea-a27a3882b9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c1e5776f-27ea-4cb7-91b6-31aed8a685fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_us-gaap_DebtInstrumentAxis_c1e5776f-27ea-4cb7-91b6-31aed8a685fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1e5776f-27ea-4cb7-91b6-31aed8a685fb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_fc0a3fc1-e4d7-493b-bacd-cb6090aa5148" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_fc0a3fc1-e4d7-493b-bacd-cb6090aa5148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_eda2e055-9173-4552-96f8-2f7910f1204b" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_eda2e055-9173-4552-96f8-2f7910f1204b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanBFacilityDue2026Member_7457de3c-e5f3-4f5f-90ac-3adb5ce78c4c" xlink:href="pcrx-20211231.xsd#pcrx_TermLoanBFacilityDue2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:to="loc_pcrx_TermLoanBFacilityDue2026Member_7457de3c-e5f3-4f5f-90ac-3adb5ce78c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2024Member_91a6312b-8682-4d5d-a362-bcec92ff9542" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d707792-f404-4630-b7ed-1d2392547b75" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2024Member_91a6312b-8682-4d5d-a362-bcec92ff9542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsAxis_0509d812-6982-4488-af98-538a55548aa4" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionAndRedemptionTermsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsAxis_0509d812-6982-4488-af98-538a55548aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionAndRedemptionTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsAxis_0509d812-6982-4488-af98-538a55548aa4" xlink:to="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member_6f48e409-6204-4880-b3c7-743cbec2978b" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:to="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member_6f48e409-6204-4880-b3c7-743cbec2978b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member_8ea25d36-0814-4302-a43a-7b0c41745a70" xlink:href="pcrx-20211231.xsd#pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:to="loc_pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member_8ea25d36-0814-4302-a43a-7b0c41745a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_2f35056d-3b03-446d-b436-a3c71a0fd6be" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:to="loc_pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member_2f35056d-3b03-446d-b436-a3c71a0fd6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_362c2b28-8945-4755-a496-fb068d9519db" xlink:href="pcrx-20211231.xsd#pcrx_DebtRedemptionTermsonorafterApril12020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_DebtConversionAndRedemptionTermsDomain_22fa1d66-1bff-4168-8d4b-0dee621084cc" xlink:to="loc_pcrx_DebtRedemptionTermsonorafterApril12020Member_362c2b28-8945-4755-a496-fb068d9519db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_54746441-3a83-4e3f-be38-8e13097bbfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_us-gaap_VariableRateAxis_54746441-3a83-4e3f-be38-8e13097bbfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_54746441-3a83-4e3f-be38-8e13097bbfcd" xlink:to="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_fe1a6b56-f389-4fbb-aa38-037e764c3ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_fe1a6b56-f389-4fbb-aa38-037e764c3ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_7f111b8c-952d-49ae-a26d-fd64d4d00225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:to="loc_us-gaap_BaseRateMember_7f111b8c-952d-49ae-a26d-fd64d4d00225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FederalReserveBankOfNYRateMember_a39e1982-26c8-4ed6-9946-1d1d3c6443ea" xlink:href="pcrx-20211231.xsd#pcrx_FederalReserveBankOfNYRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1b7c1b9e-bc3e-4d98-9b8d-3793ee8f9e02" xlink:to="loc_pcrx_FederalReserveBankOfNYRateMember_a39e1982-26c8-4ed6-9946-1d1d3c6443ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f3bc4d7e-0da7-4964-b59e-57bafd255e87" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_dei_LegalEntityAxis_f3bc4d7e-0da7-4964-b59e-57bafd255e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_34b2e4bf-48b3-4d35-9b4c-1ca9a25cbbe0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f3bc4d7e-0da7-4964-b59e-57bafd255e87" xlink:to="loc_dei_EntityDomain_34b2e4bf-48b3-4d35-9b4c-1ca9a25cbbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_2c3e4f85-cb93-4be6-8ec6-00ba8e78870a" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_34b2e4bf-48b3-4d35-9b4c-1ca9a25cbbe0" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_2c3e4f85-cb93-4be6-8ec6-00ba8e78870a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_39573b15-81fa-4b78-a255-deb38aa664da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_39573b15-81fa-4b78-a255-deb38aa664da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_edde2b3d-96d3-4785-94c3-a60a23901a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_39573b15-81fa-4b78-a255-deb38aa664da" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_edde2b3d-96d3-4785-94c3-a60a23901a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_82fbaac0-1850-43f3-a26f-19b4b193605a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_edde2b3d-96d3-4785-94c3-a60a23901a03" xlink:to="loc_us-gaap_SubsequentEventMember_82fbaac0-1850-43f3-a26f-19b4b193605a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ae691546-4462-45d4-92d6-e8002534781c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_srt_StatementScenarioAxis_ae691546-4462-45d4-92d6-e8002534781c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a6602677-f8a9-4829-bd38-463a7dd88ce3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ae691546-4462-45d4-92d6-e8002534781c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a6602677-f8a9-4829-bd38-463a7dd88ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0f06c14a-ad67-4660-9fd4-ec87d41f176d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a6602677-f8a9-4829-bd38-463a7dd88ce3" xlink:to="loc_srt_ScenarioForecastMember_0f06c14a-ad67-4660-9fd4-ec87d41f176d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5404f5c-641d-4eab-855b-577ea075c8fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_srt_RangeAxis_a5404f5c-641d-4eab-855b-577ea075c8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba9adca0-17f3-4e52-853c-66f350770119" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a5404f5c-641d-4eab-855b-577ea075c8fb" xlink:to="loc_srt_RangeMember_ba9adca0-17f3-4e52-853c-66f350770119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8063e018-b66e-4886-b842-e13ff7732236" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba9adca0-17f3-4e52-853c-66f350770119" xlink:to="loc_srt_MinimumMember_8063e018-b66e-4886-b842-e13ff7732236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e7d96759-dba3-4172-a240-2bbfe1eef68d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentDiscountRate_2f2bae32-1772-4e90-a877-b49e8be4c3b8" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentDiscountRate_2f2bae32-1772-4e90-a877-b49e8be4c3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_05d33297-7716-46d1-8111-c74efef7e933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_05d33297-7716-46d1-8111-c74efef7e933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_6d1d0a4e-3788-4bc6-aced-5d4465bec346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_6d1d0a4e-3788-4bc6-aced-5d4465bec346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8452c2df-e342-4dba-9bd3-f76d57258d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8452c2df-e342-4dba-9bd3-f76d57258d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_7097dcf4-7bca-44be-9e42-1d7115a7aee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_7097dcf4-7bca-44be-9e42-1d7115a7aee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_a6e89b08-ca3b-4b14-8bff-dd9775409127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_a6e89b08-ca3b-4b14-8bff-dd9775409127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear_d242ef46-3388-4b37-92e1-a7ea6011a7b0" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear_d242ef46-3388-4b37-92e1-a7ea6011a7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1_e7842c84-1a4d-4c70-952c-244d898ab001" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1_e7842c84-1a4d-4c70-952c-244d898ab001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2_02be755f-53c7-4317-964e-fa6fbeb0eb18" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2_02be755f-53c7-4317-964e-fa6fbeb0eb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter_29dc94bd-5c1c-4682-997d-ba21dd88fcb6" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter_29dc94bd-5c1c-4682-997d-ba21dd88fcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximum_52dd33b4-b343-4620-8632-15b0ce6c9a83" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximum_52dd33b4-b343-4620-8632-15b0ce6c9a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue_4b6c948c-5824-4e32-922c-ab0b4326597d" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue_4b6c948c-5824-4e32-922c-ab0b4326597d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentVariableRate_5f528fbd-f7c2-417e-bc01-50e67d810ca7" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentVariableRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentVariableRate_5f528fbd-f7c2-417e-bc01-50e67d810ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate_1f894b22-49f5-44ed-8686-f269c784b984" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentBasisSpreadOneOnVariableRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate_1f894b22-49f5-44ed-8686-f269c784b984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate_2d9b6f1f-c0dc-4658-8abc-794e1a997f4f" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate_2d9b6f1f-c0dc-4658-8abc-794e1a997f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0220190b-19fe-42ff-9fd2-d4be62242cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0220190b-19fe-42ff-9fd2-d4be62242cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_8c079de1-11cb-4367-8262-be196bd9b9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_8c079de1-11cb-4367-8262-be196bd9b9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0c410360-48cc-49f6-865d-5b522c06eb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0c410360-48cc-49f6-865d-5b522c06eb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62d1756d-8740-45b3-a26e-5f3ac0f8125e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62d1756d-8740-45b3-a26e-5f3ac0f8125e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_f90fd516-2ede-4fb9-b669-a07d6db93b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_f90fd516-2ede-4fb9-b669-a07d6db93b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_643e14c6-3873-4730-88f2-8679bce3e72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_643e14c6-3873-4730-88f2-8679bce3e72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_3ec8e037-5dd9-4aa4-a1c8-6e31d7f47b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_RepaymentsOfDebt_3ec8e037-5dd9-4aa4-a1c8-6e31d7f47b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9d6ba207-1291-4be0-b5c5-203d8601c26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9d6ba207-1291-4be0-b5c5-203d8601c26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_bdca59c3-2465-4733-9c67-40c516952b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_bdca59c3-2465-4733-9c67-40c516952b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_931fa367-fd91-472a-82e7-dd4501e9c7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_931fa367-fd91-472a-82e7-dd4501e9c7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock_c2849d13-6094-486f-89cf-115b9cc39955" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock_c2849d13-6094-486f-89cf-115b9cc39955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_8802f695-d712-4025-b7fe-74addc49360a" xlink:href="pcrx-20211231.xsd#pcrx_SettlementPeriodConvertibleDebtConversionRequest"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_SettlementPeriodConvertibleDebtConversionRequest_8802f695-d712-4025-b7fe-74addc49360a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_236d84b6-0747-4c63-b0b3-9c584aa39f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_236d84b6-0747-4c63-b0b3-9c584aa39f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_95c74678-34da-4b05-a317-a4edebadbcac" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock_95c74678-34da-4b05-a317-a4edebadbcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_5c13fe68-6fa4-4987-9d22-3657c8110621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_SharePrice_5c13fe68-6fa4-4987-9d22-3657c8110621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_bd038833-2882-4427-a009-0bcde7a1cac9" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice_bd038833-2882-4427-a009-0bcde7a1cac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent_bd964500-e51b-4f53-a4fd-e9c70af154e2" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent_bd964500-e51b-4f53-a4fd-e9c70af154e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_e122f307-2780-43a9-929e-de2fe567558e" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConvertibleAssumedBorrowingRate"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate_e122f307-2780-43a9-929e-de2fe567558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_85b7f351-2237-49dc-a65c-fa547ff0dca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_85b7f351-2237-49dc-a65c-fa547ff0dca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_429b0abe-595d-4da6-baed-1cdce08333a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentTerm_429b0abe-595d-4da6-baed-1cdce08333a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt_2afd7f07-20ab-443f-b2c1-a7525a6d3fce" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt_2afd7f07-20ab-443f-b2c1-a7525a6d3fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_8375eca7-6195-4cbe-a577-23d9f12e6764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_8375eca7-6195-4cbe-a577-23d9f12e6764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt_67483fdd-6b60-45ab-830d-155cba2100b4" xlink:href="pcrx-20211231.xsd#pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt_67483fdd-6b60-45ab-830d-155cba2100b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt_5a42f9ee-15b3-4505-a1d5-3031db6dffc4" xlink:href="pcrx-20211231.xsd#pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt_5a42f9ee-15b3-4505-a1d5-3031db6dffc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d03c1b0-6c22-49fc-afcf-76890c7907ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d03c1b0-6c22-49fc-afcf-76890c7907ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentMarketPrice_22901661-9063-4aa9-8e9b-7c07f65d832d" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentMarketPrice"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentMarketPrice_22901661-9063-4aa9-8e9b-7c07f65d832d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_2b56f829-75f8-447e-b9b7-d2b6a8b8ed7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_2b56f829-75f8-447e-b9b7-d2b6a8b8ed7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount_05f20dfd-ed02-44fc-bff2-d199d8b8c489" xlink:href="pcrx-20211231.xsd#pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount_05f20dfd-ed02-44fc-bff2-d199d8b8c489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes_81dbbe71-0ee6-47e9-82ec-68306415a5cb" xlink:href="pcrx-20211231.xsd#pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes_81dbbe71-0ee6-47e9-82ec-68306415a5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_265a5ba2-eb23-45a5-a504-4ac6520ae0bc" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice_265a5ba2-eb23-45a5-a504-4ac6520ae0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_4823e7d2-621c-4c4f-b0a5-420a353f26f5" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays_4823e7d2-621c-4c4f-b0a5-420a353f26f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_20befad1-6e7d-41d2-9736-8573b4546574" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_20befad1-6e7d-41d2-9736-8573b4546574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_ce325bf9-645c-4e27-a953-73e0f5136e08" xlink:href="pcrx-20211231.xsd#pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_ce325bf9-645c-4e27-a953-73e0f5136e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_610988d8-73c3-4d5c-85df-b7f5c0f515b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_ConvertibleDebt_610988d8-73c3-4d5c-85df-b7f5c0f515b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_28905931-c62d-44cd-98be-f8bcaf0ecddc" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault_28905931-c62d-44cd-98be-f8bcaf0ecddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_ffeb111f-4675-4048-8420-1f603791a13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_ffeb111f-4675-4048-8420-1f603791a13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5e91e909-8327-44a9-a191-85472a55c10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9e4abf1-9564-4c53-8a11-54af22b8a6e3" xlink:to="loc_us-gaap_LongTermDebt_5e91e909-8327-44a9-a191-85472a55c10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d34cc9c5-b3ae-40d9-8cd7-0dcd7876cc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_41f60605-3f73-4f22-af28-1511f5d2b84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d34cc9c5-b3ae-40d9-8cd7-0dcd7876cc8a" xlink:to="loc_us-gaap_DebtInstrumentTable_41f60605-3f73-4f22-af28-1511f5d2b84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_afb13fe8-2e81-4115-91fa-8fbb2a1f2b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41f60605-3f73-4f22-af28-1511f5d2b84f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_afb13fe8-2e81-4115-91fa-8fbb2a1f2b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7c7ab339-1b75-4a17-9add-235c18d949cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_afb13fe8-2e81-4115-91fa-8fbb2a1f2b2e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7c7ab339-1b75-4a17-9add-235c18d949cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_51a1a26f-ca3a-4561-aba4-d8b60011842e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c7ab339-1b75-4a17-9add-235c18d949cc" xlink:to="loc_us-gaap_UnsecuredDebtMember_51a1a26f-ca3a-4561-aba4-d8b60011842e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_415b83ba-2746-4a04-b744-ed9a6eb45319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c7ab339-1b75-4a17-9add-235c18d949cc" xlink:to="loc_us-gaap_SecuredDebtMember_415b83ba-2746-4a04-b744-ed9a6eb45319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_503e5934-f7b4-486a-8f2f-89d702242a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41f60605-3f73-4f22-af28-1511f5d2b84f" xlink:to="loc_us-gaap_DebtInstrumentAxis_503e5934-f7b4-486a-8f2f-89d702242a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_503e5934-f7b4-486a-8f2f-89d702242a96" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanBFacilityDue2026Member_b964b2f1-cb44-4209-bc62-879610508d17" xlink:href="pcrx-20211231.xsd#pcrx_TermLoanBFacilityDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:to="loc_pcrx_TermLoanBFacilityDue2026Member_b964b2f1-cb44-4209-bc62-879610508d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_4ce8f766-d781-4978-847e-94a82bf0b093" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_4ce8f766-d781-4978-847e-94a82bf0b093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_a91aefcf-3ae9-4b36-94f3-045d020ac5af" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5e964646-4239-4a29-9523-4234ba1912ae" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_a91aefcf-3ae9-4b36-94f3-045d020ac5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41f60605-3f73-4f22-af28-1511f5d2b84f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_81a454f3-01ac-42a7-af91-b05ae2d528fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_81a454f3-01ac-42a7-af91-b05ae2d528fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_999c13dc-9f7d-43cf-ad47-107b81c4627d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_999c13dc-9f7d-43cf-ad47-107b81c4627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_f6ab7d26-088d-44c5-a925-ff03973a28ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_f6ab7d26-088d-44c5-a925-ff03973a28ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7677b968-ad07-4bb6-a1ad-fca31c1e39bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7677b968-ad07-4bb6-a1ad-fca31c1e39bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9a352577-a51c-4df2-95db-d3c61aceea8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d9907e0-977b-435c-b601-e4fb233225c9" xlink:to="loc_us-gaap_LongTermDebt_9a352577-a51c-4df2-95db-d3c61aceea8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#DEBTScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_aaf9ad58-c0f9-4e83-a4de-4663e5bc2a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8aa0c690-93c7-4469-85d9-2eb32a7ccbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aaf9ad58-c0f9-4e83-a4de-4663e5bc2a0b" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8aa0c690-93c7-4469-85d9-2eb32a7ccbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_adb1b441-9901-4253-b474-3fdbd75aeaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aaf9ad58-c0f9-4e83-a4de-4663e5bc2a0b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_adb1b441-9901-4253-b474-3fdbd75aeaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_806679c1-3580-4c61-9b69-bad6f8596fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aaf9ad58-c0f9-4e83-a4de-4663e5bc2a0b" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_806679c1-3580-4c61-9b69-bad6f8596fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalizedAdjustment_0764c739-5bfd-4368-8ccc-69a21a836072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalizedAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aaf9ad58-c0f9-4e83-a4de-4663e5bc2a0b" xlink:to="loc_us-gaap_InterestCostsCapitalizedAdjustment_0764c739-5bfd-4368-8ccc-69a21a836072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b6fd4ee6-9728-49ac-847c-b64155153be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aaf9ad58-c0f9-4e83-a4de-4663e5bc2a0b" xlink:to="loc_us-gaap_InterestExpenseDebt_b6fd4ee6-9728-49ac-847c-b64155153be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_e9cc385a-e53b-4060-b13b-cabffc0514ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_aaf9ad58-c0f9-4e83-a4de-4663e5bc2a0b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_e9cc385a-e53b-4060-b13b-cabffc0514ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5de613b9-4555-4396-bac6-398a06e821e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_d1749aae-2421-494a-83a3-b9cd3dda36c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5de613b9-4555-4396-bac6-398a06e821e1" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_d1749aae-2421-494a-83a3-b9cd3dda36c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9429473e-ec2b-4e7e-90f4-686e490a4d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_bb46bcf5-f673-42f1-a7a3-90309bb75349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9429473e-ec2b-4e7e-90f4-686e490a4d15" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_bb46bcf5-f673-42f1-a7a3-90309bb75349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_451bf769-5c28-41f1-9dcb-ab3cd64e052c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9429473e-ec2b-4e7e-90f4-686e490a4d15" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_451bf769-5c28-41f1-9dcb-ab3cd64e052c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_79a664ee-2309-44f5-918a-9e790a50ee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9429473e-ec2b-4e7e-90f4-686e490a4d15" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_79a664ee-2309-44f5-918a-9e790a50ee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1ae8ca3c-733b-45c3-bd72-b0b7ca73253e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9429473e-ec2b-4e7e-90f4-686e490a4d15" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1ae8ca3c-733b-45c3-bd72-b0b7ca73253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_88233e9b-cc87-4281-bfe6-99ebb383d529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_88233e9b-cc87-4281-bfe6-99ebb383d529" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5e2793cb-e398-4c35-b2b7-1d2701633f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5e2793cb-e398-4c35-b2b7-1d2701633f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5e2793cb-e398-4c35-b2b7-1d2701633f51" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c3f5eba6-2f3a-49c2-95b2-67301a2fa61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c3f5eba6-2f3a-49c2-95b2-67301a2fa61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ec683dc0-6115-4e11-b433-299aacd27c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ec683dc0-6115-4e11-b433-299aacd27c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bd607390-f782-47f0-99c5-d22dc38b1094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4dfa138e-04ae-414d-93df-7f9acf3efd97" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bd607390-f782-47f0-99c5-d22dc38b1094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e69d87d3-79d7-4406-bf3b-61a88437270b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e69d87d3-79d7-4406-bf3b-61a88437270b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e69d87d3-79d7-4406-bf3b-61a88437270b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8b9fe693-7467-4c52-a94a-d76782b62c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8b9fe693-7467-4c52-a94a-d76782b62c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8536bd1b-6026-4eab-9970-0e073a184ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8536bd1b-6026-4eab-9970-0e073a184ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_50834dd5-f7eb-4559-8052-d84465d5912d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d3d072eb-05e8-4448-819d-f9b81fc67622" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_50834dd5-f7eb-4559-8052-d84465d5912d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d8c503d0-301e-4676-8c48-a33b36ae75de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_us-gaap_DebtInstrumentAxis_d8c503d0-301e-4676-8c48-a33b36ae75de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d8c503d0-301e-4676-8c48-a33b36ae75de" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TermLoanBFacilityDue2026Member_ebb52dab-65f9-4583-b7ca-0b7f55d6a0b9" xlink:href="pcrx-20211231.xsd#pcrx_TermLoanBFacilityDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:to="loc_pcrx_TermLoanBFacilityDue2026Member_ebb52dab-65f9-4583-b7ca-0b7f55d6a0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_678a8527-b2d6-4c53-8740-9dd7a4b99bad" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_678a8527-b2d6-4c53-8740-9dd7a4b99bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_f815fd0e-5f71-4c26-807f-feb0853bfb65" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_f815fd0e-5f71-4c26-807f-feb0853bfb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2024Member_89f09130-1d3e-4265-9934-4ef660544ea0" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fff87669-0e0f-4c83-a871-f47a7833b7d0" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2024Member_89f09130-1d3e-4265-9934-4ef660544ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4559a014-0e29-4a4c-8a1c-33524a9ec18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4559a014-0e29-4a4c-8a1c-33524a9ec18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eadd58f2-7654-4f8f-8113-4c36ec2ba225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4559a014-0e29-4a4c-8a1c-33524a9ec18f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eadd58f2-7654-4f8f-8113-4c36ec2ba225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_ad62eaf3-0a04-480b-bcd3-dd33bafec364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eadd58f2-7654-4f8f-8113-4c36ec2ba225" xlink:to="loc_us-gaap_UnsecuredDebtMember_ad62eaf3-0a04-480b-bcd3-dd33bafec364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_dd1a4657-2ce2-4832-8682-f41109fe5c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eadd58f2-7654-4f8f-8113-4c36ec2ba225" xlink:to="loc_us-gaap_SecuredDebtMember_dd1a4657-2ce2-4832-8682-f41109fe5c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2eba2cf5-da45-4090-97a0-b7a394a88acc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_srt_RangeAxis_2eba2cf5-da45-4090-97a0-b7a394a88acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_762bdec6-b59c-437a-bef9-1fffdce5b1e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2eba2cf5-da45-4090-97a0-b7a394a88acc" xlink:to="loc_srt_RangeMember_762bdec6-b59c-437a-bef9-1fffdce5b1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_016e9cdf-81cd-480d-8f03-c04fc3ba9271" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_762bdec6-b59c-437a-bef9-1fffdce5b1e1" xlink:to="loc_srt_MaximumMember_016e9cdf-81cd-480d-8f03-c04fc3ba9271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4d4147b3-0d4e-42d5-9966-eae315906f67" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_01cf6411-122e-49c0-aec1-8895eff074a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_01cf6411-122e-49c0-aec1-8895eff074a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableFairValueDisclosure_93668fdb-acf7-46dd-81c2-5f6be66b644f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_NotesReceivableFairValueDisclosure_93668fdb-acf7-46dd-81c2-5f6be66b644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ee5f84ea-b1d5-496c-ba7e-edd910e864d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ee5f84ea-b1d5-496c-ba7e-edd910e864d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_8f560563-0c94-4b69-900d-cdd02f43b509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_8f560563-0c94-4b69-900d-cdd02f43b509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9d111405-486a-441a-aa94-a3ab3d367d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_SharePrice_9d111405-486a-441a-aa94-a3ab3d367d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53701fed-d0d6-448e-ae32-171e05f7c35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_53701fed-d0d6-448e-ae32-171e05f7c35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_969624ba-0670-416b-a641-8da51db90d13" xlink:href="pcrx-20211231.xsd#pcrx_DebtInstrumentConvertibleConversionPremiumShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f8cb6e32-e436-4aa6-9ee0-031fd8fad56a" xlink:to="loc_pcrx_DebtInstrumentConvertibleConversionPremiumShares_969624ba-0670-416b-a641-8da51db90d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_96d8f130-3d9f-42be-bf8b-115867970ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_96d8f130-3d9f-42be-bf8b-115867970ed7" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_636e3b14-98cd-429d-bfe6-970082ef8ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_636e3b14-98cd-429d-bfe6-970082ef8ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_636e3b14-98cd-429d-bfe6-970082ef8ddf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_31b5a1d1-4746-44e7-bd90-fab5d99d5653" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_31b5a1d1-4746-44e7-bd90-fab5d99d5653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_96cf4ba7-5707-4777-b34e-36f392232ef6" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:to="loc_pcrx_FlexionAcquisitionMember_96cf4ba7-5707-4777-b34e-36f392232ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAndMyoscienceAcquisitionMember_aafceee9-b6e4-4729-823d-5fa0811257b4" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAndMyoscienceAcquisitionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6623886b-ae6b-4b7d-8a4a-aee80a4e97ce" xlink:to="loc_pcrx_FlexionAndMyoscienceAcquisitionMember_aafceee9-b6e4-4729-823d-5fa0811257b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_279a6c52-b99e-4637-9929-bf49dfabc059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_279a6c52-b99e-4637-9929-bf49dfabc059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3205f2df-03fd-4588-a6d0-cff07502672e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_279a6c52-b99e-4637-9929-bf49dfabc059" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3205f2df-03fd-4588-a6d0-cff07502672e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2f694432-9532-44d0-a749-c19f4601443d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3205f2df-03fd-4588-a6d0-cff07502672e" xlink:to="loc_us-gaap_UnsecuredDebtMember_2f694432-9532-44d0-a749-c19f4601443d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d787bbae-c7b1-42c2-85e2-641759e2d2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d787bbae-c7b1-42c2-85e2-641759e2d2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d787bbae-c7b1-42c2-85e2-641759e2d2c8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4cb2bcd7-979a-47cc-887c-0ed862af26db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4cb2bcd7-979a-47cc-887c-0ed862af26db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_81325067-41a1-4470-9d08-e9cb127064e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_81325067-41a1-4470-9d08-e9cb127064e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4c5f978c-0a64-4256-a67b-6eb3f54f0b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_44b34acf-e115-44f5-9c65-da8e9ecfd519" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4c5f978c-0a64-4256-a67b-6eb3f54f0b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3b761a01-069b-47d3-93aa-1ca261c6b556" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_srt_MajorCustomersAxis_3b761a01-069b-47d3-93aa-1ca261c6b556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3b761a01-069b-47d3-93aa-1ca261c6b556" xlink:to="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerOneMember_249f5186-51a9-4def-85cc-9e74fc2bbfed" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:to="loc_pcrx_MajorCustomerOneMember_249f5186-51a9-4def-85cc-9e74fc2bbfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerTwoMember_0245b5d4-1c34-4481-aed1-5c4711536e27" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:to="loc_pcrx_MajorCustomerTwoMember_0245b5d4-1c34-4481-aed1-5c4711536e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerThreeMember_ca1ffcdb-cce4-4d38-bee6-6a24767487e9" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:to="loc_pcrx_MajorCustomerThreeMember_ca1ffcdb-cce4-4d38-bee6-6a24767487e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MajorCustomerFourMember_1dee0af2-4a2c-4d0a-b335-1d0be6c8e0b9" xlink:href="pcrx-20211231.xsd#pcrx_MajorCustomerFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_acb2710e-86c5-4a01-a9d1-5f98cb78367b" xlink:to="loc_pcrx_MajorCustomerFourMember_1dee0af2-4a2c-4d0a-b335-1d0be6c8e0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5142fb59-2da2-4a01-9069-2db7fb323f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5142fb59-2da2-4a01-9069-2db7fb323f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9cf19efe-4fc3-471d-82f5-b4d77a091098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5142fb59-2da2-4a01-9069-2db7fb323f2b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9cf19efe-4fc3-471d-82f5-b4d77a091098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_81428518-805a-417b-aac5-66196fa1f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9cf19efe-4fc3-471d-82f5-b4d77a091098" xlink:to="loc_us-gaap_AccountsReceivableMember_81428518-805a-417b-aac5-66196fa1f0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a86056ae-3b64-4110-bbc8-95467107837a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a86056ae-3b64-4110-bbc8-95467107837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0c3385c7-9aa2-40be-b68f-4972553e1aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a86056ae-3b64-4110-bbc8-95467107837a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0c3385c7-9aa2-40be-b68f-4972553e1aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_88b75d7a-3583-428c-930b-663ca4c35c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0c3385c7-9aa2-40be-b68f-4972553e1aaf" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_88b75d7a-3583-428c-930b-663ca4c35c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4549e6dc-b006-4ad5-966a-70964e78343c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_4549e6dc-b006-4ad5-966a-70964e78343c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a1aa9c43-2e16-44ee-8e2f-cfdceb8a7189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4549e6dc-b006-4ad5-966a-70964e78343c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a1aa9c43-2e16-44ee-8e2f-cfdceb8a7189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2022Member_0952286d-f79b-48e9-afd3-6af812f3b192" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1aa9c43-2e16-44ee-8e2f-cfdceb8a7189" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2022Member_0952286d-f79b-48e9-afd3-6af812f3b192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDue2025Member_806b4be9-0da5-4e17-b5cf-2a469615613a" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1aa9c43-2e16-44ee-8e2f-cfdceb8a7189" xlink:to="loc_pcrx_ConvertibleSeniorNotesDue2025Member_806b4be9-0da5-4e17-b5cf-2a469615613a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_6c8002b8-0317-4576-8502-88daf2054688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_6c8002b8-0317-4576-8502-88daf2054688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_efbeb1fd-0e69-4241-80df-b20c4370efc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6c8002b8-0317-4576-8502-88daf2054688" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_efbeb1fd-0e69-4241-80df-b20c4370efc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cdefbe76-7bd8-40bb-a02e-a2c9f9ea6e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_efbeb1fd-0e69-4241-80df-b20c4370efc3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cdefbe76-7bd8-40bb-a02e-a2c9f9ea6e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bf74a7d7-c274-4110-a355-2440d66af322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cdefbe76-7bd8-40bb-a02e-a2c9f9ea6e87" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bf74a7d7-c274-4110-a355-2440d66af322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_924c6daa-d948-4fc6-a148-c42fdafdc510" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_srt_RangeAxis_924c6daa-d948-4fc6-a148-c42fdafdc510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7fe4800e-5e83-4448-b49b-5103cc1fcbd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_924c6daa-d948-4fc6-a148-c42fdafdc510" xlink:to="loc_srt_RangeMember_7fe4800e-5e83-4448-b49b-5103cc1fcbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_84262af5-c94b-4e99-97a4-4a8d8889bc1d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7fe4800e-5e83-4448-b49b-5103cc1fcbd3" xlink:to="loc_srt_WeightedAverageMember_84262af5-c94b-4e99-97a4-4a8d8889bc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3aa7e6d6-0e8c-4318-8e16-5cea4a3ffd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3aa7e6d6-0e8c-4318-8e16-5cea4a3ffd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3228b595-9233-46b1-bcdf-befe27d2e384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3aa7e6d6-0e8c-4318-8e16-5cea4a3ffd72" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3228b595-9233-46b1-bcdf-befe27d2e384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_65b611e7-bfb2-40a9-9f2b-11f67c94bd8b" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3228b595-9233-46b1-bcdf-befe27d2e384" xlink:to="loc_pcrx_ContingentConsiderationMember_65b611e7-bfb2-40a9-9f2b-11f67c94bd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d539b928-8be0-41bb-9bb2-f1b6a1472bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d539b928-8be0-41bb-9bb2-f1b6a1472bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e28296e1-6f36-4f87-a8be-5fe942ca625b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d539b928-8be0-41bb-9bb2-f1b6a1472bcd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e28296e1-6f36-4f87-a8be-5fe942ca625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_ec5ec89f-6353-4cd8-9ea3-ba3881202077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e28296e1-6f36-4f87-a8be-5fe942ca625b" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_ec5ec89f-6353-4cd8-9ea3-ba3881202077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_afd2bf50-e79a-4165-8abe-d5994b346d9b" xlink:href="pcrx-20211231.xsd#pcrx_MeasurementInputExpectedMilestonePaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e28296e1-6f36-4f87-a8be-5fe942ca625b" xlink:to="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_afd2bf50-e79a-4165-8abe-d5994b346d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5af6ccfd-a6a6-4dc7-8633-72404434e73c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5af6ccfd-a6a6-4dc7-8633-72404434e73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5af6ccfd-a6a6-4dc7-8633-72404434e73c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TELABioMember_1aa27621-9d96-4d00-9361-f5b4420d2eef" xlink:href="pcrx-20211231.xsd#pcrx_TELABioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:to="loc_pcrx_TELABioMember_1aa27621-9d96-4d00-9361-f5b4420d2eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GeneQuineMember_73e5c4ee-360a-48d7-a921-7e0a39f4ad35" xlink:href="pcrx-20211231.xsd#pcrx_GeneQuineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:to="loc_pcrx_GeneQuineMember_73e5c4ee-360a-48d7-a921-7e0a39f4ad35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CodaBioTherapeuticsIncMember_9bc1af10-8b3e-493e-96c4-ff3f93510e54" xlink:href="pcrx-20211231.xsd#pcrx_CodaBioTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:to="loc_pcrx_CodaBioTherapeuticsIncMember_9bc1af10-8b3e-493e-96c4-ff3f93510e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GenascenceCorporationMember_904a13c2-d0e0-4932-a379-4d468f8ccfbb" xlink:href="pcrx-20211231.xsd#pcrx_GenascenceCorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49b430ae-bb99-4059-8b74-8b5c8f6c7b8c" xlink:to="loc_pcrx_GenascenceCorporationMember_904a13c2-d0e0-4932-a379-4d468f8ccfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2186024b-7836-4461-ac18-d107782509bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2186024b-7836-4461-ac18-d107782509bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a6f79266-58eb-4c99-942e-833d22d53113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_2186024b-7836-4461-ac18-d107782509bf" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a6f79266-58eb-4c99-942e-833d22d53113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SpineBioPharmaLLCMember_c31a55ee-1ff0-4ca3-ab95-2d488ba10fa5" xlink:href="pcrx-20211231.xsd#pcrx_SpineBioPharmaLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a6f79266-58eb-4c99-942e-833d22d53113" xlink:to="loc_pcrx_SpineBioPharmaLLCMember_c31a55ee-1ff0-4ca3-ab95-2d488ba10fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_b8630f58-d8f1-411d-a3d2-662a1dc9b811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_b8630f58-d8f1-411d-a3d2-662a1dc9b811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_072e8bc0-fd06-4ba8-95dc-96fac69eeea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_b8630f58-d8f1-411d-a3d2-662a1dc9b811" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_072e8bc0-fd06-4ba8-95dc-96fac69eeea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_c4dec7b0-44ea-49d9-8594-9083aec6fa73" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_072e8bc0-fd06-4ba8-95dc-96fac69eeea0" xlink:to="loc_pcrx_ContingentConsiderationMember_c4dec7b0-44ea-49d9-8594-9083aec6fa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_030ad12f-bfe3-44d3-91df-818bbb35fbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_030ad12f-bfe3-44d3-91df-818bbb35fbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1e8e4bac-6d1f-4324-bdb7-b5e5d058eeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_030ad12f-bfe3-44d3-91df-818bbb35fbc5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1e8e4bac-6d1f-4324-bdb7-b5e5d058eeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0e09a7b8-c827-4d76-9c3a-ff1da0ca091d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1e8e4bac-6d1f-4324-bdb7-b5e5d058eeb8" xlink:to="loc_us-gaap_SubsequentEventMember_0e09a7b8-c827-4d76-9c3a-ff1da0ca091d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_88582113-9851-4d10-af4f-4829400873ba" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d1c34ac0-d546-4e86-b51f-a2571a05efcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d1c34ac0-d546-4e86-b51f-a2571a05efcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8d47d73d-a3d1-42eb-a854-ce6d2bdac7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8d47d73d-a3d1-42eb-a854-ce6d2bdac7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_48c5f31a-41a1-41c6-bb40-e4eeb4b127f7" xlink:href="pcrx-20211231.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_48c5f31a-41a1-41c6-bb40-e4eeb4b127f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_11daba7b-a08d-4a2c-8956-7dc757d14903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_11daba7b-a08d-4a2c-8956-7dc757d14903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1b142777-c7ad-4fe6-a70b-a88e6371c713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1b142777-c7ad-4fe6-a70b-a88e6371c713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition_0fb77f85-b370-40b1-9b0b-2bafbeb02704" xlink:href="pcrx-20211231.xsd#pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition_0fb77f85-b370-40b1-9b0b-2bafbeb02704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_11152142-09f4-4f03-b9c6-4911b5492493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_11152142-09f4-4f03-b9c6-4911b5492493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7738775b-2730-47ed-aab4-739add88594c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_7738775b-2730-47ed-aab4-739add88594c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_dfb32bd9-c750-47ea-8943-7cf693edcda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_dfb32bd9-c750-47ea-8943-7cf693edcda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_27375dc9-e50e-4f11-9365-5ddfe911e44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_27375dc9-e50e-4f11-9365-5ddfe911e44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_3c48fbf6-3704-427c-a619-93f58d1a85a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_3c48fbf6-3704-427c-a619-93f58d1a85a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_8bf234e9-4195-4dc0-a1bb-f9649f176164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation_8bf234e9-4195-4dc0-a1bb-f9649f176164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones_23c88023-3d45-454c-a851-be558d11928e" xlink:href="pcrx-20211231.xsd#pcrx_PotentialAdditionalInvestmentUponAchievingMilestones"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones_23c88023-3d45-454c-a851-be558d11928e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_57689a61-9faa-44df-a1fa-ecccbf4d2e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_57689a61-9faa-44df-a1fa-ecccbf4d2e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_bea3b58b-7782-4412-a0e9-0a89abe90afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_ConvertibleNotesPayable_bea3b58b-7782-4412-a0e9-0a89abe90afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_69200929-e2c0-4d68-b185-3c089f026f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_69200929-e2c0-4d68-b185-3c089f026f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_8a57c874-7fa1-4cb8-a08b-6598e9e11336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_8a57c874-7fa1-4cb8-a08b-6598e9e11336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_0cbae76b-5d4d-479a-9eb2-0dc82a667534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_0cbae76b-5d4d-479a-9eb2-0dc82a667534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_2e35434f-04df-40fd-a33a-d9dc7ee0981a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_2e35434f-04df-40fd-a33a-d9dc7ee0981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_a60ce9db-cd01-4413-bd82-cada17117452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_ImpairmentOfInvestments_a60ce9db-cd01-4413-bd82-cada17117452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NumberOfMajorCustomers_01c90def-5987-47c4-a046-c2c59d7b974e" xlink:href="pcrx-20211231.xsd#pcrx_NumberOfMajorCustomers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_pcrx_NumberOfMajorCustomers_01c90def-5987-47c4-a046-c2c59d7b974e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9d57aa9f-d493-4177-8592-68fdc8dec417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_60f0f80a-436e-4775-a958-3d3f835b089f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9d57aa9f-d493-4177-8592-68fdc8dec417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_817c2198-9f2f-4693-b173-9fc5bae2f741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_817c2198-9f2f-4693-b173-9fc5bae2f741" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0abcff2-5996-4017-9c02-42b3ae3bb8d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_srt_RangeAxis_e0abcff2-5996-4017-9c02-42b3ae3bb8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63a96085-b8c9-4cfe-82e4-50284688ad1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e0abcff2-5996-4017-9c02-42b3ae3bb8d3" xlink:to="loc_srt_RangeMember_63a96085-b8c9-4cfe-82e4-50284688ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_67b5b335-084d-4136-aea2-dc9ee2ad0215" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_63a96085-b8c9-4cfe-82e4-50284688ad1c" xlink:to="loc_srt_MinimumMember_67b5b335-084d-4136-aea2-dc9ee2ad0215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ddaa8713-8ea0-44b7-93ab-24e464496307" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_63a96085-b8c9-4cfe-82e4-50284688ad1c" xlink:to="loc_srt_MaximumMember_ddaa8713-8ea0-44b7-93ab-24e464496307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a18448e7-fc15-457d-926d-a8e211f35a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a18448e7-fc15-457d-926d-a8e211f35a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4c353a-e735-4513-b52a-4654e8e45d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a18448e7-fc15-457d-926d-a8e211f35a59" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4c353a-e735-4513-b52a-4654e8e45d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_4f441d7e-8c54-45e3-ae02-e436448acfb1" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4c353a-e735-4513-b52a-4654e8e45d7d" xlink:to="loc_pcrx_FlexionAcquisitionMember_4f441d7e-8c54-45e3-ae02-e436448acfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_1ad63ffd-6849-4549-81ed-2b5cc0d1b159" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a4c353a-e735-4513-b52a-4654e8e45d7d" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_1ad63ffd-6849-4549-81ed-2b5cc0d1b159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbe43290-a366-4b15-8b9f-e9c5217c945f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbe43290-a366-4b15-8b9f-e9c5217c945f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f55eb96-a8df-45fe-9018-390f667dc221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbe43290-a366-4b15-8b9f-e9c5217c945f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f55eb96-a8df-45fe-9018-390f667dc221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b26dc452-2ec8-471e-8ae3-14f44ef8bed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f55eb96-a8df-45fe-9018-390f667dc221" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b26dc452-2ec8-471e-8ae3-14f44ef8bed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4c4e0120-7428-48e3-b6b5-33748c6ea165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4c4e0120-7428-48e3-b6b5-33748c6ea165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2825e24-d763-4662-9776-45fce22c93c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4c4e0120-7428-48e3-b6b5-33748c6ea165" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2825e24-d763-4662-9776-45fce22c93c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_161b2544-b291-4a00-9d26-b7a352e33a15" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2825e24-d763-4662-9776-45fce22c93c1" xlink:to="loc_pcrx_ContingentConsiderationMember_161b2544-b291-4a00-9d26-b7a352e33a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_46702c32-a455-496c-b03a-36e0f89e03f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_46702c32-a455-496c-b03a-36e0f89e03f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fc0c034d-dab7-44db-b674-73c3172ddf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_46702c32-a455-496c-b03a-36e0f89e03f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fc0c034d-dab7-44db-b674-73c3172ddf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_460c58b3-8288-43f5-a677-f5ab4ecf828a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fc0c034d-dab7-44db-b674-73c3172ddf75" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_460c58b3-8288-43f5-a677-f5ab4ecf828a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_9bfeb1dc-cfff-4766-96fa-5acd9318eb5b" xlink:href="pcrx-20211231.xsd#pcrx_MeasurementInputExpectedMilestonePaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fc0c034d-dab7-44db-b674-73c3172ddf75" xlink:to="loc_pcrx_MeasurementInputExpectedMilestonePaymentMember_9bfeb1dc-cfff-4766-96fa-5acd9318eb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e581310e-a4c5-41d7-ad7a-5acf47533a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_398bfc76-0cab-436f-83f2-726a0acbb67e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e581310e-a4c5-41d7-ad7a-5acf47533a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d39cdb7a-29dc-4d93-b5f1-12f7cc43ff2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e581310e-a4c5-41d7-ad7a-5acf47533a9f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d39cdb7a-29dc-4d93-b5f1-12f7cc43ff2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e4895665-deab-431f-8e84-eb702d6b1582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_90254c78-da1d-4330-b873-277a4ed9c3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e4895665-deab-431f-8e84-eb702d6b1582" xlink:to="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_90254c78-da1d-4330-b873-277a4ed9c3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4b5938a3-f906-455e-ad14-24326c990b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_90254c78-da1d-4330-b873-277a4ed9c3c1" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4b5938a3-f906-455e-ad14-24326c990b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f562837-e69b-4a16-8fcc-d71c9db7e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4b5938a3-f906-455e-ad14-24326c990b51" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f562837-e69b-4a16-8fcc-d71c9db7e0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_ecab2b50-218c-4117-b4d0-f7783eb6b211" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f562837-e69b-4a16-8fcc-d71c9db7e0c0" xlink:to="loc_pcrx_ContingentConsiderationMember_ecab2b50-218c-4117-b4d0-f7783eb6b211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_b746a0b5-e4f4-4ce5-9479-8582642e528c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable_90254c78-da1d-4330-b873-277a4ed9c3c1" xlink:to="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_b746a0b5-e4f4-4ce5-9479-8582642e528c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract_b746a0b5-e4f4-4ce5-9479-8582642e528c" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e7f9b1c1-9472-429b-98e4-b877e54a08f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e7f9b1c1-9472-429b-98e4-b877e54a08f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice_3c838ea9-eda7-4ed4-b4ba-710f1003ec76" xlink:href="pcrx-20211231.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:to="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice_3c838ea9-eda7-4ed4-b4ba-710f1003ec76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_08e7456e-7e6b-4092-a8b0-fe8928ea4bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_08e7456e-7e6b-4092-a8b0-fe8928ea4bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fac123ef-da2e-4d4b-8e2a-4d95789d4866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_fac123ef-da2e-4d4b-8e2a-4d95789d4866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1819bbf3-7345-4aae-bdaf-e44d2fe5301c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_12406c0a-1b29-412d-a3ce-5466dd193b5e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1819bbf3-7345-4aae-bdaf-e44d2fe5301c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bc8f4ac6-ba10-4732-a04d-fc346b038391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3bcec3e3-cc2d-4096-9ac7-7ad93d28f951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc8f4ac6-ba10-4732-a04d-fc346b038391" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3bcec3e3-cc2d-4096-9ac7-7ad93d28f951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b9b6c0e0-3714-41b0-8bb5-6023bc7f7f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3bcec3e3-cc2d-4096-9ac7-7ad93d28f951" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b9b6c0e0-3714-41b0-8bb5-6023bc7f7f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b9b6c0e0-3714-41b0-8bb5-6023bc7f7f82" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7f525845-c492-465e-9090-9220a69c2536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7f525845-c492-465e-9090-9220a69c2536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_99ee3c98-3966-4163-b3aa-ea7a02273174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:to="loc_us-gaap_CommercialPaperMember_99ee3c98-3966-4163-b3aa-ea7a02273174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_55d6f637-4585-484f-b64b-8990d1e2abdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_55d6f637-4585-484f-b64b-8990d1e2abdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_54f956b6-35a0-487f-8610-0502a74a8d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5062d86b-90bc-4ad1-a825-f45bb5d9c26f" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_54f956b6-35a0-487f-8610-0502a74a8d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4db78dd8-2107-47dd-8697-9563b408bb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3bcec3e3-cc2d-4096-9ac7-7ad93d28f951" xlink:to="loc_us-gaap_InvestmentTypeAxis_4db78dd8-2107-47dd-8697-9563b408bb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5294875a-4931-4f3c-b640-ed2ddacdb67b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4db78dd8-2107-47dd-8697-9563b408bb7c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5294875a-4931-4f3c-b640-ed2ddacdb67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_bc47fd0a-f241-4c50-bcd4-dac00fde33a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5294875a-4931-4f3c-b640-ed2ddacdb67b" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_bc47fd0a-f241-4c50-bcd4-dac00fde33a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LongTermInvestmentsMember_283804b4-0777-4b68-ae6a-e1c38a64a36b" xlink:href="pcrx-20211231.xsd#pcrx_LongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5294875a-4931-4f3c-b640-ed2ddacdb67b" xlink:to="loc_pcrx_LongTermInvestmentsMember_283804b4-0777-4b68-ae6a-e1c38a64a36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3bcec3e3-cc2d-4096-9ac7-7ad93d28f951" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b40910ed-d425-4e61-9eae-2dea5f8b104a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_b40910ed-d425-4e61-9eae-2dea5f8b104a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e4ef61f-2e62-4b82-af67-1a143220de9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e4ef61f-2e62-4b82-af67-1a143220de9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8297e45-dd1f-4b9d-9f85-04bddb37b253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8297e45-dd1f-4b9d-9f85-04bddb37b253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6f866cbf-09aa-4f35-a0f7-6c71beac9e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ff3c2bc-2a7e-45c2-82db-7df4986c297f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6f866cbf-09aa-4f35-a0f7-6c71beac9e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_08b49e9f-eb14-493e-9c35-eb18e80a8d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_62b65670-677e-4d98-a623-d7d57dfbe7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_08b49e9f-eb14-493e-9c35-eb18e80a8d66" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_62b65670-677e-4d98-a623-d7d57dfbe7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_07bfe759-9181-432c-b7ec-a020bb158719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c9f6fd69-c01b-47dc-9dda-e3832343e4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_07bfe759-9181-432c-b7ec-a020bb158719" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c9f6fd69-c01b-47dc-9dda-e3832343e4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_024b341b-012f-4401-ac0b-a9c0aee977cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_08c0818f-b13e-4506-b0c0-82dc9f60ec60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_024b341b-012f-4401-ac0b-a9c0aee977cf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_08c0818f-b13e-4506-b0c0-82dc9f60ec60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_50127cae-cf03-43c9-8935-34b886d1d36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_024b341b-012f-4401-ac0b-a9c0aee977cf" xlink:to="loc_us-gaap_CommonStockSharesIssued_50127cae-cf03-43c9-8935-34b886d1d36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4407128d-250d-418c-a168-8c62340d427d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_024b341b-012f-4401-ac0b-a9c0aee977cf" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4407128d-250d-418c-a168-8c62340d427d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0c661799-42d4-402e-bdc6-aff2882eb3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_024b341b-012f-4401-ac0b-a9c0aee977cf" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0c661799-42d4-402e-bdc6-aff2882eb3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_79dc9937-02c5-4f68-903e-a05d5d4043cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_024b341b-012f-4401-ac0b-a9c0aee977cf" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_79dc9937-02c5-4f68-903e-a05d5d4043cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_520c8078-65c0-4599-9f9e-96d8af458e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_024b341b-012f-4401-ac0b-a9c0aee977cf" xlink:to="loc_us-gaap_PreferredStockSharesIssued_520c8078-65c0-4599-9f9e-96d8af458e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKHOLDERSEQUITYAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a022d8a1-e2b0-4db0-ba77-d3ac681d6398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e51873bd-dccb-4ac3-a785-86a2f1379489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a022d8a1-e2b0-4db0-ba77-d3ac681d6398" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e51873bd-dccb-4ac3-a785-86a2f1379489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e00bd098-5471-4f83-93f3-0756a037f3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e51873bd-dccb-4ac3-a785-86a2f1379489" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e00bd098-5471-4f83-93f3-0756a037f3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e00bd098-5471-4f83-93f3-0756a037f3eb" xlink:to="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_24a6c03f-188a-493f-b2af-8ab4e9a01fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_24a6c03f-188a-493f-b2af-8ab4e9a01fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_23488c5d-1190-4c61-bb0e-9ea3190a65d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_23488c5d-1190-4c61-bb0e-9ea3190a65d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fad6a6f-1c1c-4481-9630-c5d886e314f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dce5997a-1e22-4e9e-8163-00164ee96b63" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fad6a6f-1c1c-4481-9630-c5d886e314f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e51873bd-dccb-4ac3-a785-86a2f1379489" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6f0756d1-c652-4fab-ba8d-8303c23b792c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:to="loc_us-gaap_StockholdersEquity_6f0756d1-c652-4fab-ba8d-8303c23b792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9a13934-8720-45be-882e-30b9b9ba293e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9a13934-8720-45be-882e-30b9b9ba293e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8583f6f7-52de-431f-926d-8164f3fedac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8583f6f7-52de-431f-926d-8164f3fedac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4b866a6-dead-472a-8cb2-630fa3815122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_227a3cfe-ec1f-43f7-b986-c44289b00cf0" xlink:to="loc_us-gaap_StockholdersEquity_d4b866a6-dead-472a-8cb2-630fa3815122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ddd6ded1-3161-42bc-8406-0dbdbb730b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c5f67c7f-3166-45d4-b94e-58f9ee90446c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ddd6ded1-3161-42bc-8406-0dbdbb730b8c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c5f67c7f-3166-45d4-b94e-58f9ee90446c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f47ca703-aa4d-435f-bc16-941d9543889f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_2546152b-0c64-4a47-af71-ed934bf9905f" xlink:href="pcrx-20211231.xsd#pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f47ca703-aa4d-435f-bc16-941d9543889f" xlink:to="loc_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock_2546152b-0c64-4a47-af71-ed934bf9905f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1d749623-ad12-4d12-919e-5119b5f7a99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f47ca703-aa4d-435f-bc16-941d9543889f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1d749623-ad12-4d12-919e-5119b5f7a99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0b43e399-17b1-4021-a7bc-4ea9eac897d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f47ca703-aa4d-435f-bc16-941d9543889f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0b43e399-17b1-4021-a7bc-4ea9eac897d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b1454702-0b2a-4b45-ad50-5ea6c915ed28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f47ca703-aa4d-435f-bc16-941d9543889f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b1454702-0b2a-4b45-ad50-5ea6c915ed28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_623b9e71-b7d6-4bdc-b7cf-67d68eb4e287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f47ca703-aa4d-435f-bc16-941d9543889f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_623b9e71-b7d6-4bdc-b7cf-67d68eb4e287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1a8c589f-b651-4442-a34a-918d420a49d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f47ca703-aa4d-435f-bc16-941d9543889f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1a8c589f-b651-4442-a34a-918d420a49d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e80a2ca-26b5-4ad4-af5d-dd4ed2baa463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21e27597-05a0-49b3-8d8c-f1a3525c6212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e80a2ca-26b5-4ad4-af5d-dd4ed2baa463" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21e27597-05a0-49b3-8d8c-f1a3525c6212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c8b35fd6-c7b5-46f8-a82a-7242c6654397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21e27597-05a0-49b3-8d8c-f1a3525c6212" xlink:to="loc_us-gaap_AwardTypeAxis_c8b35fd6-c7b5-46f8-a82a-7242c6654397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_224427ed-bcf1-4bd0-ae2c-afe344dc42e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c8b35fd6-c7b5-46f8-a82a-7242c6654397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_224427ed-bcf1-4bd0-ae2c-afe344dc42e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_404b0c18-e7fe-48e2-96aa-bc84bf526fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_224427ed-bcf1-4bd0-ae2c-afe344dc42e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_404b0c18-e7fe-48e2-96aa-bc84bf526fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c454409c-dc48-4859-8d36-d5cfed19a46d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_224427ed-bcf1-4bd0-ae2c-afe344dc42e3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c454409c-dc48-4859-8d36-d5cfed19a46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_21e27597-05a0-49b3-8d8c-f1a3525c6212" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_199cf1bd-30c8-4538-964e-a1a00549769e" xlink:href="pcrx-20211231.xsd#pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_199cf1bd-30c8-4538-964e-a1a00549769e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c339cd4b-b5a5-4700-8c81-53d1b3e16d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c339cd4b-b5a5-4700-8c81-53d1b3e16d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3191df18-7084-422d-91ae-0fcceab2d3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3191df18-7084-422d-91ae-0fcceab2d3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_e6e903c3-e0de-477c-8fa3-13edbb942276" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanESPPSharesinESPP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP_e6e903c3-e0de-477c-8fa3-13edbb942276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_c1e56f4c-b17a-48ec-96f5-46426641689c" xlink:href="pcrx-20211231.xsd#pcrx_MaximumFairMarketValuePurchaseofESPPShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_MaximumFairMarketValuePurchaseofESPPShares_c1e56f4c-b17a-48ec-96f5-46426641689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanfairvalue_5c1fd3cb-83b9-47d1-94f5-1445f4011155" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanfairvalue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_EmployeeStockPurchasePlanfairvalue_5c1fd3cb-83b9-47d1-94f5-1445f4011155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a8abf909-34ca-47fb-8621-9ace78827f02" xlink:href="pcrx-20211231.xsd#pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a8abf909-34ca-47fb-8621-9ace78827f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_511624bd-1b3d-42b9-8224-f3ea20aa821b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_511624bd-1b3d-42b9-8224-f3ea20aa821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_afcc6610-e43b-4edf-9f6b-ac8e9e1c8e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_afcc6610-e43b-4edf-9f6b-ac8e9e1c8e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67320ae3-a15f-4586-9b53-b5d7c8431027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67320ae3-a15f-4586-9b53-b5d7c8431027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d746848a-2638-4e8f-bc0f-c1834a0875bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e04c71d4-bafc-42d3-87b0-05233f2c0f38" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d746848a-2638-4e8f-bc0f-c1834a0875bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSStockIncentivePlansDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251ecb5c-00d1-4262-9ab4-bb7ac2239098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aaf6300-4c3e-461f-8d67-ce96e45bb8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_251ecb5c-00d1-4262-9ab4-bb7ac2239098" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aaf6300-4c3e-461f-8d67-ce96e45bb8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a58119eb-2d4a-467b-a74d-62052a5d0d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aaf6300-4c3e-461f-8d67-ce96e45bb8a2" xlink:to="loc_us-gaap_PlanNameAxis_a58119eb-2d4a-467b-a74d-62052a5d0d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a58119eb-2d4a-467b-a74d-62052a5d0d90" xlink:to="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_StockIncentivePlan2011Member_cafa28b5-c59b-4db6-9e92-09ac79bf48ce" xlink:href="pcrx-20211231.xsd#pcrx_StockIncentivePlan2011Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:to="loc_pcrx_StockIncentivePlan2011Member_cafa28b5-c59b-4db6-9e92-09ac79bf48ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_InducementPlan2014Member_0c933f89-8bc3-4d79-a68c-35f55e0a3a33" xlink:href="pcrx-20211231.xsd#pcrx_InducementPlan2014Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:to="loc_pcrx_InducementPlan2014Member_0c933f89-8bc3-4d79-a68c-35f55e0a3a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanESPP2014Member_9298b26e-075c-4ea0-9ea9-2f03aa384e89" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanESPP2014Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8c08a82e-8269-4ab9-a8f7-f94a26315b6c" xlink:to="loc_pcrx_EmployeeStockPurchasePlanESPP2014Member_9298b26e-075c-4ea0-9ea9-2f03aa384e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7aaf6300-4c3e-461f-8d67-ce96e45bb8a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d66e2700-9374-4262-b516-541c83425811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d66e2700-9374-4262-b516-541c83425811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_23612975-8425-4328-abbd-2bdd71f56166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_23612975-8425-4328-abbd-2bdd71f56166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fefdff5b-e131-4082-8a0b-3e43461f3765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fefdff5b-e131-4082-8a0b-3e43461f3765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_dc20e772-e053-4cb8-a0f0-83f9a822140a" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized_dc20e772-e053-4cb8-a0f0-83f9a822140a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e00bb394-49a4-49cd-815f-53e5cb6315b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e00bb394-49a4-49cd-815f-53e5cb6315b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_a4811ee2-feca-42d4-bef5-eb507a5673b7" xlink:href="pcrx-20211231.xsd#pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c5c0249-4d64-4c8a-80da-657bc3f9355a" xlink:to="loc_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase_a4811ee2-feca-42d4-bef5-eb507a5673b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9fdd0d3-d1b7-41b4-8256-877572e01222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6015e70b-bbff-4cf9-b178-13c52a0f2a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e9fdd0d3-d1b7-41b4-8256-877572e01222" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6015e70b-bbff-4cf9-b178-13c52a0f2a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cec9d3c0-3dcb-417e-bf83-6dc7e42b50ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6015e70b-bbff-4cf9-b178-13c52a0f2a81" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cec9d3c0-3dcb-417e-bf83-6dc7e42b50ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cec9d3c0-3dcb-417e-bf83-6dc7e42b50ec" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_44ba34e9-960d-4e6c-a79b-7a7c384d29c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:to="loc_us-gaap_CostOfSalesMember_44ba34e9-960d-4e6c-a79b-7a7c384d29c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c6ab7137-0b76-48e4-8f3d-21efbd7294d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c6ab7137-0b76-48e4-8f3d-21efbd7294d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f25ce240-b1b5-40f5-a04a-9544f2aca838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_426c2b3b-1455-4b2a-8d52-406e571c0c93" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f25ce240-b1b5-40f5-a04a-9544f2aca838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_62533053-9ae2-44e8-b5ac-3f1e408e38b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6015e70b-bbff-4cf9-b178-13c52a0f2a81" xlink:to="loc_us-gaap_AwardTypeAxis_62533053-9ae2-44e8-b5ac-3f1e408e38b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_62533053-9ae2-44e8-b5ac-3f1e408e38b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a9c5abd-1882-4db1-be92-fed9731c6119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a9c5abd-1882-4db1-be92-fed9731c6119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9596a5d8-0c86-442e-b309-118161124dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9596a5d8-0c86-442e-b309-118161124dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_757ab5e1-826e-496d-9a8e-a22c41e3f70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cc3b882-4544-4b1b-8294-2bc7a43ae7f4" xlink:to="loc_us-gaap_EmployeeStockMember_757ab5e1-826e-496d-9a8e-a22c41e3f70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3fac4245-f973-401b-ae29-fe4074f89de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6015e70b-bbff-4cf9-b178-13c52a0f2a81" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3fac4245-f973-401b-ae29-fe4074f89de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27e00a78-6eb2-4488-919d-cf4680b6b37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3fac4245-f973-401b-ae29-fe4074f89de8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_27e00a78-6eb2-4488-919d-cf4680b6b37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_11d63dd9-0b7d-4117-adbc-2d2bc5266952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3fac4245-f973-401b-ae29-fe4074f89de8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_11d63dd9-0b7d-4117-adbc-2d2bc5266952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80c724fe-40e5-49d0-aa1e-b7f6704e7f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4de44145-e3c5-404b-b12f-0499a3871830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80c724fe-40e5-49d0-aa1e-b7f6704e7f86" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4de44145-e3c5-404b-b12f-0499a3871830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b5cbd822-2b28-4658-893b-5d58d2a2385f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4de44145-e3c5-404b-b12f-0499a3871830" xlink:to="loc_us-gaap_AwardTypeAxis_b5cbd822-2b28-4658-893b-5d58d2a2385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_598ac405-0edf-440d-a376-0a2e9897436c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b5cbd822-2b28-4658-893b-5d58d2a2385f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_598ac405-0edf-440d-a376-0a2e9897436c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_82bb6f2f-04f6-4330-a644-dc0bc98bdbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_598ac405-0edf-440d-a376-0a2e9897436c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_82bb6f2f-04f6-4330-a644-dc0bc98bdbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4de44145-e3c5-404b-b12f-0499a3871830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12ec806d-acd5-4975-8ea0-2815e950d408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12ec806d-acd5-4975-8ea0-2815e950d408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_965abe4f-33b0-4a9b-bbe7-97cd4630b6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_965abe4f-33b0-4a9b-bbe7-97cd4630b6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_996073bf-cd97-4a31-a2a7-4d92b157552b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_996073bf-cd97-4a31-a2a7-4d92b157552b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eabbd885-6ac4-4cdf-8729-8d6fd8b3dff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eabbd885-6ac4-4cdf-8729-8d6fd8b3dff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4eb9a2d5-fdd5-4fcf-8508-2c205925cb89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4eb9a2d5-fdd5-4fcf-8508-2c205925cb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5d233a6-9a95-4762-acf8-c3b9a1b08e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ef5de57-2bdf-4505-be2c-feb401508c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5d233a6-9a95-4762-acf8-c3b9a1b08e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_da8aec34-a28a-4525-8a87-f6063f008605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_da8aec34-a28a-4525-8a87-f6063f008605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c2f37eb1-b981-428c-a5bb-0313395bacc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c2f37eb1-b981-428c-a5bb-0313395bacc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16c79d28-6856-4608-9ca3-d014924f8976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16c79d28-6856-4608-9ca3-d014924f8976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8953ecef-f4da-4129-801f-7751386723b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8953ecef-f4da-4129-801f-7751386723b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4063c60d-f23f-45e1-a8fb-79a8c0ddb768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4063c60d-f23f-45e1-a8fb-79a8c0ddb768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70d2ba8f-bfd8-4c58-8595-18bd3b639ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70d2ba8f-bfd8-4c58-8595-18bd3b639ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_686e0ddc-5042-4b24-bf75-0f22b7da22d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_686e0ddc-5042-4b24-bf75-0f22b7da22d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9864d15-d649-434e-b2ae-69ebafb59b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_39acbf97-752d-45dd-86a3-463d6b7faa4f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9864d15-d649-434e-b2ae-69ebafb59b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_45171097-3b36-4523-ad89-a5cff21f370a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_45171097-3b36-4523-ad89-a5cff21f370a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_002a728a-9cc9-493a-a099-2e3e140e8663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_002a728a-9cc9-493a-a099-2e3e140e8663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e081909b-a70e-4e8e-988f-5740f40ea087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e081909b-a70e-4e8e-988f-5740f40ea087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0d413649-56d3-45b2-8989-f132f791e049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0d413649-56d3-45b2-8989-f132f791e049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_760ef232-bbb5-4566-8594-2e85f661b562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward_8e1021d6-0b68-4789-a23a-db404e1d491f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_760ef232-bbb5-4566-8594-2e85f661b562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6158f4b0-4060-4965-806c-f0a629320dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6158f4b0-4060-4965-806c-f0a629320dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d5f328c9-9342-4e35-9bc2-cca6c259184d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d5f328c9-9342-4e35-9bc2-cca6c259184d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_be24b06d-8313-44f1-919b-ae5cf020f825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_be24b06d-8313-44f1-919b-ae5cf020f825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_473117aa-e9f2-4403-bf43-746c48889b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward_f84b54c5-4cda-4139-a173-240f6dda8bba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_473117aa-e9f2-4403-bf43-746c48889b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bf298077-52aa-4145-a8fa-6d8c0328853a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69b85d4c-7430-4653-ae78-1c7cec4b2990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bf298077-52aa-4145-a8fa-6d8c0328853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e108ddc-3d65-4993-a535-6fe2e875e831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5e87e86-d268-4799-ab15-a59ae5c79968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e108ddc-3d65-4993-a535-6fe2e875e831" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5e87e86-d268-4799-ab15-a59ae5c79968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f012cfda-4aac-4a2f-b22c-5fa107fe174e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5e87e86-d268-4799-ab15-a59ae5c79968" xlink:to="loc_us-gaap_AwardTypeAxis_f012cfda-4aac-4a2f-b22c-5fa107fe174e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ece956-2083-4822-82d4-4dcf4e855477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f012cfda-4aac-4a2f-b22c-5fa107fe174e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ece956-2083-4822-82d4-4dcf4e855477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bf991497-760f-40f4-98c2-eca5526c66d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ece956-2083-4822-82d4-4dcf4e855477" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bf991497-760f-40f4-98c2-eca5526c66d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d7546412-dd00-484b-b139-0cac98f665ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ece956-2083-4822-82d4-4dcf4e855477" xlink:to="loc_us-gaap_EmployeeStockMember_d7546412-dd00-484b-b139-0cac98f665ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b70c5a79-e4d2-4f56-830a-0026e331f75b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5e87e86-d268-4799-ab15-a59ae5c79968" xlink:to="loc_srt_RangeAxis_b70c5a79-e4d2-4f56-830a-0026e331f75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f35a0d6-d9cc-46af-9eed-8d681fd95ff1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b70c5a79-e4d2-4f56-830a-0026e331f75b" xlink:to="loc_srt_RangeMember_5f35a0d6-d9cc-46af-9eed-8d681fd95ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b8447ed8-5981-4bd0-8fa0-0cb20f825cac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f35a0d6-d9cc-46af-9eed-8d681fd95ff1" xlink:to="loc_srt_MinimumMember_b8447ed8-5981-4bd0-8fa0-0cb20f825cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb7749f6-6965-47db-b24a-0f94b777496a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f35a0d6-d9cc-46af-9eed-8d681fd95ff1" xlink:to="loc_srt_MaximumMember_bb7749f6-6965-47db-b24a-0f94b777496a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21c4cebe-6209-47e5-b486-ebb86ff051a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d5e87e86-d268-4799-ab15-a59ae5c79968" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21c4cebe-6209-47e5-b486-ebb86ff051a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21c4cebe-6209-47e5-b486-ebb86ff051a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a1306cdc-1b9e-4b2c-922d-081199a2a616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a1306cdc-1b9e-4b2c-922d-081199a2a616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a4c1e439-181a-491e-bf45-3caf56b108ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a4c1e439-181a-491e-bf45-3caf56b108ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_664aacce-efc3-4aa5-9476-b3f4d00c384b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_664aacce-efc3-4aa5-9476-b3f4d00c384b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2c322c86-cbed-4bc6-9260-ff08744cd9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2c322c86-cbed-4bc6-9260-ff08744cd9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_841c29d3-8187-4a72-9da0-225c3e0417dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_841c29d3-8187-4a72-9da0-225c3e0417dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e4c6229-e389-42bd-9c7a-d774003d21b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4069b175-07b7-43a8-b7e8-23e162194e85" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2e4c6229-e389-42bd-9c7a-d774003d21b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/STOCKPLANSRSUActivityDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#STOCKPLANSRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/STOCKPLANSRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f47edc26-5c39-413b-93c0-2c56418fbecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6833380-748b-4b31-902e-5ecdf8565397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f47edc26-5c39-413b-93c0-2c56418fbecf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6833380-748b-4b31-902e-5ecdf8565397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6922abb9-c4da-4116-b4ea-d185c10740ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6833380-748b-4b31-902e-5ecdf8565397" xlink:to="loc_us-gaap_AwardTypeAxis_6922abb9-c4da-4116-b4ea-d185c10740ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01278ee6-9e72-4ff8-a688-f38224f4a92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6922abb9-c4da-4116-b4ea-d185c10740ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01278ee6-9e72-4ff8-a688-f38224f4a92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_befe4e69-9dc9-4972-944c-80647749786b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01278ee6-9e72-4ff8-a688-f38224f4a92c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_befe4e69-9dc9-4972-944c-80647749786b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a6833380-748b-4b31-902e-5ecdf8565397" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe2d6ab9-c86e-4b2d-b921-4edbaccbd20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe2d6ab9-c86e-4b2d-b921-4edbaccbd20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fe82e8b8-66b6-4584-ba52-9befed6e18e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fe82e8b8-66b6-4584-ba52-9befed6e18e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22fdfe26-e9a8-491b-a9aa-8667045605c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22fdfe26-e9a8-491b-a9aa-8667045605c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_14ec297f-047f-45c0-ac48-ccf0638f7d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_14ec297f-047f-45c0-ac48-ccf0638f7d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5780fa39-91c2-4c24-9271-e1f79e3f38ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d5d23d7d-24e2-4640-8e5c-d9af55be67b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5780fa39-91c2-4c24-9271-e1f79e3f38ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad6742f4-767d-4104-8a4e-da173f860d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ad6742f4-767d-4104-8a4e-da173f860d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67b134ac-3a6a-40fe-aa87-7328cf7a4fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_67b134ac-3a6a-40fe-aa87-7328cf7a4fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_513de0a3-7bbd-49c3-a31b-514dee984c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_513de0a3-7bbd-49c3-a31b-514dee984c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ce8b7f23-f551-4008-a2d0-dd8b1cc5352c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ce8b7f23-f551-4008-a2d0-dd8b1cc5352c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c701756c-dfb4-40c5-a0f7-18114236e1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_46c21c8f-fc76-4781-b755-e8724e1ed47d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c701756c-dfb4-40c5-a0f7-18114236e1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_f18693b1-f664-498b-9152-9f2691723212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688214af-391d-4dac-8027-a51097ed0633" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_f18693b1-f664-498b-9152-9f2691723212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2a0825d3-4910-4055-9b4c-3a76e057c43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_f18693b1-f664-498b-9152-9f2691723212" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2a0825d3-4910-4055-9b4c-3a76e057c43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHARE" xlink:type="simple" xlink:href="pcrx-20211231.xsd#NETINCOMELOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b6a475db-5e45-4983-b303-71a6bbc09fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2f0cfea9-c300-4618-939a-7d98af707ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b6a475db-5e45-4983-b303-71a6bbc09fc6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2f0cfea9-c300-4618-939a-7d98af707ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHARETables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#NETINCOMELOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2416b1ac-3f7f-4eff-a502-c0be30af7724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_341dcb46-5af0-4bd0-8591-b6cecceec63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2416b1ac-3f7f-4eff-a502-c0be30af7724" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_341dcb46-5af0-4bd0-8591-b6cecceec63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_209b5764-324b-4915-bc24-78b17e03f461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2416b1ac-3f7f-4eff-a502-c0be30af7724" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_209b5764-324b-4915-bc24-78b17e03f461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#NETINCOMELOSSPERSHARECalculationDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8c48056a-f162-47c9-b251-41e455b67eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d8d0d15-69a6-403e-b80f-4123197b6c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8c48056a-f162-47c9-b251-41e455b67eaf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d8d0d15-69a6-403e-b80f-4123197b6c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_485ccbf3-3fb2-451a-bf09-3279c577ecc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d8d0d15-69a6-403e-b80f-4123197b6c15" xlink:to="loc_us-gaap_AwardTypeAxis_485ccbf3-3fb2-451a-bf09-3279c577ecc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_485ccbf3-3fb2-451a-bf09-3279c577ecc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0e9534c-0edb-4c65-b320-dacfa2287bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0e9534c-0edb-4c65-b320-dacfa2287bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7f599259-0dfd-4422-ad34-9c8ce4ed018f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7f599259-0dfd-4422-ad34-9c8ce4ed018f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConversionPremiumOn2022NotesMember_720d9c76-4368-4363-bd2a-b4ceb0896402" xlink:href="pcrx-20211231.xsd#pcrx_ConversionPremiumOn2022NotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:to="loc_pcrx_ConversionPremiumOn2022NotesMember_720d9c76-4368-4363-bd2a-b4ceb0896402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a371def3-8d03-4f1f-ae8b-78720c145643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8840ade9-d6d0-4e48-8ecd-b4f1550cc052" xlink:to="loc_us-gaap_EmployeeStockMember_a371def3-8d03-4f1f-ae8b-78720c145643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d8d0d15-69a6-403e-b80f-4123197b6c15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0e822013-325b-4ff9-b914-f0c6541568b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0e822013-325b-4ff9-b914-f0c6541568b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a9640409-79a9-4db8-bcb3-bcbd2d46febc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0e822013-325b-4ff9-b914-f0c6541568b9" xlink:to="loc_us-gaap_NetIncomeLoss_a9640409-79a9-4db8-bcb3-bcbd2d46febc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d37352a7-4e40-4388-9d65-5b6e5d4e55a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d37352a7-4e40-4388-9d65-5b6e5d4e55a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_71baf59a-bf7b-4275-958a-1bd69164da72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d37352a7-4e40-4388-9d65-5b6e5d4e55a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_71baf59a-bf7b-4275-958a-1bd69164da72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_430b108a-173e-4bcf-a226-67462881d85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_430b108a-173e-4bcf-a226-67462881d85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_f0d372cd-65cf-4fbc-a1be-50395a17df21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_f0d372cd-65cf-4fbc-a1be-50395a17df21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ce1396bf-f8d4-4918-bd1f-e1b0a24a0e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_668a67e6-78c0-4ec1-9340-36aeb3a0153e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ce1396bf-f8d4-4918-bd1f-e1b0a24a0e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_987865d4-59f1-4d00-a526-5d5c26367e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_60a35451-2ea0-4d89-9fe9-f8b06ae357d1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_987865d4-59f1-4d00-a526-5d5c26367e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bd55a8e6-cb05-4932-a385-d59ab0f45f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_987865d4-59f1-4d00-a526-5d5c26367e10" xlink:to="loc_us-gaap_EarningsPerShareBasic_bd55a8e6-cb05-4932-a385-d59ab0f45f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7d1a6cc5-c7a7-4e2c-9d34-b6e83099d12b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_987865d4-59f1-4d00-a526-5d5c26367e10" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7d1a6cc5-c7a7-4e2c-9d34-b6e83099d12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_daffc9be-40c6-4101-944f-55a664133e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1769763-bcf8-4423-95ec-897ff2f2b38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_daffc9be-40c6-4101-944f-55a664133e0d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1769763-bcf8-4423-95ec-897ff2f2b38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a679b5f-b017-4aad-938a-239678f9ecae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1769763-bcf8-4423-95ec-897ff2f2b38b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a679b5f-b017-4aad-938a-239678f9ecae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8a679b5f-b017-4aad-938a-239678f9ecae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_76b72f01-0d09-4256-9464-d2805779fa98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_76b72f01-0d09-4256-9464-d2805779fa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2663bf50-77a8-4272-9e54-1e1ddcfa929a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2663bf50-77a8-4272-9e54-1e1ddcfa929a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_736c3436-37a2-450a-966a-dc61b6366100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4731c123-047d-40f9-b7a9-168f7037857e" xlink:to="loc_us-gaap_EmployeeStockMember_736c3436-37a2-450a-966a-dc61b6366100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5e68f90c-bb53-480d-b8d5-b1663f6ae990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1769763-bcf8-4423-95ec-897ff2f2b38b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5e68f90c-bb53-480d-b8d5-b1663f6ae990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e149ee8d-936f-442a-a7aa-cccc74b78c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5e68f90c-bb53-480d-b8d5-b1663f6ae990" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e149ee8d-936f-442a-a7aa-cccc74b78c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXES" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2b18945b-02b3-42bb-bebb-130e1a8b40de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5ce83e96-3628-426f-9985-1b4b776fab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b18945b-02b3-42bb-bebb-130e1a8b40de" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5ce83e96-3628-426f-9985-1b4b776fab4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0a9bb0b3-a922-474b-915d-4ee724720460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_57a2e583-3644-49a9-8e72-f6b48bc44675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a9bb0b3-a922-474b-915d-4ee724720460" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_57a2e583-3644-49a9-8e72-f6b48bc44675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e49a0abd-dba3-4140-9cad-12eb97168f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a9bb0b3-a922-474b-915d-4ee724720460" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e49a0abd-dba3-4140-9cad-12eb97168f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_59f5cec3-7507-475a-92d0-1c7324863ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a9bb0b3-a922-474b-915d-4ee724720460" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_59f5cec3-7507-475a-92d0-1c7324863ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e7b3f102-2d3c-48f5-aaef-ccfc340c5153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a9bb0b3-a922-474b-915d-4ee724720460" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e7b3f102-2d3c-48f5-aaef-ccfc340c5153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_76c04731-8b43-42a1-9f10-3e7b866c4d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:href="pcrx-20211231.xsd#pcrx_IncomeTaxProvisionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76c04731-8b43-42a1-9f10-3e7b866c4d2b" xlink:to="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_903f7d16-359f-45dd-9189-f08ff068b742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_903f7d16-359f-45dd-9189-f08ff068b742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_903f7d16-359f-45dd-9189-f08ff068b742" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f1c3c69f-c8f2-4177-ad58-ff20ef192582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:to="loc_us-gaap_DomesticCountryMember_f1c3c69f-c8f2-4177-ad58-ff20ef192582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ccd38f30-6b3e-44c1-9fe5-66e9aa756e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ccd38f30-6b3e-44c1-9fe5-66e9aa756e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_3db0333a-d0db-445e-b0ea-588ac7fcfb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f48a7954-e2b6-42f2-bb8c-3ccf0bbe852c" xlink:to="loc_us-gaap_ForeignCountryMember_3db0333a-d0db-445e-b0ea-588ac7fcfb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_b7848aa2-c13c-4b7f-b169-7b419f8fea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_b7848aa2-c13c-4b7f-b169-7b419f8fea3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f595c288-ab75-4f53-bd96-c313b427885d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_b7848aa2-c13c-4b7f-b169-7b419f8fea3b" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f595c288-ab75-4f53-bd96-c313b427885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_d71ec330-8a92-42bd-bf6a-b572faaa3324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f595c288-ab75-4f53-bd96-c313b427885d" xlink:to="loc_us-gaap_ResearchMember_d71ec330-8a92-42bd-bf6a-b572faaa3324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_9ec0010c-637b-4d0f-9ade-10b72666a4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f595c288-ab75-4f53-bd96-c313b427885d" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_9ec0010c-637b-4d0f-9ade-10b72666a4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f7bca794-9017-433e-b609-7c99bce8caf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_srt_StatementScenarioAxis_f7bca794-9017-433e-b609-7c99bce8caf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fb2b4cf8-3ba0-4fe4-b96f-c6c00ac4318d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f7bca794-9017-433e-b609-7c99bce8caf9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fb2b4cf8-3ba0-4fe4-b96f-c6c00ac4318d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ccf95db4-ae1a-46f1-a600-a5669d06d4b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fb2b4cf8-3ba0-4fe4-b96f-c6c00ac4318d" xlink:to="loc_srt_ScenarioForecastMember_ccf95db4-ae1a-46f1-a600-a5669d06d4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_18de3693-11af-482c-927f-8e12ae892c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_18de3693-11af-482c-927f-8e12ae892c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00764543-3138-4153-98be-7c5e05f3fc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_18de3693-11af-482c-927f-8e12ae892c15" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00764543-3138-4153-98be-7c5e05f3fc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_d3c36f9c-152d-4718-b16e-c440a9923ee5" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00764543-3138-4153-98be-7c5e05f3fc51" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_d3c36f9c-152d-4718-b16e-c440a9923ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_49c68bfc-a8c0-4a42-9899-090b0a27701e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_49c68bfc-a8c0-4a42-9899-090b0a27701e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_13e8def3-ba11-483a-b563-fcfa075f8d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_49c68bfc-a8c0-4a42-9899-090b0a27701e" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_13e8def3-ba11-483a-b563-fcfa075f8d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ForeignNetDeferredTaxAssetMember_af7bbb90-8fbf-4809-8265-a6fc7eaaff08" xlink:href="pcrx-20211231.xsd#pcrx_ForeignNetDeferredTaxAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_13e8def3-ba11-483a-b563-fcfa075f8d3a" xlink:to="loc_pcrx_ForeignNetDeferredTaxAssetMember_af7bbb90-8fbf-4809-8265-a6fc7eaaff08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:href="pcrx-20211231.xsd#pcrx_IncomeTaxProvisionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionTable_86a818b6-7db0-4258-9a52-c7ce5aa3bbc8" xlink:to="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_23edc732-bec3-41e9-82c0-2d3ba85e1e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_23edc732-bec3-41e9-82c0-2d3ba85e1e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5721e6fe-cca2-4fb4-9c02-8e2d6f604b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5721e6fe-cca2-4fb4-9c02-8e2d6f604b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_68bef483-1915-444b-ab56-4240834a4286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_68bef483-1915-444b-ab56-4240834a4286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_723d4b96-d83c-449e-bcb9-b2eb848c8070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_723d4b96-d83c-449e-bcb9-b2eb848c8070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_56aa8ce3-4b0a-4da9-8e34-8bb7913b01a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_OperatingLossCarryforwards_56aa8ce3-4b0a-4da9-8e34-8bb7913b01a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_3dc9d982-b8e8-4f90-a362-07d7dab429b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_3dc9d982-b8e8-4f90-a362-07d7dab429b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_4735c23a-7f0e-4c8d-a4c9-e28f61340942" xlink:href="pcrx-20211231.xsd#pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax_4735c23a-7f0e-4c8d-a4c9-e28f61340942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NetOperatingLossSubjecttoLimitation_de093115-8e92-4b05-813b-f9c14b6d7b40" xlink:href="pcrx-20211231.xsd#pcrx_NetOperatingLossSubjecttoLimitation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_NetOperatingLossSubjecttoLimitation_de093115-8e92-4b05-813b-f9c14b6d7b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_OtherTaxAttributesSubjectToLimitation_14918866-d2a3-43be-bd0f-844e7a05dc7e" xlink:href="pcrx-20211231.xsd#pcrx_OtherTaxAttributesSubjectToLimitation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_OtherTaxAttributesSubjectToLimitation_14918866-d2a3-43be-bd0f-844e7a05dc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne_bf39d216-2697-436c-b098-0d0f367cd3e2" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearOne"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne_bf39d216-2697-436c-b098-0d0f367cd3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo_341b0733-c14e-4a1b-984f-960aaf5a26b4" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo_341b0733-c14e-4a1b-984f-960aaf5a26b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree_13c259bb-ef0c-4066-ba34-7d29604d47de" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearThree"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree_13c259bb-ef0c-4066-ba34-7d29604d47de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour_4469b2c6-243b-460b-87b6-283b4369f85a" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearFour"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour_4469b2c6-243b-460b-87b6-283b4369f85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive_7debb8bb-8a4f-41f4-9f15-805beaf5d5d3" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearFive"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive_7debb8bb-8a4f-41f4-9f15-805beaf5d5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix_60861b57-6db0-46ae-90bf-c8aa5428d688" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearSix"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix_60861b57-6db0-46ae-90bf-c8aa5428d688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix_714ef61d-cd45-476a-8959-f2fc71eaa3e1" xlink:href="pcrx-20211231.xsd#pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix_714ef61d-cd45-476a-8959-f2fc71eaa3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f9d3f413-2991-457f-9742-7ec5b760a763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f9d3f413-2991-457f-9742-7ec5b760a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3e5ab358-88dc-4d1b-bab6-1ea07f219858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3e5ab358-88dc-4d1b-bab6-1ea07f219858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b3935fcb-b35c-4426-a64c-1c13597b43e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b3935fcb-b35c-4426-a64c-1c13597b43e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e810e5cf-62ec-419a-9ed3-835d3940bcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_IncomeTaxProvisionLineItems_b4c71ba4-7b14-4462-8126-264a26302d06" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e810e5cf-62ec-419a-9ed3-835d3940bcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESCurrentandDeferredIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_074ed819-2494-4897-a592-bb56ab209d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_2f9703e7-e40c-4466-9dea-6ac4b8789d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_074ed819-2494-4897-a592-bb56ab209d0a" xlink:to="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_2f9703e7-e40c-4466-9dea-6ac4b8789d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_13b14651-ff12-4eb8-a97d-bf71ed5ff93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_2f9703e7-e40c-4466-9dea-6ac4b8789d23" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_13b14651-ff12-4eb8-a97d-bf71ed5ff93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_527d1d33-db21-4779-81a4-fadd1d1421cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_13b14651-ff12-4eb8-a97d-bf71ed5ff93c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_527d1d33-db21-4779-81a4-fadd1d1421cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_7129bfc2-2da5-4f36-b9d4-be220367e317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_13b14651-ff12-4eb8-a97d-bf71ed5ff93c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_7129bfc2-2da5-4f36-b9d4-be220367e317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_98ec2e6f-0b97-4a8e-9adf-97ebe38b1210" xlink:href="pcrx-20211231.xsd#pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_13b14651-ff12-4eb8-a97d-bf71ed5ff93c" xlink:to="loc_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal_98ec2e6f-0b97-4a8e-9adf-97ebe38b1210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4a3fab19-cb4d-4148-a443-9ca220c359ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_2f9703e7-e40c-4466-9dea-6ac4b8789d23" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4a3fab19-cb4d-4148-a443-9ca220c359ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_80211b96-848c-4271-99bc-c4e82335435e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4a3fab19-cb4d-4148-a443-9ca220c359ca" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_80211b96-848c-4271-99bc-c4e82335435e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_36a8dcab-4f5b-4926-bea6-3cd00b66aa38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4a3fab19-cb4d-4148-a443-9ca220c359ca" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_36a8dcab-4f5b-4926-bea6-3cd00b66aa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f09f401c-349b-40a1-b5b2-7677215b170a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4a3fab19-cb4d-4148-a443-9ca220c359ca" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f09f401c-349b-40a1-b5b2-7677215b170a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_70529d15-29be-49ac-a336-bf5b7e6b45fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4a3fab19-cb4d-4148-a443-9ca220c359ca" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_70529d15-29be-49ac-a336-bf5b7e6b45fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6bd2dd6e-974d-42c2-a350-590851460ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_2f9703e7-e40c-4466-9dea-6ac4b8789d23" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6bd2dd6e-974d-42c2-a350-590851460ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c5ec219b-562e-4987-b6ee-ecaf2e9a52bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6bd2dd6e-974d-42c2-a350-590851460ec2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c5ec219b-562e-4987-b6ee-ecaf2e9a52bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_93963db6-b8c4-4dfe-8062-5a5eeb0b6b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6bd2dd6e-974d-42c2-a350-590851460ec2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_93963db6-b8c4-4dfe-8062-5a5eeb0b6b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_18149a5d-c8b2-48fe-816c-4b62f7ddff32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_6bd2dd6e-974d-42c2-a350-590851460ec2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_18149a5d-c8b2-48fe-816c-4b62f7ddff32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_53d655ed-ee22-4858-9821-8ac3771a2cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_2f9703e7-e40c-4466-9dea-6ac4b8789d23" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_53d655ed-ee22-4858-9821-8ac3771a2cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESReconciliationofEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e9b58d6e-a50f-4530-b976-9fda6c8c3bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9b58d6e-a50f-4530-b976-9fda6c8c3bca" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_99765b56-d497-4d13-b06e-981b17cbda39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_99765b56-d497-4d13-b06e-981b17cbda39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8ce2453e-964d-45f3-8f52-d58139414545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8ce2453e-964d-45f3-8f52-d58139414545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_22cb4370-b188-4b6a-9645-67983193c604" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationForeign"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationForeign_22cb4370-b188-4b6a-9645-67983193c604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3db2e69a-11dc-4c20-8d8d-5f2d233c6202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3db2e69a-11dc-4c20-8d8d-5f2d233c6202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_bc4d9a39-2995-4c54-a83b-c7c6b1b6edd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_bc4d9a39-2995-4c54-a83b-c7c6b1b6edd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b14382f2-105c-4d68-85f3-dd00643ca878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b14382f2-105c-4d68-85f3-dd00643ca878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit_7cf14cb1-b4be-4be4-8dda-813a3573c864" xlink:href="pcrx-20211231.xsd#pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit_7cf14cb1-b4be-4be4-8dda-813a3573c864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_79436477-2cf6-4cc5-9472-20b624b08432" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing_79436477-2cf6-4cc5-9472-20b624b08432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_bc665eed-3be9-4a92-a0b5-93185ca7e0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_bc665eed-3be9-4a92-a0b5-93185ca7e0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent_9a2e31c0-ff43-42a5-b8e8-d6530c18379d" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent_9a2e31c0-ff43-42a5-b8e8-d6530c18379d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent_0da1b117-0f3a-4d80-827c-c4c244501bda" xlink:href="pcrx-20211231.xsd#pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent_0da1b117-0f3a-4d80-827c-c4c244501bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_f30c3500-3cb2-4807-9626-58943119a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_f30c3500-3cb2-4807-9626-58943119a13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_81db15b9-b2a2-498a-a6bd-7a1a472be291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c5c2116f-2ad1-470d-9ee2-3b1f121aa23d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_81db15b9-b2a2-498a-a6bd-7a1a472be291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e8d0394a-db3f-4246-b7fa-16906254132f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_89be5c4f-af82-4f45-b7a6-4ada4b052f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8d0394a-db3f-4246-b7fa-16906254132f" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_89be5c4f-af82-4f45-b7a6-4ada4b052f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_89be5c4f-af82-4f45-b7a6-4ada4b052f21" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e23094f3-c0a4-4a2a-91b1-9e324a1232fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e23094f3-c0a4-4a2a-91b1-9e324a1232fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a42363bb-47e5-4c4d-915c-d2f31ee9f556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a42363bb-47e5-4c4d-915c-d2f31ee9f556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_b43a133e-45f1-446f-ad34-e1fec2358b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_b43a133e-45f1-446f-ad34-e1fec2358b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_12b76d17-9bab-4092-93d1-d4635d80a765" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxAssetsStockBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:to="loc_pcrx_DeferredTaxAssetsStockBasedCompensation_12b76d17-9bab-4092-93d1-d4635d80a765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_98232f41-d0b6-4749-ac7f-98e5b4fa7311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_98232f41-d0b6-4749-ac7f-98e5b4fa7311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_7af18e11-5f41-44ee-8565-d9c6a74d9808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_7af18e11-5f41-44ee-8565-d9c6a74d9808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5b55694f-91f4-4c14-8453-0ab056aae2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_5b55694f-91f4-4c14-8453-0ab056aae2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5b939966-8319-420b-a7da-4e4e0bf3344f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_ef53b2ce-a79c-459a-88c0-508cb34dae85" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5b939966-8319-420b-a7da-4e4e0bf3344f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9916df43-7e34-4c29-9eab-d6122eec9f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_89be5c4f-af82-4f45-b7a6-4ada4b052f21" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9916df43-7e34-4c29-9eab-d6122eec9f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_f68f571c-0afd-4d3f-9aaa-dff418b97e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9916df43-7e34-4c29-9eab-d6122eec9f9c" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_f68f571c-0afd-4d3f-9aaa-dff418b97e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_83e8678a-f0a4-4279-8071-a60feb3ca519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9916df43-7e34-4c29-9eab-d6122eec9f9c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_83e8678a-f0a4-4279-8071-a60feb3ca519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0ead6f1f-5260-4166-9cca-a156d522bb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9916df43-7e34-4c29-9eab-d6122eec9f9c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0ead6f1f-5260-4166-9cca-a156d522bb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_8598067b-afd8-4940-b171-956cf6a35df8" xlink:href="pcrx-20211231.xsd#pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_89be5c4f-af82-4f45-b7a6-4ada4b052f21" xlink:to="loc_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance_8598067b-afd8-4940-b171-956cf6a35df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aff9beea-66a0-4f6c-b5da-4a0f94eaa5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_89be5c4f-af82-4f45-b7a6-4ada4b052f21" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_aff9beea-66a0-4f6c-b5da-4a0f94eaa5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_03853f45-2bef-4f64-88a2-4939cc04c39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_89be5c4f-af82-4f45-b7a6-4ada4b052f21" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_03853f45-2bef-4f64-88a2-4939cc04c39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#INCOMETAXESUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a035a649-5e7d-4a4d-9421-35e9853c8cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ef86c065-273d-4582-a01e-c4e452987ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a035a649-5e7d-4a4d-9421-35e9853c8cfe" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ef86c065-273d-4582-a01e-c4e452987ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a2b3cc11-6707-4a8e-94a4-a4f214999fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ef86c065-273d-4582-a01e-c4e452987ffa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a2b3cc11-6707-4a8e-94a4-a4f214999fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d3db731f-a112-4021-8c6d-15e3b4b17438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ef86c065-273d-4582-a01e-c4e452987ffa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d3db731f-a112-4021-8c6d-15e3b4b17438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_01f672cc-dcee-4a84-8504-2602fd4bff9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ef86c065-273d-4582-a01e-c4e452987ffa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_01f672cc-dcee-4a84-8504-2602fd4bff9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fa60c644-ceea-4428-9a8e-255d8958eeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ef86c065-273d-4582-a01e-c4e452987ffa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fa60c644-ceea-4428-9a8e-255d8958eeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a8dfc56-95fd-442d-9dba-3d662f622f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_edad0f17-2bce-41f9-9d95-ec11553cd7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a8dfc56-95fd-442d-9dba-3d662f622f19" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_edad0f17-2bce-41f9-9d95-ec11553cd7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_19f3b6bf-b772-44ea-9716-5c9f038b64a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b8c9ba3a-c6c2-468f-81bf-f62999350cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_19f3b6bf-b772-44ea-9716-5c9f038b64a7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b8c9ba3a-c6c2-468f-81bf-f62999350cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_861368b3-cb4c-43a0-9325-2edf11d33b0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b8c9ba3a-c6c2-468f-81bf-f62999350cb2" xlink:to="loc_srt_RangeAxis_861368b3-cb4c-43a0-9325-2edf11d33b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_475b493d-86cd-4264-943f-c5919783340c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_861368b3-cb4c-43a0-9325-2edf11d33b0d" xlink:to="loc_srt_RangeMember_475b493d-86cd-4264-943f-c5919783340c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7d60f5b7-f72c-4a7f-a2c4-ec1886f92b18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_475b493d-86cd-4264-943f-c5919783340c" xlink:to="loc_srt_MinimumMember_7d60f5b7-f72c-4a7f-a2c4-ec1886f92b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8cf79a3a-1a7f-43b9-9a89-de3632ec7d9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_475b493d-86cd-4264-943f-c5919783340c" xlink:to="loc_srt_MaximumMember_8cf79a3a-1a7f-43b9-9a89-de3632ec7d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b8c9ba3a-c6c2-468f-81bf-f62999350cb2" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0a5109c8-74f5-4b83-a627-627a550db421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0a5109c8-74f5-4b83-a627-627a550db421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_a8f239d2-90eb-4fc2-8c1a-d28b55da8d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_a8f239d2-90eb-4fc2-8c1a-d28b55da8d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage_e51ff1f1-22dd-4147-9071-b68d962be762" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage_e51ff1f1-22dd-4147-9071-b68d962be762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_538bbc58-c2db-494d-af3d-0dc31156744e" xlink:href="pcrx-20211231.xsd#pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_538bbc58-c2db-494d-af3d-0dc31156744e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_113e3b01-83be-4310-9876-c632450afb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_113e3b01-83be-4310-9876-c632450afb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_4f158f14-4148-4bd1-9983-02e5f099a69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9b50b491-1cd8-4473-a455-4136b403819f" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_4f158f14-4148-4bd1-9983-02e5f099a69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNET" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNET"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17c794ff-1202-4195-bda1-26591fbcc96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock_17f52a0d-5c55-4168-9404-4e320a06e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17c794ff-1202-4195-bda1-26591fbcc96c" xlink:to="loc_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock_17f52a0d-5c55-4168-9404-4e320a06e4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c5fd2d3-9679-4e7d-acc5-3f0c0ef1788b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_a94597c8-6dab-47db-b36b-fd46c00d136b" xlink:href="pcrx-20211231.xsd#pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c5fd2d3-9679-4e7d-acc5-3f0c0ef1788b" xlink:to="loc_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock_a94597c8-6dab-47db-b36b-fd46c00d136b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0ba97071-f604-49fb-a04a-c79dd0e45960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0ba97071-f604-49fb-a04a-c79dd0e45960" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7e09e48b-b026-4c0a-899b-d12be7c6007d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7e09e48b-b026-4c0a-899b-d12be7c6007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_544d7b51-a8c5-427c-90b6-bd5087d39e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7e09e48b-b026-4c0a-899b-d12be7c6007d" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_544d7b51-a8c5-427c-90b6-bd5087d39e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedFeesMember_14d165a5-bd1d-4652-adcb-47388334f26e" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_544d7b51-a8c5-427c-90b6-bd5087d39e61" xlink:to="loc_pcrx_AcquisitionRelatedFeesMember_14d165a5-bd1d-4652-adcb-47388334f26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_fc76ed72-df65-4932-9dd5-957709eb93b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_544d7b51-a8c5-427c-90b6-bd5087d39e61" xlink:to="loc_us-gaap_OtherRestructuringMember_fc76ed72-df65-4932-9dd5-957709eb93b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_85759717-2909-4823-ba8b-90322a01b3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_85759717-2909-4823-ba8b-90322a01b3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91359536-56f2-42b9-b1bf-d6069c4b4465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85759717-2909-4823-ba8b-90322a01b3c7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91359536-56f2-42b9-b1bf-d6069c4b4465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_ba76950a-b384-410c-9b89-929f956a7eab" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91359536-56f2-42b9-b1bf-d6069c4b4465" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_ba76950a-b384-410c-9b89-929f956a7eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_01e01b91-9e1a-4211-bb5a-5bc839618639" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91359536-56f2-42b9-b1bf-d6069c4b4465" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_01e01b91-9e1a-4211-bb5a-5bc839618639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7bc4f928-476c-4605-9d8d-dc296b555881" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:to="loc_srt_CounterpartyNameAxis_7bc4f928-476c-4605-9d8d-dc296b555881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a69059c-2261-461c-8c72-da097307e4ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7bc4f928-476c-4605-9d8d-dc296b555881" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a69059c-2261-461c-8c72-da097307e4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DepoCyteMember_07717aee-ad25-41d8-b0b7-740567f48529" xlink:href="pcrx-20211231.xsd#pcrx_DepoCyteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a69059c-2261-461c-8c72-da097307e4ba" xlink:to="loc_pcrx_DepoCyteMember_07717aee-ad25-41d8-b0b7-740567f48529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NuanceBiotechCo.Ltd.Member_a1d580f0-99fd-475c-a34f-12312e32f75d" xlink:href="pcrx-20211231.xsd#pcrx_NuanceBiotechCo.Ltd.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a69059c-2261-461c-8c72-da097307e4ba" xlink:to="loc_pcrx_NuanceBiotechCo.Ltd.Member_a1d580f0-99fd-475c-a34f-12312e32f75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9944a168-ab5a-490a-a757-f31d6dc1f605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0f22694e-7d18-4473-906d-b72b94a54fb1" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9944a168-ab5a-490a-a757-f31d6dc1f605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9944a168-ab5a-490a-a757-f31d6dc1f605" xlink:to="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_7bc71785-40c1-4e39-8a89-ef4835351505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_7bc71785-40c1-4e39-8a89-ef4835351505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c8f1c93f-e260-4ee6-9729-5406acecf977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c8f1c93f-e260-4ee6-9729-5406acecf977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_4af75297-bf92-410d-966b-c0da443dede3" xlink:href="pcrx-20211231.xsd#pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts_4af75297-bf92-410d-966b-c0da443dede3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e5ff4da1-0a54-4352-9556-1266a73090b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e5ff4da1-0a54-4352-9556-1266a73090b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_9535e3eb-fb65-45f8-8d77-94c05fd2911f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_GainLossOnContractTermination_9535e3eb-fb65-45f8-8d77-94c05fd2911f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_2e59915d-19e3-47b6-a147-4a0a7baea3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_us-gaap_LitigationSettlementExpense_2e59915d-19e3-47b6-a147-4a0a7baea3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther_f8393677-27a7-4eec-b093-5ddd55533e51" xlink:href="pcrx-20211231.xsd#pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_245fa654-acd9-4b50-9ad4-8825da8f86db" xlink:to="loc_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther_f8393677-27a7-4eec-b093-5ddd55533e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdcf2f6c-53ff-43fd-8e43-86303b063de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdcf2f6c-53ff-43fd-8e43-86303b063de2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_696f7c6c-2b1e-40f8-bfd4-bd749730ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_696f7c6c-2b1e-40f8-bfd4-bd749730ccba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d98fa4f3-440c-452d-b7dc-51f821d27e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_696f7c6c-2b1e-40f8-bfd4-bd749730ccba" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d98fa4f3-440c-452d-b7dc-51f821d27e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionAcquisitionMember_33fee552-236b-4abb-befd-f1bcd99ce603" xlink:href="pcrx-20211231.xsd#pcrx_FlexionAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d98fa4f3-440c-452d-b7dc-51f821d27e40" xlink:to="loc_pcrx_FlexionAcquisitionMember_33fee552-236b-4abb-befd-f1bcd99ce603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_752b177e-f8fa-4e54-b34c-1d77c3978c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_752b177e-f8fa-4e54-b34c-1d77c3978c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_29767b90-8124-4baa-8398-0c36378ef9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_752b177e-f8fa-4e54-b34c-1d77c3978c55" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_29767b90-8124-4baa-8398-0c36378ef9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LegalFeesMember_25928d71-8d76-4262-9971-47c49ada7474" xlink:href="pcrx-20211231.xsd#pcrx_LegalFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_29767b90-8124-4baa-8398-0c36378ef9c6" xlink:to="loc_pcrx_LegalFeesMember_25928d71-8d76-4262-9971-47c49ada7474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_452d5691-86d2-4a47-84a6-e8cd15c3fe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:to="loc_us-gaap_FinancialInstrumentAxis_452d5691-86d2-4a47-84a6-e8cd15c3fe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d3dd6b-775d-45c9-8c30-b29312040833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_452d5691-86d2-4a47-84a6-e8cd15c3fe15" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d3dd6b-775d-45c9-8c30-b29312040833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_17199faf-7662-4764-bb14-86dd5ad5313f" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63d3dd6b-775d-45c9-8c30-b29312040833" xlink:to="loc_pcrx_ContingentConsiderationMember_17199faf-7662-4764-bb14-86dd5ad5313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_8197f256-8774-4a04-b668-f84b643716ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_8197f256-8774-4a04-b668-f84b643716ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ecb10705-209d-4d6e-976d-90c200171917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8197f256-8774-4a04-b668-f84b643716ae" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ecb10705-209d-4d6e-976d-90c200171917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ContingentConsiderationMember_58e837ce-c866-44f4-91dd-be110af211d6" xlink:href="pcrx-20211231.xsd#pcrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ecb10705-209d-4d6e-976d-90c200171917" xlink:to="loc_pcrx_ContingentConsiderationMember_58e837ce-c866-44f4-91dd-be110af211d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e0fe8230-1125-4919-b84d-aff453363f41" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_e08f4a7e-acec-42a0-8b7c-4627ff772865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_e08f4a7e-acec-42a0-8b7c-4627ff772865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6d1168f8-e2d2-4ad0-b370-a5af1c650d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6d1168f8-e2d2-4ad0-b370-a5af1c650d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_344cb602-e25e-494b-a450-5dac81d8f67a" xlink:href="pcrx-20211231.xsd#pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_daba1d42-89e3-4520-815c-1258843a0da9" xlink:to="loc_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare_344cb602-e25e-494b-a450-5dac81d8f67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cdfb2d1d-afcd-43f8-b1b4-3927089935fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_72f9313c-8cab-40b0-8793-55fc9b1dbcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cdfb2d1d-afcd-43f8-b1b4-3927089935fb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_72f9313c-8cab-40b0-8793-55fc9b1dbcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d23c3226-2af0-4c75-a1a1-bb796f2b508a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_72f9313c-8cab-40b0-8793-55fc9b1dbcf7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d23c3226-2af0-4c75-a1a1-bb796f2b508a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04254acc-6872-4ed1-8417-a27151332b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d23c3226-2af0-4c75-a1a1-bb796f2b508a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04254acc-6872-4ed1-8417-a27151332b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_MyoscienceAcquisitionMember_980dd9a2-cdc8-4b57-9e12-80f5dd49eb44" xlink:href="pcrx-20211231.xsd#pcrx_MyoscienceAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04254acc-6872-4ed1-8417-a27151332b48" xlink:to="loc_pcrx_MyoscienceAcquisitionMember_980dd9a2-cdc8-4b57-9e12-80f5dd49eb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_675be319-9822-4582-bdc2-41eb5e3d5aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_72f9313c-8cab-40b0-8793-55fc9b1dbcf7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_675be319-9822-4582-bdc2-41eb5e3d5aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_655891ea-2416-43a7-9cb4-4eae6d39497e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_675be319-9822-4582-bdc2-41eb5e3d5aa8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_655891ea-2416-43a7-9cb4-4eae6d39497e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AdvisoryCostsMember_3cb39c45-1b07-4ae7-a9fa-266cbcacbb38" xlink:href="pcrx-20211231.xsd#pcrx_AdvisoryCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_655891ea-2416-43a7-9cb4-4eae6d39497e" xlink:to="loc_pcrx_AdvisoryCostsMember_3cb39c45-1b07-4ae7-a9fa-266cbcacbb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember_a495bc53-5d3b-4260-8e7a-483359baa074" xlink:href="pcrx-20211231.xsd#pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_655891ea-2416-43a7-9cb4-4eae6d39497e" xlink:to="loc_pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember_a495bc53-5d3b-4260-8e7a-483359baa074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_96c5176b-a5c9-499b-85c7-0f179836a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_72f9313c-8cab-40b0-8793-55fc9b1dbcf7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_96c5176b-a5c9-499b-85c7-0f179836a4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3f5aa526-a42e-4c78-97e8-83259def49e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96c5176b-a5c9-499b-85c7-0f179836a4ad" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_3f5aa526-a42e-4c78-97e8-83259def49e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6a4434c1-0ade-4167-befa-bcdc74772bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96c5176b-a5c9-499b-85c7-0f179836a4ad" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6a4434c1-0ade-4167-befa-bcdc74772bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_988690d5-8f42-425b-89c6-761ce690969b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef789cba-5a5c-43d9-bd9c-f98c75f894fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_988690d5-8f42-425b-89c6-761ce690969b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef789cba-5a5c-43d9-bd9c-f98c75f894fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_11944ee2-df07-495a-b0a0-6e565e57d571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef789cba-5a5c-43d9-bd9c-f98c75f894fd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_11944ee2-df07-495a-b0a0-6e565e57d571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc2fead0-b706-4c1d-a24d-2771f84f60cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_11944ee2-df07-495a-b0a0-6e565e57d571" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc2fead0-b706-4c1d-a24d-2771f84f60cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_NuanceBiotechCo.Ltd.Member_44b76998-08c9-4792-be98-8e3e1286c08e" xlink:href="pcrx-20211231.xsd#pcrx_NuanceBiotechCo.Ltd.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc2fead0-b706-4c1d-a24d-2771f84f60cd" xlink:to="loc_pcrx_NuanceBiotechCo.Ltd.Member_44b76998-08c9-4792-be98-8e3e1286c08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_05b86800-6c70-4267-9725-d008815f3239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef789cba-5a5c-43d9-bd9c-f98c75f894fd" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_05b86800-6c70-4267-9725-d008815f3239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_ee02ef31-5780-41f1-99cd-12901a435370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05b86800-6c70-4267-9725-d008815f3239" xlink:to="loc_us-gaap_LitigationSettlementExpense_ee02ef31-5780-41f1-99cd-12901a435370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepoCyteDiscontinuationDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepoCyteDiscontinuationDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepoCyteDiscontinuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9bfcc6b1-436b-4929-9d73-6f4ffef47d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_6135e90e-c0d8-4e5f-9e70-60e6c1a4ac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9bfcc6b1-436b-4929-9d73-6f4ffef47d98" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_6135e90e-c0d8-4e5f-9e70-60e6c1a4ac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_f70616df-47d4-48e2-acb8-0cc313c5b12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9bfcc6b1-436b-4929-9d73-6f4ffef47d98" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_f70616df-47d4-48e2-acb8-0cc313c5b12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepartmentofJusticeDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepartmentofJusticeDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepartmentofJusticeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_700d865e-2b96-4e37-b271-738f274cbb19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_6d6c52f6-12fc-4d68-a4a5-9dfbb97aec99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_700d865e-2b96-4e37-b271-738f274cbb19" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_6d6c52f6-12fc-4d68-a4a5-9dfbb97aec99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#COMMERCIALPARTNERSANDOTHERAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_663984b7-8759-46ba-8a36-170d1f502866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CommercialPartnersAndAgreementsTextBlock_3611c950-a42c-4d00-b1a7-b73e46e55104" xlink:href="pcrx-20211231.xsd#pcrx_CommercialPartnersAndAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_663984b7-8759-46ba-8a36-170d1f502866" xlink:to="loc_pcrx_CommercialPartnersAndAgreementsTextBlock_3611c950-a42c-4d00-b1a7-b73e46e55104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16856925-e11b-431f-8e15-c2e530cbddf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16856925-e11b-431f-8e15-c2e530cbddf7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8a644e2f-64a7-4c2c-93f7-667864b67f57" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_srt_CounterpartyNameAxis_8a644e2f-64a7-4c2c-93f7-667864b67f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bc7b12f-6921-48a4-a3f9-183b6cc46059" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8a644e2f-64a7-4c2c-93f7-667864b67f57" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bc7b12f-6921-48a4-a3f9-183b6cc46059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_DePuySynthesSalesIncMember_b29a9353-0fad-40a4-9430-b59c19d2bd66" xlink:href="pcrx-20211231.xsd#pcrx_DePuySynthesSalesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7bc7b12f-6921-48a4-a3f9-183b6cc46059" xlink:to="loc_pcrx_DePuySynthesSalesIncMember_b29a9353-0fad-40a4-9430-b59c19d2bd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_3cb7dcc5-e4d3-4cb7-b81f-500fb2838d71" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_3cb7dcc5-e4d3-4cb7-b81f-500fb2838d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_60865e75-b3ba-4371-9bae-2541eddc6545" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_3cb7dcc5-e4d3-4cb7-b81f-500fb2838d71" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_60865e75-b3ba-4371-9bae-2541eddc6545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_bedf9c74-332a-405c-b6eb-2b82d28d4420" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_60865e75-b3ba-4371-9bae-2541eddc6545" xlink:to="loc_pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember_bedf9c74-332a-405c-b6eb-2b82d28d4420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98d0006b-74ea-4bf3-beb4-fd71cd0f3093" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_srt_RangeAxis_98d0006b-74ea-4bf3-beb4-fd71cd0f3093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17e91c72-8488-4378-a799-66676c9a6f38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_98d0006b-74ea-4bf3-beb4-fd71cd0f3093" xlink:to="loc_srt_RangeMember_17e91c72-8488-4378-a799-66676c9a6f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4c2d5d4e-eed9-401a-97b5-b0c30027ee44" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17e91c72-8488-4378-a799-66676c9a6f38" xlink:to="loc_srt_MaximumMember_4c2d5d4e-eed9-401a-97b5-b0c30027ee44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8f5687e7-df49-4579-b101-f94b773f3146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8f5687e7-df49-4579-b101-f94b773f3146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8f5687e7-df49-4579-b101-f94b773f3146" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AratanaTherapeuticsIncMember_7371dfc1-fd93-4372-aea1-2a770641eba6" xlink:href="pcrx-20211231.xsd#pcrx_AratanaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:to="loc_pcrx_AratanaTherapeuticsIncMember_7371dfc1-fd93-4372-aea1-2a770641eba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_EurofarmaLabatoriesSAMember_06f7496b-bf15-475a-8b31-dad60a739a37" xlink:href="pcrx-20211231.xsd#pcrx_EurofarmaLabatoriesSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:to="loc_pcrx_EurofarmaLabatoriesSAMember_06f7496b-bf15-475a-8b31-dad60a739a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_HongKongPharmaTainuoLtdMember_e1d80588-4a52-4e50-84e3-d34cff7ff89d" xlink:href="pcrx-20211231.xsd#pcrx_HongKongPharmaTainuoLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c936ad10-ecf8-4fac-9850-133c74b03c0b" xlink:to="loc_pcrx_HongKongPharmaTainuoLtdMember_e1d80588-4a52-4e50-84e3-d34cff7ff89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_8fd49963-8d3d-41b7-8f06-6cd70cbb88c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_us-gaap_TransactionTypeAxis_8fd49963-8d3d-41b7-8f06-6cd70cbb88c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_59d01895-92c9-4fe2-9da6-c3e022117b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_8fd49963-8d3d-41b7-8f06-6cd70cbb88c2" xlink:to="loc_us-gaap_TransactionDomain_59d01895-92c9-4fe2-9da6-c3e022117b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CoPromotionAgreementMember_dcf4aeef-7c85-4d3a-98fb-5f0f41e0bba5" xlink:href="pcrx-20211231.xsd#pcrx_CoPromotionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_59d01895-92c9-4fe2-9da6-c3e022117b46" xlink:to="loc_pcrx_CoPromotionAgreementMember_dcf4aeef-7c85-4d3a-98fb-5f0f41e0bba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ac3b1d0c-8ee4-4860-aeae-3b84abbe598a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_PaymentOfEarlyTerminationFees_1b1bf91f-1312-4b68-a10c-7adfb6724148" xlink:href="pcrx-20211231.xsd#pcrx_PaymentOfEarlyTerminationFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_PaymentOfEarlyTerminationFees_1b1bf91f-1312-4b68-a10c-7adfb6724148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_6653c81c-2c0f-44ee-af29-a2f29d899af1" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_6653c81c-2c0f-44ee-af29-a2f29d899af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementOptionToExtendTerm_f961232b-b269-4c76-8841-000a94ec0d30" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementOptionToExtendTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementOptionToExtendTerm_f961232b-b269-4c76-8841-000a94ec0d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementUpfrontPayment_d7c5b7cf-caed-4ace-9317-85dcb5ee0a39" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementUpfrontPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementUpfrontPayment_d7c5b7cf-caed-4ace-9317-85dcb5ee0a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach_d16fe6ff-b342-419b-a6ec-fb063c3629ba" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach_d16fe6ff-b342-419b-a6ec-fb063c3629ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation_c0c8a12c-70a6-4fc8-a865-6ac1bfea99ae" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation_c0c8a12c-70a6-4fc8-a865-6ac1bfea99ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_606cfbdd-8f6c-4039-a00d-23999b255a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_92904394-b9d6-4a98-aaa5-54d0a344adaf" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_606cfbdd-8f6c-4039-a00d-23999b255a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_fe671e42-3fa8-45ce-933f-778f2cdd6aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a28533b1-3419-46f0-8dd5-5401d96a2145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_fe671e42-3fa8-45ce-933f-778f2cdd6aec" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a28533b1-3419-46f0-8dd5-5401d96a2145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_da793932-3076-4a42-a15a-3af21eb0c0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_da793932-3076-4a42-a15a-3af21eb0c0d5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6bc56adb-70c6-46a7-a51c-831f5f924b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6bc56adb-70c6-46a7-a51c-831f5f924b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_826fc324-51cc-452b-8b0e-011df2ea0cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6bc56adb-70c6-46a7-a51c-831f5f924b9a" xlink:to="loc_us-gaap_RelatedPartyDomain_826fc324-51cc-452b-8b0e-011df2ea0cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_eb53a898-82c3-4a6a-996b-aaa70c10d39a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_826fc324-51cc-452b-8b0e-011df2ea0cad" xlink:to="loc_srt_DirectorMember_eb53a898-82c3-4a6a-996b-aaa70c10d39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EnergyAxis_20c0c964-5a38-4015-8a25-40e6c01f4579" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EnergyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:to="loc_srt_EnergyAxis_20c0c964-5a38-4015-8a25-40e6c01f4579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EnergyDomain_9dfd86a4-a051-4fa1-8982-1bc1c59df318" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EnergyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EnergyAxis_20c0c964-5a38-4015-8a25-40e6c01f4579" xlink:to="loc_srt_EnergyDomain_9dfd86a4-a051-4fa1-8982-1bc1c59df318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConsultingAgreementMember_5dfc045b-213c-4744-a2e0-95376f545d40" xlink:href="pcrx-20211231.xsd#pcrx_ConsultingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EnergyDomain_9dfd86a4-a051-4fa1-8982-1bc1c59df318" xlink:to="loc_pcrx_ConsultingAgreementMember_5dfc045b-213c-4744-a2e0-95376f545d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eab3cd49-0a9c-4fa3-9fd2-f9853afc8df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eab3cd49-0a9c-4fa3-9fd2-f9853afc8df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_99c75859-3879-43f0-82e8-5f4a8734f00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eab3cd49-0a9c-4fa3-9fd2-f9853afc8df9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_99c75859-3879-43f0-82e8-5f4a8734f00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FirstPriceOptionMember_bcfd6eb0-c03e-45fb-90e6-add7011b2124" xlink:href="pcrx-20211231.xsd#pcrx_FirstPriceOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_99c75859-3879-43f0-82e8-5f4a8734f00a" xlink:to="loc_pcrx_FirstPriceOptionMember_bcfd6eb0-c03e-45fb-90e6-add7011b2124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_SecondPriceOptionMember_d839a6ca-c30d-4b3d-b8fe-9ea8b9ee852f" xlink:href="pcrx-20211231.xsd#pcrx_SecondPriceOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_99c75859-3879-43f0-82e8-5f4a8734f00a" xlink:to="loc_pcrx_SecondPriceOptionMember_d839a6ca-c30d-4b3d-b8fe-9ea8b9ee852f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_70f07ba6-6a63-42c7-8a19-a46f422f1341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_02c69312-baab-4dfb-b23f-30c6f8499708" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_70f07ba6-6a63-42c7-8a19-a46f422f1341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_c68902dd-3f00-4699-a689-8cca217ac821" xlink:href="pcrx-20211231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_70f07ba6-6a63-42c7-8a19-a46f422f1341" xlink:to="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares_c68902dd-3f00-4699-a689-8cca217ac821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_9b6ab030-8a8d-4dd4-ac75-2a5654615c0f" xlink:href="pcrx-20211231.xsd#pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_70f07ba6-6a63-42c7-8a19-a46f422f1341" xlink:to="loc_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice_9b6ab030-8a8d-4dd4-ac75-2a5654615c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="pcrx-20211231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8214dfbd-2b47-46e4-bf66-5f1d1ea2f0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3eb3d45d-e03a-4097-b131-7e78d0cbf89a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8214dfbd-2b47-46e4-bf66-5f1d1ea2f0ae" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3eb3d45d-e03a-4097-b131-7e78d0cbf89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_47e4374a-0dd5-40be-be8b-6b9f1b0dce01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_47e4374a-0dd5-40be-be8b-6b9f1b0dce01" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1f10c4d1-9156-48e2-8408-58ac1cbf524a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_srt_CounterpartyNameAxis_1f10c4d1-9156-48e2-8408-58ac1cbf524a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1f10c4d1-9156-48e2-8408-58ac1cbf524a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FortisMember_47d5ab3a-db0b-46e2-a15a-fbe4a262da11" xlink:href="pcrx-20211231.xsd#pcrx_FortisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:to="loc_pcrx_FortisMember_47d5ab3a-db0b-46e2-a15a-fbe4a262da11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_GeneQuineMember_ae7dfa82-0dc9-45ab-9fb3-255f105114d2" xlink:href="pcrx-20211231.xsd#pcrx_GeneQuineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:to="loc_pcrx_GeneQuineMember_ae7dfa82-0dc9-45ab-9fb3-255f105114d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_XenonPharmaceuticalsIncMember_ab7d4a49-8fb3-4d14-bdf5-6f991392a4ab" xlink:href="pcrx-20211231.xsd#pcrx_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0960a565-eedc-4946-abf1-a1b9fd9d8e1a" xlink:to="loc_pcrx_XenonPharmaceuticalsIncMember_ab7d4a49-8fb3-4d14-bdf5-6f991392a4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fb2340fe-38b3-4eb7-b8c4-b684ee62e53a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_srt_ProductOrServiceAxis_fb2340fe-38b3-4eb7-b8c4-b684ee62e53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_81e717a3-0786-4c4e-a3a1-ea322f00a009" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fb2340fe-38b3-4eb7-b8c4-b684ee62e53a" xlink:to="loc_srt_ProductsAndServicesDomain_81e717a3-0786-4c4e-a3a1-ea322f00a009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_4b4f8a74-d3ea-4211-b34d-33645b77fe86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81e717a3-0786-4c4e-a3a1-ea322f00a009" xlink:to="loc_us-gaap_ServiceMember_4b4f8a74-d3ea-4211-b34d-33645b77fe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_a3ff15cb-95cd-4518-b7c4-abe1a0eeafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_81e717a3-0786-4c4e-a3a1-ea322f00a009" xlink:to="loc_us-gaap_PublicUtilitiesInventoryRawMaterialsMember_a3ff15cb-95cd-4518-b7c4-abe1a0eeafa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_5d4ab352-5d2e-4600-a6d4-f77678c36e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_5d4ab352-5d2e-4600-a6d4-f77678c36e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e3b3c03c-2a80-4b54-8cc3-8edcccd8cca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_5d4ab352-5d2e-4600-a6d4-f77678c36e39" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e3b3c03c-2a80-4b54-8cc3-8edcccd8cca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_bac6c552-bf1a-430a-abcb-900ed013ad2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e3b3c03c-2a80-4b54-8cc3-8edcccd8cca8" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_bac6c552-bf1a-430a-abcb-900ed013ad2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_37885bfe-e4f8-40aa-8954-76f19aebb9e9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_dei_LegalEntityAxis_37885bfe-e4f8-40aa-8954-76f19aebb9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fa5bfcda-bccb-48f3-b35d-38cdc7c87b3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_37885bfe-e4f8-40aa-8954-76f19aebb9e9" xlink:to="loc_dei_EntityDomain_fa5bfcda-bccb-48f3-b35d-38cdc7c87b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_FlexionTherapeuticsIncMember_ad17b305-5bbd-4bd3-b880-f88f46478831" xlink:href="pcrx-20211231.xsd#pcrx_FlexionTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fa5bfcda-bccb-48f3-b35d-38cdc7c87b3d" xlink:to="loc_pcrx_FlexionTherapeuticsIncMember_ad17b305-5bbd-4bd3-b880-f88f46478831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneAxis_1ab9f891-421b-471b-a9bb-ce3b1efca1b9" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_pcrx_AchievementOfMilestoneAxis_1ab9f891-421b-471b-a9bb-ce3b1efca1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfMilestoneDomain_b26991b0-99f8-4926-9767-c89a53ea0da0" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneAxis_1ab9f891-421b-471b-a9bb-ce3b1efca1b9" xlink:to="loc_pcrx_AchievementOfMilestoneDomain_b26991b0-99f8-4926-9767-c89a53ea0da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_38b199f6-ea25-4b2a-8188-1e5074f8dbed" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_b26991b0-99f8-4926-9767-c89a53ea0da0" xlink:to="loc_pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember_38b199f6-ea25-4b2a-8188-1e5074f8dbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_AchievementOfSalesRelatedMilestonesMember_c4ba6623-8fd5-4ba4-b6a4-769d63f13cf3" xlink:href="pcrx-20211231.xsd#pcrx_AchievementOfSalesRelatedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pcrx_AchievementOfMilestoneDomain_b26991b0-99f8-4926-9767-c89a53ea0da0" xlink:to="loc_pcrx_AchievementOfSalesRelatedMilestonesMember_c4ba6623-8fd5-4ba4-b6a4-769d63f13cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_d7136c55-b96e-472a-9513-dea0b2e784c5" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_da49e077-0c13-4829-b31a-663f0725a508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_da49e077-0c13-4829-b31a-663f0725a508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_LitigationInvestigationTerm_36da6ac7-8301-406e-85ff-df06ae776628" xlink:href="pcrx-20211231.xsd#pcrx_LitigationInvestigationTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_pcrx_LitigationInvestigationTerm_36da6ac7-8301-406e-85ff-df06ae776628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_b906d770-42de-4b4b-be83-26f1ae9e5bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_b906d770-42de-4b4b-be83-26f1ae9e5bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_c1f15db9-10e5-47a6-98cf-0b5def9fc39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_PurchaseObligation_c1f15db9-10e5-47a6-98cf-0b5def9fc39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_0189944d-aac0-461a-982c-2546b3d662ad" xlink:href="pcrx-20211231.xsd#pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum_0189944d-aac0-461a-982c-2546b3d662ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f7ced73e-f08e-47b2-b1e1-0159e09437ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_f7ced73e-f08e-47b2-b1e1-0159e09437ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3352a335-854b-457b-9198-06f2d57bc9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_06bf9930-f38d-4180-95aa-1071f65bde62" xlink:to="loc_us-gaap_RestructuringCharges_3352a335-854b-457b-9198-06f2d57bc9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3db882f8-7355-4084-be80-fe7986cd7350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_41ded393-359b-46af-b249-b27ac6de0552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3db882f8-7355-4084-be80-fe7986cd7350" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_41ded393-359b-46af-b249-b27ac6de0552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacira.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="pcrx-20211231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.pacira.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3fe4ce7a-d30b-407d-9795-de6d7303f812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3fe4ce7a-d30b-407d-9795-de6d7303f812" xlink:to="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d3171b33-240f-4aac-b416-94ccf27c7274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d3171b33-240f-4aac-b416-94ccf27c7274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2aabac43-87e3-4291-ad2b-481d9dd96293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d3171b33-240f-4aac-b416-94ccf27c7274" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2aabac43-87e3-4291-ad2b-481d9dd96293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c2780ef2-2b00-4ba9-8451-ed29413d72e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2aabac43-87e3-4291-ad2b-481d9dd96293" xlink:to="loc_us-gaap_SubsequentEventMember_c2780ef2-2b00-4ba9-8451-ed29413d72e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_98c248a8-04e0-43d8-a446-e2d778f14fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_98c248a8-04e0-43d8-a446-e2d778f14fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2991c461-9fac-42ca-b9db-ae126092bd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_98c248a8-04e0-43d8-a446-e2d778f14fad" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2991c461-9fac-42ca-b9db-ae126092bd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member_e23947be-72b1-47dc-8f7d-0ae0a100ddac" xlink:href="pcrx-20211231.xsd#pcrx_ConvertibleSeniorNotesDueMay2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2991c461-9fac-42ca-b9db-ae126092bd63" xlink:to="loc_pcrx_ConvertibleSeniorNotesDueMay2024Member_e23947be-72b1-47dc-8f7d-0ae0a100ddac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6f733ddb-d63e-4fd7-a0a7-107c32531481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6f733ddb-d63e-4fd7-a0a7-107c32531481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dbd6d5fe-23c1-4366-b7d2-c32767fe5b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6f733ddb-d63e-4fd7-a0a7-107c32531481" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dbd6d5fe-23c1-4366-b7d2-c32767fe5b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_82ed85b1-2e72-43e6-aafd-39fc325b7518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dbd6d5fe-23c1-4366-b7d2-c32767fe5b2f" xlink:to="loc_us-gaap_UnsecuredDebtMember_82ed85b1-2e72-43e6-aafd-39fc325b7518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_11c33e64-9d18-4829-8a07-9f1dab9b83eb" xlink:to="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_9b2737da-b551-49d0-9b9b-7c27a5074bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_9b2737da-b551-49d0-9b9b-7c27a5074bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f73f6cc-a8be-4ed9-8b9f-21eb70880205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f73f6cc-a8be-4ed9-8b9f-21eb70880205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_558386df-86a7-46d4-9959-bc7fba8e1263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_87de791a-ca6a-4c23-ab38-9ac866593de4" xlink:to="loc_us-gaap_LongTermDebt_558386df-86a7-46d4-9959-bc7fba8e1263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pcrx-20211231_g1.jpg
<DESCRIPTION>PACIRA BIOSCIENCES LOGO
<TEXT>
begin 644 pcrx-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #% ?0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ^P^&.GV8_>-/.?]IMH_2M6U\-V-G_J[6'\5W?SHYBCD;,9-:UG;R''[M_\
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MN7^1\RLXHK;#P^[_ (!_,GXJ_P""DW[<_@<-<ZWXR^+NCHO+->Z,UO&OUWP
M55\$_P#!?[]K+P3>+(/BI-JT0ZP:EH]A<(_U)A#C\&%?T[$9%> _M7?\$O\
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MMX=OI'@666TEMI(Y4P)(V210=RDX)&5ST)KT:O&O^">/P.A_9N_8;^%?@N*
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MH'_]EK^6FOZL/^"P%I]M_P""8?QO3^[X5NI/^^0&_I7\I]?LGAO+_8:J_O\
MZ(^VX7?^SS7G^B/V\_X-'-/\OX;_ !NNL?Z[4M)BS_N171_]GK]A*_)3_@TJ
MM-G[.OQ;N/\ GIXCM(\_[MMG_P!FK]:Z^!XQE?.*[\U_Z2CY[.W?&U/E^2"O
MB/\ X.)=*;4_^"2/Q*91DVEQI,_T U.U!_\ 0J^W*^0_^"\MI]M_X)*_&-/[
MMC8R?]\ZC:-_2O.R.5LRP[_OP_\ 2D<V7NV*IO\ O+\S^7NOWB_X-,=/\O\
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M,-T/<H>#['FG:^Q.VY]]33);0M)(RQQQ@LS,<*H'4DU_+G^W[\==8_X*M?\
M!4/4)/#<C7EOXFURV\)>$8VSY:6:RB"W?&,JLC,\[#^$S/V%?LY_P7?_ &^M
M-_9\_P"";VI-X9U>";7/BVC>'M%EMY/F%O(I^V3@<,-D.Z/(PR231YP1BOS]
M_P"#7#]C0_%7]I_7OB_JUKOT;X;6IL]+9U^675+I&7<.Q\JW\PD=0T\3#I7Z
M)PE3CE^ KYU56J7+'^O-V7R9]1D\5A\/4QT_1?UZV7WGYR?M"?!#6OV:_CCX
ML\ ^(D1=:\(ZI/I=TT8;RYFB<J)4W $QNH#J2!E64]Z^P_\ @W7_ &Q?^&7O
M^"@NDZ!J5UY'AGXJ1#PW=JS8C2\9MUE+CNWG?N03T%RYKWS_ (.I?V+_ /A#
M?BYX4^..D6FVP\81KH&ONB_*M_!&3;2L>[2VZLGH!:#UK\EM+U2XT34[>\LY
MY;6\LY5G@FB8K)$ZD,K*1R"" 01W%?H&%JT\ZRCWO^7D;/REL_N>J^1])1E'
M'X+7[2L_)_\ #G]G-%>)?\$Y_P!K.W_;=_8Q\!_$:-X?[0UG3UBU>*,!1;ZA
M"3%<KM_A7S49E!ZHR'H17MM?S_B*,Z-65&HK2BVGZK0_.*E.4)N$MUH%%%%8
MD!1110!^"/\ P=CQX_;-^'#_ -[P6!^5]=?XU^8WPZ_Y*#H/_81M_P#T8M?I
MW_P=D?\ )XOPV_[$W_V^N*_,3X=?\E!T'_L(V_\ Z,6OZ$X6_P"1-1_PO\V?
MI&4_[C#T_P S^R>BBBOY[/S<***KZMJUKH.EW-]?7-O9V-G$T]Q<3R".*"-0
M69W9L!5 !)). !F@#Y/_ ."Z'QRM/@5_P2\^*5Q/,L=WXFL!X:L8R<-<2WC"
M)U7W$)F<^T9K^7>OT _X+X?\%4[7]OOXWV/A/P3>23?"_P  RR"SG&577;YO
MEDO,?\\U7]W%D9VF1N/-VK\9?L^?L_\ BS]J/XQ:%X#\$Z5-K'B3Q#<"WM8$
M'RH.KR2-T2-%!=W/"JI)Z5^\<'Y9++LMY\3[KDW)WTLK:7[:*[[7/T+)<*\+
MA;U=&]7Y(_5W_@TL^!5U+XK^+/Q,FA9+&WM+;PQ9RD<32._VFX4'_8$=L3_U
MT%?MA7B__!/[]C+1/V!_V5/#'PVT61;R32XC/JFH"/8VJ7\GS3SD=0"WRJ"2
M5C1%R=N:]HK\BXBS)8_,*F)A\+=EZ)67W[_,^,S/%+$8F56.W3T6@445YO\
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M%OO^44_QH_[ T?\ Z505YV3_ ._T/\<?_2D<N!_WBG_B7YG\M5?T*?\ !JW
M(_\ @G+XB?O)X\OB?PLK 5_/77]#'_!K!_RC=US_ +'J_P#_ $DL:_8./_\
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M@XK[4_X+^_\ !$B$V.L?'CX/:*L+P*UYXQ\/6,.U'4<OJ-O&HX(&3,BC!&9
M 1(6_%JN3(\/DN/H+$X:A"_5.*;3[?Y/J8Y?3P.(IJK2IQ\U9:,^VO!/_!)[
M]L3_ (*":Q8^*M:T/Q+JT&L0)=P>(O&&N!8Y()0'1T,TC2M&RL&'EHPQTK[L
M_9 _X-3_  SX5O;35OC7XVF\4RQ,'?0?#P>TL7_V9+IL3.I_V%B/ ^:O+?\
M@W,_X*Y_\*U\06/[/WQ'U3'A[6)]G@W4KF3C3;N1N;!V/_+*9CF/^[(2O(D&
MS]S*^.XHX@S?!UW@U:G#[+BK7CZN]O.UK,\/-LRQM"HZ"M%=&ENOZ['-_"3X
M.^%?@-X#L?"_@OP_I/AGP_IJ[;>PTZW6"%/5B!]YCU+'+,>22>:Z2BBOS>4I
M2DY2=VSYB4FW=A1114B"BBB@ K\#?^#H[]M+_A:O[2V@_!W1[OS-%^&\ O=6
M5&^2;5+E P4]CY-N4 /4-<2J>E?MA^UA^T5H_P"R5^S=XS^)&N[6T[PCI<M\
M8B^PW<H&V&!3V:65HXUS_$XK^83]DKX.>(O^"GG_  40T/1-8N+B\U+XB>(I
M=5\1WJ#:T=N7:YO91V4B,2; >-Q1>XK] X#P$/:U,SK_  4D]?.VK^2_-'T?
M#^'7/+%U/A@OQ_X"_,_;7_@V\_8T_P"&:OV#;?QAJ5KY/B;XN3)KDQ9<21Z>
M@9;&,^JE&DG!]+K':ON7XJ?"G0_C/X,NM!\06:WEC<C(/22!^TD;?PN,\'Z@
MY!(.SH>B6?AG1+/3=/MH;/3]/@2VMK>)=L<$2*%1%'90H  ]!5JOC<RQT\9B
MIXJ>\G?T71?):'B8K$2KU959=6?#/A77?%7_  35^+/]DZV;C6?AOKTY:.YC
M0E4/3S5'\$RC&].C@<9PI%S_ (+B?LGV/[>'_!-[6M1\.B'5=<\'1#Q=X?GM
M_G-TL4;&>)2.6\RW,F$'61(NXKZ^^)'PWT;XL^#KS0=>LH[[3;U=KHWWD/9U
M/56!Y!'(KY7^'>OZY_P3T^)J^$_%,\VI?"_Q#.W]F:HPRNG2,>=W9?\ ;3H?
MOK_$I6!QD\-B(8FG\46GZV_SV,\/6E1JQJQZ.Y_,'7] /_!KU^V1_P +@_9+
MUCX4ZI=>9K?PON_,L [?-+I=TS.@&>6\N?SE/95>$>E?D-_P59_9?M_V0?V^
M?B)X-TVW6W\/B_\ [4T,1_ZK[!=J+B%8S_$L8D\K/K$:V?\ @CK^V5_PP_\
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M?$\:Y7]3S*4XKW:GO+U>Z^_7T:/"SW">PQ3:VEJOU_$*_EY_X+L?!Z;X,_\
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MJRODW_@NA<?9O^"3_P 9F]=+MD_[ZOK8?UKS<G_Y&%#_ !Q_]*1RX'_>*?\
MB7YG\N-?T,?\&L!S_P $WM<_['N__P#2.QK^>>OZ#O\ @U4O/._X)W>*(O\
MGCX\O0?QL; U^P<?_P#(I?\ BC^I]IQ%_N?S1^F3#<,'D'@@]Z_GQ_X. /\
M@C\/V0?'$WQ<^'6F;/ACXHO,:E86T?[OPO?2'A0H^[:RL3L_AC<^7\H,0/\
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M30+ZS6\\.^'[C_A)=;1TW1FULV60(X[K).8(C[2U_4J!@5^3_P#P:I?LJ_\
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MV2_C?X@^'_C73SI_B'PY<F"=02T4ZD;HYHF(&Z*1"KJV!E6' .0/[!J^!/\
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M_/!I5NX;![CSIPB@]"L$RGK7ZB7]_!I5C-=74T5O;6T;2S2RN$2)%&69B>
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M^33?Z?J?KYKG[;_P7\,V+7.H?%SX96=N@R7F\3V2#]9*^;_VA_\ @X:_9C^
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MJ\%\UOZ;UC8E<^X&:[JG4ISA+EFFGV>A4HN+M)6"BBFRRK#&SNRJB@LS,<
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M[V>[  &Z::5&DE<X&7=BWO7MFG:?;Z1I\%I:PQ6]K:QK##%$H5(D4855 X
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pcrx-20211231_g2.jpg
<DESCRIPTION>PRODUCT PIPELINE
<TEXT>
begin 644 pcrx-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" -J X<# 2(  A$! Q$!_\0
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M4U%K3:_GK;[[?BBHXB\DK?U_7YH^C*7XW_\ *.']H+_KPT;_ -.D-)2_&_\
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MT:5OQ/9PV33K.*4E[T>;\;'[DT5_,_\ \/#_ (\_]%E^)O\ X4EW_P#'*/\
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MN5?YT?T245_/1!^W=\:S_P U9^(G7_H8+K_XNK4'[=?QI8_\E7^(?_@_NO\
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MGQQXK_\ !I-_\55J+]I?XA@'_BM_%//KJ<Q_]FJ99-5_F1/U"?='Z5?99/\
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M^&C^V[S_ )^KC_OX: &?V9<_\^\__?LT4_\ MN\_Y^KC_OX:* /S;_X*M_\
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M*\%K#"]IX7\#/J_AS0[)XO+\F.WTR^620IG 9Y0Q' (01@C*UP4__!33P?\
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MN?\ OZW^-/\ UAS9_P#+[\(_Y#_M;'?\_/P7^1\ Q_\ !M/HD>/^+MZKQ_U
M(_\ X_4T?_!MCHB8_P"+LZK_ .""/_X_7W@VN7O'^F77_?UO\:C.O7V/^/R[
M_P"_S?XTO[>S7_G]^$?\@_M3'/\ Y>?@O\CX93_@V]T1!_R5?5/_  0Q_P#Q
M^I4_X-RM%A_YJKJAYS_R 8__ (_7VU)XAOPO_'[>?]_F_P :JW'B340X_P!/
MO?\ O^W^-/\ MK-'_P OOP7^0?VCC?\ GY^"_P CXV3_ (-V-%C'_)5-4_\
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M"'&E+_S474/_  3I_P#':]1D\?ZZ,_\ $ZU;_P #)/\ &H'^(6OC/_$[U?\
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M ,<K@I?C#XM _P"1I\1]/^@E-_\ %53G^,OB\'_D:_$G_@SF_P#BJ/88]_\
M+W\%_D')B?Y_P/34_P""4^FH<_\ ";7O_@L7_P".5*O_  2QTT?\SI>?^"Q?
M_CE>27'QI\8K_P S9XF_\&D__P 55*?XW>- /^1N\3_^#6?_ .*JOJN._P"?
MJ^[_ ( _98G^?\#VQ/\ @ESIL9_Y'*]_\%J__'*D'_!,735_YG*\_P#!:O\
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MO5]Q7]GXC^?\#]#X_P!A73XS_P C-=?^ (_^+IX_8@T]>/\ A);K_P  1_\
M%U^<#_M/?$H9_P"+A^.?_!]=?_%U1N_VH_B8O3XB^.O_  ?W7_QRG_8.,?\
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MG@_X;B^-7_18/BC_ .%7?_\ QVC_ (;B^-7_ $5_XH_^%7?_ /QVE_J)BO\
MG\ON8O\ 5JM_S\7W']$*_#73E_YB=Q_X#_\ UZ4?#O35/_(3N/\ P'_^O7XN
M_P#!/S_@L'XU_9\^)?V7XC^(/$?C?P5K,BI>/J5[+?WNE-T$\+R,S%1_%'G!
M'(PW7]G_  =XSTKXB>%;#7-#U"UU72-5A6YM+NV</%/&PR&4C_(KYG.<GQ67
M5%&KK%[-;/\ X)X^88"MA)6GJGLR4> M-7_F)7'_ (#_ /UZ>/!>FK_S$;C_
M ,!__KU:?[M,KQ>9GG<S(U\'Z:#_ ,A"XY./]1_]>IKSP=I]C<O"]_.&0X/[
MG/\ 6FK_ *Q?]X5:\3?\AVY_WOZ"E=A=E0>'=-'_ "_W'_?C_P"O4BZ'IR_\
MOT__ 'X_^O7*_%'XL>'_ (,>%?[9\2:@+"R,\5I"%ADN)[NXE8)%!!#$K2SS
M.Q"I%&K.Q. IJO\ "GXU>'_C18WTVAR:JCZ9.+>[M-4T>\TB]MG*!UWVUW%%
M,JLK JQ3:W."<'!=BN=H-(TX?\OL_P#WX_\ KTX:9IP/_'[/_P!^/_KU4HI7
M NBPTX#_ (_)_P#OS_\ 7IPL]/ _X_)O^_/_ ->J%% %_P"R:?\ \_DW_?G_
M .O1]DT__G\F_P"_/_UZXOPQ\4M/\6?$3Q1X9MX;Q+_PG]D^V22(HAD^TQ&1
M/+(8DX YR!STS6MX?\26_B6&Y>WCOXQ:74MFXN[&>T+/&Q5B@E12\9(^61<H
MXY5F!S0!O?9-/_Y_)O\ OS_]>C[)I_\ S^3?]^?_ *]4** +_P!DT_\ Y_)O
M^_/_ ->C[)I__/Y-_P!^?_KU0HH O_9-/_Y_)O\ OS_]>C[)I_\ S^3?]^?_
M *]4*H:+XDM]?N=1B@COT;2[HV<QN;&>V5W"))F)I$431XD4>9&63<&7=N1@
M #>^R:?_ ,_DW_?G_P"O1]DT_P#Y_)O^_/\ ]>J%% %_[)I__/Y-_P!^?_KT
M?9-/_P"?R;_OS_\ 7JA10!?^R:?_ ,_DW_?G_P"O1]DT_P#Y_)O^_/\ ]>J%
M% %_[)I__/Y-_P!^?_KT?9-/_P"?R;_OS_\ 7JA10!?^R:?_ ,_DW_?G_P"O
M1]DT_P#Y_)O^_/\ ]>J%% %_[)I__/Y-_P!^?_KT?9-/_P"?R;_OS_\ 7JA1
M0!?^R:?_ ,_DW_?G_P"O1]DT_P#Y_)O^_/\ ]>J%% %_[)I__/Y-_P!^?_KT
M?9-/_P"?R;_OS_\ 7JA10!?^R:?_ ,_DW_?G_P"O15"B@#TBBBB@#YD_X*N?
M##P=\6?V=-$T[QA\28_A+]D\56&I:)XHN[1+G3M.U.W$LL/VQ)<0>0RK(/W[
MQQF0Q+N+,B/\?_#_ /;M\;7_ ,2?@5XU\<ZKX?\ !?P_B^)_B;PYK_C+P_/-
MHWA+Q^L>F*EIJ,_F,(Y%DEAD57D9D+6SE" A"_JW10!^/7P4^-_CKX[>(OV>
MM&O_ (D?%&WTCQM\7/&VFZKY/B'4-.O;W3[<1R06DC;UGB1 "@7Y'B#ML,;<
MCK+OXD:]\7_V^]4\ 7'Q*\5^'-1T'XQ6FGQ&X^*[:%:S^%[:P3.F)I0OX[VZ
MN;B8IMN5MG\YI-QN-JN&_5FOE_7?^"4?@7Q)XGUB2[\4>/I?">O^.#\1-0\(
MFZLO[)N=9)5FF,OV7[<$+HK^4+H(",!0ORT ?%'P-_:4\7:]X1^$,?Q)^)?C
M+1_A-K/Q0\:Z?XO\2S^*+O3&@:VC#:192ZHLJ36T#2>< BRHK>6!G Q3O^"D
M'[:4G@;PIXQTOP)X\\<0:W\/O"WAO4/#VN:[\1+W0[_6%N92YFT_2(+54UM?
M)B!N9[UCM#N0 JDM^N;C-1[3Z&@#XK_8.U!]5_X*G_MDW4@427,'@*5@HX!;
M1)2<>W-?,W_"\?'_ (I\='19?B'X]MK/5/VNM=\&S&VU^YBE31C!&HL(W#YC
M@4.VQ4QY;'<FQP&'ZUE#GH?RJ)HF_NM^564C\<_B?->?%&/P[X=\0^(/&VKV
MO@;]L2#P9I$]UXJU*2YMM)D+NL/G>=YK31$$17+.;B)6(2106SI^/?&NN>)?
MB-9Z;JVO:]K=GX9_;)T+2M)35-3GOCI]K'%-LAC:9V94'7&>I)ZDU^NCP.?X
M&_*HFMI/^>;_ /?-:7*/QV\6^(U_9B_9J_:S3PKXV\4^&?B7HGQ>=[2U'BZ^
M>_329;[2Q%>-;RSMYOF[BK74B,\JML>1E.VO6O\ @I/\5D_9UT_5?AOH?B;Q
M]8ZIX=\ S:SI6KZY\5-3TF:[NWGD7=:F-))]6O"P!,$\P@C5%$:Q N:_2QK6
M7'^K?_ODU$]G,?\ EE)_WR:I- ?FIHU]877_  4!\&^-?%GB+5M*UCQM\ ;+
M5;&[D\27>GQ:IK?VE6>V@19DC8;663[$@\HL3)Y6XEJY;]G/]H35O%'P_P#V
M?8_C!\2O%GAWX;:OX*UC4KKQ!+XIN])EUC6X]0FC2&XU&.5)G*6WS)"9 &('
M#X"C]3S8S_\ /&7I_<-1RZ?.0?W$O_?!K1-%+8_+/X(?$+XH?%;QS\*?#_CS
MQ;\0M/AU/X7:UJ$T4&LW>E7.II;WLO\ 9]Y,8723SC"D#&3Y7D'#EED=7^P/
M^"9GQ/UOXR?L&_#/Q%XBO[C5-9O=+:*YO+A]\UR89I(0[MU9RL:DL>2<DDDD
MU]#2:;<'/[B;_O@U!)I5T<?Z-/T_YYFK35RD]2BW6HI.IJZVD7>?^/6X_P"_
M9_PJ-]&O#G_1;G_OTW^%6I(JYFOT%1-TJ^VAWO'^AW7_ 'Z;_"HSH-]C_CSN
M_P#ORW^%7S(=T9DOW*J7/WQ6O)X?ORO_ !XWG_?EO\*JW'AS42X_T"]_[\-_
MA6G,NYI=&1)_6H9_NUJ2>&=2/_,/ONO_ #P;_"H9O"^IE?\ D'7W_@._^%7S
MQ[A=&/+T%5Y/NFMB3PGJA_YANH?^ [_X5 _A'5BI_P")7J/_ (#/_A6D9Q[E
M\R,:?[_XU5EZUN3>#M7+?\@K4NO_ #[/_A5:7P5K)/\ R"=3_P# 5_\ "K4X
M]RN9&)<=*K3]:W9_!&M$?\@C5/\ P$D_PJO-X$UPG_D#:K_X"2?X5HIQ[E*2
M,"7O5:3H:WY/ .NG/_$EU;_P#D_PJ!_A]KYS_P 2/5__  #D_P *M5(]RU)=
MSG)>E5KCI712_#KQ!C_D!:S_ . 4G_Q-5Y_AQXA(_P"0#K/_ (!2_P#Q-:JI
M#N/FCW.:E[U5FZ?A72R?#3Q&<_\ %/ZW_P" ,O\ \35:7X8^)2/^1>USI_SX
M2_\ Q-4JL.Z-.>/<YB7[IJK+TKIY?A;XG*G_ (IS7?\ P7R__$U7D^%7B@C_
M )%O7_\ P7R__$UJJL.Z&IQ[G)7'2JMQTKJY_A+XJ(_Y%GQ!_P""Z;_XFJT_
MPB\6'_F6/$/_ (+9O_B:T]K#NB^>/<Y*;I^%4;CK78R_!_Q:1_R*WB/I_P!
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M>/O_  GKO_XW6GUFC_,OO1I[:G_,OO/,[CI5"?J:].G_ &3_ (ID?\DT\?\
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M_P Z^]&GUBE_,OO/+**]3_X8:^-G_1'OBE_X2E__ /&J/^&&OC9_T1[XI?\
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MI/APO7Q[X#'_ '&[7_XNOR'N:S[OHU4N%J3^VRO[%A_,S]AO^&J?AJ/^9_\
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M12X?IO[;/WL/[;/PA7K\3_A>/KXBLO\ X[4<G[</P>7K\4?A9^/B2Q_^.U^
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M_IQ^''Q_\(_&*SN;CPCX@\'>*8+)Q'<2Z/>P7R0,1D*YB9@I(Y -="=<.?\
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M\,_ FN6%A<:YJ&I2:E'8203Z)H.H:U9D7[[+(-<6<$L*-.<>6KN"X92 0P)
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MG_\ ?@5GT4 :'_"0'_GST_\ [\"C_A(#_P ^>G_]^!6?10!H?\) ?^?/3_\
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MX8DDT^)[26)K?5(E<E;M0C$J9-Q9@^&+[F(&[%?43_LS:\W_ "]:3_W]D_\
MB*B;]E[7V_Y>](_[^R?_ !%6L71_F*5:'<\LEZ56N.E>JR?LK^(6'_'WH_\
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MQDY_Y"'AO_P(F_\ C56LPPW\Z*^M4OYCP6YJA<=*^@YO^"??C1_^8CX:_P#
MF;_XU567_@GAXV<?\A'PQ_X$S_\ QFM/[2PW\Z+^M4?YCY[N/N5FW'6OI"7_
M ()S^.'7_D)>%_\ P)G_ /C-4Y?^";'CM_\ F)^%?_ J?_XS6JS/"_SHOZW1
M_F/G";I5*YKZ5?\ X)G^/6_YB?A3_P "KC_XS5>7_@F'X_D_YBGA+_P*N/\
MXQ5K-,)?XT4L91_F/F>7[C5G7/4_6OJ*3_@EW\064_\ $U\(\_\ 3W<?_&*J
M3?\ !*WXB2?\Q7P?_P"!=Q_\8JUFN$_Y^(KZ[0_F/EV?H:H7'6OJJ7_@E)\1
M7'_(6\'?^!=S_P#&*JR_\$F/B1(>-7\&?^!ES_\ (]:+-L'_ ,_$:?7J'\R/
ME&YK/N^C5]:R_P#!(SXER=-7\%_^!ES_ /(]59_^"0'Q-D!QK'@GG_I\N?\
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ML?\ !/\ N-9U[P!K47B'PQX=U3X5(C^$[7PYX3&FZ-IMQ+,6U%FL_M+EX[J
M)"(Q*OE?O'#,[@K]2?\ "+7_ /S[M_WT/\:/^$6O_P#GW;_OH?XT ?(/@O\
M8D\<^,K"YMO%7C,Z#H%AXT\7>)-$TW3-.6+5+&?4+W5DM+K^T$N&!18+\W*1
MB%)%DD4.^$,='P3_ ."9*_"/1-9M5UWPA:?VOJ'A&],7AOP:NB6B_P!@ZF+[
M+Q"ZE,DUR%"/*SY4_-A@ @^OO^$6O_\ GW;_ +Z'^-'_  BU_P#\^[?]]#_&
M@#YC^,/[#&J?$.#Q8NE>*/#NE7/BGQ)+XBCU*[\.W%QJGAZ1]/LK)6TZZ@OK
M=[:=1:LWG#.X2["A56WW[_\ 8SUC2/&=SXI\->-K>Q\3CQ/-X@M)]6T0ZC:>
M5/I-KILUM<1)<0O*2+59A(DL1#X!5E#!_HW_ (1:_P#^?=O^^A_C1_PBU_\
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MQ7X1\<:%9ZS)<V4USIMHC,K/&L8NH@&21=\0P6.%XR7R(?*C]&O^$EY_U/\
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MKQVA_P"6DW_?(H J4C_=JWY5G_SUF_[Y%(8K/'^MF_[X% %*BK?E67_/6?\
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M_P!LZ3!?_8W;;N:+S4;83M7)7&=H]*[K[/IG_/Q=?]^Q1]GTS_GXNO\ OV*
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M$PU+1I+759_#]QJVN?;%260B$@WNH) ;4BRD60$S'-LQ<Y\]^$?Q-UCX?_\
M!1GQ?!X@UG7_  U\(M5^-NK6UW?Z+J,MB+G7##']AM=0D1E/V-QOP@.UW!\P
M;%J^5=A-:GZYOKUV,_O?_'1_A2-X@NP1^]_\=7_"JDG4TUNHI\J[%61:?Q%>
M _Z[O_<7_"HY_$=Z/^6W_CB_X56?K^-17'6JY8]AV1._BB^!_P!?_P".+_A3
M#XJOPO\ K_\ QQ?\*I/UIC?<%/ECV"R+;^+M0&?](_\ (:_X4T^,-1_Y^/\
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M&>M-DIQZTV2@!M(>E+2'I0 RHSUJ2HSUH 1_NTRGO]VF4 "_ZQ?]X5:\3?\
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M]W;Z[8S>*+#03XB\07XU)[F:$7EM<R)/ (O,6)KT13+]H"M)(I8H ?>=<O\
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M^?>S_P"_(H SZ*T/^$DD_P"?>S_[\BC_ (223_GWL_\ OR* ,^BM#_A))/\
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M  [U1/$OAW5K#PSX!UW0-5=FFAFEU34[R:[8P1^6P^S(TQ4,[[\*#MYP,?\
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MXXLIM+^*SWJ>%[@V=RBZC]C#F[9@T8,"PB-][3!%7;R:\N_9E_X)Y:A^S_\
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M-(#G=]7_ /!.+X6ZC\%?V#/A'X8U>-H-5TKPM8I>0M]Z"9HE=XS[JS%3_NT
M>TO]VF4]_NTR@ HHHH **** "FR4ZFR4 -HHHH **** $/2F4\]*90 4444
M(_W:93W^[3* "BBB@".BBB@ IC_>I],?[U "4444 ,?[U)2O]ZDH *CJ2HZ
M"F/UI],?K0 E-DIU-DH ;2/]VEI'^[0 RBBB@",]:;)3CUILE #:0]*6D/2@
M!E1GK4E1GK0 C_=IE/?[M,H %_UB_P"\*M>)O^0[<_[W]!55?]8O^\*M>)O^
M0[<_[W]!0!1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ](HHHH **** "BBB@ HHHH *
M*** "BBB@ HHI"<4 +149E(IK3D>E.P$U%5FO&'85&VHN.R_E3Y6.Q=HK/\
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M\*?^ UQ_\>I_V%BNR^\?]G5C[=^QR>GZBC[')Z?J*^&)O^"F'CN,\:3X2_\
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M ),H_P"(BGXV?]"O\+?_  6W_P#\F57^I69]E]X_]7<9V7WG[3'0+O/^J_\
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MW\7_ !K.HH T?^$4O_\ G@/^_B_XT?\ "*7_ /SP'_?Q?\:SJ* -'_A%+_\
MYX#_ +^+_C1_PBE__P \!_W\7_&LZB@#1_X12_\ ^> _[^+_ (T?\(I?_P#/
M ?\ ?Q?\:SJ* -'_ (12_P#^> _[^+_C1_PBE_\ \\!_W\7_ !K.HH T?^$4
MO_\ G@/^_B_XT?\ "*7_ /SP'_?Q?\:SJ* -'_A%+_\ YX#_ +^+_C1_PBE_
M_P \!_W\7_&LZB@#1_X12_\ ^> _[^+_ (T?\(I?_P#/ ?\ ?Q?\:SJ* -'_
M (12_P#^> _[^+_C1_PBE_\ \\!_W\7_ !K.HH T?^$4O_\ G@/^_B_XT?\
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M^-,E\-63=8?_ !]O\:T*;)3YY=PNS-/A73V_Y8'_ +[;_&D;PCII_P"7<_\
M?;?XUHT4<\NX<S,L^#-,/_+O_P"1&_QI#X'TH_\ +L?^_C_XUJT4_:3[AS/N
M9#> M(;_ )=3_P!_7_QIG_"N]&/_ "Z'_OZ__P 56U11[6?=CYY=S$/PVT0_
M\N?_ )&D_P#BJ8WPPT)O^7(_]_I/_BJWJ*?M:G=ASR[G/'X5>'S_ ,N!_P"_
M\G_Q5-;X2>'7ZZ>?^_\ )_\ %5T=%'MJG\S^\.>7<YE_@]X;;KIY_P"_\O\
M\53#\&O##==./_@1+_\ %5U#_=IE/V]3^9_>/VDNYR[?!+PJW_,-/_@1+_\
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MW$_\_)?>Q_6*O\S^\\I?]A7X2OU\,2?^#*[_ /CM1G]@WX1-U\+2?^#*[_\
MCM>M44?7L3_S\E][#ZS6_F?WL\?;]@3X/-U\*R_^#.\_^/5')_P3\^#;]?"<
MO_@TO/\ X]7L%%/Z_BO^?DOO8_K-;^=_>SQMO^">7P8?KX1E_P#!I>?_ !ZH
MI/\ @G3\$V//A"7_ ,&M[_\ 'J]IIC_>I_VABO\ GY+[V'UJO_._O9XHW_!-
MWX'M_P R=+_X-KW_ ./U&_\ P33^!<G7P9*?^XM??_'Z]NHH_M'%_P#/V7_@
M3_S'];K_ ,[^]GA<G_!,KX#MP?!<W_@WOO\ X_43?\$P/@&_7P3-_P"#B_\
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M .TU\_3]:K2]!6BRO"_R_B_\RU@Z/;\SZ$E_X*#&,?\ (HJ?^XG_ /::K/\
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M\,^FZW9WGPXTN35]4M8+[2-6F>&.8PR*HT^]N0DJ. #%,8Y#N&%.#@ ^H?\
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MU806&H:FN&Q+'!+#<QP.I&]I[ILXV&HOAS_P38\0V/[+FN^ ]3T?P[H?B$>
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MG_EA_P"1&_QI#X0L&_Y=_P#R(W^-4L1$KVB. DJ!_NFO1#X)TT_\NW_D1O\
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MHP_Y%D?^#*Z_^.U$?V%?ADW_ #+ _P#!G=?_ !VK7$.'_EE]R_S*_M2EV?\
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MX0E?_!U??_'ZB;_@E?\ !)^O@=?_  =W_P#\?J_];,)_++[E_F7_ &Y0[/\
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M "BBB@ HHHH **** "BBB@!'^[3*>_W:90 4444 %%%% !39*=39* &T444
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MJ=QI'VG1PNH00ZGK&VUL_M$-E91S2(CW,=P#]FDE=94,?F>S_LA?%;QEXM^
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M/]FG]HL>,?B/XLT?5-,\SQ_I^L>)[W4K?5KG5=)$]O-]GDD,4217*!46%45
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M*+<L[WMN(?WT<4AV1LTGL_[(7[/=U\)_@)XQT;1K+QSX+O-;N;A[*U\21Z!
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MX6K<:N^M": WRZ!+;2Q-&)=^\6[%\FV!QO=G,>XEJ /J^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#TBBOD;]K7]I[QS\,OV\?AGX,T/6_L7AKQ!_97]
MH6?V.WD^T>=J,L,OSNA=<QJH^5AC&1@\UY3^W1^WK\4O@M^U/XH\,^'/$,5C
MHVF_9/L\#:=;2E/,M()&^9XRQR[L>3WKV<-D>(KN*@U[T>;KM>W;?4_-<[\5
M,IRNG7J8FG4:HU51E91=Y.+FFKS7NVB]79WZ'Z'T5^2O_#T?XV_]#;!_X*+/
M_P"-4?\ #T?XV_\ 0VP?^"BS_P#C5=_^J>,_FC][_P CY/\ XF%X;_Y]5O\
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MH@_\%5I_\;J4?\%)/C%G_D:(?_!5:?\ QNE_JQB^\?O?^1JO'3('_P NJO\
MX##_ .3/U#ILE?F(O_!1[XP'_F9X?_!7:?\ QNIE_P""C'Q>8_\ (S0_^"NT
M_P#C=3_JUBN\?O?^1HO&_(7_ ,NZO_@,/_DS],Z*_-)/^"BGQ<(_Y&6'I_T"
M[7_XW4J?\%$?BVW_ #,L/_@LM?\ XW2_U;Q7>/WO_(U7C5D3_P"7=7_P&/\
M\F?I117YMI_P4*^+)_YF2'_P66O_ ,;J9/\ @H-\5S_S,D/_ (++7_XW4_ZN
MXGO'[W_D:+QER1_\NZO_ (#'_P"3/T>HK\YT_P""@/Q6;_F8X?\ P6VO_P ;
MJ5/V_/BH?^9BA_\ !;;?_&Z7^K^)[K[W_D:KQ@R5_P#+NK_X#'_Y,_1.BOSQ
MC_;W^*;?\S%%_P""VV_^-U*O[>?Q1./^*AAZX_Y!UM_\;J?[ Q'=?C_D:+Q;
MR9_\NZG_ (#'_P"3/T)HK\^U_;N^)Y'_ ",$7_@NMO\ XW4R_MT_$X@_\3^+
M_P %UM_\;I?V%B.Z_'_(T7BME#^Q4^Z/_P F??K_ ':97P4G[<?Q,;_F/Q?^
M"^V_^-U)%^W#\2V(_P")]%_X+[?_ .(I?V'B.Z_'_(T7BEE+^Q4^Z/\ \D?>
M-%?"<?[;OQ);'_$^B_\ !?;_ /Q%2Q_MK_$<_P#,<BZ_] ^W_P#B*G^Q:_=?
MC_D:+Q.RI_8J?='_ .2/N>BOAU?VT_B,W_,=B_\  "W_ /B*E3]L[XBL>=<B
M_P# "W_^(I?V-7[K\?\ (T7B3E;^Q/[H_P#R1]NTV2OBF/\ ;)^(;'_D-Q?^
M %O_ /$5(O[8_P 0BW_(;C_\ 8/_ (BE_9%;NOZ^1HO$7+']B?W1_P#DC[0H
MKXT3]L+X@-_S&8O_  !@_P#B*D3]KSQ^1_R&H_\ P!@_^(J?[)K=U_7R+7B#
MEK^Q/[E_\D?8]%?'J?M<^/F8C^V8_P#P"@_^(J4?M:^/-W_(8B_\ H/_ (BE
M_95;NOZ^1HN/<N?V9_<O_DCZ\/2F5\E1_M8>.C_S%X__  "@_P#B*DC_ &K/
M'+M_R%X__ *#_P"(I?V95[K^OD6N.<O?V9_<O_DCZQHKY27]JGQQG_D+Q]?^
M?.'_ .(J4?M2>-S_ ,Q:/_P#A_\ B*7]FU>Z_KY%KC; /[,_N7_R1]3O]VF5
M\OI^U%XU+?\ (5B_\ X?_B:D7]IWQH3_ ,A6/_P#A_\ B:7]GU.Z-%QE@7]F
M7W+_ #/IRBOFA?VF/&9'_(4C_P# 2'_XFI(?VE?&+#_D*1_^ D/_ ,32^H5.
MZ+7%V"?V9?<O\SZ/HKYS7]I/QAC_ )"<?_@)#_\ $U(G[1_B]@?^)E'_ . D
M7_Q-+ZC4[HM<5X-_9E]R_P SZ(IC_>KY^7]HCQ:?^8DG_@+#_P#$U*O[0WBT
M#_D))_X"Q?\ Q-+ZE4\BUQ/A'TE]R_S/>Z*\'7]H+Q6Q'_$QC_\  6+_ .)J
M0?'_ ,5<?\3"/_P%B_\ B:7U.?D6N),*^DON7^9[B_WJ2O$T^/?BEO\ F()_
MX#1?_$T\?'CQ1G_C_C_\!HO_ (FE]4F6N(,,^DON7^9[34=>/I\<_$Q_Y?T_
M\!HO_B:<GQQ\2MUOH^G_ #[1_P#Q-+ZK,O\ MW#OH_P_S/7J8_6O*%^-OB0K
M_P ?R?\ @-'_ /$U(GQK\1D?\?R?^ \?_P 32^K3*6=4'T?X?YGJ5-DKS+_A
M<WB''_'Y'_X#Q_\ Q-2)\8O$!_Y?(_\ P'C_ /B:7U>1?]L4.S_#_,]'I'^[
M7GH^,/B M_Q^)_X#Q_\ Q-.B^+>O,/\ C\3_ ,!X_P#XFE["12S6B^C_ *^9
MWM%<,OQ9UTC_ (^T_P# >/\ ^)IR?%C721_I:=?^>$?^%'L9%K,J3Z/^OF=F
M>M-DKD_^%J:W_P _4?\ WX3_  I1\4M:)/\ I*?]^$_PI>R97]H4^S.II#TK
MFQ\3-9/_ "\I_P!^(_\ "GI\2]8/_+RG_?A/\*7LF4L;3?<WJC/6LD?$?5SC
M_24_[\I_A3A\1-6S_P ?"?\ ?E/\*7(R_K<#3?[M,JBOQ$U7)_?Q_P#?E/\
M"I/^$^U0C_7I_P!^4_PHY&/ZS$M+_K%_WA5KQ-_R';G_ 'OZ"LT>/=3X_?1_
M]^4_PJ0>/-3=N9DY_P"F2_X4N5E>WB%%.'CC4C_RV3_OTG^%.3QMJ+?\MDZ_
M\\D_PI6*]JB.BK'_  F6H?\ /5/^_2_X4\>,;_)_>)_WZ7_"BQ7,BI15Q/%]
M^W_+1/\ OTO^%.3Q;?$_ZU/^_2_X4AW*-%:/_"57O_/1/^_:_P"%'_"57O\
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M?OV]/"'C3P;XT\#_ ! T+P5\//#?B'2Y$BN/#.A30(]PX\LF1(S*2^TJRMM
M'ED$\@5\8UZ&44ZE&,\/.+2B]/1ZVOY.Y\AXC8S"9E6PV;X>M&I.K"U2VCYZ
M?N\SCNN:/+:^]G;R!UJ6'[]1#K4L/WZ]@_.Z99CJQ'T-5XZL1]#63V.R!/#U
M%6+?K5>'J*L6_6LWL=L"S#U_&IAUJ&'K^-3#K6;V.VF64ZU83K5=.M6$ZUF]
MCL@3IT_"IXOZU G3\*GB_K6;V.V!.G2K$=5TZ58CK)G93)XOZ5/'U%01?TJ>
M/J*A['7 L1=JF3M]:AB[5,G;ZUF]CL@3KTJPO0U77I5A>AJ#KAL6(OZ5)!]X
M5'%_2I(/O"LSK@3Q=1]:GB_K4$74?6IXOZUF=<">.IXNM01U/%UK,ZH$\/WO
MPJ5/O5%#][\*E3[U0]SK@31]!4Z=*@CZ"ITZ5F]SI@31_?-3#[]0Q_?-3#[]
M0SJ@3Q?TJ:'[U0Q?TJ:'[U0]CIB2K][\:G7I4"_>_&IUZ5!T1)(_O_C4R=:A
MC^_^-3)UK,ZHDZ=/PJ6#I42=/PJ6#I4R.F!*OW?QJ6+[IJ)?N_C4L7W34'1$
MGCJ4=*BCJ4=*@Z(DL?45*.HJ*/J*E'45#.F!-%_6I!]XU'%_6I!]XTCHB3QT
M^+^E,CI\7]*S-XDR?=J2/H*C3[M21]!2>QO$E[5-'4/:IHZ@W1(OWS4L'W/P
MJ)?OFI8/N?A4R-XDB?=I\?WA]:8GW:?']X?6I-HDU.7J:;3EZFH>YNB=>_TI
M\?44Q>_TI\?44C6),O:G#K35[4X=:A[FZ'+U-3C[IJ!>IJ<?=-(TB.';Z5+'
MU%1#M]*ECZBI9JMAXZ5)%_6HQTJ2+^M2:HEIX^\:93Q]XT&R'1?TI\?6F1?T
MI\?6LS1$E%%%!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!YK^T?^Q;KWQG_:_P# ?Q$L=5TBUTSPI_9_VBVN#)Y\
MWV>]DN&V84KRK@#)'(KS;]KO_@F)XM_:'_:'\0^,-,U_P[96.K_9O*ANC-YJ
M>5;10G.U".3&2,'H17VW17J4,XQ-%Q<'\*Y5ITO<^#S;PWR/,H5J>*A)JK45
M65I->^HN*?DK-Z'YM_\ #EOQY_T-7A'\[C_XW1_PY;\>?]#5X1_.X_\ C=?I
M)179_K-C_P"9?<CYO_B!G"?_ #ZG_P"!R/S;_P"'+?CS_H:O"/YW'_QNC_AR
MWX\_Z&KPC^=Q_P#&Z_22BC_6;'_S+[D'_$#.$_\ GU/_ ,#D?FW_ ,.6_'G_
M $-7A'\[C_XW1_PY;\>?]#5X1_.X_P#C=?I%)45'^LV/_F7W(/\ B!G"?_/J
M?_@<C\XO^'+?CS_H:O"/YW'_ ,;I/^'+OCO_ *&KPC^=Q_\ &Z_1P]?RJJ_6
MJ_UEQ_\ ,ON0_P#B!7"?_/J?_@<C\[?^'+GCO_H:O"/YW'_QNC_AR[X[/_,U
M>$?SN/\ XW7Z&2=:B?I5?ZQX_P#F7W(?_$"N$_\ GU/_ ,#D?GQ_PY=\=_\
M0U>$?SN/_C='_#ESQW_T-7A'\[C_ .-U^@C=*P=8^(.@Z%XMTOP_>ZWI%GKV
MNI,^FZ;/>1QW>HK$NZ4PQ$AY B\MM!VCDXIKB+'O[2^Y!_Q GA/_ )]3_P#
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M_$U(O[(^JK_S&M%_[ZD_^)KX"F[UGW/4_6J63U?^?O\ Y+_P35>'F7=W^/\
MF?H@O[)NJ ?\AG1OSD_^)J2+]E'4T'_(9T;_ +ZD_P#B:_."?H:H7'6G_8E5
M_P#+W_R7_@FB\/< NK_'_,_3 ?LKZD%_Y#.C_P#?4G_Q-/C_ &6]2 /_ !.=
M'_[Z?_XFOR^N:S[OHU4LAJO_ )??^2_\$T7A_@5U?X_YGZJK^S%J _YC&D?F
M_P#\33Q^S/?C_F,:1_WT_P#\37Y./]VLZ\_UE5_J[4_Y_?\ DO\ P31< 8+^
M9_C_ )GZ[K^S7?K_ ,Q?2?\ OI__ (FG?\,X7V?^0OI/_?3_ /Q-?CU<?ZMJ
MS[FG_JW4?_+[_P E_P#MC5< X/\ F?\ 7S/V93]G6]7_ )B^E?\ ?3__ !-.
M_P"&>KP'_D+Z5_WT_P#\37XK7'2J$_4U2X7J/_E]_P"2_P#VQ:X#PG\S_KYG
M[>+\ +M?^8MI7_?3_P#Q-.7X!W2_\Q;2_P#OI_\ "OPON_O5FWOW#5+A.;_Y
M??\ DO\ ]L:1X$PO\[^[_@G[R+\";H<?VMI?_?3_ /Q-2+\#+E1_R%=+_P"^
MG_PK\ +SK63<_<>M%P?-_P#+_P#\E_\ MC:/ >&_G_#_ ()_0N/@E<$?\A72
M_P#OI_\ XFGK\%YU_P"8KIG_ 'TW^%?SH7WWFK)N?O5I'@F;_P"7_P#Y)_\
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MO$.AW%X]]-IBV\5_$\K7<*&2:W"AL^;&@+,GWE4$D 4 ;G_"-?\ 3[:?F?\
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MYA_:&%_Y^1^]'R]17U#_ ,.9/VE,?\DW_P#+@TO_ .2:3_AS+^TI_P!$W_\
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M][I*F]L6)=6$LP9"Z@21N1\OTC10!\;>)_B%\1=#^(/BSPX^A_%:&^\0>/\
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M#NMCIOMMI_SY?^1FI'OK3'_'C_Y&:JE-?I7(<Y;^W6G_ #XC_O\ -1]NM/\
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M0_[_ #4?;;7_ )\A_P!_FJG10!<^VVO_ #Y#_O\ -1]MM?\ GR'_ '^:J=%
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M\86GCOQ+J7AN\L(&UNYTF]2TGN+N5-EP[3EB+D%U(FA3S"=L:_L65R:0Q T
M?D#^SS^R+XIM?@5JMY/!XD\/_$>U^%WBK1?$?AZT^$.NZ?=^,[RYM)@!?ZU+
M-+::E<+<A9(9(ANE\PA1@@+]M_\ !/7X!W/P3_X)R^%;'0O#D?A#XAZQX1AN
MM3>]LO(OY=9>U_UEYYJF1I%E(&)0=BJ$ "J%'U'Y0S47V?ZU5P/RC_9V_9X\
M3+>_ =_#WP^^)7A'XI>';3Q)+\7_ !.=$N-+U'5UGB=94;5+I1#JES<73I);
ME99U1E63=$J;APNN?L=^)M6_X)\_&GX?Z)\)I_$]OX8L_#=YX7\1-\/;[PUK
MGB&YAO?,O-^FW99I+Z.VDFA>[MT#3QD1L\F%5?V6^S_6D^R@GO1<9^5O[4_[
M,Y^*'[1EZL?A>[\/?!K6/A^FF>")#\&=;UY/"5P9V^U?9-.LS;S:1?%]DRS2
MP_.J+@D J9?V@_V?]>OO$OQGL_B)X/\ 'OQ>\0:O\.]"TOX1>(D\)WMZ;34%
MTYH;B?>JLNDW#:D$N9#.\;!>KD#:?U,-F#_>I#9*3_%3NAW/R _;&^'_ ,8O
M%EG)9:C\--3NOB7X-'@_^SO$]GX,U;Q#K.K3V\=M)>W=EK<<OV73HHYDD+6Z
M1[I':1R \C,/:? ?[$"?%?XZ_MBZCXI^&Z:IJ.MWC0>#+SQ!I6;>4S:<4:2R
M>X7RAND2)7ECY_=H&;"C'Z*_V<N/XZ9)I:%OXZKF0[GY+_!;]E&W\:6'[$VC
M3?![7+32/#TFNQ?$*SU'P1=:=;K?MI5HIFOUE@195E*1IYS[DE\LIN8HRBE^
MSW^R5XI\=?$/]F/PSX\^''B>[\"^&?%7Q!@U&QU71;D:=9:>4@GTY+E778ML
M\\2>4DG[N3RPH# $5^N9TE6_YZ?Y_"FG1DQ_RT_S^%',@N?D5\:OV.]<\0VG
MQJU.[^%>KZO::;\==+UJSB_X1F2ZGN]$W11W3V</EE[B!EV!UA5@RIR"$..I
M^)O[,,_Q'^+7[2\5KH'Q"\$_#SQ1I7@2/0;S2/ MU/"+:WMD'DC3#'')/!#A
M$FM8T\R,#:R (RU^I8T2//63_/X4AT*/;UE_S^%'.@NCYO\ ^"<CZ^?V8K%?
M$/@FR\ 7,6J:BEMI=E8W.FVC6WVJ0PSPV-R[364;J01;L1MY(558*/<Y.AK9
M_L"//67_ #^%(WAV,_\ /;_/X4^=#YD8?>F2=36]_P (U%ZS?F/\*0^%XF[S
M_I_A5>TB+F1SO>D/WZZ'_A%(?6?\Q_A2?\(G"3UG_,?X4>TB5S(YN7[E-KI'
M\'P$?>N/S'^%-_X0^'UN/S'^%5[6(<Z.8DZ&HGZ5U1\&0-WN/S'^%-?P1;E?
MO7/YC_"G[:(^='(R=34+]*[ ^!;=N]U^8_PII^']N?XKK\Q_A1[:(U41QLG4
M?2HA]RNS?X?6Q/WKO\Q_A0OPXMBOWKS\Q_\ $U?MX#]I$XR;[M5G[UW<GPXM
M2OWKO\Q_\349^&5JW\5[^8_^)H]O /:1."?I4!_UAKT%OA=:'^.]_-?_ (FH
M_P#A5-H6/S7WYK_\336(@'M(GGS_ ':C_C_"O0S\)[,C[]]^:_\ Q--_X5'9
M9^_?_FO_ ,33^LP'[2-SSM^]0R5Z4?A!9'^/4/S7_P")J-_@[8G^/4/S7_XF
MFL3 KVT3S1_O56GKU$_!JQ)^_J/YK_\ $U')\$[!C]_4OS7_ .)JOK5,/;1/
M+CTJ.7I7J7_"DK _QZE_WTO_ ,32-\#=/8??U/\ [Z7_ .(H^M4QNM$\HDJK
M)U:O7F^!.G'_ )::G_WTO_Q%1-\ M.8GY]5_[Z7_ .(JEBZ8*M$\@?I43_>K
MV%OV?]-/_+35?^^E_P#B*:?V>=,8_P"LU;_OI/\ XBJ6,I%>W@>.R_ZLU6?K
M7M4G[.^F%?\ 6:M_WTG_ ,141_9RTMC_ *S5_P#OI/\ XBG]=I%?68'BK]ZA
MDKVX_LVZ6?\ EKK'_?2?_$4T_LTZ2W_+76?^^D_^(I_7:0?68'A3_>J!^E>[
M']F/22?];K7_ 'TG_P 133^R]I!_Y:ZU_P!])_\ &ZKZ]2#ZS \&?K4$OWZ]
M^/[+6CG_ );:W_WVG_QNHV_94T=G_P!=KG_?:?\ QNCZ_2&L3 \7\'^";WQ[
MK*65DG/620_<A7^\3_G-?1W@;P-9> -$6SLUY^]+*P^>9O4_T':K7@[X>6W@
M/1_LEA;3!2=SR.N9)3ZL<"M7[#-_SQE_[X->?B<4ZCLMCFKUW-V6Q%37Z5/]
MBF'_ "RE_P"^#37L9B/]3+_WP:Y#G(**E^PSC_EC+_WP:/L,Y_Y8R_\ ?!H
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MQ*32MYHZ/]6^*G.,(UVU*2BFJK:]Z#J1E=/X'!-\WDSQ/_AK/XH?]%#\9_\
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MSK,?^?\ /_P*7^9Z"G[3OQ&/_,]>+?\ P:S?_%5.G[37Q%)_Y'GQ9_X-9O\
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M[_G]/_P)_P"9W4?[1'CTX_XK/Q/_ .#*;_XJIH_VAO'A_P"9R\3=?^@E+_\
M%5P\7:IXOZUA+ X;_GW'[D=,<UQO_/Z7_@3_ ,SMU_:$\=_]#CXE_P#!C+_\
M54W_  T#XZQ_R.'B3_P8R_\ Q5<0G6I^U82P6'_Y]Q^Y'7#,\9_S]E_X$_\
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M7[OXT]>AK)TH=D;QQ%7^9_>;J?$/7C_S&=3_ / E_P#&I5^(&NX_Y#&I=/\
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MLO\ C_"I!T%9N*[&\9R[FI'XKU,_\Q"\_P"_S?XTY?%6IE?^/^\Z_P#/9O\
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M\.7],_Z'^^_\%*?_ !VO?_XB+D'_ #^?_@,__D3Y+_B#/%W_ $#+_P &4_\
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M+?#K_P #A_\ )'Q@G3\*FAZ"OLM?^"46GJ/^1UO/_!8O_P <IZ?\$J-/4?\
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M_ 0?_%5D\ZP?\WX/_(UCPQF*^Q^*_P SQ&/J*E3[U>V#]D>R7_F/W'_@(/\
MXJG+^R79 _\ (>N/_ 0?_%5F\XPG\WX/_(VCPWF'\GXK_,\7B_K4@^\:]F7]
ME.Q7_F.W'_@(/_BJ</V5K('_ )#L_P#X"#_XJLWFV%_F_!FZX>QZ^Q^*_P S
MQZ.I%^]^%>P+^R[9+_S')_\ P%'_ ,52_P##,=DK?\AN?_P%'_Q59O-,-_-^
M#-HY#COY/Q7^9Y)']X?2GQ]!7K:_LT6*_P#,;G_\!1_\52C]FRR7_F-3_P#@
M*/\ XJH>9X?^;\&:K(\;_+^*_P SRI?N_C3UZ&O5!^SI9+Q_;,__ ("C_P"*
MI1^SO9#_ )C4_P#X"C_XJLWF.'_F_!FL<EQB^S^*_P SR^.IE^[^%>FK^SW8
MC_F,S_\ @,/_ (JG#X!V('_(8G_\!O\ [*LWCZ'?\&;1RC%)_#^*_P SS-/N
MU*GW5KT<? :Q _Y#$_\ X#?_ &5/_P"%&V* #^UY^/\ IV_^RJ'CJ/<U658G
M^7\4><]JFCKT'_A2-C_T%I__  &_^RIW_"E[!/\ F+3?^ W_ ->H>-H]S6.6
MXA?9_%' _P ?X4]?O?A7>?\ "G;'/_(6F_\  ;_[*G?\*AL%Y_M6;_P'_P#K
MU#Q=+N:++J_;\4</%VIR=*[A?A18+_S%9O\ P'_^O2K\*[!?^8I-_P" _P#]
M>H>*I]S58&MV.)'W*ECKL?\ A6&G@8_M2;_P'_\ KTX?#73T_P"8G-_X#_\
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M_/[+_P!^?_KT?8M._P"?V7_OS_\ 7H SZ*T/L6G?\_LO_?G_ .O10!W%%%%
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M^[OP1^-_AK]HKX9Z9XN\):E%J>BZK'OCD7AXF_BCD7JDBGAE/0U_-/7ZE?\
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M1H9OM6XOO %>E?L5_"N]L_VCO%FE7'D3^$/@1/>^&_"4L#AHW;4Y(]1F1@,
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M_<_\RO[:K]E^/^9^1TW_  3*^-[H<>"?_*Q8?_'ZIS_\$P/CF_3P/_Y6=/\
M_C]?KY]M_P"F4/\ WQ1]M_Z90_\ ?%/_ %LQ?\L?N?\ F/\ MROV7X_YGX\3
M_P#!+CXZL/\ D1O_ "M:?_\ 'ZJ2_P#!+#X\L>/ G_E:T[_X_7[(-?8/^J@_
M[XI/M_\ TQ@_[XJO];L8OLQ^Y_YC_MW$=E^/^9^,5Q_P2D^/LAX\!?\ E;T[
M_P"2*S[K_@DU^T!)T\ Y_P"XYIO_ ,D5^UOV_P#Z8P?]\4S^T?\ IA;_ /?%
M5_KCC?Y8_<__ )(I9_B%T7X_YGXBW/\ P2,_:%DZ?#[_ ,KNF_\ R16;=?\
M!'_]HIU;'P\Z_P#4>TS_ .2*_<S^T?\ IA;_ /?%-?4L'_46W_?NM%QICE]F
M'W/_ .2*_P!8<2OLQ^Y_YGX1W?\ P1Q_:/E)Q\.<_P#<?TO_ .2:H7'_  1E
M_:38?\DW_P#+@TO_ .2:_>K^T_\ IA;?]^Z1]3Q_RPMO^_=6N.,>OL0^Y_\
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M[Q+!XAV_9_-^V>5!/%Y.=R[,^?G=\V-N-O.1R7QG_9+_ .%N^/\ 6-<_M_\
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MFS\=_%;P!IGAEDN=&\3C6(M1%_I]S8ZC87%DD!$3P3B.6!\RDLLL08J488#
MGSKX@_\ !.*]^-$%]=^./&.A>)M;BATBST<S^$T_LJ*WTZYDN$2]LGN'%X9V
ME=9MLD*E<>6L)&:[?X0?L>)\,=>\&:BA\!:0WA-]4=['P?X0_P"$?TZ]-['
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MOFH E_L^;^X?SH_L^;^X:AW4;J )&TZ8G_5G\Z3^S9_^>9_.H7;YJ3=0!/\
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M@"__ ,(M?_\ /NW_ 'T/\:/^$6O_ /GW;_OH?XU0WGU-&\^IH O_ /"+7_\
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M*@1AM\SR2#D$[1DCS[PU_P $3OA+X;T/X861U?QYJ'_"KM6EU:">\O[:27Q
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M\1^&-;\!:VGB#0]8T-[875E<K&\?W;F&>%T97.5>,YP/?/RO^VY_P2KU#5=
MT]_AI)XJUW5O&/QKT7Q]XKN)]4LK672H(8YHKBYM6*PA=@96"CS'W'Y00,
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M9%%%% !39*=39* &T444 %%%% !1110 4444 %%%% "/]VF4]_NTR@ HHHH
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M_P"K^,+'Q=XL_LFZ\!:5::WKR?V7>3_8;.ZG6W@ES%"PDW2LJ[8RS#.2 .:
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MTSR[;_GI+_WS4=1T 6/+M<?ZR7_OFFM':Y_UDO\ WS4-,?K0!8\JT_YZ2_\
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M_P _%U_W[%'V?3/^?BZ_[]BLZB@#1^SZ9_S\77_?L4?9],_Y^+K_ +]BN?\
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M,31O L2B*"%Y?(S$&JD/VPOBE:>"OVK(/AMXLOK_ $K0O#_AK5-/DT3QW?\
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M@#\>?V@?C/\ $'_A&OVS/$\'Q+^)-CJ/P@B\&7_A2.S\3WEO:Z;-=VUL;DM
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M6?10!H?\)))_S[V?_?D45GT4 >D445#+J$$#E7FB1AU#. 10!\^?\%.?V/\
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M@M[K5O#7_"'_ !P^'FE>$]5U%;V?^U- O;&PFMA-#;&W,=W$[M&QWSP-@OW
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MM%_WV* ):*B^VP_\]HO^^Q1]LA_Y[1?]]B@"1_NTRD:[B(_UL7_?8IOVF/\
MYZQ?]]B@!]%,^TQ_\]8O^^Q1]IC_ .>L7_?8H ?13//C_P">D?\ WV*//C_Y
MZ1_]]B@!]-DI//C_ .>D?_?8I'F0_P#+2/\ [[% !12>8A_CC_[[%)YJ?\](
M_P#OL4 .HIOFI_STC_[[%'FI_P ](_\ OL4 *>E,IQD0C[\?_?8IN1_?C_[[
M% !11D?WX_\ OL49']^/_OL4 (_W:93VP1]^/_OL4W9_M)_WV/\ &@!**79_
MM)_WV/\ &C9_M)_WV/\ &@"*BG>4?5/^^Q_C2^23W3_OL?XT ,IC_>J;R#ZI
M_P!]C_&FM;,3_!_WV/\ &@"*BI/LK?['_?8_QH^RM_L?]]C_ !H @?[U)4S6
M4A/\/_?8_P :3[$_^Q_WV/\ &@"*HZL_8W_V/^^Q_C3/L$G^Q_WVO^- $-,?
MK5G^SY?1?^^U_P ::^FRD]%_[[7_ !H KTV2K/\ 9DWHO_?:_P"-(^ES'^%?
M^^U_QH JTC_=JU_9,_\ =7_OM?\ &D;2+@C[J_\ ?:_XT 4Z*M?V-<?W%_[[
M7_&C^QKC^XO_ 'VO^- %$]:;)5TZ)<D_<7_OXO\ C37T*Z/\"_\ ?Q?\: *5
M(>E7?[!NO^>:_P#?Q?\ &D.@76/]6O\ W\7_ !H H5&>M:/_  CUW_SS7_OX
MO^--/AJ\S_JA_P!_%_QH SW^[3*TF\,WI'^J'_?Q?\:9_P (O??\\1_W\7_&
M@"@O^L7_ 'A5KQ-_R';G_>_H*F7PQ>AU_<CJ/^6B_P"-6-=\.WEWJT\D<09&
M;(.]1GCZT >7?&[X&:;\<M%TN*ZOM5T35?#^HQZMHVLZ6\27VDW2!D\R(RI)
M$VZ-Y(V22-T=)&!4YX\Z\>?L$V7Q&LXWU'XD?$PZW+I.I:#J>MI<Z=]MU?3[
M]H6GM74V9@MTQ;PA39Q6[KM+;B[,Y^BO^$5OO^>(_P"_B?XT?\(K??\ /$?]
M_$_QH \#U[]ACP[XV\8:/J'B77O$GB72O#VE76C:9H=['IZ6=E;W5B+&Y59H
M;6.\82PYW*]PR%B&V@I'L['X(_!G4?@WIC6-SX_\9^-+&.WAM;.'7H]-_P!
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MA%2>!DNH)X'CDV1,=T18-"A5EP<^G_\ "*7_ /SP'_?Q?\:/^$4O_P#G@/\
MOXO^- 'A7B#]BS1_&'Q!T/QAJ_BKQCJ/C+PRMDFE:X\MG%<Z>L._SUC2*V2$
M+>"1UN1Y?SJ5"[!''LX/X;?\$VK*3X>R:/X_\4>(_$5O);:]9V^C17L7]EZ.
M-5\^*>:V?[.ER96MYY%_?2R)&9Y1&JC;CZQ_X12__P"> _[^+_C1_P (I?\
M_/ ?]_%_QH ^?O"'["VC>'=1EOM1\7^-O$VI3:KI&K/=ZE)8HV_3-PM8E2WM
M88EBVMA@J MC.0Q9C8\0_L2Z-J7B1-<TGQ5XS\+:_'JVI:HNIZ5-:>>$U!81
M=VF)[>6/R'-O P^3S%:)2L@(KWG_ (12_P#^> _[^+_C1_PBE_\ \\!_W\7_
M !H \:O?V1/#ES^RY8?":/4-?MM"TF&SCL;^.Y1M2M9+2XCN;:<2/&R-(DT,
M;Y=&!*_,#DYY;7OV!+'Q)\.?%OAJ\^(WQ"N;3Q_J;ZIXEFN8M&NI=9=[*TLS
M&XFT]XXXQ'9QLHA2,HQ.TJH14^CO^$4O_P#G@/\ OXO^-'_"*7__ #P'_?Q?
M\: /&/"7[*=O\-_B+=ZUX6\9^,_#FE:G>17^H^'+=K"XTS4)XX(H"[-<6LMT
MA>.&(/Y4Z9*[N&9F/JU:/_"*7_\ SP'_ '\7_&C_ (12_P#^> _[^+_C0!G4
M5H_\(I?_ // ?]_%_P :/^$4O_\ G@/^_B_XT 9U%:/_  BE_P#\\!_W\7_&
MC_A%+_\ YX#_ +^+_C0!G45H_P#"*7__ #P'_?Q?\:* /D+]N_\ Y2?_  :_
M[@G_ *=IZ\%_X*<_\GP^-_\ MP_](+:O>OV[_P#E)_\ !K_N"?\ IVGKP7_@
MIS_R?#XW_P"W#_T@MJ /$_#7A?4_&FMP:9H^G7VK:E=$B&TL[=YYYL*6.U%!
M8X ).!T!-;7BWX'^-? &EF^UWP?XHT6R#!3<7^E3VT0)X W.H&3]:]2_X)C?
M\GP^"/\ M_\ _2"YKZ[TG_A*_@SX:^.6I_&/5C)X+UF:[70--U+5$NY+B)S/
MM2%=[;%=&C58\@@C[JXR0#\X=7^'^O>'_#MCJ]_HFKV6DZI_QY7MQ9R1V]WW
M_=R, K_\!)K(K[&^+GPPNO$/[./[.&DZEXIUZ^TCQ3?VMJUDZ6J1Z>LOEKF%
MEA$A*K(P'FO)]*T[O]@SX*6W[0US\+/^$R\;?\);=0-/8X2W-M9GR!*L,S>6
M#)(4W2#:$&W"Y#8W 'Q-6Q\/_ &K_%+QE8>']!LS?ZOJ<GE6UN)$C\QL$_><
MA1P"<D@<5]%? O\ X)_6^M>'?'.O>,SXMO-.\'ZO-H,6G>%+'[3J6J7,,@21
MXU9&'E@D#./[V2NSGT+P-^R#9?LZ?M=?!C7]"FU]] \5RSLEKKENL&HZ=*ML
MS&*90%Y(;^Z,%6]L@'R+K/P.\7Z'KGB+3I?#FK2W/A(D:S]E@-U'I@ 8EI9(
MMR*N%8[BV,*>>*Y6ON^Y\/7VJ^+OVP+NT\0:MH\5A;9GM;2.V:+4E:"\^24R
MQ.X7"L/W;(V';GIC@+S]D7X0?#?X"?#WQQXV\2>-[9/%UHAFM--C@E9IG"-O
MC+1X2.-=Q8-O9LC;R,, ?)]%?57B7_@FZ(?VV;7X9Z7K=RVB7.FC6Y+Z>-6N
M+6TRR,I VJS[U"@@ ?."1P16C\4?V /"[_!OQEXA\()\3=(O_! ,\\7B_3!:
M0:M NXO);,(T)&U6(SD\*&5=X:@#Y$HHHH !UJ>+^M0#K4\7]: )XZLP=35:
M.K,'4T 6HOZ5/%VJ"+^E3Q=J )X^@JQ%_6J\?058B_K0!8B_K4\=01?UJ>.@
M"=.M6(OZ573K5B+^E $\7:IX^@J"+M4\?04 3ITJS%_6JR=*LQ?UH GCJ=.M
M01U.G6@"Q%_2ID^[4,7]*F3[M $D?05.G2H(^@J=.E %B.K$=5XZL1T 3IUJ
M5?O?A42=:E7[WX4 31=JGB_K4$7:IXOZT 3ITJ1>IJ-.E2+U- $Z=:L)UJNG
M6K"=: )5^]^%31=JA7[WX5-%VH GB_K3TZ4R+^M/3I0!8CJ0=?PJ..I!U_"@
M">+^E3#I4,7]*F'2@"6+M4R_=_&H8NU3+]W\: )$Z5-VJ%.E3=J )8OZ5+W%
M11?TJ7N* )H^HJ5/O5%'U%2I]Z@"5.E2)TJ-.E2)TH E[U-%_2H>]31?TH ?
M'U%2CJ*BCZBI1U% $R?=J2+^M1I]VI(OZT /7J:FJ%>IJ:@"1?N_A4D?45&O
MW?PJ2/J* 'Q]!4J?>J*/H*E3[U $H[?6GTP=OK3Z )1]TT].GX4P?=-/3I^%
M $D7:GQ]!3(NU/CZ"@"2+^M/BZTR+^M/BZT 2+U-2+U-1KU-2+U- #TZTX=*
M:G6G#I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'RG^W?_ ,I/_@U_W!/_ $[3UX+_ ,%.?^3X?&__ &X?
M^D%M7Z-?%+]C_P )_%[XV^'/'^JR:NNN^%_LWV-8+A4@/V>=ITWJ5)/SN<\C
M(K ^,7_!/'X;_'3XC:CXIU^VU>35M4\KSV@OFC0^7$D2X7''RHM 'YK?L>?&
M;3/V?/VC?#OB_68+^ZTW2/M/G162(\[>9:RPKM#LJGYI 3EAP#]*Y/XL^++?
MQ[\5/$VN6B31VNLZM=7\*3 "1$EF=U# $C=AAG!(SWK]+_\ ATO\'_\ GSU[
M_P &;?X4?\.E_@__ ,^>O?\ @S;_  H ^6K/]J'0OBUIG[.O@O3[+5H-4\&:
MYI\5]+<1QK!*?-A0>65<L>A^\JUZ[^T1^T9\)O@#^VWKWB74_"_BJ\^(/A^V
MC@@>UFA_LZ]:6RBV2R;F#HZQR&+(## S@G&/3M/_ ."4WPFTF_ANK6'Q);7-
MM(LL,T6K.DD3J<JRL!D$$ @CIBK/B;_@F!\,O&NN3ZGK,OBW5M2N=OG7=[K<
ML\\NU0J[G?+'"@ 9/  ':@#Y&^ __!02UT3PCXU\/^-4\6VMGXMU>?7(]2\*
M7WV74-.N)G#R+&6=<)N&1ECU8$,&J.?]L_PCI/QZ^'6N6$GQ0UC0O!\UQ/?3
M>(]9.H7]Z\D>P%(FE\F,J/[I7=NY^Z*^KO\ ATO\'_\ GSU[_P &;?X4?\.E
M_@__ ,^>O?\ @S;_  H ^4K+]MSPO;WG[0<C:=K^WXL0"+2,0PYMB([E/W_[
MSY?]<OW-_0_CR?[0G[4.A?%K]F3X9>"]/LM6@U3P9#Y5]+<1QK!*?+5!Y95R
MQZ'[RK7VS_PZ7^#_ /SYZ]_X,V_PH_X=+_!__GSU[_P9M_A0!\U^./\ @I%I
M7_#:6D_$OP]H^JR:/%H:Z)J%E?".&XEC,LCN4*.Z\%HR,GDH0<9S63\:?VO_
M  +XE\ >);/P_JGQRU'4?$$9BBM]?\3/_9NG*Y^<+'',QE7;D;)=P(-?57_#
MI?X/_P#/GKW_ (,V_P */^'2_P '_P#GSU[_ ,&;?X4 ?EA17ZG_ /#I?X/_
M //GKW_@S;_"C_ATO\'_ /GSU[_P9M_A0!^6 ZU/%_6OU(_X=+_!_P#Y\]>_
M\&;?X4Y?^"3?P@7_ )<]>_\ !FW^% 'Y>1U9@ZFOT]'_  2A^$2_\N>O?^#)
MO\*>G_!*CX2)_P N>N_^#)O\* /S)B_I4\7:OTR7_@E?\)5_Y<]<_P#!DW^%
M.7_@EI\)U_Y=-<_\&+?X4 ?FE'T%6(OZU^DX_P""77PH'_+IK?\ X,6_PIX_
MX)?_  J7_ETUO_P8M_A0!^;L7]:GCK]'1_P3%^%:_P#+IK7_ (,&_P *=_P[
M,^%B?\NFM?\ @P;_  H _.=.M6(OZ5^B(_X)I_"X'_CTUG_P8-_A3A_P39^&
M"]+36?\ P8-_A0!^><7:IX^@K]!U_P"";WPQ7_ETUC_P8-_A3Q_P3D^&2_\
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M[77_ '__ /K4 <+'T%2I]ZNU'A?1!_RZW7_?_P#^M2_\(WHJ\_9;K_O_ /\
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M ']_^M1]JTW_ )];C_O[_P#6H SJ*T?M6F_\^MQ_W]_^M1]JTW_GUN/^_O\
M]:@#.HK1^U:;_P ^MQ_W]_\ K4?:M-_Y];C_ +^__6H SJ*T?M6F_P#/K<?]
M_?\ ZU'VK3?^?6X_[^__ %J ,ZBM'[5IO_/K<?\ ?W_ZU'VK3?\ GUN/^_O_
M -:@#.HK1^U:;_SZW'_?W_ZU'VK3?^?6X_[^_P#UJ ,ZBM'[5IO_ #ZW'_?W
M_P"M1]JTW_GUN/\ O[_]:@#.HK1^U:;_ ,^MQ_W]_P#K4?:M-_Y];C_O[_\
M6H SJ*T?M6F_\^MQ_P!_?_K4?:M-_P"?6X_[^_\ UJ ,ZBM'[5IO_/K<?]_?
M_K44 =O1110!PW[0O[27@S]E;X?#Q3XZU:31]$:\@T])HK"YOI);B9MD4:16
M\<DK,S<#:IKDM-_X*$?!V_\ AEXR\73^-+;1M&^'LWV;Q(NMV-UI%]HTI4,D
M<UG=11W*O)D"-?+S*WRH&;BO)_\ @MA\,_%7Q7_9&T33/!VBZIKFM1>.-#NU
MBL=,FU!K>..YRTSQ188Q)P6.5&/XEZUXY^VE_P $WO&?A3P[JGQ9%Q??%_QS
MJ/Q1\+^/?&>DZ!I/]F)JVC:)#- FGV-DT\S/(L4Q.&F=Y2@P"P&0#ZO\3?\
M!1[X1^"?"%QK.N:UXBT.*VU.ST=[+4O!^LV>JM<WGF?956PDM%NW68Q2A)%B
M*,T4BABR,!7N?^"FWP3T[P/JWB&]\7W6EZ=X>UVW\-ZPNH^']3LKO1;ZX7=
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MQU\<:/K?@_4(O#-X=(FL99K*0O<7?E^39_9EMWWQW#QNIV@)7L7CZSM/ _\
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M$[S3O OC7P?\<_!VK^(-4^+OC;4]&FTU;NT7[4)_/UJY"VNHK.Y@> )/+&%
M?,2*S#S;]C7X5W'C_P #V^M>%H_#O@SX\:K\#]2MO!PMM,U2QUKQIJ,T@GN=
M734;ZPMH#?"&3R5DM+BX<B>1_M"Q)P ?M[39*_'"]_8ZUH_L0?%*;P?I?B.S
MUG6?A3IN@WOP^T7X)Z_X46_OH;VUE2[FENI)8[_4(E-S$[P M(LC/G"Y/1_M
M ?LI_%CPKK?QOT?X0>#?%7AZ+QA\&- NKF;3K&>TCUS5X=1B;4$:;Y1/J,EF
M]XK@L9Y#*P)W.20#]:J\P_9=_:P\._M::1XQO?#EEK5E%X)\5W_@^^&I0Q1M
M+=V902O%Y<CYB/F#:6VL<'*BO!/^"7?P'M_AE\0_B!KVBW\VD:+XALM+2?PE
M;?"/6/A_I6GW,22H+J&/4991-.\8VS- Q!*1LY)*$_)6C?LA>+_"/A:_\<:=
M\,/%$'Q'M?VKWU.TU-?#]S_:2^'VG!>9&V;QIT@9][#]R^?F)P* /U_KS7XZ
M?M3>'_V??'OPX\.ZS9ZS<WOQ/US_ (1_2GLHHWBMY_*:7=.7D4JFU3R@<Y[=
MZ_.[3?"7Q$\7?\% _A?XKC^$NI^#=5TOXH:M!KUW9>!-8.H_V4_GQI/?^))I
M7AU"VE3A$C BA01HI6-8T/+?L\?LU>)--\;?LQRZQ\)?B##\7_"_Q.U:[^*7
MBJ;PU=I!?-)<7;174]^5$5]$PP8IT:2.(;QNB\]1, ?L)17Y%_LC_LA>/+6[
MT:]\9W&N^'/C)X?D\4#Q#+!\)-:EO/&QN(KL/%>>)?.?3[NWD41/!\B[66)(
MQYF"S/V=?V2OB5\*]#_9%U/P9X"\2^%O'^J>!?'.C^,-9ETB>VN;>?\ L[_B
M3QZK.Z9C5)XX%MUN#M41HB#:BJ #]=Z*_)WX!_L7S_%W4?@?X;TWX:^+_!>J
M_P#"':_H_P <];UCPW=Z4->:]M1$4GNIT5=5F:^_TB-XWEV;5<.F!C@?!O[,
M7[2'QO\ V=_B)=W_ (5\9>'?'?P7^&4'PQ\(&:.XLI=?*ZD[WUY9-(%:4R:=
M#' &4X?S %R3F@#]H**_);Q9^R7XKB_9F^+EY\+3XCM[#Q%8Z!%X@^'GA[X1
MZYX BO+&"Y O?LT=]/)]JNI;0213I;R9F1=K%S(JR?:'PG_:#^%/P#\6>"?
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MY!]HMOWC((Y-\7S?NV;;T;!XKL*_+SQQ^RWXD\/_ +0O[8MSX,^&U[X>\?\
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M6>&W=5*S2!1DHA+>U 'Z3>&_$-GXN\.V&JZ?+]HL-3MH[NVEV,GFQ2*'1L,
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M4X_/CFGP%?4VM&N =[>>V\DG+$UB?&+]E+7D_8>^,]Q\/+/Q,-3UW0?#-N/
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M<5I^"_CKX=\3^ K76[K5]%TMOL-C=ZC;RZC%G2FNXT>&.5B5VEO,4+N"[\C
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MT5TD?AW1[;6IM<&AV*0HHA-_/;6T\_[P.1YR.Z+M'FN,!?6Z "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ](HHHH **** "BBB@ HHHH ****
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M"_F+\K?>':K7B6-CKMS\I^]Z>PIR^)+XNO\ I#]1Z58U[7KRUUB>..=U16P
M,<<4 8_E-_=;\J/*;^ZWY5<_X2:__P"?E_TH_P"$FO\ _GY?]* *?E-_=;\J
M/*;^ZWY5<_X2:_\ ^?E_TH_X2:__ .?E_P!* *?E-_=;\J/*;^ZWY5<_X2:_
M_P"?E_TH_P"$FO\ _GY?]* *?E-_=;\J/*;^ZWY5<_X2:_\ ^?E_TH_X2:__
M .?E_P!* *?E-_=;\J/*;^ZWY5<_X2:__P"?E_TH_P"$FO\ _GY?]* *?E-_
M=;\J/*;^ZWY5<_X2:_\ ^?E_TH_X2:__ .?E_P!* *?E-_=;\J/*;^ZWY5<_
MX2:__P"?E_TH_P"$FO\ _GY?]* *?E-_=;\J/*;^ZWY5<_X2:_\ ^?E_TH_X
M2:__ .?E_P!* *?E-_=;\J/*;^ZWY5<_X2:__P"?E_TH_P"$FO\ _GY?]* *
M?E-_=;\J/*;^ZWY5<_X2:_\ ^?E_TH_X2:__ .?E_P!* *?E-_=;\J/*;^ZW
MY5<_X2:__P"?E_TH_P"$FO\ _GY?]* *?E-_=;\J/*;^ZWY5<_X2:_\ ^?E_
MTH_X2:__ .?E_P!* *?E-_=;\J/*;^ZWY5<_X2:__P"?E_TH_P"$FO\ _GY?
M]* *?E-_=;\J/*;^ZWY5<_X2:_\ ^?E_TH_X2:__ .?E_P!* *?E-_=;\J/*
M;^ZWY5<_X2:__P"?E_TH_P"$FO\ _GY?]* *?E-_=;\J*N?\)-?_ //R_P"E
M% '=4444 ?.__!3?]JWQ1^QY^SKI_B;P?;:!<:WJ?B;3-!C.LVTMS:PI=3>6
MTACBEB9BHY \P5X%XT_X*T>/_A#JGQ3\ ZEH'@WQG\2/#/CGP_X \*:II$5S
MIVA:UJ&M6TLT"W$32W,D36ODR><BS,6.U 8R=]?2W[?W[&%O^W=\#[/P3=ZU
M#H=K;Z]8:S-)-IHU".Z2VDWM;M$9$&)!E222!G[IZ5F?M&?\$Y_ _P 7OV?+
M+P/X.M=-^$LWAS7[?Q=X9U#PSH]M;QZ'K5N28+S[,JK'+C)#J<%U)&Y3@@ \
MW_;F_:V^,_["?P1TS6]<UCX/:I-KOC+1_#]MKK:'?:?8Z=:W7GBYDN;-[]R/
M)\I'647@5P[ADC\L/)QEO_P49^-VM?L]?&WQ;X5TCX;_ !"@^#FMVT]EXDTC
M3[N'0_'>C"'S-06Q'VN7;=6VUB9%GFC)&P(3R?8/V@_V&/'?[5W@SP_I_CKX
MHZ$]UX<\8Z/XIM1HG@YK&Q5+!YG:+RI;Z>;S9C-AI3.4588ML(;S&DX_XG_\
M$FM0\6#XO:!X<^*$GA'X<?&OQ+8>(?$'ARVT'?)&$4#48;>Y6Y01F^*1&1_*
M)4(5PX8T =S_ ,$_/VU]:_;VO?&OC;2=+L=.^#EM=PZ9X0N;BUEBU?69HXP;
MRXEW/L2%9&$2*J9)20EN,5R'_!1W]NWQS^R+XBT^+PEJ/PKUS6KZ]TJVTKX=
M3K<7?BWQ9'<W/E2RP>7<1?95&V548V]PA,3%G!_=CHO@W_P2P\"?"/QC\0;"
M33_"?B3X/^--2M]?L/A[J_AB"[L/#.JI#Y,MU:M(S(%E0\IY(V84*P7*M9_:
M\_8)UW]I[X2:I\++#QSH'A/X0:Y!IMI/H,7@V*>]TFWM)8'^SZ;<)<106\3+
M;Q[1-:W#1,SE&V^7'$ >/_M#?\%2?B'\.;;XY>.O#^C>#I?AO^S]XGTWPUJV
ME7MI<2:UXC:2:!+R:"Z6X2&U\L7,8C5X)MVQB6&0H]'B_;@^(S?\%/?#GPBO
M?"'AW1?AYXDT"_U;3-2ENVNM6U9;=4(N0$816T+,Y41.KR'RRQ*;@HY[QU_P
M2"'B5_B)X:T_X@_V?\*/BSK&EZSXG\.W&A?:M1DDLS"72VO_ +0JPI/Y$6_?
M;RL-IVL,UVOQ _8?\?>+?VY/"_QEL?B+X+TV/P=IMQH>F:(_@BXF'V"=@9%E
MG&IINF !"R+&B#(S&V,$ I_\%4?VG/BG^QG\%9/B)X'U#P!-I-I=:?IDNCZY
MX<N[RXEGN;L0M,MU#?P*J*LB8C,+'*-\_P P"\#\7OVQ/B]^S?\ \% O O@K
MQ!=/\1=%OO >J:_J6C>"_#=KIGVR:&X(291?WDC1^7$K;LWBJ^,*A=E4^_?M
M^?L@?\-R?LYW7@#_ (2'_A%_M.IV.H_;_L'VW;]FN$GV>7YD?WMFW.[C.<'I
M6?\ %?\ 8D_X6?\ ME:+\6_^$F^P_P!D>"]0\(?V5_9WF>;]J<M]H\[S1C;G
M&S8<_P!X4 <LW_!67P!KOA7PKJ'A'PWX]\?7OBCP=-X].DZ'96@OM)TB)S%)
M/<_:;F&($3+)$$CDD=WC8(&&"='P)_P4^\$?%WXX>&? G@KP[XX\8W_BCP]I
MWBR&_P!-M+5=/LM*O&9?M5Q)-<1M&(2 )(]IERX5$D8,J^+>#O\ @AEI?@+0
M_ADT/B#P!XMUSP!X5N?"-T?''P]3Q!H^JVKZA-?0S)9&\B:VN(I+B9?,6=MR
MN00!7N7P-_8'@^"W[6;?%*WU;0+:.7P!9>"3X>T/PZ-*TVV>"<3O<6ZB>3RH
MF;<%@PVP$9D<C) .#^'/_!:/P+\5=/\ A[=Z/\.OBY-:_%<WL'A"9]/TY%UR
M[M"!<6B9O<QNK$KYDP2#*/\ O<*Q'5>&?^"JG@'Q[X'\#7WAK0/&WB+Q+\0M
M2U#2M*\(6=K:)K2S6!87IF\VY2UCCAVC<YN-IWKM+$X'%? 3_@D1_P */\'?
MLT:3_P +"_M/_AG;4]<U'S?["\G_ (2#^TI)I-F/M#?9_+\W&<R[MO1<\5OA
M=_P2&O\ X&R^"M>\*?$JS@\=^!/$WB#6K'4=1\,M=Z;<VFL+BXLYK-;R-R5*
MQE9DN$.5;*D-@ '70?\ !77X>:U:>"[;1/#GCOQ!XK\:ZCJ^DP>%;2VL8M7T
M^[TI0U_#<+/=1PB2,,N%CED:3</+#\XU?C#_ ,%2? ?P@\3^*K-O#_CS7],^
M'MOIEUXRUG3--A6S\(I?L/(^U)<317+.$822)!#*\:'YE!!4>:^-_P#@C>OB
M?]F&^^'B^,?"^I7/B6\UG6?$.J^)/ \>K>9J^IE#)J6G1I=0OI\\6TK$%ED0
M*V'60C=5K6?^"..AV'QHU?Q;H]Q\-?$J>(=+TJQU"W^)_P /H_&5P)["W^RB
MYM[@7=JT330I%YJE75I$+#&=H .I\7?\%?/AWX.\0>+8)O#?CZYT3P#XHL_"
MWB/Q!;VEFVF:3+=O"EO<EC="6:W<RGF".211$Q:-0T7F=!=?\% ]!\>>*?BI
MX6\,Z3XV#?#EK[2-1\5VVG6EUIVG:E#8/=M'Y)N/M'RA74230QV[RQ&,2DNF
M_P T^+7_  1WB^)OPS^/'AJ#Q]'I,/QK\5:;XEC>/P^'705LY(G%N$%PHF#"
M+&[,>W/W3BN@^*7_  2^F^+G[4S_ !+U#Q?X?L+F&WUBW@FTKP?'8ZU?QW]E
M]C2#4K^.X"WUO;1X$2- CA8T!D)#,P!YK^S?_P %.O'OBGXH_L\^#X- \0_$
M;0_B5X.NM;O_ !)=Z5I>D:MJ,L4H0W"6\>HBWMXHLGS8\,Y 'E>8<UU7[#W_
M  4WT3Q7:>$_#/B[Q#XU\2ZQXVO?$LFF>)M6\-Z?HMDRZ5*[SV9CM;B0!H8
M&5L$N@W,5)VC7^$?_!+;4O@7?? +4_#OQ#L3K7P4T*]\-W,NH>&WGMO$%E=2
M*[[8DNXVMI1AMK^9*,D$HP&#P_C7_@AX/$_[&VD_#*R^*$VC>(M!\6:GXDL/
M%<&@9FMXM06=+BT$'VD<-', 7$H.8U( H [SP_\ \%E? 7CGP'9ZWX8\"_%+
MQ1)+X5OO&][IEC86$=[I.BVMP]O]LG$]Y'&?.:.1H88GDG=%W>4 1E?^"H'[
M9VK?"W_@G5;_ !9^$WB98?[7O-%N--U6WL8[L7%E=W,()6&:-^7B<C!3>,]
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M<>%)?$VN:_9>'M-TIX;6$R>9//$UW';*^(W/D6LLTBJFYE 92SO#?_!,S4O
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MG5P',/\ )_VD_.CR?]I/SIE% #C%Q]Y?SIGD?[:?G0>E,H ?Y'^VGYTOV?\
MVX_SJ.B@![6^1]^/_OJF_9O^FD?_ 'U37^[3* )/LW_32/\ .C[-_P!-(_SJ
M.B@!?LG_ $UB_P"^J7[)_P!-8?\ OJH:* )OL?\ TUA_[ZIC6>3_ *V'_OJF
M4Q_O4 2_8O\ IK#_ -]4?8O^FL/_ 'U4-% $C6.3_KH/^^J3[!_TV@_[ZJ%_
MO4E $_V#_IM!_P!]4S^SO^F]O_WW4=1T 6/[._Z;V_\ WW37TW)_X^+;_OO_
M .M4-,?K0!8_LS_IXMO^^_\ ZU(^F?\ 3Q;?]]__ %JKTV2@"Q_9G_3S:_\
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M '_UJSJ* -'_ (1[_I_T[_O]_P#6H_X1[_I_T[_O]_\ 6K.HH T?^$>_Z?\
M3O\ O]_]:C_A'O\ I_T[_O\ ?_6K.JGK?B"P\,V27&I7MII]O)<0VB2W,RQ(
M\TTJ0PQ@L0"\DLB1JO5F=5&20* -W_A'O^G_ $[_ +_?_6H_X1[_ *?]._[_
M '_UJSJ* -'_ (1[_I_T[_O]_P#6H_X1[_I_T[_O]_\ 6K.HH T?^$>_Z?\
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M OQ.U#X>P?#:/1;FXM(=7F\/ZWKU_J4T$AB:V9X[DP6M@6,R/&-DMQM=0T)
M_2GPC^S=X-\ _&OQ3\0]&T9M/\6^.(;:WUZ[AO+@1:FMNNV!I(-_D^8BDJ)
M@?#,-V"<R_'K]GKPC^T[\.9?"?CC1SK>@374%X]K]JGMLRPR+)$V^%T?Y74'
M&[!QR"*M ?FM^T5^TQXS\6_"K]J/XU>'?B+XF75?A%XRT;3_  -!H^O3KH)T
MX369R]G#(+:]2Z6Z=F>9)"P*;6"@"O>-1\0_$+PW_P %G/ &G:M\0?$=_P"&
M/&'A#5-4A\+K_H6EZ0D818XFA0_Z1,K^8S3RY8E@%"*H6O?_ !G^P#\)_'WQ
M4N_&.J>$WGUG5+RSU#48X]4O8=.U6YM#FVFN[%)EM;F2,_=::)R,#G@4WQ7^
MP5\.?&?QSMOB1J%IXQD\9V186NHQ>-=;@^R(Q#/#%%'=K%'"Q W0H@C;G*G)
MIC1XW^WE?:GXE_X*%?LI>!/^$C\7Z1X5\9'Q<=;LM"\17VBG4OLNF0SV_F2V
M<L4A\N3YA\W=AT)!\2G_ &_?&_['GC/XL?#FUU/4/'UMHGQ,\/\ @[PAJVNP
MWFN7&E)J]K/>313B ?;-1^R^1(BH':=RZKO("U]T?'+]D?P3^T5XJ\+:[XHT
MW67USP4;LZ'J6EZ]J&C7FF_:D2.XV36<\+_O$15.2>,CH3G&'[!7PKC^#,W@
M%?!L8\.76K?V_/B\NOM\VI^8)?M[7WF?:S=[E7_2#+YN%"[MHQ3+/E7XG_\
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M:[;36ME WRVTJ%)+AAZ@\A?YTIUH1CS-@ZD8J[.G_9C_ +=_X1B3[=_R"/\
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M@/5?$%]I=F8+WQ3J']JZK.\\DTEW<>3% &)=F("Q0Q(J+A55  !6[0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'I%%%% !17#?M"_M)>#/V5O
MA\/%/CK5I-'T1KR#3TFBL+F^DEN)FV11I%;QR2LS-P-JFN2TW_@H1\';_P"&
M7C+Q=/XTMM&T;X>S?9O$BZW8W6D7VC2E0R1S6=U%'<J\F0(U\O,K?*@9N* /
M9J3=7AWB7_@H[\(_!7A"XUG6]:\1:'%;:G9Z0]EJ7@_6;/56N;SS/LJK826J
MW;K,8I0DBQ%&:*10Q9& J7/_  4S^"FG^!]6\0WOBZZTO3O#VNV_AO6%U#P_
MJ=E=Z+?7 #0)=VTMNL]M&^<":9%B)R-^1B@#WS</6C>/45P_A+]H+PAX\^+W
MBCP)H^KC4/%'@F.VEUVTAMIBFF_:5+P*\VSRO,95+>6'+@#)4"N8\<?MM?#[
MP#\6;_P)<W'BO4O%FE6L%[?:?H7@[6-;:RAGW>4\KV=K*B!MK8W,.AIV ]?W
MCU'YTGFK_>'YUXO\0_V^/A-\+OB;<>$M;\5_9=6T^YLK/49(]+O+C3](GO&V
MVT5Y>QPM:VCR=56>5#@J<88$ZG_#8'PUG_:43X10^+=.NOB,;-[^31;99)Y+
M:)5W'SG13'"^TAA'(RN596"D,"789ZIYR_WE_.D^T)_?7\Z\J^.7[67@;]G7
MQ5X6T+Q1?ZNFN>-3=C0]-TO0-0UF\U+[*B27&R&S@F?]VCJQR!QD] <;7P:^
M-7A;]H?X;:7XO\&:S;:]X=UA"]K>0JRAMK%65D<!T=6!5D=0RD$$ C%/E'8[
MO[3&/XT_[ZI/M4?_ #T3_OH5E2??_&N,\;_%L^"_BAX,\,CPOXNUC_A,'O$_
MM73=/$VF:']GA$NZ^F+#R!)G;'PV]P5%/D#E/2/M<7_/2/\ [Z%)]LB_YZQ_
M]]"L3M3#]T4_9CY3>^W0_P#/:+_OL4G]H0#_ );1?]]BN=KC?&7Q6/A+XI^#
M_"__  C7BS5/^$N%Z3J]AI_G:5HGV:)9/].FW#R?-W;(OE;>X(XQFJ]D@Y3U
M3^T;?_GO#_WV*3^T[?\ Y[P_]]BN4;J*8?O"CV*'R'7?VI;#_EX@_P"_@I/[
M7M?^?FW_ ._@KC9*\J^.G[9/PV_9K\9^&- \;>)DT/5?&$IATF%[*YF6X;S(
MXOF>*-DB7?*@W2,HYZX!Q7L%W'R'T-_;%H/^7JW_ ._H_P ::^MV?_/W;?\
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M2WN(HO-6*9BX96D 8)M5@2ISMX)/J<>X_8*^Y]7OXTT8#_D*Z;_X%)_C3?\
MA-]$'_,5TS_P+3_&O +C[E5'ZU:P,>X_JR[GT2?'.AC_ )BNF?\ @6G^--/C
MO0Q_S%]+_P# R/\ QKYTE_I5>7I1]0CW*^JKN?2?_"?:"/\ F+Z5_P"!D?\
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M-.^'NKFSN=5N6C59I)XK4I,9 J[K@,Z +\T@"U]^FW)(Z4UK5BW:G<9\._\
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MPM<Z9>7U^\@\L+:3)')J%Q$HE:5XPS/&[QK*S2A3^H[?!S4S_P M['_OM_\
MXFHV^"NJY'[^P_[[?_XFM/;T^X_:1[GY5ZM\+_B#JOP3\-:9'X'BLO WA_XA
M@ZC#;>"-16T\0V"6L,<.H7'ATR+<&/SD#RP1[5:0F78QW,=KQQ\.'^&/P-^#
MNBV&MWVI27_QRT_4-%MYO"][X;718G:622V@LKMFF2VCS,022NV7'/?]-V^"
M.JG_ );Z?_WV_P#\37*>+_V*[3QYXZ\,^)-5MM.O-9\&O<2Z/,UW<!+-YXQ'
M(_E@"-V*# +JQ7DK@DT>WI]Q^TC?<Q[C[E5'ZUZ%-\!-89?^/C3?^_C_ /Q%
M0-^SYK1/_'SIG_?Q_P#XBM%B*?<KVL.YP$O]*KR]*]$?]GG6F_Y>=,_[^2?_
M !%1/^SEKC#_ (^=+_[^2?\ Q%-8BEW+]M#N></UJO+_ $KTIOV;-=)_X^M*
M_P"_DG_Q%1/^S)KS?\O6D_\ ?V3_ .(JUB:7\P>VAW/,I>E4Y8VEF55!9F.
M ,DFO5'_ &7O$##_ (^](_[^R?\ QNNN^$_P"3P3>_VAJ;07FH(?W CRT< _
MO#(!+?AQ2GC*48W3N#Q$$KH7]G[X8WO@+1I;F_FE2>_ 8VF[Y(0.A(_O_P N
ME>B4;3Z4NTCL:\2I4<Y<TCSIR<GS,2BEVGT-&TGL:@D:>E,J0J<=*9L/H?RH
M 2BEV'T/Y4;#Z'\J &O]VF5(R';T/Y4S81V/Y4 )12[&]#^5&PGL?RH BHI?
M+;^Z?RH\MO[I_*@!*8_WJD\MO[I_*FM$Q;[K?E0 RBE\IO[I_*E\IA_"WY4
M1/\ >I*>T3;ONM^5)Y3?W6_*@!M1U-Y3?W6_*H_)<?PM^5 #:8_6I?)?^XWY
M4UX7)^XWY4 1TV2I/(?^XWY4V2!_[C?E0!'2/]VI/L\G]Q_^^:1H'*_<?\J
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M#Y4J!)6A6XERV\8"<>K]DBN1'W__ ,)): _Z[_QQO\*#XELQ_P M_P#QQO\
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M+0+.QBN$LH+R6 W4HDDMK>--RI&H4[G;@*3FG]7B'LD??I\=:8/^7K_R&_\
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M09/_ (FD_P"%HZ*O_+^?^_,G_P 37D\G0U%)5?5(>8_8Q/6_^%K:'_S_ /\
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M49_:"\+C_F,'_P !IO\ XBOG>;I59_NU7]GT^[_KY!]5@?1[?M$>%EZZR?\
MP&F_^(KI= \4VWBC2X[VPNA<VTOW77/Y$'D'V-?(<_0UT/PO^*=Y\,]7\Q-T
MUC,0+BWSPP_O+Z,/_K&LZF7KEO!ZBEA5RWCN?4GVN3^^WYT?:Y/[[?G6;X=\
M1V?BO1X;ZQF6:WF&01U![@CL1Z5>KRFFG9G#MHR3[7)_?;\Z:U[+N^^U-IC_
M 'J '_;)?^>C?G2_;9?[[5%10 YK^8'_ %C4GV^;_GHWYU&_WJ2@"7[?-_ST
M;\Z9_:$W_/5_SIM1T 3?VC/_ ,]6_.FOJ4X/^M?\ZCIC]: )O[2G_P">K_G3
M7U.X'_+5_P ZBILE $O]J7'_ #V?\Z&U6X _US_G4%(_W: )?[6N?^>TGYT?
MVO<_\]G_ #JO10!*=8NL_P"OD_.FOK-T/^6\GYU >M-DH G_ +9NO^>\GYT'
M6KK'^OD_.JU(>E $_P#;=W_S\2?G3#KMYG_CXE_.H*C/6@"TVNWFW_CYE_[Z
MIG]O7G_/S+_WU5=_NTR@"XNOWI=?])EZCO5C7];N[;6)T2>145L  ].*RU_U
MB_[PJUXF_P"0[<_[W]!0 W_A(;W_ )^9?^^J/^$AO?\ GYE_[ZKR#]IGXCZS
M\/M:^%L6D7GV2/Q'XWM-'U$>2DGVBU>UNY&C^93MRT2'<N&^7K@G/'?&;]N6
M?X1?M):/X(3PY8ZYIE_J6E:7?7]C=ZC+<Z/+J$PAA^T*FG-8PG<RL$EOHY6C
M8,J'<@8 ^D/^$AO?^?F7_OJC_A(;W_GYE_[ZKY\T7]MC^U_"GA/4_P#A&?+_
M .$H\2^)/#OE?VCG[-_9']J_OL^5\WG?V9]W V>?]Y]GS<KX=_X*&:V/!*ZK
MXC^'=MH]UKOAG3/$?ABRL_$0OCJ/V^[ALX;>Z<VT:VK">ZM<LGGKLE=NJ;&
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M_DHWAC_P*%(?VROA&W_-1O#/_@2*?U:M_(_N8_[9R_\ Y_P_\"7^9\M^!_\
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MJ=WV?W,K^TL)_P _(_>BK)T-125=.O>!G_YGS1OR_P#LJ:=6\#/_ ,S[H_\
MWS_]E5<WD_N8_P"T<+_S\7WHSJ8_6M/[;X(/_,^Z/_WQ_P#94C77@EO^9\T?
M_OC_ .RHYUV?W,?]HX6W\1?>8S]*B?[U;9/@IA_R/ND?]\?_ &5(;?P8Q_Y'
MW2?^_?\ ]G5*HO/[F-9AA?\ GXOO.>DJ%^]=*=-\&L?^1]TC_OW_ /9TTZ+X
M.;_F?=)_[]?_ &=4JT?/[F5_:&%_Y^+[SE9>E5G[UV#>'?![C_D?=*_[]?\
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M3 ?^8C8_]]'_  H HT5>_LB#_H(V7_?1_P *7^QX?^@C8_\ ?9_PH H45?\
M[&A_Z"-E_P!]'_"C^QH?^@A9?]]'_"@"A15_^QH?^@C9?]]'_"C^QX?^@A9?
M]]'_  H H45H?V)%_P!!"R_[Z/\ A1_8D7_00LO^^C_A0!GT5H?V)%_T$++_
M +Z/^%']AQ'_ )B%G_WT?\* ,^BM'^PH_P#G_LO^^C_A2?V''_S_ -G_ -]'
M_"@#/HK0_L./_G_L_P#OH_X44 ?GS_P4X_Y3/_L]_P#<N?\ I]N:^8_^"R/_
M "DH^(__ '#/_37:5].?\%./^4S_ .SW_P!RY_Z?;FOF/_@LC_RDH^(__<,_
M]-=I7ZID/\3#_P#7E_\ I<3^5N/O]WS#_L+A_P"FIGB/P7^#_B/X^?$33?"7
MA+3CJWB#5C(+2T$\</F^7&\K_/(RH,(C'EAT]:Z/QA^R]X\^''QOLOAQK?A^
M:P\9ZE<VUI:Z>]Q"WGR7#*L(64.8B&9@-V_:#G)&#CU'_@C9_P I&_AS_P!Q
M/_TUW=?5?BY(OVM_B+\-/B+;QH?%OP<^*]EX.\1A2 \VG'5T%E<$9+$ E4SW
M9Y3C X]#'YK5P^+]E9<G*G?KS/FM\M+>K/G\@X5PV/RE8OFE[;VCC;2SA%4W
M*VE^9*;EO:T7H?!5S^S1X[TWXT7'PZ/AK4+CQI:3+;S:7:;;J1&(5N6B+)M"
ML"6W;0.21@UZ5XR_X)B?';X<^%9]9U7X>Z@MA:1F69K6]M+R1$ Y)CAE>3CO
M\O'/I7W)X"N7\'_M+_MM^,-,AC_X2CPQHEO+I-P8P\D+?V?<RD*.I!D@A) Z
M[17R]_P1S^*GBN;]O'2K3^T]5O[/Q1!?'7?.FDG%P%M9)5EE))^;S4C&]N?F
MQGYJXO[6Q4Z4ZU-12IQC)WOJW%2=M=/+<]S_ %2RNABJ.$KRJ-UZDX1:<4HJ
M-1TTY)Q?,VU=V<;(^<_A%\'/$_QV\:1>'_".BWFNZO-&THM[=1\B+C<[L2%1
M1D#<Q R0,Y(KT?XE?\$_OB_\%K?2Y?$G@NZL(=8OHM.M94O;6XC:XE.V-&:*
M1@FX\ N0/>OL3X16$/P9_9J_; \1^$8UTW6K+Q=J^E6MU:_+):VD3@1^65QL
MV":5@5Q@@'^$5\/?LZ^/=<G^,'A#2WUG5GTR_P#%-A=W-HUW(8+B;[2A\UTS
MM9^3\Q&>>M:TL?7KRG*E91A;=-MZ7[JV_9G#BL@P.!IT*6)<Y5:UVG%I1BN=
MQ6CBW*]FWJK>9UVA_P#!._XQ:Y\2-8\)6O@\R>(- MX+J_M?[5LE\B.;)B;>
M9@C9VGA6)&.<5L>*?^"97QO\ ^%M3UW5O!/V32M&M);Z\G_MBPD\F&)"[MM6
M<L<*I. "3C@&NI_X+(_\GRZK_P!@NQ_]%5ZE_P %C_#%YXW^/7PGT73H_.U#
M5])2RM8\X\R62X"(,]LLPKDAF.*FZ#O%*HFWH]+)-_:_X;S/8K</991CCDHU
M)2P\U%>_'WN:4HK3V;M:ROK[W3E/F'2_V0?B-JOP.?XD6_AJ:7P9'&\S:@+J
M#.Q)#&[>5O\ -P&!!.S& 3TYKSZW_I7ZYZ#I.JZ-\<K3X*-X9UZ?X41> !H$
MNIG2KC[)+>%,N3<[?*^:'CK_ *PXSGBORH^(G@.\^%OQ%UWPW?\ _'YH-]-8
M3-M*AVC<IN /8XR/8BKRS,Y8J4HS2756_E>U_/N8\3<-4\LITJE%R>\9WZ3C
M:]M%[KOIOL]3-A^[5F.JT/W:LQUZC/F(%J+M5E.M5HNU64ZUDSH@6;7I5J#H
M:JVO2K4'0UBSJ@3P]:LIVJM#UJRG:HD=4"U%]^ITZU!%]^ITZUFSHIEFWZ58
M3I5>WZ583I63W.B)83I4\7]*@3I4\7]*S9U(M1?UJ9/O5#%_6ID^]6)O$GCZ
MBK476JL?45:BZTI'1$L1U+!U-11U+!U-8LZ(%A/NU/#T%0)]VIX>@I/8WB64
M^[4L7:HD^[4L7:LI&\2=/NU/%_JQ4"?=J>+_ %8J#>)/%TJ5.E11=*E3I69M
M$GBZ5*G2HHNE2ITJ7N;HE3[M6!TJNGW:L#I42-8DR?>JPGWJKI]ZK"?>K.1M
M$D3[U2)UJ-/O5(G6I-XDPZ5+'U%1#I4L?45F;+8L1=JE3[U11=JE3[U2S1$B
M?>J1.M1I]ZI$ZU)JB>GCI3*>.E0]S5;CTZ5-%VJ%.E31=JDU1)4J?>J*I4^]
M2-42QU(G2HXZD3I4E(E3[M*.M(GW:4=:@U1-'4HZ5%'4HZ5/4LD'2G)]ZFCI
M3D^]4%DB?>J1.M1I]ZI$ZT%H?4E1U)29HAT=2CI44=2CI4O<M#DZT^F)UI](
MH>GW:?'3$^[3XZ2+0]/O4^F)]ZGU/08Y.E.IJ=*=2-!XZ4Y/O4T=*<GWJ"D/
MIT=-IT=!0]/O5(GWJC3[U2)]ZH8Q]*GWJ2E3[U(L?1110 J=:?3$ZT^@:%3K
M3Z8G6GT%(*='3:='692W'4J=:2E3K38#Z***13'CI2T@Z4M PHHHJD!)1114
M@%.CIM.CH =1110 4444 ?!/_!3C_E,_^SW_ -RY_P"GVYKYC_X+(_\ *2CX
MC_\ <,_]-=I7[*?$3]DOX=_%CXMZ%X[\0^&;74_%GAK[/_9FHO/,KVGD3-/%
MA5<(=LKLW(/7G(XJ/Q_^QO\ "KXJ^+KO7_$GP^\)ZWK5_L^TWUYIT<L\^Q%C
M7<Q&3A%51[**^QR_B2AAI4I.+?+!Q>V[DG^A^-\1>&^-S*GBJ<*L(^UKQJK?
M90E&STWN_-'X4?L9_M&?\,F?M&>'/B!_8_\ ;_\ 8!N?] ^U_9?/\ZUFM_\
M6;'VX\W=]TYVXXSFO1?V6/\ @H-J7[,_[2?BKQU#H$>L:5XQN)[B_P!"DOC$
MA9K@W$+"7RV^>)_NMLZ%N!NX_7M?^"?7P/4<?"GP+_X*(?\ "E'_  3^^"(_
MYI7X&_\ !3%_A7?7XJR^LY.I1D^96>O1.ZZ]WON>'@/"OB#!1IQPV,A%4Y.<
M='I)I1;UCK=)*SNO+5GY2^$/^"GWB3P-^UYXQ^*.DZ%8KI_CG;'JGAV[N&GM
MYH5555?,"K\ZA3A]F!O8;2"172:#_P %,/"WP?L]=O?A+\$O#WP\\6Z_"T$N
MM/K$NIFU5B"P@A>-5B&0"$4[,JN48+BOTX'[ ?P3'_-+/ __ (*8O\*</V"/
M@JO_ #2[P1_X*8O\*Y9Y_EDMZ$MDM]&EM=7L[>=STZ/ /$]-/EQL+MRE?D3:
M<OB<6XWA?^ZT?D3^R+^W7XB_9;USQ"L]C;>,?#GB^-EUS1]4D+1Z@Q# R;R&
MPY#,&)#!PQ# X4C?\2?MA?#R&#3AX(^!OA_P=-;ZW:ZQ<WDFL3:G>/Y$JR^3
M!+)&#;JY4 A05QGY>:_5<_L'?!=?^:7^"?\ P51?X4+^PM\&5Z?"_P %?^"N
M+_"JGQ'@)5'5]E*[WL[)V[I.S^:,Z/AQG]+#K"K%TW&-[7@I-7U?+)Q<HWZV
M:/R!_;$_::/[7'QTN_&9T7_A'_M5K!;"S^U_:MGEIMSYFQ,YZ_=&/>O8?'?_
M  4S@^(_[4'@#XB7O@%/*\!V3V\6E_VQN^URD/ME,I@^7:S*P78>4'S5^CO_
M  PY\&P?^28^"_\ P5Q?X4G_  Q-\'$/_),?!G_@LB_^)J7G^ <(P=&5HII:
M[)JSZ]CHI^'O$$*M2LL7#FJ2C.7N[RB^9.W+;1N]EIW1^6DG_!0GXF7'QT/B
M_P#X2SQ4NG_VT-4&@C6[@6(A$WF"TV9V>7M^3[G(YQ6!^U;\?++]IOXW:CXS
MM/#O_",OJL4(NK47QNQ)*B!/,W;$QE53@+U!.<DU^M)_8P^#R_\ -,O!O_@M
MB_\ B:;_ ,,<?"!/^:9>#O\ P6Q?_$TX<08*$U4A1::5M+;?>*MX<Y[6HRH5
M\7&492YG>[][75-JZW>UD?BQ#]VK,=?L]_PQ_P#")1_R3/P?_P""Z+_XFFG]
MDGX1K_S3/PA_X+X__B:Z/]::+_Y=O\#B7A)CU_R_A^/^1^-L7:K*=:_8C_AE
M+X2K_P TT\(?^ $?_P 32-^RU\)X_P#FFGA'_P  (_\ XFI_UFI/_EV_P-8^
M$^/7_+Z'X_Y'Y VO2K4'0U^N9_9D^%,?3X:>$O\ P!C_ /B:8?V</A4G_--/
M"?\ X!1__$U'^L=-_P#+M_@;1\*L<O\ E]'\3\EH>M64[5^KW_#//PK7_FFG
MA3_P#C_^)I&^ /PM7_FFOA3_ , X_P#XFE_K!!_\NW^!O'PNQR_Y>Q_$_*R+
M[]3IUK]23\#/A>N/^+:^%O\ P$C_ /B*;_PI3X8#_FFOA;_P%C_^(I?V['_G
MV_P-8^&..7_+V/XGY@V_2K"=*_3,_!_X91KQ\-?"_P#X#1__ !%1R?"WX:1'
M'_"M/"__ (#Q_P#Q%1_;2_Y]O\#5>&>.7_+V/XGYL)TJ>+^E?HX?AS\-5_YI
MIX8_[\)_\137\ _#:,<?#3PS_P!^4_\ B*7]K_\ 3M_>O\S9>&^-_P"?D?Q/
MSOB_K4R?>K]!V\'?#A/^::>&?^_*?_$4QO#'PY7G_A6GAK_OTG_Q%3_:;?\
MR[?WK_,U7AUC5_R\C^)\!1]15J+K7W@^A?#N-O\ DF?AO_OVG_QNF-8?#U#_
M ,DS\.?]\)_\;H>9-_\ +M_>O\S5>'F-7_+R/XGPU'4L'4U]NR1?#V,?\DS\
M._\ ?*?_ !NHWE^'\9_Y)EX=_)/_ (W4?7I/_EV_O7^9K'P_QO\ /'\3XN3[
MM3P]!7V,VI> (_\ FF7A[_QS_P"-TPZ]X"3_ )ICX>_\<_\ C5/ZY-_\NW]Z
M_P S5< XW^>)\BI]VI8NU?6+^*_ :#_DF/A__OI/_C51OXU\"1#_ ))AX?\
M^^D_^-5+Q%1_\NW]Z_S-5P)C%]M'RRGW:GB_U8KZ;;XA>!4_YI?H'_?:?_&J
MB;XG>!XQ_P DOT'_ +^)_P#&J7MJO_/M_>O\S5<"XW^9'SA%TJ5.E?0S?%KP
M0@_Y)=H/'_35?_C51M\9O!2#_DENA?\ ?Y/_ (U2YZW_ #[?WK_,M<#XS^9'
M@D72I4Z5[@_QV\%Q#_DEFA?]_P!/_C-1R?M ^"X_^:5Z'_X$+_\ &:+UG_R[
M?WK_ #-5P3C/YD>,)]VK Z5ZT_[1W@U!_P DJT/_ ,"5_P#C-0R?M.^#X_\
MFE.A_P#@4O\ \9I6KO\ Y=O[U_F:+@K&KJCS%/O583[U>@R?M4>$(_\ FE&B
M?^!:_P#QFH7_ &N/",?_ #2?1?\ P,7_ .,4G2Q#_P"7?XK_ #-%P9C>Z.(3
M[U2)UKKW_;%\(QKG_A4VB_\ @:O_ ,8JL_[:_A./_FDFB_\ @>O_ ,8H]AB?
M^??XK_,U7!V-[HY\=*ECZBM9_P!N/PH@_P"21Z-_X,%_^,5#)^WEX5B_YI%H
MW_@P7_Y'I?5<5_S[_&/^9HN$,;Y%>+M4J?>I&_;^\+HI_P"+0Z/Q_P!1%?\
MY'JO)_P4/\,1'_DC^C_^#-?_ )'H^IXM_P#+O\8_YFBX1QOD74^]4B=:R7_X
M*.>&(_\ FCVC_P#@T7_Y'J&3_@I5X9C/_)'-(_\ !JO_ ,C4?4,9_P ^_P 8
M_P"9:X1QOE]YT=/'2N2D_P""G7AN/_FC>D?^#8?_ "-5>7_@J3X<A!_XLSI'
M'_47'_R-2_LW&O\ Y=_C'_,T7">-\OO1W"=*FB[5YT?^"K'AU?\ FC&D?^#@
M?_(U03?\%:/#T/\ S1;2?_!R/_D6G_9>._Y]?C'_ #-%PGCNR^]'J%2I]ZO)
M)/\ @KMX>C4G_A2FD\?]1H?_ "+4$G_!8CP_'_S1+2?_  =C_P"1:/[)QW_/
MK\8_YEKA3'=E]Z/9XZD3I7ALG_!9?08_^:(Z5_X/!_\ (M0/_P %I="C_P":
M'Z5_X/A_\BT?V-C_ /GU^,?\RUPKCNR^]?YGOR?=I1UKYXE_X+<:'#_S0W2C
M_P!Q\?\ R)56?_@N7H</_-"]*/\ W, _^1*/[#S'_GU^,?\ ,M<*X[LOO7^9
M]+QU*.E?+,W_  7@T2'_ )H1I?\ X40_^1*J3?\ !??1H0?^+"Z6<?\ 4QC_
M .0Z:X?S)O\ A?\ DT?\RUPIC_Y?Q7^9]:CI3D^]7Q[/_P '!VCP$_\ %@M+
M./\ J91_\AU5D_X.(='B'_)O^E_^%,/_ )"IKAO-'M2_\FC_ )FG^J>8?R_B
MO\S[03[U2)UKX@D_X.-](C/_ ";YI?\ X5 _^0J;_P 1'FD_]&^:9_X5(_\
MD*J_U8S7_GS_ .31_P#DBEPGF'\OXK_,^Y*DKX7_ .(CS2O^C?=+_P#"H_\
MN*C_ (B/M+_Z-^TS_P *G_[BI?ZL9K_SY_\ )H__ "1?^JN8?R_BO\S[JCJ4
M=*^$1_P<?Z8/^;?M+_\ "H_^XJ/^(D+3?^C?],_\*C_[BI?ZKYK_ ,^?_)H_
M_)%+A;,/Y?Q7^9]X)UI]?!G_ !$A::/^: :9_P"%1_\ <5+_ ,1(FG#_ )H!
MIG_A4?\ W%1_JOFO_/G_ ,FC_P#)#_U7S#^3\5_F?>J?=I\=>!_L%_\ !8KP
M%^V9X\F\*:KX,TSP%XDF^;2[:>]%Y#JH RR)+Y<6)1UV%?F'()(('V-ML ?^
M01IG_?G_ .O7BXS"U\)4]CB(N,OZ[:'#B,MK4)^SJJS/.$^]3Z]#(L5'_((T
MS_OS_P#7I/,LO^@3IG_?G_Z]<?M-#'ZL^YY^G2G5WZR66X#^R=,Y./\ 4_\
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M=IT==!_:\/\ T#=._P"_7_UZ/[6A'_,.T_\ []G_ !J2DC!I4ZUN_P!KQ?\
M0.T__OV?\:/[9B'_ ##M/_[]G_&FQ6,6BMO^VH_^@=I__?L_XT?VU'_T#M/_
M ._9_P :0WJ8XZ4M:_\ ;<?_ $#[#_OV?\:/[;C_ .@?8?\ ?L_XT#,BBM?^
MVX_^@?8?]^S_ (T?VW'_ - ^P_[]G_&FF!F45J?VZG_/A8?]^S_C1_;J?\^%
MA_W[/^-(#+IT=:7]NI_SX6'_ '[/^-+_ &\H_P"7"P_[]G_&@#.HK0_MY?\
MGPL?^_9_QH_MY?\ GPL?^_9_QH SZ*T?[?7_ )\+#_OV?\:* .WHHHH \K_;
M _:WT#]BWX2P^+_$>F:_K%I<ZK::-;V>C10274]Q<R>7$!YTL48&>I9QBL?X
M0_M[>"/B4_Q%MM;34OAIJ_PFN+>'Q;I_C"2TLVT9+B+S;:X>>*>6U,,J;BKK
M,?NG.,KGA_\ @KK^S?XT_:E_9?TGPUX$L)K_ %J#Q?I&IR>3<VUO);6\$^Z6
M=3<$1DH/F"D-G'W6Z5YY^U#_ ,$P[W1?#-EXI\%OX@^*/CB;XH>'_'GC+_A(
M-0LHM0\:66FK)"FGKB.WL46))=T<;)''^[P3G;@ ^IH_VL_A7-\+Y/&Z?$SX
M?MX+BN?L3Z^/$5F=+2?('E&Y\SR@^2/EW9Y'%<+XP_X*6?"#P1^TAX,^&5YX
MLT@ZMXZTK^U]-U%-4LO[,$;[#;H\IG#>9<AU, 5&$H/RFOESQI^PAXZ^*7Q!
M^)GQ-U?P%X]\/2^+OB!H?BGPSH7AGQ%HT7B'PK<:5ILULFJ.DTS:7<-<3,/,
M@,Y/ER,=[,-M=)\*_P!F[XX>"OC5^R]\1?&'@RRU_6/#?A'5="\:VWAB73++
M^Q[J]E21)VB:6W@<#<?.^R[AYB2F-7!3< ?7$7[6'PLN[;Q--%\2O $L7@EM
MGB)T\0VA70&WM'B[/F8MSO5E_>;?F4CJ*M^(?VA_ 'A&YOX=6\<^#],FTNPA
MU2]CN]9MH6M+25Q'%<R!G!2)W(57;"LQ !)-?G3JG_!.7XQ:E\#OBS\-/"_A
M35O#W@"_\"7D6@:1XNU71M1NK3Q!<:LE_<6FEZA:DW!TR18CC[=Y3F3RG=5)
M?9#^TK^Q1\=?VD8_C)JD'PKO="D\5_"?0_">CV-YX@TJ2YN;ZTU*&:=',=RT
M4?RI(ZGS"K($)99&:) #] M:_;'^$7ASPS;:UJ'Q4^'%CHUY=2V-O?W'B6RB
MMI[B$CS84D:0*TB9&Y0<KD9 KG?A_P#M@Z5\2OCAKFA:9<>"[[P9I?AR'Q#;
M^*+#QG87IO$:1DDS9QL9(H$VD_:&/EL00.0<?&'[>?AG6=(_:7T/P?X9L?)&
MD_L]:EIFOV.GZ-8ZFVCZ///';2RQ075_86\6T1,$>*:9CY>UH&CY.'XD_8H\
M3?MA^"?'VN_":WO8/A[X_P#@GX?\/>#M4UB\BAN;V6QN8)6LYT#^8DC10&-I
M"HB)<D,5.:LI'Z%0_M8?"V]^'%QXQA^)7@"7PC:W?V&?7$\0VC:;#<$*1"UP
M)/+$F'7Y2V?F''(KB?&_[;ND:/\ M#_ WP7H%OIOBS1_C;'K<MIXAT_5TDMK
M--.M$N=R!$=;@2%BF1(NW&?FZ5YA\;--^+_C*X\!:]X.^#=]\/A9:PR>(#I<
MGA>Z\806RZ:\,;6;W;R:>D.]A"293,8E "1J2#X]^QM^P;\7?A9X[_94O?$?
MA=[.W^&NK^/;KQ'(VJ6,W]G1:G%BR;$4@$GFL3Q"AVY^94%:E'WA\4OC[X%^
M"#Z>OC3QIX2\(-JYD%BNMZO;Z>;TIMW^5YKKOV[TSMSC>N>HK.^(7[3/PX^%
M-_<VGBCX@>"/#=U9F%;B'5==M;.2 S+(T(=9'4J76*0KG[PC<C.TU\M?\%+/
M@5\;?C3XH\=Z1X.\.WM[X6\3^!4TBTN-".@03:A>K-._V;5)]0Q<BV02,8EM
M2,-,QW*68CC?$/["/Q,U74OC%=-X3CGG\4? [3O!VDROJ%F7N-4CM56:V!,N
M4_>(N7;$9*@AC@&JB!]N^.?CWX&^&7B?3M$\2>-/"?A_6=8VBPL-2U>WM+J^
MW/L7RHY'#/E_E&T')XZUYOX(_;<T;7_C-\:O#/B"'3/"&C_!NXTN&YU[4=72
M.VO!>P-*&?>J+ %8!.7;<6'3I7QS^T=^R3^T=\1?V>=>\ VOA/4C#J/@_P )
MV5G'HUSX<@M+^]LK>!K[^UKBX/VUYHYH@D!MG$6$3+8+97]L;X,>-OAE^T'X
M^\1-IBV__"R?BUX(F\&G?;7C:S+96ER9%%L9XE.UU&4N9;93U$@(7.B+6Q]V
MVW[6GPKU/P=?>(;;XF?#^X\/Z;-';7>IQ>(K-[.UE?[D<DHDV(S=@2">U2ZY
M^T?\//#WA?1M<O\ QYX,L=%\0G;I6H7&MVT5KJ9]()6<+*?]PFO@SPE\%=:^
M*]OH&J^!&\:7'BCX6_%+7-3\>:9;6NCZ=J,&HW\8+26$5S/=:;MARH5'GD.&
M<A@Y!KIOB#^PWXE\(?"_0]2^''A3XMQ>.]./B"\TRXU75_#,KV-UJ.U9K>^L
M]W]GO83@NX%ON>,_P#C%K<I;GU=H?[1<$GQ3^)^C:ZGAOP_H7PXCT^9M7D\3
M6DKRQW-NTTCW5L"'L%0C"F<CS1EU^45UG@/XF>'/BQH!U7PMX@T3Q+I?F-#]
MLTJ^BO+?>N-R;XV9=PR,C.1D5\8ZU^S-\;/"'Q+^-_B31/"^ASWWBF[\"2Z;
M-:'3I?-73K41:A+IT-V?)BF@DYA-TJ# RN6"UZC_ ,$\_@KXX^%'B#XO:CXS
MT_6;+_A,?% U?3I-6NM.EOKN$P(IDF6P/V=)<C#!% R.-P^8Z(9V/PO_ &OM
M \1> SK'C+4O!/@>4ZA?VD$#^,+&_BGBM' DE$R,$!"E6>/DQ;@&P37I'A;Q
M=I7CSP[:ZOH>IZ?K.E7RE[:]L;E+BWN%SC*2(2K#((R#V-?"_P !OV'_ (D^
M$OB5\$[[6O"J16/A'QQXLUK56>_M)1:6]XD?V.7:)26+.N0$!9" 6"UZS^RI
M^S3XU\(?L1^/O 6M0)X<U[7[SQ!'IA:ZCD2VCO#)Y$NZ!FVC+[L#YAZ U11U
MJ_MO^%_$G[2?A+X?>%[O0?%D'B6SU"XN=5TO6XKE-+EM%1O)>.,,"S!^[J1Z
M&NV\+_'3P3\1-:OM/\/^,?"NNW^EJSWMMI^K074UFJG:3(B.2@#<'<!SQ7QO
MH?['WQ.\;2_#.R?P(/ 3^%?A;JO@6^UF75+&1A?2V)@AG46TKR&$RNTBG[X9
MY<HO#R8OQP^"GC#3O@-X9U+7/"!^'6F_!_X7ZUH.IW4^I6KC7;F[L$M$2#[$
M\K^6LJF;,RKEI,;>6:M#0^Q-*_:L^%WB-+QM/^)/@&_&GV[7ET;?Q!:2BV@4
MJ&E?;(=J LH+' &X<\UTWAGQCI/C[PY;ZOH6J:=K6E7@8V][87*7-O.%8J=L
MB$JV&4@X/4$=J^#O /PWMOBK;>*_!'B[1?%^H^.-?\$>'[A=+TQ-/T(MHUG<
M(D5Q;2I>W4+7228DVW+PAMJ (BYQ]+? 'PI\1M(_9R\4P>*K'3+OQ9J%WJDN
MF6^J06B27L+;EM/[2%G_ *.TKA5\PQ,P*$98L#C0#M=-_:!\!^((M7>P\;>$
M;U?#\;3:JUOK%O(--C4D,\^USY2@@Y+X P?2G>'_ (R^$/&-WJ5MI'BKPWJM
MQI">;?Q6>IPSO9)_>E"L2@X/+8Z5\83_ ++WQF\<7>K7^L:#K[WEW\(;KPDX
MU&ZT*W3^TW:-Q;6L=@RHMINSY;2_,,'=M 7.G\0_V*_B'XDTW0K#2=*@TI4^
M"R^$+V87D"1IJ(>.1K5@CEB&96RZ@I\QRW-:1+/?_"/[7.@?$K]I-? GAN?1
M_$&GGPR_B$ZYINK1W<*NEVMN;;;&"N[#ARV_(R!MYS79:]\4/#7AWQ?9>']0
M\1:%8Z]J:A[/3;B_BBN[M22 8XF8.X)5AP#RI]*\+^ 'PC\76_[6>E^,M4\!
MGP;HUG\.8O"\OF7UE-++>17-N_*V\C_)L5E1LGY8AD(2%K4\-_"_Q-\//VFO
MB-J$_A%?%FC>/[[1]0L]4:[ME@TT6HVE+A)6\X-"R"2+RHY 2R\QG)6T4>EW
M/QV\$#5]4T__ (3+PK_:&AQ2SZE;?VM;^=I\<9Q(\R;\QJA(W%@ ,\UQWPP_
M;-^'?Q7^$]MXRC\1Z5H6ERR^1-'K&H6UK/8REG"QS#S65'<1LRJ6R5YKQSX/
M?!/XK3_M ?"S7?%>AWEC:^#XM8AU$1OH\&DV0N8G6%+"*TQ.8?ECSY^Y@6!
M'SDYWA#]G'QEX<_9=\"^&[OPAXKM_%WPXU.[GTW4M&U;2P1,[W+PW"1SRF*6
MW(=%D27RY!N 56&\C1%H^N(+R+4+2.>"6.>"=%DCDC8,DBD9# C@@CH:BDZ&
MN=^"6CZUX?\ @[X:L?$<.FV^NVFG017T=A&L=LDH0!@BH @]P@"YSM&,5T4G
M0UI$I%27I5:XZ59EZ56N.E:HHJ2]ZJS=/PJU+WJK-T_"KB:%27[IJK+TJU+]
MTU5EZ5JAHHW'2JMQTJU<=*JW'2M#0J3=/PJC<=:O3=/PJC<=:T195N:H7'2K
M]S5"XZ5J65+C[E9MQUK2N/N5FW'6M4:%2;I5*YJ[-TJE<UHMRD5)?N-6=<]3
M]:T9?N-6=<]3]:T194GZ&J%QUJ_/T-4+CK6J-"C<UGW?1JT+FL^[Z-6L30H2
M=#5"\J_)T-4+RMEN64;C_5M6?<UH7'^K:L^YJS0HW'2J$_4U?N.E4)^IK:)<
M3-N_O5EWO]*U+O[U9=[_ $K:)I'<RKSK6/>_<:MB\ZUCWOW&KI@;1,B^^\U9
M=S]VM2^^\U9=S]VNJ!NC)N/O5%4MQ]ZHJW1J%%%%4 4444 %%%% $VGZA/I-
M_#=6LTMM<VTBRPS1.4DB=3E65AR"" 01TQ7[*?\ !(__ (*CR?M36,7P]\;L
MY\?:9:F2VU!8_P!WK=O&/F9\#"3*/O= _4<Y%?DC\$O@EXE_:(^)>F>$O"6F
M3:KK6JR;(HDX6-1]Z21NB1J.68\ 5^Z__!/[_@G[X:_84^&OV2T\K5?%VJ1J
M=:UHQX:X8<^3%GE(5/0=6/S-S@#XCC6O@EAE2K*]3[-MUYOR\NOXKYSB*KAU
M1Y*FL^G=?\#\SZ ?[M,I[_=IE?DQ\,"_ZQ?]X5:\3?\ (=N?][^@JJO^L7_>
M%6O$W_(=N?\ >_H* /$?VT_VK'_9!^&VD^(U\-R^)X[[6$T^XMHKLV\EO!]G
MGN)IT C<RND=NY6( %R0 PJC\3OVT;3P7^T!\-?!&D:*/$5OX\:-[O58[[RH
MM&AN(;F2RDV>6WG?:/L5YM&Y,"W<Y/ /9_'#X(Q_&JX\&F:]2UA\)^(X=>DB
M>U$ZWZI!<0F @L H83YW8;[N-ISQY#\+_P#@F]:_##2M#MHO&.HWTF@^,5\0
MV]W<6F;E--@T^YT^PTI7\SY5MK>=0LO.YD=M@,AP =^?VX?AM:Z/XDOM1U36
M_#T'A&RBU+5%U[PSJFC2PVLDK1+.D=U;QO-%YBE6>)653C<1D9Q&_;:T;3_B
MZUCJ/VS3/#-WH.GWNFI>:!J-KK=W?W5_>6OV<64D8N3D6P8((-VT/(28QN'F
M/PR_X)2'P#HNNVK^*_#0EUCP_::!)>:9X/%A=7YM[R.Z-_?RFZD>\O92A$DI
M* DY"+R&]4^,W['+_$O]H&R^)VE>)?\ A'O%V@Z9:6&BW/\ 9_VA+4Q7%Q).
MDR^:GGV]Q%<-%)#E"-JNKK(B,@!K:[^VIX$TNZUNTM[O6;^]T>VO9HQ#H&HM
M::I):!OM%O9W2VYANYHRKAHK=Y)%\J7*?NI-N3X._;W\%ZY\%_"?B[4[;Q7I
MDWBG3!J2Z3!X6U>_OH$6.)YY1!%:&9[6-I47[5Y0A8NF&^=0>8^"_P#P3ITG
MX,_$74]0MH/AI<Z9>SZG-#??\()'%XNMQ?-,S(=8%SAPGGN@)MMQB"HQ."QQ
M->_X)J7GBGPW\/%UK6?AAXLUKX>Z$_AB!_$WPZ_M;2KRPQ!Y3FS>^#1W:>0,
MS1S!6$L@\H KM .S_:4_;V\+?";P\\'A[5+;6O$4O]ERV[1:;=WVDI%?7$:1
M>=>P+]FA>6(NT2R3(TF8RH8.H;H?CY^T_%\!OC+X#T;4(+B;1_%5EJLLRV&C
MWFJZD\UM]D,2006JR2N-LTK/B)\*F[*JK&N'\9?L%ZQK%SK5EH7C30_#'A;Q
M6-%N-:TJT\*YVW6F)!'']B?[4$M;5X[6V0P-'*RB-MDJELCT3XY? _Q+X^^)
M7@_Q;X3\5Z7X:UCPA;:A:I'J6AMJMI>I>?9PPD1+FW<!1!D;)%.XJ2=JLC@#
MM)_;+^&FO>$=2UZR\40W>DZ5;Z;=7%Q%:7#@QZCM^Q&,"/,OFEPH$88A\H0&
M4@5?VO/VGG_9>\"6.I67AV;Q=K&I7,J6^D078MII8+>UGO+N56*/GR[>VE(7
M'SR&*/(,BFO*-,_8 F\'_&_X+Q:=<7][X6\$Z(X\3:A<FW5==NK.X%QIBM&I
MWK(EW=7ER-J>6H!7<"5#>I_&;]D/2OC[\9='\3>(]8\0#3O#^CW&G:?IND:O
M?Z+)%/<2(T]PUS9W$4CAHXHX_+(V@!B=V0% -F^_:J\#V?CC1?#D>I:CJ.L^
M(-+AUNQM],T6^U#S+&5F6.Y9X(72.(LI&]RH!* D;USQ'Q,_X*%^#?!'PP\2
MZ]8:?XMU'4?#"V4MSHM[X6U?2K_RKJ=H8IO)GLQ-Y):.8"41E-T13<&XIW[/
MW[$TOP-M9+0^,M0O[.'PFO@W37@MC:WFFV,5W>2VNV8RR$R0P7,<*MM&?LX?
M W;1YU\+?^"6,GP[\ >.M*_X2GPC:7WB_P /:9H<5SH'@I=)ABDL))98[VZC
M^URO>7$DDF97:1"X4 %>M 'N=S^UMX,T[Q#H6FWW_"7Z7-XD>VAL)]1\':Q9
M6;2W!"PPR7,MJL,,SL0HBE=7W$*5#$"JW@_]M/X<^/?&4^@Z1K&IWFHPO?Q
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MI=?V9H,^G^=<F4E)4\R\GV1B+"F,[V+@OYB@^6.FH **** "BBB@#TBBBB@
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MH;?\N'_D:3_XJFGX3Z"1_P >'_D>3_XJNEHH]M4_F?WASR[G,-\(?#[==/\
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M;,/^19/_ (,+K_X[4#?L.?#1NOA<_P#@QN__ ([7L=%'UW$?\_)?>Q_6*O\
M,_O/&C^PK\,6_P"96/\ X,KO_P".U&W[!OPN?KX4/_@RO/\ X[7M-%/Z]B?^
M?DOO8?6*O\S^]GB;_L#?"PK_ ,BF?_!G>?\ QVH7_P""??PI;KX1/_@SO/\
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MP^NXC_GY+[V?*+_\$>O@#)U^'3?^#W4O_DBH)?\ @C9^SY)_S3=N?^H]J?\
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;WW_/M)^5=W10!PG_  C=]_S[2?E17=T4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pcrx-20211231_g3.jpg
<DESCRIPTION>ITEM 5 CHART
<TEXT>
begin 644 pcrx-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   2=%$2
M  0    !   2=        8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( <4#J ,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M_P#DN@#O:*X+_AG'P_\ ]!'QY_X7&M?_ "71_P ,X^'_ /H(^//_  N-:_\
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M^'_^@CX\_P#"XUK_ .2Z .]HK@O^&<?#_P#T$?'G_A<:U_\ )='_  SCX?\
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M_P#"XUK_ .2Z .]HK@O^&<?#_P#T$?'G_A<:U_\ )='_  SCX?\ ^@CX\_\
M"XUK_P"2Z .]HK@O^&<?#_\ T$?'G_A<:U_\ET?\,X^'_P#H(^//_"XUK_Y+
MH [VBN"_X9Q\/_\ 01\>?^%QK7_R71_PSCX?_P"@CX\_\+C6O_DN@#O:*X+_
M (9Q\/\ _01\>?\ A<:U_P#)='_#./A__H(^//\ PN-:_P#DN@#O:*X+_AG'
MP_\ ]!'QY_X7&M?_ "71_P ,X^'_ /H(^//_  N-:_\ DN@#O:*X+_AG'P__
M -!'QY_X7&M?_)='_#./A_\ Z"/CS_PN-:_^2Z .]HK@O^&<?#__ $$?'G_A
M<:U_\ET?\,X^'_\ H(^//_"XUK_Y+H [VBN"_P"&<?#_ /T$?'G_ (7&M?\
MR71_PSCX?_Z"/CS_ ,+C6O\ Y+H [VBN"_X9Q\/_ /01\>?^%QK7_P ET?\
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MX9Q\/_\ 01\>?^%QK7_R71_PSCX?_P"@CX\_\+C6O_DN@#O:*X+_ (9Q\/\
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M^;_]\UT8?"U:SM31<82EL?17COXD:'\,M'-]KNI6VG6_.WS&^>4CLBCYF/L
M:^7?C-_P4%U'6O-L?!UL=,MCE3?W"AKAQZHG*I]3D_0UY)H/A+QM^TIXNDEA
M34==O7($UW._[J >C.?E0>BC\!7TO\&/V!=#\(>5>^*94U_4!AA;*"MG$?<=
M9/QP/]FO66&PN%5Z[YI=OZ_4VY(0UEJSYQ^'7P1\:?M$:V]W;0W-TDTG^D:K
M?R-Y0/<F0Y+GV7)]J].\1?\ !./Q%'=1+I.L:)- L2^9+=RRQ.\G\6$6-@JC
M@#YB3@GC.!]?6EG%I]K'!!%'!#$H1(XU"JBCH !P!4E<]3.*SE[FB[$NO*^A
M\6_\.YO&_P#T%/"O_@3<?_&:6+_@G5XYAD5TU;PNCH0RLMU< J1W'[FOM&BI
M_M?$>7W"]O,R_!4.JVWA/3XM<>UEU>*!4NY+9F:*20#!9254\]>G&:U***\Q
MN[N8A1112 **** "BBB@ HHHH **** "BBB@ K@O$/\ R<]X0_[%?7/_ $KT
M>N]K@O$/_)SWA#_L5]<_]*]'H [VBBB@ HK\P_\ @H+^V7\8_P!G3_@J<^K^
M'/$.HWOPG^%G@G3O$GC'P?'$KQW^G7-[+;75XG&[SK==DH /*HWO7MO[/O[5
M?B#Q[_P4B^/-G8ZUJOC'P%H_@CPWKOAK1[!XI(I#=12NTEN3M!:4!>6?'TI4
MGSP4UL^?Y<E__2N5\O>S6Z85;PFX/IR_/FY?RYXW[77='V?17S5X#_;VU^T_
M:5T?X8_$WX97'P_U?Q9HU]K?AZXM==BUJ"_CL]K7$,ICCC\B94=6"_.&PP#<
M<M_8T_;_ -7_ &SH['Q+H?PZ\GX6ZW)=0Z=XDA\26UU=0O"[*%O;$*'M2P1O
ME\R1E)0,HW9#6NODW\DVM>VJ:U[";LKONE\VK_/1GTO17YE?\%&_^"AWBSXZ
M_P#!/+X@>)?!'P\\367PRO=1MM+TCQU9:]'!>3-%JEO$]U]C4++':.Z2()1*
M6(*DQ[7X^N/CE^TG\0O@OX/%[X6^$EWX[TK0M#74]4OYO$5OI89%AWLELK)(
MT\H56R&$8S@;CGB>9*FZLM%?_P!MYM>VG<OE;DH+5Z_@TM.^KZ=CWVBOEJ__
M ."GVF>-_#7PE7X7>$-2\?>+/C+H[^(=%T:XO$TA++3XE!GN+N=U<1!&81A0
MC%G( ]:ZW]C#]MM_VMO$WQ*T.]\#ZYX$UOX6ZS#H6JV>I7,,YEN'MUF+1-&2
M&BPPVO\ QJ0<+G U<)*4H-:QO?Y-1?K:3LVNNFYDIQ<5);.WXJZ]+K77H>\4
M5\>:KXH\7_MP?MQ?$WX;VGC'Q7\.OAY\&+?38+N7PU=)9ZIXAU6\@:X.ZX*L
MT=M#"T8V*!O=R2<(!75_$+XWWG[!?ASPAX$2^\6_&SQ[X^U::Q\'Z7J-U;P7
MT\4:B64W5YM"B&",DM.Z,YRHVDFLXN\4W]JUO.[TV[[KRU=MBY+EDUVW^Z_X
M;/S/IBBODS5?^"HI^&WA?XN6WQ ^'M[X4\??"+PU_P )==>'H=8BOX=8TPAM
MD]K=A$#?.K(P:-2C#N#FN>@_X*U>)+37OA?#J?P$\765E\<+8GP-)%K5I<7%
MW<_9UN!%?1# LX_++/YN^7"KG;D[0E)-V6NWX\R2]6XR5M[IK<&K+F>F_P""
M3?R2DG?:S3V/M2BOD'4_^"LEKX(_9W^./BSQ7\/=7T;Q7^S]/'#XF\,V^H1W
MGG"6-)H)+6ZV*DJR1OD952&5E([UT/@O_@H=JT?QH\"^&?B#\+=8^'6D_%:.
M<^#]5N]7@NVN98H?M'V6]@0 V=PT&7";I1E'7=D52U=O)/\ \"5UKMJMN^VX
MF[1YGY_@[/3RZO9;['T[17QM>_\ !6'4[OX9ZW\5M#^$6KZU\!_#UY+#=>+E
MUR"*^N+6"7R;B^M].*%I;='#D$RJS(C,%Z ])XN_X*3RZU^T5+\-_A=X(A^(
MNLZ=X?LO%&H>=XCM]&9[&[&Z%[-)48W9V EL;%4E06!:B/O62Z_Y7U[:)O7L
M^S&]+WZ?YJ._75I67==T?4M%?#/QO_:5D\"?MC?%J7P7X0\3WOQ1T+X/VVOI
M'JOBC[-HJVYN'PGV0B2*.YB8%F< [PNS=WJW^S__ ,%+_'5I^P?\,/'/Q'^'
M]O>>/?B9!I.G^%=+T36HI6\87]W;^87(,:)8QC#2/N,@C0,<MMP2/O1<ET:7
MJW*<$EW=X/Y[72;%-J,E%]4WZ)1C-M]E:2U[;V>A]MT5X;^R_P#MC7?QJ^*O
MC/X=^+_!TO@#XB^"(;2_N]*_M2/5+:[L+H-Y%W;W*(@=2\<J,I165HSU!!KW
M*FTTD^_]?UV>FX7U:[?U_P %=UKL%%%%(84444 %%9&K?$#0= OFM;[6](LK
ME "T,]Y'&Z@\@E20>:K?\+9\+?\ 0R^'_P#P8P__ !5:JA4:NHO[BN678W+J
MZCL;:2:5UCBB4N[,<!0.IKSCX.?M4>'/C9XIOM)TQ+ZWN+1#+$;E @NHPVTL
MF"3W!P<'!Z<&O._VT_VC]-3P0WAG0-3MKZ\U<;;R2UD$B0VYSN7>,KE\;<?W
M2W3BOF'X?^-KSX;^---US3S_ *5ILPD52<"1>C(3Z,I*GV)KZG*^&WB,).K5
MNI/X?^#ZG=0P?/3<I;]#]+:*XGP-^T%X5\:>$K#4_P"V](L6NX@[VUQ>QI);
MO_$C!B#D'(SCG&1Q6M_PMGPM_P!#+X?_ /!C#_\ %5\Q+"UHR<90=UY'"X26
MECH**J:-KMEXBLOM.GWEK?6Y8KYMO*LJ9'494D9%6ZQ::=F2%%%%( HHKY[_
M ."HGCGXK?#G]C/Q+JWP<TV^U/Q?;R6XD73[=;G4+>P,JB[FM(FXDN4@WM&I
MSE@.">*F<^57?]>O9=WT6I<(.4N5'T)17R5_P3K^,GPW^)GASQ1J/P]^/WB_
MXBP64'E:MI'C6_$FJ>&+J,?,T\4T45Q;@9*LKKL)4X/%? ?[$7Q(N_VH?CSX
M:LO#6H:_!\7_ (:>+[[Q3\2_B==^*IQH_B#P]%=W,2C3K4R%;ZVN(ML0*0K%
M"(,[RQ7.EOWJIRT5KM]E?5]K)>\W?;9-W2RYG[)U$M;VMW=F[=[M^ZE;XG9V
MTO\ MC17PC_P4H_:ZTOQ/\(_V<O$WA'XLZCX)^&OQ-\=6EMJ7BC3-171_/TJ
M6SNI,FXN$_<HSI&=Q / ]:T/^">'QDU_Q!^V;\3?!WA?XB:[\9O@7HVBV-[I
MOBS4[A-2%GK,CLMQ80ZE&H2[01JDA"[O*+%2><4H1<I2@]&FU\XQ4G?MH[*_
M73=J[G)12DM4TG_X%)Q5N^JN[;+79,^WJ*^ ?VWOC%8VW_!3WP_X'\<?'?7O
M@U\/)/AQ<:U']B\56WAZ*]U%;^.(9EE'[QA$S?(#[XXKP_QA^T_\3M5_88\(
M^(-:U/QKXNT_0_VA='TOPAK-O ;'5_'?A]+Z'R'*9B6;S<O'O;:DP4-C!R50
MM5Y+?::7_E54OON[I;M7[#J>YS?W5?\ \INI]UE9OHS];J*^>/@G^W#K?C#X
M]^*?A?XY^&M_X)\;Z!X?C\4V-I9ZO#K%OKFGO(\689@L6)EE388V48W*=V#F
ML_0/V]O$GAW]I#P3\/OB5\*[OP$/B;]L3POJ,.O0ZL+B:VC65X+J..-?LTAB
M;<,-(I*LN[C)(^\TEUV^5T]>]TU;>ZMN*344V^F_W)_=9IWVL[['TO17RI^S
M+_P4BUS]J?Q1XX_L/X3:I8>$?ASKVJ^'M:U[4-;AC$EQ9;L&UA$9:=6 7<2R
M;"V/FP:\TT'_ (+=WU_\!_ GQ:N_@/XT@^&'CO58M M;^VU:TNM5%]-,\$(2
MR&-\#RJ%$IE4_,24 ',QDI*+7VN5K_M_X?\ P+IW*DG'FO\ 9<D_6/Q?=9W]
M#[VHKYY^"O[<^I^-_CGXT^&7B_X<ZIX1\=>%-"A\46VGVFI1:K'K6FRR/$K1
M3!8U682)L:)L8+*=Q!S5+P;^W?XDTW]ICPA\-OB5\+KCP!<_$:UOKCPO?0:]
M%J\=V]HJ236]RL<:?9I?*<,!EU.U@&XYJ/O-)==5\KW^>CTWNFMR7))-OI^M
MOPLT[[6=]CZ3HKX__P""MOQ;^('PFT3X:3Z(_C32?A9>:^\?Q(U_P=:M<Z]H
M6G"(F&2%45W6$S8\Z2-&9$4X')IWPZ_;<^&GP&_8L?XA^&?BIX@^/OAK4]3@
ML/#N;Z'4-7O;^Z8)#IWF;482,YSB95:-<Y&!2@^:,I=G;N[NUM%KK?W>]G;I
M>IKE<4^JOY65[Z^5KOLFGL?7U%?!?[6O[=/B+Q1^S;\?_AOXQ\&7_P *?B5I
M'PSOO%.EI9:^NI0WUCL:)IX+N%(RDL4Q564J"-RD$CFNF^#?[;^O^'_A3\'O
MAQX$\$7GQ4^(C?#;2?$VN)=:\FEV^F6;VT:1R3W4J2%YYI0P1-I+!78L O+7
M7RY;=;W]I?;^7V<K]M;VL*6G+YWO?2UO9VW_ )O:1M\NY]G45\FVG_!5S1O'
M'PJ^&UYX)\':KXC^(7Q/U"]TC3_!T][%8S:?=Z>S)J2W=P0Z11VS(RF15?>2
MFT'=QQG[9G[=W[0'P?'P270_A+I.BZEXS\>0^&]:L-1\3V\J72M'.RP6\XA.
M$E5%<7!52FTJ8SG-'VE#O)1^;:7S6JU5_OT%S+E<NR;^Z][]GH]';S/N6BLS
MP9J6J:OX4T^YUK3(=&U:>!7N[&*[%VEI(1R@E"KO _O;1GTK3IM6=F"=U=!1
M112&%%5-<UZQ\,:3/?ZE>6NGV-JN^:YN9EBBA7U9F( 'U-<O_P -'?#W_H?/
M!G_@[MO_ (N@#LZY?XF?&?PC\'[".?Q7XBT;08)W$<9OKE(O,8[B  3D_=;\
MC7DG[8'[=OA;X,? S5=2\->)_#VL>)KA?LNEV]E?0W3+._ E95+#:@RYW8!"
MXSDBOR2\6>+M5\>Z_-JNN:E?:OJ=RS-)=7<S2R-N8L0">@R2=HP!DX% '[C_
M  T^-?A#XQ6<LWA3Q'HVO16[F.0V-TDOED!200#D?>7\Q74U^!WACQ5JG@C7
M8=4T74;[2=2MR&BNK29HI4PP8<CJ,@'!R#@9%?K1^QI^W?X9^,_P+TR_\4^)
M_#^C^*+,?9-4AO;V&T:29./-56*C:XPP SC."<@T ?1-%<II/QW\#Z_JD%E8
M^,O"M[>W3B."W@U:WDEF8]%50Y)/L*ZN@ HHHH **** "BBB@ HHHH ****
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M)[(0&[GN9K>$[C("YC<.<NQ\TGBOT/HITOW=N7I_G.7YSE^'96FJO:7YNO\
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M .6= '>T5P7_  CWQ/\ ^AO\!_\ A(7?_P LZ/\ A'OB?_T-_@/_ ,)"[_\
MEG0!WM%<%_PCWQ/_ .AO\!_^$A=__+.C_A'OB?\ ]#?X#_\ "0N__EG0!WM%
M<%_PCWQ/_P"AO\!_^$A=_P#RSH_X1[XG_P#0W^ __"0N_P#Y9T =[17!?\(]
M\3_^AO\  ?\ X2%W_P#+.C_A'OB?_P!#?X#_ /"0N_\ Y9T =[17!?\ "/?$
M_P#Z&_P'_P"$A=__ "SH_P"$>^)__0W^ _\ PD+O_P"6= '>T5P7_"/?$_\
MZ&_P'_X2%W_\LZ/^$>^)_P#T-_@/_P )"[_^6= '>T5P7_"/?$__ *&_P'_X
M2%W_ /+.C_A'OB?_ -#?X#_\)"[_ /EG0!WM%<%_PCWQ/_Z&_P !_P#A(7?_
M ,LZ/^$>^)__ $-_@/\ \)"[_P#EG0!WM%<%_P (]\3_ /H;_ ?_ (2%W_\
M+.C_ (1[XG_]#?X#_P#"0N__ )9T =[17!?\(]\3_P#H;_ ?_A(7?_RSH_X1
M[XG_ /0W^ __  D+O_Y9T =[17!?\(]\3_\ H;_ ?_A(7?\ \LZ/^$>^)_\
MT-_@/_PD+O\ ^6= '>T5P7_"/?$__H;_  '_ .$A=_\ RSH_X1[XG_\ 0W^
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M_P#Y9T =[17!?\(]\3_^AO\  ?\ X2%W_P#+.C_A'OB?_P!#?X#_ /"0N_\
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M7?\ \LZ/^$>^)_\ T-_@/_PD+O\ ^6= '>T5P7_"/?$__H;_  '_ .$A=_\
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M .AO\!_^$A=__+.@#O:*X+_A'OB?_P!#?X#_ /"0N_\ Y9T?\(]\3_\ H;_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!7245X>*QU6N_>V['/.HY!1117&9A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<%XA_P"3GO"'_8KZ
MY_Z5Z/7>UP7B'_DY[PA_V*^N?^E>CT =[1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4&IZG;Z+I\UW=SQ6MK;H9)997")&HZDD\ 5D_$3XDZ/\*_#,NK:W=I:VL?"
MCJ\S=D1>K,?3\3@#-?#_ .T#^TYKGQ_U@64*S66AB4"VTZ(Y:9L_*TF/OOGH
M.@[<\GMP>!GB'IHNYI3IN1Z%^TC^W//K_GZ+X+EEM++E)M3P5FG]1%W1?]K[
MQ[8[_-;.78DDDDY)/>OJK]FO]A=46WUSQO#N;B2#2#T'H9_7_<_[Z[K7O?\
MPHOP1_T)WA7_ ,%-O_\ $5ZJQ^&PO[NDK^9O[2$-(GYLU]+?\$]/C!_97B"\
M\'7DN(-2S=V&X_=F4?.@_P!Y1G_@!]:^D/\ A1?@C_H3O"O_ (*;?_XBI],^
M#WA+1=0BN[/PMX<M+JW8/%-#IL,<D;#H58+D'W%8XG-*5:FZ;B]29UE)6L='
M1117AG,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%1W5U'8VTDTTB0PQ*7>1V"JBCDD
MD\ "@"2OFC]J3]M=/#YN/#W@ZX66^YCNM33YDMNQ6(]"_JW0=LGD<I^U1^VA
M)XN^T^'?"4[PZ5S'=:@N5>\'=8^ZQ^IZM[#[V)^R]^Q_=_%F6'6M>6:R\-@[
MHTY274/9?1/5N_0>H]O#8*%*'M\5MT7]?D=$*:BN:9SG[/\ ^S9K?[0FOO=2
MO-:Z,DI:\U&4%FE8G+*F?ON>YZ#.3V!^Y?A_\/=)^%_AB#2-%M$M+.#G Y:5
MN[NW5F/J?Y"M#1-#L_#6DV]A86T-G9VJ".&&)=J1J.P%6ZXL9CIUW;:/8SJ5
M'(****X3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BO(?VYO"?B7Q[^SKJ&B>$/$UC
MX7\0:IJ&G06\MWKL^A+J:?;(6FT];^W5[BT>ZA66!9[=&FC,H9 6 KYU^$.K
M?#71OV)-6\):U??&;X>Z3\-O%C>&K[PK:>.[V]UI]22VBEAT73-4M)SJ-W;N
M9X9+=(YTN& 6*18XUDME2=U*VZZ=]8K\Y))*[OHTKQ<G*T5%OK_E)_\ MK\K
M7>MG;[HHKX5\*_#[Q9XZ\;?!3X.?%_QE\0=*:S^&FJ>)-0.D>.;[1M2U'4(;
MRQ@CCN=1L)8)KI[2VN&$F)#')))YL@<B-A\X_LH?&_Q1\<?V)/&/QNU_XJ_$
M5OB+\-O'>G^%?"[1^*;ZVTW5["&;3HK'[1I$<J6=X^JQW#2M+- \DGVU6B=5
M2+9<(\TK+;5_)5/9/Y\VROK'5.^AFY6C?KHOFX<Z^7+N^CTL?KQ7!>(?^3GO
M"'_8KZY_Z5Z/7>UX?XCUSXA?\-'^&&'A?P9]I7P[K*P1_P#"47/ER1&ZTK>S
M-_9^58$1X4*P.YLLNT!Y+/<**X+_ (2'XG_]"AX#_P#"ON__ )64?\)#\3_^
MA0\!_P#A7W?_ ,K* .]HK@O^$A^)_P#T*'@/_P *^[_^5E'_  D/Q/\ ^A0\
M!_\ A7W?_P K* .]HK@O^$A^)_\ T*'@/_PK[O\ ^5E'_"0_$_\ Z%#P'_X5
M]W_\K* .]HK@O^$A^)__ $*'@/\ \*^[_P#E91_PD/Q/_P"A0\!_^%?=_P#R
MLH [VBN"_P"$A^)__0H> _\ PK[O_P"5E'_"0_$__H4/ ?\ X5]W_P#*R@#O
M:*X+_A(?B?\ ]"AX#_\ "ON__E91_P )#\3_ /H4/ ?_ (5]W_\ *R@#O:*X
M+_A(?B?_ -"AX#_\*^[_ /E91_PD/Q/_ .A0\!_^%?=__*R@#O:*X+_A(?B?
M_P!"AX#_ /"ON_\ Y64?\)#\3_\ H4/ ?_A7W?\ \K* .]HK@O\ A(?B?_T*
M'@/_ ,*^[_\ E91_PD/Q/_Z%#P'_ .%?=_\ RLH [VBN"_X2'XG_ /0H> __
M  K[O_Y64?\ "0_$_P#Z%#P'_P"%?=__ "LH [VBN"_X2'XG_P#0H> __"ON
M_P#Y64?\)#\3_P#H4/ ?_A7W?_RLH [VBN"_X2'XG_\ 0H> _P#PK[O_ .5E
M'_"0_$__ *%#P'_X5]W_ /*R@#O:*X+_ (2'XG_]"AX#_P#"ON__ )64?\)#
M\3_^A0\!_P#A7W?_ ,K* .]HK@O^$A^)_P#T*'@/_P *^[_^5E'_  D/Q/\
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MQ/\ ^A0\!_\ A7W?_P K* .]HK@O^$A^)_\ T*'@/_PK[O\ ^5E'_"0_$_\
MZ%#P'_X5]W_\K* .]HK@O^$A^)__ $*'@/\ \*^[_P#E91_PD/Q/_P"A0\!_
M^%?=_P#RLH [VBN"_P"$A^)__0H> _\ PK[O_P"5E'_"0_$__H4/ ?\ X5]W
M_P#*R@#O:*X+_A(?B?\ ]"AX#_\ "ON__E91_P )#\3_ /H4/ ?_ (5]W_\
M*R@#O:*X+_A(?B?_ -"AX#_\*^[_ /E91_PD/Q/_ .A0\!_^%?=__*R@#O:*
MX+_A(?B?_P!"AX#_ /"ON_\ Y64?\)#\3_\ H4/ ?_A7W?\ \K* .]HK@O\
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M/Q/_ .A0\!_^%?=__*RC_A(?B?\ ]"AX#_\ "ON__E97.2=[17!?\)#\3_\
MH4/ ?_A7W?\ \K*/^$A^)_\ T*'@/_PK[O\ ^5E '>T5P7_"0_$__H4/ ?\
MX5]W_P#*RC_A(?B?_P!"AX#_ /"ON_\ Y64 =[17!?\ "0_$_P#Z%#P'_P"%
M?=__ "LH_P"$A^)__0H> _\ PK[O_P"5E '>T5P7_"0_$_\ Z%#P'_X5]W_\
MK*/^$A^)_P#T*'@/_P *^[_^5E '>T5P7_"0_$__ *%#P'_X5]W_ /*RC_A(
M?B?_ -"AX#_\*^[_ /E90!WM%<%_PD/Q/_Z%#P'_ .%?=_\ RLH_X2'XG_\
M0H> _P#PK[O_ .5E '>T5P7_  D/Q/\ ^A0\!_\ A7W?_P K*/\ A(?B?_T*
M'@/_ ,*^[_\ E90!WM%<%_PD/Q/_ .A0\!_^%?=__*RC_A(?B?\ ]"AX#_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ3JZ<L-A$01(%4!548  P *6BBO(, HHHH **** "F3SI;0O)(RQQQJ69F.
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M>UP7B'_DY[PA_P!BOKG_ *5Z/0!WM%%% !1110 4444 %%%% !1110 4444
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M!?V<O%7CS9)%8&PM'Y^T7N8E(]0,;C]0,>]>R^!?V.-"T+9+K$\VLSCGR_\
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MQ)(/3T7OU/'7W+Q%X/TSQ;]E_M*QM[S[%*)X?-7/EN.__P!;H>]:5 !1110
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M-'>'_P#H'^//_"'UK_Y$H_X:.\/_ /0/\>?^$/K7_P B4 =[17!?\-'>'_\
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M?^$/K7_R)0!WM%<%_P -'>'_ /H'^//_  A]:_\ D2C_ (:.\/\ _0/\>?\
MA#ZU_P#(E '>T5P7_#1WA_\ Z!_CS_PA]:_^1*/^&CO#_P#T#_'G_A#ZU_\
M(E '>T5P7_#1WA__ *!_CS_PA]:_^1*/^&CO#_\ T#_'G_A#ZU_\B4 =[17!
M?\-'>'_^@?X\_P#"'UK_ .1*/^&CO#__ $#_ !Y_X0^M?_(E '>T5P7_  T=
MX?\ ^@?X\_\ "'UK_P"1*/\ AH[P_P#] _QY_P"$/K7_ ,B4 =[17!?\-'>'
M_P#H'^//_"'UK_Y$H_X:.\/_ /0/\>?^$/K7_P B4 =[17!?\-'>'_\ H'^/
M/_"'UK_Y$H_X:.\/_P#0/\>?^$/K7_R)0!WM%<%_PT=X?_Z!_CS_ ,(?6O\
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M>'_^@?X\_P#"'UK_ .1*/^&CO#__ $#_ !Y_X0^M?_(E '>T5P7_  T=X?\
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MO$-M'C$.KZ3;39QZR(B2G/N_TQ7MG@O_ (.6OB3I^W_A(?A[X)U4#J=/FN;
MMU_OO,/3MV/KQ]J_$;_@A/\ LX>/F=[?PEJ7AF>0Y:72-8N$_))6DC7\%%>*
M^-/^#:#X?7P;_A'?B1XRTO\ N_VC:6U_CZ[!!G]*T_MOA+%:UJ')_P!NV_\
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MKQ5U\SS<TP&&Q$XNO/E:\U^I^UG_  ]:_9U_Z*WX4_[^O_\ $T?\/6OV=?\
MHK?A3_OZ_P#\37XD2_\ !*O]H>WB9W^$_BI$0;F9HD 4>I.ZLOPW_P $^OB7
MJ^K_ &:_TNTT.-3B2:[O(F"8/(VQ,[9]L#ZBOF?]2<BM?ZW_ .30?Z'EO)<
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MBK>_R^:?TKR3QG_P6K^(6KADT3PYX7T:-@0'F6:[F3TP=Z+^:&@#]-J^-/\
M@I;_ ,%"M0^ VI+X&\$S0Q>))H!+J5^5#MIB. 4C0'CS64[B2/E5E(Y.5^.?
M&G_!1WXT>. ZW'CG4;*)NB:=%%9;![-$JO\ FQ->.^(O$FH^+]9GU'5K^]U3
M4+IMTUU=SM/-,<8RSL2Q. .I[4 =E9?M6_$S3]82_C\?>+_M:/YGF-JT[;C[
MY;!'J#P17Z1?\$X?VZYOVJ?#U[H?B/[/'XRT.(32/"@C34;?*J9@HX5@Q <
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M=%\E^NIX.)Q.*Q+O6EIVZ?<?<WC3XW>$OAXS+K'B#3+.5/O0F4/,/^V:Y?\
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ML=0-QQWKFZ^PRO-LSPE%4(UO<BK)<L=/G:YZV'S#%4H*G&>BVT7^1Y;\(_\
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M\>/^"?\ \-OCAX!&BIH&F^&)[7<]C>Z/9Q6KVKD#JJ *ZG RK=AP5/->VT4
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M06WCS5;I%X*ZA'%?;A[M,C-^.<UZIX0_X+0_$S1MJ:KH_A36HQU8V\MO,?\
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M?V5X+\2WO]W[7/!:Y^NTR5P?B+_@N'KUR&_LGP!I%D?X?M>I276.G7:D>>]
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M:(96/L6; !_ UZKX,_9W\)^"-KP:8EW<+_RWO#YSY]0#\H/T KMZ* $5=JX
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M ;F-55OW8(&"S$$9! ;M^G6F:;;Z+IMO9VD$5M:6D:PPPQ*%2)% "JH'
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MD,I[,I 93V*@]J /P<J2UB>>ZC2-2TCL%50,Y)/ Q7V-\6_^",OCO0_%,_\
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M'+WQGJ$6DM;--;S07MOJ2:4TID#6H#P/9J")CB4>7F3RKX#_ /!+[XQ_L^?
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MZ[VB@#@O^&5_AA_T3CP'_P"$_:?_ !NC_AE?X8?]$X\!_P#A/VG_ ,;KO:*
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MG[3_ .-T?\,K_##_ *)QX#_\)^T_^-UWM% '!?\ #*_PP_Z)QX#_ /"?M/\
MXW1_PRO\,/\ HG'@/_PG[3_XW7>T4 <%_P ,K_##_HG'@/\ \)^T_P#C='_#
M*_PP_P"B<> __"?M/_C==[10!P7_  RO\,/^B<> _P#PG[3_ .-T?\,K_##_
M *)QX#_\)^T_^-UWM% '!?\ #*_PP_Z)QX#_ /"?M/\ XW1_PRO\,/\ HG'@
M/_PG[3_XW7>T4 <%_P ,K_##_HG'@/\ \)^T_P#C='_#*_PP_P"B<> __"?M
M/_C==[10!P7_  RO\,/^B<> _P#PG[3_ .-T?\,K_##_ *)QX#_\)^T_^-UW
MM% '!?\ #*_PP_Z)QX#_ /"?M/\ XW1_PRO\,/\ HG'@/_PG[3_XW7>T4 <%
M_P ,K_##_HG'@/\ \)^T_P#C='_#*_PP_P"B<> __"?M/_C==[10!P7_  RO
M\,/^B<> _P#PG[3_ .-T?\,K_##_ *)QX#_\)^T_^-UWM% '!?\ #*_PP_Z)
MQX#_ /"?M/\ XW1_PRO\,/\ HG'@/_PG[3_XW7>T4 <%_P ,K_##_HG'@/\
M\)^T_P#C='_#*_PP_P"B<> __"?M/_C==[10!P7_  RO\,/^B<> _P#PG[3_
M .-T?\,K_##_ *)QX#_\)^T_^-UWM% '!?\ #*_PP_Z)QX#_ /"?M/\ XW1_
MPRO\,/\ HG'@/_PG[3_XW7>T4 <%_P ,K_##_HG'@/\ \)^T_P#C='_#*_PP
M_P"B<> __"?M/_C==[10!P7_  RO\,/^B<> _P#PG[3_ .-T?\,K_##_ *)Q
MX#_\)^T_^-UWM% '!?\ #*_PP_Z)QX#_ /"?M/\ XW1_PRO\,/\ HG'@/_PG
M[3_XW7>T4 <%_P ,K_##_HG'@/\ \)^T_P#C='_#*_PP_P"B<> __"?M/_C=
M=[10!P7_  RO\,/^B<> _P#PG[3_ .-T?\,K_##_ *)QX#_\)^T_^-UWM% '
M!?\ #*_PP_Z)QX#_ /"?M/\ XW1_PRO\,/\ HG'@/_PG[3_XW7>T4 <%_P ,
MK_##_HG'@/\ \)^T_P#C='_#*_PP_P"B<> __"?M/_C==[10!P7_  RO\,/^
MB<> _P#PG[3_ .-T?\,K_##_ *)QX#_\)^T_^-UWM% '!?\ #*_PP_Z)QX#_
M /"?M/\ XW1_PRO\,/\ HG'@/_PG[3_XW7>T4 0Z?80:380VMK#%;6UM&L4,
M,2!(XD48554<     =,45-10 4444 %%%% !7!>(?^3GO"'_ &*^N?\ I7H]
M=[7!>(?^3GO"'_8KZY_Z5Z/0!WM%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '$?'_ /9\\-?M+?#^7PYXHM7GM&?S8)H7V3V<
MH! DC;G# $]00<\@U\2ZE_P0\U4:Z1:>/M/.F%^'FTYQ.J_[H<J2/]X9]J_1
M&B@#R7]D_P#8Y\*_LC^%);31!->ZK?J@U'5+C_6W97. %'"("3A1[9+$9KUJ
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *X+Q#_R<]X0_P"Q7US_ -*]'KO:X+Q#_P G/>$/^Q7US_TKT>@#O:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N"\0_\G/>$/\ L5]<_P#2O1Z[VN"\0_\ )SWA#_L5]<_]*]'H [VB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVT<T,B2PRJ'1T8,KJ1D$$<$$5PWB'_DY[PA_V*^N?^E>CT;:,$[JZ.]HHHH
M**** "BBB@ HHHH **IZ[X@L_#-DEQ?3I;0R7$%HKMG!EFE2&)>.[22(H]V%
M7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***IZ%X@L_$UD]
MQ8SI<PQW$]HSKG EAE>&5>>ZR1NI]U- %RBBB@ HHHH **** "BBB@ HHHH
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MJ1PZA;RR2@BR4[HT1I%&<%HP"K@E3TO_  J#Q!_T53QY_P" FB__ "OKO:*
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M@@T>17CFU"XECE)-DQW2(ZR,,X#2$!4 "CV*B@#@O^%0>(/^BJ>//_ 31?\
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M,Q*$@PIAEW$/[%10!P7_  J#Q!_T53QY_P" FB__ "OH_P"%0>(/^BJ>//\
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M/_ 31?\ Y7UWM% '!?\ "H/$'_15/'G_ (":+_\ *^C_ (5!X@_Z*IX\_P#
M31?_ )7UWM% '!?\*@\0?]%4\>?^ FB__*^C_A4'B#_HJGCS_P !-%_^5]=[
M10!P7_"H/$'_ $53QY_X":+_ /*^C_A4'B#_ **IX\_\!-%_^5]=[10!P7_"
MH/$'_15/'G_@)HO_ ,KZ/^%0>(/^BJ>//_ 31?\ Y7UWM% '!?\ "H/$'_15
M/'G_ (":+_\ *^C_ (5!X@_Z*IX\_P# 31?_ )7UWM% '!?\*@\0?]%4\>?^
M FB__*^C_A4'B#_HJGCS_P !-%_^5]=[10!X[\5_@'XJ\0^%[6"T^(GC34Y8
M]9TNY:&>#1XU2.'4+>624$62G=&B-(HS@M& 5<$J>E_X5!X@_P"BJ>//_ 31
M?_E?7>T4 <%_PJ#Q!_T53QY_X":+_P#*^C_A4'B#_HJGCS_P$T7_ .5]=[10
M!P7_  J#Q!_T53QY_P" FB__ "OH_P"%0>(/^BJ>//\ P$T7_P"5]=[10!P7
M_"H/$'_15/'G_@)HO_ROH_X5!X@_Z*IX\_\  31?_E?7>T4 <%_PJ#Q!_P!%
M4\>?^ FB_P#ROH_X5!X@_P"BJ>//_ 31?_E?7>T4 <E\!/"][X'^!?@O1=2B
M$&HZ1H-C97<0</Y<L5O&CKN4D'#*1D'!HKK:* "BBB@ HHHH **** "BBB@
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MXFU33M"\+PVMW>7>I>&-5L%N+6ZG%O;W=H)[9&O;624A5N+42PG(._!!KO\
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M+7VK:GJ'@R\FT[6)CH-_!86MW#*8I;87DD*VTDR,,F..1G"LCXV.K'YBTO\
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M#@/B1^P'XP\<?%3QU<6OQ0TW3OA_\2_%FD^*/$&@MX3\_41_9]MID*V]K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_69a.jpg
<TEXT>
begin 644 image_69a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M223G_+[WK;3]3M+*W6SL+:V5BRPQK&">I &*TG+FDY=S.G'E@H]D?__9
'          $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_71a.jpg
<TEXT>
begin 644 image_71a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MOH[R6S;HR-+G7N#@@70W#(!P<C(![4+1W0/5<I>^Q^,/^@[HW_@HE_\ DF@
M^Q^,/^@[HW_@HE_^2: #['XP_P"@[HW_ (*)?_DF@#4TV/4HK=EU2[M;F?=E
M7MK9H%"X'&UG<DYSSG\/4 N4 % %'6-,36=(N=.DN)K>.X38TD.W>!WQN!'M
MTHZIKHT_NU'W3_JY<12D:J6+E0!N.,GWXIO5DI65AU(84 % %74;"/4K&2UE
M=T#$,KIC<C @JPR",@@'D'I2]!IV#3K&/3;&.UB=W"Y)=\;G8DEF. !DDD\
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*              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_73a.jpg
<TEXT>
begin 644 image_73a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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3 4 % '__V0$!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_75a.jpg
<TEXT>
begin 644 image_75a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M)/[U;\K_ -6'=>S<EY?<W;\?T$T:]U*PO?$VFZSKUU=2VJK-;2-#"K+ RG#
M*@!;<&!R"/E''/*=Y4O=^*[7SZ?>K?.X6Y:BOLU?_/[OR9TNB6U]::1;Q:G?
M27MYMS++(B*=QZ@!%48'TJI6O9$1[D]U>Q6D]I"ZL6NI3$FT< [&;GVPII)7
M=B[:-]O\[&5XO&I#0B^E:G)I]VLL861(XW#;G"X8.IX^;/&#QUJ'=-6'&UG?
ML_P1B:SXNOO^%=3:CI^R'6?)E5E(W""2('S3@CG&TXR,$E?6JG9R7)L[/Y.W
MXZV_X8=&-Y<L][V^?^5M?0SM2U2XTC5;2WU/Q_<Z?%-IQN$>>.T4/("!@9BY
MZ_='/I1+24U'5JUEWW_R7WF,+N,&^M[O[K?F_N.Q\)ZAJ&J^%=.OM5MOL][-
M%NDCVE><\':>1D8.#TS5S2B[+R_X;Y!%WOZOYJ^C^9LU!9SFJ:]>MXEA\.:.
MD O6MS=37%PI:."/=M'R@@L2>V1T/-$4Y<S6RM][Z?<.5HI7ZW_#K^)E>*=>
M\3>&]*6[EN-(BB6XMX7N98'\MA(^UGV^:-FW(."Q!'?T%9S2;M=O\KK[W=?U
MJM5&3WLK_CM^1H>$]?U#6+O48+DVEY:6^PP:E9(R07&X'(4,S<K@9(9AS5)>
MY=Z._P#EJ)OWK)WT^[R.HJ1A0!SFJ:]>MXEA\.:.D O6MS=37%PI:."/=M'R
M@@L2>V1T/-$4Y<S6RM][Z?<.5HI7ZW_#K^)E>*=>\3>&]*6[EN-(BB6XMX7N
M98'\MA(^UGV^:-FW(."Q!'?T%9S2;M=O\KK[W=?UJM5&3WLK_CM^1H>$]?U#
M6+O48+DVEY:6^PP:E9(R07&X'(4,S<K@9(9AS5)>Y=Z._P#EJ)OWK)WT^[R.
MG)"J2>@]!4-V5QK4IQ:M8S_9/*N%<W8)A"@DL .3CL!T.<8.!U-5;6P=+F5J
M.@:E>>+]-UJ'4[:&"QC>/[.]FSLX?;O^?S!@_*,?+QWS1#W7)OKI_7S_ *ZA
M)WBHKH[_ )K]2QJ&D7U[KMK=B]MA810O%):O:LSR!\;OGW@#[H_A/?KGB>5-
M24MFK#YFDN7H[_G_ )F(O@6[LK71;;3-8BBCTRX^T%KJU:9Y6VE%!(D7 "';
MWZ#FM%-\ZE+M;[]W\WKY$M6C*,=+O[K.Z7R-76?"\>K:]I>J"[>W>SRLR*N1
M<1Y#!&] '53^!'>IA[LF^_Y]'\KL<O>CR_UKNOF4=+O)I/&MU ;N5YAYOVBV
M,I*11@IY+!.BY!;D=>>N.%3NX?UO=Z?=^CZZD]']UO2VOX]?D7-5\$>'M7U*
MWOKK1M-DG2;S)GDLXW:<;&7:Q(R>H/.?NBB-HCOHU_7]="?5M#GGT6'3-%FL
M],CB=& -IYB*JL&"JJNF.0/PS]:+MR4GT$K)-+K?\3+U'P.;F#739Z@EO<:Q
M'Y<C20&2.+<H60HF\8+84]>PZTMH\JVO?]4OON_F5&3C-3ZI?CW^[3Y%K3M
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9E?I_GJS;J0"@ H * /_9              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_78a.jpg
<TEXT>
begin 644 image_78a.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MQ R?0 #N2<"DWLEUT'Y]OT,FX\6?9--NKNXT/4XI+6 W$ENPBW^6#R01)L/
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H0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_80a.jpg
<TEXT>
begin 644 image_80a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M2L4NY=WW2258=",GZTU:4%-=VON_0'>,^5]D_OO_ )'24AA0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 %#5] ..TW0?$'ANTN-)T5M/FTZ2622WEN9'22U#DL
M5V*I$@!)(^9?3WI.\H*$NBM?\OP&VN=S[N]O^"0CP9<:?X:C\/V]GINL:8D*
MIY.HL8SYA+,\FY4;J2,# QZBG/W]-NWDDDE_6@1;3<F]7J_-M_A^)5TBWN]#
MUK2=%FU2>XN[98XEC,K!98/+8NY3.#AP!N.2,*,\\VI<\I/[_N5G\W?UU[:0
MXJ*TT[>KD[KSM'_,Z+7/#\FNW4+RS)%':8DMMJ[B9?5P>J=/E[]>PK-7B^9;
M_P!?UY;[[6]5RO;K_7]7VVO>?4[;5+JTB1;?3[A6B9;FSN"?*E8XP VTD ?-
MR5/T]"23;6Z_K^O\@BVEOJ<FW@?4H/#EOI4%AI5S;-J/VR6QN+A_L\*9!\E,
MQMN7.3R ,GIV%:.4.;51OKUUNOPOIKT):TG;1NWX6O\ ?;7U^_<TZ+3-)\:'
M2-/,%HG]GB7[# X1%_>'YA$.!UY('/>B+<N?K;E_7_@:!)6Y7M>_Z?\ !.HI
M#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#
-_]D!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105254420648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 27, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PACIRA BIOSCIENCES,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0619477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5401 West Kennedy Boulevard, Suite 890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tampa,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">553-6680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,847,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;III of this Annual Report on Form&#160;10-K incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission no later than 120&#160;days after the end of the registrant&#8217;s fiscal year ended December&#160;31, 2021.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001396814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105253147864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Short Hills, NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105250398264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 585,578<span></span>
</td>
<td class="nump">$ 99,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term available-for-sale investments</a></td>
<td class="nump">70,831<span></span>
</td>
<td class="nump">421,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">96,318<span></span>
</td>
<td class="nump">53,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">98,550<span></span>
</td>
<td class="nump">64,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,771<span></span>
</td>
<td class="nump">12,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">866,048<span></span>
</td>
<td class="nump">651,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">188,401<span></span>
</td>
<td class="nump">136,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">76,410<span></span>
</td>
<td class="nump">74,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">145,175<span></span>
</td>
<td class="nump">99,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">623,968<span></span>
</td>
<td class="nump">96,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">153,364<span></span>
</td>
<td class="nump">106,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investments and other assets</a></td>
<td class="nump">21,987<span></span>
</td>
<td class="nump">14,019<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,075,353<span></span>
</td>
<td class="nump">1,274,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,543<span></span>
</td>
<td class="nump">10,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">127,555<span></span>
</td>
<td class="nump">70,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">7,891<span></span>
</td>
<td class="nump">7,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">350,466<span></span>
</td>
<td class="nump">149,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContingentConsiderationCurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">24,234<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">521,118<span></span>
</td>
<td class="nump">253,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">339,267<span></span>
</td>
<td class="nump">313,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">71,727<span></span>
</td>
<td class="nump">71,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">10,125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Long-term debt, net</a></td>
<td class="nump">335,263<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContingentConsiderationNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">57,598<span></span>
</td>
<td class="nump">13,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">9,847<span></span>
</td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,344,945<span></span>
</td>
<td class="nump">654,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 21)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at December&#160;31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001; 250,000,000 shares authorized; 44,734,308 and 43,636,929 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">942,091<span></span>
</td>
<td class="nump">873,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(211,895)<span></span>
</td>
<td class="num">(253,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">730,408<span></span>
</td>
<td class="nump">619,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,075,353<span></span>
</td>
<td class="nump">$ 1,274,513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContingentConsiderationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContingentConsiderationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments, and noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105254571016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">44,734,308<span></span>
</td>
<td class="nump">43,636,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">44,734,308<span></span>
</td>
<td class="nump">43,636,929<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105254435528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaborative licensing and milestone revenue</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">541,533<span></span>
</td>
<td class="nump">429,647<span></span>
</td>
<td class="nump">421,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">140,255<span></span>
</td>
<td class="nump">117,328<span></span>
</td>
<td class="nump">106,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">55,545<span></span>
</td>
<td class="nump">59,421<span></span>
</td>
<td class="nump">72,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">199,345<span></span>
</td>
<td class="nump">193,516<span></span>
</td>
<td class="nump">200,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">13,553<span></span>
</td>
<td class="nump">7,866<span></span>
</td>
<td class="nump">5,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses', window );">Acquisition-related charges, product discontinuation and other</a></td>
<td class="nump">42,911<span></span>
</td>
<td class="nump">5,166<span></span>
</td>
<td class="nump">25,230<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">451,609<span></span>
</td>
<td class="nump">383,297<span></span>
</td>
<td class="nump">410,546<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">89,924<span></span>
</td>
<td class="nump">46,350<span></span>
</td>
<td class="nump">10,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">4,629<span></span>
</td>
<td class="nump">7,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(31,750)<span></span>
</td>
<td class="num">(25,671)<span></span>
</td>
<td class="num">(23,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(2,666)<span></span>
</td>
<td class="nump">2,852<span></span>
</td>
<td class="num">(4,976)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(33,520)<span></span>
</td>
<td class="num">(26,261)<span></span>
</td>
<td class="num">(21,228)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">56,404<span></span>
</td>
<td class="nump">20,089<span></span>
</td>
<td class="num">(10,748)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(14,424)<span></span>
</td>
<td class="nump">125,434<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 41,980<span></span>
</td>
<td class="nump">$ 145,523<span></span>
</td>
<td class="num">$ (11,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per common share (in USD per share)</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per common share (in USD per share)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">44,262,000<span></span>
</td>
<td class="nump">42,671,000<span></span>
</td>
<td class="nump">41,513,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">45,630,000<span></span>
</td>
<td class="nump">43,682,000<span></span>
</td>
<td class="nump">41,513,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 538,966<span></span>
</td>
<td class="nump">$ 426,614<span></span>
</td>
<td class="nump">$ 418,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,442<span></span>
</td>
<td class="nump">$ 3,033<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition-Related Charges, Product Discontinuation And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251959688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 41,980<span></span>
</td>
<td class="nump">$ 145,523<span></span>
</td>
<td class="num">$ (11,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized gain (loss) on investments, net of tax</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 41,829<span></span>
</td>
<td class="nump">$ 145,519<span></span>
</td>
<td class="num">$ (10,414)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105246533816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Convertible Senior Notes 2019</div></th>
<th class="th"><div>Convertible Senior Notes Due 2022</div></th>
<th class="th"><div>Convertible Senior Notes 2025</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Convertible Senior Notes 2019</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Convertible Senior Notes Due 2022</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Convertible Senior Notes 2025</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 321,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 709,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (388,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">8,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">2,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">33,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss (Note 13)</a></td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(11,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 354,944<span></span>
</td>
<td class="num">$ (156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">753,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(399,398)<span></span>
</td>
<td class="num">$ (156)<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2016-02 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 45,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">45,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">2,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">39,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33,089)<span></span>
</td>
<td class="nump">$ 64,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33,089)<span></span>
</td>
<td class="nump">$ 64,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss (Note 13)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">145,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">619,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">873,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">23,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">23,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">2,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">42,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss (Note 13)</a></td>
<td class="num">(151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">41,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 730,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 942,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (211,895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258806424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt', window );">Deferred tax associated with equity component of convertible debt</a></td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="nump">$ 20,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Expense Associated to the Equity Component of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247679400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 41,980<span></span>
</td>
<td class="nump">$ 145,523<span></span>
</td>
<td class="num">$ (11,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes</a></td>
<td class="nump">10,872<span></span>
</td>
<td class="num">(126,613)<span></span>
</td>
<td class="num">(1,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of fixed assets and amortization of intangible assets</a></td>
<td class="nump">28,548<span></span>
</td>
<td class="nump">19,908<span></span>
</td>
<td class="nump">19,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization&#160;of&#160;debt issuance costs</a></td>
<td class="nump">2,754<span></span>
</td>
<td class="nump">2,156<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">23,152<span></span>
</td>
<td class="nump">18,254<span></span>
</td>
<td class="nump">13,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">(Gain) loss on disposal and impairment of fixed assets</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">42,246<span></span>
</td>
<td class="nump">39,920<span></span>
</td>
<td class="nump">33,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration (after an acquisition)</a></td>
<td class="num">(989)<span></span>
</td>
<td class="nump">5,204<span></span>
</td>
<td class="nump">16,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Gain) loss on investment (net of stock dividend) and other non-operating income, net</a></td>
<td class="nump">2,673<span></span>
</td>
<td class="num">(1,618)<span></span>
</td>
<td class="nump">4,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities (net of acquisitions):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(10,434)<span></span>
</td>
<td class="num">(5,516)<span></span>
</td>
<td class="num">(8,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="num">(4,467)<span></span>
</td>
<td class="num">(6,353)<span></span>
</td>
<td class="num">(8,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="num">(739)<span></span>
</td>
<td class="num">(3,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(10,262)<span></span>
</td>
<td class="num">(3,312)<span></span>
</td>
<td class="num">(1,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and income taxes payable</a></td>
<td class="nump">5,451<span></span>
</td>
<td class="num">(5,999)<span></span>
</td>
<td class="nump">22,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(2,467)<span></span>
</td>
<td class="num">(6,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment of contingent consideration</a></td>
<td class="num">(6,835)<span></span>
</td>
<td class="num">(9,409)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">125,717<span></span>
</td>
<td class="nump">77,032<span></span>
</td>
<td class="nump">70,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisition of Flexion Therapeutics, Inc. (net of cash acquired)</a></td>
<td class="nump">420,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of MyoScience, Inc. (net of cash acquired)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(117,691)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(45,866)<span></span>
</td>
<td class="num">(37,801)<span></span>
</td>
<td class="num">(10,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale investments</a></td>
<td class="num">(611,488)<span></span>
</td>
<td class="num">(546,516)<span></span>
</td>
<td class="num">(318,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of available-for-sale investments</a></td>
<td class="nump">1,068,736<span></span>
</td>
<td class="nump">307,870<span></span>
</td>
<td class="nump">319,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Sale of equity investment</a></td>
<td class="nump">9,057<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchases of equity and debt investments</a></td>
<td class="num">(17,187)<span></span>
</td>
<td class="num">(1,160)<span></span>
</td>
<td class="num">(1,622)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(20,790)<span></span>
</td>
<td class="num">(277,607)<span></span>
</td>
<td class="num">(128,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">23,844<span></span>
</td>
<td class="nump">45,218<span></span>
</td>
<td class="nump">8,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan', window );">Proceeds from common stock issued under employee stock purchase plan</a></td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from term loan B credit facility</a></td>
<td class="nump">363,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_PaymentsForDebtConversionPremiums', window );">Conversion premium on 2019 convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance and financing costs</a></td>
<td class="num">(4,546)<span></span>
</td>
<td class="num">(12,487)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="num">(5,165)<span></span>
</td>
<td class="num">(5,591)<span></span>
</td>
<td class="num">(6,630)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">380,694<span></span>
</td>
<td class="nump">222,304<span></span>
</td>
<td class="nump">3,670<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">485,621<span></span>
</td>
<td class="nump">21,729<span></span>
</td>
<td class="num">(54,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">99,957<span></span>
</td>
<td class="nump">78,228<span></span>
</td>
<td class="nump">132,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">585,578<span></span>
</td>
<td class="nump">99,957<span></span>
</td>
<td class="nump">78,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6,996<span></span>
</td>
<td class="nump">7,205<span></span>
</td>
<td class="nump">8,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes, net of refunds</a></td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets included in accounts payable and accrued liabilities</a></td>
<td class="nump">6,828<span></span>
</td>
<td class="nump">9,288<span></span>
</td>
<td class="nump">3,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncreaseDecreaseInContingentConsideration', window );">Net increase in contingent consideration liabilities</a></td>
<td class="nump">45,241<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from debt component of the 2025 convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">314,708<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt', window );">Proceeds from equity component of the 2025 convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,792<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotes2019Member', window );">Convertible Senior Notes 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">Convertible Senior Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(176,793)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes', window );">Retirement of equity component of the 2022 convertible senior notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (33,089)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncreaseDecreaseInContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncreaseDecreaseInContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents earnout and milestone payment made which is associated with the acquisition of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_PaymentsForDebtConversionPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Debt Conversion Premiums</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_PaymentsForDebtConversionPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Convertible Option Component of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Shares Issued Under Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retirement of Equity Component of Convertible Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotes2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotes2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251838664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira BioSciences,&#160;Inc. and its subsidiaries (collectively, the &#8220;Company&#8221; or &#8220;Pacira&#8221;) is the industry leader in its commitment to non-opioid pain management and providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The Company&#8217;s long-acting, local analgesic, EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom in November 2021. EXPAREL utilizes the Company&#8217;s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the Company added iovera&#176;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to its commercial offering with the acquisition of MyoScience, Inc., or MyoScience. The iovera&#176; system is a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature to only targeted nerves.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion, and added ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. For more information, see Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies, reliance on revenue from three products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coronavirus (COVID-19) Pandemic</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since early 2020, the Company&#8217;s revenues have been impacted by the global pandemic caused by a novel strain of coronavirus (COVID-19) and pandemic-related challenges that included the significant postponement or suspension in the scheduling of elective surgical procedures due to public health guidance and government directives. While the degree of impact has diminished during the course of the pandemic due to the introduction of vaccines and the lessening of elective surgery restrictions, certain pandemic-related operational challenges persist. It remains unclear how long it will take the elective surgery market to normalize or if restrictions on elective procedures will recur due to future COVID-19 variants or otherwise. For instance, while many restrictions have since eased with COVID-19 vaccines now widely available, the elective surgery market faced additional pandemic-related challenges in August and September 2021 due to regional surges in COVID-19 Delta variant cases, staffing shortages and fatigue from care teams addressing significant procedure backlogs, and in December 2021, the COVID-19 Omicron variant prompted some government restrictions on elective procedures and surgical staffing challenges which began to ease in January 2022. The Company&#8217;s manufacturing sites are operational and have safety protocols and guidelines as recommended by federal, state and local governments. To date, there have been no material impacts to the Company&#8217;s supply chain. The situation remains dynamic and subject to rapid and possibly material changes. Additional negative impacts may also arise from the COVID-19 pandemic that the Company is unable to foresee. The nature and extent of such impacts will depend on future developments, which are highly uncertain and cannot be predicted.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251872472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC. The accounts of the Company&#8217;s wholly owned subsidiaries are included in these consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, purchase price allocation, stock-based compensation, inventory costs, impairments of equity investments, long-lived assets, goodwill, liabilities and accruals, including contingent consideration, </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convertible senior notes, and the valuation of deferred tax assets. The Company&#8217;s critical accounting policies are those that are both most important to the Company&#8217;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue From Contracts With Customers</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s sources of revenue include (i) sales of EXPAREL in the U.S., European Union, or E.U. and the United Kingdom, or U.K.; (ii) sales of ZILRETTA in the U.S.; (iii) sales of iovera&#176; in the U.S., and Canada; (iv) sales of, and royalties on, its bupivacaine liposome injectable suspension, including for veterinary use and (v) license fees and milestone payments. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further information on the Company&#8217;s accounting policies related to revenue from contracts with customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Licensing and Milestone Revenue</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements generally involve a license to the Company&#8217;s products. In determining how and when to recognize the revenue under a collaboration agreement, the Company must assess whether the license is distinct, which depends upon whether the customer can benefit from the license and whether the license is separate from other performance obligations in the agreement. If the license is distinct, the Company must further assess whether the customer has a right to access or a right to use the license depending on whether the functionality of the license is expected to substantively change over time. If the license is not expected to substantively change, the revenue is recognized at the point in time when the license is provided. If the license is expected to substantively change, the revenue is recognized over the license period.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (e.g. obtaining regulatory approval) represent variable consideration and would be included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third-party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales are incurred or the performance obligation to which the sales relate has been satisfied.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties are estimated and recognized as revenue when sales to the Company&#8217;s commercial partners occur, unless some constraint exists, as the royalties predominately relate to a supply agreement. Royalties are based on sales of the Company&#8217;s bupivacaine liposome injectable suspension product for veterinary use.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Major Customers</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health,&#160;Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The Company also sells EXPAREL directly to ambulatory surgery centers and physicians. The Company sells ZILRETTA primarily to specialty distributors and a specialty pharmacy, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as Group Purchasing Organizations, or GPOs. The Company sells its bupivacaine liposome injectable suspension for veterinary use to a third-party licensee in the U.S. and sells iovera&#176; directly to end users.</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes the percentage of revenues comprised by the Company&#8217;s three largest wholesalers in each period presented:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Largest wholesaler</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second largest wholesaler</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third largest wholesaler</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from outside the U.S. accounted for less than 1% of the Company&#8217;s total revenue for the year ended December 31, 2021. The Company began selling EXPAREL in the E.U. and U.K. and iovera&#176; in Canada in the fourth quarter of 2021. The Company had no revenue from outside the U.S. during the years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. These include both internal and external costs, of which a significant portion of development activities are outsourced to third parties, including contract research organizations. Clinical trial costs are accrued over the service periods specified in contracts and adjusted as necessary based on an ongoing review of the level of effort and actual costs incurred. Research and development costs are presented net of reimbursements from commercial partners.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues interest and penalties, if any, on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in its consolidated statements of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation consists of grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors, in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&#8217;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value in addition to the closing price of the Company&#8217;s common stock on the date of grant:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Expected term of the option</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Expected volatility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Expected dividends</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Risk-free interest rate</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes its historical volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option activity. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero-coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&#8217;s common stock is estimated to be zero as the Company has not declared or paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. Additionally, the Company&#8217;s ability to declare and pay a dividend in the future could be limited per the agreements governing its indebtedness. The Company records forfeitures as they occur rather than estimating forfeitures during each reporting period.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with maturities of 90 days or less when purchased are considered cash equivalents. Cash equivalents include corporate debt securities, asset backed securities and money market funds. As of December&#160;31, 2021, the carrying value of money market funds was $223.0&#160;million, commercial paper was $19.0&#160;million and asset backed securities was $2.6&#160;million. As of December 31, 2020, the carrying value of money market funds was $51.8 million and commercial paper was $6.5 million. The carrying values approximate fair value as of December&#160;31, 2021 and 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term and Long-Term Available-For-Sale Investments</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term available-for-sale investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper, corporate and government bonds, and other bonds issued in the U.S. (and denominated in the U.S. dollar) by foreign entities, all with maturities of greater than three months, but less than one year. Long-term available-for-sale investments consist of corporate and government agency bonds with maturities greater than one year. The Company evaluates the classification of its investments at the time of purchase and re-evaluates such determination at each balance sheet date, which includes an assessment of the intent to hold the available-for-sale securities. The Company&#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. The Company classifies its investments as available-for-sale. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities (except for credit losses) are excluded from net income (loss) and are reported as a separate component of accumulated other comprehensive income (loss) until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. The Company evaluates whether a credit loss exists, and in the event a credit loss does exist, the credit loss is recognized in the consolidated statements of operations, based on the amount that the fair value is less than the amortized cost.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value, and is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fixed Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. Useful lives by asset category are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 10 years</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Retirement Obligations</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of such lease agreements. The Company records its asset retirement obligations, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records expense to accrete the ARO to its full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes right-of-use, or ROU, assets and lease liabilities at the commencement of its lease agreements. The leases are evaluated at commencement to determine whether they should be classified as operating or financing leases. Lease costs associated with operating leases are recognized on a straight-line basis, while lease costs for financing leases are recognized over the lease term using the effective interest method. The Company does not have any financing leases. The amount of ROU assets and lease liabilities to be recognized is impacted by the type of lease payments, the lease term and the incremental borrowing rate. Variable lease payments are not included at commencement and are recognized in the period in which they are incurred. The lease term is based on the contractual term and is adjusted for any renewal options or termination rights that are reasonably certain to be exercised. The incremental borrowing rate is based on the rate the Company estimates it would pay on a collateralized basis over a similar term in a similar economic environment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values, with some exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value can be determined, the asset or liability is recognized; if fair value is not determinable, then no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. </span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development, or IPR&amp;D, is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is recorded as an expense at the acquisition date.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to an acquisition, the Company measures contingent consideration arrangements at fair value each period, with changes in fair value recognized in the consolidated statements of operations as acquisition-related charges. Changes in contingent consideration can result from changes in the assumed achievement and timing of estimated sales, costs of goods sold and regulatory approvals. In the absence of new information, changes in fair value reflect the passage of time towards achievement of the milestones, and are accreted to the period in which payments are expected to be made.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired in a business combination and is not amortized, but is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their estimated useful lives and are recorded at cost, net of accumulated amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in equity securities without a readily determinable fair value. In the fourth quarter of 2019, the equity investment then held became publicly traded and thereafter, was recognized at its fair value at each reporting period with any unrealized holding gains (losses) included in other income (expense). The equity method investments without a readily determinable fair value are recognized at cost less any impairments, plus or minus any changes resulting from observable price changes in orderly transactions for a similar investment.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Debt Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the expected impact of Accounting Standards Update 2020-06 on accounting for convertible debt, which is effective January 1, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement of the convertible debt, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the retirement of the equity component and is recognized as a reduction of additional paid-in capital.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Per Share Data</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the RSUs expected to vest, the shares to be purchased under the Company&#8217;s employee stock purchase plan (using the treasury stock method), and the excess conversion value on the Company&#8217;s convertible senior notes. See Note 3,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the expected impact of Accounting Standards Update 2020-06 on the calculation of dilutive shares for convertible debt, which is effective January 1, 2022.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currencies</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet accounts of the Company&#8217;s foreign subsidiaries with functional currencies other than the U.S. Dollar are translated using the exchange rate at each respective balance sheet date.&#160;Revenues and expenses are translated using average exchange rates for each calendar month during the year.&#160;Translation&#160;adjustments are recorded as a component of accumulated other comprehensive income (loss) in the consolidated financial statements. Gains or losses from foreign currency exchanges are recorded in other, net in the consolidated statements of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one reportable operating segment to evaluate performance, allocate resources, set operational targets and forecast its future financial results.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105255234840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:0.5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2021-08,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amends Accounting Standards Codification, or ASC, 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. As a result of the amendments made by the ASU, it is expected that an acquirer will generally recognize and measure acquired contract assets and contract liabilities in a manner consistent with how the acquiree recognized and measured them in its pre-acquisition financial statements. The ASU&#8217;s amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (i) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (ii) prospectively to all business combinations that occur </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on or after the date of initial application. The Company has decided to early adopt this standard and will apply it to the valuation of a Flexion deferred revenue contract.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amended the approaches and methodologies in accounting for income taxes during interim periods and makes changes to certain income tax classifications. The standard allows for certain exceptions, including the exception to the use of the incremental approach for intra-period tax allocations, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to-date loss exceeds the anticipated loss for the year. The standard also required franchise or similar taxes partially based on income to be reported as income tax and to reflect the effects of enacted changes in tax laws or rates in the annual effective tax rate computation from the date of enactment. Lastly, in future acquisitions, the Company will be required to evaluate when the step-up in the tax basis of goodwill is part of the business combination and when it should be considered a separate transaction. The standard became effective for the Company beginning January 1, 2021, and there were no material impacts to the consolidated financial statements upon adoption.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2021</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which limits the number of convertible instruments that require separate accounting to (i) those with embedded conversion features that are not clearly and closely related to the debt, that meet the definition of a derivative, and that do not qualify for the scope exception from derivative accounting and (ii) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid in capital. In addition, the new guidance requires diluted earnings per share calculations to be prepared using the if-converted method, instead of the treasury stock method. The guidance must be applied in fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted no earlier than for fiscal years beginning after December 15, 2020. The Company has elected to adopt the new guidance using a modified retrospective method of transition, which would be applied to transactions outstanding at January 1, 2022. As a result, after adopting the ASU&#8217;s guidance, the Company will not separately present in equity an embedded conversion feature for its convertible debt. Instead, the Company will account for a convertible debt instrument wholly as debt. In addition, the Company will not record interest expense on the previously recorded discount on convertible debt. The impact on the balance sheet at January 1, 2022 increased net debt by approximately $64.9&#160;million, reduced accumulated deficit by $47.2&#160;million, reduced additional paid-in capital by $96.5&#160;million and decreased deferred tax liabilities by $15.7&#160;million. The impact on the consolidated statement of operations will reduce interest expense by approximately $18.0&#160;million in 2022, with a resultant impact on basic and diluted income (loss) per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251890168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text">REVENUE<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist of (i) EXPAREL in the U.S., the E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera&#176; in the U.S. and Canada and (iv) sales of, and royalties on, its bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are from the Company&#8217;s collaborative licensing agreements. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure only relates to revenue associated with net EXPAREL and ZILRETTA product sales. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and a specialty pharmacy, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as GPOs. Product revenue is recognized when control of the promised goods are transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the product is delivered to the customer. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved. The calculation of some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of activity with respect to the Company&#8217;s sales related allowances and accruals related to EXPAREL for the years ended December&#160;31, 2021, 2020 and 2019, as well as ZILRETTA for the year ended December 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:25.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Returns Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prompt Payment Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Service Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Volume Rebates and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Payments/Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,447)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,804&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Payments/Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,496)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Payments/Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,494&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Licensing and Milestone Revenue</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements generally involve a license to the Company&#8217;s products. In determining how and when to recognize the revenue under a collaboration agreement, the Company must assess whether the license is distinct, which depends upon whether the customer can benefit from the license and whether the license is separate from other performance obligations in the agreement. If the license is distinct, the Company must further assess whether the customer has a right to access or a right to use the license depending on whether the functionality of the license is expected to substantively change over time. If the license is not expected to substantively change, the revenue is recognized at the point in time when the license is provided. If the license is expected to substantively change, the revenue is recognized over the license period.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (e.g. obtaining regulatory approval) represent variable consideration and are included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third-party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales are incurred or the performance obligation to which the sales relate has been satisfied.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacy, GPOs and doctors. Payment terms generally range from&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzI3NzA_1d583239-02d3-4c41-bc38-abbb200a0e6b">zero</span>&#160;to&#160;97&#160;days from the date of the transaction, and accordingly, there is no significant financing component. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company&#8217;s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company&#8217;s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenue</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregated net product sales in the periods presented as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;EXPAREL</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;ZILRETTA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;iovera&#176;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Bupivacaine liposome injectable suspension</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total net product sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began recognizing revenue from net product sales of ZILRETTA on November 19, 2021, the date of the Flexion Acquisition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105254567960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Flexion Therapeutics, Inc.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, the Company acquired Flexion (the &#8220;Flexion Acquisition&#8221;), a biopharmaceutical company focused on the discovery, development, and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis, pursuant to an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated as of October 11, 2021, by and among the Company, Oyster Acquisition Company Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#8220;Purchaser&#8221;), and Flexion. Following the completion of a successful tender offer for the shares of Flexion&#8217;s common stock, and pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, Purchaser merged with and into Flexion with Flexion surviving as a wholly owned subsidiary of the Company. The Company changed the name of Flexion to Pacira Therapeutics, Inc. after completing the merger.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The total consideration for the Flexion Acquisition was approximately $578.8&#160;million consisting of: (i) $448.5&#160;million of cash paid to former Flexion stockholders and to settle restricted stock units and in-the-money stock options; (ii) an $85.1&#160;million cash payment of Flexion debt not to be assumed by the Company and (iii) $45.2&#160;million of estimated contingent consideration related to contingent value rights, or CVRs, that were issued to Flexion shareholders and certain equity award holders in conjunction with the Flexion Acquisition. The consideration is subject to adjustments based on the achievement of certain potential milestone payments. The Company estimates that up to an additional $380.2&#160;million in the aggregate may be payable to holders of the CVRs if each of the applicable milestones are achieved, as follows:</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) $1.00 per CVR the first time that net sales of ZILRETTA in any calendar year equal or exceed $250.0&#160;million;</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) $2.00 per CVR, the first time that net sales of ZILRETTA in any calendar year equal or exceed $375.0&#160;million;</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) $3.00 per CVR, the first time that net sales of ZILRETTA in any calendar year equal or exceed $500.0&#160;million;</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) $1.00 per CVR upon approval by the U.S. Food and Drug Administration, or FDA, of a Biologics License Application (BLA) for PCRX-201 (formerly FX-201), a clinical stage gene therapy product candidate; and</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v) $1.00 per CVR upon approval by the FDA of a new drug application, or NDA, for PCRX-301 (formerly FX-301), an investigational product candidate.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration for the Flexion Acquisition was $578.8&#160;million, which consisted of the following (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value of Purchase Price Consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of purchase consideration paid at closing:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for all outstanding shares of Flexion&#8217;s common stock (50,392 shares of common stock acquired at $8.50 per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration paid to settle RSUs and in-the-money options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid to settle Flexion debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent value rights (CVRs)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the Flexion Acquisition using the acquisition method of accounting and, accordingly, has included the assets acquired, liabilities assumed and results of operations in its consolidated financial statements from the acquisition date of November 19, 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary purchase price allocation is based on estimates, assumptions, valuations and other studies which have not yet been finalized. Prior to the finalization of the purchase price allocation, if information becomes available that would indicate it is probable that unknown events had occurred and the amounts can be reasonably estimated, such items will be included in the final purchase price allocation and may change the carrying value of goodwill. The Company is finalizing its valuation of intangible assets, tangible assets, liabilities and tax analyses, and anticipates finalizing the purchase price allocation as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the preliminary allocation of the Flexion Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts Recognized at the Acquisition Date</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS ACQUIRED</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development (IPR&amp;D) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES ASSUMED</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired identifiable intangible assets and IPR&amp;D assets were valued from a market participants&#8217; perspective using a multi-period excess earnings methodology (income approach). The identifiable finite-lived intangible asset, ZILRETTA, is a developed technology for OA knee pain with a value of $480.0&#160;million and a useful life of 9.7 years. A discount rate of 17.5% was used in calculating the fair value of this technology. The IPR&amp;D asset relates to the use of ZILRETTA for the treatment of OA pain of the shoulder and was valued at $60.0&#160;million. The projected cash flows for this asset were adjusted for the probability of successful development and commercialization, and were discounted at 18.0%.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the purchase price over the fair value of identifiable net assets acquired represents goodwill. This goodwill is primarily attributable to the value of combining ZILRETTA with iovera&#176; and EXPAREL as a safe and effective non-opioid multimodal regimen for pain management, as well as the synergies of merging operations. The acquired goodwill and intangible assets are currently not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of acquired goodwill and intangible assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexion results from the acquisition date of November 19, 2021 through December 31, 2021, which are included in the consolidated statements of operations, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification in Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisition Date Through <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Charges Product Discontinuation and Other,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information on costs incurred related to the Flexion Acquisition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Pro Forma Summary of Operations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the unaudited pro forma summary of operations for the years ended December 31, 2021 and 2020, as if the Flexion Acquisition had occurred on January 1, 2020. This pro forma information does not purport to represent what the Company&#8217;s actual results would have been if the acquisition had occurred as of January 1, 2020, and is not indicative of what such results would be expected for any future period (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended&#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630,942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of the Company and Flexion. The summary pro forma financial information primarily reflects the following pro forma adjustments:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Removal of the acquisition-related transaction fees and costs, including certain stock-based compensation and other compensation expenses related to the acquisition, from the years ended December 31, 2021 and 2020;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Removal of the income tax benefit resulting from the Company decreasing its existing valuation allowance on deferred tax assets from the years ended December 31, 2021 and 2020;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Removal of Flexion&#8217;s interest expense and associated deferred financing cost amortization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Adjustments to the Company&#8217;s interest income for the cash used to acquire Flexion; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Additional cost of goods sold related to the step-up value in inventory;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Additional amortization expense from the acquired developed technology intangible assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Additional depreciation of fixed assets; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Additional lease expense on the ROU assets.</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all of the above adjustments were adjusted for the applicable tax impact.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MyoScience, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2019, the Company acquired MyoScience (the &#8220;MyoScience Acquisition&#8221;), a privately held medical device company, in which MyoScience became a wholly owned subsidiary of the Company and was renamed Pacira CryoTech, Inc. The total consideration was $147.5&#160;million, which included a cash payment of $119.0 million and the fair value of contingent consideration in the amount of $28.5 million. The contingent consideration consisted of contingent milestone payments up to an aggregate of $100.0 million upon the achievement of certain regulatory and commercial milestones, of which $43.0&#160;million are available as of December 31, 2021. The Company&#8217;s obligation to make milestone payments is limited to those milestones achieved through December 31, 2023, with any such milestones payable within 60 days of the end of the fiscal quarter of achievement. During the years ended December 31, 2021, 2020 and 2019, the Company made $12.0&#160;million, $15.0&#160;million and $7.0&#160;million of cash payments for the achievement of certain milestones, respectively. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information on the measurement and amounts recognized in the Company&#8217;s consolidated financial statements for contingent consideration. See Note 21, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information on a dispute regarding the achievement of certain milestone payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251874168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105376655752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
<td class="text">FIXED ASSETS<div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net, summarized by major category, consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,641&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,048&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on useful lives by asset category, refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2021, 2020 and 2019 was $15.0&#160;million, $12.0 million and $14.0 million, respectively. During the years ended December&#160;31, 2021, 2020 and 2019, the Company capitalized interest of $3.9 million, $2.4 million and less than $0.1 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021&#160;and&#160;2020, total fixed assets, net, includes leasehold improvements and manufacturing process equipment located outside of the U.S. in the amount of $65.4 million and $67.5 million, respectively.</span></div>As of December&#160;31, 2021 and 2020, the Company had AROs of $2.4 million and $2.0 million, respectively, included in accrued expenses and other liabilities on its consolidated balance sheet, for costs associated with returning leased space to its original condition upon the termination of certain lease agreements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251953448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASESThe Company leases all of its facilities, including its EXPAREL manufacturing facility in San Diego, California and its iovera&#176; manufacturing facility in Fremont, California. These leases have remaining terms up to 8.7 years, some of which provide renewal options at the then-current market value. The Company also has an embedded lease with Thermo Fisher Scientific Pharma Services for the use of their manufacturing facility in Swindon, England. A portion of the associated monthly base fees has been allocated to the lease component based on a relative fair value basis. As a result of the Flexion Acquisition, the Company recorded new operating lease liabilities of $6.6&#160;million arising from obtaining ROU lease assets for three locations.<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease costs are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Lease Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, net of lease incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recorded in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to net the amortization of the ROU asset and the reduction of the lease liability principal in other liabilities in the consolidated statement of cash flows.</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.77 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.18 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.96%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.87%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, maturities of the Company&#8217;s operating lease liabilities are as follows (in thousands): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Payments Due</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105254425352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s goodwill results from the acquisition of Pacira Pharmaceuticals, Inc. from SkyePharma Holding, Inc. (now a subsidiary of Vectura Group plc), or Skyepharma in 2007 (the &#8220;Skyepharma Acquisition&#8221;), the MyoScience Acquisition in 2019 and the Flexion Acquisition in 2021. The change in the carrying value of the Company&#8217;s goodwill is summarized as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:83.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.026%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 accumulated adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill arising from milestones achieved under the Skyepharma Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill arising from the Flexion Acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skyepharma Acquisition was accounted for under Statement of Financial Accounting Standards 141, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was the effective GAAP standard at the date of acquisition. In connection with the Skyepharma Acquisition, the Company agreed to certain milestone payments for DepoBupivacaine products, including EXPAREL. In the fourth quarter of 2021, the Company met both of its two remaining milestones due to Skyepharma: $4.0 million upon the first commercial sale in the U.K., France, Germany, Italy or Spain which was paid in the fourth quarter of 2021; and $32.0 million when annual net sales collected reached $500.0 million, which was paid in the first quarter of 2022. These milestone payments were treated as additions to the Skyepharma Acquisition and, therefore, recorded as goodwill. The Company made a tax election that allows the acquired goodwill and intangible assets associated with the MyoScience Acquisition to be tax deductible.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Flexion Acquisition, the Company recorded goodwill totaling $9.6&#160;million. The acquired goodwill and intangible assets are currently not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of acquired goodwill and intangible assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consist of the IPR&amp;D and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible<br/>Assets, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average <br/>Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,097)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years, 5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,122)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,122)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible<br/>Assets, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average <br/>Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,553)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,569)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets for the years ended December&#160;31, 2021 and 2020 was $13.6 million and $7.9 million, respectively. Assuming no changes in the gross carrying amount of these intangible assets, the future estimated </span></div>amortization expense on the finite-lived intangible assets will be $57.4&#160;million through 2028, $57.3&#160;million in 2029 and 2030, $36.9&#160;million in 2031, $7.9&#160;million in 2032 and $2.2&#160;million in 2033.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251704328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:8pt;margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and wholesaler service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) At December 31, 2021, accrued royalties included a $32.0&#160;million milestone payment to Skyepharma that was met in the fourth quarter of 2021 for achieving annual net sales collected of $500.0 million on the Company&#8217;s DepoBupivacaine products, including EXPAREL. This milestone was subsequently paid in the first quarter of 2022. See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, for more information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258721640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s outstanding debt is summarized as follows (amounts in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan B facility maturing December 2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% Convertible senior notes due August 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible senior notes due May 2024 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.375% Convertible senior notes due April 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loan B Facility</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021, the Company entered into a term loan credit agreement (the &#8220;Credit Agreement&#8221;) with JP Morgan Chase Bank, N.A., as administrative agent and the initial lender. The term loan issued under the Credit Agreement (the &#8220;Term Loan&#8221;), which was issued at a 3% discount and allows for a single-advance term loan B facility in the principal amount of $375.0&#160;million, which is secured by substantially all of the Company&#8217;s and each subsidiary guarantor&#8217;s assets. Subject to certain conditions, the Company may, at any time, on one or more occasions, add one or more new classes of term facilities and/or increase the principal amount of the loans of any existing class by requesting one or more incremental term facilities. The net proceeds of the Term Loan were approximately $363.8&#160;million after deducting an original issue discount of $11.2&#160;million.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the Term Loan is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan maturing December 2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total debt, net of debt discount and deferred financing costs</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,497&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan matures on December 7, 2026 and requires quarterly repayments of principal in the amount of $9.4&#160;million. commencing June 30, 2022, and increasing to $14.1&#160;million commencing December 31, 2025, with a remaining balloon payment of approximately $188.0&#160;million due at maturity. During 2022, the Company will be required to make three </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarterly payments totaling $28.1&#160;million. The Company is also required to make mandatory prepayments of principal from (i) commencing with the fiscal year ending December 31, 2022, the Company&#8217;s excess cash flow (as defined in the Credit Agreement) existing in any fiscal year and if the Senior Secured Leverage Ratio (as defined in the Credit Agreement) for such fiscal year exceeds certain predetermined limits (ii) net proceeds (as defined in the Credit Agreement) of non-ordinary course assets sales and casualty events and (iii) debt issuance proceeds (other than permitted debt under the Credit Agreement). No mandatory prepayments are due for 2021. Prepayment penalties for the Term Loan are 3% in loan year 1, 2% in loan year 2, 1% in loan year 3 and no prepayment penalties thereafter. Prepayment penalties generally do not apply to mandatory prepayment obligations under the Credit Agreement, such as prepayments due in connection with excess cash flow.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan requires the Company to, among other things, maintain (i) a first lien net leverage ratio, determined as of the last day of any fiscal quarter, of no greater than 1.75 to 1.00 and (ii) liquidity, at any time, of at least $150.0&#160;million. The Term Loan also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of December&#160;31, 2021, the Company was in compliance with all financial covenants under the Credit Agreement.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company may elect to borrow either term benchmark borrowings or alternate base rate borrowings. Term benchmark borrowings bear interest at a variable rate per annum equal to the Adjusted Term SOFR Rate (as defined in the Credit Agreement) (subject to a 75 basis points floor) plus an applicable margin of 700 basis points. Alternate base rate borrowings bear interest at a variable rate per annum determined using a base rate (subject to a 175 basis points floor) equal to the greatest of (i) Prime Rate (as defined in the Credit Agreement) in effect on such day, (ii) NYFRB Rate (as defined in the Credit Agreement) plus 50 basis points or (iii) the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 100 basis points, subject to certain exceptions, plus an applicable margin of 600 basis points. As of December 31, 2021, borrowings under the Term Loan consisted entirely of term benchmark borrowings at a rate of 7.75%.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2025</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company completed a private placement of $402.5&#160;million in aggregate principal amount of its 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture, or 2025 Indenture, with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per year, payable semiannually in arrears on February 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and August 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year, beginning on February 1, 2021. The 2025 Notes mature on August 1, 2025. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2025 Notes is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% Convertible senior notes due August 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,940)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of debt discount and deferred financing costs</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,627&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,030&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from the issuance of the 2025 Notes was approximately $390.0&#160;million, after deducting commissions and the offering expenses paid by the Company. A portion of the net proceeds from the 2025 Notes was used by the Company to repurchase $185.0&#160;million in aggregate principal amount of its outstanding 2.375% convertible senior notes due 2022 in privately negotiated transactions for a total of $211.1&#160;million of cash (including accrued interest).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert the 2025 Notes at any time prior to the close of business on the business day immediately preceding February 3, 2025, only under the following circumstances:</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the Company&#8217;s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) during the five-business day period immediately after any five consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price (as defined in the 2025 Indenture) per $1,000 principal amount of notes for each trading day </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the measurement period was less than 98% of the product of the last reported sale price of the Company&#8217;s common stock and the conversion rate on each such trading day;</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of the Company&#8217;s assets; or</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) if the Company calls the 2025 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after February 3, 2025, until the close of business on the second scheduled trading day immediately preceding August 1, 2025, holders may convert their 2025 Notes at any time.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of these conditions for conversion were met during the quarter ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2025 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2025 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option. The initial conversion rate for the 2025 Notes is 13.9324 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $71.78 per share of the Company&#8217;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2025 Notes represents a premium of approximately 32.5% to the closing sale price of $54.17 per share of the Company&#8217;s common stock on the Nasdaq Global Select Market on July 7, 2020, the date that the Company priced the private offering of the 2025 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the 2025 Notes had a market price of $1,113 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the $402.5&#160;million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&#8217;s option).</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to August 1, 2023, the Company may not redeem the 2025 Notes. On or after August 1, 2023 (but, in the case of a redemption of less than all of the outstanding 2025 Notes, no later than the 40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> scheduled trading day immediately before the maturity date), the Company may redeem for cash all or part of the 2025 Notes if the last reported sale price (as defined in the 2025 Indenture) of the Company&#8217;s common stock has been at least 130% of the conversion price then in effect for (i) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of redemption and (ii) the trading day immediately before the date the Company sends such notice. The redemption price will equal the sum of (i) 100% of the principal amount of the 2025 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2025 Notes for redemption will constitute a &#8220;make-whole fundamental change&#8221; (as defined in the 2025 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2025 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, as defined in the 2025 Indenture, subject to certain conditions, holders of the 2025 Notes may require the Company to repurchase for cash all or part of their 2025 Notes at a repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change occurs prior to August 1, 2025, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes are the Company&#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2025 Notes, and equal in right of payment to the Company&#8217;s unsecured indebtedness. The 2025 Notes are also effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to any debt or other liabilities (including trade payables) of the Company&#8217;s subsidiaries.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the 2025 Notes are currently classified on the Company&#8217;s consolidated balance sheet at December&#160;31, 2021 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company&#8217;s common stock during the prescribed measurement periods. In the event that the holders of the 2025 Notes have the election to convert the 2025 Notes at any time during the prescribed measurement period, the 2025 Notes would then be considered a current obligation and classified as such.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2025 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $314.7&#160;million was calculated using a 5.78% assumed borrowing rate. The equity component of $87.8&#160;million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2025 Notes and is recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. The equity component is treated as a discount on the liability component of the 2025 Notes, which is amortized over the five-year term of the 2025 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. A deferred tax liability was recognized in the amount of $20.5&#160;million, with the offsetting amount recorded in additional paid-in capital. See Note 16,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information regarding the Company&#8217;s deferred taxes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total transaction costs of approximately $12.5&#160;million related to the issuance of the 2025 Notes to the liability and equity components of the 2025 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the five-year term of the 2025 Notes, and transaction costs attributable to the equity component totaling $2.7 million are netted with the equity component in stockholders&#8217; equity. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2025 Indenture contains customary events of default with respect to the 2025 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2025 Notes will automatically become due and payable.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2024 Assumed from the Flexion Acquisition</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, on May 2, 2017, Flexion issued an aggregate of $201.3&#160;million principal amount of 3.375% convertible senior notes due 2024 (the &#8220;Flexion 2024 Notes&#8221;), pursuant to the indenture, dated as of May 2, 2017 (the &#8220;Original Flexion Indenture&#8221;), between Flexion and Wells Fargo Bank, National Association, as trustee (the &#8220;Flexion Trustee&#8221;), as supplemented by the First Supplemental Indenture, dated as of November 19, 2021, between Flexion and the Flexion Trustee (the &#8220;First Supplemental Flexion Indenture&#8221; and, together with the Original Flexion Indenture, the &#8220;Flexion Indenture&#8221;). The Flexion 2024 Notes have a maturity date of May 1, 2024, are unsecured, and accrue interest at a rate of 3.375% per annum, payable semi-annually on May 1 and November 1 of each year. Upon the Flexion Acquisition, the principal was assumed and recorded at fair value by the Company. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion of the Flexion 2024 Notes, at the election of each holder thereof, each Flexion 2024 Note was convertible into cash, shares of Flexion&#8217;s common stock, or a combination thereof, at Flexion&#8217;s election, at a conversion rate of approximately 37.3413 shares of Flexion common stock per $1,000 principal amount of the Flexion 2024 Notes, which corresponded to an initial conversion price of approximately $26.78 per share of Flexion&#8217;s common stock. As a result of the Flexion Acquisition, and in connection with the Notice (as defined below), holders of the Flexion 2024 Notes became entitled to certain Flexion Acquisition-related conversion and repurchase rights, as discussed below. In addition, as a result of the Flexion Acquisition and as discussed in more detail below, any future conversion rights are subject to the occurrence of any future events giving rise to such conversion rights under the Flexion Indenture.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2021, as a result of the Flexion Acquisition and in accordance with the Flexion Indenture, Flexion provided a Fundamental Change Company Notice and Offer to Purchase (the &#8220;Notice&#8221;) to the holders of the Flexion 2024 Notes and offered to repurchase for cash all of the outstanding Flexion 2024 Notes, at a repurchase price in cash equal to 100% of the principal amount of the Flexion 2024 Notes being repurchased, plus accrued and unpaid interest thereon to, but excluding, January 7, 2022, subject to the terms and conditions set forth therein. The offer to purchase expired at 5:00 p.m., New York City time, on January 6, 2022, as scheduled. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any holder that did not exercise its repurchase right in accordance with the terms of the Notice retained the conversion rights associated with such holder&#8217;s Flexion 2024 Notes under the Flexion Indenture. For conversion of Flexion 2024 Notes in connection with the Fundamental Change and the Make-Whole Fundamental Change (each as defined in the Flexion Indenture) resulting from the Flexion Acquisition, each $1,000 principal amount of the Flexion 2024 Notes was convertible into (i) $317.40 in cash and (ii) 37.3413 CVRs, based on the conversion rate of 37.3413, prior to 5:00 p.m., New York City time, on January 7, 2022. Alternatively, holders could retain their Flexion 2024 Notes and such Flexion 2024 Notes would remain outstanding subject to their existing terms, including with respect to a holder&#8217;s right to receive interest payments on the Flexion 2024 Notes and exercise any future conversion rights that may arise under the Flexion Indenture.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 7, 2022, following the expiration of the offer to purchase, the Company accepted the $192.6&#160;million aggregate principal amount of Flexion 2024 Notes that were validly tendered (and not validly withdrawn). No Flexion 2024 Notes were converted in connection with the Notice. The remaining principal outstanding is $8.6&#160;million as of the date of this report.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2022</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company completed a private placement of $345.0 million in aggregate principal amount of 2.375% convertible senior notes due 2022, or 2022 Notes, and entered into an indenture, or 2022 Indenture, with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of 2.375% per year, payable semiannually in arrears on April 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. The 2022 Notes mature on April 1, 2022. As discussed above, in July 2020, the Company used part of the net proceeds from the issuance of the 2025 Notes to repurchase $185.0&#160;million aggregate principal amount of the 2022 Notes in privately negotiated transactions for an aggregate of $211.1&#160;million in cash (including accrued interest). The partial repurchase of the 2022 Notes resulted in an $8.1&#160;million loss on early extinguishment of debt during the year ended December 31, 2020.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2022 Notes is as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.375% Convertible senior notes due April 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of debt discount and deferred financing costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2022 Notes at any time through the close of business on the second scheduled trading day immediately preceding April 1, 2022. Upon conversion, holders will receive the principal amount of their 2022 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2022 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option. The initial conversion rate for the 2022 Notes is 14.9491 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $66.89 per share of the Company&#8217;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2022 Notes represents a premium of approximately 37.5% to the closing sale price of $48.65 per share of the Company&#8217;s common stock on the Nasdaq Global Select Market on March 7, 2017, the date that the Company priced the private offering of the 2022 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the 2022 Notes had a market price of $1,039 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2022 Notes will be paid pursuant to the terms of the 2022 Indenture. In the event that all of the 2022 Notes are settled, the Company would be required to repay the remaining $160.0 million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&#8217;s option).</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 1, 2020, the Company may redeem for cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock, at the Company&#8217;s option, all or part of the 2022 Notes if the last reported sale price (as defined in the 2022 Indenture) of the Company&#8217;s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending within five </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trading days prior to the date on which the Company provides notice of redemption. This condition was not met during the quarter ended December&#160;31, 2021. The redemption price will equal the sum of (i) 100% of the principal amount of the 2022 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2022 Notes for redemption will constitute a &#8220;make-whole fundamental change&#8221; (as defined in the 2022 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2022 Notes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, as defined in the 2022 Indenture, subject to certain conditions, holders of the 2022 Notes may require the Company to repurchase for cash all or part of their 2022 Notes at a repurchase price equal to 100% of the principal amount of the 2022 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change occurs prior to April 1, 2022, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Notes are the Company&#8217;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2022 Notes, and equal in right of payment to the Company&#8217;s unsecured indebtedness. The 2022 Notes are also effectively junior in right of payment to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to any debt or other liabilities (trade payables) of the Company&#8217;s subsidiaries.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2022 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#8217;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $274.1 million was calculated using a 7.45% assumed borrowing rate. The equity component of $70.9 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2022 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2022 Notes, which is amortized over the five-year term of the 2022 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total transaction costs of $11.0 million related to the issuance of the 2022 Notes to the liability and equity components of the 2022 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the five-year term of the 2022 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2022 Indenture contains customary events of default with respect to the 2022 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2022 Notes will automatically become due and payable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:55.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual and other interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized interest (Note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate on total debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251747224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Level&#160;1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Level&#160;2: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Level&#160;3: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company&#8217;s equity investment with a readily determinable fair value was calculated utilizing market quotations from a major American stock exchange (Level 1). The fair value of the Company&#8217;s convertible senior notes are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company&#8217;s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amounts of equity investments and convertible notes receivable without readily determinable fair values have not been adjusted for either impairments or upward or downward adjustments based on observable transactions. The carrying values and fair values of the Company&#8217;s financial assets and liabilities at December&#160;31, 2021 are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Asset:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Convertible notes receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Acquisition-related contingent consideration </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Liabilities Measured at Amortized Cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facility due December 2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2.375% convertible senior notes due 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% convertible senior notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% convertible senior notes due 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The closing price of the Company&#8217;s common stock as reported on the Nasdaq Global Select Market was $60.17 per share at December&#160;31, 2021 compared to a conversion price of $66.89 per share for the 2022 Notes and a conversion price of $71.78 per share for the 2025 Notes. Therefore, at December&#160;31, 2021, the conversion prices were above the stock price. The maximum conversion premium that could have been due on the 2022 Notes and 2025 Notes at December&#160;31, 2021 was&#160;approximately 2.4&#160;million and 5.6&#160;million shares of the Company&#8217;s common stock, respectively. These figures assume no increases in the conversion rate for certain corporate events.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">(2) Relates to the Flexion 2024 Notes. For more information, See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a non-recurring basis, including assets and liabilities acquired in a business combination and long-lived assets, which would be recognized at fair value if deemed impaired or if reclassified as assets held for sale. The fair value in these instances would be determined using Level 3 inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recognized contingent consideration related to the Flexion Acquisition and the MyoScience Acquisition in the amount of $57.6&#160;million and $28.3&#160;million as of December&#160;31, 2021 and 2020, respectively. Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Charges, Product Discontinuation and Other,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a probability-weighted discounted cash flow approach that is based on unobservable inputs and a Monte Carlo simulation. These inputs include, as applicable, estimated probabilities and the timing of achieving specified commercial and regulatory milestones, estimated forecasts of revenue and costs and the discount rate used to calculate the present value of estimated future payments. Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, as part of the purchase price consideration related to the Flexion Acquisition, the Company recorded contingent consideration of $45.2&#160;million, which represents the Company&#8217;s achievement of meeting regulatory and sales-based milestones. For the period of acquisition through December&#160;31, 2021, the Company recorded an additional $1.2&#160;million liability due to an estimated $0.02 increase to contingent consideration per CVR fair value, which was included in acquisition-related charges in the consolidated statements of operations. At December&#160;31, 2021, the weighted average discount rate was 12.2% and the weighted average probability of success for regulatory milestones was 12.7%.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an acquisition-related gain of $2.2&#160;million and for the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2019, the Company recognized acquisition-related charges of&#160;$5.2&#160;million and $16.7&#160;million, respectively, related to the MyoScience Acquisition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a result of revisions to the probabilities of regulatory milestones being met and future projections, which have been included in acquisition-related charges in the consolidated statements of operations. At December&#160;31, 2021, the weighted average discount rate was 11.8% and the weighted average probability of success for regulatory milestones was 1%.</span></div><div style="margin-bottom:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the key assumptions used in the valuation of the Company&#8217;s contingent consideration:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Flexion Ranges Utilized as of <br/>December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MyoScience Ranges Utilized as of <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.39% to 12.92%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.42% to 12.13%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achieving regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00% to 15.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of achieving regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 to 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum remaining potential payments related to the contingent consideration from the Flexion Acquisition and MyoScience Acquisition are $425.5&#160;million and $43.0 million, respectively, as of December&#160;31, 2021.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the Company&#8217;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.588%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent<br/>Consideration<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to the Flexion Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Payments made or offset against amounts due </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate and government bonds with maturities greater than three months, but less than one year. Long-term investments consist of government bonds with maturities greater than one year but less than three years. Net unrealized gains and losses (excluding credit losses, if any) from the Company&#8217;s short-term and long-term investments are reported in other comprehensive income (loss). At December&#160;31, 2021, all of the Company&#8217;s short-term investments are classified as </span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available-for-sale investments and are determined to be Level 2 instruments, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. At the time of purchase, all short-term and long-term investments had an &#8220;A&#8221; or better rating by Standard&#160;&amp; Poor&#8217;s.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company&#8217;s investments at December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021 Investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>(Level&#160;2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020 Investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level&#160;2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;U.S. Government bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;U.S. Government bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, there were no investments available for sale that were materially less than their amortized cost.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elects to recognize its interest receivable separate from its available-for-sale investments. At December&#160;31, 2021 and December&#160;31, 2020, the interest receivable recognized in prepaid expenses and other current assets was $0.1&#160;million and $1.6&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity and Convertible Note Investments</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, the Company held an equity investment of $4.1&#160;million and $1.2&#160;million, respectively, in GeneQuine Biotherapeutics GmbH, or GeneQuine, a privately held biopharmaceutical company headquartered in Hamburg, Germany. This investment has no readily determinable fair value and is recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments. During 2021, the Company purchased a convertible note from GeneQuine in the amount of $1.2&#160;million and invested an additional $3.0&#160;million in equity investments. During the year ended December&#160;31, 2021, the valuation of the convertible note was reduced by less than $0.1&#160;million due to changes in foreign currency exchange rates. The Company has the right to make additional investments in debt securities of $1.7&#160;million predicated upon GeneQuine achieving certain prespecified near-term milestones.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company purchased preferred shares in Coda BioTherapeutics, Inc., a privately held preclinical stage biopharmaceutical company that is developing a gene-therapy platform to treat neurological disorders and diseases for a purchase price of $10.0&#160;million. There were no adjustments to this investment during the year ended December 31, 2021.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company purchased a convertible note in the amount of $3.0&#160;million from Spine BioPharma, LLC, a preclinical stage biopharmaceutical company. There were no adjustments to this investment during the year ended December 31, 2021.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company held an equity investment in TELA Bio, Inc., or TELA Bio, in its consolidated balance sheets in the amount of $11.6 million. During the year ended December 31, 2021, the Company sold its investment in TELA Bio for net cash proceeds of $9.1&#160;million and recognized a realized loss of $2.6&#160;million, which was recorded in other, net in the consolidated statements of operations. In 2020, the fair value of TELA Bio increased by $1.6 million, which was recorded in other, net in the consolidated statement of operations and in 2019, the Company also recognized an impairment loss of $5.7 million in other, net related to its investment in TELA Bio. The fair values of TELA Bio at December 31, 2020 and 2019 were based on Level 1 inputs.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2021, in January 2022, the Company purchased preferred shares in the privately-held Genascence Corporation, a preclinical stage biopharmaceutical company, for $7.5&#160;million, recorded as an equity investment. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally insured limits.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, four wholesalers each accounted for over 10% of the Company&#8217;s accounts receivable at 30%, 20%, 17% and 11%. At December&#160;31, 2020, three wholesalers each accounted for over 10% of the Company&#8217;s accounts receivable at 36%, 28% and 23%. For additional information regarding the Company&#8217;s wholesalers, see Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. EXPAREL revenues are primarily derived from major wholesalers that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company&#8217;s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of December&#160;31, 2021 and 2020, the Company did not deem any allowances for credit losses on its accounts receivable necessary.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251727048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 250,000,000 shares of common stock, of which 44,734,308 and 43,636,929 were issued and outstanding at December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 5,000,000 shares of preferred stock. No preferred stock was issued or outstanding at either December&#160;31, 2021 or 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the changes in the balances of the Company&#8217;s accumulated other comprehensive income (loss) for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gains<br/>(Losses) From Available<br/>For Sale Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on investments, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on investments, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on investments, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105257757704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK PLANS</a></td>
<td class="text">STOCK PLANS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Incentive Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s amended and restated 2011 stock incentive plan, or 2011 Plan, was originally adopted by its board of directors and approved by its stockholders in June 2011 and was amended in June 2014, June 2016, June 2019 and June 2021. The June 2021 amendment and approval by the Company&#8217;s stockholders increased the number of shares of common stock authorized for issuance as equity awards under the plan by&#160;1,500,000&#160;shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2011 Plan allows the granting of incentive stock options, non-statutory stock options, restricted stock awards and other stock-based awards. In April 2014, the Company&#8217;s board of directors also adopted the 2014 Inducement Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock option grants have an exercise price equal to the closing price of the Company&#8217;s common stock on the date of grant, generally have a 10-year contractual term and vest in increments (typically over four years from the date of grant, although the Company may occasionally grant options with different vesting terms, including grants made to its non-employee directors). The Company also grants RSUs to employees and non-employee directors generally vesting in increments over four years from the date of grant, except for such grants made to non-employee directors. The Company uses authorized but unissued shares of its common stock to satisfy its obligations under these plans.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2014 Employee Stock Purchase Plan, or ESPP, was adopted by its board of directors in April 2014 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved by the Company&#8217;s stockholders in June 2014. The purpose of the ESPP is to provide a vehicle for eligible employees to purchase shares of the Company&#8217;s common stock at a discounted price and to help retain and motivate current employees as well as attract new talent. Under the ESPP, up to 500,000 shares of common stock may be sold. The plan expires in June 2024. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 of the Internal Revenue Code, or IRC. The maximum fair market value of stock which can be purchased by a participant in a calendar year is $25,000. Six-month offering periods begin on January 1 and July 1 of each year. During an offering period, eligible employees have the opportunity to elect to purchase shares of the Company&#8217;s common stock on the purchase dates of June 30 and December 31 (or the last trading day of an offering period). The per share purchase price will be equal to the lesser of 85% of the fair market value of the Company&#8217;s common stock on either the offering date or the purchase date. During the year ended December&#160;31, 2021, 55,483 shares were purchased and issued through the ESPP.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain information about the Company&#8217;s stock incentive plans at December&#160;31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Incentive Plan</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards Reserved For Issuance</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards<br/>Issued</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards Available For Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011 Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,431,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,425,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Inducement Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,461,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Reserved<br/>For Purchase</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Purchased</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Available<br/>For Purchase</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for stock options and RSUs is based on the estimated grant date fair value of an award recognized over the requisite service period on a straight-line expense attribution method. Compensation expense for ESPP share options is based on the estimated grant date fair value of the ESPP shares and the grant date number of shares that can be purchased, which is recognized as expense over the length of an offering period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense in its consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,920&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,920&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity and related information for the period from December 31, 2018 to December&#160;31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price (Per Share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value<br/>(in Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,722,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425,495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,428,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,235,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(732,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,050,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,646&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.38&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,972&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,050,540&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $47.3 million of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a weighted average period of 2.6 years. The Company&#8217;s stock options have a maximum expiration date of ten years from the date of grant. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of stock options granted for the years ended December&#160;31, 2021, 2020 and 2019 was $26.74, $22.40 and $20.92 per share, respectively. The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43% - 1.21%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22% - 1.60%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33% - 2.54%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.22 years</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSU activity and related information for the period from December 31, 2018 to December&#160;31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair Value (Per Share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value<br/>(in Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and expected to vest at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $41.0 million of total unrecognized compensation cost related to unvested RSUs is expected to be recognized over a weighted average period of 2.9 years. The Company&#8217;s RSUs have a maximum vest date of four years from the date of grant. The fair values of RSUs awarded are equal to the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the ESPP share options granted were estimated using the Black-Scholes model with the following weighted average assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share option fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.16 - $15.23</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.02 - $17.54</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.13 - $11.36</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50% - 0.90%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14% - 1.57%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% - 2.56%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of ESPP share options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251769208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME (LOSS) PER SHARE</a></td>
<td class="text">NET INCOME (LOSS) PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential common shares are excluded from the diluted net income (loss) per share computation to the extent that they would be antidilutive. Because the Company reported a net loss for the year ended December 31, 2019, no potentially dilutive securities were included in the computation of diluted net loss per share for that period. As discussed in Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has the option to pay cash for the aggregate principal amount due upon the conversion of its 2022 Notes and 2025 Notes. Since it is the Company&#8217;s intent to settle the principal amount of its 2022 Notes and 2025 Notes in cash, the potentially dilutive effect of such notes on net income (loss) per share is computed under the treasury stock method. As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU 2020-06 will require the Company to use the if-converted method upon adoption; this new accounting pronouncement was not adopted as of December&#160;31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income (loss) per common share for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,016)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computation of diluted securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of conversion premium on the 2022 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of ESPP purchase options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,513&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the outstanding stock options, RSUs and ESPP purchase options that were excluded from the diluted net income (loss) per common share calculation because the effect of including these potential shares were antidilutive in the periods presented (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ESPP purchase options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251774248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes and the related tax expense (benefit) is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,089&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,748)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total current taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,613)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,424&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,434)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense of $14.4&#160;million for the year ended December 31, 2021 represents the effective tax rate applied to domestic operating results adjusted for certain discrete tax items including deductible stock-based compensation, non-deductible capital losses and tax credits. For the year ended December 31, 2020, the Company had an income tax benefit of $125.4&#160;million primarily related to the release of a valuation allowance on its domestic net deferred assets. The income tax expense for the year ended December 31, 2019 consists primarily of state income taxes in jurisdictions where the availability of carryforward losses are either limited or fully utilized as well as state taxes on the one-time gain from the deemed sale of assets resulting from an IRC section 338(g) tax election made by the Company related to the MyoScience Acquisition. This was partially offset by a reduction in the Company&#8217;s valuation allowance on its deferred tax assets due to the MyoScience Acquisition. </span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647.87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.00)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes refinancing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338(g) tax election</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rates of 25.57%, (624.39)% and (2.49)% for the years ended December&#160;31, 2021, 2020 and 2019, respectively, differed from the expected U.S. statutory tax rate of 21.0%. The difference in tax rates for the year ended December 31, 2021 was primarily driven by non-deductible expenses and valuation allowances recorded against capital loss carryforwards, partially offset by stock-based compensation deductions and tax credits. The difference in tax rates for the year ended December 31, 2020 was primarily due to the release of a domestic valuation allowance of $126.6&#160;million as discussed below. The difference for the year ended December 31, 2019 was primarily driven by pretax losses for which the Company concluded that a majority of its tax benefits are not more-likely-than-not to be realized, resulting in the recording of a full valuation allowance.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. At each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. During the year ended December 31, 2020, the Company determined there was sufficient positive evidence to conclude that it was more-likely-than-not the domestic deferred taxes of $126.6&#160;million were realizable and, therefore, the domestic valuation allowance was released. The Company maintains a full valuation allowance on its foreign net deferred tax balances as it is more-likely-than-not the tax benefits are not realizable.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities at December&#160;31, 2021 and 2020 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,521)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,485)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company&#8217;s federal net operating losses, or NOLs, and federal tax credit carryforwards totaled $662.6 million and $25.9 million, respectively. The Company also had state NOLs and state tax credit carryforwards of $171.6 million and $9.5 million, respectively, which are subject to change on an annual basis due to variations in the Company&#8217;s annual state apportionment factors. The Company&#8217;s federal and state NOLs carryforwards include $538.6&#160;million and $28.6&#160;million, respectively, attributed to the Flexion Acquisition. Additionally, the Company&#8217;s federal and state tax credits include $11.0&#160;million and $3.6&#160;million, respectively, as a result of the Flexion Acquisition. The federal and state NOLs will begin to expire in 2032 and 2028, respectively. The Company had non-U.S. tax NOLs of $10.3 million at December&#160;31, 2021. The non-U.S. NOLs do not expire.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company had cumulative changes in ownership of more than 50% within a three-year period, under IRC sections 382 and 383, the Company&#8217;s ability to use certain net operating losses, tax attributes and credit carryforwards to offset taxable income or tax will be limited. Such ownership changes were triggered by the initial acquisition of the Company&#8217;s stock in 2007 as well as cumulative ownership changes arising as a result of the completion of the Company&#8217;s initial public offering and other financing transactions. Additionally, on November 19, 2021, the Company completed the Flexion Acquisition which also triggered an ownership change. As a result of these ownership changes, the Company estimates $531.7 million of federal net operating losses and $21.2&#160;million of other tax attributes are subject to annual limitations. At December&#160;31, 2021, all of these federal net operating losses and other tax attributes were available. The Company estimates that an additional $35.4 million will come available in each of 2022 to 2025, $30.8 million in 2026 and $6.9 million in 2027 and thereafter.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 740, the Company establishes a valuation allowance for deferred tax assets that, in its judgment, are not more-likely-than-not realizable. These judgments are based on projections of future income, including tax-planning strategies, by individual tax jurisdictions. In each reporting period, the Company assesses the likelihood that its deferred tax assets will be realized and determines if adjustments to its valuation allowance are appropriate. The Company had a net increase in its valuation allowance of $16.5 million and a net reduction in its valuation allowance of $126.6 million for the years ended December&#160;31, 2021 and December 31, 2020, respectively. The current year net increase in The Company&#8217;s valuation allowance includes $12.5&#160;million as a result of the Flexion Acquisition, $2.2&#160;million against U.S. capital loss carryforwards and $1.8&#160;million against foreign net deferred tax assets. The Company continues to maintain a full valuation allowance against foreign net deferred tax assets since it is more-likely-than-not the tax benefit related to the foreign losses are not realizable. During the year ended December 31, 2020, the Company determined that there was sufficient positive evidence to conclude that it is more likely than not that additional domestic deferred taxes of $126.6&#160;million are realizable and, therefore, reduced the valuation allowance accordingly.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded a reserve of $2.9 million related to unrecognized tax benefits, or UTBs of which $4.3&#160;million related to tax credit positions taken during the year, offset by a $1.4&#160;million reduction for prior year tax credit positions. The Company&#8217;s UTB liability at December 31, 2021 was $9.0 million. The change in the Company&#8217;s UTBs for the year ended December&#160;31, 2021 is summarized as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrecognized<br/>Tax Benefit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions for current year positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction for prior year positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,021&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly assesses the likelihood of additional tax assessments by jurisdiction and, if necessary, adjusts its reserve for UTBs based on new information or developments. Due to the Company&#8217;s tax credit carryforwards, the reserve was recorded as a reduction of the Company&#8217;s deferred tax assets, and any potential deficiency would not result in a tax liability. Therefore, no interest or penalties were recognized in income tax expense for the years ended December&#160;31, 2021, 2020 and 2019. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently subject to audit by the U.S. Internal Revenue Service, or IRS, for the years 2018 through 2021, and state tax jurisdictions for the years 2017 through 2021. However, the IRS or states may still examine and adjust an NOL arising from a closed year to the extent it is utilized in a year that remains subject to audit. The Company&#8217;s previously filed income tax returns are not presently under audit by the IRS or state tax authorities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251722840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">401(k) Plan</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 401(k) plan is a deferred salary arrangement under section 401(k) of the IRC. Under the 401(k) plan, participating U.S. employees may defer a portion of their pre-tax earnings which are eligible for a discretionary percentage match as defined in the 401(k) plan and determined by the Company&#8217;s board of directors (up to the maximum amount permitted by the IRC). The Company recognized $2.8 million, $2.9 million and $2.6 million of related compensation expense for its 401(k) discretionary match for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Compensation Plan</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company&#8217;s board of directors adopted the Company&#8217;s Deferred Compensation Plan, or DCP. The Company intends that the DCP constitute, and be construed and administered as, an unfunded plan of deferred compensation within the meaning of the Employee Retirement Income Security Act of 1974, as amended, and the IRC of 1986, as amended, under which eligible participants may elect to defer the receipt of current compensation. Eligible participants include select management and highly compensated employees of the Company, including the Company&#8217;s named executive officers. Pursuant to the DCP, subject to any minimum and maximum deferral requirements that the administrator of the DCP may establish, participants may elect to defer their base salary and annual incentive awards. In addition to elective deferrals, the DCP permits the Company to make matching and certain other discretionary contributions to the participants. The Company recognized $0.2&#160;million of related compensation expense for its DCP discretionary match for each of the years ended December&#160;31, 2021 and 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Long-Term Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company&#8217;s board of directors adopted a cash long-term incentive plan, or LTIP, commencing in 2021, focused on pre-determined, objective performance goals. The LTIP provides cash awards to participants based on the achievement of certain performance goals during each applicable performance period from January 1 through December 31 of each calendar year. Award amounts ranging from 0% to 225% of the target cash award are earned based on achievement of two equally weighted financial metrics: net revenue and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), with a relative total shareholder return modifier based on the Company&#8217;s stock price performance relative to the companies comprising the S&amp;P Pharmaceuticals Select Industry Index. The performance period for these metrics is one year, with an additional three years of time-vesting following the performance period. The first performance period began on January </span></div>1, 2021, and for the year ended December&#160;31, 2021, the Company recognized $1.1&#160;million of related compensation expense under the LTIP, which is payable to participants in January 2025 after the three-year vesting period concludes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251796312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock', window );">ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET</a></td>
<td class="text">ACQUISITION&#8211;RELATED CHARGES, PRODUCT DISCONTINUATION AND OTHER<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related charges, product discontinuation and other for the years ended December&#160;31, 2021, 2020 and 2019 are summarized below (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance-related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other acquisition expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition-related charges</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyoScience contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination of Nuance agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinuation of DepoCyt(e)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Department of Justice settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition-related charges, product discontinuation and other</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flexion Acquisition</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized acquisition-related costs of $40.2&#160;million, primarily</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> severance, legal fees, third-party services and other one-time charges</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the year ended December 31,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2021 related to the Flexion Acquisition.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, as part of the purchase price consideration related to the Flexion Acquisition, the Company recorded a contingent consideration of $45.2&#160;million, which represents the Company&#8217;s achievement of meeting regulatory and sales-based milestones. From the date of the acquisition through December&#160;31, 2021, the Company recorded an additional $1.2&#160;million charge due to an estimated $0.02 per CVR increase to the fair value of contingent consideration, which was included in acquisition-related charges in the consolidated statements of operations. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Flexion Acquisition, the Company initiated a restructuring through a headcount reduction in the sales and administrative functions. </span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MyoScience Acquisition</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized acquisition-related and other charges of $0.7&#160;million, $0.2&#160;million and&#160;$4.9&#160;million during the years ended December 31, 2021, 2020 and 2019, respectively, related to the MyoScience Acquisition. The 2021 charges relate to one-time termination benefits in the event of a facility closure. For more information see Note 21, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2020 charges relate to acquisition-related accounting services. The 2019 charges include $4.2 million for advisory costs, including legal, financial, accounting and tax services and $0.7 million for separation costs, asset write-downs and other restructuring charges. In addition, the Company recognized a contingent consideration credit of $2.2&#160;million in 2021 and contingent consideration charges of $5.2&#160;million and $16.7&#160;million in 2020 and 2019, respectively. See Note 12, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the MyoScience Acquisition, the Company initiated a restructuring through a headcount reduction in the sales and administrative functions. In addition, the Company terminated a number of existing distributor agreements that were maintained by MyoScience.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nuance Biotech Co. Ltd.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered an agreement with Nuance Biotech Co. Ltd., or Nuance, a China-based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL in China. Under the terms of the agreement, the Company had granted Nuance the exclusive rights to develop and commercialize EXPAREL. In April 2021, the Company and Nuance agreed to a mutual termination of the agreement due to the lack of a viable regulatory pathway that adequately safeguards the Company&#8217;s intellectual property against the risk of a generic product. Dissolution costs of $3.0&#160;million were included in acquisition-related charges, product discontinuation and other in the consolidated statements of operations during the year ended December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DepoCyt(e) Discontinuation</span></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company received formal notice of the termination of a Supply Agreement and a Distribution Agreement (and all related agreements as subsequently amended) from Mundipharma International Corporation Limited and Mundipharma Medical Company, respectively (collectively, &#8220;Mundipharma&#8221;). In November 2019, the Company reached a settlement with Mundipharma and made a $5.3 million payment related to the DepoCyt(e) discontinuation which had previously been accrued.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a gain of $0.2 million during the year ended December 31, 2020, and a charge of $0.2 million in the year ended December 31, 2019, respectively, related to the discontinuation of its DepoCyt(e) manufacturing activities in June 2017 due to persistent technical issues specific to the DepoCyt(e) manufacturing process. No costs related to the Company&#8217;s DepoCyt(e) discontinuation were recognized in the year ended December&#160;31, 2021 as the lease of the idle DepoCyt(e) manufacturing facility expired in August 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Inquiry Settlement</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company recorded a charge of $3.5&#160;million for the settlement of a U.S. Department of Justice inquiry. Refer to Note 21, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further information surrounding our legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire description for costs incurred to effect a business combination that have been expensed during the period.  Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251917368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CommercialPartnersAndAgreementsTextBlock', window );">COMMERCIAL PARTNERS AND OTHER AGREEMENTS</a></td>
<td class="text">COMMERCIAL PARTNERS AND OTHER AGREEMENTS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Thermo Fisher Scientific Pharma Services</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2014, the Company and Thermo Fisher entered into a Strategic Co-Production Agreement, a Technical Transfer and Service Agreement (the &#8220;EXPAREL Technical Transfer and Service Agreement&#8221;) and a Manufacturing and Supply Agreement to collaborate in the manufacture of EXPAREL. Under the terms of the EXPAREL Technical Transfer and Service Agreement, Thermo Fisher agreed to undertake certain technical transfer activities and construction services needed to prepare its Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. The Company contracted to purchase EXPAREL from Thermo Fisher, beginning with FDA approval of the first suite, which occurred in May 2018. Commercial production began in February 2019. Under these agreements, the Company makes monthly base fee payments to Thermo Fisher. Unless earlier terminated by giving notice of up to three years (other than termination by the Company in the event of a material breach by Thermo Fisher), this agreement will expire in May 2028.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in July 2015, Flexion and Thermo Fisher entered into a Manufacturing and Supply Agreement (the &#8220;ZILRETTA Manufacturing and Supply Agreement&#8221;) and a Technical Transfer and Service Agreement related to the manufacture of ZILRETTA at the same Thermo Fisher site in Swindon, England where the Company&#8217;s EXPAREL suites are located. Thermo Fisher agreed to undertake certain transfer activities and construction services needed to prepare its facility for the commercial manufacture of ZILRETTA in dedicated manufacturing suites. Flexion provided Thermo Fisher with certain equipment and materials necessary to manufacture ZILRETTA. The Company makes monthly payments to Thermo Fisher for such activities and reimburses Thermo Fisher for certain material, equipment and miscellaneous expenses and additional services.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the ZILRETTA Manufacturing and Supply Agreement that the Company assumed as part of the Flexion Acquisition expires in October 2027. The Company pays a monthly base fee to Thermo Fisher for the operation of the manufacturing suites and a per product fee for each vial of ZILRETTA based upon a forecast of commercial demand. The Company also reimburses Thermo Fisher for purchases of materials and equipment made on its behalf, certain nominal expenses and additional services. The ZILRETTA Manufacturing and Supply Agreement will remain in full effect unless and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until it expires or is terminated. Upon termination of the ZILRETTA Manufacturing and Supply Agreement (other than termination by the Company in the event that Thermo Fisher does not meet the construction and manufacturing milestones or for a breach by Thermo Fisher), the Company will be obligated to pay for the costs incurred by Thermo Fisher associated with the removal of its manufacturing equipment and for Thermo Fisher&#8217;s termination costs up to a specified capped amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eurofarma Laboratories S.A.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a distribution agreement with Eurofarma Laboratories S.A., or Eurofarma, for the development and commercialization of EXPAREL in Latin America. Under the terms of the agreement, Eurofarma obtained the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia and Mexico. In addition, Eurofarma is responsible for regulatory filings for EXPAREL in these countries. The Company received a $0.3&#160;million upfront payment that is partially refundable upon certain circumstances and will receive royalties based on Eurofarma&#8217;s future commercialization of the product and is also eligible to receive milestone payments that are triggered by the achievement of certain regulatory and commercial events. The Company recognized $0.1&#160;million of collaborative licensing and milestone revenue in its consolidated statements of operations during the year ended December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Verve Medical Products, Inc.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a licensing agreement with Verve Medical Products, Inc. for the distribution of iovera&#176; in Canada. The Company began selling iovera&#176; in Canada in the fourth quarter of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DePuy Synthes Sales, Inc.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company announced a Co-Promotion Agreement with DePuy Synthes Sales, Inc., or DePuy Synthes, part of the Johnson &amp; Johnson family of companies, to market and promote the use of EXPAREL for orthopedic procedures in the U.S. DePuy Synthes field representatives, specializing in joint reconstruction, spine, sports medicine, trauma and cranio-maxillofacial (CMF) procedures, collaborated with and supplemented the Company&#8217;s field teams by expanding the reach and frequency of EXPAREL education in the hospital surgical suite and ambulatory surgery center settings.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company notified DePuy Synthes that the Co-Promotion Agreement would terminate on January 2, 2021. The Company recorded termination-related costs of $8.8&#160;million which were recorded in selling, general and administrative expense during the year ended December 31, 2020.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aratana Therapeutics,&#160;Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2012, the Company entered into a worldwide license, development and commercialization agreement with Aratana Therapeutics,&#160;Inc., a wholly owned subsidiary of Elanco Animal Health, Inc., or Aratana. Under the agreement, the Company granted Aratana an exclusive royalty-bearing license, including the limited right to grant sublicenses, for the development and commercialization of the Company&#8217;s bupivacaine liposome injectable suspension product for veterinary use. Under the agreement, Aratana developed and obtained FDA approval for the use of the product in veterinary surgery to manage postsurgical pain. The Company is eligible to receive from Aratana up to an aggregate of $40.0 million upon the achievement of commercial milestones. Aratana is required to pay the Company a tiered double-digit royalty on certain net sales made in the U.S. If the product is approved by foreign regulatory agencies for sale outside of the U.S., Aratana will be required to pay the Company a tiered double-digit royalty on such net sales. Royalty rates will be reduced by a certain percentage upon the entry of a generic competitor for animal health indications into certain jurisdictions or if Aratana must pay royalties to third parties under certain circumstances. Unless terminated earlier pursuant to its terms, the license agreement is effective until July 2033, after which Aratana has the option to extend the agreement for an additional five-year term, subject to certain requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aratana began purchasing bupivacaine liposome injectable suspension product in 2016, which they market under the trade name NOCITA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a registered trademark of Aratana) for veterinary use.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hong Kong Pharma Tainuo Ltd.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in March 2020, Flexion entered into an exclusive license agreement with Hong Kong Tainuo Pharma Ltd., or HK Tainuo, and Jiangsu Tainuo Pharmaceutical Co. Ltd., or Jiangsu Tainuo, a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd., for the development and commercialization of ZILRETTA in Greater China (consisting of mainland China, Hong Kong, Macau and Taiwan). Under the terms of the agreement, HK Tainuo paid Flexion an upfront payment of $10.0&#160;million during the year ended December 31, 2020 which was recorded as deferred revenue as of December 31, 2021. The Company is also eligible to receive up to $32.5&#160;million in aggregate development, regulatory and commercial sales milestone payments. HK Tainuo is responsible for the clinical development, product registration and commercialization of ZILRETTA in Greater China. The Company is solely responsible for the manufacture and supply of ZILRETTA to HK Tainuo for all clinical and commercial activities. The terms related to product manufacturing and supply, including pricing and minimum purchase requirements agreed to in the license agreement, will be covered by a separate supply agreement, which has not yet been finalized. Unless terminated earlier in accordance with its terms, the license agreement continues in effect in perpetuity or as long as HK Tainuo or Jiangsu Tainuo continue to sell ZILRETTA in Greater China. The proceeds associated with the upfront payment have been recorded in long-term deferred revenue on the consolidated balance sheet, as there is uncertainty around the timing of when the revenue will be recognized.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CommercialPartnersAndAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the entire disclosure of commercial agreement and arrangement with third parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CommercialPartnersAndAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251947960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONSIn April 2012, the Company entered into a consulting agreement with Dr. Gary Pace, a director of the Company. In connection with the consulting agreement, Dr. Pace received an option to purchase 20,000 shares of common stock at an exercise price of $11.02 per share and an option to purchase 70,000 shares of common stock at an exercise price of $16.67 per share, the latter of which were fully exercised in 2020. No services were provided under the consulting agreement in the years ended December&#160;31, 2021, 2020, or 2019, and as of December&#160;31, 2021 and 2020, there was nothing payable to Dr. Pace for consulting services.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105446315832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to patents, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings that it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MyoScience Milestone Litigation</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company and its subsidiary, Pacira CryoTech, Inc. (&#8220;Pacira CryoTech&#8221;), filed a lawsuit in the Court of Chancery of the State of Delaware against Fortis Advisors LLC (&#8220;Fortis&#8221;), solely in its capacity as representative for the former securityholders of MyoScience, and certain other defendants, seeking declaratory judgment with respect to certain terms of the merger agreement for the MyoScience Acquisition (the &#8220;Merger Agreement&#8221;), specifically related to the achievement of certain milestone payments under the Merger Agreement. In addition, the Company and Pacira CryoTech sought general, special and compensatory damages against the other defendants related to breach of fiduciary duties in connection with the purported achievement of milestone payments under the Merger Agreement, and breach of the Merger Agreement and certain other agreements with the defendants. In October 2020, Fortis filed an answer and counterclaim against the Company and Pacira CryoTech seeking to recover certain milestone payments under the Merger Agreement. The total remaining value of these milestones is $30.0&#160;million, plus attorneys&#8217; fees. The Company believes that the counterclaim from Fortis is without merit and intends to vigorously defend against all claims. The Company is unable to predict the outcome of this action at this time.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">eVenus Pharmaceutical Laboratories Litigations</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company received a Notice Letter advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,033,495 (the &#8217;495 patent).</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company filed a patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (21-cv-19829) asserting infringement of the &#8217;495 patent. This triggered an automatic 30-month stay of final approval of the eVenus ANDA. On January 6, 2022, eVenus filed an Answer with counterclaims to the Complaint, alleging the &#8217;495 patent is invalid and/or not infringed through the manufacture, sale, or offer for sale of the product described in product described in eVenus&#8217;s ANDA submission.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received a second Notice Letter advising that eVenus submitted to the FDA an amendment to its ANDA with a Paragraph IV Certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (133 mg/10 mL) in the U.S. prior to the expiration of the &#8217;495 patent. In the Notice Letter, eVenus also advised that it submitted a Paragraph IV Certification to the FDA seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL and 133 mg/10 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,179,336 (the &#8217;336 patent). eVenus further alleges in the Notice Letter that both the &#8217;495 patent and the &#8217;366 patent are invalid and/or not infringed.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company filed a second patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (22-cv-00718) asserting that the 133 mg/10 mL ANDA product will infringe the &#8217;495 and &#8217;336 patents and that the 266 mg/20 mL ANDA product will infringe the &#8217;336 patent. This filing triggered a second automatic 30-month stay of final approval for the 133 mg/10 mL ANDA product.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These litigations are in their infancy, and the Company is unable to predict the outcome of this action at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Development Foundation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an agreement with the Research Development Foundation, or RDF, the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products, for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company&#8217;s U.S. Patent No. 11,033,495 issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company&#8217;s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement was set to end on December 24, 2021 with the expiration of its U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit seeks a declaration from the court that the Company owes no royalties to RDF with respect to its EXPAREL product after December 24, 2021. During the pendency of the lawsuit, the Company will continue to pay royalties to RDF under protest, however, the Company is unable to predict the outcome of this action at this time.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Inquiry Settlement</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2015, the Company received a subpoena from the U.S. Department of Justice, U.S. Attorney&#8217;s Office for the District of New Jersey pertaining to marketing and promotional practices related to EXPAREL. In July 2020, the Company formally entered into settlement agreements that resolved all outstanding investigations and claims by the United States Department of Justice, the United States Department of Health and Human Services, various States Attorneys&#8217; General and a private plaintiff. This agreement concluded a five-year investigation related to the sale and marketing of EXPAREL. Under the various settlement agreements, the Company paid a global settlement of $3.5&#160;million, which was recorded in acquisition-related charges, product discontinuation and other in the consolidated financial statements for the year ended December 31, 2019. The Company expressly denies all allegations and contentions and has admitted no wrongdoing in connection with the settlement agreements. The Company has been given assurances that this concluded the investigation that originated from the U.S. Department of Justice subpoena in April 2015.</span></div><div><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Obligations</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately $50.3 million of minimum, non-cancelable contractual commitments for contract manufacturing services and $9.2 million of minimum, non-cancelable contractual commitments for the purchase of certain raw materials as of&#160;December&#160;31, 2021.</span></div><div style="margin-bottom:7pt;margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Trial Commitments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL in pediatric patients, as well as the administration of EXPAREL as a nerve block in the pediatric setting. The Company was granted a deferral for the required pediatric trials until after the indications were approved in adults. Similarly, in Europe, the Company agreed with the European Medicines Agency, or EMA, on a Pediatric Investigation Plan as a prerequisite for submitting a Marketing Authorization Application (MAA) in the E.U. Despite the U.K.&#8217;s withdrawal from the E.U., the agreed pediatric plan is applicable in the U.K.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company announced positive results for its extended pharmacokinetic and safety study (&#8220;PLAY&#8221;) for local analgesia in children aged six to 17 undergoing cardiovascular or spine surgeries. Those positive results were the basis for the submission of a supplemental New Drug Application, or sNDA, in the U.S. and Type II variations in the E.U. and U.K. to expand the EXPAREL label to include use in patients six years of age and older for single-dose infiltration to produce postsurgical local analgesia. In March 2021, the Company announced that the FDA approved the submission of the sNDA in the U.S. The EMA and the Medicines and Healthcare Products Regulatory Agency, or MHRA, are still reviewing the Type II variations.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is working with the FDA, MAA and MHRA to finalize the regulatory pathway for its remaining pediatric commitments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Milestone Payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information on potential contingent milestone payments related to the MyoScience and Flexion acquisitions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCRX-201 and PCRX-301 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PCRX-201 (formerly FX-201) and PCRX-301 (formerly FX-301) were added to the Company&#8217;s portfolio as part of the Flexion Acquisition. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in February 2017, Flexion entered into an agreement with GeneQuine to acquire the global rights to PCRX-201, a gene therapy product candidate. As part of the agreement, up to an aggregate of $56.0&#160;million of payments could become due upon the achievement of certain development and regulatory milestones.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in September 2019, Flexion entered into a definitive agreement with Xenon Pharmaceuticals, Inc. to acquire the global rights to PCRX-301, a locally administered Na</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 inhibitor. As part of the agreement, up to an aggregate of $45.8&#160;million of payments could become due upon the achievement of certain development and regulatory milestones and up to $75.0&#160;million of payments could become due for sales-related milestones.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One-Time Termination Benefits</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has communicated to a select number of employees a commitment to provide one-time termination benefits in the event that a facility closure occurs. The Company is recognizing these expenses ratably over the remaining service period required. The Company currently estimates the total cost of these one-time benefits to be approximately $1.1&#160;million. During the year ended December 31, 2021, the Company recognized $0.7&#160;million in one-time termination charges, which are included in acquisition-related (gains) charges, product discontinuation and other in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251842344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 22&#8212;SUBSEQUENT EVENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Placeholder</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247563864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC. The accounts of the Company&#8217;s wholly owned subsidiaries are included in these consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC. The accounts of the Company&#8217;s wholly owned subsidiaries are included in these consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, purchase price allocation, stock-based compensation, inventory costs, impairments of equity investments, long-lived assets, goodwill, liabilities and accruals, including contingent consideration, </span></div>convertible senior notes, and the valuation of deferred tax assets. The Company&#8217;s critical accounting policies are those that are both most important to the Company&#8217;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue From Contracts With Customers</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue From Contracts With Customers</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s sources of revenue include (i) sales of EXPAREL in the U.S., European Union, or E.U. and the United Kingdom, or U.K.; (ii) sales of ZILRETTA in the U.S.; (iii) sales of iovera&#176; in the U.S., and Canada; (iv) sales of, and royalties on, its bupivacaine liposome injectable suspension, including for veterinary use and (v) license fees and milestone payments. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further information on the Company&#8217;s accounting policies related to revenue from contracts with customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Licensing and Milestone Revenue</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements generally involve a license to the Company&#8217;s products. In determining how and when to recognize the revenue under a collaboration agreement, the Company must assess whether the license is distinct, which depends upon whether the customer can benefit from the license and whether the license is separate from other performance obligations in the agreement. If the license is distinct, the Company must further assess whether the customer has a right to access or a right to use the license depending on whether the functionality of the license is expected to substantively change over time. If the license is not expected to substantively change, the revenue is recognized at the point in time when the license is provided. If the license is expected to substantively change, the revenue is recognized over the license period.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (e.g. obtaining regulatory approval) represent variable consideration and would be included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third-party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales are incurred or the performance obligation to which the sales relate has been satisfied.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties are estimated and recognized as revenue when sales to the Company&#8217;s commercial partners occur, unless some constraint exists, as the royalties predominately relate to a supply agreement. Royalties are based on sales of the Company&#8217;s bupivacaine liposome injectable suspension product for veterinary use.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersPolicyPolicyTextBlock', window );">Concentration of Major Customers</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Major Customers</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health,&#160;Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The Company also sells EXPAREL directly to ambulatory surgery centers and physicians. The Company sells ZILRETTA primarily to specialty distributors and a specialty pharmacy, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as Group Purchasing Organizations, or GPOs. The Company sells its bupivacaine liposome injectable suspension for veterinary use to a third-party licensee in the U.S. and sells iovera&#176; directly to end users.</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes the percentage of revenues comprised by the Company&#8217;s three largest wholesalers in each period presented:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Largest wholesaler</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second largest wholesaler</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third largest wholesaler</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>Revenue from outside the U.S. accounted for less than 1% of the Company&#8217;s total revenue for the year ended December 31, 2021. The Company began selling EXPAREL in the E.U. and U.K. and iovera&#176; in Canada in the fourth quarter of 2021. The Company had no revenue from outside the U.S. during the years ended December&#160;31, 2020 and 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. These include both internal and external costs, of which a significant portion of development activities are outsourced to third parties, including contract research organizations. Clinical trial costs are accrued over the service periods specified in contracts and adjusted as necessary based on an ongoing review of the level of effort and actual costs incurred. Research and development costs are presented net of reimbursements from commercial partners.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues interest and penalties, if any, on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in its consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation consists of grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors, in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&#8217;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value in addition to the closing price of the Company&#8217;s common stock on the date of grant:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Expected term of the option</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Expected volatility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Expected dividends</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Risk-free interest rate</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes its historical volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option activity. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero-coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&#8217;s common stock is estimated to be zero as the Company has not declared or paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. Additionally, the Company&#8217;s ability to declare and pay a dividend in the future could be limited per the agreements governing its indebtedness. The Company records forfeitures as they occur rather than estimating forfeitures during each reporting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsAll highly liquid investments with maturities of 90 days or less when purchased are considered cash equivalents. Cash equivalents include corporate debt securities, asset backed securities and money market funds.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-Term and Long-Term Investments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term and Long-Term Available-For-Sale Investments</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term available-for-sale investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper, corporate and government bonds, and other bonds issued in the U.S. (and denominated in the U.S. dollar) by foreign entities, all with maturities of greater than three months, but less than one year. Long-term available-for-sale investments consist of corporate and government agency bonds with maturities greater than one year. The Company evaluates the classification of its investments at the time of purchase and re-evaluates such determination at each balance sheet date, which includes an assessment of the intent to hold the available-for-sale securities. The Company&#8217;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. The Company classifies its investments as available-for-sale. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities (except for credit losses) are excluded from net income (loss) and are reported as a separate component of accumulated other comprehensive income (loss) until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. The Company evaluates whether a credit loss exists, and in the event a credit loss does exist, the credit loss is recognized in the consolidated statements of operations, based on the amount that the fair value is less than the amortized cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value, and is determined using the first-in, first-out (&#8220;FIFO&#8221;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fixed Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. Useful lives by asset category are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 10 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationsPolicy', window );">Asset Retirement Obligations</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Retirement Obligations</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of such lease agreements. The Company records its asset retirement obligations, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records expense to accrete the ARO to its full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes right-of-use, or ROU, assets and lease liabilities at the commencement of its lease agreements. The leases are evaluated at commencement to determine whether they should be classified as operating or financing leases. Lease costs associated with operating leases are recognized on a straight-line basis, while lease costs for financing leases are recognized over the lease term using the effective interest method. The Company does not have any financing leases. The amount of ROU assets and lease liabilities to be recognized is impacted by the type of lease payments, the lease term and the incremental borrowing rate. Variable lease payments are not included at commencement and are recognized in the period in which they are incurred. The lease term is based on the contractual term and is adjusted for any renewal options or termination rights that are reasonably certain to be exercised. The incremental borrowing rate is based on the rate the Company estimates it would pay on a collateralized basis over a similar term in a similar economic environment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values, with some exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value can be determined, the asset or liability is recognized; if fair value is not determinable, then no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. </span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development, or IPR&amp;D, is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is recorded as an expense at the acquisition date.</span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#8217;s consolidated financial statements after the date of the acquisition.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to an acquisition, the Company measures contingent consideration arrangements at fair value each period, with changes in fair value recognized in the consolidated statements of operations as acquisition-related charges. Changes in contingent consideration can result from changes in the assumed achievement and timing of estimated sales, costs of goods sold and regulatory approvals. In the absence of new information, changes in fair value reflect the passage of time towards achievement of the milestones, and are accreted to the period in which payments are expected to be made.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired in a business combination and is not amortized, but is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their estimated useful lives and are recorded at cost, net of accumulated amortization.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Investments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Investments</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in equity securities without a readily determinable fair value. In the fourth quarter of 2019, the equity investment then held became publicly traded and thereafter, was recognized at its fair value at each reporting period with any unrealized holding gains (losses) included in other income (expense). The equity method investments without a readily determinable fair value are recognized at cost less any impairments, plus or minus any changes resulting from observable price changes in orderly transactions for a similar investment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Debt Transactions</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Debt Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the expected impact of Accounting Standards Update 2020-06 on accounting for convertible debt, which is effective January 1, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement of the convertible debt, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the retirement of the equity component and is recognized as a reduction of additional paid-in capital.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per Share Data</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Per Share Data</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the RSUs expected to vest, the shares to be purchased under the Company&#8217;s employee stock purchase plan (using the treasury stock method), and the excess conversion value on the Company&#8217;s convertible senior notes. See Note 3,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the expected impact of Accounting Standards Update 2020-06 on the calculation of dilutive shares for convertible debt, which is effective January 1, 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currencies</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currencies</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet accounts of the Company&#8217;s foreign subsidiaries with functional currencies other than the U.S. Dollar are translated using the exchange rate at each respective balance sheet date.&#160;Revenues and expenses are translated using average exchange rates for each calendar month during the year.&#160;Translation&#160;adjustments are recorded as a component of accumulated other comprehensive income (loss) in the consolidated financial statements. Gains or losses from foreign currency exchanges are recorded in other, net in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one reportable operating segment to evaluate performance, allocate resources, set operational targets and forecast its future financial results.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:0.5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2021-08,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amends Accounting Standards Codification, or ASC, 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. As a result of the amendments made by the ASU, it is expected that an acquirer will generally recognize and measure acquired contract assets and contract liabilities in a manner consistent with how the acquiree recognized and measured them in its pre-acquisition financial statements. The ASU&#8217;s amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (i) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (ii) prospectively to all business combinations that occur </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on or after the date of initial application. The Company has decided to early adopt this standard and will apply it to the valuation of a Flexion deferred revenue contract.</span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amended the approaches and methodologies in accounting for income taxes during interim periods and makes changes to certain income tax classifications. The standard allows for certain exceptions, including the exception to the use of the incremental approach for intra-period tax allocations, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to-date loss exceeds the anticipated loss for the year. The standard also required franchise or similar taxes partially based on income to be reported as income tax and to reflect the effects of enacted changes in tax laws or rates in the annual effective tax rate computation from the date of enactment. Lastly, in future acquisitions, the Company will be required to evaluate when the step-up in the tax basis of goodwill is part of the business combination and when it should be considered a separate transaction. The standard became effective for the Company beginning January 1, 2021, and there were no material impacts to the consolidated financial statements upon adoption.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2021</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which limits the number of convertible instruments that require separate accounting to (i) those with embedded conversion features that are not clearly and closely related to the debt, that meet the definition of a derivative, and that do not qualify for the scope exception from derivative accounting and (ii) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid in capital. In addition, the new guidance requires diluted earnings per share calculations to be prepared using the if-converted method, instead of the treasury stock method. The guidance must be applied in fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted no earlier than for fiscal years beginning after December 15, 2020. The Company has elected to adopt the new guidance using a modified retrospective method of transition, which would be applied to transactions outstanding at January 1, 2022. As a result, after adopting the ASU&#8217;s guidance, the Company will not separately present in equity an embedded conversion feature for its convertible debt. Instead, the Company will account for a convertible debt instrument wholly as debt. In addition, the Company will not record interest expense on the previously recorded discount on convertible debt. The impact on the balance sheet at January 1, 2022 increased net debt by approximately $64.9&#160;million, reduced accumulated deficit by $47.2&#160;million, reduced additional paid-in capital by $96.5&#160;million and decreased deferred tax liabilities by $15.7&#160;million. The impact on the consolidated statement of operations will reduce interest expense by approximately $18.0&#160;million in 2022, with a resultant impact on basic and diluted income (loss) per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105246402360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Revenue Comprised of the Three Largest Customers</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below includes the percentage of revenues comprised by the Company&#8217;s three largest wholesalers in each period presented:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Largest wholesaler</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second largest wholesaler</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third largest wholesaler</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Useful Lives by Asset Category</a></td>
<td class="text">Useful lives by asset category are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 10 years</span></div></td></tr></table><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net, summarized by major category, consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,641&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,048&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105253150072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock', window );">Summary of Activity in Accrued Rebates and Chargebacks, Returns, Wholesaler Service Fees and Prompt Pay Discounts</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of activity with respect to the Company&#8217;s sales related allowances and accruals related to EXPAREL for the years ended December&#160;31, 2021, 2020 and 2019, as well as ZILRETTA for the year ended December 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:25.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Returns Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prompt Payment Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Service Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Volume Rebates and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Payments/Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,447)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,804&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Payments/Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,496)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,561)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Payments/Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,494&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregated net product sales in the periods presented as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;EXPAREL</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;ZILRETTA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;iovera&#176;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Bupivacaine liposome injectable suspension</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total net product sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MovementinValuationandQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Movement in Valuation and Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MovementinValuationandQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258061128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Contingent Consideration for Flexion Acquisition</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration for the Flexion Acquisition was $578.8&#160;million, which consisted of the following (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value of Purchase Price Consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of purchase consideration paid at closing:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for all outstanding shares of Flexion&#8217;s common stock (50,392 shares of common stock acquired at $8.50 per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration paid to settle RSUs and in-the-money options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid to settle Flexion debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent value rights (CVRs)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the preliminary allocation of the Flexion Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts Recognized at the Acquisition Date</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS ACQUIRED</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term available-for-sale investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development (IPR&amp;D) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES ASSUMED</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Information</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexion results from the acquisition date of November 19, 2021 through December 31, 2021, which are included in the consolidated statements of operations, are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification in Consolidated Statements of Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisition Date Through <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>This pro forma information does not purport to represent what the Company&#8217;s actual results would have been if the acquisition had occurred as of January 1, 2020, and is not indicative of what such results would be expected for any future period (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended&#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630,942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251947960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Components of Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251829928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Useful Lives by Asset Category</a></td>
<td class="text">Useful lives by asset category are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 10 years</span></div></td></tr></table><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net, summarized by major category, consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,641&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,048&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251898440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text">Total operating lease costs are as follows (in thousands):<div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Lease Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, net of lease incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets recorded in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The weighted average remaining lease term and the weighted average discount rate are summarized as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.77 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.18 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.96%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.87%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, maturities of the Company&#8217;s operating lease liabilities are as follows (in thousands): </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Payments Due</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251922520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of Change in Carrying Value of Goodwill</a></td>
<td class="text">The change in the carrying value of the Company&#8217;s goodwill is summarized as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:83.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.026%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 accumulated adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill arising from milestones achieved under the Skyepharma Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill arising from the Flexion Acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consist of the IPR&amp;D and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible<br/>Assets, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average <br/>Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,097)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years, 5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,122)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,122)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible<br/>Assets, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average <br/>Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,553)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,569)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251785496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and wholesaler service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258372408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company&#8217;s outstanding debt is summarized as follows (amounts in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan B facility maturing December 2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% Convertible senior notes due August 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible senior notes due May 2024 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.375% Convertible senior notes due April 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Composition of the Company's Debt and Financing Obligations</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the Term Loan is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan maturing December 2026</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,443)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total debt, net of debt discount and deferred financing costs</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,497&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2025 Notes is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% Convertible senior notes due August 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,940)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,718)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of debt discount and deferred financing costs</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,627&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,030&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2022 Notes is as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.375% Convertible senior notes due April 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of debt discount and deferred financing costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of Total Interest Expense Recognized Related to the Notes</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:55.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual and other interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized interest (Note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate on total debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of interest rate expenses related to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252960248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Carrying Amount and Fair Value of the Long-term Debt</a></td>
<td class="text">The carrying values and fair values of the Company&#8217;s financial assets and liabilities at December&#160;31, 2021 are as follows (in thousands):<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Asset:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Convertible notes receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Acquisition-related contingent consideration </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Liabilities Measured at Amortized Cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facility due December 2026 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2.375% convertible senior notes due 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% convertible senior notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% convertible senior notes due 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The closing price of the Company&#8217;s common stock as reported on the Nasdaq Global Select Market was $60.17 per share at December&#160;31, 2021 compared to a conversion price of $66.89 per share for the 2022 Notes and a conversion price of $71.78 per share for the 2025 Notes. Therefore, at December&#160;31, 2021, the conversion prices were above the stock price. The maximum conversion premium that could have been due on the 2022 Notes and 2025 Notes at December&#160;31, 2021 was&#160;approximately 2.4&#160;million and 5.6&#160;million shares of the Company&#8217;s common stock, respectively. These figures assume no increases in the conversion rate for certain corporate events.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">(2) Relates to the Flexion 2024 Notes. For more information, See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the key assumptions used in the valuation of the Company&#8217;s contingent consideration:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Flexion Ranges Utilized as of <br/>December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MyoScience Ranges Utilized as of <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.39% to 12.92%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.42% to 12.13%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achieving regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00% to 15.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of achieving regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 to 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the Company&#8217;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.588%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent<br/>Consideration<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to the Flexion Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(989)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Payments made or offset against amounts due </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Short-term Investments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company&#8217;s investments at December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021 Investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value<br/>(Level&#160;2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020 Investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level&#160;2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;U.S. Government bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;U.S. Government bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251761464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income</a></td>
<td class="text">The following table illustrates the changes in the balances of the Company&#8217;s accumulated other comprehensive income (loss) for the periods presented (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gains<br/>(Losses) From Available<br/>For Sale Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on investments, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on investments, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on investments, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105250858792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock', window );">Schedule of Information About the Plans</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain information about the Company&#8217;s stock incentive plans at December&#160;31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Incentive Plan</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards Reserved For Issuance</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards<br/>Issued</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards Available For Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011 Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,431,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,425,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Inducement Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,461,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Reserved<br/>For Purchase</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares<br/>Purchased</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Available<br/>For Purchase</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Recognized Stock-based Compensation in Consolidated Statements of Operations</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense in its consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,920&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,920&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of the Company's Stock Option Activity and Related Information</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity and related information for the period from December 31, 2018 to December&#160;31, 2021:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price (Per Share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value<br/>(in Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,722,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425,495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,428,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,925)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,235,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(732,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,050,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,646&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.38&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,972&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,050,540&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions Used to Estimate the Fair Values of Each Option Grant Using the Black-Scholes Option Pricing Model</a></td>
<td class="text">The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43% - 1.21%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22% - 1.60%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33% - 2.54%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.22 years</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSU activity and related information for the period from December 31, 2018 to December&#160;31, 2021:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number<br/>of Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant<br/>Date Fair Value (Per Share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value<br/>(in Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and expected to vest at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Used on ESPP Awards</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the ESPP share options granted were estimated using the Black-Scholes model with the following weighted average assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share option fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.16 - $15.23</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.02 - $17.54</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.13 - $11.36</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50% - 0.90%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14% - 1.57%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% - 2.56%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of ESPP share options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of shares available for issuance which includes information about awards reserved for issuance, awards issued and awards available for grant by plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252215768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Income (Loss) per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income (loss) per common share for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,016)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computation of diluted securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of conversion premium on the 2022 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of ESPP purchase options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding&#8212;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,513&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income (loss) per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income (loss) per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Effect of the Securities Excluded from the Calculation of Diluted Loss per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the outstanding stock options, RSUs and ESPP purchase options that were excluded from the diluted net income (loss) per common share calculation because the effect of including these potential shares were antidilutive in the periods presented (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ESPP purchase options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258777016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes and the related tax expense (benefit) is as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,403&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,089&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,748)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total current taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,613)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,424&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125,434)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Taxes at the U.S. Federal Statutory Rate to the Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647.87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.00)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes refinancing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338(g) tax election</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of the Company's Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities at December&#160;31, 2021 and 2020 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,521)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,485)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,364&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Rollforward</a></td>
<td class="text">The change in the Company&#8217;s UTBs for the year ended December&#160;31, 2021 is summarized as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrecognized<br/>Tax Benefit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions for current year positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction for prior year positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,021&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105251786056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock', window );">Schedule of Acquisition-related Restructuring and Discontinuation Costs</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related charges, product discontinuation and other for the years ended December&#160;31, 2021, 2020 and 2019 are summarized below (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance-related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other acquisition expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition-related charges</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyoScience contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination of Nuance agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinuation of DepoCyt(e)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Department of Justice settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquisition-related charges, product discontinuation and other</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105254391352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>product</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ConcentrationRiskNumberOfProducts', window );">Number of products</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105246473784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Major Customers (Details) - Customer concentration - customer<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ConcentrationRiskNumberofCustomers', window );">Concentration risk, number of customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Largest wholesaler | Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Second largest wholesaler | Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Third largest wholesaler | Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Three largest customers | Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenue from customers to total revenue</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ConcentrationRiskNumberofCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number of Customers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ConcentrationRiskNumberofCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_SecondLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_SecondLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_ThirdLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_ThirdLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_ThreeLargestCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_ThreeLargestCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252838440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Fixed Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252920056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Carrying value of money market funds</a></td>
<td class="nump">$ 223.0<span></span>
</td>
<td class="nump">$ 51.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaperAtCarryingValue', window );">Carrying value of commercial paper</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetBackedSecuritiesAtCarryingValue', window );">Carrying value of asset-backed securities</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ConcentrationRiskNumberofCustomers', window );">Concentration risk, number of customers | customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Sales Revenue, Net | Customers outside U.S. | Customer concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ConcentrationRiskNumberofCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number of Customers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ConcentrationRiskNumberofCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetBackedSecuritiesAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in notes or bonds that are collateralized by a specific group of underlying assets owned by the issuer of the notes or bonds which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetBackedSecuritiesAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaperAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaperAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_CustomersOutsideUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_CustomersOutsideUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258234968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS (Details) - Cumulative Effect, Period of Adoption, Adjusted Balance<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Increase in net debt</a></td>
<td class="nump">$ 64.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncreaseDecreaseInRetainedEarnings', window );">Decrease in accumulated deficit</a></td>
<td class="nump">47.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Decrease in additional paid in capital</a></td>
<td class="nump">96.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncreaseDecreaseInInterestExpense', window );">Decrease in interest expense</a></td>
<td class="nump">$ 18.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncreaseDecreaseInInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncreaseDecreaseInInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncreaseDecreaseInRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Retained Earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncreaseDecreaseInRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247346216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Sales and Valuation Accruals (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">$ 4,798<span></span>
</td>
<td class="nump">$ 4,804<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Provision</a></td>
<td class="nump">41,835<span></span>
</td>
<td class="nump">28,117<span></span>
</td>
<td class="nump">26,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments/Adjustments</a></td>
<td class="num">(34,203)<span></span>
</td>
<td class="num">(28,123)<span></span>
</td>
<td class="num">(25,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">12,430<span></span>
</td>
<td class="nump">4,798<span></span>
</td>
<td class="nump">4,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Provision</a></td>
<td class="nump">3,095<span></span>
</td>
<td class="nump">794<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments/Adjustments</a></td>
<td class="num">(757)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">3,361<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_ReserveForPromptPayDiscountMember', window );">Prompt Payment Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">962<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Provision</a></td>
<td class="nump">10,388<span></span>
</td>
<td class="nump">8,541<span></span>
</td>
<td class="nump">8,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments/Adjustments</a></td>
<td class="num">(10,217)<span></span>
</td>
<td class="num">(8,496)<span></span>
</td>
<td class="num">(8,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_WholesalerservicefeesMember', window );">Service Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Provision</a></td>
<td class="nump">10,112<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
<td class="nump">6,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments/Adjustments</a></td>
<td class="num">(7,644)<span></span>
</td>
<td class="num">(6,755)<span></span>
</td>
<td class="num">(5,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">3,636<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_AllowanceForVolumeRebatesandChargebacksMember', window );">Volume Rebates and Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Provision</a></td>
<td class="nump">17,101<span></span>
</td>
<td class="nump">12,345<span></span>
</td>
<td class="nump">11,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments/Adjustments</a></td>
<td class="num">(15,207)<span></span>
</td>
<td class="num">(12,561)<span></span>
</td>
<td class="num">(10,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">3,494<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_AllowanceForGovernmentRebatesMember', window );">Government Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning of Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Provision</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments/Adjustments</a></td>
<td class="num">(378)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">End of Period</a></td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_ReserveForPromptPayDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_ReserveForPromptPayDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_WholesalerservicefeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_WholesalerservicefeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_AllowanceForVolumeRebatesandChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_AllowanceForVolumeRebatesandChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_AllowanceForGovernmentRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=pcrx_AllowanceForGovernmentRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247945608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AccountsReceivablePaymentTerms', window );">Accounts receivable, payment terms</a></td>
<td class="text">0 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AccountsReceivablePaymentTerms', window );">Accounts receivable, payment terms</a></td>
<td class="text">97 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccountsReceivablePaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccountsReceivablePaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252869336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE- Disaggregation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">$ 538,966<span></span>
</td>
<td class="nump">$ 426,614<span></span>
</td>
<td class="nump">$ 418,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pcrx_EXPARELMember', window );">EXPAREL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">506,515<span></span>
</td>
<td class="nump">413,338<span></span>
</td>
<td class="nump">407,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pcrx_ZILRETTAMember', window );">ZILRETTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">12,683<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pcrx_IoveraMemberMember', window );">iovera&#176;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">16,162<span></span>
</td>
<td class="nump">8,817<span></span>
</td>
<td class="nump">7,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pcrx_BupivacaineLiposomeInjectableSuspensionMember', window );">Bupivacaine liposome injectable suspension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net product sales</a></td>
<td class="nump">$ 3,606<span></span>
</td>
<td class="nump">$ 4,459<span></span>
</td>
<td class="nump">$ 3,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcrx_EXPARELMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcrx_EXPARELMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcrx_ZILRETTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcrx_ZILRETTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcrx_IoveraMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcrx_IoveraMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pcrx_BupivacaineLiposomeInjectableSuspensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pcrx_BupivacaineLiposomeInjectableSuspensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105245363784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">109 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Apr. 09, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2030</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContingentConsiderationCurrent', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember', window );">Myoscience Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration', window );">Contingent value right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContingentConsideration', window );">Maximum total payments for contingent consideration possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContingentConsiderationCurrent', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ContingentConsiderationPaymentTerm', window );">Contingent consideration, payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 578,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="nump">533,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt', window );">Retirement of term loan</a></td>
<td class="nump">85,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration', window );">Contingent value right</a></td>
<td class="nump">45,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Additional amount payable to holders of the CVRs</a></td>
<td class="nump">380,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion | Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion | Developed technologies | Discount rates | Valuation, Income Approach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FiniteLivedIntangibleAssetsMeasurementInput', window );">Discount rate, measurement input</a></td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion | Acquired IPR&amp;D | Discount rates | Valuation Technique, Discounted Cash Flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate', window );">Projected future cash flows discounted, rate</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion | RSUs, In-The-Money Stock Options, and Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementofRegulatoryMilestoneMember', window );">Achievement of Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf250MillionMember', window );">Achievement of ZILRETTA Sales of $250 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Contingent value right (in usd per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf250MillionMember', window );">Achievement of ZILRETTA Sales of $250 Million | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold', window );">Annual product sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf375MillionMember', window );">Achievement of ZILRETTA Sales of $375 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Contingent value right (in usd per share)</a></td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf375MillionMember', window );">Achievement of ZILRETTA Sales of $375 Million | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold', window );">Annual product sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf500MillionMember', window );">Achievement of ZILRETTA Sales of $500 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Contingent value right (in usd per share)</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf500MillionMember', window );">Achievement of ZILRETTA Sales of $500 Million | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold', window );">Annual product sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfFDAApprovalOfFX201Member', window );">Achievement of FDA Approval of FX-201</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Contingent value right (in usd per share)</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfFDAApprovalOfFX301Member', window );">Achievement of FDA Approval of FX-301</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Contingent value right (in usd per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Liabilities Incurred, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Liabilities Incurred, Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price, Annual Product Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount of Contingent Consideration related to the acquisition of a business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContingentConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContingentConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ContingentConsiderationPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ContingentConsiderationPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FiniteLivedIntangibleAssetsMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FiniteLivedIntangibleAssetsMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate which is used to value residual cash flows generated by financial assets of the securitization, asset-backed financing arrangement, or similar transfer for initial fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=d3e107207-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementofRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementofRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf250MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf250MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf375MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf375MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf500MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfZILRETTASalesOf500MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfFDAApprovalOfFX201Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfFDAApprovalOfFX201Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfFDAApprovalOfFX301Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfFDAApprovalOfFX301Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252857736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS - Contingent Consideration Flexion Acquisition (Details) - Flexion<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="nump">$ 533,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt', window );">Cash paid to settle Flexion debt</a></td>
<td class="nump">85,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration', window );">Fair value of contingent value rights (CVRs)</a></td>
<td class="nump">45,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
<td class="nump">578,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Debt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt', window );">Cash paid to settle Flexion debt</a></td>
<td class="nump">85,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="nump">428,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="nump">$ 20,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Liabilities Incurred, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Liabilities Incurred, Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247802968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS - Schedule of Assets and Liabilities Acquired (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>LIABILITIES ASSUMED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 251,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 145,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,547<span></span>
</td>
<td class="nump">$ 99,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>ASSETS ACQUIRED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Short-term available-for-sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">820,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>LIABILITIES ASSUMED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 578,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247549928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Flexion Results (Details) - Flexion<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Total revenues</a></td>
<td class="nump">$ 12,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Net loss</a></td>
<td class="num">$ (25,010)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258844120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Schedule of Pro Forma Information (Details) - Flexion - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total revenues</a></td>
<td class="nump">$ 630,942<span></span>
</td>
<td class="nump">$ 515,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,264)<span></span>
</td>
<td class="num">$ (19,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Pro forma basic net loss per share (in usd per share)</a></td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Pro forma diluted net loss per share (in usd per share)</a></td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252996760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Components of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 36,337<span></span>
</td>
<td class="nump">$ 26,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">35,182<span></span>
</td>
<td class="nump">16,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">27,031<span></span>
</td>
<td class="nump">21,498<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 98,550<span></span>
</td>
<td class="nump">$ 64,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252108520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FIXED ASSETS - Schedule of Useful Lives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">$ 273,641<span></span>
</td>
<td class="nump">$ 215,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(85,240)<span></span>
</td>
<td class="num">(78,360)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">188,401<span></span>
</td>
<td class="nump">136,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">117,264<span></span>
</td>
<td class="nump">74,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">59,740<span></span>
</td>
<td class="nump">54,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">13,197<span></span>
</td>
<td class="nump">12,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">2,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">$ 80,557<span></span>
</td>
<td class="nump">$ 71,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247557608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Capitalized interest</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">188,401<span></span>
</td>
<td class="nump">136,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Asset retirement obligation</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">$ 65,400<span></span>
</td>
<td class="nump">$ 67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252028136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>location</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 79,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_NumberOfLocationsNewOperatingLeaseLiability', window );">Number of locations | location</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leases, maximum term of contract</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NumberOfLocationsNewOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Locations, New Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NumberOfLocationsNewOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252860712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Summary of operating lease cost and other operating lease information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating Lease Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease costs</a></td>
<td class="nump">$ 11,976<span></span>
</td>
<td class="nump">$ 10,055<span></span>
</td>
<td class="nump">$ 6,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">13,698<span></span>
</td>
<td class="nump">12,151<span></span>
</td>
<td class="nump">7,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities, net of lease incentive</a></td>
<td class="nump">12,709<span></span>
</td>
<td class="nump">14,347<span></span>
</td>
<td class="nump">7,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets recorded in exchange for lease obligations</a></td>
<td class="nump">$ 8,692<span></span>
</td>
<td class="nump">$ 42,191<span></span>
</td>
<td class="nump">$ 41,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">7 years 9 months 7 days<span></span>
</td>
<td class="text">9 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.96%<span></span>
</td>
<td class="nump">6.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247326680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of maturities of operating lease liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 13,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">13,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">13,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">12,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">12,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2027 and thereafter</a></td>
<td class="nump">39,423<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">104,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(24,547)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 79,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252096056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 99,547<span></span>
</td>
<td class="nump">$ 99,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments', window );">2020 accumulated adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">145,175<span></span>
</td>
<td class="nump">$ 99,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_SkyePharmaHoldingIncMember', window );">SkyePharma Holding, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill arising from acquisition</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill arising from acquisition</a></td>
<td class="nump">$ 9,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_SkyePharmaHoldingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_SkyePharmaHoldingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247678712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 145,175<span></span>
</td>
<td class="nump">$ 99,547<span></span>
</td>
<td class="nump">$ 99,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">13,553<span></span>
</td>
<td class="nump">$ 7,866<span></span>
</td>
<td class="nump">$ 5,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1', window );">Future amortization, through 2028</a></td>
<td class="nump">57,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3', window );">Future amortization through 2030</a></td>
<td class="nump">57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2', window );">Future amortization, through 2029</a></td>
<td class="nump">57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4', window );">Future amortization through 2031</a></td>
<td class="nump">36,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5', window );">Future amortization through 2032</a></td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6', window );">Future amortization through 2033</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponFirstCommercialSaleInMajorEUCountryMember', window );">Upon first commercial sale in a major EU country (United Kingdom, France, Germany, Italy and Spain)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition', window );">Milestone payments for EXPAREL agreed in connection with acquisition</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember', window );">When annual net sales collected reach $500.0 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition', window );">Milestone payments for EXPAREL agreed in connection with acquisition</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition', window );">Annual net sales threshold</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the milestone payments agreed to be paid by the entity for the sale of the product, in connection with the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold amount of annual net sales considered to determine the stage at which a specified amount of milestone payments for product is agreed to be paid by the entity, in connection with the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 3</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 4</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 5</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 6</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponFirstCommercialSaleInMajorEUCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponFirstCommercialSaleInMajorEUCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105245352088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 590,090<span></span>
</td>
<td class="nump">$ 110,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(27,122)<span></span>
</td>
<td class="num">(13,569)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">562,968<span></span>
</td>
<td class="nump">96,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Value</a></td>
<td class="nump">651,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">623,968<span></span>
</td>
<td class="nump">96,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">590,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(27,097)<span></span>
</td>
<td class="num">(13,553)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">$ 562,903<span></span>
</td>
<td class="nump">$ 96,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-Average Useful Lives</a></td>
<td class="text">10 years 5 months<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-Average Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Value</a></td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247750680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AccruedExpensesLineItems', window );"><strong>Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_Accruedsellinggeneralandadministrativeexpenses', window );">Accrued selling, general and administrative expenses</a></td>
<td class="nump">$ 12,063<span></span>
</td>
<td class="nump">$ 23,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_Accruedresearchanddevelopmentexpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">5,480<span></span>
</td>
<td class="nump">6,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AccruedOperatingExpensesCurrent', window );">Other accrued operating expenses</a></td>
<td class="nump">14,912<span></span>
</td>
<td class="nump">11,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">45,491<span></span>
</td>
<td class="nump">22,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">35,298<span></span>
</td>
<td class="nump">3,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AccruedEndOfTermFeeCurrent', window );">Accrued interest</a></td>
<td class="nump">5,358<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ProductReturnsRebatesandOtherFees', window );">Product returns and wholesaler service fees</a></td>
<td class="nump">8,953<span></span>
</td>
<td class="nump">2,190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">127,555<span></span>
</td>
<td class="nump">$ 70,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember', window );">When annual net sales collected reach $500.0 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AccruedExpensesLineItems', window );"><strong>Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition', window );">Milestone payments for EXPAREL agreed in connection with acquisition</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition', window );">Annual net sales threshold</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccruedEndOfTermFeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for end of term fee. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccruedEndOfTermFeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AccruedOperatingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AccruedOperatingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_Accruedresearchanddevelopmentexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services related to research and development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_Accruedresearchanddevelopmentexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_Accruedsellinggeneralandadministrativeexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services related to selling, general, and administrative activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_Accruedsellinggeneralandadministrativeexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the milestone payments agreed to be paid by the entity for the sale of the product, in connection with the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold amount of annual net sales considered to determine the stage at which a specified amount of milestone payments for product is agreed to be paid by the entity, in connection with the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ProductReturnsRebatesandOtherFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Returns, Rebates and Other Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ProductReturnsRebatesandOtherFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis=pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247088200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Carrying Value of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 07, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 10, 2020</div></th>
<th class="th"><div>Mar. 13, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member', window );">0.750% Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDueMay2024Member', window );">3.375% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">2.375% Convertible Senior Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | 7.000% Term Loan B Facility Maturing 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359,497<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,049,230<span></span>
</td>
<td class="nump">462,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 0.750% Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,627<span></span>
</td>
<td class="nump">313,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 3.375% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,249<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 3.375% Convertible Senior Notes Due 2024 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2.375% Convertible Senior Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,857<span></span>
</td>
<td class="nump">$ 149,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDueMay2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDueMay2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105235830360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 10, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 13, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Jan. 06, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 07, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 06, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 07, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 07, 2017 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 363,750<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1', window );">Prepayment penalty, year 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2', window );">Prepayment penalty, year 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter', window );">Prepayment penalty, year 4 and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_SettlementPeriodConvertibleDebtConversionRequest', window );">Settlement period - convertible debt conversion request</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing sale price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt', window );">Deferred tax associated with equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="nump">20,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt', window );">Amortization period of transaction costs attributable to liability component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt', window );">Transaction costs attributable to equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">2.375% Convertible Senior Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of notes into common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock', window );">Convertible debt, premium on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing sale price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate', window );">Assumed borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Total transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt', window );">Amortization period of transaction costs attributable to liability component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate of common stock per $1,000 of principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Debt redemption price due to fundamental change as a percentage of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault', window );">Customary events of default, percentage of principal and accrued and unpaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">2.375% Convertible Senior Notes Due 2022 | Conversion terms prior to close of business on business day immediately proceeding October 1, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentMarketPrice', window );">Market price per $1000 of principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">2.375% Convertible Senior Notes Due 2022 | Debt Redemption Terms on or after April 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice', window );">Debt instrument, percentage of principal amount for computation of redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice', window );">Conversion obligation, stock closing price minimum as a percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays', window );">Conversion obligation, number of trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays', window );">Conversion obligation, number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member', window );">0.750% Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock', window );">Percentage of last sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of notes into common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock', window );">Convertible debt, premium on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing sale price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice', window );">Debt instrument, percentage of principal amount for computation of redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentMarketPrice', window );">Market price per $1000 of principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate of common stock per $1,000 of principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0139324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member', window );">0.750% Convertible Senior Notes Due 2025 | Debt Conversion Terms Business Day Immediately Preceding February 3, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member', window );">0.750% Convertible Senior Notes Due 2025 | Debt Redemption Terms on or after August 1, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice', window );">Debt instrument, percentage of principal amount for computation of redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member', window );">7.000% Term Loan B Facility Maturing 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentCovenantLeverageRatioMaximum', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue', window );">Leverage ratio maximum amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate, at point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member', window );">7.000% Term Loan B Facility Maturing 2026 | Adjusted Term SOFR Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate', window );">Basis spread one on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate', window );">Basis spread two on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member', window );">7.000% Term Loan B Facility Maturing 2026 | Adjusted Term SOFR Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentVariableRate', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member', window );">7.000% Term Loan B Facility Maturing 2026 | Alternative Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member', window );">7.000% Term Loan B Facility Maturing 2026 | Alternative Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentVariableRate', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member', window );">7.000% Term Loan B Facility Maturing 2026 | NYFRB Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2024Member', window );">3.375% Convertible Senior Notes Due 2024 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice', window );">Debt instrument, percentage of principal amount for computation of redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2024Member', window );">3.375% Convertible Senior Notes Due 2024 | Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of notes into common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate of common stock per $1,000 of principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0373413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount', window );">CVRs issued per principal amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.3413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | 7.000% Term Loan B Facility Maturing 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible senior notes, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | 7.000% Term Loan B Facility Maturing 2026 | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Quarterly payment</a></td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | 7.000% Term Loan B Facility Maturing 2026 | Subsequent Event | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Quarterly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear', window );">Number of payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,049,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,049,230<span></span>
</td>
<td class="nump">462,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2.375% Convertible Senior Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920<span></span>
</td>
<td class="nump">9,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible senior notes, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Debt issued in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument, repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes', window );">Remaining payment required upon settlement of 2022 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,857<span></span>
</td>
<td class="nump">149,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 0.750% Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,718<span></span>
</td>
<td class="nump">80,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible senior notes, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,500<span></span>
</td>
<td class="nump">402,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Debt issued in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,627<span></span>
</td>
<td class="nump">$ 313,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 3.375% Convertible Senior Notes Due 2024 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Aggregate principal retired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 3.375% Convertible Senior Notes Due 2024 | Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 0.750% Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>DEBT AND FINANCING OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent', window );">Convertible debt, carrying amount of liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate', window );">Assumed borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Amortization period of equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Total transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Period of Transaction Costs Attributable to Liability Component of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Converted Instrument, Warrants Or Rights Issued, Per Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentBasisSpreadOneOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread One On Variable Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentBasisSpreadOneOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread Two On Variable Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the conversion price that the closing sales price of the entity's common stock must exceed for at least 20 days within 30 consecutive trading days, in order for the notes to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum number of trading days within a period of 30 consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleAssumedBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Assumed Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleAssumedBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Carrying Amount of Liability Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Market Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percentage of Last Reported Sale Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of principal amount used in computation of the redemption price to be paid on conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Principal, Number Of Payments In Next Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Percent, Year 1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Percent, Year 2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Percent, Year 4 And Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the redemption price as a percentage of the principal amount at which the debt instrument may be required to be repurchased in the event of a fundamental change by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Expense Associated to the Equity Component of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining Payment Required Upon Full Settlement of Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_SettlementPeriodConvertibleDebtConversionRequest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of trading days in a settlement period for convertible debt conversion requests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_SettlementPeriodConvertibleDebtConversionRequest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Attributable to the Equity Component of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtRedemptionTermsonorafterApril12020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtRedemptionTermsonorafterApril12020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtConversionAndRedemptionTermsAxis=pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=pcrx_FederalReserveBankOfNYRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=pcrx_FederalReserveBankOfNYRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105235741832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 07, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 10, 2020</div></th>
<th class="th"><div>Mar. 13, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member', window );">0.750% Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">2.375% Convertible Senior Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of debt discount and deferred financing costs</a></td>
<td class="nump">$ 1,049,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 0.750% Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible senior notes, gross</a></td>
<td class="nump">$ 402,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(7,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">(64,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of debt discount and deferred financing costs</a></td>
<td class="nump">$ 330,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 2.375% Convertible Senior Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
<td class="nump">2.375%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible senior notes, gross</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">(1,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of debt discount and deferred financing costs</a></td>
<td class="nump">157,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | 7.000% Term Loan B Facility Maturing 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible senior notes, gross</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(4,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">(11,060)<span></span>
</td>
<td class="num">$ (11,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net of debt discount and deferred financing costs</a></td>
<td class="nump">$ 359,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258833736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Schedule of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual and other interest expense</a></td>
<td class="nump">$ 9,759<span></span>
</td>
<td class="nump">$ 7,650<span></span>
</td>
<td class="nump">$ 8,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization&#160;of&#160;debt issuance costs</a></td>
<td class="nump">2,754<span></span>
</td>
<td class="nump">2,156<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">23,152<span></span>
</td>
<td class="nump">18,254<span></span>
</td>
<td class="nump">13,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalizedAdjustment', window );">Capitalized interest (Note 7)</a></td>
<td class="num">(3,915)<span></span>
</td>
<td class="num">(2,389)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">$ 31,750<span></span>
</td>
<td class="nump">$ 25,671<span></span>
</td>
<td class="nump">$ 23,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate on total debt</a></td>
<td class="nump">6.66%<span></span>
</td>
<td class="nump">7.15%<span></span>
</td>
<td class="nump">7.81%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalizedAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalizedAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105245585512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Fair Value of Liabilities Measured on a Recurring Basis (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 07, 2020</div></th>
<th class="th"><div>Mar. 13, 2017</div></th>
<th class="th"><div>Mar. 07, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;1 | 7.000% Term Loan B Facility Maturing 2026 | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;1 | Convertible Senior Notes Due 2022 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;1 | Convertible Senior Notes Due 2025 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;1 | 3.375% Convertible Senior Notes Due 2024 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;2 | 7.000% Term Loan B Facility Maturing 2026 | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">371,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;2 | Convertible Senior Notes Due 2022 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">166,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;2 | Convertible Senior Notes Due 2025 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">447,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;2 | 3.375% Convertible Senior Notes Due 2024 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">201,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="nump">14,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible notes receivable</a></td>
<td class="nump">4,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">57,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;3 | 7.000% Term Loan B Facility Maturing 2026 | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;3 | Convertible Senior Notes Due 2022 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;3 | Convertible Senior Notes Due 2025 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Level&#160;3 | 3.375% Convertible Senior Notes Due 2024 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing sale price (in dollars per share)</a></td>
<td class="nump">$ 60.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">Convertible Senior Notes Due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing sale price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of notes into common stock (in dollars per share)</a></td>
<td class="nump">$ 66.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member', window );">Convertible Senior Notes Due 2022 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleConversionPremiumShares', window );">Debt instrument, convertible, conversion premium (in shares)</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing sale price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price of notes into common stock (in dollars per share)</a></td>
<td class="nump">$ 71.78<span></span>
</td>
<td class="nump">$ 71.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DebtInstrumentConvertibleConversionPremiumShares', window );">Debt instrument, convertible, conversion premium (in shares)</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="nump">$ 14,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible notes receivable</a></td>
<td class="nump">4,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">57,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | 7.000% Term Loan B Facility Maturing 2026 | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">359,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Convertible Senior Notes Due 2022 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">157,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Convertible Senior Notes Due 2025 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">330,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | 3.375% Convertible Senior Notes Due 2024 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes</a></td>
<td class="nump">$ 201,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DebtInstrumentConvertibleConversionPremiumShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Conversion Premium, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DebtInstrumentConvertibleConversionPremiumShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_TermLoanBFacilityDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105244121176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Additional liability payable to holders of CVRs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989<span></span>
</td>
<td class="num">$ (5,204)<span></span>
</td>
<td class="num">$ (16,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Payments to acquire convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,488<span></span>
</td>
<td class="nump">546,516<span></span>
</td>
<td class="nump">318,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGain', window );">Loss on equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Payments to acquire investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,187<span></span>
</td>
<td class="nump">$ 1,160<span></span>
</td>
<td class="nump">1,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_NumberOfMajorCustomers', window );">Number of major customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Gain related to acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pcrx_SpineBioPharmaLLCMember', window );">Spine BioPharma, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible note paid for investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_TELABioMember', window );">TELA Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi', window );">Proceeds from sale of equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Payments to acquire investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_GeneQuineMember', window );">GeneQuine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Payments to acquire convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Investments in additional equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation', window );">Reduction in convertible note, due to foreign currency exchange rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones', window );">Potential additional investment upon achieving milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_CodaBioTherapeuticsIncMember', window );">Coda BioTherapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to acquire investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_GenascenceCorporationMember', window );">Genascence Corporation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pcrx_MajorCustomerOneMember', window );">Major customer one | Accounts receivable | Credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pcrx_MajorCustomerTwoMember', window );">Major customer two | Accounts receivable | Credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pcrx_MajorCustomerThreeMember', window );">Major customer three | Accounts receivable | Credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pcrx_MajorCustomerFourMember', window );">Major customer four | Accounts receivable | Credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember', window );">Myoscience Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Additional liability payable to holders of CVRs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,163)<span></span>
</td>
<td class="nump">$ 5,204<span></span>
</td>
<td class="nump">$ 16,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition', window );">Potential remaining milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember', window );">Myoscience Acquisition | Level&#160;3 | Weighted Average | Contingent Consideration | Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember', window );">Myoscience Acquisition | Level&#160;3 | Weighted Average | Contingent Consideration | Probability of achieving regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember', window );">Flexion Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Additional liability payable to holders of CVRs</a></td>
<td class="num">$ (45,200)<span></span>
</td>
<td class="num">$ (1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition', window );">Potential remaining milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember', window );">Flexion Acquisition | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare', window );">Increase in CVR | $ / shares</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember', window );">Flexion Acquisition | Level&#160;3 | Weighted Average | Contingent Consideration | Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember', window );">Flexion Acquisition | Level&#160;3 | Weighted Average | Contingent Consideration | Probability of achieving regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAndMyoscienceAcquisitionMember', window );">Flexion and Myoscience Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,600<span></span>
</td>
<td class="nump">$ 28,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major customers of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_PotentialAdditionalInvestmentUponAchievingMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Additional Investment Upon Achieving Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_PotentialAdditionalInvestmentUponAchievingMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Milestone Payments Yet To Be Paid in Connection, Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pcrx_SpineBioPharmaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pcrx_SpineBioPharmaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_TELABioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_TELABioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_GeneQuineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_GeneQuineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_CodaBioTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_CodaBioTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_GenascenceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pcrx_GenascenceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_MajorCustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_MajorCustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_MajorCustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_MajorCustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_MajorCustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_MajorCustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pcrx_MajorCustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pcrx_MajorCustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pcrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pcrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=pcrx_MeasurementInputExpectedMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=pcrx_MeasurementInputExpectedMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAndMyoscienceAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAndMyoscienceAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105246930040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Fair Value Inputs and Valuation (Details) - Level&#160;3 - Contingent Consideration<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Flexion Acquisition | Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="nump">0.1139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Flexion Acquisition | Probability of achieving regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="nump">0.1000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Myoscience Acquisition | Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="nump">0.1142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Myoscience Acquisition | Probability of achieving regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="nump">0.0100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Flexion Acquisition | Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="nump">0.1292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Flexion Acquisition | Probability of achieving regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="nump">0.1500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Myoscience Acquisition | Discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, liability, measurement input</a></td>
<td class="nump">0.1213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pcrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pcrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=pcrx_MeasurementInputExpectedMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=pcrx_MeasurementInputExpectedMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105250916904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Contingent Consideration Rollforward (Details) - Contingent Consideration<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 28,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice', window );">Contingent consideration related to the Flexion Acquisition</a></td>
<td class="nump">45,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustments and accretion</a></td>
<td class="num">(989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments made or offset against amounts due</a></td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2021</a></td>
<td class="nump">$ 57,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247504968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Investments at Amortized Cost and Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">$ 70,651<span></span>
</td>
<td class="nump">$ 516,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value (Level&#160;2)</a></td>
<td class="nump">70,831<span></span>
</td>
<td class="nump">517,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pcrx_LongTermInvestmentsMember', window );">Long-term:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Short-term:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">3,182<span></span>
</td>
<td class="nump">34,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value (Level&#160;2)</a></td>
<td class="nump">3,182<span></span>
</td>
<td class="nump">35,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Short-term:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">57,533<span></span>
</td>
<td class="nump">221,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value (Level&#160;2)</a></td>
<td class="nump">57,611<span></span>
</td>
<td class="nump">221,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Short-term:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="nump">9,936<span></span>
</td>
<td class="nump">120,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value (Level&#160;2)</a></td>
<td class="nump">$ 10,038<span></span>
</td>
<td class="nump">120,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Government bonds | Short-term:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Government bonds | Long-term:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pcrx_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pcrx_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105250403752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Narrative (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">44,734,308<span></span>
</td>
<td class="nump">43,636,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">44,734,308<span></span>
</td>
<td class="nump">43,636,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258198936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - AOCI (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 619,688<span></span>
</td>
<td class="nump">$ 354,944<span></span>
</td>
<td class="nump">$ 321,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">730,408<span></span>
</td>
<td class="nump">619,688<span></span>
</td>
<td class="nump">354,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Net Unrealized Gains (Losses) From Available For Sale Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments, net of tax</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Unrealized Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on investments, net of tax</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247725736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Stock incentive plan, increased number of shares authorized for issuance (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP', window );">Employee stock purchase plan (ESPP), maximum shares available for sale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MaximumFairMarketValuePurchaseofESPPShares', window );">Maximum fair market value of ESPP shares available for purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EmployeeStockPurchasePlanfairvalue', window );">ESPP fair value (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP shares purchased and issued during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Expected recognition of non-vested stock options, not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of non-vested awards not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">ESPP share option fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.74<span></span>
</td>
<td class="nump">$ 22.40<span></span>
</td>
<td class="nump">$ 20.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of non-vested awards not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Expected recognition of non-vested RSUs, not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EmployeeStockPurchasePlanESPPSharesinESPP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan (ESPP), Shares in ESPP</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EmployeeStockPurchasePlanESPPSharesinESPP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EmployeeStockPurchasePlanfairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of fair value of common stock eligible employees can purchase common shares at through an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EmployeeStockPurchasePlanfairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MaximumFairMarketValuePurchaseofESPPShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Fair Market Value Purchase of ESPP Shares in a Calendar Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MaximumFairMarketValuePurchaseofESPPShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchased And Issued During Period, Shares, Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247287432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - Stock Incentive Plans (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock incentive plan, awards reserved for issuance (in shares)</a></td>
<td class="nump">14,606,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock incentive plan, awards issued (in shares)</a></td>
<td class="nump">12,461,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock incentive plan, awards available for grant (in shares)</a></td>
<td class="nump">2,145,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcrx_StockIncentivePlan2011Member', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock incentive plan, awards reserved for issuance (in shares)</a></td>
<td class="nump">14,431,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock incentive plan, awards issued (in shares)</a></td>
<td class="nump">12,425,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock incentive plan, awards available for grant (in shares)</a></td>
<td class="nump">2,006,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member', window );">2014 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock incentive plan, awards reserved for issuance (in shares)</a></td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Stock incentive plan, awards issued (in shares)</a></td>
<td class="nump">36,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock incentive plan, awards available for grant (in shares)</a></td>
<td class="nump">138,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcrx_EmployeeStockPurchasePlanESPP2014Member', window );">2014 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized', window );">ESPP, shares reserved for purchase (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP, shares purchased (in shares)</a></td>
<td class="nump">409,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase', window );">ESPP, shares available for purchase (in shares)</a></td>
<td class="nump">90,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Number of Shares Available For Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcrx_StockIncentivePlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcrx_StockIncentivePlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcrx_InducementPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcrx_EmployeeStockPurchasePlanESPP2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcrx_EmployeeStockPurchasePlanESPP2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247343032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 42,246<span></span>
</td>
<td class="nump">$ 39,920<span></span>
</td>
<td class="nump">$ 33,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Related income tax benefit</a></td>
<td class="nump">8,989<span></span>
</td>
<td class="nump">8,578<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">25,980<span></span>
</td>
<td class="nump">26,749<span></span>
</td>
<td class="nump">23,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">15,335<span></span>
</td>
<td class="nump">12,266<span></span>
</td>
<td class="nump">9,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">5,891<span></span>
</td>
<td class="nump">5,589<span></span>
</td>
<td class="nump">4,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">5,465<span></span>
</td>
<td class="nump">5,211<span></span>
</td>
<td class="nump">5,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 30,890<span></span>
</td>
<td class="nump">$ 29,120<span></span>
</td>
<td class="nump">$ 23,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247703192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - Stock Option Activity (Details) - Stock options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">6,235,118<span></span>
</td>
<td class="nump">6,706,378<span></span>
</td>
<td class="nump">5,722,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">890,277<span></span>
</td>
<td class="nump">1,502,803<span></span>
</td>
<td class="nump">1,872,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(732,117)<span></span>
</td>
<td class="num">(1,428,111)<span></span>
</td>
<td class="num">(425,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(278,233)<span></span>
</td>
<td class="num">(426,925)<span></span>
</td>
<td class="num">(286,779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(64,505)<span></span>
</td>
<td class="num">(119,027)<span></span>
</td>
<td class="num">(176,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">6,050,540<span></span>
</td>
<td class="nump">6,235,118<span></span>
</td>
<td class="nump">6,706,378<span></span>
</td>
<td class="nump">5,722,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">3,826,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">6,050,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price (Per Share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 45.98<span></span>
</td>
<td class="nump">$ 42.80<span></span>
</td>
<td class="nump">$ 41.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">60.27<span></span>
</td>
<td class="nump">47.50<span></span>
</td>
<td class="nump">42.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">32.56<span></span>
</td>
<td class="nump">31.67<span></span>
</td>
<td class="nump">19.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">46.46<span></span>
</td>
<td class="nump">42.08<span></span>
</td>
<td class="nump">39.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">80.31<span></span>
</td>
<td class="nump">71.71<span></span>
</td>
<td class="nump">63.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">49.32<span></span>
</td>
<td class="nump">$ 45.98<span></span>
</td>
<td class="nump">$ 42.80<span></span>
</td>
<td class="nump">$ 41.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">48.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 49.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Term at the end of the period (in years)</a></td>
<td class="text">6 years 7 months 2 days<span></span>
</td>
<td class="text">6 years 11 months 19 days<span></span>
</td>
<td class="text">7 years 18 days<span></span>
</td>
<td class="text">7 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Term exercisable at the end of the period (in years)</a></td>
<td class="text">5 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Term vested and expected to vest at the end of the period (in years)</a></td>
<td class="text">6 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward', window );"><strong>Aggregate Intrinsic Value (in Thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 102,955<span></span>
</td>
<td class="nump">$ 50,652<span></span>
</td>
<td class="nump">$ 49,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">23,967<span></span>
</td>
<td class="nump">34,227<span></span>
</td>
<td class="nump">9,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at the end of the period</a></td>
<td class="nump">81,407<span></span>
</td>
<td class="nump">$ 102,955<span></span>
</td>
<td class="nump">$ 50,652<span></span>
</td>
<td class="nump">$ 49,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period</a></td>
<td class="nump">59,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at the end of the period</a></td>
<td class="nump">$ 81,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247758504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - Valuation Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted Average Assumptions Used to Estimate the Fair Values of Each Option Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">ESPP share option fair value (in dollars per share)</a></td>
<td class="nump">$ 26.74<span></span>
</td>
<td class="nump">$ 22.40<span></span>
</td>
<td class="nump">$ 20.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.43%<span></span>
</td>
<td class="nump">0.22%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">49.10%<span></span>
</td>
<td class="nump">53.50%<span></span>
</td>
<td class="nump">53.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options</a></td>
<td class="text">5 years 4 months 9 days<span></span>
</td>
<td class="text">5 years 4 months 9 days<span></span>
</td>
<td class="text">5 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted Average Assumptions Used to Estimate the Fair Values of Each Option Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.14%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.57%<span></span>
</td>
<td class="nump">2.56%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">44.90%<span></span>
</td>
<td class="nump">40.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted Average Assumptions Used to Estimate the Fair Values of Each Option Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">ESPP share option fair value (in dollars per share)</a></td>
<td class="nump">$ 15.16<span></span>
</td>
<td class="nump">$ 11.02<span></span>
</td>
<td class="nump">$ 11.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted Average Assumptions Used to Estimate the Fair Values of Each Option Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">ESPP share option fair value (in dollars per share)</a></td>
<td class="nump">$ 15.23<span></span>
</td>
<td class="nump">$ 17.54<span></span>
</td>
<td class="nump">$ 11.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247080584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK PLANS - RSU Activity (Details) - RSUs - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance at the beginning of the period (in shares)</a></td>
<td class="nump">957,453<span></span>
</td>
<td class="nump">631,141<span></span>
</td>
<td class="nump">577,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">446,450<span></span>
</td>
<td class="nump">665,476<span></span>
</td>
<td class="nump">305,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(309,779)<span></span>
</td>
<td class="num">(239,085)<span></span>
</td>
<td class="num">(192,760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(138,847)<span></span>
</td>
<td class="num">(100,079)<span></span>
</td>
<td class="num">(59,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance at the end of the period (in shares)</a></td>
<td class="nump">955,277<span></span>
</td>
<td class="nump">957,453<span></span>
</td>
<td class="nump">631,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value (Per Share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance at the beginning of the period (in dollars per shares)</a></td>
<td class="nump">$ 46.34<span></span>
</td>
<td class="nump">$ 41.87<span></span>
</td>
<td class="nump">$ 42.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">60.81<span></span>
</td>
<td class="nump">48.70<span></span>
</td>
<td class="nump">43.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">45.16<span></span>
</td>
<td class="nump">41.91<span></span>
</td>
<td class="nump">45.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">50.67<span></span>
</td>
<td class="nump">44.43<span></span>
</td>
<td class="nump">41.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance at the end of the period (in dollars per shares)</a></td>
<td class="nump">$ 52.85<span></span>
</td>
<td class="nump">$ 46.34<span></span>
</td>
<td class="nump">$ 41.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in Thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Unvested balance at the end of the period</a></td>
<td class="nump">$ 57,479<span></span>
</td>
<td class="nump">$ 57,294<span></span>
</td>
<td class="nump">$ 28,591<span></span>
</td>
<td class="nump">$ 24,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105250413976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE - Calculation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 41,980<span></span>
</td>
<td class="nump">$ 145,523<span></span>
</td>
<td class="num">$ (11,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">44,262,000<span></span>
</td>
<td class="nump">42,671,000<span></span>
</td>
<td class="nump">41,513,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Computation of diluted securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (in shares)</a></td>
<td class="nump">45,630,000<span></span>
</td>
<td class="nump">43,682,000<span></span>
</td>
<td class="nump">41,513,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per common share (in USD per share)</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per common share (in USD per share)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Computation of diluted securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of diluted securities (in shares)</a></td>
<td class="nump">1,030,000<span></span>
</td>
<td class="nump">783,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Computation of diluted securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of diluted securities (in shares)</a></td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">227,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pcrx_ConversionPremiumOn2022NotesMember', window );">Conversion Premium on 2022 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Computation of diluted securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect of conversion premium on the 2022 Notes (in shares)</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Computation of diluted securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of diluted securities (in shares)</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pcrx_ConversionPremiumOn2022NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pcrx_ConversionPremiumOn2022NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105245572712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME (LOSS) PER SHARE - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">4,352<span></span>
</td>
<td class="nump">7,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">4,237<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105245691336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2027</div></th>
<th class="th"><div>Dec. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">$ (14,424)<span></span>
</td>
<td class="nump">$ 125,434<span></span>
</td>
<td class="num">$ (268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">25.57%<span></span>
</td>
<td class="num">(624.39%)<span></span>
</td>
<td class="num">(2.49%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction of valuation allowance for deferred tax assets</a></td>
<td class="num">$ (16,500)<span></span>
</td>
<td class="num">$ (126,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax', window );">Minimum cumulative percentage of change in ownership as condition to offset taxable income</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_OtherTaxAttributesSubjectToLimitation', window );">Other tax attributes, subject to limitation</a></td>
<td class="nump">$ 21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Unrecognized tax benefits resulting from prior tax positions</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for current year positions</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reduction for prior year positions</a></td>
<td class="nump">1,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">9,021<span></span>
</td>
<td class="nump">6,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=pcrx_ForeignNetDeferredTaxAssetMember', window );">Foreign Net Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction of valuation allowance for deferred tax assets</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction of valuation allowance for deferred tax assets</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember', window );">Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction of valuation allowance for deferred tax assets</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction of valuation allowance for deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (126,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">662,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_NetOperatingLossSubjecttoLimitation', window );">Net operating loss, subject to limitation</a></td>
<td class="nump">531,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">538,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne', window );">Expected additional NOLs, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo', window );">Expected additional NOLs, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree', window );">Expected additional NOLs, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour', window );">Expected additional NOLs, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive', window );">Expected additional NOLs, year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix', window );">Expected additional NOLs, year six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix', window );">Expected additional NOLs, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">25,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward | Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">171,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward | Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeTaxProvisionLineItems', window );"><strong>Income Tax Provision [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Additional Net Operating Losses In Year, After Year Six</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Additional Net Operating Losses In Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ExpectedAdditionalNetOperatingLossesInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Additional Net Operating Losses In Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ExpectedAdditionalNetOperatingLossesInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Additional Net Operating Losses In Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ExpectedAdditionalNetOperatingLossesInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Additional Net Operating Losses In Year Six</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ExpectedAdditionalNetOperatingLossesInYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Additional Net Operating Losses In Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ExpectedAdditionalNetOperatingLossesInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Additional Net Operating Losses In Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncomeTaxProvisionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Income Tax Provision [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncomeTaxProvisionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents minimum cumulative percentage of change in ownership as a condition to offset taxable income or tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_NetOperatingLossSubjecttoLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Operating Losses, Subject to Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_NetOperatingLossSubjecttoLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_OtherTaxAttributesSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Tax Attributes, Subject To Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_OtherTaxAttributesSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=pcrx_ForeignNetDeferredTaxAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=pcrx_ForeignNetDeferredTaxAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252877576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Current and Deferred Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income (loss) before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 64,751<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="num">$ (7,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(8,348)<span></span>
</td>
<td class="nump">3,089<span></span>
</td>
<td class="num">(3,722)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal', window );">Total income (loss) before income taxes</a></td>
<td class="nump">56,403<span></span>
</td>
<td class="nump">20,089<span></span>
</td>
<td class="num">(10,748)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">3,533<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current taxes</a></td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">12,554<span></span>
</td>
<td class="num">(99,164)<span></span>
</td>
<td class="num">(1,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,682)<span></span>
</td>
<td class="num">(27,449)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred taxes</a></td>
<td class="nump">10,872<span></span>
</td>
<td class="num">(126,613)<span></span>
</td>
<td class="num">(1,828)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 14,424<span></span>
</td>
<td class="num">$ (125,434)<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The earnings or loss from continuing operations before income taxes for the entity as a whole, including domestic and foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252096552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income taxes at U.S. Federal statutory rate to the provision for income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">3.82%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="num">(7.33%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectiveIncomeTaxRateReconciliationForeign', window );">Foreign taxes</a></td>
<td class="num">(1.15%)<span></span>
</td>
<td class="nump">3.18%<span></span>
</td>
<td class="num">(3.95%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">6.55%<span></span>
</td>
<td class="num">(647.87%)<span></span>
</td>
<td class="nump">19.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(1.08%)<span></span>
</td>
<td class="num">(10.53%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(7.92%)<span></span>
</td>
<td class="nump">19.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit', window );">Effect of rate changes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.42%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing', window );">Convertible senior notes refinancing</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(5.22%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible expenses</a></td>
<td class="nump">5.13%<span></span>
</td>
<td class="nump">4.55%<span></span>
</td>
<td class="num">(13.58%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent', window );">Reserves</a></td>
<td class="num">(1.31%)<span></span>
</td>
<td class="nump">7.66%<span></span>
</td>
<td class="num">(15.41%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent', window );">338(g) tax election</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(9.61%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(1.67%)<span></span>
</td>
<td class="num">(1.84%)<span></span>
</td>
<td class="num">(2.35%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">25.57%<span></span>
</td>
<td class="num">(624.39%)<span></span>
</td>
<td class="num">(2.49%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed as the result of changes in state blended tax rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, 338(g) Election, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Convertible Senior Notes Refinancing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectiveIncomeTaxRateReconciliationForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectiveIncomeTaxRateReconciliationForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to tax reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252015560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 174,203<span></span>
</td>
<td class="nump">$ 66,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state credits</a></td>
<td class="nump">35,414<span></span>
</td>
<td class="nump">17,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">80,237<span></span>
</td>
<td class="nump">7,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DeferredTaxAssetsStockBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">24,545<span></span>
</td>
<td class="nump">21,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">2,430<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,441<span></span>
</td>
<td class="nump">2,138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">319,842<span></span>
</td>
<td class="nump">116,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(131,964)<span></span>
</td>
<td class="nump">13,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Discount on convertible senior notes</a></td>
<td class="num">(15,521)<span></span>
</td>
<td class="num">(20,851)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(147,485)<span></span>
</td>
<td class="num">(7,378)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance', window );">Deferred tax assets, net of deferred tax liabilities</a></td>
<td class="nump">172,357<span></span>
</td>
<td class="nump">108,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(18,993)<span></span>
</td>
<td class="num">(2,515)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 153,364<span></span>
</td>
<td class="nump">$ 106,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net of Deferred Tax Liabilities, Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_DeferredTaxAssetsStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Stock Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_DeferredTaxAssetsStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252005192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Unrecognized Tax Benefits (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at beginning of the period</a></td>
<td class="nump">$ 6,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for current year positions</a></td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reduction for prior year positions</a></td>
<td class="num">(1,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at end of the period</a></td>
<td class="nump">$ 9,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105235697896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Compensation expense recognized</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod', window );">Performance period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Compensation expense</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage', window );">Performance award (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage', window );">Performance award (percent)</a></td>
<td class="nump">225.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Award, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247434616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Product Discontinuance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Severance-related expenses</a></td>
<td class="nump">$ 26,371<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts', window );">Total acquisition-related charges</a></td>
<td class="nump">40,900<span></span>
</td>
<td class="nump">4,899<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration (after an acquisition)</a></td>
<td class="nump">989<span></span>
</td>
<td class="num">(5,204)<span></span>
</td>
<td class="num">(16,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Department of Justice settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther', window );">Total acquisition-related charges, product discontinuation and other</a></td>
<td class="nump">42,911<span></span>
</td>
<td class="nump">5,166<span></span>
</td>
<td class="nump">25,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_DepoCyteMember', window );">DepoCyte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Discontinuation of DepoCyt(e)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_NuanceBiotechCo.Ltd.Member', window );">Nuance Biotech Co. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Discontinuation of DepoCyt(e)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember', window );">Flexion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration (after an acquisition)</a></td>
<td class="num">(1,174)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember', window );">Myoscience Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related fees</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration (after an acquisition)</a></td>
<td class="num">(2,163)<span></span>
</td>
<td class="nump">5,204<span></span>
</td>
<td class="nump">16,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pcrx_AcquisitionRelatedFeesMember', window );">Acquisition-related fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related fees</a></td>
<td class="nump">10,963<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other acquisition expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related fees</a></td>
<td class="nump">$ 3,566<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition-Related Charges, Product Discontinuation, And Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquisition And Integration Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcrx_DepoCyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcrx_DepoCyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcrx_NuanceBiotechCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcrx_NuanceBiotechCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pcrx_AcquisitionRelatedFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pcrx_AcquisitionRelatedFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258203880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Flexion (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration (after an acquisition)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (989)<span></span>
</td>
<td class="nump">$ 5,204<span></span>
</td>
<td class="nump">$ 16,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember', window );">Flexion Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration (after an acquisition)</a></td>
<td class="nump">$ 45,200<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember', window );">Flexion Acquisition | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare', window );">Increase in CVR</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember', window );">Flexion Acquisition | Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_FlexionAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=pcrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pcrx_LegalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pcrx_LegalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247386952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - MyoScience (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration (after an acquisition)</a></td>
<td class="num">$ (989)<span></span>
</td>
<td class="nump">$ 5,204<span></span>
</td>
<td class="nump">$ 16,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember', window );">Myoscience Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related fees</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in contingent consideration (after an acquisition)</a></td>
<td class="nump">$ 2,163<span></span>
</td>
<td class="num">$ (5,204)<span></span>
</td>
<td class="num">(16,672)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember', window );">Myoscience Acquisition | Advisory Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember', window );">Myoscience Acquisition | Separation Costs, Asset Write-downs, and Other Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pcrx_MyoscienceAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pcrx_AdvisoryCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pcrx_AdvisoryCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105250465848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - NUANCE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Department of Justice settlement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcrx_NuanceBiotechCo.Ltd.Member', window );">Nuance Biotech Co. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Department of Justice settlement</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcrx_NuanceBiotechCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcrx_NuanceBiotechCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247656616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - DepoCyte Discontinuation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Non-recurring charge related to discontinuation</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105252869048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Department of Justice (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Department of Justice settlement</a></td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105235794200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 05, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaborative licensing and milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcrx_AratanaTherapeuticsIncMember', window );">Aratana Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementOptionToExtendTerm', window );">Collaborative arrangement, option to extend, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcrx_EurofarmaLabatoriesSAMember', window );">Eurofarma Labatories S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcrx_HongKongPharmaTainuoLtdMember', window );">Hong Kong Pharma Tainuo Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember', window );">Achievement of Development and Commercial Milestones | Aratana Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum', window );">Collaborative arrangement, milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember', window );">Achievement of Development and Commercial Milestones | Eurofarma Labatories S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaborative licensing and milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember', window );">Achievement of Development and Commercial Milestones | Hong Kong Pharma Tainuo Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum', window );">Collaborative arrangement, milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_DePuySynthesSalesIncMember', window );">DePuy Synthes Sales Inc | Co-Promotion Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_PaymentOfEarlyTerminationFees', window );">Payment of early termination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CollaborativeArrangementOptionToExtendTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Option to Extend, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CollaborativeArrangementOptionToExtendTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CollaborativeArrangementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CollaborativeArrangementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_PaymentOfEarlyTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Early Termination Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_PaymentOfEarlyTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcrx_AratanaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcrx_AratanaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcrx_EurofarmaLabatoriesSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcrx_EurofarmaLabatoriesSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcrx_HongKongPharmaTainuoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcrx_HongKongPharmaTainuoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcrx_DePuySynthesSalesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcrx_DePuySynthesSalesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=pcrx_CoPromotionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=pcrx_CoPromotionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105258787960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - Member of board of directors - Consulting agreement<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2012 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">First Price Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares', window );">Number of shares that can be purchased under option (in shares) | shares</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice', window );">Exercise price of shares that can be purchased under option (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Second Price Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares', window );">Number of shares that can be purchased under option (in shares) | shares</a></td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice', window );">Exercise price of shares that can be purchased under option (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise price of shares that can be purchased by the related party on exercise of option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares that can be purchased by the related party on exercise of option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_EnergyAxis=pcrx_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_EnergyAxis=pcrx_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pcrx_FirstPriceOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pcrx_FirstPriceOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pcrx_SecondPriceOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pcrx_SecondPriceOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105245611096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_LitigationInvestigationTerm', window );">Litigation investigation term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Department of Justice settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total costs, of one-time benefits, estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Termination of Nuance agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember', window );">Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_FortisMember', window );">Fortis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_GeneQuineMember', window );">GeneQuine | Flexion | Achievement of Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum', window );">Collaborative arrangement, milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_XenonPharmaceuticalsIncMember', window );">Xenon Pharmaceuticals, Inc | Flexion | Achievement of Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum', window );">Collaborative arrangement, milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcrx_XenonPharmaceuticalsIncMember', window );">Xenon Pharmaceuticals, Inc | Flexion | Achievement of Sales-Related Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum', window );">Collaborative arrangement, milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_LitigationInvestigationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Investigation, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_LitigationInvestigationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcrx_FortisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcrx_FortisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcrx_GeneQuineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcrx_GeneQuineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcrx_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcrx_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfSalesRelatedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfSalesRelatedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140105247809160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 07, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,049,230<span></span>
</td>
<td class="nump">$ 462,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDueMay2024Member', window );">3.375% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDueMay2024Member', window );">3.375% Convertible Senior Notes Due 2024 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,249<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 3.375% Convertible Senior Notes Due 2024 | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt outstanding</a></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDueMay2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pcrx_ConvertibleSeniorNotesDueMay2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>pcrx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pcrx="http://www.pacira.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pcrx-20211231.xsd" xlink:type="simple"/>
    <context id="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9f5b792563940c3a6ac3952c900baba_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib74a5ff7f32a4742bb95a41a5c1e0be2_I20220227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2022-02-27</instant>
        </period>
    </context>
    <context id="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="id7ad81457b8d40ec98c994382d3d81b3_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ib97087953997481c9eb9531b2899f6a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia919a337f89e4501a657825c42e3742f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18f0515519fd468ea2893c1d1449bb1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d43a54915fb471a881eb7c22d53ebb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if920c61660554030b10993e6540fa419_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2cf381db5a940f290c4b8ce845a8a32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c32d4b9517d48699bd04bc765bd4313_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34416a5edad84520b386d27a329de124_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b952c5725b44f818a3a4608b206c6b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87676acfa0004a61af3790653d502de3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d4add3e8085457381bf09ffb890926b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ddbaa9a26c6475c851117daf9454009_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f38afdcb06c45b49334598d858c08be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9be32dbfc52d4ab3bef56de81da70e21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82f4de158e56453ea2b40d32946b5324_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i02f22e84df6a45609376bb4bbce1cf8e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i22e2f16409934c59b4f8cb94a706dc14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96bdb26537c44cc6b5fef08200c07e6f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9261483f2cf444697023aae54718727_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa36cac814f44a06a730eb8daf40ca38_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i01b6af31fbcb4cb5b587df488ccd9a82_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ice5ead454a5844d28a4260c4149d6b73_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7691a4cd4aca428e882b620433db6759_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7f634c57178e427b9ece243062defb9c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1f2a38c35f7048949286b849f4126c2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i898bf7e1b82b4fd3a5c551aa4879fb16_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b60ec582530407797a99033b53bbf05_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff9f105ca63d4c1090d6168b48daf166_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ide58e19786fb437497710ff2a2f106c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic8363a6e4996490fac437219786a762d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib22aebb1a2f448a8b5e073383b0f94c1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic4a5e18c117b491dab5190737229f0a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i776bb75da13044258dd0d043f2083674_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i58c5737320f84dbb81a3529e36798635_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73b1bb54137c4111b70b6f8e573b2d33_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3dfaa6dfa1240039de2e6dff373a711_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3af9929d68c2470ba7dce232ee415fde_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0eafc73607f5454aafd32bc87073240c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43034ba78f184fed9391b7aa159e7b94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15739e828cad4e53af9937b4cf53b886_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d1e15ed7bcf42019a3e50c393218b9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e4dc31d7b404c919dfaf4a0a27a0aff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec4e19869fe24a178b94aa20a13f86b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia317542b2a494470b42249229135b47e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i097161875b3d423d84de836dca9e6e1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i292cbc754afb4c849eda7b618d73c0a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib617d7e96fc14f90a5109fe4b4e42246_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65bc19c293874f40856a561cd84a8945_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i61e75a83dae34a3e81787449842b080d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18af5711da6640a097e5c4348ee46f60_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if3ddd1a458e84be0b45073c62a0600f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia77d73b036584e0f9d8fe145c72c60dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabeecd1debc54d2491b639ea1e2d971c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i714f475d443c449882547155cf8a8321_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac5eb7e48d214a51937b661bf27d5c25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e7d5628512b4a3e8635bfd28f644363_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie6417dba8c0b47b8b32488655a275284_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a19a318f1bb483fa686deeaa2359f9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2b2189f4174640ff8254517903eb5f68_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7eaed297368425488f2206696292750_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotes2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i262c5548fe9c44b8aa7a185ebe27e739_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0494276ab7c45fda83381f5dde00ce2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3326fe2dfeb408fa75e3dba728e3dc1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97a72732ce3f4d6ca28e806af66ae46c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ba25e639e904a9d80a76eefeea1ce89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e7321b7b30b420f86d7944c99c15c52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i380d3a4003e54e71815bb7db455f68c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4bfeff53dc92453d8702a3c0ae51c52d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1df8ab515900456b8b8748721140d7ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52bcafe560714f84b452f8d30131893d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:SecondLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice902dc371e243acbe67af152c1848da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e0fe11f05a54770acc081985b4107dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic79b87819ddf45adb47f8de52f00559e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThirdLargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1d1b98464ce04367b1e114e9a4d74874_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71c5bbc9ad9d4d038376f6d8ca847370_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7e7c8ae84494cf49e1dc21ec2d425fa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:ThreeLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9359bc477c664a09916c4119368c7808_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:CustomersOutsideUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i33291270d39e439a99ab030eecef7f59_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:CustomersOutsideUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3861be95c084c30b8a15610c61c7be1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:CustomersOutsideUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1d024abaafbd4d6e9cda562be11efadd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d54a85658be4c869764ca7b02d10225_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f8f41343e614090bd98a3129a5dcdc4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i45c66ebd062648669078e714c644cc79_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie86add3d370c4395b397c37d521b6125_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i72dde336ea2646239cd55a4c4c35744d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifa17a81b38264f39b34ab843a76bdd7b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i14320622ef29473cb23cce50b7da7f46_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i57cd9faa19194a9c8470e9fe6d5218d4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4efcb358dc364ee385b99f35f75898ae_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iee8d9fd8299c410c8c9b5a06cf205cd2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i712922c8b31944bcb4ececbbd4ecb4a5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9e6fe451f5a2472a9296caa5f57011d7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie406c0d697dd4848bc04dae623fcce72_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81b07dbdf7694f77bc022c7d7d9afa7c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d04eaeb562d4b64900de3e69bac3a78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a88692b931e4aef8edbc75ea1bf544e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06af3d3299684224a00de2d7598b92d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i320c15f4336b4069b57910624e292a4c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9fd3c4592d3b415cba09402210cae28d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c16dbebfa7a404f8409b8c58ef412d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if63921146eb64ffe98b470ec795407f5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b2e28fa586746b9821aa10826da495f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc25a5337c794bf8bd461563d5da11b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9a8455031a245d78c33f94ce7a73d04_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c7f9a44c2e3462cb1305f9f59a302b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28deb21f2b4942ecb350c0910d65ebed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34a22ddc8218489080892a6cdaf5ebb4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id683cf836c4e4f11916c047f28e031ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3462358bbe414ffbb1b57b6e9e01c5c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia92a3c6cd7d9435cb9eff94c7851d7f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i63ac5092cc3645d7bc0aef94ffd9cee5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57086efa37da41e998389e0480dd7425_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf91a2291efc4aa296367a3d8f467bd8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied14d59a15b74bf6b3ced695a67b49f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc0dc9d1d7b14f25ad8be83ef27a2350_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5e8ea6a6bb646069500943f11b40bd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:ReserveForPromptPayDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie03f2a211d40429ba9a8f59edb0f3814_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:WholesalerservicefeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8787beaf97a040fc93e4271eaa597cf7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForVolumeRebatesandChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id086e74a59d7487d9c24f8b8d7361978_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">pcrx:AllowanceForGovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42a9830d9b244758b1ed6841c20a7f8a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74f568606f0c4823a905f91cf481d300_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i736f64d4bbd849d7be2b019552be776c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c69cb4d02b34bbca69ebe9cac7ed74e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f8edb95efe04b6799f90101e59f96cb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:EXPARELMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i30fd1b228fa24cc99396d29a977444ca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e0d7ce79dbc4e3789299398e8fce7f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5de2811811e245db84f11e1e3de5d7e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:ZILRETTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if533c736fa2840fb9422c87e1310fa3a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d56d46c5c9a4e8a9f809b42b0655590_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec6610466d344f0fa088043b24569826_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:IoveraMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i02771c45dac74870b7443cd500921e8a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i84613c0ab0204e27bfad217490c8e958_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i356e2083084446a6b5546356a72bfb5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pcrx:BupivacaineLiposomeInjectableSuspensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if66cf7a1d0974accbfeaa215c9671c3a_D20211119-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcrx:RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieb1a68217b5c4d4e873ece15e0f90135_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf250MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i9218c1eec9ef41a4992bc55da182b205_D20211119-20301231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf250MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2030-12-31</endDate>
        </period>
    </context>
    <context id="ifcdbdc73190942b1a864a717a9c9bcca_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf375MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i1e721f32c0054c3c80e74321a03292d4_D20211119-20301231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf375MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2030-12-31</endDate>
        </period>
    </context>
    <context id="ie03ed2c8aff24b4494f38ae68516f2ce_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf500MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i008e93128d4947408a9a2c78e9148223_D20211119-20301231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfZILRETTASalesOf500MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2030-12-31</endDate>
        </period>
    </context>
    <context id="i0c856dbf51f94a28b261f6eecf123ef1_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfFDAApprovalOfFX201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i8d300faae4fa47d5b99bd8a7e5282ce7_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfFDAApprovalOfFX301Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i37470c5184194ea6bcf6c2946155189f_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i936811b25a12408a9e9c474cd8eec9ba_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i63aa112e385a4b169e514d953a28f982_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ic6aad501cb7243e887c49fac7690b6ca_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ic1eb92833ae9435a9ecf1d355bbcb009_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i2e8639429a9c49ba9041fee399c2357f_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i8bf45bc62b484e8483fd1b35bcdd3bbd_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="ic1807decbe80497fafb382a9fabc9899_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i9797eb88784347c2ba91f649e7a89035_D20211119-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47f4eb49ec8441a9b58dbd98a28a2201_D20190409-20190409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-09</startDate>
            <endDate>2019-04-09</endDate>
        </period>
    </context>
    <context id="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic017681e6bcd4a53adcb05dba9e3ceea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementofRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36eb9081f8f347b192a76fc04c03d19e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementofRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ebc2eb0427e4bb0850c72962f7e29e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementofRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d3ab2a481794a02a175b6f16b61f237_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6c2512b823f4ff3b209636ae4dcafac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8eb5b42525974ef7a5b153a0d9d0073d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9863c66e56824ed29ccd21bb3ceabb02_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia90f8785504d43449257cd196f4121b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i226f17bf85d347659a1ecbbcad647fc7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i237836ce0fbe43459715133f0ac3bbcb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77820b7ad1054da597cf88e94c1572ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87a8c9c388f348728c52ecd109ff1575_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9dcb927188d04ed7a4fc660309e24cb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b2e96dbe6ff49688146016bf2c6b677_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a79447216ec4d1fbb7c60937d2de629_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i379f934d2a6348d0aa120e522eb186cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib93d52bc0a2448159425d955a92ad1b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:SkyePharmaHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5476241970e4bc8a69aaac752a07c87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponFirstCommercialSaleInMajorEUCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pcrx:MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis">pcrx:UponAnnualNetSalesReachingDollar500.0MillionThresholdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i616ccf441438422f96ae7988c62ac2d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0432a62d54346d4b0cc4ae20df8f3ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50f0a34fc053410586063c1b4fb4c582_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5ae07bdfce9402a9e491efa689e082a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i893f93318f184b3b845f1b842931685c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied35346c8e384819b7401a314ca21029_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7b03b72e8eb425dac2c21da48a1406e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9117c0cf9ab9426eb1181bbfdab3c069_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2aa9720883ec4f3787f93c48c11dae98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if02d7f7d8ef346e095ed28b213a41443_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i029b2fd1da9b426aa281eb6edf9c4164_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied606e7f1e9940e3acdfe0b049aa4169_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0a522e9d6934acc9765ff247056057b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDueMay2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i438cb9109aec4c73bc3f0bbdd10be313_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDueMay2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i531cf89254884fafb25ee2779d786c28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDueMay2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50f3b14c8eb24f87b8db39c9626146de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib156d0fef78446749f347f5513f5ceb7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ca63f94b05a4f70aa9157c96a600b08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i693f123fe4684339ab826c50fedd6ad7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i948cac0513e648dca715d8b2e62ccb32_I20211207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-07</instant>
        </period>
    </context>
    <context id="i9859fe995b1b42efbfc4b581a85bb092_D20211207-20211207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-07</startDate>
            <endDate>2021-12-07</endDate>
        </period>
    </context>
    <context id="iae2b3e809f41477ea25d6594d89a6967_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia39c7c0a086e4f0b8a4d0984865174c0_D20251231-20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i9ad5e620d8a44d559404a2918c7529ee_I20261207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-07</instant>
        </period>
    </context>
    <context id="iaaf747e09ae34640bae22f200d713217_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c7058bed2db4a56b3c7e5e12b92460d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7747ee53e646437988e64e05cfd00fdd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3552408c5bb444cbf0eb6a3ab86a409_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88770a0f88374817ab71722879f70098_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1a422b889ef4dc5a23b911b3aeae411_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5ecb39da69d4d29a362f012fbbd432c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">pcrx:FederalReserveBankOfNYRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaccaba05dfea42d581595525b0cc244f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia017c092a2784b0ca8aab079c9e5fc54_I20200710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="i40835215f27548ddb0046f269d3d2d44_D20170313-20170313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-13</startDate>
            <endDate>2017-03-13</endDate>
        </period>
    </context>
    <context id="ie208910c77e8415fa39a49e9cb6b2e10_I20200710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="ibcab94fdef344be8b8d6fd587edd7388_D20200710-20200710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-10</startDate>
            <endDate>2020-07-10</endDate>
        </period>
    </context>
    <context id="i159db211f8284627a7227966896882fc_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i098824f172bb410fbf000b0dcf738b96_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide059616fdda44779b287a0527e1ddb3_I20200707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-07</instant>
        </period>
    </context>
    <context id="i0fd176f4fa004e9e999ce2a50dcb9adb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtRedemptionTermsOnOrAfterAugust12023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i051d7dc66a2540279e60e320f1d3037d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad983f5646e34e94a2da8681ed807b5d_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="i5a977c4be98547f98b6c05154f959739_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="icd1e05a128ed42ccac04aeee92248fef_D20211206-20220106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-06</startDate>
            <endDate>2022-01-06</endDate>
        </period>
    </context>
    <context id="i43427f256a794c4db525f11b824c9893_I20220107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-07</instant>
        </period>
    </context>
    <context id="i0ce055e93fcd43c293a47474e350a43f_I20220107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDueMay2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-07</instant>
        </period>
    </context>
    <context id="if7bf6b02068a41e8a7ed404d1082e6b2_D20170313-20170313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-13</startDate>
            <endDate>2017-03-13</endDate>
        </period>
    </context>
    <context id="ia0533c1098374121979b41de75d1de0b_I20170313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-13</instant>
        </period>
    </context>
    <context id="i4fb73217f94c444aa76dcd2a69b80870_D20170313-20170313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2017-03-13</startDate>
            <endDate>2017-03-13</endDate>
        </period>
    </context>
    <context id="ib19dbd6e7ef04ec58b328d34732c899d_I20170313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-13</instant>
        </period>
    </context>
    <context id="icadb10d36c46455daf4bbf36c85eb041_I20170307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-07</instant>
        </period>
    </context>
    <context id="ia6d5ff5d3bd44ee1aeb5e1d291f7b120_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtRedemptionTermsonorafterApril12020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-13</startDate>
            <endDate>2017-03-13</endDate>
        </period>
    </context>
    <context id="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-13</startDate>
            <endDate>2017-03-13</endDate>
        </period>
    </context>
    <context id="i65dfbd8ff8d7419f9e7bcef5200f53b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:DebtConversionAndRedemptionTermsAxis">pcrx:DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i292dc4ba96214be2a65fdd56033cc528_I20211206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-06</instant>
        </period>
    </context>
    <context id="ie1a4dffa829749ac815dd4fff21096ef_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="ie577d6c271bb4749abe1c1aa7b73462a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i552e4370c49c488aaf644acf28100abb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01558abfceb343c1997fa09cb38e955a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib13ef9c89d3842a090b30092159c6baa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i833dd50b748e4f648ce8fbdc883c4185_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c6e342295e24ffeb5b662e536f55798_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie47b1b32def64bc0a3609d407c471b13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia547c4173aba4e05a06d562cb5145105_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:TermLoanBFacilityDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d7d1ef1836341deb53748bf79ee7540_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife6537b40fcd40ed8ef4f547088d8dd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59aef1e9bd7c4844a54073f163e8a93d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12a42225481b4c039ba48e07565653d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if31bdc45af904ee791953adb58a89ea7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f2492fc03ca40809334ee540cedfd2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i877fef10b449448bb4a9b1ae0125a699_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73430b1c7b5c48378305535b3e6241c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied69c02578864bbc9cb25cd5c9b8b3ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb164609df064575b1b1a48271b62b19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46eb669c6b164a9e8a7ea3de4a9b62c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b76248be1d04ab7999d2ad496cd6c18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibec8af6ae83c4cc5bb12c9babddf9666_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9513fc7cbbc24c9e8fd0a64ddc87b87a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pcrx:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib73e9b252a7f4625a0d9d5c279a031a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAndMyoscienceAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a0b1b1bfd3a47be9e86153acff8ab26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAndMyoscienceAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79da6badc4ce4c8b87bad102f47d53f7_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="ifd6c594f1a8d4d8198e32bc0c6d23237_D20211119-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d56f0f495b24f6292ed813d0fcfc838_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i596b14391d784004ad234ae361b60952_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5e8a2f34478940948a4fc588e36055b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i688afa6b83624546a44f01cdc4648f16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">pcrx:MeasurementInputExpectedMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iead150b687d149c184bc55655b3b10d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb7c445d56a64eec9a36a2231a41ca72_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5df54267e2fb4ca08078fb42498c07b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifed6c7cb25774dc791f211ce4f75f33a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide37340a89bb45a5b51beeb5442b41a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27fc0a4268ea499a866f36779e8349ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i453db66839f342d1b1291f445f8934ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9a617a44b744a1596fff6fde2d5e5bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafc9c5bceef24a519258f36b731eed51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7f2bb5426e04cc795ae3e950506e652_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id05c5a2e9e2a4674adef676d95ad516e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pcrx:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc6c788ace5a4a8fb5b0dde94e57c31f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e6b31f4d2144d96b895a72c1ba86cb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i738a868b4ee144f2a08a48f1517a777b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if8f291f33e434735b4f02c49878fd653_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:CodaBioTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i53d3e7bf6be84c83bf7d2041a67fdae2_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pcrx:SpineBioPharmaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i6ec4a3b4cc1240d59d30b940f203ee7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:TELABioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cb990da9e674a18bd073cb528fb1809_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:TELABioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i157d8e808cd54ff090acb94b024df9d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:TELABioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if556affba80d4a378bf1f3922edc8edf_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pcrx:GenascenceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ie89711155ad84669abf871469c5aeeb0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie9b8974e2c7e4284b062762071958be9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d3af74affd441a79ce03b62daff7be3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a4df30aaf1c498ba552279f52d650f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i06b2394034c140f6a4694ff381035b4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41ec2f1d36a341c69f0baa5aa111d33a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i396fdd45737f4f0b9bed95c0ddbc0622_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pcrx:MajorCustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b7a7512ce0f40b38a5bd571e54d9751_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pcrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81d1942e618045a69aca1ec725725e2e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic1b427d124e645ad81dfc92d5d66b207_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i268f623dedfe45ef8b32af260bc0891d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic646097fbe734ac9b8fd68d466e50d82_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0e8c703d659b483fba7961601663c1bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0434aab27f55421b84d92aaa462e4576_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9491f3f75e24aaeb616d1274815af74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38819c0324594ec1b66a4ffa3fcf3f56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2612fd9b7b754b8cbaeace3e57620704_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b80643a294b465ea2661625af1ab96f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie41ce2db25d34febb04acbf253c2bfcd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e72dd91549146e4b77f296c7d373601_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f5d2774f94c4c19a034c9d35c8cf659_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b3a1799953e4b7a9a6fe4c6d61c6c82_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic74c8757d0944c88a8cd93d9a4b8cf53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:StockIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc17ef4c747949b48269bf0b8a76060c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:StockIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a5d9635bc2e455f8966f9f3b2bb58fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99a2df6ef1594ed0900053be4381bced_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:InducementPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i744090d10596403bb55779bf5925f19e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:EmployeeStockPurchasePlanESPP2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6806d31d7c914f92a84099b441fe66bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcrx:EmployeeStockPurchasePlanESPP2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7da9c9dd8294201950b3c55f7f72c5e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i75ef046de56d45b6a564367b687cd904_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55f8cb56d1ea45d9b5ddb5495a729cee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2aa85351b13540518354d61849bb9f7d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6c86356bbbe45f6bfe831911514b73d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e8fd43a94a74dafbc22852d9e58719c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f91b2bb657745cc992ed2a4e6446bd4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iddb7c0b3d882467292232e9502359bf3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i432c6966dd144c3991144693194ff39e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd03b01983774133bc52f848b068b1d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd01dc35d06044bb97b415c6c22acd17_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i13fcb2c445c04b488b8969b4514b4362_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ice16f3771e3e4ef983ae97345cb147d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i917c4f0133de471d87fe63c0cf97feec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida3a6c4fe85b491991fb0aa639cee538_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaca373b6b867452b83d716b6422dc258_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic1c7481893dd4af497518d21d834ab65_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibfa96bfa146c401bafdd7c90c8ba2c6e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib38eaa600b8e42a9851a181401b7e23e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8686eb39d5c4df494e9414f7b85eb73_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d0fc32d88804baaab656363bb728911_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70c23ac5a7584fcfbb011f898d04aa74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab19655e67644e4a974aac9a1311b637_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iefedf24a9a184d26b9444aa1d2768efd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iddd1835957aa4542b486125e347c2dff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6be8009e772e4e3ba8f05b461e089043_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcrx:ConversionPremiumOn2022NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id414a99ec0d0409883eb8b2bdee4eb13_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a963ed83400446a9515a4a04cf232b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82a7bb9e5e6343258f6bed68cd00465f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1826d05ddc2f4352b6b5b4681a620e28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e541832bfb246b2a8efc0f7289d4bd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib770abe7bb5740aab0aa7d6eab698b4a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i654e613b80f445abb2eaf1e762ad8cd3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c2116fd2ce647d29354014822fa3386_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ccac5f6e0624be1b654c50898619041_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia52e5d1054ac4b44a90054d80c6509a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46f9b7c2524840cca0b7ffd47db88684_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4141a4b22784eb593c98bb5aca5ba58_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if331b6039ef04e5f968fc0addfc10181_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i119369de4e404fe3857119778cfab5ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f5ba37ffe97491eaff119eb51ec361a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fc3b655165947618391e9bed60d7390_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82f093ad3c8b4abb848c3099f207cc6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9b29e19572b4bbaa5c8f9cdba9c2d35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cb2b41bd3004482921ace6f9b9f7baa_I20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="if5bb0c9c97f24e95b1c6936b67f583e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1346b922bbbc489fa1c57f1775c4d743_I20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="ifda9345b7dc64e9cbe52d2c5cb3bfc6d_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i9893ef209dd044118e3a2ae603b1bb78_I20261231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="i890f49a134e34776a700270d248f7c7d_I20271231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2027-12-31</instant>
        </period>
    </context>
    <context id="ic0f2c982cd5b4bb8a9925e4a655e2c4b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3d452fa4ecb406494b3046bb05e2386_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">pcrx:ForeignNetDeferredTaxAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14837e0e58ba4784b70f1121737d5625_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i133d2578be2a4e5082559c610543604b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pcrx:AcquisitionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iefe2ba44a6d94addb0eb76d116d51d55_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pcrx:AcquisitionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i572235a599364bd3ade9416211dca6cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pcrx:AcquisitionRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3b2886444d644925b435f39f13c30af4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i308c4a2c1d0642d5a4d9505955982379_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c466ffc9152473caa0acde1e894a6ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifce4e7bdc7aa4d8ab4e06a6aa84c37ad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3233de79e7a2425eb18155c86074f1e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:NuanceBiotechCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3578ef27098d49db9276c9f493f654da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:NuanceBiotechCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9541d5a561504d64b4e108f280a3faa5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:NuanceBiotechCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic8de97bb7b224ffbaf4d4572322a126e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:DepoCyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia33a2f9e6ae84d97990e9334c7002dac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:DepoCyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25ae7b32599b43238324567b6549cb9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:DepoCyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i130fb5352c624061a38b0f4e0e96ed76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:FlexionAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pcrx:LegalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i866ca805578348a1a7b549671e9b226d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pcrx:AdvisoryCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9c5f7765b4224a9a8bd7a15b9a2f9b85_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pcrx:MyoscienceAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pcrx:SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id747d21ec2fe432ca5314f7a469d8620_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:NuanceBiotechCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0dbbded270634aa69782055b700085d7_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:EurofarmaLabatoriesSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id5b01a051b66415ba958a05fbf10d319_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:EurofarmaLabatoriesSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1fe450ec25c44c338992024884646e70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:DePuySynthesSalesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">pcrx:CoPromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0cda3779624d47cca8d9a4fd84dbdcdc_I20121205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:AratanaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-05</instant>
        </period>
    </context>
    <context id="i45f29cdfecdd48d8b8c24cf61151d641_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:AratanaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib670284875d746c498df6bb492cd4f90_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:HongKongPharmaTainuoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id496bf8b482742cfbd9725d700e95fab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcrx:HongKongPharmaTainuoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9733ef5993044559a5405d6f38d59438_D20120401-20120430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pcrx:FirstPriceOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-04-01</startDate>
            <endDate>2012-04-30</endDate>
        </period>
    </context>
    <context id="id5828f75d0ba48dbb5d995070ffaf73a_D20120401-20120430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:EnergyAxis">pcrx:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pcrx:SecondPriceOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-04-01</startDate>
            <endDate>2012-04-30</endDate>
        </period>
    </context>
    <context id="iba035b436915468c957402bf102c1460_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:FortisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i7b894792258e44c8853a730b680cff6c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib6b28091853f41199ae71d31aea5bf87_I20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:GeneQuineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="ia16d04ef54124f998b23dcd9e5efc8ce_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3a74aaba5c5b4ccaa7925c2b5333a951_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcrx:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pcrx:AchievementOfMilestoneAxis">pcrx:AchievementOfSalesRelatedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pcrx:FlexionTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2728c786372940b3a47b33099bff7244_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12b7f38fb2f94964a96e1740885b526e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001396814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>pcrx:product</measure>
    </unit>
    <unit id="customer">
        <measure>pcrx:customer</measure>
    </unit>
    <unit id="segment">
        <measure>pcrx:segment</measure>
    </unit>
    <unit id="location">
        <measure>pcrx:location</measure>
    </unit>
    <unit id="payment">
        <measure>pcrx:payment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y18yLTEtMS0xLTA_64ad56aa-2c84-4def-831c-48ce0de9a553">0001396814</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y18zLTEtMS0xLTA_f9b313b5-d90c-49d1-b03e-7a7ac3be1e5f">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y180LTEtMS0xLTMwNTgx_52f1dfe0-6c00-45dc-9be4-bc03e36ff8a0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y181LTEtMS0xLTA_4a6c95ce-eaa8-4c47-8b0b-04b1dab54417">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80L2ZyYWc6MmQ3OGJiNzFjNzBiNGU4YWJiZjg3N2U5MTIxOGUwOGIvdGFibGU6ZTRkNGY2NTRmOWY5NGEwYjhiNmE1MzkwN2U1YjVjNWMvdGFibGVyYW5nZTplNGQ0ZjY1NGY5Zjk0YTBiOGI2YTUzOTA3ZTViNWM1Y182LTEtMS0xLTA_66f05894-a901-45be-af1a-c07a7bd73494">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEyLTAtMS0xLTA_54d63146-003c-4c28-a1fa-c0f426679644">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <pcrx:AccountsReceivablePaymentTerms
      contextRef="i42a9830d9b244758b1ed6841c20a7f8a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzI3NzA_1d583239-02d3-4c41-bc38-abbb200a0e6b">P0D</pcrx:AccountsReceivablePaymentTerms>
    <us-gaap:InterestCostsCapitalized
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMTE4L2ZyYWc6ZWRiYzkzZDZhMDFiNGVhMjgxMTUyODMyNjliODFhZmIvdGV4dHJlZ2lvbjplZGJjOTNkNmEwMWI0ZWEyODExNTI4MzI2OWI4MWFmYl8zODQ4MjkwNjk3Mjcz_6e45b1c1-6579-4cf5-8878-1fb56d5b63a3"
      unitRef="usd">0</us-gaap:InterestCostsCapitalized>
    <pcrx:DebtInstrumentMarketPrice
      contextRef="i65dfbd8ff8d7419f9e7bcef5200f53b6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzI4_fb2e2ff2-2f6b-488e-be15-f6cf7bb95fe4"
      unitRef="number">1.144</pcrx:DebtInstrumentMarketPrice>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzcz_37e3d9d5-af23-4178-aef5-d28d2ffa1f78"
      unitRef="number">0.0149</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <pcrx:DebtInstrumentMarketPrice
      contextRef="i029b2fd1da9b426aa281eb6edf9c4164_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzEwMw_bbee9464-7fdf-44df-ae86-657a0b25df5e"
      unitRef="number">1.113</pcrx:DebtInstrumentMarketPrice>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i1e7d5628512b4a3e8635bfd28f644363_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzE0Nw_e2d8af03-8e1b-4b8c-a62c-f0088df9f8fd"
      unitRef="number">0.0139324</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i292dc4ba96214be2a65fdd56033cc528_I20211206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzM4NDgyOTA2OTc3MTU_109bd95c-ac0f-4aa1-bf22-3db3fc08027a"
      unitRef="usdPerShare">317.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pcrx:DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount
      contextRef="i292dc4ba96214be2a65fdd56033cc528_I20211206"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzM4NDgyOTA2OTc3MjQ_cbfd9eaf-bca8-493f-acc0-d676498d6165"
      unitRef="shares">37.3413</pcrx:DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ie1a4dffa829749ac815dd4fff21096ef_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzUvZnJhZzplM2M0MjlmYjlkODQ0NTdhYjVlYmMzMDJmZDg4MGI3MC90ZXh0cmVnaW9uOmUzYzQyOWZiOWQ4NDQ1N2FiNWViYzMwMmZkODgwYjcwXzM4NDgyOTA2OTc0OTM_0fe9dc10-5620-4491-ae84-2fc746db190b"
      unitRef="number">0.0373413</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i0b7a7512ce0f40b38a5bd571e54d9751_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMTExL2ZyYWc6NzQwN2ZhNGZhODhjNDFjZWJhNTY2NGZiYmUxNjYwNDMvdGV4dHJlZ2lvbjo3NDA3ZmE0ZmE4OGM0MWNlYmE1NjY0ZmJiZTE2NjA0M180Mzk4MDQ2NTExMTY1_daeeaf76-be2d-48ed-8d83-feb892ae7642"
      unitRef="number">0.122</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDU1L2ZyYWc6NTFjMWVlMGQ4Y2IwNDg5MjkyNWY4M2Y5NjM2N2U5NjYvdGV4dHJlZ2lvbjo1MWMxZWUwZDhjYjA0ODkyOTI1ZjgzZjk2MzY3ZTk2Nl8zODQ4MjkwNjk3NDA3_f57f52e2-2167-409b-b4fe-39de49a3048b">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTE 22&#x2014;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Placeholder&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF84Nw_f30ef2b5-c55b-4cd3-8573-e40ba65b14fe">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6ODM0MDI3ZjM0MDgxNGQ2ZmJhYzliYzEwMDYyMGNmNmMvdGFibGVyYW5nZTo4MzQwMjdmMzQwODE0ZDZmYmFjOWJjMTAwNjIwY2Y2Y18xLTAtMS0xLTA_f0af5d7e-288d-4755-b4c1-28319eb6abfa">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8xMjQ_7e924e2c-1858-4897-8f1b-f523258606cf">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8xMjQ_cfe32fdf-3b9c-4467-84fe-95bba38e6f82">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6NDMwZWZjOTEzYjA3NGRlZWFlOWU0NTBhNmUxYzI3ZWQvdGFibGVyYW5nZTo0MzBlZmM5MTNiMDc0ZGVlYWU5ZTQ1MGE2ZTFjMjdlZF8wLTAtMS0xLTA_110bf69a-28de-4ef9-bbfa-c26a1136f88d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8yMDE_d41b5ec2-9b94-4f4c-9fdd-c13a7e3ff983">001-35060</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8yMDk_e3d3196c-e940-4dfb-834c-06be3881acc3">PACIRA BIOSCIENCES,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl8wLTAtMS0xLTA_2152db2f-2acf-4f15-b385-475ebee7c3c9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl8wLTEtMS0xLTA_11b38465-9890-407f-82cc-2a6d3ed50fd3">51-0619477</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl8zLTAtMS0xLTA_2410ccf1-2e00-4004-a289-0ee8bdd579f1">5401 West Kennedy Boulevard, Suite 890</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl80LTAtMS0xLTA_f9d3b769-3ef2-4b08-97fd-da8c35948a1f">Tampa,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl80LTEtMS0xLTA_9f95a823-8617-4f2a-a957-5e763a831ae9">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl81LTAtMS0xLTA_79a93b57-2dcd-40fa-913e-7dc45016314e">33609</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl84LTAtMS0xLTA_81952df8-be47-4a78-9468-b7fb6b1d0e39">(813)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YWQ3MTM3MGMxZjBiNDRkMDk2ZmE3NjA5MThmYzBlYTYvdGFibGVyYW5nZTphZDcxMzcwYzFmMGI0NGQwOTZmYTc2MDkxOGZjMGVhNl84LTEtMS0xLTA_eed13a66-ce17-4f0e-b462-2355bc42badb">553-6680</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YmJiOGEwYjRhYzdlNDFmMjllYmExYzQ4NzBkMzE4NDEvdGFibGVyYW5nZTpiYmI4YTBiNGFjN2U0MWYyOWViYTFjNDg3MGQzMTg0MV8xLTAtMS0xLTA_59c8a938-fa36-4aad-acef-8f114e40f591">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YmJiOGEwYjRhYzdlNDFmMjllYmExYzQ4NzBkMzE4NDEvdGFibGVyYW5nZTpiYmI4YTBiNGFjN2U0MWYyOWViYTFjNDg3MGQzMTg0MV8xLTItMS0xLTA_f9c73ade-b183-4ce0-b2a4-0d1f5d866bc2">PCRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6YmJiOGEwYjRhYzdlNDFmMjllYmExYzQ4NzBkMzE4NDEvdGFibGVyYW5nZTpiYmI4YTBiNGFjN2U0MWYyOWViYTFjNDg3MGQzMTg0MV8xLTQtMS0xLTA_6522ca42-5423-4d13-a86d-87fdf16aa201">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF81MjU_e609718e-89f7-45e8-8a1e-b51041bf60a9">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF82NzI_cb7b5038-26b6-45d2-a26a-fbbb35f5f61e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8xMDIx_774ffd4a-2775-4d9c-8993-a45f533d6399">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8xMzQz_9e8e2b1e-d2e7-453a-a205-c38c3dfcfe53">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6MmNjZDk4M2FlZWVkNGJkM2JmNGM3MzZhYzllMmQ2YWMvdGFibGVyYW5nZToyY2NkOTgzYWVlZWQ0YmQzYmY0YzczNmFjOWUyZDZhY18wLTAtMS0xLTA_e3601c90-a9b8-4aeb-8dac-e4de1efa4530">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6MmNjZDk4M2FlZWVkNGJkM2JmNGM3MzZhYzllMmQ2YWMvdGFibGVyYW5nZToyY2NkOTgzYWVlZWQ0YmQzYmY0YzczNmFjOWUyZDZhY18xLTMtMS0xLTA_4c42f9b6-225a-48ca-80e2-0213929e9361">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGFibGU6MmNjZDk4M2FlZWVkNGJkM2JmNGM3MzZhYzllMmQ2YWMvdGFibGVyYW5nZToyY2NkOTgzYWVlZWQ0YmQzYmY0YzczNmFjOWUyZDZhY18yLTMtMS0xLTA_4196e8fd-6e7b-4dbe-9608-553ea2700e1f">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8zNjE0_9e1999ae-2c66-4a5e-a3fb-0cfab5f466dd">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8yNDE3_daa6b485-6cfc-4ecf-8944-03740998caa3">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ib9f5b792563940c3a6ac3952c900baba_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8yNzc1_a9d0957a-7050-43cd-bfde-3b1e8c836810"
      unitRef="usd">1600000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib74a5ff7f32a4742bb95a41a5c1e0be2_I20220227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8zMTg0_b256871d-ec7c-4887-b2a6-f92e12fe4b49"
      unitRef="shares">44847728</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xL2ZyYWc6YjMwODM0ZjAyMzZjNDJjOTkwYTViMjIwYTY3ZmJiYTQvdGV4dHJlZ2lvbjpiMzA4MzRmMDIzNmM0MmM5OTBhNWIyMjBhNjdmYmJhNF8zODQ4MjkwNzAxNjMx_33ffc948-14b1-4ee9-b00f-e1a56e05fcdf">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Part&#160;III of this Annual Report on Form&#160;10-K incorporates certain information by reference from the registrant&#x2019;s proxy statement for the 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission no later than 120&#160;days after the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80My9mcmFnOjBiYzY1ZGNjZmY0MzRhMTlhODljZTNmZjM4MzA3MjdjL3RleHRyZWdpb246MGJjNjVkY2NmZjQzNGExOWE4OWNlM2ZmMzgzMDcyN2NfMjE5OTAyMzI2NTYxNA_95a70d4f-3ee4-4335-82b9-a5b2075e49ac"
      unitRef="usd">578800000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80My9mcmFnOjBiYzY1ZGNjZmY0MzRhMTlhODljZTNmZjM4MzA3MjdjL3RleHRyZWdpb246MGJjNjVkY2NmZjQzNGExOWE4OWNlM2ZmMzgzMDcyN2NfMjE5OTAyMzI2ODU5NQ_472087cc-5097-4251-ad31-12659399458b"
      unitRef="usd">85100000</pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt>
    <pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration
      contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF80My9mcmFnOjBiYzY1ZGNjZmY0MzRhMTlhODljZTNmZjM4MzA3MjdjL3RleHRyZWdpb246MGJjNjVkY2NmZjQzNGExOWE4OWNlM2ZmMzgzMDcyN2NfMjE5OTAyMzI2ODcwNg_35e13d74-af23-4202-845b-42bcd2823211"
      unitRef="usd">45200000</pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration>
    <us-gaap:PurchaseObligation
      contextRef="ib97087953997481c9eb9531b2899f6a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF81OC9mcmFnOmQxZDJjYTM2NTQ4NzQ4MTBiOTZkZGVkNGY0NTkyNTQyL3RleHRyZWdpb246ZDFkMmNhMzY1NDg3NDgxMGI5NmRkZWQ0ZjQ1OTI1NDJfMTE1NDQ4NzIwOTg1MDA_1e79b6fa-0ab6-4463-93b8-757005d3b481"
      unitRef="usd">50300000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation
      contextRef="ia919a337f89e4501a657825c42e3742f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF81OC9mcmFnOmQxZDJjYTM2NTQ4NzQ4MTBiOTZkZGVkNGY0NTkyNTQyL3RleHRyZWdpb246ZDFkMmNhMzY1NDg3NDgxMGI5NmRkZWQ0ZjQ1OTI1NDJfMTE1NDQ4NzIwOTg1OTU_97fd1254-4398-456e-b264-8b821edc034c"
      unitRef="usd">9200000</us-gaap:PurchaseObligation>
    <pcrx:ContingentConsiderationCurrent
      contextRef="i18f0515519fd468ea2893c1d1449bb1e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF81OC9mcmFnOmQxZDJjYTM2NTQ4NzQ4MTBiOTZkZGVkNGY0NTkyNTQyL3RleHRyZWdpb246ZDFkMmNhMzY1NDg3NDgxMGI5NmRkZWQ0ZjQ1OTI1NDJfMTE1NDQ4NzIxMDgwNzU_d3c591bd-a30b-40dd-849e-0b43212ccf85"
      unitRef="usd">43000000</pcrx:ContingentConsiderationCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3d43a54915fb471a881eb7c22d53ebb8_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMS0yLTEtMS02NDI0Ni90ZXh0cmVnaW9uOmQxYjEwMjAwNWQ0MjQwYzg5ZjU1YzZkMzk3NTU2ZGY3XzQ_e555f7a3-3e52-42a8-ad4a-6c6ed1a7c635"
      unitRef="number">0.1139</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="if920c61660554030b10993e6540fa419_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMS0yLTEtMS02NDI0Ni90ZXh0cmVnaW9uOmQxYjEwMjAwNWQ0MjQwYzg5ZjU1YzZkMzk3NTU2ZGY3XzEw_2a15cb68-0421-41f3-b50c-db0f7ea3d8f2"
      unitRef="number">0.1292</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic2cf381db5a940f290c4b8ce845a8a32_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMS00LTEtMS02NDI0Ni90ZXh0cmVnaW9uOmM1N2U4OTgxMGUyZjRlOWRiNWRlMjNkZTBlMDNiYWY5XzQ_2ca0d2ec-c0d0-4e6b-8447-a757e658091b"
      unitRef="number">0.1142</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i7c32d4b9517d48699bd04bc765bd4313_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMS00LTEtMS02NDI0Ni90ZXh0cmVnaW9uOmM1N2U4OTgxMGUyZjRlOWRiNWRlMjNkZTBlMDNiYWY5XzEw_f13747bb-7642-4c87-ac29-1e5df3a3e4d8"
      unitRef="number">0.1213</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i34416a5edad84520b386d27a329de124_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMi0yLTEtMS02NDI0Ni90ZXh0cmVnaW9uOmVhZDk2OTA4ODIxNjQ3NGRiMDJiZjRkZDYzZjIyNTA1XzQ_965b0cac-5a10-4e1c-ae3d-a5eadef7be9f"
      unitRef="number">0.1000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i5b952c5725b44f818a3a4608b206c6b4_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMi0yLTEtMS02NDI0Ni90ZXh0cmVnaW9uOmVhZDk2OTA4ODIxNjQ3NGRiMDJiZjRkZDYzZjIyNTA1XzEw_a82055ca-7bd3-4987-a0d3-f13a2ff29d18"
      unitRef="number">0.1500</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i87676acfa0004a61af3790653d502de3_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RhYmxlOmZlZjllYjZmMzE3ZTQyY2Q5OWUyMjk3YmUzNDEyMmJmL3RhYmxlcmFuZ2U6ZmVmOWViNmYzMTdlNDJjZDk5ZTIyOTdiZTM0MTIyYmZfMi00LTEtMS02NDI0Ni90ZXh0cmVnaW9uOmIwYjk3OTBmZGU4NDQyY2ZiNjg5ZjlhMGNkN2U4MTY4XzQ_3f397d69-62ad-4b9a-bc48-4dc2c9924c9a"
      unitRef="number">0.0100</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition
      contextRef="i6d4add3e8085457381bf09ffb890926b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RleHRyZWdpb246MGE1NWNjMWRiZTE4NGVmOGJmNzM2MDFlNzgyODM3NWVfMTY0OTI2NzQ0MzQ3OTM_26c62d9f-df6c-4b85-b8b4-99afb072cb05"
      unitRef="usd">425500000</pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition>
    <pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition
      contextRef="i18f0515519fd468ea2893c1d1449bb1e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF82MS9mcmFnOjBhNTVjYzFkYmUxODRlZjhiZjczNjAxZTc4MjgzNzVlL3RleHRyZWdpb246MGE1NWNjMWRiZTE4NGVmOGJmNzM2MDFlNzgyODM3NWVfMTY0OTI2NzQ0MzQ4MDE_a496e354-721c-44e7-919d-16c11b42f6ad"
      unitRef="usd">43000000</pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition>
    <dei:AuditorName
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMTgvZnJhZzphMjQ3NmJlMDg2MGY0MDFkYjA0YTNlMjg5OWE5OWU2Yy90YWJsZTpkYjhiYmQzOTRiNjI0OTE4OTNmZGFhZGIzODMzYzM0NS90YWJsZXJhbmdlOmRiOGJiZDM5NGI2MjQ5MTg5M2ZkYWFkYjM4MzNjMzQ1XzItMi0xLTEtNTAzNDg_b57323fd-4e6a-431f-9a07-48a76825d62e">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMTgvZnJhZzphMjQ3NmJlMDg2MGY0MDFkYjA0YTNlMjg5OWE5OWU2Yy90YWJsZTpkYjhiYmQzOTRiNjI0OTE4OTNmZGFhZGIzODMzYzM0NS90YWJsZXJhbmdlOmRiOGJiZDM5NGI2MjQ5MTg5M2ZkYWFkYjM4MzNjMzQ1XzMtMi0xLTEtNTAzNDg_2eab0fee-a006-46f1-9c3b-03a2fa09a49e">Short Hills, NJ</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMTgvZnJhZzphMjQ3NmJlMDg2MGY0MDFkYjA0YTNlMjg5OWE5OWU2Yy90YWJsZTpkYjhiYmQzOTRiNjI0OTE4OTNmZGFhZGIzODMzYzM0NS90YWJsZXJhbmdlOmRiOGJiZDM5NGI2MjQ5MTg5M2ZkYWFkYjM4MzNjMzQ1XzQtMi0xLTEtNTAzNDg_c22dd209-1784-4afd-8d5e-ed45d4362353">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQtMS0xLTEtMA_c9d54283-006f-4283-a410-3f479795186a"
      unitRef="usd">585578000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQtMy0xLTEtMA_dc0dc3a4-b20c-46fe-9d05-768e72dcd0c3"
      unitRef="usd">99957000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzUtMS0xLTEtMA_160db8e3-26cc-4fa1-99e5-1c94fc0689ca"
      unitRef="usd">70831000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzUtMy0xLTEtMA_b5798f55-1338-4775-9268-7287b4cce391"
      unitRef="usd">421705000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzYtMS0xLTEtMA_7f4bcef8-9a00-4831-b496-40a61e88896b"
      unitRef="usd">96318000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzYtMy0xLTEtMA_620e1f52-ee2f-4ee3-89da-0d2c44197f9b"
      unitRef="usd">53046000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzctMS0xLTEtMA_b276ce3b-7d5d-4c80-a76c-8d2ab19b4aeb"
      unitRef="usd">98550000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzctMy0xLTEtMA_892a23c9-9540-43ef-a34d-a61387912aa4"
      unitRef="usd">64650000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzgtMS0xLTEtMA_a5342c41-0ad2-4d53-8cf3-2c25a710bf1a"
      unitRef="usd">14771000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzgtMy0xLTEtMA_c8ca09a3-ac28-467e-a455-266612bca0cf"
      unitRef="usd">12265000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzktMS0xLTEtMA_e203f17b-0190-4cdc-94c6-141fd797cb16"
      unitRef="usd">866048000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzktMy0xLTEtMA_f70ad391-a310-467e-9184-de3733a4a63d"
      unitRef="usd">651623000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEwLTEtMS0xLTA_392430f5-d8c5-4de6-b362-4d7e272ec312"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEwLTMtMS0xLTA_f20dab3b-aea8-4e8f-9cfb-4ab4f9fc643a"
      unitRef="usd">95459000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzExLTEtMS0xLTA_4e459d03-457f-45d6-8646-225ae30c0d49"
      unitRef="usd">188401000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzExLTMtMS0xLTA_b3d19b8c-8fe4-4755-8a9f-14245876aeac"
      unitRef="usd">136688000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEyLTEtMS0xLTA_e8346d37-4b80-4f85-95ee-2dfed0b681f1"
      unitRef="usd">76410000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEyLTMtMS0xLTA_336c56dc-e6fa-4c29-8585-454d13280dd3"
      unitRef="usd">74492000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEzLTEtMS0xLTA_af7b1dbf-1899-4326-8859-175767b0c9b1"
      unitRef="usd">145175000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzEzLTMtMS0xLTA_0c62b2c9-8066-4a0d-aaf6-8f880fad9b9d"
      unitRef="usd">99547000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE0LTEtMS0xLTA_9c48a815-2e73-474e-aa6d-3e3fc3bb2e04"
      unitRef="usd">623968000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE0LTMtMS0xLTA_0e67dbb6-400b-47e8-945c-bf886e0b6fed"
      unitRef="usd">96521000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE1LTEtMS0xLTA_271ae3fd-f22c-4ea0-a181-2b5b55347061"
      unitRef="usd">153364000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE1LTMtMS0xLTA_22d71192-c368-41a7-a9ff-26ef8e204798"
      unitRef="usd">106164000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE2LTEtMS0xLTA_0d621534-47ed-4db3-838b-eb84b1f30bca"
      unitRef="usd">21987000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE2LTMtMS0xLTA_51455de4-7714-464a-86ba-404f6ec32113"
      unitRef="usd">14019000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:Assets
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE4LTEtMS0xLTA_1fb4a76b-ba4a-4195-872f-6ef9422be855"
      unitRef="usd">2075353000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzE4LTMtMS0xLTA_57c5f35a-588e-4a37-8b96-952de51426cf"
      unitRef="usd">1274513000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzIyLTEtMS0xLTA_3e2ffa2b-6742-41a1-a882-74ef069ee21a"
      unitRef="usd">10543000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzIyLTMtMS0xLTA_dcb0017b-6c58-402b-9024-100cb97bc79b"
      unitRef="usd">10431000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzIzLTEtMS0xLTA_02dbc05b-6fb2-4b31-8028-5d44c3789d67"
      unitRef="usd">127555000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzIzLTMtMS0xLTA_20637da9-1bf9-4749-883a-a958be94b77f"
      unitRef="usd">70974000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI0LTEtMS0xLTA_c7af4f54-b1e1-4b1f-b315-04660c6457de"
      unitRef="usd">7891000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI0LTMtMS0xLTA_8230851d-17e6-4a56-9e43-35a2501fb286"
      unitRef="usd">7425000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI1LTEtMS0xLTA_eada0951-939d-4466-95dd-c46c55652a1c"
      unitRef="usd">350466000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI1LTMtMS0xLTA_9b2a4a10-dcd8-40a4-a3a1-3cd2ba94afd4"
      unitRef="usd">149648000</us-gaap:ConvertibleDebtCurrent>
    <pcrx:ContingentConsiderationCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI2LTEtMS0xLTA_ec90a190-ad27-4959-b7e4-2251ae0301c1"
      unitRef="usd">0</pcrx:ContingentConsiderationCurrent>
    <pcrx:ContingentConsiderationCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI2LTMtMS0xLTA_810d455e-4622-4ca1-b13a-b07b59b13ede"
      unitRef="usd">14736000</pcrx:ContingentConsiderationCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI3LTEtMS0xLTMyMjg3_f4f6e64b-2ab0-4814-8a80-db33a9e6ad1b"
      unitRef="usd">24234000</us-gaap:SecuredDebtCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI3LTMtMS0xLTMyMjg3_e9fcc3fa-6ee0-4d3c-9692-9a298c7e3944"
      unitRef="usd">0</us-gaap:SecuredDebtCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI4LTEtMS0xLTA_c27e0bcd-f443-444f-ab31-79b81a1b5d0a"
      unitRef="usd">429000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI4LTMtMS0xLTA_af0e1780-cd14-45c1-8419-ebba84f8a068"
      unitRef="usd">114000</us-gaap:TaxesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI5LTEtMS0xLTA_763c8a4a-55ed-4409-aa15-d4711fe32996"
      unitRef="usd">521118000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzI5LTMtMS0xLTA_7f8fb454-ba93-49a7-8a88-288dee9ae0c2"
      unitRef="usd">253328000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMwLTEtMS0xLTA_c6e12eb3-cf53-41f9-b3b5-d495caf046c6"
      unitRef="usd">339267000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMwLTMtMS0xLTA_1a6a56f9-8616-43cf-9b31-1465eb723dbd"
      unitRef="usd">313030000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMxLTEtMS0xLTA_f96e94ee-e920-417f-bda2-6e05974c8517"
      unitRef="usd">71727000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMxLTMtMS0xLTA_97125463-b4c9-4f1d-a868-81011c46d784"
      unitRef="usd">71025000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTEtMS0xLTQ1OTY1_0b800a53-1832-4507-8ea1-95317613f811"
      unitRef="usd">10125000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTMtMS0xLTQ1OTY1_11d42253-9d75-417e-950b-b98479e88965"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTEtMS0xLTMyMjk5_c606b44f-1770-4fa6-aee8-05eb22559946"
      unitRef="usd">335263000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTMtMS0xLTMyMjk5_bb649467-5f75-4ccd-b154-c19e765bb4b4"
      unitRef="usd">0</us-gaap:SecuredLongTermDebt>
    <pcrx:ContingentConsiderationNoncurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMyLTEtMS0xLTA_7f13b3ef-a890-40b4-b9cd-21b878ddfe3d"
      unitRef="usd">57598000</pcrx:ContingentConsiderationNoncurrent>
    <pcrx:ContingentConsiderationNoncurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMyLTMtMS0xLTA_21fc3ead-d92d-4fbd-acba-814f84937f7c"
      unitRef="usd">13610000</pcrx:ContingentConsiderationNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTEtMS0xLTA_39272d3e-6941-41bd-a724-a3f25f228fe0"
      unitRef="usd">9847000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzMzLTMtMS0xLTA_85b07d92-f140-431a-9cf0-bdeac851603b"
      unitRef="usd">3832000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM0LTEtMS0xLTA_26e3572b-9f8e-43f5-a324-3235e06e0872"
      unitRef="usd">1344945000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM0LTMtMS0xLTA_fbe00f5b-c004-4990-8e0d-c93e44972ec7"
      unitRef="usd">654825000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM1LTEtMS0xLTA_4d10a810-03f5-4bdc-9b77-2a0c02ccf9e1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM1LTMtMS0xLTA_89b72709-db8d-424e-8a9a-afc6aed53340"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl8zMQ_5dd6a07c-5454-46f4-a96a-371a652f6a1f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl8zMQ_847cc73a-2480-45ba-bf25-5c4bea4a5f6e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl8zNQ_d10834c7-96cb-4e8f-8919-fdb622faa412"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl8zNQ_da68ab9b-c6c0-4c30-a7f8-01864f4f44bc"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl81Nw_1e18375b-d111-4e08-92ab-74fc41d74706"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl81Nw_772f0162-08e2-469c-bfd8-cfdc1c0056d2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl81Nw_ce346380-336c-47e6-aa31-40eb653f048b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjpiODUwOWIyZjI1YjE0NWMyODlhMzEyNzM4ODUxMzgwNl81Nw_f8c1fa0b-a96f-49f1-9cce-3dfafc89704f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTEtMS0xLTA_a0b1a614-0330-4188-9fb5-25895b16260d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM3LTMtMS0xLTA_14610879-dd67-49a3-a98b-1aa0738a2930"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18yOA_30283716-8b2b-4ccc-bfaa-cc653c12610c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18yOA_d801be9e-ab5d-4890-afad-a6a666513f89"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18zMg_6328e4bc-d92b-4d3f-b016-8f94be3fc785"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18zMg_849ee73d-e0bb-470e-af07-4f9f2b7980d3"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y181NA_084d571f-0755-4973-bb6e-260cda39c742"
      unitRef="shares">44734308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y181NA_9ebc5d82-18b6-4387-84d1-e0dea8895e9a"
      unitRef="shares">44734308</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18xMTU0NDg3MjA5MTc4Ng_47ecbdc0-9b9f-4bac-bbaa-94c1f2a9586d"
      unitRef="shares">43636929</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjo1ODAzODljN2FlZWM0OTY2OTU3NGY4NmU1OWVhMjc5Y18xMTU0NDg3MjA5MTc4Ng_a9457dfb-99c9-44f4-ae68-d460e069acee"
      unitRef="shares">43636929</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTEtMS0xLTA_6316a543-d746-4fd3-8efe-7ebd1bb666dd"
      unitRef="usd">45000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM4LTMtMS0xLTA_e5347749-5045-4572-be91-ff108e0dcb09"
      unitRef="usd">44000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM5LTEtMS0xLTA_d6d7ea45-4c8a-4f99-8572-0ebf4f3b63a3"
      unitRef="usd">942091000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzM5LTMtMS0xLTA_00106451-0467-4306-88a3-2646b567e761"
      unitRef="usd">873201000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQwLTEtMS0xLTA_367fb10d-8f6d-492d-85ec-8327bb090332"
      unitRef="usd">-211895000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQwLTMtMS0xLTA_b366b4d6-648d-4da8-9fac-4b4eef844740"
      unitRef="usd">-253875000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQxLTEtMS0xLTA_3d38d6a3-aa34-4ea5-a406-2ff79f622bfd"
      unitRef="usd">167000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQxLTMtMS0xLTA_b8243e81-d597-49da-9d4d-36671e4f3921"
      unitRef="usd">318000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQyLTEtMS0xLTA_285bd67a-5345-4d3f-945e-adc43ffb4c56"
      unitRef="usd">730408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQyLTMtMS0xLTA_f212b7a0-5479-4d03-93ab-d78b8e4ff015"
      unitRef="usd">619688000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQzLTEtMS0xLTA_d287b103-3af7-47e7-9f12-08c08cf659d9"
      unitRef="usd">2075353000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjQvZnJhZzowYmMzNTM0ODliMmI0MGU4YTI5NDY3MDUyNTE0N2VmNS90YWJsZTpiMmI4OWIwNzE2YWI0Y2EyOTJiY2FmNjUwYjExOGE2YS90YWJsZXJhbmdlOmIyYjg5YjA3MTZhYjRjYTI5MmJjYWY2NTBiMTE4YTZhXzQzLTMtMS0xLTA_312084c8-8703-4c9d-a344-7cc5d98d1cdf"
      unitRef="usd">1274513000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6f38afdcb06c45b49334598d858c08be_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMtMS0xLTEtMA_ff434858-b7cf-4d7e-9f33-1be7547f4e5f"
      unitRef="usd">538966000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9be32dbfc52d4ab3bef56de81da70e21_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMtMy0xLTEtMA_5026bad6-f0d2-4623-a385-db45e2160bb0"
      unitRef="usd">426614000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i82f4de158e56453ea2b40d32946b5324_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMtNS0xLTEtMA_d82c15ab-edcc-4d3c-bbc4-e35b7a529e41"
      unitRef="usd">418926000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i02f22e84df6a45609376bb4bbce1cf8e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtMS0xLTEtNTc0MzY_3a286d0c-734f-4728-a8c4-14882a0eec1a"
      unitRef="usd">2442000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i22e2f16409934c59b4f8cb94a706dc14_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtMy0xLTEtNTc0MzY_844cc4b3-7f5f-4440-8c3c-f9858227deba"
      unitRef="usd">3033000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i96bdb26537c44cc6b5fef08200c07e6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtNS0xLTEtNTc0MzY_f3cc0367-f3be-4e3e-a2f4-1fd3d4584896"
      unitRef="usd">2100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtMS0xLTEtMA_c82c4cbf-3ce4-460f-a287-932aad57d392"
      unitRef="usd">125000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtMy0xLTEtMA_c112b114-b899-4c04-8749-40f3ed315905"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzQtNS0xLTEtMA_aac38bd0-a7df-425a-8939-1a442167569c"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzYtMS0xLTEtMA_f66bea6e-c42b-483b-84c5-337a1a25a77a"
      unitRef="usd">541533000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzYtMy0xLTEtMA_6880b0e7-24a2-45ac-98dc-b5ad38d0796d"
      unitRef="usd">429647000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzYtNS0xLTEtMA_d3544e70-a7c7-49c2-971c-b99187326970"
      unitRef="usd">421026000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzgtMS0xLTEtMA_103242ff-340d-4284-993a-8acf0de140e6"
      unitRef="usd">140255000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzgtMy0xLTEtMA_c6e93a56-0dd7-47a1-bc5b-4687595ee24d"
      unitRef="usd">117328000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzgtNS0xLTEtMA_7a575ae6-4279-4d51-acb0-2cb54bb50d6a"
      unitRef="usd">106712000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzktMS0xLTEtMA_c8a85cb3-34fd-4d85-a8d6-abccc007c5c0"
      unitRef="usd">55545000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzktMy0xLTEtMA_f79031a8-d6d2-4d9c-b33a-54e3bc6ec882"
      unitRef="usd">59421000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzktNS0xLTEtMA_ccdd5495-e250-476e-9c09-28e84c338473"
      unitRef="usd">72119000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEwLTEtMS0xLTA_34863e6e-da60-4107-ac80-8348a6e3b10e"
      unitRef="usd">199345000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEwLTMtMS0xLTA_949c5780-ee59-480a-9f18-23648cff11fd"
      unitRef="usd">193516000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEwLTUtMS0xLTA_fff0f5ad-3efc-4254-91ed-d5f35bc72ecf"
      unitRef="usd">200782000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzExLTEtMS0xLTA_7e08705a-bc77-45c5-b632-a478e169319f"
      unitRef="usd">13553000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzExLTMtMS0xLTA_10d749bb-a9b5-4915-b056-b44b5f210997"
      unitRef="usd">7866000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzExLTUtMS0xLTA_5e7dfee7-36f0-4d56-ae51-346b3ca2030f"
      unitRef="usd">5703000</us-gaap:AmortizationOfIntangibleAssets>
    <pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEyLTEtMS0xLTA_eb945dc1-745b-4757-9c18-18994911443f"
      unitRef="usd">42911000</pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses>
    <pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEyLTMtMS0xLTA_5c0ebb54-e72b-468f-a6f0-037dac470bff"
      unitRef="usd">5166000</pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses>
    <pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEyLTUtMS0xLTA_8f19f6b9-88d9-4025-a296-03f10bf9c787"
      unitRef="usd">25230000</pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEzLTEtMS0xLTA_48699cfb-73cb-430a-abac-71dea2ec9533"
      unitRef="usd">451609000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEzLTMtMS0xLTA_6fd3e199-5f16-4c12-b609-90941c89f5c5"
      unitRef="usd">383297000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzEzLTUtMS0xLTA_eb80c356-df55-4ea6-b378-1d69d55963e5"
      unitRef="usd">410546000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE0LTEtMS0xLTA_ebf0e855-2201-49e6-bd45-b940200b08ed"
      unitRef="usd">89924000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE0LTMtMS0xLTA_780b066b-ab0e-4874-9b8e-a551d16f9837"
      unitRef="usd">46350000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE0LTUtMS0xLTA_255dbcf9-a899-4415-b9c4-e47b340ddfed"
      unitRef="usd">10480000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE2LTEtMS0xLTA_64a53399-3c6e-4c0a-beba-befe6fc49656"
      unitRef="usd">896000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE2LTMtMS0xLTA_eda10b8d-85a4-4147-bbc7-cdc03f44e13b"
      unitRef="usd">4629000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE2LTUtMS0xLTA_e74053f9-1079-42b8-90c9-9593ae06b094"
      unitRef="usd">7376000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE3LTEtMS0xLTA_0c663c96-cb29-4f0f-b909-de0eb331383b"
      unitRef="usd">31750000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE3LTMtMS0xLTA_7b0c0b36-a24e-4fe6-908d-9032face97ca"
      unitRef="usd">25671000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE3LTUtMS0xLTA_ee7528f8-a0a8-4852-b43f-60bf88632ee5"
      unitRef="usd">23628000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE4LTEtMS0xLTA_ee0fcf0a-b0a8-4cea-ad59-01693247775b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE4LTMtMS0xLTA_25e966f8-e7e8-4b5a-9436-68cda6f9a969"
      unitRef="usd">-8071000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE4LTUtMS0xLTA_0f434b1a-4bd1-4002-bb3a-bc21c6b2cafe"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE5LTEtMS0xLTA_f3b69531-0277-4d70-a993-7b247c1ef5ff"
      unitRef="usd">-2666000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE5LTMtMS0xLTA_035a24ea-c4fa-49bb-9f10-51ce66e0970f"
      unitRef="usd">2852000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzE5LTUtMS0xLTA_ec429b4c-4eb8-457f-a870-c6f3d7287cbc"
      unitRef="usd">-4976000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIwLTEtMS0xLTA_a0af78f6-636b-4fc9-a28b-0d3a8e31b045"
      unitRef="usd">-33520000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIwLTMtMS0xLTA_259d7fcd-d1ae-42b5-acd7-6c6115321ca6"
      unitRef="usd">-26261000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIwLTUtMS0xLTA_4bac6488-7e8b-4ff8-8aa6-58db020e2ad6"
      unitRef="usd">-21228000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIxLTEtMS0xLTA_bbe2d531-9ae9-4982-bdd2-a361d1e4bd79"
      unitRef="usd">56404000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIxLTMtMS0xLTA_76b4ace6-4708-4dff-8b53-afd395d17c50"
      unitRef="usd">20089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIxLTUtMS0xLTA_0d9b9b4f-e902-4e3d-8850-7053d00fae3d"
      unitRef="usd">-10748000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIyLTEtMS0xLTA_d15c8807-78c7-4d3b-9dd5-0c3f136ebe98"
      unitRef="usd">14424000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIyLTMtMS0xLTA_95fd118f-e164-407e-bea2-9188bf996e0d"
      unitRef="usd">-125434000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIyLTUtMS0xLTA_4b2ca59f-aeac-4889-a971-09f0c5ada969"
      unitRef="usd">268000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIzLTEtMS0xLTA_c8a5c961-52e4-430a-9cca-c76b345364d4"
      unitRef="usd">41980000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIzLTMtMS0xLTA_80e95b83-0dd7-4d0b-9ae1-3571f1d0a348"
      unitRef="usd">145523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzIzLTUtMS0xLTA_6b85ac3c-cac9-4da6-bddc-f269d7c9c37f"
      unitRef="usd">-11016000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI2LTEtMS0xLTA_dd63ca6c-5ce4-4109-a606-63ed161e91dd"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI2LTMtMS0xLTA_e133da78-b813-4565-a283-3803dbf782a8"
      unitRef="usdPerShare">3.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI2LTUtMS0xLTA_5c01ea1e-4b02-443e-8b68-1562eea07f62"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI3LTEtMS0xLTA_c364a475-f5c2-457a-b4ee-2aeac54e1a9d"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI3LTMtMS0xLTA_83a9b3ee-a3d6-4181-9074-7cc70decfb25"
      unitRef="usdPerShare">3.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI3LTUtMS0xLTA_c4406b57-b65c-4aa7-857f-96a655cac517"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI5LTEtMS0xLTA_58210cd9-30bf-46a0-aff4-2fbf233a0abd"
      unitRef="shares">44262000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI5LTMtMS0xLTA_22cce838-b683-4b45-b308-664a91f13da6"
      unitRef="shares">42671000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzI5LTUtMS0xLTA_ff53cc04-f9dc-45d5-99f8-fac98108ba44"
      unitRef="shares">41513000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMwLTEtMS0xLTA_15f861c4-fb94-453e-a72d-c87ff36b22e7"
      unitRef="shares">45630000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMwLTMtMS0xLTA_94afddfc-82f5-4102-95e6-8a01d79e41ac"
      unitRef="shares">43682000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMjcvZnJhZzo1NTA2Yjk4ZmFjYzI0Yjc1YWQyOWVkOGQwM2JhYjQ1YS90YWJsZTplYzcxZTY4ZDFiOTQ0NTkwYjNjODNjZDE0MWY1ZTI5Yi90YWJsZXJhbmdlOmVjNzFlNjhkMWI5NDQ1OTBiM2M4M2NkMTQxZjVlMjliXzMwLTUtMS0xLTA_96f07b1b-eaa8-43b0-87f6-5e4f9a615a3d"
      unitRef="shares">41513000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzItMS0xLTEtMA_54479c2e-6333-4abf-acdb-55caea0f5f36"
      unitRef="usd">41980000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzItMy0xLTEtMA_6367fc46-38e9-4837-8b41-c0fee18192a8"
      unitRef="usd">145523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzItNS0xLTEtMA_2fa8a915-4933-421d-aa1e-b3ccdff58474"
      unitRef="usd">-11016000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzQtMS0xLTEtMA_8365989e-17ac-4022-8bf3-45aca598781b"
      unitRef="usd">-180000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzQtMy0xLTEtMA_007f7862-4390-4149-91f3-44ceacd90c0f"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzQtNS0xLTEtMA_aab5d478-2e97-41ad-b08f-cd439fbfa5ae"
      unitRef="usd">602000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzUtMS0xLTEtMA_0b403ca9-1898-4e4a-aa56-da01e5b9363a"
      unitRef="usd">29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzUtMy0xLTEtMA_504142d3-d286-439c-8d7e-442d934d3838"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzUtNS0xLTEtMA_a0263c3a-e111-46ee-a12a-69578928ae9a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzYtMS0xLTEtMA_d968880b-4b8f-49db-a239-814a32b4f850"
      unitRef="usd">-151000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzYtMy0xLTEtMA_b5aff1a2-9b4d-4079-8b44-830dd4bebc89"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzYtNS0xLTEtMA_74abeb56-7fe0-4dd0-9743-001195177eec"
      unitRef="usd">602000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzctMS0xLTEtMA_33fbde8d-e771-4d88-8e65-06e1cc79681a"
      unitRef="usd">41829000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzctMy0xLTEtMA_df2df453-dd45-4a22-b1f4-5f962142464b"
      unitRef="usd">145519000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzAvZnJhZzo0MWJlZGM5YmQyNmQ0ZDE5ODgxZWEzYTU0ZmY5OGYyMS90YWJsZTo0ZjAwNzI0YjNmMjQ0MGM1YTBlN2IxYjA1OWI3ZmYzZC90YWJsZXJhbmdlOjRmMDA3MjRiM2YyNDQwYzVhMGU3YjFiMDU5YjdmZjNkXzctNS0xLTEtMA_1b68340e-94d7-476f-b272-c0cd8d5d1d07"
      unitRef="usd">-10414000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="iaa36cac814f44a06a730eb8daf40ca38_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTEtMS0xLTA_96f80547-6d92-45a3-bdc7-20acb13104fd"
      unitRef="shares">41223000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaa36cac814f44a06a730eb8daf40ca38_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTMtMS0xLTA_709fd4ef-e5c5-4644-a17d-40b6e6d1a8ca"
      unitRef="usd">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01b6af31fbcb4cb5b587df488ccd9a82_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTUtMS0xLTA_b1a215a6-8cd6-4881-9861-5e30809d7597"
      unitRef="usd">709691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice5ead454a5844d28a4260c4149d6b73_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTctMS0xLTA_c75a979b-d864-4d84-9daa-1d998b67e6ca"
      unitRef="usd">-388226000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7691a4cd4aca428e882b620433db6759_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTktMS0xLTA_32a3c8ea-60e5-4ffe-aa77-50f3f7674784"
      unitRef="usd">-280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f634c57178e427b9ece243062defb9c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzExLTExLTEtMS0w_7a6d2b44-77a5-4791-9f7c-5d520c10db86"
      unitRef="usd">321226000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f2a38c35f7048949286b849f4126c2b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEyLTctMS0xLTA_9952a073-e509-40b1-ae9b-1fc5a35a7bac"
      unitRef="usd">-156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i898bf7e1b82b4fd3a5c551aa4879fb16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEyLTExLTEtMS0w_13951035-1e68-4a80-a3de-0949c2b9e4b6"
      unitRef="usd">-156000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8b60ec582530407797a99033b53bbf05_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEzLTEtMS0xLTA_70bbbec7-cd08-4d82-8e5b-c6b7c101d1fc"
      unitRef="shares">425000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8b60ec582530407797a99033b53bbf05_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEzLTMtMS0xLTA_57257a4f-4739-4263-a896-2dfc8d9d0f67"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iff9f105ca63d4c1090d6168b48daf166_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEzLTUtMS0xLTA_07be5900-3b85-4b53-a894-c6f328f53d4a"
      unitRef="usd">8468000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzEzLTExLTEtMS0w_c9e9a4b6-6c18-4fc7-b29a-0a97979f2d5b"
      unitRef="usd">8469000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8b60ec582530407797a99033b53bbf05_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE0LTEtMS0xLTA_8e0fbfb4-39b3-4956-9e81-572e64050da5"
      unitRef="shares">193000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8b60ec582530407797a99033b53bbf05_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE1LTEtMS0xLTA_cdee91a1-5491-4953-b036-d7656ce4c138"
      unitRef="shares">67000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iff9f105ca63d4c1090d6168b48daf166_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE1LTUtMS0xLTA_6fbb2453-8a10-451f-9e80-8d0c0ffb0385"
      unitRef="usd">2402000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE1LTExLTEtMS0w_49addf94-3736-4bba-98bf-40804fc5033c"
      unitRef="usd">2402000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff9f105ca63d4c1090d6168b48daf166_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE2LTUtMS0xLTA_458768d1-4b2d-456c-99d4-22f0b7266efc"
      unitRef="usd">33650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE2LTExLTEtMS0w_4f3e0f77-fbeb-47dc-8433-ba8f1ed936b9"
      unitRef="usd">33650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ide58e19786fb437497710ff2a2f106c9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE3LTUtMS0xLTA_49103684-a31e-423b-bfd1-f0ad149ac1d6"
      unitRef="usd">-233000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ic8363a6e4996490fac437219786a762d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE3LTExLTEtMS0w_c5999c4d-1c24-4f72-8297-e8019badbe37"
      unitRef="usd">-233000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib22aebb1a2f448a8b5e073383b0f94c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE4LTktMS0xLTA_5fcc1397-c27b-496a-8bee-5645cb128a4f"
      unitRef="usd">602000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzE4LTExLTEtMS0w_6804a112-7690-43c4-813d-be085ba7bec2"
      unitRef="usd">602000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ic4a5e18c117b491dab5190737229f0a1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIwLTctMS0xLTA_c799a227-e561-4cbe-829b-daacbefaffd8"
      unitRef="usd">-11016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIwLTExLTEtMS0w_ecde1b5e-63f4-4b02-be19-36dd18605e14"
      unitRef="usd">-11016000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i776bb75da13044258dd0d043f2083674_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTEtMS0xLTA_71d9f2cf-eeb6-4104-9f1c-4d3c98677d6d"
      unitRef="shares">41908000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i776bb75da13044258dd0d043f2083674_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTMtMS0xLTA_4f4e2dd3-7d23-4c00-a982-b433644f307b"
      unitRef="usd">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58c5737320f84dbb81a3529e36798635_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTUtMS0xLTA_933187e7-50a6-466f-ac41-a0884f2c9600"
      unitRef="usd">753978000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73b1bb54137c4111b70b6f8e573b2d33_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTctMS0xLTA_2a9c3344-dd94-4df7-a998-07823d540874"
      unitRef="usd">-399398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3dfaa6dfa1240039de2e6dff373a711_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTktMS0xLTA_fbf02a28-9db2-40b1-a17e-7e7d7c630b56"
      unitRef="usd">322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIxLTExLTEtMS0w_1975b186-74ab-45ee-8809-2891baa33795"
      unitRef="usd">354944000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIyLTEtMS0xLTA_77291e57-8f5b-4520-84bc-ffe34e74141f"
      unitRef="shares">1428000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIyLTMtMS0xLTA_81c176e7-6afa-448c-9797-4a7ce4fefbda"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3af9929d68c2470ba7dce232ee415fde_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIyLTUtMS0xLTA_89a9e065-dca4-4abd-bf79-e0ef15f7dae7"
      unitRef="usd">45227000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIyLTExLTEtMS0w_9fe2f3c3-944b-424f-8f99-2b9ed7064817"
      unitRef="usd">45229000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTEtMS0xLTA_80ea4dd5-79f7-4d32-ba3e-bf91b1cda4f2"
      unitRef="shares">239000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i926053e2088e4013af88a2eec9f34a12_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI0LTEtMS0xLTA_7ec527f8-1840-4e31-9d42-5053870c6e0b"
      unitRef="shares">62000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3af9929d68c2470ba7dce232ee415fde_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI0LTUtMS0xLTA_81093cc6-6c6d-4f1a-b9b3-3b029471e5c3"
      unitRef="usd">2546000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI0LTExLTEtMS0w_e2342704-09ed-4c8b-9651-12965286d63a"
      unitRef="usd">2546000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3af9929d68c2470ba7dce232ee415fde_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTUtMS0xLTA_24733611-f1ae-4591-9fb2-310cb29ae4a5"
      unitRef="usd">39920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTExLTEtMS0w_4d31de44-7bd8-476e-a129-651faa54b5c8"
      unitRef="usd">39920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i0eafc73607f5454aafd32bc87073240c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI3LTUtMS0xLTA_2dfbb9b2-792b-4f90-a7b7-f3bc6753a247"
      unitRef="usd">-33089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i43034ba78f184fed9391b7aa159e7b94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI3LTExLTEtMS0w_87fecc51-4ca9-4ae8-96cf-2147b61a086f"
      unitRef="usd">-33089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <pcrx:DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjpiMWUzYjNkZTliMjM0YTJiOGY1NzNjZGQ2Y2MwZDBhYl85OQ_876e9b3c-3081-4138-a74f-247a74ec6d7a"
      unitRef="usd">20450000</pcrx:DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i15739e828cad4e53af9937b4cf53b886_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI4LTUtMS0xLTA_8297ba5c-eac9-4bca-8ab9-639f8beb665a"
      unitRef="usd">64619000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i3d1e15ed7bcf42019a3e50c393218b9f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI4LTExLTEtMS0w_cdaf25a1-4ac0-4b06-bcfc-95c480aa1b3e"
      unitRef="usd">64619000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2e4dc31d7b404c919dfaf4a0a27a0aff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI5LTktMS0xLTA_6fdd848c-9fbf-43fe-bc6f-e50d32458e74"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI5LTExLTEtMS0w_777f6576-b65c-493e-b4c5-f97b3df043a4"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="iec4e19869fe24a178b94aa20a13f86b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMwLTctMS0xLTA_46f59dee-4f91-44e4-9ace-7ce4b8afe8db"
      unitRef="usd">145523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMwLTExLTEtMS0w_acd0bcfc-0e2e-4ffa-9ecf-870f64787ef3"
      unitRef="usd">145523000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia317542b2a494470b42249229135b47e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTEtMS0xLTA_eec5809d-70f4-4647-a700-242afa265aea"
      unitRef="shares">43637000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia317542b2a494470b42249229135b47e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTMtMS0xLTA_dd296fb4-601f-465e-9a31-596bf39c9fdd"
      unitRef="usd">44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i097161875b3d423d84de836dca9e6e1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTUtMS0xLTA_c5aaec30-0a99-487c-b9b4-031a06a38772"
      unitRef="usd">873201000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i292cbc754afb4c849eda7b618d73c0a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTctMS0xLTA_bb6e01ca-17b9-401c-8153-06d5437565ea"
      unitRef="usd">-253875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib617d7e96fc14f90a5109fe4b4e42246_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTktMS0xLTA_9ae263b3-1cdf-46a5-a18c-ef58788b72cd"
      unitRef="usd">318000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTExLTEtMS0w_ad805b7f-dc75-412c-8567-cec8360ccca0"
      unitRef="usd">619688000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i65bc19c293874f40856a561cd84a8945_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTEtMS0xLTI3MDIy_a34fc0f5-987e-46ef-bfeb-38dc161a6ea7"
      unitRef="shares">732000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i65bc19c293874f40856a561cd84a8945_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTMtMS0xLTI3MDIy_71402ad5-0380-4e7a-8ce4-8eff22a86fb3"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i61e75a83dae34a3e81787449842b080d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTUtMS0xLTI3MDIy_e97b1dac-3621-4169-aca7-c170610c9d90"
      unitRef="usd">23833000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzIzLTExLTEtMS0yNzAyMg_b7eddbc6-c9d2-4928-99c7-1ec95da266e4"
      unitRef="usd">23834000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i65bc19c293874f40856a561cd84a8945_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI0LTEtMS0xLTI3MDIy_c5ee3f7f-f600-4036-a5b8-ac102b961d07"
      unitRef="shares">310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i65bc19c293874f40856a561cd84a8945_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTEtMS0xLTI3MDIy_c190f2c8-ff65-4502-937a-b4b196536b20"
      unitRef="shares">55000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i61e75a83dae34a3e81787449842b080d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTUtMS0xLTI3MDIy_d6aa86a2-1117-4c01-8d5b-0736aa1cb24b"
      unitRef="usd">2811000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI1LTExLTEtMS0yNzAyMg_9bc5b292-fccc-45c7-baa1-d3ffb9e09c5b"
      unitRef="usd">2811000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61e75a83dae34a3e81787449842b080d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI2LTUtMS0xLTI3MDIy_2f79daff-ceb1-4fc9-8044-21ab68c34a59"
      unitRef="usd">42246000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzI2LTExLTEtMS0yNzAyMg_d020f36d-e054-4b1a-809b-81c85238dd41"
      unitRef="usd">42246000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i18af5711da6640a097e5c4348ee46f60_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMwLTktMS0xLTI3MDIy_f88314e6-e5af-4597-83a3-62c8b77ee12a"
      unitRef="usd">-151000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMwLTExLTEtMS0yNzAyMg_c3f86b1c-1d1d-43c6-a186-966c9dbdcb08"
      unitRef="usd">-151000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="if3ddd1a458e84be0b45073c62a0600f8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTctMS0xLTI3MDIy_a5eab808-0fb6-4589-8da4-6ed1a8dac7b2"
      unitRef="usd">41980000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMxLTExLTEtMS0yNzAyMg_8bfc7bc2-6438-46e8-b8a2-e04c96f9b739"
      unitRef="usd">41980000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia77d73b036584e0f9d8fe145c72c60dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTEtMS0xLTI3MDIy_8243c07d-6bbf-4a6e-b6fb-8f2a6f64980c"
      unitRef="shares">44734000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia77d73b036584e0f9d8fe145c72c60dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTMtMS0xLTI3MDIy_c3d015c1-9cfd-44a3-acb1-c3a0805a9ded"
      unitRef="usd">45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iabeecd1debc54d2491b639ea1e2d971c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTUtMS0xLTI3MDIy_d895b274-b7fe-45f2-a78d-ffe93857324b"
      unitRef="usd">942091000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i714f475d443c449882547155cf8a8321_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTctMS0xLTI3MDIy_50a12979-4656-431e-b4d4-4d1fb2c315a9"
      unitRef="usd">-211895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac5eb7e48d214a51937b661bf27d5c25_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTktMS0xLTI3MDIy_6641e0ea-a182-4eec-ae8b-5be8d50fc65b"
      unitRef="usd">167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzMvZnJhZzo3YjkwMTQwMDU3Y2M0MTlmOWUxOTdiZWU1YTZlZjg1OC90YWJsZTpiMzE1NTgyZTM4ZWM0OWY1YTQ5YmE4ZTdkYzE2OWQxOC90YWJsZXJhbmdlOmIzMTU1ODJlMzhlYzQ5ZjVhNDliYThlN2RjMTY5ZDE4XzMyLTExLTEtMS0yNzAyMg_590af16b-d33b-40aa-a3c6-a2990bb1f0a7"
      unitRef="usd">730408000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMtMS0xLTEtMA_0508775d-23e6-4372-a756-c2ee4607a266"
      unitRef="usd">41980000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMtMy0xLTEtMA_ca2c6e60-80a5-4f18-a8e3-4597c883966f"
      unitRef="usd">145523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMtNS0xLTEtMA_d5787de1-810a-4f8c-8e7b-845d755a60dc"
      unitRef="usd">-11016000</us-gaap:NetIncomeLoss>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzUtMS0xLTEtMA_95603aee-b18b-4ad8-9f9e-54427e708cbe"
      unitRef="usd">10872000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzUtMy0xLTEtMA_dafe0aef-f6a7-410a-b51e-61666cab3cec"
      unitRef="usd">-126613000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzUtNS0xLTEtMA_4df84c37-0b33-4399-b3be-5a6985bc8d2d"
      unitRef="usd">-1828000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYtMS0xLTEtMA_dda4f9f6-3ff7-4036-8d6b-9589f34b18ee"
      unitRef="usd">28548000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYtMy0xLTEtMA_3127f1ef-fcd5-4116-aac2-1cb512027216"
      unitRef="usd">19908000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYtNS0xLTEtMA_af463acb-0aed-4e03-a4ba-fc77cd6946de"
      unitRef="usd">19576000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzctMS0xLTEtMA_6b54bc95-2eba-44a8-bf55-8cbfd9c96479"
      unitRef="usd">2754000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzctMy0xLTEtMA_cbfdb3a0-dab5-462d-9426-3db13beb74c4"
      unitRef="usd">2156000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzctNS0xLTEtMA_44facc6a-0fdb-4e0a-8786-7fcd3d32a73e"
      unitRef="usd">1707000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzgtMS0xLTEtMA_dd21ce36-dd18-45c3-ab12-4e89ef62466f"
      unitRef="usd">23152000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzgtMy0xLTEtMA_62da9a06-fe22-4ef4-8ace-1df0e1717ac1"
      unitRef="usd">18254000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzgtNS0xLTEtMA_53f50da5-3861-462b-8047-93cc8808681a"
      unitRef="usd">13746000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzktMS0xLTEtMA_3f074ddb-65d0-4e6e-9732-50a282fbc2ba"
      unitRef="usd">10000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzktMy0xLTEtMA_0749c7b4-453f-4898-ae68-2a8652d7e3f7"
      unitRef="usd">-22000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzktNS0xLTEtMA_c1dfe359-6bf2-4229-9167-ed14216bdc36"
      unitRef="usd">-1010000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEwLTEtMS0xLTA_40b54c87-2c64-4d45-9974-36dff5b6424f"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEwLTMtMS0xLTA_6aead1b8-d071-4138-b235-b50772b8313d"
      unitRef="usd">-8071000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEwLTUtMS0xLTA_d2f1bc2c-64b9-4526-8663-59bc4dca2e31"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzExLTEtMS0xLTA_8d8596ef-ab23-45ff-9061-3a586c08abc5"
      unitRef="usd">42246000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzExLTMtMS0xLTA_7e2fd854-6503-4a85-9ca8-720d6850aff4"
      unitRef="usd">39920000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzExLTUtMS0xLTA_89e5cefd-56b3-4061-80e3-5a3f0503f374"
      unitRef="usd">33650000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEyLTEtMS0xLTA_98ff8fdb-953a-4368-a8da-288a56b91799"
      unitRef="usd">-989000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEyLTMtMS0xLTA_9871e014-929e-4abe-896e-e688dc9612ee"
      unitRef="usd">5204000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEyLTUtMS0xLTA_a9fcc764-448c-4777-bff8-748df518403f"
      unitRef="usd">16672000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnInvestments
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEzLTEtMS0xLTA_532d9046-b66f-4ba3-9390-51d6c6b976bf"
      unitRef="usd">-2673000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEzLTMtMS0xLTA_1c675691-9907-47fe-bb96-50f370831edd"
      unitRef="usd">1618000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzEzLTUtMS0xLTA_31292130-6154-47c1-aa6a-b7a9abbd2fee"
      unitRef="usd">-4315000</us-gaap:GainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE1LTEtMS0xLTA_544ad83b-93bc-47e5-a66a-5f46cf5107dd"
      unitRef="usd">10434000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE1LTMtMS0xLTA_e678c3e1-50eb-4568-87d1-a1c360d00eeb"
      unitRef="usd">5516000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE1LTUtMS0xLTA_a1920c56-5f22-470c-b981-b0c624240ab8"
      unitRef="usd">8524000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE2LTEtMS0xLTA_f3e2e426-07f1-4d1b-a274-1324ed6fc43e"
      unitRef="usd">4467000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE2LTMtMS0xLTA_bb52085e-b297-4bf8-951f-20886e1e8289"
      unitRef="usd">6353000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE2LTUtMS0xLTA_c82566b4-a405-4dfa-a19b-ce4f2b4daa61"
      unitRef="usd">8026000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE3LTEtMS0xLTA_dbd4bb2c-296e-48ac-9b87-3be61315a88c"
      unitRef="usd">-1142000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE3LTMtMS0xLTA_386343f7-866a-486d-8039-aedc8b0c8b13"
      unitRef="usd">739000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE3LTUtMS0xLTA_cebf94ba-be01-4c9b-a7b0-7c0d01549b5c"
      unitRef="usd">3885000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE4LTEtMS0xLTA_edf94146-57cb-4fd8-ac82-7759a9513646"
      unitRef="usd">-10262000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE4LTMtMS0xLTA_8035cde1-2af1-404a-bc85-494002c01dea"
      unitRef="usd">-3312000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE4LTUtMS0xLTA_dab27fc1-5145-4263-822e-d719343e54d5"
      unitRef="usd">-1822000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE5LTEtMS0xLTA_dd9fb587-7a66-41a6-a755-061e4d135a0c"
      unitRef="usd">5451000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE5LTMtMS0xLTA_78324b28-9984-4518-b0c7-bfc7002b06cc"
      unitRef="usd">-5999000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzE5LTUtMS0xLTA_d0ba98a9-d2e6-4158-a0c1-bc0522630d80"
      unitRef="usd">22041000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIwLTEtMS0xLTA_63c557e6-c1e7-48fd-9dbd-fb0812442d86"
      unitRef="usd">-229000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIwLTMtMS0xLTA_c59615b4-b36a-480b-9d31-a6cf6c300b1c"
      unitRef="usd">-2467000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIwLTUtMS0xLTA_a694ab17-27ca-4154-83c4-981c020ee4ad"
      unitRef="usd">-6726000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIxLTEtMS0xLTA_4482d60b-6733-4e8e-8de1-d6b9f7b8613e"
      unitRef="usd">6835000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIxLTMtMS0xLTA_b93484e2-de7a-48aa-85bd-51b1d9605d3c"
      unitRef="usd">9409000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIxLTUtMS0xLTA_4ca9a32d-6d6e-466e-9064-ba6dbcdb4064"
      unitRef="usd">370000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIyLTEtMS0xLTA_8d3e7e7a-bb70-4de0-bf2c-ed66ad5eb044"
      unitRef="usd">125000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIyLTMtMS0xLTA_b594bdbd-483f-4679-bce3-e71a0803f0a6"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIyLTUtMS0xLTA_a0eabcc2-1c30-46ab-9ff4-bdd3b830944c"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIzLTEtMS0xLTA_b26206aa-ede3-414e-bcab-504babaec88d"
      unitRef="usd">125717000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIzLTMtMS0xLTA_2f1c754e-0831-4429-ae48-02c13f083287"
      unitRef="usd">77032000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzIzLTUtMS0xLTA_83ee874d-f8b9-4215-ae63-a00367c252dc"
      unitRef="usd">70520000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTEtMS0xLTI3MTMx_d16d9b62-b833-428a-bd96-a22f72a434c3"
      unitRef="usd">420042000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTMtMS0xLTI3MTMx_2262ee2d-7264-47f9-96ec-27cb7bc75153"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTUtMS0xLTI3MTMx_db8af365-6008-4a0c-a047-fb0506863b19"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTEtMS0xLTA_1e170d9e-ba0f-4e14-b530-d753351f08f6"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTMtMS0xLTA_0bc7d5ac-5c12-4d11-bfe6-96eccdf330bc"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI1LTUtMS0xLTA_ef62bd1e-985d-4bda-986d-98f9831c261a"
      unitRef="usd">117691000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI2LTEtMS0xLTA_ba7ec147-a47a-4c7b-bc17-2b235944b443"
      unitRef="usd">45866000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI2LTMtMS0xLTA_cf9a2821-6955-4e82-a551-54aaa7157c96"
      unitRef="usd">37801000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI2LTUtMS0xLTA_7d4e4f0d-c52a-4858-8fa7-0cc2c10cced4"
      unitRef="usd">10159000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI3LTEtMS0xLTA_5ab41d74-9edd-4bc7-848f-4e914698b00c"
      unitRef="usd">611488000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI3LTMtMS0xLTA_6dba3d5d-0187-451f-9965-b16d17e219a0"
      unitRef="usd">546516000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI3LTUtMS0xLTA_1f7dab28-b878-45f6-8f24-49dd649804db"
      unitRef="usd">318484000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI4LTEtMS0xLTA_314a5ffe-172e-4399-8f79-b6f550ea5bb0"
      unitRef="usd">1068736000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI4LTMtMS0xLTA_606ebf9a-eb5c-43fa-b5fb-522da35a588f"
      unitRef="usd">307870000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI4LTUtMS0xLTA_bbf3c75c-ea67-46d5-8667-e9021b5117e9"
      unitRef="usd">319468000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <pcrx:PaymentOfContingentConsideration
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI5LTEtMS0xLTA_531ee18c-fa5f-4b89-899f-2cf759a2408f"
      unitRef="usd">4000000</pcrx:PaymentOfContingentConsideration>
    <pcrx:PaymentOfContingentConsideration
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI5LTMtMS0xLTA_0212284d-e35d-4e0a-ba52-2b9a207262ef"
      unitRef="usd">0</pcrx:PaymentOfContingentConsideration>
    <pcrx:PaymentOfContingentConsideration
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzI5LTUtMS0xLTA_a30952a2-a856-4a49-8191-9d5f30c58768"
      unitRef="usd">0</pcrx:PaymentOfContingentConsideration>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMyLTEtMS0xLTU4OTEz_a8518944-9b42-4329-a98c-9cf26bae3522"
      unitRef="usd">9057000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMyLTMtMS0xLTU4OTEz_d3eb748b-f84b-45fb-946b-dc136206c95f"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMyLTUtMS0xLTU4OTEz_2bfb9e5e-9dec-4bab-a982-9354150ec440"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMwLTEtMS0xLTA_536eb2f8-01a0-4640-b5bb-5d010a5d2a7c"
      unitRef="usd">17187000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMwLTMtMS0xLTA_023315e3-7290-456f-a038-bfffb8b30ff0"
      unitRef="usd">1160000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMwLTUtMS0xLTA_c421c4b5-1555-42fc-befa-19c9c1cde35d"
      unitRef="usd">1622000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMxLTEtMS0xLTA_1d6ca790-913b-4268-ab21-514d09338c4a"
      unitRef="usd">-20790000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMxLTMtMS0xLTA_a027986d-a7b0-4245-8ef5-3b99079c10c3"
      unitRef="usd">-277607000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMxLTUtMS0xLTA_4e3be820-f2a8-4f95-b07f-310728051bb0"
      unitRef="usd">-128488000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMzLTEtMS0xLTA_c120e662-ac95-41d5-810c-f6b49b372715"
      unitRef="usd">23844000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMzLTMtMS0xLTA_3610bbf5-af8d-4db2-8683-4a0d7aa2dd58"
      unitRef="usd">45218000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzMzLTUtMS0xLTA_0b2d70ff-fb86-4ce2-9077-1cc09edd563c"
      unitRef="usd">8469000</us-gaap:ProceedsFromStockOptionsExercised>
    <pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM0LTEtMS0xLTA_e8a1df40-4be2-42f0-a0cd-60a019d8ee75"
      unitRef="usd">2811000</pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan>
    <pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM0LTMtMS0xLTA_ea282cf5-91ba-4415-80d2-efebca01bbb0"
      unitRef="usd">2546000</pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan>
    <pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM0LTUtMS0xLTA_b7806fa4-ba7d-4a67-950b-185575cd760b"
      unitRef="usd">2402000</pcrx:ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM3LTEtMS0xLTU4OTAx_5f28510e-f226-49f4-a777-0ed4cbcfba4b"
      unitRef="usd">363750000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM3LTMtMS0xLTU4OTAx_087d4196-6869-4c4d-8b86-49ae20121b33"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM3LTUtMS0xLTU4OTAx_2ed0e026-fe73-4d1b-b5e5-f1b3767f10be"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i1e7d5628512b4a3e8635bfd28f644363_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM1LTEtMS0xLTA_2986ca31-5450-44a4-b404-6455448d5ca4"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ie6417dba8c0b47b8b32488655a275284_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM1LTMtMS0xLTA_f4104aa9-596f-4ee2-a087-e2771f3427f8"
      unitRef="usd">314708000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i6a19a318f1bb483fa686deeaa2359f9c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM1LTUtMS0xLTA_50fad56b-55e6-4ecc-9d7e-136ed738284b"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <pcrx:ProceedsFromConvertibleOptionComponentOfConvertibleDebt
      contextRef="i1e7d5628512b4a3e8635bfd28f644363_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM2LTEtMS0xLTA_d002cea2-a8c0-4f76-8d1f-9940d17b89b3"
      unitRef="usd">0</pcrx:ProceedsFromConvertibleOptionComponentOfConvertibleDebt>
    <pcrx:ProceedsFromConvertibleOptionComponentOfConvertibleDebt
      contextRef="ie6417dba8c0b47b8b32488655a275284_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM2LTMtMS0xLTA_ef834358-2a1c-4b9a-8ad4-e8d182b3e2b3"
      unitRef="usd">87792000</pcrx:ProceedsFromConvertibleOptionComponentOfConvertibleDebt>
    <pcrx:ProceedsFromConvertibleOptionComponentOfConvertibleDebt
      contextRef="i6a19a318f1bb483fa686deeaa2359f9c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM2LTUtMS0xLTA_58bf9b16-33f7-47a7-9ded-8510645edd10"
      unitRef="usd">0</pcrx:ProceedsFromConvertibleOptionComponentOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i2b2189f4174640ff8254517903eb5f68_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM4LTEtMS0xLTA_3905b32d-501a-4ee9-8626-a0a0bc9648c9"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="if7eaed297368425488f2206696292750_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM4LTMtMS0xLTA_7744c982-14bb-4471-8580-33e75d390007"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ic8363a6e4996490fac437219786a762d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM4LTUtMS0xLTA_b2b4e4ad-5c2b-4291-9510-be852f6f034a"
      unitRef="usd">338000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i262c5548fe9c44b8aa7a185ebe27e739_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM5LTEtMS0xLTA_c493c4bf-3a44-4703-b429-251d6781ab59"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i43034ba78f184fed9391b7aa159e7b94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM5LTMtMS0xLTA_322dcb1e-aebe-4145-b832-f4317a4aac1a"
      unitRef="usd">176793000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ie0494276ab7c45fda83381f5dde00ce2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzM5LTUtMS0xLTA_004c695f-7cf2-44de-8ea1-303c66627e46"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <pcrx:RetirementOfEquityComponentOfConvertibleSeniorNotes
      contextRef="i262c5548fe9c44b8aa7a185ebe27e739_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQwLTEtMS0xLTA_c29d4299-fceb-4771-a3ec-d159b7b0181a"
      unitRef="usd">0</pcrx:RetirementOfEquityComponentOfConvertibleSeniorNotes>
    <pcrx:RetirementOfEquityComponentOfConvertibleSeniorNotes
      contextRef="i43034ba78f184fed9391b7aa159e7b94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQwLTMtMS0xLTA_f137ec7f-6e3f-4a3a-a3df-4a1d22cd5ee4"
      unitRef="usd">33089000</pcrx:RetirementOfEquityComponentOfConvertibleSeniorNotes>
    <pcrx:RetirementOfEquityComponentOfConvertibleSeniorNotes
      contextRef="ie0494276ab7c45fda83381f5dde00ce2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQwLTUtMS0xLTA_31ad0f2d-fa62-42eb-86e2-5aebd1baeeb5"
      unitRef="usd">0</pcrx:RetirementOfEquityComponentOfConvertibleSeniorNotes>
    <pcrx:PaymentsForDebtConversionPremiums
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQxLTEtMS0xLTA_80d0a13c-50ea-458d-b1ff-73ee496afa55"
      unitRef="usd">0</pcrx:PaymentsForDebtConversionPremiums>
    <pcrx:PaymentsForDebtConversionPremiums
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQxLTMtMS0xLTA_4e61fe47-74fd-46ce-a3e0-4a17a2937d24"
      unitRef="usd">0</pcrx:PaymentsForDebtConversionPremiums>
    <pcrx:PaymentsForDebtConversionPremiums
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQxLTUtMS0xLTA_79a54459-d241-449f-a769-4481251a4f63"
      unitRef="usd">233000</pcrx:PaymentsForDebtConversionPremiums>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQyLTEtMS0xLTA_2a831aa3-a21b-47a1-a3f5-c49b6582f9d5"
      unitRef="usd">4546000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQyLTMtMS0xLTA_c323ddcb-5d77-4247-9415-6179d5964c03"
      unitRef="usd">12487000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQyLTUtMS0xLTA_7400afd3-6b9f-4f5b-934f-7d99c2f16c0a"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQzLTEtMS0xLTA_71f42119-0280-4252-a211-bcb70c92096d"
      unitRef="usd">5165000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQzLTMtMS0xLTA_0848d8f7-f694-43a2-8e5c-5452fbcf85cb"
      unitRef="usd">5591000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQzLTUtMS0xLTA_361abe8d-b4df-4e20-9ee7-2628acd9800a"
      unitRef="usd">6630000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ1LTEtMS0xLTA_845a12db-7276-4c4d-9ce1-14148ad30eb5"
      unitRef="usd">380694000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ1LTMtMS0xLTA_9f8a6367-d662-4240-8955-95a81744606a"
      unitRef="usd">222304000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ1LTUtMS0xLTA_5919cab2-ca58-4136-a543-34f24bcbcda6"
      unitRef="usd">3670000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ2LTEtMS0xLTA_6b9fde27-1461-4f24-838b-a3b7d022202e"
      unitRef="usd">485621000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ2LTMtMS0xLTA_c8f81c4c-1cea-4fb4-a64d-cea44a4b9094"
      unitRef="usd">21729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ2LTUtMS0xLTA_f1fc2504-16e9-424b-bc59-12fb3276c9de"
      unitRef="usd">-54298000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ3LTEtMS0xLTA_554b9b8c-e98b-4074-9b8e-e3e524dbf67e"
      unitRef="usd">99957000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ3LTMtMS0xLTA_1bbaeb61-f762-4d2a-9b04-eb4ac8a7195b"
      unitRef="usd">78228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7f634c57178e427b9ece243062defb9c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ3LTUtMS0xLTA_b2f8fe38-7ac8-4218-aca9-3f17569c35d1"
      unitRef="usd">132526000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ4LTEtMS0xLTA_d37603c5-e582-4df0-9bb6-284caa4f16f5"
      unitRef="usd">585578000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ4LTMtMS0xLTA_14ebfe9a-8056-460d-99f2-5d0e255944f1"
      unitRef="usd">99957000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzQ4LTUtMS0xLTA_e28f158e-644f-4ccd-90e2-f688e790711c"
      unitRef="usd">78228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU4LTEtMS0xLTA_45dcb941-6c07-4874-9dbd-d0376a1317ae"
      unitRef="usd">6996000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU4LTMtMS0xLTA_da936d97-399c-4162-89e5-75dca7abd780"
      unitRef="usd">7205000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU4LTUtMS0xLTA_dea32c25-5697-4d06-89cc-c82a6fdc1fda"
      unitRef="usd">8199000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU5LTEtMS0xLTA_c9b9dcfa-8822-43ec-9f39-8d85db55c890"
      unitRef="usd">3221000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU5LTMtMS0xLTA_769c3989-43e2-4eb3-ad3c-4f7eac824f86"
      unitRef="usd">2417000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzU5LTUtMS0xLTA_18f844cf-5033-4185-9151-7fd89b5ed03c"
      unitRef="usd">863000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYzLTEtMS0xLTA_b269e777-d08f-4483-8dfb-e84a0a42710c"
      unitRef="usd">6828000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYzLTMtMS0xLTA_5df1cb21-0b44-4074-b818-995e8e0fc121"
      unitRef="usd">9288000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzYzLTUtMS0xLTA_bdad7e5e-85f4-44d5-ab21-08917acb5ba9"
      unitRef="usd">3019000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <pcrx:IncreaseDecreaseInContingentConsideration
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzY0LTEtMS0xLTA_0a7e85c3-6666-45c9-8344-46c13fd7513f"
      unitRef="usd">45241000</pcrx:IncreaseDecreaseInContingentConsideration>
    <pcrx:IncreaseDecreaseInContingentConsideration
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzY0LTMtMS0xLTA_1522f72a-bea3-432f-8394-87356b37d993"
      unitRef="usd">0</pcrx:IncreaseDecreaseInContingentConsideration>
    <pcrx:IncreaseDecreaseInContingentConsideration
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xMzYvZnJhZzozMDE2MmIyMzYxNTg0ODZkYjUwYjlhN2NiOWZmYmIzNC90YWJsZTozNjc5NTIxZTE3NWY0ODAwYWI1ODI1ZjU3OGY0YTgzNS90YWJsZXJhbmdlOjM2Nzk1MjFlMTc1ZjQ4MDBhYjU4MjVmNTc4ZjRhODM1XzY0LTUtMS0xLTA_4ef2aafb-17d2-4635-9823-409bd06b5076"
      unitRef="usd">28470000</pcrx:IncreaseDecreaseInContingentConsideration>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDIvZnJhZzoyMDEyYzhmYjQxYWQ0MzhiODQ0MmFkOWJhOGY4MDg5ZC90ZXh0cmVnaW9uOjIwMTJjOGZiNDFhZDQzOGI4NDQyYWQ5YmE4ZjgwODlkXzI2NDE_22609ecd-90df-4aa5-846d-cb9fa5734f80">DESCRIPTION OF BUSINESS&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacira BioSciences,&#160;Inc. and its subsidiaries (collectively, the &#x201c;Company&#x201d; or &#x201c;Pacira&#x201d;) is the industry leader in its commitment to non-opioid pain management and providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The Company&#x2019;s long-acting, local analgesic, EXPAREL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom in November 2021. EXPAREL utilizes the Company&#x2019;s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the Company added iovera&#xb0;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to its commercial offering with the acquisition of MyoScience, Inc., or MyoScience. The iovera&#xb0; system is a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature to only targeted nerves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 19, 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion, and added ZILRETTA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. For more information, see Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies, reliance on revenue from three products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coronavirus (COVID-19) Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since early 2020, the Company&#x2019;s revenues have been impacted by the global pandemic caused by a novel strain of coronavirus (COVID-19) and pandemic-related challenges that included the significant postponement or suspension in the scheduling of elective surgical procedures due to public health guidance and government directives. While the degree of impact has diminished during the course of the pandemic due to the introduction of vaccines and the lessening of elective surgery restrictions, certain pandemic-related operational challenges persist. It remains unclear how long it will take the elective surgery market to normalize or if restrictions on elective procedures will recur due to future COVID-19 variants or otherwise. For instance, while many restrictions have since eased with COVID-19 vaccines now widely available, the elective surgery market faced additional pandemic-related challenges in August and September 2021 due to regional surges in COVID-19 Delta variant cases, staffing shortages and fatigue from care teams addressing significant procedure backlogs, and in December 2021, the COVID-19 Omicron variant prompted some government restrictions on elective procedures and surgical staffing challenges which began to ease in January 2022. The Company&#x2019;s manufacturing sites are operational and have safety protocols and guidelines as recommended by federal, state and local governments. To date, there have been no material impacts to the Company&#x2019;s supply chain. The situation remains dynamic and subject to rapid and possibly material changes. Additional negative impacts may also arise from the COVID-19 pandemic that the Company is unable to foresee. The nature and extent of such impacts will depend on future developments, which are highly uncertain and cannot be predicted.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <pcrx:ConcentrationRiskNumberOfProducts
      contextRef="if3326fe2dfeb408fa75e3dba728e3dc1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDIvZnJhZzoyMDEyYzhmYjQxYWQ0MzhiODQ0MmFkOWJhOGY4MDg5ZC90ZXh0cmVnaW9uOjIwMTJjOGZiNDFhZDQzOGI4NDQyYWQ5YmE4ZjgwODlkXzExNDU_cb43f16d-b4da-4dde-be81-546fa8bd7236"
      unitRef="product">3</pcrx:ConcentrationRiskNumberOfProducts>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQ2_9115f335-13c7-42a5-b5c7-63e05278671c">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC. The accounts of the Company&#x2019;s wholly owned subsidiaries are included in these consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, purchase price allocation, stock-based compensation, inventory costs, impairments of equity investments, long-lived assets, goodwill, liabilities and accruals, including contingent consideration, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;convertible senior notes, and the valuation of deferred tax assets. The Company&#x2019;s critical accounting policies are those that are both most important to the Company&#x2019;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s sources of revenue include (i) sales of EXPAREL in the U.S., European Union, or E.U. and the United Kingdom, or U.K.; (ii) sales of ZILRETTA in the U.S.; (iii) sales of iovera&#xb0; in the U.S., and Canada; (iv) sales of, and royalties on, its bupivacaine liposome injectable suspension, including for veterinary use and (v) license fees and milestone payments. See Note 4, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further information on the Company&#x2019;s accounting policies related to revenue from contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Licensing and Milestone Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration agreements generally involve a license to the Company&#x2019;s products. In determining how and when to recognize the revenue under a collaboration agreement, the Company must assess whether the license is distinct, which depends upon whether the customer can benefit from the license and whether the license is separate from other performance obligations in the agreement. If the license is distinct, the Company must further assess whether the customer has a right to access or a right to use the license depending on whether the functionality of the license is expected to substantively change over time. If the license is not expected to substantively change, the revenue is recognized at the point in time when the license is provided. If the license is expected to substantively change, the revenue is recognized over the license period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (e.g. obtaining regulatory approval) represent variable consideration and would be included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third-party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales are incurred or the performance obligation to which the sales relate has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties are estimated and recognized as revenue when sales to the Company&#x2019;s commercial partners occur, unless some constraint exists, as the royalties predominately relate to a supply agreement. Royalties are based on sales of the Company&#x2019;s bupivacaine liposome injectable suspension product for veterinary use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health,&#160;Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The Company also sells EXPAREL directly to ambulatory surgery centers and physicians. The Company sells ZILRETTA primarily to specialty distributors and a specialty pharmacy, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as Group Purchasing Organizations, or GPOs. The Company sells its bupivacaine liposome injectable suspension for veterinary use to a third-party licensee in the U.S. and sells iovera&#xb0; directly to end users.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below includes the percentage of revenues comprised by the Company&#x2019;s three largest wholesalers in each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from outside the U.S. accounted for less than 1% of the Company&#x2019;s total revenue for the year ended December 31, 2021. The Company began selling EXPAREL in the E.U. and U.K. and iovera&#xb0; in Canada in the fourth quarter of 2021. The Company had no revenue from outside the U.S. during the years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. These include both internal and external costs, of which a significant portion of development activities are outsourced to third parties, including contract research organizations. Clinical trial costs are accrued over the service periods specified in contracts and adjusted as necessary based on an ongoing review of the level of effort and actual costs incurred. Research and development costs are presented net of reimbursements from commercial partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues interest and penalties, if any, on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in its consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation consists of grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors, in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&#x2019;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value in addition to the closing price of the Company&#x2019;s common stock on the date of grant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Expected term of the option&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes its historical volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option activity. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero-coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&#x2019;s common stock is estimated to be zero as the Company has not declared or paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. Additionally, the Company&#x2019;s ability to declare and pay a dividend in the future could be limited per the agreements governing its indebtedness. The Company records forfeitures as they occur rather than estimating forfeitures during each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid investments with maturities of 90 days or less when purchased are considered cash equivalents. Cash equivalents include corporate debt securities, asset backed securities and money market funds. As of December&#160;31, 2021, the carrying value of money market funds was $223.0&#160;million, commercial paper was $19.0&#160;million and asset backed securities was $2.6&#160;million. As of December 31, 2020, the carrying value of money market funds was $51.8 million and commercial paper was $6.5 million. The carrying values approximate fair value as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term and Long-Term Available-For-Sale Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term available-for-sale investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper, corporate and government bonds, and other bonds issued in the U.S. (and denominated in the U.S. dollar) by foreign entities, all with maturities of greater than three months, but less than one year. Long-term available-for-sale investments consist of corporate and government agency bonds with maturities greater than one year. The Company evaluates the classification of its investments at the time of purchase and re-evaluates such determination at each balance sheet date, which includes an assessment of the intent to hold the available-for-sale securities. The Company&#x2019;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. The Company classifies its investments as available-for-sale. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities (except for credit losses) are excluded from net income (loss) and are reported as a separate component of accumulated other comprehensive income (loss) until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. The Company evaluates whether a credit loss exists, and in the event a credit loss does exist, the credit loss is recognized in the consolidated statements of operations, based on the amount that the fair value is less than the amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value, and is determined using the first-in, first-out (&#x201c;FIFO&#x201d;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. Useful lives by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Retirement Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of such lease agreements. The Company records its asset retirement obligations, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records expense to accrete the ARO to its full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes right-of-use, or ROU, assets and lease liabilities at the commencement of its lease agreements. The leases are evaluated at commencement to determine whether they should be classified as operating or financing leases. Lease costs associated with operating leases are recognized on a straight-line basis, while lease costs for financing leases are recognized over the lease term using the effective interest method. The Company does not have any financing leases. The amount of ROU assets and lease liabilities to be recognized is impacted by the type of lease payments, the lease term and the incremental borrowing rate. Variable lease payments are not included at commencement and are recognized in the period in which they are incurred. The lease term is based on the contractual term and is adjusted for any renewal options or termination rights that are reasonably certain to be exercised. The incremental borrowing rate is based on the rate the Company estimates it would pay on a collateralized basis over a similar term in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values, with some exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value can be determined, the asset or liability is recognized; if fair value is not determinable, then no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired in-process research and development, or IPR&amp;amp;D, is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;amp;D with no alternative future use is recorded as an expense at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#x2019;s consolidated financial statements after the date of the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to an acquisition, the Company measures contingent consideration arrangements at fair value each period, with changes in fair value recognized in the consolidated statements of operations as acquisition-related charges. Changes in contingent consideration can result from changes in the assumed achievement and timing of estimated sales, costs of goods sold and regulatory approvals. In the absence of new information, changes in fair value reflect the passage of time towards achievement of the milestones, and are accreted to the period in which payments are expected to be made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired in a business combination and is not amortized, but is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite useful lives are amortized on a straight-line basis over their estimated useful lives and are recorded at cost, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds investments in equity securities without a readily determinable fair value. In the fourth quarter of 2019, the equity investment then held became publicly traded and thereafter, was recognized at its fair value at each reporting period with any unrealized holding gains (losses) included in other income (expense). The equity method investments without a readily determinable fair value are recognized at cost less any impairments, plus or minus any changes resulting from observable price changes in orderly transactions for a similar investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management reviews long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Debt Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for the expected impact of Accounting Standards Update 2020-06 on accounting for convertible debt, which is effective January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon settlement of the convertible debt, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the retirement of the equity component and is recognized as a reduction of additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Per Share Data&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the RSUs expected to vest, the shares to be purchased under the Company&#x2019;s employee stock purchase plan (using the treasury stock method), and the excess conversion value on the Company&#x2019;s convertible senior notes. See Note 3,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for the expected impact of Accounting Standards Update 2020-06 on the calculation of dilutive shares for convertible debt, which is effective January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet accounts of the Company&#x2019;s foreign subsidiaries with functional currencies other than the U.S. Dollar are translated using the exchange rate at each respective balance sheet date.&#160;Revenues and expenses are translated using average exchange rates for each calendar month during the year.&#160;Translation&#160;adjustments are recorded as a component of accumulated other comprehensive income (loss) in the consolidated financial statements. Gains or losses from foreign currency exchanges are recorded in other, net in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one reportable operating segment to evaluate performance, allocate resources, set operational targets and forecast its future financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQx_431384fd-267c-4292-a9fa-deec85df8c9c">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC. The accounts of the Company&#x2019;s wholly owned subsidiaries are included in these consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQx_c57ccb3f-560f-428c-a109-ca47823a03f7">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC. The accounts of the Company&#x2019;s wholly owned subsidiaries are included in these consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications were made to conform to the current presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzAx_9b6ef44c-f864-4034-8408-ec762e51127c">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, among other things, revenue recognition, purchase price allocation, stock-based compensation, inventory costs, impairments of equity investments, long-lived assets, goodwill, liabilities and accruals, including contingent consideration, &lt;/span&gt;&lt;/div&gt;convertible senior notes, and the valuation of deferred tax assets. The Company&#x2019;s critical accounting policies are those that are both most important to the Company&#x2019;s consolidated financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results could differ from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjUy_aee41559-f492-49d5-96dc-0207cbfa6469">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s sources of revenue include (i) sales of EXPAREL in the U.S., European Union, or E.U. and the United Kingdom, or U.K.; (ii) sales of ZILRETTA in the U.S.; (iii) sales of iovera&#xb0; in the U.S., and Canada; (iv) sales of, and royalties on, its bupivacaine liposome injectable suspension, including for veterinary use and (v) license fees and milestone payments. See Note 4, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further information on the Company&#x2019;s accounting policies related to revenue from contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Licensing and Milestone Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration agreements generally involve a license to the Company&#x2019;s products. In determining how and when to recognize the revenue under a collaboration agreement, the Company must assess whether the license is distinct, which depends upon whether the customer can benefit from the license and whether the license is separate from other performance obligations in the agreement. If the license is distinct, the Company must further assess whether the customer has a right to access or a right to use the license depending on whether the functionality of the license is expected to substantively change over time. If the license is not expected to substantively change, the revenue is recognized at the point in time when the license is provided. If the license is expected to substantively change, the revenue is recognized over the license period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (e.g. obtaining regulatory approval) represent variable consideration and would be included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third-party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales are incurred or the performance obligation to which the sales relate has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties are estimated and recognized as revenue when sales to the Company&#x2019;s commercial partners occur, unless some constraint exists, as the royalties predominately relate to a supply agreement. Royalties are based on sales of the Company&#x2019;s bupivacaine liposome injectable suspension product for veterinary use.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:MajorCustomersPolicyPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzIz_1bc92f6e-7a6c-439c-b323-75a6f6d49109">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health,&#160;Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The Company also sells EXPAREL directly to ambulatory surgery centers and physicians. The Company sells ZILRETTA primarily to specialty distributors and a specialty pharmacy, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as Group Purchasing Organizations, or GPOs. The Company sells its bupivacaine liposome injectable suspension for veterinary use to a third-party licensee in the U.S. and sells iovera&#xb0; directly to end users.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below includes the percentage of revenues comprised by the Company&#x2019;s three largest wholesalers in each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Revenue from outside the U.S. accounted for less than 1% of the Company&#x2019;s total revenue for the year ended December 31, 2021. The Company began selling EXPAREL in the E.U. and U.K. and iovera&#xb0; in Canada in the fourth quarter of 2021. The Company had no revenue from outside the U.S. during the years ended December&#160;31, 2020 and 2019.</us-gaap:MajorCustomersPolicyPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzE2_bc652afc-8bf3-47d1-8c12-1354bffaff92">&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below includes the percentage of revenues comprised by the Company&#x2019;s three largest wholesalers in each period presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third largest wholesaler&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <pcrx:ConcentrationRiskNumberofCustomers
      contextRef="i97a72732ce3f4d6ca28e806af66ae46c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzUxNzE_df0a3092-7fc7-4bc2-aaf9-a4d15088f0df"
      unitRef="customer">3</pcrx:ConcentrationRiskNumberofCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7ba25e639e904a9d80a76eefeea1ce89_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzItMS0xLTEtMA_2aefbfc4-ea7c-4092-b5dc-3999ac017a63"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6e7321b7b30b420f86d7944c99c15c52_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzItMy0xLTEtMA_ff3652f8-ddde-4e97-ac42-24d86f3bc996"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i380d3a4003e54e71815bb7db455f68c9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzItNS0xLTEtMA_5fbf8324-9742-41a9-b092-6ebdc11014a6"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4bfeff53dc92453d8702a3c0ae51c52d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzMtMS0xLTEtMA_69b92880-ad12-4d14-8917-5a91ad713ab1"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1df8ab515900456b8b8748721140d7ff_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzMtMy0xLTEtMA_0a6fb97b-b352-4541-aa7d-27122a05bc88"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i52bcafe560714f84b452f8d30131893d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzMtNS0xLTEtMA_3f58932d-18b7-436c-9002-048fed00ce3b"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ice902dc371e243acbe67af152c1848da_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzQtMS0xLTEtMA_dbf583bf-dec4-4793-9ef5-382889b50711"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7e0fe11f05a54770acc081985b4107dd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzQtMy0xLTEtMA_c6694b74-fa3a-4ecb-ae42-02c1dbb43b54"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic79b87819ddf45adb47f8de52f00559e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzQtNS0xLTEtMA_af942492-3a00-4877-85ab-344db7464b76"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1d1b98464ce04367b1e114e9a4d74874_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzUtMS0xLTEtMA_0129883f-5ad2-47f1-bcd3-6571331e8b40"
      unitRef="number">0.85</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i71c5bbc9ad9d4d038376f6d8ca847370_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzUtMy0xLTEtMA_8a4ec756-897e-4278-9a51-a57ad5a88567"
      unitRef="number">0.87</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id7e7c8ae84494cf49e1dc21ec2d425fa_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTphMjRjMjNhODNhNWY0NTE1ODYxODkyYTdlODRlZjdhOS90YWJsZXJhbmdlOmEyNGMyM2E4M2E1ZjQ1MTU4NjE4OTJhN2U4NGVmN2E5XzUtNS0xLTEtMA_9d72175a-d11d-47bd-8034-6f83eb581a0f"
      unitRef="number">0.89</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9359bc477c664a09916c4119368c7808_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzE2NDkyNjc0NjQ3MDM_93fbc0c0-09d5-4ba5-9620-2d919ee85f0b"
      unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i33291270d39e439a99ab030eecef7f59_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzUyMzg_1162ce6f-265e-441b-864f-690c52b69012"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie3861be95c084c30b8a15610c61c7be1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzUyMzg_6db29f1b-02d3-417d-a8ce-b0b28d872fee"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQz_2ac34396-0cb1-4175-a157-25f8f3608d72">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. These include both internal and external costs, of which a significant portion of development activities are outsourced to third parties, including contract research organizations. Clinical trial costs are accrued over the service periods specified in contracts and adjusted as necessary based on an ongoing review of the level of effort and actual costs incurred. Research and development costs are presented net of reimbursements from commercial partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQ4_fe932ed3-c950-4a37-a5db-37397be16275">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to basis differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues interest and penalties, if any, on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in its consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQ5_9fcf20ba-496a-493f-8305-4c6834256c39">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation consists of grants of stock options and restricted stock units, or RSUs, to employees, consultants and non-employee directors, in addition to the opportunity for employees to participate in an employee stock purchase plan. The expense associated with these programs is recognized in the Company&#x2019;s consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms or the length of an offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In calculating the estimated fair value of stock options granted, the Company uses the Black-Scholes option valuation model, or Black-Scholes model, which requires the consideration of the following variables for purposes of estimating fair value in addition to the closing price of the Company&#x2019;s common stock on the date of grant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Expected term of the option&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes its historical volatility data to determine expected volatility over the expected option term. The Company uses an expected term based on its historical data from stock option activity. The risk-free interest rate is based on the implied yield on U.S. Department of the Treasury zero-coupon bonds for periods commensurate with the expected term of the options. The dividend yield on the Company&#x2019;s common stock is estimated to be zero as the Company has not declared or paid any dividends since inception, nor does it have any intention to do so in the foreseeable future. Additionally, the Company&#x2019;s ability to declare and pay a dividend in the future could be limited per the agreements governing its indebtedness. The Company records forfeitures as they occur rather than estimating forfeitures during each reporting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzA0_df14701d-f515-4e3c-86d3-d35ef0d4f136">Cash and Cash EquivalentsAll highly liquid investments with maturities of 90 days or less when purchased are considered cash equivalents. Cash equivalents include corporate debt securities, asset backed securities and money market funds.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzExNTQ0ODcyMTE3NTIx_215963d5-6ec7-4f29-8bf5-2773c778cf4c"
      unitRef="usd">223000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CommercialPaperAtCarryingValue
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzExNTQ0ODcyMTE3NTM1_d256895d-a345-4cf9-8800-8315a996c5e5"
      unitRef="usd">19000000</us-gaap:CommercialPaperAtCarryingValue>
    <us-gaap:AssetBackedSecuritiesAtCarryingValue
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzExNTQ0ODcyMTE3NjM5_0eba4039-fff3-488a-abc1-beae9a087b09"
      unitRef="usd">2600000</us-gaap:AssetBackedSecuritiesAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzg3Nzg_c9578227-3495-422c-a2ab-bc5aae331aff"
      unitRef="usd">51800000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CommercialPaperAtCarryingValue
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzg4MDY_b37f54b6-93a5-47dc-83fa-2f5e32f2a3a3"
      unitRef="usd">6500000</us-gaap:CommercialPaperAtCarryingValue>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjkx_36bbc4b5-8852-42ca-b55e-d89b7f60c735">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term and Long-Term Available-For-Sale Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term available-for-sale investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper, corporate and government bonds, and other bonds issued in the U.S. (and denominated in the U.S. dollar) by foreign entities, all with maturities of greater than three months, but less than one year. Long-term available-for-sale investments consist of corporate and government agency bonds with maturities greater than one year. The Company evaluates the classification of its investments at the time of purchase and re-evaluates such determination at each balance sheet date, which includes an assessment of the intent to hold the available-for-sale securities. The Company&#x2019;s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for preservation of capital, liquidity and a reasonable rate of return. The Company classifies its investments as available-for-sale. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities (except for credit losses) are excluded from net income (loss) and are reported as a separate component of accumulated other comprehensive income (loss) until realized. Realized gains and losses are included in interest income in the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. The Company evaluates whether a credit loss exists, and in the event a credit loss does exist, the credit loss is recognized in the consolidated statements of operations, based on the amount that the fair value is less than the amortized cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzEz_f3ec2759-c5de-49ed-b5ad-bc8aa378d6f9">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of finished goods held for sale and distribution, raw materials and work in process. Inventories are stated at the lower of cost, which includes amounts related to material, labor and overhead, or net realizable value, and is determined using the first-in, first-out (&#x201c;FIFO&#x201d;) method. The Company periodically reviews its inventory to identify obsolete, slow-moving, or otherwise unsalable inventories, and establishes allowances for situations in which the cost of the inventory is not expected to be recovered.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzI3_52f6fc42-14ca-434a-a184-9271f77a6fac">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets are recorded at cost, net of accumulated depreciation and amortization. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of fixed assets is provided over their estimated useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the related remaining lease terms. Useful lives by asset category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQ0_1c174195-3b0c-499f-a5a2-f48e8a5d322d">Useful lives by asset category are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing and laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets, net, summarized by major category, consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1d024abaafbd4d6e9cda562be11efadd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzEtMi0xLTEtMC90ZXh0cmVnaW9uOmEyNzAxZDZhNDcwYzRmMzVhOGEwNmFkNThlZjU0NDc2XzQ_fe369b86-4ea3-4c35-88c6-07cb7b996e4c">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7d54a85658be4c869764ca7b02d10225_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzEtMi0xLTEtMC90ZXh0cmVnaW9uOmEyNzAxZDZhNDcwYzRmMzVhOGEwNmFkNThlZjU0NDc2XzEw_33e1d7f5-520b-467f-a3f3-33de42744721">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6f8f41343e614090bd98a3129a5dcdc4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzItMi0xLTEtMA_fbd14764-a226-4ef0-8963-ddbb781850ad">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i45c66ebd062648669078e714c644cc79_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmFmNDBmNzJiNWUwODRkMjNiOGViZDFjOTY2ZDMxMDM1XzQ_75b78d6c-35fe-49db-af76-4d596bc0439b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie86add3d370c4395b397c37d521b6125_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90YWJsZTo1NDcyNTdlNmQxMDE0OTk5YjkwNjdlN2Q2N2Y3Mjk4OC90YWJsZXJhbmdlOjU0NzI1N2U2ZDEwMTQ5OTliOTA2N2U3ZDY3ZjcyOTg4XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmFmNDBmNzJiNWUwODRkMjNiOGViZDFjOTY2ZDMxMDM1XzEw_c514bd8d-3359-4c74-a407-0a4ad4937eef">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AssetRetirementObligationsPolicy
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjcz_f659d819-45b1-4555-a020-a11184e07c1c">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Retirement Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contractual obligations stemming from certain of its lease agreements to return leased space to its original condition upon termination of such lease agreements. The Company records its asset retirement obligations, or ARO, along with a corresponding capital asset in an amount equal to the estimated fair value of the ARO, based on the present value of expected future cash flows. In subsequent periods, the Company records expense to accrete the ARO to its full value. Each ARO capital asset is depreciated over the depreciable term of the associated asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetRetirementObligationsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzA1_cd2c06fc-d886-4162-8c1c-a1781d17033f">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes right-of-use, or ROU, assets and lease liabilities at the commencement of its lease agreements. The leases are evaluated at commencement to determine whether they should be classified as operating or financing leases. Lease costs associated with operating leases are recognized on a straight-line basis, while lease costs for financing leases are recognized over the lease term using the effective interest method. The Company does not have any financing leases. The amount of ROU assets and lease liabilities to be recognized is impacted by the type of lease payments, the lease term and the incremental borrowing rate. Variable lease payments are not included at commencement and are recognized in the period in which they are incurred. The lease term is based on the contractual term and is adjusted for any renewal options or termination rights that are reasonably certain to be exercised. The incremental borrowing rate is based on the rate the Company estimates it would pay on a collateralized basis over a similar term in a similar economic environment.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjcw_11b3b995-e196-4b7c-8767-d781eb0bfef3">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values, with some exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value can be determined, the asset or liability is recognized; if fair value is not determinable, then no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired in-process research and development, or IPR&amp;amp;D, is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;amp;D with no alternative future use is recorded as an expense at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company&#x2019;s consolidated financial statements after the date of the acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <pcrx:ContingentConsiderationPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjk5_902bcc09-a1ae-488b-894d-c926a69b9dc5">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to an acquisition, the Company measures contingent consideration arrangements at fair value each period, with changes in fair value recognized in the consolidated statements of operations as acquisition-related charges. Changes in contingent consideration can result from changes in the assumed achievement and timing of estimated sales, costs of goods sold and regulatory approvals. In the absence of new information, changes in fair value reflect the passage of time towards achievement of the milestones, and are accreted to the period in which payments are expected to be made.&lt;/span&gt;&lt;/div&gt;</pcrx:ContingentConsiderationPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjQx_7bf57b7c-1f04-40f7-8686-d330037d6149">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired in a business combination and is not amortized, but is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzE3_31fd808a-903e-42c1-bf67-3373ac6e012a">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite useful lives are amortized on a straight-line basis over their estimated useful lives and are recorded at cost, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjQ1_846727e5-70f4-4029-935c-8548974833d9">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds investments in equity securities without a readily determinable fair value. In the fourth quarter of 2019, the equity investment then held became publicly traded and thereafter, was recognized at its fair value at each reporting period with any unrealized holding gains (losses) included in other income (expense). The equity method investments without a readily determinable fair value are recognized at cost less any impairments, plus or minus any changes resulting from observable price changes in orderly transactions for a similar investment.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjc0_aa589d47-0750-45cf-b6ba-4a968061ee2b">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management reviews long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNjkz_5279eb43-82d9-49b5-a685-df1de1e9aa91">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Debt Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company separately accounts for the liability and equity components of convertible debt instruments by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. The value of the equity component is calculated by first measuring the fair value of the liability component, using the interest rate of a similar liability that does not have a conversion feature, as of the issuance date. The difference between the initial proceeds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from the convertible debt issuance and the fair value of the liability component is recorded as the carrying amount of the equity component. The Company recognizes the amortization of the resulting discount as part of interest expense in its consolidated statements of operations. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for the expected impact of Accounting Standards Update 2020-06 on accounting for convertible debt, which is effective January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon settlement of the convertible debt, the liability component is measured at fair value. The Company allocates a portion of the fair value of the total settlement consideration transferred to the extinguishment of the liability component equal to the fair value of that component immediately prior to the settlement. Any difference between the consideration attributed to the liability component and the net carrying amount of the liability component, including any unamortized debt issuance costs and debt discount, is recognized as a gain or loss in the consolidated statements of operations. Any remaining consideration is allocated to the retirement of the equity component and is recognized as a reduction of additional paid-in capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzE4_1d249f0e-9696-44eb-9810-fb90fd895d83">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Per Share Data&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share is computed by dividing net income (loss) available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net income (loss) per common share is calculated by dividing net income (loss) available (attributable) to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the RSUs expected to vest, the shares to be purchased under the Company&#x2019;s employee stock purchase plan (using the treasury stock method), and the excess conversion value on the Company&#x2019;s convertible senior notes. See Note 3,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for the expected impact of Accounting Standards Update 2020-06 on the calculation of dilutive shares for convertible debt, which is effective January 1, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzQw_a8c36767-3b9d-4eec-8437-8ae91acf38d5">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet accounts of the Company&#x2019;s foreign subsidiaries with functional currencies other than the U.S. Dollar are translated using the exchange rate at each respective balance sheet date.&#160;Revenues and expenses are translated using average exchange rates for each calendar month during the year.&#160;Translation&#160;adjustments are recorded as a component of accumulated other comprehensive income (loss) in the consolidated financial statements. Gains or losses from foreign currency exchanges are recorded in other, net in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNzA3_cbcb1c3a-5187-4e72-bb19-d17f13ff98c9">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one reportable operating segment to evaluate performance, allocate resources, set operational targets and forecast its future financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDUvZnJhZzoyNGZiNTRlMTgyYjI0ZTMzOGIyMzhlNjczMTVhMzY5Yy90ZXh0cmVnaW9uOjI0ZmI1NGUxODJiMjRlMzM4YjIzOGU2NzMxNWEzNjljXzIwNDk3_c23dc9a8-bdb9-49a8-aad7-43c8d5b973ff"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzgwNzc_1e47d44e-cecf-4f30-bf06-eb24aec811cf">RECENT ACCOUNTING PRONOUNCEMENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.5pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2021-08,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which amends Accounting Standards Codification, or ASC, 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. As a result of the amendments made by the ASU, it is expected that an acquirer will generally recognize and measure acquired contract assets and contract liabilities in a manner consistent with how the acquiree recognized and measured them in its pre-acquisition financial statements. The ASU&#x2019;s amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (i) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (ii) prospectively to all business combinations that occur &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on or after the date of initial application. The Company has decided to early adopt this standard and will apply it to the valuation of a Flexion deferred revenue contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amended the approaches and methodologies in accounting for income taxes during interim periods and makes changes to certain income tax classifications. The standard allows for certain exceptions, including the exception to the use of the incremental approach for intra-period tax allocations, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to-date loss exceeds the anticipated loss for the year. The standard also required franchise or similar taxes partially based on income to be reported as income tax and to reflect the effects of enacted changes in tax laws or rates in the annual effective tax rate computation from the date of enactment. Lastly, in future acquisitions, the Company will be required to evaluate when the step-up in the tax basis of goodwill is part of the business combination and when it should be considered a separate transaction. The standard became effective for the Company beginning January 1, 2021, and there were no material impacts to the consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which limits the number of convertible instruments that require separate accounting to (i) those with embedded conversion features that are not clearly and closely related to the debt, that meet the definition of a derivative, and that do not qualify for the scope exception from derivative accounting and (ii) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid in capital. In addition, the new guidance requires diluted earnings per share calculations to be prepared using the if-converted method, instead of the treasury stock method. The guidance must be applied in fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted no earlier than for fiscal years beginning after December 15, 2020. The Company has elected to adopt the new guidance using a modified retrospective method of transition, which would be applied to transactions outstanding at January 1, 2022. As a result, after adopting the ASU&#x2019;s guidance, the Company will not separately present in equity an embedded conversion feature for its convertible debt. Instead, the Company will account for a convertible debt instrument wholly as debt. In addition, the Company will not record interest expense on the previously recorded discount on convertible debt. The impact on the balance sheet at January 1, 2022 increased net debt by approximately $64.9&#160;million, reduced accumulated deficit by $47.2&#160;million, reduced additional paid-in capital by $96.5&#160;million and decreased deferred tax liabilities by $15.7&#160;million. The impact on the consolidated statement of operations will reduce interest expense by approximately $18.0&#160;million in 2022, with a resultant impact on basic and diluted income (loss) per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzgwODI_75063aff-3ca9-405e-ada2-ad49164be8c8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.5pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2021-08,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which amends Accounting Standards Codification, or ASC, 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. As a result of the amendments made by the ASU, it is expected that an acquirer will generally recognize and measure acquired contract assets and contract liabilities in a manner consistent with how the acquiree recognized and measured them in its pre-acquisition financial statements. The ASU&#x2019;s amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (i) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (ii) prospectively to all business combinations that occur &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on or after the date of initial application. The Company has decided to early adopt this standard and will apply it to the valuation of a Flexion deferred revenue contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amended the approaches and methodologies in accounting for income taxes during interim periods and makes changes to certain income tax classifications. The standard allows for certain exceptions, including the exception to the use of the incremental approach for intra-period tax allocations, when there is a loss from continuing operations and income or a gain from other items, and to the general methodology for calculating income taxes in an interim period, when a year-to-date loss exceeds the anticipated loss for the year. The standard also required franchise or similar taxes partially based on income to be reported as income tax and to reflect the effects of enacted changes in tax laws or rates in the annual effective tax rate computation from the date of enactment. Lastly, in future acquisitions, the Company will be required to evaluate when the step-up in the tax basis of goodwill is part of the business combination and when it should be considered a separate transaction. The standard became effective for the Company beginning January 1, 2021, and there were no material impacts to the consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Adopted as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which limits the number of convertible instruments that require separate accounting to (i) those with embedded conversion features that are not clearly and closely related to the debt, that meet the definition of a derivative, and that do not qualify for the scope exception from derivative accounting and (ii) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid in capital. In addition, the new guidance requires diluted earnings per share calculations to be prepared using the if-converted method, instead of the treasury stock method. The guidance must be applied in fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted no earlier than for fiscal years beginning after December 15, 2020. The Company has elected to adopt the new guidance using a modified retrospective method of transition, which would be applied to transactions outstanding at January 1, 2022. As a result, after adopting the ASU&#x2019;s guidance, the Company will not separately present in equity an embedded conversion feature for its convertible debt. Instead, the Company will account for a convertible debt instrument wholly as debt. In addition, the Company will not record interest expense on the previously recorded discount on convertible debt. The impact on the balance sheet at January 1, 2022 increased net debt by approximately $64.9&#160;million, reduced accumulated deficit by $47.2&#160;million, reduced additional paid-in capital by $96.5&#160;million and decreased deferred tax liabilities by $15.7&#160;million. The impact on the consolidated statement of operations will reduce interest expense by approximately $18.0&#160;million in 2022, with a resultant impact on basic and diluted income (loss) per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzE2NDkyNjc0NTkxMTQ_e9025800-3da5-427a-9e5d-f8417ee81b63"
      unitRef="usd">64900000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <pcrx:IncreaseDecreaseInRetainedEarnings
      contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzE2NDkyNjc0NTkwOTk_7f423f49-7ba9-4aad-a8ea-a735faf61807"
      unitRef="usd">-47200000</pcrx:IncreaseDecreaseInRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzE2NDkyNjc0NTkxMjk_e06d333f-25fd-430f-943c-877facbc2cf3"
      unitRef="usd">96500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzM4NDgyOTA3MTQ3MDU_30447b48-c1c3-4162-b532-9a86b92b255e"
      unitRef="usd">-15700000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <pcrx:IncreaseDecreaseInInterestExpense
      contextRef="i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNDgvZnJhZzo1ZGRmMzIyZTgyYmI0M2JmOGQzZDcxNTUzMzcwMDA2ZS90ZXh0cmVnaW9uOjVkZGYzMjJlODJiYjQzYmY4ZDNkNzE1NTMzNzAwMDZlXzE2NDkyNjc0NTkwNzk_5d1447fd-6d09-4606-8d21-cbd1268a79ca"
      unitRef="usd">-18000000</pcrx:IncreaseDecreaseInInterestExpense>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzQ0MDg_3a40f2d9-09c5-49df-a0a4-ea38ae2dd4bb">REVENUE&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product sales consist of (i) EXPAREL in the U.S., the E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera&#xb0; in the U.S. and Canada and (iv) sales of, and royalties on, its bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are from the Company&#x2019;s collaborative licensing agreements. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure only relates to revenue associated with net EXPAREL and ZILRETTA product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and a specialty pharmacy, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as GPOs. Product revenue is recognized when control of the promised goods are transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the product is delivered to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved. The calculation of some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of activity with respect to the Company&#x2019;s sales related allowances and accruals related to EXPAREL for the years ended December&#160;31, 2021, 2020 and 2019, as well as ZILRETTA for the year ended December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Returns Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prompt Payment Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Service Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Volume Rebates and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Payments/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Payments/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Payments/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Licensing and Milestone Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration agreements generally involve a license to the Company&#x2019;s products. In determining how and when to recognize the revenue under a collaboration agreement, the Company must assess whether the license is distinct, which depends upon whether the customer can benefit from the license and whether the license is separate from other performance obligations in the agreement. If the license is distinct, the Company must further assess whether the customer has a right to access or a right to use the license depending on whether the functionality of the license is expected to substantively change over time. If the license is not expected to substantively change, the revenue is recognized at the point in time when the license is provided. If the license is expected to substantively change, the revenue is recognized over the license period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognition from milestone payments is dependent upon the facts and circumstances surrounding the milestone payments. Milestone payments based on a non-sales metric such as a development-based milestone (e.g. obtaining regulatory approval) represent variable consideration and are included in the transaction price subject to any constraints. If the milestone payments relate to future development, the timing of recognition depends upon historical experience and the significance a third-party has on the outcome. For milestone payments to be received upon the achievement of a sales threshold, the revenue from the milestone payments is recognized at the later of when the actual sales are incurred or the performance obligation to which the sales relate has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacy, GPOs and doctors. Payment terms generally range from&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzI3NzA_1d583239-02d3-4c41-bc38-abbb200a0e6b"&gt;zero&lt;/span&gt;&#160;to&#160;97&#160;days from the date of the transaction, and accordingly, there is no significant financing component. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. A contract&#x2019;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company&#x2019;s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company&#x2019;s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregated Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregated net product sales in the periods presented as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Net product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;EXPAREL&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;ZILRETTA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;iovera&#xb0;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Bupivacaine liposome injectable suspension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company began recognizing revenue from net product sales of ZILRETTA on November 19, 2021, the date of the Flexion Acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <pcrx:MovementinValuationandQualifyingAccountsTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzQ0MDM_3846accd-1572-4f9f-9183-8a7e1d266147">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of activity with respect to the Company&#x2019;s sales related allowances and accruals related to EXPAREL for the years ended December&#160;31, 2021, 2020 and 2019, as well as ZILRETTA for the year ended December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Returns Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prompt Payment Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Service Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Volume Rebates and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Payments/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Payments/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Payments/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pcrx:MovementinValuationandQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i72dde336ea2646239cd55a4c4c35744d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtMS0xLTEtMA_1a909324-bc49-4ece-b055-1a16ba40590c"
      unitRef="usd">344000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifa17a81b38264f39b34ab843a76bdd7b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtMy0xLTEtMA_be8b02cd-a88b-4018-b658-caa5a49eef8f"
      unitRef="usd">779000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i14320622ef29473cb23cce50b7da7f46_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtNS0xLTEtMA_4b6ac98e-b3b3-4dff-afbf-676aa020ca9c"
      unitRef="usd">1167000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i57cd9faa19194a9c8470e9fe6d5218d4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtNy0xLTEtMA_efc9051f-e18b-4494-9677-5663ea2ea7e9"
      unitRef="usd">1010000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4efcb358dc364ee385b99f35f75898ae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtOS0xLTEtNDk2OTI_411f7d24-c06d-44a6-ad7c-1ea9a1d00518"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7f634c57178e427b9ece243062defb9c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEtOS0xLTEtMA_d345a8f3-05a0-4b3a-8b64-e06af2f29081"
      unitRef="usd">3300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="iee8d9fd8299c410c8c9b5a06cf205cd2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItMS0xLTEtMA_19ec6ca1-6435-43e2-9787-dd506bbeef88"
      unitRef="usd">783000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i712922c8b31944bcb4ececbbd4ecb4a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItMy0xLTEtMA_2714b3ad-e8e0-4e0e-8987-dfb00f1a2037"
      unitRef="usd">8426000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i9e6fe451f5a2472a9296caa5f57011d7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItNS0xLTEtMA_33e9326f-ef7f-4fea-964e-bb6d9f2e9ccc"
      unitRef="usd">6267000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ie406c0d697dd4848bc04dae623fcce72_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItNy0xLTEtMA_bf4fc4c8-dd4b-4bca-b2f9-645177e73d1e"
      unitRef="usd">11475000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i81b07dbdf7694f77bc022c7d7d9afa7c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItOS0xLTEtNDk2OTI_5c107048-90ed-4564-bbf4-5ddf66edd83f"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzItOS0xLTEtMA_3a406063-51be-435a-ade5-64c358dc06d9"
      unitRef="usd">26951000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iee8d9fd8299c410c8c9b5a06cf205cd2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtMS0xLTEtMA_deea0882-39c8-4733-9d5c-26ec29e407e4"
      unitRef="usd">587000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i712922c8b31944bcb4ececbbd4ecb4a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtMy0xLTEtMA_6ee4838e-05c3-4efd-aa0e-f3ef07ff9296"
      unitRef="usd">8243000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9e6fe451f5a2472a9296caa5f57011d7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtNS0xLTEtMA_272ae72f-e38e-4f5e-9ef7-e53293c63768"
      unitRef="usd">5948000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie406c0d697dd4848bc04dae623fcce72_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtNy0xLTEtMA_92312eb8-89c3-4696-870a-a77da606762e"
      unitRef="usd">10669000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i81b07dbdf7694f77bc022c7d7d9afa7c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtOS0xLTEtNDk2OTI_a27936ba-c3b1-4d80-bce0-ace9731bc028"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzMtOS0xLTEtMA_0c07e501-6f0f-4b2e-96de-a55f2cf4dcc3"
      unitRef="usd">25447000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6d04eaeb562d4b64900de3e69bac3a78_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtMS0xLTEtMA_796c43ab-a7ab-4799-8664-1608aea677c2"
      unitRef="usd">540000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0a88692b931e4aef8edbc75ea1bf544e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtMy0xLTEtMA_0a0e273d-72f2-4d2a-a240-fef4cf54c41d"
      unitRef="usd">962000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i06af3d3299684224a00de2d7598b92d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtNS0xLTEtMA_1d388501-dcd2-4ef4-920b-850ec51c9c30"
      unitRef="usd">1486000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i320c15f4336b4069b57910624e292a4c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtNy0xLTEtMA_b599e1b2-6af6-4665-9a66-a8835ae8bf6d"
      unitRef="usd">1816000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9fd3c4592d3b415cba09402210cae28d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtOS0xLTEtNDk2OTI_19d88f29-f873-4bc6-937e-61f4c8d518ce"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzQtOS0xLTEtMA_047e8db4-c603-4352-95ef-f511e60bb438"
      unitRef="usd">4804000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i0c16dbebfa7a404f8409b8c58ef412d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtMS0xLTEtMA_116f69d2-a25b-4e3b-94b1-5400b2e47f02"
      unitRef="usd">794000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="if63921146eb64ffe98b470ec795407f5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtMy0xLTEtMA_aa0b26d3-eede-4e5a-8567-89c1d8cfb0ee"
      unitRef="usd">8541000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i2b2e28fa586746b9821aa10826da495f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtNS0xLTEtMA_b477da64-1107-416d-89fe-3dd9d5641caf"
      unitRef="usd">6437000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="icc25a5337c794bf8bd461563d5da11b9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtNy0xLTEtMA_4649a051-66bd-490e-96bd-719a9167ce03"
      unitRef="usd">12345000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ic9a8455031a245d78c33f94ce7a73d04_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtOS0xLTEtNDk2OTI_c74b0c54-d351-4f0d-aa5f-ac14b567ff5a"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzUtOS0xLTEtMA_8016700f-6a46-4bc9-a682-8ceb31e16daf"
      unitRef="usd">28117000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0c16dbebfa7a404f8409b8c58ef412d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtMS0xLTEtMA_d2892bbe-35ca-4046-8b1e-d18b9dacc3cc"
      unitRef="usd">311000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if63921146eb64ffe98b470ec795407f5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtMy0xLTEtMA_bcbcf622-b88a-4175-949a-9f5c62d46518"
      unitRef="usd">8496000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i2b2e28fa586746b9821aa10826da495f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtNS0xLTEtMA_e8c148dd-7f3c-4f70-b236-52c433e4dd38"
      unitRef="usd">6755000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="icc25a5337c794bf8bd461563d5da11b9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtNy0xLTEtMA_05ebc114-2b00-4ef8-8051-deaefcc5b735"
      unitRef="usd">12561000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ic9a8455031a245d78c33f94ce7a73d04_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtOS0xLTEtNDk2OTI_c01f7f43-d3ca-4a1c-aa34-7e1db314543c"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzYtOS0xLTEtMA_d58fb902-b4ac-41b3-99f9-c7c0fe168938"
      unitRef="usd">28123000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0c7f9a44c2e3462cb1305f9f59a302b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctMS0xLTEtMA_ced163a9-6a8c-4f1d-b765-c0b40165f3fa"
      unitRef="usd">1023000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i28deb21f2b4942ecb350c0910d65ebed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctMy0xLTEtMA_0c23cdb1-ba94-40ab-8378-2fc7dc1fd1a8"
      unitRef="usd">1007000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i34a22ddc8218489080892a6cdaf5ebb4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctNS0xLTEtMA_2754205f-5351-4be2-865c-a6764cc2908e"
      unitRef="usd">1168000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id683cf836c4e4f11916c047f28e031ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctNy0xLTEtMA_b3411ef6-6213-4291-a6a9-4c910ea7c8cf"
      unitRef="usd">1600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3462358bbe414ffbb1b57b6e9e01c5c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctOS0xLTEtNDk2OTI_3d9d7b03-415a-4da2-8420-a64ce5990e24"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzctOS0xLTEtMA_5f36ae32-015e-40c4-a012-7fb03164e6df"
      unitRef="usd">4798000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ia92a3c6cd7d9435cb9eff94c7851d7f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtMS0xLTEtMA_708afd36-8382-4a49-9af8-39143ada0a81"
      unitRef="usd">3095000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i63ac5092cc3645d7bc0aef94ffd9cee5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtMy0xLTEtMA_e81d6b19-7f93-41f4-a7a4-cf985ec8e6ae"
      unitRef="usd">10388000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i57086efa37da41e998389e0480dd7425_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtNS0xLTEtMA_6770c488-f927-4cc0-8a35-d4968d0465ec"
      unitRef="usd">10112000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="icf91a2291efc4aa296367a3d8f467bd8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtNy0xLTEtMA_267bb377-991d-4047-b6cf-d69c984a74ae"
      unitRef="usd">17101000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ied14d59a15b74bf6b3ced695a67b49f0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtOS0xLTEtNDk2OTI_3b743bda-806d-4601-9d4d-af309fb711d7"
      unitRef="usd">1139000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzgtOS0xLTEtMA_26fa42c6-79ce-4a0b-8751-8be1bd88d6ed"
      unitRef="usd">41835000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ia92a3c6cd7d9435cb9eff94c7851d7f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktMS0xLTEtMA_08eccdd5-1ad9-4dac-9840-c816e5c99865"
      unitRef="usd">757000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i63ac5092cc3645d7bc0aef94ffd9cee5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktMy0xLTEtMA_fe629d58-2842-481c-aaec-2e8e883ca27a"
      unitRef="usd">10217000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i57086efa37da41e998389e0480dd7425_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktNS0xLTEtMA_4f8ad989-2022-49df-9da6-e456301da545"
      unitRef="usd">7644000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="icf91a2291efc4aa296367a3d8f467bd8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktNy0xLTEtMA_e98a1fc2-4637-41db-8480-81b7d4bfd404"
      unitRef="usd">15207000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ied14d59a15b74bf6b3ced695a67b49f0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktOS0xLTEtNDk2OTI_faf2ced1-09f1-4a52-b55c-fc223255157e"
      unitRef="usd">378000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzktOS0xLTEtMA_df9f6bc9-4e21-431f-999d-ecb6ebe2297d"
      unitRef="usd">34203000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="icc0dc9d1d7b14f25ad8be83ef27a2350_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTEtMS0xLTA_0f7199a3-fe94-4a2e-9505-09043393ea6d"
      unitRef="usd">3361000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib5e8ea6a6bb646069500943f11b40bd6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTMtMS0xLTA_11d1468f-b2d4-4ce8-83f0-5935beea00d9"
      unitRef="usd">1178000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie03f2a211d40429ba9a8f59edb0f3814_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTUtMS0xLTA_691ab117-7e3c-4e9b-bcb9-cd34a620e78b"
      unitRef="usd">3636000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8787beaf97a040fc93e4271eaa597cf7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTctMS0xLTA_9552b9a7-62af-49d0-8cab-aa3a954a4c19"
      unitRef="usd">3494000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id086e74a59d7487d9c24f8b8d7361978_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTktMS0xLTQ5Njky_d77ba691-657a-44ee-886f-6ac43a4716fb"
      unitRef="usd">761000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTo2OWI4Y2ZhYmVhNTU0NzkwOGI1YzkzOGM5OGVhMWEwMi90YWJsZXJhbmdlOjY5YjhjZmFiZWE1NTQ3OTA4YjVjOTM4Yzk4ZWExYTAyXzEwLTktMS0xLTA_ab4b9673-99d1-4f55-9db9-61d815a536f1"
      unitRef="usd">12430000</us-gaap:ValuationAllowancesAndReservesBalance>
    <pcrx:AccountsReceivablePaymentTerms
      contextRef="i74f568606f0c4823a905f91cf481d300_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzI3NzY_0e3cbab0-19d0-4e12-ae0b-6bab942e4d49">P97D</pcrx:AccountsReceivablePaymentTerms>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90ZXh0cmVnaW9uOjA1MGZjYmYzM2E4MjQ5M2RiZWZhY2ZkMjk3NWMyZTc4XzQ0MDY_dc2e0190-9144-4107-83b9-bcebd7e4df70">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregated net product sales in the periods presented as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Net product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;EXPAREL&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;ZILRETTA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;iovera&#xb0;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Bupivacaine liposome injectable suspension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i736f64d4bbd849d7be2b019552be776c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzMtMS0xLTEtMA_ea9861dc-e273-47bd-821b-794ad71eff32"
      unitRef="usd">506515000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c69cb4d02b34bbca69ebe9cac7ed74e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzMtMy0xLTEtMA_b94a9c34-5846-4abe-b0f4-d468e0390172"
      unitRef="usd">413338000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f8edb95efe04b6799f90101e59f96cb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzMtNS0xLTEtMA_09f8afce-b503-4f69-9309-afabfb94b28b"
      unitRef="usd">407877000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30fd1b228fa24cc99396d29a977444ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtMS0xLTEtMjY2OTU_6cd556ea-f6c0-4f79-b501-9ac93f8e2af8"
      unitRef="usd">12683000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e0d7ce79dbc4e3789299398e8fce7f1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtMy0xLTEtMjY2OTU_5c3d1ba7-aa37-4c27-9d1c-26fbd1f0d282"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5de2811811e245db84f11e1e3de5d7e6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtNS0xLTEtMjY2OTU_e1bd8dfc-2c64-4d2d-93f3-28db23c8b104"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if533c736fa2840fb9422c87e1310fa3a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtMS0xLTEtMA_b2cb4592-faa0-4fea-b42c-bd43abdb1e38"
      unitRef="usd">16162000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d56d46c5c9a4e8a9f809b42b0655590_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtMy0xLTEtMA_30ac8236-2ff7-45e9-a5c0-7b3ec0f32ab1"
      unitRef="usd">8817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec6610466d344f0fa088043b24569826_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzQtNS0xLTEtMA_802a0914-49e0-4904-a3bc-73ccc7b7d68a"
      unitRef="usd">7896000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02771c45dac74870b7443cd500921e8a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtMS0xLTEtNjU4NjE_16b0c844-9544-48e8-9ec6-fd734e675f23"
      unitRef="usd">3606000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84613c0ab0204e27bfad217490c8e958_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtMy0xLTEtNjU4NjE_27897a0c-bd95-4227-ab3f-fa2a327d854b"
      unitRef="usd">4459000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i356e2083084446a6b5546356a72bfb5d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtNS0xLTEtNjU4NjE_4d458412-112a-4e1a-915a-4e65b39e6daa"
      unitRef="usd">3153000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtMS0xLTEtMA_ba5297c6-1a06-4903-9daf-f9beed917611"
      unitRef="usd">538966000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtMy0xLTEtMA_35e62d18-d0ed-4d2c-b833-d5382bbd65e0"
      unitRef="usd">426614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTEvZnJhZzowNTBmY2JmMzNhODI0OTNkYmVmYWNmZDI5NzVjMmU3OC90YWJsZTpjYjhhOGIzNGY3NmI0ZDkyODkxNzM0MmI2MTc2MDU2YS90YWJsZXJhbmdlOmNiOGE4YjM0Zjc2YjRkOTI4OTE3MzQyYjYxNzYwNTZhXzYtNS0xLTEtMA_59444c62-03f6-470f-b76d-fcdcd0a6f903"
      unitRef="usd">418926000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzI5NDk_07a854fa-4543-4841-98b6-a77ed8a46d58">ACQUISITIONS&lt;div style="margin-bottom:8pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Flexion Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 19, 2021, the Company acquired Flexion (the &#x201c;Flexion Acquisition&#x201d;), a biopharmaceutical company focused on the discovery, development, and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis, pursuant to an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;), dated as of October 11, 2021, by and among the Company, Oyster Acquisition Company Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#x201c;Purchaser&#x201d;), and Flexion. Following the completion of a successful tender offer for the shares of Flexion&#x2019;s common stock, and pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the General Corporation Law of the State of Delaware, Purchaser merged with and into Flexion with Flexion surviving as a wholly owned subsidiary of the Company. The Company changed the name of Flexion to Pacira Therapeutics, Inc. after completing the merger.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The total consideration for the Flexion Acquisition was approximately $578.8&#160;million consisting of: (i) $448.5&#160;million of cash paid to former Flexion stockholders and to settle restricted stock units and in-the-money stock options; (ii) an $85.1&#160;million cash payment of Flexion debt not to be assumed by the Company and (iii) $45.2&#160;million of estimated contingent consideration related to contingent value rights, or CVRs, that were issued to Flexion shareholders and certain equity award holders in conjunction with the Flexion Acquisition. The consideration is subject to adjustments based on the achievement of certain potential milestone payments. The Company estimates that up to an additional $380.2&#160;million in the aggregate may be payable to holders of the CVRs if each of the applicable milestones are achieved, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i) $1.00 per CVR the first time that net sales of ZILRETTA in any calendar year equal or exceed $250.0&#160;million;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii) $2.00 per CVR, the first time that net sales of ZILRETTA in any calendar year equal or exceed $375.0&#160;million;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii) $3.00 per CVR, the first time that net sales of ZILRETTA in any calendar year equal or exceed $500.0&#160;million;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv) $1.00 per CVR upon approval by the U.S. Food and Drug Administration, or FDA, of a Biologics License Application (BLA) for PCRX-201 (formerly FX-201), a clinical stage gene therapy product candidate; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(v) $1.00 per CVR upon approval by the FDA of a new drug application, or NDA, for PCRX-301 (formerly FX-301), an investigational product candidate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total consideration for the Flexion Acquisition was $578.8&#160;million, which consisted of the following (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value of Purchase Price Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of purchase consideration paid at closing:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration for all outstanding shares of Flexion&#x2019;s common stock (50,392 shares of common stock acquired at $8.50 per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to settle RSUs and in-the-money options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid to settle Flexion debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent value rights (CVRs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounted for the Flexion Acquisition using the acquisition method of accounting and, accordingly, has included the assets acquired, liabilities assumed and results of operations in its consolidated financial statements from the acquisition date of November 19, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary purchase price allocation is based on estimates, assumptions, valuations and other studies which have not yet been finalized. Prior to the finalization of the purchase price allocation, if information becomes available that would indicate it is probable that unknown events had occurred and the amounts can be reasonably estimated, such items will be included in the final purchase price allocation and may change the carrying value of goodwill. The Company is finalizing its valuation of intangible assets, tangible assets, liabilities and tax analyses, and anticipates finalizing the purchase price allocation as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the preliminary allocation of the Flexion Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amounts Recognized at the Acquisition Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;ASSETS ACQUIRED&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development (IPR&amp;amp;D) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES ASSUMED&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquired identifiable intangible assets and IPR&amp;amp;D assets were valued from a market participants&#x2019; perspective using a multi-period excess earnings methodology (income approach). The identifiable finite-lived intangible asset, ZILRETTA, is a developed technology for OA knee pain with a value of $480.0&#160;million and a useful life of 9.7 years. A discount rate of 17.5% was used in calculating the fair value of this technology. The IPR&amp;amp;D asset relates to the use of ZILRETTA for the treatment of OA pain of the shoulder and was valued at $60.0&#160;million. The projected cash flows for this asset were adjusted for the probability of successful development and commercialization, and were discounted at 18.0%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the purchase price over the fair value of identifiable net assets acquired represents goodwill. This goodwill is primarily attributable to the value of combining ZILRETTA with iovera&#xb0; and EXPAREL as a safe and effective non-opioid multimodal regimen for pain management, as well as the synergies of merging operations. The acquired goodwill and intangible assets are currently not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of acquired goodwill and intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Flexion results from the acquisition date of November 19, 2021 through December 31, 2021, which are included in the consolidated statements of operations, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Acquisition Date Through &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition-Related Charges Product Discontinuation and Other,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information on costs incurred related to the Flexion Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unaudited Pro Forma Summary of Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the unaudited pro forma summary of operations for the years ended December 31, 2021 and 2020, as if the Flexion Acquisition had occurred on January 1, 2020. This pro forma information does not purport to represent what the Company&#x2019;s actual results would have been if the acquisition had occurred as of January 1, 2020, and is not indicative of what such results would be expected for any future period (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended&#160;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of the Company and Flexion. The summary pro forma financial information primarily reflects the following pro forma adjustments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Removal of the acquisition-related transaction fees and costs, including certain stock-based compensation and other compensation expenses related to the acquisition, from the years ended December 31, 2021 and 2020;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Removal of the income tax benefit resulting from the Company decreasing its existing valuation allowance on deferred tax assets from the years ended December 31, 2021 and 2020;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Removal of Flexion&#x2019;s interest expense and associated deferred financing cost amortization;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Adjustments to the Company&#x2019;s interest income for the cash used to acquire Flexion; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Additional cost of goods sold related to the step-up value in inventory;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Additional amortization expense from the acquired developed technology intangible assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Additional depreciation of fixed assets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Additional lease expense on the ROU assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, all of the above adjustments were adjusted for the applicable tax impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MyoScience, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 9, 2019, the Company acquired MyoScience (the &#x201c;MyoScience Acquisition&#x201d;), a privately held medical device company, in which MyoScience became a wholly owned subsidiary of the Company and was renamed Pacira CryoTech, Inc. The total consideration was $147.5&#160;million, which included a cash payment of $119.0 million and the fair value of contingent consideration in the amount of $28.5 million. The contingent consideration consisted of contingent milestone payments up to an aggregate of $100.0 million upon the achievement of certain regulatory and commercial milestones, of which $43.0&#160;million are available as of December 31, 2021. The Company&#x2019;s obligation to make milestone payments is limited to those milestones achieved through December 31, 2023, with any such milestones payable within 60 days of the end of the fiscal quarter of achievement. During the years ended December 31, 2021, 2020 and 2019, the Company made $12.0&#160;million, $15.0&#160;million and $7.0&#160;million of cash payments for the achievement of certain milestones, respectively. See Note 12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for information on the measurement and amounts recognized in the Company&#x2019;s consolidated financial statements for contingent consideration. See Note 21, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for information on a dispute regarding the achievement of certain milestone payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NjY1MzU_95a70d4f-3ee4-4335-82b9-a5b2075e49ac"
      unitRef="usd">578800000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if66cf7a1d0974accbfeaa215c9671c3a_D20211119-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDc5NDA_d94313da-6c09-487c-908b-9533130f4751"
      unitRef="usd">448500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NjY1MDI_472087cc-5097-4251-ad31-12659399458b"
      unitRef="usd">85100000</pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt>
    <pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration
      contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NjY1MTc_35e13d74-af23-4202-845b-42bcd2823211"
      unitRef="usd">45200000</pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0ODgxMDU_cac9ff12-aca6-4b56-8d32-57920d8280db"
      unitRef="usd">380200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ieb1a68217b5c4d4e873ece15e0f90135_I20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk0NjQ_b5b74f6f-bb32-479e-acd7-7dca91cf39f5"
      unitRef="usdPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pcrx:ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold
      contextRef="i9218c1eec9ef41a4992bc55da182b205_D20211119-20301231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk0NzE_ea614d9e-194f-4469-9e2d-29c47838a8da"
      unitRef="usd">250000000</pcrx:ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifcdbdc73190942b1a864a717a9c9bcca_I20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk0OTk_d0e75032-688b-481c-a272-8cc7a75b62c3"
      unitRef="usdPerShare">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pcrx:ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold
      contextRef="i1e721f32c0054c3c80e74321a03292d4_D20211119-20301231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1MDY_af295f0e-3369-4ba3-a3da-7f954f177fc8"
      unitRef="usd">375000000</pcrx:ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie03ed2c8aff24b4494f38ae68516f2ce_I20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1MjI_53af68b4-42d6-40ae-996f-da2ec043f250"
      unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pcrx:ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold
      contextRef="i008e93128d4947408a9a2c78e9148223_D20211119-20301231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1Mjk_be49662b-d984-4c0a-a218-be268394d331"
      unitRef="usd">500000000</pcrx:ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0c856dbf51f94a28b261f6eecf123ef1_I20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1NDU_cbf51b59-d83a-4c12-8038-d6a9f0e4800e"
      unitRef="usdPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8d300faae4fa47d5b99bd8a7e5282ce7_I20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NDk1NTI_025748db-336f-45c3-888f-3eeb189a6644"
      unitRef="usdPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzQzOTgwNDY1Mjk5MjQ_240811b1-0c88-4e26-ae41-8c36dd98b2e1">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total consideration for the Flexion Acquisition was $578.8&#160;million, which consisted of the following (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value of Purchase Price Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of purchase consideration paid at closing:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration for all outstanding shares of Flexion&#x2019;s common stock (50,392 shares of common stock acquired at $8.50 per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to settle RSUs and in-the-money options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid to settle Flexion debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent value rights (CVRs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzE2NDkyNjc0NTE5Nzc_5beeaff7-31fa-49ca-ad10-20825a0d5a72"
      unitRef="usd">578800000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i37470c5184194ea6bcf6c2946155189f_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzItMi0xLTEtNDY4OTQ_f6c78222-8132-4ff7-9313-c5976a2e2c32"
      unitRef="usd">428333000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i936811b25a12408a9e9c474cd8eec9ba_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzMtMi0xLTEtNDY4OTQ_9ff9d72e-9747-44a3-8464-320fb90dbed8"
      unitRef="usd">20153000</us-gaap:PaymentsToAcquireBusinessesGross>
    <pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt
      contextRef="i63aa112e385a4b169e514d953a28f982_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzctMi0xLTEtNDY4OTQ_8696bfbb-ba4d-4743-8ce7-8386a6479b46"
      unitRef="usd">85118000</pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzctMi0xLTEtNjQ5OTI_4978d741-c696-4618-a93b-983ca6cc151c"
      unitRef="usd">533604000</us-gaap:PaymentsToAcquireBusinessesGross>
    <pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration
      contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzEwLTItMS0xLTQ2ODk0_5ca29eb1-2519-4639-bd36-b04cb6fe9fd1"
      unitRef="usd">45241000</pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZToyOWU0MDVmNWVkYTY0OWNmOWYzMGE3YmI2MDgxNTFlMy90YWJsZXJhbmdlOjI5ZTQwNWY1ZWRhNjQ5Y2Y5ZjMwYTdiYjYwODE1MWUzXzEyLTItMS0xLTQ2ODk0_91ae51e1-b8b8-4e0d-a42b-d2b18aaf339e"
      unitRef="usd">578845000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzQzOTgwNDY1Mjk5MjU_09cceeb9-e03f-44d2-b31a-17065c26d9b0">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the preliminary allocation of the Flexion Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amounts Recognized at the Acquisition Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;ASSETS ACQUIRED&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In-process research and development (IPR&amp;amp;D) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES ASSUMED&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzItMi0xLTEtNDcwMjA_86cba975-6a6c-4c5d-ac3c-54dd726681a8"
      unitRef="usd">113562000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzMtMi0xLTEtNDcwMjA_e048cc56-8cc5-490d-a8ec-b9f88e50ac20"
      unitRef="usd">11153000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzQtMi0xLTEtNDcwMjA_cd254922-e3f3-484d-9c02-5b20bfc34dbd"
      unitRef="usd">32838000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzUtMi0xLTEtNDcwMjA_c31af945-f35d-41c3-a609-964d5602a5e8"
      unitRef="usd">29667000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzYtMi0xLTEtNDcwMjA_64f1c695-53a9-4129-bbaf-43d65d28c6f7"
      unitRef="usd">4852000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzctMi0xLTEtNDcwMjA_b145b51b-93af-4474-9534-feb2dfd4e0d6"
      unitRef="usd">23307000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzgtMi0xLTEtNDcwMjA_e8cb8aac-f3e7-4f36-ac1a-0d2fb6e0e640"
      unitRef="usd">58015000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <pcrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzktMi0xLTEtNDcwMjA_3d80657c-9ceb-4900-8ba8-5ad0c34e0714"
      unitRef="usd">6585000</pcrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzEwLTItMS0xLTQ3MDIw_51715947-2ee5-4709-b819-a0c8cabe0f38"
      unitRef="usd">480000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzExLTItMS0xLTQ3MDIw_f0ce067b-a4f8-4300-822e-3098efc161bc"
      unitRef="usd">61000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzEyLTItMS0xLTUzODcw_21b7125c-2484-4249-8b0b-0ff6533cefeb"
      unitRef="usd">820979000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzEyLTItMS0xLTQ3MDIw_2b8748f7-502f-4069-85d2-cc3a9836d120"
      unitRef="usd">9794000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <pcrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzEzLTItMS0xLTQ3MDIw_a9c849a2-4aca-4097-b84c-b90ab3cc748e"
      unitRef="usd">22746000</pcrx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE0LTItMS0xLTQ3MDIw_367f689e-743a-4983-b036-67874d580ebf"
      unitRef="usd">10000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE1LTItMS0xLTQ3MDIw_847f9cbb-7ce3-499a-8130-c0b5719bf7b8"
      unitRef="usd">6585000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE2LTItMS0xLTQ3MDIw_7ab45e7e-f78d-4ffd-acfb-595f9c0bd525"
      unitRef="usd">1187000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE4LTItMS0xLTQ3MDIw_fcaedf31-b3e7-4226-9cd0-4308b145a49f"
      unitRef="usd">201450000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ic6aad501cb7243e887c49fac7690b6ca_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzIwLTItMS0xLTUzODc5_1a43533a-6471-4eb0-935e-2af84d751c1f"
      unitRef="usd">251762000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzE5LTItMS0xLTQ3MDIw_641fc68e-a67e-40b6-ac77-a9e800614f65"
      unitRef="usd">569217000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzIwLTItMS0xLTQ3MDIw_1075d997-8684-43eb-ba1d-a5ece01cea0d"
      unitRef="usd">9628000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTpmNjYzODQwYzNlNGU0ZjM0YjU1NmFmNWViYWRiZjYxMC90YWJsZXJhbmdlOmY2NjM4NDBjM2U0ZTRmMzRiNTU2YWY1ZWJhZGJmNjEwXzIxLTItMS0xLTQ3MDIw_cc8c56a2-ef6a-4343-b773-1a17917b9655"
      unitRef="usd">578845000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ic1eb92833ae9435a9ecf1d355bbcb009_D20211119-20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTQ1OTA4_dd92b0ac-2e2a-4a1b-af64-7bdab96c2b5f"
      unitRef="usd">480000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic1eb92833ae9435a9ecf1d355bbcb009_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTI3MDY1_600ce2a3-4fd8-4777-a86d-32b9c57aa4c3">P9Y8M12D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <pcrx:FiniteLivedIntangibleAssetsMeasurementInput
      contextRef="i2e8639429a9c49ba9041fee399c2357f_D20211119-20211119"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTQ1OTIy_aae83938-49d7-406a-9a6c-ac4d44b61bbb"
      unitRef="number">0.175</pcrx:FiniteLivedIntangibleAssetsMeasurementInput>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i8bf45bc62b484e8483fd1b35bcdd3bbd_D20211119-20211119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTQ1OTM2_4476cfee-f53d-430e-8822-5b9ead69232d"
      unitRef="usd">60000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate
      contextRef="ic1807decbe80497fafb382a9fabc9899_D20211119-20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTQ1OTI5_52af5c43-c267-4326-9d8c-9f891d19af3b"
      unitRef="number">0.180</us-gaap:AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzQzOTgwNDY1Mjk5MjY_7bf3864b-dfd9-43d6-ba74-504541c5c200">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Flexion results from the acquisition date of November 19, 2021 through December 31, 2021, which are included in the consolidated statements of operations, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Acquisition Date Through &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;This pro forma information does not purport to represent what the Company&#x2019;s actual results would have been if the acquisition had occurred as of January 1, 2020, and is not indicative of what such results would be expected for any future period (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended&#160;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i9797eb88784347c2ba91f649e7a89035_D20211119-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTphNTc1NTkxNzI5NmU0Yjk0OTJmNzk4ZDFmZjdjNTA4MC90YWJsZXJhbmdlOmE1NzU1OTE3Mjk2ZTRiOTQ5MmY3OThkMWZmN2M1MDgwXzEtMi0xLTEtMzA5MzU_0e596014-816b-4d6a-87b6-986799deb6be"
      unitRef="usd">12683000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i9797eb88784347c2ba91f649e7a89035_D20211119-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTphNTc1NTkxNzI5NmU0Yjk0OTJmNzk4ZDFmZjdjNTA4MC90YWJsZXJhbmdlOmE1NzU1OTE3Mjk2ZTRiOTQ5MmY3OThkMWZmN2M1MDgwXzItMi0xLTEtMzA5NDM_2a5d2167-4912-4aab-9aed-5e8f262d01de"
      unitRef="usd">-25010000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzItMi0xLTEtNDcxNjE_44c4b53b-6967-4d24-b50f-bc3fba5bdc28"
      unitRef="usd">630942000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzItNC0xLTEtNDcxNjE_b6071a10-3f51-4e13-adb3-339578450f9e"
      unitRef="usd">515199000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzMtMi0xLTEtNDcxNjE_ef172aa2-a752-4e48-a2bc-f1cdccf12bda"
      unitRef="usd">-67264000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzMtNC0xLTEtNDcxNjE_b2c3db5d-3146-48bf-a924-8dc43bfa6aed"
      unitRef="usd">-19711000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzQtMi0xLTEtNDcxNjE_1add562e-1c11-4b1f-aca5-4a2cbd04ebd5"
      unitRef="usdPerShare">-1.52</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzQtMi0xLTEtNDcxNjE_feab8940-83a1-429f-b806-0304d9b01047"
      unitRef="usdPerShare">-1.52</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzQtNC0xLTEtNDcxNjE_44f57d22-1b6e-4529-a7b2-54faa8fc7788"
      unitRef="usdPerShare">-0.46</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90YWJsZTo4ZWM5NmFkZGU1YjY0ZGQzOWNkMzkwMWVmNTY3NzU0My90YWJsZXJhbmdlOjhlYzk2YWRkZTViNjRkZDM5Y2QzOTAxZWY1Njc3NTQzXzQtNC0xLTEtNDcxNjE_a27a9c20-3812-4899-9a68-a5687781c51b"
      unitRef="usdPerShare">-0.46</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i47f4eb49ec8441a9b58dbd98a28a2201_D20190409-20190409"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMxODY5_0d4b6f3d-f02e-4c68-8984-c1e24ab9d30b"
      unitRef="usd">147500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMxOTA3_ab3eb7ce-f178-4352-83fd-4845fcb368c4"
      unitRef="usd">119000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration
      contextRef="i47f4eb49ec8441a9b58dbd98a28a2201_D20190409-20190409"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMxOTc1_059c293e-e154-416c-816a-18f6d82a20db"
      unitRef="usd">28500000</pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration>
    <pcrx:ContingentConsideration
      contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyMDc0_58ef2319-fca9-4a7d-a0bb-3d464ac0680e"
      unitRef="usd">100000000</pcrx:ContingentConsideration>
    <pcrx:ContingentConsiderationCurrent
      contextRef="i18f0515519fd468ea2893c1d1449bb1e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyMTU3_d3c591bd-a30b-40dd-849e-0b43212ccf85"
      unitRef="usd">43000000</pcrx:ContingentConsiderationCurrent>
    <pcrx:ContingentConsiderationPaymentTerm
      contextRef="i47f4eb49ec8441a9b58dbd98a28a2201_D20190409-20190409"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyMzQ1_a677ffa9-9705-4e4d-88cc-b7c6124871e1">P60D</pcrx:ContingentConsiderationPaymentTerm>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic017681e6bcd4a53adcb05dba9e3ceea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTM0OTUy_33a7f606-6f00-4ae0-a6e6-e999780d5ba7"
      unitRef="usd">12000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i36eb9081f8f347b192a76fc04c03d19e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyNDcx_0e0a625f-0b5c-4d00-b195-376ced319670"
      unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4ebc2eb0427e4bb0850c72962f7e29e3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTQvZnJhZzplNTI0YjA5ZWVmZGM0MzFmYmZjOThiMTY0MDIwNTI3NS90ZXh0cmVnaW9uOmU1MjRiMDllZWZkYzQzMWZiZmM5OGIxNjQwMjA1Mjc1XzExNTQ0ODcyMTMyNDc5_f2c43332-175a-4c6f-95b6-e93fbbe6296c"
      unitRef="usd">7000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90ZXh0cmVnaW9uOjRjYTM5MjM3NzcyMjRkN2ZiOTRlYTA3ZGNhMGViNGEzXzU4Ng_3a50ee90-f014-45b5-b93f-0fef62d11c11">INVENTORIES&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories, net are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90ZXh0cmVnaW9uOjRjYTM5MjM3NzcyMjRkN2ZiOTRlYTA3ZGNhMGViNGEzXzU5Mw_5f0e35c7-8af6-46eb-88a5-f0ce17afb701">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories, net are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzItMS0xLTEtMA_d433ff50-9407-4d25-9e8a-ef44838e4bba"
      unitRef="usd">36337000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzItMy0xLTEtMA_d2bc3753-79c2-4e99-8ece-20746f72dd75"
      unitRef="usd">26886000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzMtMS0xLTEtMA_7ec4d404-4392-4ca7-b5bc-4051db2a4cf5"
      unitRef="usd">35182000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzMtMy0xLTEtMA_f966a0e4-cdfd-4af8-a1b6-8cc28806d2d9"
      unitRef="usd">16266000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzQtMS0xLTEtMA_43dbcccc-3c32-4421-aa61-a06955e6be07"
      unitRef="usd">27031000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzQtMy0xLTEtMA_c7c995f2-bafa-43aa-8bbf-9bc5a95ad97a"
      unitRef="usd">21498000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzUtMS0xLTEtMA_8a8d38b6-5cc3-432b-96c3-da08ddb999c0"
      unitRef="usd">98550000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNTcvZnJhZzo0Y2EzOTIzNzc3MjI0ZDdmYjk0ZWEwN2RjYTBlYjRhMy90YWJsZTpmM2ZlNWYyN2I2YjA0NzcyOTYzMDU5NGM5MGIxM2FjZS90YWJsZXJhbmdlOmYzZmU1ZjI3YjZiMDQ3NzI5NjMwNTk0YzkwYjEzYWNlXzUtMy0xLTEtMA_b2f79065-15d2-4276-8f09-0515e71d26fd"
      unitRef="usd">64650000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzExMTg_a9394f6f-f6dd-4935-98e2-e67accd38add">FIXED ASSETS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets, net, summarized by major category, consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For information on useful lives by asset category, refer to Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2021, 2020 and 2019 was $15.0&#160;million, $12.0 million and $14.0 million, respectively. During the years ended December&#160;31, 2021, 2020 and 2019, the Company capitalized interest of $3.9 million, $2.4 million and less than $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021&#160;and&#160;2020, total fixed assets, net, includes leasehold improvements and manufacturing process equipment located outside of the U.S. in the amount of $65.4 million and $67.5 million, respectively.&lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2021 and 2020, the Company had AROs of $2.4 million and $2.0 million, respectively, included in accrued expenses and other liabilities on its consolidated balance sheet, for costs associated with returning leased space to its original condition upon the termination of certain lease agreements.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3d3ab2a481794a02a175b6f16b61f237_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzItMS0xLTEtMA_2d05fa4e-bc6c-4a3f-8f04-11662be36f16"
      unitRef="usd">117264000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if6c2512b823f4ff3b209636ae4dcafac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzItMy0xLTEtMA_c78178d3-5c75-411f-ac88-a14dfb10df2d"
      unitRef="usd">74966000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8eb5b42525974ef7a5b153a0d9d0073d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzMtMS0xLTEtMA_843fc739-a36f-43da-b298-5758b862aec6"
      unitRef="usd">59740000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9863c66e56824ed29ccd21bb3ceabb02_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzMtMy0xLTEtMA_50521e4f-af4c-416a-bfbe-422fceb305ed"
      unitRef="usd">54434000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia90f8785504d43449257cd196f4121b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzQtMS0xLTEtMA_8eb26e72-a3b0-4e14-8853-461f7131f735"
      unitRef="usd">13197000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i226f17bf85d347659a1ecbbcad647fc7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzQtMy0xLTEtMA_def9d2c1-4b8d-4265-8ef1-aced1d5aeca4"
      unitRef="usd">12170000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i237836ce0fbe43459715133f0ac3bbcb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzUtMS0xLTEtMA_063a28f0-78c1-45c1-9d61-535a38f03315"
      unitRef="usd">2883000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i77820b7ad1054da597cf88e94c1572ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzUtMy0xLTEtMA_82b80d48-2adb-4580-8ef1-d1304ce8d7fe"
      unitRef="usd">2387000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i87a8c9c388f348728c52ecd109ff1575_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzYtMS0xLTEtMA_0e1f33e2-8f55-43bb-bca9-dd8ef868ab15"
      unitRef="usd">80557000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9dcb927188d04ed7a4fc660309e24cb6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzYtMy0xLTEtMA_ec006727-0e49-4c99-9f9f-15c05241c776"
      unitRef="usd">71091000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzctMS0xLTEtMA_27f4aec6-a746-4c32-bfde-5cb9b7f293a3"
      unitRef="usd">273641000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzctMy0xLTEtMA_67b1af6c-dea5-4b88-9f61-2d0304ab181d"
      unitRef="usd">215048000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzgtMS0xLTEtMA_560e461e-0ecf-4611-b4ca-a3131d1fe71b"
      unitRef="usd">85240000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzgtMy0xLTEtMA_8b01fdc1-40e3-4d04-97a7-1b8dc3717336"
      unitRef="usd">78360000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzktMS0xLTEtMA_1d42ba3d-f1ee-45d5-a301-5bdb97b54409"
      unitRef="usd">188401000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90YWJsZTo5OThjOTc4MWYyZDA0YjcxOWNmZDkxOGY1Y2E3M2UxOS90YWJsZXJhbmdlOjk5OGM5NzgxZjJkMDRiNzE5Y2ZkOTE4ZjVjYTczZTE5XzktMy0xLTEtMA_55df09a4-0e59-4ae2-856c-8b1377e03e2c"
      unitRef="usd">136688000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzEyMDk0NjI3OTA4NzI1_4f040d19-9005-47ce-8363-724b73c69054"
      unitRef="usd">15000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzI5Mg_cfed417a-9779-4797-881f-1c25199e269e"
      unitRef="usd">12000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzI5OQ_374f6f2b-3cb3-4978-92f7-f18d8ab5c798"
      unitRef="usd">14000000</us-gaap:Depreciation>
    <us-gaap:InterestCostsCapitalized
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzM5MQ_57c3dee1-65a4-4901-b246-2ae75329af2d"
      unitRef="usd">3900000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzQwNQ_24e55c1f-7b3e-4f7d-9a9e-44ebce2f65ee"
      unitRef="usd">2400000</us-gaap:InterestCostsCapitalized>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7b2e96dbe6ff49688146016bf2c6b677_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzU3NQ_fea60f97-f844-4d19-82a9-d98682729e07"
      unitRef="usd">65400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9a79447216ec4d1fbb7c60937d2de629_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzU4Mg_6928a8fc-5152-452b-a548-b3a09ee98b55"
      unitRef="usd">67500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetRetirementObligation
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzY0MQ_1716f9cf-60d0-422b-bce7-45597913351d"
      unitRef="usd">2400000</us-gaap:AssetRetirementObligation>
    <us-gaap:AssetRetirementObligation
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjAvZnJhZzplYmY0YjM4Yzk0OTE0MDM0ODg1Njc3ZjBmZjUyOTViNi90ZXh0cmVnaW9uOmViZjRiMzhjOTQ5MTQwMzQ4ODU2NzdmMGZmNTI5NWI2XzY0OA_a12f619d-ca55-489a-895e-380266ed9bb7"
      unitRef="usd">2000000</us-gaap:AssetRetirementObligation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzE2MDI_f23235dc-2a92-4ea1-9041-28118f21cc1c">LEASESThe Company leases all of its facilities, including its EXPAREL manufacturing facility in San Diego, California and its iovera&#xb0; manufacturing facility in Fremont, California. These leases have remaining terms up to 8.7 years, some of which provide renewal options at the then-current market value. The Company also has an embedded lease with Thermo Fisher Scientific Pharma Services for the use of their manufacturing facility in Swindon, England. A portion of the associated monthly base fees has been allocated to the lease component based on a relative fair value basis. As a result of the Flexion Acquisition, the Company recorded new operating lease liabilities of $6.6&#160;million arising from obtaining ROU lease assets for three locations.&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease costs are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Lease Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease liabilities, net of lease incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets recorded in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to net the amortization of the ROU asset and the reduction of the lease liability principal in other liabilities in the consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.77 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.18 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.87%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, maturities of the Company&#x2019;s operating lease liabilities are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Payments Due&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i379f934d2a6348d0aa120e522eb186cb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzIzNA_832ffe35-f3e9-49ce-86d1-a464c52fcb01">P8Y8M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseLiability
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzE0MjkzNjUxMTYzNTMw_1fa3a912-bb32-4f0c-a18d-494ddbdbf577"
      unitRef="usd">6600000</us-gaap:OperatingLeaseLiability>
    <pcrx:NumberOfLocationsNewOperatingLeaseLiability
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzcxNDY4MjU1ODMzNDY_940bac01-4746-45cc-a516-26c494951583"
      unitRef="location">3</pcrx:NumberOfLocationsNewOperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzE2MDM_7c3603d4-9647-4b80-8a7a-3357d70c9ab3">Total operating lease costs are as follows (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Lease Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to operating leases is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease liabilities, net of lease incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets recorded in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted average remaining lease term and the weighted average discount rate are summarized as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.77 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.18 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.87%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzItMi0xLTEtMA_fd16c6f1-dc78-42b1-8013-1fefb117dc23"
      unitRef="usd">11976000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzItNC0xLTEtMA_0f7be6ea-55ca-4ad3-8db2-b47fc27c89a3"
      unitRef="usd">10055000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzItNi0xLTEtMA_81412e44-18bc-4651-876e-1d234dfe3fab"
      unitRef="usd">6225000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzMtMi0xLTEtMA_ff54b213-63b3-49e4-bbe7-0ee7b1bdfb10"
      unitRef="usd">1722000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzMtNC0xLTEtMA_730dfcaa-b22c-4c2f-a7bf-513bbb959381"
      unitRef="usd">2096000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzMtNi0xLTEtMA_cdc3ef03-36f2-4202-acb3-a568368f10c5"
      unitRef="usd">1651000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzQtMi0xLTEtMA_7cb38841-f0ae-47fc-99d7-d3ec22480636"
      unitRef="usd">13698000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzQtNC0xLTEtMA_87f3ef99-48a5-415c-965a-9690a4c0492d"
      unitRef="usd">12151000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToyOWEwMzRiYTY4Nzk0NTBkYmNhNTNmNTc4YjQ1Mzk5ZS90YWJsZXJhbmdlOjI5YTAzNGJhNjg3OTQ1MGRiY2E1M2Y1NzhiNDUzOTllXzQtNi0xLTEtMA_ae75fc0d-8aa2-4d1c-944c-1a4bb4f9e5f9"
      unitRef="usd">7876000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzItMi0xLTEtMA_109ef761-abe8-4a13-ba01-1419f9dbfade"
      unitRef="usd">12709000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzItNC0xLTEtMA_2f6e0dd7-b055-46eb-8f72-ad504f3d1c3f"
      unitRef="usd">14347000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzItNi0xLTEtMjgwMjA_85287be3-312b-4163-b0fa-56c1118c5ff1"
      unitRef="usd">7346000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzMtMi0xLTEtMA_4b614c4a-a273-4806-942e-e8da40636616"
      unitRef="usd">8692000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzMtNC0xLTEtMA_cc96e7f7-7e37-467d-8087-6b441fa7413d"
      unitRef="usd">42191000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTowOGI4ZTQyYmQ3MDM0NjYwYWZiZmM0ZjM5NjNkNjVlMC90YWJsZXJhbmdlOjA4YjhlNDJiZDcwMzQ2NjBhZmJmYzRmMzk2M2Q2NWUwXzMtNi0xLTEtMjgwMjA_22ac5a37-264b-49c3-9bfb-d23d59562f98"
      unitRef="usd">41605000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTo1Yjg2MTY4NTliZDk0NWNlYTQwYTM5ZmVhZjdmMGM3Yi90YWJsZXJhbmdlOjViODYxNjg1OWJkOTQ1Y2VhNDBhMzlmZWFmN2YwYzdiXzItMi0xLTEtMA_9a2841cb-96cc-4ab5-8360-89230393720f">P7Y9M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTo1Yjg2MTY4NTliZDk0NWNlYTQwYTM5ZmVhZjdmMGM3Yi90YWJsZXJhbmdlOjViODYxNjg1OWJkOTQ1Y2VhNDBhMzlmZWFmN2YwYzdiXzItNC0xLTEtMA_8e9cfc80-13ff-47cd-bb79-d05905a994e9">P9Y2M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTo1Yjg2MTY4NTliZDk0NWNlYTQwYTM5ZmVhZjdmMGM3Yi90YWJsZXJhbmdlOjViODYxNjg1OWJkOTQ1Y2VhNDBhMzlmZWFmN2YwYzdiXzMtMi0xLTEtMA_ec98642c-19df-4a15-b601-03ffc918467e"
      unitRef="number">0.0696</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZTo1Yjg2MTY4NTliZDk0NWNlYTQwYTM5ZmVhZjdmMGM3Yi90YWJsZXJhbmdlOjViODYxNjg1OWJkOTQ1Y2VhNDBhMzlmZWFmN2YwYzdiXzMtNC0xLTEtMA_04e68910-d6cc-4b74-b0d9-fd6c8d57d0c3"
      unitRef="number">0.0687</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90ZXh0cmVnaW9uOmI5YzlkMjg1MjkzNzQ3ZmU4N2I0MWZkOWEyZTVhNzA0XzE2MDY_83cc1299-76e0-44bd-b66e-2398300bafcc">&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, maturities of the Company&#x2019;s operating lease liabilities are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Payments Due&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzEtMi0xLTEtMA_cfcb1e5d-6a23-44c2-99be-e55f1f4d54a6"
      unitRef="usd">13171000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzItMi0xLTEtMA_35b0961d-611a-4a3f-8f9f-cd827e14305e"
      unitRef="usd">13292000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzMtMi0xLTEtMA_1d51b141-81d1-4782-9246-7a9f779f34b0"
      unitRef="usd">13422000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzQtMi0xLTEtMA_825e26da-6071-4064-a3a7-ef2109a7feb2"
      unitRef="usd">12561000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzUtMi0xLTEtMA_ec743647-6aba-4499-bfd3-8923c0d7cc05"
      unitRef="usd">12296000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzYtMi0xLTEtMA_5f68ae82-67d8-45c2-a708-4d473bf67a95"
      unitRef="usd">39423000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzctMi0xLTEtMA_78181bc2-11c5-4eb9-b88a-1a05931236ed"
      unitRef="usd">104165000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzktMi0xLTEtMA_7f11f4b2-8eac-448e-b684-4059be28b0b2"
      unitRef="usd">24547000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjMvZnJhZzpiOWM5ZDI4NTI5Mzc0N2ZlODdiNDFmZDlhMmU1YTcwNC90YWJsZToxOTE5NzI1NjFlYjA0ZWRmOWQyZGNkMDg1ZGY0MDIwYy90YWJsZXJhbmdlOjE5MTk3MjU2MWViMDRlZGY5ZDJkY2QwODVkZjQwMjBjXzEwLTItMS0xLTA_6b5d1573-b960-4030-a49b-c8098c408984"
      unitRef="usd">79618000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIyNTA_e8408a7b-5e16-4c99-998a-728b30951438">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s goodwill results from the acquisition of Pacira Pharmaceuticals, Inc. from SkyePharma Holding, Inc. (now a subsidiary of Vectura Group plc), or Skyepharma in 2007 (the &#x201c;Skyepharma Acquisition&#x201d;), the MyoScience Acquisition in 2019 and the Flexion Acquisition in 2021. The change in the carrying value of the Company&#x2019;s goodwill is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 accumulated adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill arising from milestones achieved under the Skyepharma Acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill arising from the Flexion Acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Skyepharma Acquisition was accounted for under Statement of Financial Accounting Standards 141, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was the effective GAAP standard at the date of acquisition. In connection with the Skyepharma Acquisition, the Company agreed to certain milestone payments for DepoBupivacaine products, including EXPAREL. In the fourth quarter of 2021, the Company met both of its two remaining milestones due to Skyepharma: $4.0 million upon the first commercial sale in the U.K., France, Germany, Italy or Spain which was paid in the fourth quarter of 2021; and $32.0 million when annual net sales collected reached $500.0 million, which was paid in the first quarter of 2022. These milestone payments were treated as additions to the Skyepharma Acquisition and, therefore, recorded as goodwill. The Company made a tax election that allows the acquired goodwill and intangible assets associated with the MyoScience Acquisition to be tax deductible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Flexion Acquisition, the Company recorded goodwill totaling $9.6&#160;million. The acquired goodwill and intangible assets are currently not deductible for tax purposes. However, the Company is considering certain tax elections that would allow for the future deduction of acquired goodwill and intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net, consist of the IPR&amp;amp;D and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible&lt;br/&gt;Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average &lt;br/&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years, 5 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible&lt;br/&gt;Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average &lt;br/&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense on intangible assets for the years ended December&#160;31, 2021 and 2020 was $13.6 million and $7.9 million, respectively. Assuming no changes in the gross carrying amount of these intangible assets, the future estimated &lt;/span&gt;&lt;/div&gt;amortization expense on the finite-lived intangible assets will be $57.4&#160;million through 2028, $57.3&#160;million in 2029 and 2030, $36.9&#160;million in 2031, $7.9&#160;million in 2032 and $2.2&#160;million in 2033.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIyNDU_c3cf0cf1-e115-4543-a7b0-5d3e3d4c29b6">The change in the carrying value of the Company&#x2019;s goodwill is summarized as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 accumulated adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill arising from milestones achieved under the Skyepharma Acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill arising from the Flexion Acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzMtMi0xLTEtMA_d303f97e-4716-4ae5-bdcd-0d315934aeb8"
      unitRef="usd">99547000</us-gaap:Goodwill>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzQtMi0xLTEtMA_8327a564-d977-489c-8c8e-563bb6ad61d5"
      unitRef="usd">0</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzUtMi0xLTEtMA_c2af3114-2c4e-4220-966a-bdb022a452e0"
      unitRef="usd">99547000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib93d52bc0a2448159425d955a92ad1b3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzQtMi0xLTEtNDg5MTM_689822ce-8751-4d3d-a875-c1a9e79cdf37"
      unitRef="usd">36000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzYtMi0xLTEtMA_a635956f-925b-4f89-a120-eb3cc72392b9"
      unitRef="usd">9628000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplZTc3MTIxNjQwMDU0YjQzOGZkNTIyMGVhMzcyMDU5OC90YWJsZXJhbmdlOmVlNzcxMjE2NDAwNTRiNDM4ZmQ1MjIwZWEzNzIwNTk4XzctMi0xLTEtMA_416223ea-0ec0-441c-bfd4-4deab3371168"
      unitRef="usd">145175000</us-gaap:Goodwill>
    <pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition
      contextRef="id5476241970e4bc8a69aaac752a07c87_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzgyMQ_21c7ce82-09e5-41b3-9c43-9d9762302b68"
      unitRef="usd">4000000</pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition>
    <pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition
      contextRef="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzkxNQ_978c81a3-cf5d-4329-96c3-ecd6afeef23a"
      unitRef="usd">32000000</pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition>
    <pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition
      contextRef="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0Xzk1Ng_959041a7-c397-447f-8f1c-88fc29eeba4c"
      unitRef="usd">500000000</pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition>
    <us-gaap:Goodwill
      contextRef="id7ad81457b8d40ec98c994382d3d81b3_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzEzMTk0MTM5NTQwMzYw_303ac9c3-75a4-4a80-b37f-fbef3cd35e4a"
      unitRef="usd">9600000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIyNTI_a3635b39-8b4a-4aa2-94fb-6345391cc20b">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net, consist of the IPR&amp;amp;D and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible&lt;br/&gt;Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average &lt;br/&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years, 5 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible&lt;br/&gt;Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average &lt;br/&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i616ccf441438422f96ae7988c62ac2d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEtMi0xLTEtMjY0MTA_779b37d7-2754-4d5e-8a71-5372b5c69ca5"
      unitRef="usd">590000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i616ccf441438422f96ae7988c62ac2d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEtNC0xLTEtMjY0MTA_65a37386-f5be-4b6d-8257-84b1d6b88ad4"
      unitRef="usd">27097000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i616ccf441438422f96ae7988c62ac2d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEtNi0xLTEtMjY0MTA_a8f2af03-4808-47af-90a7-85c548c49cc6"
      unitRef="usd">562903000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib0432a62d54346d4b0cc4ae20df8f3ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEtOC0xLTEtMjY0MTA_a195b9a3-24ae-4d9a-9c96-ec0dd69c2170">P10Y5M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i50f0a34fc053410586063c1b4fb4c582_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzItMi0xLTEtMjY0MTA_e9669f39-a714-4d6e-941c-4ee3fffe6473"
      unitRef="usd">90000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i50f0a34fc053410586063c1b4fb4c582_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzItNC0xLTEtMjY0MTA_d9da8e4d-45bd-45b8-9dbf-53691b01187f"
      unitRef="usd">25000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i50f0a34fc053410586063c1b4fb4c582_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzItNi0xLTEtMjY0MTA_00e16a23-1252-47e9-bde0-4da2fa814ebf"
      unitRef="usd">65000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if5ae07bdfce9402a9e491efa689e082a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzItOC0xLTEtMjY0MTA_5f562c0b-7d37-4315-a471-c5a58df0c0dc">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzMtMi0xLTEtMjY0MTA_24179817-cc98-4478-9a65-d3da9783271d"
      unitRef="usd">590090000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzMtNC0xLTEtMjY0MTA_0c38439c-e9bd-4da7-83b0-1cb9b6d12a8b"
      unitRef="usd">27122000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzMtNi0xLTEtMjY0MTA_d623c91b-1b73-4225-8d72-89582e3411eb"
      unitRef="usd">562968000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i893f93318f184b3b845f1b842931685c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzQtMi0xLTEtMjY0MTA_21044c03-02b5-476f-a2c2-717ae8b06dc9"
      unitRef="usd">61000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i893f93318f184b3b845f1b842931685c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzQtNi0xLTEtMjY0MTA_68d3f133-8648-4606-943c-04e5844a935c"
      unitRef="usd">61000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzUtMi0xLTEtMjY0MTA_3d276c45-ddeb-436d-86fc-c098a1975ff9"
      unitRef="usd">651090000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzUtNC0xLTEtMjY0MTA_b4d8fc8d-9fd7-4fbb-96ae-4912920ed954"
      unitRef="usd">27122000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzUtNi0xLTEtMjY0MTA_4bc2e97e-47d3-45fd-bb0a-4ea8cf365393"
      unitRef="usd">623968000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ied35346c8e384819b7401a314ca21029_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEwLTItMS0xLTI2NDEw_399576a8-1a82-4c98-8ff2-334aa5804fc8"
      unitRef="usd">110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ied35346c8e384819b7401a314ca21029_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEwLTQtMS0xLTI2NDEw_9b05a399-67ec-44c6-b922-b9ec1171605b"
      unitRef="usd">13553000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ied35346c8e384819b7401a314ca21029_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEwLTYtMS0xLTI2NDEw_4f2d2ab6-7383-41a8-82c3-ab5a8794cd95"
      unitRef="usd">96447000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie7b03b72e8eb425dac2c21da48a1406e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEwLTgtMS0xLTI2NDEw_93849fa0-2ee2-4961-b7db-b3fa7e29ee97">P14Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9117c0cf9ab9426eb1181bbfdab3c069_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzExLTItMS0xLTI2NDEw_c7e69050-8855-4c42-ac19-2834ca88db37"
      unitRef="usd">90000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9117c0cf9ab9426eb1181bbfdab3c069_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzExLTQtMS0xLTI2NDEw_d4359292-7df6-4a45-a6c8-1687e6e6120e"
      unitRef="usd">16000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9117c0cf9ab9426eb1181bbfdab3c069_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzExLTYtMS0xLTI2NDEw_62f7cace-10c8-4f34-a4c3-6f5e90fa037a"
      unitRef="usd">74000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i2aa9720883ec4f3787f93c48c11dae98_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzExLTgtMS0xLTI2NDEw_2d926d12-0808-46a7-8261-784e29ee5611">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEyLTItMS0xLTI2NDEw_aee4b0db-1f76-4ead-917e-47f9c0d18afa"
      unitRef="usd">110090000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEyLTQtMS0xLTI2NDEw_d6b621f8-b492-4ca2-91fd-0685e36356d7"
      unitRef="usd">13569000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90YWJsZTplOWJmNWYzODllOTM0NTkzYWEzYWU5N2E0NzA3MmMwNy90YWJsZXJhbmdlOmU5YmY1ZjM4OWU5MzQ1OTNhYTNhZTk3YTQ3MDcyYzA3XzEyLTYtMS0xLTI2NDEw_360ef478-ef1f-4cc7-b51c-b8758bea003c"
      unitRef="usd">96521000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIwMjY_b7776617-065e-44ef-9ca6-43e8d07087fe"
      unitRef="usd">13600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzIwMzM_9faa8088-7f0e-40af-a3a6-b7fb5a0c2418"
      unitRef="usd">7900000</us-gaap:AmortizationOfIntangibleAssets>
    <pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NDk2_c5c08bfd-6cbf-4bda-b576-bea82bcf11c3"
      unitRef="usd">57400000</pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1>
    <pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTEx_48666d0b-1b14-459e-9ccd-ee00a06b9a88"
      unitRef="usd">57300000</pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3>
    <pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTEx_7ceec1e9-4007-4b6c-9947-d532bfd9c8a2"
      unitRef="usd">57300000</pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2>
    <pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTI2_36efebec-8457-4eac-898e-5b9284de2c13"
      unitRef="usd">36900000</pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4>
    <pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTQx_4336f521-81fc-424a-bdc9-00ae30f97321"
      unitRef="usd">7900000</pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5>
    <pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjYvZnJhZzowNjEyZGE0MGY0MTk0Zjg3OWQ1OTVlMTliMWE4NjdmNC90ZXh0cmVnaW9uOjA2MTJkYTQwZjQxOTRmODc5ZDU5NWUxOWIxYTg2N2Y0XzExNTQ0ODcyMDk4NTU1_ffca26dc-b5aa-4b40-be32-fbbce288e716"
      unitRef="usd">2200000</pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90ZXh0cmVnaW9uOjY5NzhlMzkwYzZmYTQwY2JhOGJiZTNhNTY3MGY3MzI0Xzk1_79e7691c-0bc1-4cd6-b8db-faab6946bfce">ACCRUED EXPENSES&lt;div style="margin-bottom:8pt;margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and wholesaler service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1) At December 31, 2021, accrued royalties included a $32.0&#160;million milestone payment to Skyepharma that was met in the fourth quarter of 2021 for achieving annual net sales collected of $500.0 million on the Company&#x2019;s DepoBupivacaine products, including EXPAREL. This milestone was subsequently paid in the first quarter of 2022. See Note 9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;, for more information.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90ZXh0cmVnaW9uOjY5NzhlMzkwYzZmYTQwY2JhOGJiZTNhNTY3MGY3MzI0Xzky_38098a34-8462-47d6-9b32-c38a3608758d">&lt;div style="margin-bottom:8pt;margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and wholesaler service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pcrx:Accruedsellinggeneralandadministrativeexpenses
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzItMS0xLTEtMA_d9b40d3a-2680-4f65-bdb8-1169e4c791ef"
      unitRef="usd">12063000</pcrx:Accruedsellinggeneralandadministrativeexpenses>
    <pcrx:Accruedsellinggeneralandadministrativeexpenses
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzItMy0xLTEtMA_7a892e45-eadc-4b24-b4dc-d386824bb97a"
      unitRef="usd">23288000</pcrx:Accruedsellinggeneralandadministrativeexpenses>
    <pcrx:Accruedresearchanddevelopmentexpenses
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzMtMS0xLTEtMA_9d81bfe4-5324-44bd-9b98-53c4f6a5a26b"
      unitRef="usd">5480000</pcrx:Accruedresearchanddevelopmentexpenses>
    <pcrx:Accruedresearchanddevelopmentexpenses
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzMtMy0xLTEtMA_57a11a7a-a942-4ad5-bfd5-ba9da96895b1"
      unitRef="usd">6682000</pcrx:Accruedresearchanddevelopmentexpenses>
    <pcrx:AccruedOperatingExpensesCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzQtMS0xLTEtMA_54950d2f-3ec4-4844-8cfc-c7ae8e773591"
      unitRef="usd">14912000</pcrx:AccruedOperatingExpensesCurrent>
    <pcrx:AccruedOperatingExpensesCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzQtMy0xLTEtMA_855f429a-36d4-4f5f-8adc-31877ff20ca8"
      unitRef="usd">11196000</pcrx:AccruedOperatingExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzUtMS0xLTEtMA_ad8b681f-ae42-4bbf-924b-a8164c79d9f9"
      unitRef="usd">45491000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzUtMy0xLTEtMA_e439e6b7-2fbf-41d5-b8e6-7fefa0342701"
      unitRef="usd">22202000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzYtMS0xLTEtMA_5a9bbd23-9f84-43ee-8eb5-f6608137eda5"
      unitRef="usd">35298000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzYtMy0xLTEtMA_900d88dd-b07a-4828-8557-6b37aa0add72"
      unitRef="usd">3040000</us-gaap:AccruedRoyaltiesCurrent>
    <pcrx:AccruedEndOfTermFeeCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzctMS0xLTEtMA_2bd2c0bc-8fb9-4546-b08b-d7759dac716e"
      unitRef="usd">5358000</pcrx:AccruedEndOfTermFeeCurrent>
    <pcrx:AccruedEndOfTermFeeCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzctMy0xLTEtMA_877e96fb-ed5a-40c7-afa7-07af5abbddda"
      unitRef="usd">2376000</pcrx:AccruedEndOfTermFeeCurrent>
    <pcrx:ProductReturnsRebatesandOtherFees
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzgtMS0xLTEtMA_6072fbcd-2207-4ca0-8d2e-2b46a4781681"
      unitRef="usd">8953000</pcrx:ProductReturnsRebatesandOtherFees>
    <pcrx:ProductReturnsRebatesandOtherFees
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzgtMy0xLTEtMA_96ad750b-029a-4389-ae57-b4ba6377f8a6"
      unitRef="usd">2190000</pcrx:ProductReturnsRebatesandOtherFees>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzktMS0xLTEtMA_416a3784-4b85-484b-bdf9-cddd24583ece"
      unitRef="usd">127555000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90YWJsZTozYjg0MWQ1Mzc2MzI0OGU4YmFkMDdmNDIxMjIxNDVlOC90YWJsZXJhbmdlOjNiODQxZDUzNzYzMjQ4ZThiYWQwN2Y0MjEyMjE0NWU4XzktMy0xLTEtMA_b4e47925-69db-4548-aee2-47a347c27624"
      unitRef="usd">70974000</us-gaap:AccruedLiabilitiesCurrent>
    <pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition
      contextRef="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90ZXh0cmVnaW9uOjY5NzhlMzkwYzZmYTQwY2JhOGJiZTNhNTY3MGY3MzI0XzQzOTgwNDY1MTE4MDE_75f46010-bedb-4509-b5ec-f96b2259772c"
      unitRef="usd">32000000</pcrx:AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition>
    <pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition
      contextRef="id91d1ee26b8d4ae3804c2c6c167cddbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNjkvZnJhZzo2OTc4ZTM5MGM2ZmE0MGNiYThiYmUzYTU2NzBmNzMyNC90ZXh0cmVnaW9uOjY5NzhlMzkwYzZmYTQwY2JhOGJiZTNhNTY3MGY3MzI0XzE2NDkyNjc0NDMyOTU_959041a7-c397-447f-8f1c-88fc29eeba4c"
      unitRef="usd">500000000</pcrx:AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MzY3_279db591-fd67-4960-ab3c-53c677c5538d">DEBT&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company&#x2019;s outstanding debt is summarized as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan B facility maturing December 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750% Convertible senior notes due August 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Convertible senior notes due May 2024 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.375% Convertible senior notes due April 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term Loan B Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2021, the Company entered into a term loan credit agreement (the &#x201c;Credit Agreement&#x201d;) with JP Morgan Chase Bank, N.A., as administrative agent and the initial lender. The term loan issued under the Credit Agreement (the &#x201c;Term Loan&#x201d;), which was issued at a 3% discount and allows for a single-advance term loan B facility in the principal amount of $375.0&#160;million, which is secured by substantially all of the Company&#x2019;s and each subsidiary guarantor&#x2019;s assets. Subject to certain conditions, the Company may, at any time, on one or more occasions, add one or more new classes of term facilities and/or increase the principal amount of the loans of any existing class by requesting one or more incremental term facilities. The net proceeds of the Term Loan were approximately $363.8&#160;million after deducting an original issue discount of $11.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total debt composition of the Term Loan is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan maturing December 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total debt, net of debt discount and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan matures on December 7, 2026 and requires quarterly repayments of principal in the amount of $9.4&#160;million. commencing June 30, 2022, and increasing to $14.1&#160;million commencing December 31, 2025, with a remaining balloon payment of approximately $188.0&#160;million due at maturity. During 2022, the Company will be required to make three &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;quarterly payments totaling $28.1&#160;million. The Company is also required to make mandatory prepayments of principal from (i) commencing with the fiscal year ending December 31, 2022, the Company&#x2019;s excess cash flow (as defined in the Credit Agreement) existing in any fiscal year and if the Senior Secured Leverage Ratio (as defined in the Credit Agreement) for such fiscal year exceeds certain predetermined limits (ii) net proceeds (as defined in the Credit Agreement) of non-ordinary course assets sales and casualty events and (iii) debt issuance proceeds (other than permitted debt under the Credit Agreement). No mandatory prepayments are due for 2021. Prepayment penalties for the Term Loan are 3% in loan year 1, 2% in loan year 2, 1% in loan year 3 and no prepayment penalties thereafter. Prepayment penalties generally do not apply to mandatory prepayment obligations under the Credit Agreement, such as prepayments due in connection with excess cash flow.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan requires the Company to, among other things, maintain (i) a first lien net leverage ratio, determined as of the last day of any fiscal quarter, of no greater than 1.75 to 1.00 and (ii) liquidity, at any time, of at least $150.0&#160;million. The Term Loan also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of December&#160;31, 2021, the Company was in compliance with all financial covenants under the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company may elect to borrow either term benchmark borrowings or alternate base rate borrowings. Term benchmark borrowings bear interest at a variable rate per annum equal to the Adjusted Term SOFR Rate (as defined in the Credit Agreement) (subject to a 75 basis points floor) plus an applicable margin of 700 basis points. Alternate base rate borrowings bear interest at a variable rate per annum determined using a base rate (subject to a 175 basis points floor) equal to the greatest of (i) Prime Rate (as defined in the Credit Agreement) in effect on such day, (ii) NYFRB Rate (as defined in the Credit Agreement) plus 50 basis points or (iii) the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 100 basis points, subject to certain exceptions, plus an applicable margin of 600 basis points. As of December 31, 2021, borrowings under the Term Loan consisted entirely of term benchmark borrowings at a rate of 7.75%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes Due 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company completed a private placement of $402.5&#160;million in aggregate principal amount of its 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture, or 2025 Indenture, with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per year, payable semiannually in arrears on February 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and August 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each year, beginning on February 1, 2021. The 2025 Notes mature on August 1, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total debt composition of the 2025 Notes is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750% Convertible senior notes due August 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net of debt discount and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds from the issuance of the 2025 Notes was approximately $390.0&#160;million, after deducting commissions and the offering expenses paid by the Company. A portion of the net proceeds from the 2025 Notes was used by the Company to repurchase $185.0&#160;million in aggregate principal amount of its outstanding 2.375% convertible senior notes due 2022 in privately negotiated transactions for a total of $211.1&#160;million of cash (including accrued interest).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert the 2025 Notes at any time prior to the close of business on the business day immediately preceding February 3, 2025, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the Company&#x2019;s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii) during the five-business day period immediately after any five consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price (as defined in the 2025 Indenture) per $1,000 principal amount of notes for each trading day &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the measurement period was less than 98% of the product of the last reported sale price of the Company&#x2019;s common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii) upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of the Company&#x2019;s assets; or&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv) if the Company calls the 2025 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after February 3, 2025, until the close of business on the second scheduled trading day immediately preceding August 1, 2025, holders may convert their 2025 Notes at any time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of these conditions for conversion were met during the quarter ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, holders will receive the principal amount of their 2025 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2025 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company&#x2019;s common stock or a combination of cash and shares of the Company&#x2019;s common stock, at the Company&#x2019;s option. The initial conversion rate for the 2025 Notes is 13.9324 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $71.78 per share of the Company&#x2019;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2025 Notes represents a premium of approximately 32.5% to the closing sale price of $54.17 per share of the Company&#x2019;s common stock on the Nasdaq Global Select Market on July 7, 2020, the date that the Company priced the private offering of the 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the 2025 Notes had a market price of $1,113 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the $402.5&#160;million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&#x2019;s option).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to August 1, 2023, the Company may not redeem the 2025 Notes. On or after August 1, 2023 (but, in the case of a redemption of less than all of the outstanding 2025 Notes, no later than the 40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; scheduled trading day immediately before the maturity date), the Company may redeem for cash all or part of the 2025 Notes if the last reported sale price (as defined in the 2025 Indenture) of the Company&#x2019;s common stock has been at least 130% of the conversion price then in effect for (i) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of redemption and (ii) the trading day immediately before the date the Company sends such notice. The redemption price will equal the sum of (i) 100% of the principal amount of the 2025 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2025 Notes for redemption will constitute a &#x201c;make-whole fundamental change&#x201d; (as defined in the 2025 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a fundamental change, as defined in the 2025 Indenture, subject to certain conditions, holders of the 2025 Notes may require the Company to repurchase for cash all or part of their 2025 Notes at a repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change occurs prior to August 1, 2025, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes are the Company&#x2019;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2025 Notes, and equal in right of payment to the Company&#x2019;s unsecured indebtedness. The 2025 Notes are also effectively junior in right of payment to any of the Company&#x2019;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to any debt or other liabilities (including trade payables) of the Company&#x2019;s subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the 2025 Notes are currently classified on the Company&#x2019;s consolidated balance sheet at December&#160;31, 2021 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company&#x2019;s common stock during the prescribed measurement periods. In the event that the holders of the 2025 Notes have the election to convert the 2025 Notes at any time during the prescribed measurement period, the 2025 Notes would then be considered a current obligation and classified as such.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 470-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt with Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2025 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#x2019;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $314.7&#160;million was calculated using a 5.78% assumed borrowing rate. The equity component of $87.8&#160;million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2025 Notes and is recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. The equity component is treated as a discount on the liability component of the 2025 Notes, which is amortized over the five-year term of the 2025 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. A deferred tax liability was recognized in the amount of $20.5&#160;million, with the offsetting amount recorded in additional paid-in capital. See Note 16,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for information regarding the Company&#x2019;s deferred taxes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the total transaction costs of approximately $12.5&#160;million related to the issuance of the 2025 Notes to the liability and equity components of the 2025 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the five-year term of the 2025 Notes, and transaction costs attributable to the equity component totaling $2.7 million are netted with the equity component in stockholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2025 Indenture contains customary events of default with respect to the 2025 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2025 Notes will automatically become due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes Due 2024 Assumed from the Flexion Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Flexion Acquisition, on May 2, 2017, Flexion issued an aggregate of $201.3&#160;million principal amount of 3.375% convertible senior notes due 2024 (the &#x201c;Flexion 2024 Notes&#x201d;), pursuant to the indenture, dated as of May 2, 2017 (the &#x201c;Original Flexion Indenture&#x201d;), between Flexion and Wells Fargo Bank, National Association, as trustee (the &#x201c;Flexion Trustee&#x201d;), as supplemented by the First Supplemental Indenture, dated as of November 19, 2021, between Flexion and the Flexion Trustee (the &#x201c;First Supplemental Flexion Indenture&#x201d; and, together with the Original Flexion Indenture, the &#x201c;Flexion Indenture&#x201d;). The Flexion 2024 Notes have a maturity date of May 1, 2024, are unsecured, and accrue interest at a rate of 3.375% per annum, payable semi-annually on May 1 and November 1 of each year. Upon the Flexion Acquisition, the principal was assumed and recorded at fair value by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion of the Flexion 2024 Notes, at the election of each holder thereof, each Flexion 2024 Note was convertible into cash, shares of Flexion&#x2019;s common stock, or a combination thereof, at Flexion&#x2019;s election, at a conversion rate of approximately 37.3413 shares of Flexion common stock per $1,000 principal amount of the Flexion 2024 Notes, which corresponded to an initial conversion price of approximately $26.78 per share of Flexion&#x2019;s common stock. As a result of the Flexion Acquisition, and in connection with the Notice (as defined below), holders of the Flexion 2024 Notes became entitled to certain Flexion Acquisition-related conversion and repurchase rights, as discussed below. In addition, as a result of the Flexion Acquisition and as discussed in more detail below, any future conversion rights are subject to the occurrence of any future events giving rise to such conversion rights under the Flexion Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 6, 2021, as a result of the Flexion Acquisition and in accordance with the Flexion Indenture, Flexion provided a Fundamental Change Company Notice and Offer to Purchase (the &#x201c;Notice&#x201d;) to the holders of the Flexion 2024 Notes and offered to repurchase for cash all of the outstanding Flexion 2024 Notes, at a repurchase price in cash equal to 100% of the principal amount of the Flexion 2024 Notes being repurchased, plus accrued and unpaid interest thereon to, but excluding, January 7, 2022, subject to the terms and conditions set forth therein. The offer to purchase expired at 5:00 p.m., New York City time, on January 6, 2022, as scheduled. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any holder that did not exercise its repurchase right in accordance with the terms of the Notice retained the conversion rights associated with such holder&#x2019;s Flexion 2024 Notes under the Flexion Indenture. For conversion of Flexion 2024 Notes in connection with the Fundamental Change and the Make-Whole Fundamental Change (each as defined in the Flexion Indenture) resulting from the Flexion Acquisition, each $1,000 principal amount of the Flexion 2024 Notes was convertible into (i) $317.40 in cash and (ii) 37.3413 CVRs, based on the conversion rate of 37.3413, prior to 5:00 p.m., New York City time, on January 7, 2022. Alternatively, holders could retain their Flexion 2024 Notes and such Flexion 2024 Notes would remain outstanding subject to their existing terms, including with respect to a holder&#x2019;s right to receive interest payments on the Flexion 2024 Notes and exercise any future conversion rights that may arise under the Flexion Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 7, 2022, following the expiration of the offer to purchase, the Company accepted the $192.6&#160;million aggregate principal amount of Flexion 2024 Notes that were validly tendered (and not validly withdrawn). No Flexion 2024 Notes were converted in connection with the Notice. The remaining principal outstanding is $8.6&#160;million as of the date of this report.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes Due 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company completed a private placement of $345.0 million in aggregate principal amount of 2.375% convertible senior notes due 2022, or 2022 Notes, and entered into an indenture, or 2022 Indenture, with respect to the 2022 Notes. The 2022 Notes accrue interest at a fixed rate of 2.375% per year, payable semiannually in arrears on April 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and October 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each year. The 2022 Notes mature on April 1, 2022. As discussed above, in July 2020, the Company used part of the net proceeds from the issuance of the 2025 Notes to repurchase $185.0&#160;million aggregate principal amount of the 2022 Notes in privately negotiated transactions for an aggregate of $211.1&#160;million in cash (including accrued interest). The partial repurchase of the 2022 Notes resulted in an $8.1&#160;million loss on early extinguishment of debt during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total debt composition of the 2022 Notes is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.375% Convertible senior notes due April 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net of debt discount and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2022 Notes at any time through the close of business on the second scheduled trading day immediately preceding April 1, 2022. Upon conversion, holders will receive the principal amount of their 2022 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2022 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company&#x2019;s common stock or a combination of cash and shares of the Company&#x2019;s common stock, at the Company&#x2019;s option. The initial conversion rate for the 2022 Notes is 14.9491 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $66.89 per share of the Company&#x2019;s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2022 Notes represents a premium of approximately 37.5% to the closing sale price of $48.65 per share of the Company&#x2019;s common stock on the Nasdaq Global Select Market on March 7, 2017, the date that the Company priced the private offering of the 2022 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the 2022 Notes had a market price of $1,039 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2022 Notes will be paid pursuant to the terms of the 2022 Indenture. In the event that all of the 2022 Notes are settled, the Company would be required to repay the remaining $160.0 million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company&#x2019;s option).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April 1, 2020, the Company may redeem for cash, shares of the Company&#x2019;s common stock or a combination of cash and shares of the Company&#x2019;s common stock, at the Company&#x2019;s option, all or part of the 2022 Notes if the last reported sale price (as defined in the 2022 Indenture) of the Company&#x2019;s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending within five &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;trading days prior to the date on which the Company provides notice of redemption. This condition was not met during the quarter ended December&#160;31, 2021. The redemption price will equal the sum of (i) 100% of the principal amount of the 2022 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2022 Notes for redemption will constitute a &#x201c;make-whole fundamental change&#x201d; (as defined in the 2022 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2022 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a fundamental change, as defined in the 2022 Indenture, subject to certain conditions, holders of the 2022 Notes may require the Company to repurchase for cash all or part of their 2022 Notes at a repurchase price equal to 100% of the principal amount of the 2022 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change occurs prior to April 1, 2022, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Notes are the Company&#x2019;s general unsecured obligations that rank senior in right of payment to all of its indebtedness that is expressly subordinated in right of payment to the 2022 Notes, and equal in right of payment to the Company&#x2019;s unsecured indebtedness. The 2022 Notes are also effectively junior in right of payment to any of the Company&#x2019;s secured indebtedness to the extent of the value of the assets securing such indebtedness, and are structurally subordinated to any debt or other liabilities (trade payables) of the Company&#x2019;s subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 470-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt with Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, an entity must separately account for the liability and equity components of convertible debt instruments (such as the 2022 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#x2019;s economic interest cost. The liability component of the instrument is valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $274.1 million was calculated using a 7.45% assumed borrowing rate. The equity component of $70.9 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2022 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2022 Notes, which is amortized over the five-year term of the 2022 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the total transaction costs of $11.0 million related to the issuance of the 2022 Notes to the liability and equity components of the 2022 Notes based on their relative values. Transaction costs attributable to the liability component are amortized to interest expense over the five-year term of the 2022 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. The 2022 Indenture contains customary events of default with respect to the 2022 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2022 Notes will automatically become due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual and other interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized interest (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate on total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3NTMzNTA_4c7cf203-c3cf-403d-9772-6305eaba7e75">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company&#x2019;s outstanding debt is summarized as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan B facility maturing December 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750% Convertible senior notes due August 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Convertible senior notes due May 2024 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.375% Convertible senior notes due April 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzEtMS0xLTEtMzMwMzE_014237fc-079f-4abe-a095-171f5c9ede7d"
      unitRef="usd">359497000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if02d7f7d8ef346e095ed28b213a41443_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzEtMy0xLTEtMzMwMzE_e4cb5946-5292-4129-be3b-4c81a5e9488c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i029b2fd1da9b426aa281eb6edf9c4164_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzMtMC0xLTEtMzMwMzEvdGV4dHJlZ2lvbjo3OTkxNThmZmJjMjI0NWRkYmI0ODAxNDA5YTAyODdjN18xNjQ5MjY3NDQxNzIx_60e9839d-a2e6-485f-9edb-a616aa4762d2"
      unitRef="number">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzMtMS0xLTEtMzMwMzE_4be2f9b7-c49c-4530-9425-c6c3a2a7fc12"
      unitRef="usd">330627000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzMtMy0xLTEtMzMwMzE_78df11ad-79e7-4109-b583-9e5bb6cb249d"
      unitRef="usd">313030000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id0a522e9d6934acc9765ff247056057b_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzQtMC0xLTEtMzMwMzEvdGV4dHJlZ2lvbjpkMjNmMzVhNTRkNzE0NDkxYmFlNzYyZGNjYjMwYzc5MV8xNjQ5MjY3NDQxNzQ0_b46fe979-da29-45e1-9fee-9e33277210f3"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i438cb9109aec4c73bc3f0bbdd10be313_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzQtMS0xLTEtMzMwMzE_3ae2e70b-5aec-4f14-99bf-746e110741a1"
      unitRef="usd">201249000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i531cf89254884fafb25ee2779d786c28_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzQtMy0xLTEtMzMwMzE_afe0eeee-9404-46fc-a582-bc7db64b8c27"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50f3b14c8eb24f87b8db39c9626146de_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzYtMC0xLTEtNTM0MzIvdGV4dHJlZ2lvbjo5YzhhMTcxMmQzYWQ0NjUwOWZkZTk3YjM1Y2Q0YjBlMF8xNjQ5MjY3NDQxNzIw_6f8800f7-84ea-4cd3-a70e-41de4abb0020"
      unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzYtMS0xLTEtNTM0MzI_37f2ca1c-c36b-4448-ac37-c2d9fd49af3b"
      unitRef="usd">157857000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzYtMy0xLTEtNTM0MzI_0416366b-6202-49eb-94c0-e7aec64ddee9"
      unitRef="usd">149648000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5ca63f94b05a4f70aa9157c96a600b08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzUtMS0xLTEtMzMwMzE_cf67553c-b12a-40d6-a14f-216517deb66e"
      unitRef="usd">1049230000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i693f123fe4684339ab826c50fedd6ad7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxNDIzMWQ0ZTk4MGQ0MDQ5Yjc2ODBhMjQwYWQ5ZDY4ZC90YWJsZXJhbmdlOjE0MjMxZDRlOTgwZDQwNDliNzY4MGEyNDBhZDlkNjhkXzUtMy0xLTEtMzMwMzE_519439e6-b2c1-4756-a55c-84dcabfd5845"
      unitRef="usd">462678000</us-gaap:LongTermDebt>
    <pcrx:DebtInstrumentDiscountRate
      contextRef="i948cac0513e648dca715d8b2e62ccb32_I20211207"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5MjU_b821852b-1e9c-4c43-9d1c-4a39e9316ee9"
      unitRef="number">0.03</pcrx:DebtInstrumentDiscountRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i948cac0513e648dca715d8b2e62ccb32_I20211207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTc2NTQz_e61c8336-0c36-450a-ae13-255fc9baf4b9"
      unitRef="usd">375000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i9859fe995b1b42efbfc4b581a85bb092_D20211207-20211207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTc2NzE3_f102ff88-3d89-4198-9817-3eb77db59dda"
      unitRef="usd">363800000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i948cac0513e648dca715d8b2e62ccb32_I20211207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTc2NzYx_9bdc13c5-8e1b-4873-8575-caed3cdacce9"
      unitRef="usd">11200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3NzYzNzY_eaaaa060-298f-46ad-a668-66449ad2a216">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total debt composition of the Term Loan is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan maturing December 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total debt, net of debt discount and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total debt composition of the 2025 Notes is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750% Convertible senior notes due August 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net of debt discount and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total debt composition of the 2022 Notes is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.375% Convertible senior notes due April 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net of debt discount and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkM2E3NTgwMzMxMzE0ZDljYTUzZDBjYjU3MTJkYTVmNi90YWJsZXJhbmdlOmQzYTc1ODAzMzEzMTRkOWNhNTNkMGNiNTcxMmRhNWY2XzItMS0xLTEtNTgwODc_8b32de92-0e4e-420b-bd86-faba9bc7c8c8"
      unitRef="usd">375000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkM2E3NTgwMzMxMzE0ZDljYTUzZDBjYjU3MTJkYTVmNi90YWJsZXJhbmdlOmQzYTc1ODAzMzEzMTRkOWNhNTNkMGNiNTcxMmRhNWY2XzMtMS0xLTEtNTgwODc_70a53352-2e39-4ee9-90ac-0e9282920578"
      unitRef="usd">4443000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkM2E3NTgwMzMxMzE0ZDljYTUzZDBjYjU3MTJkYTVmNi90YWJsZXJhbmdlOmQzYTc1ODAzMzEzMTRkOWNhNTNkMGNiNTcxMmRhNWY2XzQtMS0xLTEtNTgwODc_872cb0e8-d106-4228-89bb-6d60de3a327b"
      unitRef="usd">11060000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="i88aa5ae3e1d54fdaaa742808efec69b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkM2E3NTgwMzMxMzE0ZDljYTUzZDBjYjU3MTJkYTVmNi90YWJsZXJhbmdlOmQzYTc1ODAzMzEzMTRkOWNhNTNkMGNiNTcxMmRhNWY2XzUtMS0xLTEtNTQ2Njk_014237fc-079f-4abe-a095-171f5c9ede7d"
      unitRef="usd">359497000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="iae2b3e809f41477ea25d6594d89a6967_D20220630-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MTU0_ad3b7803-5541-4e37-b70b-ae8a01aa825f"
      unitRef="usd">9400000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="ia39c7c0a086e4f0b8a4d0984865174c0_D20251231-20251231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MTY4_d5c26865-3954-4f29-81ba-e42ca1fd60d0"
      unitRef="usd">14100000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="i9ad5e620d8a44d559404a2918c7529ee_I20261207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MTgz_23ab7fee-6588-4e69-8df3-58333a7c0b34"
      unitRef="usd">188000000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <pcrx:DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear
      contextRef="iaaf747e09ae34640bae22f200d713217_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA4MDI0MjU_839bf3ee-3621-46a9-b0d0-92abe9ea1d1f"
      unitRef="payment">3</pcrx:DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="i3c7058bed2db4a56b3c7e5e12b92460d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MTk3_b68ff39f-4aef-4f5a-adfd-7f68fd83a8dc"
      unitRef="usd">28100000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <pcrx:DebtInstrumentPrepaymentPenaltyPercentYear1
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5Mjk_8fbf7de0-dcd1-467d-bf01-cc08c9a3579b"
      unitRef="number">0.03</pcrx:DebtInstrumentPrepaymentPenaltyPercentYear1>
    <pcrx:DebtInstrumentPrepaymentPenaltyPercentYear2
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5MzM_deba1c94-c5f0-48f7-9185-3f4784cc494b"
      unitRef="number">0.02</pcrx:DebtInstrumentPrepaymentPenaltyPercentYear2>
    <pcrx:DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5Mzc_d9fc7c49-5e5d-4345-815b-b05fb3f6354d"
      unitRef="number">0.01</pcrx:DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter>
    <pcrx:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="i7747ee53e646437988e64e05cfd00fdd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MjM3_0960647a-6458-4a07-8d22-73eb3b98cc74"
      unitRef="number">1.75</pcrx:DebtInstrumentCovenantLeverageRatioMaximum>
    <pcrx:DebtInstrumentCovenantLeverageRatioMaximumValue
      contextRef="i7747ee53e646437988e64e05cfd00fdd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTg5MjI4_a54042d3-3120-48c4-a857-60b85fff329c"
      unitRef="usd">150000000</pcrx:DebtInstrumentCovenantLeverageRatioMaximumValue>
    <pcrx:DebtInstrumentVariableRate
      contextRef="ic3552408c5bb444cbf0eb6a3ab86a409_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NDY_bc1d6ea0-2588-4a40-b7c4-a231c124ddbb"
      unitRef="number">0.0075</pcrx:DebtInstrumentVariableRate>
    <pcrx:DebtInstrumentBasisSpreadTwoOnVariableRate
      contextRef="i88770a0f88374817ab71722879f70098_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NDE_cef95651-69cc-4442-bd4c-12009bba375e"
      unitRef="number">0.0700</pcrx:DebtInstrumentBasisSpreadTwoOnVariableRate>
    <pcrx:DebtInstrumentVariableRate
      contextRef="ie1a422b889ef4dc5a23b911b3aeae411_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NTA_fc396b3b-b773-4a11-baa4-a5624c5e711f"
      unitRef="number">0.0175</pcrx:DebtInstrumentVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib5ecb39da69d4d29a362f012fbbd432c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NjU_29411368-d6d0-403d-8340-d7e842d28a69"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <pcrx:DebtInstrumentBasisSpreadOneOnVariableRate
      contextRef="i88770a0f88374817ab71722879f70098_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NTU_3854d5cf-9864-4f56-8439-213528c798ee"
      unitRef="number">0.0100</pcrx:DebtInstrumentBasisSpreadOneOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iaccaba05dfea42d581595525b0cc244f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM4NDgyOTA3OTU5NjA_bd2185fe-96cd-4e51-95e6-d2ca5f1cd28f"
      unitRef="number">0.0600</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="i7747ee53e646437988e64e05cfd00fdd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTkwMzUw_42dc4c16-7092-4111-9ce3-fb6d666c0184"
      unitRef="number">0.0775</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia017c092a2784b0ca8aab079c9e5fc54_I20200710"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNQ_e470450d-3643-4da3-8b37-956214cc6b80"
      unitRef="usd">402500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia017c092a2784b0ca8aab079c9e5fc54_I20200710"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE1NQ_9ecde54c-e27e-4d00-a3bd-7ab4f5f6a800"
      unitRef="number">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia017c092a2784b0ca8aab079c9e5fc54_I20200710"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM0MA_4e1d09d8-ea03-448f-8cbe-568fec6eb7fc"
      unitRef="number">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmJjODhiZDg2ZjY0ZjQ4NjE4YjcwZjY1ODEwNjJjYjhjXzQ_97d7b466-f0c7-45c6-845a-37165a14e3fc"
      unitRef="number">0.00750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzItMS0xLTEtMA_b0d8e076-21eb-45d1-b72d-ea4d4561ea89"
      unitRef="usd">402500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzItMy0xLTEtMA_2bc1824f-7cd8-45a7-8383-e9b9289139de"
      unitRef="usd">402500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzMtMS0xLTEtMA_510dff06-291a-4434-ba81-63c2759acfee"
      unitRef="usd">7155000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzMtMy0xLTEtMA_a7b7023a-15f4-4632-a123-ed4009db4358"
      unitRef="usd">8940000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzQtMS0xLTEtMA_0df17d0d-11be-4280-94e1-9e0600551030"
      unitRef="usd">64718000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzQtMy0xLTEtMA_f7ecbca7-3d45-4e9b-a1f8-f7522df36079"
      unitRef="usd">80530000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="ia54d2ff525824d9d94bdfe6cf43288c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzUtMS0xLTEtMA_330238d3-3e31-4781-84b8-209917767cf3"
      unitRef="usd">330627000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ied606e7f1e9940e3acdfe0b049aa4169_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTo2MTFhMGY5NGRhMzg0YWI3YWQ0Y2M2MmRjYWIwNGE3Ny90YWJsZXJhbmdlOjYxMWEwZjk0ZGEzODRhYjdhZDRjYzYyZGNhYjA0YTc3XzUtMy0xLTEtMA_b74e8464-1c26-4c1e-9733-455a44b60b43"
      unitRef="usd">313030000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i40835215f27548ddb0046f269d3d2d44_D20170313-20170313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzY1Mw_27bc4dd4-eb37-40f1-addc-16a800c0af19"
      unitRef="usd">390000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ie208910c77e8415fa39a49e9cb6b2e10_I20200710"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzgyMQ_ac88fc5e-4113-483c-abfe-a5fff3046570"
      unitRef="usd">185000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie208910c77e8415fa39a49e9cb6b2e10_I20200710"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzg3Mw_56d2f2bb-5828-4a82-a8b7-c37eb26d3002"
      unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="ibcab94fdef344be8b8d6fd587edd7388_D20200710-20200710"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzk2Mg_ac6aa033-55d4-41d0-82fb-b13ac93008ab"
      unitRef="usd">211100000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i159db211f8284627a7227966896882fc_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzMzE_d90a753a-33f0-492a-ae25-f107e1fc9f0e"
      unitRef="segment">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i159db211f8284627a7227966896882fc_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzOTU_51838f38-42e0-4ab4-b7c3-1bf632bd75d6"
      unitRef="segment">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i159db211f8284627a7227966896882fc_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE1Mjg_7530340d-8bfa-496a-be8f-ad0ac58d0903"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <pcrx:DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock
      contextRef="i098824f172bb410fbf000b0dcf738b96_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4Njg_1cfc9f6d-33e1-4c44-a26f-148f676bec20"
      unitRef="number">0.98</pcrx:DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock>
    <pcrx:SettlementPeriodConvertibleDebtConversionRequest
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzI3NDU_7ebaac6e-611a-4545-8ad4-0718d092dde6">P40D</pcrx:SettlementPeriodConvertibleDebtConversionRequest>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ide059616fdda44779b287a0527e1ddb3_I20200707"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzMyMTQ_7815c598-faf1-4835-b0c7-95522ab4142a"
      unitRef="usdPerShare">71.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock
      contextRef="ide059616fdda44779b287a0527e1ddb3_I20200707"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM0NzA_63a6b8a3-76f5-48df-95a2-e34b023b50e4"
      unitRef="number">0.325</pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock>
    <us-gaap:SharePrice
      contextRef="ide059616fdda44779b287a0527e1ddb3_I20200707"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzM1MDI_f779965c-9dc4-4a12-b0d9-2aa96a2fb92f"
      unitRef="usdPerShare">54.17</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i0fd176f4fa004e9e999ce2a50dcb9adb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzQxMzk_7782f3fa-1466-473a-a11c-d81266eb94b6"
      unitRef="usd">402500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzQ3MTI_67249430-ccf9-4d78-82b1-0abdcc220031"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzQ3Nzk_bbe72f91-80d1-4b5d-8240-253da946070a"
      unitRef="segment">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzQ4MzU_60d2f7c6-f94a-4647-9521-3d05364cdad1"
      unitRef="segment">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice
      contextRef="i4eef3c84ae824409adcc0ca0ef418eb2_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzUxMTU_26b89364-06fa-4538-8ae2-146e0e6f495d"
      unitRef="number">1</pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice>
    <pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice
      contextRef="i098824f172bb410fbf000b0dcf738b96_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzU4ODk_6e2316bc-0647-4c79-8809-7fb57096e020"
      unitRef="number">1</pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice>
    <pcrx:DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent
      contextRef="i051d7dc66a2540279e60e320f1d3037d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzgwNDc_2e77a5eb-d414-4193-b890-d6852469ad43"
      unitRef="usd">314700000</pcrx:DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent>
    <pcrx:DebtInstrumentConvertibleAssumedBorrowingRate
      contextRef="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzgwNzM_230fbbc9-07ec-4c44-987f-0bbf8429d96c"
      unitRef="number">0.0578</pcrx:DebtInstrumentConvertibleAssumedBorrowingRate>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i051d7dc66a2540279e60e320f1d3037d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzgxMjQ_b0690f23-620f-4364-9aba-d2e9cba84ded"
      unitRef="usd">87800000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentTerm
      contextRef="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MzY5_083b7311-af9a-4726-963f-952e431022df">P5Y</us-gaap:DebtInstrumentTerm>
    <pcrx:DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzg3Mzc_0308086c-e32b-4ddf-84c4-3b8d32dcd383"
      unitRef="usd">20500000</pcrx:DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzg5NTk_be46589d-9d25-43c2-b26e-1997b819e672"
      unitRef="usd">12500000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <pcrx:AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4Mzcx_3ca3f248-8014-41fe-9b5d-c15735af1ef9">P5Y</pcrx:AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt>
    <pcrx:TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzkyOTQ_1f4e93e2-6a00-4e86-aaa0-48ed8fed7f86"
      unitRef="usd">2700000</pcrx:TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iad983f5646e34e94a2da8681ed807b5d_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTUwODEw_47b73d04-3060-4ee2-a6f2-3704e62e946a"
      unitRef="usd">201300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iad983f5646e34e94a2da8681ed807b5d_I20170502"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTUwODM0_4c9a841c-e07e-4d58-a766-1472f514d5ee"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iad983f5646e34e94a2da8681ed807b5d_I20170502"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTUxNDM2_4c003aae-ffa0-4912-ac46-83471497f1ce"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i5a977c4be98547f98b6c05154f959739_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTU0MzA4_4ed99183-a9c7-4865-8301-41c28f184707"
      unitRef="usdPerShare">26.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice
      contextRef="icd1e05a128ed42ccac04aeee92248fef_D20211206-20220106"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTYxMTc0_5f4c8128-4342-4026-9204-ab57351387c2"
      unitRef="number">1</pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i43427f256a794c4db525f11b824c9893_I20220107"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTQ0ODcyMTYyNTIw_5867885e-67f5-4b1c-a581-e43a3862e2dd"
      unitRef="usd">192600000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LongTermDebt
      contextRef="i0ce055e93fcd43c293a47474e350a43f_I20220107"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE2NDkyNjc1MjEzODU_82283adb-9689-4ed4-8f45-ed30ccc0976d"
      unitRef="usd">8600000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="if7bf6b02068a41e8a7ed404d1082e6b2_D20170313-20170313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzk5MjA_270a6730-b015-4702-a803-4906e5ade9c5"
      unitRef="usd">345000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0533c1098374121979b41de75d1de0b_I20170313"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0Xzk5NTY_1334ed54-8893-4b96-abb2-52162129c611"
      unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0533c1098374121979b41de75d1de0b_I20170313"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEwMTQx_956c016f-4334-4422-91b1-6764b6ac4a0a"
      unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ie208910c77e8415fa39a49e9cb6b2e10_I20200710"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEwMzk1_654e9d4c-a707-4f75-8d1f-63a6122e3bc6"
      unitRef="usd">185000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="ibcab94fdef344be8b8d6fd587edd7388_D20200710-20200710"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEwNTAw_c233a4a6-3631-4dca-9c14-c7c838bc4657"
      unitRef="usd">211100000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibcab94fdef344be8b8d6fd587edd7388_D20200710-20200710"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEwNTk3_21d77a29-3e83-47aa-85ae-c2fe767e6bea"
      unitRef="usd">-8100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzItMC0xLTEtMC90ZXh0cmVnaW9uOjcxZmY0YTQ5YjA0YzRiOGJiMDU0Y2Y4YzI2ZDc2ZjgwXzQ_8c528764-8469-467a-8c18-79d5c3bf2f4b"
      unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzItMS0xLTEtMA_21100c00-2e83-4d9b-947d-7f8e3f0d2ddc"
      unitRef="usd">160000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzItMy0xLTEtMA_08eaf71e-181f-47ca-9c8c-b0e735a86f56"
      unitRef="usd">160000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzMtMS0xLTEtMA_8765afeb-d46f-4826-8cac-aa1260932eb7"
      unitRef="usd">223000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzMtMy0xLTEtMA_326f2546-02fa-40ba-b7f7-d76354d68a65"
      unitRef="usd">1089000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzQtMS0xLTEtMA_697fec61-5102-422e-ac7a-065ec8402d2b"
      unitRef="usd">1920000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzQtMy0xLTEtMA_d0ad547e-ad62-4283-94b5-73dcd1c30de7"
      unitRef="usd">9263000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="if174d1cf0aad4e9d98b9affadc5a4ac2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzUtMS0xLTEtMA_3aab89e5-8b3d-4f3b-b8bc-5fbb9253cb1c"
      unitRef="usd">157857000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib156d0fef78446749f347f5513f5ceb7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZTpkOGM1Nzc4ZGRjYjg0MzJkOTliNzY1ZDAxOGU5YjFjMS90YWJsZXJhbmdlOmQ4YzU3NzhkZGNiODQzMmQ5OWI3NjVkMDE4ZTliMWMxXzUtMy0xLTEtMA_260e100c-d9db-4f24-9c1b-fa3f829cc89a"
      unitRef="usd">149648000</us-gaap:LongTermDebt>
    <pcrx:SettlementPeriodConvertibleDebtConversionRequest
      contextRef="i4fb73217f94c444aa76dcd2a69b80870_D20170313-20170313"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzExNTM3_74c6ebde-3eba-4cd9-b100-57fdb91a658a">P40D</pcrx:SettlementPeriodConvertibleDebtConversionRequest>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ib19dbd6e7ef04ec58b328d34732c899d_I20170313"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEyMDA2_e5b07736-630d-4b14-91f1-ae1e9150e90b"
      unitRef="usdPerShare">66.89</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock
      contextRef="ib19dbd6e7ef04ec58b328d34732c899d_I20170313"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEyMjYy_e642df66-de2a-4329-8fc3-ff2b95b6bdcd"
      unitRef="number">0.375</pcrx:DebtInstrumentConversionObligationPremiumOnCommonStock>
    <us-gaap:SharePrice
      contextRef="icadb10d36c46455daf4bbf36c85eb041_I20170307"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEyMjk0_e02b6d23-62af-4676-a9c5-dcf3471ac3fb"
      unitRef="usdPerShare">48.65</us-gaap:SharePrice>
    <pcrx:RemainingPaymentRequiredUponFullSettlementOfNotes
      contextRef="ia6d5ff5d3bd44ee1aeb5e1d291f7b120_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEyOTMy_fc0dccf4-1f52-4ed1-8ce3-344e43a547b4"
      unitRef="usd">160000000</pcrx:RemainingPaymentRequiredUponFullSettlementOfNotes>
    <pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice
      contextRef="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzMzk1_d8e729d1-8108-4abb-b8c3-4102ed2a8096"
      unitRef="number">1.30</pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice>
    <pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays
      contextRef="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzNDUw_587aec42-dbd2-4202-90a7-5fcafba75d47">P20D</pcrx:DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays>
    <pcrx:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays
      contextRef="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzNTA2_09058a80-9082-4bce-938b-054cfa0947c2">P30D</pcrx:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays>
    <pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice
      contextRef="ic7f7e93f13d04956a45b397247825fd9_D20170313-20170313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzEzNzQz_04bff6a4-fa05-4f59-a6f0-7004afb5c800"
      unitRef="number">1</pcrx:DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice>
    <pcrx:DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE0NTE3_e94990dd-9115-4bf7-9a33-3c219ab5d5e9"
      unitRef="number">1</pcrx:DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <us-gaap:ConvertibleDebt
      contextRef="ib19dbd6e7ef04ec58b328d34732c899d_I20170313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE2Njc2_934a665d-70ff-4cd5-b44a-82dd866f7171"
      unitRef="usd">274100000</us-gaap:ConvertibleDebt>
    <pcrx:DebtInstrumentConvertibleAssumedBorrowingRate
      contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE2NzAy_6ced58a1-3010-4763-ab3b-2ce8826846ba"
      unitRef="number">0.0745</pcrx:DebtInstrumentConvertibleAssumedBorrowingRate>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="ib19dbd6e7ef04ec58b328d34732c899d_I20170313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE2NzUz_6aeafa86-332a-4e42-bf84-7d20343754b4"
      unitRef="usd">70900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentTerm
      contextRef="i6f19e0fe7d2e436bab338dd26ba2d4e1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MzY1_bedef99f-0a36-4194-86a7-cc7cef5cc0a0">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE3MzY1_a7b7ebe8-7867-4f1e-89f8-da755cc3d139"
      unitRef="usd">11000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <pcrx:AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt
      contextRef="i262c5548fe9c44b8aa7a185ebe27e739_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4Mzcw_d0e645ce-a291-4447-bad5-dc3e80174970">P5Y</pcrx:AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt>
    <pcrx:DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault
      contextRef="i99e0896c5aa641788d27a94449c7ca4f_D20170313-20170313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MTAw_5114ae20-02f5-457a-9fd6-a599c18c9b0a"
      unitRef="number">1</pcrx:DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault>
    <pcrx:ScheduleOfInterestExpenseTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90ZXh0cmVnaW9uOmFjN2Q1M2FkZDk4NTQ0NWRiMzhiY2RmZjhkNmVlMGI0XzE4MzYy_233f698b-79d6-45cb-aa6d-942244632efd">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual and other interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized interest (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate on total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pcrx:ScheduleOfInterestExpenseTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzItMS0xLTEtMA_e0200c98-4562-4800-9c2c-e1e5d0d1ddc3"
      unitRef="usd">9759000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzItMy0xLTEtMA_d1657ee7-b1a7-4738-92bf-8f8f9d91a484"
      unitRef="usd">7650000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzItNS0xLTEtMA_2da6bdaa-9c1a-414e-813f-29219aad9f9d"
      unitRef="usd">8195000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzMtMS0xLTEtMA_5630fb36-714d-4b8a-8326-b9c698f85ddf"
      unitRef="usd">2754000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzMtMy0xLTEtMA_83b3854d-3e59-4684-a0dd-115d3c5fe3eb"
      unitRef="usd">2156000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzMtNS0xLTEtMA_43feee95-40d5-4a0b-a448-c814717a15b7"
      unitRef="usd">1707000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzQtMS0xLTEtMA_52ad8c05-7ff9-437e-84e2-88c24c2ebcec"
      unitRef="usd">23152000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzQtMy0xLTEtMA_f6386de5-4469-4060-9334-b32a70a147c7"
      unitRef="usd">18254000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzQtNS0xLTEtMA_a50690c6-abd5-494f-adb2-4f9ef7533632"
      unitRef="usd">13746000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestCostsCapitalizedAdjustment
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzUtMS0xLTEtMA_ab0eee79-8dd3-4789-85f8-4d548de5625b"
      unitRef="usd">3915000</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestCostsCapitalizedAdjustment
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzUtMy0xLTEtMA_c055d6c8-a7f1-4a8a-8cc0-1d66cd9095f6"
      unitRef="usd">2389000</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestCostsCapitalizedAdjustment
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzUtNS0xLTEtMA_b8aacab9-00e8-407d-ae94-0f7a5fb2c238"
      unitRef="usd">20000</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestExpenseDebt
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzYtMS0xLTEtMA_289caee2-ccb1-4e82-a3ee-ba8626c6deb2"
      unitRef="usd">31750000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzYtMy0xLTEtMA_d77aa662-c2c1-4686-9359-344615e2833a"
      unitRef="usd">25671000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzYtNS0xLTEtMA_3b57b5f8-04fe-4f12-81e3-3ad523552122"
      unitRef="usd">23628000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzgtMS0xLTEtMA_3e194f61-5e98-4e31-aa08-8325e8e7d78c"
      unitRef="number">0.0666</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzgtMy0xLTEtMA_147c118e-fd25-4c38-9154-36eb65ffa2c9"
      unitRef="number">0.0715</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzIvZnJhZzphYzdkNTNhZGQ5ODU0NDVkYjM4YmNkZmY4ZDZlZTBiNC90YWJsZToxOWU0MGFkZmQwZjE0OGYwOGQ2NzhiNzU5NjMwZWVhMi90YWJsZXJhbmdlOjE5ZTQwYWRmZDBmMTQ4ZjA4ZDY3OGI3NTk2MzBlZWEyXzgtNS0xLTEtMA_06551389-664a-4d90-8c71-67aa206ad5f2"
      unitRef="number">0.0781</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NDc_6b622d0c-8434-41ab-9840-3ac9a1cae619">FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:63pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level&#160;1: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:63pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level&#160;2: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:63pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level&#160;3: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company&#x2019;s equity investment with a readily determinable fair value was calculated utilizing market quotations from a major American stock exchange (Level 1). The fair value of the Company&#x2019;s convertible senior notes are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company&#x2019;s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amounts of equity investments and convertible notes receivable without readily determinable fair values have not been adjusted for either impairments or upward or downward adjustments based on observable transactions. The carrying values and fair values of the Company&#x2019;s financial assets and liabilities at December&#160;31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Convertible notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Acquisition-related contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Liabilities Measured at Amortized Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facility due December 2026 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2.375% convertible senior notes due 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750% convertible senior notes due 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% convertible senior notes due 2024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The closing price of the Company&#x2019;s common stock as reported on the Nasdaq Global Select Market was $60.17 per share at December&#160;31, 2021 compared to a conversion price of $66.89 per share for the 2022 Notes and a conversion price of $71.78 per share for the 2025 Notes. Therefore, at December&#160;31, 2021, the conversion prices were above the stock price. The maximum conversion premium that could have been due on the 2022 Notes and 2025 Notes at December&#160;31, 2021 was&#160;approximately 2.4&#160;million and 5.6&#160;million shares of the Company&#x2019;s common stock, respectively. These figures assume no increases in the conversion rate for certain corporate events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"&gt;(2) Relates to the Flexion 2024 Notes. For more information, See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are measured at fair value on a non-recurring basis, including assets and liabilities acquired in a business combination and long-lived assets, which would be recognized at fair value if deemed impaired or if reclassified as assets held for sale. The fair value in these instances would be determined using Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recognized contingent consideration related to the Flexion Acquisition and the MyoScience Acquisition in the amount of $57.6&#160;million and $28.3&#160;million as of December&#160;31, 2021 and 2020, respectively. Refer to Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Note 18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition-Related Charges, Product Discontinuation and Other,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a probability-weighted discounted cash flow approach that is based on unobservable inputs and a Monte Carlo simulation. These inputs include, as applicable, estimated probabilities and the timing of achieving specified commercial and regulatory milestones, estimated forecasts of revenue and costs and the discount rate used to calculate the present value of estimated future payments. Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 19, 2021, as part of the purchase price consideration related to the Flexion Acquisition, the Company recorded contingent consideration of $45.2&#160;million, which represents the Company&#x2019;s achievement of meeting regulatory and sales-based milestones. For the period of acquisition through December&#160;31, 2021, the Company recorded an additional $1.2&#160;million liability due to an estimated $0.02 increase to contingent consideration per CVR fair value, which was included in acquisition-related charges in the consolidated statements of operations. At December&#160;31, 2021, the weighted average discount rate was 12.2% and the weighted average probability of success for regulatory milestones was 12.7%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized an acquisition-related gain of $2.2&#160;million and for the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2019, the Company recognized acquisition-related charges of&#160;$5.2&#160;million and $16.7&#160;million, respectively, related to the MyoScience Acquisition, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as a result of revisions to the probabilities of regulatory milestones being met and future projections, which have been included in acquisition-related charges in the consolidated statements of operations. At December&#160;31, 2021, the weighted average discount rate was 11.8% and the weighted average probability of success for regulatory milestones was 1%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the key assumptions used in the valuation of the Company&#x2019;s contingent consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Flexion Ranges Utilized as of &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MyoScience Ranges Utilized as of &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.39% to 12.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.42% to 12.13%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of achieving regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00% to 15.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of achieving regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 to 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maximum remaining potential payments related to the contingent consideration from the Flexion Acquisition and MyoScience Acquisition are $425.5&#160;million and $43.0 million, respectively, as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the Company&#x2019;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent&lt;br/&gt;Consideration&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration related to the Flexion Acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Fair value adjustments and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Payments made or offset against amounts due &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate and government bonds with maturities greater than three months, but less than one year. Long-term investments consist of government bonds with maturities greater than one year but less than three years. Net unrealized gains and losses (excluding credit losses, if any) from the Company&#x2019;s short-term and long-term investments are reported in other comprehensive income (loss). At December&#160;31, 2021, all of the Company&#x2019;s short-term investments are classified as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;available-for-sale investments and are determined to be Level 2 instruments, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. At the time of purchase, all short-term and long-term investments had an &#x201c;A&#x201d; or better rating by Standard&#160;&amp;amp; Poor&#x2019;s.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the Company&#x2019;s investments at December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021 Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020 Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;U.S. Government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;U.S. Government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, there were no investments available for sale that were materially less than their amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company elects to recognize its interest receivable separate from its available-for-sale investments. At December&#160;31, 2021 and December&#160;31, 2020, the interest receivable recognized in prepaid expenses and other current assets was $0.1&#160;million and $1.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity and Convertible Note Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021 and 2020, the Company held an equity investment of $4.1&#160;million and $1.2&#160;million, respectively, in GeneQuine Biotherapeutics GmbH, or GeneQuine, a privately held biopharmaceutical company headquartered in Hamburg, Germany. This investment has no readily determinable fair value and is recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments. During 2021, the Company purchased a convertible note from GeneQuine in the amount of $1.2&#160;million and invested an additional $3.0&#160;million in equity investments. During the year ended December&#160;31, 2021, the valuation of the convertible note was reduced by less than $0.1&#160;million due to changes in foreign currency exchange rates. The Company has the right to make additional investments in debt securities of $1.7&#160;million predicated upon GeneQuine achieving certain prespecified near-term milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company purchased preferred shares in Coda BioTherapeutics, Inc., a privately held preclinical stage biopharmaceutical company that is developing a gene-therapy platform to treat neurological disorders and diseases for a purchase price of $10.0&#160;million. There were no adjustments to this investment during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company purchased a convertible note in the amount of $3.0&#160;million from Spine BioPharma, LLC, a preclinical stage biopharmaceutical company. There were no adjustments to this investment during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020, the Company held an equity investment in TELA Bio, Inc., or TELA Bio, in its consolidated balance sheets in the amount of $11.6 million. During the year ended December 31, 2021, the Company sold its investment in TELA Bio for net cash proceeds of $9.1&#160;million and recognized a realized loss of $2.6&#160;million, which was recorded in other, net in the consolidated statements of operations. In 2020, the fair value of TELA Bio increased by $1.6 million, which was recorded in other, net in the consolidated statement of operations and in 2019, the Company also recognized an impairment loss of $5.7 million in other, net related to its investment in TELA Bio. The fair values of TELA Bio at December 31, 2020 and 2019 were based on Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December 31, 2021, in January 2022, the Company purchased preferred shares in the privately-held Genascence Corporation, a preclinical stage biopharmaceutical company, for $7.5&#160;million, recorded as an equity investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, four wholesalers each accounted for over 10% of the Company&#x2019;s accounts receivable at 30%, 20%, 17% and 11%. At December&#160;31, 2020, three wholesalers each accounted for over 10% of the Company&#x2019;s accounts receivable at 36%, 28% and 23%. For additional information regarding the Company&#x2019;s wholesalers, see Note 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. EXPAREL revenues are primarily derived from major wholesalers that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company&#x2019;s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of December&#160;31, 2021 and 2020, the Company did not deem any allowances for credit losses on its accounts receivable necessary.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NDg_1e8cffc8-17ca-4067-ac64-090346fc057c">The carrying values and fair values of the Company&#x2019;s financial assets and liabilities at December&#160;31, 2021 are as follows (in thousands):&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Convertible notes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Acquisition-related contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Liabilities Measured at Amortized Cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facility due December 2026 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2.375% convertible senior notes due 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.750% convertible senior notes due 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% convertible senior notes due 2024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;The closing price of the Company&#x2019;s common stock as reported on the Nasdaq Global Select Market was $60.17 per share at December&#160;31, 2021 compared to a conversion price of $66.89 per share for the 2022 Notes and a conversion price of $71.78 per share for the 2025 Notes. Therefore, at December&#160;31, 2021, the conversion prices were above the stock price. The maximum conversion premium that could have been due on the 2022 Notes and 2025 Notes at December&#160;31, 2021 was&#160;approximately 2.4&#160;million and 5.6&#160;million shares of the Company&#x2019;s common stock, respectively. These figures assume no increases in the conversion rate for certain corporate events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"&gt;(2) Relates to the Flexion 2024 Notes. For more information, See Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ie577d6c271bb4749abe1c1aa7b73462a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtMi0xLTEtNjY0Mjc_2e966169-1447-450e-8103-6979060803d5"
      unitRef="usd">14127000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i552e4370c49c488aaf644acf28100abb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtNC0xLTEtNjY0Mjc_5212d7dd-578c-42fe-ba97-d6bec5e33c1d"
      unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i01558abfceb343c1997fa09cb38e955a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtNi0xLTEtNjY0Mjc_3b83c6c9-fee2-4476-82f9-ee803be1d07c"
      unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ib13ef9c89d3842a090b30092159c6baa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtOC0xLTEtNjY0Mjc_b718ac30-229d-45be-87ae-6131568de79d"
      unitRef="usd">14127000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:NotesReceivableFairValueDisclosure
      contextRef="ie577d6c271bb4749abe1c1aa7b73462a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtMi0xLTEtMA_8aee037e-6026-469b-bdea-b1c18635920c"
      unitRef="usd">4132000</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure
      contextRef="i552e4370c49c488aaf644acf28100abb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtNC0xLTEtMA_7c565663-7386-4e80-b0bd-3fc3a5a6bf09"
      unitRef="usd">0</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure
      contextRef="i01558abfceb343c1997fa09cb38e955a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtNi0xLTEtMA_38ac5b0a-9a1b-4e35-ac79-2a28ab7e6fd6"
      unitRef="usd">0</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure
      contextRef="ib13ef9c89d3842a090b30092159c6baa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzQtOC0xLTEtMA_feb81200-c22b-4adb-9f03-cbcebd8983d6"
      unitRef="usd">4132000</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie577d6c271bb4749abe1c1aa7b73462a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzYtMi0xLTEtMA_1a3a7b01-2dcb-4911-b9d0-2353946a855b"
      unitRef="usd">57598000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i552e4370c49c488aaf644acf28100abb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzYtNC0xLTEtMA_369d2eda-880b-4cb8-a58f-e00234b030b5"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i01558abfceb343c1997fa09cb38e955a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzYtNi0xLTEtMA_63e32a7e-d256-45de-8ad5-1a6634c9df9b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib13ef9c89d3842a090b30092159c6baa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzYtOC0xLTEtMA_93fb2a2f-2443-4e86-abb6-19f96806ca6d"
      unitRef="usd">57598000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i833dd50b748e4f648ce8fbdc883c4185_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktMi0xLTEtNTQ5NzQ_0fcb011d-c085-4bd3-a698-7cbfa84941fd"
      unitRef="usd">359497000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i0c6e342295e24ffeb5b662e536f55798_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktNC0xLTEtNTQ5NzQ_5adc79e0-3162-42d9-a783-65604a428e70"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ie47b1b32def64bc0a3609d407c471b13_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktNi0xLTEtNTQ5NzQ_fffa7f6f-c5a3-48c8-a53a-d6d01be1f6b2"
      unitRef="usd">371250000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ia547c4173aba4e05a06d562cb5145105_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktOC0xLTEtNTQ5NzQ_415be574-6fd8-47cb-aca1-ac3a37a5cb46"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i4d7d1ef1836341deb53748bf79ee7540_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTItMS0xLTU0OTM2_3d8ee0f5-bc3a-487c-bb9a-72583f92667c"
      unitRef="usd">157857000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ife6537b40fcd40ed8ef4f547088d8dd6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTQtMS0xLTU0OTM2_8e6f707e-b299-487d-a0f5-4b38c0722b4c"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i59aef1e9bd7c4844a54073f163e8a93d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTYtMS0xLTU0OTM2_c4184d89-4e68-4d14-8100-33c6a3d3ac01"
      unitRef="usd">166200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i12a42225481b4c039ba48e07565653d6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTgtMS0xLTU0OTM2_821e2c1b-12df-45f0-ba6c-9ea23c1046ad"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if31bdc45af904ee791953adb58a89ea7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktMi0xLTEtMA_2797df26-a663-474d-aae4-c568f99d7e36"
      unitRef="usd">330627000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i2f2492fc03ca40809334ee540cedfd2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktNC0xLTEtMA_b99852f8-0eb4-4b10-9d2a-6c8220ac1fb0"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i877fef10b449448bb4a9b1ae0125a699_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktNi0xLTEtMA_e1d96aac-94b6-4da6-9bd0-251e0ec075eb"
      unitRef="usd">447781000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i73430b1c7b5c48378305535b3e6241c4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzktOC0xLTEtMA_f3647a1c-551d-45bc-b8d6-f855df8ad8d5"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ied69c02578864bbc9cb25cd5c9b8b3ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTItMS0xLTA_081be044-d398-48eb-bbc2-fbad2fe32a5d"
      unitRef="usd">201249000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="icb164609df064575b1b1a48271b62b19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTQtMS0xLTA_46ef4ed9-973b-4610-9f31-c684d90867b8"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i46eb669c6b164a9e8a7ea3de4a9b62c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTYtMS0xLTA_1f999354-64cf-4183-a69a-977c5da76cdd"
      unitRef="usd">201552000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i0b76248be1d04ab7999d2ad496cd6c18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo4NjAwYmFiNTJmMzc0Zjc2OGRhYWI5MGZjMzhjYTEyMS90YWJsZXJhbmdlOjg2MDBiYWI1MmYzNzRmNzY4ZGFhYjkwZmMzOGNhMTIxXzEwLTgtMS0xLTA_c5f22cc3-eeb4-4110-a604-b75219698ebd"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SharePrice
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzIxMjQ_58664097-526b-409d-baae-f54bdba621db"
      unitRef="usdPerShare">60.17</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i50f3b14c8eb24f87b8db39c9626146de_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzIxNzc_ec3e41f7-cd42-4e27-92de-369ebf369206"
      unitRef="usdPerShare">66.89</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i029b2fd1da9b426aa281eb6edf9c4164_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzIyMzU_ad25d7b8-830a-4c5b-9acc-1182a238bd31"
      unitRef="usdPerShare">71.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pcrx:DebtInstrumentConvertibleConversionPremiumShares
      contextRef="ibec8af6ae83c4cc5bb12c9babddf9666_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzI0Mzk_8ee64e1f-8030-4f35-96e2-1846308af471"
      unitRef="shares">2400000</pcrx:DebtInstrumentConvertibleConversionPremiumShares>
    <pcrx:DebtInstrumentConvertibleConversionPremiumShares
      contextRef="i9513fc7cbbc24c9e8fd0a64ddc87b87a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzI0NDY_1605e867-0c4a-4c53-92c1-2eb4f5e5ba85"
      unitRef="shares">5600000</pcrx:DebtInstrumentConvertibleConversionPremiumShares>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib73e9b252a7f4625a0d9d5c279a031a2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzQzOTgwNDY1MzcwOTc_9e949033-18b5-4834-9bd7-f04d2eea59ea"
      unitRef="usd">57600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8a0b1b1bfd3a47be9e86153acff8ab26_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzMxMjU_84aa081b-0bcd-4e9c-b25b-e12a553848c8"
      unitRef="usd">28300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i79da6badc4ce4c8b87bad102f47d53f7_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDMyNDM1_009b26f6-36e4-4691-9a7c-88ce8004d162"
      unitRef="usd">45200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ifd6c594f1a8d4d8198e32bc0c6d23237_D20211119-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDMyNTc3_4e162951-3fc2-416d-b6b6-23810d782380"
      unitRef="usd">1200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare
      contextRef="i2d56f0f495b24f6292ed813d0fcfc838_I20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDMzMDUy_76009083-04e9-4077-984d-9110eb847b1f"
      unitRef="usdPerShare">0.02</pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i596b14391d784004ad234ae361b60952_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQwMTQ2_f32bc13e-973e-49e0-8e49-7763484e5eee"
      unitRef="number">0.127</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDM3NzEy_edd1c870-a71a-492f-984a-a90458a812fc"
      unitRef="usd">2200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzExNTQ0ODcyMTE5NTUz_ab61dec5-e8b0-48cb-b561-c786d5f4cbf1"
      unitRef="usd">-5200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzExNTQ0ODcyMTE5NTgx_df952203-e36f-4e33-8280-7507b82365bb"
      unitRef="usd">-16700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i5e8a2f34478940948a4fc588e36055b6_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzQ1NTE_8e3f119b-ed2f-407f-9308-a9e8f5048cd1"
      unitRef="number">0.118</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i688afa6b83624546a44f01cdc4648f16_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzQ2MzI_775fc3de-a801-4675-ac8c-c60ec94b91ca"
      unitRef="number">0.01</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NTM_03c599a0-2e13-477f-aae2-b434dca29c92">&lt;div style="margin-bottom:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the key assumptions used in the valuation of the Company&#x2019;s contingent consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Flexion Ranges Utilized as of &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MyoScience Ranges Utilized as of &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.39% to 12.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.42% to 12.13%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of achieving regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00% to 15.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of achieving regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 to 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3d43a54915fb471a881eb7c22d53ebb8_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzEtMi0xLTEtNTUzNTgvdGV4dHJlZ2lvbjo3MDJjZDM4NGZiZGM0N2Q5YTc5ZjhmNWJmNDgwNjJlNF8xNjQ5MjY3NDQxNjY2Mw_e555f7a3-3e52-42a8-ad4a-6c6ed1a7c635"
      unitRef="number">0.1139</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="if920c61660554030b10993e6540fa419_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzEtMi0xLTEtNTUzNTgvdGV4dHJlZ2lvbjo3MDJjZDM4NGZiZGM0N2Q5YTc5ZjhmNWJmNDgwNjJlNF8xNjQ5MjY3NDQxNjY3MQ_2a15cb68-0421-41f3-b50c-db0f7ea3d8f2"
      unitRef="number">0.1292</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic2cf381db5a940f290c4b8ce845a8a32_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzEtMi0xLTEtMC90ZXh0cmVnaW9uOmRhZjFiZWUwOTM3NjQ1MDM5Nzk2MDAwMTIzMjI5OTY2XzQ_2ca0d2ec-c0d0-4e6b-8447-a757e658091b"
      unitRef="number">0.1142</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i7c32d4b9517d48699bd04bc765bd4313_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzEtMi0xLTEtMC90ZXh0cmVnaW9uOmRhZjFiZWUwOTM3NjQ1MDM5Nzk2MDAwMTIzMjI5OTY2XzEw_f13747bb-7642-4c87-ac29-1e5df3a3e4d8"
      unitRef="number">0.1213</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i34416a5edad84520b386d27a329de124_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzItMi0xLTEtNTUzNTgvdGV4dHJlZ2lvbjpiMjIwYWI2M2VlYTQ0NDA2OTNkZTcxNDViZmUwMGFkMV8xNjQ5MjY3NDQxNjY1Ng_965b0cac-5a10-4e1c-ae3d-a5eadef7be9f"
      unitRef="number">0.1000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i5b952c5725b44f818a3a4608b206c6b4_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzItMi0xLTEtNTUzNTgvdGV4dHJlZ2lvbjpiMjIwYWI2M2VlYTQ0NDA2OTNkZTcxNDViZmUwMGFkMV8xNjQ5MjY3NDQxNjY2Mw_a82055ca-7bd3-4987-a0d3-f13a2ff29d18"
      unitRef="number">0.1500</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i87676acfa0004a61af3790653d502de3_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTozZTE4ZTBmYjU1M2U0NTI5YmJiOGE5ZGJiZDNhMWQzYS90YWJsZXJhbmdlOjNlMThlMGZiNTUzZTQ1MjliYmI4YTlkYmJkM2ExZDNhXzItMi0xLTEtMC90ZXh0cmVnaW9uOjAyOGQ3NDIxYWYwNjRkNTZiNzk1ZDRiMGRiMmJlYTE4XzQ_3f397d69-62ad-4b9a-bc48-4dc2c9924c9a"
      unitRef="number">0.0100</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition
      contextRef="i6d4add3e8085457381bf09ffb890926b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQwMTkz_26c62d9f-df6c-4b85-b8b4-99afb072cb05"
      unitRef="usd">425500000</pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition>
    <pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition
      contextRef="i18f0515519fd468ea2893c1d1449bb1e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzQ4NzE_a496e354-721c-44e7-919d-16c11b42f6ad"
      unitRef="usd">43000000</pcrx:TotalMilestonePaymentsYetToBePaidInConnectionAcquisition>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NTg_62a825f7-50b0-4b37-b152-0d100f37c676">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the Company&#x2019;s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contingent&lt;br/&gt;Consideration&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration related to the Flexion Acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Fair value adjustments and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Payments made or offset against amounts due &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iead150b687d149c184bc55655b3b10d9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzEtMi0xLTEtMA_42fedad8-8e90-4b83-bbbb-a826332ec199"
      unitRef="usd">28346000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice
      contextRef="icb7c445d56a64eec9a36a2231a41ca72_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzItMi0xLTEtNTU1NTI_7fe25c02-feb5-42a4-b41c-837e731e3c29"
      unitRef="usd">45241000</pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="icb7c445d56a64eec9a36a2231a41ca72_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzItMi0xLTEtMA_4c49799f-d63f-4140-b4d6-5d06ac76820d"
      unitRef="usd">-989000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="icb7c445d56a64eec9a36a2231a41ca72_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzMtMi0xLTEtMA_29c67eef-ff48-4edf-8429-11979a2a7eed"
      unitRef="usd">15000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5df54267e2fb4ca08078fb42498c07b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTpkYzQyYjJlZjQ4NmI0ZTg2YWYwMDM5Y2NhMjhlYmNkYy90YWJsZXJhbmdlOmRjNDJiMmVmNDg2YjRlODZhZjAwMzljY2EyOGViY2RjXzQtMi0xLTEtMA_38700a06-4a30-4679-9add-8d43fa7ec136"
      unitRef="usd">57598000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzk0NjQ_e8188446-755b-4766-ac2b-de673f722b99">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the Company&#x2019;s investments at December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021 Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020 Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;U.S. Government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;U.S. Government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ifed6c7cb25774dc791f211ce4f75f33a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzItMi0xLTEtNjY0ODI_c1c9d7a4-d5da-49df-9df1-49bfbb7b7140"
      unitRef="usd">3182000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifed6c7cb25774dc791f211ce4f75f33a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzItNC0xLTEtNjY0ODI_ef9b0b22-8436-4cac-8034-2f31ecc7042a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifed6c7cb25774dc791f211ce4f75f33a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzItNi0xLTEtNjY0ODI_f4f07946-01dd-46ba-a12a-43556913a00c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ifed6c7cb25774dc791f211ce4f75f33a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzItOC0xLTEtNjY0ODI_10c2465c-3790-47c0-a5ca-75deac7e6961"
      unitRef="usd">3182000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ide37340a89bb45a5b51beeb5442b41a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzMtMi0xLTEtNjY0ODI_5f1d1e28-9f3a-4acd-bd44-b4a291cbaa2e"
      unitRef="usd">57533000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ide37340a89bb45a5b51beeb5442b41a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzMtNC0xLTEtNjY0ODI_d9e9cdd1-2e07-4386-a6c8-a05e0a1bd421"
      unitRef="usd">80000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ide37340a89bb45a5b51beeb5442b41a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzMtNi0xLTEtNjY0ODI_4ac1a5d1-b279-42a3-a691-4b3e81fb62fa"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ide37340a89bb45a5b51beeb5442b41a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzMtOC0xLTEtNjY0ODI_151f7d8e-6454-4133-8d52-f846de7dcce2"
      unitRef="usd">57611000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i27fc0a4268ea499a866f36779e8349ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzQtMi0xLTEtNjY0ODI_b822af01-0be0-4680-8fcf-e64fb3cc5390"
      unitRef="usd">9936000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i27fc0a4268ea499a866f36779e8349ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzQtNC0xLTEtNjY0ODI_8afebb5f-4d22-4142-8f14-c6702d364d3e"
      unitRef="usd">102000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i27fc0a4268ea499a866f36779e8349ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzQtNi0xLTEtNjY0ODI_d950af92-8397-4748-b713-4c8115fbd997"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i27fc0a4268ea499a866f36779e8349ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzQtOC0xLTEtNjY0ODI_1566e015-32db-4944-a88b-ddb28f19c04b"
      unitRef="usd">10038000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzEyLTItMS0xLTY2NDgy_11ae7d69-e11a-4b3f-bf2f-3b855cdc0547"
      unitRef="usd">70651000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzEyLTQtMS0xLTY2NDgy_2172caff-5bd6-4d91-8f7b-446ab7560a6a"
      unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzEyLTYtMS0xLTY2NDgy_58dc7f74-5939-49e2-8cf8-bc79547a484e"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTphYWU5MDE5YmExODg0YmVhOTdmNDdlZWQxZWIyMTljNC90YWJsZXJhbmdlOmFhZTkwMTliYTE4ODRiZWE5N2Y0N2VlZDFlYjIxOWM0XzEyLTgtMS0xLTY2NDgy_6ed8f19e-c671-428a-85ab-99439df3dae1"
      unitRef="usd">70831000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzItMi0xLTEtMA_5f288b47-6486-42b0-8c61-4c462ded2f83"
      unitRef="usd">34918000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzItNC0xLTEtMA_447855a0-8e5b-4119-87e0-34d852a8cbbc"
      unitRef="usd">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzItNi0xLTEtMA_e8bfa041-ed57-49fc-8ce4-16c97838fad2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i70facf7a7d9c4c4db74b7a191a5ed76e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzItOC0xLTEtMA_a1125823-86ed-4c1e-9c77-f1b074df6e3b"
      unitRef="usd">35016000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i453db66839f342d1b1291f445f8934ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzMtMi0xLTEtMA_3b2918be-8fce-4d2b-83f1-20ebac39619c"
      unitRef="usd">221494000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i453db66839f342d1b1291f445f8934ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzMtNC0xLTEtMA_bd134389-86dc-4bc3-bd17-306ba1816672"
      unitRef="usd">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i453db66839f342d1b1291f445f8934ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzMtNi0xLTEtMA_208ced8d-e655-4650-8c98-766098a7e41d"
      unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i453db66839f342d1b1291f445f8934ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzMtOC0xLTEtMA_d01f6b84-e907-4f6b-9d58-fe827bf9a3b3"
      unitRef="usd">221512000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="if9a617a44b744a1596fff6fde2d5e5bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzQtMi0xLTEtMA_a1ba4760-4a49-4f67-8dfe-e435ea138f2f"
      unitRef="usd">120375000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if9a617a44b744a1596fff6fde2d5e5bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzQtNC0xLTEtMA_e38429b2-cedd-4ef6-beac-f1df9a07b4dd"
      unitRef="usd">179000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if9a617a44b744a1596fff6fde2d5e5bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzQtNi0xLTEtMA_2a9606b6-4f5b-419a-a198-8afcd55760fb"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if9a617a44b744a1596fff6fde2d5e5bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzQtOC0xLTEtMA_c1d8a701-6a06-4b17-abf1-7d869d01c9c0"
      unitRef="usd">120543000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzUtMi0xLTEtMA_4417005c-6d5a-4aba-ac5a-a8b3352302fc"
      unitRef="usd">44629000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzUtNC0xLTEtMA_6bb9ae3f-e566-40ba-ba5a-a5a2cfb2ad88"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzUtNi0xLTEtMA_475c757d-f5b5-45a0-b490-0f9baa9e16d5"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i425329bf80cd4c81a0af04dd5de7c5e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzUtOC0xLTEtMA_079e7e29-db96-4bbd-a5f5-eaf72061e78d"
      unitRef="usd">44634000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="iafc9c5bceef24a519258f36b731eed51_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzYtMi0xLTEtMA_03af6bee-761d-47f4-8d9f-32cd7662b960"
      unitRef="usd">421416000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iafc9c5bceef24a519258f36b731eed51_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzYtNC0xLTEtMA_2e3a7750-62ff-4198-8356-cc8d1a389c25"
      unitRef="usd">320000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iafc9c5bceef24a519258f36b731eed51_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzYtNi0xLTEtMA_da85ec75-2ac7-4794-9c83-776af9e7e012"
      unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iafc9c5bceef24a519258f36b731eed51_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzYtOC0xLTEtMA_4118dda4-4e33-463d-ab8a-2e48fbe04455"
      unitRef="usd">421705000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="if7f2bb5426e04cc795ae3e950506e652_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzgtMi0xLTEtMA_efb78a80-56fd-455a-aa1a-3139a6267d9f"
      unitRef="usd">95429000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if7f2bb5426e04cc795ae3e950506e652_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzgtNC0xLTEtMA_1abfe47e-d1b1-4727-87eb-1dc9e185b1e8"
      unitRef="usd">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if7f2bb5426e04cc795ae3e950506e652_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzgtNi0xLTEtMA_d329bc8d-a31d-4adb-a58a-972f6d6c43c3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if7f2bb5426e04cc795ae3e950506e652_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzgtOC0xLTEtMA_7cebbab7-2337-4d8c-83ff-4b1d9d984802"
      unitRef="usd">95459000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="id05c5a2e9e2a4674adef676d95ad516e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzktMi0xLTEtMA_ffdbcd59-6cc4-4f51-b984-d3663d34d3eb"
      unitRef="usd">95429000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id05c5a2e9e2a4674adef676d95ad516e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzktNC0xLTEtMA_69774d85-2420-493d-9ae9-11670161b763"
      unitRef="usd">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id05c5a2e9e2a4674adef676d95ad516e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzktNi0xLTEtMA_f4966b83-36dd-44d6-a9ea-93b704183c86"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id05c5a2e9e2a4674adef676d95ad516e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzktOC0xLTEtMA_fb392359-23cf-4724-b6b0-85094d11bacd"
      unitRef="usd">95459000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzEwLTItMS0xLTA_134553ab-2067-4a22-98c9-978c678d5fd5"
      unitRef="usd">516845000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzEwLTQtMS0xLTA_faf76099-739f-47cb-b0c9-ebb3f69057c2"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzEwLTYtMS0xLTA_8ec1419f-6455-46a4-9742-a5b086de8b67"
      unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90YWJsZTo2ZjYwYzlkM2ZlMzI0ZjJlYTlmNTRiNDRiZTRkYzc5NS90YWJsZXJhbmdlOjZmNjBjOWQzZmUzMjRmMmVhOWY1NGI0NGJlNGRjNzk1XzEwLTgtMS0xLTA_6ee78b01-543f-4abc-944e-3a99646d5f66"
      unitRef="usd">517164000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzY4MzA_7538ceb9-a9ac-4bd7-ac60-d7dd799d7f65"
      unitRef="usd">100000</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzY4Mzc_a4800c4a-50a6-43d7-a650-b523aff8b653"
      unitRef="usd">1600000</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ibc6c788ace5a4a8fb5b0dde94e57c31f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ0ODc_fac94768-5076-4865-931e-a24be758713c"
      unitRef="usd">4100000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8e6b31f4d2144d96b895a72c1ba86cb0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1MDE_743a9c9f-ff33-45f5-91b5-eadf66d48c53"
      unitRef="usd">1200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i738a868b4ee144f2a08a48f1517a777b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1MTU_d91623f3-ebd7-420b-969f-e2945c502ec6"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i738a868b4ee144f2a08a48f1517a777b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1MzE_807a285d-be72-4629-b339-103599ed2fe8"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation
      contextRef="i738a868b4ee144f2a08a48f1517a777b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1ODE_a6c010bb-6f9c-4b4e-b904-a44f75e43edb"
      unitRef="usd">100000</us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation>
    <pcrx:PotentialAdditionalInvestmentUponAchievingMilestones
      contextRef="ibc6c788ace5a4a8fb5b0dde94e57c31f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTQ1OTU_09f19e3d-7302-4ab6-827b-a976f5149778"
      unitRef="usd">1700000</pcrx:PotentialAdditionalInvestmentUponAchievingMilestones>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if8f291f33e434735b4f02c49878fd653_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTMzMzQ_9d488e1f-e3ad-480b-9121-c6a66fd3484e"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i53d3e7bf6be84c83bf7d2041a67fdae2_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NTM0MDA_d9a165aa-daad-4d56-9233-7be6b50f4efc"
      unitRef="usd">3000000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i6ec4a3b4cc1240d59d30b940f203ee7b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxMjY1_0cbe1456-273c-48e1-a41d-2ffa374751a4"
      unitRef="usd">11600000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi
      contextRef="i0cb990da9e674a18bd073cb528fb1809_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxMzgw_9fbe2551-fc09-4686-a0f9-9371ca229071"
      unitRef="usd">9100000</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiRealizedGain
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxNDE4_b696edcc-de02-41ad-9bcc-db53dc66a373"
      unitRef="usd">2600000</us-gaap:EquitySecuritiesFvNiRealizedGain>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="i0cb990da9e674a18bd073cb528fb1809_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxNTUx_2e4635d1-d366-4c67-af74-c46e8ff078d2"
      unitRef="usd">1600000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="i157d8e808cd54ff090acb94b024df9d4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE2NDkyNjc0NDQxNjk2_5ef6bfb5-fe2e-499b-b075-a0bde2885d58"
      unitRef="usd">5700000</us-gaap:ImpairmentOfInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="if556affba80d4a378bf1f3922edc8edf_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzExNTQ0ODcyMTE5MTI5_f3abe938-e5fc-44af-b650-4b3a8d93e53b"
      unitRef="usd">7500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <pcrx:NumberOfMajorCustomers
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg1NTg_50b7bdf7-c94a-4cac-94a0-7986a6d2a5ec"
      unitRef="customer">4</pcrx:NumberOfMajorCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie89711155ad84669abf871469c5aeeb0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg2NDA_55694e70-9d17-41b8-ac65-62e767db79af"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie9b8974e2c7e4284b062762071958be9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzE0MjkzNjUxMTg3MDU5_8467880b-e37c-4f5a-a114-dd337ee0de03"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6d3af74affd441a79ce03b62daff7be3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg2NDQ_6965a7a0-21df-42f5-9afb-60e7272e70af"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5a4df30aaf1c498ba552279f52d650f3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg2NTE_f7901a57-174d-412a-b545-2985e76a80ab"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <pcrx:NumberOfMajorCustomers
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg2NjI_c1878d0a-701f-4af3-97ac-cd4bbd6c694e"
      unitRef="customer">3</pcrx:NumberOfMajorCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i06b2394034c140f6a4694ff381035b4e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg3NDQ_b12e836d-70b5-40ee-9423-ee614e306091"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i41ec2f1d36a341c69f0baa5aa111d33a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg3NDg_b7b8d5c5-54f7-4239-9255-59295ee642ad"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i396fdd45737f4f0b9bed95c0ddbc0622_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xNzgvZnJhZzo3ZjlmNzRkOWM5YWM0NWExOGI3YjdjNTU2OTcxNjUzMS90ZXh0cmVnaW9uOjdmOWY3NGQ5YzlhYzQ1YTE4YjdiN2M1NTY5NzE2NTMxXzg3NTU_6471e7d7-49e6-49b5-84fd-cff17f4ee75c"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzU1NQ_1dc32877-5eb0-441c-89af-2aa23092c8ca">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 250,000,000 shares of common stock, of which 44,734,308 and 43,636,929 were issued and outstanding at December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 5,000,000 shares of preferred stock. No preferred stock was issued or outstanding at either December&#160;31, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the changes in the balances of the Company&#x2019;s accumulated other comprehensive income (loss) for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains&lt;br/&gt;(Losses) From Available&lt;br/&gt;For Sale Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain on investments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized loss on investments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized loss on investments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzg4_063d3417-410f-438c-995c-dff32128b09d"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzg4_e5d0fcb3-5773-4a2c-a5bf-f5827589971b"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzExNTQ0ODcyMDkyMjM4_4e72a445-7e63-48ef-9e24-7e22d18d79e3"
      unitRef="shares">44734308</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzExNTQ0ODcyMDkyMjM4_a5c6d96d-af5b-4be7-b753-1fd56609bf79"
      unitRef="shares">44734308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzEzMQ_76dafe87-2470-4e6f-bd94-9eaaa542b445"
      unitRef="shares">43636929</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzEzMQ_f3c174b3-cae6-46ec-9c68-624b0636f091"
      unitRef="shares">43636929</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI0Nw_16ce46fd-d0cb-422e-b56c-b6f1dc6a3052"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI0Nw_88c83f87-98bd-4052-90ad-b57ae046b893"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI3Nw_0221a050-48d2-4da3-b2a2-f502f29a00e4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI3Nw_0289b23a-ef6c-4f5d-90a8-668573de9f25"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI3Nw_443a56ae-8d8f-48a4-a6f3-82baaee8ab52"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzI3Nw_9b6af2d5-bc66-4b14-94eb-5c95c95753c5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90ZXh0cmVnaW9uOjYwYzg1M2Q4OTUzZjQwMTViNDMwYWEwNDk1N2VlYWZjXzU2NA_c1d102ee-fd02-4f91-be03-6db1edb1499f">The following table illustrates the changes in the balances of the Company&#x2019;s accumulated other comprehensive income (loss) for the periods presented (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Unrealized Gains&lt;br/&gt;(Losses) From Available&lt;br/&gt;For Sale Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain on investments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized loss on investments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized loss on investments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i81d1942e618045a69aca1ec725725e2e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEtMi0xLTEtNTE5MTc_9084f0ff-1d0b-4f88-94ed-d87f1f750412"
      unitRef="usd">-280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1b427d124e645ad81dfc92d5d66b207_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEtNC0xLTEtNTE5MTc_672c0344-25a3-40cf-a120-9c96fb40453e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7691a4cd4aca428e882b620433db6759_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzQtMS0xLTEtMA_b414ca2f-5a63-410e-81b3-038f38ff29e5"
      unitRef="usd">-280000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i268f623dedfe45ef8b32af260bc0891d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzItMi0xLTEtNTE5MTc_46a7d9d8-6755-4e06-83f8-f6770c0013b1"
      unitRef="usd">602000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib22aebb1a2f448a8b5e073383b0f94c1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzUtMS0xLTEtMA_0c82f689-9b0b-4be9-bfcf-fbea176ceb61"
      unitRef="usd">602000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ic646097fbe734ac9b8fd68d466e50d82_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzQtMi0xLTEtNTE5MTc_e568960d-cd37-404f-8402-b3a3cbf4f103"
      unitRef="usd">322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e8c703d659b483fba7961601663c1bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzQtNC0xLTEtNTE5MTc_a12e1066-5505-4a5b-82ab-36701cc1b410"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3dfaa6dfa1240039de2e6dff373a711_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzctMS0xLTEtMA_40ffbdbc-cbc7-42d2-a00c-5eb60ccfe0eb"
      unitRef="usd">322000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0434aab27f55421b84d92aaa462e4576_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzUtMi0xLTEtNTE5MTc_ef952758-2466-44f2-bdf7-31c75fa56751"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2e4dc31d7b404c919dfaf4a0a27a0aff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzgtMS0xLTEtMA_c1104e58-5757-4c64-ab22-a81134caf65e"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if9491f3f75e24aaeb616d1274815af74_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzYtNC0xLTEtNTE5MTc_77a3defe-ac44-4fc4-974a-3c97c42e7bc3"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2e4dc31d7b404c919dfaf4a0a27a0aff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzktMS0xLTEtMA_707f6ec2-a936-4ec6-b622-20ddef9b5c6b"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i38819c0324594ec1b66a4ffa3fcf3f56_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzgtMi0xLTEtNTE5MTc_dd9c84c6-5893-45c4-900f-62ef0bc0c817"
      unitRef="usd">319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2612fd9b7b754b8cbaeace3e57620704_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzgtNC0xLTEtNTE5MTc_fac153de-bd44-498f-8b0e-36eaabce1c43"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib617d7e96fc14f90a5109fe4b4e42246_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzExLTEtMS0xLTA_c7cccae5-8ed4-4271-8ed6-1ff5543c99dc"
      unitRef="usd">318000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0b80643a294b465ea2661625af1ab96f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzktMi0xLTEtNTE5MTc_47d96e22-a478-48ed-81db-41f3ad64d95a"
      unitRef="usd">-180000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i18af5711da6640a097e5c4348ee46f60_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzktMS0xLTEtMjg3MTU_63e1b5cc-d771-4efe-aa0c-14786b0d77ef"
      unitRef="usd">-180000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie41ce2db25d34febb04acbf253c2bfcd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEwLTQtMS0xLTUxOTE3_a5175733-d7a7-45ca-9920-f0b94c6a92de"
      unitRef="usd">29000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i18af5711da6640a097e5c4348ee46f60_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEwLTEtMS0xLTI4NzE1_695adacb-3d65-4d3e-bfc0-c69fdaa30f3e"
      unitRef="usd">29000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i3e72dd91549146e4b77f296c7d373601_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEyLTItMS0xLTUxOTE3_ea291408-b782-4f23-a09a-d6fcd0d7f7dd"
      unitRef="usd">139000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f5d2774f94c4c19a034c9d35c8cf659_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEyLTQtMS0xLTUxOTE3_0622c732-4966-486c-8460-d514bde13b83"
      unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac5eb7e48d214a51937b661bf27d5c25_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODEvZnJhZzo2MGM4NTNkODk1M2Y0MDE1YjQzMGFhMDQ5NTdlZWFmYy90YWJsZToyZDk5M2E4YWI2MTQ0NjFlYTlmZDY3YTI1ZjlhMWVlOS90YWJsZXJhbmdlOjJkOTkzYThhYjYxNDQ2MWVhOWZkNjdhMjVmOWExZWU5XzEyLTEtMS0xLTI4NzE1_ec68424f-8cca-4b8e-8eda-ee080bc01e1e"
      unitRef="usd">167000</us-gaap:StockholdersEquity>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2ODM_27aaebdc-8208-4c46-b410-b7ba23dace8b">STOCK PLANS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s amended and restated 2011 stock incentive plan, or 2011 Plan, was originally adopted by its board of directors and approved by its stockholders in June 2011 and was amended in June 2014, June 2016, June 2019 and June 2021. The June 2021 amendment and approval by the Company&#x2019;s stockholders increased the number of shares of common stock authorized for issuance as equity awards under the plan by&#160;1,500,000&#160;shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2011 Plan allows the granting of incentive stock options, non-statutory stock options, restricted stock awards and other stock-based awards. In April 2014, the Company&#x2019;s board of directors also adopted the 2014 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock option grants have an exercise price equal to the closing price of the Company&#x2019;s common stock on the date of grant, generally have a 10-year contractual term and vest in increments (typically over four years from the date of grant, although the Company may occasionally grant options with different vesting terms, including grants made to its non-employee directors). The Company also grants RSUs to employees and non-employee directors generally vesting in increments over four years from the date of grant, except for such grants made to non-employee directors. The Company uses authorized but unissued shares of its common stock to satisfy its obligations under these plans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2014 Employee Stock Purchase Plan, or ESPP, was adopted by its board of directors in April 2014 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approved by the Company&#x2019;s stockholders in June 2014. The purpose of the ESPP is to provide a vehicle for eligible employees to purchase shares of the Company&#x2019;s common stock at a discounted price and to help retain and motivate current employees as well as attract new talent. Under the ESPP, up to 500,000 shares of common stock may be sold. The plan expires in June 2024. The ESPP is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; within the meaning of Section 423 of the Internal Revenue Code, or IRC. The maximum fair market value of stock which can be purchased by a participant in a calendar year is $25,000. Six-month offering periods begin on January 1 and July 1 of each year. During an offering period, eligible employees have the opportunity to elect to purchase shares of the Company&#x2019;s common stock on the purchase dates of June 30 and December 31 (or the last trading day of an offering period). The per share purchase price will be equal to the lesser of 85% of the fair market value of the Company&#x2019;s common stock on either the offering date or the purchase date. During the year ended December&#160;31, 2021, 55,483 shares were purchased and issued through the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables contain information about the Company&#x2019;s stock incentive plans at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Awards Reserved For Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Awards&lt;br/&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Awards Available For Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,431,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,425,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,006,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,461,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,145,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Reserved&lt;br/&gt;For Purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Available&lt;br/&gt;For Purchase&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense for stock options and RSUs is based on the estimated grant date fair value of an award recognized over the requisite service period on a straight-line expense attribution method. Compensation expense for ESPP share options is based on the estimated grant date fair value of the ESPP shares and the grant date number of shares that can be purchased, which is recognized as expense over the length of an offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense in its consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity and related information for the period from December 31, 2018 to December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price (Per Share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,722,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,872,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,706,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,428,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,235,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(732,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,050,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,050,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, $47.3 million of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a weighted average period of 2.6 years. The Company&#x2019;s stock options have a maximum expiration date of ten years from the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average fair value of stock options granted for the years ended December&#160;31, 2021, 2020 and 2019 was $26.74, $22.40 and $20.92 per share, respectively. The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Black-Scholes Weighted Average Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43% - 1.21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22% - 1.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33% - 2.54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.36 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.36 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.22 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSU activity and related information for the period from December 31, 2018 to December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value (Per Share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and expected to vest at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, $41.0 million of total unrecognized compensation cost related to unvested RSUs is expected to be recognized over a weighted average period of 2.9 years. The Company&#x2019;s RSUs have a maximum vest date of four years from the date of grant. The fair values of RSUs awarded are equal to the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the ESPP share options granted were estimated using the Black-Scholes model with the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Black-Scholes Weighted Average Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP share option fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.16 - $15.23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.02 - $17.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.13 - $11.36&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50% - 0.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14% - 1.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% - 2.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of ESPP share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <pcrx:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="i0b3a1799953e4b7a9a6fe4c6d61c6c82_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ0Ng_be353a57-4b63-4c1d-b951-4f0342cadce6"
      unitRef="shares">1500000</pcrx:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2NzA_b550ad66-365f-486d-8cbc-7393ac438a00">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzkxMw_f3923737-e39a-4e06-b9f6-bebd4907240e">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzExODI_122f3eac-c2b4-48a3-ba6d-c8095ffb1cbf">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <pcrx:EmployeeStockPurchasePlanESPPSharesinESPP
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzE4MjQ_9141dbc3-197c-4856-9b32-20a5fdfb7397"
      unitRef="shares">500000</pcrx:EmployeeStockPurchasePlanESPPSharesinESPP>
    <pcrx:MaximumFairMarketValuePurchaseofESPPShares
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzIxMzc_2613c726-4538-48de-b72c-42cef3f2e645"
      unitRef="usd">25000</pcrx:MaximumFairMarketValuePurchaseofESPPShares>
    <pcrx:EmployeeStockPurchasePlanfairvalue
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzI0OTU_722559e5-f6bd-4259-876f-c1fccc82c7b6"
      unitRef="number">0.85</pcrx:EmployeeStockPurchasePlanfairvalue>
    <pcrx:StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzI2Mjk_a3b7e96b-b535-4385-ae2b-9e2f2bbb2f24"
      unitRef="shares">55483</pcrx:StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <pcrx:ScheduleOfSharesAvailableForIssuanceTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2Nzg_f45e70fc-5273-40d3-abb0-4e68dd4dc55b">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables contain information about the Company&#x2019;s stock incentive plans at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Awards Reserved For Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Awards&lt;br/&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Awards Available For Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,431,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,425,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,006,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Inducement Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,461,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,145,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Reserved&lt;br/&gt;For Purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Available&lt;br/&gt;For Purchase&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pcrx:ScheduleOfSharesAvailableForIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic74c8757d0944c88a8cd93d9a4b8cf53_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzEtMi0xLTEtMA_150e0e12-03a4-4779-b4e2-4aa9f31c63c6"
      unitRef="shares">14431701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="idc17ef4c747949b48269bf0b8a76060c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzEtNC0xLTEtMA_5007cd05-2e20-46e6-91a1-a72f68dfdbc5"
      unitRef="shares">12425455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic74c8757d0944c88a8cd93d9a4b8cf53_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzEtNi0xLTEtMA_4b1a4507-ca44-4bd1-86d3-13558c863875"
      unitRef="shares">2006246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i7a5d9635bc2e455f8966f9f3b2bb58fa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzItMi0xLTEtMA_3cb596c6-485c-447a-9a80-51c3577e6b17"
      unitRef="shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i99a2df6ef1594ed0900053be4381bced_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzItNC0xLTEtMA_98dc6e74-9620-48b6-9e0c-3651d833bdf5"
      unitRef="shares">36076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i7a5d9635bc2e455f8966f9f3b2bb58fa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzItNi0xLTEtMA_950bee9f-4ea0-4b0e-9348-b443f5e81675"
      unitRef="shares">138924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzMtMi0xLTEtMA_2cadf40b-efed-474c-b620-726eb56ed084"
      unitRef="shares">14606701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzMtNC0xLTEtMA_3c7c2e6a-7b8c-45ad-812e-eeb7441d3be9"
      unitRef="shares">12461531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzMtNi0xLTEtMA_c2948800-0b5d-474f-9d39-86f272f91fd5"
      unitRef="shares">2145170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pcrx:EmployeeStockPurchasePlanNumberofSharesAuthorized
      contextRef="i744090d10596403bb55779bf5925f19e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzYtMi0xLTEtMA_ab68bfdc-6eaf-47d9-9e0e-44e059d94f3a"
      unitRef="shares">500000</pcrx:EmployeeStockPurchasePlanNumberofSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6806d31d7c914f92a84099b441fe66bb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzYtNC0xLTEtMA_7c5654ec-eea0-4041-b009-04beb7222e04"
      unitRef="shares">409049</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <pcrx:EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase
      contextRef="i744090d10596403bb55779bf5925f19e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozOWNmODkxMmYyM2Y0ZjY4ODRjMTBhNmE4NDI5OGI1NS90YWJsZXJhbmdlOjM5Y2Y4OTEyZjIzZjRmNjg4NGMxMGE2YTg0Mjk4YjU1XzYtNi0xLTEtMA_29cb0fbc-b3e5-4d97-882a-9b60e26e8d4c"
      unitRef="shares">90951</pcrx:EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2ODY_55b7f7d3-c0f0-4f98-b4b0-467234d5e39e">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense in its consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7da9c9dd8294201950b3c55f7f72c5e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzItMi0xLTEtMA_32f6232a-8d71-45dd-b52e-b048fe968896"
      unitRef="usd">5891000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i75ef046de56d45b6a564367b687cd904_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzItNC0xLTEtMA_1eb99795-0f9e-4a09-a0b6-6bfacb4a88a4"
      unitRef="usd">5589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55f8cb56d1ea45d9b5ddb5495a729cee_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzItNi0xLTEtMA_cf55c29c-11c0-40af-9732-2916b214064e"
      unitRef="usd">4665000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2aa85351b13540518354d61849bb9f7d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzMtMi0xLTEtMA_3b208e81-15c5-4903-9a0f-09c6d4b1d34a"
      unitRef="usd">5465000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic6c86356bbbe45f6bfe831911514b73d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzMtNC0xLTEtMA_cfe03b8a-049f-4477-a6f0-2c7e55f717e9"
      unitRef="usd">5211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e8fd43a94a74dafbc22852d9e58719c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzMtNi0xLTEtMA_db392dbb-bf94-4c32-a1e6-0fb9f9d9be83"
      unitRef="usd">5114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f91b2bb657745cc992ed2a4e6446bd4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzQtMi0xLTEtMA_74d4ab04-1b1f-40b2-9488-61cdf6ad45f0"
      unitRef="usd">30890000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iddb7c0b3d882467292232e9502359bf3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzQtNC0xLTEtMA_5aaa325c-666c-401f-b667-c0c7201fdea4"
      unitRef="usd">29120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i432c6966dd144c3991144693194ff39e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzQtNi0xLTEtMA_5e6e1965-4144-476b-95c1-2049f43cbb93"
      unitRef="usd">23871000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzUtMi0xLTEtMA_2958880e-4037-489e-9120-50dc0189a7d3"
      unitRef="usd">42246000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzUtNC0xLTEtMA_094fce51-6cbb-48bd-b02e-2f0969c34942"
      unitRef="usd">39920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzUtNi0xLTEtMA_29be7123-45f8-4d9a-b5e8-3828ca2b244d"
      unitRef="usd">33650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzgtMi0xLTEtMA_23ede54f-c756-4398-ab46-ccb19a379ba0"
      unitRef="usd">25980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzgtNC0xLTEtMA_5e6868f5-da52-4d8b-a434-8ca81eadcb6e"
      unitRef="usd">26749000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzgtNi0xLTEtMA_b98dc5a3-6d17-4266-9d5c-f10e7a9dca4b"
      unitRef="usd">23360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzktMi0xLTEtMA_38558eff-16ac-4583-95c1-63c75014402c"
      unitRef="usd">15335000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzktNC0xLTEtMA_28775741-fe48-492d-ad06-2615b7420200"
      unitRef="usd">12266000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzktNi0xLTEtMA_7f525dd2-ad0a-4251-a7cc-20934cba46f0"
      unitRef="usd">9511000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEwLTItMS0xLTA_cd3d6934-c4d0-493b-a9ba-5fe93785b86e"
      unitRef="usd">931000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEwLTQtMS0xLTA_799f5046-aaae-4214-b0f0-9c590280af2b"
      unitRef="usd">905000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEwLTYtMS0xLTA_95fab4f8-8045-4a9b-a954-8d003211190a"
      unitRef="usd">779000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzExLTItMS0xLTA_ce81877d-24e1-48cf-80c3-1c3bb0999470"
      unitRef="usd">42246000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzExLTQtMS0xLTA_d8511963-5642-4c59-b617-d516bbb4afb7"
      unitRef="usd">39920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzExLTYtMS0xLTA_5886359f-0f83-4ac7-a16a-deb7593a153a"
      unitRef="usd">33650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEzLTItMS0xLTA_e9631ace-4b60-4de9-b493-8221b1146ea7"
      unitRef="usd">8989000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEzLTQtMS0xLTA_30b0e637-31f1-4824-bf25-e75b6693eb03"
      unitRef="usd">8578000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo0YmQ1ZWNkMGZlNzU0Zjg2OGYxNzAyOWJlMGM0OTNiMS90YWJsZXJhbmdlOjRiZDVlY2QwZmU3NTRmODY4ZjE3MDI5YmUwYzQ5M2IxXzEzLTYtMS0xLTA_4d67807c-e594-4938-9fc7-223c21fab6f1"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2ODE_89cd3882-5a4f-4895-9a25-57a3447c0bb1">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity and related information for the period from December 31, 2018 to December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price (Per Share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,722,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,872,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,706,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,428,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(426,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,235,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(732,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(278,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,050,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,050,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifd01dc35d06044bb97b415c6c22acd17_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEtMS0xLTEtMA_77602727-7f6a-4cc2-bf3b-c56443fcbb92"
      unitRef="shares">5722818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifd01dc35d06044bb97b415c6c22acd17_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEtMy0xLTEtMA_56b2dbbc-08ef-488e-bb2d-721566ef06b0"
      unitRef="usdPerShare">41.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i13fcb2c445c04b488b8969b4514b4362_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEtNS0xLTEtMA_208f4ae1-a997-4b0d-85f7-d2eb6c730655">P7Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ifd01dc35d06044bb97b415c6c22acd17_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEtNy0xLTEtMA_67c3eecd-fb81-4af0-991c-959d8045ca90"
      unitRef="usd">49166000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzItMS0xLTEtMA_faf4b94a-2b3a-4e19-9d29-7d104dfb31d5"
      unitRef="shares">1872758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzItMy0xLTEtMA_7644f7ee-7152-4ecd-88d6-8d607c85d579"
      unitRef="usdPerShare">42.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzMtMS0xLTEtMA_a600ca69-693a-4974-9f39-54d7975e57e7"
      unitRef="shares">425495</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzMtMy0xLTEtMA_a543ce18-c27e-494a-939a-2476dc52855c"
      unitRef="usdPerShare">19.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzMtNy0xLTEtMA_461c4186-80a5-4ae5-9f32-801fb35c995c"
      unitRef="usd">9441000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzQtMS0xLTEtMA_4b591907-2a11-400f-b67e-c2236e1df534"
      unitRef="shares">286779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzQtMy0xLTEtMA_955bdae9-5ab2-409b-9615-a18b1a656d45"
      unitRef="usdPerShare">39.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzUtMS0xLTEtMA_f9d7e1f2-2c6b-4da2-8c3e-c915ae915e6d"
      unitRef="shares">176924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzUtMy0xLTEtMA_30054414-e691-43b6-a72b-6675a5a703af"
      unitRef="usdPerShare">63.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ice16f3771e3e4ef983ae97345cb147d7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzYtMS0xLTEtMA_63eb9599-a18f-4f1a-aae7-b78fb79cad9b"
      unitRef="shares">6706378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ice16f3771e3e4ef983ae97345cb147d7_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzYtMy0xLTEtMA_24aa9f1e-6de5-4a29-9f19-5fb3a498877e"
      unitRef="usdPerShare">42.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzYtNS0xLTEtMA_7555be59-bae5-419c-b8d1-2a5106b3e84c">P7Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ice16f3771e3e4ef983ae97345cb147d7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzYtNy0xLTEtMA_bf1574ae-bae5-483c-b944-2a343e951af0"
      unitRef="usd">50652000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzctMS0xLTEtMA_270f1b4d-c0f9-42b3-be09-60a1758db33e"
      unitRef="shares">1502803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzctMy0xLTEtMA_fc774e6f-1a72-4b94-bd0d-aef3c5be7d63"
      unitRef="usdPerShare">47.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzgtMS0xLTEtMA_7e8b1a02-0057-4be5-8cf9-588b7bc084e1"
      unitRef="shares">1428111</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzgtMy0xLTEtMA_b1aefad7-0d6b-4937-b4d4-4a6e64a675b3"
      unitRef="usdPerShare">31.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzgtNy0xLTEtMA_4d52ff90-7b6b-467b-b0b8-0a206fb08e14"
      unitRef="usd">34227000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzktMS0xLTEtMA_b657c7de-29e1-4964-9d97-7c93a77f2189"
      unitRef="shares">426925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzktMy0xLTEtMA_d52d3bd1-e9a3-4a9b-a2f3-2dba1de4a7df"
      unitRef="usdPerShare">42.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEwLTEtMS0xLTA_62ffda7e-6956-4469-977a-e0562998bb06"
      unitRef="shares">119027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEwLTMtMS0xLTA_e2651c63-6e10-4870-8123-6b7e20108453"
      unitRef="usdPerShare">71.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i917c4f0133de471d87fe63c0cf97feec_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzExLTEtMS0xLTA_30d03322-b89a-43ca-9d2a-15010ba00a05"
      unitRef="shares">6235118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i917c4f0133de471d87fe63c0cf97feec_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzExLTMtMS0xLTA_29a1a510-2820-4952-94f9-f102ed811557"
      unitRef="usdPerShare">45.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzExLTUtMS0xLTA_5d447fa7-3e46-469f-8c01-51caa1d876eb">P6Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i917c4f0133de471d87fe63c0cf97feec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzExLTctMS0xLTA_9d3f00d9-7f59-4def-b7ce-4eaa0aff673c"
      unitRef="usd">102955000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEyLTEtMS0xLTA_8695ea19-90dc-4621-9e93-7d97e10fa0a3"
      unitRef="shares">890277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEyLTMtMS0xLTA_ba8e560e-b86f-4fef-beaa-255cb18918fc"
      unitRef="usdPerShare">60.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEzLTEtMS0xLTA_b0d9eaa5-3ca7-483f-a9a1-3bcd61b82029"
      unitRef="shares">732117</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEzLTMtMS0xLTA_e445cf12-f4e2-4b4e-aa3a-dce5fd99d276"
      unitRef="usdPerShare">32.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzEzLTctMS0xLTA_21049f2e-5d06-4172-9a2e-32d3e47d5b2b"
      unitRef="usd">23967000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE0LTEtMS0xLTA_5a772a84-534d-4b3f-90af-a08d525be030"
      unitRef="shares">278233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE0LTMtMS0xLTA_203163e8-cc72-44ae-8ca3-16eba2575088"
      unitRef="usdPerShare">46.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE1LTEtMS0xLTA_f5da98bd-3027-46f2-a0e0-7b3c8b19bc48"
      unitRef="shares">64505</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE1LTMtMS0xLTA_ce10c102-f09d-4f60-a504-28b94af67cca"
      unitRef="usdPerShare">80.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE2LTEtMS0xLTA_2b37c758-9522-45f6-b2dc-b5a63163153b"
      unitRef="shares">6050540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE2LTMtMS0xLTA_64fc7c68-903f-426d-95c3-4787068a1355"
      unitRef="usdPerShare">49.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE2LTUtMS0xLTA_66d88ded-312e-40cc-92bb-1e00b2dda65d">P6Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE2LTctMS0xLTA_dc00acce-0a37-4d5b-b804-038ea52bf0dc"
      unitRef="usd">81407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE3LTEtMS0xLTA_b0b4067a-5488-4ac1-bf1a-01c408fc14a3"
      unitRef="shares">3826646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE3LTMtMS0xLTA_8dc92cf1-6d60-464c-bbea-792fb51bb1c6"
      unitRef="usdPerShare">48.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE3LTUtMS0xLTA_35ef4a1d-68b3-4d0f-a3dc-cd4030505e7e">P5Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE3LTctMS0xLTA_f7fecb92-2800-42f1-b472-16533ef4a263"
      unitRef="usd">59972000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE4LTEtMS0xLTA_29e7d870-e255-4536-8f54-40fb19ae7132"
      unitRef="shares">6050540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE4LTMtMS0xLTA_763883cf-8abe-43e8-a8d1-6057fb1430bb"
      unitRef="usdPerShare">49.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE4LTUtMS0xLTA_5beeecab-81fb-4962-a644-cfc80419a538">P6Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTowMGFhMTRkOTMxZDI0NzgzYjg2MTdkYTA0NWY2YmY4ZS90YWJsZXJhbmdlOjAwYWExNGQ5MzFkMjQ3ODNiODYxN2RhMDQ1ZjZiZjhlXzE4LTctMS0xLTA_785060da-6b68-4557-9981-fbbc36552393"
      unitRef="usd">81407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ida3a6c4fe85b491991fb0aa639cee538_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM1NTA_afffb74e-91b7-48b2-b373-7c365419f88c"
      unitRef="usd">47300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM2OTI_76ea6c45-f863-4bee-9c63-b4bfcce1718e">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM3NTg_86ef79e3-90b4-4750-ae25-594fbd2a05d8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM4ODE_a7489be8-a356-4afc-8a08-ce37983f2a86"
      unitRef="usdPerShare">26.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM4ODU_75905af0-e66a-4846-a407-d573fa3c404b"
      unitRef="usdPerShare">22.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzM4OTI_3ff7b523-1838-4134-af2a-f2fb03368108"
      unitRef="usdPerShare">20.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2ODk_af649082-109b-4d7d-8101-18c027b22ca6">The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Black-Scholes Weighted Average Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43% - 1.21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22% - 1.60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.33% - 2.54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.36 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.36 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.22 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzItMi0xLTEtMA_232eec0d-5b70-4636-b1ca-abf2e30af949"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzItNC0xLTEtMA_f8f629f6-e8a6-41fb-8921-6f2eb8f41ccf"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzItNi0xLTEtMA_2b36dd3a-e46e-4f9a-8af4-9e2e89c8dbb2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmI3ZThmMWJmNTkyNTQ1YjRiODM5MzM2ZDBlMDc1NDc2XzQ_3a09fc7b-cc64-4b0b-be1c-589eecf54cc0"
      unitRef="number">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtMi0xLTEtMC90ZXh0cmVnaW9uOmI3ZThmMWJmNTkyNTQ1YjRiODM5MzM2ZDBlMDc1NDc2Xzk_81769dc4-58ce-498f-b74a-c8131629045b"
      unitRef="number">0.0121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtNC0xLTEtMC90ZXh0cmVnaW9uOmEyZWNjOTA4NTJjZTQ0MDk5N2MyN2JkZWJkYTg1Zjk2XzQ_2d54a666-2cf5-42ea-90e6-c9d822279ef9"
      unitRef="number">0.0022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtNC0xLTEtMC90ZXh0cmVnaW9uOmEyZWNjOTA4NTJjZTQ0MDk5N2MyN2JkZWJkYTg1Zjk2Xzk_faea1877-3ef5-49b6-83fd-27c9c0cb16d0"
      unitRef="number">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtNi0xLTEtMC90ZXh0cmVnaW9uOmFmZDgzYTE3MWJkMTQxYzNiOWUyOWM1YjBlZmY2N2NiXzQ_6624df72-a3ab-4db8-a555-fb87b441c77c"
      unitRef="number">0.0133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzMtNi0xLTEtMC90ZXh0cmVnaW9uOmFmZDgzYTE3MWJkMTQxYzNiOWUyOWM1YjBlZmY2N2NiXzk_5820542b-4958-4938-8187-530ba73e6d2c"
      unitRef="number">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzQtMi0xLTEtMA_ded4f82b-b8ac-41ff-98cb-f1679f002140"
      unitRef="number">0.491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzQtNC0xLTEtMA_87d4edf6-ad85-4944-b4a2-829e346276c8"
      unitRef="number">0.535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzQtNi0xLTEtMA_a7607165-c281-4a8f-82de-83d597b89ac8"
      unitRef="number">0.539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzUtMi0xLTEtMA_91f8bd3a-b5a1-45ee-b272-080c8432f78f">P5Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzUtNC0xLTEtMA_4a8c36dd-1f0b-4657-a850-9afcaf8a0c8b">P5Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo3N2QyZGY2MDQ4MDg0NmNmOTZlODc2NmQ5MWVlMDMwNC90YWJsZXJhbmdlOjc3ZDJkZjYwNDgwODQ2Y2Y5NmU4NzY2ZDkxZWUwMzA0XzUtNi0xLTEtMA_9f3e9c8d-a24f-4429-b5af-8b3c62085d77">P5Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2Njg_7520f11d-55e2-4d1b-b29d-2a3d4d2942e5">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSU activity and related information for the period from December 31, 2018 to December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value (Per Share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(239,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and expected to vest at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iaca373b6b867452b83d716b6422dc258_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEtMS0xLTEtMA_6a9206e7-20e0-4614-83ba-36804e9c317e"
      unitRef="shares">577964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iaca373b6b867452b83d716b6422dc258_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEtMy0xLTEtMA_a075ab55-489a-417c-bf47-3ff0b85376d0"
      unitRef="usdPerShare">42.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="iaca373b6b867452b83d716b6422dc258_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEtNS0xLTEtMA_1c3e3663-f7f8-4c59-a1ad-2fbe5391ecdc"
      unitRef="usd">24864000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzItMS0xLTEtMA_d340fcfd-8171-4b51-bf09-224919fa5753"
      unitRef="shares">305418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzItMy0xLTEtMA_404651d0-d962-415f-83d9-f8fc719597fe"
      unitRef="usdPerShare">43.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzMtMS0xLTEtMA_18d6932b-3afc-4a41-b751-a57cc5396a46"
      unitRef="shares">192760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzMtMy0xLTEtMA_0df2d80f-d08a-43ed-b655-0f4537fb7d6f"
      unitRef="usdPerShare">45.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzQtMS0xLTEtMA_1f373228-ba15-4d53-aa85-1afdc3319c62"
      unitRef="shares">59481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzQtMy0xLTEtMA_1d5bba08-f043-4dac-9fe5-756524d4239b"
      unitRef="usdPerShare">41.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic1c7481893dd4af497518d21d834ab65_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzUtMS0xLTEtMA_74658b1f-01a1-4968-9f2e-b888117469d7"
      unitRef="shares">631141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic1c7481893dd4af497518d21d834ab65_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzUtMy0xLTEtMA_77e96d67-56c7-405e-b93e-88270e75ddcf"
      unitRef="usdPerShare">41.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ic1c7481893dd4af497518d21d834ab65_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzUtNS0xLTEtMA_8f0d2aff-f78e-4fa3-8a19-77bdde89a478"
      unitRef="usd">28591000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzYtMS0xLTEtMA_75154cad-80ba-4065-94df-04aea3d9d6de"
      unitRef="shares">665476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzYtMy0xLTEtMA_d628e667-813d-4711-a2d7-275a2a9c62c3"
      unitRef="usdPerShare">48.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzctMS0xLTEtMA_d6ec11f8-59a4-479e-9d73-98ddd1d9b823"
      unitRef="shares">239085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzctMy0xLTEtMA_f7af9948-0f85-44f3-bc37-fdc83ef142a1"
      unitRef="usdPerShare">41.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzgtMS0xLTEtMA_d25b10eb-1dcd-415a-96a8-bd8d935b7244"
      unitRef="shares">100079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzgtMy0xLTEtMA_a5a3c555-08f9-4807-96dc-dca7d6413e58"
      unitRef="usdPerShare">44.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibfa96bfa146c401bafdd7c90c8ba2c6e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzktMS0xLTEtMA_8aae10a4-c82f-49f7-a842-0fa83310fa02"
      unitRef="shares">957453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ibfa96bfa146c401bafdd7c90c8ba2c6e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzktMy0xLTEtMA_fb1c025b-ef19-4798-ba52-f2b617ab8aa4"
      unitRef="usdPerShare">46.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ibfa96bfa146c401bafdd7c90c8ba2c6e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzktNS0xLTEtMA_106df534-51fd-42a5-90dc-b389e22c7123"
      unitRef="usd">57294000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEwLTEtMS0xLTA_c1c00dff-c05b-4940-9115-8af90e25265f"
      unitRef="shares">446450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEwLTMtMS0xLTA_7f533598-4741-4572-87ee-9e687069e8fc"
      unitRef="usdPerShare">60.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzExLTEtMS0xLTA_cfb410f9-de1d-4e1b-b0bd-265646d69e8b"
      unitRef="shares">309779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzExLTMtMS0xLTA_56890cbe-daeb-4f49-9484-17b52da7fadc"
      unitRef="usdPerShare">45.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEyLTEtMS0xLTA_8e85e84a-0c7d-4c89-be95-56d802cbfe30"
      unitRef="shares">138847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEyLTMtMS0xLTA_ce7d8c2b-f254-42da-8bdd-bf86c8b66d83"
      unitRef="usdPerShare">50.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib38eaa600b8e42a9851a181401b7e23e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEzLTEtMS0xLTA_73eb40a9-783f-48c5-af5f-25bd8e7e0307"
      unitRef="shares">955277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib38eaa600b8e42a9851a181401b7e23e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEzLTMtMS0xLTA_da4173cf-1e18-4759-979c-35181de0de66"
      unitRef="usdPerShare">52.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ib38eaa600b8e42a9851a181401b7e23e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTozMzhkYmI3Mjc0MDk0MTk0YmEwYjE5NThjNzA4OTI0ZS90YWJsZXJhbmdlOjMzOGRiYjcyNzQwOTQxOTRiYTBiMTk1OGM3MDg5MjRlXzEzLTUtMS0xLTA_62f0bd94-660f-4d3a-8673-d5130b7a2e38"
      unitRef="usd">57479000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib38eaa600b8e42a9851a181401b7e23e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQxOTU_e96bb34f-817e-4a2d-990d-0d6cac8b7e50"
      unitRef="usd">41000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQzMjg_33eb1ca6-6922-4b57-8492-0d5aa4f5d025">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQzNzk_a32e4e66-db68-4d8e-9ca3-bae2ef4f57a2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90ZXh0cmVnaW9uOmQ4YTMzYTQzOTU4ZjRjMmJiOWM4YjlmOTVhZDQ0NmQ1XzQ2Njk_505b4daf-e80d-41d0-87b6-7875dfcf78cf">&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the ESPP share options granted were estimated using the Black-Scholes model with the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Black-Scholes Weighted Average Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP share option fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.16 - $15.23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.02 - $17.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.13 - $11.36&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50% - 0.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14% - 1.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% - 2.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of ESPP share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie8686eb39d5c4df494e9414f7b85eb73_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItMi0xLTEtMC90ZXh0cmVnaW9uOjNhZTE0OGY1NjZkZTRkN2Y5ZDk5ZGIxYzRmYTVkODVkXzQ_83f089c0-ec0d-4471-b46c-11e879ea864c"
      unitRef="usdPerShare">15.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1d0fc32d88804baaab656363bb728911_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItMi0xLTEtMC90ZXh0cmVnaW9uOjNhZTE0OGY1NjZkZTRkN2Y5ZDk5ZGIxYzRmYTVkODVkXzk_45789999-7eb6-436a-b925-8b34ef2749ad"
      unitRef="usdPerShare">15.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i70c23ac5a7584fcfbb011f898d04aa74_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItNC0xLTEtMC90ZXh0cmVnaW9uOjU1YTIxYTA3YmY0YzQ5YWI4NTZlZGY1ZWU1OTEwZmRhXzQ_122aa965-33b9-4c2e-b119-b7d58a4717f7"
      unitRef="usdPerShare">11.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iab19655e67644e4a974aac9a1311b637_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItNC0xLTEtMC90ZXh0cmVnaW9uOjU1YTIxYTA3YmY0YzQ5YWI4NTZlZGY1ZWU1OTEwZmRhXzk_6bf17ebc-e5f3-4feb-98b7-be9f1b82f924"
      unitRef="usdPerShare">17.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iefedf24a9a184d26b9444aa1d2768efd_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItNi0xLTEtMC90ZXh0cmVnaW9uOjQxZDAyZDNhNGI4ZDQzZDE4ZGNjMTM2OGM1MTI0MmZkXzQ_5ff4677f-a0d8-45c2-ba6d-8e2ec02d0983"
      unitRef="usdPerShare">11.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iddd1835957aa4542b486125e347c2dff_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzItNi0xLTEtMC90ZXh0cmVnaW9uOjQxZDAyZDNhNGI4ZDQzZDE4ZGNjMTM2OGM1MTI0MmZkXzk_d6d3e38f-9b2d-46e4-adf1-a0bc7a917fcb"
      unitRef="usdPerShare">11.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzMtMi0xLTEtMA_53f0c2f7-5ca5-4634-bc40-d820ce8eb6f6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzMtNC0xLTEtMA_106c290f-fef1-40e0-8751-439464f55939"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzMtNi0xLTEtMA_66c5b60c-548b-4ea2-8fd8-3ed9de93068b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtMi0xLTEtMC90ZXh0cmVnaW9uOjI5ZjU5Mjg5MjM2NTQzNmRhNTU0MDZkOGExNjM1Y2U3XzQ_08d9a99e-fa2a-4022-a738-2606bac7ec1e"
      unitRef="number">0.0050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtMi0xLTEtMC90ZXh0cmVnaW9uOjI5ZjU5Mjg5MjM2NTQzNmRhNTU0MDZkOGExNjM1Y2U3Xzk_734a51b3-6069-44eb-b1a4-b5c508d1768b"
      unitRef="number">0.0090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtNC0xLTEtMC90ZXh0cmVnaW9uOmYzMDhkOTgwNTZkYjQ2MmE5NGNhYWNmODIzODVkOTJmXzQ_5769ca0c-6ced-4ce1-9545-c0a84009de1c"
      unitRef="number">0.0014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtNC0xLTEtMC90ZXh0cmVnaW9uOmYzMDhkOTgwNTZkYjQ2MmE5NGNhYWNmODIzODVkOTJmXzk_74c2fc47-ce27-4eb1-9083-6ee8ae34f817"
      unitRef="number">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtNi0xLTEtMC90ZXh0cmVnaW9uOmQ1NjkzMmE3ZWIzZDRkMWZiM2M4NGE0NDIxMDZiZGEwXzQ_5dd57f43-db44-4238-b7c9-1bd9ce739628"
      unitRef="number">0.0210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzQtNi0xLTEtMC90ZXh0cmVnaW9uOmQ1NjkzMmE3ZWIzZDRkMWZiM2M4NGE0NDIxMDZiZGEwXzk_8984efe1-06de-418a-9741-100a458dfd37"
      unitRef="number">0.0256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzUtMi0xLTEtMA_928dd558-4300-4f8c-b906-721b0d90c11e"
      unitRef="number">0.370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzUtNC0xLTEtMA_b5a1a47b-270d-4821-85d0-eed043936472"
      unitRef="number">0.449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzUtNi0xLTEtMA_103665b7-bef4-4c88-bb87-62eb2a93d359"
      unitRef="number">0.402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzYtMi0xLTEtMA_389b7a9d-2f68-4a08-8ff2-198c5c193baa">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzYtNC0xLTEtMA_d9f01ef9-1e82-4ef1-abfd-5633b16488a5">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODQvZnJhZzpkOGEzM2E0Mzk1OGY0YzJiYjljOGI5Zjk1YWQ0NDZkNS90YWJsZTo1MmM4YTJmZGRmYTI0ZjMyODJiMzBhNzY2ZTU4ZWI1Ny90YWJsZXJhbmdlOjUyYzhhMmZkZGZhMjRmMzI4MmIzMGE3NjZlNThlYjU3XzYtNi0xLTEtMA_9f16f2df-a026-4483-b95b-665a1c44516e">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90ZXh0cmVnaW9uOjQ0NTczYjMxODhmYTQ1NTI4NGJiZWQ3ODQwOGZkZDUxXzEyNTI_60c22994-46b5-4148-a34c-f19ae8eb4d09">NET INCOME (LOSS) PER SHARE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential common shares are excluded from the diluted net income (loss) per share computation to the extent that they would be antidilutive. Because the Company reported a net loss for the year ended December 31, 2019, no potentially dilutive securities were included in the computation of diluted net loss per share for that period. As discussed in Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has the option to pay cash for the aggregate principal amount due upon the conversion of its 2022 Notes and 2025 Notes. Since it is the Company&#x2019;s intent to settle the principal amount of its 2022 Notes and 2025 Notes in cash, the potentially dilutive effect of such notes on net income (loss) per share is computed under the treasury stock method. As discussed in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ASU 2020-06 will require the Company to use the if-converted method upon adoption; this new accounting pronouncement was not adopted as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net income (loss) per common share for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computation of diluted securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of conversion premium on the 2022 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of ESPP purchase options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the outstanding stock options, RSUs and ESPP purchase options that were excluded from the diluted net income (loss) per common share calculation because the effect of including these potential shares were antidilutive in the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average ESPP purchase options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90ZXh0cmVnaW9uOjQ0NTczYjMxODhmYTQ1NTI4NGJiZWQ3ODQwOGZkZDUxXzEyNTU_ba7bbb84-13f4-4e76-8b3e-ebcdd3756664">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net income (loss) per common share for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computation of diluted securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of conversion premium on the 2022 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of ESPP purchase options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzMtMS0xLTEtMA_fbd77b7e-a5ae-4f19-84d4-aedfa75877d9"
      unitRef="usd">41980000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzMtMy0xLTEtMA_0bf17b3f-3869-4b19-89a9-4c6094cb9a82"
      unitRef="usd">145523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzMtNS0xLTEtMA_b58e627b-86cc-4273-9a20-6fd7e3f7f065"
      unitRef="usd">-11016000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEwLTEtMS0xLTA_0b9387ec-3bef-494b-bbed-054d64c19342"
      unitRef="shares">44262000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEwLTMtMS0xLTA_ed7b3151-0c96-4b6a-aa28-e2d2c6009392"
      unitRef="shares">42671000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEwLTUtMS0xLTA_b884636f-3ee7-461a-a94e-10ec7992c823"
      unitRef="shares">41513000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEyLTEtMS0xLTA_dbb379ed-bf6c-4b04-8c85-6aa2bf80d926"
      unitRef="shares">1030000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icd03b01983774133bc52f848b068b1d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEyLTMtMS0xLTA_063ae7c4-00c4-47a7-a1a8-4f73a49a2bf9"
      unitRef="shares">783000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i24ad95c8123e4c47a9ad6c241a19de16_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEyLTUtMS0xLTA_48a8aacc-1ee5-402b-94a6-505dfb86ea36"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iee2f36f59cdd4f33a7518c16d2a55c59_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEzLTEtMS0xLTA_142550e5-7708-4ab7-af3b-7000b499ad1c"
      unitRef="shares">298000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4be31b71a6334121a91f3a0f0142f647_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEzLTMtMS0xLTA_68f2bfcf-d987-49a2-bc1a-12d8a9c79d45"
      unitRef="shares">227000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i63ee1013211f464fbb424f3d6b673ed8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzEzLTUtMS0xLTA_cafef63c-6de0-49fb-a72c-ea15030073b8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i6be8009e772e4e3ba8f05b461e089043_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE0LTEtMS0xLTA_9f077e8f-f8da-4d01-a0f5-a9f2039b6b00"
      unitRef="shares">38000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i79e95c7521ee4accbedc88d358e96964_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE1LTEtMS0xLTA_e56e3256-3394-48d2-bc58-04d22b371ff5"
      unitRef="shares">2000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i522cf561ced041ffb062aab7d8d17f88_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE1LTMtMS0xLTA_dc2b22b7-0f17-4f99-a990-fa46c399442e"
      unitRef="shares">1000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ice51f6d8e8be4ae1bef28f90dc96f87d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE1LTUtMS0xLTA_1ef389cc-1a47-44d8-ada0-d316175688c3"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE2LTEtMS0xLTA_db0ea1a8-22a7-4968-8771-7a2bd428d712"
      unitRef="shares">45630000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE2LTMtMS0xLTA_be4ae750-060c-4dfe-aaca-b7bc4c696e76"
      unitRef="shares">43682000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE2LTUtMS0xLTA_d85bc99f-0ad7-4410-b2de-6648dd62970e"
      unitRef="shares">41513000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE4LTEtMS0xLTA_0471bcba-00e2-4fea-8e38-aff8e667b5f7"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE4LTMtMS0xLTA_8efa565c-c9b3-4e82-8609-f5737833b833"
      unitRef="usdPerShare">3.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE4LTUtMS0xLTA_170a7dde-0fb1-4231-9bff-a90e5902e5a9"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE5LTEtMS0xLTA_cc5ef349-c246-4faf-8802-21ad9b268035"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE5LTMtMS0xLTA_7f269cfa-bf9c-4c83-ae05-47b20fa2ecb2"
      unitRef="usdPerShare">3.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZToxNmZiNmNkNDhhMWU0ZDc4YjY2YzhhYWUyNTAxY2QyMy90YWJsZXJhbmdlOjE2ZmI2Y2Q0OGExZTRkNzhiNjZjOGFhZTI1MDFjZDIzXzE5LTUtMS0xLTA_e825d9a4-4ee4-410a-a2dc-0e2eb213d2ce"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90ZXh0cmVnaW9uOjQ0NTczYjMxODhmYTQ1NTI4NGJiZWQ3ODQwOGZkZDUxXzEyNTk_d6fdd7a5-f53c-410f-b0f7-547c859e22db">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the outstanding stock options, RSUs and ESPP purchase options that were excluded from the diluted net income (loss) per common share calculation because the effect of including these potential shares were antidilutive in the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average ESPP purchase options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id414a99ec0d0409883eb8b2bdee4eb13_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzItMS0xLTEtMA_59925f5a-313f-440c-b1aa-52c892530a60"
      unitRef="shares">2141000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3a963ed83400446a9515a4a04cf232b9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzItMy0xLTEtMA_18e78e4a-be7a-4b04-b1e4-1002ddf50b6d"
      unitRef="shares">4237000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i82a7bb9e5e6343258f6bed68cd00465f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzItNS0xLTEtMA_623c6ab8-62fd-444f-8362-48cb4654839a"
      unitRef="shares">6404000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1826d05ddc2f4352b6b5b4681a620e28_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzMtMS0xLTEtMA_ff49db7a-6ebc-4e7f-9ce0-e16dbb00de9e"
      unitRef="shares">116000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1e541832bfb246b2a8efc0f7289d4bd7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzMtMy0xLTEtMA_0da2627d-5b9c-4d84-a69b-3ef5e5cbf4d2"
      unitRef="shares">99000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib770abe7bb5740aab0aa7d6eab698b4a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzMtNS0xLTEtMA_36d1dd5c-df47-4cb1-af62-427ea0e36701"
      unitRef="shares">606000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i654e613b80f445abb2eaf1e762ad8cd3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzYtMS0xLTEtMA_7523dc09-130d-4f67-aeaf-22589cb2c31b"
      unitRef="shares">13000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4c2116fd2ce647d29354014822fa3386_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzYtMy0xLTEtMA_2b2e48e2-769e-4ffe-bf09-bc3a738e827b"
      unitRef="shares">16000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7ccac5f6e0624be1b654c50898619041_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzYtNS0xLTEtMA_6ea1a71c-ff6a-4aef-ab31-26a1d7eb69df"
      unitRef="shares">34000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzctMS0xLTEtMA_c5e6418c-ee5e-43a2-90e0-9b36f0050e15"
      unitRef="shares">2270000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzctMy0xLTEtMA_e0719f75-c766-4ecc-8dc7-4652423df5ef"
      unitRef="shares">4352000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xODcvZnJhZzo0NDU3M2IzMTg4ZmE0NTUyODRiYmVkNzg0MDhmZGQ1MS90YWJsZTo5ZmYzNzA1MWE2MGE0MWZkODcwZDRhYTgwOTQ4ODkxNC90YWJsZXJhbmdlOjlmZjM3MDUxYTYwYTQxZmQ4NzBkNGFhODA5NDg4OTE0XzctNS0xLTEtMA_7a53b706-0f4f-4217-adcf-493681ccbb04"
      unitRef="shares">7044000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcwOTE_c06fc5a7-6616-4501-b28e-3bd0be748940">INCOME TAXES&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes and the related tax expense (benefit) is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total current taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense of $14.4&#160;million for the year ended December 31, 2021 represents the effective tax rate applied to domestic operating results adjusted for certain discrete tax items including deductible stock-based compensation, non-deductible capital losses and tax credits. For the year ended December 31, 2020, the Company had an income tax benefit of $125.4&#160;million primarily related to the release of a valuation allowance on its domestic net deferred assets. The income tax expense for the year ended December 31, 2019 consists primarily of state income taxes in jurisdictions where the availability of carryforward losses are either limited or fully utilized as well as state taxes on the one-time gain from the deemed sale of assets resulting from an IRC section 338(g) tax election made by the Company related to the MyoScience Acquisition. This was partially offset by a reduction in the Company&#x2019;s valuation allowance on its deferred tax assets due to the MyoScience Acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647.87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes refinancing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338(g) tax election&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(624.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective tax rates of 25.57%, (624.39)% and (2.49)% for the years ended December&#160;31, 2021, 2020 and 2019, respectively, differed from the expected U.S. statutory tax rate of 21.0%. The difference in tax rates for the year ended December 31, 2021 was primarily driven by non-deductible expenses and valuation allowances recorded against capital loss carryforwards, partially offset by stock-based compensation deductions and tax credits. The difference in tax rates for the year ended December 31, 2020 was primarily due to the release of a domestic valuation allowance of $126.6&#160;million as discussed below. The difference for the year ended December 31, 2019 was primarily driven by pretax losses for which the Company concluded that a majority of its tax benefits are not more-likely-than-not to be realized, resulting in the recording of a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. At each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. During the year ended December 31, 2020, the Company determined there was sufficient positive evidence to conclude that it was more-likely-than-not the domestic deferred taxes of $126.6&#160;million were realizable and, therefore, the domestic valuation allowance was released. The Company maintains a full valuation allowance on its foreign net deferred tax balances as it is more-likely-than-not the tax benefits are not realizable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities at December&#160;31, 2021 and 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company&#x2019;s federal net operating losses, or NOLs, and federal tax credit carryforwards totaled $662.6 million and $25.9 million, respectively. The Company also had state NOLs and state tax credit carryforwards of $171.6 million and $9.5 million, respectively, which are subject to change on an annual basis due to variations in the Company&#x2019;s annual state apportionment factors. The Company&#x2019;s federal and state NOLs carryforwards include $538.6&#160;million and $28.6&#160;million, respectively, attributed to the Flexion Acquisition. Additionally, the Company&#x2019;s federal and state tax credits include $11.0&#160;million and $3.6&#160;million, respectively, as a result of the Flexion Acquisition. The federal and state NOLs will begin to expire in 2032 and 2028, respectively. The Company had non-U.S. tax NOLs of $10.3 million at December&#160;31, 2021. The non-U.S. NOLs do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Company had cumulative changes in ownership of more than 50% within a three-year period, under IRC sections 382 and 383, the Company&#x2019;s ability to use certain net operating losses, tax attributes and credit carryforwards to offset taxable income or tax will be limited. Such ownership changes were triggered by the initial acquisition of the Company&#x2019;s stock in 2007 as well as cumulative ownership changes arising as a result of the completion of the Company&#x2019;s initial public offering and other financing transactions. Additionally, on November 19, 2021, the Company completed the Flexion Acquisition which also triggered an ownership change. As a result of these ownership changes, the Company estimates $531.7 million of federal net operating losses and $21.2&#160;million of other tax attributes are subject to annual limitations. At December&#160;31, 2021, all of these federal net operating losses and other tax attributes were available. The Company estimates that an additional $35.4 million will come available in each of 2022 to 2025, $30.8 million in 2026 and $6.9 million in 2027 and thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC Topic 740, the Company establishes a valuation allowance for deferred tax assets that, in its judgment, are not more-likely-than-not realizable. These judgments are based on projections of future income, including tax-planning strategies, by individual tax jurisdictions. In each reporting period, the Company assesses the likelihood that its deferred tax assets will be realized and determines if adjustments to its valuation allowance are appropriate. The Company had a net increase in its valuation allowance of $16.5 million and a net reduction in its valuation allowance of $126.6 million for the years ended December&#160;31, 2021 and December 31, 2020, respectively. The current year net increase in The Company&#x2019;s valuation allowance includes $12.5&#160;million as a result of the Flexion Acquisition, $2.2&#160;million against U.S. capital loss carryforwards and $1.8&#160;million against foreign net deferred tax assets. The Company continues to maintain a full valuation allowance against foreign net deferred tax assets since it is more-likely-than-not the tax benefit related to the foreign losses are not realizable. During the year ended December 31, 2020, the Company determined that there was sufficient positive evidence to conclude that it is more likely than not that additional domestic deferred taxes of $126.6&#160;million are realizable and, therefore, reduced the valuation allowance accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recorded a reserve of $2.9 million related to unrecognized tax benefits, or UTBs of which $4.3&#160;million related to tax credit positions taken during the year, offset by a $1.4&#160;million reduction for prior year tax credit positions. The Company&#x2019;s UTB liability at December 31, 2021 was $9.0 million. The change in the Company&#x2019;s UTBs for the year ended December&#160;31, 2021 is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Tax Benefit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Additions for current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction for prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly assesses the likelihood of additional tax assessments by jurisdiction and, if necessary, adjusts its reserve for UTBs based on new information or developments. Due to the Company&#x2019;s tax credit carryforwards, the reserve was recorded as a reduction of the Company&#x2019;s deferred tax assets, and any potential deficiency would not result in a tax liability. Therefore, no interest or penalties were recognized in income tax expense for the years ended December&#160;31, 2021, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently subject to audit by the U.S. Internal Revenue Service, or IRS, for the years 2018 through 2021, and state tax jurisdictions for the years 2017 through 2021. However, the IRS or states may still examine and adjust an NOL arising from a closed year to the extent it is utilized in a year that remains subject to audit. The Company&#x2019;s previously filed income tax returns are not presently under audit by the IRS or state tax authorities.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcwOTY_17d6eebe-995b-4d65-ba08-259e6f07a0ae">&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes and the related tax expense (benefit) is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total current taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzMtMS0xLTEtMA_1faeaaab-74bc-4923-b2b2-ba233721d4c1"
      unitRef="usd">64751000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzMtMy0xLTEtMA_3de36bc2-ad59-4d68-ad11-c16052674b5a"
      unitRef="usd">17000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzMtNS0xLTEtMA_fce436cc-a445-4407-bdd3-382a91d59c71"
      unitRef="usd">-7026000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzQtMS0xLTEtMA_55b9341d-25f3-4302-9a17-cefd118826eb"
      unitRef="usd">-8348000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzQtMy0xLTEtMA_418d1262-081c-4069-9403-df8e732e5567"
      unitRef="usd">3089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzQtNS0xLTEtMA_682cc15c-202a-4fa2-a769-486b9b8af637"
      unitRef="usd">-3722000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzUtMS0xLTEtMA_8e592a46-af6d-4d1f-b000-c19b19075191"
      unitRef="usd">56403000</pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal>
    <pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzUtMy0xLTEtMA_47733d6e-c7e8-43f9-86d3-2ca0d858ca68"
      unitRef="usd">20089000</pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal>
    <pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzUtNS0xLTEtMA_85cb5d51-41ae-410b-a870-96a6dce2a453"
      unitRef="usd">-10748000</pcrx:IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzgtMS0xLTEtMA_22d411bd-5626-489c-b88b-9779e46adec6"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzgtMy0xLTEtMA_a8ee941f-c3ae-470c-996c-4227afaaec5c"
      unitRef="usd">-6000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzgtNS0xLTEtMA_83acbe05-fd99-40be-98b7-ca4c3de7970c"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzktMS0xLTEtMA_e31132b8-ac80-45e1-89f6-6dfecb0572a5"
      unitRef="usd">3533000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzktMy0xLTEtMA_d0c50562-37fb-42f5-ac1c-149a2b452e42"
      unitRef="usd">1185000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzktNS0xLTEtMA_caeb82f6-88c8-46fd-9362-7e18d4692fb5"
      unitRef="usd">2096000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEwLTEtMS0xLTA_d002d806-4640-4e21-81d9-2bbe7f9c64e3"
      unitRef="usd">19000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEwLTMtMS0xLTA_27cb1f9f-ef7d-4cb2-a45a-9de64d9f3472"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEwLTUtMS0xLTA_90e46171-af9e-4eb6-9d35-78a4f7743fc0"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzExLTEtMS0xLTA_e5abadac-8a82-4ff4-a782-0bd5e02707c8"
      unitRef="usd">3552000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzExLTMtMS0xLTA_02981d8e-b53f-4bc2-9e23-c09d5a66e807"
      unitRef="usd">1179000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzExLTUtMS0xLTA_8dbb881a-8d54-4205-b74d-45e8beda4255"
      unitRef="usd">2096000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEzLTEtMS0xLTA_acd4e4a3-70ca-4f4f-84ba-c114c5f9bcc9"
      unitRef="usd">12554000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEzLTMtMS0xLTA_6f4832e4-f75b-4bd0-a303-495648986bea"
      unitRef="usd">-99164000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzEzLTUtMS0xLTA_965c6ca5-f51b-4626-a23e-6b92e6e4acda"
      unitRef="usd">-1828000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE0LTEtMS0xLTA_004a4cc8-9f4e-4c39-8e42-77f04d2524b6"
      unitRef="usd">-1682000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE0LTMtMS0xLTA_c63cfa7b-f0c9-4350-9ffb-40aab4e9127e"
      unitRef="usd">-27449000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE0LTUtMS0xLTA_bece58f8-c217-438e-b1c6-107c0728409a"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE2LTEtMS0xLTA_c9626555-8998-4d0f-9a3b-b771d76f6a98"
      unitRef="usd">10872000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE2LTMtMS0xLTA_8132a528-be5e-48a9-aa92-4f58f9433fc5"
      unitRef="usd">-126613000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE2LTUtMS0xLTA_c81bbcd3-bf76-4fe9-b16b-bf00c00cfa9c"
      unitRef="usd">-1828000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE4LTEtMS0xLTA_bb6b14a5-8de5-4df2-8fdb-e2d4a4fd37ed"
      unitRef="usd">14424000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE4LTMtMS0xLTA_12c47e6a-b1ab-4071-95bd-c55da722e942"
      unitRef="usd">-125434000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTpmZmEwYjUzMDA3ODQ0Mzk5OTViNDZiNDZlOGMxMmZiMy90YWJsZXJhbmdlOmZmYTBiNTMwMDc4NDQzOTk5NWI0NmI0NmU4YzEyZmIzXzE4LTUtMS0xLTA_19ee932d-4473-42ef-a192-d082e9212732"
      unitRef="usd">268000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTcyMDEw_58400ae8-5077-4a9b-b95a-5ff68a7ccf40"
      unitRef="usd">14400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzIwNw_3ae1a7cc-6c2a-4f0e-96fe-fa379c71a493"
      unitRef="usd">-125400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcwODg_590321df-48cb-4657-9d1d-31d3feb14717">&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income taxes at the U.S. federal statutory rate to the provision for income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(647.87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes refinancing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338(g) tax election&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(624.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzItMS0xLTEtMA_c152eaf0-4fc6-4a34-8f87-21e7c952e7aa"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzItMy0xLTEtMA_6f2c3064-c408-4d35-bb6e-921e1be02837"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzItNS0xLTEtMA_6dd95444-f2cb-4367-a0cf-94deab493930"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzMtMS0xLTEtMA_11fa6ccb-eda4-44b0-bade-d5df729b50b5"
      unitRef="number">0.0382</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzMtMy0xLTEtMA_d939f98f-4b16-463b-b3a1-15222f8226a2"
      unitRef="number">0.0315</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzMtNS0xLTEtMA_2b177fd0-3589-4561-b7c1-76742effb556"
      unitRef="number">-0.0733</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <pcrx:EffectiveIncomeTaxRateReconciliationForeign
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzQtMS0xLTEtMA_f40e0115-dd38-4339-91af-391d2b3097d6"
      unitRef="number">-0.0115</pcrx:EffectiveIncomeTaxRateReconciliationForeign>
    <pcrx:EffectiveIncomeTaxRateReconciliationForeign
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzQtMy0xLTEtMA_c445560d-e213-4210-9436-8ac6632b5469"
      unitRef="number">0.0318</pcrx:EffectiveIncomeTaxRateReconciliationForeign>
    <pcrx:EffectiveIncomeTaxRateReconciliationForeign
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzQtNS0xLTEtMA_c695c1c6-9e84-454d-b846-e15ed840ecc8"
      unitRef="number">-0.0395</pcrx:EffectiveIncomeTaxRateReconciliationForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzUtMS0xLTEtMA_1d35d8b5-6bbb-4530-a39b-0cbdf469d0da"
      unitRef="number">0.0655</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzUtMy0xLTEtMA_a9a09b71-c60c-40a1-9b88-91775fa56790"
      unitRef="number">-6.4787</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzUtNS0xLTEtMA_676c18bb-e987-42af-8c72-e7df527b5e14"
      unitRef="number">0.1976</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzYtMS0xLTEtMA_1c7b27d0-e5e8-488a-962c-968a89c45296"
      unitRef="number">0.0380</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzYtMy0xLTEtMA_9cfb1dd5-56cd-4e0a-b235-31e0f6b59c74"
      unitRef="number">0.0108</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzYtNS0xLTEtMA_58296c51-0706-436e-9088-ef7668baf1cc"
      unitRef="number">0.1053</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzctMS0xLTEtMA_bc6c6655-d075-48b3-adc3-5b6728318733"
      unitRef="number">0.0300</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzctMy0xLTEtMA_71bc1e06-d81b-44b5-bac7-e1000525b7c5"
      unitRef="number">0.0792</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzctNS0xLTEtMA_25e13eb9-2542-4a1b-945e-7d7236765bdd"
      unitRef="number">-0.1993</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <pcrx:EffectOfStateBlendedTaxRateChangesExpenseBenefit
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzktMS0xLTEtMA_dd6d7e13-c5bd-439c-b4cb-7fd6e5c20cb5"
      unitRef="number">0</pcrx:EffectOfStateBlendedTaxRateChangesExpenseBenefit>
    <pcrx:EffectOfStateBlendedTaxRateChangesExpenseBenefit
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzktMy0xLTEtMA_14696b30-0592-4fbc-a05a-9c588c1bc835"
      unitRef="number">0</pcrx:EffectOfStateBlendedTaxRateChangesExpenseBenefit>
    <pcrx:EffectOfStateBlendedTaxRateChangesExpenseBenefit
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzktNS0xLTEtMA_ccf83774-2ac9-4748-8046-80263a765891"
      unitRef="number">-0.0042</pcrx:EffectOfStateBlendedTaxRateChangesExpenseBenefit>
    <pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEwLTEtMS0xLTA_26841687-7ddc-430c-9fde-e38fb2713d6c"
      unitRef="number">0</pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing>
    <pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEwLTMtMS0xLTA_7814a698-d74e-4fb5-ab5c-76ae4cef90a3"
      unitRef="number">-0.0522</pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing>
    <pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEwLTUtMS0xLTA_c539eaaf-60d2-4525-aae1-440c7f2b435c"
      unitRef="number">0</pcrx:EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzExLTEtMS0xLTA_afa0cf50-fafd-48b5-9639-39bde6183895"
      unitRef="number">0.0513</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzExLTMtMS0xLTA_a83b2091-5aec-4b70-87a6-dacbcbe5b799"
      unitRef="number">0.0455</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzExLTUtMS0xLTA_ab5e433b-ff90-4db2-8b1f-c0a15af37c6a"
      unitRef="number">-0.1358</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <pcrx:EffectiveIncomeTaxRateReconciliationTaxReservesPercent
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEyLTEtMS0xLTA_8700ab1e-4012-4b0c-be98-3bbffd79861b"
      unitRef="number">-0.0131</pcrx:EffectiveIncomeTaxRateReconciliationTaxReservesPercent>
    <pcrx:EffectiveIncomeTaxRateReconciliationTaxReservesPercent
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEyLTMtMS0xLTA_31a70e52-a0be-47a3-93d0-9caedbcf5915"
      unitRef="number">0.0766</pcrx:EffectiveIncomeTaxRateReconciliationTaxReservesPercent>
    <pcrx:EffectiveIncomeTaxRateReconciliationTaxReservesPercent
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEyLTUtMS0xLTA_67336ff3-1416-4d72-8d8e-edd4ddf4d41b"
      unitRef="number">-0.1541</pcrx:EffectiveIncomeTaxRateReconciliationTaxReservesPercent>
    <pcrx:EffectiveIncomeTaxRateReconciliation338gElectionPercent
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEzLTEtMS0xLTA_3ed59150-75c7-42ba-8ee9-9acd108859b1"
      unitRef="number">0</pcrx:EffectiveIncomeTaxRateReconciliation338gElectionPercent>
    <pcrx:EffectiveIncomeTaxRateReconciliation338gElectionPercent
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEzLTMtMS0xLTA_4d6ffc46-7b9a-4b70-9abc-f117369131d2"
      unitRef="number">0</pcrx:EffectiveIncomeTaxRateReconciliation338gElectionPercent>
    <pcrx:EffectiveIncomeTaxRateReconciliation338gElectionPercent
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzEzLTUtMS0xLTA_3cdd8821-2cd4-4aed-b6c2-756987004a12"
      unitRef="number">-0.0961</pcrx:EffectiveIncomeTaxRateReconciliation338gElectionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE1LTEtMS0xLTA_2d81ba0d-ab8e-462c-b670-160b843fec2b"
      unitRef="number">-0.0167</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE1LTMtMS0xLTA_9dbef1ef-9eb4-462c-8373-7d204b6e98bd"
      unitRef="number">-0.0184</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE1LTUtMS0xLTA_dcf612b3-7aa1-45bc-8b43-5b73fa2c72bf"
      unitRef="number">-0.0235</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE2LTEtMS0xLTA_92d1d2a9-f55c-4fe3-a791-f2dfac697f51"
      unitRef="number">0.2557</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE2LTMtMS0xLTA_60997e57-c956-4d4b-89e6-b21fb6c57ee8"
      unitRef="number">-6.2439</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozMDk0NWE2MTQ1ODk0MWQ5OTE2M2U0MGU3NDAzYTQ3Zi90YWJsZXJhbmdlOjMwOTQ1YTYxNDU4OTQxZDk5MTYzZTQwZTc0MDNhNDdmXzE2LTUtMS0xLTA_dbe8af20-2dc4-4815-917c-2974b99b22bc"
      unitRef="number">-0.0249</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEwODk_726151b5-5fc9-40a8-99d6-9a0077e52ab2"
      unitRef="number">0.2557</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEwOTM_4ce15b44-9f41-4ba7-b825-1db61df2f615"
      unitRef="number">-6.2439</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzExMDA_e7f09974-ad03-4742-a7de-57c1e0b0d5b9"
      unitRef="number">-0.0249</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEyMDY_4e262664-18c3-480c-817b-fa06f928ccaf"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEyMDY_642816ac-66d4-4602-8eeb-0f9abbe28326"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEyMDY_7d2690f9-15e0-4ccb-beda-c15dcf60fa41"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzEzMzU_422909fa-afdc-42ff-a0ae-e861d75e996e"
      unitRef="usd">-126600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzI2MDA_654b3aa9-2652-4bb8-b3f9-6de69ab18b06"
      unitRef="usd">-126600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcxMDM_07532f00-015d-4155-8a6b-a86bed209765">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities at December&#160;31, 2021 and 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzMtMS0xLTEtMA_c6f6a5a6-5218-4e72-8f5f-344d9935ba54"
      unitRef="usd">174203000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzMtMy0xLTEtMA_da833b39-dc74-4bff-b306-2d7a3c7a7654"
      unitRef="usd">66123000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzQtMS0xLTEtMA_54d9ba8a-0d37-4f1f-af34-ef365fd47254"
      unitRef="usd">35414000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzQtMy0xLTEtMA_ba97ba7d-ba03-406c-95c6-0c48fa38343d"
      unitRef="usd">17335000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzYtMS0xLTEtMA_f670cdab-34cb-4eeb-a982-afad12c581e0"
      unitRef="usd">80237000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzYtMy0xLTEtMA_08c9db29-62d6-4115-8e9c-2eaf5a1da9e9"
      unitRef="usd">7254000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <pcrx:DeferredTaxAssetsStockBasedCompensation
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzYtMS0xLTEtNjQ1OTM_304a4600-deb0-420d-8e67-a4bb3a904049"
      unitRef="usd">24545000</pcrx:DeferredTaxAssetsStockBasedCompensation>
    <pcrx:DeferredTaxAssetsStockBasedCompensation
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzYtMy0xLTEtNjQ1OTM_88d7739c-9ecf-4019-846f-a56c43f59a71"
      unitRef="usd">21862000</pcrx:DeferredTaxAssetsStockBasedCompensation>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzctMS0xLTEtMA_5846852e-39f6-40d8-8cac-b1db3fabae3f"
      unitRef="usd">2430000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzctMy0xLTEtMA_7a98a1cd-6cec-447b-8bea-41f8cc22cadc"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzktMS0xLTEtMA_3f9ab73f-6703-44db-af34-6a09e217333c"
      unitRef="usd">572000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzktMy0xLTEtMA_b2079fe3-e33b-4eee-a6ad-229d941e8436"
      unitRef="usd">1345000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEwLTEtMS0xLTA_c3907348-995b-43cb-b2f7-7f1e2ef850c1"
      unitRef="usd">2441000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEwLTMtMS0xLTA_104553a4-ec78-4ac3-a3ef-bc83cae36aa8"
      unitRef="usd">2138000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzExLTEtMS0xLTA_45cf4437-2003-4149-b6e9-9a7e0d16c486"
      unitRef="usd">319842000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzExLTMtMS0xLTA_57badd26-8303-4181-9961-df16dc6e33e2"
      unitRef="usd">116057000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEzLTEtMS0xLTY0NTcw_db15d161-4e07-4ce5-9757-23f0941e4801"
      unitRef="usd">-131964000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEzLTMtMS0xLTY0NTcw_f364ee55-d495-4dcd-b726-6c5940a3f695"
      unitRef="usd">13473000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEzLTEtMS0xLTA_87b53ee8-50b6-4cc8-856c-cefdd4afe410"
      unitRef="usd">15521000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzEzLTMtMS0xLTA_8c9bb6da-de8f-4e33-8f29-c51b1dd2af29"
      unitRef="usd">20851000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE0LTEtMS0xLTY0NjI5_1642e4ba-8114-4268-a151-66caef97e999"
      unitRef="usd">147485000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE0LTMtMS0xLTY0NjI5_efff02a4-89bb-4e51-ac40-df55557184e7"
      unitRef="usd">7378000</us-gaap:DeferredIncomeTaxLiabilities>
    <pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE0LTEtMS0xLTA_11364ee3-b3aa-4b06-92b0-0c9a8f13aa50"
      unitRef="usd">172357000</pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance>
    <pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE0LTMtMS0xLTA_2f446f22-4db7-45ab-bac6-62384cc757ad"
      unitRef="usd">108679000</pcrx:DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE1LTEtMS0xLTA_ac3c3342-1359-45a8-96ac-27453304ffce"
      unitRef="usd">18993000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE1LTMtMS0xLTA_bfd219ae-37ea-44d3-a2be-e1ffbe8612d4"
      unitRef="usd">2515000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE2LTEtMS0xLTA_2a3bbe68-e755-42b9-a3ce-b2612e418284"
      unitRef="usd">153364000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTo0ODE0Y2E0ZGFlNmI0Y2ViOWExZmU0NDZkOGZkZWIzNi90YWJsZXJhbmdlOjQ4MTRjYTRkYWU2YjRjZWI5YTFmZTQ0NmQ4ZmRlYjM2XzE2LTMtMS0xLTA_bccee682-d138-4610-897a-e11f86fc777c"
      unitRef="usd">106164000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia52e5d1054ac4b44a90054d80c6509a1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzMyNjM_4d047ab8-c8b2-4643-8c86-9733afc09372"
      unitRef="usd">662600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i46f9b7c2524840cca0b7ffd47db88684_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzMyNzA_03890fed-1bb6-44db-91ad-cf712e383ce2"
      unitRef="usd">25900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id4141a4b22784eb593c98bb5aca5ba58_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzMzNTg_9e65f0fc-37bd-48f5-b7a1-10c4006e45a1"
      unitRef="usd">171600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="if331b6039ef04e5f968fc0addfc10181_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzMzNjU_e162991f-53c4-4c15-9f8d-df3f735aa4a1"
      unitRef="usd">9500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i119369de4e404fe3857119778cfab5ec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTc2Mjk2_94913fe6-c400-4d12-8e35-bf5a2b29ee45"
      unitRef="usd">538600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0f5ba37ffe97491eaff119eb51ec361a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTc2Mjc4_d18ef879-8ea9-4c5a-88f7-28cf77f8c8df"
      unitRef="usd">28600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i5fc3b655165947618391e9bed60d7390_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTc5MjE3_cc537304-ec5e-48a9-8042-b19a2d0a8c40"
      unitRef="usd">11000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i82f093ad3c8b4abb848c3099f207cc6a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTc5MjMy_6c03aa63-f2ba-4bcc-a25d-f5df601b957a"
      unitRef="usd">3600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id9b29e19572b4bbaa5c8f9cdba9c2d35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzM1Mzg_81c4fc5a-573e-43f0-9c38-472368933894"
      unitRef="usd">10300000</us-gaap:OperatingLossCarryforwards>
    <pcrx:MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzM3NjY_6f8bd538-7c5d-4e33-9a19-e24cb7c51b2f"
      unitRef="number">0.50</pcrx:MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax>
    <pcrx:NetOperatingLossSubjecttoLimitation
      contextRef="ia52e5d1054ac4b44a90054d80c6509a1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQyODk_2f623f61-291c-454c-8d9b-c4d9bd802b7e"
      unitRef="usd">531700000</pcrx:NetOperatingLossSubjecttoLimitation>
    <pcrx:OtherTaxAttributesSubjectToLimitation
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzExNTQ0ODcyMTIwMDg0_1bc3ef47-a8f3-4535-9d95-94a83683d548"
      unitRef="usd">21200000</pcrx:OtherTaxAttributesSubjectToLimitation>
    <pcrx:ExpectedAdditionalNetOperatingLossesInYearThree
      contextRef="i1cb2b41bd3004482921ace6f9b9f7baa_I20241231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ0NjQ_295d3f0d-baf7-4473-822f-275a8936d6f7"
      unitRef="usd">35400000</pcrx:ExpectedAdditionalNetOperatingLossesInYearThree>
    <pcrx:ExpectedAdditionalNetOperatingLossesInYearOne
      contextRef="if5bb0c9c97f24e95b1c6936b67f583e4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ0NjQ_618f9b60-0033-403a-8e30-7b9791b6e178"
      unitRef="usd">35400000</pcrx:ExpectedAdditionalNetOperatingLossesInYearOne>
    <pcrx:ExpectedAdditionalNetOperatingLossesInYearFour
      contextRef="i1346b922bbbc489fa1c57f1775c4d743_I20251231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ0NjQ_abde5851-6511-4c74-9f41-3241f5420168"
      unitRef="usd">35400000</pcrx:ExpectedAdditionalNetOperatingLossesInYearFour>
    <pcrx:ExpectedAdditionalNetOperatingLossesInYearTwo
      contextRef="ifda9345b7dc64e9cbe52d2c5cb3bfc6d_I20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ0NjQ_d2dd1a11-d29b-4642-bde7-2e53d3af5bd2"
      unitRef="usd">35400000</pcrx:ExpectedAdditionalNetOperatingLossesInYearTwo>
    <pcrx:ExpectedAdditionalNetOperatingLossesInYearFive
      contextRef="i9893ef209dd044118e3a2ae603b1bb78_I20261231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ1MTM_2e1b5c16-3594-4ada-b52a-49e373fa41d8"
      unitRef="usd">30800000</pcrx:ExpectedAdditionalNetOperatingLossesInYearFive>
    <pcrx:ExpectedAdditionalNetOperatingLossesInYearSix
      contextRef="i890f49a134e34776a700270d248f7c7d_I20271231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ1Mjg_140022ac-ed28-4d21-941c-6c639a34c519"
      unitRef="usd">6900000</pcrx:ExpectedAdditionalNetOperatingLossesInYearSix>
    <pcrx:ExpectedAdditionalNetOperatingLossesInYearAfterYearSix
      contextRef="i890f49a134e34776a700270d248f7c7d_I20271231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzQ1Mjg_d4c0771d-eac0-4b3f-97a0-40000c6cf1a8"
      unitRef="usd">6900000</pcrx:ExpectedAdditionalNetOperatingLossesInYearAfterYearSix>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzUzNzM_50748069-cdbc-448d-8c5b-ea2e53041191"
      unitRef="usd">-16500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzUzOTU_653afeb4-2ceb-40b5-873a-0306170ddb33"
      unitRef="usd">-126600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgxNTEy_52802af6-30b2-4682-b409-5700f6367228"
      unitRef="usd">12500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ic0f2c982cd5b4bb8a9925e4a655e2c4b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgxNTI3_f7125949-ac19-4167-8016-a5e0811934ff"
      unitRef="usd">2200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ib3d452fa4ecb406494b3046bb05e2386_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgxNTQx_69421328-d1b7-4b33-856c-345530e1d1c0"
      unitRef="usd">1800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i14837e0e58ba4784b70f1121737d5625_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzU2MzU_fb27fa61-e1c7-4759-a47a-5781a4e33559"
      unitRef="usd">-126600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzU5MTY_80cbe41f-1fd1-426e-824e-a633957e7de7"
      unitRef="usd">2900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgyMTg1_1f0f8643-739e-4f43-b38c-e8ec9e031352"
      unitRef="usd">4300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzE0MjkzNjUxMTgyMTk5_fd4f17aa-487a-4d69-9505-ae9d58b928df"
      unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzYwNTc_1043a79b-94b3-463c-aed1-347b577509dd"
      unitRef="usd">9000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90ZXh0cmVnaW9uOjI4MTIxNjc1N2QzZDRlOWJiM2UzMTczY2JlMWM3ODU2XzcxMDQ_495eb794-f83a-4270-89a1-40b2e29c87af">The change in the Company&#x2019;s UTBs for the year ended December&#160;31, 2021 is summarized as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Tax Benefit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Additions for current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction for prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozNjVhNDQ2MGYzYTQ0NDQ3OWZiOWM1NmI4NzYyODk3MS90YWJsZXJhbmdlOjM2NWE0NDYwZjNhNDQ0NDc5ZmI5YzU2Yjg3NjI4OTcxXzEtMi0xLTEtMA_4382028c-ba54-4a12-9804-4947fb59d177"
      unitRef="usd">6076000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozNjVhNDQ2MGYzYTQ0NDQ3OWZiOWM1NmI4NzYyODk3MS90YWJsZXJhbmdlOjM2NWE0NDYwZjNhNDQ0NDc5ZmI5YzU2Yjg3NjI4OTcxXzUtMi0xLTEtMA_ab6a9da3-238d-4da9-8594-f7a1da0e5fe2"
      unitRef="usd">4300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozNjVhNDQ2MGYzYTQ0NDQ3OWZiOWM1NmI4NzYyODk3MS90YWJsZXJhbmdlOjM2NWE0NDYwZjNhNDQ0NDc5ZmI5YzU2Yjg3NjI4OTcxXzYtMi0xLTEtNjA3Njg_a9a06d4d-f28f-4b98-bc88-32f44840d443"
      unitRef="usd">1355000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTAvZnJhZzoyODEyMTY3NTdkM2Q0ZTliYjNlMzE3M2NiZTFjNzg1Ni90YWJsZTozNjVhNDQ2MGYzYTQ0NDQ3OWZiOWM1NmI4NzYyODk3MS90YWJsZXJhbmdlOjM2NWE0NDYwZjNhNDQ0NDc5ZmI5YzU2Yjg3NjI4OTcxXzctMi0xLTEtMA_16946294-945d-40f4-befa-0bdd84467a69"
      unitRef="usd">9021000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE2NjI_c1d4ba65-8f22-4cb3-8f4f-49444dffd1f5">EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:8pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 401(k) plan is a deferred salary arrangement under section 401(k) of the IRC. Under the 401(k) plan, participating U.S. employees may defer a portion of their pre-tax earnings which are eligible for a discretionary percentage match as defined in the 401(k) plan and determined by the Company&#x2019;s board of directors (up to the maximum amount permitted by the IRC). The Company recognized $2.8 million, $2.9 million and $2.6 million of related compensation expense for its 401(k) discretionary match for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Compensation Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company&#x2019;s board of directors adopted the Company&#x2019;s Deferred Compensation Plan, or DCP. The Company intends that the DCP constitute, and be construed and administered as, an unfunded plan of deferred compensation within the meaning of the Employee Retirement Income Security Act of 1974, as amended, and the IRC of 1986, as amended, under which eligible participants may elect to defer the receipt of current compensation. Eligible participants include select management and highly compensated employees of the Company, including the Company&#x2019;s named executive officers. Pursuant to the DCP, subject to any minimum and maximum deferral requirements that the administrator of the DCP may establish, participants may elect to defer their base salary and annual incentive awards. In addition to elective deferrals, the DCP permits the Company to make matching and certain other discretionary contributions to the participants. The Company recognized $0.2&#160;million of related compensation expense for its DCP discretionary match for each of the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company&#x2019;s board of directors adopted a cash long-term incentive plan, or LTIP, commencing in 2021, focused on pre-determined, objective performance goals. The LTIP provides cash awards to participants based on the achievement of certain performance goals during each applicable performance period from January 1 through December 31 of each calendar year. Award amounts ranging from 0% to 225% of the target cash award are earned based on achievement of two equally weighted financial metrics: net revenue and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), with a relative total shareholder return modifier based on the Company&#x2019;s stock price performance relative to the companies comprising the S&amp;amp;P Pharmaceuticals Select Industry Index. The performance period for these metrics is one year, with an additional three years of time-vesting following the performance period. The first performance period began on January &lt;/span&gt;&lt;/div&gt;1, 2021, and for the year ended December&#160;31, 2021, the Company recognized $1.1&#160;million of related compensation expense under the LTIP, which is payable to participants in January 2025 after the three-year vesting period concludes.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzQ0Nw_6c7df40f-5e86-480d-a38a-d6e95040fa09"
      unitRef="usd">2800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzQ1MQ_92270ff8-ebe0-4fc6-abf4-4db2efdded40"
      unitRef="usd">2900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzQ1OA_c298bc1c-2fd0-4a38-b2af-5f9f7204bac2"
      unitRef="usd">2600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE1Njk_b24b634b-d4e8-4c3a-b7e1-8af8f60ee3d3"
      unitRef="usd">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE1Njk_d4acbca6-f98e-43d9-9347-4b2bdb7adcbc"
      unitRef="usd">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage
      contextRef="i42a9830d9b244758b1ed6841c20a7f8a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE2NDkyNjc0NDYwOTY_151a1681-27a3-4470-8828-dc182c33b8d9"
      unitRef="number">0</pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage>
    <pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage
      contextRef="i74f568606f0c4823a905f91cf481d300_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE2NDkyNjc0NDYxMDA_733c2d67-c4f4-4f91-87af-0e93c19dd050"
      unitRef="number">2.25</pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage>
    <pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzM4NDgyOTA3MDQ2NzA_f3dbfd46-79c8-49bd-a77a-bce714211527">P1Y</pcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzM4NDgyOTA3MDQ2Njk_c5aabe31-bd2f-49fd-9b30-acd80c8e5158">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTMvZnJhZzo4ZjdjYjgzNzg4Y2U0ZDA2OTgyMGFlYTQ2YmFjNjg3NS90ZXh0cmVnaW9uOjhmN2NiODM3ODhjZTRkMDY5ODIwYWVhNDZiYWM2ODc1XzE2NDkyNjc0NDU3MDg_437aa854-747a-4204-8938-2002ec341f7f"
      unitRef="usd">1100000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzI1NTI_aa0988a5-49ff-4946-b407-b98264777f02">ACQUISITION&#x2013;RELATED CHARGES, PRODUCT DISCONTINUATION AND OTHER&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related charges, product discontinuation and other for the years ended December&#160;31, 2021, 2020 and 2019 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other acquisition expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total acquisition-related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Flexion contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MyoScience contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination of Nuance agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinuation of DepoCyt(e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Department of Justice settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total acquisition-related charges, product discontinuation and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Flexion Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized acquisition-related costs of $40.2&#160;million, primarily&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; severance, legal fees, third-party services and other one-time charges&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the year ended December 31,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2021 related to the Flexion Acquisition.&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 19, 2021, as part of the purchase price consideration related to the Flexion Acquisition, the Company recorded a contingent consideration of $45.2&#160;million, which represents the Company&#x2019;s achievement of meeting regulatory and sales-based milestones. From the date of the acquisition through December&#160;31, 2021, the Company recorded an additional $1.2&#160;million charge due to an estimated $0.02 per CVR increase to the fair value of contingent consideration, which was included in acquisition-related charges in the consolidated statements of operations. &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 12, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Flexion Acquisition, the Company initiated a restructuring through a headcount reduction in the sales and administrative functions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MyoScience Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized acquisition-related and other charges of $0.7&#160;million, $0.2&#160;million and&#160;$4.9&#160;million during the years ended December 31, 2021, 2020 and 2019, respectively, related to the MyoScience Acquisition. The 2021 charges relate to one-time termination benefits in the event of a facility closure. For more information see Note 21, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The 2020 charges relate to acquisition-related accounting services. The 2019 charges include $4.2 million for advisory costs, including legal, financial, accounting and tax services and $0.7 million for separation costs, asset write-downs and other restructuring charges. In addition, the Company recognized a contingent consideration credit of $2.2&#160;million in 2021 and contingent consideration charges of $5.2&#160;million and $16.7&#160;million in 2020 and 2019, respectively. See Note 12, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the MyoScience Acquisition, the Company initiated a restructuring through a headcount reduction in the sales and administrative functions. In addition, the Company terminated a number of existing distributor agreements that were maintained by MyoScience.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nuance Biotech Co. Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered an agreement with Nuance Biotech Co. Ltd., or Nuance, a China-based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL in China. Under the terms of the agreement, the Company had granted Nuance the exclusive rights to develop and commercialize EXPAREL. In April 2021, the Company and Nuance agreed to a mutual termination of the agreement due to the lack of a viable regulatory pathway that adequately safeguards the Company&#x2019;s intellectual property against the risk of a generic product. Dissolution costs of $3.0&#160;million were included in acquisition-related charges, product discontinuation and other in the consolidated statements of operations during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DepoCyt(e) Discontinuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company received formal notice of the termination of a Supply Agreement and a Distribution Agreement (and all related agreements as subsequently amended) from Mundipharma International Corporation Limited and Mundipharma Medical Company, respectively (collectively, &#x201c;Mundipharma&#x201d;). In November 2019, the Company reached a settlement with Mundipharma and made a $5.3 million payment related to the DepoCyt(e) discontinuation which had previously been accrued.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a gain of $0.2 million during the year ended December 31, 2020, and a charge of $0.2 million in the year ended December 31, 2019, respectively, related to the discontinuation of its DepoCyt(e) manufacturing activities in June 2017 due to persistent technical issues specific to the DepoCyt(e) manufacturing process. No costs related to the Company&#x2019;s DepoCyt(e) discontinuation were recognized in the year ended December&#160;31, 2021 as the lease of the idle DepoCyt(e) manufacturing facility expired in August 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Inquiry Settlement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company recorded a charge of $3.5&#160;million for the settlement of a U.S. Department of Justice inquiry. Refer to Note 21, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further information surrounding our legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock>
    <pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzM4NDgyOTA3MTc5NDI_a048b8d4-1a77-4570-a6a1-77fbb5f2c025">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related charges, product discontinuation and other for the years ended December&#160;31, 2021, 2020 and 2019 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other acquisition expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total acquisition-related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Flexion contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MyoScience contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination of Nuance agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinuation of DepoCyt(e)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Department of Justice settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total acquisition-related charges, product discontinuation and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzItMS0xLTEtNjU2NjU_784fc264-3a09-4dad-a918-ba311e923231"
      unitRef="usd">26371000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzItMy0xLTEtNjU2NjU_a4636b6e-743c-46dd-a1a8-039fc365fcef"
      unitRef="usd">0</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzItNS0xLTEtNjU2NjU_30446c84-15ae-45cd-9978-347a7d2e78ad"
      unitRef="usd">494000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i133d2578be2a4e5082559c610543604b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzMtMS0xLTEtNjU2NjU_d5f2f8fb-28c3-488e-bf34-bfad44b330a0"
      unitRef="usd">10963000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="iefe2ba44a6d94addb0eb76d116d51d55_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzMtMy0xLTEtNjU2NjU_167cce43-24b7-4030-a6fd-01266549b539"
      unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i572235a599364bd3ade9416211dca6cd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzMtNS0xLTEtNjU2NjU_e64bb37f-12d4-4658-a5cf-d31cbb76affd"
      unitRef="usd">4211000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i3b2886444d644925b435f39f13c30af4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzQtMS0xLTEtNjU2NjU_d471854c-4d84-4413-84cb-02a2cd365e84"
      unitRef="usd">3566000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i308c4a2c1d0642d5a4d9505955982379_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzQtMy0xLTEtNjU2NjU_0d81e819-8706-4a5b-aaf1-5266a5cbc40a"
      unitRef="usd">150000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i0c466ffc9152473caa0acde1e894a6ef_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzQtNS0xLTEtNjU2NjU_b79f6356-2324-4d93-81f9-81feedbe393f"
      unitRef="usd">194000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <pcrx:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzUtMS0xLTEtNjU2NjU_33de8d30-97be-452d-ae3d-0a612bbbeeec"
      unitRef="usd">40900000</pcrx:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <pcrx:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzUtMy0xLTEtNjU2NjU_e5ded562-d9ee-4c24-b8ef-e1aee6ac2e9a"
      unitRef="usd">150000</pcrx:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <pcrx:BusinessCombinationAcquisitionAndIntegrationRelatedCosts
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzUtNS0xLTEtNjU2NjU_98a6d3bd-7856-40c3-9270-e8a59b4a2023"
      unitRef="usd">4899000</pcrx:BusinessCombinationAcquisitionAndIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzYtMS0xLTEtNjU2NjU_65ecbab9-cc26-44bd-a944-8705c39648c6"
      unitRef="usd">1174000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i00cc26ecd3e94aeb87e286287c6eb0ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzYtMy0xLTEtNjU2NjU_cba4016c-5e1d-4e49-be47-c543bafefadf"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ifce4e7bdc7aa4d8ab4e06a6aa84c37ad_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzYtNS0xLTEtNjU2NjU_c67489a9-4bd9-4f9f-8f22-a53e7da890a8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzctMS0xLTEtNjU2NjU_6c516c4b-7ff4-4408-adb8-8ae23fa68ae7"
      unitRef="usd">2163000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzctMy0xLTEtNjU2NjU_d161b7cb-d065-47d2-942c-09bd166b828c"
      unitRef="usd">-5204000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzctNS0xLTEtNjU2NjU_bcb47172-d826-4b83-a1e6-0f50e441c6fa"
      unitRef="usd">-16672000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnContractTermination
      contextRef="i3233de79e7a2425eb18155c86074f1e9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzgtMS0xLTEtNjU2NjU_5ee8008a-6d67-4b81-9c07-970f73c45685"
      unitRef="usd">-3000000</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="i3578ef27098d49db9276c9f493f654da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzgtMy0xLTEtNjU2NjU_776285af-ead9-4244-bc42-56425d0982f6"
      unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="i9541d5a561504d64b4e108f280a3faa5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzgtNS0xLTEtNjU2NjU_aec30112-873f-4909-91c8-9bc4284b01d3"
      unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="ic8de97bb7b224ffbaf4d4572322a126e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzktMS0xLTEtNjU2NjU_d633167f-64ba-41d5-988b-fb8751095eb2"
      unitRef="usd">0</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="ia33a2f9e6ae84d97990e9334c7002dac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzktMy0xLTEtNjU2NjU_9fed1a46-ab9d-4699-9704-b1b30b31b586"
      unitRef="usd">188000</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination
      contextRef="i25ae7b32599b43238324567b6549cb9b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzktNS0xLTEtNjU2NjU_a527d81f-0820-4880-addc-21e07f98e50b"
      unitRef="usd">-159000</us-gaap:GainLossOnContractTermination>
    <us-gaap:LitigationSettlementExpense
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzEwLTEtMS0xLTY1NjY1_ac6bba07-eb5f-44e5-a52f-381b296d8d8e"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzEwLTMtMS0xLTY1NjY1_07f24cc5-a608-4d8d-9607-1a7d2d865f17"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzEwLTUtMS0xLTY1NjY1_191cb866-6bda-4907-8b74-35fa8666d5d2"
      unitRef="usd">3500000</us-gaap:LitigationSettlementExpense>
    <pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOther
      contextRef="i8d5d5c6e34f0433bbda0c189e02b1127_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzExLTEtMS0xLTY1NjY1_fac6b30f-9571-4181-a26a-616f9a217a9e"
      unitRef="usd">42911000</pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOther>
    <pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOther
      contextRef="i6ddbaa9a26c6475c851117daf9454009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzExLTMtMS0xLTY1NjY1_d31b1a56-dca1-4ec9-bc35-9603067c9f42"
      unitRef="usd">5166000</pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOther>
    <pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOther
      contextRef="i4cb6ce81a4ab486980f3018e8148c7ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90YWJsZTo2NzhiZGQyMjRjYjM0ZmRmYTA2OTIzZDc5MTFmY2Y3NS90YWJsZXJhbmdlOjY3OGJkZDIyNGNiMzRmZGZhMDY5MjNkNzkxMWZjZjc1XzExLTUtMS0xLTY1NjY1_323aca70-c8b0-48f1-849d-c8b7004d4b96"
      unitRef="usd">25230000</pcrx:AcquisitionRelatedChargesProductDiscontinuationAndOther>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i130fb5352c624061a38b0f4e0e96ed76_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMDk4ODky_3c4f332f-3c32-4513-b2b8-d080f53524aa"
      unitRef="usd">40200000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i79da6badc4ce4c8b87bad102f47d53f7_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDI5MDYx_87150661-aaaf-4fd7-9647-da51e438f936"
      unitRef="usd">45200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ifd6c594f1a8d4d8198e32bc0c6d23237_D20211119-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDI5MDg5_bc2ff866-dddc-425a-8c88-a7d66fe78a7e"
      unitRef="usd">1200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare
      contextRef="i2d56f0f495b24f6292ed813d0fcfc838_I20211119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDI5MTA5_92d55d0f-4632-45de-905a-d3c96f30abc7"
      unitRef="usdPerShare">0.02</pcrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEyMzgx_c4e3de8d-0034-494e-8990-7dbff8ac93a4"
      unitRef="usd">700000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzYyNQ_540e2749-408f-44cc-abf4-116010276065"
      unitRef="usd">200000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzMDk4_525f90cc-c2e2-4fcf-bfc0-da82af08dcb3"
      unitRef="usd">4900000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i866ca805578348a1a7b549671e9b226d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzMDgz_93ee9516-2526-4262-8b88-39ea609427cf"
      unitRef="usd">4200000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i9c5f7765b4224a9a8bd7a15b9a2f9b85_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzkyNQ_7bd77987-3de9-429d-ad56-df623cc6eef4"
      unitRef="usd">700000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia9114d9b620944ae881aab35585c59bd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzNTc5_edd1c870-a71a-492f-984a-a90458a812fc"
      unitRef="usd">2200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0f2152f8d2e64b22bd8b0a8113fc5d45_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzODUz_5c52d502-4063-4416-bc1e-186ea959394a"
      unitRef="usd">-5200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie0f7595cac6c473cbbd16e8d5bf9e692_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEzODY3_e60b2334-270b-4963-84fd-e2c7eb7fccc8"
      unitRef="usd">-16700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:LitigationSettlementExpense
      contextRef="id747d21ec2fe432ca5314f7a469d8620_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTA2NTcw_cfdc1818-e2d9-46b2-9e6d-fcc92ff51a6f"
      unitRef="usd">3000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDY2OTk_08e6fda9-c6b7-4680-a54b-496b38c9d664"
      unitRef="usd">5300000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="id9261483f2cf444697023aae54718727_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE0NjA_f2f48f3f-31cc-4bc1-b1f7-20f9b0487e04"
      unitRef="usd">200000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE1MTk_18ee0ac6-fb7a-474b-9701-41cf8ce4b34b"
      unitRef="usd">200000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzE2NDkyNjc0NDU2NjY_9583e615-0c5f-4ce1-b34c-d9e59e5f3407"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTYvZnJhZzpkMTVmY2MxZGEwMmQ0NzM0ODYxNjQ2ZWVjY2M3YWM3Yi90ZXh0cmVnaW9uOmQxNWZjYzFkYTAyZDQ3MzQ4NjE2NDZlZWNjYzdhYzdiXzExNTQ0ODcyMTEyMzQy_cc09eff2-e955-4835-9ed3-e318d36f0c20"
      unitRef="usd">3500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <pcrx:CommercialPartnersAndAgreementsTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzQ2MjQ_9a268541-1ef8-4bf5-8308-27087db8abe1">COMMERCIAL PARTNERS AND OTHER AGREEMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Thermo Fisher Scientific Pharma Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2014, the Company and Thermo Fisher entered into a Strategic Co-Production Agreement, a Technical Transfer and Service Agreement (the &#x201c;EXPAREL Technical Transfer and Service Agreement&#x201d;) and a Manufacturing and Supply Agreement to collaborate in the manufacture of EXPAREL. Under the terms of the EXPAREL Technical Transfer and Service Agreement, Thermo Fisher agreed to undertake certain technical transfer activities and construction services needed to prepare its Swindon, England facility for the manufacture of EXPAREL in two dedicated manufacturing suites. The Company contracted to purchase EXPAREL from Thermo Fisher, beginning with FDA approval of the first suite, which occurred in May 2018. Commercial production began in February 2019. Under these agreements, the Company makes monthly base fee payments to Thermo Fisher. Unless earlier terminated by giving notice of up to three years (other than termination by the Company in the event of a material breach by Thermo Fisher), this agreement will expire in May 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Flexion Acquisition, in July 2015, Flexion and Thermo Fisher entered into a Manufacturing and Supply Agreement (the &#x201c;ZILRETTA Manufacturing and Supply Agreement&#x201d;) and a Technical Transfer and Service Agreement related to the manufacture of ZILRETTA at the same Thermo Fisher site in Swindon, England where the Company&#x2019;s EXPAREL suites are located. Thermo Fisher agreed to undertake certain transfer activities and construction services needed to prepare its facility for the commercial manufacture of ZILRETTA in dedicated manufacturing suites. Flexion provided Thermo Fisher with certain equipment and materials necessary to manufacture ZILRETTA. The Company makes monthly payments to Thermo Fisher for such activities and reimburses Thermo Fisher for certain material, equipment and miscellaneous expenses and additional services.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial term of the ZILRETTA Manufacturing and Supply Agreement that the Company assumed as part of the Flexion Acquisition expires in October 2027. The Company pays a monthly base fee to Thermo Fisher for the operation of the manufacturing suites and a per product fee for each vial of ZILRETTA based upon a forecast of commercial demand. The Company also reimburses Thermo Fisher for purchases of materials and equipment made on its behalf, certain nominal expenses and additional services. The ZILRETTA Manufacturing and Supply Agreement will remain in full effect unless and &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;until it expires or is terminated. Upon termination of the ZILRETTA Manufacturing and Supply Agreement (other than termination by the Company in the event that Thermo Fisher does not meet the construction and manufacturing milestones or for a breach by Thermo Fisher), the Company will be obligated to pay for the costs incurred by Thermo Fisher associated with the removal of its manufacturing equipment and for Thermo Fisher&#x2019;s termination costs up to a specified capped amount.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Eurofarma Laboratories S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into a distribution agreement with Eurofarma Laboratories S.A., or Eurofarma, for the development and commercialization of EXPAREL in Latin America. Under the terms of the agreement, Eurofarma obtained the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia and Mexico. In addition, Eurofarma is responsible for regulatory filings for EXPAREL in these countries. The Company received a $0.3&#160;million upfront payment that is partially refundable upon certain circumstances and will receive royalties based on Eurofarma&#x2019;s future commercialization of the product and is also eligible to receive milestone payments that are triggered by the achievement of certain regulatory and commercial events. The Company recognized $0.1&#160;million of collaborative licensing and milestone revenue in its consolidated statements of operations during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Verve Medical Products, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a licensing agreement with Verve Medical Products, Inc. for the distribution of iovera&#xb0; in Canada. The Company began selling iovera&#xb0; in Canada in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DePuy Synthes Sales, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the Company announced a Co-Promotion Agreement with DePuy Synthes Sales, Inc., or DePuy Synthes, part of the Johnson &amp;amp; Johnson family of companies, to market and promote the use of EXPAREL for orthopedic procedures in the U.S. DePuy Synthes field representatives, specializing in joint reconstruction, spine, sports medicine, trauma and cranio-maxillofacial (CMF) procedures, collaborated with and supplemented the Company&#x2019;s field teams by expanding the reach and frequency of EXPAREL education in the hospital surgical suite and ambulatory surgery center settings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company notified DePuy Synthes that the Co-Promotion Agreement would terminate on January 2, 2021. The Company recorded termination-related costs of $8.8&#160;million which were recorded in selling, general and administrative expense during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aratana Therapeutics,&#160;Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2012, the Company entered into a worldwide license, development and commercialization agreement with Aratana Therapeutics,&#160;Inc., a wholly owned subsidiary of Elanco Animal Health, Inc., or Aratana. Under the agreement, the Company granted Aratana an exclusive royalty-bearing license, including the limited right to grant sublicenses, for the development and commercialization of the Company&#x2019;s bupivacaine liposome injectable suspension product for veterinary use. Under the agreement, Aratana developed and obtained FDA approval for the use of the product in veterinary surgery to manage postsurgical pain. The Company is eligible to receive from Aratana up to an aggregate of $40.0 million upon the achievement of commercial milestones. Aratana is required to pay the Company a tiered double-digit royalty on certain net sales made in the U.S. If the product is approved by foreign regulatory agencies for sale outside of the U.S., Aratana will be required to pay the Company a tiered double-digit royalty on such net sales. Royalty rates will be reduced by a certain percentage upon the entry of a generic competitor for animal health indications into certain jurisdictions or if Aratana must pay royalties to third parties under certain circumstances. Unless terminated earlier pursuant to its terms, the license agreement is effective until July 2033, after which Aratana has the option to extend the agreement for an additional five-year term, subject to certain requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aratana began purchasing bupivacaine liposome injectable suspension product in 2016, which they market under the trade name NOCITA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (a registered trademark of Aratana) for veterinary use.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hong Kong Pharma Tainuo Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Flexion Acquisition, in March 2020, Flexion entered into an exclusive license agreement with Hong Kong Tainuo Pharma Ltd., or HK Tainuo, and Jiangsu Tainuo Pharmaceutical Co. Ltd., or Jiangsu Tainuo, a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd., for the development and commercialization of ZILRETTA in Greater China (consisting of mainland China, Hong Kong, Macau and Taiwan). Under the terms of the agreement, HK Tainuo paid Flexion an upfront payment of $10.0&#160;million during the year ended December 31, 2020 which was recorded as deferred revenue as of December 31, 2021. The Company is also eligible to receive up to $32.5&#160;million in aggregate development, regulatory and commercial sales milestone payments. HK Tainuo is responsible for the clinical development, product registration and commercialization of ZILRETTA in Greater China. The Company is solely responsible for the manufacture and supply of ZILRETTA to HK Tainuo for all clinical and commercial activities. The terms related to product manufacturing and supply, including pricing and minimum purchase requirements agreed to in the license agreement, will be covered by a separate supply agreement, which has not yet been finalized. Unless terminated earlier in accordance with its terms, the license agreement continues in effect in perpetuity or as long as HK Tainuo or Jiangsu Tainuo continue to sell ZILRETTA in Greater China. The proceeds associated with the upfront payment have been recorded in long-term deferred revenue on the consolidated balance sheet, as there is uncertainty around the timing of when the revenue will be recognized.&lt;/span&gt;&lt;/div&gt;</pcrx:CommercialPartnersAndAgreementsTextBlock>
    <pcrx:CollaborativeArrangementUpfrontPayment
      contextRef="i0dbbded270634aa69782055b700085d7_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzExNTQ0ODcyMTI1MzY0_638e4fcb-1f8e-4834-b2d9-c9870d72d281"
      unitRef="usd">300000</pcrx:CollaborativeArrangementUpfrontPayment>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="id5b01a051b66415ba958a05fbf10d319_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzExNTQ0ODcyMTI1Njg1_df6fdab5-e837-4ca2-b14d-1967c83c9364"
      unitRef="usd">100000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <pcrx:PaymentOfEarlyTerminationFees
      contextRef="i1fe450ec25c44c338992024884646e70_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzE4NTY_a8eaf430-9ad5-41e6-8312-8f8c4373b60c"
      unitRef="usd">8800000</pcrx:PaymentOfEarlyTerminationFees>
    <pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum
      contextRef="i0cda3779624d47cca8d9a4fd84dbdcdc_I20121205"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzI2OTE_448f10c9-df02-425e-b7f3-834a42d48608"
      unitRef="usd">40000000</pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum>
    <pcrx:CollaborativeArrangementOptionToExtendTerm
      contextRef="i45f29cdfecdd48d8b8c24cf61151d641_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzQ2MjU_2f0d33a6-f1b9-48cb-8a3f-2026da28927a">P5Y</pcrx:CollaborativeArrangementOptionToExtendTerm>
    <pcrx:CollaborativeArrangementUpfrontPayment
      contextRef="ib670284875d746c498df6bb492cd4f90_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzE0MjkzNjUxMTg2Njgw_63860214-0634-4c6a-bbc5-2c2e9adabf9a"
      unitRef="usd">10000000</pcrx:CollaborativeArrangementUpfrontPayment>
    <pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum
      contextRef="id496bf8b482742cfbd9725d700e95fab_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8xOTkvZnJhZzoxZWY0MmNkYzY0NmQ0YmU4YTc3YTEzNzRiYzY4YzBmZC90ZXh0cmVnaW9uOjFlZjQyY2RjNjQ2ZDRiZThhNzdhMTM3NGJjNjhjMGZkXzE0MjkzNjUxMTg2Njk1_da554c29-d00b-4a43-a167-2c3db8570304"
      unitRef="usd">32500000</pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzU2MQ_1b1f5dac-6261-4bcb-977d-9bccb3c0bae7">RELATED PARTY TRANSACTIONSIn April 2012, the Company entered into a consulting agreement with Dr. Gary Pace, a director of the Company. In connection with the consulting agreement, Dr. Pace received an option to purchase 20,000 shares of common stock at an exercise price of $11.02 per share and an option to purchase 70,000 shares of common stock at an exercise price of $16.67 per share, the latter of which were fully exercised in 2020. No services were provided under the consulting agreement in the years ended December&#160;31, 2021, 2020, or 2019, and as of December&#160;31, 2021 and 2020, there was nothing payable to Dr. Pace for consulting services.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares
      contextRef="i9733ef5993044559a5405d6f38d59438_D20120401-20120430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzIzNQ_169e3a18-ad0c-4546-89e4-096d20895fb6"
      unitRef="shares">20000</pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares>
    <pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice
      contextRef="i9733ef5993044559a5405d6f38d59438_D20120401-20120430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzI4NQ_7bb1077e-58c7-4653-a8fb-f865935b5556"
      unitRef="usdPerShare">11.02</pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice>
    <pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares
      contextRef="id5828f75d0ba48dbb5d995070ffaf73a_D20120401-20120430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzMyNA_e2827088-5024-4b13-8ab8-a7db07d90a3d"
      unitRef="shares">70000</pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares>
    <pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice
      contextRef="id5828f75d0ba48dbb5d995070ffaf73a_D20120401-20120430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDIvZnJhZzpkZWJjZGFmZDQ2ZTI0OTYwODMyNmRmOTllYjRiMGQyMi90ZXh0cmVnaW9uOmRlYmNkYWZkNDZlMjQ5NjA4MzI2ZGY5OWViNGIwZDIyXzM3NA_a12317e1-231a-4ef4-a39e-7015add500d6"
      unitRef="usdPerShare">16.67</pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ide89694773bb4e6db9680fef91f32d44_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzU4OTk_d2ebdac5-50bc-48e2-b996-7c2e875f2a74">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:7pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to patents, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings that it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MyoScience Milestone Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company and its subsidiary, Pacira CryoTech, Inc. (&#x201c;Pacira CryoTech&#x201d;), filed a lawsuit in the Court of Chancery of the State of Delaware against Fortis Advisors LLC (&#x201c;Fortis&#x201d;), solely in its capacity as representative for the former securityholders of MyoScience, and certain other defendants, seeking declaratory judgment with respect to certain terms of the merger agreement for the MyoScience Acquisition (the &#x201c;Merger Agreement&#x201d;), specifically related to the achievement of certain milestone payments under the Merger Agreement. In addition, the Company and Pacira CryoTech sought general, special and compensatory damages against the other defendants related to breach of fiduciary duties in connection with the purported achievement of milestone payments under the Merger Agreement, and breach of the Merger Agreement and certain other agreements with the defendants. In October 2020, Fortis filed an answer and counterclaim against the Company and Pacira CryoTech seeking to recover certain milestone payments under the Merger Agreement. The total remaining value of these milestones is $30.0&#160;million, plus attorneys&#x2019; fees. The Company believes that the counterclaim from Fortis is without merit and intends to vigorously defend against all claims. The Company is unable to predict the outcome of this action at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;eVenus Pharmaceutical Laboratories Litigations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company received a Notice Letter advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,033,495 (the &#x2019;495 patent).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company filed a patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (21-cv-19829) asserting infringement of the &#x2019;495 patent. This triggered an automatic 30-month stay of final approval of the eVenus ANDA. On January 6, 2022, eVenus filed an Answer with counterclaims to the Complaint, alleging the &#x2019;495 patent is invalid and/or not infringed through the manufacture, sale, or offer for sale of the product described in product described in eVenus&#x2019;s ANDA submission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company received a second Notice Letter advising that eVenus submitted to the FDA an amendment to its ANDA with a Paragraph IV Certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (133 mg/10 mL) in the U.S. prior to the expiration of the &#x2019;495 patent. In the Notice Letter, eVenus also advised that it submitted a Paragraph IV Certification to the FDA seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL and 133 mg/10 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,179,336 (the &#x2019;336 patent). eVenus further alleges in the Notice Letter that both the &#x2019;495 patent and the &#x2019;366 patent are invalid and/or not infringed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the Company filed a second patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (22-cv-00718) asserting that the 133 mg/10 mL ANDA product will infringe the &#x2019;495 and &#x2019;336 patents and that the 266 mg/20 mL ANDA product will infringe the &#x2019;336 patent. This filing triggered a second automatic 30-month stay of final approval for the 133 mg/10 mL ANDA product.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These litigations are in their infancy, and the Company is unable to predict the outcome of this action at this time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research Development Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to an agreement with the Research Development Foundation, or RDF, the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products, for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company&#x2019;s U.S. Patent No. 11,033,495 issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company&#x2019;s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement was set to end on December 24, 2021 with the expiration of its U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit seeks a declaration from the court that the Company owes no royalties to RDF with respect to its EXPAREL product after December 24, 2021. During the pendency of the lawsuit, the Company will continue to pay royalties to RDF under protest, however, the Company is unable to predict the outcome of this action at this time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Inquiry Settlement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2015, the Company received a subpoena from the U.S. Department of Justice, U.S. Attorney&#x2019;s Office for the District of New Jersey pertaining to marketing and promotional practices related to EXPAREL. In July 2020, the Company formally entered into settlement agreements that resolved all outstanding investigations and claims by the United States Department of Justice, the United States Department of Health and Human Services, various States Attorneys&#x2019; General and a private plaintiff. This agreement concluded a five-year investigation related to the sale and marketing of EXPAREL. Under the various settlement agreements, the Company paid a global settlement of $3.5&#160;million, which was recorded in acquisition-related charges, product discontinuation and other in the consolidated financial statements for the year ended December 31, 2019. The Company expressly denies all allegations and contentions and has admitted no wrongdoing in connection with the settlement agreements. The Company has been given assurances that this concluded the investigation that originated from the U.S. Department of Justice subpoena in April 2015.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately $50.3 million of minimum, non-cancelable contractual commitments for contract manufacturing services and $9.2 million of minimum, non-cancelable contractual commitments for the purchase of certain raw materials as of&#160;December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pediatric Trial Commitments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL in pediatric patients, as well as the administration of EXPAREL as a nerve block in the pediatric setting. The Company was granted a deferral for the required pediatric trials until after the indications were approved in adults. Similarly, in Europe, the Company agreed with the European Medicines Agency, or EMA, on a Pediatric Investigation Plan as a prerequisite for submitting a Marketing Authorization Application (MAA) in the E.U. Despite the U.K.&#x2019;s withdrawal from the E.U., the agreed pediatric plan is applicable in the U.K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company announced positive results for its extended pharmacokinetic and safety study (&#x201c;PLAY&#x201d;) for local analgesia in children aged six to 17 undergoing cardiovascular or spine surgeries. Those positive results were the basis for the submission of a supplemental New Drug Application, or sNDA, in the U.S. and Type II variations in the E.U. and U.K. to expand the EXPAREL label to include use in patients six years of age and older for single-dose infiltration to produce postsurgical local analgesia. In March 2021, the Company announced that the FDA approved the submission of the sNDA in the U.S. The EMA and the Medicines and Healthcare Products Regulatory Agency, or MHRA, are still reviewing the Type II variations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is working with the FDA, MAA and MHRA to finalize the regulatory pathway for its remaining pediatric commitments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for information on potential contingent milestone payments related to the MyoScience and Flexion acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PCRX-201 and PCRX-301 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PCRX-201 (formerly FX-201) and PCRX-301 (formerly FX-301) were added to the Company&#x2019;s portfolio as part of the Flexion Acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Flexion Acquisition, in February 2017, Flexion entered into an agreement with GeneQuine to acquire the global rights to PCRX-201, a gene therapy product candidate. As part of the agreement, up to an aggregate of $56.0&#160;million of payments could become due upon the achievement of certain development and regulatory milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Flexion Acquisition, in September 2019, Flexion entered into a definitive agreement with Xenon Pharmaceuticals, Inc. to acquire the global rights to PCRX-301, a locally administered Na&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt;V&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7 inhibitor. As part of the agreement, up to an aggregate of $45.8&#160;million of payments could become due upon the achievement of certain development and regulatory milestones and up to $75.0&#160;million of payments could become due for sales-related milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;One-Time Termination Benefits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has communicated to a select number of employees a commitment to provide one-time termination benefits in the event that a facility closure occurs. The Company is recognizing these expenses ratably over the remaining service period required. The Company currently estimates the total cost of these one-time benefits to be approximately $1.1&#160;million. During the year ended December 31, 2021, the Company recognized $0.7&#160;million in one-time termination charges, which are included in acquisition-related (gains) charges, product discontinuation and other in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="iba035b436915468c957402bf102c1460_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzE3Mzc_3d16a164-9db9-443a-bfb8-6d38e1d41db2"
      unitRef="usd">30000000</us-gaap:LossContingencyDamagesSoughtValue>
    <pcrx:LitigationInvestigationTerm
      contextRef="i7b894792258e44c8853a730b680cff6c_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzU4OTc_4b7f680e-73c2-47e9-ac8d-1fd2ac678715">P5Y</pcrx:LitigationInvestigationTerm>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzI2NzY_31c71c7e-f531-4dfe-b9db-cb0068d99151"
      unitRef="usd">3500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PurchaseObligation
      contextRef="ib97087953997481c9eb9531b2899f6a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzMxODY_1e79b6fa-0ab6-4463-93b8-757005d3b481"
      unitRef="usd">50300000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation
      contextRef="ia919a337f89e4501a657825c42e3742f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzMyODA_97fd1254-4398-456e-b264-8b821edc034c"
      unitRef="usd">9200000</us-gaap:PurchaseObligation>
    <pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum
      contextRef="ib6b28091853f41199ae71d31aea5bf87_I20170228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzExNTQ0ODcyMTQ1MDEw_df217975-8cea-4a97-9651-484ada6fa1bf"
      unitRef="usd">56000000</pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum>
    <pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum
      contextRef="ia16d04ef54124f998b23dcd9e5efc8ce_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzExNTQ0ODcyMTQ1MDI1_6cf43382-5be9-4eaf-a088-6df73a7c3bfa"
      unitRef="usd">45800000</pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum>
    <pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum
      contextRef="i3a74aaba5c5b4ccaa7925c2b5333a951_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzExNTQ0ODcyMTQ1MDQw_eb237727-a2f1-4339-aea5-6ec52c1e6a03"
      unitRef="usd">75000000</pcrx:CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i2728c786372940b3a47b33099bff7244_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzE2NDkyNjc0NTY0MzI_b5a8f2bb-abaa-4570-945f-2ef8f617d2d5"
      unitRef="usd">1100000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges
      contextRef="i12b7f38fb2f94964a96e1740885b526e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI4NGEwY2VjNjAzYjQ5MDM4MmQwZjg0MjIzNTllN2U4L3NlYzoyODRhMGNlYzYwM2I0OTAzODJkMGY4NDIyMzU5ZTdlOF8yMDUvZnJhZzo2YzJiZTVhMWJjN2U0NGM2OWU2NWM4Nzk0MDY1ZjU2YS90ZXh0cmVnaW9uOjZjMmJlNWExYmM3ZTQ0YzY5ZTY1Yzg3OTQwNjVmNTZhXzE2NDkyNjc0NTY1NDk_7ef9b8ee-5b48-4c99-93ef-c19708596d6e"
      unitRef="usd">700000</us-gaap:RestructuringCharges>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>134
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>W"WF^*Y1G?_-5A()7#)_VV ;!\@VRED^Y2#N)_@1E3PN-O0LHB9S6VK^=G
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MKBE!A= #\/<EYVI_HR<X?#RZ_A=02P,$%     @ 1H-<5"XFL(<4 @  7@4
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M)MIE6YIK^%*]VIICTFW*%K4=95:'Z;S*&9*5;+;7KE,2HL6ZP3!K$8L&$5]
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MZ_LZR2"GNB4+$+BSD"JG!J=JZ>M" 4T=*.=^& 0]/Z=,>/'(K4U5/)(KPYF
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M^W:NXZ 5!%C*]7853T7MZ._4^CN7Z2^;@-"5R:1B?W##^BA7&\67_+TM6=W
M??;DGX[;,="M#73?98!IO3HMOOM&U+[L8Q$[@GNUX-Z[!.,_L394I$PL3ZGN
MG51]+&)'=;]6W3^J>B+S'-^=_VCR_EE-?BIJ1_R@%C^X0/S%'3YX4\RP:MW]
MLI\3N>-@6#L87N[@O!8?OM'4Z?2C3A0,]L0W!$:]J#<,A\W:V\&_DRBX7/T%
M_5[1G^&A*;+9A+]ULMIKS1>JEDQHPF&!T*#5QQ=?E3>%<F)DX0[;N31X=+MA
MAK<K4#8 ]Q=2FM>)/;_K^UK\%U!+ P04    " !&@UQ418+7.7P&  "Z&@
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M/FU.+L1Z)@MQEIKUYX#A,(*=A4G%QDTQ#O#(HB*#5A/_T[!%!H%@(PD[+Z_
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MHFI_;CC+>:,!\/]*"+6_T ,<7E?=_ =02P,$%     @ 1H-<5#^F&OLA P
MC D  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6R55M]OFS 0_E<LU(=6
M:@HFY%>51&J23:NT;E73;@_3'AQP JNQ,]M)VOWU.QO"$B"T>P';?/?=?7?X
M[.%.R&<54ZK12\JX&CFQUNMKUU5A3%.BKL2:<OBR%#(E&J9RY:JUI"2R1BES
M?<_KNBE)N#,>VK5[.1Z*C68)I_<2J4V:$ODZH4SL1@YV]@L/R2K69L$=#]=D
M1>=4/ZWO)<S<@B5*4LI5(CB2=#ER;O#U;&#P%O MH3MU,$9&R4*(9S.YC4:.
M9P*BC(;:,!!X;>F4,F:(((S?.:=3N#2&A^,]^T>K';0LB*)3P;XGD8Y'3M]!
M$5V2#=,/8O>)YGHZAB\43-DGVN58ST'A1FF1YL8009KP[$U>\CP<&.#N"0,_
M-_#+!L$)@W9NT'ZO09 ;!#8SF12;AQG19#R48H>D00.;&=AD6FN0GW!3]KF6
M\#4!.SV>"JX$2R*B:83F&EY04ZV06**I2.%/BDV)MQ3=\E"D%)U_%DI=H!9Z
MFL_0^=D%.D,)1X^QV"C"(S5T-01EJ-TP#V"2!>"?" #[Z$YP'2OT@4<T.B9P
M04TAR=]+FOB-C#,:7J$VOD2^Y^.:@*;O-_=JS&?O-L>#!C7MHD!MR]<^P5?4
MY&1)?MPLE):P@7XVN L*=X%U%YQP]P4Z39*7FIE2UU4TH^A8"M-7MN, #_J0
MK.UAFJLH''0Z?OL8-JO"6AA[N%O CG1T"AV=QK1]U3&5*#S*UY&NZX9D=0LG
MW3>3M>'0;5GR![;/"KILSHZ@I25\2Y6VV^D2<6H+J,E+74(S-]VC'%3R60,J
MY[(*Z7I^?2)[A<9>HT;HKM [.?0B*2D/7Q'\:EPQDG7MZ-<FEU@GJU<)QQ^4
M1%4A+5P2585X]9+ZA:1^HZ1'H0E#XJT_I$Y1OR;<3BG@:0TH*&FJ0DX6:E"H
M&C2JFOZ?DD'-'NY7RE-%F3V,2[!9%=;"7H"#DB+WX)Q*J5S9\UY!#39<9_V]
M6"VN%#?V)"VM3^"JD=T,_M%D]Y0[(E<)5XC1)5!Z5ST(2F9G?S;18FU/PX70
M<+;:80S7)2H- +XOA=#[B7%07,#&?P%02P,$%     @ 1H-<5.S'/?\\!P
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MO'HMIKIA=%F^-'!'&:-I>;D@ =^%A '_?4YY:]0WXCV$]<M))_\!4$L#!!0
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MP.<':3*L1B#3A+GSB0!9G*2)&Z88CF1<3A0"F;4)+&P3?E!<&:+U/([=!8C
M/&9GEQV8=0SL1-G!3!$P4I ^NJ?19*%4?&7/8N%J$(+RF(0@QTQ&#PK"_N!H
MN>WI&*LZ%"Q/!"%27" )23UJ&(Y(CQX&DU-6G%D+P<ZT$#M3)2J?*PRG[0-#
M*@$T3C(O"#%<DLC8-; 8D-!TG)R..5H+P<(6XGU9YW5QOH5@UD*PL(7XW.A"
MJ64;K1J]@>V,:HIR'RY#649O^\(#.H"^OE.6<K<P@,"XH%[%!8&E7$X(#K.&
M@84-PS%!V*!MP#D,U$S!'D)F5T.FBM1F6^DGI?;?;?<+)]I6.9[!L,<5Q-W$
M82CAUB07&(K'4RO#.@AVJI PIMZI9A-5.J^C=U$!IJCLHE5>F,W=$\K/=P!,
MLD1XJ\/'>2L_!#GF9GT$"_N(N895WO0'"[:-VI2[C2DNFN>K1GS@JZY_VM2J
MNM2FCMA-Y !?_3V")R$+!#*CC.$<N340/&P@1MIZ_(#)9/#5(25,/F[B2 6!
M>]$WQV"$<C?/+Q#<Q#1R:Q_X_\4^<,0^@+5S-[4H3&2NV<5@4K(I<M9&\+"-
M0#>W*R25HQ21!Q!I+#,WNR(X2BGSROM8?W*J ,&MP>!A@[$_,M HDRLOEVIX
M]:)_OM%OP2!4^Q?&?#R KYHP&]QW!SP5DKH)%<%1DK@EIP4" _M/LPDEYJ,3
M$F&W,9\B]3*Z4_=E79N9A6A^4GF#\O0]0I9EGEU$8$E*J:N9"(PP*J9J9MP:
M#BY^E*8RU>@ 0>$7-U,A$G>#AN"0@5@@L..!."9H?0^704=UN]MNJ_X84UX-
M)%<5]%'6PRDYR#O! S76?O"P_>@'LB_G0\?F'(1JP)RB ^>; )EE7K+V40F-
MA3MJ/BHEV827XM90\+"A<,G8<G?_R,6$1:-6NXDS7QQQ%-1?X,CY!^Z6]!8(
M*I53@FM-!<^"0?%)U[,^%D9;B".I/<]]"ZOP(JSP[\<'9V \J]URV,/DSJ.2
MX53-_J'#B:*\\'5:IF[JF".HC+IEE 6"8OT9-O1XEI5]$9;](]4(/0H_1=57
M;MA:<#>F$)AKX1 ([-RF]%%8#R#"'F ^,J.W@QG]9,QHM-@I<YI0A.+(JK (
M'PC\WOVAL'HGPGIWO(?H;:@YB*'KO6OKU@.-[W+=PI<MUW4C$$9@/KP #75U
MS'ET>C L?LZ>>*B:_ 36OI1YK'U(FB29^Z0BV-,Q:2N((EP(F S4$V=6A95"
MD?S<(+6Z),*Z]$5MC_81YT_)R<WK_#1D@4!FC$U8%&'52)RSQ9U.'31T'-5*
MD(Q_ZJQ(F^1E.,G_\*S(TT?2$,B,)#+)O/.O9Y>'I<WI,IS3OZBN;-0SLT!^
MH-]'>[BJ"-'V(1!IL7OB:Q'L:F!]-?HYP$8U]_W/*MJHMQW#N?K#IX>?;KSM
M?[#@?/Z.O%X,/\"PW0R_!_F8-[ C:J-*K:#+^%4"]],,/[$8WG1ZV__HX$YW
MG=[T+]<J!_$W /A^I6&L]F_,!0X_=+GY'U!+ P04    " !&@UQ4"3G=5M@(
M  "]$P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RE6&UOW#82_BO$
M'G!(@/6NO7&:MGX!_!;4=TEL>)WT<(?[P)4HB35%JB2UF^VOOV>&DE9V';?H
M?4DLB1S.///,,\,]WCC_$"JEHOA:&QM.)E6,S8_S><@J5<LP<XVR^%(X7\N(
M1U_.0^.5S'E3;>:+_?WOYK74=G)ZS.]N_>FQ:Z/15MUZ$=JZEGY[KHS;G$P.
M)OV+.UU6D5[,3X\;6:JEBI^;6X^G^6 EU[6R03LKO"I.)F<'/YX?TGI>\$6K
M31C]+2B2E7,/]'"=GTSVR2%E5!;)@L1_:W6AC"%#<./7SN9D.)(VCO_NK;_G
MV!'+2@9UX<S/.H_5R>3[B<A5(5L3[]SF)]7%\Y;L9<X$_E=LNK7[$Y&U(;JZ
MVPP/:FW3__)KA\.?V;#H-BS8[W00>WDIHSP]]FXC/*V&-?J#0^7=<$Y;2LHR
M>GS5V!=/+Z^6%W?7M_?7-Y_$S7MQ_GEY_>EJN3R>1QBG)?.L,W2>#"V^8>A@
M(3XZ&ZL@KFRN\L<&YO!J<&W1NW:^>-'BI<IFXLW!5"SV%P<OV'LSA/J&[;WY
MAKT;7TJK?Y/$AJFX<#8XHW.9R&%S<>M54#:F%ZX0[[65-M/2B"5>*C Q!O&?
MLU6('ESZ[PL>'0X>';)'A_\_^'_)D+B5F?92G&NWS+2RF0I3<6T!*\6K$4YH
M5T'G6GJM@G@%,G&UK)793D6LE/C[W[Y?+/:/+ES=2+OEIX,CX7S_(1W0O7\M
M=.!=VN9@KM\* YE0'L]\6.;J6D?"440GK+-[KM%.YZ*!>(#4%BK 7\F[QKLU
M/+.ED..EKN'T8+\,M&6+S5%S:O"B<2'HE5'TW2L4)W!BC[S#2^0T6>&UR';6
M\E<OFZUPUFQGXAYK1\$>O#L*PCA;[I%ZV'**APR$@*NF5$%G4W'UK]NSNZL/
M .3@W>&1>+5J&[V6F:23C89#KB9 ?@&NDCP+;6B2IKV>BHU,J"A//#, 3+86
MNIL39.3W9ZLCGIB R!V _SQ;SJ;T^:SQVJ V4'B$EVP(L;0SB9ZX:CW$6UH<
MT=K(*::5([O_1$RYJVG/)VRN5T@65=ML"*N-VNC?5,KK4V1P(IQ0$6HN:L@@
MB -,6B/]$#K[W'S\\F$J<M^6$$R#55@?55999UR)/RL9!=@IFX"]")27!BAA
MK-!'A#11>6("?-!>U,AE.@0<:[/8>IQ"@7F$#8%F7VN!>#RXD\,E4$$T,.%R
MXD!$4YFA#'8(_C =AR=DGA..9$!26K\[ZK,+6O5$3BF#O2+Y1LZR%9G]VNJ@
M>Q7YN.UK+Y4> [)[F2CWZ*RP#5 ;JB4I*L15*9.+S&]=SSH*:JTS)=H /^%3
M!RK6HS%G.N"H#%KLJ9R9&49G@ZRAR+%)U0!$$G9D@,@OD,92$2NL\DCD3-R,
M6$$8$3.>($6Q$KKOC?I*]N^YFA18DX51O-WGE*8$[[^O/]Q=W=^?#84#@LHZ
MT\0)2RBJZ*S.E5!?HZ*.LM>E]QO%U.<&G,Q!"DB!CP4$WLUV1W7R5&@?DLAP
MW$\/H.J"Q.])'SLROZI1193DKBI_<5CQNG.$PH;@$<(("V,2+QFI&<D.,NI@
MK_+@1:KCF[.I>+!*L?C-!$8,$-M3=&G28K@"OG]R48FW4W&VXU40LU[:-6LX
M^<&:I\-#HF?2R(SS1(5/JJ!K3=%TZMS+08AP-%#0F6ES%KD5BLZZB"*N62:B
MF[(I%1.M"P_-,$07OSMB2O6GT3$AM#2OK96%O/)2Q$V!ILP\62B'4VS+3 -<
MFPHE'J11_D\L!M)M(4D&*$, B%RQ& <'A=$DV=I:MV98\3E7#:6\L_J@MB0/
MP5FKS.,#8Z5]OM<@=5LDPW/5I<Z$]0D^ZBS!M3XC.E*IL==8%#MRP,>Q4.Z$
M+X':'<;Z49(.6&:-5R6)(6>;Q8U3"]]DRHC(M@ @0 G!*72N"^>=E6OM6S3R
MBYLOUY=[!S^\!DT09ZTSL=1TBI(>C$<A[T^?5?0N;0'"LU9BI12XC149G;G:
M\I;2N!7P;'K#F609PE=JU!@=2):IH;/6/.L4]_=N_UX?4E:A RI;LGZC(20^
MJM2O@BZM+I!(2Y4=8@.-2,7E1R+0UR==7?+6$!_@A.IF&BSTB0M(1X8%GCI-
MRP+8M"MHI*@4>@W2T&(N)+C(T5%.<F@=FX(X_EQIDV:+7)5$;YR4H )VL N>
M6AVHE>=MW[RH$2-EW(0JM8.P<R*-3C&52<<<C!+0Q%'G1F%@2GTN-.JJ" F5
MG74TSY2/E(G?8>U8_+$(8(QPIR+0(:(Y$O_H2A<$YA&HHA<51EN:A""RX*HQ
M:!</*?[?.8';W8/J9CQ(&<T/E"==/'*/RFO8.LH(&_?$ZQZ7HN4^U?,'F*!5
MT,0'HX[FMPU:7I)0>!PE]]H-YX<GQ$>G,K%#5PQ$7"Z\D>T.;XMX<17#)"SD
M6D(XT6^F+\8+$5+<W72'[$L4IP&N+=NN#RU5$W?35Q\W)" 9XH-XS^#GI3)1
M]DB@!@.I'F(O"E;!"MV/9)VM%TAUV6MQ)JGE*UD'<A70A"2;H_KJ<X'K;O8
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MF+8O.^-+4D@I^)\5ZA 0G7%IM="2A)YAO87EQO0[5M@P*\-.F.;<;1%H.;:
M858A*]:;2E/)@7OVDJC4I*38@J_A<EV*HYEQ(.RF\[*?=3;10HLR+PW]@Q*1
M;36&W(FTFP;U6XFC6'RE+@(E1&6+73.AW-;'V*6M5D0X+"/\VM(V::WNDD[3
ME#E7HD>EBR*A8?]\^=QM,4PG!A/]HC0D.M<YXR]])BEX;>K"EBP'PX'ZO5B-
M0;5UF._QQ<P:E@!T^[Q0RZ=/YTDP7$)DW0V[@[B="1%"E54K_KD]A.C@L1"
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M6K2#8.];;]"2@A&$C_/"C@%H81<TLB+O/A0\V.!&CG!I?:R@1I/3=! :J3Y
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M-#11REO5PV1G!>=8R-\R$EN$9U-SQ'1V\_>[N B?:633<H[RYW %PC!S%46
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M>>^-/+"[X?\=D(\A8[J7\]W=[J\-%^Z-_F&Y^U_$+[+>Z(J<:XVMX]%\=N8
M&WXT9L?O]U>F@:/PUZV2\&E:@.=K8YKP@P[H_O#Q]C]02P,$%     @ 1H-<
M5.)2I(R.$   ARP  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULM5IK
M<]O*D?TK4XIR2ZJ"* )\B/*KBI;L1"G9UDKRW>RF\F$(#,FY!C&X T R\^OW
M=,_@P9>BI+)5+ID$Y]'3C].G>_#NV=@?Q5*I4OQ<I5GQ_FA9EOF;\_,B7JJ5
M+'HF5QE^F1N[DB6^VL5YD5LE$YZT2L^C?G]\OI(Z._KPCI_=V0_O3%6F.E-W
M5A35:B7M^J-*S?/[H_"H?G"O%\N2'IQ_>)?+A7I0Y??\SN+;>;-*HE<J*[3)
MA%7S]T?3\,W'(8WG ;]J]5QT/@LZR<R8'_3E)GE_U">!5*KBDE:0^.])7:DT
MI84@QN]^S:-F2YK8_5RO_IG/CK/,9*&N3/K?.BF7[X\F1R)1<UFEY;UY_K/R
MYQG1>K%)"_XKGMW8T?!(Q%51FI6?# E6.G/_RY]>#YT)D_Z!"9&?$+'<;B.6
M\EJ6\L,[:YZ%I=%8C3[P47DVA-,9&>6AM/A58U[Y87KU7]]O'FX>;[Y]?7AW
M7F)%>GX>^]D?W>SHP.PP$E],5BX+\2E+5+*YP#E$:>2):GD^1B^N>*WBGAB$
M@8CZ4?C">H/F? ->;W!@O8]5@2=%(:[,:J8SZ5PA2\2T*.#RT_CW2A>:G_YM
M.BM*"S?Y^PO[#IM]A[SO\-_4Z^MGB\^I^DGR/2Z5E;FJ2AT7@;C)H*AOF?AJ
MGM1JIJP(+YW2 E$N%1TWE]D:7H\#6I4TJYS0K[_\81)%_;?ULXX6^)?P[6D@
MI)AIDR\E7#_F364J8K_JW, UL2CFTG*)+F*(8=<! N()@9XC;,N ]8PI*V5C
M+5/]#Z=],Q<91J>!2 TM6O*YM"JPK.7U2L!+24O0V!RS\+% 8)1+L:J*N$I-
M\0-Q7;)$6<*"0R4SM=!9IK.%&VJ*4AEIRZ7%@,*I986'+!+D($2C#3I#\LH6
ME<2^I8'P8KJP2K$<=)*[5++P7Y1=0-]=1?I'S?A6BXDLH2=9T,1O<6G84F%M
MJ=F:5Y809]$U6R"^K2&]W?#/VJ1D>3+/M4KEL[0*Y[&YL:UK/R]-FJZ%><ZP
M=5'-"IUH "Z)T'6-$R_\767C)8#-=FR?-0[3$Y^QFGG67D)R :C>&U)B_3A&
M?,TK&%(!!"P>S_&WMF4!#U)\?+\@[1)>O"UJ,P#BXA]NRZ[ZV0^4716UV-LZ
MYAF:<!WG3V06*V?V!X_WT2@\69[6L_^D,GA9BL.WNKJ5S_7/#R7L1%]JI0:B
M48M8T<Z)6]UM"OGJV.&G]9>BLD_ZB50%B\M7&J)'D=U8!7MFM!L-R.1*=31'
M:KF3L;9R'Q;(.3E,;1YO+1;=NAU*XP,&8BBO@MI*>Y! /-,9\MR:GQK93^$@
MQZ.+26^"-)2F-("7*G@O,W\C3O2I.!X.)[U1,P*RQ[)8(H9U0M)3R$'(1EUD
M>N@(XA2L60P!*I>I0KX'%NN8@H='B2K39>'5?P:1S^ [:NU_-#E#P%O( "$0
MIL>342]L!74RK&M(J?=/U*P$%K&_S11L!FJ"#1&5&Q"*/;$NGV[4B[J'@Y"L
M&X*YC!1!&VQJV,*A: "VZ(QYDFF%0Q)E@/U@A*M?[QFB9"F>%6):0Q8WJU$6
M!5)76;&R)5B74#!9"3'AMHFH!V@VSV]5YH*!O?2 H9UW;$JM"_+7WQ!*#(7)
M;V B*T9AHD -\,MXJ0'XM5YKB7(#*"@!^:0KZ B6JM5?;'I[K<#"';W*/?+*
MQ*$ZEC@>3/H=K6N_\P(XL*"@7<DU&0_KRUE*7M[HH XSJ%9H& O2UL_@URDR
M&DUH1(16;7.D)* 0GC/T%=ZWPUZ_+W+%QN)5YMHBG> $RHF?@5$4,G5P][\W
MM_>?'A^GC%$4V/@A2Z05:X4_,!K.!L.KG[&"0H^C4;_7KT_I'?DXZNP8_,>W
M'%R,MK:D/0?_KWN.^EO'?-I6;)53&B/<09#4L?B]]T")R"3L^=>V6HAI CJL
MB;&1HW 0?;Z>!BXK?=0F-0N H[C5,4H():;.XNS=)Q]OIZ>,?7=7]W\]B_JA
M.''0!)#[S ^8 ,7@9<Q[BA(%BD#D*L]6U@+R)17"(X9 FK+\6P<4KSL/)'6"
M9JA;$CJ.;.7CLWRELS0B#K9%'#@1*1Z>*(@6TH?+CES_/OAOPGV =*8101[U
M"01<+,T;?G#"P6FJ GL#S<CF><F*8/ BGE,! D[?B,]26_$K@R!6J5.MN /D
M$SATI9SR)#?CJ9Z1US,V3\1Y!AX:@R%"H#?BBI!_]]0RA5-6)<P*)4'PUY$4
M<3+J!X/+J#-\X^>&:T."8Z3!?GMT.(481I-@,!CLDZG.CS[YW3]\WY/J?)(#
M=0S"D5]F:^)&8IN,@C"<B-%@$(S[PRT%'LA%XH30\E0,1T$T#,4C>\T!91\+
M^$<P&8XV$'U)K &4##:#)EYR,:K,%CZ-M$]7"A[$ON5783:5$1XST</7%/R8
MMM%9G%:)YTJ2ZKFBL0&*"RUG.L6B!.P^LY-.83E4[&P]D_NS<+XD?D$G-*EV
MK'V.>C&CRH7BOU0N_\VM6>T(G7CVN%.,N>#+00(TT(JX7Z/,G'T=GFCB)N<V
MR;7)BX&3/?<E#MG*2TQG,81&D*Y*Z)0N/I?R23&I60.F9TIE? Y47RKI48"1
M18S']6RC*J-G!\4+*(7JS+6!:,),P?E)MT]2IR[U,GLQ54J.FQ"8@<>4="Z
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M1'">T(EZJ\C7NJ'I3OJ-M=A]#@--+L2MR1;.H)QV01Z#X:@6O3L\&H7!!5S
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M.,4Y^8@>$XLE96;" 6H1RJ(V+)'5<>?,-64Q5/TKCV5S*H/]-KKP0K%[N-Y
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M[>&5U6#$?DMW[0E0][VC=-T3#TKY>B,*Q.>&;=QD16DKM[8K)+8*"/?*BRQ
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M#]RW=^S7K7;6LA 6+T@]R])5DV 40(E+L59N3INON-4S]'P%*=M^8=/%9FD
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M08ZGJC4K?L;0^  ^7Q*YG>,3] _C]#=02P,$%     @ 1H-<5&Q:%F/P P
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MTKPL.BXK,=3H<_']I'<0'95#@RUD] .^K!RKI^P5JO*IAA/1\)H]ENCG8!.
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M48>9\!T1'IRN_=U]KAV^!/RRP*>7,"2 _876;OM #G8?<V?_ %!+ P04
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M=.$OL1@VX%K_N!+H7X8V8'VAM=N^D(#FOQI7_P-02P,$%     @ 1H-<5*-
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MFSC<B%N@0D\E86DQ>BPBT#640B)$LF""S8 /"Q"K1#V1T8U,0Y<81_Q(<I6
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M' 9E>;R.4UB0Y*@6'SQQWQ\$9JR68-);@L$0.)X5= 9=4N*B 8P/ F(]<C\
MSB;><#B$]U<J1WE; =G ?.1K5@#JGH^]\7AT0=:&MY RI><^P,QT>*%1!]_S
MB)5 -CW0T)EHW_PU!G]L[)4H1I'I0-24)L3#CO&!WT# @?\)GO].WN-!TRG6
M0J35SU&ZQ6!<GP"P' 8123]5(#< Z 2O'JVC!1,_!44Y\\<#WQZ\,[+-_(G'
M8">!*O0>\9DE @<,TU22(#?ERI_/:S @M >EX[,K[P?B!SY#)L[5SUL8(9;*
M,"5"4K?R$VH3()_#(LL@$CF<["R8USMB<32SHK@E1=:==0N,D0 I,-\^GJ_R
M; L2>N'RB!B"9*] ,N"9>R5SL#!1'_^:&[38I>Y"!<H.8+,1*] "\ X*E"UP
M1B)SSFW0OZBA I[ C;GKTQFSHGU@4_M!(^\_%!AA,#_B/5BB[+B5T"84%2!P
M8XMW#"T&98%ID4(DHKF2>!NCGL7 K 82';4@,#W-TB=9#EQ$N >-RP%%&>-%
M(1.&6.18)1.P1; I/"Q\#Y:$-;7W!1^C_:I7SV!!M**@BSNDM2Q5Q _OMZ\7
M _$FVR,>$F 4)1I9A.@T$._LI[ "@"79 _RXB7HX$$PPL(#L*K$4A:3U%DB,
MWWIK1-M,,X<.9R7<GR+LWD,*>!X@ &ASHPP=,-16>%'V[U!DRR1>2[*>!UCD
ML7S V;K,0<:P_4UU0$?*TA;W00LD+0BZ8%!F'F(=6D%]A"#Z8)@1ADC^4"TE
M2&@./FP2JY3$+C'2CGX7S.!(J+16$2PMX#IXK]H&:RG7^.*Q- K8JBR-[/C@
M3R/+_ %8&2UU%[ L$ Y\Z;@5*WR=*%SGS)\,:S1L;YV0"?B%.RIT+(D*(%>P
ML:WV'?'TU9I?A!E(/GA"P EM@X!RYTTX#> DN@E\A#CX%F(9=+P4?*X5AZP;
MA<7T!+,8M.8F)O]G(*[HF8XQ;@&V+/B\M[LD)L5C:P$PWD/< 7%J(C;X:8)2
M LCQ999CY*=BE@+DW!*0> -L^J0_1,% /PD$7N4I'!KE % $E//$@-G>.WB)
M>A93E !'1N[R#<1P$D,7F@:P QB55EL!LHH>6$;[N(K^!4<&PD53?WC[\CW"
MK#H.],Z+VG65 N0+J 9CM<MB9!8H2I9?B%U2X2&2TL8A$03$@U>&QS,#870'
MP;$=9,$I^W0TIR*_03I3-DGW]]#>8!6K4T'^ JKNNQQ4Y01NP0=JM<(U 58(
M?")TYTD/W_SZ\OV+$^8BIDZ:O$,!8E/RQ0=+T_NMLT'$[$0JB(P[':D</.EI
M]Z3W*:ASW+7"U8@#8 /3X-: 5D#=Y-[&,[VJ04)"AXX"!S#X>-"([+6[\88B
M^Q_  % ^X54*7FA"^8%A$S,(+!2N+]'1NB&I2V2HC#-Y-AX&@XEU']'960-O
MU_1@3TB%;H=.=X2',@[LSK+9GC"][!LWLP.X8@1O@?-4/_VJ?HL0#M1GIX\2
M]U;/R$!6OQ8R#'.RBJ[.K>([6,\P51./JH?VWD/W5O(6MC$J(QEOY .$'C*G
M8.*E6N85&@I?% SA.IM#KV%2"J!YNJ4"(4HYGG0&>MI_:1',$0L^:F;D2."8
M&,^9YM0@C[)>IV:MS@3(BC<9#IV_]H> ,\^?3 !VY]YB/.P+!:=C;^;/\8FA
M-QE]C9A09]7.;%ZM$ZA3A$$Y(>.[=GF)9K8=NB^&;KZE';MCN (36@\ )\P
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M)2BN+#T<D@?HY;R6P%8=2KN,??@6X&A\TG6A8Z\'F3M]P4DW (,C;@ &K1N
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M(_;:S8LRV]&/=2VS$B23_MPH<(1S?  ^7V7 &/T"%["_WO;\_P!02P,$%
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MCJ%1,@0<BR!#?7MT$SAQY W%-1-TZIU'Q!J3[U@ 5+*4EDO 0DB^0%$0>[;
M_,@)@HBP0L:QR)P(#G#F98"-S(M$DF3/FW2E2]Y:8*JIP+/J"[*PUJNBPQS
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M.8&_[E$0P3'EW= R3S:UCQO%??BN/>G;L9E_5RI0SG6^,=1M5S@\EO:34W>
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M=4,3\'YE3#<.2,'T7QYO_PU02P,$%     @ 1H-<5$A61ZEG!0  L T  !D
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M#N#]4H#![<8HV'VDW?P%4$L#!!0    ( $:#7%0W754JM@X  "XK   9
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;*5::6_;2!+]*PVOO; !FN8E2LHF
M 1PG@PDPR0QB9P\L]D-+;$F=4*2&35KV_OI]54U2I$0IWAG L"BJN[K.5P?Y
M>IL7W\U*J5(\K=/,O#E;E>7FU<V-F:_46AHWWZ@,ORSR8BU+?"V6-V93*)GP
MIG5Z$WA>?+.6.CM[^YKO_5:\?9U79:HS]5LA3+5>R^+YG4KS[9LS_ZRY\44O
M5R7=N'G[>B.7ZEZ57S>_%?AVTU))]%IE1N>9*-3BS=FM_^I=1.MYP=^UVIK.
MM2!)9GG^G;Y\3-Z<><202M6\) H2'X_J3J4I$0(;O]<TS]HC:6/WNJ'^$\L.
M66;2J+L\_8=.RM6;L\F92-1"5FGY)=_^K&IY1D1OGJ>&_XNM71N&9V)>F3)?
MUYO!P5IG]E,^U7KH;)AX1S8$]8: ^;8',9?O92G?OB[RK2AH-:C1!8O*N\&<
MSL@H]V6!7S7VE6\_?K[[]=,'\7#[SP_WKV]*4*3[-_-Z]SN[.SBRVP_$ISPK
M5T9\R!*5] G<@)66GZ#AYUUPDN)[-7=%Z#LB\ +_!+VPE2]D>N$Q^;)YOE;B
M03Z)]]K,T]Q4A1+_OIV9LH!'_.?$$5%[1,1'1']0A2_?+6IN+\&FN1(SA:!3
M0MN;I7Q21L@L$>5*(1Y26:J$[@KUA! UV#93F5KH\DIH+#1BD:>(.2,N=88]
M>66PV5R]$O]2LK &$U"W6L]4T:J<_GGXYT]_S,PK\1[7IM1S<2[BR!F/?%SX
M8\?S/%Q<XB*(KP2B![&1B<N)$T:3*Q$ZWF0J+D-G' 17XB$O9=J0/2'XN1C%
M3N2%N @\IH 3?,\9$\F[JBA45C9L_:0258#JN?CK7R:!'_R-UH*3W??[$MH#
M)Z,P%+[C3T8B<+QIW/(*\9NES:=E=-X]"01!8A20U(X_)I8LF?=JH; N.63(
M#[ A(GZF4\>/HRL6PYD$D,(RA6_Q!(JY#,9.%$VO]AA(>J2)HN=,Q@&3"6(G
M]L,NR9YVAWT%%"(G"B)+8>1$(3,5Q!/QL%)#>_.%./<C-P(>I2E!*ZS%3OE,
MCJ6..%:AD#4,=&=XK5HL%",RDRY(<KG9I)HDRT72.!:R#W[3V1+[#9 6CIU\
M RQB&9TZ5T6)S",2Q':A2DM,EVIMB/&T2F@G^*EPU"Q5 G@Z_WY-,)X(R$7R
M2,H.CLCR[+JS<"XWFE1'#MF$'4CCD$0C"Y*C_$ADS^$5=SA&9L]B)1.0Z>JS
M-H'59S#J*'13:*1(G3[OXCQOPEY):P(I'F5:29O;*-!E-L</. %*:O67(:^W
M+B,A"S%_Q*X_-B/"8IXC(1L<L>,1S!AVW5[ PBK?JD*;1'/^-6*[4@AJ.D ^
M2IW*F4YUR;OGLBB><?I6%DFK<:Q5&JL+D>JU)AV O465XL"JQ-;_LD!BBX1.
MGY8#>W2>\3%YIJY+5!!B22ZR*/(UWTZ46F.OD:G5(RNE=B]R%UX(2WW\<B=,
M73R$X>1R>66UU104:YDH,7ON&7G/7)^>\_NY5F28V_GOE3::=I(!@-!;<+V1
M1:EERDI<@ ^B)T&%_9!LF77),Q*,_V9.6KZ##XUL2:5^Q-$M#H5IYU"L)0S-
M]!-/R?N_NO>N6-1P1CJORKQXMO%;'[$I\D=M&ESH^T0W+[TX$9TZ,_!=))N+
M@\_[CCN$[B3 K=#U1_BX'+LA,/*BQ7J[Z-+'SU=VV826A>Z4O]^M9+8DWQ[4
M>NR.F&@<C=W)F-;[4W<<,P?#4$.4)QZMQ)'>Q%YX[HAY>MAA#*WS[+JQ.PUJ
MTM,0GQ\8.\E$K(,Y<VC:1''1N;KTW(CWWN79(\#2HJ#*-$R3Y:4BQU_H#+*0
MZW?VC=R ]^UN?<ZS#D#6H&'$R/6)IZA6A!^Z(Q;J"\"^>+2:#7VZ,W;CF)<
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M>Y/Q)0UJRM("O)\:Q*"Z(07-[S^G_P%02P,$%     @ 1H-<5,T'_/Y'#0
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M0E=@^(<T(8%BR%"RLLI7VYQ6T%8T_L[L5>/?6)O\4I'8/IDE[KQF/.JJJUF
M\E)\2=9CY:@EBNVKP^*U+=@DD$9W1[@"'Z2>#UC=I8X/R%20.3/+"GQ-IN4-
MKQY#8NEO_=+=(L?8)@TC ':L:ZMZ)V "DLJJH.&-)X^:G.%8N[K*NA0DNBK)
M;20*DY'#<C8D6UC2W89L'^^.%<H_K"HI65Y';E--LQQ9TBR>,]D2$5@O-+#J
M5O66]4LD3$7:F>B;THMWFSS=T(J(&;(FZ78T;/R.(VB2D@0L:=^KO!7*QR/J
M!L9F:L1LZ7&)$B6%RTP Z%,MBWRM-EPYWF^+B+4ZOO*#+3L6&]FZWP:I9R)C
M#6<=U :FHT>K.OXCN#Z>58B#PQH09]65#%], 0U=':P59B=5K@6B:DT)9B2^
M4:P&<4_(Z-BQG995^]D19CTNR9O /IFSHKN*(!B3EN91-NM/1+QY2Q8@&UO$
M[UF ["X:SQG:ZT/C*>QQJ%+XR)G^L%7,GDQY%GG&$'F==ENL"QJ>\$9-NB-S
M1GY,1[T]G$3L,B2*J%[.1;=N;4MFG(8D^6"NR6C91;7#*VK)P_ /[6*](&8&
M.L7D"M]AULT.!#;%(T .0:#)+2%K5L,]ZRMR5'5%1J(VA-PQ7E: 00?R*Z,T
M8N1RSV/10SGO4H]RA**B2O'2JFN!SZ)]R7&V0.!K,9?AA'HZ8D-B6,&O*9A%
MR$^ ,#N;V.3T$K Y_Q&@J<[FI =(2B" >HA5UQ(4(MY_3?(WLE!:X9*9Q#+2
M\8=OTDU.2\9#C$75%K8;(BXY,5F?)[VR&F>N0X$!=6H,[&6%B-X!>?(TZ@W!
MI<B@.%C&1A4:-B#JE6G";ROQ007V=H "FU4.X;MF&[[WTG'M;3JF='@]4^\P
MK+KQ6^4%*S'&S1#1F[0@XV@<1PG$5*6TF1F9F *JD'%"X"0ZW9Q1J1'O(0 -
M8F7".^RID38(3$7'T>UV\)>#&N]OQ4N;QSUC2[T_@''&=02]3'EY+SR<?3&)
M.PEJDOIJ@^_UUOQ*$TTBV=\W8HQ&R( 61>.A*3%YU:TWT$8$2^?-)M]A^^O:
M;!4D",=5=8:!0&[Z&$8..EQ?AJMO07QZXF$ ?QRI$*S\TM8$<I(_63HV0M=5
MO:N<@W!A:GJ:&$@^G!&@204-OTW_3//0CE[5W=JM_]&,3K)-L%#OTK#(Z)EA
MA:P2,_)0TY;XAG@H)PU.)@E"Y\(6,Z^(-U6SRUMV:,QVZ;0L:?ZUA1-E$7!H
M-,CBA\FJE!YK%CW2TAC5@+[Q*CXS^FZS;PB<DE)>C!R8Q_NDJK>D[65(8ED(
M'TDY<$R=$VDJ'<Y$'^XVAK1)N@<\8T$NV?B2*TCSL[1ADC 'C1Q6,TM28K@\
M5?NH$9.MS5A;NQT0OWE"CE EX&I/$0;8&S[T5/D*L,'3&IC6NIB1.ZR?B>-V
MR7MQC,%D[^JU(<4EB$^"8N_?C5+PR[R8,=>%M5%L?!2(V-BWXM7KC+'[%7,"
MV3T,Z/A'YEXBI^6L=./L .AKUK87@H##3Y)%$KC<C^HZF"X8'F(RPK&Q>-)"
M+=D[A4XN@F6S[Y*_65-+.B5Y129RNR39=PD1_'-"_YQ^F[PY&)2>2OY3_WE"
M_]R0+4$<Y_#!LQ?NP;-OZ9\/H.3H<\_PR%/\@Y\^5,14R0O\_N(Y_J&7)_3P
MMUX/?_L9_[^A+8.M2FS98Y;D4J,[8XKX=PZ9])Z(@)*$E+(< $H-M+S"!MGA
M@X4&HUVT84G^CT@*%*A$IO07#?XP[( "-Q&(:A,.58FMB!?!2<W<&U8"5**^
M,['_."XP_B TYV2;U0AOKHJ%DEQGUA^T*-)0;FD\ 8>28F2/B"60J+!G(RH,
M<$9CD:I#6+]EOY)]$_J4%A8)8AJ0-\(!ZTJP\RWRN<Z?PGXY$+8B$6\UI,6
M3!86B'WTL,(.O #1&EH1TIS4?-VH:Z]!A0.4- 4D3D]"MO5DDM_(5$*!?3"?
MQKGU"U[O*<RN407$T<!>6'8//V9#J@-(.016H"US&:[%< MB_Y5E3$N_'XGO
M,@4CZ+E2^!NPJ7H4& (8D@T6Q_M;,7:L.('K.;.3Y2N:4YY8VO;.*MX>"?8F
M9'+J/<=O0HR7L2G_[<ARQ1W):W Z_%A$@K V<-T7;'EK#0+9L &8S99&7&)Z
MJ^9X<>PE&P:_D#_SB;>K9%:3LR<.9;7N/(,*ALIN ;#J?8\D3JNXD<49@NR)
MYT'K;0OP_5],T:D#69!-,N'M!A3/FXW5 %,0/ XU$0*#^W=(!74?A-:'BS %
MSG\ &U@W-*+>8" 8(Q&M"M4_*SBI,\@Z U5UPCCL&3%B'.GKRHC9^-PD -6(
M/PZS2N[<< RGB4%D/-M+5$79 WJIVJGG/2W?437%Z:2 WG"4_R7KM(LHRC\J
MZU\WU'B ^TAV0<(+C6R6? 3=-C].FY>HF_B30*.I4 @?=N3T"SR[OOE(/P $
M;7=%M;<X2PS;%:UQ21@$3=S'"IP(ULXXRYEEN7.&V>G?P99A^#WK#S\J@U@8
MJS3?P97,V2;X4659(<-2F%+XSYTV<6Y%.@-;<.E4SL2P;S1T]?/QR/.]6"78
M+-$M*T/_W)((VD:]Y+T(GZF12A6OC*6)- .95>@$Y'(X1D68N7%1A,*6:UHX
M%#4L_<K6<7;JBD[3%"DGA36Z%>E=OX;#\^5SMUD_8.HMQLO"$.O<I(SF]!T>
M21AH6V6V8#[H/ZA_%R76RR_V(UHN?5=!,6'=+O+5\.G3>1*HER" [H:M4]C.
M" LAKZC)]]0>"Q_ AB/$(*0H>PE%ILAW"9X](Z1_Z=4;G88;3REQ\,QMA0-@
MPWKP&7N;'"-S'UWGS6_S5<T>AZI%#H;WC#>&^X<5AR>*JT4ST<(-=N\2!Y%=
MB)[RJ,Q_J)O 2XM#P #QZFW=,_9@)3P](Z.8LQSZW,O0]9&MYGV!07JS $#<
MY[;@/[(3]@II@M89!#SWH6:KNT_^8>MJ3L %X;]E!>HRYRCB9*Q&VHCG\G44
M]OB1J@_GSBJLX[-<A'"XES@QA5B;"XTYVB*VA]A]AAH%-=4[DV<<HPTL0BR<
M,CBP.PFLE/1<5C$?2#D$G@<M2\?\694TE=-=1 12<);5B<"N17*NDH+<U&QT
M0PX4,C/Q^L1.FSU"2HXF;@I!<ZF+2*,R WO?.846I<3 ?!SYSAF29W9)3Y8$
M-OJ,!QU<RQ&NK/.>5&ER(!),(_D5L&>D$J(7-(O/CO%!&G_*D)\%0WXV':$S
MS49SKO3#):DWTD;8Z*@E_\JQ4!ZSR=>; H$)^G,6)_F%EVGSKLB'F/C;$Q+%
M/=N+0C-<I3>)&1L=IWT!!#"=#=,M9 '17[Q?FFJ #V!PV1*P=*5%,_4HEJ3[
M81+[-4<D&G1L6U/_9I%](ZZ>I'ZHQ3S]9AK[;.A(YQ\@NICF#:H=^+>K0)_1
M@_C*8<]O35Y D.:OJWI^0\2)9TKD/=8DQC])_,AYHMZ9*=SR%3+S0[IQ!K=%
M^IB!R'*?I'18.3LXF28[V#[.HI%AL?B8(K^4V'T6'1QV)$+(+["BE-H R;F*
MYLR;I@OPAS7O0W&6RRJJNO(?9EAM_0C+A+[)UR23I(Z4-8IBC$M)*7 &A258
M(EM;+OZ52#!S+G^&5 S<H84<Q1<2^.C6S9K<I[UN>+B^WN+" F(5907].#C3
MJS-C3X,%)ZQ)TT:<7J6//4057#T/PW%,U)EP]==:T6):&)=(*3YPBL-6/KY(
MZY7$=FPDQ3Q FR/Q)4KYD(*!_1:C[D/$:%QP@0@L;0P5"MMNZQCT[YWDN5,:
MBE2M$15@/O$S2N*]V(C&@8B83L#W$C(6 R[U;IZLJ>%@]$QU(<:2L#AP )DT
MV+E: 5QM:;:R?VSNH!1(]4ZH&:'*(A+[$4KY6$>=26HP8-)9 #2NLE!UH,?-
M1.B/I?.3^6Q@H=8F5W^+$"RCWG+ZN)*']A/P 1-,CT%>?:31 4T1,SA#1$O=
MX(=XZI$0L(X+Y. W^Y*,G@--_GNW[<3W%I7!86N[07S]U@Y&1ABIB"(!UVZO
M!WL<5H]Z=-B/B]S/]7(;(@LG.>'&^4(:>4P3()@V"*Q&OT# N.Q&IFR\($4T
MIV5DQS2"J_XP\6F$'&F 3@C]MX/'&-SQLX+-XL]&W=-[T636A]<:LN$B3JF4
M"*Y4$RE??9:@TS\X:-"TD[8[M#F<3C<H7&DY8WXDPGGOMY/XYTCOK^@ .:"%
MBD=R4X#><;HL.FS+7&:-475M[J"<H+"*1@LLZM] 8<V++GH3<3JRE3R[E@-4
M=U(. !H=:F6-1D91*S<;:3*4:HD-)NNTL29C3QIR*I(CL0#1*<P\37#Q8N9>
MY773SG/:COQ4D1U]R#[FR?>OKUZ_XQ]/OW^DW-[G7L'%<.0X<XC8>E"14GF*
ME*N(#:'P)?&<A0%J:.OS+6GL<LWK9JUPES<H1R-J:W#3TTZV$$*.31R-Y!,B
M^!XJO4)E1"R'84TC%5!Q '226T.WPNETA\'K_!,-?<Y!SU%VO?_KB?SBPL@#
MZR',HSF'6-5FJ E"W,K5_ZA0:L%[WW<*9[=#46K=DI>'2)@$6X'L-2\DB^ @
MOZ\F9G?!(D; RHG=""GBDLKQ7B$54N<I5W0X13((P&N82MR#+;F/.*QP0& .
M]NK#YEAV(Q)%E6<^=$&Z*KC876-779&@SEE,9<)%*>M-.\=!2!*!P"/A \OP
MA_9* [KB\#I6<,=>CU)90/DBZ=,+J;6\2,ZOMELM^2JP#HGHD?6/7R'T+'0"
M1==<$X;%-1H6:[X3%B+_3#_6M]_D*SG]#@N+CA<9ZVK5WF&84TC&-YI7>+=:
M(2:V(G3$OO* +Y[J8V]-V:&$3OQH-M9258K)X\=IZ-,3>6E*WD+#Q.ETQX3L
M\]JV>2UIG7>A_'-4_KY^N)[H(";CTI'(',95IPV95:YWD]R?UDLHT)=#C0(=
MG#<!^I2/Z"#0OL$:E$4J7^>2SBTU:"EE:Q'F1X 6GL!PZ/% B60[&C89?IO1
M\EDSGU^_@SN&-@5V>) ;J9'SJJ044K&U#B21=9?; :QWD=5C 65\QG/TH$8H
M9M3'O*YV@2/$&U;@< Y?AQ(6%[WKQZ3=EEU$7^IS:=O6+<"1F82CD&D7R27\
M)WPVV&035&N<L79_Y$1D%!R,T@<\P*1]"9T0I],]"ZR;QCG[/B\>< 3CPT9*
ME>?5:DZ:29(T[S[.>AE,YJU>'E.U.(=+4U\\.<;CPHB%K(#=#,6_:LFB$7HQ
MZ:@T>@]UJE%#[YBQ^Z' %>6EM4OT.N7IE+G+UP\R.N'5:&UQO?$1'<^@K= =
MZ=BKD=D/QO/URUZS1YC,<H>4>$;JT8RA+P;]L(T^I'NXZ0\!M].1T%E.'V5
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M7.7QF2J6+QZD'^DD%=3/?J.%2-Z)DIR@-K)(G%[/T)T60_N^/^'JS=!>CRH
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M2VULC0?H\U55M>X73."_7/RG_P=02P,$%     @ 1H-<5']Y[E,N!   "0D
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MMQE]JZ T O1_*H0^'@Q ]_4S_0Y02P,$%     @ 1H-<5"K!G4[5!   Z H
M !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULC5;;;MLX$/V5@5L4"4#$
MHD114IH8<%*W6Z M@B1M]X)]H"7:5BN)7I*RF[_?(27+[L5&7\3K')X9SASQ
M:JOT5[.2TL*WNFK,]6AE[?IR/#;Y2M;"7*BU;'!EH70M+ [U<FS66HK"&]75
M. P"/JY%V8PF5W[N3D^N5&NKLI%W&DQ;UT(_W<A*;:]'=+2;N"^7*^LFQI.K
MM5C*!VD_KN\TCL8#2E'6LC&E:D#+Q?5H2B]O8K??;_A4RJTYZ(/S9*[45S=X
M6UR/ D=(5C*W#D%@LY&WLJH<$-+XK\<<#4<ZP\/^#OVU]QU]F0LC;U7UN2SL
MZGJ4CJ"0"]%6]EYM_Y"]/YY@KBKCO[#M]P8CR%MC5=T;(X.Z;+I6?.OC\#L&
M86\0>M[=09[E*V'%Y$JK+6BW&]%<Q[OJK9%<V;A+>; :5TNTLY/[V:?9AX\S
M.'L4\TJ:\ZNQ152W-LY[A)L.(3R"0$-XKQJ[,C!K"EE\#S!&.@.G<,?I)CR)
M^$KF%Q!1 F$0TA-XT>!CY/&B8S[*C6Q:"0NM:KA%KAIS >-L5W#K(RPU_#.=
M&S__[XD#V7 @\P>R(P<^=!D.:@%3EW6E?8*RP7ZN6UG O9P+*PV(IH#;E=!+
M'.=?#<$%V^H&.Y]7"B]#5$CL0>I-F4MX+7N+._1B;>%./,&KTN2J;:SYU:V=
MI.AJ_=*L12ZO1UC,!@^1H\GC"H.D*BS4LEF"=1D!:ZTV9>'.WA6N<TOLW/)1
M1( U5AE8!18A;I&@:)Y>/$M#FKPTX!PQN*E"KPL0#E\T>>^.<$$1U7X=069_
MWDWO9^^0B_: 3U)H ]*E%V!RR'J.@=DEB/\&'BL,:$9 &-ABE;OV[[?O[F>/
MC]/OD(X!P1G>D5VIUB"6.;_<70=,]XSWP4=ALOL+^/Z:/JFJK>6Q>X8W:B-U
MXP%V6QZ5%17<B,H= \+^R(ZF\!PBQO";)!E^*:$\\6U  VQ]L,.7;A>)@L 1
MW91>.9,T@I2PD ,G(=I02E@2#P8A)UE,=QZ9\;3X@C7A^W 6I\DYG*4D9!&V
M,<E8BBT-".?9^0!Q%L:$,=QY@G\&,0L@XR$R9BG';TKY@,!(&K!#SAE#SC&C
MR)E%R#DD$3O@G!)*DR.<(TH]9Y9Q;#E)XMAQ#DG,Z2%GQ BC4YPQJ3"Z8>2^
M0>(CGN*78W3WO),L/> =D2"+ >,3I:EK*(HC30@-J#./,F#H=Q0?89[$21==
M+!OL)(0SYB9B$@9N(DI<]".&P]/$:9<&G':)DOCD(3SBOF693Z-N-<3X!G!"
M\^)!\^*3FH>E()9++9?"_VU1(WK9_94VG83Z?6W2TJ^[X!7[X[&V&WS-H' 5
M+8I2ISZ^M%'-I"Y58:"W<W)D>ECS4_W_Y<1B=D0L?'[XQ/[PXV&7@X ]ASC@
M)*8Q]AC%*XG<5; @(6F2[-4);X%CE>ZR:M>63B?$BV<TX2^!<LR_$*LBQ<Q'
M^XS#3;LN-R+'EY>$JEPK@W\R=/0+2K$/CVE1EIL^,7G ,5U9G&&?QE&O.#\'
M"BE'*<FXRQ44#<(I\^1Q#B7D5XDR/GA]X*]TZ=]8!KPP=@^1879XQDV[U\M^
M>_<&?(\B6:+B5G*!IL%%@HFBNW=5-[!J[=\R<V7QO^V[*WR*2NTVX/I"*;L;
MN .&Q^WD?U!+ P04    " !&@UQ42+<\5 @&  #+#0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6R-5UM/XS@4_BM'731JI93FWI0!I%*&W4K,#$MA
M5JO5/KB)VUB3Q!G;H<S^^CVVDQ*@H'EI$_O<SW<N.=UQ\5WFE"IX+(M*G@UR
MI>J3R42F.2V)/.8UK?!FPT5)%+Z*[436@I+,,)7%Q'?=>%(25@W.3\W9C3@_
MY8TJ6$5O!,BF+(GX>4$+OCL;>(/NX)9M<Z4/)N>G-=G2%57W]8W M\E>2L9*
M6DG&*Q!T<S:8>R<7L:8W!-\8W<G>,VA/UIQ_UR_+[&S@:H-H05.E)1#\>Z +
M6A1:$)KQHY4YV*O4C/WG3OJ5\1U]61-)%[SXBV4J/QLD \CHAC2%NN6[/VCK
M3Z3EI;R0YA=VEG8:#B!MI.)ERXP6E*RR_^2QC4./(7'?8/!;!M_8;149*R^)
M(N>G@N] :&J4IA^,JX8;C6.53LI*";QER*?.YXL_[Y>KY=WRZY<5#._(NJ!R
M=#I1*%H33-)6S(45X[\AQO/A,Z]4+N%3E='LN8 )VK0WS.\,N_#?E7A)TV,(
M/ =\U_?>D1?L'0V,O. ->1>-Q!,I8<'+-:N(Q425P5Q*Q/X\_=$PR<SI/_.U
M5 +Q\N\[>L.]WM#H#=_0N\(RRIJ" M^@ZDJQ:DLKI1\ERZBP=F!QP55!'_5S
MSY)#>7A7FR[A$UF3E)X-L$8E%0]T<'Z74U!<D0+25UH5WAW0##LBX2B:)L<)
MHJXH\,B!7<[2W,J0BF;:(\V^X066-OH%0U;A"6\DQE4Z0!]36BNH*3:!G @*
MI.1-I>3H!*X($_"-%(V)RTTCTAQ+"VX$2^F+V,P-D^5XZ#CJCN.Y1S5A&1 %
M:<$QV]L36!"9'_":% 5@AY(*#=6&&_.D%MS&XL-OB>]-/TKD+4MDPCI,O\,P
M<IU@YO?(GUT3'3]!C05'R7'D/KD^@B,(_<0)@N"03<9NQ0&1J! JMZM[:;#)
MJC%&>(PJZ$_@M::56!".%[5B7C!VF<SH6D$2.9Z70!0$3NR&+P*8/D'1G@G=
MOB0,%]]NY0C"R/%##^X,:MX(]A$@/IPDC."=,HGV91+]<IG<TI1O*_8?1G*9
MH85LPVA;I]*"U 09XW/-R)H5B%C,!MXWY<O68VOF7=5OU\P3L)7IBSK*&CXJ
M-[A'XH)A2\99I@'%4QN6MBH.%=4^D+7!.>9-4U*I&(X7=&GS+$7ZKD*-Q#K>
M1Y>^(CW!&;(_KSZL,5LXLA_.EK5OTZ5FG:]6G^Y68(;![:=+BRT=X%0_4*1&
MJZ@6=@2>%SA1[,,JQTB,%14ED ?""AVB,49G+)$4D?N ?I6&Q_,,8.=I:@T2
M-*4H$.DA\)TD2&")U)7B0N?1GSEQ/,560 VXZ2/N'Y+:>N!HO>@"$CI)Y,,5
M>]2.V2,_< )W"I=T0X4.E2*/W564.*X7@=DZQGPS;C -[57L1$FTAYJQBU78
M&K9,/W;:$M=Q71=-'=>"IWJ2:+ 0S*@Q+:,/N.'4VF,8+F]N/Y"R_G@Y@M@S
M;+:26EE'D& 1SZ8SN%[.+Y;7.'X_K702[C]C\/=QJLE/8\P1S)SI+-07HJ&]
MD/B^,PWC)W<%VE A>#QKZC756"MZ-6(]_6JBV#_'!"53N.;5UB;4] _?]9PP
MZDSOD_N1YTP1 O:&]0-W"+!1/'.PF\+OG&<['";H3NPG+??SGH)CMY*M-[_4
M7^)]?XE_N;_<" YFI<-DVK7VC5G[OLBNPA$&N )*V A>'JY,U/F%/]!RC6'W
M9G:E04K!FVV.V4OM3;?L=(-63TQ6I46#"Q68VK8=F!<L,^T"QY>BML10 ^[I
M-H@X><VPE6T#DZ\ZPZ+ %&'&VHZ%MXN^W-4SN5_W<E_WC;O6!YO*%GZF2?A.
MG 3P!=& HUB?#/T("] =P=]8,W9+?.VZ_G%?2XL#K);0UXCP<*C-9D^"A_'4
M\>-P!$,,[-3S1B:[)JMZ6V>I+4Y6--JSJF-[VDG0,N\X\O6 'KK'83PZ!+9)
M;\$NJ=B:SPB]'&"=VEU[?[K_4IG;!?V)W'[F?"9BRS"6!=T@JWL\Q>$D[*>#
M?5&\-NOZFBM<_LUCCE];5&@"O-]PKKH7K6#__7;^/U!+ P04    " !&@UQ4
MN^QZ(9 "   [!0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q]5$U/
MXS 0_2NC: \@!?+5AE*UE2@?6@ZPJ.W"8;4'-YDV%HZ=M1T*_W['21N*1'N)
M9^R9]V8F?AYME'XU!:*%]U)(,_8*:ZMA$)BLP)*9<U6AI).5TB6SY.IU8"J-
M+&^22A'$89@&)>/2FXR:O2<]&:G:"B[Q28.IRY+ICRD*M1E[D;?;F/%U8=U&
M,!E5;(USM+^K)TU>T*'DO$1IN)*@<37VKJ+AM.?BFX!GCANS9X/K9*G4JW/N
M\[$7NH)08&8= J/E#:]1" =$9?S;8GH=I4O<MW?H=TWOU,N2&;Q6XH7GMAA[
M P]R7+%:V)G:_,1M/WV'EREAFB]LVMB$@K/:6%5NDZF"DLMV9>_;.>PE#,(#
M"?$V(6[J;HF:*F^899.15AO0+IK0G-&TVF13<5RZGS*WFDXYY=G)_>/S[>/B
MU^S^=@XG"[84:$Y'@25D=QYD6Y1IBQ(?0(EB>%#2%@9N98[Y5X" 2NKJBG=U
M3>.CB#>8G4,2^1"'<70$+^GZ3!J\Y%"?\@VE5?H#;KC)A#*U1OASM316T\7X
M>X2AUS'T&H;> 88YZ26O!8):P;4J*R6)T#AOQ\W1?#?:H[!.E$-3L0S''JG.
MH'Y#;[(H$+(O'/R3PP=)8F;4'S.P4H)T9^"$2["%J@V3N3D= LT7RR7J;L;N
M$\*,;>AV6=2<"0,_($G])+D@(T[]P2"%%Y+8&9=GE589&@-)WX\&,42I'Z<I
MW'')Z2KFL%8J-Q!?^&%"P)'?NQS 0EDF".ERX/?[(1EIST_)^&[TP=Z%+E&O
M&]D::KF6MKW;W6[W,ERU@O@,;Y^5!Z;77!H0N*+4\/RB[X%NI=HZ5E6-/);*
MDM@:LZ#7#;4+H/.54G;G.(+NO9S\!U!+ P04    " !&@UQ4IV-AAF0#  #_
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R%5=MNXS80_96!T(<$
M(**K+<6P#3@W=($-UEAGVP)%'VAI9*M+D5J2BN-^?8>2K'C;3?9%(D<SY\P9
M#8?S@])?S1[1PDLMI%EX>VN;F>^;?(\U-U>J04E?2J5K;FFK=[YI-/*B"ZJ%
M'P7!U*]Y);WEO+.M]7*N6BLJB6L-IJUKKH\W*-1AX87>R?"YVNVM,_C+><-W
MN$'[I5EKVODC2E'5*$VE)&@L%]XJG-TDSK]S^*W"@SE;@U.R5>JKVWPH%E[@
M$D*!N74(G%[/>(M"."!*X]N Z8V4+O!\?4)_Z+23EBTW>*O$[U5A]PLO\Z#
MDK?"?E:'7W'0,W%XN1*F>\*A]TUB#_+66%4/P91!7<G^S5^&.IP%9,$; =$0
M$'5Y]T1=EG?<\N5<JP-HYTUH;M%)[:(IN4JZG[*QFKY6%&>7#Q_^N+^#U69S
M_[2!BR>^%6@NY[XE:.?@YP/,30\3O0$31O"HI-T;N)<%%M\#^)33F%AT2NPF
M>A?Q#O,KB$,&41"%[^#%H]"XPXO?P%MK:F1MCPS6@DL+7!9P_ZVM&NHP"W^N
MML9J:I&_WJ%*1JJDHTK>H-K0R2E:@:!*^&*P; 5\I-8SL#W"RA@Z:;?<XD[I
MXX\*_2ZV.Z,ST_ <%QX=0H/Z&;WE0").)+PCR0<2X!K)!*42= 3-[#\YO*98
M(MRJNFDM:L"Q-*Y01I7VX&!"L IB."+7!CZ5994CE*V6E6T=";F^!DX&MT<N
MVY)*V^I*[CH?P;=*<^O(S]T).@R&H(?J!8M>B&$@T;)A;E3_D)TTUOQOI4>-
M#')%@\)85W.[QT&L([RH)%E4:XC97,Z &@OK+4D\-9=[!)1EOJ=:NW)]I^(7
M",.41=.$5FG"KJ=3^(@T!O9*%%#5C5;/Z!P-3*Y9F@0P25@2)S^O9,S"ZQ3"
MB(5I\+-21BS+8GK&64K DEJU[8<:::,,=M0)!K* 328II"$+KD-X4I8+B-*8
M31.2&$Y8D&24NJ$&X'G>UJV@VA4TP:B/\HIW<!?9A$5)< D7:<;B*2W^]Q]<
M0;*,)4'H5O&43;,,?G1H_+.A5*/>=:/7T']JI>WGTV@=I_NJ'VJO[OW5\,CU
MKI(&!)84&ERE$P]T/V[[C55--^*VRM+ [)9[NJ%0.P?Z7BIE3QM',-YYRW\!
M4$L#!!0    ( $:#7%0HO5>IX0,  -<(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;)U6;8_;-@S^*X37#G> &]N*7Y(L"9![*3:@AQZ:KL4P[(/B
M,+90VW(E^7+Y]Z7D)$U[=]FP+S8EDP_)1Z3HZ5:J+[I$-/!85XV>>:4Q[20(
M=%YBS?5 MMC0EXU4-3>T5$6@6X5\[8SJ*F!AF 8U%XTWG[J]>S6?RLY4HL%[
M!;JK:ZYV5UC)[<R+O,/&!U&4QFX$\VG+"URB^;.]5[0*CBAK46.CA6Q X6;F
M+:+)56+UG<(G@5M](H/-9"7E%[OX8SWS0AL05I@;B\#I]8#76%46B,+XNL?T
MCBZMX:E\0'_K<J=<5ESCM:P^B[4I9][(@S5N>%>9#W+[.^[S<0'FLM+N"=M>
M-TX\R#MM9+TWI@AJT?1O_KCGX<1@%+Y@P/8&S,7=.W)1WG##YU,EMZ"L-J%9
MP:7JK"DXT=A#61I%7P79F?F[V\7R=@D7'_FJ0GTY#0R!VD]!O@>XZ@'8"P 1
M@SO9F%+#;;/&]8\  45S#(D=0KIB9Q%O,!_ ,/*!A2PZ@S<\ICAT>,.74D0Z
M-0U_+U;:**J"?\Y@QD?,V&'&YS!]N);:/$?9>>./TO *J*\4-Z(IH+)@D!.6
M!JX0N(:-K*A=-%R(!DPI.\V;M;Z<P%_(54\T$$U8KU YJMX?P5QD+C#M"+2/
MD![1&-Z*1[([]?8*HL@?9ZD50C],$A)2G[$$/G$E;$G\H![Y&6/ _'"<DIPF
M$?2ID/703\<C*S _HOU7D/DCPEUV;5LA-;%5R[DN84-Y@6CZZZ3O[(H;BLO(
MGRG1(/3_(>.GM*^MVY:+-0&I)[17E*:HA!&H?6CH%I2;_1?1Y!0WW1E]6EDX
MMD+L#^/,Y3>,4W"7V!NY>=-I>VX:B26%N50V* H7'_.2-P4ZUSVL7%6B<*E;
M_D?$&Z-W3+R-+6\Q$1LF+R7TV=TRA,T?* W"56AOWN_I&%0U9(,L@QVQHV$\
MB$9[\8GM6NA<=HT!(@0A'8S3U_0<9:_/-$AR;)#D7QJ$R, GA>G#NSW?.Q_N
MN.D42<]UT%ET.ZDFNN4YSCP:11K5 WKSA;9G]X0XGZY+YX=.V"J8TK9'W?)F
M]^LO(Q9EO^ES1?&?.G)1% H+R^(]W]EJUW#3H77/^N:(,G> 0RLS.G"28RO'
MS,F)+; D=3JIE1EU&,D9D!<;,<W;C;%)C<EDN&^[/M;VX#$*8S]*$[#43T#4
M;6=<$9(=:@,7+/:3.+N$YZ^?TY2INL=^2H7S7"$$)\.F1E6XD:K!55(_=XZ[
MQZF]Z(?5=_5^Y-]Q50AJ@PHW9!H.,CIUU8_1?F%DZT;72AH:A$XLZ<\#E56@
M[QLIS6%A'1S_9>;? %!+ P04    " !&@UQ4V3PX1B0$   Q"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S.2YX;6RM5MMRXC@0_94N-C45JCS!-AA" E1Q
MF<E2E612(3MYV-H'83=8&]EB)#F$_?IMR>"P"?"T+V!=^IR^G);46TOUHE-$
M V^9R'6_EAJSNFHT=)QBQO2%7&%.*PNI,F9HJ)8-O5+($F>4B4;H^^U&QGA>
M&_3<W(,:]&1A!,_Q08$NLHRIS0B%7/=K06TW\<B7J;$3C4%OQ98X0_/'ZD'1
MJ%&A)#S#7'.9@\)%OS8,KD:1W>\V_.2XUGO?8".92_EB!].D7_.M0R@P-A:!
MT=\KCE$("T1N_-IBUBI*:[C_O4/_[F*G6.9,XUB*9YZ8M%^[K$&""U8(\RC7
MO^,V'N=@+(5VO[ N]T;-&L2%-C+;&I,'&<_+?_:VS<.>P:5_Q"#<&H3.[Y+(
M>3EAA@UZ2JY!V=V$9C]<J,Z:G..Y+<K,*%KE9&<&-S]^3)ZGM[<PO)_ ]/YI
M>'\S'=U^@^%L]NUI!N=/;"Y0UWL-0V36I!%O@4<E<'@$. CA3N8FU? M3S#Y
M+T"#O*Q<#7>NCL*3B!.,+Z 9>!#Z87 "KUF%WG1XS6.A2YFLN1# \@2FN6'Y
MDE.P,-0:C88)U[&0NE (?P[GVB@2T%\G:%L5;<O1MH[0SDKY@US ."5.!)[#
MF"FUX?D2?C)1H%W;>7<H\R<);!M?Z16+L5^C/M6H7K$V>$H1XHK.V-&.\G5'
M:6?',ENQ?//EM\LPZ%QK6.Z2Q/6V<?D_F #3L)"".EK#N<.3A:8TZOK5QU!&
M3+ \1F &J("8S5%MBQATX0RZ72]J=6Q)?>K0N,@*P8PE2/XF\5/W4R6<,^'U
M"2@RW@*]%U5Q;;U8*)E1XY"(C<Q1$TG*\948"I*E<C'/7C:X2AGU. SC7P79
MN0.CV?9\WS^":.V^"WRS&_>-NEX[O#SE:4!!!ZW("SH1G%!35*DI.JTF.J63
M0KCZ?=+P(>V<A#NLG3U<YG ]R-%X$$LZF[7926?Z\/B%9:OKB6NHA)(LZ.Y(
MP&"<YE+(Y>9TZHY:V87R**0T*B2!T':=\I5^![S;R%G,T2;](R:C#CXBW80^
MF *6R<(*[8.2/Y?N1DFM/RI\N"?;O50]NPL!DZ_#5U1TOQ'<I]@X"?(,HJ[O
ME'8&YV''\[N=NIULAU[7;T+@PP:9HIQ'D)4'ZOAP+KH^V4=U:$>5$3Q)PP0L
M>,X-?A7<ZIX?K&;IA(/H>$$8UDL'VI=E.I6-K:IO.W#^[OIR.RRYCL"?D5N!
M(SA[IZ#)L.E(/O?S_YWJC>V[H$ITT/2BJ&E=Z+:]%AT<06N;LA/9#=IUZ+0^
M9O=HQ(ZN6]&UNUNZB)1TJ/4;>]<X.;!TCQ5-;4;B+&_T:K9Z#PW+9\#[]O(Q
M=<?4DN<:!"[(U+_H4-NK\H%2#HQ<N4?!7!J*UGVF]*9#93?0^D)*LQM8@NJ5
M./@74$L#!!0    ( $:#7%20(L!5!@,  "(&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;'U5RV[;.A#]E8'010((T=N6 ]N X[BX7;0UXKZ H@M:
M&EM$*=*7I.+D[SND;#D%FFPLDIISYLR(9SP]*OW;-(@6GEHAS2QHK#W<1I&I
M&FR9N5$'E/1FIW3++&WU/C('C:SVH%9$:1R/HI9Q&<RG_FRMYU/56<$EKC68
MKFV9?KY#H8ZS( G.!P]\WUAW$,VG![;'#=JOA[6F732PU+Q%:;B2H'$W"Q;)
M[5WNXGW -XY'\V(-KI*M4K_=YD,]"V(G" 56UC$P>CSB$H5P1"3C_Q-G,*1T
MP)?K,_M[7SO5LF4&ETI\Y[5M9D$90(T[U@G[H([_X:F>PO%52AC_"\<^-LL"
MJ#IC57L"DX*6R_[)GDY]> $HXU< Z0F0>MU](J_RGEDVGVIU!.VBB<TM?*D>
M3>*X=!]E8S6]Y82S\\5R^?!U=0^K'^O5I\UJ U=?V%:@N9Y&ENA=4%2=J.YZ
MJO05JB2%CTK:QL!*UEC_31"1KD%<>A9WE[[)>(_5#61)"&F<)F_P94.QF>?+
M7N%;LV=?'#!9PZ*J=,>$@9^+K;&:KL>O-U+D0XK<I\A?2;$AU]2=0%"[/@/6
ML'HB"QDT_VKIFVS.D;?FP"J<!60Y@_H1@_F9%D^T4"GRB+$NI6T0=DJ0U;C<
MPQ67=*(Z0_6:ZUN@?F*[13WTU/W$@T[R"@G8A[!'B9H)WR96TZWCKD'./I>D
M[R!)PWB4T2+-PK0L!QHGE.FJ\? :'\GX![*QO6"+,"]C&(6C,H7/)%F3.7LL
M#1N7B+0/P4D>3NAJ)4F83$:P5*T[9[VE*<&6M.ZX-9 3ZX0J2D,JZB)&/3-A
M.?%<)=>0%6$Z*2$+X_Q2-I<62;,E65E10AIFXQ&LM:J[RE(QMM.ROS''1M'E
M88+TND_!*^HU$G,93HJ,<,DDAB_*4N-<<\9A412T&L?A9)S#O^Y6],*W+>J]
MGT[N>W;2]A8>3H<!N.A]?PGOI^='IO><= K<$32^&1<!Z'XB]1NK#GX*;)6E
MF>*7#0UQU"Z WN^4LN>-2S#\+<S_ %!+ P04    " !&@UQ4"&&+>]L$  #N
M#   &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6RM5]MNXS80_96!FK0.
MH-H2=776,9#;H@$V;9"D+8JB#[1$V\1*I$M2N>S7=TC)BA=K.PFV+Q9%<0[/
MS)PAQY-'J3[K)6,&GNI*Z!-O:<SJ>#32Q9+55 _EB@G\,I>JI@9?U6*D5XK1
MTAG5U8@$03JJ*1?>=.+F;M1T(AM3<<%N%.BFKJEZ/F.5?#SQ0F\]<<L72V,G
M1M/)BB[8'3._KVX4OHUZE)+73&@N!2@V/_%.P^.SU*YW"_[@[%%OC,%Z,I/R
MLWVY*D^\P!)B%2N,1:#X>&#GK*HL$-+XM\/T^BVMX>9XC?[1^8Z^S*AFY[+Z
MDY=F>>+E'I1L3IO*W,K'7UCG3V+Q"EEI]PN/[=J,>% TVLBZ,T8&-1?MDSYU
M<=@PR(,=!J0S((YWNY%C>4$-G4Z4? 1E5R.:'3A7G362X\(FY<XH_,K1SDPO
M+L_N87!/9Q731Y.104C[851TYF>M.=EA'A*XEL(L-5R*DI5? XR02T^(K F=
MD;V(%ZP80A3Z0 (2[L&+>@<CAQ?MQ)L9N."ZJ*1N%(._3V?:*!3#/WO XQX\
M=N#Q#O [K)&RJ1C(.7R28O&S8:H&M^65P&T:E*_1V\*Z%]=6XK%>T8*=>%AJ
MFJD'YDWOEPP*JM0S%PMXH%7CMC4X>R[K%17//_Z0DS#[H &+3QLJ2KNPM&2X
M[JJ.?V$E4 US66$Y:AC06C9($;A )-EHM-)'Q^A"P>H94WTF[$\ ]]:]2E(!
M9S"G!:^X>48UFD;9K7HC7)O" 43)V(_'&8X<,_(!@F&6!(?(5SPP93B*#C03
M7"H0TC -)?ITVBQ0]A8C@2@*_)1DR"+R@RB :!AER2OVU_39&L?X$_HD'O>;
MDS<8GZX4KZPY@3#)_#S)((S'?AKG<"\-K="7T ]PAB"; XA3XJ=9#GNDE/12
M2MXL)9M/J;D[MKY.\4^Z51>F"3YR045A __;K.(+:I=OU=K>C7=KS3B'G7Z*
M;PDY*7RR4D!Q;2KJ526]6.Y63I;X01#@_)PIA9*=][X64J-<![$?Q]&1*VPK
M8$!BCND@Q/RDP5&7+COG@\#+#6F[!>7:PH:PW(7_(M[7(^&4^JN3T'M#X8KJ
MO46!L@N(GP3!QFAWH#(_3)(C&.3^. ZV!2R-_2S,[8K 3Z+_(W)=T1[T9?NF
M&)+OB>$[:QNK. V<PEY&NT-(""IM@+K*QUL5YX\)AFV AT(:?7_XUN?.07_R
M[#E=TOYT2=]\NK0$KP3>50PU=?F$#9YF<,L*N1#N@KAE%37X--(EQ^5EV\&R
M?T^;]3:-UCU#VZ08FUMEE@ZY%05?4V$=%?5"Q:6?P8HI+DL-[H02EMN@1&BJ
M8,<%]A?#;ZXGV2F9(!Q;P;AFH$$:-B\2-U/?$CJ L9\E8WQF?II8U>1^.$[@
MM$97^!>ZEG)WV>H&<\JZC!*TQ,L(RS#%NR,+LNU6O3Q(A$OQ^LE]@G9805F<
MPCE=<0Q5%Y*.W< F!C*47N2/0UODQ(^L1@>D+V-;A$C 4B8)WE6A'418GSE<
MSN?,]<0OB K3;H6]4:SI,$WA$+)AF+A''L+A-D&.-GK0FJF%Z[0U.)_:=K2?
M[9OYT[:'?5G>_A.XIFK!A8:*S='4'H\>J+:[;E^,7+F.=B8-]L=NN,0_)$S9
M!?A]+C$PW8O=H/^+,_T/4$L#!!0    ( $:#7%3JT<0/8P<  #D3   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*U86U/C.!;^*ZH,/055[L3R)4XR
M0!70EZ&JH2@",P];^Z#82J+!MMR2#)W]]7N.Y#B&=M(\S$ML24??N5_BTQ>I
MGO2:<T-^%'FISP9K8ZK9:*33-2^8'LJ*EW"RE*I@!I9J-=*5XBRSEXI\%/C^
M>%0P40[.3^W>G3H_E;7)1<GO%-%U43"UN>2Y?#D;T,%VXUZLU@8W1N>G%5OQ
M.3>/U9V"U:A%R43!2RUD211?G@TNZ.PR07I+\)?@+[KS3E"3A91/N+C.S@8^
M"L1SGAI$8/!XYE<\SQ$(Q/C>8 Y:EGBQ^[Y%_V)U!UT63/,KF?\M,K,^&TP&
M).-+5N?F7K[\R1M]8L1+9:[M+WEI:/T!26MM9-%<!@D*4;HG^]'8X3T7@N9"
M8.5VC*R4GYAAYZ=*OA"%U("&+U95>QN$$R4Z96X4G JX9\Z_7-]>W%Y=7WPC
MU[?SA_O'F\^W#W-R_, 6.=<GIR,#/)!RE#9XEPXOV(-' W(C2[/6Y'.9\>PU
MP B$:R4,MA)>!@<1/_%T2$+JD< /Z &\L-4XM'CA/HV94.0OEM><?!(ZS:6N
M%=?D/Q<+;10$R7\/\(A:'I'E$>WA,8?<R>J<$[DD5TRIC2A7Y**0=6D(*S/2
MD0$HS)J3;[)<?31<%>037Y@^NQ_F^  8Z9;3,R)KRVF)G)IUP^I*%A4K-[__
M-@EH\H<F2U&R,A4L)TQK;MR]7+"%R(41B&- J)07"ZY:1Q"F.-"3I<PAKS4Y
M%B6 RUK#97TRVVG=4?6&,[0UI#0P>=1X^HT_\YS0YADTSY!\:66ZV,FTV_S6
MD:Y!S5#,KETAX\D]3VNED-$ETT+/WN+.R.?OM3 ;(LIGKHV3[(C0R*-! B_6
M1L$?K]Z:PRL)5Y01D">DE 8$46 C\8R) U1 % 9[$-Q9KS8S<I&"1%I@R?JH
M>,X,:)9"1H$2(!V^:I%QQ6Q-.R)QXL73R1Y&S>&O[0:A":K\#Q974H-5'C 0
M<\E*B)\4+VQ(AOFRC0*(@#'@A_'4BZ:O#14FU MBO[,7#,,D_H"2MP;3O!12
M-79#9  ,R#$]0?N"U)/X-2@=CSUH,YT]?YC$_J]!XP8T#'UO_,:E491XR81V
M]L+W21J1XP!! Q]4C::O0'$OCKN>1P%L=D*EP4BLE$CYOEQ,95& 7Z'LIT^8
M7HI7X!GPBRPM_2W3&?M.ON9R >Z<V^9&;IAZ@O;] O1'8W]($U*!C_3:IFA?
M[J;(%5UO)"2)4]=VV5:VH_%X.)EV<*#]6P&LHVZM-3 E]]Q.Z#"9]-^.W>TA
MV@0:L%3<ZQ72LQ?>HFORPE&KA7SFEL!9RIY92.R-HJB+US=Y(6#+K!DF4)UG
M9,W@_H+STOJT,>X;W7;"]EL1[<VJ2DE@"&F:;R#2(^C1>6['#4"(A^-V;0VQ
MMP9W_>Z!UW7%[;B2;ZQ6&DPH5K9/08VN"RPY4+-2&,,T[(GRK;&@/CBKIQ#(
M,)K!F8)(PEVHL%#EAC:&[VV!T1@'"/ EYS_PMHWQQDTP^Q"H#AR8N!$0"#R(
M/&X)" 5K8,<BPP-M,V[;9GRPB?7W"G)=5G73 O#0E;X'GJY+\1WZ6E^S/,P'
MX\0U+DQ(8TLV6#.O,[0%'#[QC3-TA;PTJ34D2V/EYU:$O;[LK]8S[#D-9&OJ
M>P:4T T-5%FLO\R&R,U&SE/!2TBG?@*<7.PTH:S_*!V&TP_H1AH,I\$'W(B"
M[08-/Y [!15CX4HYW&?I6O!GU%[Q50U!(-4&0Q6:H"P1T!_ZOKL?VS=J?P'E
M'PA,$&/#F7H/D.T4  //"?Z$!\)DW(;)^)UAXO5W-+3KZ\[OD<=2+C17KC_;
MB$(:66)[L^[I"Z.#<N#_I9FN6,K/!E!B$)P/W""V1J=M ^:]\8$#A%29Z\B[
MN0V";S<IA:3H#E%"'YS!=HPN6<XPFGH*&7;58.*%T;A[X:UD;A!Y4R<ZLPJ)
M8NB%U$U@3FZ6_5-O9RK;*U*H5Y;V>#J9GI [MG&'!<N@!F,X+6$F(VP%!4O#
MT\[+KNL>T]CS??_DD")T-_$<"+*D#;+DW2/\? U-V$WGU[M!L2]@#F+N#YA=
M,7)_CB'3=6_L=.?4_K'<-2[_IV#XF;2CRLS.?>2KDEHWOYU:O%-_YL;FCPN6
M/D$X:$PREWLP8GETLF_B=6>@3,&5'40KAL,!>BL,R<2WS0A68TJ!:MNI%A)$
M)U-O&HZA( 4M'O4]/YR0!VD Z8@D,-K%Z'S'W\UFL#D):4^P_]M:1]Z4XOS]
M9@@/(5[I^&>5 YALHFE$0*5C.CFQZY@&/VE- ]^#89309 J$,$+B1AR%Y'$X
M'Y*O,/ZHTC9'1QY%,-Y.26*UQT48D7F],-9$$?($84(,BQ"P<"/QX]V?SMD>
MV&GL10 ;^JUFN!-/=]A[*;;>B>G8FT2Q-0F6&BL ;B<>'4>]F3KJ?,X ZZWL
M1QNLFU .W)>-=K?]+G3A/H?LR-U')1B-5U!,2,Z7<!7_- R(<A]JW,+(RGX<
M64AC9&%?UQSJD4(".%]*F'*:!3)HOY:=_Q]02P,$%     @ 1H-<5/18UUQ%
M P  C <  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULE55M;]LV$/XK
M!ZW8;*"(7IP7)[4-Q$ZV!FN;+'$V#,,^T-+9XD*1+DG%R7Y][RA;=H?:6('$
MXE%WS_/<B7<<K(Q]<B6BAY=*:3>,2N^7%W'L\A(KX8[,$C6]F1M;"4^F7<1N
M:5$4(:A2<98DIW$EI(Y&@[!W9T<#4WLE-=Y9<'55"?LZ1F56PRB--AOW<E%Z
MWHA'@Z58X /ZQ^6=)2MN40I9H7;2:+ X'T:7Z<7XF/V#P^\25VYG#9S)S)@G
M-FZ*892P(%28>T80]'C&"2K%0"3C\QHS:BDY<'>]0?\YY$ZYS(3#B5%_R,*7
MPZ@?08%S42M_;U;O<9W/">/E1KGP"ZO&]X08\]IY4ZV#R:ZD;I[B95V'G8!^
MLB<@6P=D07=#%%1>"2]& VM68-F;T'@14@W1)$YJ_B@/WM);27%^]#"]G?SZ
M_O;#U?7]PT]P_=OCS?1/Z$S%3*'K#F)/%.P8YVNX<0.7[8%+,_AHM"\=7.L"
MBZ\!8M+6"LPV L?90<0KS(^@E[Z%+,G2 WB]-N%>P.OM2]B;_*DTJD#K*.'/
MM?2O\,EXA+\N9\Y;.B9_'Z Y;FF. \WQ/AKJGJ)6"&8.EWE>5[42'@NX]25:
MF)B*6JCDL_V,<*-S4^&WBGV0@_OUPBU%CL.(T!S:9XQ&TQ)A;A0UF]0+\/PA
M02I5<VH>'1 _Y*70"UI+'<R94$+G9)-6MEF=T*\__M#/TK-WCCIGJ]\$_?E7
M^F70#QUEG.L2N0TH2[32% Z"-,VQG<!G:B=TX;H7\(EFSJ.F4:+DO_3Z%QHA
M;G>#VHZ:2L.DMA9U_@I3*[0C'=S._Z^HT/D01(V;%$%XH .%U8S\FT.5]N$-
M=+)^TJ5G2#E[U^ZPPGHK:$$*@;BE?D;G:31Y]Q8T^7#AQ N<)ED+P>L#K.?0
MR[;.O/X/%Q?S$%>GUVW#>;TI5KXIEM\IEBC^J=<@VZ"T&_[WB\P26IP'IQZ5
MZ7L%IES!+1M;WRTR.^>_ Q)3^E9I[YQ^,_Z0Z>D9?*M[XYT)6:%=A'O T3FN
MM6^&9;O;7C67S83=NC?WU$=A%WQ0%<XI-#DZ.XG -K._,;Q9AGD[,YZF=UB6
M=%VB90=Z/S<T;=8&$[07\.@+4$L#!!0    ( $:#7%3&=P4U-0@  %06   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;-58[V_<N!']5XAMW-J HB4I
M43]RM@''Y^L%;1+#CG,HBGZ05]Q=(9*X%;EV?']]WU!:>9VL-T9;%.@7B93(
MF4?RS9N1CN]-]\4NM7;L:U.W]F2R=&[U9CJULZ5N"AN:E6[Q9FZZIG#H=HNI
M776Z*/VDIIY*SI-I4U3MY/38/[OL3H_-VM55JR\[9M=-4W0/;W5M[D\F8K)Y
M<%4MEHX>3$^/5\5"7VMWL[KLT)N.5LJJT:VM3,LZ/3^9G(DW;W,:[P=\KO2]
MW6HS6LFM,5^H\ZX\F7 "I&L]<V2AP.U.G^NZ)D. \<_!YF1T21.WVQOKO_BU
M8RVWA=7GIOZM*MWR9))-6*GGQ;IV5^;^5SVL1Y&]F:FMO[+[82R?L-G:.M,,
MDX&@J=K^7GP=]N$E$^0P07K<O2./\N?"%:?'G;EG'8V&-6KXI?K9 %>U="C7
MKL/;"O/<Z?6GC^=_89=_/?MPS0X_%;>UMD?'4P?+]'XZ&ZR\[:W(9ZP(R=Z;
MUBTMNVA+73XU, 6D$9?<X'HK]UK\6<]"%HF 22[%'GO1N,[(VXN>6^>RZ/1K
M.K^2718/H)5C9UU7M OMVW\_N[6N T?^L<=9/#J+O;/X.6<(G7)=:V;F[%W;
M1PY1\.P68<'<4K/+NFCMKGW>:Y@B](U=%3-],D$(6MW=Z<GI)]B;FQKA5;4+
MYOP9LAF. R')JBWWQ>C^W#2KHGWXXQ\R*=*?+ /-9E\P=H:M0)"P%<%CA6,X
M!MW<ZFX\BC?LVH]]-XZEI;"S^Z(K+;OJ,94,$</>6;LN,&SS<G.[*ZJ:0/I!
M?\81.%@6HC<DXB"&KY0+)F002Q7$2C$90&,"&2<T,H;S<CWKSZV?E"H,X"Q*
M IXF3$19D,N8?3*NJ,EB@LD;BXD(5"1@4<0J$"EG%\VJ-@]:#PN[7'>S)6C2
M6_:TV5K7T!]NCTOQL"ZN+R^9XMQCB7D>\#AG.0]R)=@>5JF15>K%K+K2,[-H
MJ]\)$L$>F$WG"L'LCQNG?VY::^JJ+)P?B!MMFB4+'U>Z\^-VTG ODN=I./ *
M:CW"LUOP9MOP]%=J:X)9.4_81ZCV"50S0@7/.T_@!UUTEFD2F^\YZJ^<%6U)
MYY*SP@[Q8=DAO+FE65N\M$=OV-]@I]>L[\WT5KR%<V,=(5D8 P8#9\E>,15D
MN?!WE>6X@V>)\E0I0"'OOM1W2'LKSU0P&:]5($%U, ]\N48N0L@&;*%;K+#V
M4XH2*E^1%OGHBCB\ $4>" (3!5DJ!F+#H_0Q\8I%.0C/J1$%B>)/./%DT^>=
M:38A;%;]GKYBB+(\H^D2<1+36N H2CB[NKZQ3*@@BA0%CTP2E@<*"_!4SQ%'
M.5<L3?,?0[K2M3]:B(QI-&3J*[O%LN>5PQC$J]_"+%!IAKL7)OG3OJA)QJA)
M7APU6]+W)SOLPL=5+\U4'53NP9_!!NN6=N\*DKV.7ZS50SV$8+%[M+D_K+Z(
MV<#LQBU]U/A-@"!D*E/Z\_Z6V2)CSNQ2]@]K_P ;]9LO9F!Z;)S=@:$+:/EB
MT>D%W+*/:X<P;4M:R/>9 DY4D$H99((.-!9ADK,TY"EU0&8PR4L_3 MP6@:I
MRD">,%7LXJON9A51]]#K?ZZ.F,C#G,B4!W$L*'',=45S#V4&RJ;Y$?@62HFY
MJZJCYR)-* <<L20*H^A'8'-&"2()HM2#0"P JJ+8YB"OW(*J.);$(Q:G(4B]
M!54@664(:P$H6"RM,XH#*=-MM+$D5%@/G/!L"ZU LI#I$4M%B/C>CQ91A5P8
MD88 K0KSC"5A3@X%P.5(EQNX4(Y IBE+> @<6V#3"/E/P%\D0Y7T\9XG3Z#*
M-(.3"%"3$ $]0DUB[ %6D/$P^B%2 :0<>ZAB[L\]C"2P*A_JV# ^@O*!L-,
M% ^;EGA-B;,P J]"+U$* I-*]EE;PDOQ0!EE1AW0^PZ/_SU$>S0G'34G?;'F
M?!]!*(N:07IO;(_VPKJJH:"BT/VEJ#KVN:C7VF>_BP+)9%"IOEJZL5X\,/1M
M74#GX<Y0S3<,NNRJ&0UX;TI=[]*M_>"]1!&$NQ&"?9(O%@.[[G6GF1Z0EVS]
M#*J&8."KQBW]RT?UN]_L3#'L3/&X,\]GYJ?&]^SNMSG\8L..$@I:HG1@#Y5&
M(O]@6KUUN:KLE]?S3E-AXK!"T*BCD^%A'!VPUTR$4AR@)V7?2_@!KI%_AV"*
M#QX=W1GH<U637(-HF*6B4/EKOC4*3IJ^RNFW5X51,M0W3YI0-]_<P\]LY&?V
M8GYN?QAMEX\!53(.5'*;&I/=M%2H^3)^S)>[^+77^7\M+Z(V^9^DPT>*C:GO
MIKT;5&=GWDM3B&GLBZ%0T%W&088'&UF..+(::7=$XCL(V*'(D003?D22#@W?
MDF(H79PAKR")@@3[G"./H260(C$VHY2 G*10I6Y<HT(-8GPB04GQZ;-Q+5&L
M\4QY#_F3]"KH:X;2:QR#__M\(\QRE>)K+:*,$=&RT97YX[+C.,%K3MDH$Z/O
M"-])/H%CV2)YXAN?<5F,)*4XY=-'WR^6>N1"G_\ !4E=]9!B5*M[8B@?8RA_
M<0R16 ]?^-^*.Y[Y6KG_^-T5+?O=[%!CXK.W:2ET_^]E^=N5;"V7O1*>%*]]
M0T:XB9!+WT?]%?N^B'Q?D%;^QQJO..DX1[%)&B_B7N-5>@!M%WS0^&2WQD>H
M&0\H4*#N,1+$#HW?<6P)3L+_.?NNL8NDTZT_?8WN%OY_)GT\KUO7__0;GXZ_
M3,_Z/X6/P_O_K>^+;E$!0*WGF,I1>4]8U__#[#O.K/Q_PUOCG&E\<ZF+4G<T
M ._GQKA-AQR,/Y)/_P502P,$%     @ 1H-<5,3]B:Y6!   ] H  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&ULG59M;^)&$/XK(_=4!<D">VU>"TAY
MH;I(EQP*N9ZJJA\6>\!6;*^[NPZY_OK.KHU#"D%IO^!]F7GVF5=FNA/R226(
M&E[RK% S)]&ZG/1Z*DHPYZHK2BSH9B-DSC5MY;:G2HD\MDIYUF.>-^CE/"V<
M^=2>+>5\*BJ=I04N):@JS[G\<869V,T<W]D?/*3;1)N#WGQ:\BVN4'\KEY)V
MO18E3G,L5"H*D+B9.9?^Y*IOY*W ;RGNU,$:C"5K(9[,YC:>.9XAA!E&VB!P
M^CSC-6:9 2(:?S683OND43Q<[]%_M;:3+6NN\%IDW]-8)S-GY$",&UYE^D'L
M/F-CCR48B4S97]@ULIX#4:6TR!ME8I"G1?WE+XT?/J+ &@5F>=</698W7//Y
M5(H=2"--:&9A3;7:1"XM3%!66M)M2GIZ?K]XA-O[ZZ]W"[CX\G6UZL!R\0"K
MSY</=/#(UQFJSK2GZ24CWXL:U*L:E;V#ZC.X$X5.%"R*&..W #VBV/)D>YY7
M["SB#49="'P7F,?\,WA!:W=@\8)W\!9<%FFQ5;!$":N$2X0_+M=*2TJ3/\_@
MARU^:/'#=_!75#UQE2&(#5R+O*PTMUE(VRNNT@AX$<--FE4:8[@M(I$C!4 H
MU8%RS^B4W\^_^I@@;$1&E4:V@3;A X5:T:'4"6BZCMZ26;=DXH9,09T@;0AE
M+2':YZ2AK*<(S6+]0"X5H DQ4( P7Y/D/DCVU[/0S//'<)$6I"0J12?*!7R)
ML-06NP;EN:@*K3H3^)U@Z\0Y1JU!+>!]E:/D6L@)W!]Q_@2A[XY''BW\L._V
M64"K"]]W/7_0(=A"4#'5RM]MY=)C_)GPMECS4<8[>ZNUB)Z 6IK21)Y<^_-/
M(^:S7VKGA:'+!@Q"Y@Z&OGFV[P?_COG>N0JC2J8Z136IHT\M"7"SH1YEQ)J'
M2J.F@,@&'@Q' 33OG5)Y6'U3P,8C8&QX3BX2!9EG>REU[SRM<A"%C2)YE,&]
MT&1R,&HASD M5LLEE)6,$FJ'+5L&?JOT_UVZ=Q3%;$#&AX$[&+&]4X_#W*;/
MI"FK#V3O)_"ZXSY]@F[HFZSPNFS8:8OQHPC,(@1!BW"F:_3;KM'_<-=84D0*
MG?+L-02+-@0F;JLVEV#Q$F65J9>-%+F]O.995&5M_NV-,QWF?(,Y2]","!-5
M\@AG#F610OF,SNFN8__DT[^)G*%S$.BW2>[6"6RZQ.FTT@G7L$/R.AX9^1]:
M5G3@CS5&O*(G#,1K5A, P5L+$K(,RM;_3?):$IR.XGT\TKJ Z+%4Q JL1PI#
MZ$VO^WA'.RJ;HK*B1YV!N3ZE+O6=8 @#-_3"<ZK6P;X_@/$8!M[@6/2TXZG>
M2"<(X5%H<@)SV9#JT0WZ#(:N%X9P*M][!Y,(=>>MG;<4A8):>SV4M*?M2'=9
M3S*OXO4\>,?E-B4>&6Y(U>L.*3-E/6/5&RU*.]>LA:8IR2X3&DM1&@&ZWPB*
M8+,Q#[2#[OP?4$L#!!0    ( $:#7%0#7]Z0H08  ,D0   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;(U866_;.!#^*X2WW;4!KBR2.M,D0(X66Z 7
MDG0/+/:!ENE8J"QZ23I'?_W.D+)L-XXW+Q9%#6>^&<XW0_KX7IMO=JZ4(P^+
MIK4G@[ESRZ/QV%9SM9 VTDO5PI>9-@OIX-7<CNW2*#GUBQ;-F,=Q-E[(NAV<
M'ONY+^;T6*]<4[?JBR%VM5A(\WBN&GU_,F"#]<15?3MW.#$^/5[*6W6MW-?E
M%P-OXU[+M%ZHUM:Z)4;-3@9G[.@\1WDO\'NM[NW6F* G$ZV_X<O[Z<D@1D"J
M495##1(>=^I"-0TJ AC_=CH'O4E<N#U>:W_G?0=?)M*J"]W\44_=_&10#,A4
MS>2J<5?Z_C?5^9.BODHWUO^2^TXV'I!J99U>=(L!P:)NPU,^='%XR0+>+> >
M=S#D45Y*)T^/C;XG!J5!&PZ\JWXU@*M;W)1K9^!K#>O<Z?M/%Y\_OB4W9W^^
MO2;#&SEIE!T=CQVH1H%QU:DY#VKX,VH8)Q]UZ^:6O&VG:KJK8 R8>F!\#>R<
M']1XJ:J("$8)CSD[H$_TC@JO3SSG:%OIA2(W\H%<UK9JM%T91?X^FUAG(#7^
M.6 BZ4TDWD3RC(EK8,QTU2BB9Z0S-U' &T4VQBFYA)%U=45D.R6069 W[;Z
M'[2%7#VR2UFIDP&0T2ISIP9K'X?@G!VM;==ATLD'9;U--U= IT8Z-<59HAZ
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MJ3OZX8I>1ZC= =K/E++/$Y>@>L$-?P-02P,$%     @ 1H-<5']!;3Z>!0
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M/J"'NSEZ]^8]>H/2 MUO6"5HD8BQ+55^S6+'3:Y9G<L]DPN[Z!,KY$:@19%
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M_J+[LJTV0&[&!8M*8; @"N+-?_)0.J(B8. & :,4,)X)Z%:#@%D*F%T%K%+
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M:&5E=#4X+GAM;*V8:V_B.!2&_XJ%1JN.M#2Q<R&9I4@4F%FDSDRWM+N?36+
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MKZ0V\^"VN7F 0-D <[Z64A\-*] \:<EO4$L#!!0    ( $:#7%3ERF?ET@(
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M:^^)-RJ4L2@%5\ES015UA?[]S=A@JC%7?P[DZ-0Y.BY'9T^.>Z$),_=NC;S
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M25EJ)\CCO\;4:=^IA=WKD_MG P\P&RS)DI>_::Z*N3-U4$ZV^%"J[_SX#VF
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M%;0TYK* -I4('0#/MYRKTT"_H&U\%W\!4$L#!!0    ( $:#7%0#EDFCK (
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M])J21&7%1]T5_Z621/4Z;L/6]HC*.HZZ:^;+MS*JG\>;&.@GUT-5/C?IK5D
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M3M"";,:S9J'%OIYP'H7&>:E^S'"D!6D$\/M6"/VR,$-3-R3/_P-02P,$%
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MP;:,C2('S'(A65J!505IG)7?Y&<EQ X ^2< N +@2P%>!? N!?@5P+\4$%2
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MC4KZ:,#B/&3!/"1!MPJZ*TT%1&/;Y2=T3">4_8ENIV06K6D_ODXJ+)1ZIM8
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M#W-Z[U [ =I?*&5W$^>@?D$'?P!02P,$%     @ 1H-<5(YET*D;!0  !!L
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MN]7[*YI\O^WYGM-Y)WX-T N]\,P]6Z\]:+0'']>NCC$A<9&28K++0+"O@37
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MR 1EJ8TA].V,)+DU&9FQ*9^,6"G3)*=3#D29983_O:8I6X\M9&T&'I-E+/6
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M;(XJ#^_[HPL#Z 8==%IWQ/WNN$-G5VK_FRJ\;X@!#+R7GQ5[J_;-*%^:"E^
MD)6YK,K@9K2Y15Q5M7,[O;J"/!"^3%2]F]*%"H47 W4N>5755QW)"E-)SYE4
M=;EIQNHF1+F>H-XO&).;CEZ@N5M-_@%02P,$%     @ 1H-<5#CM41'4 P
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M3F#Z,)-3-6$*(._O*17O)^H![9R^^!]02P,$%     @ 1H-<5#=3'<OE!0
M)!L  !D   !X;"]W;W)K<VAE971S+W-H965T.#4N>&ULK5E;<YLX%/XK&D\?
MDID6D+AW$L\DMG>WL]LV$_<R^ZC8LLT4D%>2<_GW*P$&#$*F:?O0 /[.T?G.
MD?0=T-4393_XCA !GK,TY]>3G1#[][;-5SN286[1/<GE+QO*,BSD+=O:?,\(
M7A=&66HCQPGL#"?Y9'I5/+MCTRMZ$&F2DSL&^"'+,'NY)2E]NI[ R?'!?;+=
M"?7 GE[M\98LB?BZOV/RSJZ]K).,Y#RA.6!D<SVY@>\7KJ,,"L2WA#SQUC50
M5!XH_:%N/JRO)XZ*B*1D)90++/\\DAE)4^5)QO%?Y712CZD,V]='[W\4Y"69
M!\S)C*;?D[7874^B"5B3#3ZDXIX^_44J0K[RMZ(I+_X'3Q76F8#5@0N:5<8R
M@BS)R[_XN4I$RP#Y P:H,D!=@V# P*T,W(X!'#+P*@-OK(%?&134[9)[D;@Y
M%GAZQ>@38 HMO:F+(ON%M<Q7DJN)LA1,_II(.S%=?OD\^QO<_7/S:0G>@:6@
MJQ_@\[ZHX8VJ82)>P,6<")RD_+)&T +!Y?W7Y1Q<O+D$;X -^ XSPD&2@Z]Y
M(OA;^5!>?]G1 \?YFE_90@:LAK5757"W97!H(#B(P$>:BQT'BWQ-UJ<.;,FT
MIHN.=&^1T>.<K"S@PK< .0AJ IJ--W<TYO/1YC#6F"_&FT>&9+AU[=W"GSO@
M[],A>R ,T$U5<6[PZ=4^O<*G-^#S%J<X7Q& !1 [ A[(-LGS)-^J4=2#/6$)
M78,+.3'*Z7*IFQ;E&$$QAMKJ'J<!<GVH6#^VJZ7!A4[@AAW<O(_S0X2BEK\3
MLGY-UC>2_9/A7)"S;/S>Z%'LH##LD.G#H.^@R'$[9#2X*$2A/T FJ,D$1C*+
M9\)6"3]/)^B-_RYT$81=/AH<]&32(>P0T@ ]Y'NQKR<4UH1"(R$I)!N2C*A/
MV!\?A1%R.XF?:7 >"F+D=_CH_$5!&,9Z/E'-)SI3H'W"SK.)^J,'GN]T@IQI
M8!"J:=DAH\.%DK2G)Q/79.*?V2=(OOZY'2+NKWQ'DO2<#DT-3K>3S#4XW4ZR
MZ..,.PET&AUVQBP__)"^/BG5$.WHW @%@1<,1-?J$J QNF^$JX4D91R0Y[UL
M\N2-H.!1/GY]M/!L#4^C14VTR"ALWXOV4(9X\TB8;'?!<6\#=RR1D^[B3LK>
M4D5V:9 \V.@H='^7Z*UIFF+&U:,R-_K4E.-%K=1XOA5WY4\'0U9W:NM0T H&
M=B/8*#TT2WU;_4;2*AU"[Z3D5G?/F>EP7FAU]UDM#%GA@&[ 1M:A6==/I7 D
M-[\?C(LL/^ART^%D.;K[K@X'8VNH:HW*0[/,GZKB2&Z!)M&!Y?6XZ7#(<GHS
M4H-S8PNA 7*-XD.SY+<E<B2UL!]*Y%@N[%+3X$)HA4[<^M>EJ;$)7*O55YS2
M;!H!:.X$1HGG2/Z1IF2QY:(N_VC,CC37P7H[TD*',NQ(34\!S4W%: T=F9M8
MDYO(<@>T'C5:C\Q:_VHU'1=W-7HT6-+3L)LF ,&?D]5[HCY%*:&;R==TAE?B
M@%/PA; ,7/Q+9* F>46-G"-D3%?AT)B7%\U@52[,KH/2%(0@*S\T(+#&+[I/
M%;.1GB \NH+QD*_Y&5_AT5<TY&$QT@/R-1Y.R]!T.<C<Y11E(&.7F*$DYF'\
M*G2_+DEPED/3LR!SSU)P>'SM\C-P,@\[:IJ=4FJ:%>0;5^7-=LO(%@L"/L@U
MF.0\68%O.#V0(N3ZZYMQ*3;= S)W#^,Z76V&2L=^NYUQ4.QWWTLU.-\)_(X>
MS34P+X;!P(L.:CH(=*Z#J%H_+8?^FSURXV[K-M/ 7 _UWJPUL-CSX "#ICE
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M)%=OJ<+)\<,_7R=_@NE?UW\_@,_@.\Y6V,3C6JB5L-27 GQ(B,0T$Q^5Q2_
M!V*!.1$C7ZKQ-8L_J\:Z*<="1\:""-RQ0BX$N"U2DK8)?#7Q>O9H-_L;Y&1,
MR,P#(?P$4("@94*3T^&!!9Z<#(=#AS=A'8O0\$7'8B'9[!FP4G4'7U3S188O
M/,+WPRQZDH+K->%J$[>"^DVH%Y*!6R&IVCX$R 4!7S#E9A$0 =@<W.+9 GPU
M / ;QX5T3"JN)Q4[G;Q]F$[+%51Y"N9ZT+4>%'R@!4A9EF$NP)+PTNZC;:65
M@UR8071N6X]1WQM$(W^]'WZ+%?(.C!*+4> -46W5<K-?N]EWN_FR5)E-29S2
M-4U)D8(M)5EJ<\5-%'A!\*MM:9\'2UX-:[D_J-T?.'GNJ7C^/.>$ %I(HK*%
M!%PMLD\ZA=%\E=MT<#,&7A1:=>B"(635P0V#7G@X6DN'BUJ'BS-UP"_'=' S
M0@]!JPY=L+Y]/;AAR(LCEP[#6H?A:=MAS3)58#(JMS;7W231T(/VO>#&Q:$7
MVYWOQ V=NP$&394-3O-?+8)<IU9KEJ^*J)LJ!ENB\V,$\K*8#D&*MS:FR9LQ
M)2<RH1T3M%&UM=OK4&!GQ7 1H88(O9]Z")NJ#]UE_Q6EHH/I:*TX$Y>\'M?6
MH.E48/3F]:*#,CBRZ2>=.'B8\BHQW#CT<W)JB]%T2-#=(IU3-#HH@Y\S626&
M&P>]>& 7PXU3=:/O%*/IH^")C92[<G2PA(.C6\,-C*(CRB5=0-5YN-=#TTM!
M=S/RJN+AINI7"=JJQ-G0Y"QH6XVFHX+NEL1\0/P'[FR)H4W9-"=P^'X* VJ:
M!M31-+S-IU(UROX'#HP]V#_X5K*902] !U]+=C,8VC^74%/E47>5UV&UI;@V
M95/OT3NJ]ZBI]ZBCWK]16$-;6%%X&%:+V4!U]8=AM9BICZ#^05C]O9.FG/ G
M<V(GP(RM"ED>V]1/ZU/!:W,6=O#\!EXFY=E>0U,>-=YA_D15@#(R5Y2!-U"5
MAI>G=^6-9$MSGO7(I&2YN5P0G!*N#=3[.6-R=Z,'J,]0Q_\#4$L#!!0    (
M $:#7%2HLH+F0P0  !X0   9    >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM
M;*V877.;.!2&_XK&TXMDI@4$$A\9QS-.2'<[N^UFXB:]5HQL,P7)E>2X_?<K
M <$VR)1V>A.#>,^1'DGG2"?3/1=?Y892!;Z7!9/7DXU2VRO7E<L-+8ET^)8R
M_67%14F4?A5K5VX%)5EE5!:N[WFA6Y*<36;3JNU>S*9\IXJ<T7L!Y*XLB?AQ
M0PN^OY[ R6O#0[[>*-/@SJ9;LJ8+JAZW]T*_N:V7+"\IDSEG0-#5]60.K^Y@
M: PJQ5-.]_+H&1B49\Z_FI</V?7$,R.B!5TJXX+HGQ=Z2XO">-+C^-8XG;1]
M&L/CYU?O[RMX#?-,)+WEQ9<\4YOK23P!&5V17:$>^/YOV@!AXV_)"UG]!?M&
MZTW <B<5+QMC/8(R9_4O^=Y,Q)&!!K4;^(V!WS5 9PR"QB 8:X : S36 #<&
M%;I;LU<3EQ)%9E/!]T 8M?9F'JK9KZSU?.7,;)2%$OIKKNW4;/'YO]M_P/V_
M\T\+\ X\+![!W"Q=KGZ BY0JDA?RLOX@]<_C(@47;R[!&^ "N2&"2I S\,AR
M)=_J1OW\><-WDK!,3EVEAV<Z<9?-4&[JH?AGA@)]\)$SM9'@CF4T.W7@:JX6
MSG^%N_$'/:9TZ8  O@6^YT/+@&['FWL6\W2T.4PLYG?CS>.!R0C:E0XJ?\$9
M?Y]VY3,5@*_J]1KPB%J/J/*(SGA\9"]4*IKI2"T(6U) %% ;"I[I.F<L9VO3
MF6G84I'S#%SH_5'OFDO;[J@["ZO.3'Y[F24X0CB8NB_':]:7A0&$")[*TKX,
M1U$2HE9V@HQ;9#R(_)<@S!#_! 7W.D<H1-CKH/1E88A1%'90^K+ P\AL"AM*
MV**$@RA/]=K]A"3L]?TN\!(]DQT4B\X/$B_&'1:+#B9^%'IVF*B%B09A]*&Q
MHOD(GLC2?Q#'*.KPV'2>YW6Y4XL.)RB&=IRXQ8E_*[(HRWXMIF)+3&$_ZM+:
M9/W02_NR3NB=P"8M;#*8F+Y4A[F&G;]0H2\GH HRH(\S"MZ37( G4NPHN+C7
MV6MA4"\'<A?T#@>?]\>S5\:+@@AIFH9FO>DY/H[_T E09]9M,NC$G<5);3+?
M@6<R&3PZ^>'H7-8#LW,U=PETO ,\)X9=,(L.Q4X/S"8+'!R>(?,/9/[8U#82
MS+>,!#LP[(+9=-!)NH?/&7\8GR$[G.$P^(4\-Q(NZ \&>T[830(V'4(.ZF8!
MJPXZOG\&[G"=@+]WG[!GO;&QB'K1@WVG>R[=6F26D$UMLI.0/44_7"L@'LR!
M\_5:T+7)>!^8$KFNPY:O:>_X4CV8^0X'/QP^^4?/LW4^:]_XY&*%>O<!J\Q/
M>O/9E_DQ[L;3G4V&XMYESCVJ@THJUE4!*L&2[YBJJX:VM2URYU5IUVF_@5=I
M7:H>W-25\T<B]/$@04%7VJ7G1'I,HBY&ZQ?%MU6U]<R5KMVJQXTNX*DP OU]
MQ;EZ?3$=M/\2F/T/4$L#!!0    ( $:#7%2X&IIR3P0  /T0   9    >&PO
M=V]R:W-H965T<R]S:&5E=#@X+GAM;+U8;6_B.!#^*Q;:#U3:DMB! !5%:@FG
M76G;165[^]E-#%A-;"YVRMZ_/]M)DT",V]->[TOK.//BYQG/3(;9@>?/8D>(
M!+^RE(GKWD[*_97GB7A',BP&?$^8>K/A>8:E>LRWGMCG!"=&*4L]Y/NAEV'*
M>O.9V5OE\QDO9$H96>5 %%F&\[]O2<H/USW8>]UXH-N=U!O>?+;'6[(F\G&_
MRM635UM):$:8H)R!G&RN>S?P*D*!5C 2?U)R$*TUT%">.'_6#U^3ZYZO3T12
M$DMM JM_+V1!TE1;4N?XJS+:JWUJQ?;ZU?H?!KP"\X0%6?#T)TWD[KHWZ8&$
M;'"1R@=^^$(J0"-M+^:I,'_!H9+U>R NA.19I:Q.D%%6_L>_*B):"C \HX J
M!72J,#RC$%0*P7L5AI7"T#!30C$\1%CB^2SG!Y!K:65-+PR91EO!ITS'?2US
M]98J/3F_7_X 7^\7W^^6H/_M^WI] 5;+![#^<O.P!)=@@=.X2+&)4#\B$M-4
M7*C]QW4$^I\NP"?@ ;'#.1& ,O#(J!2?U:9:_]CQ0F"6B)DGU3&U,R^NCG1;
M'@F=.1)$X(XSN1-@R1*2'!OP%+X:)'H%>8N<%B,2#T  /P/D(V@YT.+]ZKY%
M/7JW.IPZT 1UR )C+S@7LB(C.98\OW(8&];&AL;8\)PQ55HHBWE&0#_E0ES8
MXE6:&!D3NI"\S(=P.E%4O+1)[$K!X6B$@F.QJ"MV":$/PUKL",>HQC%RDA(1
MQE5ZO$5+6)L+G;3\-/6") "_**ZW!"B&,I4$U657!51(=;LIVZIL4'6'QJ!/
M7U];.2S]A6T.ARA4Y?F41HL@"L>P(QA9!.$(!FW!(^SC&OO82>6"9_M"EDG/
M-R"A::&9$"0N<BHI$2Z")[63R;\CF!79$\FU0RO'KZ=X@^5)EY-1J"DY9=DB
M&(23;C@BBZ"3Y6E-P-2=Q:>)!_8*OH'FXA?Z36'WG0S?FEO)K&[:M]E0J@MZ
M[=_*;.5MTB+"'TQ')[1:I(+!$)YP:I&Z] =H;&<4MGH9=$*.JDORWX&&-M#H
M%'17*A@$IW7/(N4"C1K0R EZ+7G\#/A>YZMPW9RFOT!W@_FM @";S@/=K<=$
M2WWT ;+9J*] NZNW$K[RT<Y/Z-L2WB(XG@3=?+?(G<ETV/0F.'(B?5@_.B/3
M="48?F!DF@8 Q_]#9,8=(I'Z:.@&QB*'QI; =.7.!:9I0M#=A1:<J?9C9IA5
M3C):9$ MU6<> O=<$F?0FD(/W97^MX*&FGJ/W/7>$K2X@;=OX,D=:4%\*XR5
MUS;MP>1L]T--K4;N6KU<KU8NW$W]0^@#Z6V*(@H^/B<J'T=WO9L1%BG+YY]%
MZC0H7FLN5#/#ULS70EV+@LER>JIWZQG^QDRN)_NW:K8O)_'&3/G#P!W.MY0)
MD)*-,ND/QJH2YN6L73Y(OC?3YQ.7:I8URQW!"<FU@'J_X>H65@_:0?V+Q_P?
M4$L#!!0    ( $:#7%2AZ?'SY0(  +$)   9    >&PO=V]R:W-H965T<R]S
M:&5E=#@Y+GAM;*U6W6[:,!A]%2M7K;0UL1-"J0")OZV55HI(NUV[B2%6$YO9
M3NG>?K83 @T0555OB.V<<W*^8_39_2T7+S(E1(&W/&-RX*1*;6Y<5\8IR;&\
MXAO"])L5%SE6>BK6KMP(@A-+RC,7>5[HYI@R9]BW:PLQ[/-"9921A0"RR',L
M_HU)QK<#!SJ[A25=I\HLN,/^!J])1-339B'TS*U5$IH3)BEG0)#5P!G!FRGT
M#<$B?E.RE0=C8$IYYOS%3.Z2@>,91R0CL3(26#]>R81DF5'2/OY6HD[]34,\
M'._4?]CB=3'/6)()S_[01*4#Y]H!"5GA(E-+OKTE54$=HQ?S3-I?L*VPG@/B
M0BJ>5V3M(*>L?.*W*H@# @S/$%!%0$U"<(;@5P3_HX2@(@0VF;(4F\,4*SSL
M"[X%PJ"UFAG8,"U;ET^9V?=("?V6:IX:SF>/X&X^>;B?@8M?#U%T"1:S)8AN
M1\L9^ Y&3-&$9H79&Q"1N!!442+!Q90H3#-YJ3$RQ4(O50_*P&/*"XE9(ONN
MT@[-=]RX<C,NW: S;B "]YRI5((92TCR7L#5I=7UH5U]8]2J."7Q%?#A-X \
M!$\8FGR<[IV@3S],A[V6:OQZMWRKYY_1FXV6\[OYSVB_22VB02T:6-'@C.@C
M5S@[M5<E+;0TTS]>APAU=0JOA_D=@P*_@]Z#IL>@KA<$->B=[4YMN]-J.U(\
M?@%\8]J';(DAK/7"K\NV6XMV/Y=M]SA;&,!&ML>@ /G=1K;'H##PSF1[7=N^
M;K6]C)[:(NW5,KVOBQ1Z^Y;E?2[4BG>8!81A(]03H%ZOD>D)3.B%IS.%!ZT6
MMOJ>18M%6P!H+X2^,-=]<X'^)W/UCW/UF[&>P(3-6(\Q?O.?ZAZ<93D1:WLG
MD"#F!5-EVZ]7ZWO'R)ZVC?6QN8_8,W(O4UYF[K%84R9!1E9:TKOJZD8CROM!
M.5%\8T_,9Z[T^6N'J;Y3$6$ ^OV*<[6;F _4M[3A?U!+ P04    " !&@UQ4
M2?61- $'  "?)   &0   'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6RU6F%/
MXS@0_2M6=2N!M-LF=IRV*Z@$+=RR6E@$R]U)I_O@IB[-;1+W;)?"Z7[\V4FH
M4^*X699^@23U&[\9CY_'3H[6C'\7"THE>$R33!QW%E(N/_9Z(EK0E(@N6]),
M_3)G/"52W?+[GEAR2F8Y*$UZT//"7DKBK#,ZRI]=\]$16\DDSN@U!V*5IH0_
MG=*$K8\[?N?YP4U\OY#Z06]TM"3W]);*N^4U5W>]C959G-),Q"P#G,Z/.R?^
MQ\^AIP%YB]]BNA:5:Z!=F3+V7=]<S(X[GF9$$QI);8*H?P]T3)-$6U(\_BF-
M=C9]:F#U^MGZ>>Z\<F9*!!VSY/=X)A?'G4$'S.B<K!)YP]:?:.D0UO8BEHC\
M+UB7;;T.B%9"LK0$*P9IG!7_R6,9B K #QL L 3 EX"@ 8!* &H+"$I T!:
M2P!N"PA+0-@6T"\!_;: 00D8M 4,2\"P+<#WGD<N3\E>,>1YODR()*,CSM:
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M<[%C8;(&LD78,P'_S&D4 ;E%]I@%_QJ&L8MA['08^\@P"_),F$IRFY$("Q(
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M,G\2E#;!/%\(H7<;6Z#Z-W7_ E!+ P04    " !&@UQ4EG"I.6<"  #6!
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ME-; W&^$T$?!!FB?LN@O4$L#!!0    ( $:#7%20YG8I5 0  / 2   :
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M\S%G*3/G*&_) 3X6A;=.*[7'G1/CK1)]W'R,'F\IT<M<G?N2C3DVQI28+"P
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MCM;I4V;J'BFAOU*-4_UH,HC&/R?CZSL8W^LQ@M,1*D(3>0;G,(E&<'IR!B=
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MT-_G7&M=+,Q)6U[%^O\ 4$L#!!0    ( $:#7%3,UIGZ30,  +P5   -
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MM?2R:1I#==/*V [H;ZI9[4W9JU?I>@5_S/67A1F.K/IPE[!;Q5*^K/K+M#&
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MK'IG@-Y9]<X O8OJ70!Z%]6[ /0NJG<!Z%U4[P+0NZC>!:!W4;T+0.^B>A>
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M4$L! A0#%     @ 1H-<5 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !&@UQ4**NCI.X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !&@UQ4F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( $:#7%0W;$J<P@8  $@:   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !&@UQ4+B:PAQ0"  !>!0  &               @($%#P  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 1H-<5(!?]PP=!P  3QX  !@
M             ("!3Q$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( $:#7%3@1O!\U (  +L)   8              " @:(8  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !&@UQ418+7.7P&  "Z
M&@  &               @(&L&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ 1H-<5#^F&OLA P  C D  !@              ("!7B(
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $:#7%3LQSW_
M/ <  *@D   8              " @;4E  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " !&@UQ4PWP+_&$"  !I!0  &
M@($G+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 1H-<
M5"B'.5K;"@  ]#(  !@              ("!OB\  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( $:#7%0).=U6V @  +T3   9
M      " @<\Z  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ 1H-<5% ZID/0'@  &%X  !D              ("!WD,  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !&@UQ4UY,';84)  #N&
M&0              @('E8@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( $:#7%1;<GPY&0T  /PA   9              " @:%L  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 1H-<5.)2I(R.
M$   ARP  !D              ("!\7D  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " !&@UQ4^)I.Y'X"   D!0  &0
M@(&VB@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $:#
M7%1L6A9C\ ,  '8(   9              " @6N-  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ 1H-<5 3KF_@/!@  V T  !D
M         ("!DI$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " !&@UQ4)1<9Z\D&  #A$   &0              @('8EP  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $:#7%2C0 8[OP,  )T'
M   9              " @=B>  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ 1H-<5.#FCQWY&@  R6T  !D              ("!SJ(
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !&@UQ47('1
M]DH3  !0.P  &0              @('^O0  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( $:#7%03,AM+R0,  "0)   9
M  " @7_1  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M1H-<5#;@KG0\#   \2$  !D              ("!?]4  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " !&@UQ42%9'J6<%  "P#0  &0
M            @('RX0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( $:#7%0W754JM@X  "XK   9              " @9#G  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 1H-<5-3 DDAQ!@
M1 \  !D              ("!??8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " !&@UQ4A<SMVRP)   +&@  &0              @($E
M_0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $:#7%3-
M!_S^1PT  $@F   9              " @8@& 0!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ 1H-<5)%2?U8) P  [P8  !D
M     ("!!A0! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $:#7%0JP9U.U00  .@*   9              "
M@;!3 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 1H-<
M5$BW/%0(!@  RPT  !D              ("!O%@! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " !&@UQ4N^QZ(9 "   [!0  &0
M        @('[7@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( $:#7%2G8V&&9 ,  /\&   9              " @<)A 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 1H-<5"B]5ZGA P  UP@
M !D              ("!764! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " !&@UQ4V3PX1B0$   Q"@  &0              @(%U:0$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $:#7%20(L!5
M!@,  "(&   9              " @=!M 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ 1H-<5 AABWO;!   [@P  !D
M ("!#7$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !&
M@UQ4ZM'$#V,'   Y$P  &0              @($?=@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( $:#7%3T6-=<10,  (P'   9
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M970T-RYX;6Q02P$"% ,4    " !&@UQ4? I\V2H"  "]!   &0
M    @('CF $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M $:#7%1?F7QR5 ,  (4-   9              " @42; 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ 1H-<5'6 'J[& @  SPD  !D
M             ("!SYX! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " !&@UQ4&TN"[H,#  #8"@  &0              @(',H0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( $:#7%3,&5JSW0(
M .P&   9              " @8:E 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ 1H-<5']!;3Z>!0  0QP  !D              ("!
MFJ@! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !&@UQ4
M]$)7/3T"   (!@  &0              @(%OK@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( $:#7%1L^W/#4 ,  .<+   9
M      " @>.P 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ 1H-<5&'=U#81!P  HR,  !D              ("!:K0! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !&@UQ4\3F;J^T"  !?"0
M&0              @(&RNP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( $:#7%1N%6-II00   X1   9              " @=:^ 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ 1H-<5*&G)L$Z
M @  W@0  !D              ("!LL,! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " !&@UQ4Y<IGY=("  !J!P  &0
M@($CQ@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( $:#
M7%09@[WK>0(  $(&   9              " @2S) 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ 1H-<5$.T>'9W P  RPP  !D
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M=#8V+GAM;%!+ 0(4 Q0    ( $:#7%0=?B(2\P(  *L(   9
M  " @2_< 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
M1H-<5#2P.>XL!   SPX  !D              ("!6=\! 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    " !&@UQ4UU$%G"0$  #3$   &0
M            @(&\XP$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    ( $:#7%0&GRW"K@,  # +   9              " @1?H 0!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ 1H-<5)CV'ZX=!
MZ!,  !D              ("!_.L! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    " !&@UQ4C)#[%G4/  #,7P  &0              @(%0
M\ $ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( $:#7%2I
M99[KG00  +D5   9              " @?S_ 0!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ 1H-<5(BFV=E4 P  !0H  !D
M     ("!T 0" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $:#7%2.9="I&P4   0;   9              "
M@9@? @!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ 1H-<
M5,EC](V5 @  +@@  !D              ("!ZB0" 'AL+W=O<FMS:&5E=',O
M<VAE970X,"YX;6Q02P$"% ,4    " !&@UQ4'-KW-2T$   J$0  &0
M        @(&V)P( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0
M   ( $:#7%2M03@_7 0  &D0   9              " @1HL @!X;"]W;W)K
M<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ 1H-<5!(JC\I( P  9PT
M !D              ("!K3 " 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q0
M2P$"% ,4    " !&@UQ4..U1$=0#  "S#P  &0              @($L- (
M>&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( $:#7%0W4QW+
MY04  "0;   9              " @3<X @!X;"]W;W)K<VAE971S+W-H965T
M.#4N>&UL4$L! A0#%     @ 1H-<5!42Q<5S!   3Q4  !D
M ("!4SX" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " !&
M@UQ4J+*"YD,$   >$   &0              @(']0@( >&PO=V]R:W-H965T
M<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( $:#7%2X&IIR3P0  /T0   9
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M970Y,BYX;6Q02P$"% ,4    " !&@UQ4TUE=?_D#  ")#0  &0
M    @('>7@( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    (
M $:#7%0:VG<%MP(  (X&   9              " @0YC @!X;"]W;W)K<VAE
M971S+W-H965T.30N>&UL4$L! A0#%     @ 1H-<5-4QTY$P P  L H  !D
M             ("!_&4" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"
M% ,4    " !&@UQ4-CDCH,0$  #4$P  &0              @(%C:0( >&PO
M=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( $:#7%3-0[A&)0,
M &H*   9              " @5YN @!X;"]W;W)K<VAE971S+W-H965T.3<N
M>&UL4$L! A0#%     @ 1H-<5%9,LA=[ P  40L  !D              ("!
MNG$" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    " !&@UQ4
MI"#UD;$"   @!P  &0              @(%L=0( >&PO=V]R:W-H965T<R]S
M:&5E=#DY+GAM;%!+ 0(4 Q0    ( $:#7%12=&Y!S0(  *<&   :
M      " @51X @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0
M   ( $:#7%26<*DY9P(  -8$   :              " @5E[ @!X;"]W;W)K
M<VAE971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( $:#7%20YG8I5 0  / 2
M   :              " @?A] @!X;"]W;W)K<VAE971S+W-H965T,3 R+GAM
M;%!+ 0(4 Q0    ( $:#7%2KL^ :P@(   X(   :              " @82"
M @!X;"]W;W)K<VAE971S+W-H965T,3 S+GAM;%!+ 0(4 Q0    ( $:#7%36
M.$ ZGP0  (X2   :              " @7Z% @!X;"]W;W)K<VAE971S+W-H
M965T,3 T+GAM;%!+ 0(4 Q0    ( $:#7%3\6:0"XP(  )8)   :
M      " @56* @!X;"]W;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0
M   ( $:#7%3,UIGZ30,  +P5   -              "  7"- @!X;"]S='EL
M97,N>&UL4$L! A0#%     @ 1H-<5)>*NQS     $P(   L
M ( !Z) " %]R96QS+RYR96QS4$L! A0#%     @ 1H-<5&2VNV*S!P  9T0
M  \              ( !T9$" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M $:#7%3B50\<^ (  + ]   :              "  ;&9 @!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $:#7%0.2"\Y:@(  '4[   3
M              "  >&< @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !Q
- '$ %!\  'R? @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>422</ContextCount>
  <ElementCount>648</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>149</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1007009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/REVENUE</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - FIXED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FIXEDASSETS</Role>
      <ShortName>FIXED ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2156113 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2160114 - Disclosure - STOCK PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANS</Role>
      <ShortName>STOCK PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2168115 - Disclosure - NET INCOME (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NETINCOMELOSSPERSHARE</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2172116 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2179117 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2181118 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNET</Role>
      <ShortName>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2189119 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTS</Role>
      <ShortName>COMMERCIAL PARTNERS AND OTHER AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2191120 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2193121 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2195122 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/REVENUETables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/REVENUE</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/ACQUISITIONS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/INVENTORIES</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - FIXED ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FIXEDASSETSTables</Role>
      <ShortName>FIXED ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FIXEDASSETS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/LEASES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2344309 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/DEBT</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2350310 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2357311 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2361312 - Disclosure - STOCK PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSTables</Role>
      <ShortName>STOCK PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/STOCKPLANS</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2369313 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NETINCOMELOSSPERSHARETables</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/NETINCOMELOSSPERSHARE</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2373314 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/INCOMETAXES</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2382315 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables</Role>
      <ShortName>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNET</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - REVENUE - Sales and Valuation Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails</Role>
      <ShortName>REVENUE - Sales and Valuation Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - REVENUE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/REVENUENarrativeDetails</Role>
      <ShortName>REVENUE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - REVENUE- Disaggregation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/REVENUEDisaggregationDetails</Role>
      <ShortName>REVENUE- Disaggregation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - ACQUISITIONS - Contingent Consideration Flexion Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails</Role>
      <ShortName>ACQUISITIONS - Contingent Consideration Flexion Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - ACQUISITIONS - Schedule of Assets and Liabilities Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails</Role>
      <ShortName>ACQUISITIONS - Schedule of Assets and Liabilities Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - ACQUISITIONS - Flexion Results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails</Role>
      <ShortName>ACQUISITIONS - Flexion Results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - ACQUISITIONS - Schedule of Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails</Role>
      <ShortName>ACQUISITIONS - Schedule of Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - INVENTORIES - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails</Role>
      <ShortName>INVENTORIES - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - FIXED ASSETS - Schedule of Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails</Role>
      <ShortName>FIXED ASSETS - Schedule of Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - FIXED ASSETS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FIXEDASSETSNarrativeDetails</Role>
      <ShortName>FIXED ASSETS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - LEASES - Summary of operating lease cost and other operating lease information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails</Role>
      <ShortName>LEASES - Summary of operating lease cost and other operating lease information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - LEASES - Schedule of maturities of operating lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails</Role>
      <ShortName>LEASES - Schedule of maturities of operating lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - DEBT - Carrying Value of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTCarryingValueofDebtDetails</Role>
      <ShortName>DEBT - Carrying Value of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - DEBT - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTScheduleofDebtDetails</Role>
      <ShortName>DEBT - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - DEBT - Schedule of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails</Role>
      <ShortName>DEBT - Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - FINANCIAL INSTRUMENTS - Fair Value of Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Fair Value of Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2452429 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2453430 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Fair Value Inputs and Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Fair Value Inputs and Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - FINANCIAL INSTRUMENTS - Contingent Consideration Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Contingent Consideration Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Investments at Amortized Cost and Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Investments at Amortized Cost and Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - STOCKHOLDERS' EQUITY - AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - STOCK PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSNarrativeDetails</Role>
      <ShortName>STOCK PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - STOCK PLANS - Stock Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails</Role>
      <ShortName>STOCK PLANS - Stock Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2464437 - Disclosure - STOCK PLANS - Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails</Role>
      <ShortName>STOCK PLANS - Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2465438 - Disclosure - STOCK PLANS - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails</Role>
      <ShortName>STOCK PLANS - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2466439 - Disclosure - STOCK PLANS - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails</Role>
      <ShortName>STOCK PLANS - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2467440 - Disclosure - STOCK PLANS - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/STOCKPLANSRSUActivityDetails</Role>
      <ShortName>STOCK PLANS - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2470441 - Disclosure - NET INCOME (LOSS) PER SHARE - Calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE - Calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/NETINCOMELOSSPERSHARETables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2471442 - Disclosure - NET INCOME (LOSS) PER SHARE - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails</Role>
      <ShortName>NET INCOME (LOSS) PER SHARE - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/NETINCOMELOSSPERSHARETables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2474443 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2475444 - Disclosure - INCOME TAXES - Current and Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Current and Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2476445 - Disclosure - INCOME TAXES - Reconciliation of Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2477446 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2478447 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2480448 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2483449 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Product Discontinuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails</Role>
      <ShortName>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Product Discontinuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2484450 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Flexion (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails</Role>
      <ShortName>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Flexion (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2485451 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - MyoScience (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails</Role>
      <ShortName>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - MyoScience (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2486452 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - NUANCE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails</Role>
      <ShortName>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - NUANCE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2487453 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - DepoCyte Discontinuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepoCyteDiscontinuationDetails</Role>
      <ShortName>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - DepoCyte Discontinuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2488454 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Department of Justice (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepartmentofJusticeDetails</Role>
      <ShortName>ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Department of Justice (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2490455 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails</Role>
      <ShortName>COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTS</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2492456 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2494457 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="pcrx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2496458 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacira.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacira.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>105</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="pcrx-20211231.htm">pcrx-20211231.htm</File>
    <File>pcrx-12312021xex103.htm</File>
    <File>pcrx-12312021xex1036.htm</File>
    <File>pcrx-12312021xex1037.htm</File>
    <File>pcrx-12312021xex1038.htm</File>
    <File>pcrx-12312021xex104.htm</File>
    <File>pcrx-12312021xex211.htm</File>
    <File>pcrx-12312021xex231.htm</File>
    <File>pcrx-12312021xex311.htm</File>
    <File>pcrx-12312021xex312.htm</File>
    <File>pcrx-12312021xex321.htm</File>
    <File>pcrx-12312021xex44.htm</File>
    <File>pcrx-12312021xex45.htm</File>
    <File>pcrx-20211231.xsd</File>
    <File>pcrx-20211231_cal.xml</File>
    <File>pcrx-20211231_def.xml</File>
    <File>pcrx-20211231_lab.xml</File>
    <File>pcrx-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pcrx-20211231_g1.jpg</File>
    <File>pcrx-20211231_g2.jpg</File>
    <File>pcrx-20211231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1341">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>140
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pcrx-20211231.htm": {
   "axisCustom": 3,
   "axisStandard": 42,
   "contextCount": 422,
   "dts": {
    "calculationLink": {
     "local": [
      "pcrx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pcrx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pcrx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pcrx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcrx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pcrx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 923,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://www.pacira.com/20211231": 4,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 17
   },
   "keyCustom": 111,
   "keyStandard": 537,
   "memberCustom": 76,
   "memberStandard": 64,
   "nsprefix": "pcrx",
   "nsuri": "http://www.pacira.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.pacira.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.pacira.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "id9261483f2cf444697023aae54718727_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2487453 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - DepoCyte Discontinuation (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepoCyteDiscontinuationDetails",
     "shortName": "ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - DepoCyte Discontinuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "id9261483f2cf444697023aae54718727_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i4baa20d612cd4ccaa14fa3448e5dd17e_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2488454 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Department of Justice (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepartmentofJusticeDetails",
     "shortName": "ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Department of Justice (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2490455 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details)",
     "role": "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
     "shortName": "COMMERCIAL PARTNERS AND OTHER AGREEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i45f29cdfecdd48d8b8c24cf61151d641_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "pcrx:CollaborativeArrangementOptionToExtendTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i9733ef5993044559a5405d6f38d59438_D20120401-20120430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2492456 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i9733ef5993044559a5405d6f38d59438_D20120401-20120430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i7b894792258e44c8853a730b680cff6c_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:LitigationInvestigationTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2494457 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i7b894792258e44c8853a730b680cff6c_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:LitigationInvestigationTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i5ca63f94b05a4f70aa9157c96a600b08_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2496458 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - REVENUE",
     "role": "http://www.pacira.com/role/REVENUE",
     "shortName": "REVENUE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - ACQUISITIONS",
     "role": "http://www.pacira.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - INVENTORIES",
     "role": "http://www.pacira.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - FIXED ASSETS",
     "role": "http://www.pacira.com/role/FIXEDASSETS",
     "shortName": "FIXED ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - LEASES",
     "role": "http://www.pacira.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.pacira.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.pacira.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - DEBT",
     "role": "http://www.pacira.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - FINANCIAL INSTRUMENTS",
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156113 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160114 - Disclosure - STOCK PLANS",
     "role": "http://www.pacira.com/role/STOCKPLANS",
     "shortName": "STOCK PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168115 - Disclosure - NET INCOME (LOSS) PER SHARE",
     "role": "http://www.pacira.com/role/NETINCOMELOSSPERSHARE",
     "shortName": "NET INCOME (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172116 - Disclosure - INCOME TAXES",
     "role": "http://www.pacira.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2179117 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "role": "http://www.pacira.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2181118 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET",
     "role": "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNET",
     "shortName": "ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:CommercialPartnersAndAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2189119 - Disclosure - COMMERCIAL PARTNERS AND OTHER AGREEMENTS",
     "role": "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTS",
     "shortName": "COMMERCIAL PARTNERS AND OTHER AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:CommercialPartnersAndAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2191120 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.pacira.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2193121 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2195122 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.pacira.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MajorCustomersPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MajorCustomersPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:MovementinValuationandQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - REVENUE (Tables)",
     "role": "http://www.pacira.com/role/REVENUETables",
     "shortName": "REVENUE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:MovementinValuationandQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.pacira.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.pacira.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - FIXED ASSETS (Tables)",
     "role": "http://www.pacira.com/role/FIXEDASSETSTables",
     "shortName": "FIXED ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - LEASES (Tables)",
     "role": "http://www.pacira.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.pacira.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344309 - Disclosure - DEBT (Tables)",
     "role": "http://www.pacira.com/role/DEBTTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350310 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357311 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:ScheduleOfSharesAvailableForIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361312 - Disclosure - STOCK PLANS (Tables)",
     "role": "http://www.pacira.com/role/STOCKPLANSTables",
     "shortName": "STOCK PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:ScheduleOfSharesAvailableForIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2369313 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)",
     "role": "http://www.pacira.com/role/NETINCOMELOSSPERSHARETables",
     "shortName": "NET INCOME (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2373314 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.pacira.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2382315 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET (Tables)",
     "role": "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables",
     "shortName": "ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "if3326fe2dfeb408fa75e3dba728e3dc1_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "role": "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "if3326fe2dfeb408fa75e3dba728e3dc1_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:MajorCustomersPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i97a72732ce3f4d6ca28e806af66ae46c_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:ConcentrationRiskNumberofCustomers",
      "reportCount": 1,
      "unitRef": "customer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Major Customers (Details)",
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:MajorCustomersPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i7ba25e639e904a9d80a76eefeea1ce89_D20210101-20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i1d024abaafbd4d6e9cda562be11efadd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Fixed Assets (Details)",
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Fixed Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i1d024abaafbd4d6e9cda562be11efadd_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Details)",
     "role": "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i6567973ef2374ec79029286dd86eb3ce_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:MovementinValuationandQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i6ddbaa9a26c6475c851117daf9454009_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - REVENUE - Sales and Valuation Accruals (Details)",
     "role": "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails",
     "shortName": "REVENUE - Sales and Valuation Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:MovementinValuationandQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i7f634c57178e427b9ece243062defb9c_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i74f568606f0c4823a905f91cf481d300_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:AccountsReceivablePaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - REVENUE - Narrative (Details)",
     "role": "http://www.pacira.com/role/REVENUENarrativeDetails",
     "shortName": "REVENUE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i74f568606f0c4823a905f91cf481d300_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcrx:AccountsReceivablePaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - REVENUE- Disaggregation (Details)",
     "role": "http://www.pacira.com/role/REVENUEDisaggregationDetails",
     "shortName": "REVENUE- Disaggregation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:ContingentConsiderationCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i47f4eb49ec8441a9b58dbd98a28a2201_D20190409-20190409",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i138b6ba6b5f34268a5ed1d1330dab65b_D20211119-20211119",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - ACQUISITIONS - Contingent Consideration Flexion Acquisition (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
     "shortName": "ACQUISITIONS - Contingent Consideration Flexion Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i63aa112e385a4b169e514d953a28f982_I20211119",
      "decimals": "-3",
      "lang": "en-US",
      "name": "pcrx:BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ic6aad501cb7243e887c49fac7690b6ca_I20211119",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - ACQUISITIONS - Schedule of Assets and Liabilities Acquired (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails",
     "shortName": "ACQUISITIONS - Schedule of Assets and Liabilities Acquired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ic6aad501cb7243e887c49fac7690b6ca_I20211119",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i9797eb88784347c2ba91f649e7a89035_D20211119-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - ACQUISITIONS - Flexion Results (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails",
     "shortName": "ACQUISITIONS - Flexion Results (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i9797eb88784347c2ba91f649e7a89035_D20211119-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - ACQUISITIONS - Schedule of Pro Forma Information (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails",
     "shortName": "ACQUISITIONS - Schedule of Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "idcde3f9b776a49ffb0a39cb3b0c4f806_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - INVENTORIES - Components of Inventory (Details)",
     "role": "http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails",
     "shortName": "INVENTORIES - Components of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - FIXED ASSETS - Schedule of Useful Lives (Details)",
     "role": "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails",
     "shortName": "FIXED ASSETS - Schedule of Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - FIXED ASSETS - Narrative (Details)",
     "role": "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
     "shortName": "FIXED ASSETS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://www.pacira.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "pcrx:NumberOfLocationsNewOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "location",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - LEASES - Summary of operating lease cost and other operating lease information (Details)",
     "role": "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails",
     "shortName": "LEASES - Summary of operating lease cost and other operating lease information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - LEASES - Schedule of maturities of operating lease liabilities (Details)",
     "role": "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails",
     "shortName": "LEASES - Schedule of maturities of operating lease liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i6ddbaa9a26c6475c851117daf9454009_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)",
     "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "id9261483f2cf444697023aae54718727_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)",
     "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "pcrx:FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)",
     "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "iaa36cac814f44a06a730eb8daf40ca38_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "iaa36cac814f44a06a730eb8daf40ca38_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:Accruedsellinggeneralandadministrativeexpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - ACCRUED EXPENSES (Details)",
     "role": "http://www.pacira.com/role/ACCRUEDEXPENSESDetails",
     "shortName": "ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:Accruedsellinggeneralandadministrativeexpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i029b2fd1da9b426aa281eb6edf9c4164_I20211231",
      "decimals": "5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - DEBT - Carrying Value of Debt (Details)",
     "role": "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
     "shortName": "DEBT - Carrying Value of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - DEBT - Narrative (Details)",
     "role": "http://www.pacira.com/role/DEBTNarrativeDetails",
     "shortName": "DEBT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i4fb73217f94c444aa76dcd2a69b80870_D20170313-20170313",
      "decimals": null,
      "lang": "en-US",
      "name": "pcrx:SettlementPeriodConvertibleDebtConversionRequest",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i029b2fd1da9b426aa281eb6edf9c4164_I20211231",
      "decimals": "5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - DEBT - Schedule of Debt (Details)",
     "role": "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
     "shortName": "DEBT - Schedule of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ia54d2ff525824d9d94bdfe6cf43288c1_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - DEBT - Schedule of Interest Expense (Details)",
     "role": "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails",
     "shortName": "DEBT - Schedule of Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i552e4370c49c488aaf644acf28100abb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - FINANCIAL INSTRUMENTS - Fair Value of Liabilities Measured on a Recurring Basis (Details)",
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Fair Value of Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i552e4370c49c488aaf644acf28100abb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452429 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)",
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i6ddbaa9a26c6475c851117daf9454009_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedInvestmentIncomeReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i3d43a54915fb471a881eb7c22d53ebb8_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453430 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Fair Value Inputs and Valuation (Details)",
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Fair Value Inputs and Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i3d43a54915fb471a881eb7c22d53ebb8_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "iead150b687d149c184bc55655b3b10d9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - FINANCIAL INSTRUMENTS - Contingent Consideration Rollforward (Details)",
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Contingent Consideration Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "iead150b687d149c184bc55655b3b10d9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Investments at Amortized Cost and Fair Value (Details)",
     "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Investments at Amortized Cost and Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)",
     "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i6ddbaa9a26c6475c851117daf9454009_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - STOCKHOLDERS' EQUITY - AOCI (Details)",
     "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails",
     "shortName": "STOCKHOLDERS' EQUITY - AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i81d1942e618045a69aca1ec725725e2e_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i0b3a1799953e4b7a9a6fe4c6d61c6c82_D20210601-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - STOCK PLANS - Narrative (Details)",
     "role": "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
     "shortName": "STOCK PLANS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i0b3a1799953e4b7a9a6fe4c6d61c6c82_D20210601-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pcrx:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:ScheduleOfSharesAvailableForIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - STOCK PLANS - Stock Incentive Plans (Details)",
     "role": "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails",
     "shortName": "STOCK PLANS - Stock Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:ScheduleOfSharesAvailableForIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464437 - Disclosure - STOCK PLANS - Compensation Expense (Details)",
     "role": "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails",
     "shortName": "STOCK PLANS - Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i917c4f0133de471d87fe63c0cf97feec_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465438 - Disclosure - STOCK PLANS - Stock Option Activity (Details)",
     "role": "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails",
     "shortName": "STOCK PLANS - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466439 - Disclosure - STOCK PLANS - Valuation Assumptions (Details)",
     "role": "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails",
     "shortName": "STOCK PLANS - Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ibfa96bfa146c401bafdd7c90c8ba2c6e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467440 - Disclosure - STOCK PLANS - RSU Activity (Details)",
     "role": "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails",
     "shortName": "STOCK PLANS - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "iaca373b6b867452b83d716b6422dc258_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470441 - Disclosure - NET INCOME (LOSS) PER SHARE - Calculation (Details)",
     "role": "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails",
     "shortName": "NET INCOME (LOSS) PER SHARE - Calculation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ic188959fbb8a4518ae528b4899aab3bb_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471442 - Disclosure - NET INCOME (LOSS) PER SHARE - Antidilutive Securities (Details)",
     "role": "http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails",
     "shortName": "NET INCOME (LOSS) PER SHARE - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474443 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475444 - Disclosure - INCOME TAXES - Current and Deferred Income Taxes (Details)",
     "role": "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Current and Deferred Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476445 - Disclosure - INCOME TAXES - Reconciliation of Effective Tax Rate (Details)",
     "role": "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails",
     "shortName": "INCOME TAXES - Reconciliation of Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477446 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "INCOME TAXES - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i8d5d5c6e34f0433bbda0c189e02b1127_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i6ddbaa9a26c6475c851117daf9454009_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478447 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits (Details)",
     "role": "http://www.pacira.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480448 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)",
     "role": "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2483449 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Product Discontinuance (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
     "shortName": "ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Product Discontinuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2484450 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Flexion (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
     "shortName": "ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Flexion (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i130fb5352c624061a38b0f4e0e96ed76_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485451 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - MyoScience (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
     "shortName": "ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - MyoScience (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "i866ca805578348a1a7b549671e9b226d_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "ide89694773bb4e6db9680fef91f32d44_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486452 - Disclosure - ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - NUANCE (Details)",
     "role": "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails",
     "shortName": "ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - NUANCE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pcrx-20211231.htm",
      "contextRef": "id747d21ec2fe432ca5314f7a469d8620_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 149,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r860",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r860",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r860",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r860",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r860",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pacira.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pcrx_AccountsReceivablePaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Payment Terms",
        "label": "Accounts Receivable, Payment Terms",
        "terseLabel": "Accounts receivable, payment terms"
       }
      }
     },
     "localname": "AccountsReceivablePaymentTerms",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUENarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_AccruedEndOfTermFeeCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for end of term fee. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).",
        "label": "Accrued End of Term Fee, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedEndOfTermFeeCurrent",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_AccruedExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses [Line Items]",
        "label": "Accrued Expenses [Line Items]",
        "terseLabel": "Accrued Expenses [Line Items]"
       }
      }
     },
     "localname": "AccruedExpensesLineItems",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcrx_AccruedExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses [Table]",
        "label": "Accrued Expenses [Table]",
        "terseLabel": "Accrued Expenses [Table]"
       }
      }
     },
     "localname": "AccruedExpensesTable",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcrx_AccruedOperatingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).",
        "label": "Accrued Operating Expenses, Current",
        "terseLabel": "Other accrued operating expenses"
       }
      }
     },
     "localname": "AccruedOperatingExpensesCurrent",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_Accruedresearchanddevelopmentexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services related to research and development activities.",
        "label": "Accrued research and development expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "Accruedresearchanddevelopmentexpenses",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_Accruedsellinggeneralandadministrativeexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services related to selling, general, and administrative activities.",
        "label": "Accrued selling, general, and administrative expenses",
        "terseLabel": "Accrued selling, general and administrative expenses"
       }
      }
     },
     "localname": "Accruedsellinggeneralandadministrativeexpenses",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the achievement of development and commercial events on the basis of which certain milestones are achieved.",
        "label": "Achievement of Development and Commercial Milestones [Member]",
        "terseLabel": "Achievement of Development and Commercial Milestones"
       }
      }
     },
     "localname": "AchievementOfDevelopmentAndCommercialMilestonesMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Development and Regulatory Milestones",
        "label": "Achievement of Development and Regulatory Milestones [Member]",
        "terseLabel": "Achievement of Development and Regulatory Milestones"
       }
      }
     },
     "localname": "AchievementOfDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AchievementOfFDAApprovalOfFX201Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement Of FDA Approval Of FX-201",
        "label": "Achievement Of FDA Approval Of FX-201 [Member]",
        "terseLabel": "Achievement of FDA Approval of FX-201"
       }
      }
     },
     "localname": "AchievementOfFDAApprovalOfFX201Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AchievementOfFDAApprovalOfFX301Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement Of FDA Approval Of FX-301",
        "label": "Achievement Of FDA Approval Of FX-301 [Member]",
        "terseLabel": "Achievement of FDA Approval of FX-301"
       }
      }
     },
     "localname": "AchievementOfFDAApprovalOfFX301Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AchievementOfMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by categories of milestones achieved.",
        "label": "Achievement of Milestone [Axis]",
        "terseLabel": "Achievement of Milestone [Axis]"
       }
      }
     },
     "localname": "AchievementOfMilestoneAxis",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcrx_AchievementOfMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different categories of achievement of milestones.",
        "label": "Achievement of Milestone [Domain]",
        "terseLabel": "Achievement of Milestone [Domain]"
       }
      }
     },
     "localname": "AchievementOfMilestoneDomain",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AchievementOfSalesRelatedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Sales-Related Milestones",
        "label": "Achievement of Sales-Related Milestones [Member]",
        "terseLabel": "Achievement of Sales-Related Milestones"
       }
      }
     },
     "localname": "AchievementOfSalesRelatedMilestonesMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AchievementOfZILRETTASalesOf250MillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement Of ZILRETTA Sales Of $250 Million",
        "label": "Achievement Of ZILRETTA Sales Of $250 Million [Member]",
        "terseLabel": "Achievement of ZILRETTA Sales of $250 Million"
       }
      }
     },
     "localname": "AchievementOfZILRETTASalesOf250MillionMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AchievementOfZILRETTASalesOf375MillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement Of ZILRETTA Sales Of $375 Million",
        "label": "Achievement Of ZILRETTA Sales Of $375 Million [Member]",
        "terseLabel": "Achievement of ZILRETTA Sales of $375 Million"
       }
      }
     },
     "localname": "AchievementOfZILRETTASalesOf375MillionMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AchievementOfZILRETTASalesOf500MillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement Of ZILRETTA Sales Of $500 Million",
        "label": "Achievement Of ZILRETTA Sales Of $500 Million [Member]",
        "terseLabel": "Achievement of ZILRETTA Sales of $500 Million"
       }
      }
     },
     "localname": "AchievementOfZILRETTASalesOf500MillionMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AchievementofRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Regulatory Milestone [Member]",
        "label": "Achievement of Regulatory Milestone [Member]",
        "terseLabel": "Achievement of Regulatory Milestone"
       }
      }
     },
     "localname": "AchievementofRegulatoryMilestoneMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition-Related Charges, Product Discontinuation, And Other",
        "label": "Acquisition-Related Charges, Product Discontinuation, And Other",
        "terseLabel": "Total acquisition-related charges, product discontinuation and other"
       }
      }
     },
     "localname": "AcquisitionRelatedChargesProductDiscontinuationAndOther",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition-Related Charges, Product Discontinuation And Other Expenses",
        "label": "Acquisition-Related Charges, Product Discontinuation And Other Expenses",
        "terseLabel": "Acquisition-related charges, product discontinuation and other"
       }
      }
     },
     "localname": "AcquisitionRelatedChargesProductDiscontinuationAndOtherExpenses",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_AcquisitionRelatedFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Related Fees",
        "label": "Acquisition Related Fees [Member]",
        "terseLabel": "Acquisition-related fees"
       }
      }
     },
     "localname": "AcquisitionRelatedFeesMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AdvisoryCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advisory Costs [Member]",
        "label": "Advisory Costs [Member]",
        "terseLabel": "Advisory Costs"
       }
      }
     },
     "localname": "AdvisoryCostsMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the milestone payments agreed to be paid by the entity for the sale of the product, in connection with the acquisition.",
        "label": "Agreed Milestone Payments for Sale of Product in Connection with Acquisition",
        "terseLabel": "Milestone payments for EXPAREL agreed in connection with acquisition"
       }
      }
     },
     "localname": "AgreedMilestonePaymentsForSaleOfProductInConnectionWithAcquisition",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_AllowanceForGovernmentRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Government Rebates",
        "label": "Allowance For Government Rebates [Member]",
        "terseLabel": "Government Rebates"
       }
      }
     },
     "localname": "AllowanceForGovernmentRebatesMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AllowanceForVolumeRebatesandChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Volume Rebates and Chargebacks [Member]",
        "label": "Allowance For Volume Rebates and Chargebacks [Member]",
        "terseLabel": "Volume Rebates and Chargebacks"
       }
      }
     },
     "localname": "AllowanceForVolumeRebatesandChargebacksMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Period of Transaction Costs Attributable to Liability Component of Convertible Debt",
        "label": "Amortization Period of Transaction Costs Attributable to Liability Component of Convertible Debt",
        "terseLabel": "Amortization period of transaction costs attributable to liability component of convertible debt"
       }
      }
     },
     "localname": "AmortizationPeriodOfTransactionCostsAttributableToLiabilityComponentOfConvertibleDebt",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold amount of annual net sales considered to determine the stage at which a specified amount of milestone payments for product is agreed to be paid by the entity, in connection with the acquisition.",
        "label": "Annual Net Sales Threshold for Determining Milestone Payments for Product in Connection with Acquisition",
        "terseLabel": "Annual net sales threshold"
       }
      }
     },
     "localname": "AnnualNetSalesThresholdForDeterminingMilestonePaymentsForProductInConnectionWithAcquisition",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_AratanaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Aratana Therapeutics, Inc.",
        "label": "Aratana Therapeutics Inc [Member]",
        "terseLabel": "Aratana Therapeutics Inc"
       }
      }
     },
     "localname": "AratanaTherapeuticsIncMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.pacira.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pcrx_BupivacaineLiposomeInjectableSuspensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bupivacaine Liposome Injectable Suspension",
        "label": "Bupivacaine Liposome Injectable Suspension [Member]",
        "terseLabel": "Bupivacaine liposome injectable suspension"
       }
      }
     },
     "localname": "BupivacaineLiposomeInjectableSuspensionMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUEDisaggregationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_BusinessCombinationAcquisitionAndIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Acquisition And Integration Related Costs",
        "label": "Business Combination, Acquisition And Integration Related Costs",
        "terseLabel": "Total acquisition-related charges"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionAndIntegrationRelatedCosts",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Liabilities Incurred, Contingent Consideration",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred, Contingent Consideration",
        "terseLabel": "Fair value of contingent value rights (CVRs)",
        "verboseLabel": "Contingent value right"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurredContingentConsideration",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Liabilities Incurred, Debt",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred, Debt",
        "terseLabel": "Retirement of term loan",
        "verboseLabel": "Cash paid to settle Flexion debt"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurredDebt",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]",
        "label": "COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]",
        "terseLabel": "Schedule of Acquisition-related Restructuring and Discontinuation Costs"
       }
      }
     },
     "localname": "COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcrx_ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price, Annual Product Sales Threshold",
        "label": "Class Of Warrant Or Right, Exercise Price, Annual Product Sales Threshold",
        "terseLabel": "Annual product sales threshold"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceAnnualProductSalesThreshold",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_CoPromotionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-Promotion Agreement",
        "label": "Co-Promotion Agreement [Member]",
        "terseLabel": "Co-Promotion Agreement"
       }
      }
     },
     "localname": "CoPromotionAgreementMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_CodaBioTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coda BioTherapeutics, Inc",
        "label": "Coda BioTherapeutics, Inc [Member]",
        "terseLabel": "Coda BioTherapeutics, Inc"
       }
      }
     },
     "localname": "CodaBioTherapeuticsIncMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.",
        "label": "Collaborative Arrangement, Milestone Payments to be Received, Maximum",
        "terseLabel": "Collaborative arrangement, milestone payments to be received"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_CollaborativeArrangementOptionToExtendTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Option to Extend, Term",
        "label": "Collaborative Arrangement, Option to Extend, Term",
        "terseLabel": "Collaborative arrangement, option to extend, term"
       }
      }
     },
     "localname": "CollaborativeArrangementOptionToExtendTerm",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Option To Terminate, Days From Material Breach",
        "label": "Collaborative Arrangement, Option To Terminate, Days From Material Breach",
        "terseLabel": "Days from material breach, option to terminate"
       }
      }
     },
     "localname": "CollaborativeArrangementOptionToTerminateDaysFromMaterialBreach",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Option To Terminate, Days From Payment Obligation",
        "label": "Collaborative Arrangement, Option To Terminate, Days From Payment Obligation",
        "terseLabel": "Days from payment obligations, option to terminate"
       }
      }
     },
     "localname": "CollaborativeArrangementOptionToTerminateDaysFromPaymentObligation",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_CollaborativeArrangementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Upfront Payment",
        "label": "Collaborative Arrangement, Upfront Payment",
        "terseLabel": "Collaborative arrangement, upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPayment",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_CommercialPartnersAndAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the entire disclosure of commercial agreement and arrangement with third parties.",
        "label": "Commercial Partners and Agreements [Text Block]",
        "verboseLabel": "COMMERCIAL PARTNERS AND OTHER AGREEMENTS"
       }
      }
     },
     "localname": "CommercialPartnersAndAgreementsTextBlock",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcrx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ConcentrationRiskNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number Of Products",
        "label": "Concentration Risk, Number Of Products",
        "terseLabel": "Number of products"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfProducts",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcrx_ConcentrationRiskNumberofCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number of Customers",
        "label": "Concentration Risk, Number of Customers",
        "terseLabel": "Concentration risk, number of customers"
       }
      }
     },
     "localname": "ConcentrationRiskNumberofCustomers",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcrx_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the consulting agreement entered into by the entity with a related party.",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting agreement"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum amount of Contingent Consideration related to the acquisition of a business.",
        "label": "Contingent Consideration",
        "terseLabel": "Maximum total payments for contingent consideration possible"
       }
      }
     },
     "localname": "ContingentConsideration",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ContingentConsiderationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Current",
        "label": "Contingent Consideration, Current",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationCurrent",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration [Member]",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ContingentConsiderationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Noncurrent",
        "label": "Contingent Consideration, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationNoncurrent",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ContingentConsiderationPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Payment Term",
        "label": "Contingent Consideration, Payment Term",
        "terseLabel": "Contingent consideration, payment terms"
       }
      }
     },
     "localname": "ContingentConsiderationPaymentTerm",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration [Policy Text Block]",
        "label": "Contingent Consideration [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcrx_ConversionPremiumOn2022NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Premium on 2022 Notes",
        "label": "Conversion Premium on 2022 Notes [Member]",
        "terseLabel": "Conversion Premium on 2022 Notes"
       }
      }
     },
     "localname": "ConversionPremiumOn2022NotesMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ConvertibleSeniorNotes2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the series 2019 senior convertible notes, which is a written promise to pay a note that can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Senior Notes 2019 [Member]",
        "terseLabel": "Convertible Senior Notes 2019"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2019Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ConvertibleSeniorNotes2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes 2025",
        "label": "Convertible Senior Notes 2025 [Member]",
        "terseLabel": "Convertible Senior Notes 2025"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2025Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ConvertibleSeniorNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2022 [Member]",
        "label": "Convertible Senior Notes Due 2022 [Member]",
        "terseLabel": "Convertible Senior Notes Due 2022",
        "verboseLabel": "2.375% Convertible Senior Notes Due 2022"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2022Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2024",
        "label": "Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "3.375% Convertible Senior Notes Due 2024"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ConvertibleSeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2025",
        "label": "Convertible Senior Notes Due 2025 [Member]",
        "terseLabel": "Convertible Senior Notes Due 2025",
        "verboseLabel": "0.750% Convertible Senior Notes Due 2025"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2025Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ConvertibleSeniorNotesDueMay2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due May 2024",
        "label": "Convertible Senior Notes Due May 2024 [Member]",
        "terseLabel": "3.375% Convertible Senior Notes Due 2024"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDueMay2024Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_CustomersOutsideUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to customers outside U.S.",
        "label": "Customers Outside US [Member]",
        "terseLabel": "Customers outside U.S."
       }
      }
     },
     "localname": "CustomersOutsideUSMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_DePuySynthesSalesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy Synthes Sales Inc",
        "label": "DePuy Synthes Sales Inc [Member]",
        "terseLabel": "DePuy Synthes Sales Inc"
       }
      }
     },
     "localname": "DePuySynthesSalesIncMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_DebtConversionAndRedemptionTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information regarding the conversion and redemption terms of the debt instruments.",
        "label": "Debt Conversion and Redemption Terms [Axis]",
        "terseLabel": "Debt Conversion and Redemption Terms [Axis]"
       }
      }
     },
     "localname": "DebtConversionAndRedemptionTermsAxis",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcrx_DebtConversionAndRedemptionTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the conversion and redemption terms of the debt instruments.",
        "label": "Debt Conversion and Redemption Terms [Domain]",
        "terseLabel": "Debt Conversion and Redemption Terms [Domain]"
       }
      }
     },
     "localname": "DebtConversionAndRedemptionTermsDomain",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion, Converted Instrument, Warrants Or Rights Issued, Per Principal Amount",
        "label": "Debt Conversion, Converted Instrument, Warrants Or Rights Issued, Per Principal Amount",
        "terseLabel": "CVRs issued per principal amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentWarrantsOrRightsIssuedPerPrincipalAmount",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion Terms Business Day Immediately Preceding February 3, 2020",
        "label": "Debt Conversion Terms Business Day Immediately Preceding February 3, 2020 [Member]",
        "terseLabel": "Debt Conversion Terms Business Day Immediately Preceding February 3, 2020"
       }
      }
     },
     "localname": "DebtConversionTermsBusinessDayImmediatelyPrecedingFebruary32020Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion Terms Business Day Immediately Preceding October 1, 2021 [Member]",
        "label": "Debt Conversion Terms Business Day Immediately Preceding October 1, 2021 [Member]",
        "terseLabel": "Conversion terms prior to close of business on business day immediately proceeding October 1, 2021"
       }
      }
     },
     "localname": "DebtConversionTermsBusinessDayImmediatelyPrecedingOctober12021Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_DebtInstrumentBasisSpreadOneOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Basis Spread One On Variable Rate",
        "label": "Debt Instrument, Basis Spread One On Variable Rate",
        "terseLabel": "Basis spread one on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOneOnVariableRate",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentBasisSpreadTwoOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Basis Spread Two On Variable Rate",
        "label": "Debt Instrument, Basis Spread Two On Variable Rate",
        "terseLabel": "Basis spread two on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadTwoOnVariableRate",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of the conversion price that the closing sales price of the entity's common stock must exceed for at least 20 days within 30 consecutive trading days, in order for the notes to be convertible.",
        "label": "Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum as Percentage of Conversion Price",
        "terseLabel": "Conversion obligation, stock closing price minimum as a percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumAsPercentageOfConversionPrice",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum number of trading days within a period of 30 consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.",
        "label": "Debt Instrument, Conversion Obligation Common Stock Closing Sales Price Minimum, Number of Trading Days",
        "terseLabel": "Conversion obligation, number of trading days"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationCommonStockClosingSalesPriceMinimumNumberofTradingDays",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.",
        "label": "Debt Instrument, Conversion Obligation Number of Consecutive Trading Days",
        "terseLabel": "Conversion obligation, number of consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument.",
        "label": "Debt Instrument, Conversion Obligation Premium on Common Stock",
        "terseLabel": "Convertible debt, premium on common stock"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationPremiumOnCommonStock",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentConvertibleAssumedBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Assumed Borrowing Rate",
        "label": "Debt Instrument, Convertible, Assumed Borrowing Rate",
        "terseLabel": "Assumed borrowing rate"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleAssumedBorrowingRate",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Carrying Amount of Liability Component",
        "label": "Debt Instrument, Convertible, Carrying Amount of Liability Component",
        "terseLabel": "Convertible debt, carrying amount of liability component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_DebtInstrumentConvertibleConversionPremiumShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Conversion Premium, Shares",
        "label": "Debt Instrument, Convertible, Conversion Premium, Shares",
        "terseLabel": "Debt instrument, convertible, conversion premium (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPremiumShares",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcrx_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "pcrx_DebtInstrumentCovenantLeverageRatioMaximumValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum, Value",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum, Value",
        "terseLabel": "Leverage ratio maximum amount"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximumValue",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default",
        "label": "Debt Instrument, Customary Events of Default, Percentage of Principal and Accrued and Unpaid Interest Due and Payable Upon Default",
        "terseLabel": "Customary events of default, percentage of principal and accrued and unpaid interest"
       }
      }
     },
     "localname": "DebtInstrumentCustomaryEventsofDefaultPercentageofPrincipalandAccruedandUnpaidInterestDueandPayableUponDefault",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Discount Rate",
        "label": "Debt Instrument, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DebtInstrumentDiscountRate",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentMarketPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Market Price",
        "label": "Debt Instrument, Market Price",
        "terseLabel": "Market price per $1000 of principal amount of notes"
       }
      }
     },
     "localname": "DebtInstrumentMarketPrice",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "pcrx_DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Percentage of Last Reported Sale Price Of Common Stock",
        "label": "Debt Instrument, Percentage of Last Reported Sale Price Of Common Stock",
        "terseLabel": "Percentage of last sale price of common stock"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfLastReportedSalePriceOfCommonStock",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of principal amount used in computation of the redemption price to be paid on conversion of convertible notes.",
        "label": "Debt Instrument, Percentage of Principal Amount for Computation of Redemption Price",
        "terseLabel": "Debt instrument, percentage of principal amount for computation of redemption price"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Principal, Number Of Payments In Next Fiscal Year",
        "label": "Debt Instrument, Periodic Payment, Principal, Number Of Payments In Next Fiscal Year",
        "terseLabel": "Number of payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipalNumberOfPaymentsInNextFiscalYear",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcrx_DebtInstrumentPrepaymentPenaltyPercentYear1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Percent, Year 1",
        "label": "Debt Instrument, Prepayment Penalty, Percent, Year 1",
        "terseLabel": "Prepayment penalty, year 1"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPercentYear1",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentPrepaymentPenaltyPercentYear2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Percent, Year 2",
        "label": "Debt Instrument, Prepayment Penalty, Percent, Year 2",
        "terseLabel": "Prepayment penalty, year 2"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPercentYear2",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Percent, Year 4 And Thereafter",
        "label": "Debt Instrument, Prepayment Penalty, Percent, Year 4 And Thereafter",
        "terseLabel": "Prepayment penalty, year 4 and thereafter"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPercentYear4AndThereafter",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtInstrumentVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate",
        "label": "Debt Instrument, Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentVariableRate",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the redemption price as a percentage of the principal amount at which the debt instrument may be required to be repurchased in the event of a fundamental change by the entity.",
        "label": "Debt Redemption Price Due to Fundamental Change as Percentage of Principal Amount",
        "terseLabel": "Debt redemption price due to fundamental change as a percentage of principal"
       }
      }
     },
     "localname": "DebtRedemptionPriceDueToFundamentalChangeAsPercentageOfPrincipalAmount",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Redemption Terms on or after August 1, 2023",
        "label": "Debt Redemption Terms on or after August 1, 2023 [Member]",
        "terseLabel": "Debt Redemption Terms on or after August 1, 2023"
       }
      }
     },
     "localname": "DebtRedemptionTermsOnOrAfterAugust12023Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_DebtRedemptionTermsonorafterApril12020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Redemption Terms on or after April 1, 2020 [Member]",
        "label": "Debt Redemption Terms on or after April 1, 2020 [Member]",
        "terseLabel": "Debt Redemption Terms on or after April 1, 2020"
       }
      }
     },
     "localname": "DebtRedemptionTermsonorafterApril12020Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Net of Deferred Tax Liabilities, Before Valuation Allowance",
        "label": "Deferred Tax Assets, Gross, Net of Deferred Tax Liabilities, Before Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_DeferredTaxAssetsStockBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Stock Based Compensation",
        "label": "Deferred Tax Assets, Stock Based Compensation",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsStockBasedCompensation",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Expense Associated to the Equity Component of Convertible Debt",
        "label": "Deferred Tax Expense Associated to the Equity Component of Convertible Debt",
        "terseLabel": "Deferred tax associated with equity component of convertible debt"
       }
      }
     },
     "localname": "DeferredTaxExpenseAssociatedToTheEquityComponentOfConvertibleDebt",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_DepoCyteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DepoCyte [Member]",
        "label": "DepoCyte [Member]",
        "terseLabel": "DepoCyte"
       }
      }
     },
     "localname": "DepoCyteMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_EXPARELMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EXPAREL",
        "label": "EXPAREL [Member]",
        "terseLabel": "EXPAREL"
       }
      }
     },
     "localname": "EXPARELMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUEDisaggregationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_EffectOfStateBlendedTaxRateChangesExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed as the result of changes in state blended tax rate changes.",
        "label": "Effect Of State Blended Tax Rate Changes Expense (Benefit)",
        "terseLabel": "Effect of rate changes"
       }
      }
     },
     "localname": "EffectOfStateBlendedTaxRateChangesExpenseBenefit",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_EffectiveIncomeTaxRateReconciliation338gElectionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, 338(g) Election, Percent",
        "label": "Effective Income Tax Rate Reconciliation, 338(g) Election, Percent",
        "terseLabel": "338(g) tax election"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliation338gElectionPercent",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Convertible Senior Notes Refinancing",
        "label": "Effective Income Tax Rate Reconciliation, Convertible Senior Notes Refinancing",
        "terseLabel": "Convertible senior notes refinancing"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationConvertibleSeniorNotesRefinancing",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_EffectiveIncomeTaxRateReconciliationForeign": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to foreign operations.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign",
        "terseLabel": "Foreign taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeign",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_EffectiveIncomeTaxRateReconciliationTaxReservesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to tax reserves.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Reserves, Percent",
        "terseLabel": "Reserves"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxReservesPercent",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_EmployeeStockPurchasePlanESPP2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan (ESPP) 2014",
        "label": "Employee Stock Purchase Plan (ESPP) 2014 [Member]",
        "terseLabel": "2014 ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanESPP2014Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_EmployeeStockPurchasePlanESPPSharesinESPP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan (ESPP), Shares in ESPP",
        "label": "Employee Stock Purchase Plan (ESPP), Shares in ESPP",
        "terseLabel": "Employee stock purchase plan (ESPP), maximum shares available for sale (in shares)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanESPPSharesinESPP",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcrx_EmployeeStockPurchasePlanNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Number of Shares Authorized",
        "label": "Employee Stock Purchase Plan, Number of Shares Authorized",
        "terseLabel": "ESPP, shares reserved for purchase (in shares)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanNumberofSharesAuthorized",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcrx_EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Number of Shares Available For Purchase",
        "label": "Employee Stock Purchase Plan, Number of Shares Available For Purchase",
        "terseLabel": "ESPP, shares available for purchase (in shares)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanNumberofSharesAvailableForPurchase",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcrx_EmployeeStockPurchasePlanfairvalue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of fair value of common stock eligible employees can purchase common shares at through an employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan fair value",
        "terseLabel": "ESPP fair value (as percent)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanfairvalue",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_EurofarmaLabatoriesSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eurofarma Labatories S.A.",
        "label": "Eurofarma Labatories S.A. [Member]",
        "terseLabel": "Eurofarma Labatories S.A."
       }
      }
     },
     "localname": "EurofarmaLabatoriesSAMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ExpectedAdditionalNetOperatingLossesInYearAfterYearSix": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Additional Net Operating Losses In Year, After Year Six",
        "label": "Expected Additional Net Operating Losses In Year, After Year Six",
        "terseLabel": "Expected additional NOLs, thereafter"
       }
      }
     },
     "localname": "ExpectedAdditionalNetOperatingLossesInYearAfterYearSix",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ExpectedAdditionalNetOperatingLossesInYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Additional Net Operating Losses In Year Five",
        "label": "Expected Additional Net Operating Losses In Year Five",
        "terseLabel": "Expected additional NOLs, year five"
       }
      }
     },
     "localname": "ExpectedAdditionalNetOperatingLossesInYearFive",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ExpectedAdditionalNetOperatingLossesInYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Additional Net Operating Losses In Year Four",
        "label": "Expected Additional Net Operating Losses In Year Four",
        "terseLabel": "Expected additional NOLs, year four"
       }
      }
     },
     "localname": "ExpectedAdditionalNetOperatingLossesInYearFour",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ExpectedAdditionalNetOperatingLossesInYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Additional Net Operating Losses In Year One",
        "label": "Expected Additional Net Operating Losses In Year One",
        "terseLabel": "Expected additional NOLs, year one"
       }
      }
     },
     "localname": "ExpectedAdditionalNetOperatingLossesInYearOne",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ExpectedAdditionalNetOperatingLossesInYearSix": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Additional Net Operating Losses In Year Six",
        "label": "Expected Additional Net Operating Losses In Year Six",
        "terseLabel": "Expected additional NOLs, year six"
       }
      }
     },
     "localname": "ExpectedAdditionalNetOperatingLossesInYearSix",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ExpectedAdditionalNetOperatingLossesInYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Additional Net Operating Losses In Year Three",
        "label": "Expected Additional Net Operating Losses In Year Three",
        "terseLabel": "Expected additional NOLs, year three"
       }
      }
     },
     "localname": "ExpectedAdditionalNetOperatingLossesInYearThree",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ExpectedAdditionalNetOperatingLossesInYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Additional Net Operating Losses In Year Two",
        "label": "Expected Additional Net Operating Losses In Year Two",
        "terseLabel": "Expected additional NOLs, year two"
       }
      }
     },
     "localname": "ExpectedAdditionalNetOperatingLossesInYearTwo",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Per Share",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Per Share",
        "terseLabel": "Increase in CVR"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarningsPerShare",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchase Price",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchase Price",
        "terseLabel": "Contingent consideration related to the Flexion Acquisition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasePrice",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_FederalReserveBankOfNYRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Reserve Bank Of NY, Rate",
        "label": "Federal Reserve Bank Of NY, Rate [Member]",
        "terseLabel": "NYFRB Rate"
       }
      }
     },
     "localname": "FederalReserveBankOfNYRateMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 1",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 1",
        "terseLabel": "Future amortization, through 2028"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod1",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 2",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 2",
        "terseLabel": "Future amortization, through 2029"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod2",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 3",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 3",
        "terseLabel": "Future amortization through 2030"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod3",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 4",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 4",
        "terseLabel": "Future amortization through 2031"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod4",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 5",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 5",
        "terseLabel": "Future amortization through 2032"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod5",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 6",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Per Year, Period 6",
        "terseLabel": "Future amortization through 2033"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpensePerYearPeriod6",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_FiniteLivedIntangibleAssetsMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Measurement Input",
        "label": "Finite-Lived Intangible Assets, Measurement Input",
        "terseLabel": "Discount rate, measurement input"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMeasurementInput",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_FirstPriceOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Price Option",
        "label": "First Price Option [Member]",
        "terseLabel": "First Price Option"
       }
      }
     },
     "localname": "FirstPriceOptionMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_FlexionAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Flexion Acquisition",
        "label": "Flexion Acquisition [Member]",
        "terseLabel": "Flexion Acquisition"
       }
      }
     },
     "localname": "FlexionAcquisitionMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_FlexionAndMyoscienceAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Flexion And Myoscience Acquisition",
        "label": "Flexion And Myoscience Acquisition [Member]",
        "terseLabel": "Flexion and Myoscience Acquisition"
       }
      }
     },
     "localname": "FlexionAndMyoscienceAcquisitionMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_FlexionTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Flexion Therapeutics, Inc.",
        "label": "Flexion Therapeutics, Inc. [Member]",
        "terseLabel": "Flexion"
       }
      }
     },
     "localname": "FlexionTherapeuticsIncMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacira.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ForeignNetDeferredTaxAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Net Deferred Tax Asset",
        "label": "Foreign Net Deferred Tax Asset [Member]",
        "terseLabel": "Foreign Net Deferred Tax Asset"
       }
      }
     },
     "localname": "ForeignNetDeferredTaxAssetMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_FortisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fortis",
        "label": "Fortis [Member]",
        "terseLabel": "Fortis"
       }
      }
     },
     "localname": "FortisMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_GenascenceCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genascence Corporation",
        "label": "Genascence Corporation [Member]",
        "terseLabel": "Genascence Corporation"
       }
      }
     },
     "localname": "GenascenceCorporationMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_GeneQuineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GeneQuine",
        "label": "GeneQuine [Member]",
        "terseLabel": "GeneQuine"
       }
      }
     },
     "localname": "GeneQuineMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_HongKongPharmaTainuoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hong Kong Pharma Tainuo Ltd.",
        "label": "Hong Kong Pharma Tainuo Ltd. [Member]",
        "terseLabel": "Hong Kong Pharma Tainuo Ltd."
       }
      }
     },
     "localname": "HongKongPharmaTainuoLtdMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The earnings or loss from continuing operations before income taxes for the entity as a whole, including domestic and foreign operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Total",
        "totalLabel": "Total income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_IncomeTaxProvisionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Income Tax Provision [Table]",
        "label": "Income Tax Provision [Line Items]",
        "terseLabel": "Income Tax Provision [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxProvisionLineItems",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcrx_IncomeTaxProvisionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Provision [Table]",
        "label": "Income Tax Provision [Table]",
        "terseLabel": "Income Tax Provision [Table]"
       }
      }
     },
     "localname": "IncomeTaxProvisionTable",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcrx_IncreaseDecreaseInContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Contingent Consideration",
        "label": "Increase (Decrease) In Contingent Consideration",
        "terseLabel": "Net increase in contingent consideration liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContingentConsideration",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_IncreaseDecreaseInInterestExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Interest Expense",
        "label": "Increase (Decrease) In Interest Expense",
        "negatedTerseLabel": "Decrease in interest expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestExpense",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_IncreaseDecreaseInRetainedEarnings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Retained Earnings",
        "label": "Increase (Decrease) In Retained Earnings",
        "negatedTerseLabel": "Decrease in accumulated deficit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRetainedEarnings",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_InducementPlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Plan 2014 [Member]",
        "label": "Inducement Plan 2014 [Member]",
        "terseLabel": "2014 Inducement Plan"
       }
      }
     },
     "localname": "InducementPlan2014Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_IoveraMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "iovera\u00b0 [Member]",
        "label": "iovera\u00b0 [Member] [Member]",
        "terseLabel": "iovera\u00b0"
       }
      }
     },
     "localname": "IoveraMemberMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUEDisaggregationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_LargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the largest customer of the entity.",
        "label": "Largest Customer [Member]",
        "terseLabel": "Largest wholesaler"
       }
      }
     },
     "localname": "LargestCustomerMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_LegalFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Fees",
        "label": "Legal Fees [Member]",
        "terseLabel": "Legal Fees"
       }
      }
     },
     "localname": "LegalFeesMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_LitigationInvestigationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Investigation, Term",
        "label": "Litigation Investigation, Term",
        "terseLabel": "Litigation investigation term"
       }
      }
     },
     "localname": "LitigationInvestigationTerm",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Investments [Member]",
        "label": "Long-Term Investments [Member]",
        "terseLabel": "Long-term:"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_MajorCustomerFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Customer Four",
        "label": "Major Customer Four [Member]",
        "terseLabel": "Major customer four"
       }
      }
     },
     "localname": "MajorCustomerFourMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_MajorCustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity.",
        "label": "Major Customer One [Member]",
        "terseLabel": "Major customer one"
       }
      }
     },
     "localname": "MajorCustomerOneMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_MajorCustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity.",
        "label": "Major Customer Three [Member]",
        "terseLabel": "Major customer three"
       }
      }
     },
     "localname": "MajorCustomerThreeMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_MajorCustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity.",
        "label": "Major Customer Two [Member]",
        "terseLabel": "Major customer two"
       }
      }
     },
     "localname": "MajorCustomerTwoMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_MaximumFairMarketValuePurchaseofESPPShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Fair Market Value Purchase of ESPP Shares in a Calendar Year",
        "label": "Maximum Fair Market Value Purchase of ESPP Shares",
        "terseLabel": "Maximum fair market value of ESPP shares available for purchase"
       }
      }
     },
     "localname": "MaximumFairMarketValuePurchaseofESPPShares",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_MeasurementInputExpectedMilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Expected Milestone Payment [Member]",
        "label": "Measurement Input, Expected Milestone Payment [Member]",
        "terseLabel": "Probability of achieving regulatory milestones"
       }
      }
     },
     "localname": "MeasurementInputExpectedMilestonePaymentMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to milestone payments for products by the stage at which they are payable, in connection with the acquisition.",
        "label": "Milestone Payments for Product in Connection with Acquisition by Stage at which they are Payable [Axis]",
        "terseLabel": "Milestone Payments for Product in Connection with Acquisition by Stage at which They are Payable [Axis]"
       }
      }
     },
     "localname": "MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableAxis",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcrx_MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments for Product in Connection with Acquisition by Stage at which they are Payable [Domain]",
        "label": "Milestone Payments for Product in Connection with Acquisition by Stage at which they are Payable [Domain]",
        "terseLabel": "Milestone Payments for Product in Connection with Acquisition by Stage at which they are Payable [Domain]"
       }
      }
     },
     "localname": "MilestonePaymentsForProductInConnectionWithAcquisitionByStageAtWhichTheyArePayableDomain",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents minimum cumulative percentage of change in ownership as a condition to offset taxable income or tax.",
        "label": "Minimum Cumulative Percentage of Change in Ownership as Condition to Offset Taxable Income or Tax",
        "terseLabel": "Minimum cumulative percentage of change in ownership as condition to offset taxable income"
       }
      }
     },
     "localname": "MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_MovementinValuationandQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Movement in Valuation and Qualifying Accounts [Table Text Block]",
        "label": "Movement in Valuation and Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of Activity in Accrued Rebates and Chargebacks, Returns, Wholesaler Service Fees and Prompt Pay Discounts"
       }
      }
     },
     "localname": "MovementinValuationandQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcrx_MyoscienceAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myoscience Acquisition [Member]",
        "label": "Myoscience Acquisition [Member]",
        "terseLabel": "Myoscience Acquisition"
       }
      }
     },
     "localname": "MyoscienceAcquisitionMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_NetOperatingLossSubjecttoLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Losses, Subject to Limitation",
        "label": "Net Operating Loss, Subject to Limitation",
        "terseLabel": "Net operating loss, subject to limitation"
       }
      }
     },
     "localname": "NetOperatingLossSubjecttoLimitation",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_NuanceBiotechCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuance Biotech Co. Ltd. [Member]",
        "label": "Nuance Biotech Co. Ltd. [Member]",
        "terseLabel": "Nuance Biotech Co. Ltd."
       }
      }
     },
     "localname": "NuanceBiotechCo.Ltd.Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_NumberOfLocationsNewOperatingLeaseLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Locations, New Operating Lease Liability",
        "label": "Number Of Locations, New Operating Lease Liability",
        "terseLabel": "Number of locations"
       }
      }
     },
     "localname": "NumberOfLocationsNewOperatingLeaseLiability",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcrx_NumberOfMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of major customers of the reporting entity.",
        "label": "Number of Major Customers",
        "terseLabel": "Number of major customers"
       }
      }
     },
     "localname": "NumberOfMajorCustomers",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcrx_OtherTaxAttributesSubjectToLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Tax Attributes, Subject To Limitation",
        "label": "Other Tax Attributes, Subject To Limitation",
        "terseLabel": "Other tax attributes, subject to limitation"
       }
      }
     },
     "localname": "OtherTaxAttributesSubjectToLimitation",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_PaymentOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents earnout and milestone payment made which is associated with the acquisition of business.",
        "label": "Payment Of Contingent Consideration",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentOfContingentConsideration",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_PaymentOfEarlyTerminationFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Early Termination Fees",
        "label": "Payment Of Early Termination Fees",
        "terseLabel": "Payment of early termination fees"
       }
      }
     },
     "localname": "PaymentOfEarlyTerminationFees",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_PaymentsForDebtConversionPremiums": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Debt Conversion Premiums",
        "label": "Payments For Debt Conversion Premiums",
        "negatedLabel": "Conversion premium on 2019 convertible senior notes"
       }
      }
     },
     "localname": "PaymentsForDebtConversionPremiums",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_PotentialAdditionalInvestmentUponAchievingMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Additional Investment Upon Achieving Milestones",
        "label": "Potential Additional Investment Upon Achieving Milestones",
        "terseLabel": "Potential additional investment upon achieving milestones"
       }
      }
     },
     "localname": "PotentialAdditionalInvestmentUponAchievingMilestones",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ProceedsFromConvertibleOptionComponentOfConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Convertible Option Component of Convertible Debt",
        "label": "Proceeds from Convertible Option Component of Convertible Debt",
        "terseLabel": "Proceeds from equity component of the 2025 convertible senior notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleOptionComponentOfConvertibleDebt",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Shares Issued Under Employee Stock Purchase Plan",
        "label": "Proceeds From Shares Issued Under Employee Stock Purchase Plan",
        "terseLabel": "Proceeds from common stock issued under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromSharesIssuedUnderEmployeeStockPurchasePlan",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ProductReturnsRebatesandOtherFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Returns, Rebates and Other Fees",
        "label": "Product Returns, Rebates and Other Fees",
        "terseLabel": "Product returns and wholesaler service fees"
       }
      }
     },
     "localname": "ProductReturnsRebatesandOtherFees",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise price of shares that can be purchased by the related party on exercise of option.",
        "label": "Related Party Transaction Option to Purchase Shares of Common Stock Exercise Price",
        "terseLabel": "Exercise price of shares that can be purchased under option (in dollars per share)"
       }
      }
     },
     "localname": "RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockExercisePrice",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pcrx_RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares that can be purchased by the related party on exercise of option.",
        "label": "Related Party Transaction Option to Purchase Shares of Common Stock Number of Shares",
        "terseLabel": "Number of shares that can be purchased under option (in shares)"
       }
      }
     },
     "localname": "RelatedPartyTransactionOptionToPurchaseSharesOfCommonStockNumberOfShares",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcrx_RemainingPaymentRequiredUponFullSettlementOfNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Payment Required Upon Full Settlement of Notes",
        "label": "Remaining Payment Required Upon Full Settlement of Notes",
        "terseLabel": "Remaining payment required upon settlement of 2022 notes"
       }
      }
     },
     "localname": "RemainingPaymentRequiredUponFullSettlementOfNotes",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ReserveForPromptPayDiscountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Prompt Pay Discount [Member]",
        "label": "Reserve For Prompt Pay Discount [Member]",
        "terseLabel": "Prompt Payment Discounts"
       }
      }
     },
     "localname": "ReserveForPromptPayDiscountMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units, Money Stock Options, And Common Stock",
        "label": "Restricted Stock Units, Money Stock Options, And Common Stock [Member]",
        "terseLabel": "RSUs, In-The-Money Stock Options, and Common Stock"
       }
      }
     },
     "localname": "RestrictedStockUnitsMoneyStockOptionsAndCommonStockMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_RetirementOfEquityComponentOfConvertibleSeniorNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retirement of Equity Component of Convertible Senior Notes",
        "label": "Retirement of Equity Component of Convertible Senior Notes",
        "negatedTerseLabel": "Retirement of equity component of the 2022 convertible senior notes"
       }
      }
     },
     "localname": "RetirementOfEquityComponentOfConvertibleSeniorNotes",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_ScheduleOfInterestExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of interest rate expenses related to convertible notes.",
        "label": "Schedule of Interest Expense [Table Text Block]",
        "terseLabel": "Schedule of Total Interest Expense Recognized Related to the Notes"
       }
      }
     },
     "localname": "ScheduleOfInterestExpenseTableTextBlock",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcrx_ScheduleOfSharesAvailableForIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of shares available for issuance which includes information about awards reserved for issuance, awards issued and awards available for grant by plan.",
        "label": "Schedule of Shares Available for Issuance [Table Text Block]",
        "terseLabel": "Schedule of Information About the Plans"
       }
      }
     },
     "localname": "ScheduleOfSharesAvailableForIssuanceTableTextBlock",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcrx_SecondLargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the second largest customer of the entity.",
        "label": "Second Largest Customer [Member]",
        "terseLabel": "Second largest wholesaler"
       }
      }
     },
     "localname": "SecondLargestCustomerMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_SecondPriceOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Price Option",
        "label": "Second Price Option [Member]",
        "terseLabel": "Second Price Option"
       }
      }
     },
     "localname": "SecondPriceOptionMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation Costs, Asset Write-downs, And Other Restructuring Charges [Member]",
        "label": "Separation Costs, Asset Write-downs, And Other Restructuring Charges [Member]",
        "terseLabel": "Separation Costs, Asset Write-downs, and Other Restructuring Charges"
       }
      }
     },
     "localname": "SeparationCostsAssetWritedownsAndOtherRestructuringChargesMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_SettlementPeriodConvertibleDebtConversionRequest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of trading days in a settlement period for convertible debt conversion requests.",
        "label": "Settlement Period - Convertible Debt Conversion Request",
        "terseLabel": "Settlement period - convertible debt conversion request"
       }
      }
     },
     "localname": "SettlementPeriodConvertibleDebtConversionRequest",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options, Outstanding Aggregate Intrinsic Value [Roll Forward]",
        "terseLabel": "Aggregate Intrinsic Value (in Thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollforward",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Outstanding Weighted A Average Remaining Contractual Term [Roll Forward]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAAverageRemainingContractualTermRollforward",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Award, Percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Award, Percentage",
        "terseLabel": "Performance award (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceAwardPercentage",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period",
        "terseLabel": "Performance period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcrx_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Stock incentive plan, increased number of shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcrx_SkyePharmaHoldingIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to SkyePharma Holding, Inc.",
        "label": "Skye Pharma Holding Inc. [Member]",
        "terseLabel": "SkyePharma Holding, Inc."
       }
      }
     },
     "localname": "SkyePharmaHoldingIncMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_SpineBioPharmaLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spine BioPharma, LLC",
        "label": "Spine BioPharma, LLC [Member]",
        "terseLabel": "Spine BioPharma, LLC"
       }
      }
     },
     "localname": "SpineBioPharmaLLCMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_StockIncentivePlan2011Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information about the entity's 2011 stock incentive plan.",
        "label": "Stock Incentive Plan 2011 [Member]",
        "terseLabel": "2011 Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2011Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchased And Issued During Period, Shares, Employee Stock Purchase Plans",
        "label": "Stock Purchased And Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "ESPP shares purchased and issued during period (in shares)"
       }
      }
     },
     "localname": "StockPurchasedAndIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcrx_TELABioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TELA Bio",
        "label": "TELA Bio [Member]",
        "terseLabel": "TELA Bio"
       }
      }
     },
     "localname": "TELABioMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_TermLoanBFacilityDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due 2026",
        "label": "Term Loan B Facility Due 2026 [Member]",
        "terseLabel": "7.000% Term Loan B Facility Maturing 2026"
       }
      }
     },
     "localname": "TermLoanBFacilityDue2026Member",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ThirdLargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the third largest customer of the entity.",
        "label": "Third Largest Customer [Member]",
        "terseLabel": "Third largest wholesaler"
       }
      }
     },
     "localname": "ThirdLargestCustomerMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ThreeLargestCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Largest Customers",
        "label": "Three Largest Customers [Member]",
        "terseLabel": "Three largest customers"
       }
      }
     },
     "localname": "ThreeLargestCustomersMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_TotalMilestonePaymentsYetToBePaidInConnectionAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Milestone Payments Yet To Be Paid in Connection, Acquisition",
        "label": "Total Milestone Payments Yet To Be Paid in Connection, Acquisition",
        "terseLabel": "Potential remaining milestone payments"
       }
      }
     },
     "localname": "TotalMilestonePaymentsYetToBePaidInConnectionAcquisition",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs Attributable to the Equity Component of Convertible Debt",
        "label": "Transaction Costs Attributable to the Equity Component of Convertible Debt",
        "terseLabel": "Transaction costs attributable to equity component of convertible debt"
       }
      }
     },
     "localname": "TransactionCostsAttributableToTheEquityComponentOfConvertibleDebt",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcrx_UponAnnualNetSalesReachingDollar500.0MillionThresholdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the stage for milestone payments when the annual net sales reach 500.0 million dollars.",
        "label": "Upon Annual Net Sales Reaching Dollar 500.0 Million Threshold [Member]",
        "terseLabel": "When annual net sales collected reach $500.0 million"
       }
      }
     },
     "localname": "UponAnnualNetSalesReachingDollar500.0MillionThresholdMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_UponFirstCommercialSaleInMajorEUCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the stage for milestone payments upon the first commercial sale in a major EU country (UK, France, Germany, Italy or Spain).",
        "label": "Upon First Commercial Sale in Major EU Country [Member]",
        "terseLabel": "Upon first commercial sale in a major EU country (United Kingdom, France, Germany, Italy and Spain)"
       }
      }
     },
     "localname": "UponFirstCommercialSaleInMajorEUCountryMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_WholesalerservicefeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler service fees [Member]",
        "label": "Wholesaler service fees [Member]",
        "terseLabel": "Service Fees"
       }
      }
     },
     "localname": "WholesalerservicefeesMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_XenonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xenon Pharmaceuticals, Inc",
        "label": "Xenon Pharmaceuticals, Inc [Member]",
        "terseLabel": "Xenon Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "XenonPharmaceuticalsIncMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcrx_ZILRETTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZILRETTA",
        "label": "ZILRETTA [Member]",
        "terseLabel": "ZILRETTA"
       }
      }
     },
     "localname": "ZILRETTAMember",
     "nsuri": "http://www.pacira.com/20211231",
     "presentation": [
      "http://www.pacira.com/role/REVENUEDisaggregationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r68",
      "r70",
      "r151",
      "r152",
      "r370",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "auth_ref": [
      "r2",
      "r164",
      "r174",
      "r281",
      "r520",
      "r521",
      "r522",
      "r560",
      "r561",
      "r619",
      "r625",
      "r626",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r164",
      "r174",
      "r180",
      "r281",
      "r520",
      "r521",
      "r522",
      "r560",
      "r561",
      "r619",
      "r622",
      "r625",
      "r626",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r164",
      "r174",
      "r180",
      "r281",
      "r520",
      "r521",
      "r522",
      "r560",
      "r561",
      "r619",
      "r622",
      "r625",
      "r626",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r164",
      "r174",
      "r180",
      "r281",
      "r520",
      "r521",
      "r522",
      "r560",
      "r561",
      "r619",
      "r622",
      "r625",
      "r626",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "verboseLabel": "Member of board of directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EnergyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Energy [Axis]",
        "terseLabel": "Instrument [Axis]"
       }
      }
     },
     "localname": "EnergyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EnergyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Energy [Domain]",
        "terseLabel": "Instrument Type [Domain]"
       }
      }
     },
     "localname": "EnergyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r248",
      "r441",
      "r446",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r369",
      "r408",
      "r475",
      "r478",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r738",
      "r804",
      "r808",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails",
      "http://www.pacira.com/role/LEASESNarrativeDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r369",
      "r408",
      "r475",
      "r478",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r738",
      "r804",
      "r808",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r248",
      "r441",
      "r446",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r245",
      "r441",
      "r444",
      "r744",
      "r803",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/REVENUEDisaggregationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r245",
      "r441",
      "r444",
      "r744",
      "r803",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/REVENUEDisaggregationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r369",
      "r408",
      "r459",
      "r475",
      "r478",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r738",
      "r804",
      "r808",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement[Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails",
      "http://www.pacira.com/role/LEASESNarrativeDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r369",
      "r408",
      "r459",
      "r475",
      "r478",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r738",
      "r804",
      "r808",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails",
      "http://www.pacira.com/role/LEASESNarrativeDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r69",
      "r70",
      "r151",
      "r152",
      "r370",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r175",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r175",
      "r180",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r246",
      "r247",
      "r441",
      "r445",
      "r806",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r246",
      "r247",
      "r441",
      "r445",
      "r806",
      "r838",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r175",
      "r180",
      "r345",
      "r476",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r714",
      "r716",
      "r719",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r167",
      "r168",
      "r169",
      "r171",
      "r253",
      "r254",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r352",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r560",
      "r561",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r656",
      "r657",
      "r691",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r52",
      "r703"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r13",
      "r31",
      "r250",
      "r251"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInvestmentIncomeReceivable": {
     "auth_ref": [
      "r31",
      "r764",
      "r795"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.",
        "label": "Accrued Investment Income Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "AccruedInvestmentIncomeReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails",
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r56"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r50",
      "r324"
     ],
     "calculation": {
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r79",
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Net Unrealized Gains (Losses) From Available For Sale Investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r34",
      "r77",
      "r78",
      "r79",
      "r792",
      "r816",
      "r820"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r76",
      "r79",
      "r87",
      "r88",
      "r89",
      "r161",
      "r162",
      "r163",
      "r610",
      "r811",
      "r812",
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r72",
      "r79",
      "r87",
      "r88",
      "r89",
      "r610",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unrealized Foreign Currency Translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-Average Useful Lives"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r32",
      "r524",
      "r703"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r520",
      "r521",
      "r522",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of convertible debt"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Decrease in additional paid in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r480",
      "r482",
      "r527",
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r482",
      "r512",
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r103",
      "r128",
      "r389",
      "r670"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r96",
      "r128",
      "r389",
      "r672"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization\u00a0of\u00a0debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r128",
      "r308",
      "r316"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "EARNINGS PER SHARE"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails",
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in notes or bonds that are collateralized by a specific group of underlying assets owned by the issuer of the notes or bonds which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Asset-Backed Securities, at Carrying Value",
        "terseLabel": "Carrying value of asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r264",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetRetirementObligation": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.",
        "label": "Asset Retirement Obligation",
        "terseLabel": "Asset retirement obligation"
       }
      }
     },
     "localname": "AssetRetirementObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetRetirementObligationsPolicy": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.",
        "label": "Asset Retirement Obligation [Policy Text Block]",
        "terseLabel": "Asset Retirement Obligations"
       }
      }
     },
     "localname": "AssetRetirementObligationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r146",
      "r228",
      "r237",
      "r243",
      "r277",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r606",
      "r611",
      "r646",
      "r701",
      "r703",
      "r765",
      "r788"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r67",
      "r146",
      "r277",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r606",
      "r611",
      "r646",
      "r701",
      "r703"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate which is used to value residual cash flows generated by financial assets of the securitization, asset-backed financing arrangement, or similar transfer for initial fair value measurement.",
        "label": "Fair Value Assumption, Date of Securitization or Asset-backed Financing Arrangement, Transferor's Continuing Involvement, Servicing Assets or Liabilities, Discount Rate",
        "terseLabel": "Projected future cash flows discounted, rate"
       }
      }
     },
     "localname": "AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r483",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails",
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Alternative Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacira.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r474",
      "r477",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacira.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire description for costs incurred to effect a business combination that have been expensed during the period.  Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Acquisition, Integration, Restructuring and Other Related Costs [Text Block]",
        "terseLabel": "ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET"
       }
      }
     },
     "localname": "BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails",
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Pro forma basic net loss per share (in usd per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Pro forma diluted net loss per share (in usd per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r582",
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r582",
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related fees"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r592",
      "r593",
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase consideration",
        "verboseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r127",
      "r599"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Additional liability payable to holders of CVRs",
        "negatedTerseLabel": "Changes in contingent consideration (after an acquisition)",
        "terseLabel": "Changes in contingent consideration (after an acquisition)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r598"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Additional amount payable to holders of the CVRs"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r591",
      "r594",
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Severance-related expenses"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "ASSETS ACQUIRED"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Short-term available-for-sale investments"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "In-process research and development (IPR&amp;D)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "LIABILITIES ASSUMED"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r133",
      "r134",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed assets included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital Loss Carryforward"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r11",
      "r46",
      "r130"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets",
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r19",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r122",
      "r658"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r143",
      "r146",
      "r185",
      "r189",
      "r192",
      "r194",
      "r196",
      "r205",
      "r206",
      "r207",
      "r277",
      "r353",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r406",
      "r407",
      "r411",
      "r415",
      "r646",
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Contingent value right (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Commercial Paper, at Carrying Value",
        "terseLabel": "Carrying value of commercial paper"
       }
      }
     },
     "localname": "CommercialPaperAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r62",
      "r344",
      "r772",
      "r797"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 21)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r348",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r161",
      "r162",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r703"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.001; 250,000,000 shares authorized; 44,734,308 and 43,636,929 shares issued and outstanding at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r457",
      "r458",
      "r479",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Significant components of deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Income Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r82",
      "r84",
      "r85",
      "r94",
      "r775",
      "r799"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r248",
      "r643",
      "r644",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r248",
      "r643",
      "r644",
      "r821",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r248",
      "r643",
      "r644",
      "r821",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r215",
      "r216",
      "r248",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (as a percent)",
        "verboseLabel": "Percentage of revenue from customers to total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r212",
      "r215",
      "r216",
      "r217",
      "r643",
      "r645",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r248",
      "r643",
      "r644",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r137",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r430",
      "r431",
      "r442"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r25",
      "r768",
      "r791"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r364",
      "r366",
      "r367",
      "r369",
      "r379",
      "r380",
      "r381",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r25",
      "r768",
      "r790",
      "r822"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible note paid for investment"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r98",
      "r146",
      "r277",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r646"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current taxes:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r556",
      "r567"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r556"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r556",
      "r567",
      "r569"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r556",
      "r567"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r213",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r383",
      "r390",
      "r391",
      "r393",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r22",
      "r24",
      "r25",
      "r145",
      "r153",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r399",
      "r400",
      "r401",
      "r402",
      "r673",
      "r766",
      "r768",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r25",
      "r395",
      "r768",
      "r786"
     ],
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Convertible senior notes, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Carrying amount of equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r368",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Initial conversion price of notes into common stock (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r59",
      "r368",
      "r423",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate of common stock per $1,000 of principal amount of notes"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r366",
      "r399",
      "r400",
      "r671",
      "r673",
      "r674"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r381",
      "r399",
      "r400",
      "r640"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Debt Instrument, Increase (Decrease), Net",
        "terseLabel": "Increase in net debt"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r58",
      "r386",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Effective interest rate on total debt"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r58",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "DEBT AND FINANCING OBLIGATIONS"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r60",
      "r145",
      "r153",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r399",
      "r400",
      "r401",
      "r402",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Quarterly payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Balloon payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Aggregate principal retired"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Debt instrument, repurchased face amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r60",
      "r145",
      "r153",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r399",
      "r400",
      "r401",
      "r402",
      "r423",
      "r425",
      "r426",
      "r427",
      "r670",
      "r671",
      "r673",
      "r674",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Amortization period of equity component of convertible debt"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r379",
      "r670",
      "r674"
     ],
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Discount on debt",
        "terseLabel": "Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates.",
        "label": "Debt [Member]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible Debt Transactions"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "terseLabel": "Total transaction costs"
       }
      }
     },
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Fair Value (Level\u00a02)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r557",
      "r567"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred taxes:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r51",
      "r379",
      "r672"
     ],
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r534",
      "r535"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r128",
      "r147",
      "r557",
      "r567",
      "r568",
      "r569"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred taxes",
        "totalLabel": "Total deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r26",
      "r27",
      "r546",
      "r767",
      "r785"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r557",
      "r567"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r547"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "pcrx_DeferredTaxAssetsGrossNetofDeferredTaxLiabilitiesBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r549"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r552",
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Federal and state credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "negatedTerseLabel": "Discount on convertible senior notes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Compensation expense recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer discretionary contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r128",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r128",
      "r226"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation of fixed assets and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technologies"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUEDisaggregationDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUEDisaggregationDetails",
      "http://www.pacira.com/role/REVENUENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation",
        "terseLabel": "Non-recurring charge related to discontinuation"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepoCyteDiscontinuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r95",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r183",
      "r185",
      "r194",
      "r195",
      "r196",
      "r200",
      "r201",
      "r626",
      "r627",
      "r776",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net income (loss) per common share (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r95",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r185",
      "r194",
      "r195",
      "r196",
      "r200",
      "r201",
      "r626",
      "r627",
      "r776",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net income (loss) per common share (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Per Share Data"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of income taxes at U.S. Federal statutory rate to the provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r149",
      "r537",
      "r571"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r537",
      "r571"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r537",
      "r571"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Nondeductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r537",
      "r571"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "negatedTerseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r537",
      "r571"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r537",
      "r571"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Expected recognition of non-vested RSUs, not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of non-vested awards not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Expected recognition of non-vested stock options, not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Related income tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails",
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails",
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r87",
      "r88",
      "r89",
      "r161",
      "r162",
      "r163",
      "r168",
      "r177",
      "r179",
      "r204",
      "r281",
      "r422",
      "r428",
      "r520",
      "r521",
      "r522",
      "r560",
      "r561",
      "r625",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r811",
      "r812",
      "r813",
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r9",
      "r146",
      "r277",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r9",
      "r146",
      "r277",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r47",
      "r121",
      "r276",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r638"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGain": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Loss on equity investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r381",
      "r399",
      "r400",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r628",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r381",
      "r399",
      "r400",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r472",
      "r629",
      "r711",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r381",
      "r399",
      "r400",
      "r628",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r381",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r381",
      "r460",
      "r461",
      "r466",
      "r472",
      "r629",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r381",
      "r399",
      "r400",
      "r460",
      "r461",
      "r466",
      "r472",
      "r629",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r381",
      "r399",
      "r400",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r472",
      "r629",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Carrying Amount and Fair Value of the Long-term Debt"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r632",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]",
        "terseLabel": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the gain (loss) of assets and liabilities measured at fair value on a recurring basis.",
        "label": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]",
        "terseLabel": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]"
       }
      }
     },
     "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r633"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Fair value adjustments and accretion",
        "verboseLabel": "Gain related to acquisition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments made or offset against amounts due"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r632"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at December 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r381",
      "r399",
      "r400",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r472",
      "r711",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSContingentConsiderationRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r271",
      "r272",
      "r273",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r392",
      "r420",
      "r615",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Major Types of Debt and Equity Securities [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss, Foreign Currency Translation",
        "terseLabel": "Reduction in convertible note, due to foreign currency exchange rates"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r309",
      "r312",
      "r315",
      "r318",
      "r745",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r315",
      "r749"
     ],
     "calculation": {
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r309",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r315",
      "r745"
     ],
     "calculation": {
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currencies"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnContractTermination": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.",
        "label": "Gain (Loss) on Contract Termination",
        "negatedTerseLabel": "Discontinuation of DepoCyt(e)"
       }
      }
     },
     "localname": "GainLossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r128",
      "r321",
      "r326"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "(Gain) loss on disposal and impairment of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r101",
      "r128",
      "r259"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "(Gain) loss on investment (net of stock dividend) and other non-operating income, net"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r128",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on early extinguishment of debt",
        "negatedTerseLabel": "Loss on early extinguishment of debt",
        "terseLabel": "Loss on early extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r300",
      "r301",
      "r703",
      "r763"
     ],
     "calculation": {
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails",
      "http://www.pacira.com/role/ConsolidatedBalanceSheets",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill arising from acquisition"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r303",
      "r304",
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Translation and Purchase Accounting Adjustments",
        "terseLabel": "2020 accumulated adjustments"
       }
      }
     },
     "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments",
        "negatedTerseLabel": "Impairment loss"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r320",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeApproachValuationTechniqueMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach converting future amounts to single current discounted amount.",
        "label": "Valuation, Income Approach [Member]",
        "terseLabel": "Valuation, Income Approach"
       }
      }
     },
     "localname": "IncomeApproachValuationTechniqueMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r148",
      "r570"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r228",
      "r236",
      "r239",
      "r242",
      "r244",
      "r762",
      "r773",
      "r778",
      "r801"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r148",
      "r570"
     ],
     "calculation": {
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "pcrx_IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (loss) before income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r327",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r538",
      "r544",
      "r551",
      "r565",
      "r572",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r150",
      "r178",
      "r179",
      "r227",
      "r536",
      "r566",
      "r573",
      "r802"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "negatedTerseLabel": "Income tax (expense) benefit",
        "totalLabel": "Total income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/INCOMETAXESCurrentandDeferredIncomeTaxesDetails",
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r532",
      "r533",
      "r544",
      "r545",
      "r550",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r124",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes, net of refunds"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities (net of acquisitions):"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r190",
      "r191",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Dilutive effect of conversion premium on the 2022 Notes (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of diluted securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Value",
        "verboseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r138",
      "r314",
      "r741",
      "r742",
      "r743",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r307",
      "r313"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r669"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Capitalized interest"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalizedAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred.",
        "label": "Interest Costs Capitalized Adjustment",
        "negatedTerseLabel": "Capitalized interest (Note 7)"
       }
      }
     },
     "localname": "InterestCostsCapitalizedAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r90",
      "r225",
      "r668",
      "r672",
      "r777"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r103",
      "r387",
      "r398",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r105",
      "r388",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual and other interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r118",
      "r123",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r38",
      "r298"
     ],
     "calculation": {
      "http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r12",
      "r65",
      "r703"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets",
      "http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r18",
      "r66",
      "r139",
      "r203",
      "r296",
      "r297",
      "r299",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r298"
     ],
     "calculation": {
      "http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r39",
      "r298"
     ],
     "calculation": {
      "http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r100",
      "r224"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments, and noncurrent assets classified as other.",
        "label": "Investments and Other Noncurrent Assets",
        "terseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "InvestmentsAndOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r628"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments fair value"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r687",
      "r689"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Operating Lease Costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating leases, maximum term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r55",
      "r146",
      "r238",
      "r277",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r607",
      "r611",
      "r612",
      "r646",
      "r701",
      "r702"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r37",
      "r146",
      "r277",
      "r646",
      "r703",
      "r769",
      "r794"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r57",
      "r146",
      "r277",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r607",
      "r611",
      "r612",
      "r646",
      "r701",
      "r702",
      "r703"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Department of Justice settlement"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepartmentofJusticeDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Department of Justice settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r25",
      "r380",
      "r396",
      "r399",
      "r400",
      "r768",
      "r791"
     ],
     "calculation": {
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt outstanding",
        "totalLabel": "Total debt, net of debt discount and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term available-for-sale investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-term Purchase Commitment [Line Items]",
        "terseLabel": "Long-term Purchase Commitment [Line Items]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-term Purchase Commitment [Table]",
        "terseLabel": "Long-term Purchase Commitment [Table]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r60",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate, at point in time"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r344",
      "r346",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss contingency, damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MajorCustomersPolicyPolicyTextBlock": {
     "auth_ref": [
      "r212",
      "r215",
      "r216",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.",
        "label": "Major Customers, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Major Customers"
       }
      }
     },
     "localname": "MajorCustomersPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Short-Term and Long-Term Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rates"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Carrying value of money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r122",
      "r126",
      "r129"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r9",
      "r80",
      "r83",
      "r89",
      "r93",
      "r129",
      "r146",
      "r167",
      "r172",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r193",
      "r228",
      "r236",
      "r239",
      "r242",
      "r244",
      "r277",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r627",
      "r646",
      "r774",
      "r798"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r165",
      "r166",
      "r169",
      "r170",
      "r180",
      "r181",
      "r182",
      "r255",
      "r256",
      "r282",
      "r283",
      "r451",
      "r452",
      "r454",
      "r455",
      "r523",
      "r562",
      "r563",
      "r564",
      "r623",
      "r653",
      "r654",
      "r655",
      "r692",
      "r746",
      "r747",
      "r748",
      "r815",
      "r816",
      "r817",
      "r818",
      "r820",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesReceivableFairValueDisclosure": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.",
        "label": "Notes Receivable, Fair Value Disclosure",
        "terseLabel": "Convertible notes receivable"
       }
      }
     },
     "localname": "NotesReceivableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "auth_ref": [
      "r333",
      "r334",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.",
        "label": "One-time Termination Benefits [Member]",
        "terseLabel": "One-time Termination Benefits"
       }
      }
     },
     "localname": "OneTimeTerminationBenefitsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r228",
      "r236",
      "r239",
      "r242",
      "r244"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r681",
      "r689"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESNarrativeDetails",
      "http://www.pacira.com/role/LEASESScheduleofmaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r677",
      "r683"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities, net of lease incentive"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r675"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r686",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r685",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r10",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r604",
      "r605",
      "r609"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Net unrealized gain (loss) on investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r604",
      "r605",
      "r609"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r81",
      "r84",
      "r604",
      "r605",
      "r609"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss (Note 13)",
        "totalLabel": "Total other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r73",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gain (loss) on investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r333",
      "r334",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other acquisition expenses"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "negatedTerseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for settlement"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETDepoCyteDiscontinuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance and financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r106",
      "r109",
      "r257"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of available-for-sale investments",
        "terseLabel": "Payments to acquire convertible note"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "terseLabel": "Acquisition of Flexion Therapeutics, Inc. (net of cash acquired)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r110",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Cash paid to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of MyoScience, Inc. (net of cash acquired)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Payments to acquire investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-term Investments",
        "negatedTerseLabel": "Purchases of equity and debt investments",
        "terseLabel": "Payments to acquire investments"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "terseLabel": "Investments in additional equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r483",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r29",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r29",
      "r703"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at December\u00a031, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r14",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from debt component of the 2025 convertible senior notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Debt issued in private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r114",
      "r145"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from term loan B credit facility",
        "verboseLabel": "Proceeds from debt"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r106",
      "r107",
      "r257"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of available-for-sale investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Sale of equity investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": {
     "auth_ref": [
      "r120",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Proceeds from Sale of Equity Securities, FV-NI",
        "terseLabel": "Proceeds from sale of equity investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r113",
      "r515"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r50",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r329",
      "r841",
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "FIXED ASSETS"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r49",
      "r323"
     ],
     "calculation": {
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant, and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "FIXED ASSETS",
        "verboseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r325",
      "r703",
      "r783",
      "r796"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Fixed assets, net",
        "totalLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets",
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r325",
      "r841",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r20",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Useful Lives by Asset Category"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSTables",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r20",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryRawMaterialsMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic goods that are to be consumed directly or indirectly in the production of finished goods or services.",
        "label": "Raw Materials [Member]",
        "terseLabel": "Raw Materials"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryRawMaterialsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r467",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r467",
      "r695",
      "r698",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r693",
      "r694",
      "r696",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Repayment of convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r530",
      "r740",
      "r855"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails",
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r333",
      "r336",
      "r338",
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Total costs, of one-time benefits, estimate"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r128",
      "r332",
      "r337",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Termination of Nuance agreement"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r333",
      "r334",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r428",
      "r524",
      "r703",
      "r793",
      "r815",
      "r820"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r161",
      "r162",
      "r163",
      "r168",
      "r177",
      "r179",
      "r281",
      "r520",
      "r521",
      "r522",
      "r560",
      "r561",
      "r625",
      "r811",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r601",
      "r602"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Collaborative licensing and milestone revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails",
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r222",
      "r223",
      "r235",
      "r240",
      "r241",
      "r245",
      "r246",
      "r248",
      "r440",
      "r441",
      "r744"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total net product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUEDisaggregationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r222",
      "r223",
      "r235",
      "r240",
      "r241",
      "r245",
      "r246",
      "r248",
      "r440",
      "r441",
      "r744"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r443",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RECENTACCOUNTINGPRONOUNCEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue From Contracts With Customers"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r91",
      "r146",
      "r222",
      "r223",
      "r235",
      "r240",
      "r241",
      "r245",
      "r246",
      "r248",
      "r277",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r646",
      "r778"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r684",
      "r689"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets recorded in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns Allowances"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r215",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationofMajorCustomersDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r79",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHAREAntidilutiveSecuritiesDetails",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Dilutive Effect of the Securities Excluded from the Calculation of Diluted Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r780",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Contingent Consideration for Flexion Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETMyoScienceDetails",
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails",
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSFlexionResultsDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofAssetsandLiabilitiesAcquiredDetails",
      "http://www.pacira.com/role/ACQUISITIONSScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r60",
      "r153",
      "r399",
      "r401",
      "r423",
      "r425",
      "r426",
      "r427",
      "r670",
      "r671",
      "r674",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Composition of the Company's Debt and Financing Obligations"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of the Company's Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Income (Loss) per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Taxes at the U.S. Federal Statutory Rate to the Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r482",
      "r511",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r482",
      "r511",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Recognized Stock-based Compensation in Consolidated Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r309",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary of Change in Carrying Value of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r18",
      "r41",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r50",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails",
      "http://www.pacira.com/role/FIXEDASSETSScheduleofUsefulLivesDetails",
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r483",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails",
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r489",
      "r500",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of the Company's Stock Option Activity and Related Information"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions Used on ESPP Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumptions Used to Estimate the Fair Values of Each Option Grant Using the Black-Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r543",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Rollforward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r212",
      "r215",
      "r216",
      "r217",
      "r643",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Percentage of Revenue Comprised of the Three Largest Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtCurrent": {
     "auth_ref": [
      "r22",
      "r766",
      "r789"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt, Current",
        "terseLabel": "Current portion of long-term debt, net"
       }
      }
     },
     "localname": "SecuredDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-term Debt, Noncurrent",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Adjusted Term SOFR Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested balance at the end of the period (in shares)",
        "periodStartLabel": "Unvested balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested balance at the end of the period (in dollars per shares)",
        "periodStartLabel": "Unvested balance at the beginning of the period (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value (Per Share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)",
        "terseLabel": "Vested restricted stock units (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted Average Assumptions Used to Estimate the Fair Values of Each Option Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails",
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Stock incentive plan, awards reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Stock incentive plan, awards available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "ESPP share option fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r491",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price (Per Share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Vested and expected to vest at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Stock incentive plan, awards issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r481",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails",
      "http://www.pacira.com/role/STOCKPLANSCompensationExpenseDetails",
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails",
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails",
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r483",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Closing sale price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in Thousands)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Unvested balance at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSRSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r507",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Term exercisable at the end of the period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Term at the end of the period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Term vested and expected to vest at the end of the period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r23",
      "r770",
      "r771",
      "r787"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term available-for-sale investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r834",
      "r835",
      "r836",
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term:"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r136",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r143",
      "r146",
      "r185",
      "r189",
      "r192",
      "r194",
      "r196",
      "r205",
      "r206",
      "r207",
      "r277",
      "r353",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r406",
      "r407",
      "r411",
      "r415",
      "r422",
      "r646",
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r63",
      "r87",
      "r88",
      "r89",
      "r161",
      "r162",
      "r163",
      "r168",
      "r177",
      "r179",
      "r204",
      "r281",
      "r422",
      "r428",
      "r520",
      "r521",
      "r522",
      "r560",
      "r561",
      "r625",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r811",
      "r812",
      "r813",
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r204",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r29",
      "r30",
      "r422",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "ESPP, shares purchased (in shares)",
        "verboseLabel": "Common stock issued under employee stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/STOCKPLANSStockIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r30",
      "r422",
      "r428",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/STOCKPLANSStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r29",
      "r30",
      "r422",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r63",
      "r422",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r35",
      "r36",
      "r146",
      "r252",
      "r277",
      "r646",
      "r703"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets",
      "http://www.pacira.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.pacira.com/role/STOCKHOLDERSEQUITYAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r666",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r666",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r666",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r666",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r704",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.pacira.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction [Domain]"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r264",
      "r265",
      "r271",
      "r272",
      "r273",
      "r392",
      "r420",
      "r615",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETFlexionDetails",
      "http://www.pacira.com/role/ACQUISITIONSContingentConsiderationFlexionAcquisitionDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofFairValueInputsandValuationDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETNUANCEDetails",
      "http://www.pacira.com/role/COMMERCIALPARTNERSANDOTHERAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r333",
      "r334",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONRELATEDCHARGESANDPRODUCTDISCONTINUATIONNETProductDiscontinuanceDetails",
      "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. Government bonds"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsatAmortizedCostandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r531",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits at end of the period",
        "periodStartLabel": "Unrecognized tax benefits at beginning of the period",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reduction for prior year positions",
        "terseLabel": "Reduction for prior year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for current year positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails",
      "http://www.pacira.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits resulting from prior tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTCarryingValueofDebtDetails",
      "http://www.pacira.com/role/DEBTNarrativeDetails",
      "http://www.pacira.com/role/DEBTScheduleofDebtDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSFairValueofLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacira.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Reduction of valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "terseLabel": "Provision"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r154",
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "End of Period",
        "periodStartLabel": "Beginning of Period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments/Adjustments"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/REVENUESalesandValuationAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Valuation Technique, Discounted Cash Flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r682",
      "r689"
     ],
     "calculation": {
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/LEASESSummaryofoperatingleasecostandotheroperatingleaseinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Computation of diluted securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r184",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted average number of shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:",
        "verboseLabel": "Weighted average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r183",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pacira.com/role/ConsolidatedStatementsofOperations",
      "http://www.pacira.com/role/NETINCOMELOSSPERSHARECalculationDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2029-109256"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r856": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r857": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r858": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r859": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r860": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r861": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r862": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r863": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r864": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r865": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r866": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r867": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r868": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r869": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r870": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r871": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r872": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>141
<FILENAME>0001396814-22-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001396814-22-000021-xbrl.zip
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MA-G9?./@\#Y&O^:J[ZT&=W[;^L.*%:???Y_K%>S-W+[_Y8^O__L6VWNT<NH
M,;V;I)ZTF/KX[,0=->H;9"FWYCLVOY&&T->]T\ ^[H]O)!!3HXM/@F1OO,.W
MU&'=/ MXUJ8IC'TMRS[;>(]/D9I1BE/;QW6G-AF7A4TY1_+ ]PO_<[$^>_DU
MJ>ZCW^;?#/6/5@)W!_'O)8'GJYZO>K[J^:KGJQY31F@I&=2_8IVK3J\/7_6O
MNK^S7O^J^6]V=4WO&+]XUVVU/K0Z_9*GB:KV_X&C_Y'N_/]02P,$%     @
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M$SLN#Q 61Y=@'(+? :8?XI?R9N;$@C'$#((9316&?PMP+?!+#)XI*MSC1?)
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M?.C00_1&.MXO0JD.WUH"HF&J]OUB@GE^P,2%C(G;Q+FS W42>A(GG)*51U%
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MU=.3P',"'SE;MS<K#X? /C#DG)X$'C;_R&3_62\N<LD=>/9&')#T9!"+'YY
M!%[EJJNA,NVQX_3N16V.E87SK4MS=BP+@2=5;J0G4 A+;_NK8,#Y[7#OHH6J
M$2C@YW<9O-?.\L9I^DK!6DGVFIZPF^_S)4UE]T+Z L_IW,R$FFV_NE!]";O.
MC@4@\-"^7^$2@@!8)=1X8R- QT;\R=%O/'RZXW=83Y2G6[Q0/E;C74ZH=&NN
MJ!TDJMIF+UIQOMAI*\Y1=)??JQ+/) $L42M..9[ZN-N>A HZR5!4<<Z2^XBY
M9VG3*RMC-";=PL.GVN\W+4S:G=\W3#*B2 M1WN=U1?DES&#-5%* OJ1\:#)5
MK8^ZQVWDIZ)U'E<W+-??0F!OU,R4DO0Q?DM7SYFO]]]E8-,21HM?+)]C4MSB
MM6B,< 8M\!>O*5IOF&Z+U!BAR<0Y2RDVF^7>TS*\TY/ DU\WK5+LLF*>LVWW
MH!SOOX7Q&'B.0SCY K(:[I,ZK[J&P>ISA ,T,(5/GG^/-1R(U*>_Z);6S1R5
MIP-P19US5SV45#*0%B)7H-4MA3$JK &.C5@* /!NPG16MG551*VTFH2;F&.!
MKMT?5.KI2>!9EMOD<TA"B$+%YA;: \EG!X\%-FO'^"Z+"'%@* :JXN)1"(P2
M]UCJYATHMGP!JBV=@9@0,J5K":&28[&)5&RT=3[IY& NU#U]CE"2655D CS1
MY'PH_P^(PX+'R$T)3H/CUH508M_\5!*MWU_A#AF<M@CK*I>"=/D[;(HFR]E-
M<S!B^CA/[JN<NZC"S;*JF[06F /[I^F8J,8;N];G_G-'#&E#[)F"+V.I$!@G
M"HM3:AY_3"5%X"S ,_1?9+JHD@BG26//]F$?G@:>Y-ITWH:P/;=FB]@+80@\
MV84MSH-?=)OCW)3H6@>#VA?PU,L#>.H GO*51^ 94X-<#4&#L%6WH3&U4\/<
MRL#1FDKP[*/L!L4QN#N.E^%P&<)GHZ^-7>P4>',:>*KU=I;763CU2KH(D\G!
MP;"NB"% Y20]B? UE&121Q?3*5CF2+#*Z&[\;!]$(O",JR,2T9L*XZSA2 :/
M!V.R75T3V3DL/'@P7=&B$*1%DH-?.:FK#NZ JL6^3+YMJ<MNA2/PA.A*GCH$
MV=BRRO'9$^VA_^N1S]T*2>!)T]N?/ESMC5Q\"7YSMZL>>!;DYXO;O5GT)^,G
M>]%^Z/0T\!S'WW)5[ ]H'W$Q^['7 T\IT+)''[TZ\0_)<B\BF5\C#&=/X/G_
M_HC5\\&WO/AX>WWYYHHZ [R]>/?3ZXO+VY\^7K_[,;JY^OCS]>753> "?C8^
M#15G@RG;8$K20E=4B(*]Z29_=XJN85?,.8&;5B5SM3&Y--%!4 H8D\\Y)O(\
MN,V"M4?C[]5 I<3OUK%;$)O&7G'G&<J,9DIP5H, 9<84X<4-2[N+=MH4QK,D
M56,#_J(@7H,?&;XL"M.942'#E,^1I1\%.EK?!;G"B68+4Y+$:(B<DK72S(["
M/$ZI3RKUMZ*&L@479/R24M8_#W[G3$;1AR_ <L=FJHBG+E/WJJ@6#)20F:8/
MB/:QGNNK#9^A+PH?&$ WWNXRC,!M8LZ#)37<9;"FTZZF8%U:)#4W/H?EN:C;
M/(4-\W/P"Y..>CO*SHDBZ,('395IB=PL/>]1/EHGKGVN?+\8@,&H*P1B0O&6
M\VV1Y;+([6U_?/O!D/IP?-UI$/PF>0A^LK/^9"M$."@AV^N0>9/83,MN/E$U
M<PIE"M1)JT!O@0Y.N>4A\:HN8! *YH9P)%.XLD8\*'(_XB7,+_0Z2;G3(C'5
M4DU&Y:TP;*R25"*%$)%C%K^V5 F?4O=5T<U]-8;G%5XG.?+75:W2I&G'?<7,
MY1Q,P(1LGJP//2:D.8P5QQLEM+1ZN5L&QAC\[%=Q5;C&K&_+_C:9O^TD (Z8
M2Y>I]K96";''1!\-^^&V6(,=V.?K,LJG)X>4\B&E;$?CP]OQ<R$<@TDWV]KH
M)H>L24P#5T/)U5^$C]RABE<C8[I@64I]SP2F$0D'OI_0G"+OL:$ $.ZX!64!
M2U5@4UN0J!7.5*U4Z7S5]JTYC<?1]=1<#0:EV*IT=))=JA^MP?LZ!YTF95GA
MB!*ZB'8963KEBL6D;S%EYF;]!K'_ $,N#%9MUS0VZ[V*'%\I\:-J!S!O5<\U
MNOH\RR=Y"S[(<R^M0639UH3$=S-3LS=)CJ-IWS(87&I=5JELB0C.Q2?ERDXU
M=44FP0DECU5[GC"WQI"5":?/CX*.P/T5WO&#?L< 8FZC<>0-2>IFE%96;NN5
M.'J_$/\_*>P?M?4K?[#T<'8M45_"ER;%4N CQ\AH["%(5@PO\8C=&I^JU-S-
MA5.+0WS)2?KI#FP_1*Q,A?L>.>P15^N]'KA"%5F/M-&]SXQR0-H[M$B-3K-V
MWV!!,++@\-C-+28*7F(Z]KT\5D[SZE[U!J7[(O2U% ]6,UMC  8?=X3W$4;H
MTIE90D"K(HMM# =>'VX 'D^R5&"TJ\^I6AB3%VUF>K\-4P&S.*_8G:^I/8)M
M-)XLX.#C)N096'\S*EI"YSXO;8@H3;I&]:8!_L)37",2' 9NW@'&-)T2\S]:
MU7F9SY$<&X[/$E'B.&YOE.QET3VUM&R*@YCF[!E82?*&N";(\.\2>3_,5$EP
M\04V F 23CG94N:VT#J^/QHX,68Y5G)B^_8X M-O9@XGEFHY282NU;PV;0J4
MHP06(V_I;\ZQ%+K:/QN?!1KR,\4I<?0#RLD/H">BZU9)L/-"^E* .@L!&!'Z
M.F/@^()B*[KDQ_K!^EA>;_.29[]/8>+3\;.=%NWVC\2FZNJ4HUG]DEQG7JO#
MO#[F9%K[<Z82JN,1FU'/MY0 9LX$AVU6RL"/5P<>@HTI)-9H9M@)U<Y57MY7
M><J]6TQB 6X]0V.1XW@$'@:1-[D*ZT[2J8LE3]&BZ%"I;S(!?A_!^9T55+BE
MU-H,!8^(V=7%B?/UELGD_ARX6.C9#H8'933V,R)Z16-3,N_R$@RLCZ=$UF]D
M_9#5_:"Q!N$WCY-W&-C3\@Z[)93HR@*-:<OP+84!CWIV2/H "TY;418>]EE+
MV6CO3*,%3UP[N< $&B&&$[P%6]M\5^.W)I^(@:$HW"\N,+HO99<P0#=?X3\3
M;13TKQJ;'Z=.5-JK0:ITO%;6B[K&M35SG;$'-%/3E2S")Z46)@4"XT*9I@ B
MYDP[8C)9.='W,#5JLLLI]L$K5$:^$DZRV=&-IL/(9/-BQ@0F>5H51?40I:JF
M3,H]#D(\? ZYZFX+MLL=6IPXN>#&9E4M]>\@>H<\2_!YEM/H^)!F.:199#3.
M<:\CYUUMHF]&(U(G21NX(KUB<Q2T'1HOR\#W<50J05P241A.(U.P(+$NI6S!
MY&3-XZ4L>B@.L%F17: @]JF5R-]4*<OR(]%O30S QF5.6SGILIQ3&+ZNL['&
M81Y"M[@.5&Y"-N]J'"/XXR(=>;-*=CR>AK!I%1OT&AY0HGDHJ W7.G1SZOMB
MN>W4[96HI4E8OGKU(3JZ+M.*(5EG)Z<G(UR&LN(%<.8:_EJ -;49:(9Q5=@=
M(/&</EC+!TN>EX,3Z7'5.'O8C291TD<U9#NL@::59'Z2&Z'_)K;H!1NGKW1+
M1AP&)1II1M:NE[$':VH2!Q_]2A.@WQ$A=!2?9SXTS5OIO!29.:A)\HJ2&^0,
M4W:CIBW?*I/.H!N-*42G[]0X.*^!]X.5F!J++#;Z#;VN^2(I10]>@E7&*DH=
M-2.\XP6U\,U%I;J&J\,)Q[D@$U<7D!L:M=3\N(>*<F]BM*E/N]9S'JL)V8IR
M9L ,(9&=HMZ?CZZK&;>3M4\[<$TP,HQMD:CO&I$LP3L,=8JR@[$O:1L12[($
MYZ^N/L'0]-0Z;N?U'->0"6@^DD^@G=.IO>70X'/^8M;?T>--7](#P!21>[;
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M6NTJS@D^TV$)_'0P.'M%UZ/! (M'4.N3T^HLL9LXPB<LZIR*2J5WIVT,S&N
M[IUYKZHK,C96B8+"+/0>@(.>1Q>AYKE_P,,]>M<A?Y(N)+BR=6MH=.T4%,AX
M"RJY)#ND;YUYI++]+O03RE>"]9K#81@5L!E*>M$((XBVW1K?N#1ST"SAX)QC
M!AVW$']#AVY!8LO6@3T4J")RD-TT61@.,CR*3?T'"#H. ^/<6%5H2CCYQ.(:
M$]KYN)L0"53;-S6!,T,JQT>]<(GK4GEG$LQ6[=^CAZXTJ"/M]CB5BJLD"\98
MY[M.N)V,!,"=+PL_6M^9TQR]CD<A+SWT!IHBD9X5>C@+-'.@.WOXL#EDMC9G
MMH8"T@Q1N*=F+-&B:L787G.:&TY-USMSV2L<RZ0?;-:-%"U%(A9R>:U)X;BM
M^%^I\^+(!I?22?F\;NP(+[)FD*:]JWD;:G9KACK\M;%71$_-;DVP@TO:1E)?
M)2VW$BGG1C1?7E($8C78T\L4.DJ\*G5)%_=19Z!9E6>:AR6KNDDK?1.=^]L>
MP?-<MXT$K=Q@1&!U&#H:<\R%$$A)D-RYS.U'7$UH"M[-2VME3GMOY':1,+1C
ME*+#K P/PTP,)A*IX=9=;S;Z==@2:<3HWZ,L-API,'*W6@9G(G-;QB_EC@;;
M9?8!+G\C_<U4QOP<^E,2^+(JG3B[-)-'"X[S7\8,M"0;2">;MA9".2PYI7V]
M(QT+L@&2_CGF3RV8K1X5J>PNR;ZMV2E.3"2)F@0=D$=V"=GDMA/S".0G[,JP
M5TK TS@)."4AA./'T8U%*ZY6[,(7=$?J\_'I">T]^.$LUIZ"*8:2%K?>RJ-0
MK+RURRCC--)^9(^XG#*ESU>U+:6, X5X!.!,#^SM<MB*9N<1W88=>[]0;#74
M[R25'5^3<<MV!SO;P;:;R%OJ:\O[F5HV()?)VEGEG->73FOP)L.DGW: .>,3
M-JJKJCWF8S71A"\@ \@I O:[QD]8%]>F_=#.6']PDWZ9(JU'S&:&T'"SUMSB
M&'=UVD1DH$T^:;(XQS%7]^#@6 */M0$,4HL]X1L=@)M[$&E]<8BT'B*M=C2^
M[:G=$2>%FE92=,4^O$F7$ZRB-/8W-HLOEU(\M:H'^P=3#S#C<%L*W:16<HET
M>;M+J$.;T:)NN&$K/?IE!K#*Z2F>A;O!NZIJE[F.)F'U7/2)+GOG]@U^QR-0
MTF@DHL]<@4HYH59_JF2@YEA8/^K@CUKB,P[8C-8B;0TG=%,#L*4- C)A/[(O
M/ ZQF/9/-Y(G.VE@;31N3(688IE-#Q95\Y@!O*::>"/;FQ?3V63'T"X1RK[A
MU30!FT$B(0W7,4! GOBCSZ-!H&_BHDJ'H&[)*B82020E@CB;%>](GN%&MEVB
MI,&F;0[B23<DQ.^[3!*":>M,X_#-F:^1<$KH[H8>*077679U[8)@^*[Y"O!Z
M@X)]2"3TA$QY*Q1T\ET":HO*6]'<P\L;.&3N1D_9)4Y9 )IE)#G),*>KJG=:
MMGFT'*W9![T(@XODZA4TZ"KVC8T]&\G']G?I8[H4-ZHO4BM8L4>\2$[48#%B
MK#,ZL!QXNZ30T52/.FW$@5SZ&HP0-2.=#C!5R00V:+RB\!Q(.U5LZ_G<]&*V
M-M\J21P;Q8.-762C( [4]^7X*:8!I#P?(XR]3XY.720_([3R4K)Y-K&%6<(:
MX9ZBL!NK^'J$;WPP#(1:',WN'KDP9R[L?WLIT9!+?\GE>#Y;?2MY$S/E'L>S
M([+>X):CS:'ZH?@X+D2A/+Y\ N))%.KK3NK@S=F,</"/''+.>Y:VT$9<GJ1<
M^_:1+($?#D(4JGN1($0$O+[N2&3,NM57L<,^;()/,D;$#JBZ'3+3$,."94"^
MB^DO/U634;=%FW^QLK QYNZK'Y)B1P4%+PT*I<&%4=+6&X@@KB'-?'$T<4JL
MV'.$X=GR*JY ,S4&MC3-;N9\O;],F.X>I!-L*H;Z)*9+CA&W]?=9!0XQ:E7H
M FB-X<X+K'Z0N\)W28N_A4FXTT7U;&/C686A)6+EO)X.7YXF)4>IX5)Y97F"
M/YQ#N#+X<.7+0[CR$*[L T-%=3C[FC+^&$?,U *Y4DHB6\>#B1+@TQY8D6MI
M.>T<IBLC*FJ7_LP(\?4"62B2B31#31H]A3W^C]"3WFRHA.!#,[K.9-KZ7<E
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MC5!G\F<8#O 8A2G=;HF+#YKK2SIHNDOPR.FXL@1R??AFR?W(Q00D'9C&-=R
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M]?!:NHVMH;MJL&9':'8M->YXD"^"6^<1D\-B4>4X%I0;.L1X@/6>V#@]LSH
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MQNV*'0.08U]FZH6)D$CK+>$(1P?ZS@CQ#2W0H#7+F;&717; T)SER#H?BUV
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MJ=?U:"$OX9YME:4M6M4HZ32OX8#"X!<UP\ NA+'_"D1+[+;C'80 ."=,8MT
M>N6&Z_FH,QBV$2M+;!Q(1D@^,CEI_&_.>=TJ10]*20H]\3L8\;NLGOC:X)"\
MA3[1.9IN_92&Z@5AY;I&0T6Q$I)GC\!^/"#)X'!7RUGB9&7 Y. L2:9[,R8Z
MM4,)FV1-K!RA?MI)3B*$\DKYN*;4LS7W6%#AX@F]\!@,TIVV7G6H9G!MF2Z
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M5>9V ^7X=UV>47]+G2YW6#ZL<Z<14YMI6,=NP$QOZJ-'&M"!@]J@=S"T23E
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M4%E$TK@6>>CG,1IK@6IH+3<?V0XZA+HWA[J]9! "H]91P6A@2J(/"$V6 7N
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MDB:'#M%;Z+;H<BD7O/=:^ U1D'+<4FD FCX!?KZ^OJ:@+#8M?K %F9A98U7
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MT];)QUTGZLX/B;I#HLZ.!@Z=U6/HD0Q==(3GU!XJ*OL&KJK2ZF*7*@N->J)
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MM[DPM]9_GC6(!S:74I-]\(G.8 WEI+7+Q4B-2-3QBL/@!>2_=05I)WS!$CX
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M1[:2>DZT%T--/:?.02:^ W63S,O42SX[>"KFS=>AL3R0G;)VJS30M;K.)P2
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MPN/1^=&;P]';X=D@N/AU&+P^/1O^<CHZ^248_H[HA><N8N'Y\ (ON/@U&)W
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MMB-LT0;@'&/[Q*5A!O)C!V$K'6$C%-8(6=&$L'JB=OAX!=/\JJE=-!*R%NH
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M/@5.]=U]I Z(I<'R4.[=$;)$5_&T+7M+<KG[_+D! DD191!@89#,?OJ[IAP
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M?C%\/;H<W8S>77IOL-_0)D8Y)LE7Y:QB/3^-[A3O:17E\%T%NK7&_5Y/87?
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M>V=$Y<7@Z2ZLO^?(A?,L2F<[L^;/!B=@2^W"LGN> S\O9O-,N4F@&P5FVHV
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MKMD'$ Q'I5Y]O&6&K.QCFM75%)D.KB]/@A[>LEV0&<_3+*\O/+/C.@6CFJ*
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MQ&OD@8!L6AM[=+07[X1+YWDNV<'M^K#ZN-MW9+Y0./WKB-!6K92LEGP[_6T
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MH/W.'2V[;T+%:@Q%JXSCMW:V5U@NCE]/=IA6'#W8H:];&9=#K^;R.%-N 8_
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MD8EI5?CMK9C]Y<G?_[IH_F-=S!^7L%B#D_@/35AL9R%8V^FR8@+D/JR-'!6
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M792Y6E2B'H*)4CJW(YU\L&W1?J )SY:RHJMFC7D7>K6 _T9*[*N1<J4I-"@
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MM-#&_:P ,U5 -%6?E]"R (C^66?7!6LCCNGJ\YJZ8G!,TWA9B-_)8Z&B$&P
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M244%II:GE&P"Y-P#*V(1FL[U] O8EWA&FYH,U &)@+#!F82180/+T$E^6X)
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M3":KIT-UU'%3K0U__% PVK& 'QYQN/1@J?/^'T0IUHMNBBLNN'R6B; 05M?
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M)&*?@P!H#:!CQ_VJ4NHHHX.)<W+_^GBL>I30TZWI(.P;5%BJ7*0V]GO VGZ
M([V,YJJ!Y:C"8)3'*P.G?_0(S^I:9O(MV+:1RK#]QF*&48.W%[X,\@9VVWP*
MQA2/=)TK\&_&G-?'K;<?J#[^=@/5)X^!:B\"U4,\SWZ;C;8]Q?N1.[/&Q1QC
M:?PV;\ 7SSP?-Y]P-C'J_0EW5@O_["X,=LB\IV!L7J1@HM5$1GP"P_Y1Y7!
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MZVU]X 5YOEJKMEG55,LG+L8_"=BLD_MG7XVRSM*H]IA/SF5]PB_/FO999;^
M[!Y.[F6FLR'+4Z1YG-J1.@;9Q1=>$@L'A)T=.,T&P@(R(0JC<T"K$PL*VID@
MZ8  /CQ@/934PSD'R_8\05*\C6&L7JO!KD8MMO>B6_#H9$'YY;78$$K,X7!B
M8?6P[2=".P@7J!W@F?67L<&@21B'"&S%5[AK@HED(>N$%(7<IF2V*9\UV.A.
M!"YZXZ^%'T=3U.9'_>.3\[]AEP)\#SWN@AKSLAM6TOU4+D,MMF4/O0A2F4,
MJA:K0RA@#59'&HM 66(IW$0B=#59H&>JCO XXD%@NE@^;7-YGLFRK;8T IVW
MR&\^@>"X9T<'AV<O4*'AL:(Z'^=:"U*JN7I6O*+77ZRAU1IM<P$;1KW)"EC2
MX#V,FT-'1_7..W60CNM2K^M J@CK'!^R/Q"$@?-]TLBY>&0:D=X'%6X1,<<+
M$8=AL?FX.+L3%.<>)M([%.FT<H'ACJ[T5BV!WEV9(NBR" :@3#8$9S5$JN@
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M_@ (+]Y*H<V!)R?/1XCQ0Q0(;[3H;(,'22>)UAR/$I+(PRT0:7#08A@():K
M;V!ON?<%"S;/@H7O"*6RHT)\JDW"A':%)4- IT!-AJDQ^?#$85X:9X'H0/JB
M&&HH]>=^<?3ED3Q_=OSZ-/?W'3964_1-,\*QXMQ5)KK2*T<PYE0F*M4F6E\X
M$S44(3BN.=',0U[,S#]X0]F!K:5!V1))##HV)VSVM 5>R38,I!Y;*K;PKA5D
M\_FSHY>GE*C\@%XLTKFI2@./A%LXHT%A$T;G ONU5X7#&7WAIK%A[!=NDO<S
M%B.<ZL*98%!1'N13:ZU:YF;#](#S5DJC*<];EH50F+:\OW(>[LEMB3E6HD8A
MK"R:%?,:I)=)4GB/M8JE&-6:HGBJAO9ET9N5V5%$4],6<;+HV)+[PNE(8B+P
M;AJ02YJ?$$2)XLK N%Y" 9.[+"WMDR!%'ADYE-XN1,X2A@IFB)*4@B"/9AH:
MD/=>/UU[^J*J]O2ZM#.6'7ZJED%]^/0^Q/@V]X\?C?DUX?B_[-T*)D:[:OX*
MP8O%4L8WQ^?*W"V%P)"C!U:F>R9=%<WF!^C@O0"'H;$,6='B3K$)M#[X".U#
M9?]/SNNV[2JU797_8$!W+/8[[[H7@X^]-KN^>-=F;Z_>O[^ZZ9>N6MQ&EK\J
MLKQ.:38TVYTNN^D,NNU^G]W\WNZUK]YNTA*6CT=C/CQM37DE-R&_F,=-S6TZ
MV05QV9WRP.\$#Y":X5,O!69>R"*W)ZKWV6!Y3YU_RC;W# W%=F@#,^.37R!P
M=LTW#X\>LNA7U/K>:G#O?UOR0"1;A8C?9YRK%>S-S-R6]N>7?[[%\!ZMG+I
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M_C[K@4C%#)R='Y_T.\ P;?NBTK'M;M %7X-O)Z!J.2X(!$PD590GD-EV[]0
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MZ &>)1_*5-H9E=7[IJ6UY(#F,.27P9KH2G?FBL1=Z5!>Z!P8-JX-"$.E(V>
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M__S'-+SUPNG_^4L8C%]/=L71P7AO\OIP^G9O/-U[#?\8B[?OW@1'[\3_?W
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MI%4W;E"&<@4(Y6+[.:YL6SWM+".W<$C#/\>R/AV?'%%Y0S*&TULV@C?-WW'
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M.QSE4X]AH\" 4M"FD@=Y\Z2VZM7QK9 $*86_3\C&MHCAW=@&8S6^J1I?!2#
M$ 7TDL*<$ O2D^ ?UC!'"8DL ]U:<W.[I'0@*,YM\0UO7D91]!8$6 O0"I#C
M4U@KHZ=!LZ:"3FZ4UY@03X1;LK^9556Z!5\A09XF"TOWU_>NA+20EP7J'?&]
M*.L2<25F,_+0V8F;2AP8[1:##6-@=@D3)!U3B1EH]XKC>Z7(X+,L\TZ"C98.
MK&$GL_V+_YH&*HR6WR#*U1L&>0&6">*_O"%""J6BIW_8^)Q3@; :;/8)XX3=
M@O4&A%2$M_@C2;]26,0< '8T K91%-SA1Q( =BL,3F@2)1D%+V KT;_=!VXY
M('S'P0(Q"MXP3R9?'9(^@@& G"%>*[]GF2-<%"C(C'(9"+7FS!O\D^K?,D)*
M2SP6"'"0I@'EP!)J1X?N&F7,PX5"+JHD.0K8;1 A^R.*(L4PY;U1+>_<)'=(
M]00J%F&O"!_KP/S C"D0&2EX<!_5<,=%+DUOS->KI#IM'#'.K6@G1@\UR!X>
MFK!T3PB(2]ZBF@GK-P8W@3 U>&)!GFII+4N)ODI0N3T17-^4&;IV><Z %A>V
MY6.S=OMMULY],8LH[],#<Q1;>(Z=L=0?*VR'.Y-6V+9#V-ZWPM8*V\\2MN-6
MV'Z\L&T)E)-&O[]\K[18SA;+R4.0@8,9.&T<B'%!47"P\HAJ9W9WO45WWO5V
M=(CD&'NZ8)K2->70GD1U2I"Q MBT'ETK;4\N;?,PRQPQ=DQ2\'-WV%7-J!1:
MHB^#7)X9="M>[HL7:(/^OPN+\'Z3$B:AOB6,:SD*6L:I<I VS+QK$6,2(I(!
M9H3U@GK#4.EMD@O%2B B X8MI;/M6R:IMS/N8)V%_2D\ R._09FR2MW?1K5:
M06G]X,Q^,GYPK=NYCI/I/0>R$43K2X!N:H+9&;_D71A%&H1<0?(BCK09R-ON
MP*W8@6YE:R0*FD:6J5U7HH0 <44&B$)X?]OM[N[N(:<#IW%\A4I6V>TRJ-G'
M^L7_EAE(VQIYTTJJ\Y*Z:2Z\QUBZA)(/TRQ'60VNTV!QTR2-:+A8$LFD$ F7
MUS*CG:RCW=OS-?:.DW](<@*:%GE@\!2A9":QZ&2M*&^%*'N7"#5P0: 5DNDN
M10B=XDJI*EV4+5FN%&MJM\O9+)P(*7\M8FA;!;)<(.&"3#XFG(#1A%;&MD;&
M3API['Q\Q,JYY$DK9LO%[%)SRFVCL.VUX=%M$C8JKW%!SJ0MEZE8%F9U?.]O
M>T@#ZSM&4H5$0L3QME&W3EJY>BD'&#D(3"0+9[#=B5NS$P=;:EVT"G\;Q$P1
MHI-G*[U?%Z3-!$X3&I/RWA7/)T;PJ63"KDE&!]YPO%/#! U:0/%4U1HKN"&"
MZ3R,PRQGLE-^A!P!_"!*),5P[NV$'3O2-2%$508?ATP+!?\(.[YW<'#@#;O>
MAQ0_Z]V*N(#3ZRB_\4ZC)$E];UB$,-2CGN]]ZATS$VA_?_?UX:M=_.P\R;Q>
M?"VHEOJXY[W;W7VSYWL]C&K@1N,?Z%6$FQ1Q*#G4,8683=+D#G9E>@LO +>@
MT=5&K<9:K6@AW]G+]*_I])"3P1,61%E"2U5:J908E"?WU353LV?7:S$Q($YH
M3187DETVH[GQ+MX=[.Z^VGT#I_[KW5UOF!0XBTF!?1Z&>2I$#M>%<2P"S-W@
MCRZ\HZ/#O2.B1Z!7E&_ 5+#3*9(PJF)?-48D[M!5# U,K^-[S%OA:\J0D"*%
M5;0K.KRDN&LTJWU5,HU@4_F""GV:1A])NF3 3)=3^\&/&GNKMEU7VXKKPRU-
M+?<0,>%,U!"I/F=DN!X2ZL"-\J]W2E7OX+TL0HG,]U2)CQ9YKB-BHN@\:>75
M;7D]">">MDOR.^8ZG1%>KJ9CFG ^L0YWJ7),U5 JSHF3X!Z[?J1$>P*778[Q
M<&3PVA4,) &3(8%'8?.A4(!0[^S]_:^';WX[W-TH 75^L\FI[AAV^&1:L/5%
M6)(&+Q43Y'BV61/.QM28KV=!^OU+[XJ6K'JMHWI@N^E^#UJ,>(L17T_#?Q)!
M!MX48:C<4O%,6:%#%2?8-3GU>MQG:H<Y@#MM.+%1KQWN.JI76_NJM/L,?%X*
M]B:E1O.P_D#3BF,.U'F&W&>*?C@OFIMK%816U@1+Y66G/=9VW/=&NEG8<H*A
M,1C/,B9639.KF)9]4=6@;S+?'M>>;(-SQ1#EQ[V<;$V8K9HX:@I;S,<\RTS-
MP>WF#%+5K(E:A6DXFX%KBSQVJ@7PBJ&I^,W2(9B3I+J&RVWI5N^NJ7=Q"ITQ
M=+[;EP6S7=PB'4J3YB7W34&2O5LPUN="#@JCX2"-8%]CJ'-"F<9IF"VBX+[4
MY_A&\'/ELKV/D@0WQ35-GZY7B#WS!=KLZO+3\W]=P+]?[_XFJ+@"_KG_F]?[
MYT#]<D=V>C5,-5:T2-4>T!U5Y<$M+!X2R'1JF0%Z5WAO&4+%>H/)C9@66 61
M+ 07'<AI!(T:1I5K=,&DND@[P.&<6AS*CS-!53V-FF7'&O;J^8;W*6+]-KZL
M94B_BEQ"RI&P)Q9R[0P(TFB?IN<KZFO,@F &Y1I[%"X9QUSD-R@EH%U, VS8
M&*F8)-?<[QK[$,',8;H%_GTKLIS4DVJ2/0O3N8>D<?A 2?4)[R7)O"O4H)+!
ML]W_C0G:L;#6CD*K28'-DZZ16@]IRM#]?04?8B&,DL_4HOW7'Q8Y=O@S??"H
MJU%->-7?=,?647#\P!*SH(B<P,,:GG-QBZI 5IYQK)\ZW,I<%19C!5F&B@9%
MD> _R&('TNI[=TD13;EY9>SUZ49('\FOV4KC5DBC[;A^HJ/$&?FTVI7[WM7-
M?19.L')2C[?K71J.1VE,4><YMA_0FF=9UOENFP^5N/&P3L$TH1Z(J9@ON-U$
MG<U:%\^\EGSJV')>>G(4=A53^PXG 9=2DLG/E9@\FE,Q3@NT1/9\ZE-?;K2*
M:619>LP<[4M6"8]E62%A=?O02<!*?)_!!!AJLV@QK1]TM!>CL]*Z?D-J H8:
MW;,Q$L-R+Q\:%XC66,6[WA -G0=^R]"&Q2(BREH9<Y#OD:D6Y%DM;6DH/)??
MFUCNA<FX:ZN[ B?WDLD$3VA[U2B$J8U,VUCC1K+*DI_*3 J/ARP[.8%$<BA+
M6EKEN!7*$5::@WD.L:X0UR@/"N5,$=_"YJ92/I!#7QN>43B7]/FL$2SU1!!C
M_O04"7%E;])C5CT#H3M'RPL-DH9[4#,!:8<M!_1M5 L_)!?%O]'-6Q3Q)"_(
M'5D$(='E$O.T[KP*SD:[%5S?"JI+B#-[H Y:H9!+K0V*9#MH!,GN=W>/=B8=
MA4"S>J%4[TTZ7$)A.. 06-$-"YA+S.JFI0;NDS$XX:J?59GR5M@]5\I5NDUE
MO82UH9/(=\+W=DHH> T("4GDR%S27,;IM6K&<36CN!"Q*V":@ WO!HE+RXGX
M4Z?]L,6[M'B7AT2\3YU',)^RK<6_!Z E?$I@+CCX1K!=:IA:U2>E-M?XR9$3
M%H![:V"@1DR54O'$=>ZWEH'!(+I0=1&65:8:';!14?V6LSR^#LW?87>15,R(
M&ZN:UN/T3P8_)GXK_G-BV!>KK<M;@^%A :S$FUT0P<>H@=?=W3W'#(56QJHR
M]NW5"8$W0 6W:LZH.15?(AV'8T2?-A43$4K)Q^ Z1LX5^"7FV(_%=XZ/^G<A
M,M9^.M=OVO#YF($W [&NR404,:"G,9%NOX],Q>\H#JTDG1-=8@'>>AA%68GK
MD((!5OIV?+_LANV^=7W?RA7K39PX%RP4M*&9M0>)0KGW[N"0[8 Y8C6FOLE3
M8#M?^HMW(?>'6L!^**)KRCOE;>_);1/-OB11=4$^'^F^[!VT4N:VE)W*@ZY'
M'(Z4 T7U,4KAGC.7: )S@R5[8,SJ=T&>!YB'14W9HW_3I0<JK*YN0TDQ?3&7
MJN)O^M]NPC&X8;U6AK=#AE>G)QF]X;1 K_,"#TCW?BO=SU2Z<2&=EEX<8$TZ
M6X';9H&3<#>#>G)= &L#?D!=[K7J\KE);RI$=$^X.XP&N22PLD4 PQ(QKB^B
M\#I4S9&S()(E8M*.M:L",![&M3ZF5,>*$&!@P$:-# J$GQX>>COJ'F-!?IKA
ME#*(+T*'<=$(!Z[B6%;!X8B:;NM:WKK=!-5-4#,D7=@'5N6+F#-;.T42"$2;
M,E\;"C:Q8!DPK=DO20K[A8N69,-RI@1046P#L&5<;EMY_'#E<:!.T05AX'2)
M7ZH^OTZ38J$^1G4B0^0J]@-SKR,^!SM3S2-C1RW]*II<DTIA,2#W).*L@OSW
MEYL$5_GR#L/KPV*<A=,P2&U(MI@OHN1>()@N%C,XF1=1$-OY#,H.$ 3UD8_P
MO5E(850-X_9&EYK;2G[DRQ1!"MIYD:2YI9=+X=IIF&&=(>=Y@UP"_'3+)9I<
MV 69 @!R57%ML'(M^%TG(6SK!,:=ZO)]RD?,*!D!R\-Z^F#ZZF#)L/S*/.%M
M]M[\EGFEUECX:JG(D,0+AC]/4L$+>+3['^KWMPE]MTCN:IT;FN_)A>:.:W#%
M8X0%N<5\'J@65CN]#@D!+ EWYPK_1R;EX9,(VZ# XLBK4U6<T91AV[&V U^6
M(9"TB&@V*7^%T-$QYL0R=3L# J#\4R!_@0\P-0VEQZBR*UD8D9-TY D59JE<
M%4&K?8\:'OEN$:L\5ZJFHQ:ZYCATC;=GI@UL=7XM)-Z43H,L$WG&^FSG/2L&
MANNHK>63 DFB<*IUPERDUS5-6;*QEVWED$VG\DXFWA#?&JA.4R\=*A::'<O1
M!GB.10*#B_IWVOL(8ZI'I[^#B7J! (EF9<,]ZROF?8<A$D7%.,OA;:@>CS^<
M:77*LT%^.(YIV7E=/H_SX"L"YJG6#$YM01T(K8Z)EC:5/8*:SJ''V #E8\H-
M=:AJ87SO!H[;V\TF9WQ9SU.2CZG()FDX9B-$D1:_)^8&(]8WLFY0"@R=FZ(J
M"$L,DG .?D,(\D.E0;*LDMGR;3&]BWVYVM&]O=Y8'EHS8RJ#*#_02"Z<S(4L
MPL^*]!8.9OC#ZHI)1,)R[PBA:85!'U#5-/,GV^-G!Z<V^#"N;" "LH S1SL:
M&2MQM^VH,T'7M- >Z&C:83(/LYMPL>:<L6^&I5C(KMV4B2A7I8297N!QAW:+
M6YO%=<]KPA8FF5W6CBCIP@7N>,&5RA&7K) ,@-Z6Y!O"BT(05'.^@+M!![_5
M<U7O**G]'9^8::?)7%:G4ZD])_DVT;W"T%*<H.--\#S+4$K'.#T949FGWK^+
M1)*:RX !DI/@H*D3/3^GKP]N^K(W/.G]4Q6+#:E4V?O$.#%)EER^1'ZWHW@Z
M:/[#5)6(X6XUG1,[KGA"WWD*;?;P<4O9N'H>JR-)V6B-YW/0(>]2*W,O&*/6
M,0<"FFUYF!=Y\\' \,N<[,C<>V=B \0 .)7= 13HD_8B[TW]R?C>JZM O?NI
M^H'KE9DF;Q'<XP RTH&SE%\.AB,1K6A"EJ^;(YRUS!Z%>I+<GDQ:&HQ.)28)
M''@L(UI4XEDW,"KS*KD.LS)U7$E7Z>IGAS42WD/Y&5E2'^G=C8A5X+440?B>
M.>/&L:4HQH._,=%@&2V3WA#E4,@?HEN4!.^GBH^WL[*K;KFK7]#I=#'OJ/BS
MM/13)"]49[A*<M8WG@[^Q?>E:2-9,[LV>]B>0Y8>6R'0)!B-4!^7,FBK(?W&
M)X%%@L8GAR+7N6W7.YO5WDI2;91\B9*5$&9KQ+D&0A$VJMI1M7ME+%ON6J'M
M_R!FTX-[&?A6D@$N741"K1,'!IG=Y1,XK*_0N6SD3+B2M#,$7>=X^"1@*KJ@
MOI <Q+/JQIMN29[YZJ<BW8*R&EDLDY)O8+V77*+IBB7R*VPF0E=YJ0[HU=W<
MH:(GGOQ,[0_-L1.S3V$]2+6=!B443/F\L']MM5SAE7GJG.13."!MEK(BI$H>
MW 'K/0KQ?-1V:]U2P;-PEJ[4;SU>\ISKY+<E61D:_>LV*^-X5L9YS;'-I]:X
MLQ.ZIC[:@^M1XN=,,^AG<'*Y)7H8V<%J8Q?X/*[AS',!!^X$N<D\"*/-QL)=
MF@WD+YTY0<9EX(N;G ^,$;HP&U6B0O2P38O9L?!H3],WDM:WGNVU: 8M%CUY
MEYUO'7./"DNB:OG +6^10;C*;XC);HK/8K G+62P5[,X6/>JW,KW-)4I)A$H
M'IXF<3CQ<%\V43/#WV*!$;H%!7XGC)A9I,E$3 L*_^:U\=="=!9]),7,=^X[
M'BL"'9B2LPB#8NX- AC01;X'=\ZY+X1 KE,?GXEO974.#G/,_HJ J855V!O.
M^FOJ>=TP)LUZ3:.BN"+! O *OVDF]/G[IKM[T%6U,UFB8;^XG"N0VXH\L29+
M\O<\(?7]J)F-;>RJS=ZA$*NVS+4T1P\K&TLJ7= YC[$!B6)UW)J CDL8*[6-
M9KFK.H-UD:*V]@V,,0OA\=@'!:SFS-O!Y(?) ^85<]J"U7,B6CX&]*BATI98
M0\H_8;>;&#%9I8H51'N!(B3V(]+7829KMU#?-6KR5N3=%GE] KF@4E4=89A)
M2XFI+S*[+DI\PPYBE*!G8 93!#%L$78,M3G@,EA,Y($T&U@I8@>39;]H)=5U
M266B?>^*<0O.I#%8:LD8_13<>WL$+KA(;@4U6]Q#\Y6^O =SUP<#$I:3Z\IB
MZRIL@ *6:BN#3LO@.2+ !E0/AWAZ+!]V)B;97(:ES06NH+@GA 3C2P)/%>YQ
M'31U\9L765[NW=91 "["/1AN@H8?F]:,LFU@G#1=1E8#SR%W)U -_.0KC,.I
M1$]]Y5]D2MD;;#N60: +&#)JEIS AENI/]4M[<_,[3N>PJ+0.P9F?(S\FI.O
M+,I8+0,U4>U /G>'7=UWD"LGKR7TRM2O& K%I3B?'=4&M;QT'9PXHJZ<$G[H
M4;]#G*/$N\T2J[D>PFT>/>X2H2].F6^S5;0;]('J<(*UXT E[!"%DW>&DJDU
MEY57 LZ0]!7\X]4$6^$(3?79M% EV1[?>Y>C8XFAS+P/5*I[%D^ZL@Y*>AA)
M>@VN+1>"?I_@@='%K]K*R6/EI*+/YN'T%75541^0'#4HS,=)4J.H4'Q2=?#5
M^.?\!JM_OKN[:K:L)5JMVVIK"[EM"ZT$8[JPCTQDHP*YMAI]/@@BWK&(![AN
M #>:18W,56[77"['(%$5L>&F!@SL3B14-RHR$_RGO6@0H3Y!6.NM<G&7N(7]
ME/#:3:ZR7>&Q"FKM6M!UFQ!C;UK$6(L8^U/G@"P%<.$X>'QCFA:SX[[LD:=S
M$F9IP<T\J1>*"^(FVS/J*(%5 J6L!VH@+/N78A^&8I'$5HM?+E3R9D$8%:E0
MYC+8]W/,VC_2:;>]PN7E1:8B+IC.L>=Q.5J 5@S8]Z7/9+=IS.^KQACJ*WA=
MQ>VC"(<D$UK,_=3%-WP>_J'K]O>(TFQWUUMTYUW?5 L>8^P*LU"^"D<M:T'<
MX/?@A^70$>B"V2LPLU+5(ENU^[B^1KL+O!_Y7M5WPM]DJAHJ*T![Q.H=#>&@
M%V+$2&;$Y ]WQN@J!1G74LTQ\$O%=Y2@0-\?K45!E]*-,AR97 .Y]*:'$KV5
MO;A6YXXPKD\ ]S.A"LF%KNC,$2%"\)!9D1,VQ'S()[GIIFW?K56*KBO%G$.]
M;B5(*#?"?=Y;"7)<@D!/@4*@X,WV&G![+>1_.X2-&,.<,=P>*V9O6C_!>1ES
M!3/H!FJ;&"9<F(YUMEJNV_LM@C2X3H/%C0KVI7!9'D0-G>+;_>C^?M00P6V1
MQ!*8M]7Y6R1C:= *62MD3R1D3K:0>:P1N]]6)VR1K W$5,P76]DR\W5;#+T-
MLG8YAA_><C#;G0A04YDG'?,9)16F5(4RHU8".HE"P4=**G@[8<=N$*30 V'8
M(7!I*<1NU#F%414YF\Y3G(IQ6F >1H8T&=EVN$N($JQ00*8P.S$A\PPV_)O;
M&NL*3[X%.#)I.:5A<Y@1F2%G"0@\4AFF)&N'-UKWA23IN>Y%H\C-FJBJ52MS
M+LAL4D>U%3*$AG9-; ^KB+"#QVN: 3VII0%;=SW1$-,?,,&'^_!9<_*HS"0M
M)M9$5T;#$XUWA\G^\V)EK\*32=:C7QQ_5$HFM%K;<:T]FPG*6GX2\R0%$2CF
M+JAM4S, LH7)S9A*W=5@YWJP'G=.Z(%"B+S](ZZ)X;(MN[3+I$,#KG0/)R2N
M6/"8W0B1E^_S6MVGFM34(\#-0O4)4O&1QFJ%W7EAA_/'"<=>8CV:#C_=!PS_
MN((O0PQ1\I_'-Z&8>?UO2JG+-[*_/(6]$E/=;L.7O0DA_E&"2]^.4L[?R3^Q
MBSBU6ZA^\4'$(D6H%MPE$Q%_")9Z*I 7PB?SRHP.#JBAB/&D_CV<6.\B&X>Y
MN5NVNX_2VQ9_Z3C^LK(5=NYN!)56P)[ PA?F<0GDH15X<4'5GO@M_8O0-W=)
M.E7_)9(4O%K,DE243?,\S"-=/%-^L"KG;\^LK3BS3/,?Y':GEGH;34]JU@DB
MP"\0N;;R+).5%=[$#)_+*8C@6M+?J%^-TB++A>S\*R\B=B/>$W#&R%FIN)U=
MKX^U1TQX;SU(T68S.X^D5\HEFD[5^E,4P(X[O>GN'G$S53TP4&RX9U-D0D^-
M65EFM*?'R[MTJ0&!&JTL^0AB;\6JEMQ>-9C#[N[;<I67J2$5ZKS%)IWJ[$<U
M8,[ZI'FZVJWO]-8GX"PLV;C(X+O,B?P[[^-W"G(;=.==;Z<.N6V/%<=EZW(1
MQK))@[3EG9&N![PBA&/+P2/O$,+6,>*FCX=(7(/^FR@'Y>XF\>;!/;5PBTV'
M9'AO"OK250V>5_5DHEI9(LI#1K;*0>5+?+P:%SX/@=$!%IS!%0G![ZW:/KS;
MOPLPD55O7&*XDS>=!SEV4?$R0<TI\ANN2PMC^WA3C]K<T<9W:?>YZ_M<EGML
M=P)PKY4SM^4L*7)%6>JF6Z):'(&ZHUBMI&SUO;6Z4[WM[AZR$T.Q95G,8W';
M<9T1"C7GKH(";@;&]X0;^U(!N#I+I&I57DX3N:<O3PNRLYP7_0VVQ@PZ<L+I
MC,P3BH%,,.48U6>:G2(FNZU\12E@^EE$!_+ZG2@W^/+CCI)E).Q5?7!SU8V*
MK!C9)(M:PV'%(&5/@WNR8CCC9S=Q8SMFGL18"BBAM+' 9GAHP7#EH:V\J?O6
ME(F!)?@6)Y0W767JF6P862,#ZD_:NZ;XE]6HVK+!B$2X^B"TB (,7W'Z1<C"
M.^NY%8*0G;#</I9O&$QR)A3.L"5P:3B/Z$"ZV4:Y2NC-"L/\('5R8_A@O[O[
M&B>4?P6S%86BT.OMRV(_ZK&,S!;X$TWZI?J\\V^K2[)*SU4YK9EWU-*J-*PB
MCI#A&?0N&IBP^;(9+% "XE:)!B'/"X@J)_2X=R055(+ 2IT+6_]&1+2WX78Y
M<\:H5A#<)P^WP 0+,L56K/14K;3IXM>(BCBDJ=?&.[-.2WTFELK$VZV8 Z'F
M -Z,J;:;@2$&8.'X"\W,"RGAK%$;5??.0L1%!$8&A3-Q"TA0C5G-O=V6$?QA
M>\96]MOF""'HMEM;XBW)3M);OVNSDXYG)UW8HD0J[L+F5'1@R%(7WH;3(@!_
M,8"S. 5C6W92#IA[ 79J% ;C, JI>ZZ)5099EDQ"?3&ZC#&\X$VXP#__FXCY
M;I73ISY@M@9S&[9NZ7X%Z <U .+=,$R+S,%XC>2.\5S#+#P0UWARSU\N$A@@
M]<0 8P_?*;-;##OO:+[PL\ON9^)0-@A91X(8!<Y*NDZ-LV'Q_8-7,5?MTM$:
M%W&"V+Y<Q5O^MN?O(I.+3FY*EY,]U1P\/OALCI;0(A)9*[A;)KA#D>>,R71!
M>A]?\=16H3@O:N@D8KQ*1CM<D+-ZM)@J4&03 #BM"4%_&R9%QM\(S-K%A%!&
M"94G=YK+A"UE^;#3RE2,*9)%P1#Y(W8E*2I2>:#VCYLIQBJ]YGU3*K,JQL/!
MZU) QPHO<5Q)LT[-Z$WF11X2#-OWH@2MFJG(\C2YE_TU\B02L:S1J;?84F_9
M- GB$;?F#"_F.Q=1,&FAVZ[OZX' 5FUN\5/5@0K4\R D$041G&(=>3@NE&TN
M(]U-S,*A3;''_98RQF8TMF8PO>$L1FY]D*4X8!P.EN6$M]R/;A)D-[Y-]*=O
MMD@3L.#R>[E;OZ/#@-K@##30Q70<F9?3 L[,6%IZ^&(/#\<WQ66S\)N\M^)!
MU/>QYFK](:,RRV5K0C5'#!I\>)(T7I>9F -N:<4CE#&\]PFR,,.(3D*X>YZD
M("FHD_, 6:/IWXHVKTS$URHAUY50J:+/!4745E(_:S%SIL.$Q4VK[,),IID:
MTS(E\([OX<V4CJXY]PI8)G/9CO'61\5&0RV(6$@+:7<7,:5X0]G7C+O9$6 Q
MX4X NI\CGYX5A>7MR&1KTW<S4"29K!T)D 6'' ?+[J('L-%2*K]>4FS>V'S-
M-Q8&]>E5;Z+?4MZS\<=@;K$[0), 5WXTAW_*XRR)$@Y65F+77L;7O9VJNTT_
M12!"DPB&UQ;>5K4ZKUH5#NQ*&G0N*->6/_(Y2EI-Y[@!C&QP69>H:E.$SV7Q
M>T>H^R_!HZ'^DT>UVD7I$MVC1Q1X[V79"M)%=%;P15C.+#?#I-"=[H6Y9'#R
M%<!UB]I")N?W E$E## 8%[(:&UEN_*;WQG>3[4U:+>R^Y"V2. M1N3C(_K"R
M=E87%U$3!EG!B1=*7*Y& 4CLZU1@P)\3_[/R'32M#]WKEAJO&F*)0+,]+/\F
MLS@>](>Y10Y!0]!UINPE<NBL4GRJX)Q8F*6*H\*(.(DP.YQYLR*6_5)UPWJ<
M$.PO+Z\QH3;&BF1T,[OOO,X<</R/1V#C9:<4FJ,I)_E@X(;*BV KDYA80$W.
MI0S/?Z;T$7N[+4++<826;?BP%QM$6;(T(V%G :L:@RL-_8:]"K^$+27;#?)E
MW(,9W"<J81$3HBQ3WN^"]J$N9_\:)W>1F'(34APBS408$"V8K@VP1B:+<%H$
MZUI'&EE1V(16)RI<.-1:\^GYR5I!Q06'+H@7>Z-J1)CQ7Z3)O(BX D@5T0EK
M4W@]T"BMA&V%A/7<$[%>*V//0\8:"4S=D;> 0F::YT@/EK-K08EU579=-UF(
M#?1T['IG#6 +^!F% ),'?NV[T,[&>8FP8Z>M>G%<O90. W>DJ'Y0H3>V]^[@
M@#@,L.OR%)&2*A&:%@BIYSI2S%UP#,8^  EN3Z=@*Y.NRZ0"VGL]RE.[()8W
M"J6[#M!^)[SMM.& 1ZWT)Y'?N-%U804\UNJS -I(0GX:"D1\[SC(;JP/T* X
MMD"D]J4@6"+B<O\=0HDJN+@A*I#?=RJ%UJTBVQKQYNX1+HCW(Q59V':4=5[,
MPNN8"A?AT<-BG(73,$B=\@C,J"HLKNPYSH7(62A-"0]>*.<VL]XOTW=2SP"I
MY:#'*Y#8NPXW:%$FH#=\]2\K]-%7OB38DV7ZD">:I<?B-27GX48QF[@DON)/
M(J C];]9>PTG8+/#HP.JE)#-80XZZD?6"LL"6()FHONM+MXC_B3UU_Z*G_J2
MU-$,C>/X>+=2Y17%(IKWB>+PJ=S)= &*B7X*C^8HR;*.-P.G@FH@PK@@?N*%
M2*6_(6G,Y4_RX!O:!^);G@9).N4V(# W<W94)L6\X/RC)V8SR6$5>%)"8?XM
M#F09,XDX'A*!@WW+RT+V,=POYV(=Q>^)RQ(G\2LJU4BB".^AX*J9SA1'0993
MH7XD*- 19FC&W(N@ I)539(8(E6J8D&F-S'-O+\=8>TS_O_VM'#\M-#G_0D(
M!BRU.SZ6<?WGP;=P7LRIIDF!E6&;+2VQ5]:X1O537=34*Q8@HY;5CJUUJMV6
M:U::;8:;JP.+DG:9I=3137I*#H,F%&CWANM[ Z;A<C9S83,\%E=]V*:DW9<O
MRC8X4Q?U6!$[:$7,?1%SSP%LCJ4Q^M&7QZ1-2F633EF44Z:>6?64X%KH>YO[
M-17,QGIDJI[R!-PO[S9A0SJY8S0GR'[*W!''P0(=-)D*U \QYO*.0:#:P]$7
M6#79._BF28'8S&NLHU:=][#M9:IH#Z5A@.-!<JL.7G6+O [2(*%HGW2!IZ8*
M&Q8EN!;XKVO9R$R-!@?]7#&=>RVFTW%,9\Z8:$UH104T%IPYN8LYHZZ<44'T
M$BC7D>1M4'\1O0"W+8;=?"5QF;K'K_4I>=!)S*@ W/5:[X7"='NP[P 7<N_:
M-7_5YF_6.6PFDJY(QH)<.',>9=7L=7?WVH)$YP7-4:3+E%%-;'R@WI(X(762
M+V' 460NAJ<<XWX1G$<HIUAMMJ!B[CFQP@L=<L,,H#S[47/J7MK8INVB-SSI
M_=/[$"5CL P^2:!4JEMRK\V'@[%3I,S24*CE]_?KD"Z^X2.!7=_%VU,:XX]Y
MS^!Q U_Z^@_"U!Y\+Y0C29M )U_@G6.L=B"020W!\R@D7/&O@KFU!S0(U&S%
M<X/;((PH?JR8!U:"\-KTR8KTR7<)8PE]R +@!-[04=UKHPSK[/FM0.KB><?F
M9%:D*/^;G1+:I*@-;1))=<Q2J:E,K&'+C6H2(8G14VEWYGI6T;<..X:LYI1E
M<A)F:<'$-7TB$:2C[GZU!?5#;!_'3)PU+9D-&RRU42Z!QW/CK^5GX%8![1W=
M7B5X?>L[KKV,SJ1=9%Q:TWP1\:J$6)31%28A'L#A$W!),I$'"SB/IH@GD5MW
M'&)3UB17;/1C[-]JL7K"U\,$#NB0KY#]RW#'_6U?(3=6I-6Q7]4"K)EOU,0'
M%/ !-?<[@-]TYUV?9JC<1-G7;D3YE9@3%2$T^4V*C;'BJ5@(XB;0>@SNCY1H
MUS%,[M169%,!ODR:E=NB4;A<@5JPSQ8?Z:V#\J"#@O-/2P32DV''+=3-2(L!
MBS".J.WPFH*$$*[\+K'NAOW,U(]]Z=36Y1A_0Y=KS@MD%.&R#A@B6EH4KU7W
MQ4%^UPBER8?WPMN4'J=KPI:\7'UB^)FX*R*!?KFZ[=K[B39 L*[ :R51VTG6
MS);4W'I@F14[M(&]'/Z0_(NP!N_>6JR"R;28:-Z6I8&*)I9C5;YS;*SK 3R^
M#<>Z?:02#?C,#3JBEKGAV8G7* VOKT&!D6>X;3+68K&V1<@PNZ)9L=PK?VT8
MH*R!?5>I@<5VP-Y=0/VJP 2!LU;FWY57(;Z!2=',!M::R=L1-KU)[K#;C@-A
M4X52HK#= X)*B2664\G.K<72-/KFYLHJXM-PM[(:YD;V$EDEON4X#-T\6+4/
MHH?.I>'_\%[*$C5,1]7VEJ.X]EL4E^,H+E=.9.%$B,Z<PA)N%@=SK@'!S]JY
MLN=*G@>S, 45NPC2X#H-%C=U2\/#6K;("[C/ J'&)'30MJ_'@FKGF)BQTD?<
M(MLF$R%3G3>K!*<RK !;E<Z<=KWJS@Q*.(,O$=L,!VE@L)5(2*LR/H'FO&WY
M4[9$CQ9QF',9=-LOHI6XGS%%OP=1P<%CT""A&S0N;<SF^<G9EYL$<R675%&P
ME95.918%J]R@A)WPP2&-,,U:A2C5^MP2]YG6\_! N4JE2JB*I=9(LC&L$6M4
M4T"RVRSYV$'C0W%&Y*]]R1X13103AR[2XOMRLR_A<0_U2 .N9);H3Y1KR;<$
M%U+<5J@>P'Z?!_=<(2X#!C#Z# :8S>Z]*$'Z QA.0N!LW=Y+7HO1!!A!D6.#
M 37.SS"1*(MYT)9WK]XH6M=V=_?="JUUC:5$! *J:<]/6LXE:?K/IML=%DZ)
M;[EIMJI$,F.E4MJ+6FQ1/7!77*6/,-RF&V/3-BGY9PTY7^4=]*;34&+,=$NC
M<$8L,=Q[ED?H-U^(>C&@*L6[I(BFW 7OGOTXR\7C5B'Z4(8S^?7.M..7/Q =
M\N[49Z^[NP?=Q\R5^(8M0D /8,TFJZ7&,7/&7;N9,EQ9YI>!9V4Y]S?,3/?"
M9?>374",XRIO>4?H2)K&ZN D7&X>3)\\)?[(/;.VMOG-@1@DC;@W&)T=G_>]
M%:%(5X9Z]B1K_;9[M)ZB'G[N;S;-<++1]^\/CP=G5Z.SRXO-SL+3+,*ZL_"O
M_O'GS<_!8+.2\.%L.!KT-CT-3Y.)7'<2>A=/LQW7??D-;X/CC[V+#QO5AYM=
M_LO3C;[[TVR\M5]^U!]NB5NUW]W=<\M$['HG JD[V?U'HYV9YC;K5HTT\MYR
M=WB8M03?0??@S=%_2'!J3GT8AR(.J<4KW@&+P_9W]P^[*F2"-P^NKY'\)6]N
MMRU9ZH@QDR,108%YECR<\ !@FJ8B"N&!5M.6DIL68H@#' R"#4?A/)1\<W_;
MW]WS]X\(>NRKIF1V._O][MXN/4!&FF;Z15:. :O?L*K(=!2D,AT"@))+R4ZF
MKG6:80T3?Q:%HL"WYA"-9NBS@!O2X^$6BK(.Z*<EFI[*Y]F\*G NPG*:I',M
M_ZYH (4^EQE.3?DZP=T^H]U ?$UF=Q#W+$'AQTF*H'\)-ZIH%&0IQB:CO$=U
M0%+U/O2X5V@F: _F-WA%_]M-. YSKV<043S <J;;#J%2^"',BUQFO+'D O?.
M^-[:5LA%*QLG3CFJ,:5X@FRN6,^>=[U1:8>:I+M?JKNI3)XOZR_"U$(;6IKD
MOBE/;X897&,Q2BXK2!K?GAXHY[Y0"?[Q?1=N6*8J9GJM&8P:HS3YG1"U4!=-
M%ZV:KVH8EL()S&PC>Q']]#J!-XHKJDS%\]6S6^WUN/@,+)LLO:7XI#P>13Q-
M4MUE&(X5RNA5I9JWS+=<<U#12D3B&GZ><5DL%O5$]&\^ISBTAC>*L24PKJ!I
M[KE*'!J2"*HM W8$GH8,K, /3@3!TZCS,%:Z-J8?B(!9=A:EC650+E%PI]H1
MF[8V_(YL&B2I&71S"QRY(99P>8!J2^8TB;IXT,ON83;F?.Z;<F#6<'+X59Z*
M1@*Z+0$HDO#M';0 1<<!BI:5CH9KF&'>8$)23)LHQD/5[*(BPS+#<CH6]TV>
M^/(G2#M'1SSM#X0%@.HA>UIM'50;W*^6_J:^PD36A)D!T_]7&A,4Q-^.3L"]
M6)/XFWU-BE7J3>R9G/E>7,S'DE_2$ 603J$>ZVPCJ8.>?AJK$F3?UKY2B7,&
M5?I8EZJON307XFNN; [FK/NIWAA&M&/,":7<V0J )5=,^ ++!22[)L._Z<=!
MQ,FB@%?G^_3](S2W5-?Z;]3(DI-!Z6XRO4S2BR7RH1]]MPY?1X,OV5=^96/!
M/WE+O?C-TT>DI&VIL'V8"K1E4:P8N]K@_.,J('X 7 -*%,IWMQT'C4XBT9#V
M.G\MJV)D$49>>VS^8/"A_FPNQ$>63K1E\;_:WN+-%DL[/_B^^^O1"6VODP36
MGSLFHPYKK%DL88L5$]YFJ9AAB3]^).8+J5W@SD4*FR##Q.X$)3:*E.8Q7#WP
MAPI54"<.9?I9@LXFDDG9\L!WRK8]+:GY!8KKK(BO*22DM4C]E95[:$L+;C)B
M;9G!ZR"+K^D6PHMM=CGJ$X7^Z50").CXH!JW5"OW#[&?94T>K9Y>*=R$:KI9
M"<A_2UOZL6NJ!9CTFS2'%7!8$=0IZ]C7Y6E$^ZK+TBQ?4N$*8+/&(J5Y(7LT
MI(2[5"G7H/IC];"/23254"'CD,LF*NF4+ 6Y4&5G]RJX5W-G1-IB?,9[#[3@
MR5)VY?N>@A6.=4.(1SIFA3S0<LG7$IV/,>D[$H0QQ8$Q= #?+5X$X;0,W0@:
M=(R:8"F<#>^L&'Y4Y=^"7\]776X"(AI(I_("?:Y3O4.% XMOC]WI0I9T$B?J
MK*'NB\%(W14#)9NUEO,ZW J5';CEIG>]$SY6I^ ],CA.[1"2::[7E%)+2Z8Q
M)OR;65!$N#4YV+[A6-M.T&F*N),F18D*56B90LW:@D<&]4F".Y[V\-2:"'KE
M9<P61!L"TW&->G4.\\ MDZ3=V/7HZ"[OIZEJ#JNW3)AGU9"?.83'V!Q)[U/)
M8R-_:PYON0EG@662XF-!9<M=;VUUZ^S0HT++LLC-G<8!V*RLWP]>[[Y"AC5J
MTX37)71B@@*]$Q'LS /^>@Z+<T/A )]1I&ARX:S0YW[MQO@'F_ND!L!M! V5
M%Q3 !%]WD<GP8>G^VQCB>KTQI;,SYLT@JVQ"*K2!<P)KRPPN#VE"402OT-R1
M=5+X!?&$6IO%$AQL>$<?JX,5J5])\G2G!,D@PYWQ4O@O'0*D:IH@RUJGJ./Q
MI$0*H_L=6"<"/E=+M8+W*8:9QOMU:3::#$DS&=\ZM4YTB*A6+5<Y@JO'I1XK
MIR$A%Y-\).JT4&U<-P]@P"7R(/6-)LK5X&LUB@3[-O")7\+^$I!P#H(Q"?Q2
ME-[DZL9"/D-&+F55,CO"F@"QX74M0Z#A9<?H@2+:V^3DO' ^%V!J$567(?8%
MDW6J$W"RNYR:$Q.J]*0 DLX5<I4TVQ:[(@$'-"?4HH_*)(-[@CX281(\@:[0
MXK!#M/OUI0,[NT?M+Y2I<0/_)1*C\E4WP2V1<L8/.""F"QV.#@T>2DM,;L3D
M*ZZV%%EC.RG5E^F44"Z3&. 1$!23R17 @ -UJZ6@LNEPY=[_R/<PZ'WS1N"^
MA&2K-;P0%>]M=P#VL W .AZ 5=Y&ZK,O)IT:,I T[8+R2>0NLS9*"L<.1N"P
M/U[*PETJTV@XFORZ;H,-^*!N@SW,H] )7:7K\*B36[BLO$-II,G1W]C-_JQS
MP2*3$#)S:%Y.NKDE36B2,Q@V!#G$,Q+-7)ZVF YXU+DP\'GP5<9?2Z^L3A-[
MNE7H!P\PPEYP_U NL+8\0YAO-$@S<JCO,*J U*H-"R.7BW*<\@C8"8W2MCW1
M)S]N'#?B)AV*N]0<+;DHE-"G99]00(5CU>JLKCCNE2V@G&KR)I!2D6_)D0++
MN*(S!XQU9>>0,:$!"=J=*(& *)@5$SM0, XCHNF4X71.)9;3CC[Y-I*(405#
M9+O=QO'Z)@=0FQID:[D6='C1S' T3;V.##26+)NP:I%1S C%1#?'0K''8P\-
M);_:G5,U#PX[6I3'(DKNB+74=0D+.R63"^.E(I++2$IB86)60:,HRO5F1R,K
M>QJ9Y6_NL,X*4QN<4G4\L@[%.RW78Z67H;,!=J!)-:FP1KY,5&S;>8RT$M],
MBG^61+"(J%XY,-ADFY+.*P<@C?)3ZJ<<DZ]/(,@2^]5J^X;D< D=/U 10!4T
MD%DD_I%ZRYW*N]#QIRDT]X^DFZUYD<B56N2U^.E,Y]8HH%B8:J=1B4 #4UM"
MU5+!8-,HA#OC$#LRYIB;'!M'WVO3-V7%;$XN]0@T6BT#-18@E?\N8)V5@M<6
MK;S,FKI2#=J2E<>-*JDI4,:#-,5X*D>YN$(SP$9X]^IY:ES:55,C9X1B8P/K
MIE622HW?Z XI+^2-].K?B(@ED-PU)<IC$8M9J&5([37;-5[RHD&FB^^DGE*J
MB^0Y%61>U9<&ML*?W5[5W4759=K9V%,2":)2EM6]7?[F$;.Z_";K"#R%H[@;
M\]+=]3W[H-&;A9-N@;WH&E2'FLF&6=<T,Z6T!0V< SIZOXEO"Q%GHA)^4 <>
M.]$/O.SR%56#:)(+.EIGO&($=%:@7N4S&CMQU6(OFX&N:IC]1*.6[O(8 7Q9
M8H;O+[MKV8+8X"FX;,:L2'*<>%$2(\WIDG+8\H&G+1HT:21&P<YB>$A?0<(]
MJI,JQ0F]&B(?I.UW!UY2EB"CH%8>E6+]1LO">>L\;#">UK.99,4OY\/  IX5
MD4H_+@>.E*D!-@+3T+E1RT98@E&4-<;KC,FG\F[6U/*>I72KFM_*8;Q,$6QW
M;.JHC4TY'ILJZTUM6/DE%(%)A]>H#A8I&)?2^RT;(]N4RCYT*QW7]?H*NN=[
MO7I&]<2J#'"J+L3 L6"[&>]3FW48\!1PS:R:4)*B V,IN!L3^"Q9"(/E6P6$
M'Y<IYN.;4,S4#-UJ/*2/ED=&\$I?7G,:QJ#JT9+0UXP0K0,W2XD=(Q4JD"8I
M-/#^YL[PN2Q;^STD,CAY_R>?[^=6H9#3_)+CC&)0![$9SV;]&IB\8JW(:Z4H
M\GWJ"<H&)[B,6:C&W +]T\MT:EE]#4@'>[0&3%5S=YK0571Y^4$RAFE5&-H/
M*3U 03\H \MM A&$(!,,]NOK"@B&PUBQ^B OC7%ERAI\';FC=*;@V"K](@\.
M+EF$L;2)C\%4S$14W?8R5TCT<GS>$'Y:(9W56'!UK28R:)DARY#K8G^)37@L
M4)V%5PU2%;W%!L8KJ^8:2^((\&/*X&34PZX5!"\K!T>52W-UC9RGD/QZ>[#*
MC4@%8Z0*'IZDU$V'00!I!6)(3I^\4(T2,[/7LN0M"6-KU^D8F!5EAJ\TI=6;
M[MYNQV\6-BM6U%1-E)#_=PLJDLS\9 PF7D!QKIG4YQ*"T/6&5%UFS7)E=+K!
M[)+WZLB\G0)7+-,M%@JICK#7.XQA5$FE=A@S9^2O3PO,!:VH*S9%3"6$L8Q(
MA-DC)M'Y+706,YZ#M&)9'M6D(^>NY;%+RR.H%FK(D)&56J(55S<=8]Q$V-<G
MZE8ECF41KUR;LF 1U&,:9AII5DW-6,HAQI "?$G1I#4JW"MW)HV9%->R+,/0
M$:N7,$^Z"3B^.&'(>,-DE&?8] C6&T".3]Y[E57'6" 92 HRC6!FB%PI$EKJ
MM:'':RD'O$@7OU1#@D$DW[_2P:-VYUI!:VF0Q+=&G3:E/I /='ZGV)V:W+).
MT9N1D1,4HD&)$6&&[==T.MP"Z@[L&ACL,RLOXV]-%MP-F&[Y!)#H+MI87Y$P
M0LKD,@";#HYZ.QP;DW]9,#N%ZS?(O%+8[2' GA4$LSU^BR!PGPUJ![AJ2Q@Q
M!QAJ.QP #R<W)5R S.A+JU24:H<9^X9:$BL^)FDXKO@KY<(DY5*DE:UAR!9P
M.54YCO'ZV;#1XF)0XIRVS47,AJ*1%OIS$BP88PH'DJ 0.?.T,+HZ*?]6(G\"
M^U47Q%5-@X+Y+@?/PTQ1*1C\IC$+W1.Q-'!!QDPBDFU6G%NUKE;!&]I[-3%
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M.^DW;:X&:2*?QE@C=.C8UX!Y,NR"66C\(9[QLR$_!5Y!+H@4Q;-SL@5Y05Z
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M4+$[,!WB<BP*2><NTI&R0']0-'$B,ZPX16P25IZ1".?I,9RCGU>9V!YA-99
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M481@35JWI)VB[;5O5P_<TA2_MWQWC^OU(T$KH4Q3+8TKZ69.MA?CBM[/)V]
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MW.AL]N@4SW\ENB;?__NZ:N?+NMW1)D&3?GP['K:/"\440E$!%8%E&@ ]B@7
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M?W[#R%#H&DWE*H0%1P]54]Y.'*">:@;KLMHV#YO3=[1OEOF:IB9NI<^;!C"
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MBNRE?(MW.R!E/+#P3ULP^-GSQVS7^+-=>*H87T=V:[2;S[C9)OXZ$@C<"/(
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MWK6%A_VAAE:=][IVE89/GZXKF &,(AM/*\F+W4^[L]U-N04N7;0VD\L6B(G
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M>DP82W5 V^HS5&&WU^WD#-.>:S+0S& >QY><1QA46_'YW8L+,)#NV=P2 ;:
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MQE/>L6HQ:>A);9;Y)]TDOZTKV$@?M@@;<Q]>NGU;S7.B,/P@1 DHILG)P=?
MEU!1K?&5"]=6LRKW=/E=OIVS[K-/^=D]R2+2]I1(V=B'PO VX(NH>PBJYCX_
MYBH;^_:= 8IQ51;0NHNX:2@$7-'V+;FPSZ5"W,JDTXJ]'$I4PUP0EKS&Z&'4
M<\2V%E( A Q\M=[9E6IG[73  1>C;,CTF](;"LK1PK%(X-#BZ-G9>>Y)48E-
M54][7%[H4S3.\N5P8),3 1G#I"-AD6LA*UC23@W8GLSG7</:2<3&B@@VBW^3
M6EOXO<QS3]-O-KOU?+MS=S1XX$X_!SHX\SD2WN*[K3> F@M:5[R)_,7+W77N
MPL^/U3E%D:=TPX0U%XCDW):D50.7PW$U#11A*S:?!-VW*QL8#27LL4Z=<%[M
M+?0S0H NE2BGX;*YTR&$/$$BG('@">PTD3X#69*\K.3!C^*B!NH<O&FU:.>[
M;U5?(H>^5S+7("VX #3F=5Z04-TZ7S$FI%JK4E#>>)C6HFK<NH*/T(*DAA5=
M UP-I.6]:V6&B/I;R'W<5G [T#U,A>XU8QH!/ E/8:"V],]X='"IQJL;+XD5
M!8]K(1SEEHHB@"R-!=+QS9F6/,%$T+>UU6G(O$VI&UL#[8X-%#G*O$C-M8&Y
M!D":S*Y]^**'&+4*9C8DA$W)&BVI&I4M++,P!7S,KXC!F)VP 2!#YONBJ$+E
M;GQ3U3MPW&+Y0T/Y[@>31YI+99WE'YG1!1>CI.(-EE\4=\U#] R[046QF$MG
M50Y;<=I/\):$(3J?7/(<*4P!%[,,:(RAPK'0[8?5,FQG84^'>/J2$##>A%I.
MUT5,.UQ>B^^>J)EYP%37<.+%J<V*-I(IW:M-X$LSN*$P.C$>P2(HU[<,Z!,G
M[ZZ'MHT#)V> :48 :=+L3C,Y<[3VS"]LBYH7^%,.*,F\\9!R8&G0&L"*50FL
MG>U<?M7DF^O$V)UIO[U2RN$*C&%XO T UTM#P7?@YCF_7[N="1=384HIW"34
MRQO8=I_J'7HQ; O^=\>'BN4U,+???WSQ^1AHD<\@3,>_LB ;F&8WR#,@RL-S
MBWOY<!"(JJWI'OGZ4QN=I9<Y.PBG03E_(C5:?/H7SQYKM"-O4_JZ40[O9^%*
M=)M^<]VXS]W+7)&K@?&'M:[:KZ &9Y47I6T7;:U-H7-3SH56-1P]M==)A>:C
MP^TGL$$4E__=;4N,T<<!G5KT9/>JMIN8%$:/+XC>O2JQ=,=8[>W0T<53EQ%9
MQ?TA6:3W?JO2;5\K":'7,4D(/*FK!;+4)K.=E0&D)7B:NIFW(<!J# X+$FOC
MVA G+/DR@(\:R[,>5^SDYY]_^^7MQ__YUP44O/OQ7UGJYM6[][^^>W_Y\=W[
MAP'VG BNZ..[5__UCW<_O7YS[&%X=]1A^/''MZ^./ 3_VNBBA[G[H6__]OV;
M5]82C#UT>#I"A%&84:'([4.]A(*ME/G*R3N?C3EVNQP*@^Z /4H9-0?J79!M
MVE/NXGPP!!R-=H#.EWFUFLPPG47(A77 MP#NM%+:4"Z3TLMK\X [H3Q5K76?
MU<JT7$6*RLQK'2>UN^EZJG(,\W96\6O-2LI?2VT)Q*U-'R'\>+8MBS6$1E8A
M?4N$WZ9F!$E>J_\,"E&T2H#'M=W6\S^NL;\XFY0N7JAOD7OU"JN#'%&ADB7W
MUB'GB=2K6&'*Q2"9F]36_8*?!#4W=E1$K3N]@3X)PE&EP;%D4BRB&RZYF9"8
MPJ+K#%Q$.,9FMY.;JMGN-/."\J%00J/P:9LC/Q)H;>Z6^*5E_@F+)%R\2) E
M03&O;86M;./6Q')[FZ @JX"D Z$3BG?!!>;&O"XXV*1"Y+4F7F\-:;O_&3+1
MT(;0G"T6"+5N-)'E+!^;TBT2]G;:47NRLU2PLVG>QU#Q:X6* VG:L3SK?_[;
M]Q=_.W+$\/'-+]"&<?G33\<-&H_K*?_\]N/'-T?U%=U:>'88\=XXM]OS\6^W
MXS=[O/]PY(ZG?^G<S,.,_,$O__%T%(B?CS 2,VI[OS;53;4LKXY<KP$ ONGJ
M4#!D%T Q3#+R/.N0N1--K2F](- ?;HZL&"F.T'I#7C91>H#"G(#HD)6M;G!J
M :.'S\/_IM(C_Z#$_O-_O\C<P"5D-) F X+#J\9]NH*F Q=A28 W#? N$Z"*
M-! LA6P:**/!8146M!$LP[/9- NP&.ZYB' 5+[%DL8C9KJTP/F/@V _R[]>
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ME(,Q,T<,@ 5B]\Y=L5K>]PG<JU\!.D/&#:S>_T+?LQNSAYUVI%T^^SR-9P*
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M@)_TI&+5"\0S0-+EAV[2A>GJX/CJ(VD0;1HZ-43H*@NXIY2MX:[<?E]&YO>
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MO)4*DNB,>5]11'83[N*'](KD*[M9D++)P'8BR9)X^6BTQ%%J(KC+>J\</ 8
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M+F/\ETV57SRFRD>>*C=&M&HE,6%@8U')&!+22<WO[JE)I^#0[MQML":8N-J
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MB$2UU>M0D;[*ST')#%)E=B]"97F*"*?\J%23OQ!K-Q%UVJ0W%E+GP1TZNRH
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M@(T$)L6: XGQTFD\5T:.TF12SYI6Z6)Z$V9)Z0_+-#^:6)'"W4V1B<W0X&L
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MY%XG5T^4+PROJ.O35"I [[H$LO,9ULGCI^-@#D>\9^IN8=(-,3G!$DS29@J
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M BLGFQ1$2:"0$B;@,6'\,@V1O"$YH"EF#CN=M()'>(W:(YHKVU(@];O;7%W
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M51V2QT@J(W"XO6U[ML[L0$.)DB&B_^(GJ@6W7HW?D.5LCL/(G6TS!+PA>8G
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M#+,EPAP4B_$JLRPZ-PI7@?8]4<X2$(A:K=F.R\Y&B-6'J( <%B@:(CD495T
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M8Z"'8*\,$!+>GSI262/\Y$U3=32LPKA,A3-+M18I1Z@8+@] MY4AFG"*YU'
MQ:8)**.PFHX0Q'Z%LQ"S@,:K%W:@<Z]I >POQDW'C'@:($HAT;@9P3:)6&N.
M+EX!VCV@;SX+YLH<L>6)'>99Q:FEWN=R-[9*M\G[3.6*7W2'66C+5G/,O!N$
M<JD<.XQ13RU='D=XJUG\>\]#'FO=HXUPCXK6\-PC4G8VV1N(9T!?F[F,Q#IG
MJN%:V6T')[HRB$QIB,TU!@L@.VXCNM3/(^>@3HZ8+Z#^1$%J?#MEP#KY\7RM
MW*V,IW/4W3YP$6\P_9%4OD7  #!Y6:'Q).6HTO%S-=E5/G#2YJMP=(3U5#ER
M[AV+47*$7UU*V4 WE:]S41,J;B0<P7CT2H"CUPF \+RCV! ];K]I>MQ5F,V
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MF$[.KGO9VL%3(7++9T!\'9S#6_GR*%,"Q<R5*M]+H'C<2@"=8A/<)@\AX>[
M8$M2_)4U%)HL_VC6^&U5*$=DSP>9R5*&*Q.U&!$T8.O/446EK4<O@5#<^9D1
M4HRFHS<8ZX,FTQ1O\X'JN6.*&XP-JGQ8(@BX#X-Y:*1V-LARN3U:/E-_KH=@
MG%<D!,H SO0LFA%NO9W6Y R.TC"D;D;B(S'>F,;OINV^;5S+O5_95PAR\CQX
M9+W[O^:@M TY)6>]/MR;W\ZNO;.+C_V+FZ]7?:]W\='K]TY_\RXN;_H^_=F[
M^-,[/>^=??:]T\N+FZO+W_M7UW]ZEU?>Q[/K+U]OX$=76+KYJ_<5AKG"+Z[Z
MY[V;_D?$:5X\_O5OO?-S[T/?^Q5'O8"??/B3WPJONKZY^@J?G%UXO=/3RZN/
MO8O3OO?'V<UO/HS:]\Y[?UQ[EY_HW]<W\#[\XZ+_A_?GY=7_]K;PP<NO-S"7
M7WM7,I4^#OOI_.STAGY)(WS1<7E\X*I_^6DC<V/6[%O3B4FZ'/*)P0_CF17<
MSGR=N'@;QN$HTL:7DH"L>*!6B/J)=& SN5TY>U6*&<DR#>\P'TP\R]D\R@<8
M@SML HPW;?%R-<C0CFGK@HQ/ G+DYBQ'KA'+HVT7M4^S!HDMWJ;)',,'*B,L
MF:<F\']-L-Y8=Z'2>&4(][&O,?FHZ>D,C/.!G2K](:$WX+.?@QCH!)I>+B_8
M^I/*YB6J("52JK2!+ I=[%!506%U!2*+"2^/VP4,P<:TMICC)'X7?I=J0^_?
MEGS$UQ"<#]V'1("&G4^LA"+?3#!9;SNU.PZ\C)\VM0\[ ]H<M#[<#?#ASF/=
M2Y/"4WFI&G">1Y4\'K$]&8Y'.9&"0H$;B[%[,0#;0F1&BO;Y? .,QJHKL91N
M =I,OA*$H_EXC$%1X#]4T4U<'(3I.'AD]-2$R@8BC8P3S22!^A&IC**7L_4Y
MQI1(U@@E]P.%B8C:<&$A'L!^A!D5S2C_(FY:YNY:P7%:Z_IKWE6G;J<1O +O
M]GI[9"DR;/TFWG0<!AP&'@?1A+MY/5DWE5%0))N\\CQ81,H-H1/:G4?0_8+5
MLW$D]2#S2>./A6VF-:Z_5Q]='S$[^DYS88=3TS7X"V$N ,W9DK-@)9@_+J=1
M'$F3)DF 0$81C76]!1=?IU)-(55ORI-96K:3AP#!/[$OI9'KTD;%DB)NCZI\
M444Q/P?.7QQE]_E7U8'OB!6E+4+[HBAB>$7A>%CGCCH:V/)T00F("Y_B*;"C
MXCN-1R:?D6C[U/,2<NL[HS$E:03G$GO\9>B6'9AV<2JJ0(4O@FQ@M:UQC(NM
MIPX3I(@U8?M[=7^:P\9+"@*I7<8#)9MAX[Y1H@?ZU*LBO<5D:JME8Q$#)Z_@
MY&.3N;'R[3H7K";7:,,J<-SO;A]W%# O^=M#*GD/N"Z6JG]T?)F-$ _]\\C^
M?(58-,/T,-RL*+"@:B0)*U07O]C8Q;. Y:8!W$%1.+)>;F"^XD"3,!N ^J:H
M'7X/=#]+6MP#PNQ(P)RK!S6ZGQG727DO6\DM=KR4F0V*!-&N[7_/AW>J2(J+
M%XE*:*!2>/J>(03)G<JQWT7S#2C)#HYRF&4!(P^%,;EV[^'Z9]V+/N0D>[ZG
M)758SX1IEG.E+Y93Q>T@5)&AN_"R@9<3HOZ;6?*R0UG=AU-U'UH> #X9$NIK
MO*RQM9+#IFDEY^37^BT91T.P'M?>0U3A-4F4%?\\4SC*"BY$H<H]E4'-/=7H
M0ZTL  ?HG<X=!LP<B#$)E5@ZB6##@*82Z[IKND-C4+15:EWQ:\Z_$]^<_IKD
M&EABG&;/BKJ#<*;%:(8H;(62@(#2A\O>A@^!/J%!J"79GZ&FBSXVN)00>G^#
M3M)1TT[2!;4588;2/'L*EC*(NG4WWL*$B+L2?825 >UD]=WBK8BEK O8AE%\
MUEW<J)]:NN8XTR(3;&N\HJBG$_9YH=1M;GRN4O3&F-8REJPEJH+.>1K@%B3\
M)>F3R/SO*VO6]N=N%!<?-XV+/W#<A"P6S2=O@GT9_#*QDB_]?",3B1()NAAG
MLQ$/SA*^6URP#/S$0O.U/K7ZM'-L2']C)7&E0:H"3E%J%U;JN#C_1(>R4BL2
MA<%T, =GI!M*AG>*)0M/QEM49LXM.!T;GIF]H*]HZ]5OA%??%GPG31-\-PRO
MAJ9^C)YQD *_A=0NB$OAU@]E,E,S',@,=;@:;N&QN ?O9<[:[\X^&8F)ZJSM
M0HJC,:ZB&&;I "BB"Y@]1VE()2KX!V%'(ZJD>*IO#3PE-?@B[$;V*_E6(B?(
M:U!+@:>]23*41/94\&-L3Y^XS5+;Y<>C;=+]OK/=+";O>CWW9J([:\T90I8+
M#.VC8#I-(@)_*KU&[=KE0E4&U7W'%.(3EYRD B@4+,HP5>GT2GFP7R,.*G'2
M/1EW:6D8JLS!.A-G*AW.%"@S"@4L(916\9D9U;KJ3;HKW]N*C7:[V_N^_=>!
M\]>A\]>1^6MG&W[(31G4)P?T248Q0/(M\8DTPD07I5(N)\6\\@32^W ?#%E@
MB-(U?K(WH]RW U]GH9H/5TZ8H1WWJ((-^Y0OEZWP^]?:0W')ERZGI/+S=NFP
M5LL":57HE@Y)LSX!!+<]C,@@[MCA=^SDRG!/KC]9G0ZJ>JX]>T8PYT)I"1V0
M^\34P.;49YT[94V>/,D+YXT@<^C?JYX5!B@1J(2D!O7[DTHC(.1=)&FK5"%+
M;">+-=,L:]Q)IE.S9&O3KZ7>$DP(D .)N,JK3!CEOP(K_DZJD[D_#/]!0M%)
M&!"E@+R+,S3%Q(99-(\\1AF"M^'[4M\:*U+E6]KZ6CYY<V>0<O)4:S:68\ZT
M&Y&B:H:.- V21@ML/_URS@'/@6J4"UCK;A!18WZX<"<S4^=A#IEE#3H:BJD<
MXV@*]9/F44?16%(ZN*7NU)0;J,P&N7&5P:P#M8[QK!RNI<M4.)&UUM9XY:^W
MZ.C8W;92JG-!F7X7/>!C"N/25 RE4BDN[.U&L*TB?P9D*2I2UMM0G8YBU2$#
M9\0-<BH/RZ)YJ<%D7EFE_"^;)>4(<"6'#B(&%8M6" WRD/5>7V4&4:L;:Z%+
M3K]NNGB[\&2XO0$<K=3BT]+W;+$44I[^>[MMB.6(*E*5%\FOF82F@LK F2H;
M2JE(BW^+3^J"GH:?&CN?S535$B1N4BTYBLG<7#-#=C+&",,X,[4G5 +%%3:@
MWXXM]=;&",T=E%)9'F$2(>P"/ZNZCM"76F<:A1HW%[L5J6EMQ$ZX63:6RK7K
MVW_M.7]9-LHQ?&?"_,YE8UW"IEI/)7.6$+OQ]#H;5>KD"$K-1S(<YNHBBW>P
MF[]/WI@P'B9IICKT4(.=6&.&Y"Z$>KHZ-2X"U@_3F%R?2RP2,0ZX&Z#DU$Z6
MM%O><"?R4>M#;K8/^?\L_#^_JD_##T]@STH];;Z&<\I46E5$&3^$+FB7NPQ5
MS7I35B3"@(OKWV%3N&&MJ)(MIH_7)J8_2)OX!;S3%$+WC!/MFC1A[$#7\%O0
MOLP:A^G;UR9M%%,B)\A$M$_7#-Y[X[I'Q6#07D#);#!M90?6S"41&3YE:\-H
M5;'V2 OBE^3YZY_*L[JGH)7%@<\K1%*=<\2X#1/2Q6[(0<!.;)[2-"ISR=((
M:)80_^('>">1_]4@A(%*CG!SY"*?1)G5I,N:$N=YH*IB'!-Y)VS^W3IC-.>$
ML(!7YQE3>!R%<]UG3GGRS5!Y4+^NG$@")RGW=,AR5'YC8;GE;F9. = SR,Q;
M"E-HUNG:),'4.#3E:X1#$ BL]<JB,[[<&9YF&;)J/FQ@L"ABZE@)=LI8)ZG,
MXS"FM$7=*3OVMN1\5I2@<>6":G[I<\)+Q%AH>C#&#9,SF(:3(**<=,MT-1@H
M(DH?^>PS(HI.$0JPI*(]5<\^58U#,_XC(.<8L,9_S>&"N$FC8+S>TT6 %((D
M<7KY^0LB7B &!?Y]<_7U^J;?]Q :XL.?WMG55?_WR]/>A_,_O3]Z9[_WKWT%
M+?'IZ_EY__K&Z__KIG]QXWWI7WT^N[DA2 NO]^7+^1G^BF K?$^] =$OKLY^
M_>V&!KDZZYWCT__U]>I/@KV I\[[O\*'7ZXN3_O]CPBRH< V$-L"YJS0-O"C
M MP& V5<7-[TK_%!7D_OXKIW>D. %XCGT?_\A<$Z>(7M27OV26L<\,PG2D?_
M'/P[1!-PW1=8G,C])0JN'3BG<,L4TY-N615#%(YQJ'$G57-H!K0*3 ,DQN57
MA7.4%VO /*P8=;%LF:":\$I3D-1CACB+U5\^I_-C2/PID>X:F-F5)N.EN(Z8
M+_4-$UX?L> X R8E!=O'!'^L,IW1/SF+]S&@H!WH_RDHF-G$]P;1 P.-8:T6
M8:\-HPRN]EM<)_PRG@_&(?^*U%"XR0?!+("7)M-[@2V1P7]-AK[D9.,+YE.%
M<I)D&8-CCT?SV&2=@09O8#UM!&,%QCG'9.^M+!G-'@,Q).Z#=(A_=(S[7D<%
MY['TWG/T@4_AD #"KT).*_@0Q-^ CKS!CDK.HZBO7)PS>)!&Y7HHA'(,=78.
MD#P9>H5&[LQZB-%E12+ ADG0\.)2[53RY#+2?2ADCBVZIN0D9B@OSC;"<6%'
MOG'J\Q!>P/5@W";=84W$[4H2:>%NT,!,!OX@2@?S"6+Q#5H3XB^(X(-FD:Z+
M'9,'JMW/>C-4^]R +K!S#W35*0K**"ZKT,Z)YA')#.)Y\@18R\,_5'=HP]FF
MNV06NH]+.2N[052B*@E1,KM]'< +M'3BHTP)M*;YIE5>4/R%JH4TUI <<,R*
MH16QMZ+L3><@4;$T+:'\F>N <"M9O.DZX@DPWO4L&7QCVGT$6??D_?Y'[TMF
M?V 5(?P>C.>A\^5U.)N-.?6KQ\A+OM2!#4VQ3JZ]M(N&90U_)9$BE_2Y/9U0
M&3_?P<5=\>Y0=,*-BY(/4:&"VXP3).)H1,@D>%$YO&*B6_90FH%&Y#0AA '3
MLTOW[1A53U3X$X/Z@_MP.!_K6]YY$=;;BKNMD(/ADD>7@ PK?Y%_&KW_E-LB
MD,$$Q \,)%!5"I6?HM&# 5S&@WSWVW+J*+4!6TA.0S+>&3M<Y^W9^2*/$:(E
M)"G<L\.RL3<;\.FX+0UI>%@O?][PC!I<8Q9'^ARHW!G=WV7$NI7\0'0R:E^%
MV/&2>TW8\?DN5LXAL'"9HUC$P!240/+OPL7FUF[Y;COCLK-=AHFKT!84"+Z^
M_5B#G24FL42<\&/J2%NXC!9=5$B^@MR7TK3AOV&U$\F\@Q6G*B6J5-1+AJ2E
M/\KE:R5;FA$K1K%Z,1F(WXI:;01+2 :,[T]97LNOV%(,DOW&IX[8BF7C< &^
M7O>\+[V;J[/+&VSV]^K36YZ4E OF#+[%R2/<F7<A'_X20'!%X+W=0PWSY2[+
MR?/SN;4>X0:!1A%3H7(DH:A(-6.(,,(F':3NP_$4GD7,+$J4F8OV,3+6-D>=
MDCA$US:='#+J[>YDA!"*8"2^-/?P!8P.5R/P'I)L20O%JYQ3"$C'$%26))7*
MT-!J\0?2$=2Z*$.K'9MAB(2]CZ9D_*)(]+A'-/6YSO?Q8O&H**\REZQ0&Z;J
M:2OXB;4(I53-[G/0-M);PRR'NQR@6%227!,W5XI@US/,[D.[GB&KV-I-M7(;
MTX#Z'W\_V7G?+")>49Q'E +4AZ1X2<'HC</1S+L=!_&W=4HK(-Q>PPCW!O/U
M6+,_:17[9BOV9Q<(J7[1O[[V_F#X\S)T!=:&Q66>NV0$[0Z;1.CDF$!+?8+>
MX08[RBR@YA(+M+\IYM#&=^]06ORR>[S=/3D@'9#KJS4CX#WT#L@T#J99^(OZ
MQ_MAE$W'P=,O44R+I1^]%QDNW(/]VDDY!:M&.(.8A+^6K=O?Z>[M'^+NS6#+
M9D/U8MG8+FWL/V?#DN\.N@>'AY5?;W=WGO4=S.>@^J6+?UG].R#OX?%^K6'_
M281@8@"Y,S#0_O-O>W]3/U"$CT&9LH9[\2=+IW'RMQSW_+([_>[MN-<U,E1A
MXY/INAK+G/?_=79Y05T'>E_Z7V_.3J]][^SB5&M&]G)S8E/,HG*J*1)L(P'*
M"'RX^-$E&[TQ%):D4H><SZ38!J[^'W_?/WJ?T?]ZGZ/!?1".O8]=[Q3.TP3A
MD3]W/Y9RV@O2J,:C(L=1N][N'H%D]JB"U%/TV1AR7P23D'.8FTOLC2'F#;K;
MF9JG]P@X*CG"#QI&M4C,?])5OZ(+O"&ZQF[W9/_X6;K&7O=X]^#%M8*][O9V
M/:5@E5&/3KK'1_64GS>L:U1Q'QT-&B$BW?J7=_C)F@[@'_WS\VOO4^_JUTOO
M0^_B?_O>10]SQGKG>)QZU]>7IV?T ;G0<^#F8MBTVDNKO;R,]@*3?O)^F]_=
MA]GZ+]&WJ+$TBL ;0T!+2_D=8WQ?$!L!17<-Y:3$.T4HD;7<>ZWO+.<[6T+-
MUV.,HU+&Z/_KM[,/9S=>;T.C"I\NKSYC<OFGWBEW5;R\Z9/7?$/7<W9Q>O[U
M8]_[='E^?OD'ILJ?]W_M7WSTSC[!'OUZ?OFA=_Z,1:YS25\OSM%G2_G^I_VK
MF[-/9Z?8 _,,.UKVK_L7JO+@PNM]O?GM\NKL_X,/KOKR)>ANO_=5S</'_I?+
MZ[.;RZL_N=Q!%4'X0!S=4//T\NK+Y17I?-Z6@*E]O#D5!+6.;SIL<@'%Y95W
M=G/M]7[%8HA/5*;PZ]GUC8R ;\9*A$_]*]_K_^OTM][%KWT??_2E]^=G^(G5
M>]19W36U!+V6T?I7W""4RAQZGVE%IWW8Z7_\?0]MQ\LNS>/"N_Z*)1[H:N/G
M>M<\R']_[5_7I!0LUMM2DY)94M$$MSV%X3[WX,U AN(,X$-K!O##LYL_GSF'
M#E>/&.I].>]_%-KQ\%^ON5P%#S!\^'OO_&M??_O'&7S[X4^9%"VE?W4-.P)3
M^>/J\N+73U_/@6"]Z\\XWQXU1;6)??G'!;Q"10K<E?K>;_ #6,/9!3Y\S>0Y
MN^B^7=F!J[PZ.\7MN^Z??KV"?=T<&4+"0TU;5SS! ?X,_'!]<WD*9A^N$B4!
MGCRJ7_KZ!;X\O;S +L#J)#OC_-;[G6J.O _]_H7-.GQ.J%TO/WO6!VXYI3*F
MG9.]/1_9#0XG//;1V\+G1,RXCQN)@S/^W/M37@;#?,+W^-[UY?E'=2X^NIRO
MC@W.!\1._\M-27]A+N?2^TW"%+[KXKDAF7;ZWU_/0&#B\N6@X4N0'S[T+_H@
MJ["0*W<(N!:+?GK5OUJ"TF(QR>':>&1KIV-$$ J"'A#K1LME)-I7D>U__'8&
MT@*^/*,M0JKAO]0&_O?7WCF(<)+5UR#[OK(KP?OP]4\D!6-P4L=FD>6?^[T+
M*G+[Y%U]!:;;V=_O5?)/1UB7I]?_5__J%+;Z&MD ;@Q@U.L;DM4?SZY/K_JT
M:[3+L+ O_5,JO:,*0)+0LBIFKH;OSRZL_->K/BSUDU3W,?O1B:H.+SEG2ZYK
M=:@T&?\X.R>5B$\5G*G^^;DZ4^5'*B<&X!GDDNH# 7K*&=]"I(/@]<XOOY;V
MWC=].E1;_^IXEQ=][\]^#X;\=",\<-Z#D>"B_/4,.8D4 Q[$G$C:T&NX3?$W
M<,V=77XD<77&"H!3H:G8;(&4X@7!H*>@>:&FHCJ'<^-PNDY!</W9X1?S G!*
M1HKVKDE@?>C3M7]V55X=RH)I(T1$KU.B]S&9/ER??3SKH4ZIM 7XJN'+^=#Q
MOGR]@ION@L1"SU5:J<L\B1*6=ZCM?.C#POM>'T[)*6EI5?RS>/D;F^9#L%R]
M=SMM!G_#$WVV3CO,T@LO8]2&\"2?GQEM:/D-O E'^V/N:%^@IO#Y"QWL3U>7
MG]VC3K+]XXI7 YM?O=][9^<DS',O,):4O$3N@,^D7HDM[H[<^!QYYP[/6_BV
MG5JF9I^>]]!6!3T&=Z?WX?)W02RH F% 5?3J]SZ_3,$F"!7%DW$.,ACN''@[
M7\($GW#YY>P" 0]\RYE   C:9N[C;N/$Y(:^ZO? *":8!_NRAD7 "OJTXH_]
M&U0@+D1MP=<#UWRYO(;GS*KQAD!-EGP#)8>KA)M(P38J =TZ]C.@(UQW03=S
M_ -LP=-;T&CG#1%6/#LGA8PWY 68<HF%N^EWV6Y[E?T%O_M:/38+C)Z-\S[M
M=?>.#OZ7U&IQ(=5U&$<)M][PAO/0V]W>W:^91[O=W5Y'9@LLI;O-#+5J:LO^
M2??XX/@5TFB/CYZ7G+MPL@?=XYHYOTU.;=G (.Q%TO7(F^DY=1UK#$6O,QZY
MR)$=P^6#93BO5_]RW#VH-9_7AB!=7&OS'V7LDDM9JHS7-T/M/OUZ??;%R[%^
MPRVP3^/P.U85WMR':3 -YW!P,KB;XT'7Q]Y+5D\1JB5)TKL@)I1=++8DM$&J
M,(FRF>G!A14FX^!15YM<SP3_XB,H9010M(4?BZ_SQW!=>4J %+2OD_%]Y6GG
MTG L8E<@+!E5>]?K7F,H;VJ J.^@JI6-I0042\Q#:0K8(30MW,9Y*-U%!';F
MEL L)U'F])0@MG:CB^L76Z\-4+I8;)5(K;50X;4!)1?S,/>C1(@'[F.9(1:O
MZ@B< CM'4P3HG4^87HB\%<Z0]V;W"K1+114M2)E^H?.?[@PWFP7XH!3"K9_\
MKXTR6(,)@4;V';I^FKPV[-<2EA2H#0'QF 7?PMC@=^N:?<.=_"0W)!N/1;HF
M\QGB=Q! @:"$:(1<'X3N&%N8.5"\C@C&WMK8",W[C]WM'7_W8-N'51/HPMT=
MG!?JWFC:,/EE< PDM>>J%RT(Y0&<#PM)^V-(#HP@Q<YLL?<9)/6.3S:H!3&(
M* '2#\5S#M]M.$X>&^_/)-!WLJ\5>E60FH4)<DTJ2H98Z-AU[0F?HWY'2)9=
M),O.$0DK;H($OYH@U U>?; JJHK5'?'T^+IEYS2(AKJY[E! U1 3#;'28*,5
M]B2.&X.-H?&QL.>##/8E>"+,EX_X+N"W:&QO6=<\""M6\&)9.(G>!7$\IW)]
MY!&XU0-$Z8H9S()&H-V^2!Y"@K[?8:C($)B;D;WL;Y@,L%(+[DN ,X28@W'"
ML#^F3Y]@>R*MZ#CTX.B,O9T#>N_E8);0X ?8RHO/6$*]MAC 8AA0@[W ^Z#&
M^Q@\=7S"\6&H^O%3U^OE =:24L1L0;P<JJ]O@RSB<^OM'6Z_PW?1SN-S";6U
MAZ/R&(X?0F^/OYX R]UG#*2&FTAUU2 #^'._,##MJ.XI "-DB.7)^Q&2;X9;
M#SCCPWJD[1#!X\N2".WC-M2;F[\+%?S*?G?[<&O8\=T/PH[3F_80>T;)_*3'
MR(21'>P^(RP(N*.IZD2-77T-E55C.-D.C[M//_&9FS$.81D(ORBJI0N-1B3/
MI)5"C$:W7_X@(K(&!$_ZF,S'0YLZ-DB1]+FF 9=2*4D=(AD22-]=3^AD&A+P
MN80_2^<8YP#>7:(@GTO7SAEQ,"Q'"X2J ;FMKX6]/I,>R(_X7UYG?K; COBN
M23!L?E,T;.KX,1P%\S&>54%15-UMZ:1;2(H$;05'S)'FMTD:A^I25=>O:4M-
M:/@NM+TBH> +FVYI8'CZ)/75K>A(ZS0<AP_(9HH-Y"HH%>WT'7:SYB8BN$U5
MRS3]X>GND)4H.,4%X$N[P+-;@X[BSE5;!C6C)Z' 109/.4U+VGR[4EYN>.H3
M2$T;$V^<(*!I9OI%\Q7RZSBYA5'D:3@3<,T-(]@4[*7-N,9CAI72/4V,DN1)
M3\,X0:RXL QK3G]F630&54]/!L1[9E2!*,XW39\5>@+F5,,BK&L%J9[D MQ*
M!-(MB.43!8Z\$M#D>B)X]1M(541*=C<L4K+;/=E^^9#&R7[W^.1%D$'6'TM8
MV3']%LK3SD1E0C'GW;$HBU&<O$;M?'MJ?MY3L]N>FO;4M*?FN7[T-W=JIO=/
M&<ZJ/3?MN7G% ,B;.S?M;=.>FE</D;VY4[/R;?-6\I3WVIJ;AM?<6/[#K*/\
MS0D!V%'GAKLP'CQA*WGJ)QP6W+:,L@Z_D^[";H\<[,00J:0^>Q2GI4U&3DB[
M%89?:)1Q"L\FPRB(*SK@V.&:7/\A'%S6(>D5&($!2E#/B*\Q=7.BM"QR3/8F
M0,E!@-."DSL.T!M-,0@>4=H_8R0"N6DH(;,GU0YCI+,_5'+2B#LZC\BK/]3=
MKQOOO;[2\;$HHR"+<N2.YBGY7O,.71V7UB&\TD2KI:T)K7'OH@=D"AS$>)W-
MFVAPG#).3?IY6%]',7X<9/>4J"!Y G9++&)Q#(W>2F<M:DD./V#_=>EOR"-N
M@BDZ/HK):EF9W]LLK233QPIF7*,SO82V[ [/=_'F<,I,]5CG+N?LK$_F=S@0
M'CGSOD (0QS=(-XKST6\,2$0%:L<C(,(.T\FV-\2^8G"%Z@!8I=WU3V38UUT
M!L<L:1([GF*%S55TLB3PA*^\PW?$1N"5YG#B:O_$_IE;BH\QD24=JJV'MXR
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M2<S# ]FFX0#-RF%)1L]I,*5P)PI[3@^:9^I!.UT"TP:&X2B*\U]:X7[.HU(
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M#G<@Y/%2M<=(<#]/R1>E'0D%$!VW(5Q-HY)](TPZ>Z#' )4B2JS$FU+=X7
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M+^PNZ[19H]/^;'=[,%MO]V1=+>!DG5_CQ,O/.R<WESUL)-:YT-SFZ)BEPI7
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MK(HQN0DXLUD$*/?+#<J3G L>,G 4,6@T".Z5AP1<]OLF4YTUNXLILL?E4O6
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MXM50[+9<XQ>]8T0D7OPJ(K+]?GO_E9SOM3CU_%X4%'ZK9-C4:@:F>I((./)
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M@J%MIJT6]'DM\%UM)D@OC3V3X\CHT1-Y\$J44BFAT1*W$B@J?GT06VDF:'F
ML;+5H$!20(%)A EC=8D+J6KET:X98->?"5H>5#'$0(PU!52@:DZ6P03-B"Z%
M7,.:0=6%3-#RP"LM# D@4"T:64N,::!&BB58K]-Q>>N:@G>]F:#E008&)5I4
M)9$!""Z2%I8906>C,-38AXU/OJ]F)@&J\U%81U49HK&8VKRASA6B+E;U(2Y8
M^Q8B%P&SOGHH0!*G@QA&8D-*)^<,<0B]V%B[(72RN_OCZ;-C3G'.#F[]Y\GM
MIUN/UA$\R#YE@J(,64$PHT],G#+FP.+CN ?U&)T ;R4U%FFQ6B,YX;\*R(>4
MZF(1%3MYX3/U8%E5%\!;S5(IJVK19%J!HX&<4Y*'6DS"% ( Y+X0D[\ []7#
M1T^W=G=OKZ/=U*Q*R!Q2H0QL0TRF(1@Y5OFTZO[;S6M";S6[>Q8V46OYPZT*
MD6*KR6#-MK K@7W_#>?UH+<:RUF=M;FQ3C015*4$K2U$8&VUJFC7P'(^;,$V
M'G]M':UG*LX7\*UX!H$C"I%1B4#B!N^<2WW94*D;"*ZFL7_V7BOPOEB *FJG
M8E1@2<RI3]&L@06]/@178T65"4%G\7X2ZD$,BH1VVES:5(_1W)O$V%\@>.?P
M8/@.,P['_&AX,)E-]OGA^ WG.=*(GQW.#H[/LXX&-H+7-BLDT7E@$ZAB,3I
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MBA"]DP@SJX6\NL9'!J<O-O*ZD=<FA.XB ?LK>77+J^O"XH27J2*""L6)956
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M()52D_>^!^UL/K=K+WY8YJZ]75G[O_JN-<EI6W/($G>VMK8<:U'HH90< \6
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M69.H1I4+Y"CD$JN"4ESAD!WK-1",Y\]VIXO\Z=&BIG4C&E_;F+?FE!UEYFH
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M%_3] POEOW[]HU_.^L>L8TPN5:*(X'1$=B82Q)0DFK?4AZ7-9Y+\'J?ECY.
M6_L'H\D1\[/Y)+]]?+"NO7B93;6^NI1+@=;8-0B:68)R@\YEUZ?B]#\!\JEX
MDNFP]:1?0/E\/)S/GCY[OHY@Y@ Y!A>*2B"O(L9<DBT)6RA7G>V^]WDRPO&E
M94P+U!XN2BN&[[@-D !4]\2_E*P#5Q!@0H*6DC8^496H#8,7KY)[I%XKA&;U
MFA70E>2MH]SRTJU9I?<U54NMW56L/6B'_1GX'H[+85YPO1/HH"=:)2S#E.JY
MZI9?%&LGC\Q98K!14^8^1<$K@J4#&@4@N!6M7/*@A#(Z%X+81I>,JSIQ+S7J
M FE\<CC->SA;V,6M9T^>]$C!?%2^6%U"3EIB68-1P!+W!;JR][VB]]U :?7Z
MQJ%@RJF4:!*T.5PGL6\65Q9J,-EQCR 5QC'9Y[-$Q:-)QD\EC)\*=V?SQ_49
MCJZB-?;JX0R.JP)?V/D"CCPZ#]:'MJ61<'[5IXG4CL&YDAG31BDS"9::$81J
MDBN%'"P:_*7,W*,*LV[!N9H",H,8G76:M'6@G([R3_$Z2@A(J88^$=2O@O,I
MS[@5<=^61]:*M"<'BPSRAP,YVUKV_&O)80D'A0I)U.&JI\K1BEYJIX&"+>MF
M?E<)\$H,LN98"UA,@ $*5@G\372F)'8QZ)37S2"O$.#5F&A5DV[9&]\V.',Y
MIV2X&&P5^>#II/?8&IGH9SP:#<>O6R?6*8X$YMME?S@>SA;KU=[Q"=)KR96%
M2H4LT4Z)T8 70F6,-:TKO;$NT4F;AS4RUMV >C4+QZW)/GE?B@;(-HE'%G5.
MXII;*X2T=CRZ$U"O:)%&49;DA-&* =?64G:F1HBD?"1=8H^TNC-3T"O160/8
M%L2W]6X,&5H11O'9@$:="FO?(YWM"I"KT4@@MIJ"1F\M:*.QE?JCJDJ#J1Y"
M_S5R-;4$*]%*;YD%*2O4MX*'2FV#YFJ+)Q\L'YO7?FOE2L!<C6:&)'0W!V<T
M,V#.U'KOQF)=Y"1TJ4_!SM>8V'4,8IPQN3JO,Q<%NM;611210HE%AQK7C>ZL
MHTG-['3UK>,YB1:R)JXFUJ1*3K[&T*=EY*N'<#6&M!:E2[:N**\ B%(@T"X+
M736811&[W[EAE13U2IHS:%LSF0S@L@*"&"F*3R-HF7BP?E'"K>.I5FVP^1K=
MBE^O6W&)YE'[*L&\9HD#N4I@CYR"%5Q)0RBA^VOW.Z);RUN>GW3((/&;M84A
MZ!)#96^SRC7)*\[=7P[:#4B6N9<F6O0""D='D'22&)L42LC=R@2<C=VOF^L(
M),NKEL.,-ECR%'T 9RC:$K3$R6!,R<;%WI*":XN0KZC+5FY])6*RI0!6:.T)
M8S%BQ2P@>==;?[(*6);G4ZAB\O*7!C%C2A/6TNI,58Z$)O=A,^#NP++,[8!M
M9'$C2E%D,)BBTRA&JR$4V-@>U&-W");E^1:./GHFFXK+4,2( 2?04 -%QQ3Z
MM$7!$G(&7[S69YI[;@_'P_W#_77,">JB:K:FQ!@E]$5L7LU;;XF"B4GKC7!\
M43CPP[H*1U#96,P.@XM0<R526M>88E& V*M66VMM.5:2BD;2R3O'/G@ !DQ!
M9"(GU%9K\G8-IFK7PW*L1#BX<JE&A$(((!3C*0&(>.AB@H]<O[-YBLY:CM7,
M@)12VG*&Y (B.# $T6OCV$+(IM2Z$8Y.6([5"(<GCDHE#L$PL"6,53D"KUG%
MI*#'T<KIM@SO>-K&/9GR_O!P__%8?H;9F<S7M'!:(DU,B;,2SJA2C)8IDJ'"
M@B[I7L$I9RC#T6&KBGW&^7 ZG ]YMO4ACPX+E_O3R7[K='4X7]38/JY;.!T/
MQZ]G3WCZ; ^G?.?H\R=8=<'F:MK38?*M!,R"4@ >D],. 17D:JRAU"?RN)YB
ML1+:& T&HL0255BPQL4J[J#XF(N(B7>]8@9K*1:KX00Z&E^4*R6;"M89\M0H
M0=3HC6(3-TZD V6I*\I?L@,))@Q5,N#)H$276=66O"Q I5=9B/45C94X$PI!
M(;$X%!= (;8:AU \(_D4"7#C3#H@&BL*,AVPUY:BJ@ .B0QCU1R\P2)D8Q.5
M_!7/6$<W EE0]K68S!Y",:DUW= 0C:EH;>S3)C)K)Q K<1XA9\RN>E;> +$F
M,1G9J9BB%Y\!>N,\OK.R?72&7>LU")B! # I>5VBRMZIA#UHJ'^\&GP7/]P^
MG.]-!,2CBQ#>DZ.S^3#?;1O53H]Z4MWR_[/W[=U-(\N^7T6+O>=<N,OVZ&E+
ML,^L99+ SFR2,$D8-OPSJR6U8H$L>?1(8M;]\+>JNEL/VWD "7&,SV, 6Y9:
M7=55OWK;P\CS1X'IF+9KZW!J=7\412$(<=]UAZZ]_G0!BLCISRS/YU&6H]MX
M=6N5[PTE;#8KH*_98+9OFB/7YK[C60$ ?=]A 7-\YCR"O.:;Z$*M',9IB)T<
MDM]!$!<A /;'D^8<619H4MWRL/,@=R+80+#661A&@8'YS3\OA1Y 6JP+4QB&
M9PV]D-O<UNV(6ZXS@H]&(S>(F._("I&U9HI;#4,_G?"<S3B@J*  +MJ*\NM;
M:X'$MD"1<V]D>P98YQ'P!,AT@P?6T'@$S=(?7%#< U.N"W<X46"!0>880\>S
M1T/#M8!%/(P4Z>'(\O3UYXX'P'Q;(777;.B:D>Y9++0"="?[OFN[@:5[7F3J
MHR 8;H74SW(.UH4A0\\W/6YXSLCT;=]GS G<R M"GWF!&5K.XV?(5UG.X[/T
M<<D)(_"!'H8?6ICLXIJ>:;" H]_"BT9 )2*+O8YDP5S#NGW@2<!3!B_=I"&J
M3Y J 2O*3507]MT9OX[OZX$7>*/(M+GG^$8P!,O''XXBQ[6X\%296S982S8P
M[[#9B#WT/=/T?3^P72]B1N",(F,TPNJ\D2TFK#E;-EA+-G#N3AJ$S+-LQQ^%
MP1"D0>!SQPS-P E\RX^"84AL8&W98"W9P+J[]BBN9W$P&+PP!&Q@&"ZWF,GX
M4+=\P_='PF<]W++!6K+!\.Y,24^/;*R=L[$*9C1D(UTW1WIHVFXT"D9"&HRV
M;+"6;#"ZNWXC>F0&GFL&H8,&G,L\SW2XS;#.T@SLQS0T[1:6_0Z;Q25+<#9[
M^Z)-S"_RK=!VS(C9//!M?6A[MF_I@ -]'0BK\HL>!V'_9$DEVL@G27;!TH"_
MG._RB.= ;3R/1<'+MD-%6.R'O%R\:!/I;-BN->(Z=UR?V2/7]D=Z!-0T1M8H
M=(:F\XCRR!Y<PCY\$A@VK3.=D>MSG.KBZ*[I.%XPQ"0@:Z@_*G%,R;U54%9Y
MG)[AZ+1Q&J)G-3]O5R>V?*+'/(%="U_QS:Q+!%EDPA$%U1IZ-@M#7^?^:!@:
MQC!TC-!Y3 =UC4G[,(,01Z9I.<SQ/&MH^Z'%0NQW-(3S&09L&#RFW@/K2]J'
M2<*T?--UA[9MA_ ?@,:^;3F1Y46&%5@ZBQY3$_H;2:LN/"HG/.]<O8GRV-+=
MP&9F8(2 CLW087;H.;KC@<)U36OTF J"UY>R#R*.]< >#J,H\ S'M$=6P)C.
M@I ;W 7%.^2/J:9W;2G[0)WL V[SD1\&V,<E=)EO<WW(AHRY=F"-V&-2M.N1
M%/#P)+5,[-,]\OB(F;;I<-]P#<<)W*$^LB.#>X] P:+7D6Q2GL]@R^:';-H&
M2X<5N2SBK.3!9"<;O"G#P48J5+!;>62.=,\-;2_T/7,T#+S(]JQHZ-@A>P0*
M=?TH^2 *U'-LL$B9,S0<'8$OB%E#=R/3U9D5,>8\ C&[=I1\H'F3+IBB(]\?
M^:9I1Y$/%DMH@[EJF28SS"%__-)UE\^RG7FYD0/;F64Q,_+XD'$7K).1Y^G<
MLRP[P%A=R(+'+U%_$/4>9D2HPP"K6J;C>;X-,,>U3-L9CK"NUPM\SW_\4O3'
M4.^!.@!9>N0[EF,&0]/6AP:S7%^/P-[@WI"'H\<4/[MV*#,1\@T_8\DM7'AW
M:]VTOMQ$Z>T.AP%S=0=@L66[S& C'T[^<(2%(Z8YW!QC]6">%4', 5#=GJ)W
MR+SC\#PNLGR.[I&-]$%[@1.-1D/'MTUJ<.SZX8@9CN\A./#=QP#''P4CG7!0
M<O0AL1*E#+S/XY*'V45:C--PV<FV,V'YV69&/L(1MJ4Q>&!&'.!+P!P+1W@P
M>^B%[M#4'Y$"Q(ZX1]$XS[&G,?[V)_3.Z*'OASPT1_K0LAD;>B/7!-WD@RFA
MNXYL6V?H0TE.N$I_C.3<J_(L8OF4O6$^*[,\YL7)^/[I.;PU/>%22[^+X^GX
MNL%TQ_"'0QN4 ?,<%_X9^9&AAY;Q&/RF]T7/&Q\L8]B3F)_3\XZB@S@!L9ZE
MW2!WZX)=^%N2S6AU:;B33:<\#V*6U#_<R)P5 T2_HX,*< +;#BS+]3PL4')=
M>V@/^>A1Z0#@KH)1*>E2@_2W>3;-" R<Y9P(_KT<=J/A_+::G\Q3P!/%"0,.
MNO?@S@,IG2!DUFCD@0D=VMC@S T]9D>A:X=^&(34:,,P#5!$Z\8V#R$B[D1@
MC@'!LI3]P')B@RK5=*?>]N]HK>5$IA>$$0_"T'9#UW<#TPZBH6$X1CBT']-L
ML'6@T<,+ '\XTDW7=D> ,'%TIN>&T=#W;<\,0COR'I4"N8:@_\[2L__ _[^=
M(%0Y97%:96!(;")%0QL'H;J^[9HCVPPB/_1&)E!7U[GG1,Q?WXK_1RO2?QAW
MW4LO F]D63S"W%C=MAW'8XZM.^$PLMS0\6R+6ND# K"%]PK^LKZ&I^A.R@J.
MK#"#;\E91)\6LF;A"P_?I2'/6_,1WB: /%_.]RZ1=PK^-H\#WIJN)#SB<5Z4
M],VM9BK<>L4R._<M8M 6 H;EM+]IBN=VXYP'8&;=!?[=2WE^-N].(BJJI(S3
ML]OB[.]UG $LL6_I.*-+[\@R=TTW HVG^PQ C.\[H><Y^DB/(A:-+/:(&/ZA
MV.?^#]P)!YJ%=WCB?F:.]YEN86;\T#,<>^@&'HX_,-$390:&/10H#T">RE/0
MUP\<W&"PO\KR,K[_VA5#OWV6@GY';<=]U[-'GFDZ+K?MP'4=BXTLW1^Z>A!%
MPV AN*1;]T^[>PV/Z-9=63:^Z>J> ?L5V8;A>8R/C- R&&<.X.,1N3; ^#'=
M=6/U[\;!Q_RL2M 9.[\[''S#^7O-4_Y'%:<WI9K<^)R0QR+;88^(\:!]V(Q1
M7S?[IGL'()L9PU"W 6;;A@EVM>?ZIA4&(<XUBP(WX,2-GNZM']2X@?#_Y2DH
M=#)\ B(*2^ZB3>1:GH&UXDV0E%X+'7P';X(^L1GSF1, 1@@"QD#;.('I.Y9E
MX1C&+6]^-V]2#$%"\BT_WL"/YLAT@Y$[M$:F9^N^Q>R1;V$753^*1J;]".8W
MW+XJ+.6G\/-3GD_CE&RGEZ!(H_@^\J3NIY&EZ8\BRXU\,_)L;V@S;\@-,"X
MIOK.X\A?7VNB_6!_\J_QY7,PW;,J#W@A_CGA+*3%A_'Y;_^"_\A#ZMI,#WB
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M0IYK+ A -N8X?H[D SK9TI6?@J&<]E=^44Q!J,)3<H660)I,81/F/<2G<#L
M=*A0SK2S/+LH)^KK <!53FLCIQYU$2M03&):G0FO><4*Z6OCA;KLQ@NN7I^Z
M$/&IO/B*M:HK.VY'P_3[IH+>;;P]6,-4LI$S<(?F-W45L0>68]]]&M7 MN^^
M6>@]+G:TR?,1?GCHLNDFE^_ V3W+\OF*R"5=1*<ZD!<]ZB#FP?3PT\?=S_:!
M^2KY^/[/SX>OX1GF[]/#UP<6W /' R2P3O/#^Z6Q /,/YN'GH].S+Q_>_PF_
M_4/_,/WCRX?I!_W#EP!P"(X'>#?_N OW,+I]3[@UU(W T_O,\]V^S;C?=T,6
M]+D=<H-'8,CA_-8WJX7MCVB#\K4<?MLFN[=C\7H>PL._V)T>W?$R*1_^#>^!
M=/:+K\DH?%PT/%P%N7X..FX"^4ZN I[K\*9W2\)[!PJTER^K IY<%)O;I?P'
M 00 !@<U0+ #VXP\?]@W38?U;3=@?5?G9A]H87FFQSUK:-RN2_DMA>^WEN5N
M@DS86VU?;B7"5TL$M9.O:2-WQ#YN)<-W2H9Y1S(8WI"[4=@?\I'?MT.?][VA
M[O8=Q^+,'.DZQ^8RMY8,=SW!<5V<;]$U3JZ>%M\V&05#%A2H *2'62EEIE6%
M<)#!BW*<C[6JWWZ6T[.2.3[\(H9'PV.U%-XM0^AQ'A>$'%.6!GB^ 4]BCU&J
M7"I9&K(\7)GGHAG64_9LI7=K_5VQ.%#W<?'05P>W9-* !)<:$ R]F*PL.;8?
M0@("+;$A,ZR-G5%,O2Y79D4!* H_4O3E4<0I5H/P"C_$7\9X%%/@&13>>99H
M&6B8%BLUN)9FT=><8^MVJ[3VA.4^@]OVCRX3/J=TA*>&H[T;G.!P[I$YQ#K<
M9_CBS5O*'%T_ <W18M@HSJ<B[#6#9S.\"'B<LD-#6C&KPKB4ZWKP_*M[U(#[
M092/\5VS?-Q0_%7"SKJST:+XDH?],J\>9U'8-P?>OAQ^VM/_\KCA>1[C?3,8
M8F67P_O,BOR^'D3,=R)[. Q#BG2M5ESK$?E:[_C79B8/4("LF/ D46I<>WI5
M[OF50:!GWRZ [@R)_YBY%2>X4QL,P+]]J,7A[I[U5\C8T+==IS\,HJ!O\R#J
MNYYM]W5K9.N>!_8VLVY$T5MAM#FIHJ<@*=C9&0@<E$A3JA23Y<39HE508[;S
M3&+V#(07'#C*!Z68?(39DW"G8OG7/<UG"/^K&>)!^"I(LH)NPQ+,.HJ#^I&!
M*' 6]Z<L(@11B+#$+Z^I<L-+?J]2*1 M70P2[='/$LS>+&6KA)#-KWG#:58@
M=D,+,)D+FX;C D"(9"F:,#0L^.^*YHOT\$;_'.J#H=L47U/Z$YO-\NPR!AG$
MX3;_E-+O%>4BP4*K-!:RKRK")UUAZ'N1XX\\TQE:GJT'%ANRP/(<,_!TW6<^
M^VN?A.'0TI^ +@C@$4GQOT_ZSK)$?$O0]562L>Y$Q>=I->V'6=F7/W^BX3O!
M3[V?33!^"8R_F!?JGC-B_9'NZ'W;"L*^'X6\;_D&=P/7&KJ&_N0W8S!40E$1
M\3?-CY,$_C+03I#NQ/D=!E8'A%I2A#%P54FY*"&8TJK98$;-!G-0[2DFT_$8
MS>5B)NP@K3E6(G]9W0R8K:"V%IF67:2%9NB"[>'S@ RJ'!@YKX]55I5D9DOO
M?[-"N [O 5 C0PAR 6:ZYO,DYN<BU7L!DHAL1$ >K+;&9IGT!$S8.1=YU?P2
M&T[Q<*"=8JIA".<GGX*])GOB-R^%MG]9%:H )H535Q0L!UDG'@"W*7 7NG=
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M?2^ZX_.X!-D0K-^NW]7JOHX.QWB*7]$I?G Y7Y_4#J:]K0O&0(&H6N?U<0[
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M:K>1J+/U$6P&20]$*S%L(G;,SW"^%$M++. T1B\*BK)EJ;;W=Q67\QY<(2J
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M3#M112,)&ZJ*NH4':K ?H6RHDN5G+ 5RUC)MEN,;B.ZQ(-2K%)O!2G5@2G5
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M3UE,P3:AARHY7$I-\^N)82>]EI>D,WE0MF./<L ^-/IN<]OCGY*30FP70"P
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M<6!P%9Y*BC).5VAI99-*N2#>"J=.D740\H"%5&9Y00.8</Q+6H]^0,E2S83
MP?DHM7:GFXBRY.>B=K?7ZK 88#UHC[IWXT8GO*#>V@46M&;8E%G9)+VZT)@2
MU\XR?( L^(C3<T90LD4!+#V=8-UQ&2<:;: 8:(-MZK!F9<+"QKX]9W%">6V(
M*3 "K)JCPZZHGBK8Z+DG>K/ 5IR!(*A;O+2\6;C #"B5*JE*%:1URW2!D\H,
M)]%(+(2_HCX/8JH8I0G3ZFI%25,)ZU<;8.4U.UN-LV(UNNRZ=6YS5[\[=]70
MM\FKZ[&6S4Q>?9C5H"<9_3X3+'\3XXY",9!0B,-VLR]5-2=$60!PP:_*#G*Y
M9O2Z4C2-E%6XLU601[6,+)CTI)C$(B34O-1]6:75U>*O,QV>RJ95$PE +H!+
M8$<*T;1TBHYR,C0!_Y59+G^NKO\*"W-9DCXNNZ'I!=7R[ZYLJ-;I=*S #>XR
MVA.BEX$ Z+A//E9+\@(TU3BM8>SJ%FVU=USB#SF+157ABS#XWQ4+25VVBD;;
M$[@:F[ #OL$R3/SL H #DEY:A+)G>#T._0T"#]%JHK8\6AG+A:BHE V\BIA\
M[04P525<H3@U67BXY+Q1FMQ94JXT#LT6S:)6O;H$B:JA!C4&5(Z0919L6T_2
MIO+GLOB/,"KP/6P3PM3&-5NWE5)84  3.1\%0'V2A:)1%>X)C4L4/4#$PZ5E
MQS[+ ?$!;3QKCH.L5156W#@,8S&U+YDWR:8YCZ=^E1<"X\:%ZILFVR?6&:9D
MXLU5!ZR")Q$<$#C;Z*VB+BQJM+6:D$HC^!KWD5AK<XB[!B=)(-'+;"&W62"J
MQ^DI&HM^W-)$W<%U8,.DY)$+I7&;1F5>I2B>Y9$AC,QI*&2GA)QUMB*HMZ)S
MU$^O[F4N>_.\%4*"TTR^7)HNHMFY7$ ]JG/112+:+EU05Z"6!;G0HDTEEZ\P
MMII7$')(MKAI.2OX#8Z816TEY 0%?(4'2 R$IXHXO*,L%U:K;4N]U77!RW[C
MEG]8./>0=%FSO]<19''F,0"/[IZB:L'9F31L\Y&>T?<XL*JN*Q3=SQ_Y^3PE
M'H\7>SFVP0"VC:]G:XF977A8I[7=6@.^%MR3W< &:G149TRPN D\5#T">S3
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MZPQSI3.P16S'9!_<NV] 1LEZ@UH/915)1XW^2(45U<;EZ6RA;,LL2TV/$.!
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MVOK.[)9-WC4U.N<$PLD4GN&_H0>H#P&;Y(9(X..^!BOZ7 A*W5<8J TZ8J\
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MVWH.H]N"I\@7[#>J^7R!D[-3SH8(#RKGB&+K3\=@P,T*71=69=*''!PU#/8
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M3(Z.)G>.CR?W?KJ?<(F+\QCLL1W=MT0IN)ISKGY/9)F1=558C^+8\%,&\O(
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MV2"PW2QL*P?9&,#$L7?<G6DP:,@Y?[!,UULSEE?-@BYNYQ(%CXNEGE;T/TL
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M#I-=H!6 %^,CV<9;]YU:BJ+Q^0V[Y9A1<+&H;R..">>D0A/=XWK;SFJJRON
MQP!A1[Y(R_GD,S;E2 MYT8;DARL6B8%.;]4MG*&1MERTQJ811K[O%N2H(5Q/
M.;/*\3A9P8RB<)DE)UMIT\E-P=SZN=8>?.VVTR9\U5!KDT<!M$F<6=-0:T6
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MIJ46%/OCJTFA2_E84B_8,I)W\'Z+O!!_WM.*3SMM)I.40QOD'([O"#A26ER
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M>MNT+XOW /==25\N'\84^L[XQVP4,J<R[*6A' LQDF-A(QT'N9P&XC31)7*
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M3:;DS<N322PE'*42''=Q1-E]/N@[^!_%EIX)QY/G#9#6@_\Y>PM82LYI"M"
M ]U"/J3<*P1YJ5;P)B]<H/EHXR2=OMR&8"&'>9G2YNX.#0X[A*?:(+Y.CC%
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MT:SE;7&R@BLY(AFY3;LHYBZ&B"7'&"EY=$_0E?0C'GUYQB8/H]R@OTG+GP$
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MSN_XZJL/<5!"FD3X]H6FCA5\V*V5Y?F]]J0R2L-Q+T9 X=0=RXYR3](,CKE
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MWQ)?LK3+91GV1,HYZ"/KN;3-JG).3VK0!A?NH#%$)85Z(Q!*[&#!M@1 ":$
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M0#$PAQAU\&.NFSCM37O!-)]Q+LIJ%1U**XA8C\",;CM<KK-&;]TZKK&_=1_
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M"^V16Y=/05 [P0WBT]#!-@!8Y150>]QOSY ]U?W_4YR01<!&E&9H<!.@</3
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M&A$1SS?A PHBC,43J-25*"Y-:U#Y'S%[5R\>BZZN_A19@([J&"1J2/-@.@2
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MY^23J;$ G@P]NH)Y^*%7L1(0)'4W*X^[?%\,[$D-RG$4$QN\Z <7^D=.S(H
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MQBQQ$ZT,=.*YW)9IV, 9PN[*C\; 8/K-S.%Z7!5&2\JJ< W=*&_(X4#GA[0
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ML"L/1B1+T5%*87,[YQO !^=U_<7KRJ6!DXW<=W.&[YH&F""9N#=I@),-2>,
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M^Y3+JAF%O)3FZ93W6H4%0,NKZ+XAET+]%53"X-0_[08KU.X+K@+<::D%&T+
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M>PAC9OLW)!HF UM4N7QDZSWF83%!&[7+>MT6W-1$LZ]<%@PX$6@G2*7;V9Y
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M]+'J+4PZ%8M\76B2B?FD\PI1L;&9"LSJ8<:GN;I+.58Z3OD4I4&B7<3L6EH
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M*$$$".U[[O?2F8"%=)D8\+-'_)UU[F)-HE(PO-Y#'658$QY51*%9*8J1DOU
M#_)[*@KEAE2PUKC6VN+3+J5WR;+0*R;O@SU9F>JL<HZ-%T*K>C1ZM9S_MH@@
M==VQ0"7QH#?P.\^S7@Q-[/92YNV:_I8\HT/BPDM),$U]P<A<3\!4RIN%T;\
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MW_O<A1XQ\ZS,*/YCK'0_UM+FM=#L3/)SZTW+]^A]6B!S: 1"Z+6F#A-[*-V
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MM05XFH^/D'>53B[QY8A6._4A;9.[ATDY%YZ6>38!\CZ&3>.C7IN,>SUW>:/
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M[89#%0QBA@81FP>NZ\)/*ID'1FI$W/V7SZXVT \G%]H/AKU>'U,OIS(B2="
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M[BC)R^AZ8Q8@Y K<.>JBZ&W? 4R<%>?"LWG\.H.)17Y;VGX&$.K$ZQK' 6-
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MV*^B2=]ZC;K5JD[7F:JHD>M4<XTSKEJ)3-IH88PF9!75UR]Y]JJVC[[,2,(
M*AP"[>@_YZQ)S[EMBQ16R)<  8(HBUAE&%\:O/; F54F]<?ES(\=MTW!4M/G
M2$1B5E0E#&YEZM1IZ0O5W&-5;OVBFKO]+=2_U6+1U4E/,VCJ:_CPOH;CJ:_A
M?CS+GZVO(3X^/]%9.2+FLD-AEK/KU("Z*JH+#V=0$1E!,@39VR!<Y"$+1G-G
M#+\78?<"8$]UCQ@-QP YIE-FD)Z1,[R!]W*O.C]'@"PX#B-DR@X4$-%)1ZA
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MF&<K7M#9-FSSQ0(HT5.K(,LM2(O*W9B2P:DZ^ H&"2A^<D-\[@5&EUOKM0_
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M//E==',"=51MW ?2(PJ4AA8^*[T>*+;7)&L#W^N16#G;UWZ$GA0=9$RBS36
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MFB<?_X2Y_?WCFX'/_?43YGMW]O7(.OMZ&IP8WP<G/Z]^GAPZXU/CM'=R?=2
M^< <CHW3RV]WI_O_=!IVJ^Y:O:KI>5;5,LU&M6UT.U6[T37JK89G=6SGU1^-
M5KO6_N^WQ</_@^-FTGN0-^P.,\^#DA'ZVC+:-3/S-3##B[T\>/>Z76O4*4L
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M**S"B"F\&AW"&8PJ+A(1E45<"KW<-N%KYCBA MO5L8<8$>"(C6/'\1@F?(O
ML)69$>]D%#D_JEV*W,$.XOOX)6(:B,M*,;D\@C(=^=@N,KSD%(I)<EF&.#"
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MJN*+]:PY8#2VGPRO?$:)PA=75"@13"K'XM6:]A7K5>7490U@/OF\E%E.>\;
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MATZ!>B8P15J@"LA96.":CHL2H6MIA*[.?(2NY1E6JYXQK!+6JX3UVK6VJL?
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M?TKL3XE_0>#:7\KUU8F]EIU+RX9N[)B4I\0A@2B\49T8^?+$STO!FO$NT76
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MEY]^7ET>??F;--M_MH[V+[!]+SS:?_/U_,LN/#]KMHZ^7+#CCP?V_Q_P^;6
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M.4QQ-<U[U^];LM/;[6AWT:THY^V/?*OEH!^3%@0UEEPT)("R*+%_Z!#PD(8
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M1D@#%=[:P:[G!EX9V&]8"*/ZY-.-<)<6E'PZ+@/N6:LZUCKZ/A7N" W")B9
M)<RR%DH$B$GLC!7!E'6WJ-5 6SN$B 8.?3G_-<;P@O)//887A>&QY8%D*%EH
MD<M#% )*5 *$"UDB&C(31YCH6%L,(]* !-8(PQN6+%+-A=F-.%9>\(593TH+
M(:4?DX9%(D(CJ#' " RM81$EP*XB!J&!3$34Z9=H:R="C0C7J<VZSQ"IJ5WA
MH;QD*$]<<8D09C0D(*9* )H@#20/.> ((J1HJ"-."RC#^2_.^ALN<S<WSLPW
MT^G[U(MEA"MZ[NL^IKW+O7YNYVXR3TR+)::)8E]_H^.S<_09QAQ"R0A G&!
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MSQE<[KV,2?J(#&?!6AXTIU*(A$!1;B$\5ZGLGE3VUV<J$]R+:,$330%5:<Y
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M'?>W1!DJ 3PT 4S#NMR[*(24)"4GT8//!I=\9PDUEHND)+5&;FP*Y[K"W22
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M!>17*ZA; NH9D6R,R5H9E,9:12)=Z> NHR+9F3+QFTKAVX/J-6OT@3=_I]=
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M<WZR_&((3Q2),A49<3$G(J47Q,? 2!2>6JJ\2Y"0+!?5;ZH2927*2I2W$F4
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M(/<^HI[PHQ&,1QW?QS]/RX"33Y]?T.N/??]=K]1B3UZU9M,?GE9V3(V%?Y]
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M%D%H@DN+)5)%07Q@I3>M=9 UE\WV%B[0Z9B[-JI&,EL,Z8=5$!72#PWIJ8Q
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M)BP.TS,R(:+$!Z$<T2&C\N?<$<>T(9"8Y$R'%,N0AM(1HDV-L]8LY_#SI3P
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MW\VVA*BIBU:D+AJ['%ZU[[A&6)63[L%)>]<FA&H1E3)(1Y&!(=+F1%P*B>1
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MU@;YR[FN4S=W2]3.;"L#9QF#CF"9ESY(JYVE65!F\1%IH_&QP/DN\>@*YR>
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M.1=W.=>LEW)33G3FT7Y(7$A?N+; :#Q/H[@531NM9F9HX3OD]R[OH)=X2QU
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M51]T.%=_RWNSB5/?%R E%6 <Q'R\3D$L'M?O(I^)8G0T7J.X@[+0&*:AYHT
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M>'?TH+O(4]CF<$+-E(X54,6DGL'. >G%B[5R&5IH"U#>-T:,$5)4,I:#=.M
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M>OUNC2<Z&HF[(Q_USOSVAX6O=B>JVWK^6'I_UBT$IN6.CT/-FU \'_!8C=M
MXNC[ZU7>"56<,;HU?F5'L#03*FR'L-KY&,XRU/:?IMJ'H9!2/Z88ZSQBI/'Z
MT-LK]\3"Q74([VG/H3?]$$7SX/E3#/>>P2)"0#66.9YC!6Z<!;9,B+&[::!8
M8K2I-(UAPTV!QO/J4N)WX1TKH8RI&4'WLS:NIJEDA$4]//K*," *5JUC??)%
M4TYJM;1EL^2FM"F6]C8&ENV:"33;#+QQ$E^[.WJ,\=GXW=HBZRZ&H-_RH?DP
ME$7O5:OJU5$- WS36* _'4S!!?_W4!D(*P/1 V-SDY7>$"O0"DK+G @ 5D!9
MT#4MK3+&_)T(_XFG?H48D5L)N&VP=#T*G7_)S)-E[6)IY:>O=E:*_P<@7&D!
MD&)K0K$YX]J2[UL .:)F^#15X$_!X"F^J#?"2D6_)E(\E$*KCYJ::VV60HC%
M3U'<@* P[=0CH0D(:0)4FNXL:W68NT=[<^N%D)\7MQ*B02=I16ELO^7M&^,U
M -=%J_2"/4&W3\T8VO#^;6&=(0(>(Y;:@GB;BW[9!;'#D<!9?OHHNQ#+)G:^
M#L%7@4_HLYB:<W82^$=\.M7X3\RAMYS47 (#92,?!+#7P.=B?6+,F,#&#+%*
M\=I88;=P86VFP_KEZ%(QUJ/\(Z]:"2\]:[(FNC9)_8FNUV#L2Q[M2N!';4\A
M'T)ZD6JF[A3%DU0!&D.2>I)#H*0ZQI[%N:;,F[-6;(G;[3Y@&EK=3.W\#=N8
MZEPE;MOF5B21(-1)/ UD@M4+P_5=SY7KXJZP_1,@C)JG#9GV/H$-QF0V,W+3
M]^/Y+"2%7<!MARH#UU)E@ U5!F[!7(8J T.5@:M5&;BP:L!:P*"VI<^E+:C6
MDFN'1<JD=UQ65C++O+GQ*@._H>0!.@PP$9V8UP]M)#H]H%0S+65!')6@ONC*
M$%&5%;&@O3B=:=A?]IT:B<S_+,>1A7Z76LL3E$UTNK H$S8W-LJ?JEO>]KYN
MO1X:26UIY&$3OK";#<[J&NC.-G)QS(6H&T-$T^MB_>5Q\-7.:KT>+#M1[:@Q
M93<F)<<TYP>7G,SXO&UHQ$W,T4KM)</"0>YHDMO@[R@$3L[ZTO-*2O;NZ(GO
MVY0,G+-VO<2TG5XS/:PAV_;26TF\_14;@JUFS,;2WTE*!EX9!IK"QQ<.MCOZ
M?64DZWQ(D4OUQ6$30Q9(ZE82=N&T41-C'8A6<N_>%2J/HS5M#E?2!TFX>_U/
MH00\R-%AR)];!6,. OKX!.7^^>@8$]>4?:]"?^O9LFZ+^J7\A&W+BOU',2 2
M&^'AJU.!MZ;'7QJC;30TC24 <+S4:B\H03;H4-\C%3]H[C?,+R5A=OUAU_JI
M!B/$DV?/_[<Z/OGUT<Y:;O?*O4TIXT JX7K#C4 ]#J;X,27K3T/Q=<P?73@R
M"5<"-&RX-V.4V\)9P0OF/9H-+7);VT-'F.V$@K$:[]0D]-:-A!X-JLLZ4M+*
M@Y@]E2#'S@(]8&;K8KQ88NV-CJ9['9DNP+1(C/U[A,IJ_+JY\W5W[5=0*K3%
M"GFTI^/)9)WBGDRW/K;33XW'#$_3)+YNV9Z <TC?6_>G>6.#JJGK0FB5M=A8
M?;CPW^5]1]7\0[CFB5=T/<("7OVTVLZIP2/8RI][G2NVV/O#@+T[U9[ VL8V
M1[P[>MF[*,D8-K7I;\%=4H,\8V*;TO[%-4T3R$^UG^X9TF"@Y611KS!''*>]
MX=$FXB?1"7&99F=;^I[",'[1. NV\^)OXALX,?,/OSQL>._B8?]X!Q_!_MMW
MQ8',<FU,)HFBRF'Q74V$Y)88F9>JE%I:<[527K=&R.[.?;1R\+??"_NB<_HA
MG$\W8;^Q-"9!I.X$S,5:3SHUGZ-$UI9UZO'I4*4I6FJ3)-S+X>W][C.+N 1.
MTDV<-$FB*! <HE7\82]C^+SIH] ;,2P)TMTS2; +DCBL9.S>=U9I@.C@@? ]
MN,;"%*$A9=/D,M2MP,HXJ:S5(>91AYQ%K/4*:X\NV/ >.)!I[+\WA3,>3V.
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MEMENS:3MCL5(&ER>'7L/[UK?QA14TNWZ$ '_%2+@^1 !?POF,D3 #Q'P5XN
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MMOGBL>=]&S_6)OYN]I#?_=__'RVS7Y]C],0R1; F2UB]_44-"U]Y642A\#I
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M^HEO36ZEPGH@;I$^"T5&6_G8MD?5P%0HZA%>@<F,((RU2%<;8-,]$2'P@VZ
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M"T*5E1B<8 AH$!DQ@I:N,%**LKAWORIN23/VH>;A=5/M5S;J#ZF3-T32G77
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MCA4%6>N=)#0%/2!V6)ONF/9Y?65K_8Y>::]'X;E[]M.K)4CL.B>$SD!!RI0
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M318?\,H&*S$B+ 3$,^N0,9E"_Y^]-VUJ(]G6A?]*!>?N-[HCE)R<*H?N&X[
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MWP[GZ?6%SU!2EOQ]1.C;=8?!#]MA)XZEYU5#WN:7?<=<Q"X2%  V$,\Y0P"
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M+AN7V_#Z,9_+,O,,LZAE0%PFV]&$'%GO/,*>D5PS>,&"::7UTC/.!XYPJ8Y
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M%/[QT/FJ#["=7L9!:06LKQY8[]3)]O&1M0HU>1*LG?<*"2LHB0I9KE.HG:&
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MD5G%:"4^EPOQ.5@S""F_O(C% 8RJXM >$)T.ILF%P))&ZSRB-%4H<P8CY6E
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MK"H2]G.1_,N" ]%%(?.<.60)3=5UO4"&\(@H$3F1/EB1BF.3&@8LIS]^CO:
MN^9E1,=6F%EAYBT%DC2+@(@Q<*$X8]I8187+@0][G\I25NSWIV/FG/LV)[KH
MYH8L=01QF0-FYKE#BGMG4A=ZQ?.U-US0FI /U8WH9R+FO6LB7>4<7U>6X>D+
M+-RQ5$:1(/9WF2#V?I0@=NUC/)N4ZYW.5>Z:'!>#FLJXSHKLP[+K2S<SV6"2
M!N?@U=8@,ZE44U'MY[?TM7040?&?[\HW-\9O%B^3/W_/SEJ#P^ROCUF]VSN
MB[P[-/V0O36=XUK66-]8KZ74;>-3#9W^H%<TM(,[I*NG B3I!O#.H&7:63O
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M=5H_^7P$?Y_!^%GC8K[Y[=YY_>L6/,,Q_O9AZS*->>_('W[;A.]<[EU\^]"
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MXY<9WWSTW>QY$9>.R=/4I.:]I&?1 M/,<MT)^T5R;C.11-7)S[[,-#<_)TH
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M ]2FIB"(44"X-YR%H+%5B1IK2GU'#1PU<"P(.!X8-]? \43 48F6(6<,$:D
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ME:D'4X3585D-52\LA?U@J*JS1_=&J4I.FW#EL'<:2 DC2EDC@68R  \A)M1
M @VKLT<U3"W%LSU#3KN&J6>$J:$SQ8DG6 L/'&8<4.8\D-HQ@#3GA%KE@C(U
M3-4PM13/]@Q)[CKP>V:LJF2]%0D&:QP II2D,@$.HE_, 5(A]6+D5G.WA('?
MC*9+[$[TSR\A<5E?8SFO\4K*G>_=W&=6'Y_UDTY\@.OXCXU.K^X04E_CZ3N$
MO(A%FOW4#+S=T8DFQA:4,:EA>+^];>IJR^^W+%-O"WN;V\(D(<XQ: 25G@9.
MI?4R&&>E))8BR>;USD<I9@<5*+4'OC@/_/NP'<C^1]:\_G@(@S40H2BI4#)
MC2- <R6!L"9H215%(;KAA*E5JI9IUU<-2C4HW9C9M-P3BK%B'M,0O&&&<^P9
MX8$QH>1"0:G.7MX;CP;=/DH\8MI9H3P$!'$,*'8*:"$)X(Q#JBF67L!Z[WR-
M1TOQ;'>I7:'"($.P\]%#,A9JPJ%R% I+!3*(U$[2,H'2F),4 T<M @_ ,DU
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M%/0BCA>>4_5J&3IZZ4/O7)]FOZL_!.?/??<D/H!K7.24PE\1.]H-$H\]NYB
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MI5\Q!$BP&%#$'3#<<(")1- )&?^&*^_0;;HQ6'0JB*V3@3RMF+W[5%YAQWB
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M-M785&-3W5WA&3%KZ%-Y:8*&% 'OF !4!1M]*D\!XE8)2630#K_BQ@HU<-7
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M\$UMP)1"GLK 6GO@.[W!J%\;@)O( =E<6]]5'+PU;Q)**7<NRTWA#7&Y,WP
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MAAB$.%6K,XYE^>,B_JC>+7((;I#)PY1K9 >EB):AX7RC _LM3J/D=)P3;A[
MBA6#4Z/VU [4H>__>/,>5 BHANVLG@[S##@_'?:ZJWZ_';^#(&^V0;6&O6ZL
MX?1F@@F6%YM$3&0!*89I3GI(I*ERR!HEDR#<**6SY;WJN,.)8!YFN/ Y[5^,
M8$VF*)R=+$_A 15M%9'-Y+J=VO#I+J!LV;(62.=D^>X0&[\F!S$WP8R-;K$*
M9+KS4UX,$Y1B/[L# _ 9*CU_VPLVNQZM*=>C46QT_?(,;P-NX.&[2WX^&%H
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M>.C5:=8Z\#47>/GILO^3C,C]X1#E>6,C3^#ZY/.J&/%*)"ND$KE%_3WRM76
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M=$ E@-CBT.;ZA/9A)L!9]XHL;-U@*WZ1G_B_;U%8<S?%.2NL*?5FLWJB=_!
MF^7S_)T?9Z) O72F/K7BS%:<C1^;)WZ72L*\HA)QP7(GD]S735%0(>IC8HE&
MR07P&C%3;Y:+[?8/!/H"OE ONT)EE*?D[6"]XQ[("HC"G[8[LOWC@HP#^IW\
M*\@=,-C]4H"6BZH30E:0"[=IS+(M9?0G2W[O\+#7'V91.R[]HPXHQUTMSSCD
M='IIIL;EE:6.,UP.?K+KI6"D^*5769".'0SSCO;2W0O9:TPS'F3LWAWF:&0>
MU)3.ER;NJ W6RET(G'7B8%"E)JY4KRI[\2 :1F]FF#*&E-AQJCN(OC[E@?%\
MVE64"F&B0$FZ "HC#-)*)N1)\MYKZI632RM:7%*<?TU$<B8@WT168[N,;)=:
M,)&TRIOK7Y;C4P7+[Y2079FGV9NX&K<D0G>J+?A)QFI:X,)J-VR4SN-TLY0*
MV*^4T!KRKY):NOGUVZYE+K=A=,@))A!G6B ;J4,FTD2=<_"3 U<2#:XOGQTT
M@=2CV)^F"1D<QT[^V ,Z9=?+EVH0'J%(I9(<OQ_#J!.W)JG*[[;=R45;[WK]
MC7'6MBSB>LU%*<V3O=W$150X>22H8HCCP)!U#B.8=!T"#UX(=['(9''36*F7
MLXTE_.7%'Y1"9\NH: 4391L:UQL-K_:5+]1.#*[> OOFALD_>7[6""WGJ!SA
M635M65<,<]6QAX/X9O++;Y/]Q^UN%7/(%UTL(H:;CBM!C5D6DN1BT/'VY/'M
MQW6BRV6=Z(5*Z.H]+I<-45>^C9?)'=\3C-_IRI\-EHAE;E@]V$<:K+C1;:_;
M!5])=-XJ,UTJ_]/6L//4\,I<5Y:)KZHYN\G.^/M/SI6=5AY[":J2WWE:A-6J
M".1CA,MS)/1=CH>,24"]&,^R&&4FHV+SB[4"_>I17OP"%:>,N527/W+Z[]Q*
MW;7)R6V:?L_UGLK3$K;G[JG]:@X2F!ER\(I[K80*V'#X35OM@V'!V'QH2!+L
MVMS+O2L5JJ+8K5=6%#O>^'FR];EYL+7V[<?FP<YQWBSZY>L.A^__NMGZ?;]Y
ML)Z_3\#UI'EIX^>FV*'PV=;Z\1=X!G!6#YI?]^!9-W]L_K%.=UKYV;Z!X_HI
MIW9.^VYOKNX2@2..A"+,+$=<*8,<CQ1Q:TUBQ$OF<T$M;W#PQ!2^?/[(O79^
M/O\A)#5V/!!V!$]43!P@1!EN'-=4&I>PTU9)++&_>;CRWB!2@4?%B#9FU8K6
M ')/ )D<7@0 (C!6/F"!:*08<1DE,L029!5-4H<4G!< (+3!J6AP<3EH7P-(
M#2!S23ZFPMPE9:\AY$$AY(R#<$<L%U@A;_/19RX0I&5@B# AM,][)E5.EC<P
ME@W*Y:(@R&OH03]KGT[=;_Z1D5)9$8QDPGD:P:(F;:1,P-8==4[H9&LW[25
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M;A4/-CE/J18TF"BT(L;7KLHBJ/69M0Z.&1J<0RX9CK@'+\62*!%.0+X,N**
MVEFM":D[F#ZM4F['#KRXURCV8C?V;:?T2FPX:'?;>6]"+J%_[NWU+QOJ<#(D
M-W&60BDNO#>&QD MCY)SZ<)U'0=KJ'M^J/LP[9B O>+688[ U00&@QU%N2\8
MDL2')&T EHJ75AAN:/-0N^?G*.Q<Z_5I%7UPRF/'@M8TEVD;2AF-1N"\N\,E
M5GLF"Z#7TZ?>66L9%1Y)*3WH-2BWDU(AC[V"Y4LAYE03-0U":[U^P7K-&?72
M2!D"X4!DC0'.RJ5AQ/"4F*FS* NAUV?V6D09B9$"<9*/HE/2(2-\7CQN$F?>
M.0.N"64-<#SG2*\?*%-2?K=:5F+.W92['ZMP3<SENNM>;9[\UL__8A#^GCW@
M:X1_?H3_=.YP"".TUKF#&68*<6TB K.,D<#!8Z*-50$0GM.'.&GTMEKSS!'G
M&OUJ]+N(?H9*PC5+U">>F:T"C]7:*+@B6E%5^ZT+@'Y3?BL&O\1'09 $*IO/
M$ S(81H131BLG&?<<+JTPDS#W-]OK=&O1K_%1C_NK*4X2$)]X-Y;2WBRC',=
M!3C\JO;N%P+]IKF?BPI6"7&1=&Y"9Y$342.FJ?:6.LIY /1C#2D6!OWN<"+'
MW>-]3W2/!SMHHQ[E74;Y&NINMZ]J(9/ZO8,WCUI]6]_C8>[Q&@HR+A\INSW=
MJ/(Y=HF_9*H[ZQ%?#)OU1&LC3').6RZ(!B^>:L>U,=8Z=FT3]IK-/C^;W3L7
MR60Q1,$3\DI(Q)G1R#HND?>.&,N4<18OK5#1,/H%YJ!KF'JI,!4P<^!-:Z84
M)XPY+VC27#LLM2-!UR''!8"IZ5*9*+742:!@!06G6SMD.>,(/&Y-H@W>R0@P
M)1OJP0Z&J&&JAJE'WT+(;3#":\"?R#U7UM@@/>7$$A,BD75L<!%@ZHQ-.:.#
M%Y8A&8A"G$J)3! >)8(C+&[PEKNR\H?)>6)3KR%6<]D)SF<SU#ND'[4Q6*2)
MR22,#X$GQJP"C]$3&:@5P@M3.XMS#V_?SNV0UD)H !U$I/6("\VJPD;)P'O$
MA'-,_=(*$0W&ZBW2+UBON8N,.$6L9(P32FRN8[,X@0C0)'E=T+$(>CWE75&M
ME  _&:7(->*&!F0#EHA*(ISBY6*"7M,&$)I:KU^N7DL6(R@M U.<N.3).4[!
M;@?II&*QBIK4[LB\Z_74QL$DJ B!9FVVX(X(@JSR'A;/,.Z=Y3)O'#0-,5>M
M#UYG2FX>3AU_V>BF3 2VJ@0E,7+KO8O!:QT84%HCC7R\(OP:P&X!8.M'?[4V
MAIO;&<16=WT ZP-@A3P/&)@)<\@:9Y%(T3"EA=,Y[FO8/.VCJA7WH;M,4NJ3
MD,3'@#E)R6%)K74JZ$!4TH^7S*D5]Y:*^^%4<94Q26 ND;4V O4@'+E\T)CQ
MPF"JL4W4Y:-Z'ZJ/9*VX<ZBX>9- DD%'[<#B1N)BHCH9'+R125<=$A_%GZ@5
M]Y:*NW.JN$8DZWC22&,N$ =K"Q97<*0#QMDQA/6R2RM*S5.:]97M7+[L/-1[
MF>O]+/5>YAKQ;XKX/\[Y6%$3K51 E$>"N/8)L-\S1#RL,#8&UAK7FYEK^*OA
MK][,_&+@[\Q3#5H J94,"<DIXN"?(B>)0D&0W .:V^14O9NYAK\:_NK=S"\&
M_L[\?:%SMWN3$$Z:@;_O%;)$6IA;IX1AE@AF7\AV9E%O9ZY'66]G_LDQ0IT,
MQ$6[ZWL'L1C:'X6+W9C:CW*0T+U+;>9N_F[-'UXF17CP -'ZP6&G=QSC=NQ_
M;_LXFRBT[(_?*V%]U^\=U!3B<2G$R70 *8+W1*R/B#N)$0\1/"AN&-*4$D<(
ME]&"!Z4;YOY'9LY?]6 -8R\5QAXZT%/#V#S"V%D@B&&'HV0*,9)R')QRY!(5
M*"KAI#0L.LPRC FE:QBK86Q!8.S! S:/ 6.I_2,&=!+[O1K!;HU@9[$<'J32
M6'D413X3RS"-3/(*4<H\)<DZF4@N']"4T-_F",-*Y_K7H04O'/X-[>\KD\$U
M1P>@(7XB\.,_'\#?."_3VWX_AE$G;J79XESV2]JJVB6MPFQ];P^/6WFX+1C%
M[QUX<T&E]<L_^]@?_-VUG\UHZ^ #WVEMGNRT/IQLM3Z!Q'W\NGGP9WOK\R:'
MZP^V6G_O?UF#:T&R_SGY0+?6UG>U\8%I39&P/.5&V (9"S93J(PQ^;0:!Y,=
M0:</8;J'_5&$-8<%GHC5@>WOM;ME),9,[$F[&V)W^(;2Y2I@]\0 2\O# ?8C
M %2GTSL"V2Y*R2P&HP,8+MQD4 SA[2P?MGM<:I/Z;0 C/.NI5=BQD)1GG_5/
MXRH5YI4=XGK]\BZ',+Y>*!O&%6O1QP,7^P4CC0+ 6!?#WNF+E796[U!RUERN
MU);+,UHIV!L)3SLUQZR*@%:/,U;L*A8&$]NQAX/X9O++;Z$]..S8XS?M;CD]
MY447U1CN^=M1.PSWWQBSK+#*IFD<)!O?OGJ7+)=6ZP*F5.]QNDR$N/)MO$RN
M?.]GMR4@/DS>Z;8_?T\P5@]VL0:K;W3;:T*\MP@\_R3HZP':8O]IR*2Y '5J
M)I<$FYHQIY?^X_J_KFS=N"?@2YV/S^4?,933L0H#LWNQ_'W]1^S[]B 6[X&"
MQ.*7]S!K)5WX=SU;H9B>J8_QP+:[\ SE7V_A)IECCFRG_+L5^P?%+SO1]@>O
M>>96]_;Z<0^(03DI&S!'[>X N.W?MC.J7ONEW2U:^[T1?$FX,%6O88_DUF@X
M&,*C9P9FAS.)$-%7"M --E_<KWQE@:("@XQ2@PN!@10P"9Z)@"7FW#FC'"?"
M2T^I]8&HW8T\OQ?C 1O-=Y><IYDNTVJ_;[M[\0#T[O?CLX^\M\?YI=4CVP]C
M6S.USI4MNEF($R^HRS4.$!QM_O%N?[/U\=M6:_/'E[4-W#S9@S'NT<U6^+;3
M6L7-SSMTYP <_TL!@M6CG<_K/YI_P/.<O/NV^?4#VUIKMK?6=GXT*8Q_[0/Y
M\O5+^\O7_<X_)^OCX$"U'UQ)3!552"5I$?>>(I>80UY(SEG*!]/1?&:VHK2A
MR;VCG+=5LSGOLO=JJ]UN_?P+"I.C00!.5V+5@V E?42DG/"N,>V:<-.2FM80
M>5N(/#YK-"H=#<YYA'7, 2T=D8-7D*)$2!D3EBYOAB#+\J$VP"T*/-ZQP.K:
M9UH(L)@9>";99%+/N?"8.Y 5EP/1C@L"?S%)R]2*GJ16],S <U9W=STBN%LC
MPJD/-N5^9<^+GF-7,"W^31CUC\$;J\'B1F#1/.-3%.N4]S4C:XQ"W.& M$@*
M!1J=](IA*<32BEK&ZE(^XQG.7*CYR\OG+P_"6R[G?!^0N)P&.LHXQZNH9GDZ
M:#KC,5)Y%J,/*#E-$+>Y]88A'AEA0M[9[ZW)/,8TR/U;^CT5D7EEV_S_ .W*
M<>B[1+A>8+O"F4&L>S90?X1H5KEJ@XWN^S*Q^T>_-QC4\:R' [F-Z7A6LHD[
MPRVBCEG$(S'(!&J0"@3SD!PC ?@7:6A%&TJ\P*J]UXH%5T=J[@D(MP_9#&Z%
M!W78YB&1X(SN*,EY4C$B1?+Y,)GX:!TD@O]CY;4(0IG<PP*L_@M&@?OM1YL_
M_9^],O64W6[*'BA7O"BT>8*I=R/.B]N7[Y=G9\ZY ')C,!C%L#8"'W^O,GFE
M=1Q,5]">KE!-C!_.'&Y.$V,K,?96&B1-)L9&<602,TCPH(P24:BHLCD4#6XN
M&\1+53E/T<.O;K[Y6ACQ1/UK4OPH*'!&BJW@S$>BD:<J @J HVR8 6^9*QF\
MH%J(?%R/63;S=!C9,_;G6 @(N <IKH^9O-4CSK<</.<QD_<-DEXR 64#VSHU
M]'AF82HUQ"7QG&B)-+:YPW,4F1Q2^),DQX0W)IL%T^!\GDY5>&7)GW>]?HKM
MUY?^>7XO]I[0-EZX4?\,W&HW]^&0[,.TF\N=,+"Z"E%+" *!2LA)H+J>4B8C
M"4DPOK1"M6S,ZE=_<S=WCD.^+Q,%7H*;.P,(:D?W(7'@C-$8(5RPT2!A'04<
M, X9202R1#MBI9"!B]S"=YG2.OOS&AS=>LI>;_;GL-VO<S^+QIK+92NOJ5GS
M(UC+3^>JIDQ0D22*J)<.\6#!]?<,6+,A HPH$5&&I16B9,-07B>'%@<%7@)K
MG@$$-6M^2!PX8\T,8\$YX2A* ]XS<Q)911V24@DKK,+,IJ45R989FZ,X8)T>
M>J[TT&N:LM?0[OTF_37,?<+/K[N_A@?SF9A2)()IC<EH!N1*,2Z\(UR%:N_5
M4W#KNK_&(UK4G6EF+5ET1AB3 T\)\40LLC8JY)1.3AD/7,N!16TH+!OLP;H(
MS\T&\CIF?4OV?3>(J-M*+ HRG'%M\+.L220B&6+.N5.#X$^#1'+,<J.U4K'<
MGZ ?ZI"E>53\EQ9N_5ESB#MYUG5SB 57^:GF$$H(X6(^33)7V'!B/'(ZP&I;
M0;!T+&KNR^80XD&:0]3]_6_UB L!+#>I[;L;AZA;/"PJP)QQ"I>(4-S&,<!H
M!@!C. > 89Q%(XA->&E%X(84\Y3V?F4)R?MT<7B!J8C9H9* F0.4TH!CG##F
MO*!)<^VPU(X$?<U12W47AT7#,3\=-:$*)^(X2#U.!G'J&'(1&R2Q)4KHX!B+
MN8N#P+2A\4O.1;PR+/A)8.1^@%!W<5@D)#AC-,G#<D>9$+&*HMS:!;F  [(Q
M,0_.E J2+:UPM7S_HZCG& 5>07JMGK+GRD@N"FV^7Q>'Q<TBW+*2[Q&8<]W%
MX1G-X=ZY=OTQEZ]CBC 6N;TL>/G: T466COE/-8\DDR,.=4-0BYOUJLWN,RM
MFK\$3ESW<7A4')@*]!$@P#8HA$,NV#5,(7"7.>)61@D_E'! BQE9EFJ.XGS/
MF#Q\C'O4"927FD"Y'Z[6S1$6'VNGFR,$6/UD,%(N8ZU4#CGL-,*68ID<UI%P
MP%K>H'2>P/:5)57NUQUA<4.IS^\=UMT1YAG*ODV[CTX*Y56(B)I(@#9*CDPP
M"BEOF%4J4:++GKAYGU?=!'"!4. E.(]U=X1'QH$S2@.,)C 7"(K&,G :C4.6
M)H9H<):$R*T*J:P]Q0]UXN,\0L$K2!'44U9G51ZO.\+B!EL7GC77W1$>]^"L
MH])2ELQY=5>"_Q^LBD@:(1'GTB"CE$41"TF-T0[D8&F%$-/ ,T( =<YE;F'@
M)=#FNCW"8P/!YBD01"H%\9(A&0E&7"N,\FX>))V*L-98<\&65A195O?NDSK'
M6/#2]FS57<7FJ*O87)/E&_1'H/@^ >C7W1_!$.5YPF!50^0*C*E*43*/?3+P
M6_1YX]*3L.NZ/\)CFM0?T]R:82!4C%+DM+&(,V_S@8T6$0'VU%F,+1:Y00)E
MHD'(0X6CYJ9!0AVVOB7_OAM&U T2%@8:SM@V-9;DG=&(:@ILVPB*#$\&)8)I
M#)H0(?*156+9U%'JQ:&./^N0<"?GNNZ0L/ Z_^E4YT7@7"6K$(M<(BY-0MK#
M<H/;;6U&>QESOZ1EHQZD14)]_-'K//[H;BRB;I&PL CC3Q'&!)8P#@:I) SB
M(2;DE(^(1VNQ34DJEH_ P[1AQ+U/AJY/.WJ.)@DO,"$Q.RU)M#;").>TY8)H
M&P75CFMCK'7,N9(ND0E=(G63A(5'LN/IT(F61D1+##(X>.!*E" 3#4,J&!4)
M3@!G;&E%&]R@:IXJD^O<Y&/E)N^'!W6/A(4"@K- B;,Z"HDC<EKF)K.9T@";
M053DEE_:$)V TDB\/%<;%.H<6YV67)BTY*+0YOLU25C<3,)M"_H>GCG731*>
MTQZ>3!-C!^X]V#^!F+<JMT%,R!I+$',^2.(T+*E96E&,-@BY3[W>'&<-7J:6
MOP1.7/=(>%P8F*K6XUSX1"A*/.;>83PB:YE%P4>1@C&!*KFTPNBRD',4YWO&
M_.%CW*-.H;S0%,H]@;5NDO 2P/8LK0)+S4VB$8F )>)$460L_,EH8)&K(!QU
M2RN4-<S]6]+4697GZ9*PN,'4YW</ZRX)<XUE>-I_%%8I:C5'@O$ Q!'\1X,M
M.)%8!T&%BYAAP#*E&W3&09CU?J^YA8&7X#_6;1(>&PBF*E Q(Y)%C;S/W:?S
MR1K:6X:(C,Y2H036>FF%RV5^;P]RCK'@%60)ZL=]R8_[ZG) =V_IL+BQX86G
M^'5+A\>U[&2:XB<1K-$N((:I0EPF"NP^YAZ/S&M'C/,<++OD#8'K1F@+A (O
M@>'7'1T>&P?.&+Z/!'N"*4K8@*N?)$968(Y  @RW22KO[=**QLOLWAT=YA@+
M7MH>LX?KA%8_[D(\[@.%\>>:UM^D^02Y3US_=3>?")99Z7F*6CANB#$D.6RM
M9 941#!=;@E["C^@;C[QF-:?3GL!U#'EE=#("$H1%TDB1X-'3L"Z$_B?8'FW
M:0,+W!#\WB?,W5;/GCD 6)]O\5)*-Z[P?.X&>74OC85!NC,_1_+DE9> =)@E
MQ*D,@'F>(:ZTPE);PH186N%FF<W3P>!U)N,>O33N$M:H>VDLO,Z?]=*0,F@=
M8D",T(@X]AX9ZAPB$6.@.<%*$7(O#6$>I)=&S29>"9MX$!91]])86(0Y*_H,
M'F/K?438,H5X$ XYC3G"3$<KJ$LX^*4531H<S]/.T]?0JG1,G:WKQ >.%EUN
MH<A@'4)OE+^J#A<]=;AH:J'K<-&#PQT[OZ_0<2R518)KC;CU!+E$+,+$<ZR3
M)SPWW& -365#WK\D[-:*]LSII$=&C+F#V%MO!+K%!"PH5,Y]K&D*+>M8TX/"
MY%FL20=OJ$\$R2 QXI)[Y%RT2!F:G"#.$2^75KA>9H_0SGF^(?(V][C50RT$
M7LQKG.IJ4+@J3D7J.-5]\>(L3L5$3-R2@*1V#+Q(G)!EP2,?.&988!%57%H1
MR_QAXE0UBZE9S+/&N!X&J<['N$@=Y'I8>#H+<B65HG>&(JHQT!D*Q,9Q11&1
M@K&,7%2"UR=,PZA[Y\Z>C,^\AH*IO^, +'EANZ&(/PZCSW\,>\5W>/E1"ZBJ
MAYZU<G7,;#YB9I5DK';#^E@N6KW\4EUY]9B@RL]57IFH0CX_+U(A$!=,(IT$
M1QPG1XR-BC#Z:)57#Z&@<UZ;]=A0-'=@?^MD[$/.T(*"]-Q'ZZ['Z3J(]Z
M?1;$4Y)IS7Q"VKJ(>-X$;W4@2&*A *(YP\X];,'8RP'GV]SC89]Z(8!H7L.
MMT:;.CKX:$ T=2*4BS%ZZY &&X2XD119R3GRR6O,@2N".9J?*K::=]6\Z[GC
MBX]*N%;W]OIQSPYC76/WF/AW%GY46F")@T7220V>LE#(&$T06$K/I!"4&?;
M-79SP,3*^.2OPQSHAG]#^_O*)72'%R=/<F#[>^WN9, :M'/\2AZAGB!HNQM
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M1 KDJ2:(6YU !4-$F@5AE-/&CO30_$ /ER&.X(*;@XX?Y[.5HY/.<QQ(,+^
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M<4[A?NF\/$DV6FL=4CR?ES>4(4<=1<Y2QA0E@?M\^(ZO*E%J%1;L6ACLFG:
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M_2O0\@S0,C9@"4RB= PC+ QPS^0\LEA89+S0VH-UJUF!E@(M"[&Y>/O9P/N
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M0V#13#&D L7<R6BTRTD%US0OP%* 92&LU@(LSP<L8PLV^ 13Z@!)8$81%PZ
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MWWDOK.)YY_WKSN;&QZA2-FXXL@&SG,R<(JM"1$+EBG\.!^',;<S@7SD@MQK
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M-<%P$C5G.9W-*ILK5^*2.1Z6L6SV/#"$>MP+]$P/>K:^3%9&\\Q@Q7A.K2\
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M%T^#=?"]8%2$Z[AA$")8%W71!S%5J4F\*H+K(_9A6:U"30; SE@*D\1SL#5
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M>_STL&.YW"9B]=M?C?*:;F>I? Q(6KI9;$;(=\'/3?GS1,4]0RMV?V':WSJ
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M1%NA0<FE*?6&6W:?SI<2GA=^VPB(OX. F'.5;)JE.C<ZMDG&8Y9;$DM&3)R
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MX_[? >[Y7KUFAPI,DSJZWWQF-B36CAHM>@4AX#7=Q'KWZKV<($7_^[_K=RK
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MM6PZ=#8=.NMUZ-P95IT+PR:Y)"+)-"49!W*22H USAE3W$M!G%HBUIZ((N^
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MOI&G0I=,/LSH\X5)+#Z5_]0S%D"2 /\\#_[<KMEP'.IQ#/PF_&ZYM)PI#;Z
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MUEF>CY\^,^HO/YT%Q2V/+,XTCQ</OHF(.O +PIQ=2 [F@($1ON)_$<>PO=6
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M]44%Z?U72*U"3^6/FT96^O+.B:*JE=ZBIG%KH4.0&4MNB68;KV(:%5B\+P[
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M%F5Y%_- O.E3][(76[/SZQ9 ^EX78W^Z@*Z[DSE(H)]_^']02P,$%     @
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M;Z$V=W_SD/8T#Z<A.TGFH,KP]:QB/TDK3;X!_?Y3F.,O85%3L8[K3S8:O_:
M95HAS1&$@IR"'Z? Y5C *.T=0ZEZ!1KMQS*H:R<#THD=&7%09J\*TYS]:/KQ
M)0E@\1;GJ=ZY28I[6I (G&M/49^CT$R6 BBU0%%O@79J + O\B'5$1L0:9L)
M^Z 4/3H]DJ]VY(2>]^W"AT<NAKJ!G\%@**"*TQ!+CC1U+M4,%NEYGVK #< /
MJ0S:@(C:4N0'Y>KU!P:U7G (,M(* X;&@,I"0HBLQGE&"6Y,X7A_JG0;ZB$5
M:QL0.YL(N67P\V.X]8>XP/D7/-/UCI0Y<B; <EFKTA@!WI8 ]+""1C*N4[I%
M"'3;]^_"*_<X>'4H*=U[.#2R2:*7%.IG4RL:1PK_O9=U,]^E%$KDGMW?)M!U
MB'=AH7\<+#RH< ]*1?KA^G+38N154IDY"2XX<F"ES30G*D.2RBL6 B9W?U'W
M=YP[[9.S_X$A]1U%>3A#>IHRKYQ)7*$!K3,MAA0D>"89H?,^16UT0=W,>M[B
M?@/_GW:\<A>!'(XN4KJ/SR?U8[/IJ4D7UC(;,P,G52WN39QVB3$(*3'.45BN
M;3/J7 -@)QH]DB..@PGJ,%D)5TY?PO1\Z>HV20D[OJ1I3L)=!M:L0,RE5]?:
MO"*4C.35@#.K(]F(%,4Y#L4ZB=*+)'F?;FW7H=E+2UUYX*J^ #VU%M(^^]6Y
MN5[?$KOF6"_RDEBFH):5>C)C**B-U@F@91^L4\ZQO%M;H6:0AI1NL#>-+JBL
M^Y%:\ZSG'YT2YT FNZ0"&6N[=TL3Y#FY>]PI[U!*AIV+C[=+ NA=U*01LWI)
MI]]UDW,$'Q6>,=(8P=<R$DII<O"\45#+)[.D4_'=RHEL1]5PH9Q[ZEEAS:/Y
MO)Z1K^JGC8K@3* U4&J13>6E!R<$@UI;CV)S'?3EGG_M%\Q-((>HD?=FTP_6
M3U.A]5._;^<S\J.7W]Y.PG1Y-,W/__MDO&I@-XK,%<V2!?2A'DHS"<%%<G2E
M8\I;'\@'/HP6WHIQD,JX)ZE:RJQ-J-O.'=&,(P$N%$1E#0KI.U^[WP4TA>6D
MK2B[[9MT<B(;&RU=(D?,$G2H/3YP=5\\%^!9H+.!9\WZWNBZV6C=4YN5>^35
MC?=8[BK!?@I\W:*Z!":T$YZ<,E]O,.8(4=#"CY&0"*YR#GWJG5^/9PBIL@.D
MT1Y"ZTX@\D1,L5BK$-3R%2Q6;R0 -S'XVGS,E#YI,KL0J,$H5\E-H^1#*9+F
MN12M2(C.0PBU2*)C@GY!%AG[1@H7\0S1)]Z#%S?2_O9"Z.2DO%_.TC^OY&*.
M;)3!Y=HP)ZFZ(Q(+N)052)8-^5625NL=79#K7S@$-=E!_MWFO)\2K-7(IS63
M;.13S#861>RLE>2#,D3,$L!*Q6*P6N5.J5C;,0WI9L AU,3=A-&/'/3-Z<\V
M&0^GN3@4?*W*F8;)8B0CH75&0PQ5K446()I"8JYAF&08K3R0;=D)[Y :;1^"
M5.V%V(]P9^W!:\V^56<W<DI_#_.\&+GL5!8Q0LXF@[*!02C>0SV1U,A"K2UQ
M( ]F*\@AY=<?Q*UI(ZY^?+H8QHX"M\6:2"A*+?*</(4<2I155H33T7G#^MR?
MO@'8D-+=#\&;/<32U=BM\ZPN$+GJ2GK;IQ%Z*[RS!;)@1.C:7=)KYVJ[<AUE
MMLJQ YW-_1CHD)+3#V3>6HEMQX25S<_KETA>_5_^\/\!4$L#!!0    ( $:#
M7%2J]ZYO@^8  ,=>"@ 5    <&-R>"TR,#(Q,3(S,5]D968N>&UL[+U9=ULY
MDB[ZWK\B;_;K127FH597GR5/=;16INUC.ZOJW!>N !"PV4F1:@Y.NW_]#5"4
MK8G2)KE!49*KLV6->W^(^ !$! (1__&_OIR,?OJ,T]EP,O[;S^(O_.>?<)PF
M>3C^^+>??__PBOF?_]=__MN__<?_P]B_GKW[]:<7D[0XP?'\I^=3A#GFG_X<
MSC_]],^,LS]^*M/)R4__G$S_&'X&QOYS^4?/)Z=?I\./G^8_22[EU9]._VIM
MD8D;S7)0DFD1-?.Z".:"B]XF+;+G_^_'OVKAZ3N@6; \,^T$LB@#9P)U--JJ
M*+1;/G0T'/_QU_HAP@Q_HL&-9\LO__;SI_G\]*^__/+GGW_^Y4N<COXRF7[\
M17*N?CG_[9]7O_[EVN__J9:_+4((ORQ_^NU79\.;?I$>*W[YUV^_OD^?\ 38
M<#R;PSA]?P&]/L^__>%%-.:7LQ_2K\Z&?YTM__[728+Y4CUW#N&GM;]1OV+G
MO\;JMYB03(F_?)GEG__SWW[ZZ4QR,$W3R0C?8?EI]>GO[XZO(QV.Y[_DX<DO
MJ]_Y!48C0KQ\POSK*?[MY]GPY'2$Y]_[-,6R%OWYD"LH4^'\>WW:+SMC^D1
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M_0IG;\8OO]0QDVW[J?+S37F!<3[0W%M+>QBS2-:0+D&PF 1G2BIT3J)1V"9
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MCUO+!3PUF6V%:/9BN8QV C6X4OVA+XU?A]/G-K&N=L5WI?>CJ>MJ[TG,>^-
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MMX$6\C9'<P<0L6JJO*M!BYTDW\!,O3[4 :W;&&7R3&;MZFTKPZ(UG 6+A"E
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M1Y2AEE_3S#M1RV'1DI]KBA2TJJ%X"<@]Z+^%PJX50-A>VFW*(IXU=<)9131
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M36;JS7CV%53JF0(]"OE0@DS7AO+LZS,<IT\G,/WCS)-"KX CR<D(Q;0C844
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MG0\N^_O+:5 BBJR$8,+&1-- (CE3)=:!<QDC=Z%;^A,]_@(7Z*NK/+CY_8_
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M_7<V4,)]7*'J@N_'_;L=];IQ_YTME'(?Y%&EQ!RB901+,9UD89 T?9 RISJ
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M>D2J;R#;OF^S__/3I!Z@C'!:40X3%OS&2.3.%Y.!<2<4X0J6A5Q=!F<L@4R
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MT>04\P=,G\:3T>3CU[/R5JM]/44GH>C">,2::X:)!2X,L]9;Y5.FCZH)I^X
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MK3=9:!&O+BFY&[6Y<*V#3MYCL)!S]-ADU ^L_>$F[-BX_>$F2NC[TE@/C?;
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MRQ]IG&L3C72.<VTBSOMKCW.#4=][5YQ;WM&H&4[745T)BB4?B@[1*<F+5CI
M4LD;GQ!+K 4-UO3 N>5M#6-DQFNA0FV=**)A6FK!?$3+"@K+M7:*Q[;IURUC
M9!>-OG/Q?KO#!>0D8HPL>9_J6;IBT4O.K$3IDU)!-+[A= NX@UC>MN-(AYUL
M)U4TC$S=!/$USFDMGIQ@C4P,E)#<*NL8#UPR'>O]<FLDR][HHM!)P+8UR>^$
M^$28L[U:]F,QG^,\CVR]Q>G[3S#%9S ;ID$T&'5--_2%H-)6$1EH@I]I1Q<D
MDX2A;9GAKD@?-YOZ4U+#*_,=\+X8CA9SS -(G)ME@K,T9("Z*%F,#IC,Y(J
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MFJBKG87@96WLD:RU2B;KVUPV?%K551NK90<21JVNFB+J%%4&&GW-!,@(4?
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MN0FR3P0SI,T/4@&H"\"_;H+L2>C.N?W[L'&0FR!HK2XAD+?H-7TA 6NFA0N
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M5;QQB$KN^#3$=37..I;YC/YC NX-Q6D,4/,(JI#I@BH9:MS&0N%:8;=^P#U
M')V0VE&P03M#IM)> _YBN:1?Y9?SQ6+^!PU@G9N!7(@BF05A7:T 'SQXX1$R
MBH+:6*W=@Y5P=G_M,>NCMYDW**+=YO%M-7_YAJ__=79#S4Y3C"8U!R&DK06<
M$@2C$Y2@E2V%Y3L)V,U#H0=!/VV!C<W:!L4-O(5<+T]/E/"1T7\)VNL,Y)@;
MB $S\)03,EIK91BC%T/%<HSZV-G&&VCONW=;<+' _"7\^?K/[SA;ULEPGJ8U
M=^?+_*Y(Z[[AC1VCB0@EVU+G21H$>5VR0!2I7G;60@>394E=EZ.>4)ZV0@Y
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M@-,B&7GML:Y'63$.%68/1-?](MC#U@,Z#<O%:O)Y1<%^70L_)YR%Q72^UGE
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MTSVT30_1"B1X'K"D C(@#3Y*0]#JZ;;2F0D6D@ZE-^>/KQ5($\[WL>E63V_
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M-EA'(&V^K]_I4Y'#[G>JFZAA%VN/?*<:8]0BDW=C=/&T@!&T:%, %FW1.IO
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MXF&.T@8AM(-(^K,QTC1T$ZA>MZ&4 =#*"I3731D10!FMZHF"SK;-@<J!Y/+
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M:W?U.<V^W33:3**X Z("XA6Z'+H<+0SYCUX0D6@4EFX9"+O&D)R4CV>S8\Y
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M6Z51:2FX1CU"VC'U1%Z%>D&U[NE?#3(- IWW4W;3L^E 7]/WHH<H/-';S[E
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M.,MWNS_?S^<X0Q^GSP(G;ND:Z (,# S 0^@'H,\!]W4"G)\ @)$1( T P#&
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M>)+/T*9AI[3$QL4[\YW4>ZK?)A@J^9D6_;&^()DFPUY6J/GS? 7XD"MV#&3
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M'*3<9MKIV%^#P9;Y?YPM7C#4V66HW.A9[OG0'729I0H\FRV*XER#56 [0-X
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M0'QB0%2%1Q+:/=6BSXZZDB-_.^B)R56+[3YD/HAWR]Z ^@VK,+'S.\FQ>/I
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M>$M8TO9INSNQP_<$:=(TMMH4QM)ZQOWZY<M/Z@N95]9ZP8:D8"I::%N[<5Z
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MA1PG4#T:$I#;L@^<MNQ#[ G0(5M'_VBE6!?$.?H,BED.QK1<ZR>8P#%O?S=
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MO55Z"C(*/N!Z*V6A![6@$[268$CY*[I\E1DD7Q">G9N+A^9YB*$"AH&ZZ9!
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MB-Q'QX+9WY3X\&L5O/)L-(9P#V&-2TM$).?[WSF40_V$]HM][XOYWK\=&?_
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MVW?4SC;YB]GY%[3.Y[O*7OW8<DXTKQ9FGB#<Z]^(X"\R7ARI?URX+)BRB^E
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M(A1"Y1U25,]^-B_M3IIXRX,:3<26?]$^VVFQDK%C244\B*B\M'9L?F!)N I
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M3)_X]7Z03D<+6CL#$FP+@&_K+5*3+?"H@OHT;:Z;5I^PO$#$ C7+>= #.*L
M_S!P= [$GG4/68Y8>$*M)JJLB4?Z<,R/.$G:KZ<!AP%\U^8  [KF]R1I=A#0
M6B]X9@Z._K-"_1L3II\'ZPU^AKK!5!_::!MG8$EHN<EZ2;H?-DH2YL95J/8B
M[69^B!N+3USS_.7+S*GO:U='QA(2B*U=85G*"8X?G$-L3_[8</]>W;5T>OF?
M/*B).\KE>K'2X2'5;T]AQO(,AB4N?5XT3+H\."H@[[@PXS5K&-6TY[%6W2<]
ML.@D+G+VC&*!HSR(=ID\V4196J1@W,0F@H0[<'O#P@"7BV=8-] -@ &:14[X
MT70JY:=AIC2<MQL>[8<Y;%?L<S&HB(%#9KHS&+7Z/^"W9^8!_B%)NAPZS)@>
M347G=;*V$_\E&O_/D6X23N7J/ CGAUMDMG>=*>L%QW;@N(V/UIV GYO!<SD@
M'8)2I07X:7$2K*'"&?SH. /#MN+_=02YL)U;4 [(]T'-N'\-XT%3I2U+RR#6
MTD+(_SZ\O87[%%0U1L"6@3S3?P_$<Z[.84$Y^)FAY'\=O13\#W.W_H=Q!*P7
MG*-DDCF(ZW\XY*/\'Z7_MRMM_1\T5>&?\\+6%O$@U1;N,_PTJ"&_W1VO. YB
M% /^9(6!2N$'8!OHZA?(J*079DWAZ,$_0+9(%^@(> $";#T/>I2,$GC0!SLL
M\4KF0HX\MEL&*Z-Q=ROW.1/E-)?9H$)Y<P&NDD_P0S>E#IF8P'1G+1[TT7YB
MDH"HBT7!5VC\52SW63ICDI:W4$M-S5RZ)3/=/NVDT?H'7]E2XHEB#L/W&M2(
MV&%KBEFA-30(]@0]9O\?K,NON/%#?:++YEY7T7#E6?'LGP=]3;*FYO9P.Y03
MV5Z]I=7$O-0&S7"B.*9,@MD/.)>+<YJ\,T^3/#!)+!740KV/"CF.\<8_#LI?
MW,:_;WNI]EK9[BRUX])DM8[V1QU+);I,FGYNA=H+5NOS9)]/%4V/BV:[ERBG
ML(:!]3?$$ VQ26/0_A)8I99"$4%K/-C+/C^942 ##1SG$SE(W,==*'F=N_Z#
M.13$?VX6MPYV7X+=6Y"]ZE4>ZS3=AF!^(^I0L^A'^BSZ9&J^Z6?LX:>5+H^T
M9%=M,!'^U"6 1S>U@QC]KF5RB.E22>0K*&#MJ$](5PX+\$_3B&(?L::H.>?)
M!ZA\CKUZJ5_09MO]2\\9!&MN!M[%2Q!DFPNH"*NF.DE;'#&P*Z*5L0Y'BR[C
M)R.7=";"]*_,^IF/&N;&_<P<0NN55V]E8:E.QTK9UX8?N7-T7::+*AZW/YOD
M]AT7R_Q6;MJX=,:E,;LH</_U&QQR:L"^;(3#\+K-@]PCQ7KL#GDAIS#9#]^$
M@@O6>QR)J'9]&3WM>R!=//F8I%1?\C,/K6M_3)KSQP(NN9+(-0.Y^I.]3(G*
M"H6"0JR#^];'@GODQ-RS:Y%V!:KNQ6.<YLYCTL5)?UX:H>W'N^)[[EESW^+=
M-2XWU=(D4!=_9JHMZU%;==>MX)_-A2_>'IB03%2W^V'7=*=(37AQ'21M:/>-
M5AB*2M% ]1AR)Y<80A0-$B,QJBM$BO(C:T!&BC#4\#9ZY;5=;9^'[\WML0+F
MT%H]]<L'NH>M,V,OW)22UVH+FK/HB_*4MZ'9*7_FKKKI<Y9XZ7%L1\IK6UNB
M02GM<!&ZD3$HRX/R0*$Q8,^4^PI2W/W+!QSZNW],NVE\-AA\\%STK+0)**3L
MON$E? AA/9J34YRCS1Q[:LA/Y*:Z4]7@WASZ._\Q.; F\X2#FEH_W'YU?23D
M9.WM-UUQ[D3FB9GN\0ELK3]SD1&8&I7TI<F*&?SE&3UE_P[VC=ZZ,&%]/L$Q
M^WM/PJ/VD_.H>[=U/< ^XHK@&LN#0:T4D2!UTN.1IB&76D[YD9-?=07;<W9W
M$8H?TP^_5S*7:8RJ&GKJM[/#/^@OQ^>LO0%G=WI(GHPKB3;@4!/'"<\>S@?Z
M^AWM2#F;'^]VJ$]EP#10AJ9)^>4_.IEH=$ ,V4ZI'D!<0.<!#^VLX/BA]VC#
M./8+T\\\B#S3!V=S\'U+W+U]9T;1C>UU%*DR.Q 5@EDW<++*TK@-^41^R]3^
M])B/ 4]0CNI%POQ!!;S2RY_7@JY(U L]((G11RO),33F,5PH13# BQ6'25+#
M#;7H%B]\AT'^WY'F8;A%L]J4$W]J*7;,\:\'C*O"'^DT5,*#H5G)@Q 0G:86
MT]VI+"]L(W75&=)A#S,45&K"!=R8B8^[-08F>9!S[ZZR74=GZML=;:HMV^I2
M" -Q+VA^NR\_SU]DN\V;%7]-V.'S<<;(PS^&PX/TFF_B5EN=[>98!*Q']C%I
M59UV--&*_7!U:\=H^88S;C1F\( KQ?EV<BZE^<6GPBU6OJ)! ?."9<<K1J)=
M.\B&7EXZ[9S$/Y<=?#8QFF70=N*+NQ$JV=$K]_#69"]W],(E:O$TAU*O16/G
M[?:W>C,Z&O='I'IVN _+&5_XW.TK5F)4<*UWN6.OT:_ECB:OB=.-7XPY\(2=
M1DF'P>^WSI/:SM\K?IXI&CM%Y\1?&TBYN&=_@F+F.^YXBIQ3Z(SM'FWG_ D[
MA7&U1)_,!PN2<3\^%TG/9SZ$CZ7^XZW:Y)J&([>G%&=U*AN;<B*G90T?<N_)
M-OX6Z)Y=X!"9MMQ)N";_LQ<N4_MQ +\UW6LQV#$TE7&Z/-Q?RG,Y2-=7_FZZ
MXSSJ/GE P%E15>H"5N"YW\:,ENUX//YYV*Y>[G*1W*DBSL+5_5^.2IT#< 8[
MQF0<6@3U>)'<I46%Z=-%$[9T+/[D0+9CY++ME>:XFK8<XZ^!:L\/J T[";6]
M%[]@]#JKESMDDSRNUDSKEWP>YO^8/F5=T_DRLH @YO#9^%E0@:?1U"D@IGWZ
MVX%&_[BJ1=/.K#JN>S[N1J#[9V+G^ST:1Q;=3X^K!$U9R%T62#/HB.DX*[IP
ML>#RD1^/=\=?!0#'G_S[?8_X'NY,=6KD\BF11=K:),VQ$VQM97):YH;Y#-:"
MY 7Y>.AT9 'XL?O]>OGR,<JMM^27:=8SIUKG)9](;<<*_AA#OFG!#D]NH.[R
M(Y=:88=8/ WYYOV/][95I'&?7^["*R_R]!TQ;XG%)QJL-7]D=:].[\PRYJJ5
M^&2*P\<.[Y2K>,3J8KX5'3A&FD!.^F\X1O%]0RBU2NU+EYC^!N7__53L?V2_
M*39ERH-6U^9RW](\*:'$+:.LP/Z'UYD<CGY36W)[YZ5RCAQ:=&_/4S[+$4O*
M#<:6T92;+E.98(AR&^T*M<>EEK9Q=Y#B^-9U_8J<W1/"^9<^G#:,-/,,D?W\
M9OBPS,OZ25]JA2O53NP%PW5OB761VD\'#:J_9Y]<?IZLI=[S'1[J&H7X7:!]
MVOQ"#(O 0#MR?QY&@\A(B#)8G*]IF?#0 1RH6JGM1#D2YS#B-&30[%_;TQDW
MU"=V_,3BK9C4FW(I*1F/UZZ+;3RLLNN3H-GPG?ZG3 X='UJA@1QNKY67[,KW
MDG#=&L*#WH\[6$[Z%?H9R"4'QM9_CBYH?33(_'1H>.L4#W*8(RYQ$5,TACQ5
MYH>BJ/02[BF-M>XXZ N-8="[5-_"8WA3](C$*Q[42NR@,9/((*1UC3MO@K-O
M4E$,5<0.<8MB0 %%N0MZY-D63"$<]->_J.,#" $@W/"+!X5=N(%?5E\NPB1
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M$>WYD_9U52PKJTZW3Y_N_7;L?:^3$&K/_+BY7K]A:X_X^:*-XV13V=[K0![
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M75]>S?21!\E=N\.XT0^>1*W<J'>JL7F'O\LTY%[UW4B0P5T%A_<O#C8VVE1
M/=>X9.U[Y=3QV7Y#=Y]CKY;>"#?BEI&O55+)(Y@?-7ITXBQC5&0G=P>8R! 1
MQ*7!N$C4MT[6H^)DW=M,CY']Y:G6"Q;]QFKG7 [/'2F><SF^E^D74T$S'S3_
MK(U7 H/HYM*XO :%#75@W-M?T\=DG4I(@P[?^ B/B$,[+60NN7E'6#M^RU"*
M%_"SOM'/]C409)$FC ><H36 :CV>?H27#<G"2;C88V"^";W)H[I)S^*7B3-
MLA^\GKG04FPL&O=[IWQ'1Y)?0F'F3E$KL VV_0,4$C=MRJRK96"V>:0?Z-OI
M;-:I*W1S9(!SY>B7FX2O#X;TTWYOD?(X\=?IB9C",_U+Z#*XN!F(06OBQ%M1
M0-LUF%V\Q:#"^H!R[\B99W3?B/+JPM>>FB\9[?=*8]LOSU]UD-8Y:".9-)>I
M_B0_)M=DRU/$-O4CCC"<+T,V'J^1ND$_!L:.6C/9N5U9R1\".1:NN)^1GH_\
M[Z7M:1%M\U;Q./_CL&=ND+!5;]BP")<="W'$(Z_<!]H\R/-%3F9^'%/N\7+6
ML=AW7^'!;&[-QR6/R!7LKR]KL_#/;42OO=1@4*NO)B(5]^[[Y/8&ADNS$J/S
MF[$GX\-5HFMT59[<6EHMDZXY.5 J.A5T:(_6,1NA%K,LT?C11XAM?U1[Q+_]
M-L!/V3 @!QA8A,88Y@X05N^%0]#V50S;BT>N48.E;RUC221-/)[!NQZ+/%;A
M-[I(=_#4RK<X:MNN+IH1%YF,[XN[NNUJ^N'+U$=H[/PVPL,P45800?_,J&_D
M JZPNUVHMB_VEH^W*8EZP7>3NJW<G2J/A1/9,U)^'.T_E-D0\]4UF&V0P[D>
MT*]2Y,*R-Q\!V'*QX^T[V!F. +NM!]K]_LE;'?+V>GI@K^3*[5>F?K^CSITZ
MWA+DNR@<[#WO*!6%]J!&UDFSI#N6M>1!/?.>U!G/:6?_@D&C.SX7SN_:^JOQ
MWHL$[1*YHOU^B]O)>9H,ML>*R&R;UBJW#!:<!^D0!WO1BZM86' *%SOF&T$L
M5TAAH!6X]IW+>2$BVSTQVY:/JVL&ALQ:2(Z,N<1^7[Q>_:Y!<-.6M!-3)VV=
MW^'Q3*T8#9WH4HHLSMPBLDEJM[WG'?LI]J)FE@Z^YHK$':5 >>L[QG[F4WF5
MO 2#(3#B,] VF\V#,*SW)G0S?:"-E[+^A;2U Z4':C6G/+6?#--BUF4%!NWI
M.B-4F+>Y\]+3(I.7UM<2%/^RCJ*9"PH4PYS7@Q Y*1E^B$4)?^1T\$ZJ]FNO
M09_"^B87A]=\1-V^+YA$])%-!;;=?7=J'\Z%BL%X[7PJ>@QJA/@($MB)E/ ,
MAVY*(E=XZ)8:N1;BKB61R&1F&VDZ%14IT7:R8>WQS-VV0^>.'K?\[9*K=J35
MR#)XT[6N]:2!ATG1(Q(DAMS.1S1HC=_##"('>OF(OZB?W*AH(.4U55,OD$Z:
MLIA3J ]"/4-I=+9RF]:WP6TU9V7"+5M-D(MB70!S'[JESKFG#HT3,V:R7^<Y
M@GT--M4V!7L2KXVTYSMDU4Z=/_WLW=.Z/FLE']4+,C+3%XBR-?+^M"I='->.
M]E+GQ3RZ)'TY\()0]?4$J2]'?0:4OFYR"W*)/Y%[;6M=5JAC$.H52KM3D-NL
M0^5N,V>]7S\_-H.P&NL)@.)$!N;P+RZ&F5[&B"4(V8$9C15ABJ7#$Y-7IJY\
M#1&FUE;O&NR3D?G"V%^S0I>:]7N'/\S+TJ@1I MT+IF=!(1>AY8-&UK']VX=
MG$6=KE"=DE*1$1H/\9XWYYPT:%UV'>+<!Z>-D(M2G62F*IKUGJC@$0XYR\+,
MNP)FCRUU:N'LJ'!K7O9;,-#[AD1[&26\K_GCM*B3H(E%(?2C2/W&[3.;CS]%
M&QQ;*2!OX[HQ(YL>W!U18&$BEL>Z>ERJ3][-WO*SW.J55'^KQRF'1$)UJ&JO
M@U0W8.U(*433_O(PA)Q/&D-;6N&P9GY<$N4CCM0B^8A-,$"7!=7HMK-^M'FA
MR1'1&N98;QSCE+DXKKJUX8[Y^ZF.K_+A0Q&H&QZ-$:[;15(6$J3OJ-4RYY^4
M$F0'AMHSO*I]"H2R&@?,E9.^7?[X_<6PG+B2H(R,U9<ON7;7D0.';HA-A=ZB
MBM:@!+F1 ;[<G;%<ST@Z)C(%<DY5@02:UU^J?;NSE-LGKTHNOL%M7$N="_4(
M4P%O ]]#SO(1G_O)8*XGF$$KXB.T!1[#6;L#8%DOB-=.Y0^CMV<]/\-[;]OM
M/,21@R0K(HRYWT\*0H+K?5HB8U%2?,1; IR^0*3(^ELPJ;85,^N4+ Q;!_TR
M[B^XS5]<1V8N'_&]C4;E2AO"C:PP#*E'K=SO=7(P[7B"YEKC]?PZ<X<"<J&F
MR,6CY!+&$"<?MOM3F/,3&S'@D4B8$KTGQCGM0B[J@,Y\A, 56#?F=5BQ#+]>
M$F<[<?$('^%N7+6V,4P/=QSXWD,#N#+UZX+,6]$"(JMI^FI\1/B%]7>6[*I<
M*=@"'V%*=TJ-<Q3]/2Q6KQ78LKYH(N@QFNGI"[?J=F?,/Q3DMD.P[^H+R'^_
M2[9%WBGQ.=E3*/\>&M3B:"*_AR43!P0_-T+NR*W Z "5CXC-1)?J/9""W-&"
M_UP@?8^NME9+)2W?(2X6Y>>*S"(_F''.@5NUN/'I0G#7M7#:E;(@#AA^W@$;
MO>(AF>GG_?<KYE*R7][)B9RUGD+93&@0R3Z'?DG,$V0_!_'H\2 F',>5S>M-
MS="EE,;F:09I$Q\Q.M[WKU?(:[)O_7H+;C>KL'\!_4S(+:P<.0#0.I=9?0\
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MHX;4=:%P;'! >+(886A2D'@ODGN7G!9\D(^X<IN/6%SF?4'_2Y[<NKP*G@0
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MS<P)*28O=9&9TZVP8ES)?-SRM/I%ZA3E:M<\&I UE#[:K!QS8>;Z$S7$):0
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MJBY#=N&TV+F; C.VW>8<;6P[S-?MS7F\Q'5]TMA.?8.0TQ*!PU'A(T1MB@*
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M]V;*^T],N)V %)$;:Y^_" -\M(7?]X\58 <S:<*^M983A\%?!^HWU&F;=F%
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MS=K4'";*:GGLGO_5WU7W1YK'DV\4V1;-=QL2C*B[ZIT?,Y07]BUD+&&AW4Y
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M.^!TOF.P^<#\T!E_+Q=KZWWGD@=/?^\W(+8X6EDRJ0_1'L1HFQ%=5AV1(8(
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MPAMK_]YNS-W?V_\QL_AHW;5VK:?M^Z^R_/4T;XIA,MK@16Q%UD6,2RMQZWZ
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M%D%4/66K]*9Y8FYX<TSQI[+/L5XXFXO]V!+WL@O?9VNZMU"U"$.HIG;6M9G
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M$4F-\VV]DB)+9"&QL0?'N;#;WK]J:-*-% *>#Y0'AIMSZ:WSO>,LCNU:D'T
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MSFQ_A?]@2[R['OG/F%MA)H#B<^2-/\BE"JA\AM2Y[_C\_U,@9"Y?0,N2_]H
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M_-X;)5</R'**UW'9'2YG>\X$; 6F%2/7!:S9B*VP,KY^"8!'E-',3S"Z?@A
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MFNY58KBZ;C;Q5:XHL$LE6MMK3ZE*DG^\S.O*Z&KUU$^?PZ*_BIBIOS^X9^N
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M[ES/X;1Z=[NNY4B6<MB$92D<F#Z]\TV[75R&ECL7ZL]@"\\1_P>G .4ZL">
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MG:3M*\#> /E+T""UEB31>B6([E%0O6HH?D+;X4V<XCZQX"_J=ZVL8S%>Z,<
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M+HX6+,ZA'PGI@-L]]L,O8I@UO0M\0E[>!Z=%*,#=+S(!X[T8_C:P[R"L7KP
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M*7#9C01U.(C)=:X4..JVQ2%9Q)^0"TM!_2.DU4$\Z%KD+GFLMU]Q=EE@4,E
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MRZR$>13]X5&PO%OC0:Z4'9SG$*[^L4;RWO<B) M&I>!6V)RMN"[2#CS8;J\
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M*,F+I !:;K+X7TG'8"O8_3\RZXG;7Z HOMEPQ^.]#A?WQUZDKVL"C5=,P*T
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MH71U3-7QB)O>A6I>_/$!BKWFQUH,:\1 @1[<'M");D\2"[OK :(HK0'J!,/
MHW'S H-NS@H6URI$YA83C_B%U=IZWS8(*F8!=?A^9&-B:;V@WF3] "<V],DL
M)#/"[*W3PU_6)U7<FW=/FLNY=]6]V?%5?2_D,;[_ZZY9A"2R%C^(UZU@2M+(
M]5*G[4P,ND'/-)>!IZL64N+=$QT*ARH=HRP,N\,- QR7K(3)WS+.F=:OW[-2
MX3D71&-;,F'HN<6]ILA_;;3G4,>>9''67<LKT8<39MO&GMH*X(]N>RRMR##*
MW15BBA5N(- ,TBCN?+4VWDQ27=^S,8+@;PAIF.Q0*WVULD #NW"BK,LN/_:N
M_>3]=+),;NM.=\=C@@''<,U)'F/Q;(!C62]+G]"JZWO@07#D(JRA$6R[9[GV
M7M).+L(U!R\ ]?FC'IE.]YW_D8M%>5-0VZ?]"2$K A%W@D^;&ZXXS\EW[#R=
M,)F0?GY0>MWUT:E!W @7(7"(%I>7=]UM("76*?6<HZ^O5,[8L*%1I>CJRX@
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M# O#M<;O&"O8!91*)'M6*OG9EDL\.6+-J=4W&VZF^PDP1>RC"EK 8ZS#SXS
M] B[QL-4#ZPIR!8J:L-'+NJ+">CY^&P 4CKKC;J'X:D]?#JC_K"I(\!PB@C"
M RLZ*+#P;SJ2L;;M45T@4:I"^:_,F&BORLIW^7J/_;A#HNM_\'"]/NOQK2;Q
ME=F ,.*RL-5OY6/PCLL!D*.>X;+T;\QI46.T1UQ]PL6."(SO^9XM3:\;\)_
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M!3>;$A"=&6H7'(RP"*"1W^'G(8X/U;(X#/&2[E!\)_Y3O-V=]V%#=XY?+E=
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MZ64 OOT_2C8!,/P?.;@JRVKPGY2GF0%@8BU,E^#$UFP?_,SLW/7[D2.]H0U
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M#-@%)DLRW;&+8I;=(:/P3F"PUB1ZH^KA>^>YFP3_H&"/)W?3OTQEN3IB3]@
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MOWE2\T)Z+X[B,GV2C2W6$,-Z'XOG-V/OT@'27FC=]=/.UR,L_!(_/ZJ".>%
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M>16\E,_LB.TD3#,XJ,Q4ZN$1?=^HC_K0_2'V#)@_6;B8^F@XH*FRJMZ)SXI
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M^NSW@/_(LLO5XIZ*V[L?;%\/Z3> [GE&.GPM"9!XNO7:/69G7Y-^PI@!V%L
M_ZDA($+"P7E_EK^D_',/OI#M?*)V2#^^ !K;.W^*,+"!\,CU:5&-7C\RTSWQ
MI&/<M27%4RI;Q/!'RA6IAG0.*9N]+/FB4.W')$O"9)P.B'J3,#NZ.KS" /#[
MN[>,?;LD]<A.<]IA&E%[_+7N.Q\^V0=,:/,X3=.@DLD$.3A3%$PGP>7@<P3_
MTBL =+<3'BDR^(Q^WF=>ABC^43F^F-Y?.Q3@TU\EZQR6KKT]:ZS1Q7:^\,/L
MS:LGSHZ*U;%'-0%ER'K,1;"_KH;,50AU[<LY3S2-4RZGBH*?+<8H]#]VS^T+
M/.4#]36=MM"?OZ=;\?CG*RMT'G]:524<RX]BRH:53E<F#S/UNH@!H!+^1[&U
MKG<S #6]B')R L5I%&:$&^0FIZQU6Y#3Q1Q,TH=+:G*<=,1T;"VNX)>>+D!/
MWRH<_GR=NGKGO9\6F'+*L_U$.T%QXR4.)+"RGQ$IC4K;M/;Q*B%RH)CK# /0
M&%RMT8@^&^_F>C3^18KDA4K^4#CU3 8#L/T)_J=-@O^E7T/LL508+5D%@<B1
M1HTM$<'/81?.-N>J1^\T_=9,]$QU&&W\O,+=ZRD=,#4Z6(_UQ/ UG;OZJ;^:
M%J4%+H(9U4]6P"P7C4-%G<(Q/3)7DWTNE)B^ZW(5BVM^V3Y 2O]VHO3"'MUZ
M\_69%X5A'/_& @193YDYAT?\I:O;KY#5@F_\O(K[BF%7R8GY1KFKF>EY^:8>
M9U_?'SXSQAWS\[M@RI<OS]YPV&3 5NJ??#MR=1V"<L\^M$FR'0WGE2;5^V%I
MDOHUP[Z;]S+!^*.\ _<$M]DOO/[V_FY2\_,\R;2.GI#E_X4+$= ,DMBHELM[
MC'$I%-.7:DM.T)0FWL[\,&7@@UOQLS*_WS+M*:X.74RX<KA@IJ#P9M'#MR20
M,!TP0W6>:-,NGX$F=H<#B3+1Z 6O_=YXDG5SLNBS.SE'C$MEGBZFNMT*NF&K
M(FN5P:Z#_-^X@'4^34M4@9^$71VBWBTCE_5J()ZW76PP*O)!*+ZUT0CI0@W:
MCBBX/5-<>#GQ(QBND<95;2#^'8AMI/)Y?S6-_>!)!Q,-XJAZ$.F&CQZ0 KU0
M(9)SLJJ+CMS/!GAMT9>TBN67\+!S\<(YYB*E,XCR_T5!=<()L>N*!= @\W2*
M.1&>U&;RSN3]BDCMW*J%;0%D5)W+-DT1?S?^'GKJCU(NURO<=DF(X_3N%K4B
MW(U)%:0 =+ 330UI*'JO5%)DXK7\;$SP1)!7/'X)\?DQA!68^LTZ_N;GHU7!
M3!!NP0#0H<"#A<'@W\0#()9AIOFZ,L ?EF([/7=XPF>NC=RM3>ZE:[[RNSEA
M;!RWX5?"J^6;=,:$&Y*ASU;U[=CM8+]0$EL-4:8+*4CVWL:I=RMDF8)6(>^A
MZ3ZOZWS>!6:$*AA?$HVOVTV^W/WDX8<XBXO/;X^\/V'Y:_/?I #_E_DC%WB2
MD+%> B%@<(KS]5B(,'FP*].Z)%B 7H#M?U+=-*K*L1@IRU7K:-\?$+T8<YI^
M9R6EM>G^?9T*>_"_38'_-E)=X3%KQ']7QB.! @7_FY9DZWG^VR27'Z%SC=;*
M "S), !'4!M,.ROQ6NN +Y2 MV ZZLP) 4@[W5 5\O\LD@OD(TQ&[X!%?!YX
M9>IDAY5YV]R(\SN'GP_^V9FN:7[5-8+CLAB+:CT.\Y2N2CB2#JG'L),+]#YP
M\\^ZK%C.W.!8X/F>ZT;S&4,MO,8PZ1YETF4 :*>;JRI_(\DWZ=QDG\7T$B+"
M^B)4V2X3'\"C;C'.NV$<]W:P7L()7^,DHFJ[=51RH_*B+OAR(#QV?S>6JNE:
MAOF5^3$]]3V\+PW?\_;ES-PN;?;Y(125+?-S54V[$NQ\"Q&XODBY[*61D1"X
MAI?L42<U5+BM>+]<65-.;XY./R$A_^&\N,^7WQ6:J*E+"T6->)['A%HZG[(H
MO-,AD-74]5FCVH3'9][R2^KIW"G\<Z?1Q_TZ?ZBI V F#B @E:6,:D%,BXW]
M+7H)7K;Z*-AZ G<#\<V7;_=M]*E#CPQ/V0R['&)" >3$_F0L['$5]!NY8?LV
M(;Q*+4HP&VL,JENU+_IVD>WEHK6^N*T4]R)E6J$6>8V@OA[E3M$(GW0YHDKC
M] O[#13HUY2N;/:O]M8(*//]=N^-KK,A9..Y ,0W I983CU&#(^MA";>SNC*
MK&O4X97R ;M'S!D4 TZFIQLVGJD42,9-=>9 *ZW;-YL).Z0RW.;,H8W1;I$&
MA$!T@T=]7?)T_EA:;MN>],7N#2'.KEW?I%C_$->(-MK+\.,P=3('8;=/7(TH
MDX1/[9F(NU\WZAII[?56$O*\#FJXZ-03!;G_>>9S%P"&U NSPKF0S_Z*)4W7
MDSV*UH(4\QU7"AQ2]J'CE8I^%S]_U4674\9D3[-L1QJP62-Z0%.LG9L$2*^S
M!"$29C*B3#W.O=V#HYVWOUJFVYKXQ;=31<K/6O**EJR[$[:4]<?!^XPL$R6)
M^V.L%:9".[D<BV7G U7M-6K9+74%\^EI6D[OCZ**3(6\ 3DZD>5Z-.^VL,.V
MB?M#A^-0%:9B5X5VWBWF<HQ6,).L M:LS]!?L3!K0/<Y(Y7&M<(. VYGRW]S
MF2B3N5G[)^UWHQ57Q6YG>Q[J=ADI-FTUZZ')NU'J6*3"#C,+'MWGS-8P.QRW
MVAWHK%$CQJSK;47!1-_XGW\ $R'O'.4U,SWT_\?>NT=#]7__XR.5$)/KY#J%
MJ-S*):_$C"X(:4BYQKPB]YA*,A@SE1!"4;P0$T)RS;7<)O=*)9=<QF7,"+GE
M#!F'N?@=K_?G\_VN]?NMWUJ?W[^_]5UKSLR<<_;9S[WW<U\>>ZUSSA,2]OO.
MN;Y7;@5Y%Y\KK>GQ&087"PX6%SI70(RW22'**.(ZW<Z4>D\M?K._/U]'>P%S
M\1F?N^&38,[1O^9/#P$O!1F\Y\?FM@6XUG?O4'S-!4H(\[7[DIWV.(2NS\W9
MW7UMEV]-A<YL7F[J,$7\*0J/@V6@<O,Q3;;F Y>+UE_ON#QW2<TRP?!R+'3]
MLITI]ZCBFAZV[QX2:7LI,3<WZ761N:V)A-IXD1*O1C:"FJR]8 )W*RAX[5!4
M]'J'*9L298&TM2T?YQP]OQD'(T3LLB2'Y2:]++);MMF95S=(OJ#07+T)>Q;1
MC[E(CCKVGQ^8!<(/HM31&@ WA6 01TQ\J<Z_W[#S3=;0Q^S?;YBQ87^,I5]P
MH>@S6/7VO:O_'S="(3MD"_89PQ,AC4ELP2[V#SW8@K5<)/T$";@M6"!R\W0
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MO-H'-R$PF+&\9Y3@,A2\L[<:;-15C?67<W9R^10<RB7?O);Q;4C.YGF=2;_
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M!=I.3'V84 1/E8%G]!IK?I2JL*_[!JG0?!L<4T^K?[AX1L"CD\&W2;/-KMF
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M+IG%_O&9O^[\4QH8KU]RXRFYPK)/:]!G_276(!EFO$EC_0/>"IGD>K<?)Y@
M%^H%8K10GXK]?,NHF<9: 9^;+Z\LCTC\]I2[&IG*+Q_WGIZ4I"C ++\72'#(
MPW>W9M1%+<:7=K[U+![MN<9W 0<W/)EP]Z>W9J>9_W3/:-6D>1P!68P%ZUIE
M@[M& M?@0N;7D#&+,QFKY@'':PS"(_>>,,CTV!'N,Y"?/R0C(GY87!L#M-%%
M:YAM/,'2,E >3UQNW2RCB!9?+V:<G UZ;6$\UF<1;I#N[:^CL6*ADJGX3=R
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MQ)RA9FG;*+?REO'/6^23>4]SHM620TS'IV%F#CRA^VQO/YHP:3++?@LF393
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M1C[=3:VS4[&-VKW'Y/+I9"<+H5#-H43N/?3DJXD#3(%%.C"XT&6/%D<I$>S
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M#,_WR_C&1HK,U7L5L.P=4DPUQSM>A9R94+F4JW?^>K*%I<CK;QW^GTB3:5C
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M5D;Y3KFFK+UQRA;?2[Z&95KHX-)07>X$(=\I1\+]Y!)GNC 0^ Z8ZK,>V@J
MZ0YZ2?0^'=FRQ?5X<**DJD,>%CRH:3@=9Z4?<G95NM32Q3>$?O)&D:]>2S-+
MPZ] WJ4&[[P9RC+J])\1\U$E/A^<0GNZ8&WM8Q]G5C+NH5:?^*2J^+<GC_J/
MB_+C5 ,HLKXB1+>.+^IEV0;"\_4*,>V]DS597HY>YT<<8JK*]5DCA#$135]]
M+7G#'^D>C>S^!4XP6WC&E?YD@Q'/7L>V,YUY!CF:TI5$-3WCAF#F/-W9C84,
MPISNO;BV%H<7E_=D0_]BUX"TTY*:Q:BW@1"R 7$N/$I2584[G(#B4DS)T7,H
M4FMO.R$I><6"%6GWAO.R]_NN0;GPQ"R<$5=?&L*15D/UEVDUB AI;> )1<@1
M#9C@PDTE27E$YJR1F/+A8[7C]A4)]T4OIFC(ZG$FM!%^CBE=XMK2#FEF CR^
M"JB-JNIE?\O'+64(;8R;,)DUQH^LW8D4-?.N\;MW&"E](B[WA-!C7M:.^L:R
MWWT$>FZ&"%]H6%,QFF>L)CV_N8CH9F(8YX:[+18YN5#G70678SU6CV)]JRU:
M!]E$\@;B R^2D!TPX#93JY3!0^S ?31;1-HM?;B)'G/I+Z%Q5TEE:^L?7]J6
M5D9-+./E0F?2:M"UBHT\D6ZSS8 O3XM2L\PO#(<KTJ$T*OTND?Y]W937\@,[
MHJ"YXP$4]JH+$#7TR\.ZC[%]N]W.K3P,)R7C7$84=T;*?%QGI)Y,V>A*1?$&
MXNP:X#6)$ZU>?:GM%@7"OJ4^A+(5CFG\,5^TZ6CU\>'M& ^CT>WT5^<Z"@)<
MW1]?R9)?L>5WJ+O:^?+=_4<\1I]_//BKYR/DU/J8RDY(,^TSYI!'X5*#3[BG
ME/'@]$VO;&=<;SMMZOV\O,>I%1]N[WC<1'#G58QC3#%O&->2:1=5&+A P >;
MI;Y_Q6I5I%?\,*IHN<G$ O-K_?FLQ8@"WL-'LI+K@>;)G)VRZT=$U+S^C_%6
M7VER&FD<^_O_@7_^X;OBESL%$T82_,:'M_,>7?E<)/<QUF!!W]D:.05+5SGT
M/#+S*7)=:<&HNG46L;HWT&T:HRPAO&9_:A=?MELHYR5-H'0R(,TQZAISBOG%
ML.H>U'8\$J_UP?T*#N8O0MMRFGW<[3[P<&$\EP')&&1 \$\_!]QZP8!(@<?-
MO>85C[N].,VOX&(ZM-?G#\Y<7?+A#_^G"'O2V>6U9<Z[G]/%@"1',"#KA'QD
M]5HE P)5@NZ2AG;8ZF@I$T,/G]9ICTAW4IL>@M*'Z I'4W_-,^W;]-%H[N3<
M\M5M:(5CYNHNI]LN%RAU/+D>Q(8]991]_(Q1<Q,"-K>Q3F= E("A_<HU@>\9
M*;431K43YDFPM^Z=U.8I)!YLP_<60!GB8$-EL/5-9 S4+*!U3&Y$D1()_FW(
M +H*YT'825NG,2#NY'Q\&^X= _(A=/?OP[QM\XG ]LK?LGJ@S"ALI)<L R++
M#X*,$TAR/G][:JXV]1Z(94F7&)".HJ67:[!'E S\/QJ$P:*\C,#::K<9D,-0
MJ@NSZN.B0PS()7UM\!A.==K_V!A>'M#GY]"U)):FUN[+2I<;.8SL,C=F0+[F
M@3H7TA5';C(@[VK @]<&= 6](])S 9:[ZF_'UL006"_J\H*8JGL)VU[44CIL
M8<F G"]$'JEAHH8IP*DL"51GVBV;3E#Y?9.>7?A/E,PD4GDOCNI?>@34(-T:
MU& 6["+8X"T?B(L_3)4-T9%"X(F<Y._;;(7-"\.V\ :ZYR@*UE:]T88^4TV"
MS=XH1D[;HV=L'%O@J&0^@<^27N,II<5Y[DGSYC+"C5!C/PEJH6/01SO/-9&P
M>'-MS!Y\569!#^RE"IVNR5FD>O=/]Y_I:Q4?PY@^'4]_R'25 1&A95/_;"!Q
M!C]3-"'7VSNGX#]39I$UZ'2FG&M!T+]+,F/@A*,V\_]D,E4W:^-1]/U<6AH]
M%1S! !/XVI#H88-*Y) . Z*LWLN Z M2EY1%#P5^!XM/P.57\'<)I!3-A7RB
MA]V_,"!#%LCU0CM+4*F2<%"4"73=\"@6K)I;#BZ\!P%1]-164/(#><.C,78)
M] 8VRE+""G0+!W[^D^V5%D)/NWG0-ZP2N]B$I>T:#7L>LJ.HT-/&00&>HT,O
MD3/$<3J% 5E^(-^YK,$-JX0M_L<)8_44$*UQXW?Q#(A5T9!])@MT#+VUZ0J*
M.P@#R:_7#2["WC+:+@,R4CB,VG4ZW+FC35.S0N+[Z-70,>C6MC,#@H3M_S*.
MA%1X!B)GEOKH=.1V 2IK@6Y[D"QR 93[K_2O2C2UL;\;7AJH ZVE48:R=R#6
M,SP'8DUO8T#R>J!_1]W+O<""!FCE_X3O*S#*J#KD5R6)^K_.N.\PT6!@MW^'
M^GN !@?\R$U/MG3D4!4]BVX%JEW8T?B9EF>63A]S$)C_.9K,>GU-UF+YO[PC
MAZ0*XK? 7I'X=?!:2"CD$#W][["/O](U(0=1\D$.:+#O0Z,?Q QD0$[LTF"+
M^+_#.5H.&QY'_6];ARJ]E92J7G83UQO7V=;K\7N^NH)SX.ACU3_;<_F*SS5!
M_1-/CYQTB#[__%R]!A_L/[4<1O[G+LVXUM]6T93,*\KKFBN#&1#C3?5.-Z'N
M2AL_.X\]I_MPIQO7F8Z4/,P\!06TL8L,R/U_HE3"" *@5C25OZ-*%BE'0@88
MD#?^=/36^M^Q)[/H[.O[R"'L.CAX5I7Y_X?6!<N!%\M)O?$/7<QK4@,PR6=P
M0K5RDCJ;^N*W61]]@6#BN^(*MY]Z&<5K9)["__>I\?^CUA+*__$RC;HJ2"_Q
MB'NCZER!'0W//V4N3PF35G;5Y0:>E996\?>DZ2U*V=>U?1$<9U?Z@7&+7E-C
M4MC4!JT@&LT7R.6+[%"&A7OA(P// B9D:R(^E,HTW>33X?ZJ6:C_F;M;KLV3
M)9'A7V5/PGMC%8+UHJ\QGTMPC1Y=E.E$CAT\2J_J#%GU9.-?A(Y;Z6=DN1?=
M9L+EU8QY/*<0$CREH[UKKXLXKYVR  @DB198%;KUE,FW#.7^9PA=0OI3F/A2
MQY\+)1/7*MZ1N_(2/<67-,1OGLMDB\).%V:P_8+98\?&6]"D8*!GABF.6!9A
M*S!46LS3J1S:N_6NOLYRNJ:YOI[R .XD8%6A,-C&JM-]^8J6^R5U5?+32HI
MX(B 8 U02V8B5">WLG&U^A%L9-ILA9L:R&RA,L\(-Z5BJ*N2)2]< P2UXNZ(
MU+U)[DYZU-*\=9 Q#0T_B;F9==.AV FW_C:PI]AB^8N-:Z#XKVJ]N8:*:PIY
M^Z;M/3^?1.2F)!VFZSCGN*5X7\&V&0 BL&]]D?@S"BB.Y2DVUTGK-JO<M.*E
M1B__/U+5$DTWSDG.9N!N)#&K5GOS6YZL"7STF_/0)HK*(;?3/:(N[:M'U.Z
M1_+0K^O[&)&%;'G=(7]PBI5%9:^3<!-GPN_7!NL:Z_[&H%2T4=M.#Z^*'>QF
M'PL$)SYB DB&#WNZ'Z;>'U87^$;"J7'/$P<OV+JS+;_:IN?(G^5-'<M023A6
M\MKNFJJ=?2V_S>U;&C0Q$FIE<AH/H;J2#=K4^+7<8.W-U\-P>-O&L(UIS8*2
MAM77V2'(A/G+\9\U7I-^*#WZV$->WGE%0JVJD.;AS,",MO+4:X5A'I3K3L%J
MI>0UR3A%P 8ZY\7$7_ZBZW+)H;T2BF;@D( <V;VE#(>:,0\/O RD>,'?V%X;
MJ&) CMS,6AXJ#?8D**3TC+5>K&G2RVGP=DP1DCSI]BCSY&Z,=AOL#$8)O,"/
MI./I18B;Y L,2)CJ8\(IDP?A+<OTT)Q%9E[-V"NA;/MWNNEV\AMS$8\X+^=;
M@79RCOX5QDP-(!NO=RCGO9D*<'R J1Q6X)WY)?-XJ-HZ[7::<^F*L4-U?;S<
MKI73Q^C3OIQX+OHW^&F$(_GG.%'KD_/,.55'>PNK)5G?4>N0E;=M<JV<1I/%
M1BUMI_H_GQC_6/ ]5]X7OSH74  DTT]R4<1\.>AG83R+ ESD./*+D94J&7:X
M4YXQ13J%=8=N7_.R_=+&[%YX[V3XK9MD,1!0X?GIG1ERP!?2_*C)L&J VV?$
M/1" A& N%;F63[DF\QF[[%1.Z7,2#^WT:J\TWWF;?R'OY5)C%PO<$_&2%D?E
MH&CZ%K7@UB/E)QVV^X[Q5WY:LK)MRG<:377'Q0G6C2E\)&'7V;GNZ\X(?KK1
M 2TW;ZFCL_9.<Y&>V;4F6]7N4 %, P6!0W\0IOC#_="N2OZ)R$'6YN><TJM9
MG#WJIL#!5NQ]((L"0W"E=3;+DFS05,$I;O+W?@7+YQBY L!EH5WY 2F\NFE(
MJIKY3MR]V L.D7#Y,Z&)7W].LH&S]$U;_1*@O6-'ZGR;]XM^[O9,D]U7)?@9
MJ,X@5:H$2!2NA6#8E<>ZN;LA?-=GFS.\WWZ?=XL6YR[+X]F! DCI+$)CNO9=
M,EO$4U(B;20G1^DM5:]P^3/./\JK-O$MIN[]]8WDDV7U=I(KKRW'4!>@U+/)
MTZ$U(7F+WO13OTHD/2?% XY?+T'H%WU;<*Y\J/ C28ZS_KB_G5SCWK7D:.YG
MHD<CBUY/3X$3$9Q"-2*;?9$/9!O"',FV&J>RU  ="Y;EC=AW70,J34$;I8_Y
M+:HT='\=KI>X,LTMQ4\_V3L#/?8MU]7V&CAA80JG.$ 'ROQ<_<JB-Y^\Q[C-
MF"X[;T6JGWV<\.D\=9=V@1:=WT!/@&X>_2L#PK)5(.2K*GA9?HK)(&P-625S
MVO.889'CCZ8@!@A':FD-@5&4D]1K_0K0TS8WI[OLD2>!IP;'%[],]+WP.OKJ
M=DR9$UEG]7QWS[=K1;)'@_WR7F01T9'H6O..];?PBEK4[W']K/87I!^^I>/M
M#?#7"@S(Z6^?IU# WI!=QIH#1Y==O&+P!@\+I9XY]#5OSHL LOC,3C?MH_MH
M6P97,SFQL\6:0BC$_ZDUMO;3DD\X^VVG3]'Y[9Z50=5%R7E]C)_;SGHP\C'Z
M$,#T-34\M'@+SV4#P(T'4.%S ]5P+I?]4O2%B)O0.*ZF7S_B6@Y#,CL*NS&'
MF;AX0I"/8>%8-NIMPJ3U?1*]8C_YS5;!EOYE(N7A<-E4=_<SIEH3U?7W7P_=
M_/D58I,5V9AIC9;H ]>?%5DF"FD/.AF\-OK;OG94-?2HBX!XXP"2<&X$H;5K
M;*DG7#FOHG@S;TQUX+S-PQ]+C=T$3(W'$!Q<?IH(5YYH.M>2<FS49T"&@$=1
M93^YD)>M2N.0 0[(_"49;IH\W%HI^=&?^#D!HHB9J ^G,5^3$_*;9"#K-T*3
MB$XMZ7Z.0]Z?_3M3T# 5-:1IC=SBT,.FX22?4Q=:JG^<DH^E/YP;E?SKZ@MK
M'SS)H"\L-1)X+H81RU=(#G637Y;@9UMUT[#0Y4:CO@1\_JT_.UEE<<B6(/0,
MPGR=<RVR?K.Y!+S BV2BK^(Z,: YC2 ,N#N2+_I"*2?U),)&A:LYI(IL:>4/
M3W";R$I?I*B(:C"E&O1:X,RIG)7$NV54(9]]Y&OM-RO-<K"6GB+19]+@_?=*
MT ]3=V./%W-9G^7]HMN(MWC#4)>TAUTI1ZDWHHCN5.&L%O/P!_1)=5&*[+![
MVEWZB.P*O9_>=XV&6K50P:R+^"(_*C(@J44P*@<#0J@$7KI=!!1G*,HS[9V=
M+S5WEO%I5D)*N%J_QH;7%,P><L5T\O3"3^A)\$:9 S^C+D[5+,<.8?@]"@#Q
M]8Y:]7/U0U7KQY;-E5)-W_A_YON86GC\"^)>8\:DX,3;K\>?,)>.[GRB8120
M)RP0-PS"7]W)W>UH5JPB16-)'P!'\X%!MJI6,5TCD5CF\Q*%9Q]<O7B-FATF
MT$? _FYML64FT_ 1\FH2[7Q2.Y\*U,N\7/-\PTVK!]=*)PX)#5IH*^/DU \]
M:_,1N&^@T$*?0GYYWDBQ+FL9M[8H,=$GH6*>;=.>J-1+2\W6540(61H?CV!A
M?HM\OW;/:RK[9/: CW87O!J^>I,,F_%.RT,H"@@G?VN6&&R6L_856+ AQ;1/
MH;ASW-2*.\XI[E7H"2@%D_WBI6=-^KA: G\A:V&QS3#Z=S[/*1ZR]EN$2"E"
MBE3\*CEV33[]OK5*2+'BI]/)%[)1+!*LB9BZWQ;!N8(_#\$^I\*I'.N$$=3C
MK/'VZ9X.>BOY*CFQNFUW=VA2M_BPP;A(^MRU"5V0QCW\*?LZ^I#I-A(00;7J
M.[8>_/BWGGI\OI.8L^%B*Z:S)CVC7-*BMR"19'E$.^+:[^A\X33!^1NE]CS:
M(*\ZQX XX[D".QD0#J33^DD7Y9'JXDD@1+>6#&M]C\$D65Y.W=<L][<.:$O4
M*1-^6ZRC86H&$Q6*+=HQ=^>AJM*:K0EK33-L'+ZQIU@(BNEJ.!>^XEVCAR['
M%\U<2TK;_*+U3H%$Y_GQOR06X9'8+Z-O A6H6J3P*(3!].XOA.:T7H+/IRG9
MNICBG*E8WL)KQ1]\!][K\(H=#;KF@9[!_T:UX-D#1; Q,I[NW):^N6YJ\@5>
M%Z 'F:$D:_+G1D0H0N3CAFT9-U?_7!U.#/?T45L2D]"CLS=IP\@$?P8DD)\J
MKD3ZF8V<AP;\<U3_;DCK7J)-0^0HDL7%D?YXE $!3H-KVU I5.$>"D@"*>BT
M"@,2ZORC,='3X;MISJ*U#$'J 0/R0^X@0X,C W(RV(!IJ0W9)6/T'\>(GKJU
MTB</ [KS::ZOD,==C\%FN0J0TQ*@%%/D,5<A!J1+T 2L:P[6';BOUC.OI8H=
M+.H9K!4B:54AY]D+/1D0M"6L)3/A:\,8=(/I%Y)TUH!4:()ZN1?WAN:"P0[6
MHK^^(L VCO_"'GR3+T0ZCD'.,Q>!S ]] ]92<E^M-87W[%:A.32PP5)=8'D6
MV<5F 78H!FMIZ'N#A:PI]-Z!N]8,68UIX*6J\HWUP@0R-WCV!M.=M%1[0PIX
MBRKS:!\8D%HD@3=A%;]Q@@%)EI%3?^KQ$[\#*[N[??*9D22[^.7"RY#"PJN<
MIX-.>OER.?8I20@\G.N5?O0Y4N+:'36Q]YN#*7\_> -;>Z<8(!OO91Z.%,T\
M\>=S)$0,M5NPU4D9AKPWTH3(TK>%)6A+=R'BRO%9F8<_T)RW.I<UF/7CT_7C
M@_AUP-9)<?15R+6#QGU6S][/C*0)0Q3?;>5DJXD>2CRW;/S L00B2,,Y'"1>
M#3K&@%A@UT]6$]WW3D\P($VT8Z;P[2@ZJ<CV"@/R;K6/@N\W9/H)K5V(WD*&
MQU$%1JIIYOK]6P$PHD)TK?E^Z*"UM;7([[*PA;@NTW,7[>-&,/XS!JMC^=\I
M<,"L]2ORS%8/BG7*-?#\T-P0VGIP+@1>.RS-+?9<GN*TM2?]_.*=O_@6*+>$
M=!/?"3X;%YEX8,C487N.5EM=HFU)PK[))H>^;U8.Z0B\-H30SBEIJF^H^E(9
M99VLSZ'%L7O7+KA]!OG^1_Y]>P&')[C 01@GG9\J6#-<#1.P]8V?:8>?VD)S
M3^ GG6J,\MY$U]:4PVVM.X^*\O&ZE<[675[X>?+9-Y''7C"/ 0THOVO+##&\
M QV>X,LV,Y)#A E^$Y#[ #1_DY>Z[^=MZ^M#X^5UT_QP<OX:OEZFZMHL]^E:
MK N,PY:* /'.2ZKXB)<4]/9H-91OB7ZTJ7&PFF/..36ZUBKCX[J[[,;<^)&J
M4/[=EX]YJ:A=@U'/@WSET)56HGL8E)W.X_M2[64K82(5_Q;$5K@Q7V71YR6J
M(J["V7<L?O/W($5<E<_9I/9++Z>T=&079_71+X.W8HWFB\Z!YP%_/Z9HPJ#"
M'T\I?L/A50662<6.H?8RZ1RI*JQ]A9NR?U'!R9N7ZL[86&6?()=+Q+MN/8V$
M  E$@]70&;9PNB+PRR';MV.\4^!R?U4C34][<,NZ1,YP */D=NQ7%6OMP$TW
M6I8K\J3.FO'3C'-'7R;N)7\W>$A[W7P%2"8:A*GJ[*^WP2!4[>JJIHAG[A@5
MHK]^H+_AP+S.\Z=5Y>5!+X]<//.\57'^N03^3R9; @/R&"Y 533 E<U@PZGG
MB/C3+ALV2ZF!GUBYZ1=M[J^1I-&''_ZTR8FW]+[7?N&[BO5)G:^@]Q^ \WAA
M!7HI6@A8 E%MJLE+)D2!DBZC1TH?B<JW=/+>(6OECNQ#*](HKJ/"GR_K"L=J
M9ICP:XIG1JTUB!XA0GD"QV6I9TD!TU'$N=S&SU/4*_6_$)>*;1B0IS_VYVM9
M=W66G[MEZJQ=B5(<^&!T^O#A+FO_\S+14(%MY-M 6/AM,EN;7;;+*Y\V@T.M
MN0"[9''?SE3&Z+[PN(L#M:QJ\X40'A.K^5J];[;"+UQD'>QRWF ,.N.#"A1#
M.&!(@=A"/3GJE2^-0ZKPOT8,-6F-!3V^Y@8?N&)NB7T)FJBX<^;ISD5?0[8A
MK]!I$/GB9(*VX6?@SMY/6?"<2U!<0_&Z:H*NSXO9=L@3FP]!7VZ?%9?F,H5
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M*BZ)TW,;4;^E%VJ1+3;9J+V(@U^YGD7/Z"#LLMGV(A;Q "=ZQO:"L!\#TL:
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M5A6>[CNRI'X1\"*K?,MKO[IT-RD.7E&I66._Z6['S'JI*T5 3M9!W;A+F<2
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M?"XWWHYR*I[.LU"##!NZW'<W/NQDAF+0S8=-I\?*I:N?9S8_MZWO7F]AXPC
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M,<$VSJ+-2K?:6QT/P6 PX0]J'\BOGFG^U?^(BS&<F@B7;NDY*S_.]I8X<?#
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MPQSK@J>:[('Q4+H@7("1+\'$17 (WK[1\X8'.J:<XLU!6,!J_J7I$;5RF(.
M[2Y)'Y9! 0=A6H&TM0(NO,5(=<,KY'&E"7$0(GS&<"PN? $L2UY/@@2D>RBH
M9:]-#+2OF8-X5OA.HDNJG[CL"N];_F;^2T"%0OS&O*"]9I#I0=F%GIP*.03'
MQ<,,KB17T0S>##C:2KFA5[W272!A>/>?%1$'G@Y!P; \/?!?K+W\?U@\SRF#
M):/(="E"\1O&<)J#=?&Q  ZON$KBI@859LJ+ARBY4,D=XLH,/ .,@&4QF\7_
M&5VD^<*W+%R?=0#(0S*JJ; 7\^(@2C9TZ&(?,$M:[68=13-C4S?+TCF(;CPK
M'<U*-(ZH0/YF63'P6!BC!\/&*"CME@VY[DB#-03G0F_8F5L,TN_#6MV2!Y!A
MI#EV#2ABE+$8< 2&1>M LJV^H9/HF.F0/_B'>$DL:D$4UGDL392:-M51IU $
MJEZFB<8<9E36NBWI_M(LV'HL1B551$[RH3 CZN#SG2@GS_<\T 5Q%S;,<'XH
M[FG34-.U]=/1'SLWJ6^:HSL]KN(KBDJZ3YO6FY;I'&K59X6I=7-O0 WEK!PC
MS@KE 20\5._---D=6L+,"LU4&""5I-@]@CKZSL![!V>EH<*UY/+R_ND8WU*U
MHE-;CO?.*/Y4[?Y;'BUJ#[EQ$.<S52$6![$VRW3(9_]3^2_S[$SDSXK8?'V'
M_%$E4U83?'4-OOK:<03'B' C;L!QIDS_-#OI]*^_A<]\Z#B<O<[7:T!L8&T.
MJ%0BSHK"&(=4!M7+*^*&55_ 99N#U7H\D;U5;>DOIURHE_N%XQW8*D*)FZOO
MK*0[>QSTUU^A5G?W$;EWY!QQU-/H6;%\@,M$5$#GY97*S3F]0@0'\?).YK^#
M '<X!I\?/\N==/:CSX$1O_PA'78Q]XB]>UP2'-@+1]8F]+3$?[B(QR<\S)3T
M18W0.(@?&MS?G\&P ]&$-Z@5 >[]EV$.0OSY\^-N%J7WX'%P&#Y/14-L/#V;
M>0?VJ>/_=O):G41B1Z$1'/1X!& ST5/ZZ_W ZG^-UPE\"9=S'AR$)QS/SS.1
MS'6@#4?]R$',HF["(G6#/U0/Q0Y!H_#P==3& IR;4*.P6_[0;O[+_*78"\O\
M]3] =T34O[S_JVFPN\;7+Y==@U\A_\L(7IL7'!)2^?[.\4BUH!1)_0UC#C[4
MOW/^=_OO-Z/4-6[_+VTL@LH]Z7J9.+IUO?H'^A8I_#U(; F\0RRQM?]3E:Y>
MGQ6_;Z^#J?<#^=0]4K[E>CL"4[QCVT$=9A!6AF+!TJT:[#,'W8I9AS]61[76
M $]E*RL\Q90/K7B^D\+FI_0W'[UW=/X$,__TUQDX=H;50%V0&KL0<&;+-SMN
M>P_[G>V3UDV]?/FD!YY><H0ZH<44/XUM>D;(EPK\KT(&YQP#F#"V:3R^Y(O9
M/8S-;_2B(&.U3V=0HJ)8 5,JH($ZWQ$"4MS&K5A6(?^=3'6Y;HS<^(&[B>W,
M.J',CXC-=/1(-]F>Q/>+7A-\&0R=X(N=63 MPPG:9"K)?Y$R^[2B]9HA\WL\
M2U^X"6R&>&UH3QI1E5%/M,4<L14&FM4)E674$ TS$_-.YG$])G^-5M[]"><O
M?L>WZ^U]LIS.>-"&?Q^5T* 0? %,HVM8T41QP>=4XAH.NH8JT+Y'D/&"KCW8
MJ*9J<<L,]0_N"4F71QR:[2\W?WOTW3151G*AV=,7S\M!W%E*D.(%!Y@JP;KT
MJ"?'"&RGYE#! 5\5\5'L+8>3G4RI/^O7$N5=T^VP!_C;OS.5R=.R>>KW+>[S
M# F&#J+XE*EU)FJ8O75;CCGN\LPZY$OG?^.PI;H26ZM]1^G[FC-[FI1F\.<H
M*1IP!1!8O6E(TJY=&]EWN'=!>D#%J7;0\XV'L:&]OO"WQZ_VQ8Q%6-U5/('8
M:Q+J^P=/NX)Y:IOZ>2D.S:^E0C:Q:YY $&EROVQW)%*H5GK]]TJU+G@7R[%;
M\U(+;)/N^W:(R."J Z[<7LX<, QY!O42R_7;,2-ZZ*?I.2C>)5\%+2L:7H>6
MA7,*H/ ?-<[(F#<Q$LO7/S%6:<8JE"E<X?VP32Y%S_79UE4^6W8Y)(A]T'QJ
M9/ -W8+<FA ?X*<47\]NC[G[MBJ+LE?KI[G>,T6#-(D7!][IG7_G#P-)ZI/<
M8".0_,[5UKD];*E.+!?T0>T9!=\VMST4S:.+ZQFJNDB('7I\*FD]4MMNS_E?
M!X)O,@- %YM>M%L(LA$2*U_62V*><[>]0W3*GQW4S'#=U%II]SQ6?L$/N.DE
MTB.T#9N7ADLEO'9EG Z59<=JF3!O@O+M(TM-'D$_M:5 [J\K1;'.35(MK.MB
M)3*&[]Z[D5PR<QZZ9=!SWLF--SK&1T?X3+$"ZLU5[B$)7J$'[+%MJ!A'1&K3
MJ6K@)M[>=,_(J0S^1MY+2O=EEUM>^C&,7:8/^"C&T(G4VAPXHU:B/Y.VSXIL
M>L6I ?'E\SXCV"C3@5YC#[6^TKTS/MOT[1Y+WTK;JSSF,CWG>)->80(2IQ1Q
M6SPF!$"-$!IHX[$[ZZ"F?99H#3U<I#.O[@0A8[PN/5"G/EPV[7*;'$+6W4#[
M'%,BM)$H&BJ"75J_5D]'14Q\)Y'?E4V-E@E^&<E]2AKN<?>^U5&^[Y'A=+G6
MQ:A[H<X7;%^$D.G&4TN/0W=J9S6HT?/#ZPZ.?'IF_:ZZ>'1N>C5O'+)*GR?>
M6_T^-A4X4U"R%(VI[&[&16ALG,HZ CZ>Q/&/V[RTI$A:.1 JGF\]^>5'E(VD
M4:IUCB*^3L9'M7*H$T,S[WZ,D0A5 [/; _6?U)T-"B)["8'":G'&\3MG]Y@4
M.);T$8<)AFN[[>-N[ST1XVG0?+G=)^76:=(>J DMI.Y@/"7<A[UR9H:N_YEZ
MMG'D<EF!3>K' 1G"]?2?0LH6&]&?'K;<+I!.V%(4C;H'SDR1'C>(8?%7>K0,
MITQW@8#-X*DX/GYCJ^K*FH8QINC7!/W=#."%)X]\ F$:VLFN5O,$IC3:RG:#
M89*J3>+HQMIX98G,(+.!WK,>C4%;C<0VBHYML=[V>]3[9E]N\ .F?F@'NM*_
M!3,\XTCC+PM?DQ'@OJR[:]BF/=L>].$S9HXJ8L693%O*))LPG> :=M[SE6[X
MY2H^9^"NUQ.I4Z S\P+(;#')4R*RCN'C''=F-.:'$*8\3@[;VJ?MLQ.C6!#Z
MG96=JRSZ#7;:S\;9H1Z.A@[B>=?0/!ALY"C%I9F)0\Y5Z'OZ%[92%#4J",G0
M+Q\CV9]/QQ\?S!I0_L349VG1-B)6/>'"O#UK=WE/\,6'<[81;=6>PN_R0@XF
MOSJ6SV[RF.S>%2P\V* X.BM>]EBB+57J"&A'-[;O9P7DV=G.;C[,WI$-[%>2
M"[=2'7>KO?DU0C]+)])G_YD=-5[1Z/>DF&!I&E&GO^$ UH(RYGBV#Q>MHM89
M;V5%^U;FY%= M2E=*MD 7.K#)VL?>WV:0G\^W5KZU0YOY0I4VN\-M@#QV1Z%
M9")R%B,@TS?MZ6@J9&NTW/[@7I_!AN7GJ/?79'A=9+K$_!BZ?EE;P31R=YSX
MEH%@)0J_4$L-YN4/=H510^PR*7#*QRL^S7_WTZ>_;ENU:0XM=-$KFE![(0TP
MZ1*M(>K<1NP]UB[E#/4W?;DK5E<(@NY[YWZ,XP\KO$YZ:=+[^O/7WV%#!=QS
M,B!><(JL'ZVMXJZMVK>6H0)>#KZJ'J)I8CM_)65S4>@?A>?.[]$NAC['&_?M
M3M! OIR-?(CF@T$$=6N+XU;-]J<$E6V@E$4!9N3"5K"I#5*@5-Z7?7'YZ9X]
MN393OUH_[FA4GY,2H3],GNH6&/FS*96?/Z]Y?3FUJK[\DW%<4,3WD\^ECS8?
M?/KD)_>+BRU$& #$:.\%DVE7F+:T(ETG,NH ML)VP&:)*B>2LA&#^OE[1$XN
M3O/7MNW/'EDK!78O%#+5P*$F5#D*5[>]]'S6@2$"LWN/?IY(3<*EJ@1:QR_C
MFAV>V2JU6Z>E'@WL\RMF>H&8%GPE/KP!A75<ND"_+257T:^L[.>@8A?[6^V3
MI[!$!W9J-]_QT,6<0'%JG0J]KQ$MJ%Y,13=#)VCO:H'<XG/4*GSQ!3_U],*1
MR]$)1H@QR<\/6H.]WD#M)*$Z3Y7FL_*T@S0AT(I\KWC2CGK'P;Q-3[3WYTOI
M3-W*,NGPK]1#^ :QWU]5D(=5VI%A6<?[&K9B7<R'M Z&2KH1>2#1>5N!?#_M
M7/<IAT^U[XTO&6BW+!-3/A1FJ![]G=,V85.LH[-@HKA> CI0U.H\T1331UYM
M^'M#J7JD%I'G<:[["MPP=Z/<__G*=V#+QP==OA-B](2DJ24!NS^;(H7Y'K;7
M)YV\@F[ZI)Y:B;B5?S?:J$K,X/2Y"Y+%DTL(ED856.Q)(6[#UNK20[.GXH%&
M*=1'!Y7+)NB+2MDV8X=TO3V/.HY?'#(\+#OJ0XL<>71(V7NU^C.*-UBO%^VB
MLJ^14BQY<JDU/6*B4#G-J^B"ZW/'IM&4/J8!7*!G5[X3#FX6.GY$S_K]Z1\"
M0R;LU\$\E)T$__?TZG OJV9ZY4BQW;S(,O\I=5G5;D+WB]=/GH-;>7HSX7SX
MM&$//7XBUS,'6]P<6-KV+,N391GX2K7^.1!XM<1( *F4D$P/YR ^;+1Y'7#X
M,[39]J2L_C>I2:)LU^G^>Y6*OE#?P_A60LG#W055&16_*XG'&\<KMW_'MZ!_
MEE%0,6KCO,V&O:][D[7Y5,)5[H@^DW4KB$K0(]Q(L(YTOEL3AC_1^<#V4@6)
M)<.TGT7M);JIT^0C9WI8%_+QNXG15S[E_>D9;WJ7ZG'/LZJ-=[$Y2HDH<]!S
M1GW8@[1/2YU,$AW& E?I(A%.9>[N4MTF'XFQBK4$V4=.,2_/AEV/0BSG]]:I
M3/(TH47MH,% S%."Z1;\CME!0. 6K:[!>>U%;V> <%?M<M4RNJ/<QNQ#J'7D
MQ;TB!"T-&K&%A$2[E46/A$."&!'7"71#SQK?.;-WU!1^-=OX7.6]EBM/+GZ1
MC?N:<-Y8Y<2KY$JS.7^T9-T>]1 +4PXBO+.).")^P+R[T [PL&.,!'N_,E@Y
MS&HK,!BS1JAV>9-VH^^2H@!A2&@4^Q4M.&<KDGJLX5+/O'@$H63]9,K]\F]:
M@]?\!2N.IG0X>L 0+%@(+$53M] J'.B.40%.'I,@(=I/4&*6YG;JXK2\M7F3
MXN4K-QE.W?A/CV^<1YTY,[&'_2K8F=P][/^Y0:*6%A5+93G0IBQJ\2;]E9YV
MQMLN+_G0QF0??+V5,A:EFRBW_$OBT?6;=?&"KIL4OB\$/H.9,.N9,%\;F>>G
M=C]7$-N]<S),4SSV2N0G4IBM-@$VF2<-XN7T YJ>#;5N^1>$5Q\*ECSL.')^
M_Z'7.\\U(3Y][WEJI2NO8WLIYUIJKN7'.4OGN>OO-"T+WN;4_RD91_,25 *+
M-4R;WAV., R=*_JP6FS.[KON/&?[YFU\NU&Q=V^IO6]1M:2BSL4<F#C;>[#,
MI(]6I"'I<<G&<KK WK=X0_WB5*Z[C?G4HJ5GNVWO1V9RAO<@02_"L.:Z8GJM
MAE'N UNEK[J&H5.6?MT6:Z5B_[,AZ&RX*?X&YM?]8X O@5"D=F1L,(2D5\J7
MWET[.U!BPKO75_WB<ED'_-^OP_=L]*;8=I8A7:[V0+%[]Z=BF-JW2&A-/70J
M]RJ^L/2M_>518KV-/[&7H RM.4]P$$8CAQ/'OM;-6V\0O8MOK90Z3;#;WKV4
MN/2E@=EEXX]^2%!I6+%TZ!Y_5R"1?7AJZ=IUI?:)@F)?]WUFNE>W_^?GO(7<
M-L,W35@:EA7&G@\\#W7N[CEC>,COC*7E@;"=VP3[A)D*',0V'%P:97<P+:Q;
M:1MM"S/M(\Z%ST>O6G,0_J6C;=IW@G?+?M7>.,_6/R/,D*$93Z;& *ZXF$"7
M\#JY/).B>=N2C$,QIZW[0^9D[\6()]C@$%:+1)80$]K%))?]M""7#2MIE5JU
MCN2X^Y6ZMD=^O-F=)!)@<&U5TIK5]1T!)JB7A5D[&WVH-ZWP',I87IX'RUY1
MCG[TTW^>5S$W#GQF=;]&+?8I+&VX)3-.T#[_[X>"%17_'\>+TU&CINLEP# /
MN2J)HDX;:Y!/8%J;:%-&%"N\Y.I0+ED4MQ\[Q[[.2=8F1R/LGVWES::?7>^I
MI&%@AQAJ%->+U=+UFFJ+7URS7JHKJ'2])_WI^5>3++L DBM3>+KGTW&EL5\T
MI N]>?(I(/Y.2_Q.O;%UL#SEM-_<H2 S35+1!>]=C\(^'[FI[7^S8?'4*_HO
M;O:=S!@D[E8K%1A1V?]'H]=5^P1FS^CXF.V=WVH_U9B9VLU&5BO:UZNJ,R]V
M?I_6]WSTY?X6$OY_M'>MX5!N;_\I%>T<(IH.HG*.4!%)IG9D(TUHYVS^5$X3
MDW\8A^$IA2*$'2&-E'.2XSA/&I$B4=C&:2:G8B;/4.-AGIEY'WOO__OEO=Y/
M[]?WPW-=:ZWK_MVG=:^UGONZUF$DGE7[(N6+#<?RPB!R0OSVU?S/M19#S4=*
M??OI!-5RN0^I8ZX=2Q8S6A?#'CPX9R2;^NB,H*X&76/FG>:P5S^9'B'E?5MN
M]/?PW97T@DH"0\!P B_HBJK7U)3K)HF]8S6FMQ]VL&:PDC3F'_&O3'2;_(7:
MT,=,)TA0>%-M)HO)]0R)#EA0:31:7LPI45KDV=^VTM+<?$RB.>XG[MY$Y7O$
M1I!WM57#ST-M[8G=-PSI+#_/_-&UZVB?'#SKB)$[EZZ7_3BJI=U12O[^M 3C
MQ8NJ_8<! H%65W33H*D\L']\P9G6TL>I\+YW.L__H%^IE>]NSG8>R2;0LRG[
M\(M=VJ0TB\6"=]%SM@UFTH(6!/."C($HB;7'B0K?TL.*SNY*^Z8?YNI(:[VY
MW?AQN+FLR\['@T<?8#@>YV,3"W?/G@]/B1$!T+E<#69ONSON?-TM5L&'K$BS
M(@.C"2C&$I-8_F;I;'>\$\;XVN/(//61H#L'#AGK!!DNP.H%LPED(X@;4N[#
MBD\TK(AOW 9[B7.-Z!6<@ .+]*WAYZZ.PP8DORG)'L4V)YN]BS>T:\2J!058
M(G$+61U::F-Q[$=<N/*TX7^/U+@$C/'24O%N9U+#AU[J#3\)]]+MTTE7L7KX
M+D[Z2:-R"J4&P:]K/0S+G/F\MS['DOM[1IG.>\^GX_Z-Z3T!O--RIS:6=FDG
M55OWWJ'\DE-5^IP0S\UD8YX3,"8#&;&3MC)T]%?-J2_0L/S I]<-(R&%JK*=
M/ W^>1M7Q^3!84DIQ>?Y1X</9+S]@4O&BR%HOG370X9+O(TX%L $)RBV[HE_
MZIS+;O^ZS))PWK77YC8YI'7F.W>K.M27:/A7&8O54$;T6(4MK#TV'E5<<Z.(
M<P^(A6-N;A9^UYB=Q1R^[#V));UL-TW9N'V+MS?9;\0SEGB/P>'(5QDF#S+C
MO;FAE25N[S)6S3%>#+]_46L?+W[_W2N%HCO.L,<HF\9I+DHF$-X9]/ZYGBB.
M$&&][;E!()ID;?B:;&I;[)83XAXZ]X'IYI?05S)>I38V,/V6\=CEAN,UM=,1
ME [BL(PUS.=F6G*-[OQ,V2IUG+YZHB.WZ%OCF0HPOTM^64X%=VWH*$GV-];3
M!&.DZNB-';G#ZTX>)=+\*\2&X4D+:"HBXVGQO-G>?M8@.^!'SW;^^26=*]Y.
MWYV9L?W&B5J[1XLWY*D2W;C*V[#,)]%2D"5=1FY^<!>8&++'DK[ERL$/B9&L
M +PU;?%%D:]73M?C;MNIC.1_J<G^,29KVU9?%-T[46E $PNX7&-V^+,>FP5E
MPT:V80>3RF=R+BF,3=4U>1]^>_9^VW7% R-GHC\HBX7VS>*W@,R,P^3CD'AR
M305L35;QB_HB F3\LA4=3<1C,JWBM'14,YP6 I_RW2K"@U33O!W]MM:?7^=1
ML^X["5M+O66PL/6K2\ RHK;J-JX:Z7M5XS-YSW-GYQKJ!AW]KNL'2^F2']HU
M$QP=1W]]('FR=%Q&4"-4A)<['+Z:G*DL&??7;T%.2HG9.>EZ5X;:U._+RI/%
MF5YQU6_OV2=VS;YY*!-&YW-6&=D>%N0C)X<09R9?<)%N]['6JHBXL29SL+>P
MNZJV+O>ZVGQMTC/VSNR]J@&+33MW''(8H+)M]T)@?' ]^5*4IU'\3Z+<7.J$
ML\M#W=,$98;QXL/?SMJ[YB!E2_6OI3&D=^N^@A(BP!<G20YL&2@WT HI7OBA
MISKQY]RJE# Q/+!:_-"QF,4=SS2%;CEN6O9V-XXYI&SG8C@WN3X6#7#!I>O0
M FL\-PCJI,>[M30E=F1FQQQ*ZY^+#%+4.'OC_9*KYT!!XKK6B^I4$>"%_S,$
MO"R%;Q]*!%F;09;*RWZV5$4<HMZJ5)/(WC\5_B'FRW6=_L0;[L-5UA%;R_IA
M.L\5G>DJ?H?IUP5-4^#K/R%.ZTTJVY56U5Q&*#8=7;G5T\L@!:P<JMYY["V0
M^ I;MWR#C&=JCWG8NBSN#'8E; [90OJXP,R^V**34=B/N6T3FBFG\DPJ4&V;
M0ON5'AR)3R0;5_?]B"S\_+,CQZ.U_I-.S5OD4*E56<M 8WRV^$O7ZR3%NSOE
M'J2IF=G)@64K94DP%UV^^97P/*^C9?#YSASSCP8CKI$"6<,M>ECKEH9&*]V]
MX>M'3QDQSA(W7>"(RZT_Y5YQ6[GR-?G0H.D>,@6J^!$*%<P4A/(\I"$2HL((
MX391DZ4Z9&IZZBQD[[7.C*^_ISMZ7_KQ)(\*F5&^""Z=IC4._4@Z;5[=2LOA
M.]!-<F]C])UE>5D'O;/']C=)['05['DV^NSP='BIB3B'!O6V-YXKCR2\F) (
MCB2X#KHF20O'";!N@;Z+S17%^]H3JDLRNNJUSN8OWA8[YY[BVKH*-U- 5J\L
M3'MS=%=O?$C2Q:7?N!8M#U/H5H07\X?]\RV33YR^$)EAI'1*6Q[;='>[F03+
M>NPSR'P4T=D!QA_2:,<K?&U\T4+(\]MU)ET94=&\&ORSJC%Y"3/("5(E<513
MGUT/\/4*&XA1O4(%9((A'XX-,T5I_.M@QJZ".?P\==G$O3R)EQKN&99Y$8HJ
M=/*."4MS)6WU.JE^833Y7H-TP^1SD(C= L=/7HF_;1"YA^1PR^'C]Q!"E,<)
MC#U?.6MC%]7W64CMY20QU9Q"'T;!K\Q,MR^^(N#E3!F3(_[: 7:UAQV9M&UA
M6(^FP8 1^H2,*^XC<?O,F^?35C]^T*3[V5?V7VEPX!>WV>?=(K!2V+ARLCH-
MNL<@)0<0I5/RYR*DJX96I9<'F,TM?*\NV>0OAG59BB]5GQ<SH;L)P'RS+!\?
MYO#F/FSVJ:>U9<C4^9D?@Y::]W7U<87/I3US@;$S#386VZ$&F2J;6JI.9;6"
M[7/,,_@X=YX.*M6\SUF0M'KN_HTW?=3#W9?$B"J?J^-4N=H$2?I=W_G+;VGK
MO\44&7M2C& UOFH8A1<V4*,'GVDFYG<56#[QC5!O(93 @39W0V38(V!U^&!:
M9SAFV,6I,G7_Z,8K]M@[AGJQ$]6S[<K#0T[9 9OXKW?EAU%=/WFU?@INV35I
M#BW$L?<9'<&[MUU>7OJCL4%:17V]0J&^E:IY^.)]Z85)<<Z10C1KR7GZE3%
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MHZXH]HHT#MZ_P.;JX>/N@=^QI>"B[6D]1-:2%TQ<*<2)@-A-*+S+D*>@@&?
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M'@0"<8'865E [,P:"U-NL++^V^M? 5F=^/?ZWR<K?A#;O[\OX&\E\)_UO^U
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MZ93%I$L#S:0M4V6\0>;^@ZVK-T^V85S"(POBRLQJ7,78!:VL;S-I" L1)<8
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MH].GI#%KYIS$A_XW4]_G?^ZWE6\_BI.GKPQ*0/85S/^\P_)^^U9A:_XG@,
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M);KTN]PZ6!S\"/5Q ,U6I^8B/*5^<"9_'\H3;LMV'<$5"H3F_SLG_/YQ>'&
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M=I6GO+JT*OQ!V*S<+;1XUO8O7[+#LO?I'.U_0Q:^*G+)S/0)\'W[NZW^/7J
M2%U )/M&<#V(IC"'VK3(P@7;B$8A)J9KCG& ^YA*#I 3I,UU&Z9___;_LB.>
M=/YT([#;4!O(00.L8JQKK7J]W;X^+<6L<<5F[*=C%=_.E.O%Z4>.-M!_M(7/
MGC-LWNWWX;+9QP_[LT3E'&]2A!9:/]HRK:EWK#I((P&N%GY):O7X68RY&)#H
MR&CH%4.?HW, AN<<9'_(@DK#N%]DIII9NII2(8[U$>1ELGZ'9?A+H3Y_'C2X
M3H-22C,$>YC0 .K<.BYZJDDBFHV\3WAI8<_XE2V<3)9^.HZ)*0<)A+-6DS9E
M?*^=B:SI/$'?Q1"=PQ\Z(JEKMG_&BM_^>;'<IEX/!^@]K[V-O>+5N2U_WB0"
MQ>LC]#Q(;M!'$:QPY<**$Z/71GAL=!GQ<GZ7SVN+R)@6LT+60K7$RJ<)KDB\
MWH;_WTVP_I/CSXU^UL9Q?VH&Q/7E_Z,/_W]CZ.3-^FTJH53'1JE6PR,?$BV=
M'D4?B<]^]5WD%?4 Z0:2@FXX-SL\-FPUW%(?CU;QNV+WI:67>F&'*H4#+.Q@
MW'!'@=:>.O%U.'V(OE3>FZGAF@91,$1B-F8T!4>7@Q\%'"9)I2I-O?Y=*17.
M,&"/KLRQX;&$2J?2XLD3?11S5]85VV[$,*.E_")SX)=MM$SB#4/MN5GT$)HF
M>L<ZU+N9LN@I\\Q F^<#"L?J9,Q5X6JYOB*6HL_B'1?AIOW&6 X@;/>YA?@5
M6YV-GH(M'!,X#G^(Z\%33$SB0$-V1VLHOA/?GMWJ&(L@KS\P77G/ 0*O(@@\
M YB7'"!<E(#</%"CP UD:0CV\=Q>L%" D5[?\>H22D6DHE+!H-9MW8\-$@E?
M9\S")D!>=TG>U\SRJCR5;SE;&EJUZ.L=M(CP_B_)_G]KXPE<:L$.JU^A"V1Y
M5L/*W7KSU*I"C!FM%ST=F+P9TWB 5(D:AM$JO])584I)V6]\A?97D1_XZSED
MO)#+#Y(C/3J+2M+:1IEN0I1R@,930S*IRU/.^Z&SZC(;?K/!1<PSG[4O (+:
M-E+0G[5EH<<VTGIS$$'6>ZF06"THXU:(?K2M<]\:?_(I=V>@42TO(T93/OY<
M(ZU5=2UE'L<X_ANUBX"\W5?S[G9C7*6*QT]SR]FB'?C^3KGRW=XXYD&ZT ?F
M7LKZT/EO(2.5EQAFJY^UYI+7M5.Z]7>,3F0,)*N<F;9KBW_);-*L6'?8.B,_
M^>9_V$/\[Z_P._X6IH,CAN=[9,XTYHSKW_L<HR'SZOOV)S+H5(B;R8BM%MA3
M2YLP%Y[,>+-8=GXC<:3H+O(RNZ#+KW7B,:I,?^&#7"RFEXCGO4'Y;=/B^TG)
M;(G'%UG5,AM4\94QB"I>GT?X4Q_<]2T(?%!,&;R8=>.6K>Y0Z('^ZE6IK)&&
M>Q^N2>%%*O18</TKISX5NJ9/SW.#BYH[HO0$9OU6S4#5N6M6*Z:O#[G>32_^
M"&=D3+__97(//DE'4-8-Z5!BU/D7A[H53Q.F=R0G55=7F#O,(EX6"!S0+:$,
MO(+9VWL(O'OW>0\Q0G8XX=/\+NO"TP\T?<?*D0Z:21)A,2<+#YS)C#D)_)=&
M321MBH**#@EF:,X>D7NN9>Q 1.QS2XUXMZNF(FA^<_^L*^V'E8<V;*%_45%J
M5B1Y5\;8$9>?'UX>VH[QI>OFAZAV8^\;6]=;]:\WPR*K3!I@A]0CT#4*KN3J
MD3'7-9GRF+L^MBIW2M-GU?T6G2.,?.)]OMT[=.K0A0$C)\.Q:R.%[]9BF!.)
MUQ8WSZ-%Y13T]##822Z+*\<JV,XYPZI.HL-#%"B,I@Q-:D6=R3.4*-.)RG/-
M'1*1FANMNB,[8(IQM:],\K)XNYAT_+3IUV3>PHR>8>+S-R];9!(#BWF.JX$N
ML-M XDQ3:@M-AHIL7D"0T(WF]%C*2$L0(CQ$J9O^<7/$N'_^6-J-F):%(U<>
MY[PCSQ:-GB\XW:65&%IF)6=F4&XCW:&@6(:0O3T$0:FU;;;<6?J0EI0%KU).
MB]3<>+RXJ7T:7O./'?8"$%%KG5%02C=;S)Z(V!V:$W+QRQ=A;G P]9YL%:[J
MJ2A1I\'-G@H3+W^]F':Z^E+@Z76^OU'.2"[EY)/:HIP8+N5,>HVHU^52SG"A
M+<8)Y3+.MK:_,\[]H"W&>3* RSCY&%BVN2F7>0IM,<Z#6ES&&1[*99P*)_].
MC W@6\3X Y<8*RQRB;&E/E,&LD6,;W*)L<@Z@OGE#V)\;(L87X[<(L;H+6+L
M!**\9&X18UTN,;88XQ+CXG\CQG^A_ OE7RC_0OD7RO\>I3WS"KV;C C/$$LS
M'ZA1)_!;&P3L8.]G%*^H.^JQ.]K/KC)O "?2[T_,5PAT7J>*1GT)D<T<==-,
MZE,S5XO&6.8\E!=:Z?(]@9%EY2+<8Y?B*FZY:NJD-C08# ZM.V&ELPQG,-'T
M]'0'%!W/T N(I;W *1("I'H:-0L^)CU<.+DB=%@.^#%!$>S&/3GG/8O@RL 1
M)LH$]Q>LS2WMI9M850X6#X^X:3)I$:V;DV2C4TGI7DC4CEYM[>&[00$7@MTV
MVS,U'42,O8V\($Z(P8(R9$E ;+-YAV3N?BO7Q+WG60UM%Y4S?;7I!);S7B/8
M_DSYS*-\G[.V79H!"@_\2Q)6:&TDY=K9])Y)'WTW]+=5R3^)-NL?'F.A(?>W
ME:T_&P#R'_3TQ[+DG_4/^4=%_;%X^H\&\$\,:MN_!O,FSU\H__^'4C>W9OGN
M99QIDT#[U8\NI)>M1\#@>U_,C #OL#O.73Z93S0@PT($]0B$*S>+Q\A0A.)\
MVHVM&S).%0<K_%!2M*\TZSPEG_V#NI'PS7)?L1I.[Z&CA;H_@Y=YL(_--X,5
M5,8(AZCTU>P@#KWX]98XTLD_..KJI_)N\F/\4.99F3C'UREF>Z_'&V[$AUK%
MF)N[UZ*71Q9G+M9JH6'OT.N#R[4PVB&Z- GZ?%/_21GH&8IOB<E/9*34]# U
MO(D7>7W>J?DKV=U5M)(^>*/9D-?IILF;#<C9 EM]FBG=.I]YI[O&UY^"^ZYN
MITY9J+)R!1]+:QA ?O[]Z+V3P?O*LQM%QR,?B8@!DE\U5/'=9OYPSPIL)_;3
MEP)8RMQ&^'^<2QK\<:#^?X6AT 9QX0##6=?HHKEEV5)V622-5V>&(C;N\62U
MZ>O,U%H//CZ?<\U7MG67W_DT/WU#:CXY.9IRL>$$XTY*:./[6*.3@X&XZQ>W
M#>G[:0GE 4P(N3/*3I[U"7S\>X$$+L5"\/[7WH6ZY8777,DZI6\ZI@M*]Y0B
M1=E]^ .@W1ZW[U1=_)BJ6RYNL-*7$?7L*^@2KRHM=RN1U'#!;_-1+/]NY[9^
M<M<8HU#J!N,F@L^Y CY!M9O,NR?MOW0'@5L;_;WNJJR2P7J+<*R%$,JR@S(^
M'N_3,I;W5E*1?*EM?GI]'IHW<T8%Y9@90U4P?V?IW3&6WO/J537?R<SB_ZYK
M.%P'WHN@/!)M5GX&+44V"NUQ!1^FNZJE$$V$9X^H9J?XB:*U$JQ'6_E*XRK<
M<J(NW3BX-R-IWG'CD()*>A[Q5HW9V%C\3ZG=A?(WSE>!T*46)!/FE21J.SL<
M&@ZBG^Z#;*AAHK<:AB+J8$P=QG7FPX%5DUCO$"4*)&*5M=WCAH">S*OK H]2
M#E&_7#5*2]%]G7SU.\!\.R,01,?P=#SJ<[++-LL:&F.U.#V,%;TAF)U8O (Q
M<D&_J>%.^EV)K#0XZ%KW*/-&+VQ*\H!1<1568#7@OB-ST.)50 5;4)$N\'[W
MH2.P1DDOBE^:A]*>+#D)QW;-?1""W&\[,RF)#@7WO5I<=W$(JY)XV$\>(:"^
M#@HVA;ZMX@!,B2:">RA^"+&7:1G8"QM&+RR4S+W#/(#8,"RT/R/J?B4+[V2(
MUJ55KKQC(V+,)3%OFK*<L3G^+6$E>1XZ+"HT3?.083QB>8D*G8+G=4-?62&9
M$@O>BAA%,+_.WDI&;\#7MF^;_*IL7_-VMJ!7?U;5;2^*_XUD$,F :4 MVCQ;
M?@\B;<4!/KT=0\\CEET0RWH<X!X9^VKK>17=T-?E"(IWH_+C,$18HCXO1$6?
M1)CG*4X[*C2E<+^!+>A&Z4LY:AMR G<LED?Q4,7!%Z@/T?IS-^G2%ZV[.$!K
M%G?L7]9ZS #%< "5-;X8YB3WSX1)D^<X<4AIC0!U?Z]""N.\G[^X=9?GNW/:
M]$T+VTQ$72.DA/U9M#.RI<KSMA?C!E+< S(&MNGL_-UB-8GBG=Z'%U).QB:\
M:O.*#7K(*([9V'&%J_IY]L_ASSL@\;#5GIMJ2B&03V=W<@"A12)<?W+)-@+)
M5:,/*VVM*P05*P6Z[@!QB2'AT29K">A<\+NY^,!#3D*Q0A#F;NB$P^G=)R[V
MIHQV9LV@)7NX:#^@MJT]8ELTFT0839+!B&C%H[]"U7^HT"U,LME]B+UETR,.
M5-'O*04E/QN/L+(C82#U_5(:$@R<S-<+;T+N3&"N-W5]KHAEQ"_&-);0DXAC
MEX=./(-V.T?H)"5>G'E[-WC?(+ICB7[!FI9.A=;_8 NC&Y:BCG" R-WO?9]]
M0M1K%[2[>*J%/FM;N:[$[Q"2YH\(++)]"S:U.-.LRR/:-AEJ-9_&$O@:8'A?
M05[!B!MC.GO;%#;2.$#$"GV2 ^BA2%BVR' D!Y#,0=+6Z=,'8QK(ZDT/\WYT
MQBK_8.JD[,:0V<?B%=@(_47G:G9^/]L'<=V'.V'OAWS[KS;]_Q?K"?\G#K.R
M%P]Z&X9MUBMP^X:MK(\E6G[<6N.?2-W@H:6P*I1JW*=G,H23W26/3LIA#ALN
M\3RJ[890R?/GA,Q%>6_5% A4I^S1T!:ZS,KE !X*L&T%S>%$0_N:@8WXX+K(
MB,9U_J$)4.)ZZP]T!IN?N8<*6I E#>6N.!_*\&3IFE6V/VE)W*95$]FKW6P@
MT@OO@!8-Y% ?WU7U<#'.H<..O28_7"?WG E29CA3.DUIN1%:9W/I*I<K>GVJ
M#1Y^\;!PO-GXS0S4EY&=83B!R[LM;,0#<M*U]$7@)AY.'G'K'FVE6U#2].@7
MB0&KM8<&]4 "YSM^5BBSUCVG5R6![556)]&"MQZ'](Q.>=3>-=43.?KW7; [
M-;HD14B]E>ROG,]XR]^IOJ\?6,=65R:+'=7I?S<8;KIHS(U".IBH:H-%Z<L_
M+P&.K[KXF)LL-)9 6(K@ #Q6TX9T#R>Y1H_'YVZ.P]QMC^_^C3KS8N4>38]/
MWU!A19R6SYV,;YD.K*_9&?@F.X7*\JZ/<D>DDM(4+RBO6ZE>S&EQ4-!81Y>U
M71 ZVVSE:U$<&0A;CN< H4@8STN2>W#OND4&!_!GGF48,HP0=7:8G>R?4)?R
MOA![GFC5;^<$DXA=JOPO&CZ7Y.UK_D[1_9&;D40_QM +N5Y![V7H!,PUJR7W
M6@[32QHU(TH$:AH/'S5*>WOBSOT+,CP .2YF"?$ 19=3;H8._ZQ3?U9SX+-Q
M]@U]IO'2:TO7NN"OJ==YSX[J5];F8;CN.NP1TYLB%Z_Z;A]3GA[^!>& -W:@
ML90;+-;5U#$V<1D^^S>D?T;3%LV_M[U\I +-IK!O)SF)R-U(<I)_$8Q+9%:%
MK('3E.OMSSSVBEM2JG!?UKI67L-+F6Z$'"PCYM"==09"]/)>K^S*2'%2')U\
MO'LA(>^ATVMG28.UPE^]- 5ZZR<W]4./0F3I;U7'/FK1I2FU*X:"09ZFA_3)
MT !$'19?HMZ(? 8MAT3[FHB%0*@5X>=;F8=]747&2SZ,W:V3Z0B]7Z\::'JG
M\HYWJ031<,'NE_N[[GK"[/U3;>>\+*[-W2X1C0^7/Y=W*,U6*22?P@'8O+P,
M?:;!'7?E\-3)U[ P:[-4 95[O\Z9DZYX:@-RP[7^=0B*)ZZE<_^\Q]6Y[W"I
MVV&D%;-$"]/F1T<C+IG(T9]LF&CSLGYF8D^B25>=(<1FX0WU#6S7A@95Z13S
ME/)<'].O"T(8PDO8A+/[Z&E$(W UICUWU(;<*QX7R &TW;-[L83!M+<>*_[4
MCWN<.L<BZQ^8M?2-*R^C!ZP4?J&DG&%NY1R@PF'SHS=701)L/ '[@YG7BR ,
MYM_-/;%"-FZD+GR_&W+R^+V Z1,+W^::(4=*N _>W>*J_+ >3SZ4=1!?WQ/@
M(6.Z9OHXFWT?>]OE"Q87M[A.XQ+^TXB-_8B*L_A.NO(R1$X90A@,3!SZ"1*7
M3KP'-GM5+WL0Y2>:C?PQ /[ ?6 ;/?7BPV'FW:Z/*=*3*5>295OZKK6LHG%5
M"@;4<;^* @3##S)QJ[.H?8'K%Y!-'3"V0#Z]9#<'F%^28%ZL:@A!N28NXQ^M
M7;P7 O*$E[6Y<P6+;V$I_%Q6"MF6-W]4J,1M&?UV4>O'@;4F^+2I[1FJT(7X
M164V-U=1.%)XO%EQ&"%-.6##-5)A>.\10YATG:9G;N0PN(/$+S(*J=%JO8W$
M922US$$H!M!A_<LA)I0L.\0;]*86#2<M/:YAC81'8#.K%(JE9*>,2+D\RRD<
M0,9#ZD1C 1G4PNR<RKK#?;)_2&!W]W4L#U@60WXZ$> WZTU_KALSY8L<,B(A
M(Y-U$921EH'CAX:.?:.LC=I9.XM=S!+30/^FQ<Q%1@^BRBY#@J%3#[]EHN\J
MU[#O*K/% E*N59X9"PBV*7\-7#.RES_#,UCHKGZG"U:JC?(HKBY=\2[I#,_"
MQSD?EE@#O4.8JU*5F8=4V+QE9"3]Y$VZ+P?8\R"?:'R&KL\P6D"-6*COV\"Z
M,DYT*K=%V)#GE]+)G\E:Y(%V+?W<J,;F^!.IN:+![:FT[MK*H%JPLYUHM/2M
MS^%WEPO7.< 3N& W]#V>*H!N4=X\@CF(('3>Y  3\J9<S0XS'W>"%>BF7(]$
M5>'R2CY,!>MA*S=;.RY7P$(_XP"H*%999HS"1BFS[_]YZ]!_&_^):\?^/QJG
M)!M=+*. O8E!VXSL5!B>S'O<I-6#DF&L.6";FANU;J7W;$5?$!+$ 1+XUT)H
M!2X]OF[R7K,7\JNEATP;HPX;'(T+TQ2V26G"OZCBJ3/F6:CJZ+*4 )4,ZT=D
MS,2W83*R"4)6&ZAZ:$4._AE\S^]-+37%0)*1C%J^[R/$HY>%6A5')4IV;7BU
MC+7*74 K4UJ>,1T8-P,V+>)&9RM6]N$L4@2B/%+*IV8^:]0_'7EJEW,Z+T_#
MPB^&:4S6M6YWT"7#%H1()L-RC<(C(LF2%]H.=5XK;P]K"5>,=T2$^!/VXDK9
M'8BOC4'V%3@MC_W&7HTO7>7V)JSO]OR)&/P]E_&L%^+, 8:@E^F'W5(N"9A
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MT& @!:'HTN0H^/HE^?4[O"0!IT?CCE0.D/4=/W_5.Q%2,Z3]761!.N8D6JK
MM3]%5=_/N\VX^FMF#!ES MXUOIU^UG,YH+HYXQ"E*\[QA<F=B*'*W^%^.U\-
M;GMU^T;ZK%$RW](/:5$YE\S(!2.&@0NT6/U[:# )%.VQ9E1[H*%^AY?@N_U&
MOG+OO"2K=EKXW%YIJVP75(%*;#F@'0BN T)O.2#(E@.*YW[BLL>Z.VS>D(>L
M>"U7"KYN_%1:(T8:=Z3)WET;[.5Z.((][C]V/N8SW"!ME[KC2P7J,O8VT8ZO
M@?35L]#IABE*I6Q)\G15T.AF3:Y,KGEL\@G%BYNN'QBN'$!8-D2  WRP(&'9
M_.<Y -NX<-J:^T)J"-"-$7"%*[#[!J:Q_>0D(F54+?H$>G>KG=:-_&,1$J]'
M=[3QZIL#4]B=^7-<W]3"YNU\SW2C.V33>QM3.QC#;AYGD<8E.H([;VOIA^1Z
M'7W3R7?PB7Z'[5 GK^/AT%U1C97-ZN7Q"S.K(^VA:J-X\==.] #Y)/%K' "1
M, ,MQ3-%462A!5 >)!(CY@HC&&M2XTP%-(QI93[:.2/+!^H:#<00(;A73"[H
M,'>F 7VDH+60OG3GU15VUZO.2M3-)'2946;@Z0;_VZ,_B)'KQJ'=E'P"-!PL
MX%K?7C^\*SY98J=SA'9OYV^,;@JB,75="&"WCY^D8EJ=RH_HI7E/C6__HL\X
MRR+3"<&X]G[R!?M[,XZE(MQ0H3)@LKDRI57I;)HC=?W@0=%0_-HZ2I$IR.)F
M!$R>LS:_-R_UK;E\O9J51R+YPNZ(\1Y>U^/I2]T\\!W*4Z-+/6[*>IO;UN4L
MX*V\2(#2A>=6#X/[5V%/$$Z0O0'GLW%>:F4!-4M5.]IXAL^VL-:J:I5.)N])
M$C83WMUO)L:G#:#CFLCNI,_!-E=&<\:J,Q2M^N7_EC\X$Y?F/;)GJN5PB]9F
MWR3>'/_I-QO:.0[K_6V'S7892-T59C4XHN,* XW%B-6?9.ZRS*R,"_N?=5[@
M/W%=X']X\J 9XK8TPHU"%O,.V:49ZE3M,LQ'AY6CW5^XOL'W(MKX:U[;LZ$)
M>=2"^6"(JM6:B+SPXU<S24,^OW]E5QXM['1&@^DLAAE3DY6B!6'ED)=$7<;%
MPU_6F-ITI*6]O "^P_^6FX8^.85N%1HFLP4/T5]0[]FZ0O>NSL"E7(J==C&2
MJONG[-[NU4\1U'<RMQ^^1D?J4=:YD])-*!HF^0(=S0PD=5@R6_E.#X<OU!%$
M_3;2=L252&SKBV$=4*#,UI 72DY]]IK_@N^8QQZ8H=1HF!:&7*^T(+.-J) ;
M$-=.NH;2P"^C=Q B**R#N/.S.UCZ?D+&D-'=-"_).M<[JVU^Z$[DL#*-0<<R
MS$U.4BOB?0NNUM_F $=_R#!.9&1]96A9.UQ8NV?-M; 5FCDWLOG4!%-W6L]"
M#Y:-F&S_W1&AZ91@M&#<DG4&?!UJVR-UYH[%#'J^FP/LS*-+,A18&60=BFU&
M?H%.F.H+[R,O%HG=?=^62;" !(6!P!8!1\PBGU1/YBR7FK>BV,.^+._3=:Z7
MM7J6L"0.H$N9IL&YT\\GQ)65&Q(=(LWE\K:5O84:QC>6CSG<LZCFG9)_@;QR
M.G0;.O\56Z"'B@N'[PW(:L3(4/W2U"JR7"I2(U#<-$-PT/A39YY-RXY6D:\)
M-2658V:/$BIE",[/H*5W+)[&4<7/Y4-&/]5#@AGXF83I =+UZZAOKRW&$2H(
M2AV*2]?BMHHIZO5O<@"RF4C*O#HU_W:YY0)\'_-&]=.5<G<$_WB[.(% 3#XN
M=#1>Z*;[IBBK$',&49]%U_,96)[O+PL9LKS'_'$W9%EHW8*;=@2@"P)P\ZJ,
MJ[\Q_%V^RH(!R%MA];]&T]H/%X+<XE#C5X1P>WE":H/O,'6:?STK."+<V_'.
M/5KAPLICY<8)! '/367@"O2S#/& 5]>ID1$A.D3C:^1F?PLO*_<C/@,JK;Q%
M13I'#<WN?G!\)"[6AKK&2*XA08>GB3_/B8!/%?]@S]_ZRJR_GZ_/>, \GTAH
MU#*1(ABT%E?RMS"N:L'+-@:<+81?-)F(RGMH7!PZ$;(HGSW7GV1>X-UW$GVQ
MG/4%(VD[#8LII584KB5 4F,&O]*7" 772:!#=*\WZ;LTXZZU8(%R]U\^\@4D
M-CDMV3:^^!M2#/Z3JP7P,>>_70H5YMLQAB@]KV"=OLK>!"VB6<O:"NC>LF#;
M^Z!S/5/CLY EW:->&\_,3UW._EU=5\HLE7 Z6=TTN($D"3&%6V@P>ERA)_RP
M:^K#GV!+G[3\%Q#G;P;9=R QJ92M _\>TW6L$*T,*:I%?(VVBK.;D6KM6E60
M_74W#I">D;0)T@NBPV4Z7!""-1A/KC57#IF<:](E?F(SV,YD7".2KN;?;.5)
MHR ;\0+N$I,'+'JG>^.U^:\ZMS)WA^9/<X!H;ESO'-8E=OLCZ]38Q\LOZZ#T
M^Q6G.WO4'%]S +P(:WNW'5N\46LXA2KA/(O=$)<*5SK>K$\J68-..FP$T1,8
MYYEZ=&TL>S]V>T!#0]3;GZG)2"^/PSOR]LX<1#[R,@=+L/M1!S#[HG!<KK*O
MQO6]OEA]@\.745U!34(FID<[J@EA4C8-$N8 #DOA$-%GJ ,A%R@WRA3B#B^6
MNONEA\J.U,!W6E2;-'[VE6Z-:[ -O,@6@.?Z!*2>,R_@1C](-RH*(8@E?.-2
M8&3#0K3<"X\:70^ILX+H[!'C]* ?48GI#&ROR$(&/U<ZR1B9WUR=':,'$][=
M$<PU29WZ7@%=JFGHK7"8:QG&"F,)SSE 223R[3B^WBHEPOGE9$Z/:NQS9J)Y
MHBKSH$4,O9<M\)X>&B+.%L9'2YWKX0#5K"Q7#P2RL&XWXEHO _:\R&K@ S?W
M\>1Z8 .G4/^3^=3>BG9FC-W6V]^&2(98L/<KAX_+]BS#8?,+M_B9H>I?#K,4
M^K54.0 /'[S3:M[%,X=:&&/SQ'SEZM[;VIVO9)XA'S(>8*RI%4SQB^18+OF@
MQ(<84S[FQ\VS>WH7S[/&O%"G.^/':TURP;8D9;IZ!2VBV[*I5&IO/RU,IW2@
M?*G%?JH%! T))J70H#PDU5SK%/:X.P<PTEFSR<AMN!B"G_7&4ZS0P[@Z4+G^
MPD5BYX& '18HB^Z'-:=VOU,Q<E7-BYB$*<LX#LGG0602)-L35K:EA_&T]/\&
ME8G.IY%1@WB29$4X$Y&CFSTGFLR;5R=A\7+L=/GB\E5TE=H]<$"VV 6(DE<8
M[TH02^[4A\@/SW*-^)5<9+.J_.WR=7\_>OV[/L[><%SA09#)O >97R@27X:O
M[_ WJT4:]Y3"1%TM*G"/]^\?'K_X(\/B/N3YT?NA)=!:KA36T$,X=@P^'++$
MY5-45>9"@$+=,*H1>M@5#.KVL&/<Q<'L>[\H)H25-:YHMAS9W@A8OMF;R*.5
MNO[.A,TKR]!W5=F90H1$#18O[CX49H_\;' )W+^2;I+@-+C9E:R&+7%U08OX
MKFB-]FZ+:+RA5+-AM0+-8UAR "$KUCO$3 ']-IN-Y0 '])G:[C1?#I!9031A
M;'( IC%<QH@;+O)9'Q9(SHCG;/DK.I5O,R\=#'I55<Q4Y_YGDYZ2/\L!'F![
M%LY?Z",9%BX=O_=&ZT612GGH5W FQIEE^*, 4< !)KH0'R9K4H D5@4).8JE
M!^'FN3]5#U:/6E_C /14' 7+/ @CI,0?T<EDZO24>0MM=A;I:K&AN(?.(ANJ
ME%PV[Q@1M#MJ477#F:HZ2WC]ZLQP'DU/ T8_L"]4X;?07J8X[AXE%1M1(U)@
MY_HU;Y]N]N^']Q\B^#RV;6->0F<T3P0:J[='ID].;=QBHC>DS*7YG\>_MD&-
MIDR$:E/=V7RR$FXTC$!O;(5)!;[P8'#VI0G&(6E6+U2.Z<O*SBKGL:9.QUR>
M!EO;MIGTWX\.Y-*&9FQXX'0C-A);IAR;&PJI0^W2TL^\2@BO[=M5B9)ZK[)A
M ,^IS:]71=!E_!?,J/R-QKYY(9H#2VO\Z8L9ZY9%AYMO\-<0MLVHQ-?7IN<?
M^WY[O4B$N(M]H1+N!QV(?'! ,:O6+2%FS0)<1;=GV,+;CQA_=I-2HA<HY9XC
M8HM+\4*SG\03&JX-M*,>50<]:J[]V,GF+V*<#3G? ZY[WTHZ5%*QHSW6I$M*
M]66Z(_+,1Y,\SV^S[BLQG>P],(;)F,T7&&5<P=>SV)"D>/HSRV_TU0;?[U((
M77V)%M-?@X5<IWQ\B[V(Z2UH'K=3P;4+X4:T@RT^0&6(>1<'FKT#@PW@4?/)
MT"369QP'J$B905:H8ND:0H3PR#?E\,/T-/CL[N8CH>FFD.O+..M(ULH(M5"H
M"4_QMHB8;T?<8\KA5(46TUB>"I"?,K<X@":E@Y\M4$4?04R6+46S#P]*.P>Q
M,,N6MPLO'*J^$<!6BJ04SM5#*0_1T;#M7(_$O-NU2F9>;KB2O"[AIWS:E@-T
MNDUO1N[N'O#5P#Q&;!J"&V0CFQ28^)G[]&JVH T=&8R:!T7">7M#P7CM_D5-
MA!<WV+FO2*5O@!J%Z,H6"Y)DEQA+.E*74J^^]WS!H;T)[%62.>BF#KI(BVOF
MN_N9ZMW$E1!]JD*S>H+^B@'MD=4@H+%TO#W^[ ;([OP"EI#$ 8HA=;^Q/=RD
MY$  >U8Z0;*YY!12^J.5D.R>3BWGW_$GV4-$";723]Z(D0HN?QT,]9;+I5SF
M  ILYTE8(V+$@4NKFII\J*#&3@FWKP9\9355/TFCSW#KU^H@U.&)FL.4M";$
M@6R']W1_6QSXGDSBKS;+?MX+[>?"1#,F</,#:00.$ G>*:XE2LDEKH?7O\CS
M.1\%4_Z^RKC2UK$!]WULN"9T<%;X@WOMY<DG\3(;V2&",5D9VD!>'DF/[^Q$
MG?V7FF%H&/133N-K0L'E)*Q0'2@E:'U>I#!$@97*M"5##S<./\C)Y;_3Z[.:
MJB&TI/3AQ43"RZ^,PN]*WJ]>Q=W'!'7 F;\Y0)%="16F%PS:Y[+IYH*SOCZP
M66-T[IK(L[WUNHX1P(OOC[<MV.@W(^ARZF'P?5HJH&UT:=/>$]OT>@*"^M4@
MODZ#7@N=JLG6I.L?#M<\E,B>]&W/O-9J">W&OKW@*>ME,M*\@$F3_1A)7(#_
M1-2)8;:!8J%%N'!/V/!R[[5RAEOT?3,6@X4AGQ1;_;[TC&[A0!%E\^((H-@C
MN<.><"GZN1'=\A#C,UT>NC?TF24F8VMKVI@R&NX)6&H&PA=RS(EK&'MGAITC
M5[4U+#T>GF<X5E0\41'U^/0$L'S[)MVQ9/]C0]5)JH58=\?7A(;;'TE]K\O<
M2Z!YK:G39YJZ[Y /?5FB0U9.TD&$Z4BP9+B'RO5P):!E6(8UT<+>&0C2>;I@
MJWW0XCL(_ _K-!8J9,@+L!#],8B!: )+=E_;?FU\]LQW_),'.U'V=H9D$[H\
M3QUT]Q*4;@0I<S;9<,JU- 8O92UPV0:Y;]NJ@ A5+HX#$"KL]O7&"NRHRSC6
M?^W_8N_=PZ'^VK[A\4/*)B)[F<JN"&6?W239)51"=C/9A22[,!@S2;(G"44,
M"=E.]F',9)^$[$.,(60_8S.&V3W3]=SO<;S/=3WO<=_W\][W\][/>UQ_K,-Q
M^)[S_:[S7&N=Y^>SUKG6>LL:&<"3T(CM6T(.H].[$00';)S#)_<AW<OX2#$-
M-HXW]UO>Z%T,?4?W\F+=G<+\X=.9#$#;U7K>)U,OR>)MJH;"\;)/S$LA&<>G
M7+78I:Y =^PMYTT/;%ZE6-HM(,40;29P->B<]D_H\JV:^&;9W).VCARUU\H8
M@!P!L,Z\,O\#?>5QS]%@'\J,]<UFWQ%GYX&1_DO=*@.=U5JLI1M73F5D;3@2
M5:W&^>D@(!2[X47W?#U5M_&)LOC1Y(/N"<A[",$2.%WE-U72,=$,C*,/ I/J
MM)X-ZYZ3LC#&R1??*XRYU\D!8#\8C>IEW0ZOAYU:J/3#S]8UIT25KX;+YI?=
M=/KAK(<NL+K5=%1+KPL WQN"I&!X_V@)>T#P-DKM;K0C*JE*%OBPCU/#:PL0
MO>6C5" #P%Y!CBGR=?;LR!,<6W#R*#"KE/%SREW'OOS.L=(J2%B._F-FNAB:
MBX:=\PVU G4^IGQ!@4[/*^\<3)0QB2]G"\&Q2^<:_31VR!T>_\&[EK>_T.X6
M.1MPJ)\P1P52;L&TB$2;(6HPWGP%\OY\:;LL X#UB(9GS!BJ_+Q6E525PJIP
M_LN]<#XOEM'_A9S<_XB,87 DY1I\E Z@O4)+! \"H3F6!-H;CB\IGC-!T ZR
M2TR0=/)Z6<#H7)##[:+;%6/:9DUZ+\<RCE[WRY1?WQ4CXJ8Z2#MD"$78"_2
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M>M:<DA@0< %\[F/S<Z$TQ4<73M9M<ARM%&]^:@6H9LT+N *T&X*D0P299JN
M".F&SC=MUCG?!G)Z.\8U?JQK3+ 6^S6'KHK)K4[*$Y:*$5R'?%RF"OK8$SF2
M*W1EB"J.CI_VS)X)9<\EWX-*/Q*4O</"*?!$ F!WV=7D-.ON\?^DY 0%G2ZX
MXC#Z&'ZZ%>(X6J$6*=^NJMB_N-'>QM[,.Q_J*FC2I#;L._E(_'>RV+*^/ Q,
MP'YF #B<H-%=AZ0L?+_8!,UCAM;>(1EQ;O!"3TV5V3H/'$:?PA+\EV,PDCF5
MO'-+V7D7QR8N-33!4X6R'LVH2B NI*<-RKGNGOZ$ZD,Q.]DI_?/P:>0)1!W,
MJMR'KC;N>/;H":XNK_>T'_E);/%Z(1].#>I.S+JCV9.Z9!Q%:!D@4.+FR@XE
M%<'^PK:L:2TBC8J8@PU^QTV[T8_+>U+ T00=\RE]K\'XO42X%1,R5QX\?QWI
MN@7)T=Z*0R,H=ZEV N"?3'"%N33^:WM!)/-P>XYTS2"]+L1&Y-9W%O $ 4@_
M5H2"=F^*8T4L-%)+?@G55"LHKA=*R4->SW^1X]EY87(>\I@J1/8#?E;FQF3,
M.:M:$FQ:.UUURLLO.M[&2B"JFB]GU!B'<-QA>WMZ!0*Y,"CSQ9MR@>U.R1AN
M)W-K6'XVMH+X6H(MS']U>XMI3&HJ.RT;.Q<WCCF5,@&A%<"<O>?6+AS+:C]T
M7PLH_ZE\4\;]YUF.I&?'_</.^6Q ..!#F+]HKV&B3*>#;4N-/0R)*5'2=++,
M 2_&LOQJ4[GQ$YEMIDHM'SQ#T&NYX=&<&='DM!D2TKVP&D&O+_4L-G#KO-@#
M],L( R7#COAVIO=<)[^YC%H$KPOWA>XT[?SX]K7X#'UO)F02 2[4]26FS_-V
M]?>5/FAD -S3HWU/4-0Q>IQ*FO#+Z@.35.VTICR\W>01A'7"'H2;Z</M$DDY
MBOSD[AF9#-W77_:XR1P$U#5"S[I%.7@CTM&FMMJZUY1O@ $PS,T'%JC/HX?+
MG.I>)FR;\#9D]ADNMX#8?CC<>SUUG^-R&C;_<V4<[V3EMTLL)V\$NB7Y7D7,
M2-B-97.L)\[1."_N>X>5JB35.CF=-"#+SNJ_'T^'3N!#V_WVLB>B8/J];=ZH
M2E]<H^U]CD^K$0GX4G"158K%FR;-IIWC482LSEFYF^,.DD4JFF;<[%(@@NQG
MFD_5$%-!D.@#Z$[^QY$V!@"9^((Y^&&/4#>8(^FDW!SVN2H)&:=](2<,Y,X_
MPP#\?O\ KVO"Y+H19/5WCRCJ6W'J28\IDIE]+2@KK9Z5PU28NUEC(;VC%G.\
M8/YH^ICB1N(RG>T;*.-Q>.BZ';X<)IY(<UULB9+V*B'\L%H#\\P#R8K+T1N)
M" ^H<F<C=H;B1'!87JOK=0+&,7U3^-X7OW4DP%O(A R?*#4+3LD->1^V=>4X
MK0XN34:0[,GQ&E$N031L9/5]BKQ9_;I-$Y?J LM' \!?IJ=?-(EN0UCI4QIB
M/7$;E<&M.A39[C!!Z=84PXL-;'.UIYT[CY?XZ?KSP&CSV),X,JYSXK"[-$AF
MJ:CTI][8MZW]HK3>^VY[LK6_64D=GX&URT_4_=A7LD(:/OID3F2NZ-K1@^8W
M[AXY?O$SP&#N>$;(&LF.H/XUM]FPW6S@%SKGL E8!&.E<"+:+!41]R'/D80X
M,M)D;"]7@ZLQ;V!^P%W%OGM.*,Z88N",S]E*<2Y?L_J+&5MLZ%SD$=?^>:Z9
M(YY:)QZ$PTH/T"X+P,2;'!X?Z-W@DRT<O9_&%:U\TPM9F#[Z/*@R*+QQ7>NB
M16J<58V5-P-0>X2>L3K+0<;/X>(30'A)(B2VOMAOKF;T[)N>:AM7 ]+9YFS
M@94#+14&*7:?KLK]D-+.E5S"   Y00X+>ZAHS'D"R6(\JNQL2M4+43[$YRRI
M/50C$VM$UZ%./( +?Y+]2J)8O0+F]+YY=WF_37"2V0J%Q+RG .ULG#'HZ:9@
M.HAPFA5>O_>H"7]*H;.W\=;(0[_GERADH1MPUT^Y")(UX7[3IZ*DPXA&XM1
M7^J[AD4F/1C<Y9U^NGBQN3B&.P_E<_D&XO-=37J,,R:*XDP&W9U2DL6,B! 3
M$P.-X:4M>U6&$%IL5)]W.!$XD[+*2\NUHO<Y&6,ILN2^:[T) ].WC%;'&UD/
M](?_A&3+WZ 3:L"3;A30W9&JR6;I4$X(_6  <7T2]6P/Q[JF+^)&*RAZ('1W
M2[WE++) ZDAN(73'D;"IWU:^&G(OH$$\RX@:U06('/XM?;6"A>W>4ZVS'WZ2
M'6^TWI0=J9 !_.)H-.Y94ECD$2>])U:E7-$NF\FGBR<^AM%/'Z'Y%(^ ?"O#
M)2)19L-5@+7%L#2!@UJ$?*C//?UH)N03OL8 Y&MD, !/TAB &'#]B&*%X\7I
MMF/=/]^[0'?GT?*#I,7X:E(JSY=<%;=6'B28DW?9X2)].EM<;K!PM6PVP<WE
M8/-DD.8GIQT&8&IDKK$3F8P4R([@Y:W+EGT#G%P_AFVPNA@<IO&&A3UGU).S
M?DX3Q[G'(QG1XH.3%U^S.^=J]M+CIW;R[^OT:SL0<Y@#K0K7!9?4AD?YA1;3
M\@4_?<IX\D)YW]I;:S#H[6'X1+Q=H<1PW>G2-NFTLDKIBF30<U"M7Q>0"QIK
M2E1*+C"Y5)^FE)^FKG,U73D J5EX_C1% /+8_L:^1H"9M**?5+YG?)RBJ%2&
M-/^Q4UK2=CU()H+W.A6!M\Q5+TJ=K*J4T<D4+_(T=6QRNBBEUQW@(-:X 5EP
MOL&7'=/Z,N\=ESO]H0B]_KF"J*ZAI;?WCS>C@3\/YZO5<?%@(&' B%Y?[/"1
MSO')F0'8'P@ZM.L.W^K4B^BD/"^H>&#W8.:V^?/S3*>V#"Q2-2 <;YQ_"JJM
MRS4F:!HGS+P!"75S+#L] UZ'(DEMA.+$IH>8Z7)3K2,BZ$\[FX/1!ZS@T'G$
MM)7S:*AL5LF/E0_A.DMA'//^6/)*!8('WBNI/&&J>='!^Q9RONFM4$]-\<+!
M?*M ![!:(\.S?L_7=OL@5E;G,9_<]_1/R XF*<F3)Y?,*XO_I6X!)JUJK)V(
M3$/@N&)H\G['8$"B9C(I5\<$G2F[HHK*.,%$PPTL5)Y(3[S?TUDA@K=M]="%
MS#N_S.7#AEE71;=-\,Y&3)WPRC\R2<L^:^%HH?+1#J_GMOI=.0#@YXDRLBHI
ME(!\JH$6<W7^J4QM1.L'+8^R;D?O_M42?HY%,*0*\%D"H'-[1$E)JBYJ,6/X
MW +[FYF/91R!/E_H,O19W%'ZR6/"UD1,6D"0I$'CR%M<7POE_541IB&A"8"]
M0P4\-AY!<$0<7\&X@_D)\/(R[)E'ZCK/:I. -^.75'E=[] 4EK'Q2((M(DD2
MM"-5/5HWR.4(D@1GN+<PL6C5RRW_R-%* /SC@^;6JA@7F;&-_M;<.D-EM>VC
M"P:;G4\4NC R3']HHG^<JKS#O]"MX5 Y[!XF=K5^Y](N3N12:E<7W!2*FN=-
MT%?T.7HX7EL%33FTZT3X-&>N7NVI>2Y-_ZN5%U^RSD*,F$=E'B*>!CN:>_8<
M&A>S/[N'@(9UV<=2\K]S--,GD02;?M "JCT9TH8Y22"A2J;6Q*5R;J.;3(M.
M*)2_.F'2LN7;=G#(?S$((C Q ^3^0P^F]AB +.5$JF>Q=_E8Y6ZY9TN(9)[;
M@8L5E3UV!Z5%9E):MG?D# *V<UCY^4-@=[A$K,:^;0S_8PZR>UR#(:_-UP6)
MI_X ?7#5\F=DK7(G*/ZCD4;T'%)@U7;D W33=:2(HA/]/=[TV. XYCDM S&7
M#E8A;B7ZHJB(^[!+^!;[VV:^16D..S=9FI)M'/?O13W]9B#*=F3C,+C8N^%0
M*<?/TYO-=CPSK>)B!W^,:=H5SC(.  # .O4$)*?+Q$]LF>3!^9KB-=/AQVR!
M%P]32H"LHW&P;F!F9/DXE4EPV/3&Y'[,GB5NQ%3I[SJ$O-T7QZ2LOV8 ,!;P
MV*$K0!FH*OWH&*&\ ^]X!TTT;I75#\XFGHY#>L0+QM)(/N-44<I1*I!PPK"$
MJD]8JW,7]/G!0SE_ZJAJUN5]E,.[)_)>S>RIS]>-&G(]O%T>MIYMB'$U8 !8
M;K([_CL/#E00[X(<A^DM?$H*GXTN]#EG/-PX?NOG7WH75WWN)P"(5DQRK,T,
MI],!303)C <;7WSU%JNG(I]=*">["2[F_:'7RE25\43]C'(RRNC%KD&08*<"
M63<"2SP\/$P 4#>(""K?SMT&[BG>U+KI@37)@A*]!KU$J=Z##:K"\M:4U9_Y
M R('R8'0&3X1YS;\:#=>R79DPR%XY,:'=9&J10];0(QN1H_!: (MO4(Y'GE<
M#9F(^6M,5[-JJG(VH_SSO3S5"8X77R-47HA:N>:3\GG;OKX<E\M;54LV-UT7
MO,/]*_US5V0RT8]^M&^AE;=+]<]&NE)OL:5$J?1'CY8IZJ/FM$D6Y_<I;ZP'
M5&-6P&T4?D3;>03>DMS>US6KAZD9#4[6N*6/+)Y<,O<) QRX9_SX:Z#DQ<E[
M@AQ!CP% 5ZBV0A_BZ(KW!WZ_X0&9)NE?;Z[R4!F UNSA_YFYJX1)261*$;T?
MQ.5)-"YW*7_01YI65.JS&.&718]N^2F]JZMOB.N7]B\WTQW*]W9/49_)"KYI
MBG<DC;000M>+(HC 'A G1@9J93]T^\XH]0S/*^VJ0FZBL;O+2=*V>N%TAJAC
M2;860.H;]+5*Q=> )(_+>E)8//W!6M%$</C-=&^E%@1$;E^_I_D6^!+1CM3?
M0. GZT]TT%F(^YVI?.21ZUG@NN]HC>9 L,,*\8*L^9O9P^VI&4'PTM'V^*24
M;5@<W@F5"_6D<Z[,^4EXVV).?T>+$A7LR%"EW0W-N\0*#=M+WOJBK:U\OO7H
M!,>ZUITSFK9K.H8^%_SKGNE$2[2H_<K2B:FWQ*4JS_1OXA[Y*D=RCXXD9$^6
MTX4I&Y6-#2U VW_]*.H]F?_Q7KDPNXW+%%_815J*\#70":JEK@X#<$S\1K,_
M?; %K2D+5/[VN3'AJL9!-6W=T[_;9\QG!T'G*B_TSM,E>K93TI@==I;7U\*S
MD55'IDGHN8K5C0^-@28W[2V"YVQ/C4,<L3)YT[,#?7?V0QS%;Y(>(5JQ2BU^
M#<CX=2 _8JX6Q ,#A=W/$ZD?1UNS%4EG_W+0>^4CNEI6^RP+NNO.^G.\/Y8J
M9#=W08Q-N)D!B%>WXC+3S;-OQ PI+;GK!H)G+[L!EI,^Z0:RPZWO:#_//5)Y
MG[1_LR> #1E^63BP$6[D:3!$*AVW>GDX63[=6^]#C8N5TU[&*F<N_P9N,)$J
M.YW VZ%36L<;H^W.  CH6GYS25@4G!\N3"_AYGCC'S1U4;#%#'*,>H> W6":
MA5V2*!&.3*VJVIV1,'6OKQD563F,C%NFV;SNV^P1GS&_V.VT5P+UZ1:F<]9[
M/39N_+X0$"OF6V'KP0#,7I)_&=DO%IM<GPL!^8S5Z[S=VWF4NW.0?9BDR>]2
MPW3FQUX_+J'NP(8/9-PQ)N56*D6QD/6Z/;KW Z:W/Y75@2#++$?!_I+Z1,S$
M!.>\ZE"S.%?;<.KPT4^$4-LNRH\PL]6.>W9XKW9$":WNY@>DUM1[_7 /E7_3
MNU"E"E'VDN0:A]F?=E8V&]V3=7NBZ MVM;Q"YXM(.Y@(QN-^=,P/)ES-L8J%
M*TTQV6MQ[Z,*[5^B?R5%3*2E#NYP^V#.EOLT]&TZ2-Q-@I]MH:WGZ-502*4$
M_>P6M]'WGZ:[?_A*?Z:.<G:VTNK1ZESSIT ..:.O%VZ180<T!;D.'.$Z+GF*
MQ)TGV#CB]B@UM,PA%8*W%XVU7/A4M=.!)1CYQ3M$\7Q8HQ\?*91[T2@P>)K*
M9H @KA('#%\FDG:''F^US)7W&_48?QKK/)'7ZF::&/[X1>CAV&_07!G]/ $G
M*4ZP>J)V(W(R^>V^IL(*I2<+^;75A_EBP\"0ADJB".^6D7>AYTAA'0Z"WSVT
M"\9OD<\B.R( QXOFE456C^N8J*.9KT47^UG-;UP!RD$3Z9Q%Q!;PE]0NV\.'
MGF4.WB%]*U0+\8LK/_;5V\B)I'YR]?P+(URGE?#&(]'3HXN-MI(Q;O(\\ QH
M!/V8-<'\ZIGWA-;Q]ZN!8EMWFD#OM$NI1J%@"5H"G!]JYS>I?PIJED ;;QHI
M;'89>?M59#EJ<&+T.\>"$'9!S[.K9G-,W=G*.C#08FSDF]FOY26Y)E#N VC$
M'#*)ZIRZCCI*1EK/C*QG.^UXHO;O' *_3&S*Q:*YWD'-K@S7^2K< -SC,C?%
M?V8"^BB'.A9R!QY'EMOJ]COI2]'LF G7ZV0AU9N#+#%!2MK[55M,$YDBDZ:^
M0^I6IH32\MYMW4ENH,%0JKN[J''M<ZP[$&;378.(.2U0[+K!(C5[%&GK&3?4
M?B;([]MAT"Q3VZ.A[Z8SZ./DZ#(P NK@'3 --WK_$K/^[@GH//8AB,S$3@EP
MM@<E-PF1Q:7S.$YMU-;9U %,K6]A:([8N8.@3\]M/HOP1$_TT$_2>T$G]%7(
MQ3P*QH3B6HP=ETQ7?_GTM*.R\[#IG'P2ZV; DV/SV$=>^;P#O'Q,2,8'N^57
M=.70+D6-JV4\_L;WF2ESWY.!;DLV:;#VOK=SKVZ;N(!-%I!D&6PWDFTSF-#I
M,,HU[JQR>+YV]VH?TQ]B?/8VF>'U#!'5KBP$4T^+C=-51_WV.'X,\S'SIV<#
MUSF.Z?$&- _E%M68_."FUY^M0L]N$3XJ%4@Q80+\QRN:PCZGZ;C7I+VA K=*
MV@N3 I0><7 ]@] W;[E301;N$+[=NU_BR/8\B 'PY5.@U[$<],Q!R H]W<K'
M3@KO9P/CI<!'1]46C:5HO[EAE+>4I=;TSSB"T[DWMB!^,J?1Y8.2$77 Y*'1
MV52:*+B4J8@4KAUX<K%NE,C['%>6J'CE*S+NK6G K@M8D_GPS&;!T5#"1.K#
M316XJ;J>7D'/N.DDDY'!. '[$%:FN1S@W.0.K^:Q>K_C7V@"MT>0J!;#I7-4
M2X5)71[*-3+7O(O1=UT/?*6M_9%K&H=)%IH+DAL+1,&#Z 4460;8C3@2EGPD
MQ@75 ;17Z[^J\85DQGF9*JR^ +],%EB /#?"XL\0D'&[[N ;6=F/JXU-/@2V
MF.X?>0(*]D)U\++"O]-UR??YO"0O$972)2+/-(YZF")$]GU!<2AW H@JB%S0
MC'Y:.8 J@CY7^YV=]S97C\MPL9IJ&?F;=:^J.A@9*PDD"L&GWZV$7D D;[S
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MFWK\#MA^XR$HJDI_F&1^/F-!ZEP@ZSD/JL$74#*<-G%F 37) 'S&"5Q#$EY
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MM2T( _!7#-)\2O?0&7)M?0_B:GRW6Q,@+O$DD.5PI"PVAJKCA^?E7IFR*&8
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M_MR:7621+X*.84+& G)3'U #A)Z@0L+74]9.\!?<'IJ=T,JE7PKR ;K\A(T
MGM-8W'LMJL&9?_5O'XL"$=4=#1+%OGD_[!^1##&_NF;GMVA?5)[9^VM.?64Q
MU)6-\!D]G(BCH,6L)[ @!MB=Z/@H;")POFQ+C8KR=U7@9'DP%4=>B+OS#QI,
MH7QT8JR(F^+Q-10:6J(N6@V/B;J+9GL9Z'CP^AQEOUD)["HV9=R \H\ <?RE
MT.6I]?$/Z/6\ CE;8B&ZTA>X?4GCYQX%UN@74ZC>%6)&6/UE)?!=M^/7,/]L
M934'T).^$4"XZN_&9PR!DT5-/8&7 BJPGMR[",@@Z68O;+Q^^_6ZU)4!*<J^
M;M>K.U17/>L\KV]VRUUST'%%#9P[8% !$+YH6\9RNQ+)#NE@%R7'@DT9-"%
MX?==8\S4N=J<8[_ '6YQL?NNN9?Z0QYYKA+R)0H1/Q(C)E=%8O&32!'C%:_.
M4Z*ZO9FN)[!(*IGF[,/96#:_"6BIRX]1^9/88I(CUU5RT6S5\]PUG\/9Y0-[
MG(_?F5S[7FF&>AX67KHILW./T#9%;,-(G 1<K-#KH$1V(_YH;X'P('R8M:.;
M<RYH"<H^7^W;JNMR\-_(\+?T"2][1D?[OB3Q3F#!#O 22 >8K1Q%,PP8=V3
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M3<PF?5@.&4P&3S#C+L:S91M%^'SUC3[(8Q 9D[M, Q;XC(D](6,$(H?ZD)#
M@V'J((9)ZM) *\+KT !SXZ%.1M )":24>BQT$,3C7&,#FK%/@<U0T2:.4ZKO
MH8>*T^_OBZ\_B%L5,_P#R1]A\Z.B@X,/G>2C/Z52]VF?O&Z8\2'C@;>GDY=%
M_I67=496O/FQ4ENMC')WB7B:D"1T89)0#R+/(Y!@EL @0($;>1Q3:G1^J#WR
MW#[YZURPJ,S(V\@)GJ2@TFV:%S67_MFZ$']^?!1_:L*:Y'Z(%:L5+JO!7B#]
MJ=*S54:9@)&)186O;X5>@)[8W3_4C"C)[5DJQEA9-53T1Y_43C$&9==,,7_
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MVC72K,U_\;K9KE:MZMO2 -))U6H^FWJ; R9J'DN7B>"_C;5KP%38+B]@-/;
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M0F(O900ZOG37I2F"Q',93!,GH1&BB(=$MQ'"T9'F1BR-L$!*"W^1XH).WJ8
MED&3A.,('R<9J[B-S"W#(3/JIJ %Q^#6"L>?/EF?!2TE^TT7]&ZPL?/\K,[,
M,MH6BKWCY6/U#J]619%WORK><>6]X<3S'2IK%E)AE: DB&$2<F&D>+*<F./0
MD!A%@@\59&[DTDHI?6I2S'.VH@:S,61_.@[&4V]:.RTVQ;25'@O0S4/WZ^9X
MU:[#[5P\1]SD&@CSACM?<\B.;X<'/,_6>>C[MJKC%_Z5YVN^#!D+4$A3& <D
M@@@%""8)0=#U0L^E/.%IHE6&1WO$N1%A)QXH&_G./?W<!7CHT><9L+W-N><&
MR"\G@+1PZ'D G)%//'='?>/CS@,@G#[K/'3C,(YYMZ[$'K"J+HM'DN6XJ>1"
MB_M<UD&^9C(F*<WPJ]*-8A/Y<7MV)_XFF)%=RB,+N:G<_&'W<W(\$J#4I="/
M&84H3"(8<]>3(:5!X,8$17IEP]Y$^O]9W#?MQ.OQZ&RG<V1.[O0&/<478*LZ
MZ.N^6_E6N>!Z:H(6@ 5H(>C_<3$BT;_)[%E=-*;58-(%Z$TF9W<Q>QLA!N14
M_%A\57UMLESFT"M!Q5?V7VN\RM+G++_OXHUV^@XFB71U4D^\7XQ %(<^3%(9
MJACX+'"IYQ"]DCEGR#"W1>IV_?B(RV>5D$7K[*MT\#5A=BH Z LGN):]%_*N
M$"#!])=*DE^]+F6;JK\^"%%E%\,2W/+RJPQS_L#;.SZ+U_Q)!K@\;WJ3F(38
M#YSEXVO91',W\HK4*2#G:J."PGRKQ#96TJ"+I+59,$AC&'\V)DI2&&U6S&+]
MS\/S:"3_P$=/%Z=_GNXOHO#/?-2P_=[5X].J>.:\Y=(#G=U6Z@U0^8K;!;KQ
M>UT655UMC[A3''B4,0]R%G.(O#"!B8]CR!T_]GS?EVYZDQV=9?EFMQRJQHSO
M7C5P--N[V9Y$O=W9&T[-R*O=WG:9V^Z&BR;(MFKW6FVXIM1KT4:OC13X,!+B
M5O=,MF6<=%<T$L"[^YZQAAFX!.QDH M),KID(77\R(^@BQ,7HA3[D##$((O3
ME/@4HP0Q(R+?-\K<Z%@));.FNEI8;8&L)[';Z+(P51$(V07YI]OWZ@_J-X;-
MD/=CKLF[YR(Y=MC&JYH9\F!4R&B1"(]!8)?.]HXT+2D=4_85M1R]>(#KX\\\
MQQ7E0M++HGPJ7G2Q"9(X(3Z/(&5N E'D([%HAC'T6<HXI2C$D7[7CR,#S8TF
MMJ*"GJP&>]QCH&JX$RQ!-3(/[$=I2"^E8W 9[/LMP3;1YM[P)3/;LFM <71?
M?NS^Z3;?&EJ\V&'K7#^T9KKR,7>UYF0YN+]F]</ENJJ%&5%NW51B^^L%.(AA
MZ,8>1(S$,$XX@QZC?LQC0A(:FE51UQMX;A3ZY>HO5Y]^NC*MI:Z)LIXA-09V
M(W-J*_*VDJ<46I4? 9W8X&>K'KZA8%FNRZXY^,25VLT@>5V[W?#^L[CI.L_J
M#*\NFGHQDOG:O633WR#[RJ_2E-/ZKL1YT\)GZQ BW*5QS&(8)$X*$?$Q3!*.
M(0VHE_J()]0LJ_U\D6;'9XU&LDRNT@GTE&K#1<%6+=#H!;:*Z7F,QII?([Z<
M:-:F8=*1)VPHS5K > P"/D>LMZ!F"S >(&T;3QY8)WB_MW#KGG[WO+VD]5Y?
M_(I+UI0OWL8M5ZKWVMT#SF^>5$7D3X4J:LQ94\IIZ3-'\GL*"?$01#0(Q?8^
MBJ'C))Q$?A0F+EXV%<]N:US6>MP_F?PF9+.KQ7B\\U,K(R!8_%Y6#ZA5:3;"
M[[-<NFZZ\F]M*3GI:50>QLK0Q3C=>^+Z04!9Y,$TD*YBUT\@H0F"(7,I=QW?
M=\.H?4^N<LTB7#-^2SH=IG]'>,Y^>V^'GFTQR_F>\)BQKW7_K!&09[#W.%+J
MONCZ-?34;SJCBG<$YZ!%0'5K:##H"I%:K%X]]<39+6P]F?33UKR>>E)>E<.>
M7(!AQM2F+=*/',OV5')(N0?_*2](Q4M5.NXZ?UJK4G("^VR5-=TCOLC*WK**
MJSQ@J;JHT^>V3QH*/8RHV"X3&LIS$1<FU(LA2SC#LD]:0F)SPVD46>=I)+W;
MKGOO.54.6N"["R"^8L=LG1MG@N,P(CX+A3T<JKP5AB%.TACZ'@VI$PBS!V%3
MBV<FTSN^=7-D<MTY3*Z>P?+FTS6R<;+MWK< /14;7W-?2=!H"5ZJJ=)5&CW5
MX;\P0C:J-H^U9X*,.A56S8UQ))W4M!@5[%TS8MS!!D1#]%J!WJI.H)]D(]#W
M0D#\+.8<M8?2/'9"SL3:'SL)@RCU'!B[8KG@3A +VP %'M>JHV4PYMP<XO[W
M?A3\O_T>YJ"1'BCQ@9!?,CXR" /0!%\C@,(^I".S\5$8A= *RB&A%9J8&D19
MV,=VHH ++8PMQ5^8@70T%$/S4=-%99CI]B) P_#6H64TFOY^;1"W+.:QY&)'
M1OW AQ1[1.S8&(&QV,-!Y@8DQ%'JQ Y;UD6-5WK&_)XQC AZ,])XK_N=',.T
M/L9KY/2LY3/Q&)E=-]U+6_%D5C2Q6(+VB/:6BUR\'F?BLA8'%7U=R.+PI0,,
MLPOZD/$F?^HF_?#^XN+IJ2R^XI7XQ]]\QVV7,9(2[KFA!W% '5G..H)QG*:0
M)P%&+*6^[Z?:=IG6D',SRWI"RZ,$(3;HY%;__AL4HAO8#WJX:YADUM$<F3/Z
M0-[L 'G3 3G$(M-#U, @LX[L1/:8%L*6[#$CC(Z:8WI/FLX:,]+LA3%F=N>9
M_G>9K[\JY!Y?QD@T6735^^(19_DR0 @QA\;03;@'$1*LG:11#,/4Y]1A/ F3
MV"3Z3&?0N?'VUAWWPAOW<R.M8<28%NJ&;E!+6$[FU32#<;A/4@.7<5R,QP9^
M&X^A!A0''8 Z]YI14%76R]UHK2:&ZR:]8(4Z;;Q@_[UNNKRWRV[LI2YWDQ2Z
MJ6 AA,,$8I[ZLOF<APCVN(^U''M#!I\;);V*CNSJHJKB+JT2"[!50X^D!LW+
M<;(:&^VQG7^F0)\V.[7Y[!SHCO&:>&Z/T\2_=OELT,"3\-HYD'3\=M8SAIE:
M/V)AS^6\?.X7_&\_'X=P:4P%,*2IV!>'D0MC-Q"TAB+/00%U.3=*]CXRUMQ8
M;".JJN7 .V'-#*ICV.K94980&YF)7H+5Z_-AC6\,\+!J-AT;;U)K24/Q72-)
MYY:!;2^+QT=>T@RO/N,G7G9IWWX2.1@',"*J*9Q+81+P&,8^"S@+6.@$@5&/
MRWVCS(TGMD*")RFE87_*O4#J4</9\(Q^-KE!1@DX AL<A<!N1\F](TW;/O*8
MLJ]Z11Z]>&CWGK\4*[&_PN7SAVPEOJVE[S,O27D"/<\77SQC*20T<F""41!Q
M#SM>I.6!.3C"W+[V1DBPD1(T8IKVZ-G%\?@';P6=D3]V4V &=.(YH/R9'7AV
MGSIQYYT#2KWNN'/HPF$+^*:2H*PF]:L,NZR$D?"%R^ I\>-FAU$M'832 (6Q
MK/(D/W$W$5]W%$*?,-=' ?89UVK,93SRW#[]SV7Q-:N,:_#I(ZVWZH^"W\CD
M<'MU"6[I V?K%5\ UX-.LN@5)MUJHK8/G2XR!?=U#PH-MY&Q&6&,J5730G_T
M2<T-8U!V31#S!PP+O*1<UDA01<*SZI<F_:-(NVH)U3*,28(2WQ%&2HBE$T/L
M2&*20A^CA!).(B?4/]P_/=[<>.N%Q* 4(B] KH26;D+:B6T6&W@*\^-<-@*2
MH^]E^B!^42!^VH!X.0Z(9L&5%L&<+K#R+%"-0RLU(3H55GGJ,9.&5&KJM!M.
MJ7O;P$:.LLJ^K%B]YNQ&;#_50'?X6^/0ODFO517-CT55R2(WXNJGHI(!!'OO
M6[(DQ)&7)A"CU)<$3F'B)![T<(I#-XTP<I%1=T>;TLV-[C\5.2PW*394]4H
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M]I[._;II>3D/W#KP2+V-UI%M:S(FU@K\E-5XM?1]XJ+$13!! 8(H]7U(DH!
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MYD902E:P%19(:4V[E%N9+CV+9_))F.)D8JO  FP4A$)8*/L(+4!/+;!WPA:
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MHIZR]KC[;>;(ZLHPL0J3KCMO,SV[J]H;23%QQNK5/]99_;SM=U?=U ^\O'O
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M0ZWT3;G73G[PJU  =!HLP$8'T"DAHQ[LT=09$%HEL"%R3$IM9P"U2WKG/&K
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MSP1LEQ;/?=PPJKQZ?%H5SYSW>MJVX=PX3ED4T@!BG"00.9S!)/8PC"/*L.Q
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M/>T<G.WDY @DWP:7/3Y6[=4Z$.C=:>W<<P=KNM:AV&[_M:Y+^W:</N,3;BI
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MB-8-DN<\MO<Y'NM6NSNOS5'UO3-)WM^4(E6\P12GJ<PH83#&/->]LU*(DU3
MA+),QB3)XRBS(9/.$<?&*:6<_5O9=R-L1BA.<?/,*VU5([8"N^,18VR<TDGW
MJ(.RBC$(A^1B?F./@R$=HL36@E]Q7NX%D;FNZ+<9<:G\L>)Z\7=!5M]G/Z:8
MY9AG>0;S0*00)22 >4I"F-$T0#BF-(S-^[]:#3TVUFF$!V0C/?AV\[68@#<E
M,"AF/RPVY>TFP>!@Q1NTGHEI@^K5#JIBO5OFII0=7"^ EAY\]XBSQ9F&-[P'
M.JIPBKO=R4(OZ%H/#.R>.-PY0"]-][;W^SVA9QW^:FTY4W!Z2G$01SBG$#/,
M(,(\A%00#D-&XYBE7(0"V93_:1_.BOT'*P54+[]].DUUH&MF<KK#S#.M-[D!
M;97N'=:Q-X+%;9GZ]B&'K4)OI/Y1D7FSNWKV5A)4/5DYQ.5:]D6])%=ED\<I
MRB,1$1E %@G%(G'&(*&9@"@0<9@0%@2)57CZN8'&9CUJ.<%L(^@$2'5=W?G2
MLL71.6C-*,0%8)[)H\3J>@<K+26X:L?*OA%1!Q!N6PR=&VS8YD$=*A^U!>JZ
MOH?[><5?9\5R]5;V%&H":GF,1!@AF.HC.$2(<C?C*(<Q2G(:90@GU*BV^[D!
MQD8&C8A5"S0+=^84> ;.X860>/[<]]'H$ZM]\ITR]^4NA&<@C\T6)CNGK 6#
M5M?KU'W#.5@M4N^Y46W7]6P:_/0\7[X)\5VL7F=,E.GX'PXS]I5559M37Y3<
MNW^IC:UI%M(XS'@.,<D"B+(\A,HXRB'#84PD"0,IK;I:N!%K;'S9=(S<]OD%
MM%+ LMNOFTDS,[2&GPK?9Y/MW2(GC8<W*=V]#QT39-_DURF>;GO\NA%MV!:_
M3N$\ZO#K]ND7E,RZ7:GQIY*EBDV3 &+)B.+9*(8TBW.8RC1/PTQB1J,>):[*
MA]M\HL.4I/HX7Q9Z"[<@<]TJ7<D(?IHM %_.YV15Z-!T4&CQSV_!=.%I1H']
M,!J"QD IE>/23'N:NB^E5#U^^-)'>VJ=+%6T?T4?IY ]SL1KN8S<R/^X_GKW
M^?[^ZKMZ>XL;&27!;[/Y7+%";=EC+C,:2P)S&7'U+0NJ%J4D5[ 13!(1)EEL
MM(5D/?+8S*(=V76YN49Z4(JO?_,O2@-0JV#C3MG,AHG[Z0ECWW[I#KPW1_#>
M[,/;RVVUP=G&G_6$]U".K@WNKMS?'I"U^\4V#QS08>ZAY[XGW><!ES:'_*1L
MQ(7@M;&H(WAW$@:J=F[3,$.9##,&*4XCB&(=RQ]1#'-"4X[#+$;4J.Y[K]''
MMC+LMC2LQ6\<LC)L?3=+IFEP:%GXQFYV#.U%7YC[-BF=PGU!$TD+V#SUD321
MX)U:25J <[Z;I,U#W'6HNQ>KIQNI>WZ7 >_J+0R2B,20AT(7;%9S0N,@AAE'
MDF&<)'ELE;?4/>38"&X;IC37PA83\$1^S)Y>GH :_4E_AZR6_/+N<P?@FU&9
M6T@]\]?9WG+W-9@?N\!TTD7N-#[>F\8=#/ON/>).PV#2$N[,G3T<\OV3WZJ;
MQ+I.U]2U#S\L5ZOE7VK<.[(64TPISF,60,*C#*)<Y)#J?39!0THC204BN;%'
M;C7TV'BIEA'01DB@IL<PL[('\ ;.MS<X/7/241#(CNB3I@@MV$@/[GSB;.%\
M>\-[(._;*>YV3G@OZ%J]<+LG#N>&]])TSP_O]X1^%NF=4./,=!ARF?7V^V*V
M+NZ^_]Y49$1A@C.NEMJ4QA!QF4+*\@QF..=Y1"*N_F5CC+:.-C:^5X)9Q@&W
M@VEF7#J#R#.';^4$I:"@E!3\I%'[V6$$BQ4N3NW)]A$'-26-E#^T(LUNNG3_
M[KC$MN &!;8/NGPG<2(SGL=J&A(*$<H32#'5-:XQ)7$2QU2B?CM\3N0;&S7M
M;DJ=J/6O4W_,*OWWW1=T,^NV.X>#S^6 >XL73:/7IO">\/>T2>E&QG?:QG0*
M\/F-3K?#],TBD6*E1MKDJ.R,-T4,99PF 90A01 QED <DQQ*W50]H;'Z<SA=
MB <=.7AOGI;6-J81+>"*%HY&]D<156X:KP4OPR-[%T=HA=R,BR]&<*@-AAHO
M':VX(^($_+I:%@Z[U9C@X3C9I&7 @1-.NE4_3CHQN.>R]F4[E3"_JE]<K\53
M,0UXG%/MO49YDD 4(0J5\\JAD#D169S'W,Z/;1ML;+;BID/4;C'B/[6XH)37
M\FRX%6<S$G&%GF<2Z0]<[Z97;8AXZ4UU<L!W:2'5IOJY3D^M]_0X&?DBU(5D
MKAQGL7H5'\CB'S?RV]_U+EN]A1,1F2'UXL HCA6/I*& 5,8<LI 1S@6+U9^-
M#T.Z1AL;D7S[^Y>[#[9[\9V0&AQSN 3*,V?4HH):5J"%U6%MW_X^*9'K$TK8
M":'%"89+* <ZM.B"U-$!A2DRK6<2G0\9[AC"5)^]DP?CF_K9:+I/;94=(MCC
M8O;/%Z'C:W36L> ?2?'X9;[\JV%:C%F2!@+BG&<0Q6H5PRR+(4:,YG',1(BM
M2HB;#STVVMU(#C:B3\!6>*"E!UI\.SO.8B[,K#H_"'OF:V-P/9QHV /FU 2T
M&'Y0@] >ED/SL,<3^O9"T&[L=[4"ED'3FZ*U84YC&489Q(JFE)D8$(C3)(!A
M3(*4L52M&9%=_X.3XXR-J>J"0!LY>S?>/(>K&1$Y0,LSZ_0!JD<K@U88'+<O
M.#W6P"T+6A4^;E/0?GG/@U'!7E:"?UTN'G3$G@[EF&*D7@B91)#F^DB3APA2
M(?5_\A"E"0JCQ*H0P(DQQD8%6C98ANMR)=T$+(1EL.XI' V/"R]#Q_>17R4=
MV +TJ03(1Z'>%B3<'KZ=&&?8 [3SBAX=@K5<:O?%<S&;?EZL9^NW._$PT^2Q
M6']3,S]-HD@F 8I@GNG.(SE-()81A8+G29QD2<:$T6;SN0'&]JU7,H*MD$!+
M:?:YGP6Q_5MW 8WG#]T2%>./NTOU$U]V(=@O#\O7?U.WEA_U/Y'^$58_EE_R
MV8<.\AEWJ=1\PYW7]:R-NGQZ7BYT?[4R!:@\H+HG/^H#\?V#\(V%K[YQE @"
M4_4U0R0%AB0).41)3$1 !:5FK:HOD&%L-/!]]K"8R1G3KSK;J*-#6_9.KTFI
MDF5]U1XS9&8L>,;=,\=\W(-Y[]"[#APZC!?RX6A<@*';LJT]Y!BVEFM_H(X*
MO%[P*&?GZ[>KY1?=$_4S6>E>J,6M6)4E0S[-YB]KP:=1((6(TQS2&*<0X2B!
MZM$9Y)2A* YSRO&EI^X=(HR-(Y6XH&PC"W@EH':,P'Q9[!3N*<OYO!2\=RF?
M'C-E1I9^\??,E:=.\R>Z=S,H%0"-!D"I $H=]$9PJ877<WY#!'V?_G>)\=XQ
M 88P&40*F#[I,II4!$UGBW(7^CC:DFQZ8[;&6]95O*LKU5/$[%7?64QQ1$1.
M!%,V9R A2E,$*4\"F(9,,"+S4*!>Q.I3Z+%1\14K3P0*L-K(V(]FO<ZT'3&/
M9?Z&HO(=?2>G NC)3NO@KA#Z"6CZ&E0WE ]LE'>_ @PQ55[6#*^"O\LJ,\14
MG%N7!AF[5]&^S7I9%^C](D13?IO&,69,AE#*B$$D90+S%(>08,EI(/*0(&%1
MI._\2.-;,S:RPE5=MUBY.%95WMN ;6=[IW!YINC=D-FFPK,6M%\IO1;(K$KG
MN8%NL%)YIR%T5A6O&XV.*G@M#QBRZEVW'@=5[@QNN#"^[6H^7_Y%E/!Z+Z:.
MIBL^"?["]%^+:4A#$84Q@G' $$0QB2#)N( HI!@E 8MSAC?Y33V"W#K&-WK;
M#W*=AM@=J0J/%_]VQ?_SI5B7/_<,:NN: #.[VBF> YTO?_X(FD2_"0@C&. )
MV$:Y;14I[>!&E0G8*.,AOLT0/3_1;5V#OT]LFR$D9R/;3._O>R*V*3E2!EZ$
M49J$@H>Z#74 44I2F+,H@R3/ YKD<2;,&L6>>?[8S+P=\<KP%=O#JGWP3 ^B
M>D/B_9!IB\:G-C1Z'!R=U-GQH=#^& ,?^)Q4\/@PY_1E%W1&..K'L-/,H_CP
MMKVF7G.O_B(K?O-<DL>7Y4J*V5K7O+Q>W(K5;,G_$+.'1]VJ5,E)'L3G'V+%
M9D7=+T"PF(8I83 3"88H3Q-(XSR (HUS$I"$D-PJ5']H!<9&/[7XRMQWUMAA
MR-?!C._&/,F^3;2=7CN[RN\VW"D ?0,GF_)H"'0USQ*$"=B! :BWI0)B AHH
M0(T%:,#PTASC'>;1?0N.(948OM''.TS1R78B[R'')<D=Q]V<!1>1P%17J4I3
M74M &<,1UM&>$>%41KKK6^.[FRUXE[1\WO?2/:],U]L>;3^)2M:?^W5K.P=N
M('B" I'"*-65_G.&(!$X@4$@8QR%DM$HZ[$QX@[A(?9!_,,L"$>9C ,81T29
M;"A)(<U#KOZ9\Y3E 4EI9-/O_;]5H_>=3H.BZ5M.N_J66\%K9@*-O]/[,!W>
MAVSM/HJ>[I;-W-UV<2_WP#_>_/;;Y[N/UU=?;Z_N[K]]OOM^]>W3S?W_^7QW
M]>O=Y\^_??YV__V@5E^<H(CB#$,1E G9+(2YR#-((\X1RA&7869\Z&<__MB<
MM-W2?:>.!<OBFR],&2NZD++>:RUS4!?KV:+>BK7M#]UCS@S.$_W.A.^MJ8WP
MH)$>*/%!*3_8*F!3'M$)\!:GDGXG8*"S2A\387><V1_&UD/.'H\=[NBSO\Y[
M!Z(7/*:?9]6$WFUC5;Z)=1W%,J4Q9XSE(4SB-(&(( P)#P,82(P01RS,L57_
MF[;!QK:HG(A)[)$ZVPJOF6GJ"C3/_+_!ZVX'+R+55&T/.G6\/?BX$GRV!E^7
M1;&)\W-GP)J@Y=2*;1UP4%/61/5#>];HGLN*RFY28:X7K^JIR]7;-*4HP3D7
M4" 60<4C'%(DJ?HGI23/<AHG1O9K]U!C8Y6-8/VJQ9[ THQ$W"#DF4).),U-
M0#=BO0O%G@?#2YG8$\.]2Y'8\VJ?*Q';<D<_;OA=N<YE[K\^8ZVC!]5WC_.4
MY1#3((!($@D)2B6D092F82SS'(<VI'!BC+&QP4;$]L-\8PC-N.!"8#R3P#XF
M'DI]M:CO]+,_-<Z@WWN+HH<?>MNEO?V*EZ>7<O_E9OTH5OJ8:24>Q:*8O8IJ
M%TU;@%77VB2/6!0E&42("(APCF%.HP#F@<A)$+$PL\NALAE\;)RP(SLHA0=[
MTH-Z'_@GK<#/_5H*6\V-L9/B!7'_3HM#L/LX*]:HN79>S 48VIFQAN:$<V/_
MC+Z%AY2-U.0*L7*'[]M+N2:'E B""(4DS4(=5,X@)AF"A,5I'I.09&;E[CM'
M&AN1U45WM"V_+RZHY+4M2G0.X':"<@J;9S;JC5B/@D4=:%Q8N>C<TP<N8=2A
MY'$MHZX;>F7O/<[$:QE3<R/_X_KKW>?[^ZOO9"Z*&QEGR6^S^5R-TV3S99CG
MF*00IV7#M43Y0#D-8$Q$S'B*E9UDM.%J/?+8R&-'=GVJUT@/2O'U;_Y%:0!J
M%:SRURQFP^#(SA?&WNV>+;PW1_#>[,/;+T_0 F>KO$$_> ^61VB!N[/D0GO(
M.I(-+1XX9/*AO9X'R8@]'M WGO%55$EU]^H!5S]FQ31C@N1IA&&BFZLI1SB&
M).$!%'F "&,IY]0HD?O\$&/C^*V$0(L(_M1"6E>G/@+2S&&]#![/]&R)3(\H
MKW/*.P[P.AIFX-BN<VH>AW6=O=+>'_Q4KR5?9@4C\RHV^HOZ73$E>2 $"244
M::)\P8!S2)DR]** (L)1&*>9L2]X=I2Q?>:-H*"2M$Z+ *6LYC[@>5"[_3\G
M4/D^^^J#DI7?UXE";Y_O_),'\_<ZE=OU];HO[N'G*?- 4<AR(9K,^2_+U>UJ
MJ;. KQ<?EXN%*-.!_YBM'W=B%#^\?5^3!W&U_N-QQA[O'\7;U4H_06])?5H^
MD=EBFL9(B(QD,)=2E[ .8I@CO3F>9Q$+&4,(&:7T>95R;*2ST;-)UBK*V)-:
M59V=M546_*6TW6LLJ/.]M,* K,%?6F6P5CH#71"RUAK\6>EMXQ-Y>T,,_-0Q
MS+MG!OU_:LHM7.8Q3/U [O7[OP)VKKGOJ6EUX[T-/IS+[QN_O>T![X/U/&@O
M W.:D%).)2%!1&$F1  1D1&DB*<PP33+&449IM0FF6SOZ5:+_& I9'6KEE[%
M[/?!,SSJ[@N)[SW=.F#.?4CM*87='D/OC3#L.?,IY8X.DD]>Y"K@OMX%)R+"
M!$D)(ZZ3NEB&($XX@5$LTH2S,!',*BCVW$!C,]4O+OY[%E'#[]D!3MZ/:XYB
MZST$QG4!X3EL_CU"Y+I4[@Z7=W(<\%4H@A$WSV*E#.3%PU=!U%=7UY9]:\R-
M3R]BBG"4!1E&,*09@PA)#'%.*60BPWE.DSSDJ<WR;CKP.%?^N187/-=BVI&&
M,>1F).(#2,^D4HFLR]?40H-2ZLFF(/?;!*R7@&KO9^:P[X(M5$YIQWCP06G(
M%I)#6K*^WU,ULW,U8SXK=VC]=KW0:=BE+&4XWOTC6>Q7DQ&\J24S922)PRP/
M(2$)@@@CW6X\8#!)4T8QD6'"4(_B(P.J8/2I#U_09+^B65G%K'!=QLSA>V!&
MOV.;UO$4+^NH75;I#W8 J..@UPJ"H\IFZOY-7;,!RY:YG[QA*Y8YE']<Q<K<
M3XQUG3(/(KA<'*O!KA9J%*;C2E_%K?J$B]OE?,;>IB2+$QJC%/*$AQ#1B$,L
MXA@*'>I)PT @857+MX<,8]L-^+Y>LG_ #T><YF*%:I^,2U8:9Q /N&)L5H*=
MQ>+/2F*W-4$<0#< 7[?+,0+>-0+*C#_-'M63!]?*DJUB*+_,%F3!9F1^NZP.
M0S8-877*OT R@3A)%?'%7!$?R1,8IV&0Y2A$B4RLB,]@T/$Q72VS#F??2 T:
ML4W:P_:? $.R<PRK;W:['%%[4K. R"V+F0P\+&U90''$4S;W]HC.TGG-56GW
M0CVQ+O*N;;_&/OR#Z&50F8FK.UW%MK@NBA=E48K5[6JFI'DF\ZLGO?4[%4$H
M1)QP&!(U*2B/,:19G,,LQGF<!Y$((Z-NXV[%&ANY??S;70%FI;!EM?3G1EQ
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M,<X@9E3 F,N,\#2D.#7B!X.QQD80E:B@T+).3IP;6A\5FN#=SAF.4?1NEY8
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MNP,)IR;\N;$&M<L[%#XTMKLN[YMGL7K6*6#BPU)'-93E)F:BJ*/F=#8%EB*
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M\7Z?^WL6#2>+63%[*A_$HEY/UM&Y,0ZS7)G_,,=40L18"/,\#J# 22)#*J,
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MTD#*1'=4YVJK'2B"(W$80LDH"QC&.K?1F-L.CS$V=JNE!+68K5%@\?4>@=&
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M210QDJ8Y@P'59GR>)9 B)&% <D'#5 3$+N-M]>"Q60HKN>PX80U3BJ)8<![
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M?TX]8,#&/P9Z;+?_,;GATL3$%>UN$A."..%,1,I883&"B%$":<XBF(:2Z29
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M8V-0)6;CE08?244L[=$ST!K:FNX \VU'MI*"-6C#-#0V1,BMZ7=FS&'-.C,
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MLZ,.&U9F"L)>8)GQC?VHIG%DZ22"^I#DLYY.G5Z@FS*P,))$!@)&B"&(8II
MPJ,$Q@&.>9:'&*/$AF1.C#4V>FE=JFM9P4K87ETO3H%LQB^.H//,++U1LR85
M SR<TLFI\08E$@/%=RG$Y):>,1[%K*C$9UV%^VY6J3>AZ&27LN7+LN:LZY?Y
MHFJK:T\P9I3Q5$*1"@Y1*AG$&8U@RE(4)Q$6 :*3F7C2-SY:Q'M82V+TV>3-
M9[,GC[]/J",MZ(IK&=QA/S%F/.0)YX'"/&KA82T]V(B_WJ)98V\?^=$;/K?A
M'_9B#!L#TANFO4"0_D^R[U+[59>':<]6,DP8YVD$@Y2%$ E=#3+D#.9( Q+S
M"!.C@+:=YX[-3M*K2E%6!2/3;JA:C\:T7?!.<]$%D'@FF-YH6/6B/:#[Q=UG
MN\\<K-_L 46Z'68/_;EGD47QI.?AJWC5W_GLJ<G.V<TADT&6DHS&D(1(0(0B
M 7$:8$AQ3+(D"P0.C8[=K48=W0?=" W64EO6&#1"VLS6<(Z?[Z]_%[IA4O:L
M8');P,YHY&%KR]F L5?VS>IF.RKBHIC<UF$'>CNV>)TW ??UKNQFOIQ5B[>;
M.1<32HE( MV3@7-E-X0$09I2M5T*2!Y%BH8P-NHH:#C>V.BG$1ELR7S5.!2
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M.#03U2I-E[3:O%\.F)Y2,X/R'2?*\ZK@*>]+*3G.C*\.^J/-]=(R_K197AV
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MFFVSA'A8\IZ:2WL11,)+8$;B "*4^9X?>&&J5[#5K-FI1;R_+PM.%E5B<"O
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M5?4K59FV,G^.0H1HEE&81*H2#^=R+A;X&'H!B3WJ^2'RA;VN@)U16APTOM!
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MU'C^&U_GS2$%56V;%T]@L2*:\U=7?20R[&?<8Y#XQ(<HBWR8QEX,/<2)2'G
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M1C"Y57O5:WI<S5<C.-XIOYK=;7F23%7FJL^D7:O3:<OU/ MIB!+FPYB%,B3
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MZD\;+G]W3UZ5>;\_KY;-<^8^]7V*>00)1A%$0G@PBSB!H23$$*5A%.J)YU_
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M:<S.&)BVJ@+;.S=FH./(#+2N@*MMGVR] =<C]XF!P-Y(?3.2 -^@?60FT^<
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MJ5!(6[=ILJ"0UL[ 4VWO2!K5IMVON2(SP4X=>OWF?#7KG?@'Z+@_ PH H!
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MR-E&31;] 'KI#+1^J1,CNY)6.]>J0R6M<^ /Y1YH_#.,"FUZ42]6'+AO!AX
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M^SXD/&60A2B*<))R/\4FS&AJP-1(\1MG&]KFO;]LSXZ3/:DWUL[Y568+J=3
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M;[)%3C\O5F0]][A@B9>&D$5Q!%%*4Y@&S(-IS'&2>"Q)*-.M/_;NZ5-CH-I
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M?)1;(&6>+%@^SRMS1:4$WOQJ\:1=9*3=HBH3SQ+H4XI8#,),^*J^5P1(&OB
MQUC$<1(F:0AM:.A2@:;&4UI6.R*Z>$S,F&I,I >FLHTJ7J6+]NY7VGB[ZEQ5
M><M;"E5>>E=>K9,[NG.%KE,^O%BH40G3%83[C.JLW<N"G>I$?/K,Z7K!/\M/
M:BYEJ0\N/HB%R/+5)GU!EJ X20@#**!(\BR2.SA?5;0)PRRA@8^PC_KD1;>2
M8FKDNHGF69&?PK8J6+]Q,/7[&!C=P?T_:F!K!:ZJHU%]F*:5J)*CUWIXO]2:
M_&6@=!07@#E(3)6=).\29=4+K%-Q5_T:ZT>/=;TH3&!&4 KE*& &(!44$"[_
M@V,_9# 3..-\MEJNR-R,[^Q+2&T;']!O3?71J]J655FMR=7/NN[6V)HB!BQB
M]1[5JKK+4EU4?TJ=5WW,"VD +8OZA%.PU)>3C0-*_%"9%A#@D F014&" Q8D
M"89FH06'C=M\<^-$!%1RJ0,CNB0%5S_P6F3#*7@$PO.'Q/UA&7JIKP5S?#A\
M7-^+#X7WFAWM,/BX.NU#X!-/],S+(H?HBQRTNEQWZ"=1$! ".,L(@ $,  YX
M"&B0P#!D69(RNQ0L.\U/S:I7TGE*O)X5T/? ,ULB^T,R\/RT0,,^.\I1I=TF
M0MGM8MR<)T?5.TAO<ORIGK<V.V'.#\MYSMZJ_VZ].!(B2)#Q &1A& ,88@*P
MH!@(3K 0@I LL@I*-NAS:E/\1@W@8E6G<Y5+\%X* LN;&P/0#6]OW$(Y] W.
M+FA77B6J]T?]OX/XMEA Y/8NQZ#?<>]SS($XN-.Q>+4?#]TMY#06Y>J!Y/R+
M6,UB'TDSWH]!FG').7%  0WC$/B1'_/ YQ '5@5D]]J?'+^0\ME[E;)YF9PA
M>2VL':OL0VC&(!< ,S!;-))Y2K1V*>J6=YS7/'35>#_*OU^KP_)\E7=4G+1F
MD1,P.66,_3Y&98<3"NXSP:G''.1$T7D-YLJO57F7J;,Z5O\<S" /THPF!(2!
M2HZ2,0J0P"G B,9^)L(X15;.(Z8=3XTGJO,WIKSOKI09LEP(L,JEK4VK,TWY
M6U68YD4J<T%NE*Z1,&.5(? =F&YV<Z14Z5&TT#I?2N6@RYI_#I0EQ0"IX3*E
M='7^?ME2#"#IS)AB\GX/MU7QI-RV?Q/+IX*\/N>,S.O=>XR$STD4@50HSU42
M"(!P**V7(!(I\1G/B%%45&<O4Z.EMH26AR#=:)X_IW2"T<#48@>/G4_K.?4O
M=VL]V<-XGJWGE-QQ;CW[<(_Z; <)'77^#&D +;/6GS[GA.9S;7E^$-*0%T>2
ME&:1@)2D$(A8"&G)8 :(\-4-1@1)Z"/*?&IR3^A6K*G=,[8=)>KKQBMO(5;Z
M]J/]M_E6-XNB:>Z&LYN@WF^0AKZ$.9:65NMUY7VIAFGGD99V5UZEGU46VR&'
MT*)BWKL,Y4BU]HX.Z1!C:5>RSSGDG<7^W/4V7IE YPCM%!ATWWJ/Y7<3KZ8"
M8Q_D%_],2J'O0=;J\G*9Z0BV\OH'R>>Z\,2R:)Z:(<)CA! #D&$*(-)%"#-?
M+K@\06$*:<2,BB9?*LC4;/;;KP\/5W6.08\T NOSQ]=:9/LLA!>/EL%Z.M(8
M#+R"-EI4P=Y>(Z$NV"%Y=]TX?53*>!MM/*G.YNF1!L5BA1QI<$9:$X<=)+N%
MT &RG4O?)>V/M]@Y0&%G>7/17N^S;R%?>KY>\(_BAY@O=8F2VD5UYD.,((XX
MP#")Y#8Q30$->0!$&& F<$9@8A6FU-G;U):F1EA]"LNWXEH?:7< ;'R.[0:V
MX0^OMXBU)&T\WIV>5Y]'Q/4A=4>/8Y],GU?^R'&TP4L]K&*5^U!.Q>))E*O-
MY7SMX(DP5U57,0A#7[FCARG *I\"1DP$-$&9H0?>N8ZF1AU:5&]>R>HQ._^<
MLZ@:6*>.L!J8+RJ8:C';E53.^=3:X65A.#K";23#\ 1^CDP] RPZ3;FN]\<S
MU0RTV#'%3)[O=71_F#JV5!&3=)X_Z<^D,O7N,Y5:2["UBK1L9TY.A!]1)+D3
ML9 #R(4/, \I$ D5'*OC?&H4R>A$FJGQ[58#;[E1X<I;;+9&;*M&CUS7;D;0
MZ)!^O'$9_&S^:"YL/49;=5J[UY9&9@FR!Q@BJT/X\89JI.7D4;S*YG0>O]6S
M,)@]'J_<5/Y\SJ71K]Y1]775;UZ+G.GT,NJ7LL5\]?8OI6SGY46.>:F/,5XD
MN7KB)Q/J#DT^15Y?YSG3YQ9L^ZE4#:GC0++RYD*E8PK]JO-\4=&O_JMJ@:M/
M+M^,B=1BZ=&F-9VG^U=GUP%N!O_,+<"%G8QY^.\&C[TS?T>-]EBN58OKN?+C
MO'Z2]H 2H-G2P# +!?1!0)(00#_A@!#?!YG %(K$%S@V2K/>W<T$%]A:4(\T
MDEH0\VDX#19%)R -O-JU\-D(V6<;<QHHBZ7)"6#OL^:P(]^96C^$NO;-%XK0
MWUIKBO=GOGKVB%?4/I*OI%B]N2+YLS!VLO?IM\>CY;,:[/#M^:=[9GS.GQ9Y
M)I?VQ>J:,95%5G:AXS9RT<K2&R*8L3A,  \#)C<X- (XHJDDUDS%?<' MRLZ
M:=;MU(CVZ_???[]^_ _O_I/W]>ZW+W>?[FZNOWSSKF]N[K]_^7;WY3?OX?[S
MW<W=[5?+[,IF@V!V'NT>VH'IN26PMY78:T3V_A@FG[$53&Z3$YMU/6ZF82LX
M#M(&V[UM[TQ]LWY9RU5$VI!5IJLJQ?!]=LV7NG19[0O,XX0)1CF(,8( 4H0
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MP4'D@Q3&2/G!$I55#@.$(WV8%PAF%?9XO)NIT6TCI?=:B=DK3]P^E&9,=SE
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M$, !(B#A)(1<($Y3(P]Q@[ZFME VHGI%6U;;7<9I:$TW$TX &WS/4&.U(^8
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M1,KS%*(, YQ!N8FF"!,1<42A4;VF?MU/;0K??GUXV%2-W"EF\%IK8U\_LN?
M&-PT#0KWP&2Q/790PGN-]-II]<JK%&C7"MGH,"CH%K=+@X(_TLV2^T&PNU[J
MC6'GU9)]J^-=*_76>.=*J7\KO?P9F#H$*N7V7.0_U':\/D12_E3E#$,>JA33
MP,<HE@M(D@ ,B8KM8SPC. Y(:)1\WJ"OJ:T6C;1RI6C$O?)>ZQ,V=05BYX_0
M";.1XX$K\ ;W,*AQ>VSAUIQ,?G.+FY6_@"O\1G,,Z(VCK1N "3)G[OL[FQCS
M8M]$E[T;?*-7+@NST#ZM=6:'AV+Y2178>A0_Q&(M9ED<TACY(<!^)HWT6!"
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M$[4J]\%C7O[]4R'$W4*2AC3R'B6E_DY^YB_KEYG/B A0QD! , )0U?$@7"0
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M/A#V=\&W1QWU-YW&'&*?1H#& @&80@QP'(0 89^+&/,X(E97?QU]38UXM:B
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M;6^1KG5>3G=[+BO<G.Z9S'H>=<]C!<;^GL7NY9YU'Y9EX\Y3'^WZ6 0^2SC
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M'#EEMQ$ AYF[S5[K>VB_4&$&156'("___N%-\A5[?B'%WZ]_YN6,T#A"688
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M%OXP $Y@RRQ E4!:KVV=:\)=*1UV4F//AUU5-34QXZHKAQL[S7S*U'M&D$7
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MH)HUZU<I#>#LZM7IW?W"DQ2:Q4Q"!$\DUY$$+0Q)U-BHE>6V4L>+QR@:MNU
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M&<*Z >JEI>K[U$8#X'H[F\/X;/JJ=,J>(A]S/UV@B$K.!>.:]6\G-U,P-Z[
M0&5)DR4^)%&N4@U^%25AZ#)PG3UUH4YUV-XD=P/D2\OI'T>##4#U,YP5#^$3
M7,SFC[]K"=1&R"P104MG#(RMT2M(@4!043% CX'6"4T[D=<-@B_M J!_S30
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M)J%UIT99Y!R2"YH@^1C 1([Q:QE6XSE/L3#JCM8*YD4]%=@)![L^%=A%*0V
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M?]Y4H:[CQ&ABL*(0G$I6._)RPHM(E';H_X-WBO67+7F(@B;/M#UT.^M1T&T
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M];&T7P)U#V-M%&,T71JX+QR>V9YR>3QPZ[[C=F+6^D/XL2U2-H4)5"H#UR*
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MB+%\VP/7<A9D&NGV]8AFY3H=\_,EE^TPMD*^AG92*1M6LWO(:']TGE8/;<J
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M&H#<S7.#F=.<EVPB2*G(;66H2#0E  H;?,A*2S;.:<]-*AJU5CMJ>#F0N!N
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M:1#M(/WV8'25I\P8#;EN9$5#-:59@\,DP$IRWB3+T>MQHN][R6D./KNH^G$
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MQL_7=D*#.X;]93=)MJ#^2]3&X$.NW3FXK7<Y4 LB6Q(7IA;K6,LX[]1HH#L
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MFVQQ"C\%XYY%X+[. Q>EU%)? ;E>EQ1"B93N1/NC)-@?IK ;YHXXHSZ0<AH
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MV4(2]O(N+TBM02C%,B4_18HV<_9W)'1<1#8#S/V+K(;:ZV&?T>KP\$(EDT.
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M0/+,R8(S%)U:H9A24J'=KNASJSNQ0RC=SK>=WC#>HVIP9*1NXN-J6I"/2K*
M$*/WE,AH3\&(5?2+3HZ8M-$-A\7':1GOHO9X6)@U4<S8Y^NG5V]>_#2YFN/
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M BLI88BDD=+HQ7M +D:>^]R!'8P!A['#H8UOE*\^OG^_/N8FJ]^?H4'/9)*
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MA/N+)_?52D>(NJPCKDOM0QTA[83QH$+T$%RQ4+P*%*)P'1L-<NRI2V5_?6X
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MT@&HFMS]:.\HN&(:6!VBK13+$*0UP() [[Q5LM%$L.?^-K83N([Q-K:+ICM
M^^8'%B=B-&5E\<6 DI).)*,4Y,1B\B[FB&T"@K_2V]A.:-GZ;6P7U76 P0&:
MP(R/3F>5@"3&JAN0E+O6"\=D$R85A6\TQ?/OT49#! Q'1L I8_YRJ\"[B^5B
M&:9Y,OW]P^S\_)?9O/[PC&/1&;6MDSKJ\@#R+!%%@H)1,:Z92ZJS$5^/\M.Y
MQQ\8E0,OGA@ (L_+4-9]O6=<8'+,T$F;<DVUZYB;.OU/.*[1:Y85:U2X.S0K
M)VH> ^*SG<GL 9:]K>7K>BS",LR77=C,W94U_YC/%HLS;S1]D2H@921/%GQ]
MW$4+WJ:LC&04<)["LJ,5,YT7-IV>W1P*F+TMYQO.X^P8(VEN+R)\]2?.TX0D
M<>:]85;& BE[2SQ*#D$$^EWV(G)MM19M5A3M3FOG!54C8+ZMNG>'M%]#>HJ_
MUP>#+@X"DG/!R?*B3@B\F@V(=1*@<QI,2'7>"@G>6>'K'-N2792YE#8]FPV8
M.=$!8_T>!(<"YEE8S:L_OT[FJW]S(P2%T0=!(63)-8XLB81 J@"1!-->Z!3O
MSW+OQ&H>8.9$9YKU:S6' N996,V/N5?664@9#/C@2036",K"BH,D230\,H?B
M.27J_0U9Z]=B#@/+@8GZJVD?%G,9F-;;]RLA!!<P245AJ0ND$J'!!6>A&&9D
M8<P9UMF\XDVLG&B*WL?-[V' Z",9/U $_UPOD9WF6EI:>[8^S>I_^M%O)%&D
MQ=H]Z%W=H.@2!!TC,,FE]#J&E#I[.=R1PQ--_/NPI"8P>A8&=DL$]W::7]V7
MO)]/$M: H5P&#-*'%(NW8+7(Y(1R!F>"))7*;*(M(:@V!7K'Y_5$+Q;Z,+K&
MT'I>CYJ/2>B,FV1]%@Z,TX:$0?FC3R26S+CRHO9TV,X6N^S&X+-Y &V"\W',
M<B?0G<Z3Z<;JIP>?P!X5D/-:8L("164*QGF]"V6\@+6:2V>LD'&D>XWAF#S1
M_*U3RQP)?*<1J#XEG"O^MY./HH0XU<F81<AZJX6\[AV-8'UPB>4<K>G4.'?B
M\T2SPA.USW80?!XF^L"SX:,2LBR+2#*!6+(#E6K7A_8:N(M91B,]-AKX>FQ.
M3S2//%$S;0G#4\@ZGW9C/[Q3/BH?XPR2OTJ@F1)UP*LB25D-K @1;0Y"Y)&>
M(P;F]-F\B)^$F;:$X2F8Z4!Y>O3.J,PU9%.W9TF%$$5 ,!YC*%'[*$[Z.O;9
M/+IW890C@.[Y/=,_'O9K;CDC]<DH37VCE1"R\Q!T*D74+;*-QB\>B<$3/23[
M>!-I :+3R!T/?J%]5%Z,B6!K381/B?R1EP$"\QX$2N2*H3.FSVKFP_@^T;.Q
M#UL\(N1&-='5EM06@<&E6#Y@G8% /W@YFZZF(%V$\T\X_W([IG'(R7ZR 18-
MI=BVNC)!$LM1,84\*\_O!:D;5N2.R\=6]F:?F;UU(/>=\--+[A>?EE;<.0S?
M)"QQALQQSWR$8!F"0H?@G2N@K6*%_%%@KF%GYW&9':=@X.0,X:$#LV-4/@/#
MW1S?;Q(1/V-9<5G3:&TR9?DZ"G">]%JX%,5ZCDPU? 4Y+K/CU!/\U0VW-2J?
M@>'NG QLEIPU#(N0 F*L6^JT,?4Y25%BX'0QAD=MVDS#[D<&XY0E_-7-?"0,
M/ZOD]L7OO\]7W92O22*3Z6*2_AG.+^[<SQ>GHE9U.%I:E5Y)4C&W$@1%-";G
MX&(,Q\YEGR9[*Y-T?Z>NQT1'+^?F,,*Y*Y,SP[4KJLZ,88;5O48:'#,)"@M&
M>"E83GTV,6YDZ7EDG4-CN-T+Y & .IV"]%U+#C_-EN'\GF2R+E*XY,'+6AF!
M4H./24!*P22A/7<J=VEJVW#W/%+&SJUN<)@]ZZ,MHB _9#(XR2DW5H77+4]U
MSXY.A0E6G'B.1UOW"5OG1C8,H'HJIQGF3NJN,/B9LI)S&P*@+W6)&I,0BY(4
M^)NDG',^BH;'61.>QBD /T7[&A]2?Y%ZF@W*/(M%>,>L!2U"U:#2M6TE@,DN
M,3K_G99]UJ_MS?)6QNF?V=7(Z%+?"6@#VF2C/8&5I[7H%HN++VO9#+(H\+$/
M'G13X-8<]+$J4"!GKK8#R&SJ2&]/H->4DIB" IW52+%4$S_U7%8%9A*116<@
MB]53A:>C.G(R0NUKW$E_;M4B^_>JP!WQVVY5X"X@Z""GO[LUK# N4JEQ9@B)
M?A$%HA )= F<V8+<JD;;LV^3\5Q6!>X$A4=7!>ZBEPY M;_@'ED)YCTF]-H0
MA!RE]'6WG1-9@<JI*'1:*SO2HH437Q6X$[B.L2IP%TUW@/;-^^9B\9ZKVGAF
M6(%:GP?>)0&8@M;")&/RWZL"CXJ6K5<%[J*ZWC!XR4*V6AG%!>3,*(EUJ\5S
MT@-+(7E7C-'WRRI:H&\'W(TW]FA4W.VAKA$1MY@OSSY4N:W7S%J6=+ >4&4!
MJI XG&0!&!,&I>3%ZJT6O="GWL(7_>D^MNY\[7-9#;E/@+B__'L S276=9$Z
ML$R,^T0AAPD%/&*NJR\<+]GK4K:Z:M@>-F,>?P>H[+[2]Y#?R&K_=3*=?+GX
M<G6L.J4L9@=Z-0XX9@:N!$9.+JX?Y<C9#:;X.U\]LNKW4=QL""F.K?[PYVW"
MH[7*%P.F%ALIF^F,$XJP7[RB']'/S%8AR7;JO_W5XQP9@ZE_;REV$)L.\!XC
M>%()(X(1S!/'J"$J.C<Q1F=*89J'SNI#WNRTQKK=0,$N+K..C(!3QOPO83)?
MO>;=>C.BW.-77'Z>Y=GY[/?OU_?=BAD?>9W79*,%)8.#2!H"(9$;P7U-0OHR
MBNV9Z_R>8F"\#F4NC<!SRO:TS2#@U0]_#DN\EM]9X)*9E!/PZ+&.1DO@A<C
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M<MN*,P4N*(1<-S449UANN2E\9.Z?_3UO._/IT!7LA.6_W!WQT^*CX(Q+10>
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M8AKP/R<EB5Y4:F?7B;S!2WKZAL7CP.M11NT";QW#FA4>SE+YJ9O]O/M'J_>
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M1B.#!I*IMH8K)UR=F:I'YT2T4Z'0<\3@,.$T!+0.S^T\HST@T1]V@J7B#QO
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M@Z$!6" 92OLS<)E9< S_C<9:E[NE,QU#Q;"QBS;P>#(IM@K7#]^6IO3T8ED
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M@X4'B'7V<&.>3#@-Z+![K\S+4,O222XI#1<_OJ6P_IJ.L@XI:IX@$U,<(\_
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M,C,Q,C R,7AE>#$P,RYH=&U02P$"% ,4    " !&@UQ41DWS_:+A  #GO 8
M&               @ 'U#P  <&-R>"TQ,C,Q,C R,7AE>#$P,S8N:'1M4$L!
M A0#%     @ 1H-<5%(6)) O?P  *J8# !@              ( !S?$  '!C
M<G@M,3(S,3(P,C%X97@Q,#,W+FAT;5!+ 0(4 Q0    ( $:#7%1$06/ON L
M !T_   8              "  3)Q 0!P8W)X+3$R,S$R,#(Q>&5X,3 S."YH
M=&U02P$"% ,4    " !&@UQ4U[%FJ500  #M=@  %P              @ $@
M?0$ <&-R>"TQ,C,Q,C R,7AE>#$P-"YH=&U02P$"% ,4    " !&@UQ44/]/
MK18$  !V'@  %P              @ &IC0$ <&-R>"TQ,C,Q,C R,7AE>#(Q
M,2YH=&U02P$"% ,4    " !&@UQ42_:X7(<#   2"P  %P
M@ 'TD0$ <&-R>"TQ,C,Q,C R,7AE>#(S,2YH=&U02P$"% ,4    " !&@UQ4
MFK4S\0,(  #;)   %P              @ &PE0$ <&-R>"TQ,C,Q,C R,7AE
M>#,Q,2YH=&U02P$"% ,4    " !&@UQ4R9B'6P8(  #U)   %P
M    @ 'HG0$ <&-R>"TQ,C,Q,C R,7AE>#,Q,BYH=&U02P$"% ,4    " !&
M@UQ4H04IG@$%  ""%P  %P              @ $CI@$ <&-R>"TQ,C,Q,C R
M,7AE>#,R,2YH=&U02P$"% ,4    " !&@UQ4Q8=Y ZUT 0"MTPP %@
M        @ %9JP$ <&-R>"TQ,C,Q,C R,7AE>#0T+FAT;5!+ 0(4 Q0    (
M $:#7%0LUBYZ\10  "N.   6              "  3H@ P!P8W)X+3$R,S$R
M,#(Q>&5X-#4N:'1M4$L! A0#%     @ 1H-<5'CKZ#@X:P4 QBXR !$
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M2P$"% ,4    " !&@UQ4<B^(N>'>  "#' $ %               @ 'U\ P
M<&-R>"TR,#(Q,3(S,5]G,RYJ<&=02P$"% ,4    " !&@UQ4*'J!M!3, 0"F
MX!( %0              @ $(T T <&-R>"TR,#(Q,3(S,5]L86(N>&UL4$L!
M A0#%     @ 1H-<5.)DJLGO)0$ EJ,- !4              ( !3YP/ '!C
I<G@M,C R,3$R,S%?<')E+GAM;%!+!08     %0 5 (T%  !QPA     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
